



F. A. ROBINSON  
*M.S. Tech. Med. Soc. H.P. Lect'g F.R.I.C.*

---

THE VITAMIN B  
COMPLEX



LONDON

CHAPMAN & HALL LTD.

37 ESSEX STREET, W.C. 2

1951

*First Published 1951*

*Catalogue No 403/4*

PRINTED IN GREAT BRITAIN AT  
THE UNIVERSITY PRESS  
ABERDEEN

BOUND BY G & J KITCAT LTD, LONDON  
FLYBACK BINDING





## PREFACE

importance, and I must confess, an urge to systematise the heterogeneous, rather untidy, array of data, so that others, not so intimately acquainted with the field, may have an over all picture of what the vitamin B complex is and why it is of such significance in human and animal nutrition and in the economy of micro organisms

The task has not been an easy one, but I hope I have succeeded in presenting a coherent story in a form that others will find useful. I have tried to include all that is essential, and exclude all that is non-essential, but I am certain that my choice will not always meet with approval, especially as the subject is of interest to such a large number of specialists in so many branches of pure and applied science—chemists, zoologists, physiologists and bacteriologists, clinicians, nutritionists and agriculturists. Obviously it is impossible to give in one book all the information that workers in these diverse fields require, and it is to assist those who wish to have more detailed information in any particular field that I have included, at the end of each section, references to the original literature

The story of the vitamin B complex, as will be evident in the pages that follow, has been compiled from many sources, some having no obvious connection with human nutrition. It would not be surprising, in view of the paramount importance of these substances in the metabolism of all living organisms, if further fascinating discoveries remain to be made with consequences of perhaps even greater significance than any we have so far witnessed. I hope that this monograph may help to sustain the interest of research workers in these important substances

F A ROBINSON

*Waldrons",*

*Tewin Wood, Herts*



# CONTENTS

CHAP		PAGE
—10	Effect of Folic Acid Deficiency in Man	495
11	Metabolism of Folic Acid	503
—12	Intestinal Synthesis of Folic Acid	505
13	Human and Animal Requirements of Folic Acid	506
14	Pharmacology of Folic Acid	508
15	Folic Acid in the Nutrition of Micro organisms	509
16	Folic Acid in Higher Plants	512
17	Folic Acid in the Nutrition of Insects	512
18	Analogues of Folic Acid	513
19	Function of Folic Acid	526
IX VITAMIN B <sub>12</sub> (ERYTHROTIN)		
1	Introduction	530
2	Isolation Purification and Properties of Vitamin B <sub>12</sub>	532
3	Estimation of Vitamin B <sub>12</sub>	534
4	Occurrence of Vitamin B <sub>12</sub>	537
5	Effect of Vitamin B <sub>12</sub> on Animals and Man	538
6	Vitamin B <sub>12</sub> and Micro-organisms	543
X p AMINO BENZOIC ACID		
1	Introduction	545
2	Isolation of p Aminobenzoic Acid	548
3	Estimation of p Aminobenzoic Acid	549
4	Occurrence of p Aminobenzoic Acid in Foodstuffs	550
5	Effect of p Aminobenzoic Acid Deficiency in Animals	551
—6	Effect of p Aminobenzoic Acid Deficiency in Man	553
7	Metabolism of p Aminobenzoic Acid	554
8	Pharmacology of p Aminobenzoic Acid	555
9	p Aminobenzoic Acid in the Nutrition of Micro organisms	555
10	Effect of p Aminobenzoic Acid on Higher Plants	559
11	p Aminobenzoic Acid Requirements of Insects	560
12	Analogues of p Aminobenzoic Acid	560
13	Function of p Aminobenzoic Acid	562
XI INOSITOL		
1	Introduction	564
2	Isolation of Inositol	565
3	Chemical Constitution and Synthesis of Inositol	565
4	Properties of Inositol	568
5	Estimation of Inositol	568
6	Occurrence of Inositol	570
7	Effect of Inositol Deficiency in Animals	577
—8	Effect of Inositol Deficiency in Man	575
9	Human and Animal Requirements of Inositol	575
10	Metabolism of Inositol	576
—11	Intestinal Synthesis of Inositol	577
12	Inositol in the Nutrition of Micro organisms	577
13	Inositol in Higher Plants	578





## INTRODUCTION

*It is the stones and bricks of the foundation on which the edifice of human life is built. It is the time for them to be laid and not the time for them to be removed.*

NATURE Sept 20 1947

THE YEAR OF 1944-45 focused attention on the vital importance of food and nutrition as a life-or-death matter. Vulnerable are the food supplies of a large industrialized nation to enemy attack. The weapon of the enemy is a new and terrible weapon of offense and precautions against it have been given the same high priority as air raid protection. It is a fortune to be able to eat the country—the most dependent of all the Western nations on external sources of food supply—that our hunger has been known concerning the nutritional value of foodstuffs. The level of the level of substances to be found for food in that supply is not all that good. Our system to be built up which although it is not perfect, it is well below the level controlled by nutritionists to be kept at prevented any serious symptom of malnutrition developing in the population as a whole and gave to primary school children, expectant and nursing mothers and certain types of manual workers—a generous allowance of special foodstuffs to take the additional strain of growth, pregnancy, lactation and heavy work. It assisted in the development of new methods of processing and storing foodstuffs to reduce to a minimum the loss of food value and it helped to determine what foodstuffs should be selected to ensure the best possible use of the limited shipping space available for bringing imports into this country.

Although the title has now ceased the importance of the science and technology of nutrition remains as great as ever, for a large proportion of the world population is underfed. Even in this country we were until recently subsisting on a diet only just adequate for ordinary activity. For some sections of the population particularly adolescents it is probably less than adequate. Sir Jack Drummond has stated in a monograph published by the Royal Institute of Chemistry (1946) that adolescents are often the first among the population to reveal signs of inadequate feeding. In Western Europe in 1940-45 that was true and it is also true that this 'red light' is showing here today. Many of these young people who were well

nourished for most of the war period are not gaining weight today as they should, some are even losing weight " If this is a picture of the state of nutrition in this country today, what is the picture like in less fortunate countries? The problem of adequately feeding the world's population has by no means ceased to exist with the cessation of hostilities. Indeed, now is the time to examine the problem afresh in the light of the vast experiment carried out in this country between 1939 and 1945. The theories of nutritionists were then put to the test in a way that had not previously been possible, and as a result many widely accepted generalisations had to be modified.

In order to feed everyone properly it is obviously necessary to know the nature of the substances present in food, how much of each is needed to maintain a certain level of activity, and how much is present in the foods commonly consumed. Investigations carried out during the last forty years have gone a long way towards supplying complete information on these points and as already stated, this was used in formulating the food policy of this country during the 1939-45 war. With the additional information accumulated during the war and since, we have an even more complete picture of what is necessary for proper nutrition. What is now lacking is the machinery for applying this knowledge to rid the world once and for all of the spectre of famine.

The foundations of the science of nutrition were laid during the nineteenth century when Liebig demonstrated that foods consisted of three main elements—proteins, carbohydrates and fats—and Voit and his colleagues showed that carbohydrates were burnt in the body to produce energy, that proteins were used for building up the tissues of the body, and that fats provided a reserve of food on which the body could draw in an emergency. It is difficult to say when this simple concept came to be recognised as inadequate as a basis for assessing the importance of different foodstuffs, for even in the eighteenth century sailors knew that scurvy could be prevented by lime juice and fresh vegetables, while in 1885 a Japanese admiral Takaki, eliminated beriberi from the Japanese navy by improving the sailors' diet. Perhaps the most significant date is the year 1897, in which Dr C. Eijkman, a Dutchman employed in his country's colonial service in Java, began to study beriberi, a common disease of the tropics, which had hitherto been attributed to a bacterial infection. He noticed that hens in the prison yard suffered from a kind of leg weakness similar to the paralysis of beriberi from which the prisoners themselves were suffering. If anyone else had noticed this similarity, they had drawn from it the obvious conclusion that the hens had caught the infection from the men! Eijkman, however, made a further observation, he noticed that when the food of the hens was

## INTRODUCTION

inadvertently changed from polished rice on which the prisoners were fed to unmilled rice the paralysed hens recovered. This suggested to him that beriberi was in some way connected with food and not with infection. Forthwith Fijkman began to experiment and found that he could induce paralysis in hens by feeding them on polished rice and could then cure the paralysis by adding rice polishings to their diet. His colleague Grijns subsequently showed that beans also prevented paralysis in birds and that an extract of beans or rice polishings cured both paralysed bird and beriberi patients. The factor thus shown to be present in the cereal material was later known as vitamin B. Thus a fourth dietary essential—vitamins—was added to the three elements—carbohydrate, fat and protein—recognised by the nineteenth-century nutritionists. The main materials for building this particular edifice of human knowledge were now available but the story of how it is being erected—for it is not yet finished—is a long and complicated one. It has been built like any other house brick by brick and plank by plank. Sometimes progress has been rapid and one individual or more often a team of workers has contributed several courses to the building. Sometimes indeed the building has assumed a distinctly lopsided appearance with one wing completed almost before the foundations of another have been laid.

This book is concerned with only one aspect of the story of nutrition and does not even set out to tell the story of all the vitamins but only the story of those water-soluble vitamins which we now call the vitamin B complex. Progress in this field has been so rapid and so much information has accumulated in recent years that a complete review of all that is known about the vitamins would fill more than one volume. Besides the story of the vitamin B complex is a coherent one and the pattern which it follows gains in clarity when this group of vitamins is considered apart from the other factors of nutritional importance. This review of the vitamin B complex is an attempt in the words of the quotation at the heading of this chapter to stand back and survey what has been built and how it has been done even though the building is still surrounded by scaffolding and the workers are still actively engaged in completing various parts of it.

Recent research has made it more and more evident that the members of the vitamin B complex although chemically diverse constitute a group of biologically related substances responsible for effecting transformations of fundamental importance to the life of organisms ranging in complexity from men to bacteria. They are in fact some of the building blocks around which the fabric of all living structures is built. It is to emphasise this oneness of function that a book dealing with the vitamin B complex alone appeared to be desirable.



nourished for most of the war period are not gaining weight today as they should some are even losing weight If this is a picture of the state of nutrition in this country today what is the picture like in less fortunate countries? The problem of adequately feeding the world's population has by no means ceased to exist with the cessation of hostilities Indeed now is the time to examine the problem afresh in the light of the vast experiment carried out in this country between 1939 and 1945 The theories of nutritionists were then put to the test in a way that had not previously been possible and as a result many widely accepted generalisations had to be modified

In order to feed everyone properly it is obviously necessary to know the nature of the substances present in food how much of each is needed to maintain a certain level of activity and how much is present in the foods commonly consumed Investigations carried out during the last forty years have gone a long way towards supplying complete information on these points and as already stated this was used in formulating the food policy of this country during the 1939-45 war With the additional information accumulated during the war and since we have an even more complete picture of what is necessary for proper nutrition What is now lacking is the machinery for applying this knowledge to rid the world once and for all of the spectre of famine

The foundations of the science of nutrition were laid during the nineteenth century when Liebig demonstrated that foods consisted of three main elements—proteins carbohydrates and fats—and Voit and his colleagues showed that carbohydrates were burnt in the body to produce energy that proteins were used for building up the tissues of the body and that fats provided a reserve of food on which the body could draw in an emergency It is difficult to say when this simple concept came to be recognised as inadequate as a basis for assessing the importance of different foodstuffs for even in the eighteenth century sailors knew that scurvy could be prevented by *lime juice and fresh vegetables* while in 1885 a Japanese admiral Takaki eliminated beriberi from the Japanese navy by improving the sailors' diet Perhaps the most significant date is the year 1897 in which Dr C Eijkman a Dutchman employed in his country's colonial service in Java began to study beriberi a common disease of the tropics which had hitherto been attributed to a bacterial infection He noticed that hens in the prison yard suffered from a kind of leg weakness similar to the paralysis of beriberi from which the prisoners themselves were suffering If anyone else had noticed this similarity they had drawn from it the obvious conclusion that the hens had caught the infection from the men! Eijkman however made a further observation he noticed that when the food of the hens was



As already stated the existence of vitamin B<sub>1</sub> or, as it is now called in this country, aneurine or, in the U.S.A., thiamine, was first demonstrated by feeding experiments on birds and human beings suffering from a deficiency disease. The same method was used for four other members of the vitamin B complex. The biological importance of nicotinic acid, for instance, was discovered as the result of Goldberger's study of pellagra in negroes and "poor whites" in the Southern States of the U.S.A. and his subsequent experiments on humans and dogs. Riboflavine was similarly identified as a vitamin necessary for the growth of rats, pyridoxine as a factor that cured a dermatitis in rats, and pantothenic acid as a factor that cured a dermatitis in chicks. Up to this point, the isolation of the several members of the vitamin B complex had followed an invariable routine—first, the observation that an experimental animal developed characteristic symptoms when maintained on a certain type of purified diet, then the discovery that an extract of some foodstuff, more often than not yeast or liver, would cure the symptoms, and finally attempts to purify the factor using the deficient animal for following the progress of the purification steps. With pantothenic acid, however, events took a different course and one that had an important influence on the subsequent history of vitamin science.

It had been observed in 1901 by a Belgian microbiologist, E. Wildiers, that certain yeasts failed to develop on a medium made up of purified constituents, but that they grew satisfactorily when an extract of yeast was added. He concluded that these organisms required for their growth a factor derived from living cells and he gave this hypothetical factor the name "bios". Many years later it was shown that bios was not one single substance but a mixture of several substances. Various components were shown to be identical with aneurine, riboflavine, nicotinic acid and pyridoxine. Thus, the substances that stimulated the growth of yeasts proved to be the same as those that stimulated the growth of animals. In other words, the

bios complex, if not actually identical with the vitamin B complex, overlapped it. One member of the bios complex, which overlapped with any member of the vitamin B complex, was a substance to which the name pantothenic acid had been given. Concentrates of this substance prepared from liver showed chemical properties similar to those of the filtrate factor that cured chick dermatitis, and an interchange of specimens by the workers concerned showed that pantothenic acid cured dermatitis in chicks whilst the filtrate factor stimulated the growth of yeast. Shortly afterwards the identity of the two substances was established by degradation and synthesis. Here indeed was striking confirmation that the bios complex and the vitamin B complex had much



is that of intestinal synthesis. When certain sulphonamides, not readily absorbed from the gut, were given to experimental animals, symptoms of vitamin B complex deficiency developed, and investigation showed that the sulphonamide had checked the growth of the intestinal flora which normally synthesised certain members of the vitamin B complex. Many animals are able to utilise the vitamins thus formed and are therefore independent of external sources of supply. The phenomenon undoubtedly occurs in man, but normally only in respect of certain vitamins, and it is not known what the conditions are for stimulating the growth of the appropriate organisms in man and whether the vitamins so formed are invariably available to the host or are only available under special circumstances.

The names of those whose labours have contributed to the accumulation of the vast amount of knowledge we now possess about these substances, those who, so to speak, have "piled brick on brick on the edifice", is legion. In some instances, a particular individual may have contributed only one little item of knowledge and then transferred his energies to other spheres. In other instances, the contribution of one individual may have extended over a period of years, indeed over a whole life time. There are others again who have built up large schools of vitamin research and have carried out elaborate programmes of investigation as leaders of teams of specialists. There are also industrial organisations, who have used their research laboratories and development departments for the improvement of manufacturing processes and testing techniques, and who have often made discoveries of outstanding importance.

Of those who have thus contributed to the advance of vitamin science, only a few can be referred to specifically. Mention has already been made of Dr C Eijkman, the pioneer in the field, who showed that beriberi was a deficiency disease caused by the absence from the diet of the factor we now call aneurine or thiamine, in 1930, a few months before his death. Eijkman was awarded the Nobel prize in recognition of his discoveries. He shared it with another pioneer of vitamin science, *Sir Frederick Gowland Hopkins*, one-time President of the Royal Society, who showed that the growth rate of rats maintained on a purified diet rapidly declined until the animals died, and that the addition of milk to the diet, in amounts that supplied only negligible amounts of protein and carbohydrate, checked the fall in growth and enabled the animals to live and thrive. Hopkins' classical experiments have been repeated, with appropriate modifications, by all subsequent investigators who have studied growth factors for higher animals. Another name closely associated with vitamin science is that of Casimir Funk, a Pole working at the Lister Institute, London, who in 1912 coined the word "vitamine" to describe the then



## THE VITAMIN B COMPLEX

is that of intestinal synthesis. When certain sulphonamides, not readily absorbed from the gut, were given to experimental animals, symptoms of vitamin B complex deficiency developed, and investigation showed that the sulphonamide had checked the growth of the intestinal flora which normally synthesised certain members of the vitamin B complex. Many animals are able to utilise the vitamins thus formed and are therefore independent of external sources of supply. The phenomenon undoubtedly occurs in man, but normally only in respect of certain vitamins, and it is not known what the conditions are for stimulating the growth of the appropriate organisms in man and whether the vitamins so formed are invariably available to the host or are only available under special circumstances.

The names of those whose labours have contributed to the accumulation of the vast amount of knowledge we now possess about these substances, those who, so to speak, have "piled brick on brick on the edifice", is legion. In some instances, a particular individual may have contributed only one little item of knowledge and then transferred his energies to other spheres. In other instances, the contribution of one individual may have extended over a period of years, indeed over a whole life time. There are others again who have built up large schools of vitamin research and have carried out elaborate programmes of investigation as leaders of teams of specialists. There are also industrial organisations, who have used their research laboratories and development departments for the improvement of manufacturing processes and testing techniques, and who have often made discoveries of outstanding importance.

Of those who have thus contributed to the advance of vitamin science, only a few can be referred to specifically. Mention has already been made of Dr C Eijkman, the pioneer in the field, who showed that beriberi was a deficiency disease caused by the absence from the diet of the factor we now call aneurine or thiamine, in 1930, a few months before his death, Eijkman was awarded the Nobel prize in recognition of his discoveries. He shared it with another pioneer of vitamin science, Sir Frederick Gowland Hopkins, one-time President of the Royal Society, who showed that the growth rate of rats maintained on a purified diet rapidly declined until the animals died, and that the addition of milk to the diet, in amounts that supplied only negligible amounts of protein and carbohydrate checked the fall in growth and enabled the animals to live and thrive. Hopkins' classical experiments have been repeated with appropriate modifications, by all subsequent investigators who have studied growth factors for higher animals. Another name closely associated with vitamin science is that of Casimir Funk, a Pole working at the Lister Institute, London, who in 1912 coined the word "vitamine" to describe the then

## INTRODUCTION

mysterious factors responsible for curing deficiency diseases. He it was who brought Eijkman's work to the notice of a larger scientific public and who predicted the existence of other deficiency diseases. Thus prediction was fulfilled within a few years when Dr J. Goldberger proved contrary to all previous opinion that pellagra was a deficiency disease. Goldberger was appointed in 1913 by the U.S. Bureau of Public Health to investigate the outbreak of pellagra in the Southern States of the U.S.A. He was struck by the fact that nurses and doctors attending pellagra patients in an asylum never contracted the disease and came to the conclusion that it was due to the particular diet on which the patients invariably poor had to maintain themselves. He proved his point first by adding milk and eggs to an orphanage diet and thereby eliminating pellagra from that particular institution and secondly by giving them diets consisting solely of deficient foods. This diet was in fact similar to that eaten regularly by thousands of poor farmers in the areas in which pellagra was endemic.

The years immediately following the work of these pioneers saw few developments of scientific importance although the empirical knowledge gained as the result of their labours was used in various parts of the world in the prevention and cure of both beriberi and pellagra. In 1916 however events began to move more rapidly and in that year pure crystalline aneurine was isolated. It was synthesised ten years later by Prof. R. R. Williams of Columbia University in collaboration with a group of chemists employed by Merck & Co. Rahway. A year earlier in 1935 riboflavin had been synthesised independently by Prof. R. Kuhn of the University of Heidelberg and Prof. P. Karrer of the University of Zurich and in 1937 nicotinic acid known since 1867 as a chemical of no particular importance was recognised as the pellagra preventive factor. Pyridoxine was characterised as a vitamin in 1938 and in the following year was synthesised independently by Prof. R. Kuhn and the Merck workers who had already achieved fame in connection with the synthesis of aneurine and who were to enhance their reputation still further by the successful synthesis of other vitamins. Shortly afterwards they collaborated with Prof. R. J. Williams then of Oregon State College and later of the University of Texas and brother of Prof. R. R. Williams in studying the constitution of pantothenic acid which they synthesised in 1940. This was followed by an investigation into the structure of biotin in collaboration with Prof. V. du Vigneaud of Cornell University. They synthesised biotin in 1943. Another name associated with biotin is that of Prof. F. Kögl of the University of Utrecht who isolated it from egg yolk in 1936 studied its constitution under particularly difficult conditions during the



German occupation of Holland and suggested a formula which he subsequently admitted, in the light of du Vigneaud's results, to be erroneous. Actually, Kogl's biotin is probably different from, although closely related to, du Vigneaud's, and what is believed to be the correct formula for egg yolk biotin was suggested by Kogl in 1944. Folic acid was isolated in 1941 from spinach leaves by Prof R J Williams, of pantothenic acid fame, and Dr E E Snell, who had already carried out a large amount of microbiological work in connection with members of the vitamin B complex. Similar substances were subsequently isolated from yeast and liver, and synthesised in 1946 by research chemists employed by the Lederle Labs Inc, Pearl River, New York, and the American Cyanamid Co, Bound Brook, New Jersey. The latest member of the vitamin B complex to be discovered, vitamin B<sub>12</sub>, was obtained in crystalline form in 1948 by the Merck group already referred to and by Dr E Lester Smith of Glaxo Laboratories Ltd, Greenford.

This is the story in briefest outline of the vitamin B complex. In the chapters that follow, details are given of the isolation, chemistry, biological properties and functions of each vitamin in turn, and in a final chapter an attempt is made to show the close biological relationship that exists between these substances by indicating the different stages of metabolism in which each participates.

## CHAPTER II

# ANEURIN (THIAMINE)

---

### I HISTORICAL

#### Beriberi

The existence in foodstuffs of substances essential for the proper functioning of the animal organism was first recognised by C. Eijkman and H. Grijns, two Dutch medical officers working in the Dutch East Indies. They suggested that beriberi was not caused by a toxic principle or by infection as had been supposed, but by a nutritional deficiency.


#### Discovery of the Vitamins

In 1911 C. Eijkman<sup>1</sup> published a series of papers describing the isolation from rice polishings of a substance capable of curing beriberi. In the following year he wrote<sup>2</sup> 'The deficient substances which are of the nature of organic bases we will call *vitamines*,<sup>3</sup> and we will speak of a beriberi or scurvy *vitamine* which means a substance preventing the special disease. The word *vitamine* remained in use until 1920 by which time it had become clear that only a few of these substances were organic bases. It was then proposed<sup>3</sup> that the name should be changed to *vitamin* with the implication that a vitamin is a neutral substance of undefined composition.

Although several of the vitamins contain nitrogen atoms and are basic, only one or two contain the amino group  $\text{NH}_2$  characteristic of a primary amine. One of these is vitamin  $\text{B}_1$  now known in this country as aneurine hydrochloride and in America as thiamine hydrochloride. At first it was called vitamin B and it is the absence of this substance that is responsible for beriberi which, as already mentioned above, was the first deficiency disease to be recognised as such. The condition is due to the use of polished rice as a major article of diet, the bulk of the vitamin being contained in the outer layers of the grain which are removed in the processing. The resulting rice polishings have a marked curative effect on the course of the disease and an aqueous extract possesses similar activity.


# ANEURINE (THIAMINE)

The formula now known to be correct



and subsequently proposed by R R Williams<sup>13</sup> takes into account the revised formula for the pyrimidine half. The point of attachment to the pyrimidine ring was settled by the position of the sulphonic group in the sulphite cleavage product whilst the point of attachment to the thiazole ring was established by titration experiments.

When aneurine chloride was titrated with alkali<sup>14</sup> one mole was taken up in a normal manner and therefore the pH failed to increase except transitorily almost immediately recovering its former value. This continued until a total of three moles of alkali had been added when a steady rise in pH occurred. This curious and unexpected behaviour was interpreted to indicate an intramolecular rearrangement. It was found<sup>15</sup> that 5  $\beta$  hydroxyethyl 4 methyl thiazole methiodide behaved similarly on titration whence it was concluded that aneurine chloride was also a quaternary ammonium salt. The explanation of the titration results is that the thiazole ring is opened according to the following series of changes



(where P = the pyrimidine ring). The third molecule of sodium hydroxide is required to neutralise the mercapto group.

## References to Section 3

- 1 R R Williams Vitamin B<sub>1</sub> and its use in Medicine Macmillan 1938
- 2 R R Williams *J Amer Chem Soc* 1935 57, 229 R R Williams R E Waterman J C Keresztesy and E R Buchman *ibid* 536
- 3 R R Williams E R Buchman and A E Ruehle *ibid* 1093
- 4 R R Williams *ibid* 1936 58 1063 J K Cline R R Williams A E Ruehle and R E Waterman *ibid* 1937 59, 530
- 5 R R Williams A E Ruehle and J Finkelstein *ibid* 526

## SYNTHESIS

- 6 J K Cline R R Williams and J Finkelstein *ibid* 1952
- 7 F R Buchman R R Williams and J C Keresztesy *J Amer Chem Soc* 1935 57, 1840
- 8 M Wohrmann *Annalen* 1990 259, 299
- 9 A Windaus R Tschesche and R Grewe *Z physiol Chem* 1934 228, 27
- 10 H T Clarke and S Gurin *J Amer Chem Soc* 1935 57, 1876
- 11 A Windaus R Tschesche and R Grewe *Z physiol Chem* 1935 237, 95
- 12 I G BP 456735
- 13 R R Williams *J Amer Chem Soc* 1936 58, 1063
- 14 R R Williams and A F Ruchle *ibid* 1935 57, 1856
- 15 E R Buchman R R Williams and J C Keresztesy *ibid* 1849

## 4 SYNTHESIS OF ANEURINE

The complete synthesis of aneurine was first announced by R R Williams and his co workers in America but important contributions were made by A R Todd and his collaborators in England by A Windaus and his school in Germany and by K Makino and T Imu in Japan. The subject is one of some complexity and papers of fundamental importance appeared within a few weeks or even days of one another so that it is well nigh impossible to give a strictly chronological account of the course of events.


The matter is further complicated by the policy of the German workers of withholding publication until patent protection had been adequately effected. Thus H Hörlein<sup>1</sup> states the priority of the synthesis of the product undoubtedly rests with Andersag and Westphal. This may very well be true for the I G began to file patents as early as 1935. Since however the paper by H Andersag and K Westphal<sup>2</sup> was not published until 1937 over a year after Williams publication this belated claim to priority seems rather like an attempt to secure the academic cake as well as the economic half penny!

It will simplify matters if the method of synthesis adopted by each group of workers is discussed in turn.


### American Method

R R Williams and J K Cline<sup>3</sup> condensed ethyl  $\alpha$  formyl  $\beta$  ethoxy propionate with acetamidine and converted the resulting 5 ethoxymethyl 4 hydroxy 2 methyl pyrimidine into 4 amino 5-bromomethyl 2 methyl pyrimidine by the following series of reactions

# ANEURINE (THIAMINE)



The final product, in the form of its hydrobromide, was reacted with 5-β-hydroxyethyl-4-methyl-thiazole, obtained by E. R. Buchman<sup>6</sup> from α-aceto-γ-butyrolactone by the following series of reactions:



Aneurine bromide hydrobromide was formed and this was converted into the chloride hydrochloride by shaking with silver chloride. Attempts to prepare the pyrimidine half by other methods<sup>5</sup> such as by Curtius, Hoffman or Loessen degradations of the appropriate derivatives of 4-hydroxy-2-methyl-pyrimidine-5-acetic acid (obtained from hydroxymethyl malonic ester) were not very successful.

The method of Williams *et al.* has been adopted for the large scale manufacture of vitamin B<sub>1</sub> by Merck & Co., Rahway, and a large number of patents have been filed in this country, in the U.S.A. and elsewhere to protect this process. The first group<sup>6</sup> describes the preparation of halogenated acetopropyl alcohols, esters and similar derivatives, which are required in the synthesis of the thiazole half, by halogenation of acetopropyl alcohol or the appropriate derivative or by hydrolysis and decarboxylation of halogenated α-aceto-γ-butyrolactone. The second group,<sup>7</sup> comprising a single patent, protects the condensation of halogenated acetopropyl alcohol with thioformamide to give 4-alkyl-5-hydroxyalkyl thiazoles. The third group<sup>8</sup> covers the condensation of acetamidine with α-formyl-β-ethoxypropionic ester to give 5-ethoxymethyl-4-hydroxy-2-methyl-pyrimidine, and the preparation from this compound of the

# SYNTHESIS


corresponding 4 halogeno derivatives and thence the 4 amino compound. The preparation of the 2 methyl 5 halogenomethyl 4 amino pyrimidine is also described.

The last group<sup>9</sup> covers the formation of aneurine by condensation of 5  $\beta$  hydroxyethyl 4 methyl thiazole with 4 amino 5 bromomethyl 2 methyl pyrimidine or with 5 alkoxymethyl 2 methyl 4 amino pyrimidine or with (4 amino 2 methyl pyrimidyl 5) bromoacetic acid.

5  $\beta$  Hydroxyethyl 4 methylthiazole has also been prepared by reducing ethyl 4 methylthiazole 5 acetate with lithium aluminium hydride the ester being prepared by the reaction of ethyl  $\alpha$  bromo laevulinate with thioformamide.<sup>10</sup>

## British Method

The method of synthesis discovered by Todd *et al* differs in one important respect from that of Williams: the thiazole ring is formed as the last stage of the synthesis being produced by the action of 3 aceto 3-chloro propyl alcohol on the appropriate thioformamido methyl pyrimidine. The preparation of such thioformamido compounds was first described by Todd *et al*<sup>10</sup> who showed that 5 amino pyrimidine yielded the corresponding thioformyl derivative on treatment with a solution of potassium dithioformate: the reaction does not occur with 2, 4 or 6-amino pyrimidine. By reacting 4 amino 6-ethyl 5 thioformamido pyrimidine with 3 aceto 3-chloro propyl alcohol an isomer of aneurine was obtained identical with the compound represented by Williams' first formula (page 13). The fact that it was biologically inactive helped towards the rejection of this formula. Potassium dithioformate was subsequently used by A. R. Todd and F. Bergel<sup>11</sup> to prepare aneurine itself: the complete series of reactions being as follows:




In an alternative process acetamidine was coupled not with ethoxymethylene-cyanacetic ester but with ethoxymethylene-malonic


# ANEURINE (THIAMINE)

ester. This gave the 5-carboxylic ester which was converted to the corresponding amide, and thence to the nitrile.


The use of potassium dithioformate was patented by Hoffmann-La Roche,<sup>12</sup> who also patented a number of other reactions enabling them to synthesise aneurine by a unique process which was used for its large-scale manufacture. The requisite pyrimidine compounds were synthesised<sup>13</sup> from acetimino-ethyl ether hydrochloride and aminomethylene malondinitrile, the preparation of the latter being described in a later patent.<sup>14</sup>



The product was reduced, as in Todd's process, to the aminomethyl compound, which was then converted<sup>12</sup> by treatment with potassium dithioformate into the thioformamidomethyl derivative. This was treated,<sup>15</sup> not with 3-aceto-3-halogenopropyl alcohols or their esters, but with 3-chloro-2-ethoxy-2-methyl-tetrahydrofuran to yield aneurine. The relation between the two types of compound is evident from the following formulae :




The preparation of this furane derivative, due to Klingenfuss, was covered in another patent<sup>16</sup> A variant of this process, due to Chinoin,<sup>16a</sup> comprises the treatment of 2:3-dihalogeno-2-methyl-tetrahydrofuran with an agent capable of removing hydrogen chloride and then condensing the product with the thioformamidomethyl compound. The constitution of halogenated acetopropyl alcohols has been the subject of extensive investigation, and J. R. Stevens and G. A. Stein<sup>17</sup> showed that halogenated acetopropyl alcohols, more especially the bromo-derivative, exist in the form of a dimeride of the formula :



It is thus the acetochloropropyl ether of 3-chloro-1-hydroxy-1-methyl-tetrahydrofuran. The preparation of this compound has been patented.<sup>18</sup>

# SYNTHESIS

Roche Products patented the preparation of keto alcohol acetates such as 3 aceto propyl acetate by heating lactones such as  $\alpha$  aceto butyrolactone with glacial acetic acid in presence of anhydrous sodium acetate <sup>19</sup>




though the conversion can be effected by means of sulphuric or phosphoric acid <sup>20</sup> The latter procedure can also be used for the formation of the 3-chloro or 3-bromo acetates Roche Products also protected the bromination of 3 acetopropyl acetate by the action of sulphuryl chloride in presence of an alkali metal bromide at 60° C with silica as catalyst <sup>21</sup> and also <sup>22</sup> by reacting 3 acetopropyl alcohol or its acetate with (a) a dihalomide of a salt of pyridine or quinoline (b) bromine and a salt of pyridine and an alkali metal bromide The crude products obtained from these reactions can be used for the preparation of ineurine directly by condensation with 4-amino-2-methyl-5-thioformamido-methyl pyrimidine <sup>23</sup>

The preparation of 5-alkoxymethyl-4-amino-2-methyl pyrimidines by reacting 4-amino-5-amino-methyl-2-methyl pyrimidine with an alkyl nitrite has also been patented <sup>24</sup>

## German Method


The method of synthesis devised by the German workers are described mainly in patent specifications The first publication however was a paper by R Grew <sup>25</sup> describing the condensation of acetamide with ethoxymethylene malondinitrile to give 4-amino-5-cyano-2-methyl pyrimidine which on hydrogenation with a palladium charcoal catalyst gave the corresponding 5-aminomethyl compound



He stated that Prof Hörlein had informed him that Andersag and Westphal had already synthesised the vitamin in the laboratories of the I G Farbenindustrie and that as a result he had decided to abandon his own investigations A publication by H Andersag and K Westphal <sup>26</sup> appeared in 1937 in this paper they described the



synthesis of the pyrimidine half from acetamidine and formyl succinic ester as follows




They synthesised the thiazole half by condensing 3 bromo 3 aceto propyl acetate with barium thiocyanate to give 2 hydroxy 5  $\beta$  hydroxyethyl 4 methyl thiazole from which the hydroxyl group was removed by chlorination followed by reduction. The product was condensed with 4 amino 5 bromomethyl 2 methyl pyrimidine giving aneurine bromide hydrobromide.


The I G patents based on this work cover not only the direct coupling of the thiazole half and the pyrimidine half but also the preparation of aneurine from the thioformamidomethyl pyrimidine. One group of patents<sup>27</sup> covers the preparation of pyrimidine compounds by combining acetamidine with a great variety of formyl- and alkoxymethylene acetic esters and acetonitriles substituted by a group convertible into the aminomethyl group.

The preparation of the thiazole compound by Andersag and Westphal's barium thiocyanate method was the subject of another patent<sup>28</sup> which mentions incidentally the preparation of the necessary 3 bromo 3 acetopropyl alcohol esters. The final stage of the synthesis was described in another patent<sup>29</sup> which includes both the direct coupling of the two halves and the condensation of 4 amino 2 methyl 5 thioformamidomethyl pyrimidine with  $\gamma$  aceto- $\gamma$ -bromopropyl benzoate.

A variant of the I G method of preparing the pyrimidine half of the molecule was described by Chinoin<sup>30</sup> who condensed alkoxymethylene cyanoacetic esters with a base such as acetamidine to form the intermediate  $\alpha$  cyano  $\beta$  amidino acrylic acid which on heating with water or acidulated water yielded the amino pyrimidine.



Another variant is provided by the following series of reactions <sup>31</sup>




#### References to Section 4

- 1 H Hürlein *Z physiol Chem* 1938 233, 82
- 2 I Andersag and K Westphal *Ber* 1937 70, 2035
- 3 R R Williams and J K Cline *J Amer Chem Soc* 1936 58, 1504
- 4 J R Buchman *ibid* 1936 58, 1803
- 5 J K Cline R R Williams and J Linkelstein *ibid* 1937 59, 1052
- 6 Research Corporation BP 472396 490571, USP 2216574 2223885 2218349 2218350
- 7 Research Corporation BP 472459
- 8 Research Corporation BP 496738 522531
- 9 Research Corporation BP 496726 507918, USP 2166233
- 9a A J Iusebi L V Brown and L R Cerecedo *J Amer Chem Soc* 1949 71, 2931
- 10 A R Todd I Bergel and Karimullah *J Chem Soc* 1936, 1557
- 11 A R Todd and I Bergel *ibid* 1937 364
- 12 Hoffmann La Roche BP 478993
- 13 Hoffmann La Roche BP 486414
- 14 Hoffmann La Roche BP 542403
- 15 Hoffmann La Roche BP 500519
- 16 Hoffmann La Roche BP 496801
- 16a Chascom BP 615404

# ANEURINE (THIAMINE)

synthesis of the pyrimidine half from acetamidine and formyl succinic ester as follows




They synthesised the thiazole half by condensing 3 bromo-3 aceto-propyl acetate with barium thiocyanate to give 2 hydroxy-5-β-hydroxyethyl-4 methyl-thiazole from which the hydroxyl group was removed by chlorination, followed by reduction. The product was condensed with 4 amino-5-bromomethyl 2 methyl-pyrimidine, giving aneurine bromide hydrobromide


The I G patents based on this work cover, not only the direct coupling of the thiazole half and the pyrimidine half, but also the preparation of aneurine from the thioformamidomethyl pyrimidine. One group of patents<sup>27</sup> covers the preparation of pyrimidine compounds by combining acetamidine with a great variety of formyl- and alkoxymethylene-acetic esters and acetonitriles substituted by a group convertible into the aminomethyl group

The preparation of the thiazole compound by Andersag and Westphal's barium thiocyanate method was the subject of another patent,<sup>28</sup> which mentions incidentally the preparation of the necessary 3-bromo 3 acetopropyl alcohol esters. The final stage of the synthesis was described in another patent,<sup>29</sup> which includes both the direct coupling of the two halves and the condensation of 4 amino 2 methyl-5-thioformamidomethyl pyrimidine with γ aceto-γ-bromopropyl benzoate

A variant of the I G method of preparing the pyrimidine half of the molecule was described by Chinoi,<sup>30</sup> who condensed alkoxymethylene cyanoacetic esters with a base such as acetamidine to form the intermediate α cyano β amidino acrylic acid which, on heating with water or acidulated water, yielded the amino pyrimidine



Another variation is provided by the following series of reactions:



#### References to Section 4

- 1 H Hörlein *Z physiol Chem* 1938 253, 82
- 2 J Andersag and K Westphal *Ber* 1937 70, 2035
- 3 R. R. Williams and J. K. Cline *J Amer Chem Soc* 1936 58, 1504
- 4 F. R. Buchman *ibid* 1936 58, 1803
- 5 J. K. Cline R. R. Williams and J. Linkelstein *ibid* 1937 59, 1052
- 6 Research Corporation BP 472396 490571 USP 2216574
- 7 Research Corporation BP 472459
- 8 Research Corporation BP 496738 522531
- 9 Research Corporation BP 496726 507918 USP 2166233
- 9a A. J. Lusebi E. V. Brown and L. R. Cerecedo *J Amer Chem Soc*, 1949 71, 2931
- 10 A. R. Todd I. Bergel and Karimullah *J Chem Soc* 1936 1557
- 11 A. R. Todd and F. Bergel *ibid* 1937, 364
- 12 Hoffmann La Roche BP 478993
- 13 Hoffmann La Roche BP 486414
- 14 Hoffmann La Roche BP 542403
- 15 Hoffmann La Roche BP 500519
- 16 Hoffmann La Roche BP 496801
- 16a Chunoim BP 615404

## ANEURINE (THIAMINE)

- 17 J R Stevens and G A Stein *J Amer Chem Soc*, 1940 **62**, 1045
- 18 Research Corporation B P 547664
- 19 Roche Products B P 549306
- 20 I C I, B P 552617
- 21 Roche Products B P 550197
- 22 Roche Products B P 554428, U S P 2397333
- 23 Roche Products, B P 559106
- 24 Roche Products, B P 588806
- 25 R Grewe *Z physiol Chem* 1936, **242**, 89
- 26 H Andersag and K Westphal *Ber* 1937, **70**, 2035
- 27 I G B P 473193, 475559, 475507
- 28 I G B P 456751
- 29 I G B P 471416
- 30 Chinoim B P 538743
- 31 G V Tschelintzev and Z V Benevolevskaja *J Gen Chem Russ* 1944 **14**, 1142

## 5. PROPERTIES OF ANEURINE

Aneurine hydrochloride is 3 (4' amino 2' methyl pyrimidyl 5'-methyl) 5  $\beta$  hydroxyethyl 4 methyl thiazolium chloride hydrochloride. It forms white monoclinic plates generally in rosette like clusters. It is said to be odourless when pure, but generally has a slight smell of bran. It is readily soluble in water (ca 1 g per ml) less soluble in methyl alcohol 95 % ethyl alcohol (1 g per 100 ml) and absolute ethyl alcohol (1 g in 315 ml), and insoluble in ether, acetone, chloroform and benzene. It crystallises from aqueous alcohol as the hemihydrate m.p. 248° to 250° C with decomposition. The crystals were originally described as monoclinic<sup>1</sup> but subsequently three different crystalline forms were described<sup>2</sup>. Form I is orthorhombic and form II monoclinic and the latter is converted into the former in solutions up to 80° C. The reverse change occurs in the solid phase at 182° C. Form III has the same optical properties as form II, but the crystals have a different shape, this is the least stable form.

Aneurine hydrochloride has a characteristic absorption spectrum in 0.005 N hydrochloric acid with a maximum at 247 m $\mu$  at which wave length  $E_{1\%}^{1\text{cm}}$  is 425 to 450. It is optically inactive.

When a solution of aneurine hydrochloride is allowed to stand for two or three days with a solution of sodium bisulphite it gives a quantitative yield of the sparingly soluble 4 amino 2 methyl pyrimidyl methane sulphononic acid. When a solution of aneurine hydro

## STABILITY

phase. This is the basis of Peters' formaldehyde test (see page 27). When a slightly alkaline solution of aneurine is treated with potassium formaldehyde solution, thiochrome is formed and the solution acquires a blue fluorescence extractable into isobutyl alcohol. This reaction also forms the basis of a method of estimating aneurine (see page 38).

Aneurine hydrochloride was included in the Third Addendum (1941) to the British Pharmacopoeia 1932 which laid down tests for identity and purity. Each gram contains 370,000 international units. The monograph was slightly modified in the Seventh Addendum (1945) and revised in the British Pharmacopoeia 1948. The prophylactic and therapeutic doses are given as 1 to 3 m<sup>g</sup> and 10 to 30 mg daily respectively. Injection of aneurine and tablets of aneurine were made official in 1948.

### *References to Section 5*

- 1 J. D. Bernal and D. Crowfoot, *Nature* 1933 131 911
- 2 Armour Research Foundation *Anal. Chem.* 1949 20 683

## 6 STABILITY OF ANEURINE

Aneurine hydrochloride is stable in the dry state and acid solutions can be stored for some time without loss of activity. It is unstable in neutral or alkaline solution, however, especially when exposed to air. Gastric juice, which is of course acid, has little or no effect on aneurine, but when antacids have been used, some destruction may occur.<sup>1</sup> Gastric juice from patients with achlorhydria did not cause destruction, but bile and duodenal pancreatic juice, which are slightly alkaline, rapidly destroyed aneurine.

According to L. T. H. Iversen,<sup>2</sup> aneurine is completely destroyed in fifteen minutes at 100°C at pH 9, whilst at pH 8, 7, 6, 5, 4, and 3 the proportions destroyed within one hour are 100, 67.8, 53.4, 40.0, 20.3, and 16.0 % respectively, and within three hours 100, 96.4, 86.3, 67.4, 44.5, and 29.1 % respectively. No loss of activity occurred in 1 % hydrochloric acid solution in seven hours. The stability is not solely determined by the pH of the solution, however, but depends on the nature of the buffer employed. For Beadle *et al.*<sup>3</sup> showed that on heating a solution of aneurine of pH 5.4 for one hour at 100°C, 100 % destruction occurred with a borate buffer, 10 % with an acetate buffer, 3 % with a phosphate buffer, and 57 % in an unbuffered solution. In general, the destruction increased as the pH increased. The protective action of the phosphate buffer was confirmed by R. G. Booth,<sup>4</sup> who showed that less vitamin was lost in phosphate buffer than in phthalate

buffer, whilst Myrbäck *et al* <sup>5</sup> showed that the pyrophosphate ion had a marked stabilising effect at pH 2 to 6.5, the optimal pH for stability on sterilisation was 6.5

K T H Farrer <sup>6</sup> subsequently showed that a linear relationship existed between the reaction velocity of the destruction of aneurine and the hydrogen ion concentration for any given buffer in the pH range 3 to 8. The relationship varied for each buffer, however, and the slope of the curve changed as the ionic constitution of the solution altered, where this was accompanied by a large change in pH there was a correspondingly large change in the slope of the curve obtained by plotting pH against the logarithm of the velocity coefficient. The reaction velocity increased as the pH rose. R G Booth <sup>4</sup> also showed that copper (2 p.p.m.) catalysed the destruction of aneurine, whereas iron, aluminium, zinc and tin had no effect. According to K T H Farrer, <sup>7</sup> however, the effect of copper is variable and, whilst destruction is more rapid in presence of copper in phosphate or phosphate phthalate solutions, the rate of destruction may actually be decreased by the addition of copper to phosphate solutions containing tartrate, citrate or glycine. Arising out of this work, it was noticed that aneurine was destroyed more slowly in buffer solutions considerably more dilute than those used in earlier experiments, and further investigation showed <sup>8</sup> that in phosphate buffer the concentration of buffer salts affected the rate of destruction of aneurine below pH 6, the addition of citric acid eliminated this effect, whereas phthalate enhanced it. The rate of destruction was also dependent on the initial concentration of aneurine, being higher the more concentrated the solution, irrespective of the nature of the buffer solution <sup>8a</sup>

### Stabilisation of Aneurine Solutions

F C McIntire and D V Frost <sup>9</sup> claimed that aneurine solutions could be stabilised by  $\alpha$ - or  $\beta$  amino acids, and that the effect was lost when the amino group was acetylated or the amino acid was converted into a betaine, but, rather surprisingly, not when the carboxyl group was converted into an amino group or when one or two methyl groups were introduced into the amino group. Removal of the amino group farther from the carboxyl group than the  $\beta$  position gave compounds that promoted the destruction of aneurine although lysine was said to be as effective as glycine. Anthranilic acid had a protective action, *m* aminobenzoic acid was without effect, whilst *p* aminobenzoic acid had a destructive effect. Taurine, benzylamine, diallylamine and tri-*n* butylamine were protective and all other amines tested proved to be destructive. Nicotinic acid and nicotinamide were also destructive.

## Thiaminase


C. A. Elvehjem and his co-workers appear to have been the first to correlate the effect of feeding raw fish with aneurine deficiency. They observed that the addition of 25% of raw carp to a diet adequate for the chick cured vitamin B<sub>1</sub> deficiency and that incubation of aneurine with raw carp in the dark for fifteen minutes resulted in a loss of 5 to 100% of the biological activity. C. A. Evans *et al.* showed that the so-called Chastek paralysis of foxes caused by feeding 10% or more of fresh whole fish in the diet and of which the characteristic symptoms are injuries to the liver and brain could be prevented by administration of 10 mg. of aneurine per day. The paralysis was caused by feeding the thin scale skeleton and heads but not the muscle tissue of carp. The viscera were particularly rich in the responsible factor which was shown to be a protein probably enzymic in character. The same conclusion was reached by P. S. Owen and J. W. Ferrebee who showed that the factor was destroyed by cooking. The enzymic nature of the factor was confirmed by R. R. Serlock and R. L. Goodland who showed that its destructive effect on the vitamin was inhibited by certain inorganic substances *e.g.* copper, zinc and iron salts, potassium cyanide, sodium fluoride and sodium sulphate by certain organic compounds such as iodoacetic acid and cysteine known to inhibit enzyme and most interesting of all by a number of thiazol and pyrimidine derivatives related to aneurine. These included the 3-aminobenzyl 3- $\beta$ -aminoethyl 3- $\beta$ -thiazolium chloride and the 5-bromomethyl 5-ethoxymethyl and 5-methylene sulphonic acid derivatives of 4-amino-2-methylpyrimidine 3-*o*-aminobenzyl 4-methylthiazolium chloride actually competed with aneurine for the enzyme of the Chastek principle. Other thiazole compounds of this type were the benzyl *o*-m and *p*-nitrobenzyl and the *o*-m and *p*-aminobenzyl quaternary ammonium salts of 2 and 4-methyl and 2,4-dimethyl 5- $\beta$ -hydroxyethyl thiazole 3-*m*-Amino benzyl 4-methylthiazolium chloride however accelerated the destruction of aneurine by the enzyme so did *m*-nitraniline and *m*-amino benzoic acid. This result was shown to be due to combination of the amino group with the 5-methylene group of the pyrimidine moiety formed by destruction of the aneurine since N (6-amino-2-methylpyrimidyl 5-methyl) *m*-nitraniline was isolated from the product formed by inactivation in the presence of *m*-nitraniline.

The enzyme was shown to be present in raw herring as well as in carp, feeding either to cats resulted in the onset of vitamin B<sub>1</sub> deficiency with convulsions in twenty three to forty days followed by death. The enzyme to which the name thiaminase has been given



## ANEURINE (THIAMINE)

also appears to be present in raw clams <sup>16</sup> According to L Ó Krampitz and D W Woolley,<sup>17</sup> the enzyme consists of a heat-labile, non-dialysable portion and a heat stable dialysable portion. It appears to effect a hydrolytic cleavage of the aneurine molecule into the thiazole and pyrimidine halves.<sup>18</sup>



The presence of thiaminase in raw carp tissues and blood was confirmed by K Bhagvat and P Devi,<sup>19</sup> who also demonstrated the existence of another anti-aneurine factor in certain cereals and oil seeds. This second factor was soluble in water, but not in salt solutions, and could be extracted from cereals by means of a water-chloroform mixture. It was stated not to be enzymic in nature, but it could be separated by dialysis into a heat labile, non dialysable part and a heat-stable, dialysable part, both of which inactivated aneurine. The inactivated aneurine could be utilised by mosquito larvae, but not by rats or pigeons.

Thiaminase is also present in the tissues of shrimps and some mussels, but it appears to be absent from crabs and some salt-water fish.<sup>20</sup>

The existence of another natural product capable of producing vitamin B<sub>1</sub> deficiency on a vitamin B<sub>1</sub> rich diet was reported by Weswig *et al*,<sup>21</sup> who showed that bracken, which causes "fern poisoning" in cattle, also poisons rats when given to the extent of 40 % of the diet, the animals died after twenty days with symptoms of vitamin B<sub>1</sub> deficiency. Animals given aneurine recovered. Bracken inactivated aneurine *in vitro* and so to a smaller extent did the faeces of rats fed on a diet containing bracken.<sup>21a</sup>

### Stability of Cocarboxylase

Aneurine pyrophosphate or cocarboxylase (see page 93) is the form in which aneurine functions as a co-enzyme. It is somewhat more stable than aneurine when the two are compared at the same

# STABILITY

$\Delta H$  value is more sensitive to change of  $\Delta H^\circ$ . Between 3.5 and 7.0 the rate of destruction is proportional to the logarithm of the velocity constant for the destruction of coenzyme minus the logarithm of the concentration for the destruction of aneurine at any given  $\Delta H$ . The rate of thermal destruction like that of aneurine is higher the greater the initial concentration.

## References to Section 6

- 1 D Melnick W D Iversen and H Field *J Biol Chem* 1941 128 49
- 2 K T H Farrer *J Proc Austral Chem Inst* 1941 8 113
- 3 B W Howell D A Greenwood and H R Kribbll *J Biol Chem* 1943 148 31 342
- 4 R G Borth *Indian J* 1943 37, 515
- 5 K Myrnes I Vallin and B Kihlberg *Svensk Kem Tidskr* 1942 64 97
- 6 K T H Farrer *Indian J* 1945 39, 128
- 7 K T H Farrer *ibid* 1947 41, 162
- 8 K T H Farrer *ibid* 1947 41, 162
- 9 J C McIntire and D A Iversen *J Amer Chem Soc* 1944 66, 1317
- 10 I H Spitzer A I Coombes C A Elvehjem and W Wisnicky *Proc Soc Exp Biol Med* 1941 48 11
- 11 C A Iversen W J Carlson and R C Green *Amer J Path* 1942 18 79
- 12 R G Green W J Carlson and C A Iversen *J Nutrition* 1942 23 165
- 13 R R Sealock A H Livermore and C A Iversen *J Amer Chem Soc* 1943 65 215
- 14 P S Owen and J W Letteblee *New England J Med* 1916 162, 267
- 15 R R Sealock and R I Gaudland *J Amer Chem Soc* 1944 66, 507
- 16 A H Livermore and R R Sealock *J Biol Chem* 1947 167, 699
- 17 R R Sealock and A H Livermore *ibid* 1947 177, 553
- 18 R R Sealock and A C Davis *ibid* 1957 177, 553
- 19 D C Smith and L M Prout *Proc Soc Exp Biol Med* 1944 66, 1
- 20 D Melnick M Hochberg and B L Ober *J Nutrition* 1945 30, 61
- 21 L O Krampitz and D W Woolley *J Biol Chem* 1944 152, 9
- 22 R R Sealock and A H Livermore *ibid* 1944 156, 379
- 23 K Bhagvat and P Devi *Indian J Med Res* 1944 32, 123 131
- 24 P Jacobsohn and M D Azevedo *Arch Biochem* 1947 14, 83
- 25 P H Weswig A M Freed and J R Haag *J Biol Chem* 1946 165, 737
- 26 B Thomas and H F Walker *J Soc Chem Ind* 1949 68, 6
- 27 K T H Farrer *Biochem J* 1945 38, 261

## 7. BIOLOGICAL ESTIMATION OF ANEURINE

**Polyneuritic Pigeons**

A few of the methods used in the estimation of vitamin B<sub>1</sub> in natural substances have been referred to above when discussing the isolation of the vitamin. The prevention or cure of polyneuritis in ricebirds was used by B C P Jansen and W F Donath,<sup>1</sup> whilst Edie *et al*,<sup>2</sup> H W Kinnersley and R A Peters,<sup>3</sup> and K H Coward *et al*<sup>4</sup> used polyneuritic pigeons, comparing the amount of test substance required to cure the symptoms in one group of birds with the amount of a standard preparation required to cure those in another group. Alternatively the minimum amount of substance required to maintain the weight of a standard bird on a polished rice diet was sometimes estimated, as in Seidell's method.<sup>5</sup> K H Coward and B G E Morgan<sup>6</sup> found that there was a direct relationship between the dose and the percentage of birds cured, but not between the dose and the duration of cure thus confirming the earlier work of Kinnersley and Peters.

**Catatorulin Test**

An interesting variant of the pigeon method is the catatorulin test, proposed by Peters *et al*,<sup>7</sup> in which the oxygen uptake of avitaminous pigeons' brain was measured before and after the addition of the test solution.

**Chick Method**

A method of estimating aneurine, in which chicks are used, was described by T H Jukes and H Heitman.<sup>8</sup> The basal diet consisted of polished rice, fish meal and autoclaved yeast, and the results were evaluated from a curve obtained by plotting the 'polyneuritic mortality index', i.e. the length of the test period (twenty eight days) minus the number of days' survival, against the amounts of aneurine added to the diet. Chicks required 135 to 150  $\mu\text{g}$  of aneurine per 100 g of diet to maintain normal health.

**Rat Weight Test**

The pigeon has been supplanted as a test animal by the rat. H C Sherman and A Spohn<sup>9</sup> devised a method that was in general use for some years and is similar in principle to that of Guha and Drummond<sup>10</sup> already referred to. The success of the method depends to a considerable extent on the selection of the experimental animals. An inbred strain is preferred, many would say is essential, and the groups of

animals used for testing the unknown sample and the standard are made up of pairs of litter mates of the same sex and of approximately the same weight so that a fair parallel difference in response due to variation in animal response is reduced. The quantity of aneurine fed is such that the rate of growth will be maximal. It is the normal practice to give the test material at a level of three dose levels and the standard at two levels.

Sherrington and Spink originally recommended a test period of eight weeks subsequently reduced to four weeks whilst K. H. Coward<sup>11</sup> claimed that satisfactory results were obtained after only two weeks and J. W. Smith<sup>13</sup> and F. M. Knott<sup>12</sup> believe that results can be obtained in ten days. When the test is complete a dose response curve is plotted the slope of which is a check on the reliability of the assay. The vitamin content of the test substance is calculated by reference to the curve. According to Coward the accuracy of the vitamin  $B_{12}$  assay is a half that of the alkaline method. The sensitivity is also such that differences between doses of one  $\mu\text{g}$  being detectable. Care has to be taken to give an accurate reference<sup>12</sup> (see page 75).

A curative method using rats is similar in principle to the original test with pyridine was proposed by M. I. Smith<sup>14</sup>. In this method the rats were fed a basal vitamin  $B_{12}$  deficient diet until they died and the weight gain on the basal diet was calculated. Then a series of graded doses of the test solution was compared with the gain in weight of animals fed on the same basal diet supplemented with known amounts of a standard solution of vitamin  $B_{12}$ . Your rats on a vitamin  $B_{12}$  deficient diet were found to develop polyneuritis in fifty to eighty days. Oral administration or injection of aneurine resulted in improvement within three to five hours and definite cure in eighteen to twenty four hours. After a certain time the effects were still symptoms of polyneuritis recurred and were again alleviated by another dose of the vitamin. Although the curative response was proportional to the dose Smith did not believe the relationship to be quantitative and he therefore made his comparisons on the basis of the minimum curative dose. Other workers although confirming Smith's general conclusions found considerable variations in the occurrence of polyneuritis but the effect is suggested can be reduced by the use of a sufficiently large number of animals.

Of the four procedures considered by the Committee of Revision of the U.S. Pharmacopoeia only the rat curative method was recommended. The preferred procedure is substantially that of Smith the main variation being a more adequate diet which is claimed to give a 100% incidence of polyneuritis in rats and repeated production and cure of polyneuritis in the same animal as many as ten such periods are said to be possible.

## ANEURINE (THIAMINE)

method Moreover, riboflavine deficiency has a similar effect on the oestrus cycle, and the presence of riboflavine in the test substance would presumably interfere with aneurine assays

### References to Section 7

- 1 B C P Jansen and W F. Donath, *Proc K Akad Wetensch Amsterdam* 1926, 29, 1390
- 2 E S Edie, W H Evans, B Moore, G C E Simpson and A Webster, *Biochem J*, 1912, 6, 234
- 3 H W Kinnersley and R A Peters, *ibid*, 1928 22, 419, 1933 27, 225, 232
- 4 K H Coward, J H Burn, H W. Ling and B G E Morgan, *ibid*, 1933 27, 1719
- 5 A Seidell, *U S Publ Health Rep*, 1922, 37, 1519
- 6 K H Coward and B G E Morgan *Biochem J*, 1939 38, 658
- 7 R Passmore, R A Peters and H M Sinclair, *ibid*, 1933 27, 842, R A Peters, H Rydén and R H S Thompson, *ibid*, 1935 29, 53, 1938, 32, 2031
- 8 T H Jukes and H Heitman, *J Nutrition*, 1940 19, 21
- 9 H C Sherman and A Spohn, *J Amer Chem Soc*, 1923, 45, 2719
- 10 B C Guha and J C Drummond *Biochem J*, 1929 23, 880
- 11 K H Coward *ibid*, 1936, 30, 2012
- 12 F W Schultz and E M Knott, *J Nutrition*, 1936, 12, 583
- 13 L S Fridericia P Freudenthal, S Gudjonsson, G Johansen and N Schoubye, *J Hygiene*, 1927, 27, 70
- 14 M I Smith *U S Publ Health Rep*, 1930, 45, 116
- 15 F F Heyroth *Bull Basic Science Rep*, 1932 4, 1
- 16 H W Kinnersley, R A Peters and V Reader, *Biochem J*, 1930 24, 1820
- 17 T W Birch and L J Harris, *ibid*, 1934 28, 602
- 18 K H Coward and B G E Morgan *ibid* 1941, 35, 974

## 8. MICROBIOLOGICAL ASSAY OF ANEURINE

An entirely different method of assaying aneurine preparations from the foregoing are fermentation tests, these are carried out with micro organisms for which aneurine is an essential growth factor The principle of the method is that the selected organism is grown on a medium that gives optimal growth on addition of aneurine, and the amount of growth obtained with the test solution is then compared with that given by a control containing known amounts of aneurine The amount of growth is measured in some suitable way, e.g. turbidimetrically or by the amount of carbon dioxide, lactic acid or other metabolite formed

## Cast Fermentation Method

In the methods of A. S. Schultz *et al.*<sup>1</sup> of K. Heyns<sup>2</sup> and of H. H. Bunzell<sup>3</sup> a sugar solution is fermented with yeast and the carbon dioxide produced is measured. Schultz *et al.*,<sup>4</sup> however, found that other yeast stimulating substances were present in urine and therefore modified their original method by carrying out two fermentations, one before and one after oxidation with potassium ferricyanide to convert the aneurine into thiochrome, the difference between the two results was proportional to the true aneurine content. For the estimation of aneurine in wheat yeast, bread liver milk and orange juice they used another modification<sup>5</sup> the aneurine being destroyed by treatment with sodium sulphite solution at 100° C. for thirty minutes at pH 5 to 6. Again the difference between the results before and after this treatment was claimed to be proportional to the aneurine content. Interfering substances were said to be unaffected by sulphite and the sulphite degradation products were supposed not to stimulate the growth of the yeast.<sup>6</sup>

A modification of this method was used by R. J. Williams *et al.*,<sup>7</sup> who employed the old process strain of *Saccharomyces cerevisiae*, which was grown on a medium supplemented with yeast and liver extracts freed from aneurine by adsorption on fuller's earth. This method is said to be simpler than the original method and to be capable of estimating as little as 0.00005  $\mu$ g of aneurine per 2.5 ml. of medium. Unfortunately it is not specific the thiazole moiety (5  $\beta$  hydroxyethyl 4 methyl thiazole) of aneurine and the pyrimidine moiety (4 amino 5-ethoxymethyl 2 methyl pyrimidine) giving 60 and 30% respectively of the response given by aneurine hydrochloride. Cocarboxylase does not stimulate the growth of the organism under these conditions.

N. S. Scrimshaw and W. B. Stewart<sup>8</sup> also found that the method of Schultz *et al.* lacked specificity for instance it gave poor results when used for the assay of meat and egg products. They claimed to have eliminated the sources of error in the method by first carrying out a preliminary assay with graded amounts of aneurine added to the blank to determine the range over which the response was linear and then in the main assay using three tubes one containing the sample another the blank and the third a blank plus a suitable amount of aneurine. The aneurine content of the sample was calculated by comparing the amount of gas liberated in the first tube (after correcting for the value obtained for the blank) with that produced in the third tube similarly corrected. The effectiveness of sulphite cleavage of a known amount of aneurine added to the blank was determined for each type of substance and if necessary,

a correction was applied for the activity of any cleavage products present in the sample.

The lack of specificity was confirmed by H. F. Deutsch,<sup>9</sup> who found that the pyrimidine half of aneurine was more active than aneurine itself on yeast at low concentrations, but less active at high concentrations. The pyrimidine and thiazole halves together were almost as active as aneurine, whilst the thiazole half alone or 4-amino-2-methyl-pyrimidyl-5-methane sulphonic acid were less active. These results are therefore not in complete agreement with those of Schultz *et al.*, who stated that the sulphite-cleavage products did not stimulate the growth of yeasts; the discrepancy may be due to the use of different strains. It is evident therefore that the yeast growth method must be used with caution, especially when the test solution is suspected to contain degradation products of aneurine. H. G. Obermeyer and L. Chen,<sup>10</sup> for example, showed that substantial amounts of biologically available thiazole or pyrimidine derivatives remained in foodstuffs in which aneurine had decomposed.

Westenbrink *et al.*<sup>11</sup> used the yeast fermentation method in rather a novel form for the estimation of cocarboxylase in blood. The blood was acidified to pH 3 and heated to 100° C. for 1½ minutes, neutralised to pH 6.2 and centrifuged. Alkali-washed brewers' yeast was added to an aliquot portion of the solution, aneurine and a manganese salt were then added and the suspension was incubated at 27.5° C. for fifteen minutes to re-synthesise carboxylase. The yeast was then centrifuged off, re-suspended in acetate buffer solution, pH 5.6, and reacted at 27.5° C. with sodium pyruvate. The amount of carbon dioxide liberated was proportional to the cocarboxylase in the blood.

Although the yeast growth method, as generally used, is an aerobic fermentation, aneurine can also be estimated by an anaerobic fermentation. This was first demonstrated by L. Atkin *et al.*,<sup>12</sup> who found that the addition of 0.01 to 0.04 µg. of aneurine to 5 mg. of yeast suspended in 3 ml. of medium considerably raised the anaerobic carbon dioxide output during the second hour of incubation and that the increase in fermentation by 0.01 to 0.02 µg. of aneurine was proportional to the vitamin concentration. The observation was confirmed by H. Laser,<sup>13</sup> who also showed that different yeasts behaved differently, bakers' yeast giving a regular response and *Torula utilis* no response at all. He also noted that in yeasts that responded with an increase in anaerobic fermentation, aerobic fermentation was also increased quantitatively by the same minute amounts of aneurine. E. S. Josephson and R. S. Harris,<sup>14</sup> using a Warburg manometer, were able to estimate the aneurine content of tissue extracts containing as little as 10<sup>-8</sup> g. per ml.

### Phycomyces Assay Method

Although yeast is the micro-organism most commonly used for the estimation of aneurine other micro-organisms have been used. Next in importance to yeast is the mould *Phycomyces Blakesleeanus* which was employed by W. H. Schopfer<sup>15</sup> A. P. Meiklejohn<sup>16</sup> H. M. Sinclair<sup>17</sup> and T. Morell<sup>18</sup>. A suitable aneurine free medium to which graded amounts of the test solution have been added is inoculated with mould spores incubated for seven days and the mycelium then removed, dried and weighed. The results are compared with those obtained using the same basal medium to which have been added known amounts of aneurine and the aneurine content of the unknown solution is calculated from the dose response curve obtained with the standard. The method has been used to estimate the aneurine and cocarboxylase contents of blood plasma and cerebrospinal fluid<sup>19</sup> and for the routine assay of vegetable extracts<sup>20</sup>. A. P. Meiklejohn<sup>21</sup> used the *Phycomyces* method to estimate the aneurine content of potatoes and found that the green sprouts contained a factor toxic for the mould whilst the centre of the tubers from April to August and the skin layer always contained an adjuvant factor that stimulated the growth of the mould only in presence of aneurine.

### Assays with Other Organisms

*Lactobacillus fermenti* was suggested by H. P. Sarett and V. H. Cheldelin<sup>22</sup> growth being measured turbidimetrically sixteen to eighteen hours after inoculation. Cocarboxylase was 30% more active than aneurine. *Staphylococcus aureus* was used by P. M. West and P. W. Wilson<sup>23</sup> *Glaucoma piriforme* by L. Emerique Blum and A. I. Wolf<sup>24</sup> *Streptococcus salinarum* by C. I. Niven and K. L. Smiley<sup>25</sup> and a yeast *Saccharomyces macedoniensis* by Emery *et al*<sup>26</sup>.

Probably the most satisfactory of these methods is that of Sarett and Cheldelin. Under the conditions prescribed by the authors the organism *Lactobacillus fermenti*<sup>36</sup> does not respond to the pyrimidine and thiazole components of aneurine alone together or in presence of aneurine. A quantitative response is obtained in presence of 0.005 to 0.04  $\mu\text{g}$  of aneurine per 10 ml of medium. Unfortunately the basal medium is rather complicated consisting of alkali treated peptone acid hydrolysed casein glucose sodium acetate cystine adenine guanine and uracil with the usual inorganic salts and the following members of the vitamin B complex: riboflavine calcium pantothenate *p*-aminobenzoic acid nicotinic acid pyridoxine biotin and folic acid. The growth response is measured turbidimetrically.

The original method of Sarett and Cheldelin gave unsatisfactory results with some materials containing inhibitory or stimulatory



substances, and E. E. Fitzgerald and E. B. Hughes<sup>27</sup> eliminated this particular source of error by subtracting from the response to the test solution, the response to another portion of the solution in which the aneurine had been inactivated by autoclaving with sulphite.

Some of the difficulties of the *L. fermenti* turbidimetric method are said to be overcome by using a plate method of assay, similar in principle to that used for the assay of antibiotics, except that the zones formed around the holes cut in the agar are zones of stimulation and not of inhibition.<sup>28</sup> The method is not very sensitive, but with yeast and yeast products the results are at least as accurate as those obtainable by other methods.<sup>29</sup> Takadiastase was used to liberate the aneurine from the yeast.

### References to Section 8

1. A. S. Schultz, L. Atkin and C. N. Frey, *J. Amer. Chem. Soc.*, 1937, **59**, 948, 2457; 1938, **60**, 1514.
2. K. Heyns, *Z. physiol. Chem.*, 1939, **258**, 219.
3. H. H. Bunzell, *Ind. Eng. Chem., Anal. Ed.*, 1942, **14**, 279.
4. A. S. Schultz, L. Atkin and C. N. Frey, *J. Biol. Chem.*, 1940, **136**, 713.
5. A. S. Schultz, L. Atkin and C. N. Frey, *Ind. Eng. Chem., Anal. Ed.*, 1942, **14**, 35.
6. A. S. Schultz, L. Atkin, C. N. Frey and R. R. Williams, *J. Amer. Chem. Soc.*, 1941, **63**, 632.
7. R. J. Williams, J. R. McMahan and R. E. Eakin, *Univ. Texas Publ.*, 1941, No. 4137, 31.
8. N. S. Scrimshaw and W. B. Stewart, *J. Biol. Chem.*, 1944, **155**, 79.
9. H. F. Deutsch, *ibid.*, 1944, **152**, 431.
10. H. G. Obermeyer and L. Chen, *ibid.*, 1945, **159**, 117.
11. H. G. K. Westenbrink, E. P. S. Parvé, A. C. van den Linden and W. A. van den Broek, *Z. Vitaminforsch.*, 1943, **63**, 218.
12. L. Atkin, A. S. Schultz and C. N. Frey, *J. Biol. Chem.*, 1939, **129**, 471.
13. H. Laser, *Biochem. J.*, 1941, **35**, 488.
14. E. S. Josephson and R. S. Harris, *Ind. Eng. Chem., Anal. Ed.*, 1942, **14**, 755.
15. W. H. Schopfer, *Z. Vitaminforsch.*, 1935, **4**, 67.
16. A. P. Meiklejohn, *Biochem. J.*, 1937, **31**, 1441.
17. H. M. Sinclair, *ibid.*, 1938, **32**, 2185; 1939, **33**, 1816, 2027.
18. T. Morell, *Deut. med. Woch.*, 1938, **64**, 1722.
19. A. P. Meiklejohn, *Biochem. J.*, 1937, **31**, 1441; H. M. Sinclair, *ibid.*, 1938, **32**, 2185; 1939, **33**, 1816, 2127; E. N. Rowlands and J. F. Wilkinson, *Brit. Med. J.*, 1938, **2**, 878; T. Morell, *Deut. med. Woch.*, 1938, **64**, 1722; G. Guhr, *Klin. Woch.*, 1939, **18**, 1028; R. Goodhart and H. M. Sinclair, *J. Biol. Chem.*, 1940, **132**, 11.

- 20 K C Hamner, W. S Stewart and G Matrone, *Food Res*, 1943 **8**, 444
- 21 A P. Meiklejohn, *Biochem J*, 1943 **37**, 340.
- 22 H P Srett and V H Cheldelin, *J. Biol Chem*, 1944, **155**, 153
- 23 P M West and P W Wilson, *Science*, 1938, **88**, 334
- 24 L Emerique Blum and A Lwoff *Bull Soc Chim biol*, 1940, **22**, 179
- 25 C F. Niven and K L Smiley, *J Biol Chem*, 1943 **150**, 1
- 26 W B Emery, N McLeod and F A Robinson *Biochem J*, 1946, **40**, 426
- 27 F E Fitzgerald and E B Hughes, *Analyst* 1949 **74**, 340
- 28 A L. Bacharach and W. F. J Cuthbertson, *ibid*, 1948, **73**, 334
- 29 A Jones and S Morris, *ibid*, 1949 **74**, 333

## 9. CHEMICAL ESTIMATION OF ANEURINE

### Azo Method

The first chemical test proposed for vitamin B<sub>1</sub> was the so-called formaldehyde azo test of H W Kinnorsley and R A Peters,<sup>1</sup> who found that vitamin B<sub>1</sub> concentrates gave a pink colour with diazotised sulphanilic acid and formaldehyde solution and that the colour increased slowly in intensity for thirty to sixty minutes, thereafter remaining constant for a considerable time. The method was later modified by them<sup>2</sup> to make it quantitative, the error was stated to be not greater than 5 %. H J Preblud<sup>3</sup> and E V McCollum<sup>3</sup> and D Melnick and H Field<sup>4</sup> used diazotised *p* aminacetophenone (without formaldehyde) for estimating aneurine. The latter authors extracted the coloured product with xylene to make the test more specific, and thereby reduced the error to 2 %. By hydrolysing cocarboxylase preparations with yeast phosphatase the test was made applicable to the estimation of the coenzyme. In a later paper, Melnick and Field<sup>5</sup> introduced adsorption on Permutit followed by elution with potassium chloride solution to effect purification.

The azo method is now one of the standard methods of estimating aneurine, and has been modified by various workers to eliminate interference from other compounds present in the material to be assayed (cf Emmett *et al*<sup>6</sup>). Diazotised *p* aminoacetophenone was used by L J Harris and W D Raymond,<sup>7</sup> by E F Yang and B S Platt,<sup>8</sup> and by Y Sakurai *et al*<sup>9</sup>. The last named group of workers purified the sample by adsorption of the aneurine on "acid clay" and elution of the adsorbate with alcoholic phenol. H Willstaedt<sup>10</sup> used diazotised 2,4 dichloroaniline, which gives a yellowish red colour, as the reagent. E R Kirch and O Bergeim<sup>11</sup> used *p*-carbethoxybenzene trichloroacetate and extracted the colour with isoamyl alcohol, both vitamin A and vitamin C interfere, however, and must be removed, the former by extraction with isoamyl alcohol before addition of the

reagent, and the latter by oxidation. Cocarboxylase gave no colour and could be estimated separately after hydrolysis with phosphatase B. Alexander and J. E. Levi<sup>12</sup> found that uric acid and vitamin C interfered with the estimation of aneurine by means of the Prebluda-McCollum reagent, they removed uric acid by precipitation with zinc at pH 7.4 and vitamin C by precipitation with lead acetate at pH 8.2.

### Thiochrome Method

The other reaction on which is based a chemical test for aneurine was also discovered by R. A. Peters<sup>13</sup>. He observed that when aneurine was oxidised with potassium permanganate or manganese dioxide at a pH not exceeding 6, a blue fluorescent substance was produced. G. Barger *et al*<sup>14</sup> prepared this fluorescent substance by oxidation of aneurine with potassium ferricyanide solution and obtained it in the pure state as pale yellow crystals having the formula,  $C_{12}H_{14}N_4OS \cdot 2HCl$ . It showed an intense blue fluorescence in neutral or alkaline solution and had all the other properties of thiochrome described by R. Kuhn *et al*<sup>15</sup>. Its constitution was established and its synthesis worked out by Bergel *et al*<sup>16</sup>.

The conversion of aneurine into thiochrome was studied by B. C. P. Jansen,<sup>17</sup> who established the optimal conditions for the oxidation with potassium ferricyanide, he extracted the thiochrome with isobutanol and measured the fluorescence of the extract in a fluorimeter calibrated against standard solutions of quinine. The method has been extensively employed for the estimation of vitamin B<sub>1</sub> in foodstuffs and urine and indeed may be said to be the most important method of assay. It was officially adopted in the Seventh Addendum (1945) to the British Pharmacopoeia 1932.

According to D. J. Hennessy,<sup>18</sup> it is more sensitive than the colorimetric method and capable of estimating lower potencies. This was confirmed by Brown *et al*,<sup>19</sup> who also obtained good agreement between the two methods. They stated, however, that neither method was satisfactory with very low potencies, only the rat growth or pigeon weight maintenance methods giving reliable results in such instances. Hennessy *et al*<sup>20</sup> found little difference between the results obtained by means of the thiochrome test, the rat growth test and the fermentation test when pharmaceutical preparations were assayed by these methods.

J. C. Moyer and D. K. Tressler<sup>21</sup> obtained good agreement between the thiochrome method and the sulphite-cleavage modification of the fermentation method.

The method has been modified by individual workers to meet their particular requirements and there is, therefore, a bewildering

array of methods to choose from. The objects of these various modifications are of course to eliminate interference from other substances present in the sample being assayed. Some substances prevent the formation of thiochrome leading to low results whilst others enhance the fluorescence and produce high results.

Perhaps the most important modification is that introduced by D. J. Hennessy and L. R. Cerecedo<sup>22</sup> in which the aneurine is adsorbed on a zeolite Decalco and eluted with hot potassium chloride solution. This method which is analogous to Melnick and Field's modified procedure has been adopted by the majority of workers. Perlzweig *et al*<sup>23</sup> used Superfiltrol for removing aneurine from urine and a mixture of pyridine ethanol and hydrochloric acid for elution.

Even when adsorbents of this type are used interfering substances may remain. H. I. Mason and R. D. Williams<sup>24</sup> experienced trouble in assaying urines owing to the presence of fluorescent derivatives of nicotinic acid. Satisfactory results were obtained only when the amount of aneurine in the sample exceeded 100  $\mu\text{g}$ . When the excretion was low or when 300 to 500 mg of nicotinic acid were ingested per day the non thiochrome material accounted for most of the fluorescence. They suggested that the difficulty could be overcome by repeating the fluorimetric assay after destroying the aneurine in the urine by heating with sodium sulphate at pH 5 for fifteen minutes and then subtracting the intensity of the fluorescence from that given by the untreated solution.

V. A. Najjar and K. C. Ketron<sup>25</sup> however showed that the fluorescent metabolite of nicotinic acid,  $\text{I}_2$  (see page 254) which was responsible for this phenomenon was attacked by sodium sulphite so that Mason and Williams' procedure did not give a true blank. They recommended Hennessy and Cerecedo's method with the rather unsatisfactory expedient of assuming that 21 % of the fluorescence was due to  $\text{I}_2$ . Y. I. Wang and L. J. Harris<sup>26</sup> destroyed interfering fluorescent substances in extracts prepared from foodstuffs by oxidation with hydrogen peroxide before extraction with isobutanol.

Another group of substances that may cause interference in the fluorimetric assay of urines are salicylates. These may be removed<sup>27</sup> by acidification and extraction with isobutanol before oxidation.

J. G. Organ and F. Wokes<sup>28</sup> experienced a reverse effect in estimating the aneurine content of cereal extracts. These appeared to contain substances that quenched the fluorescence and interference from this source was only satisfactorily overcome by adding known amounts of aneurine equal to at least four times that originally present and then subtracting the amount added from the results.

P. Ellinger and M. Holden<sup>29</sup> found that certain inorganic salts also had a marked quenching effect on the fluorescence of thiochrome.

reagent, and the latter by oxidation. Cocarboxylase gave no colour and could be estimated separately after hydrolysis with phosphatase. B. Alexander and J. E. Levi<sup>12</sup> found that uric acid and vitamin C interfered with the estimation of aneurine by means of the Prebluda-McCollum reagent, they removed uric acid by precipitation with zinc at pH 7.4 and vitamin C by precipitation with lead acetate at pH 8.2.

### Thiochrome Method

The other reaction on which is based a chemical test for aneurine was also discovered by R. A. Peters<sup>13</sup>. He observed that when aneurine was oxidised with potassium permanganate or manganese dioxide at a pH not exceeding 6, a blue fluorescent substance was produced. G. Barger *et al*<sup>14</sup> prepared this fluorescent substance by oxidation of aneurine with potassium ferricyanide solution and obtained it in the pure state as pale yellow crystals having the formula  $C_{12}H_{14}N_4OS \cdot 2HCl$ . It showed an intense blue fluorescence in neutral or alkaline solution and had all the other properties of thiochrome described by R. Kuhn *et al*<sup>15</sup>. Its constitution was established and its synthesis worked out by Bergel *et al*<sup>16</sup>.

The conversion of aneurine into thiochrome was studied by B. C. P. Jansen,<sup>17</sup> who established the optimal conditions for the oxidation with potassium ferricyanide, he extracted the thiochrome with isobutanol and measured the fluorescence of the extract in a fluorimeter calibrated against standard solutions of quinine. The method has been extensively employed for the estimation of vitamin B<sub>1</sub> in foodstuffs and urine and indeed may be said to be the most important method of assay. It was officially adopted in the Seventh Addendum (1945) to the British Pharmacopoeia 1932.

According to D. J. Hennessy,<sup>18</sup> it is more sensitive than the colorimetric method and capable of estimating lower potencies. This was confirmed by Brown *et al*<sup>19</sup> who also obtained good agreement between the two methods. They stated however, that neither method was satisfactory with very low potencies, only the rat growth or pigeon weight maintenance methods giving reliable results in such instances. Hennessy *et al*<sup>20</sup> found little difference between the results obtained by means of the thiochrome test, the rat growth test and the fermentation test when pharmaceutical preparations were assayed by these methods.

J. C. Moyer and D. K. Tressler<sup>21</sup> obtained good agreement between the thiochrome method and the sulphite cleavage modification of the fermentation method.

The method has been modified by individual workers to meet their particular requirements and there is, therefore, a bewildering

array of methods to choose from. The objects of these various modifications are, of course to eliminate interference from other substances present in the sample being assayed. Some substances prevent the formation of thiochrome, leading to low results, whilst others enhance the fluorescence and produce high results.

Perhaps the most important modification is that introduced by D J Hennessy and L R Cerecedo,<sup>22</sup> in which the aneurine is adsorbed on a zeolite, Decalso, and eluted with hot potassium chloride solution. This method, which is analogous to Melnick and Field's modified procedure, has been adopted by the majority of workers. Perlzweig *et al*<sup>23</sup> used Superfiltrol for removing aneurine from urine, and a mixture of pyridine, ethanol and hydrochloric acid for elution.

Even when adsorbents of this type are used, interfering substances may remain. H L Mason and R D Williams<sup>24</sup> experienced trouble in assaying urines owing to the presence of fluorescent derivatives of nicotinic acid. Satisfactory results were obtained only when the amount of aneurine in the sample exceeded 100  $\mu\text{g}$ . When the excretion was low or when 300 to 500 mg of nicotinic acid were ingested per day, the non-thiochrome material accounted for most of the fluorescence. They suggested that the difficulty could be overcome by repeating the fluorimetric assay after destroying the aneurine in the urine by heating with sodium sulphite at pH 5 for fifteen minutes and then subtracting the intensity of the fluorescence from that given by the untreated solution.

V A Najjar and K C Ketron<sup>25</sup> however, showed that the fluorescent metabolite of nicotinic acid, 'F<sub>2</sub>' (see page 254) which was responsible for this phenomenon was attacked by sodium sulphite, so that Mason and Williams' procedure did not give a true blank. They recommended Hennessy and Cerecedo's method with the rather unsatisfactory expedient of assuming that 21 % of the fluorescence was due to 'F<sub>2</sub>'. Y L Wang and L J Harris<sup>26</sup> destroyed interfering fluorescent substances in extracts prepared from foodstuffs by oxidation with hydrogen peroxide before extraction with isobutanol.

Another group of substances that may cause interference in the fluorimetric assay of urines are salicylates. These may be removed<sup>27</sup> by acidification and extraction with isobutanol before oxidation.

J G Organ and F Wokes<sup>28</sup> experienced a reverse effect in estimating the aneurine content of cereal extracts. These appeared to contain substances that 'quenched' the fluorescence, and interference from this source was only satisfactorily overcome by adding known amounts of aneurine equal to at least four times that originally present and then subtracting the amount added from the results.

P Ellinger and M Holden<sup>29</sup> found that certain inorganic salts also had a marked quenching effect on the fluorescence of thiochrome.

in isobutanol Maximum fluorescence occurred at pH 11 D F. Clausen and R E Brown<sup>30</sup> attributed certain of the errors in the thiochrome method to the effect of dissolved oxygen and changes of temperature on the quinine standard generally employed, and advocated the use of glass standards and a constant temperature Certain foodstuffs may contain substances that interfere with the quantitative adsorption of aneurine on Decalso<sup>31</sup>

An alternative oxidising agent to potassium ferricyanide was suggested by W I M Holman,<sup>32</sup> who claimed that a saturated solution of mercuric oxide in alkaline potassium chloride solution gave more satisfactory results, especially when applied to Decalso eluates

C A P Carbajal<sup>33</sup> instead of estimating the thiochrome fluorimetrically measured the ferrocyanide simultaneously formed by titration with ceric sulphate solution Little information is available as to the merits of this method, which is claimed to be capable of estimating as little as 5  $\mu$ g of aneurine

In addition to ensuring that the conversion of aneurine into thiochrome is not inhibited or the fluorescence enhanced by the presence of other impurities, satisfactory assays also necessitate the complete extraction of the aneurine from the material being tested with, at the same time, the minimum of substances likely to interfere with the development of the fluorescence A large variety of methods exist for extracting aneurine from foodstuffs but, in general, these resolve themselves into extraction with acid, digestion with enzymes or a combination of the two According to R G Booth,<sup>34</sup> extraction with acid is as efficient as is enzymic digestion, but most workers appear to prefer the latter method L J Harris and Y L Wang<sup>35</sup> used a combination of takadiastase and papain, whilst takadiastase alone was used by E C Slater<sup>36</sup> for milk and cereal products, by Brown *et al*,<sup>37</sup> who claimed it to be the best of the enzymes for cereal products, and by A Z Hodson<sup>38</sup> for milk R T Connor and G J Straub<sup>39</sup> digested the material for one hour with dilute sulphuric acid and then incubated with clarase

The thiochrome method can also be used for the estimation of aneurine pyrophosphate (cocarboxylase), and it is possible to obtain an estimate of the free and combined aneurine in the same solution On oxidation with ferricyanide, aneurine pyrophosphate and orthophosphate give derivatives insoluble in isobutanol,<sup>22</sup> but by incubation with a kidney phosphatase preparation, both esters are converted into free aneurine, which can then be estimated by conversion to thiochrome H G K Westenbrink and B C P Jansen<sup>40</sup> used a different method for the fluorimetric estimation of aneurine pyrophosphate, after oxidation with ferricyanide, they evaluated the fluorescence in the isobutanol layer to estimate the free aneurine, and

the fluorescence in the aqueous layer to estimate the cocarboxylase. This method obviously suffers from severe limitations and is only applicable when the aqueous phase is free from coloured impurities and other fluorescent substances.

A simplified base-exchange method not involving adsorption columns was used by E Papageorge and M V Lamar<sup>41</sup> for the estimation of aneurine in urine by three different thiochrome methods. Agreement was generally good. The use of benzene sulphonyl chloride to destroy aneurine is recommended for the estimation of non thiochrome fluorescent impurities.

A different principle was used for the estimation of aneurine by H Wachsmuth<sup>4</sup>. On adding potassium mercuric iodide solution to a weakly acid solution of aneurine a crystalline precipitate of aneurine iodomercurate was formed. The iodine in this precipitate or in the excess of the reagent was titrated after oxidation to iodate by treatment with bromine.

### Physico-chemical Method

Although aneurine exhibits characteristic absorption bands in the ultra violet region of the spectrum these can only be used for estimating the vitamin when relatively pure solutions are available. The only physical method of estimating aneurine that appears to be promising is the polarographic method although it does not seem to have been generally adopted. J J Lingane and O L Davis<sup>42</sup> discovered that with potassium chloride as base solution aneurine gave a step with a half wave potential of  $-1.25$  volts vs the saturated calomel electrode and that riboflavine and nicotinic acid gave steps at other voltages so that it was possible to estimate all three vitamins in one and the same solution at the same time.

When electrolysed in a very dilute solution containing ammonium chloride boric acid and potassium chloride or in a phosphate buffer solution aneurine gave a current voltage curve with a prominent maximum at  $1.7$  volts vs the saturated calomel electrode<sup>43</sup> this is believed to arise from a catalytic effect of the aneurine.

### References to Section 9

- 1 H W Kinnorsley and R A Peters *Biochem J* 1934 28 867
- 2 H W Kinnorsley and R A Peters *ibid* 1938 32 1516
- 3 H J Prebluda and E V McCollum *Science* 1936 84 488 *J Biol Chem* 1939 127, 495
- 4 D Melnick and H Field *J Biol Chem* 1939 127 505 531
- 5 D Melnick and H Field *ibid* 1939 130 97
- 6 A D Emmett G Peacock and R A Brown *ibid* 1940 135 131
- 7 L J Harris and W D Raymond *Biochem J* 1939 33 2037





occurs with vitamin C<sup>22</sup> Freezing caused no loss of vitamin B<sub>1</sub> and appears to be an excellent way of preserving the vitamin content of vegetables Storage at temperatures below 0° C was better than storage at normal temperatures<sup>20 23</sup> The rate of destruction of the vitamin B<sub>1</sub> in dehydrated products at elevated temperatures (above 37° C) appeared to be affected by a number of factors and could not be prevented by storage in vacuum nitrogen or carbon dioxide or by addition of an antioxidant<sup>24</sup>

### References to Section 10

- 1 M A Boas Fixsen and M H Roscoe *Nutr Abs* 1937 38 7, 837  
1939 40 9 815
- 2 D I Allen *J Nutrition* 1943 25, 521
- 3 For the aneurine content of different varieties of wheat see also  
E C Slater and E J Rial *J Proc Austral Chem Inst* 1941  
8, 71 R G Booth *J Soc Chem Ind* 1940 59, 181 for the  
distribution of aneurine in the wheat grain see G F Somers  
M H Coolidge and K C Hamner *Cereal Chem* 1945 22 333  
J J C Hinton *Biochem J* 1943 37, 585 L H Pulkka and  
K Puutula *Biochem Z* 1941 308 122 for the distribution in  
the rice grain see J J C Hinton *Brit J Nutrition* 1948 2 237
- 4 M I Bailey and A W Thomas *J Nutrition* 1942 24 85
- 5 R Melville *Chem and Ind* 1947 304
- 6 C D Miller L Louis and C Peterson *Food Res* 1943 8 27
- 7 For variations in the aneurine content of potatoes according to  
variety and season see J Meiklejohn *Biochem J* 1943 37, 340
- 8 For the aneurine content of eggs from different varieties of hens  
see N S Scrimshaw F B Hatt and M W Scrimshaw *J  
Nutrition* 1945 30 375 for the distribution of aneurine in the  
embryonated egg see N S Scrimshaw W E Porter and M W  
Scrimshaw *ibid* 1949 38 237 267
- 9 N Halliday and H J Deuel *J Biol Chem* 1941 140 555
- 10 P B Pearson and A L Darnell *J Nutrition* 1946 31, 51
- 11 For the aneurine content of different animal tissues see also  
M Pyke *Biochem J* 1940 34, 1341 R C Miller J W Pence  
R A Dutcher P T Ziegler and M A McCarty *J Nutrition*  
1943 28 261
- 12 M H Haydak and L S Palmer *J Econ Entom* 1940 33 396
- 13 G Kitzes H A Schuette and C A Elvehjem *J Nutrition* 1943  
28 241
- 14 H Fink and F Just *Wochsch Brau* 1941 58 17 79 R H  
Hopkins *Nature* 1943 152 274
- 15 E C Barton Wright T Moran and H S Sarson *ibid* 273
- 16 J M Chaves *Rev Aliment* 1944 8 173
- 17 A L Daniels *Amer J Dis Child* 1941 62, 127 A D Holmes  
C P Jones A W Wertz and J W Kuzmeski *J Nutrition*  
1943 26, 337

## ANEURINE (THIAMINE)

- 18 Y Sakurai, S Omori and S Huzita, *Bull Inst Phys-Chem Res, Japan* 1941, 20, 308, M Swaminathan, *Indian J Med Res*, 1942, 30, 409
- 19 M L Fincke R Little E Redelings and J Perkins, *Food Res*, 1943, 8, 123
- 20 B Barnes D K Tressler and F Fenton, *ibid*, 420
- 21 F Fenton, B Barnes, J C Moyer, K A Wheeler and D K Tressler, *Amer J Publ Health*, 1943 33, 799, F Fenton, E Gleim M Albury, J R McCartney and K Visnyei *Food Res*, 1946, 11, 468, F Fenton E Gleim, A Arnason J F Thompson M Albury and M Phillips *ibid* 475
- 22 E Gleim, M Albury J R McCartney, K Visnyei and F Fenton, *ibid*, 461
- 23 E Gleim D K Tressler and F Fenton *ibid*, 1944 9, 471
- 24 G E Rice J F Benk, F L Kauffman H W Schultz and H E Robinson *ibid*, 491

## II. EFFECT OF ANEURINE DEFICIENCY IN ANIMALS

### Effect in Pigeons

Incidental reference has already been made to some of the symptoms associated with vitamin B<sub>1</sub> deficiency in experimental animals. One of the first recorded signs of vitamin B<sub>1</sub> deficiency, actually used to follow the isolation of the vitamin, was the characteristic head retraction of the pigeon, termed opisthotonus,<sup>1</sup> this is a form of convulsion, and is analogous to the convulsions produced in rats and other animals by vitamin B<sub>1</sub> deficiency. Vitamin B<sub>1</sub> deficient pigeons also show ataxia and leg weakness, cardiac failure with tachycardia, abnormalities of the electrocardiograph and necrosis of the heart muscle. Starvation alone produces bradycardia and variable heart block.<sup>2</sup> In most instances the symptoms rapidly disappear on administration of aneurine unless the deficiency is severe; recovery from leg weakness is slow however. R L Swank and O A Bessey<sup>2</sup> consider paralysis to be a characteristic symptom of vitamin B<sub>1</sub> deficiency, and maintain that it is unnecessary to postulate the existence of vitamin B<sub>4</sub> (see page 612). Nerve degeneration is also characteristic of vitamin B<sub>1</sub> deficiency in pigeons<sup>3</sup> and leads to mild myelin degeneration in the peripheral nerves of the spinal cord, the extent of the degeneration depending on the severity of the deficiency.<sup>4</sup> Incidentally, aneurine can be detected in the myelin sheaths of peripheral nerves by fluorescence micro spectrography.<sup>5</sup>

In vitamin B<sub>1</sub> deficient pigeons alcohol disappears from the blood at the same rate as in normal pigeons,<sup>6</sup> whilst the onset of acute vitamin B<sub>1</sub> deficiency symptoms in pigeons is delayed by the substitution of alcohol for the fat and carbohydrate of the diet in isocaloric

## EFFECT OF DEFICIENCY IN ANIMALS

quantities, the vitamin  $B_1$  requirements for metabolising fat appear to be intermediate between those required for carbohydrates and alcohol.<sup>7</sup>

Finally, E. Sárfy<sup>8</sup> reported that in vitamin  $B_1$ -deficient pigeons the adrenals show a small increase in adrenaline content, whilst that of the blood undergoes a decrease, followed later by a reduction in the amount in the adrenals and an increase in the amount in the blood. Reversal of these changes occurs on administering aneurine.

### Effect in Chicks

Chicks respond to aneurine deficiency in a very similar way to pigeons and exhibit opisthotonus, owing to functional impairment of the inhibitory fibre from the upper to the lower brain. In chronic deficiency, leg weakness and nerve degeneration occur, the axis cylinder degenerating and then the myelin sheath, finally the cell undergoes chromatolysis.<sup>9</sup> Myelin degeneration in the peripheral nerves and spinal cord is not observed in acute aneurine deficiency in chicks.<sup>4</sup> Heart failure is shown by some birds, with necrosis of the myocardial fibres. Actually, changes in the electrocardiogram occur two days before the other symptoms of vitamin  $B_1$  deficiency make their appearance,<sup>10</sup> the changes becoming more pronounced as the deficiency progresses. On administration of aneurine, the symptoms rapidly improve, but the electrocardiogram only slowly returns to normal.

The blood-sugar of chicks is reduced during the first ten to fourteen days on a vitamin  $B_1$ -deficient diet,<sup>11</sup> it then increases and when convulsions occur it may have twice the normal value. Injection of aneurine restores the blood-sugar level to normal. Changes in the nerves due to vitamin  $B_1$  deficiency have been demonstrated in tissue culture experiments,<sup>12</sup> the length and density of nerve fibres in embryos grown in plasma from vitamin  $B_1$ -deficient chicks and the density of the spindle cells being less than in embryos grown in normal plasma, the density of the macrophages was not significantly affected. Addition of aneurine to the deficient plasma increased the spindle cell density, but did not affect the fibre length or density. In blood clots washed with sulphite to destroy aneurine, normal axon growth occurred, however, and the abnormal growth in vitamin  $B_1$ -deficient plasma may be due to the greater fluidity of deficient plasma.

### Effect in Rats

Rats, when fed a diet inadequate in vitamin  $B_1$ , show a steady decline in weight, once the tissues have been depleted of their stores of the vitamin, this change in weight, as already mentioned (see

page 28), is used for the biological assay of vitamin B<sub>1</sub> preparations. Rats also develop convulsions and slowing of the heart beat (bradycardia) on diets low in aneurine, these symptoms have also been proposed as the basis of bio assay methods (see page 30). The electrocardiogram shows a good response to aneurine treatment within twenty-four to seventy-two hours. Changes in the electrocardiogram can be observed about a week before other signs become evident.<sup>13</sup> In addition a condition of anoestrus is produced and can be cured by administration of aneurine,<sup>14</sup> the accompanying disturbances of reproduction and lactation, however, are not cured until the stock diet is given. Riboflavine deficiency also causes anoestrus, and administration of riboflavine restores both the normal cycle and normal reproduction and lactation. Attempts to use this condition as the basis of a method of assaying aneurine were not very successful,<sup>15</sup> it is not considered specific for aneurine.

Other symptoms of vitamin B<sub>1</sub> deficiency observed in rats are<sup>16</sup> loss of appetite, without affecting the gain in weight per unit of food, a decrease in the fat and energy output, a lower body temperature, decreased efficiency in the utilisation of metabolisable energy, an increased loss of energy as heat and by excretion in the urine, an increased C/N ratio in the urine and an apparent depression of the oxidative processes of the body. In addition achlorhydria, loss of muscular tone and lesions of the nervous system may develop.<sup>17</sup>

Vitamin B<sub>1</sub> deficiency resulted in a rapid and marked deterioration of the work performance of swimming rats, and this was promptly restored by the administration of aneurine,<sup>18</sup> reduction of the food intake without rendering the diet deficient in aneurine did not decrease the work performance.

When young rats were allowed to develop acute deficiency symptoms, which were then cured by a small amount of aneurine and the process repeated several times, most of the animals at autopsy showed enlarged hearts due to dilatation of the right auricle, a few rats showed pleural effusions and ascites.<sup>19</sup> The auricles generally showed necrosis of the muscle fibres, cellular infiltration and proliferation or a decreased number of muscle fibres and fibrosis. Changes in the ventricle were uncommon or slight. Half the rats showed pathological changes in the pulmonary veins.

Different strains of rats may behave differently towards aneurine, a point to be carefully considered in bio assay work. For example, one highly inbred strain was observed<sup>20</sup> to develop polyneuritis in fifty-eight days, whilst another strain showed only mild deficiency after ninety days. One result of vitamin B<sub>1</sub> deficiency in rats is marked creatinuria,<sup>21</sup> a correlation being observed between the excretion of creatinine and the bodyweight. Even in mild chronic

deficiency, the blood urea and non protein nitrogen increase considerably. Only mild creatinuria was observed in animals deficient in riboflavin, pyridoxine or pantothenic acid.

### Aneurine and Riboflavin

A connection between aneurine deficiency and riboflavin has been remarked upon by several workers. Although no change in the excretion of riboflavin occurs in the early stages of aneurine deficiency in the later stages rapid excretion occurs.<sup>22</sup> This is believed to be due to the rapid metabolism of tissue *e.g.* shrinkage of the liver. It has also been shown that the concentration of riboflavin in the liver is increased in aneurine deficiency and *vice versa*.<sup>23</sup> A deficiency of pyridoxine, pantothenic acid, biotin or vitamin A had no effect on the concentration of aneurine or riboflavin in the liver. Chronic aneurine deficiency does not affect the riboflavin content of the body tissues<sup>24</sup> but riboflavin is not utilised so well in this condition as in normal rats on an isocaloric diet.

### Aneurine and Fat Metabolism

Some workers appear to have established a connection between aneurine and fat metabolism. This was first suggested by H. G. K. Westenbrink<sup>25</sup> who found that fat in the diet conserved the vitamin B<sub>1</sub> present in the tissues. This sparing action of fat was confirmed by H. M. Evans *et al.*<sup>26</sup> who showed furthermore that fats differed in their ability to inhibit the onset of deficiency symptoms, the optimal effect being obtained with fats containing C<sub>8</sub> fatty acids. The nutritive value of fats was different for vitamin B<sub>1</sub> deficient and normal rats. A. R. Kemmerer and H. Steinbock<sup>27</sup> on the other hand could find no support for this hypothesis, the vitamin B<sub>1</sub> contents of the tissues being the same whether the animals were fed a high carbohydrate diet or a high fat diet. Nor was any evidence in favour of the vitamin sparing action of fat obtained by Reinhold *et al.*<sup>28</sup> from experiments on humans. The subjects were maintained from ten to fifteen days on a basal diet, then for the same period on a diet high in fat and then on one high in carbohydrate. Aneurine was estimated in the urine, faeces and food. Urinary excretion of aneurine decreased in five out of the six women when the carbohydrate to fat ratio was increased. The high fat diet had the same effect on urinary aneurine as had the basal diet. Faecal excretion of aneurine was not affected by the change in diet.

Another and somewhat different connection between vitamin B<sub>1</sub> and fats was reported by Longenecker *et al.*<sup>29</sup> who found that loss of

body fat occurred when rats were being depleted of aneurine and that the iodine value of the total fatty acids was increased indicating that the more saturated fatty acids were preferentially metabolised, addition of aneurine caused rapid decomposition of body fat. Le R Voris and H P Moore<sup>30</sup> reported finding the exact opposite, however namely an increase in body fat in vitamin B<sub>1</sub> deficiency, but this is contrary to the experience of other workers. F W Quackenbush *et al*<sup>31</sup> found that on a high carbohydrate low fat diet the normal deposition of fat was prevented by a deficiency of pyridoxine or pantothenic acid, as well as of aneurine, and suggested that the production of fat in the body is not a function of any one dietary factor, aneurine did not prevent the rapid loss of fat that resulted from a deficiency of other members of the vitamin B complex, nor was it more effective than any of these in increasing the total fat content.

G E Boxer and D Stetten<sup>32</sup> also observed a decrease in the deposition of fatty acids when rats were fed a high carbohydrate, fat-free diet low in aneurine, they attributed the phenomenon to low food intake rather than to a specific effect of aneurine.

On the whole, therefore, one must conclude that no case has been made out for a connection between aneurine and fat utilisation, and that claims to have obtained evidence for such a connection depend not on a specific effect of aneurine, but rather on reduced food intake due to loss of appetite or to the deliberate restriction of the diet.

### **Aneurine and Carbohydrate Metabolism**

On the other hand there is no doubt as to the connection between aneurine and carbohydrate metabolism, first pointed out as early as 1914 by C Funk<sup>33</sup> for the symptoms of vitamin B<sub>1</sub> deficiency are accentuated or, alternatively, the aneurine requirements are increased, by conditions that demand a greater output of work, *e g* by exercise<sup>34</sup>. The effect of raising the environmental temperature is controversial, C A Mills<sup>35</sup> stating that rats require twice as much and chicks four times as much aneurine at 91° F as at 68° and 70° F respectively, whilst Kline *et al*<sup>36</sup> declare that the aneurine requirements are reduced. The relation between aneurine and carbohydrate metabolism has been elucidated largely by the brilliant researches of R A Peters, and is more fully discussed in a later section (see page 90).

According to J B Leonards and A H Free,<sup>37</sup> the rate of intestinal absorption of galactose by normal rats is 66 % greater than in vitamin B<sub>1</sub> deficient rats and 12 % greater than in pyridoxine deficiency although the absorption was unaffected by riboflavin deficiency. These workers<sup>38</sup> found that there was no change in the

rate of metabolism of galactose as a result of chronic vitamin B<sub>1</sub> deficiency

### Effect on Infected Animals

Rats and mice have been used to study the effect of aneurine deficiency on resistance to infection. Mice apparently became more susceptible to *Pneumococcus* Type I infection when made deficient in aneurine or riboflavin and administration of several times the normal intake of either vitamin at the time of infection did not affect the mortality.<sup>39</sup> Similarly administration of aneurine markedly increased the resistance of mice to respiratory infections by *Streptococcus haemolyticus*.<sup>40</sup> Aneurine deficient rats and mice were more susceptible to *Salmonella typhi murium* than were animals fed an adequate diet, thus was a primary result of aneurine deficiency in the mouse but secondary to inanition in the rat.<sup>41</sup>

Vitamin B<sub>1</sub>-deficient mice showed a lower incidence of infection than normal mice to the murine strain of poliomyelitis virus, though the vitamin B<sub>1</sub> deficient survivors became paralysed after a prolonged incubation period when given adequate aneurine.<sup>42</sup> A similar increase in resistance to the Lansing strain of poliomyelitis virus was observed when mice were maintained on a vitamin B<sub>1</sub> deficient diet both the mortality rate and incidence of paralysis being lower than in normal animals.<sup>43</sup> Restriction of the caloric intake to 40 % of the normal was however equally effective even when extra aneurine was given so that this striking effect of aneurine on susceptibility to virus infection would appear to be quite illusory. In spite of this the effect of an aneurine antagonist oxythiamine (see page 127) on poliomyelitis was tested it afforded some protection but not as much as that given by a vitamin B<sub>1</sub> free diet.<sup>43a</sup> Vitamin B<sub>1</sub> deficiency did not appear to make rats more susceptible to Flexner's MV cotton rat-adapted strain of poliomyelitis virus<sup>44</sup> but with the Lansing strain a group of rats receiving an excess of aneurine showed a higher incidence of paralysis than a group of vitamin B<sub>1</sub> deficient animals on a second passage however there was no difference between the two groups.

The resistance of aneurine deficient mice to the Lansing strain of poliomyelitis virus or to Theiler's encephalomyelitis virus was only partly due to the accumulation of pyruvic acid or similar metabolite (see page 90) for the addition of pyruvic acid to a diet containing aneurine did increase the resistance of man to these virus infections but not to the same extent as did aneurine deficiency.<sup>45</sup> Chicks on the other hand were protected against avian encephalomyelitis to the greatest degree when given large doses of aneurine throughout life.<sup>46</sup> If however the chicks were fed on an optimal diet for two weeks,



and then with different levels of aneurine, those on the lowest level were protected. Monkeys (*Macaca mulatta*) showed no increase in resistance to poliomyelitis virus when deficient in aneurine,<sup>47</sup> and aneurine deficiency had no significant effect on susceptibility to influenza virus.<sup>40</sup>

Vitamin B<sub>1</sub>-deficient rats are said to be more susceptible than normal animals to rat leprosy,<sup>48</sup> whilst rats rendered deficient in aneurine or riboflavine have been claimed to be less resistant to infection with the worm, *Nippostrongylus muris*.<sup>49</sup> Plasma from an aneurine- (or riboflavine-) deficient animal did not give such adequate protection as did immune plasma from normally fed animals.

A moderate impairment in the antibody response to inoculation with human erythrocytes was observed in aneurine deficient rats.<sup>49a</sup>

### Other Animals

The phalanger, *Trichosurus vulpicula*, appears to be unique in being able to synthesise aneurine,<sup>50</sup> though in the light of work on intestinal synthesis published since the appearance of this suggestion, it must not be concluded that this animal is capable of synthesising the vitamin in the actual tissues or body fluids.

Vitamin B<sub>1</sub> deficiency in pigs follows the same general pattern as in rats, and the main symptoms are anorexia, vomiting, dyspnoea, cyanosis and general weakness.<sup>51, 52</sup> Cardiac dilatation without hypertrophy occurs, together with a local and diffuse myocardial necrosis.<sup>53</sup> Neurological symptoms, however, are absent.<sup>51, 54</sup> The blood shows increased pyruvate.<sup>51</sup> The symptoms are cured by administration of about 125 mg of aneurine per 100 g of carbohydrate plus protein.<sup>55</sup> The aneurine content of the blood is directly related to the proportion in the diet and the muscle tissue, it increased within a week from 21 to 30 µg per 100 g when the diet was supplemented by 25 to 50 mg of aneurine per day.<sup>56</sup> Deposition of aneurine in the tissues is dependent on the dietary intake.<sup>52</sup> Pigs rapidly store supplementary doses of aneurine in the muscle tissue, the effect being detectable within eight days of feeding an additional 50 mg per day. Maximum storage occurred within thirty five days and beyond this period no further increase occurred.<sup>57</sup> Owing to storage of aneurine, pigs can be maintained for about three months on an aneurine-deficient diet before loss of appetite occurs.<sup>58</sup>

Vitamin B<sub>1</sub>-deficient dogs show tachycardia, hypotension and changes in the electrocardiogram,<sup>59</sup> and these disappear on administration of aneurine. The pyruvic acid content of the blood is increased and the lactate pyruvate ratio is decreased.<sup>60</sup> Administration of alcohol to vitamin B<sub>1</sub> deficient dogs decreased the pyruvate and

## EFFECT OF DEFICIENCY IN ANIMALS

increased the lactate whereas in normal animals both were decreased <sup>60</sup> Injection of glucose had the reverse effect increasing the pyruvate and lactate of normal animals and the lactate pyruvate ratio of vitamin B<sub>1</sub>-deficient dogs following an initial decrease <sup>61</sup> Anaemia is not a symptom of vitamin B<sub>1</sub> deficiency in dogs <sup>62</sup>

Cats exhibit three stages in the development of vitamin B<sub>1</sub> deficiency <sup>63</sup> (a) an induction stage with development of anorexia (b) a cortical stage with neurological disturbances particularly of postural mechanical and tonic convulsive seizures and (c) a terminal stage in which the animal is prostrate this is followed by death in one to two days The first and second stages but not the third are reversed by injection of aneurine After one to two weeks on a vitamin B<sub>1</sub>-deficient diet cats showed a 50 % increase in the length of time they were able to maintain respiration in 3.25 % oxygen <sup>64</sup>

The symptoms exhibited by monkeys (*Macaca mulatta*) on a diet deficient in aneurine were <sup>65</sup> loss in weight decreased food consumption general muscle weakness loss of reflexes convulsions inco-ordination increased cachexia signs of cardiac insufficiency prostration and finally death No vomiting or opisthotonus was observed About 15 µg of aneurine per kg of bodyweight per day were required to prevent the onset of deficiency and 25 to 50 µg for adequate growth The pyruvic acid content of the blood in normal monkeys was found to be higher than in normal human or pig blood it increased in aneurine deficiency

Vitamin B<sub>1</sub> deficiency in the calf results in weakness inco-ordination of the legs convulsions head retraction and sometimes scouring anorexia and dehydration the blood and urinary pyruvate are increased above the normal levels <sup>65a</sup>

### Aneurine and the Alimentary Tract

It was at one time supposed that absence of vitamin B<sub>1</sub> produced adverse changes in the alimentary tract but this is now known not to be the case For example two groups of workers <sup>66</sup> observed gastric ulcers in a large proportion of rats on a vitamin B<sub>1</sub> deficient diet but these are now believed to be due to a secondary and not a direct effect of the lack of vitamin B<sub>1</sub> B P Babkin <sup>67</sup> appears to have obtained evidence that absence of some member of the vitamin B complex reduces the response of the gastric glands to the normal stimuli provided by the right kind of food Feeding yeast restored the response to normal but unfortunately no attempt was made to establish the nature of the responsible factor It is possible that Babkin's observations provide an explanation of the association between vitamin B<sub>1</sub> and anorexia

Aneurine had no effect on the movements of the intestine either *in vitro* or *in vivo* <sup>68</sup> It is readily absorbed from the large and small intestine and in chronic diarrhoea appreciable losses may occur through faulty absorption

References to Section II

- 1 U Suzuki T Shimamura and S Okada *Biochem Z* 1912 43, 89
- 2 R L Swank and O A Bessey *J Nutrition* 1941 22, 77 *Arch intern Med* 1942 70, 763
- 3 R L Swank and M Prados *Arch Neurol Psychiat* 1942 47, 97
- 4 J H Shaw and P H Phillips *J Nutrition* 1945 29, 113
- 5 F Sjostrand *Nature* 1946 157, 698
- 6 R L Berg E Stotz and W W Westerfeld *J Biol Chem* 1944 152, 51
- 7 W W Westerfeld and E A Doisy *J Nutrition* 1945 30, 127
- 8 E Sárffy *Z physiol Chem* 1939 262, 87
- 9 R L Swank *J Exp Med* 1940 71, 683
- 10 M L De Finis and J B Odoriz *Rev Soc argent Biol* 1943 19, 314
- 11 L I Nitzescu and V Isanid *Compt rend Soc Biol* 1940 133 490 492
- 12 A S Burt *J Cell Comp Physiol* 1943 21, 145 1943 22, 205
- 13 J M Hundley L L Ashburn and W H Sebrell *Amer J Physiol* 1945 144, 404 J M Hundley and W H Sebrell *U S Publ Health Rep* 1946 61, 847
- 14 K H Coward B G E Morgan and L Wahler *J Physiol* 1942 100, 423 V A Drill and M W Burrill *Endocrin* 1944 35 187
- 15 K H Coward and B G E Morgan *Biochem J* 1941 35, 974
- 16 F J McClure Le R Voris and E B Forbes *J Nutrition* 1934 8 295
- 17 D Glick and W Antopol *J Pharm Exp Ther* 1939 65 389
- 18 M Kniazuk and H Molitor *ibid* 1944 80, 362
- 19 L L Ashburn and J V Lowry *Arch Path* 1944 37, 27
- 20 R W Luecke L S Palmer and C Kennedy *Arch Biochem* 1944 5, 395
- 21 B Sure and Z W Ford *J Nutrition* 1942 24, 405
- 22 J W Ferrebee and N Weissman *ibid* 1943 26, 459 B Sure *ibid* 1944 27, 447 R W Luecke L S Palmer and C Kennedy *Arch Biochem* 1944 5, 395
- 23 H O Singher C J Kensler H Levy E Poore C P Rhoads and K Unna *J Biol Chem* 1944 154, 69
- 24 B Sure *ibid* 1945 157, 543
- 25 H G K Westenbrink *Acta brev Neerland* 1933 3 95
- 26 H M Evans S Lepkovsky and E A Murphy *J Biol Chem* 1934 107, 437
- 27 A R Kemmerer and H Steinbock *ibid* 1933 103, 353

## EFFECT OF DEFICIENCY IN ANIMALS

- 28 J G Reinhold J T L Nicholson and K O S Elsom *J Nutrition* 1944 28, 51
- 29 H F Longenecker G Gavin and E W McHenry *J Biol Chem* 1940 134, 693
- 30 Le R Norris and H P Moore *J Nutrition* 1943 25, 7
- 31 F W Quackenbush H Steinbock and B R Platz *J Biol Chem* 1942 145, 163
- 32 G E Boyer and D Stetten *ibid* 1944 153, 607
- 33 C Funk *Z physiol Chem* 1914 89, 378
- 34 N B Guerrant and R A Dutcher *J Nutrition* 1940 20, 589
- 35 C A Mills *Arch Biochem* 1942 1, 73
- 36 O L Kline L Friedman and E M Nelson *J Nutrition* 1945 29, 35
- 37 J B Leonards and A H Free *ibid* 1943 26, 499
- 38 J B Leonards and A H Free *ibid* 1944 28, 197
- 39 J G Wooley and W H Sebrell *U S Publ Health Rep* 1942 57, 149
- 40 J W Riddle *Ohio State Univ Abs Doctoral Diss* 1943 43, 143  
*Biol Abs* 1945 19, 1408
- 41 E Guggenheim and E Buechler *Proc Soc Exp Biol Med* 1946 61, 413
- 42 A F Rasmussen H A Waisman C A Elvehjem and P F Clark  
*J Infect Dis* 1944 74 41
- 43 C Foster J H Jones W Heube and F Dorfman *J Exp Med* 1944 29, 221
- 44 J H Jones C Foster and W Henle *Proc Soc Exp Biol Med* 1948 69 454
- 45 J A Toomey W O Frohling and W S Takacs *Proc Soc Exp Biol Med* 1943 54, 153 *Yale J Biol Med* 1944 16, 477
- 46 H A Waisman H C Lichstein C A Elvehjem and P F Clark  
*Arch Biochem* 1945 8, 203
- 47 J M Cooperman H C Lichstein P F Clark and C A Elvehjem  
*J Bact* 1946 52 467
- 48 P F Clark H A Waisman H C Lichstein and E S Jones  
*Proc Soc Exp Biol Med* 1945 58, 42
- 49 L T Badger E Masunaga and D Wolf *U S Publ Health Rep* 1940 55, 1027
- 50 J Y C Watt *Amer J Hyg* 1944 39, 145
- 51 B B Carter and A E Axelrod *Proc Soc Exp Biol Med* 1948 67, 416
- 52 A Bolliger and C R Austin *J Proc Roy Soc NSW* 1941 75 118
- 53 M M Wintrobe H J Stein M H Miller R H Follis V Najjar and S Humphreys *Johns Hopkins Hosp Bull* 1942 71, 141
- 54 W W Heinemann M E Insminger T J Cunha and E C McCulloch *J Nutrition* 1946 31, 107
- 55 R H Follis M H Miller M M Wintrobe and H J Stein *Amer J Path* 1943 19, 341

54. M. M. Wintrobe, R. H. Follis, S. Humphreys, H. Stein and M. Lauritsen, *J. Nutrition*, 1944, 28, 283.
55. C. van Etten, N. R. Ellis and L. L. Madsen, *ibid.*, 1940, 20, 607; N. R. Ellis and L. L. Madsen, *ibid.*, 1944, 27, 253.
56. J. W. Pence, R. C. Miller, R. A. Dutcher and W. T. S. Thorp, *J. Biol. Chem.*, 1945, 158, 647.
57. J. W. Pence, R. C. Miller, R. A. Dutcher and P. T. Ziegler, *J. Animal Sci.*, 1945, 4, 141.
58. M. E. Ensminger, W. W. Heinemann, T. J. Cunha and E. C. McCulloch, *Washington Agric. Exp. Sta.*, 1945, *Bull.* 468.
59. L. de Soldati, *Compt. rend. Soc. Biol.*, 1940, 133, 323.
60. R. L. Berg, E. Stotz and W. W. Westerfeld, *J. Biol. Chem.*, 1944, 152, 51.
61. A. Chesler, E. Homberger and H. E. Himwick, *ibid.*, 1944, 153, 219.
62. A. R. Maass, L. Michaud, H. Spector, C. A. Elvehjem and E. B. Hart, *Arch. Biochem.*, 1944, 4, 105.
63. G. M. Everitt, *Amer. J. Physiol.*, 1944, 141, 439.
64. D. C. Smith, R. H. Orter and J. E. P. Toman, *ibid.*, 1944, 140, 603.
65. H. A. Waisman and K. B. McCall, *Arch. Biochem.*, 1944, 4, 265.
- 65a. B. C. Johnson, T. S. Hamilton, W. B. Nevens and L. E. Boley, *J. Nutrition*, 1948, 35, 137.
66. G. Dalldorf and M. Kellogg, *J. Exp. Med.*, 1932, 56, 391; B. Sure and H. S. Thatcher, *Arch. Path.*, 1933, 16, 809.
67. B. P. Babkin, *Canad. Med. Assoc. J.*, 1933, 29, 5.
68. H. Molitor and W. L. Sampson, *E. Merck's Jahresber.*, 1936, 50, 51.

## 12. EFFECT OF ANEURINE DEFICIENCY IN MAN

### Beriberi

The classical pathological condition arising from vitamin B<sub>1</sub> deficiency in man is beriberi. This condition occurs extensively in the Far East, where it has been known for centuries, according to T. Lee<sup>1</sup> since the fourth century A.D., but has only recently been recognised in the West. It is characterised by degenerative changes in the nervous system, including a multiple peripheral neuritis. This is often accompanied by generalised oedema and serous effusions, with a tendency to cardiac hypertrophy and dilatation.

Death in cases of beriberi is not due to the neuritis but to cardiac hypertrophy. On autopsy the heart is found to be greatly enlarged, especially on the right side, with a thin wall and a generalised arteriolar or capillary dilatation. Pulmonary oedema frequently occurs as a result of the back-pressure caused by the failure of this side of the heart; the liver, spleen and kidneys may also be affected.

The nerve changes are generally detectable only by microscopic examination. In the spinal cord, degeneration of the medullary

sheath is the most usual finding, but in some cases the axis cylinder itself is fragmented. Changes may also be seen in the posterior ganglion and anterior horn cells. Degeneration is found as a constant factor in all peripheral nerves, it generally starts in the legs, spreading to the arms later, and then to other parts of the body. The myelin of the sheath is broken up into balls or threads and eventually disappears. In this last event the axis cylinders appear to be coiled and may be fragmented and atrophied. Parallel with these nerve changes, hyperaesthesia and then anaesthesia occur in the legs, and the leg and thigh muscles become atrophied with loss of cross striation and shrinkage of the sarcoplasm. Later the hands and arms and even other parts of the body, become affected in the same way. These nerve and muscle changes are of course not peculiar to beriberi, but occur in all forms of polyneuritis.

In cases where oedema occurs, it is first observed in the legs and thighs, and may later spread to other parts of the body, oedema of the lungs being a frequent symptom. At autopsy serous fluid may be found in the subcutaneous tissue, usually the pericardium, the pleura and the peritoneum. The oedema is probably due to generalised capillary dilatation with increased permeability to plasma and may disappear quite suddenly after a sudden diuresis.

In Europe and the U.S.A. classical beriberi is rarely seen and vitamin B<sub>1</sub> deficiency occurs in the form of polyneuritis induced by special circumstances. Alcoholic polyneuritis<sup>2</sup> is a vitamin B<sub>1</sub> deficiency arising in chronic alcoholics whose high intake of calories in the form of alcohol increases their vitamin B<sub>1</sub> requirements. The condition is often aggravated by the gastro intestinal disturbances that arise in such cases. These lead to defective absorption of such vitamin B<sub>1</sub> as is taken in the form of food. Polyneuritis of pregnancy<sup>3</sup> may arise through the increased metabolic requirements of the foetus, and lack of the vitamin may be aggravated by loss of food in vomiting.

Beriberi was encountered in Japanese prisoner of war camps during the war of 1939-45<sup>4</sup>. It was characterised by anorexia, nervous manifestations tachycardia and arrhythmia. The symptoms were cured by aneurine but a vitamin B complex preparation was even more effective.

### Other Conditions Associated with Vitamin B<sub>1</sub> Deficiency

Aneurine deficiency may also be associated with pregnancy accompanied by a poor diet, pregnancy anaemia, pernicious anaemia accompanied by myxoedema, steatorrhoea, idiopathic hypochromic anaemia, scurvy, carcinoma and ulcer of the stomach, fatal pulmonary tuberculosis, anorexia nervosa and following gastrectomy<sup>5</sup>. In some forms

of anaemia, in certain cardiovascular disturbances and in subacute combined degeneration of the cord aneurine deficiency is usually associated with deficiencies of other members of the vitamin B complex <sup>6</sup>

Aneurine is probably of no value in diabetes,<sup>7</sup> diabetic neuritis,<sup>8</sup> or pre eclamptic toxæmia <sup>9</sup>

Wernicke's encephalopathy, characterised by anorexia vomiting nystagmus, and emotional changes with, subsequently, mental and eye changes, was observed in a Japanese prisoner of-war camp <sup>10</sup> and was cured rapidly and completely by injections of aneurine. As acute aneurine deficiency appeared to be the sole cause of the condition the name cerebral beriberi is suggested

In pyloric stenosis colitis and fevers, the diet may be limited with reduction of the vitamin B<sub>1</sub> intake to a figure below that essential for adequate metabolism, which is generally taken to be 2 to 3 mg a day so that vitamin B<sub>1</sub> deficiency may accompany these conditions

The symptoms present in these special types of polyneuritis are similar in every respect to those described above as characteristic of beriberi. They differ in detail from those encountered in other polyneuritides

A deficiency of aneurine leads almost invariably to gastro intestinal symptoms, especially anorexia and nausea, and administration of aneurine produces immediate relief, though it should be borne in mind that not all forms of anorexia are due to vitamin B<sub>1</sub> deficiency. Occasional symptoms of vitamin B<sub>1</sub> deficiency are glossitis, achlorhydria, anaemia and diarrhoea

## Treatment

Aneurine hydrochloride is a specific remedy for beriberi and the polyneuritides arising from vitamin B<sub>1</sub> deficiency, and its administration in such conditions is generally followed by a quick recovery. From 20 to 50 mg of crystalline aneurine hydrochloride are given in cases of beriberi by intramuscular or intravenous injection and after about a fortnight, the same dose may be given orally until the symptoms are completely relieved. Since patients suffering from vitamin B<sub>1</sub> deficiency may also be suffering from other deficiencies, it is frequently necessary to give other vitamins in addition to aneurine sometimes in the form of liver or yeast extracts. The time required for recovery depends on the extent to which the disease has progressed. Peripheral nerves are capable of regeneration as long as the cell body in the spinal cord or posterior ganglion remains viable. Where the cells and axis cylinders of the central nervous system have degenerated however, restoration cannot take place. The heart condition and

oedema generally respond dramatically to vitamin B<sub>1</sub>, these being assisted by the diuretic effect of the vitamin, which helps to remove accumulated fluid from the tissues

### Experimental Vitamin B<sub>1</sub> Deficiency

Perhaps the simplest picture of uncomplicated vitamin B<sub>1</sub> deficiency is obtained in experiments with human volunteers, though it must be confessed that the results are not always as consistent or clear-cut as might be desired, perhaps for reasons that will be referred to later (see page 76)

Jolliffe *et al*<sup>11</sup> produced aneurine deficiency artificially in four out of five subjects by maintenance on a diet low in vitamin B<sub>1</sub>. Subjective symptoms were observed on the fourth day and objective signs on the fifth. One subject, however, developed no symptoms or signs after thirty days on a diet containing 60 % of his calculated aneurine requirement. Addition of aneurine cured all the symptoms within three days and the objective signs within five days. Between 7 and 25 % of the ingested aneurine was excreted in the urine. Urinary excretion appeared to be well correlated with the aneurine intake (see page 63), though the amount excreted varied from one individual to another with the same intake.

Oedema was reported by Elsom *et al*<sup>12</sup> to be an early symptom of experimental human aneurine deficiency. The changes in carbohydrate metabolism included failure of the blood-sugar to return to normal within three to four hours of ingestion of glucose, and maintenance of a high pyruvic acid content in the blood. The blood lactic acid also increased, the R Q was unaltered and the response to insulin decreased as the deficiency progressed. The abnormalities disappeared on administration of aneurine.

A considerable number of experiments of this kind were carried out over a number of years by R. D. Williams and his colleagues<sup>13</sup>. Anorexia, fatigue, loss of weight, absence of or low free gastric acidity, constipation, tenderness of the muscles of the calves and abnormalities in the electrocardiogram were more or less constant findings, but no oedema, cardiac dilatation or peripheral pain, such as are encountered in classical beriberi, were observed. Subjective symptoms were usually experienced by the patients before objective signs became manifest. The first of these signs, which appeared about the thirtieth day with subjects maintained on a daily intake of 0.2 mg (i.e. about 10 % of the normal intake) was a diminished aneurine excretion, and by the fiftieth day the urinary excretion following administration of the test dose was also reduced (see page 63). After this stage was reached administration of glucose raised the blood pyruvic and lactic acid



## ANEURINE (THIAMINE)

levels, and anorexia and increased weakness and paraesthesia of the legs appeared. Only after 110 days on this regimen did signs of polyneuropathy appear with sensory loss, loss of tendon reflexes and paralysis of the leg muscles, so that this sign of aneurine deficiency is particularly late in making its appearance, it can only be cured by weeks of treatment with high doses of aneurine.

Experiments on the simultaneous administration of aneurine and desiccated thyroid showed<sup>14</sup> that the latter was less efficient in promoting metabolic activity in a state of vitamin B<sub>1</sub> deficiency. This may be connected with the observation of other workers<sup>15</sup> that thyrotoxic patients are unable to store aneurine but excrete large amounts in the urine, faeces and sweat, and the claim that aneurine is of benefit in such cases.

A comparison of the effects of acute and mild chronic aneurine plus riboflavine deficiency was made by Horwitt *et al*<sup>16</sup>. They divided their subjects into three groups. The first received a daily diet containing 2200 cals and sufficient vitamins, with the exception of aneurine (400 µg per day) and riboflavine (900 µg per day). The second group had the same diet, but with 6 mg of aneurine and 13 mg of riboflavine per day. The third group served as a control. In the first group some dulling of interest and restriction of activity was observed and within nine months, an abnormally high level of lactic and pyruvic acid was found in the blood after administration of glucose. After two years the members of the second group were transferred to a diet that supplied 250 µg of aneurine and 800 µg of riboflavine daily, within three months, the blood lactic and pyruvic acids had risen higher than in the first group. Shortly afterwards clinical symptoms developed—non pitting oedema of the facial skin, budding of the blood vessels into the cornea with plexus formation, decreased vibration sense in the legs and some loss of inhibitory control with exaggeration of psychotic symptoms. Immediate recovery occurred when 6 mg of aneurine per day were administered.

The effects of a combined deficiency of aneurine, riboflavine and nicotinic acid were studied by Keys *et al*<sup>17</sup>. One group of young men lived for 161 days on a diet that supplied only 0.61 mg of aneurine, 0.95 mg of riboflavine and 12.2 mg of nicotinic acid per day, whilst another group subsisted on a diet that supplied rather more of the vitamins. No serious deficiency symptoms developed. When the vitamin intake of some of the subjects was reduced to 0.032 mg of aneurine, 0.052 mg of riboflavine and 0.4 mg of nicotinic acid per day, however, symptoms of vitamin B<sub>1</sub> deficiency appeared and were quickly relieved by administration of aneurine. Thus, aneurine deficiency is probably the first to manifest itself in a multiple vitamin deficiency (see page 607).

## Aneurine and Cancer

J E Ayre and W A G Bauld<sup>18</sup> noted that abnormal oestrogenic activity in cases of menorrhagia and uterine cancer was often associated with a vitamin B<sub>1</sub> deficiency though not with a deficiency of other vitamins. They therefore suggested that aneurine deficiency over a prolonged period may pre dispose either to menorrhagia or to malignancy. It is suggested that the finding of a vitamin B<sub>1</sub> deficiency together with an abnormally high level of oestrogen may be indicative of a dangerous pre-cancerous state.

## References to Section 12

- 1 T Lee *Chinese Med J* 1940 58, 314
- 2 G R Minot M B Strauss and S Cobb *New England J Med* 1933 208, 1244 N Jolliffe and P M Joffe *Proc Soc Exp Biol Med* 1935 32, 1161 N Jolliffe C N Colbert and P M Joffe *Amer J Med Sci* 1936 191, 515
- 3 E D Plass and W F Meugert *J Amer Med Assoc* 1933 101, 2020 M R Strauss and W J Macdonald *ibid* 1933 100, 1320
- 4 R E Hibbs *Ann Int Med* 1946 25, 270
- 5 H M Sinclair *Proc Roy Soc Med* 1939 32, 807
- 6 R Goodhart and H M Sinclair *J Biol Chem* 1940 132, 11
- 7 K A Smith and H L Mason *Proc Staff Meetings Mayo Clinic*, 1940 15 529
- 8 W Needles *J Amer Med Assoc* 1943 121 914
- 9 R Kapeller Adler and J A Cartwright *Edinburgh Med J* 1943 50, 305
- 10 H E de Wardener and B Lennox *Lancet* 1947 1, 11
- 11 N Jolliffe R Goodhart J Gennis and J K Cline *Amer J Med Sci* 1939 198, 198
- 12 K O Elsom F D W Lukens W H Montgomery and L Jonas *J Clin Invest* 1940 19, 153
- 13 R D Williams H L Mason and B F Smith *Proc Staff Meetings Mayo Clinic* 1939 14 787 R D Williams H L Mason R M Wilder and B F Smith *Arch intern Med* 1940 66 785 R D Williams H L Mason B F Smith and R M Wilder *ibid* 1942 69, 721 R D Williams H L Mason M H Power and R M Wilder *ibid* 1943 71, 38
- 14 R D Williams and E C Kendall *ibid* 1943 72, 185
- 15 R H Williams E Egana P Robinson S P Asher and C Dutoit *ibid* 1943 72 353
- 16 M K Horwitt E Liebert O Kreisler and P Wittman *Science* 1946 104, 407
- 17 A Keys A F Henschel H L Taylor O Mickelsen and J Brozek, *Amer J Physiol* 1945 144 5
- 18 J E Ayre and W A G Bauld *Science* 1946 103 441

levels and anorexia and increased weakness and paraesthesia of the legs appeared. Only after 110 days on this regimen did signs of polyneuropathy appear with sensory loss, loss of tendon reflexes and paralysis of the leg muscles so that this sign of aneurine deficiency is particularly late in making its appearance. It can only be cured by weeks of treatment with high doses of aneurine.

Experiments on the simultaneous administration of aneurine and desiccated thyroid showed<sup>14</sup> that the latter was less efficient in promoting metabolic activity in a state of vitamin B<sub>1</sub> deficiency. This may be connected with the observation of other workers<sup>15</sup> that thyrotoxic patients are unable to store aneurine but excrete large amounts in the urine, faeces and sweat, and the claim that aneurine is of benefit in such cases.

A comparison of the effects of acute and mild chronic aneurine plus riboflavine deficiency was made by Horwitt *et al*<sup>16</sup>. They divided their subjects into three groups. The first received a daily diet containing 2200 cals and sufficient vitamins with the exception of aneurine (400 µg per day) and riboflavine (900 µg per day). The second group had the same diet but with 6 mg of aneurine and 13 mg of riboflavine per day. The third group served as a control. In the first group some dulling of interest and restriction of activity was observed and within nine months an abnormally high level of lactic and pyruvic acid was found in the blood after administration of glucose. After two years the members of the second group were transferred to a diet that supplied 250 µg of aneurine and 800 µg of riboflavine daily. Within three months the blood lactic and pyruvic acids had risen higher than in the first group. Shortly afterwards clinical symptoms developed—non pitting oedema of the facial skin, budding of the blood vessels into the cornea with plexus formation, decreased vibration sense in the legs and some loss of inhibitory control with exaggeration of psychotic symptoms. Immediate recovery occurred when 6 mg of aneurine per day were administered.

The effects of a combined deficiency of aneurine, riboflavine and nicotinic acid were studied by Keys *et al*<sup>17</sup>. One group of young men lived for 161 days on a diet that supplied only 0.61 mg of aneurine, 0.95 mg of riboflavine and 12.2 mg of nicotinic acid per day whilst another group subsisted on a diet that supplied rather more of the vitamins. No serious deficiency symptoms developed. When the vitamin intake of some of the subjects was reduced to 0.032 mg of aneurine, 0.052 mg of riboflavine and 0.4 mg of nicotinic acid per day, however, symptoms of vitamin B<sub>1</sub> deficiency appeared and were quickly relieved by administration of aneurine. Thus aneurine deficiency is probably the first to manifest itself in a multiple vitamin deficiency (see page 607).

administration is resorted to the possibility of anaphylaxis must be kept in mind and the dose given slowly. C. A. Mills<sup>5</sup> however suggests that parenteral administration should never be used.

### References to Section 13

- 1 C. L. Steinberg *Am J Digest Dis Nutr* 1938 5 680
- 2 M. B. Richards *Brit Med J* 1945 1 433
- 3 L. R. Cerecedo and L. J. Vinson *Proc Soc Exp Biol Med* 1944 55 139
- 4 C. Mino *Japan J Med Sci* IV 1940 12 *Proc* 98
- 5 C. A. Mills *J Amer Med Assoc* 1941 116, 2101 1941 117, 1501
- 6 Z. A. Leitner *Lancet* 1943 2, 474
- 7 M. H. Stiles *J Allergy* 1941 12, 507 L. Scheff *J Amer Med Assoc* 1941 117, 609 C. L. Laws *ibid* 176 W. S. Eisenstadt *Minn Med* 1942 25 861 M. M. Mitran *J Allergy* 1944 15 150 W. Stein and M. Morgenstein *Ann Int Med* 1944 20 826
- 8 F. Halz *J Invest Dermat* 1942 5 135
- 9 T. J. Haley and A. M. Flesher *Science* 1946 104, 567
- 10 H. Molitor *Proc Fed Amer Soc Exp Biol* 1942 1, 309
- 11 I. M. Reingold and F. R. Webb *J Amer Med Assoc* 1946 130, 491
- 12 N. Jolliffe *ibid* 1941 117, 1496 1501

## 14 METABOLISM OF ANEURINE

Both microbiological and chemical assays have been used to measure the amount of aneurine in the blood and urine of normal and avitaminous humans and animals. The results indicated that the blood and urine concentrations were lower in vitamin B<sub>1</sub> deficient than in normal subjects and quite early in the history of aneurine therapy it was recognised that low concentrations of aneurine in both body fluids supported a diagnosis of vitamin B<sub>1</sub> deficiency.

### Urinary excretion and the Test-Dose Method of Assessing Nutritional Status

L. J. Harris and P. C. Leong<sup>1</sup> introduced a method of assessing the nutritional status of an individual with respect to aneurine that was more reliable than a simple measurement of the urinary concentration. The concentration of aneurine in the urine before and after administration of a test dose was estimated by the thiochrome method. In vitamin B<sub>1</sub> deficiency very little of the test dose was excreted whereas well nourished subjects excreted a relatively large proportion.

## 13. EFFECT OF EXCESSIVE DOSAGE WITH ANEURINE

According to C L Steinberg,<sup>1</sup> daily doses of 100  $\mu$ g of aneurine given to rats caused sterility in the second generation females whilst daily doses of 200 and 400  $\mu$ g resulted in the appearance of a toxic factor in the milk of the third generation females and in complete failure of lactation respectively. This observation was confirmed by M B Richards,<sup>2</sup> who found that failure of lactation was more severe the higher the intake of aneurine, and that litters from does with a high aneurine intake (plus calcium carbonate) failed to survive were in a poor condition or showed convulsive fits due to pyridoxine deficiency. Excess of aneurine, in fact, appeared to precipitate pyridoxine deficiency. L R Cerecedo and L J Vinson,<sup>3</sup> on the other hand failed to find evidence that amounts of the order of 625 to 700  $\mu$ g per day had any harmful effects on the fertility or lactation of rats. According to C Mano,<sup>4</sup> the respiration of mice was stimulated by small doses, whilst respiratory arrest and chronic cramps were produced by large doses.

C L Steinberg<sup>1</sup> also reported that, in humans overdosage with aneurine may give rise to herpes zoster, and C A Mills<sup>5</sup> and Z A Leitner<sup>6</sup> found that an intake of more than 5 mg per day produced symptoms of hyperthyroidism, *eg* nervousness, tremors tachycardia and sweating. It was suggested that these were due to overdosage or, more correctly to supersaturation. When the vitamin was withdrawn the nervousness and other symptoms disappeared.

Several cases of sensitivity resembling allergic reactions have also been reported.<sup>6-7</sup> In at least one instance the patient was desensitised by the conventional procedure. As according to F Kalz<sup>8</sup> injection of aneurine hydrochloride intradermally invariably causes a histamine like reaction the intradermal test cannot be used to test sensitivity towards aneurine. Anaphylaxis plays no part in aneurine toxicity as seen in rabbits<sup>9</sup> but the injection of a sensitising dose of 100 mg increased the resistance of the animals to toxic injections of the vitamin, increasing the lethal dose from 126 to 238 mg per kg. H Molitor<sup>10</sup> was unable to sensitise dogs and guinea pigs so that anaphylactic phenomena appeared. Anaphylactic shock has been reported in man.<sup>11</sup>

Aneurine is usually regarded as non toxic. N Joliffe<sup>12</sup> for instance observed no toxic effects in over 3000 patients. He also reported that Borsook treated seventy patients for three years with 100 mg of aneurine hydrochloride per day without untoward results. It seems to be generally accepted that aneurine can safely be given by mouth but should be given by injection only in severe intestinal dysfunction and acute beriberi. In the rare instances in which parenteral

a normal diet 120 to 930  $\mu\text{g}$  of pregnant women on a diet supplemented with 2 mg of aneurine hydrochloride daily 400 to 780  $\mu\text{g}$  of nursing mothers, 145 to 1070  $\mu\text{g}$ , and of cases of complicated pregnancy 210 to 765  $\mu\text{g}$ . Intramuscular injection of 10 mg of aneurine hydrochloride resulted in the retention of 32 to 70 % by the normal women and the pregnant women given the aneurine supplemented diet whereas more than 70 % was retained by the pregnant women on an ordinary diet, by those with neurilgic complaints and by the nursing mothers, 100 % was retained in subjects with pregnancy toxæmia. A C Siddall and J W Mull<sup>12</sup> stated that the average daily excretions of forty two pregnant women were 286, 263 and 249  $\mu\text{g}$  in the first, second and third trimesters respectively, these excretions were doubled on administration of 750  $\mu\text{g}$  of aneurine hydrochloride daily by mouth.

Much lower values were reported by K V Toverud<sup>13</sup> for pregnant and non pregnant women. Normal women were found to excrete 80  $\mu\text{g}$  per day by the thiochrome method or 137.5  $\mu\text{g}$  by the azo method and 2.6 to 16.1 % of a 5 mg test dose was excreted within twenty four hours. Pregnant women excreted on the average only 38  $\mu\text{g}$  per day, but nearly half of the group excreted none at all, and only 2 % of the test dose was excreted within twenty four hours. Lactating women excreted 70  $\mu\text{g}$  per day and the response to a test dose was intermediate between that of pregnant and normal women.

H L Mason and R D Williams<sup>14</sup> stated that the diet prior to carrying out a test for aneurine deficiency should provide 800 to 900  $\mu\text{g}$  of aneurine per day that a test dose of 1 mg equivalent to 0.4 mg per 1000 cal, should be used and that the excretion of over 100  $\mu\text{g}$  in the urine in twenty four hours increasing to at least 20 % of the test dose, was evidence of an adequate intake of aneurine.

Y L Wang and J Yudkin<sup>15</sup> showed that aneurine excretion decreased rapidly in subjects fed a vitamin B<sub>1</sub> deficient diet and reached a steady value in six days. When vitamin B<sub>1</sub> was restored to the diet, the excretion rapidly increased and with a normal intake of about 900  $\mu\text{g}$  per day, it rose to 137 to 233  $\mu\text{g}$  per day. Benson *et al*<sup>16</sup> gave the urinary excretion of children aged 4 to 10 years, as 92 to 602 (average 268)  $\mu\text{g}$  per day and claimed that on an adequate diet supplying at least 990  $\mu\text{g}$  per day 27 % of the ingested aneurine was excreted. The excretion of less than 20 % of the daily intake was claimed to indicate vitamin B<sub>1</sub> deficiency.

According to Kraut *et al*<sup>17</sup> some of the aneurine in urine is generally present in the form of cocarboxylase 10 to 210  $\mu\text{g}$  of aneurine and 0 to 180  $\mu\text{g}$  of cocarboxylase being excreted per day, the average of thirty-eight estimations was 100  $\mu\text{g}$  of free and 40  $\mu\text{g}$  of bound aneurine. The ratio of free to bound aneurine in individual instances

## ANEURINE (THIAMINE)

Using this method, Y L Wang and L J Harris<sup>2</sup> found that normal humans excreted 36 to 105 (average 65)  $\mu\text{g}$  of aneurine per day and that, on administration of a test dose of just over 1 mg of aneurine hydrochloride per 10 stones of bodyweight, this increased to over 105  $\mu\text{g}$  per day. Excretions of less than 30  $\mu\text{g}$  per day, rising to not more than 45  $\mu\text{g}$  after giving the test dose, were taken to indicate sub optimal levels of intake, whilst values of 15  $\mu\text{g}$  per day or less were regarded as indicative of more or less severe vitamin B<sub>1</sub> deficiency.

A somewhat similar method was used by G M Hills<sup>3</sup> with similar, though somewhat higher, results. He found that normal humans excreted 50 to 170 (average 100)  $\mu\text{g}$  per day and that, except in thyrotoxicosis, oral administration of a 1-mg test dose of aneurine hydrochloride resulted in the excretion, three hours later, of 26 to 110 (average 65)  $\mu\text{g}$ . In a fully saturated individual, 200  $\mu\text{g}$  of the test dose were excreted within three hours. H C Hou and E F Yang<sup>4</sup> using a modification of the test devised by E F Yang and B S Platt,<sup>5</sup> in which diazotised *p* aminoacetophenone is the reagent, obtained values of 28 to 170 and 0 to 16  $\mu\text{g}$  for the daily urinary excretion of normal Chinese adults and beriberi patients respectively. R C Guha and B Ahmad<sup>6</sup> reported values of 84 to 228  $\mu\text{g}$  for the daily output of normal Indian adults, this was computed to be 6 to 19 % of the intake.

The test dose method has been used extensively by various workers in different parts of the world. Some have employed the thiochrome method for estimating the aneurine, some various modifications of the azo reaction and others the yeast growth or the *Phycomyces* method. Different routes of administration, different test doses and different criteria for assessing the response have also been proposed, some workers have suggested estimating the aneurine output within twenty four hours of giving the test dose, others within three hours, and yet others within four hours.<sup>7</sup> Again some workers have recorded the absolute amounts excreted and others the percentage of the test dose excreted.

Melnick *et al*<sup>8</sup> using diazotised *p* aminoacetophenone, found that the average daily excretions by well nourished men and women were 198 and 93  $\mu\text{g}$  respectively, and that, after oral administration of a 5 mg test dose 14 and 12 % respectively were excreted within twenty-four hours. Elderly men (66 to 75 years of age) excreted slightly more aneurine than women of the same age.<sup>9</sup> I Magyar<sup>10</sup> claimed that the excretion within twenty four hours of less than 18 % of a 2- to 10 mg test dose administered intravenously was indicative of vitamin B<sub>1</sub> deficiency. W Neuweiler<sup>11</sup> found that the daily urinary excretion of normal women was 45 to 665  $\mu\text{g}$ , of pregnant women on

a normal diet, 120 to 930  $\mu\text{g}$ , of pregnant women on a diet supplemented with 2 mg of aneurine hydrochloride daily, 400 to 780  $\mu\text{g}$ , of nursing mothers, 145 to 1070  $\mu\text{g}$ , and of cases of complicated pregnancy, 210 to 765  $\mu\text{g}$ . Intramuscular injection of 10 mg of aneurine hydrochloride resulted in the retention of 32 to 70 % by the normal women and the pregnant women given the aneurine supplemented diet, whereas more than 70 % was retained by the pregnant women on an ordinary diet, by those with neuralgic complaints and by the nursing mothers, 100 % was retained in subjects with pregnancy toxæmia. A C Siddall and J W Mull<sup>12</sup> stated that the average daily excretions of forty-two pregnant women were 286, 263 and 249  $\mu\text{g}$  in the first, second and third trimesters respectively, these excretions were doubled on administration of 750  $\mu\text{g}$  of aneurine hydrochloride daily by mouth.

Much lower values were reported by K V Toverud<sup>13</sup> for pregnant and non-pregnant women. Normal women were found to excrete 80  $\mu\text{g}$  per day by the thiochrome method or 137.5  $\mu\text{g}$  by the azo method, and 2.6 to 16.1 % of a 5-mg test dose was excreted within twenty-four hours. Pregnant women excreted on the average only 38  $\mu\text{g}$  per day, but nearly half of the group excreted none at all, and only 2 % of the test dose was excreted within twenty-four hours. Lactating women excreted 70  $\mu\text{g}$  per day and the response to a test dose was intermediate between that of pregnant and normal women.

H L Mason and R D Williams<sup>14</sup> stated that the diet prior to carrying out a test for aneurine deficiency should provide 800 to 900  $\mu\text{g}$  of aneurine per day that a test dose of 1 mg equivalent to 0.4 mg per 1000 cal should be used and that the excretion of over 100  $\mu\text{g}$  in the urine in twenty-four hours, increasing to at least 20 % of the test dose, was evidence of an adequate intake of aneurine.

Y L Wang and J Yudkin<sup>15</sup> showed that aneurine excretion decreased rapidly in subjects fed a vitamin B<sub>1</sub> deficient diet and reached a steady value in six days. When vitamin B<sub>1</sub> was restored to the diet, the excretion rapidly increased and, with a normal intake of about 900  $\mu\text{g}$  per day, it rose to 137 to 233  $\mu\text{g}$  per day. Benson *et al*<sup>16</sup> gave the urinary excretion of children, aged 4 to 10 years, as 92 to 602 (average 268)  $\mu\text{g}$  per day and claimed that on an adequate diet, supplying at least 990  $\mu\text{g}$  per day, 27 % of the ingested aneurine was excreted. The excretion of less than 20 % of the daily intake was claimed to indicate vitamin B<sub>1</sub> deficiency.

According to Kraut *et al*,<sup>17</sup> some of the aneurine in urine is generally present in the form of cocarboxylase, 10 to 210  $\mu\text{g}$  of aneurine and 0 to 180  $\mu\text{g}$  of cocarboxylase being excreted per day, the average of thirty-eight estimations was 100  $\mu\text{g}$  of free and 40  $\mu\text{g}$  of bound aneurine. The ratio of free to bound aneurine in individual instances



## ANEURINE (THIAMINE)

varied enormously—from 19 to 91. Administration of aneurine increased the excretion of both forms and generally left the ratio substantially unaffected.

The presence in urine of a pyrimidine compound capable of stimulating the growth of yeast in a manner similar to aneurine was reported by Pollack *et al*<sup>18</sup>. They found that on depriving a subject of aneurine for ten days the ratio of aneurine to pyrimidine changed from 9:1 to 1:9, the absolute amount of the pyrimidine excreted remaining substantially constant. The intravenous injection of 100 mg of aneurine was followed by an enormous increase in the excretion of urinary pyrimidine.

A novel method of studying the metabolism of aneurine was introduced by Borsook *et al*<sup>19</sup>. They injected aneurine containing radioactive sulphur, S<sup>35</sup>, intramuscularly into a man who had been deprived of aneurine for thirty six days, and found that there was a rapid increase in the excretion of S<sup>35</sup> in the urine, indicating that significant amounts of aneurine remained in the tissues after prolonged ingestion of a vitamin B<sub>1</sub> free diet. The results also showed that injected aneurine interacted very quickly with pre-existing aneurine in the blood and tissues, and that metabolism was very rapid, yielding neutral sulphur compounds and inorganic sulphate in the urine.

The efficiency with which different amounts of aneurine are utilised in the rat varies, but doses of 5 to 50  $\mu$ g per day were the levels most effectively utilised<sup>20</sup>. The efficiencies for doses of 50, 100 and 1000  $\mu$ g per day were 92, 83, and 52 % respectively. The results indicate that appreciable destruction of aneurine occurs in the body. Such destruction was shown to take place when aneurine was incubated with liver, lung, heart, stomach and intestinal tissue. Comparable figures are not available for humans, but it has been shown<sup>21</sup> that in normal subjects the urinary excretion is directly related to the dose given and, with intakes of 50 mg, approximates to 100 %. On a synthetic diet yielding 1 mg of aneurine per day and on a natural diet containing 0.84 mg, the daily urinary outputs were 113 to 147 and 90 to 112  $\mu$ g respectively<sup>22</sup>.

Doubt was thrown on the validity of the excretion test method of assessing aneurine status by E. C. Allbone and E. Finch,<sup>23</sup> who found that children on an ordinary diet excreted in the urine 10 to 14 % of their intake of aneurine and that after giving 0.5 to 1.0 mg by mouth, the output in different individuals varied considerably—from 0 to 41 %—but the average was still only 14 %. Many recently ill children excreted amounts of aneurine considerably less than the accepted levels without showing signs of beriberi.

Somewhat disturbing results were also obtained by H. H. Giffit and H. M. Hauck,<sup>24</sup> who compared four different methods of assessing

aneurine status. Normal adults were maintained for forty four days on a diet that provided 600  $\mu\text{g}$  of aneurine per 1000 cals, and the following estimations were carried out: (a) the twenty-four-hourly excretion for the last four weeks of the period, (b) the percentage recovery of a 5 mg oral test dose given at the end of the period, (c) the recovery of a 1 mg intramuscular dose at the beginning, and (d) at the end, of the period. The twenty-four hourly excretion was found to be equivalent to 9 to 13 % of the intake, the recovery from the 5 mg dose to 15 to 22 % of the dose and from the two 1-mg doses to 15 to 24 % and 8 to 21 % respectively. Each test in fact gave a result that indicated a different nutritional status in the same individual. C. Papageorge and G. T. Lewis<sup>25</sup> compared the twenty four hourly urinary output of aneurine in normal young adults with (a) the percentage recovery from a 1-mg oral test dose after four hours, and (b) the urinary output in a "fasting hour" specimen collected in the hour immediately following the completion of a twenty-four-hourly period and after an overnight fast. Satisfactory correlation was obtained between the twenty-four-hour output on the one hand and the "fasting hour" sample and the response to the 1-mg test dose on the other, but the "fasting hour" test did not agree so well with the response to the test dose. Nevertheless, the "fasting hour" test was recommended as being the most convenient for nutritional surveys. The excretion of less than 4  $\mu\text{g}$  in the "fasting hour" test was regarded as indicative of aneurine deficiency.

Possibly the most critical study of the test dose method is that carried out by Mickelsen *et al.*,<sup>26</sup> who made a statistical examination of the values obtained for the aneurine excretion of groups of "normal" young men. They showed that with dietary intakes of 0.6, 1.0, 1.8 and 2.0 mg of aneurine per day the amount of aneurine (as determined by the thiochrome method) excreted in the urine was linearly related to the intake although one individual might excrete twice or three times as much as another individual on the same diet. The variations between individuals and groups increased with increased excretion. These workers also studied the excretion of the pyrimidine half of the aneurine molecule, which for brevity they term "pyramin". This was estimated by the yeast fermentation method of Schultz *et al.* The excretion of pyramin was found to bear an exponential relationship to the aneurine intake a plateau being formed at high intakes corresponding to an excretion of 400  $\mu\text{g}$  of pyramin per day. At more normal levels, however, i.e. 1 to 2 mg per day, the relationship was linear. Moreover, the pyramin excretion was less variable than the aneurine excretion, and statistical treatment was therefore easier. The results suggest that insufficient attention has been given in the past to the statistical significance of the values obtained in aneurine

excretion tests Another factor that appears to have been ignored by previous workers is that, when the aneurine intake is changed the rate of response in the urinary excretion is such that only half the change is completed in ten days Mickelsen *et al* recommended that at intakes between 0.7 and 1 mg of aneurine per day, the aneurine excretion is a better indicator of nutritional status than the pyrimin excretion, but that outside these limits the pyrimin excretion is the more reliable

The urinary excretion of aneurine by human subjects maintained on a diet rich in aneurine was reduced when viable fresh bakers' yeast was added to the diet,<sup>27</sup> and pure aneurine hydrochloride ingested with live yeast was not recovered in the urine<sup>27a</sup> No such depression occurred when the yeast had been boiled in water

### Blood Concentrations and their Value in Assessing Nutritional Status

Although urinary excretion following the administration of a test dose has until recently been the accepted procedure for assessing the degree of vitamin B<sub>1</sub> deficiency, attempts have also been made to use blood concentrations for assessing nutritional status Among the first papers reporting the aneurine content of blood were those of A P Meiklejohn<sup>28</sup> and H M Sinclair,<sup>29</sup> who employed the *Phycomyces* test The concentration of aneurine in plasma and cerebrospinal fluid varied from 0 to 1.3  $\mu\text{g}$  per 100 ml and in both instances the aneurine was present in the free state and not as cocarboxylase The amount of aneurine present in the whole blood of healthy adults was  $7.4 \pm 1.4$   $\mu\text{g}$  per 100 ml, values less than 4.5  $\mu\text{g}$  per 100 ml were taken to indicate vitamin B<sub>1</sub> deficiency E N Rowlands and J F Wilkinson,<sup>30</sup> using substantially the same method, obtained similar values They found normal blood to contain 6.5 to 16.5  $\mu\text{g}$  per 100 ml and the blood of subjects with alcoholic neuritis nutritional neuritis, scurvy and malnutrition 5  $\mu\text{g}$  per 100 ml or less I Magyar<sup>31</sup> obtained values ranging from 1 to 15 with an average of 7.6  $\mu\text{g}$  per 100 ml for blood serum and confirmed that the level depended on the dietary intake of aneurine

According to R Goodhart and T Nitzberg,<sup>32</sup> normal blood contains 3.1 to 9.2 with an average of 5.4  $\mu\text{g}$  per 100 ml, and a value of less than 3  $\mu\text{g}$  per 100 ml is indicative of vitamin B<sub>1</sub> deficiency They used the yeast-growth method of Atkin Schultz and Frey and found that a heat labile factor was present in blood which enhanced the stimulatory activity of aneurine on yeast, they were able to eliminate interference from this source by heating the blood at 100° C for four to five minutes

Benson *et al*<sup>23</sup> obtained values ranging from 4.8 to 12.3 with an average of 7.8  $\mu\text{g}$  per 100 ml for the aneurine content of the blood of healthy children, values not differing appreciably from those obtained by other workers for adults. They commented on the fact that daily variations in the blood aneurine of an individual did not follow the daily urinary aneurine outputs of the same individual, and that the blood concentration bore no relationship to the absolute amount or proportion of the dietary aneurine excreted in the urine.

It has been reported<sup>24</sup> that the amount of free aneurine in the maternal blood decreases during parturition whereas the "bound" aneurine concentration remains unchanged. It is suggested that the decrease in the free aneurine concentration is due to an increase in the amount of acetylcholine hydrolysed, to changes in the nervous action and to increased passage through the placenta.

When aneurine hydrochloride (1 mg per kg) was injected intravenously into normal dogs a temporary increase in the blood co-carboxylase occurred.<sup>25</sup> The injection of insulin (1 I U per kg) into a normal animal was also followed by a rise in the blood co-carboxylase. If aneurine hydrochloride was injected into an insulin treated animal, a still greater increase in the blood concentration of co-carboxylase, together with a decrease in the concentration of inorganic phosphate, occurred. No significant changes of this type however resulted from the injection of aneurine hydrochloride into depancreatized hyperglycemic dogs, and these responded normally when controlled with insulin except that the blood inorganic phosphate remained constant. The results suggest that insulin increases the phosphorylation of aneurine.

Because the administration of aneurine to rabbits or humans was found to increase the capacity of their serum to inhibit the haemolytic action of digitonin, D. L. Farley<sup>26</sup> suggested that anti-haemolytic activity could be used as an index of aneurine status, but the observation does not appear to have been made use of for this purpose.

### Distribution of Aneurine in Blood Elements

A number of workers have studied the distribution of aneurine in the blood elements. The low proportion of aneurine in the plasma has already been noted. This was confirmed by E. Deutsch,<sup>27</sup> who obtained values of 9 to 16  $\mu\text{g}$  per 100 ml for normal blood, of this only 3 to 10 % was present in the plasma. The aneurine content of leucocytes and platelets were reported<sup>28</sup> to be ten fold that of the erythrocytes. In leukemias, the concentration in leucocytes and platelets increased five fold.<sup>29</sup> The yeast fermentation method estimates in

## ANEURINE (THIAMINE)

addition to aneurine a pyrimidine compound (see page 106), presumed to be a metabolite, and the abnormally high concentration of aneurine in the leucocytes in leukemia is attributed to impaired utilisation of the vitamin in this condition, since the amount of the pyrimidine metabolite present was found to be substantially the same as in normal individuals

The red cells of humans and rats contain 2.1 and 1.4  $\mu\text{g}$  of aneurine pyrophosphate per  $10^{11}$  cells respectively and white cells 340 and 280  $\mu\text{g}$  per  $10^{11}$  cells<sup>39a</sup>

### Phosphorylation of Aneurine

The phosphorylation of aneurine (see page 93) is extremely rapid,<sup>40</sup> intravenous administration of the hydrochloride into normal human subjects being almost immediately followed by an increase in the aneurine pyrophosphate content of the blood, this fell to normal again after about six minutes. Hepatic cirrhosis, but not nephritis, impaired the phosphorylation of aneurine. Similarly, the intravenous injection of cocarboxylase was followed by an increase in the plasma and red cell aneurine diphosphate and free aneurine, the level of the latter rapidly returned to normal, but the diphosphate remained at an abnormally high level for more than one hour. Patients with advanced cirrhosis showed no immediate increase in the amount of free aneurine in the blood, and exhibited a smaller rise in the diphosphate than that observed in normal subjects.

### Aneurine in Faeces

The amount of aneurine excreted in the faeces by rats was constant whether the rats received 0, 5 or 50  $\mu\text{g}$  of aneurine daily<sup>41</sup> but, in deficient animals, the volume of faeces was greatly reduced, the aneurine was largely present in the form of cocarboxylase. The faeces of aneurine deficient rats did not alleviate symptoms of aneurine deficiency when given to other rats.

The amount of free aneurine excreted by humans on a synthetic diet containing 1 mg of aneurine per day or on a natural diet containing 0.84 mg was 13 to 17 and 25 to 49  $\mu\text{g}$  respectively. The combined faecal aneurine was 2.4 to 5.1 times as high on the natural diet as on the synthetic diet.<sup>42</sup> The faecal excretion of aneurine is relatively constant, and independent of the dietary intake.<sup>43 44 45</sup> Most of the aneurine in the faeces resulting from bacterial synthesis<sup>43, 44</sup> is present within the bacterial cells.

Faecal excretion is discussed more fully on page 76

## Aneurine in Sweat

Ordinarily no appreciable quantities of aneurine are excreted in the sweat whether this is produced thermally or as the result of exercise <sup>46</sup>. The sweat produced by exercise following the injection of 50 mg of aneurine hydrochloride however contained a much greater concentration (4.5 mg per litre) than the urine excreted by the same subjects (63  $\mu$ g per litre) <sup>47</sup>.

## Foetal Aneurine

Aneurine appears to be incapable of passing the placenta although it accumulates in this organ which thus serves to regulate the supply of aneurine to the foetus <sup>48</sup>. The concentrations of aneurine in the venous and arterial blood of the umbilical cord were found to be 7.5 and 5  $\mu$ g per 100 ml respectively compared with 2 to 12  $\mu$ g per 100 ml in the maternal venous blood and 2.7 to 10  $\mu$ g per 100 g in the placenta. When 50  $\mu$ g of aneurine hydrochloride were given intra-venously before parturition the aneurine contents of both the cord blood and maternal blood and of the placenta increased but the injected aneurine disappeared rapidly except in the placenta.

Aneurine only passes into the placenta when free <sup>49</sup> although bound aneurine is present in this organ in concentrations greater than that of free aneurine. The placenta contains 18 to 38  $\mu$ g per 100 g of total aneurine of which 4 to 8  $\mu$ g per 100 g is in the free state. Oral administration of aneurine to newborn babes resulted in its excretion in the urine but administration to the mother had little effect because it was stopped by the placental barrier <sup>50</sup>.

## Aneurine Content of Milk

The aneurine content of breast milk can be increased by increasing the amount of aneurine in the diet but only to a maximum of 25 to 32  $\mu$ g per 100 ml <sup>51</sup>. Breast fed infants do not excrete aneurine and require less aneurine than do artificially fed infants <sup>52</sup>. According to E. C. Slater and E. J. Rial <sup>53</sup> breast milk contains about 9  $\mu$ g of aneurine per 100 ml in the second week of lactation rising to about 15  $\mu$ g per 100 ml after twenty weeks and then gradually falling. Free aneurine is maximal in the third or fourth week but a large proportion of the aneurine is present in phosphorylated form. Knott *et al* <sup>54</sup> from an analysis of 111 samples of milk from fifty women record an average concentration of 15  $\mu$ g per 100 ml. None was present in the colostrum but the concentration in the later milk increased gradually to a maximum of 20  $\mu$ g per 100 ml in the first three weeks thereafter.

falling to 9.3  $\mu\text{g}$  per 100 ml at weaning. This was confirmed by Roderuck *et al*,<sup>55</sup> who obtained low aneurine values for the first few days after parturition, and rapidly increasing amounts during the first few weeks, rising to a maximum value of 14.0 to 14.7  $\mu\text{g}$  per day. The diet was the principal factor in determining the concentration in the milk.

Intramuscular injection of aneurine during labour, or oral administration after parturition, accelerated the increase in the milk aneurine during lactation.

### Aneurine Content of Tissues

Aneurine is fairly uniformly distributed throughout the tissues of the human body. Brain, liver and kidney contain approximately<sup>56</sup> 1  $\mu\text{g}$  per g, heart muscle 2 to 3  $\mu\text{g}$  per g, and skeletal muscle 0.5  $\mu\text{g}$ . Higher values are obtained immediately after administration of aneurine. Unlike other tissues, the brain maintained its vitamin B<sub>1</sub> content in face of a deficit of the vitamin for a considerable time.<sup>56a</sup>

Westenbrink *et al*<sup>57</sup> studied the distribution of aneurine pyrophosphate in the tissues of man and of the rat, pig, duck, chick, pigeon, goose, blackheaded gull and frog. Compared with other animals the amounts present in human liver and kidney were low and the amount in the heart muscle was high. In most animals, with the exception of the pig, little difference was found in the amounts present in the liver, kidney and heart muscle. In general, the spleen, adrenals, pancreas, thymus and sex organs contained less than the liver, kidney and heart, though rat testicles contained an exceptionally large amount. Except in the pig, lung tissue had only a low aneurine content. The amount present in the nervous system was low, both in man and the pig. Pig skeletal muscle contained an exceptionally large amount of aneurine pyrophosphate and there was a marked difference between the amounts present in skeletal and in smooth muscle.

According to B. Alexander,<sup>58</sup> most of the aneurine in animal tissue is present as pyrophosphate.

The concentration of aneurine in the skeletal muscle of infants increases somewhat with age. A value of 20  $\mu\text{g}$  per 100 g was recorded for a premature foetus, somewhat higher values for a full-term foetus and a value of 147  $\mu\text{g}$  per 100 g for a seven year old child.<sup>59</sup> More aneurine was present in the combined than in the free state, for example, foetal organs from the third to the ninth month of pregnancy contained 3 to 7  $\mu\text{g}$  per 100 g of free aneurine, and 20 to 50  $\mu\text{g}$  per 100 g of total aneurine.<sup>49</sup> The concentration was highest in muscular organs.

## References to Section 14

- 1 L J Harris and P. C Leong *Lancet*, 1936, 1, 886
- 2 Y L Wang and L. J Harris, *Biochem J*, 1939 33, 1356
- 3 G M Hills, *ibid*, 1966
- 4 H C Hou and E T Yang *Chinese J. Physiol*, 1939, 14, 269
- 5 E F Yang and B S Platt, *ibid*, 259
- 6 R C Guha and B Ahmad, *Indian J Med Res*, 1939, 27, 465
- 7 V. A Najjar and L E Holt, *Johns Hopkins Hosp Bull*, 1940, 67, 107.
- 8 D Melnick, H Field and W. D Robinson, *J. Nutrition*, 1939 18, 593
- 9 L W. Weitz and H S Mitchell *Proc Soc Exp Biol Med*, 1941, 48, 259
- 10 I Magyar, *Z Vitaminforsch*, 1940, 10, 32
- 11 W. Neuweiler, *Arch Gynäk*, 1939, 169, 19
- 12 A C Siddall and J W Mull *Amer J Obstet Gynec*, 1945, 49, 672
- 13 K V Toverud, *Z Vitaminforsch*, 1940 10, 255
- 14 H L Mason and R D Williams, *J Clin Invest* 1942, 21, 247
- 15 Y L Wang and J Yudkin *Biochem J*, 1940, 24, 343
- 16 R A Benson, C M Witzberger and L B Slobody *J Pediat*, 1941, 18, 617. R A Benson L B Slobody C M Witzberger and L Lewis, *ibid* 1942 20, 454
- 17 H Kraut, A Weischer and G Stumpff, *Biochem Z* 1941, 308, 309
- 18 H Pollack, M Ellenberg and H Dolger, *J Nutrition* 1941, 21, Suppl, 10
- 19 H Borsook, E R Buchman, J B Hatcher, D M Yost and E McMullan, *Proc Nat Acad Sci*, 1940, 28, 412
- 20 B Sure and Z W Ford *J Nutrition* 1943 26, 659
- 21 B Alexander, G Landwehr and F Mitchell *J Clin Invest* 1946, 25, 294
- 22 M L Hathaway and J E Strom *J Nutrition*, 1946 32, 1
- 23 E C Allbone and E Finch *Arch Dis Childhood*, 1945, 20, 169
- 24 H H Giff and H M Hauck, *J Nutrition*, 1946 31, 635
- 25 E Papageorge and G T Lewis, *ibid* 1947, 34, 301
- 26 O Mickelsen, W O Caster and A Keys, *Proc Soc Exp Biol Med*, 1946, 62, 254. *J Biol Chem*, 1947 168, 415
- 27 H T Ness, E L Price and H T Parsons, *Science*, 1946 103, 198
- 27a M Garber, M M Marquette and H T Parsons, *J Nutrition*, 1949 38, 225
- 28 A P Meiklejohn, *Biochem J*, 1937, 31, 1441
- 29 H M Sinclair, *ibid* 1938, 32, 2185, 1939, 33, 1816 2027
- 30 E N Rowlands and J F Wilkinson, *Brit Med J* 1938 2, 818
- 31 I Magyar, *Z Vitaminforsch*, 1940 10, 32
- 32 R Goodhart and T Nitzberg, *J Clin Invest*, 1941, 20, 625
- 33 R A Benson C M Witzberger, L B Slobody and L Lewis, *J Pediat* 1942 21, 659
- 34 W Neuweiler, *Z Vitaminforsch*, 1942, 12, 329



## ANEURINE (THIAMINE)

- 35 P P Foà J A Smith and H R Weinstein *Arch Biochem* 1947 13, 449
- 36 D L Farley *Surg Gynec Obstet* 1942 74, 1154
- 37 E Deutsch *Schweiz Med Woch* 1942 72, 895
- 38 A T Gorham J C Abels A L Robins and C P Rhoads *J Clin Invest* 1942 21, 161
- 39 J C Abels A T Gorham L Carver and C P Rhoads *ibid* 177
- 39a G Smits and E Florijn *Biochim et Biophys Acta* 1949 3 44
- 40 R H Williams G W Bissell and J B Peters *Arch intern Med* 1944 73, 203
- 41 G A Emerson and H G Obermeyer *Proc Soc Exp Biol Med* 1945 59, 299
- 42 M L Hathaway and J E Strom *J Nutrition* 1946 32, 1
- 43 L Wildemann *Biochem Z* 1941 308, 10
- 44 B Alexander G Landwehr and F Mitchell *J Clin Invest* 1946 25, 287
- 45 H G Oldham M V Davis and L J Roberts *J Nutrition* 1946 32, 163
- 46 D M Tennant and R H Silber *J Biol Chem* 1943 148, 159
- 47 E L Hardt and E V Still *Proc Soc Exp Biol Med* 1941 48, 704
- 48 W Neuweiler *Z Vitaminforsch* 1940 10, 40
- 49 W Neuweiler *ibid* 1941 11, 88
- 50 W Neuweiler *ibid* 1943 13, 280
- 51 A F Morgan and E G Haynes *J Nutrition* 1939 18, 105
- 52 F Widenbauer and H Kruger *Z Kinderheilk* 1939 61, 52
- 53 E C Slater and E J Rial *Med J Australia* 1942 1, 3
- 54 E M Knott S C Kleiger and F Torres Bracamonte *J Nutrition* 1943 25, 49
- 55 C E Roderuck H H Williams and I G Macy *Amer J Dis Child* 1945 70, 162 *J Nutrition* 1946 32 249
- 56 J W Ferrebee N Weissman D Parker and P S Owen *J Clin Invest* 1942 21, 401
- 56a J Salcedo V A Najjar L E Holt and E W Hutzler *J Nutrition* 1948 36, 307
- 57 H G K Westenbrink E P S Parvé and H J Thomasson *Z Vitaminforsch*, 1943 13, 101
- 58 B Alexander *J Biol Chem* 1943 151, 455
- 59 M C Hulse N Weissman V Rowland R Gross and J W Ferrebee *Amer J Dis Child* 1944 67, 30

## 15 INTESTINAL SYNTHESIS OF ANEURINE

As long ago as 1915 it was observed by Theiler *et al*<sup>1</sup> that ruminants could be maintained for long periods of time on a diet low in certain vitamins and they therefore suggested that the vitamin requirements of cattle are so low that they may even be covered

indirectly by synthesis carried out by the extensive bacterial flora of the intestines

Thirteen years later Bechdel *et al*<sup>2</sup> showed that calves developed normally on a diet low in vitamin B and they therefore supported the hypothesis put forward by Theiler *et al*. Later work however indicated that the source of the vitamin B in ruminants is the bacterial flora not of the intestine but of the rumen. Nevertheless recent work has confirmed in a most dramatic manner the prophetic words of the South African workers in respect of other species of animals.

Most of the early results on aneurine excretion in animals were confined to estimates of urinary excretion and no reports appear to have been made of the amounts excreted in faeces until 1935 when Guarrant *et al*<sup>3</sup> showed that vitamin B<sub>1</sub> was present in the faeces of rats owing to bacterial synthesis in the caecum. In the rat the nature of the ingested carbohydrate had a marked effect on the elaboration of the vitamin readily assimilable carbohydrates such as sucrose and glucose being ineffective. Dextrin however was assimilated at a much slower rate enabling it to reach the caecum where organisms had an opportunity of multiplying. For many years it was believed that rats could only benefit from this microbiological synthesis by ingesting their faeces<sup>4</sup> and in fact they may do this in vitamin B<sub>1</sub> deficiency tests unless prevented from gaining access to their faeces for instance by using cages with wire screens. many experiments have been invalidated through failure to take precautions against this contingency.

## Refection

In 1946 it was reported by L. S. Fridericia<sup>5</sup> in Denmark that a young rat on a vitamin B deficient diet containing rice starch had begun to grow at a normal rate after its weight had declined in the anticipated manner. At the same time the faeces became white and bulky owing to the presence of undigested starch. The phenomenon was termed refection and appeared spontaneously some months later in a group of rats at the Lister Institute London<sup>6</sup>. It could be induced in any rats by feeding the bulky white faeces. The phenomenon is due to the sudden loss by the rat of the ability to digest starch though why this should happen is still a mystery. It has been suggested<sup>7</sup> that the presence of undigested starch and of starch splitting organisms in the caecum leads to a vigorous fermentation with the development of an acid pH that favours the growth of organisms capable of synthesising members of the vitamin B complex. These then become available to the rat by virtue of the acid pH of the caecum and the caecal region therefore behaves like the rumen.

in ruminants (see page 79) Refected rats excrete more vitamin than non-refective rats on the same vitamin B deficient diet

Refection has also been observed in the pigeon,<sup>8</sup> whilst the rabbit may derive some, and possibly most, of its vitamin B supply from the consumption of its faeces Rabbits excrete two types of faeces one normal, voided during the day-time, the other, softer and produced during the night The latter are normally swallowed by the rabbit directly from the anus<sup>9</sup> They swarm with bacteria, and are presumably rich in the vitamin B complex

### Rôle of the Intestinal Flora

The presence in rat faeces of components of the vitamin B complex was demonstrated by Light *et al*,<sup>10</sup> who found that the animals lost weight when sulphaguanidine was added to the diet and that growth was restored either by giving the vitamin B complex or faeces from normal rats They concluded that the sulphonamide inhibited the bacterial synthesis of essential factors belonging to the complex

The aneurine content of human faeces was shown to be independent of the aneurine intake by L Wildemann,<sup>11</sup> who ascribed this to synthesis of the vitamin by bacteria in the intestine He put forward these results rather to prove that faecal excretion, in contrast to urinary excretion, is not a measure of the nutritional status of an individual His conclusions have since been confirmed by Alexander *et al*<sup>12</sup>

The possible significance of the independence of faecal excretion and diet was not appreciated until the publication in 1943 of a paper by V. A. Najjar and L. E. Holt<sup>13</sup> who, in an attempt to establish the aneurine requirements of man with greater accuracy than had hitherto been possible, maintained nine young male volunteers for several months on a diet supplying only 0.1 to 0.2 mg per day Five showed the anticipated signs of aneurine deficiency, but four showed no signs at all, even after the complete exclusion of aneurine from the diet for a further seven weeks Free aneurine was found to be present in the faeces, and on giving one of these four anomalous subjects sulphasuxidine the faecal aneurine fell to zero, rising again to the original value when the administration of the sulphonamide was stopped

This appeared to indicate that aneurine formed by the flora of the intestine could, under certain conditions, be absorbed in sufficient quantities to prevent the development of aneurine deficiency That it was probably absorbed from the large intestine was demonstrated by giving a retention enema containing aneurine, a pronounced rise in the urinary excretion of aneurine followed

## INTESTINAL SYNTHESIS

What conditions are necessary for intestinal synthesis and why the phenomenon had not previously been discovered in the course of the innumerable experiments that have been carried out is still a mystery, although some of the factors that affect the phenomenon are now known. The authors conclude their paper with these very significant words: "The demonstration that intestinal bacteria can synthesise thiamine carries interesting implications for human nutrition. This phenomenon may explain the discrepancies in thiamine requirements found by different observers. Since it is likely that the biosynthesis of thiamine is greatly affected by diet, as is known to be the case in animals, it follows that we must think in terms of requirements on particular diets rather than of requirements in general."

In fact, the result appears to call into question the fundamental concept of a vitamin as a substance that must be present in the diet to enable animals to remain healthy. For why, if man can derive his aneurine requirements from his intestinal flora, should vitamin B<sub>1</sub> deficiency ever be observed? The complete answer to this question has not yet been found, but similar observations in respect of other members of the vitamin B complex have been made, with results even more striking than those obtained with aneurine.

Although their results anticipate much that should properly be reserved for later chapters, it is useful at this stage to refer to the work of Denko *et al*<sup>14</sup>. These workers measured the faecal and urinary excretions of seven healthy young men maintained on a normal diet containing *p*-aminobenzoic acid, biotin, folic acid, pantothenic acid, pyridoxine, aneurine, riboflavine and nicotinic acid, the amount of each of these factors in the diet being measured. The following results were obtained ( $\mu$ g per day) for the range of the averages of the seven subjects and the mean of the averages:

	Urine	Faeces
<i>p</i> -Aminobenzoic acid	131-198 (148)	183-361 (246)
Biotin	27.5-35.6 (31.7)	114-201 (133)
Folic acid	2.94-4.99 (3.99)	222-393 (304)
Pantothenic acid	2.68-3.46 (3.04)	0.89-3.66 (2.20)
Pyridoxine	0.57-0.69 (0.63)	0.33-0.42 (0.38)
Nicotinic acid	1.31-1.39 (1.21)	2.14-5.41 (3.63)
Aneurine	144-323 (227)	109-895 (548)
Riboflavine	543-913 (678)	823-1313 (1029)

They indicate that the faecal excretion was higher than the urinary excretion in every instance except pantothenic acid and pyridoxine.

A comparison was then made of the ranges and means of the average daily vitamin intakes with the ranges and means of the average urinary and faecal excretions:

# ANEURINE (THIAMINE)

	<i>Intake</i>	<i>Urinary and Faecal Excretion</i>	<i>Excretion as Per Cent Intake (Mean)</i>
<i>p</i> Aminobenzoic acid	97-220 (188)	331-398 (373)	230
Biotin	37-54 (44)	136-236 (163)	378
Folic acid	43-86 (62)	226-397 (310)	542
Pantothenic acid	4-19-5-30 (4-73)	4-07-6-72 (5-25)	112
Pyridoxine	1-32-2-46 (1-76)	0-94-1-07 (1-01)	57
Nicotinic acid	12-4-20-9 (15-6)	3-32-6-64 (4-82)	31
Aneurine	1-24-1-63 (1-44)	0-36-1-02 (0-78)	57
Riboflavine	1-74-1-98 (1-84)	1-74-1-98 (1-84)	91

A similar series of tests was carried out on five young men maintained on a diet containing limited amounts of all the members of the vitamin B complex. Two other men were given the same diet supplemented with amounts of each vitamin equal to or greater than the amounts contained in the normal diet previously given. With the restricted vitamin intake, the faecal excretion of aneurine and of the other vitamins was at least as high as that on the normal diet, and was unaffected by vitamin supplementation. The faecal excretion of aneurine actually exceeded the dietary intake. The urinary excretion of aneurine, on the other hand, and of riboflavine, N<sup>1</sup>-methylnicotinamide and pantothenic acid decreased markedly on the restricted diet, but returned to normal on supplementation. With the other vitamins the urinary excretion was affected to a smaller extent.

It is evident from these results that all the B vitamins are synthesised by the intestinal flora, but that the requirements of aneurine, riboflavine and nicotinic acid as reflected in the urinary excretion must be met from the vitamins supplied in the diet. Possibly with the other vitamins absorption takes place to a sufficient extent to prevent the development of deficiency symptoms. This may be the reason why deficiencies of *p* aminobenzoic acid, folic acid, biotin, pantothenic acid and, probably pyridoxine are virtually unknown except in experimental subjects. Only with aneurine, riboflavine and nicotinic acid are characteristic deficiency symptoms produced when the diet contains inadequate amounts. It must be presumed that although bacterial synthesis of these three vitamins may occur in the intestine they are not normally absorbed, although sometimes, as in Najjar's experiment, animals may be able to make use of the aneurine, riboflavine or nicotinic acid produced by bacterial action. That no absorption of bacterial aneurine normally occurs was the conclusion reached by B. Alexander and G. Landwehr,<sup>15</sup> for neither aneurine nor cocarboxylase was absorbed from the large intestine when administered by retention enema. This is a complete contradiction of the result obtained by Najjar and Holt.

It is possible that the results of intestinal synthesis have been noted previously without the real explanation having been appreciated. F. M. Meyers,<sup>16</sup> for example, reported that healthy Javanese excreted from 0 to 63  $\mu\text{g}$  of aneurine per day compared with 40 to 3000  $\mu\text{g}$  for the inhabitants of temperate climates. He concluded that a chronic low vitamin B<sub>1</sub> intake may produce an adaptation of the body. Might it not rather be that the needs of the body were being met in such instances by the bacteria of the gut?

A little information is available concerning the effect of certain factors on faecal excretion. Increased amounts of aneurine, for example, were excreted in the faeces of humans when large amounts of plant fibre were ingested,<sup>17</sup> although no change occurred in the faecal excretion on altering the carbohydrate: fat ratio.<sup>18</sup> The nature of the carbohydrate may also be a factor affecting the bacterial synthesis of aneurine, for Schweigert *et al.*<sup>19</sup> observed that the amount of aneurine excreted in the urine increased when the sucrose in the diet was replaced by lactose. Feeding live yeast stimulated bacterial synthesis, and Parsons *et al.*<sup>20</sup> found that compressed bakers' yeast increased the faecal excretion in humans, at the same time the urinary excretion was reduced, showing that the vitamin B<sub>1</sub> in the yeast was not being absorbed. Better absorption was obtained after the yeast had been boiled with water. A similar result was obtained with rats.<sup>21</sup>

Of considerable interest in relation to bacterial synthesis in the intestine are the results obtained by R. C. Thompson,<sup>22</sup> who found that the intestinal micro-organism *B. proteus vulgaris* synthesised *inter alia* aneurine, and by P. R. Burkholder and I. McVeigh,<sup>23</sup> who found that aneurine was also synthesised on synthetic media by the intestinal organisms, *Escherichia coli*, *Bacillus lactis aerogenes*, *B. mesentericus*, *B. vulgatus* and *B. faecalis alcaligenes*.

## Synthesis of Aneurine in the Rumen

Closely related to the phenomenon of bacterial synthesis in the intestine of man is that of bacterial synthesis in the rumen of ruminants. As already noted, Theiler *et al.*,<sup>1</sup> in 1915, observed that ruminants could be maintained on diets low in certain vitamins, and their results were confirmed by Bechdel *et al.*<sup>2</sup> Several years later, Wegner *et al.*<sup>24</sup> and Hunt *et al.*<sup>25</sup> found that the rumen contents of a calf, obtained by means of a fistula, had a higher vitamin B<sub>1</sub> content than the diet. L. W. McElroy and H. Goss<sup>26</sup> reported a value of 7  $\mu\text{g}$  per g for the concentration of aneurine in the dried rumen and reticulum contents of a sheep that had been fed on a diet containing only 0.4  $\mu\text{g}$  per g of the vitamin. They concluded that the vitamin

## ANEURINE (THIAMINE)

in the rumen was derived from microbial growth and not by concentration of the vitamin already present in the diet. On the other hand the rumen of a cow maintained on the same diet contained no aneurine but the milk contained 2 to 2.5  $\mu\text{g}$  per g. The conclusion was therefore reached that aneurine was not a dietary essential for the ruminant. A later report by Hunt *et al*<sup>27</sup> failed to confirm the earlier result since no evidence could be obtained that aneurine was synthesised in the rumen of a steer the amount present being less than that present in the diet. This may have been due to the nature of the diet however, since on increasing the amount of maize or carbohydrate in the feeding stuff the difference between the two values tended to decrease.

### References to Section 15

- 1 A Theiler H H Green and P R Viljoen *Rep vet Res S Afr* 1915 3 4, 9
- 2 S L Bechdel H E Honeywell R A Dutcher and M H Knutsen *J Biol Chem* 1928 80, 231
- 3 N B Guerrant R A Dutcher and L F Tomey *ibid* 1935 110, 233, N B Guerrant R A Dutcher and R A Brown *J Nutrition* 1937 13, 305
- 4 T B Osborne and L B Mendel *Publ Carnegie Inst* 1911 No 156 part 2 p 59
- 5 L S Fridericia *Skand Arch Physiol* 1926 49, 55, L S Fridericia P Freudenthal S Gudjonsson G Johansen and N Schoubye *J Hygiene* 1927 28 27, 70
- 6 M H Roscoe *ibid* 103
- 7 P M Kon *A Bacteriological and Physiological Study of the Phenomenon of Potato Starch Refection in the Rat* Ph D Thesis Univ of Reading 1935 P M Kon S K Kon and A T R Mattick *J Hygiene* 1938 38, 1 S K Kon *Proc Nutr Soc* 1945 3, 217
- 8 J Taylor and U Thant *Indian J Med Res* 1919 16, 747
- 9 H Madsen *Nature* 1939 143, 981 E L Taylor *ibid* 1939 143 982 A Eden *ibid* 1940 145, 36 628
- 10 R F Light L J Cracas C T Olcott and C N Frey *J Nutrition* 1942 24, 427
- 11 L Wildemann *Biochem Z* 1941 308, 10
- 12 B Alexander G Landwehr and F Mitchell *J Clin Invest* 1946 25, 287
- 13 V A Najar and L E Holt *Science* 1943 98 456 *J Amer Med Assoc* 1943 123, 683
- 14 C W Denko W E Grundy J W Porter G H Berryman T E Friedemann and J B Youmans *Arch Biochem* 1946 10, 33 C W Denko W E Grundy N C Wheeler C R Henderson G H Berryman T E Friedemann and J B Youmans *ibid* 1946 11, 109

## ANIMAL AND HUMAN REQUIREMENTS

- 15 B Alexander and G Landwehr *Science*, 1945 101, 229
- 16 F M Meyers, *Amer J Med Sci*, 1941, 201, 785
- 17 A Williamson and H T Parsons *J Nutrition* 1945, 29, 51
- 18 J G Reinhold J T L Nicholson and K O S Elsom *ibid*, 1944 28, 51
- 19 B S Schweigert J M McIntire, L M Henderson and C A Elvehjem *Arch Biochem*, 1945, 6, 493
- 20 H T Parsons, A Williamson and M L Johnson *J. Nutrition*, 1945, 29, 373
- 21 H T Parsons, A Foeste and H Gilberg, *ibid*, 383
- 22 R C Thompson *Univ Texas Publ*, 1942 No 4237, p 87
- 23 P R Burkholder and I McVeigh, *Proc Nat Acad Sci*, 1942, 28, 285
- 24 M I Wegner, A N Booth C A Elvehjem and E B Hart, *Proc Soc Exp Biol Med* 1940 45, 769
- 25 C H Hunt, C H Kirk, E W Burroughs R M Bethke, A F Schalk and P Gerlaugh *J Nutrition*, 1941, 21, 85
- 26 L W. McElroy and H Goss *J Biol Chem*, 1939 130, 437, *J Nutrition*, 1941 21, 163
- 27 C H Hunt E W Burroughs R M Bethke, A F Schalk and P. Gerlaugh *ibid* 1943, 25, 207.

## 16 ANIMAL AND HUMAN REQUIREMENTS OF ANEURINE

It is clear that from what has been said in the preceding section on bacterial synthesis in the intestine that animal and human requirements for aneurine may well be affected—possibly to a very considerable degree—by the incidence of this phenomenon. Unfortunately, no precise information is available at present to indicate how common intestinal synthesis is in man or in other animals or to what extent the aneurine thus provided is available to meet the requirements of the host.

One can only suspect, from the fact that it was discovered comparatively recently, that intestinal synthesis is an infrequent and circumscribed source of aneurine, and that the values arrived at for human requirements before the phenomenon came to light still remain generally valid, although possibly wide of the mark in exceptional instances. This supposition is believed not to hold good with some other members of the vitamin B complex.

The first attempts to determine the amounts of aneurine needed by an animal were carried out by T B Osborne and L B Mendel,<sup>1</sup> who showed that the amount required increased with the weight of the animal. This was confirmed by G R Cowgill,<sup>2</sup> who studied the aneurine requirements of four different species of animals and obtained the following results.



# ANEURINE (THIAMINE)

<i>Species</i>	<i>Weight (g)</i>	<i>Daily Requirement (<math>\mu</math>g)</i>
Mouse . .	20	3
	26	6
Rat . .	97	3
	153	7
Pigeon .	300	6
	400	12
	500	18
Dog .	6000	25
	8000	35
	10,000	54

He concluded that the requirements for man would be proportionately lower. Young rats required twice as much aneurine for growth when maintained at 90° F as they required at 68° F<sup>3</sup>

The first calculations made for the human requirements of vitamin B<sub>1</sub> were based on an examination of diets known to have been associated with epidemics of beriberi and of diets known to be associated with the absence of beriberi. G. R. Cowgill<sup>2</sup> set out the available data in detail and summarised the results in a graph relating body-weight to the vitamin-calorie ratio. It can be deduced from this that a 60 kg man consuming 2500 cal per day would require not less than 210 I U of vitamin B<sub>1</sub> per day. A. Z. Baker and M. D. Wright<sup>4</sup> and A. G. van Veen<sup>5</sup> arrived at values of 200 to 500 and 150 I U per day respectively as the minimum intake to prevent beriberi in man, these are equivalent to 0.7 to 1.7 and 0.5 mg per day.

The difference between these estimates may be due to the smaller average weight of Indonesians, on whom van Veen made his observations, compared with Europeans. Stepp *et al*<sup>6</sup> gave the requirements as 0.25 to 0.75 mg per day, whilst Vorhaus *et al*<sup>7</sup> estimated that the normal American adult requires about 1 mg of pure aneurine daily, although they did not imply that this was the minimum necessary for health.

More recent results have been based on controlled experiments with human volunteers, or on saturation tests with individuals on different diets, or on nutritional surveys of particular sections of the population. An example of investigations of the first type is provided by the work of Elsom *et al*<sup>8</sup>. They maintained six volunteers on a diet containing just enough aneurine to satisfy the 'theoretical' requirements and three others on a diet containing half this amount. Three of those on the higher level developed typical signs of aneurine

deficiency whence it was concluded that the *minimum* intake to maintain health was 0.65 mg per day

Saturation tests were used by D. Melnick<sup>9</sup> who stated that adults required 0.35 mg of aneurine per 1000 cals or 0.875 mg per day assuming a caloric intake of 2500 cals per day. He recommended a minimum intake of 0.5 mg per 1000 cals however. Of the subjects tested (Americans) only 73 % excreted sufficient aneurine to pass all clearance tests. Saturation tests were also employed by R. D. Williams *et al*<sup>10</sup> who found that an intake of 0.1 to 0.175 mg of aneurine per 1000 cals caused a rapid and one of 0.22 mg per 1000 cals a slow depletion of the tissue reserves whereas an intake of 0.45 mg per 1000 cals was associated with only a slight depletion of co-carboxylase. H. Oldham *et al*<sup>11</sup> found that 0.5 mg per 1000 cals satisfied the aneurine requirements of adults.

As an example of the third type of investigation the results of T. Moran and R. G. Booth<sup>12</sup> may be cited. After carrying out a dietary survey they concluded that 50 % of the population of Britain in the early days of the 1939-45 war had an inadequate intake of the vitamin. They gave the average requirement of the population as a whole as 2.3 mg per day on a diet supplying 2810 cals per day; this is equivalent to 2.05 mg per 2500 cals. Excluding lactating women and young children the aneurine requirement was estimated at 1.4 mg per day or 1.25 mg per 2500 cals—a value identical with the intake recommended by Melnick. M. D. Wright<sup>13</sup> however considered this value to be inadequate and stated that 1.9 mg per day should be regarded as the minimum. E. G. Young<sup>14</sup> made a dietary survey among Canadian families with incomes ranging from \$450 to \$1500 per annum and found that the average consumption of aneurine was 0.20 mg per 1000 cals for men, 0.19 mg per 1000 cals for women and 0.22 mg per 1000 cals for children—considerably lower values than those generally accepted as desirable. Yet no evidence of clinical aneurine deficiency was observed.

Lane *et al*<sup>15</sup> stated that prior to the introduction of enriched flour the average vitamin B<sub>1</sub> content of the American diet—due in the main to lean pork, bread and milk—was 0.8 mg per 2500 cals—a much lower figure than the minimum standard suggested by Melnick and by Wright. The use of enriched flour increased the value to 1.3 mg per 2500 cals—a figure just above Melnick's minimum but below Wright's.

On the whole there is a surprising unanimity about the minimum human requirement for aneurine and we may safely assert that at least 1.25 mg per 2500 cals should be given in order to maintain health. The optimal quantity—that is the amount required to ensure full activity—is probably much higher, probably in the region of 2.5 mg per 2500 cals.

## ANEURINE (THIAMINE)

Infants of about six months of age require at least 200 mg of aneurine daily,<sup>16</sup> and thus can normally be supplied when the mother's milk contains 20 mg or more of aneurine per 100 ml

An attempt to evaluate the effect on the aneurine requirements of man of bacterial synthesis in the intestine was made by Alexander *et al*<sup>17</sup> They defined the minimum aneurine requirement as the amount utilised or otherwise altered in body metabolism plus the amount required to cover uncontrollable losses from the body When subjects were maintained on a restricted intake of aneurine, excretion of the vitamin fell to a point where its concentration was too small to be measured In computing the daily minimum requirement, therefore, the urinary aneurine can be deducted from the intake The minimum requirement for a male consuming 2400 cal per day was in this way found to be 0.44 mg per 1000 cal or 1.06 mg per day An increase in the intake of aneurine increased the urinary excretion of aneurine and of a related factor that accelerated yeast fermentation When the intake exceeded 1.3 mg the increase of this second factor must also be subtracted from the aneurine intake because it represents aneurine breakdown Alexander *et al* suggested that the amount of aneurine and cocarboxylase in the faeces could be ignored, since they are the result of bacterial synthesis and exist within the cells of the micro organisms

M. L. Hathaway and J. E. Strom<sup>18</sup> recommended a daily allowance for women of 1.1 to 1.2 mg, whilst Oldham *et al*<sup>19</sup> recommended a total daily intake for young women of 20 µg per kg of body weight say, 1.2 mg per day

It is instructive to compare these estimates with the actual intake of aneurine in this country during the 1939-45 war The civilian consumption per head per day was about 1.2 mg in 1939 and rose steadily to a value of 1.87 mg in 1947<sup>20</sup> Experience showed that 0.35 mg per 1000 cal was marginal and that signs of vitamin B<sub>1</sub> deficiency appeared with 0.25 mg per 1000 cal Deficiency was rarely encountered in the Netherlands, however, during 1944-45, when the inhabitants were subsisting on a starvation diet, because the aneurine/calorie ratio remained above the limiting value whereas a deficiency was common in Japanese prison camps where white rice was the basic cereal and the diet contained less than 0.2 mg of aneurine per 1000 cal<sup>21</sup>

### References to Section 16

- 1 T. B. Osborne, L. B. Mendel and H. C. Cannon, *J. Biol. Chem.*, 1922, **54**, 739
- 2 G. R. Cowgill, *The Vitamin B Requirement of Man*, New Haven, Yale Univ. Press 1934.

## PHARMACOLOGICAL ACTION

- 3 C A. Mills, *Proc Soc. Exp. Biol Med*, 1943, **54**, 265.
- 4 A Z. Baker and M D Wright, *Proc Roy Soc Med*, 1936 **29**,  
1145
- 5 A G van Veen, *Geneesh Tijdschr Nederl-Ind*, 1935, **75**, 2050
- 6 W Stepp, J Kuhnau and H Schroeder, *Die Vitamine*, Stuttgart,  
F Enke, 1937
- 7 M G Vorhaus, R R. Williams and R E Waterman, *J. Amer.  
Med Assoc*, 1935 **105**, 1580
- 8 K O'S. Elsom, J G Reinhold, J. T. L Nicholson and C Chornock,  
*Amer. J. Med Sci*, 1942, **203**, 569
- 9 D Melnick, *J. Nutrition* 1942, **24**, 139.
- 10 R D Williams, H L Mason and R. M Wilder, *ibid*, 1943, **25**,  
71
- 11 H. Oldham F. Johnston, S Kleiger and H. H. Arismendi, *ibid*,  
1944, **27**, 435
- 12 T. Moran and R G Booth, *Chem and Ind*, 1940, 533.
- 13 M D Wright, *ibid*, 578
- 14 E G Young, *Canadian Med Assoc J*, 1945, **53**, 527
- 15 R L Lane, E Johnson and R R Williams, *J Nutrition*, 1942,  
**23**, 613
- 16 E M Knott, *Proc Soc Exp. Biol Med*, 1940, **45**, 765, E M  
Knott, S C Kleiger F W Schultz and G Collins, *J Pediat*,  
1943, **22**, 43, L E Holt, R L Nemir, S E Snyderman, A A  
Albanese, K C Ketron, L P Guy and R Carreters, *J.*  
*Nutrition*, 1949 **37**, 53
- 17 B Alexander, G Landwehr and F Mitchell *J Clin Invest*, 1946,  
**25**, 287
- 18 M L Hathaway and J E Strom, *J Nutrition*, 1946, **32**, 1
- 19 H G Oldham, M V Davis and L J Roberts, *ibid*, 163
- 20 *Food Consumption Levels in the United Kingdom*, Cmd 7203  
HMSO 1947
- 21 J C Drummond, ' Nutritional Requirements of Man in the Light  
of Wartime Experience ', Royal Institute of Chemistry, 1948

## 17. PHARMACOLOGICAL ACTION OF ANEURINE

### Toxicity

The acute fatal doses of aneurine hydrochloride for the mouse, rat, rabbit and dog were found to be <sup>1, 2</sup> 125, 250, 300 and 350 mg per kg respectively by the intravenous route, and six and forty times these values when given subcutaneously and orally. Death occurred from respiratory failure G Hecht and H. Weese,<sup>3</sup> however, reported that 160 mg per kg caused the death of rabbits by paralysis of the central nervous system, whilst T J Haley and A M Flesher<sup>4</sup> found that the lethal dose for rabbits was 126 mg per kg but, after a sensitising dose of 100 mg of aneurine hydrochloride, this increased to 238 mg per

## ANEURINE (THIAMINE)

kg E L Stern<sup>6</sup> found that 600 mg administered by cisternal puncture killed a cat.

According to T J Haley,<sup>5a</sup> aneurine nitrate had approximately the same acute toxicity for mice and rabbits as had the hydrochloride

### Effect on Isolated Tissues and Organs

The effect of solutions of aneurine on isolated tissues and organs has been studied by many workers. A dilution of 1 in 1000 to 10 000 produced acceleration and an increase in the amplitude of the isolated frog's heart.<sup>6</sup> A dilution of 1 in 1000 increased the tonus of the exposed frog's heart, but at higher concentrations,<sup>7</sup> aneurine acted as a cardiac depressant due to acidity and hypertonicity. A dilution of 1 in 1000 depressed the frog's ventricle to stoppage at pH 5.2 to 6.0, and a similar, though less marked, effect was produced by a dilution of 1 in 10,000. 1 in 100,000 had no effect. Cocarboxylase also had a depressant effect at pH values up to 7.6. The depressant effect was not annulled by atropine.<sup>8</sup> Dilutions of 1 in 1000 to 10,000 produced coronary dilatation and an increase in the amplitude of the perfused rabbit's heart.<sup>6</sup>

The movements of the perfused isolated rabbit's intestine were increased and the rhythm of the isolated rabbit's uterus was inhibited by dilutions of 1 in 100 to 10,000, but augmented by a dilution of 1 in 100,000. The contractions of skeletal muscle were decreased by aneurine in a dilution of 1 in 1000.<sup>6</sup> Aneurine and cocarboxylase inhibited the action of nicotine on the isolated rabbit and guinea pig intestine and on the isolated striated muscle of the frog. These effects were not influenced by prostigmine.<sup>9</sup> The total work output of frog's gastrocnemius muscle when perfused with Ringer's solution and stimulated electrically was significantly increased by the addition of aneurine<sup>10</sup> up to concentrations of 0.001 millimoles per litre. Aneurine pyrophosphate had a greater effect at lower concentrations, and an equal effect at 0.001 millimoles per litre. When the sciatic nerve of a frog was stimulated and frozen in liquid air, the stimulated nerve liberated aneurine, as shown by rat bradycardia.<sup>11</sup> The total aneurine in frog's nerve after poisoning with iodoacetate remained the same after stimulation, but the free aneurine fell to half the amount present in the non-stimulated nerve.<sup>12</sup> This difference is believed to be due to the effect of iodoacetate on phosphorylation.

The aneurine content of guinea pig's sciatic nerve diminished after cutting the nerve and in fifty to seventy hours fell to 40 to 50 % of the amount present in a control nerve.<sup>13</sup> Stimulation of the branch of the vago sympathetic nerve fibres supplying the heart of the frog led to the liberation of aneurine, or a compound resembling it, as well

to liberation of acetyl choline<sup>14</sup> The substance exhibited a different polarographic behaviour from aneurine and is believed to be a reserve substance connected with the disappearance of acetyl choline

Aneurine in a dilution of 1 in 10 000 inhibited the vasoconstrictor action of nicotine in frog vessels<sup>15</sup> The action was due to the thiazole moiety and the site of the action was the myoneural junction in striated muscles and the postganglionic nerve endings or muscle elements of the vessel walls in smooth muscles

### Effect on Intact Animals

In the intact frog aneurine produced central motor and respiratory paralysis and pupillary constriction In mice small doses stimulated respiration whilst large doses produced chronic cramps and respiratory arrest In rabbits intravenous injection of 0.05 to 1 mg stimulated respiration and raised the blood pressure<sup>6</sup> Aneurine did not increase the purgative effect of phenolphthalein in monkeys<sup>16</sup>

The toxic symptoms observed in rabbits were<sup>4</sup> peripheral vasodilatation decreased respiration due to a direct action on the respiratory centre in the medulla asphyxial convulsions due to anoxia resulting from decreased oxygenation of the blood death by paralysis of the respiratory centre and cardiac arrhythmias probably due to anoxia and not to a direct action on the cardiac muscle of the conduction system In dogs intravenous injection of aneurine hydrochloride solution caused a marked but transient fall in blood pressure bradycardia transitory vasodilatation and transitory changes in the electrocardiogram death was due to respiratory arrest<sup>16a</sup>

When applied directly to the cerebral cortex aneurine produced motor reactions consisting of rhythmic contractions of the muscle corresponding to the cortical motor point at which it was applied<sup>17</sup> The reaction was at first weak but subsequently increased in intensity When all the skeletal musculature was involved generalised epileptiform convulsions took place with a tonic-clonic sequence Epileptiform convulsions were produced in thirty four out of forty five dogs by means of a 2 to 10 % solution applied in this way but in eleven of the dogs only localised muscular clonic reactions could be obtained Identical results were obtained with cocarboxylase but the pyrimidine and thiazole halves of the molecule had no effect

### Relation between Aneurine and Acetyl Choline

An association of a different type between aneurine and acetyl choline was indicated by Kuhn *et al*<sup>18</sup> Like choline aneurine is a quaternary ammonium base and a primary alcohol and its acetyl derivative was found to behave like acetyl choline in stimulating the

## ANEURINE (THIAMINE)

rat intestine The question as to whether acetyl aneurine is an additional nerve messenger has not yet been answered, but the idea is an interesting one, because if it is essential for the proper functioning of the nervous system, its absence may result in atrophy of the nerves, a characteristic feature of vitamin B<sub>1</sub> deficiency that is not explicable if aneurine acts simply as a metabolic catalyst of pyruvic acid oxidation or decarboxylation Further work on the connection between aneurine and the nervous system is highly desirable

An attempt to explain the connection between aneurine deficiency and the appearance of nerve lesions was made by D Gluck and W Antopol<sup>19</sup> They noted that many of the symptoms of vitamin B<sub>1</sub> deficiency, such as hypochlorhydria, loss of muscular tone, certain forms of nerve dysfunction and tachycardia, were relieved by administration of choline esters, and that certain symptoms of hyperthyroidism were alleviated by aneurine and choline esters They suggested, therefore, that aneurine might inhibit choline esterase activity so that a deficiency of the vitamin might result in enhanced enzyme activity and a reduced concentration of acetyl choline

This suggestion, if true, might also explain McHenry's observation that aneurine cured fatty livers in rats kept on a low choline diet, for the increased choline esterase activity produced by administration of the vitamin might lead to an increased availability of free choline, which would tend to reduce the amount of fat in the liver When this ingenious hypothesis was tested, it was found that aneurine did inhibit choline esterase, but only in concentrations far in excess of the normal Thus, whereas the blood rarely contains more than 1  $\mu\text{g}$  of aneurine per ml, detectable inhibition was produced by 1000  $\mu\text{g}$  per ml of serum The authors conclude "the possibility that thiamine may be histologically localised in some tissue should be borne in mind, for then it might exert its enzyme inhibition *in vivo*"

Aneurine appears to have a curious effect on acetyl choline V Erspamer<sup>20</sup> observed that *in vitro* aneurine in concentrations greater than 10 p.p.m. reduced the effect of acetyl choline on isolated tissues, and that the intravenous injection into rats of 30 to 100 mg per kg of bodyweight increased, and 100 to 500 mg per kg decreased, the toxicity of sublethal doses of acetyl choline previously injected subcutaneously Moderate aneurine deficiency in pigeons enabled them to resist the effect of twice the minimum fatal dose of acetyl choline, and twice the usual concentration of acetyl choline was required to stimulate the isolated gut of such pigeons After the deficiency symptoms had been cured by treatment with aneurine the response to acetyl choline was normal The opposite effect was noted by E A Zeller and H Birkhauser<sup>21</sup> in avitaminous rats, the liver of which contained less choline esterase than normal, although the brain

was unaffected. In such animals the effects of acetyl choline would presumably be prolonged. C. Torda and H. G. Wolff<sup>22</sup> on the other hand failed to observe any inhibitory or potentiating effect of aneurine hydrochloride, aneurine pyrophosphate or acetyl aneurine on the response of frog's rectus muscle to acetyl choline. Aneurine hydrochloride and pyrophosphate increased acetyl choline synthesis by about 10 % in concentrations of  $3 \times 10^{-6} M$  and  $2 \times 10^{-6} M$  respectively. Higher concentrations decreased the synthesis of acetyl choline whilst adrenaline increased the synthesis 40 to 150 %.

E. M. Boyd and R. W. Dingwall<sup>7</sup> reported that concentrations of 100 to 250 mg per 100 ml prevented bradycardia in the exposed frog's heart due to acetyl choline and other drugs.

B. Jackson and G. Wald<sup>8</sup> found that aneurine in dilutions of 1 in 1000 to 100 000 progressively antagonised acetyl choline. The effect was not shown by cocarboxylase.

References to Section 17

- 1 H. Molitor and W. L. Sampson *E. Merck's Jahresber.* 1936 50, 51
- 2 V. Ersparmer *Arch. int. Pharmacodyn.* 1940 64, 1
- 3 G. Hecht and H. Weese *Klin. Woch.* 1937 16, 414
- 4 T. J. Haley and A. M. Flesher *Science* 1946 104, 567
- 5 E. L. Stern *Amer. J. Surg.* 1938 39, 495
- 5a T. J. Haley *Proc. Soc. Exp. Biol. Med.* 1948 68 153
- 6 C. Mano *Japan. J. Med. Sci.* IV 1940 12, *Proc.* 98
- 7 E. M. Boyd and R. W. Dingwall *Quart. J. Pharm.* 1941 14, 209
- 8 B. Jackson and G. Wald *Amer. J. Physiol.* 1942 135, 464
- 9 K. Unna and E. P. Pick *J. Pharmacol.* 1944 81, 294
- 10 N. W. Shock and W. H. Sebrell *Amer. J. Physiol.* 1944 142, 265  
*Proc. Soc. Exp. Biol. Med.* 1945 59, 212
- 11 A. Liechti, A. von Muralt and M. Reinert *Helv. Physiol. Pharm. Acta* 1943 1, 79
- 12 A. and F. Wyss *Experientia* 1945 1, 160
- 13 A. von Muralt and F. Wyss *ibid.* 1944 2, 445
- 14 A. von Muralt *Nature* 1944 154, 767
- 15 H. Haimovici and E. P. Pick *Proc. Soc. Exp. Biol. Med.* 1946 62 234
- 16 S. Loewe, I. Loewe and R. Knox *Amer. J. Digest. Dis.* 1943 10, 65
- 16a J. A. Smith, P. P. Foa, H. R. Weinstein, A. S. Ludwig and J. M. Wertheim *J. Pharmacol.* 1948 93 294
- 17 M. V. Dias *Science* 1947 105, 211
- 18 R. Kuhn, T. Wieland and H. Huenschmann *Z. physiol. Chem.* 1939 259, 48
- 19 D. Glick and W. Antopol *J. Pharmacol.* 1939 65, 389
- 20 V. Ersparmer *Boll. Soc. ital. Biol. sperim.* 1939 14 655 *Arch. int. Pharmacodyn.* 1939 63, 385
- 21 E. A. Zeller and H. Birkhauser *Helv. Chim. Acta* 1940 23, 1457
- 22 C. Torda and H. G. Wolff *Proc. Soc. Exp. Biol. Med.* 1944 56, 88 89



## 18. FUNCTION OF ANEURINE

### Lactic Acid

As long ago as 1914, C Funk<sup>1</sup> suggested that vitamin B<sub>1</sub> was concerned with carbohydrate metabolism, and the first step towards an understanding of its more precise function was taken in 1929 when H W Kinnersley and R A Peters<sup>2</sup> showed that avitaminous pigeon brain contained more lactic acid than did normal brain. T. W. Birch and L J Harris<sup>3</sup> suggested that the bradycardia of vitamin B<sub>1</sub>-deficient animals was correlated with the accumulation of lactic acid in the organism, although they did not consider that the symptoms were directly attributable to the presence of the acid, since bradycardia was not produced by injection of sodium lactate solution.

H G K Westenbrink,<sup>4</sup> however, claimed that either pyruvic acid or lactic acid was the toxic metabolite responsible for some of the symptoms of vitamin B<sub>1</sub> deficiency, and in a more recent paper, it has been claimed<sup>5</sup> that convulsions similar to those resulting from vitamin B<sub>1</sub> deficiency are produced in pigeons by injection of lactate or pyruvate solution and that, provided not more than 0.15 ml of a 2 % solution has been administered, the symptoms can be relieved by the intravenous injection of 2000 to 5000 I U of vitamin B<sub>1</sub>.

Whether the physiological effects observed in vitamin B<sub>1</sub> deficiency are due to an accumulation of lactic or pyruvic acid or of some other substance the fact that these substances do accumulate both in the blood and the urine, instead of being further metabolised cannot now be questioned.

### Pyruvic Acid

B S Platt and G D Lu<sup>6</sup> showed that the blood of beriberi patients contained not only pyruvic acid, but other ketonic substances as well. The amount of ketone bodies increased on exertion and the increase was accompanied by clinical manifestations of fulminating beriberi with cardiac symptoms. They did not believe that these cardiac symptoms were directly attributable to the accumulation of pyruvic acid, however.

### Bisulphite-binding Substances in Blood

Attempts have been made to use the increase in ketonic substances in the blood to assess the degree of vitamin B<sub>1</sub> deficiency. Thus Shils *et al*<sup>7</sup> observed that in rats on a diet low in vitamin B<sub>1</sub>, the increase in bisulphite binding substances (BBS) in the blood was proportional to the extent of the deficiency. The increase was stated to be due mainly to the accumulation of pyruvic acid. A Göth<sup>8</sup>

## FUNCTION

claimed to be able to detect incipient hypovitaminosis by measuring the BBS in blood, when the nutritional status was such that 11.4% of a test dose of aneurine was excreted, the BBS were 7.8 mg per 100 ml, whereas when the excretion fell to 3.6% the BBS had risen to 13.4 mg per 100 ml. Similarly, H A Harper and H J Deuel<sup>9</sup> found that during aneurine depletion the urinary excretion of pyruvate increased more in males than in females. The excretion was reduced when optimal amounts of aneurine were given, although not when amounts adequate for minimum growth were given. They did not claim that the phenomenon could be used for diagnosing vitamin B<sub>1</sub> deficiency. Shils *et al.*,<sup>10</sup> on the other hand, failed to observe any increase in BBS in the urine of subjects fed a vitamin B<sub>1</sub> deficient diet.

The method of assessing vitamin B<sub>1</sub> deficiency by measuring the bisulphite binding substances in the blood never met with general approval, however, and was explicitly rejected by Robinson *et al.*,<sup>11</sup> by Wortis *et al.*<sup>12</sup> and by H A Davis and F K Bauer.<sup>13</sup> The last-named workers compared the blood pyruvic acid in various diseases with that of controls. The normal level was 0.5 to 1.3 mg per 100 ml, but in various hepatic disorders it increased up to 4.25 and in toxic goitre to 3.5 mg per 100 ml. No increase was observed in non-nutrient diseases. It was estimated that half the cases of infection examined also had increased pyruvic acid levels in the blood. Obviously, therefore, elevation of the blood pyruvic acid cannot be used for the diagnosis and evaluation of vitamin B<sub>1</sub> deficiency without excluding other conditions that might equally well be responsible. M K Horwitt and O Kreisler<sup>14</sup> however claim that the levels of lactate and pyruvate in the blood can be used to diagnose vitamin B<sub>1</sub> deficiency under the combined metabolic load of ingestion of glucose and exercise, although quite useless in the fasting state.

## Methylglyoxal

Another substance that was at one time implicated as the toxic product responsible for the symptoms of vitamin B<sub>1</sub> deficiency is methylglyoxal (pyruvic aldehyde), CH<sub>3</sub> CO CHO. The presence of this substance in the urine of vitamin B<sub>1</sub>-deficient infants was reported by A Geiger and A Rosenberg<sup>15</sup> and in the milk of women with beriberi by several Japanese workers.<sup>16</sup> Infantile beriberi is a condition in breast fed infants first described towards the end of last century by Japanese clinicians and because the infant recovered when removed from the breast, the condition was attributed to a toxin in the milk. The presence of a toxin was, in

fact, demonstrated by T Suzuki and A Takamatsu,<sup>16</sup> who showed that it was methylglyoxal and that the administration of vitamin B<sub>1</sub> diminished the methylglyoxal content of the milk. R Orimo<sup>17</sup> showed that the milk of vitamin B<sub>1</sub> deficient women was low in glyoxalase, the concentration of which could, however, be raised by giving the vitamin, whilst A Takamatsu and A Sato<sup>18</sup> showed that methylglyoxal induced pathological changes in rabbits similar to those in infantile beriberi.

J Vogt-Möller<sup>19</sup> suggested that the symptoms of beriberi were due to poisoning by methylglyoxal which accumulated as the result of some breakdown in the action of the enzyme glyoxalase or its coenzyme, glutathione (glutamyl-cysteyl-glycine), he favoured the latter alternative. B S Platt and G D Lu,<sup>20</sup> however, could find no evidence that methylglyoxal was responsible for the symptoms of beriberi.

Unfortunately, it appears never to have been decided whether the cure of infantile beriberi was due to the administration of vitamin B<sub>1</sub> or to administration of glutathione, as no information is available as to the nature of the vitamin B supplements used. In many instances these were probably concentrates prepared from liver or yeast and therefore likely to contain both.

There is no real proof that aneurine deficiency leads to an accumulation of methylglyoxal, although there is convincing evidence that methylglyoxal is responsible for infantile beriberi. In the light of present knowledge, however, this is just as likely to be produced by a deficiency of glutathione as of aneurine.

## Experiments on the Respiration of Brain Tissue

The explanation of the relationship between vitamin B<sub>1</sub> deficiency and the accumulation of lactic or pyruvic acid in the blood was discovered by R A Peters,<sup>21</sup> who, in a paper of fundamental importance, showed that normal pigeon brain slices in Ringer phosphate solution containing glucose as substrate had a higher oxygen uptake than avitaminous brain slices. The same results were obtained when sodium lactate or sodium pyruvate were used as substrates. When aneurine was added to the solutions, the oxygen uptake of the avitaminous tissue was raised to the normal value in all three instances. The reaction was extremely sensitive and highly specific. It was described as the catatorulin effect, and was made the basis of a method of assaying vitamin B<sub>1</sub> (see page 28). Peters was able to show also that, with sodium succinate as substrate, normal and avitaminous brain tissue respired at the same rate, and he therefore concluded that the vitamin was concerned with the oxidation of pyruvic acid but not of succinic acid.

**FUNCTION**

The accumulation of lactic acid as well as pyruvic acid in the blood and tissues of avitaminous animals was at first sight puzzling but the difficulty was disposed of by W C Sherman and C A Elvehjem <sup>22</sup> who pointed out that pyruvic acid completely inhibited lactic dehydrogenase activity, so that lactic acid accumulated in the tissues instead of being metabolised. By removing pyruvic acid, vitamin B<sub>1</sub> thus indirectly brought about the normal metabolism of lactic acid. It has been suggested that the accumulation of methylglyoxal might similarly be due to the inhibition of methylglyoxalase by pyruvate but there appears to be no direct evidence on this point.

**Pyruvic Acid Metabolism**

Pyruvic acid can be metabolised in various ways. In the presence of air the acid is oxidised to acetic acid and carbon dioxide.

$$(i) \text{CH}_3\text{COCOOH} + \text{O} \rightarrow \text{CH}_3\text{COOH} + \text{CO}_2$$

(2)  $\text{CH}_3\text{COCOOH} \rightarrow \text{CH}_3\text{CHO} + \text{CO}_2$

**Aneurine Pyrophosphate**  
Actual

$$\begin{array}{c} \text{N}=\text{C} \quad \text{NH}_2 \\ \parallel \quad \parallel \\ \text{CH}_3-\text{C}=\text{C}-\text{CH}_2-\text{N} \begin{array}{l} \nearrow \text{C}=\text{C} \text{ CH}_3 \\ \searrow \text{CH}_2-\text{S} \end{array} \\ \parallel \quad \parallel \\ \text{N}=\text{CH} \quad \text{Cl} \end{array} \quad \text{CH}_3 \quad \text{CH}_2 \quad \text{O} \quad \begin{array}{c} \text{OH} \\ \parallel \\ \text{P} \\ \parallel \\ \text{O} \end{array} \quad \begin{array}{c} \text{OH} \\ \parallel \\ \text{P} \\ \parallel \\ \text{O} \end{array} \quad \text{OH}$$

## ANEURINE (THIAMINE)

This structure was confirmed by K G Stern and J W Hofer,<sup>28</sup> who synthesised aneurine pyrophosphate by treating aneurine with two molecular proportions or more of phosphorus oxychloride. Both groups of workers found that the substance produced carbon dioxide from pyruvic acid in the presence of yeast cells freed from natural cocarboxylase. Enzymic methods of preparing cocarboxylase from aneurine were subsequently described by H Tauber,<sup>29</sup> by H von Euler and R Vestin<sup>30</sup> and by M Silverman and C H Werkman,<sup>31</sup> whilst an improved synthetic method was described by H Weil Malherbe,<sup>32</sup> in which the 5 bromoethyl-thiazole analogue of aneurine hydrobromide was treated with silver pyrophosphate in pyrophosphoric acid solution at 100° C for fifteen hours. The cocarboxylase was isolated after conversion to the silver salt, precipitation with phosphotungstic acid and recrystallisation from dilute alcohol.

Phosphorylation of aneurine *in vivo* apparently takes place in the upper part of the digestive tract,<sup>33</sup> although attempts to convert aneurine into cocarboxylase by incubation with juices from the stomach, pancreas, duodenum or jejunum of dogs, or by mixtures of the juices with mucosa extracts were unsuccessful. The reverse change, however, that is, the hydrolysis of cocarboxylase to aneurine, was readily effected by incubation with duodenal or jejunal juice. The hydrolysis of aneurine monophosphate could also be effected by phosphatase preparations, at a rate comparable with the hydrolysis of cocarboxylase. H Weil Malherbe<sup>34</sup> showed that neither aneurine nor aneurine monophosphate functioned *per se* as coenzymes of carboxylase, the latter has a longer induction period than the former, presumably due to the fact that it must first be hydrolysed to free aneurine. Aneurine could be converted into cocarboxylase by the action of adenosine triphosphate. That aneurine monophosphate was not an intermediate in the formation of cocarboxylase was confirmed by the fact that, although it reduced the pyruvic acid content of the blood of aneurine deficient rats<sup>35</sup> it had a somewhat lower activity than aneurine itself. The conversion of aneurine into cocarboxylase by adenosine triphosphate was confirmed by Elvehjem and his colleagues,<sup>36</sup> who also showed that cocarboxylase was formed from aneurine in presence of washed dried yeast, hexose diphosphate and boiled tissue extract.

F Lipmann<sup>37</sup> reported that Lohmann's pure cocarboxylase functioned as a coenzyme in the oxidation of pyruvic acid, and suggested that aneurine was first converted into cocarboxylase which then acted as the coenzyme of a system capable of catalysing the liberation of carbon dioxide from pyruvic acid with formation of either acetaldehyde or acetic acid. This theory was not at first generally accepted, however, for R A Peters<sup>38</sup> had found that pure

## FUNCTION

coccarboxylase had only 10 % of the activity of vitamin B<sub>1</sub> in the catatorulin test. Later however I Banga S Ochoa and R A Peters<sup>29</sup> obtained evidence confirming Lohmann and Schuster's hypothesis brain preparations that responded to aneurine apparently synthesised coccarboxylase sufficiently rapidly to account for the oxygen uptakes observed whilst the inferior activity of coccarboxylase in the catatorulin effect was due to its failure to reach the active centre as it was much less permeable than aneurine itself with finely minced brain dispersions coccarboxylase was very much more active. I Banga S Ochoa and R A Peters<sup>30</sup> were further able to show that the oxidative decarboxylation of pyruvate in brain and probably in other animal tissues was not so simple as reaction (1) above indicates and required the presence of inorganic phosphate C<sub>4</sub> dicarboxylic acids (e.g. succinate fumarate malate etc.) adenine nucleotide magnesium ions and probably coenzyme. They did not however believe that the oxidation of pyruvate in brain involved the Krebs tricarboxylic acid cycle (see page 6-6).

### Aneurine Triphosphate

When aneurine was phosphorylated with phosphoric acid that had been desiccated at 350° C the triphosphoric ester was formed. This reduced or abolished the bradycardia produced by electrical stimulation and increased the amplitude and regularised the rhythm of heart beats affected by fatigue or potassium chloride. Coccarboxylase had no such effect whilst adenosine triphosphate only affected the rhythm and not the bradycardia. Aneurine triphosphate restored the coccarboxylase activity of washed yeast cells but had only about one-quarter the activity of coccarboxylase<sup>30a</sup>.


### Dismutation of Pyruvic Acid

A considerable body of evidence has now accumulated to suggest that aneurine in the form of its pyrophosphate is concerned with the dismutation reaction (3) rather than with reactions (1) or (2). G M Hills<sup>26</sup> reached this conclusion from a study of the oxygen uptake of *Staphylococcus aureus* in presence and absence of aneurine and his results were confirmed by Kligler *et al*<sup>31</sup> who also found that under aerobic conditions *S. aureus* produced pyruvic and lactic acids from glucose in the absence of aneurine. Under anaerobic conditions the presence or absence of aneurine made no difference the reaction being purely glycolytic. When pyruvate was used instead of glucose the absence of aneurine resulted in dismutation producing equimolecular amounts of lactic acid acetic acid and carbon dioxide. This reaction

## ANEURINE (THIAMINE)


was obscured under aerobic conditions, owing to partial oxidation of the lactic acid. Lactate was utilised as a substrate only under aerobic conditions and, in the presence of aneurine and nicotinic acid, was completely oxidised to acetic acid and carbon dioxide; in the absence of aneurine, oxidation was incomplete, 25 % of the lactic acid being converted to pyruvic acid.

H. A. Krebs and L. V. Eggleston<sup>42</sup> and H. A. Krebs,<sup>43</sup> suggested that reaction (3) actually occurs in two stages, in which oxaloacetic acid acts as a hydrogen carrier:



The net result of these reactions is, of course, reaction (3).

The formation of oxaloacetic acid, which cannot be isolated owing to its instability, was demonstrated indirectly by E. A. Evans and L. Slotin<sup>44</sup> and H. G. Wood *et al.*,<sup>45</sup> using carbon dioxide containing radioactive carbon. Furthermore, D. H. Smyth<sup>46</sup> showed that the catalytic effect of aneurine on the oxygen uptake of "avitaminous" *Staphylococcus aureus* could be reproduced by oxaloacetic acid, and R. W. Benham<sup>47</sup> observed that oxaloacetate produced the same effect as aneurine on the growth of the mould, *Pityrosporum ovale*. Krebs suggested that aneurine catalyses not the oxidation of pyruvic acid, but the formation of oxaloacetic acid from pyruvic acid:



So far this hypothesis has not been tested on animals, but, if true, it would provide a more than adequate explanation of the importance of aneurine, since oxaloacetic acid has been shown to act as a hydrogen carrier and to take part in the synthesis of citric,  $\alpha$ -ketoglutaric, succinic, fumaric and malic acids, glutamic and aspartic acids and their corresponding amides, glutamine and asparagine (Krebs *et al.*<sup>48</sup>).

## Citric Acid

A number of papers have been published claiming a connection between aneurine on the one hand and citric acid and various amino acids on the other. It has been observed,<sup>49</sup> for example, that rats on a vitamin B<sub>1</sub>-deficient diet low in citric acid, excreted less and less citric acid as the deficiency became acute, but that on administration of aneurine, the citric acid excretion increased to a maximum after four to six days. It was therefore suggested that cocarboxylase was an essential factor in the synthesis of endogenous citric acid from

## FUNCTION

precursors but A H Smith and C E Meyer<sup>80</sup> claimed that the reduced citric acid excretion in vitamin B<sub>1</sub> deficiency was merely the result of a lower intake of food and not a direct result of the absence of aneurine

## Amino-acid Metabolism

The connection between aneurine and amino acids is even more obscure although rats receiving 5  $\mu$ g of aneurine per day were said to utilise protein more efficiently than rats receiving half this amount<sup>80a</sup>. When extra phenylalanine was administered to vitamin B<sub>1</sub> deficient rats phenylpyruvic acid was found in the urine<sup>81</sup> but no evidence is available<sup>82</sup> to suggest that aneurine deficient rats are less able than normal rats to metabolise either phenylalanine or tyrosine. On the other hand it has been claimed<sup>83</sup> that in vitamin B<sub>1</sub> deficiency there is an increased enzymatic degradation of histidine due to a disturbance of the intermediary carbohydrate metabolism whilst the administration of aneurine to normal rats has been said<sup>84</sup> to reduce the excretion of histidine. An attempt has also been made<sup>85</sup> to reduce the administration of aneurine thus returned to normal on stopping the administration of aneurine as it had been found that tissues from vitamin B<sub>1</sub>-deficient rats were much less effective than tissues from normal rats in transferring the amino group from L-glutamic acid to pyruvic acid. It is now known however that this reaction is brought about by a coenzyme that contains not aneurine but pyridoxine (see page 333)

## Oxaloacetic Acid

The hypothesis that cocarboxylase catalyses the formation of oxaloacetic acid is apparently directly opposed to the results of L O Krampitz and C H Werkman<sup>86</sup> who prepared from *Micrococcus lysodeikticus* an enzyme that catalysed the reverse of reaction (6). This decarboxylation required magnesium ions but not cocarboxylase or aneurine. Moreover contrary to Smyth's observations with *Staphylococcus* oxaloacetic acid did not replace aneurine in the decarboxylation of pyruvate with a culture of *M. lysodeikticus* from which cocarboxylase and magnesium had been removed. Further data of this type were reported by J H Quastel and D M Webley<sup>87</sup> who worked with vitamin B<sub>1</sub> deficient propionic acid bacteria. They found that the oxidation of acetate and propionate was accelerated by aneurine only in presence of magnesium and potassium ions whereas the oxidation of pyruvate was accelerated by aneurine alone and not by magnesium or potassium ions alone. The



## ANEURINE (THIAMINE)

rate of disappearance of pyruvate, however, was increased by the addition of magnesium and potassium ions even in the absence of vitamin B<sub>1</sub>, but the oxygen uptake was not increased. This observation probably explains the acceleration that takes place in the oxidation of lactate by vitamin B<sub>1</sub>-deficient bacteria in the presence of magnesium and potassium ions and in the absence of aneurine, since the removal of pyruvic acid by these ions would enhance the oxidation of lactate, which it is known to inhibit. The oxygen uptake, with succinate and fumarate as substrates, was also greatly increased by magnesium and potassium ions, even in the absence of aneurine. This is explained by the fact that these ions accelerate the breakdown by propionic acid bacteria of oxaloacetate, which inhibits succinate oxidation. Since it is known that oxaloacetate inhibits succinic dehydrogenase, this also explains the effects of cozymase and nicotinamide on succinate oxidation by animal tissues. Thus the breakdown of both oxaloacetate and of pyruvate by propionic acid bacteria is catalysed by a mixture of magnesium and potassium ions independently of the presence of vitamin B<sub>1</sub>. The accelerating effects of vitamin B<sub>1</sub> in the absence of magnesium and potassium ions are explained as due to the catalysed oxidation of pyruvate or acetate formed from the substrate as intermediaries.

Quastel and Webley also found that the rate of oxidation of acetate, succinate, etc., by vitamin B<sub>1</sub>-deficient propionic acid bacteria could be increased not only by the addition to these substrates of magnesium and potassium ions or hexosediphosphate ions (which had the same effect), but also by previously incubating the organisms with these ions, followed by thorough washing. They suggested that the ions completed or induced the formation in the bacterial cell of a system essential for the oxidation of the substrates.

These results may be accounted for on the assumption that incubation of the propionic acid bacteria with hexosediphosphate enriches the cells with adenosine triphosphate and that such cells then have the ability to phosphorylate vitamin B<sub>1</sub>; the cocarboxylase so formed then catalyses the oxidation of pyruvate and acetate. The magnesium ions are believed to be necessary for effecting phosphorylation.

The fact that succinate, fumarate and ethyl and propyl alcohols do not require aneurine for their oxidation is explained by assuming that adenosine triphosphate is essential either for their complete oxidation or for their oxidation to pyruvate or acetate, where cocarboxylase becomes necessary. Thus, adenosine triphosphate is a coenzyme for the oxidation of fumarate, ethyl and propyl alcohols.


The suggestion made by Krebs and Eggleston and by Smyth that vitamin B<sub>1</sub> catalysed the formation of oxaloacetate was regarded by

Quastel and Webley as untenable because oxaloacetate cannot replace aneurine as an accelerator of acetate and propionate oxidation by propionic acid bacteria. Thus, aneurine exerts its catalytic effect on acetate and pyruvate oxidations by a process other than by the formation of oxaloacetate as suggested by Krampitz and Werkman.

### Aneurine, a Catalyst for Several Reactions


The most recent results favour the view which now enjoys wide

it functioned as a dehydrogenating catalyst promoting reaction (1), whereas in yeast it catalysed reaction (2). He showed<sup>59</sup> that on hydrogenation in presence of platinum black or on reduction by sodium dithionite, hydrogen was taken up by the quaternary nitrogen atom of the thiazole ring giving dihydroaneurine pyrophosphate



He drew an analogy with the reduction of Warburg's yellow enzyme and suggested that such a change may occur *in vivo* as well as *in vitro*. In pigeon brain tissue however, cocarboxylase appears<sup>60</sup> to catalyse the dismutation reaction (3).

Lipmann's views were supported by E. S. G. Barron and C. M. Lyman<sup>61</sup> who observed that the extent to which cocarboxylase catalysed the oxidation of pyruvic acid on the one hand and its dismutation on the other, varied with different organisms according to the oxygen tension. Thus under optimal conditions for oxidation, pyruvic acid was directly oxidised to acetic acid and carbon dioxide, under optimal conditions for reduction it might be reduced to lactic acid or split by dismutation into acetic acid and formic acid.




The "oxydismutation coefficients", i.e. the ratio between the amount of pyruvic acid used by the cell under conditions optimal for

## ANEURINE (THIAMINE)

oxidation and the amount used under conditions optimal for dismutation, were determined for gonococci, *Streptococcus haemolyticus* and for several strains of *Staphylococcus aureus*. Only with the strain of *S. haemolyticus* and with one strain of *S. aureus* was the rate of pyruvic acid disappearance greater in the absence than in the presence of oxygen. In rat tissues also anaerobic metabolism was lower than aerobic metabolism, whilst in goose erythrocytes, pyruvic acid was not utilised at all in the absence of oxygen. Further results by E. S. G. Barron and C. M. Lyman<sup>62</sup> confirmed these views. They showed that kidney slices from normal rats produced an increased amount of glucose when incubated with pyruvate, whereas kidney slices from vitamin B<sub>1</sub>-deficient rats did not give such a marked increase until aneurine was added. Heart slices from vitamin B<sub>1</sub>-deficient rats produced less citrate from pyruvate and oxaloacetate than did normal heart slices. In this instance, however, no increase occurred on addition of aneurine, due to a failure to phosphorylate the aneurine during the short time of incubation. This evidence strengthens the view that aneurine catalyses not only the oxidation and dismutation of pyruvate, but other reactions involving it. It is therefore suggested that cocarboxylase is an integral part of an enzyme system concerned with the activation of pyruvate, enabling it to take part in a number of reactions.

The problem was also studied by K. G. Stern and J. L. Melnick,<sup>63</sup> who showed that pyruvic acid was not decarboxylated via the "Langenbeck cycle" i.e. by combination with cocarboxylase to form a catalytically active substituted imino acid



and confirmed Lipmann's results on the reduction of aneurine. They pointed out, however, that no evidence was advanced by Lipmann to support his view that aneurine acts as a reversible oxidation-reduction system in the same way as pyridine coenzyme. Stern and Melnick claimed that dihydro aneurine was devoid of biological activity, but that dihydro cocarboxylase was as active as the oxidised form in both the polyneuritic pigeon and in yeast. In a re-investigation of the problem, however, they found<sup>64</sup> that the supposed biological activity of reduced cocarboxylase was due to the presence of traces of unchanged coenzyme. Fully reduced cocarboxylase, like reduced aneurine, had no biological activity.

Barron and Lyman and their collaborators<sup>65</sup> showed that cocarboxylase was more resistant than aneurine to the action of oxidising


and reducing agents the rate of reduction of aneurine by sodium dithionite and by hydrogen in presence of colloidal palladium or platinum black being three times as fast as the rate of reduction of cocarboxylase a similar relationship was observed for the rates of re-oxidation of the two reduction products. The reduced cocarboxylase had neither vitamin nor enzyme component activity nor had the substance formed by re-oxidation by means of histidine and ferric protoporphyrin thus confirming the later result of Stern and Melnick. It was concluded therefore that cocarboxylase is an integral part of the activating protein when acting as a component of an enzyme system and that it does not owe its activity to reversible oxidation and reduction.

This was confirmed by *in vitro* experiments with tissues from avitaminous animals in which it was found that the addition of aneurine accelerated condensation reactions of pyruvate leading to the synthesis of carbohydrate  $\alpha$  ketoglutarate citrate acetoacetate and succinate. All these reactions start as condensation reactions of pyruvate and in all of them there is a step in which an oxidative decarboxylation occurs. Thus in the synthesis of carbohydrate aneurine pyrophosphate may catalyse either the carboxylation of phosphopyruvate to phospho-enoloxaloacetate or the decarboxylation of this compound to phosphoenolpyruvate and it is impossible to determine whether aneurine is a component of a condensation enzyme or of an oxidative decarboxylation enzyme. The increased stability of aneurine to reduction and oxidation following phosphorylation rather argues against the latter alternative.


The addition of aneurine also increased the oxidation and utilisation of  $\alpha$  ketoglutarate by the tissues of avitaminous rats but only when the aneurine had previously been incubated with the tissue to make its phosphorylation possible. It was therefore concluded that the activating protein of  $\alpha$  ketoglutarate oxidase is like that of pyruvate oxidase an aneurine pyrophosphate protein.

The possibility that aneurine might be an oxidation catalyst has been considered by other workers and O. Zima and R. R. Williams<sup>22</sup> suggested a mechanism different from that proposed by Lipmann. They pointed out that aneurine chloride hydrochloride could only exist in solutions far more strongly acid than living tissue and suggested that in the cell the vitamin probably exists as a hemichloride thus can be obtained from the chloride hydrochloride by treatment with excess potassium chloride. Two well defined crystalline sodium salts were obtained from aneurine chloride hydrochloride by addition of alkali the one obtained with sodium ethoxide was deep yellow in colour and the other obtained with strong aqueous sodium hydroxide solution was white. These were assigned the structures

# ANEURINE (THIAMINE)



and



respectively On treatment with iodine, a disulphide was obtained, which, on reduction with tin and hydrochloric acid, was reconverted into aneurine This disulphide was antineuritic, having 60 to 70 % of the activity of aneurine

Zima *et al*,<sup>67</sup> discussing the implications of this discovery, suggested that aneurine and this disulphide might function as a biocatalyst for oxidations and reductions in the same way as do cysteine and cystine Aneurine was oxidised to the disulphide by treatment with dilute hydrogen peroxide at pH 7.5, whilst the disulphide was reduced back to aneurine or to the corresponding thiol by cysteine or glutathione, though not by ascorbic acid


So far, however, no conclusive evidence has been put forward to indicate that the disulphide is ever formed *in vivo* On the contrary, it has been shown<sup>68</sup> that cocarboxylase and its thiol form liberated carbon dioxide from pyruvic acid at about the same rate, whereas the disulphide pyrophosphate was inactive The suggestion that vitamin B<sub>1</sub> is part of a redox system must therefore be rejected

This conclusion is supported by R. A. Peters,<sup>69</sup> who found that aneurine disulphide was at least as active as aneurine in the catatorulin test, and that, in presence of SH-compounds, aneurine disulphide pyrophosphate was able to effect the decarboxylation of pyruvic acid by washed yeast Cysteine, for example, was very effective, whereas cystine was inert Presumably, aneurine disulphide pyrophosphate must first be reduced to aneurine by SH-compounds before it is active in the catatorulin effect

## Aneurine, a Catalyst Activating Pyruvic Acid

Doubtless the final word has not yet been said as to the precise rôle played by aneurine pyrophosphate in pyruvate metabolism, but the most satisfactory hypothesis at the present time is undoubtedly that of E. S. G. Barron, C. M. Lyman, M. A. Lipton and J. M. Goldinger,<sup>70</sup> who suggested that aneurine activates the pyruvic

acid molecule in a manner that can be represented schematically as follows



The activated pyruvic acid is then able to react with catalysts for its oxidation to acetic acid reduction to lactic acid decarboxylation to acetaldehyde dismutation to lactic and acetic acids or carboxylation to oxaloacetic acid. By inhibiting the activation of pyruvic acid the absence of aneurine resulting from vitamin B<sub>1</sub> deficiency would interfere with all the chemical transformations in which pyruvic acid plays a part.

### Aneurine and Vitamin C

According to Roy *et al*<sup>71</sup> narcotics such as chlorotone stimulated the synthesis of vitamin C by rats but the effect was reduced if the animals were made aneurine or riboflavine deficient. Since pyruvic and lactic dehydrogenases are known to be affected by chlorotone it was suggested that pyruvic acid might be utilised in the synthesis of ascorbic acid and that both aneurine and riboflavine might be necessary for effecting this transformation.

### References to Section 18

- 1 C Funk, *Z physiol Chem* 1914 89, 378
- 2 H W Kinnersley and R A Peters *Biochem J* 1929 23, 1126  
1930 24, 711
- 3 T W Birch and L J Harris *ibid* 1934 28, 602
- 4 H G K Westenbrink *Arch neer physiol* 1934 19, 94
- 5 I Nitzescu and C Angelescu *Z Vitaminforsch* 1942 12, 82
- 6 B S Platt and G D Lu *Quart J Med* 1936 5, 355 *Biochem J*  
1939 33, 1523 1538
- 7 M E Shils H G Day and E V McCollum *J Biol Chem* 1941  
139, 145
- 8 A Göth *Z Vitaminforsch* 1944 14 231
- 9 H A Harper and H J Deuel *J Biol Chem* 1941 137, 233
- 10 M E Shils H G Day and E V McCollum *Amer J Med Sci*  
1941 201, 561
- 11 W D Robinson D Melnick and H Field *J Clin Invest* 1940  
19 483
- 12 H Wortis E Beuding and W E Wilson *Proc Soc Exp Biol Med* 1940 43, 279
- 13 H A Davis and F K Bauer *Arch Surg* 1944 48 185 190 193
- 14 M K Horwitt and O Kreisler *J Nutrition* 1949 37, 411
- 14 A Geiger and A Rosenberg *Klin Woch* 1933 12, 1258

# ANEURINE (THIAMINE)

- 15 M Chiba, *Tohoku J. Exp Med*, 1932, 19, 486
- 16 T Suzuki and A. Takamatsu, *ibid*, 1934, 24, 202, see also L Fehuly, *Brit Med J*, 1944 2, 590
- 17 R Orimo, *Tohoku J Exp Med*, 1939 35, 374
- 18 A Takamatsu and A Sato, *ibid*, 1934, 23, 506
- 19 J Vogt-Möller, *Biochem Z*, 1931, 233, 248
- 20 B S Platt and G D Lu, *Biochem J*, 1939 33, 1523, 1538
- 21 R A Peters, *Lancet* 1936, 1, 1161
- 22 W C Sherman and C A Elvehjem, *Biochem J*, 1936, 30, 785
- 23 K. Lohmann and P Schuster, *Naturwiss*, 1937, 25, 26, *Biochem Z*, 1937, 294, 188
- 24 H A Krebs, *Nature*, 1936, 138, 288
- 25 H A Krebs and W A Johnson, *Biochem J*, 1937, 31, 645
- 26 G M Hills, *ibid*, 1938, 32, 383
- 27 H G K Westenbrink and J J Pollak, *Rec trav chim Pays Bas*, 1937, 56, 315
- 28 K G Stern and J W Hofer, *Science*, 1937, 85, 483
- 29 H Tauber, *ibid*, 1937, 86, 180
- 30 H von Euler and R Vestin, *Naturwiss*, 1937, 25, 416
- 31 M Silverman and C H Werkman, *Proc Soc Exp Biol Med* 1939, 40, 369
- 32 H Weil Malherbe, *Biochem J*, 1940, 34, 980
- 33 E S Nasset and J F Waldo, *J Nutrition* 1941, 21, Suppl., 10
- 34 H Weil Malherbe, *Biochem J*, 1939 33, 1997
- 35 F Schlenk, R B Vowles and H von Euler, *Arkiv Kemi, Min, Geol*, 1940, 13B, No 20
- 36 M A Lipton and C A Elvehjem, *Nature*, 1940, 145, 226, M A Lipschitz V R Potter and C A Elvehjem, *Biochem J*, 1938, 32, 474, *J Biol Chem*, 1938, 124, 147
- 37 F Lipmann, *Nature*, 1937, 140, 25
- 38 R A Peters *Biochem J*, 1937, 31, 2240
- 39 I Banga S Ochoa and R A Peters, *ibid*, 1939 33, 1109
- 40 I Banga, S Ochoa and R A Peters *ibid*, 1980
- 40a L Velluz, G Amiard and J Bartos, *Bull Soc Chim*, 1948 [v] 15, 871, *J Biol Chem*, 1949 180, 1137, L Velluz, R Jequier and C Plotka, *C R Acad Sci*, 1948, 226, 1855
- 41 L J Klügler, N Grossowicz and S Bergner, *J Bact*, 1943, 46, 399
- 42 H A Krebs and L V Eggleston, *Biochem J*, 1940, 34, 1383
- 43 H A Krebs, *Nature*, 1941, 147, 560
- 44 E A Evans and L Slotin, *J. Biol Chem*, 1940, 136, 301
- 45 H G Wood, C H Werkman, A Hemingway and A O Nier, *ibid*, 1942, 142, 31
- 46 D H Smyth, *Biochem J*, 1940, 34, 1598
- 47 R W Benham *Proc Soc Exp. Biol Med*, 1945, 58, 199
- 48 H A Krebs, L V Eggleston, A Kleinzeller and D H Smyth, *Biochem J*, 1940, 34, 1234
- 49 H A Sober M A Lipton and C A Elvehjem *J Biol Chem*, 1944, 134, 605
- 50 A H Smith and C E Meyer, *ibid*, 1941, 139, 277

- 50a H L Mayfield and M T Hedrick, *J Nutrition*, 1949, 37, 475
- 51 K Closs and A Fälling *Z physiol Chem* 1938, 254, 258
- 52 M M Kaser and W J Darby, *J. Biol Chem*, 1945 161, 279
- 53 S Edlbacher and G Viollier *Helv Chim Acta* 1943 26, 1978
- 54 J Dawson, *Biochem J*, 1944, 38, *Proc.* xv.
- 55 M G Kritzman, *Biochimica* 1943 8, 85
- 56 L O Krampitz and C H Werkman, *Biochem J* 1941, 35, 595
- 57 J H Quastel and D. M. Webley, *ibid*, 1942, 36, 8
- 58 F Lipmann, *Nature*, 1937 140, 25, *Enzymologia* 1937, 4, 65
- 59 F Lipmann, *Nature* 1936, 138, 1097
- 60 F Lipmann, *Skand Arch Physiol*, 1937, 70, 255
- 61 E S G Barron and C M Lyman *J. Biol Chem*, 1939, 127, 143
- 62 E S G Barron and C M Lyman *Science* 1940 82, 337
- 63 K G Stern and J L Melnick, *J. Biol Chem* 1939, 131, 597
- 64 K G Stern and J L Melnick, *ibid*, 1940 135, 365
- 65 E S G Barron and C M Lyman *ibid* 1941, 141, 951, E S G Barron C M Lyman M A Lipton and J M Goldinger, *ibid*, 957, E S G Barron, J M Goldinger, M A Lipton and C M Lyman *ibid* 975
- 66 O Zima and R R Williams *Ber.*, 1940 73, 941
- 67 O Zima, K Rutsert and T Moll, *Z physiol Chem* 1941 267, 210
- 68 P. Karrer and M Viscontini *Helv Chim Acta* 1946 29, 711
- 69 R A Peters, *Nature*, 1946 158, 707
- 70 E S G Barron C M Lyman M A Lipton and J M Goldinger, *J Biol Chem*, 1941, 140, xi
- 71 S C Roy, S K Roy and B C Guha *Nature* 1946 158, 238

## 19 ANEURINE IN THE NUTRITION OF MICRO-ORGANISMS

Aneurine is not only a vitamin for animals, but it is also a 'vitamin' for many micro-organisms. E Wildiers<sup>1</sup> in 1901 postulated that yeasts required in addition to sugar and inorganic salts a hypothetical organic substance which he called 'bios'. This was subsequently shown to be, not one single entity, but a mixture of several different substances. One of these, which had provisionally been designated "Bios V", was ultimately shown to be identical with aneurine\*. Since then, a considerable amount of work has been carried out on the aneurine requirements of a large variety of yeasts and other fungi and bacteria. Some of these micro-organisms have been used for the assay of aneurine.

### Yeasts

Reference has already been made (page 33) for example, to the yeast fermentation method of estimating aneurine, in which a strain of yeast that fails to produce carbon dioxide in the absence of aneurine



thiocyanate and potassium dihydrogen phosphate had the same relatively weak effect, but sodium fluoride, potassium sulphate and magnesium chloride were more potent, and lanthanum nitrate still more potent, inhibitors of this adsorptive phase. The second stage was of longer duration and was very sensitive to pH, maximum absorption occurred at pH 3.5 to 4.0. This stage was inhibited by iodoacetate or azide and slightly by potassium cyanide or sodium fluoride. Absorption was also almost completely inhibited by 4-amino-5-aminomethyl-2-methyl-pyrimidine, which was also found to inhibit the dephosphorylation of cocarboxylase by yeast phosphatase. It is therefore suggested that phosphatase may be connected with this second phase of aneurine absorption, which probably involves phosphorylation.

### Other Fungi

The aneurine requirements of other fungi exhibit the same wide variations that have been noted for the yeasts. *Phycomyces Blakesleeanus*, as already stated (page 35), fails to grow in the absence of aneurine, and the weight of the mycelium formed on a medium containing aneurine is, within limits, proportional to its concentration. The test is highly specific and only closely related analogues of aneurine (see page 122) give a response.<sup>15</sup> An equimolecular mixture of the pyrimidine and thiazole moieties, however, gave the same growth response as the corresponding amount of aneurine,<sup>16</sup> though the organisms fail to grow when only one of these fractions is present.

*Phytophthora cinnamomi*<sup>17</sup> and *P. erythroseptica*<sup>18</sup> also require aneurine for growth, but these fail to respond to a mixture of the two halves of the molecule. *Pythiomyces gonapodioides*<sup>15</sup> will respond either to aneurine or to the pyrimidine moiety alone, and it has been suggested that by means of this organism in conjunction with *P. Blakesleeanus* and *P. erythroseptica*, an estimate might be made of the amounts of aneurine and of the thiazole and the pyrimidine halves of the molecule in a mixture of all three.

F. Kavanagh<sup>19</sup> observed that aneurine disappeared from cultures in which *Phycomyces Blakesleeanus*, *Phytophthora cinnamomi*, *Mucor Ramannianus* or *Sclerotium rolfsii* were grown and that with *P. Blakesleeanus* the pyrimidine half of the aneurine molecule was liberated and the thiazole half destroyed, the addition of the thiazole compound, but not the pyrimidine compound, increased the growth of the mould. *P. cinnamomi* utilised aneurine without destroying either the thiazole or the pyrimidine moiety, whilst *M. Ramannianus* synthesised the pyrimidine half and grew well in the presence of the thiazole half. *S. rolfsii*, when grown in solutions containing aneurine,

synthesised the thiazole half. Like *M. Ramannianus*, *Rhodotorula rubra* cannot grow in the absence of aneurine but the two moulds, together will grow and develop satisfactorily in an aneurine free medium because the former is able to synthesise the pyrimidine half of the molecule, which the latter cannot synthesise, whereas the latter can synthesise the thiazole half which the former cannot synthesise. The behaviour of these two moulds is a striking example of symbiosis, and is due to the ability of each partner to supply a nutrient that the other needs. Another illustration is provided by the phenomenon well known to horticulturists, that orchid seeds will only germinate when a mycorrhizal fungus is present. It is now known that the latter synthesises aneurine, which the seeds require.

An increase in the amount of glucose consumed by *Melanospora destruens* or *Phycomyces nitens* occurred on addition of aneurine to the medium,<sup>20</sup> owing to the increased rate of respiration. *Phytophthora infestans* also required aneurine for growth and this could not be replaced by a mixture of the two halves of the molecule.<sup>21</sup>

Aneurine is also necessary for the growth of *Ustilago violacea*, and *U. scabiosae*, but not of other species of *Ustilago*.<sup>22</sup> It is also necessary for the growth of the wood-destroying fungi, *Stercum frustulosum*, *Hydnum erinaceus*, *Polyporus Spraguei* and *Fomes ignarius*,<sup>23</sup> of a number of other wood-destroying *Polyporiaceae*,<sup>24</sup> and of *Lophodermum pinastri*, *Sclerotinia cinerea*, *Helvella infesta*, *Polyporus adustus*, *P. abietinus*, *Fomes pinicola*, *Trametes cinnabarina*, *T. serialis*, *Lenzites sepiaria* and *Tricholoma nudum*.<sup>25</sup>

Other moulds for which aneurine is a growth factor were reported by P. R. Burkholder and D. Moyer,<sup>26</sup> of seventeen fungi tested, the following required aneurine: *Hormodendron pedrosoi*, *Phialophora verrucosa*, *Sporotrichon schenckii*, *Trichopyton faviforme*, *T. sulphureum*, *T. violaceum*, *Fomes annosus*, *Coryne sarcoides*, *Cytospora* sp., and *Lenzites betulina*. W. H. Schopfer and S. Blumer<sup>27</sup> reported that aneurine was necessary for the growth of *Trichophyton album* but could be replaced by an equimolecular mixture of the thiazole and pyrimidine halves, either alone was without effect.

According to N. Fries<sup>28</sup> pyridoxine is essential for several species of *Ophiostoma* (*Ceratostomella*). Some of them, including *O. multiannulatum* and *O. pluriannulatum* required aneurine in addition, whilst the growth of *O. ulmi* was stimulated by the addition of aneurine. *Ascoidea rubescens* required pyridoxine, aneurine and biotin. Aneurine was an essential growth factor for *O. coeruleum*, *O. quercus*, *O. piceae*, *O. stenoceras*, *O. pini* and for *Mitrula pusilla*. These species were apparently capable of synthesising the thiazole moiety but not the pyrimidine half of the molecule. W. Schopfer<sup>29</sup> also observed that *Ceratostomella ulmi* could grow without added aneurine, but not in the

### ANEURINE (THIAMINE)

aneurine, and it was therefore suggested that the thiazole half was synthesised from the above four amino acids.

*Other Micro-organisms.* Aneurine is essential for the growth of the following flagellates: *Polytoma ocellatum*,<sup>46</sup> *P. caudatum*,<sup>47</sup> and *Chilomonas paramecium*,<sup>47</sup> which utilise the thiazole half in place of aneurine; *Polytomella caeca*,<sup>48, 49</sup> which requires either the intact molecule or both halves; *Strigomonas oncopelti*,<sup>50</sup> *S. fasciculata*<sup>50</sup> and *S. culicidarum*,<sup>51</sup> all three of which require the intact aneurine molecule; *Chlamydomonas orbicularis*,<sup>52</sup> *Chlorogonium tetragamum*<sup>52</sup> and *Haematococcus pluvialis*.<sup>52</sup> The ciliate, *Glaucoma piriformis*, required the intact aneurine molecule and failed to respond to a mixture of the thiazole and pyrimidine halves.<sup>53</sup>

## EFFECT ON HIGHER PLANTS

- 22 W H Schopfer *Ber deut botan Ges* 1937 55, 572 W H Schopfer and S Blumer *Compt rend* 1938 208, 1141
- 23 N L Noecker *Amer J Bot* 1938 25, 345
- 24 N Fries *Symbolae Botan Upsalienses* 1938 3, No 1 *Rev Applied Mycol* 18, 335
- 25 F Kögl and N Fries *Z physiol Chem* 1937 249, 93
- 26 P R. Burkholder and D Moyer *Bull Torrey Bot Club* 1943 70, 372
- 27 W H Schopfer and S Blumer *Ber Schuetz Bot Ges* 1943 53, 409
- 28 N Fries *Symbolae Botan Upsalienses* 1943 7, No 2
- 29 W H Schopfer *Arch Julius Klaus Stift* 1945 20, 27
- 30 W J Robbins and R Ma *Bull Torrey Bot Club* 1943 70, 190
- 31 W H Schopfer *Helv Chim Acta* 1944 27, 1017
- 32 M N Musil *Compt rend Acad Sci URSS* 1943 41, 248
- 33 J E Mackinnon *Bull Torrey Bot Club* 1942 69, 21 J A Herrick and C J Alexopoulos *ibid* 1942 69, 569 1943 70, 369
- 34 E Haag *Arch Sci phys nat* 1940 (v) 22, Suppl 136
- 35 R W Benham *Proc Soc Exp Biol Med* 1945 58, 199
- 36 H P Sarett and V H Cheldelin *J Biol Chem* 1944 155, 153
- 37 C F Niven and K L Smiley *ibid* 1943 150, 1
- 38 P M West and P W Wilson *Science* 1938 88, 334
- 39 A Schuetz *Schuetz Z Path Bakt* 1942 5, 238
- 40 C E Lankford and P K Skeggs *Arch Biochem* 1946 9, 265
- 41 R E Feeney J H Mueller and P A Miller *J Bact* 1943 46, 563
- 42 C Lamanna and C Lewis *ibid* 1946 51, 398
- 43 I J Kligler H Grossowicz and S Bergner *ibid* 1943 46, 399
- 44 H McIlwain *Nature* 1946 158, 898
- 45 H Katznelson *J Biol Chem* 1947 167, 615
- 46 A Lwoff and H Dusi *Compt rend* 1937 205, 882
- 47 A Lwoff and H Dusi *ibid* 756 *Compt rend Soc Biol* 1938 127, 1408
- 48 M Javillier and L Emerique Blum *Compt rend* 1940 211, 374
- 49 A Lwoff and H Dusi *ibid* 1937 205, 630
- 50 M Lwoff *Compt rend Soc Biol* 1937 128, 771
- 51 M Lwoff *ibid* 1938 128 241
- 52 K Ondratschek *Arch Mikrobiol* 1940 11, 239
- 53 A and M Lwoff *Compt rend* 1937 128, 644 L Emerique Blum and A Lwoff *Bull Soc Chim biol* 1940 22, 179

## 20 EFFECT OF ANEURINE ON HIGHER PLANTS

The pronounced stimulating effect of aneurine on micro organisms suggested that it might be a growth factor for higher plants and possibly even a plant hormone biologically similar to auxin. Expectations of this type however have not been realised for in no plant

treated with aneurine has any convincing evidence of growth stimulation been obtained. The addition of aneurine (0.01 mg per litre) to the nutrient solution failed to affect the fresh or dry weights of plants or their times of flowering, or the size, number and colour of their flowers<sup>1</sup>. Aneurine had no effect on the growth of *Agrostis tenuis* or *Brassica alba*,<sup>2</sup> of rice,<sup>3</sup> or of radish or cauliflower<sup>4</sup>. It did not affect pollen germination or pollen tube elongation<sup>5</sup> and did not promote growth in, or alter the yield of, sunflowers, maize, flax, wheat or beans<sup>6</sup>.

Three reports have been published, however, claiming that aneurine had a positive growth effect on certain plants. The first is a statement<sup>7</sup> that the growth of aster seedlings was increased by aneurine, although it had no effect on the growth of the roots, the authors suggested that aneurine might be an activator of indolyl butyric acid.

The second report claimed<sup>8</sup> that aneurine stimulated the growth of cosmos seedlings at 20° C but not at 26.6° C. A temperature favouring luxuriant growth did not favour stimulation by aneurine. The third records<sup>9</sup> that aneurine could not replace indolylacetic acid for promoting the growth of carrot tissue, though root cultures could be maintained in presence of aneurine.

A little work has been carried out on the changes that take place in the distribution of aneurine as plants develop. In cereals, beans and peas, no increase in the aneurine content took place during germination or, in oat seedlings, during the first five days after germination, although the riboflavine, nicotinic acid and pyridoxine contents increased<sup>10</sup>. Half the aneurine present was found in the embryo, although this represented only 6.5 % of the dry weight of the seed. No increase occurred in the amount of aneurine in the coleoptile although the riboflavine and nicotinic acid contents increased. All three substances appeared to be synthesised in the leaves. In tomato leaves, the maximum concentration was found in newly developed leaves, the concentration decreasing progressively towards the roots<sup>11</sup>. It would seem that aneurine is synthesised in the mature leaves and translocated to the actively growing tissues, in which it accumulates.

The aneurine content of forty one genera of herbs and medicinal plants was 1.25 to 28.8 µg per g of dry weight<sup>12</sup>. The amounts of aneurine in a variety of foodstuffs have been listed on pages 43 to 45.

Although aneurine does not appear to be a growth hormone it is present in soil and natural manures,<sup>13</sup> from which it is presumably taken up by plants, since its concentration in pasture was increased by manuring with farmyard manure.

## REQUIREMENTS OF INSECTS

### References to Section 20

- 1 C L Hamner, *Bot Gaz*, 1940 102, 156
- 2 D G Clark, *Plant Physiol*, 1942, 17, 137
- 3 C E Minarick, *ibid*, 141
- 4 E C Minnum *Bot Gaz*, 1941, 103, 397
- 5 P F Smith *Amer J Bot* 1942 29, 56
- 6 L Gisiger, *Mitt Lebensm Hyg*, 1943, 34, 315
- 7 A E Hitchcock and P W Zimmerman *Contrib Boyce Thompson Inst*, 1941, 12, 143
- 8 J Bonner, *Bot Gaz*, 1942, 104, 475
- 9 P Nobécourt, *Compt rend*, 1943 216, 902
- 10 P R Burkholder and I McVeigh, *Proc Nat Acad Sci* 1942, 28, 440, I McVeigh, *Bull Torrey Bot Club*, 1944, 71, 438
- 11 J Bonner, *Amer J Bot*, 1942, 29, 136
- 12 A S Chaikelis, *J. Amer Pharm Assoc*, 1946 35, 343
- 13 M A Roulet, *Experientia* 1948, 4, 149

## 21. ANEURINE REQUIREMENTS OF INSECTS

Insects require in their diet several members of the vitamin B complex if they are to develop normally, and aneurine has been shown to be essential for the growth of the fruit-fly, *Drosophila melanogaster*,<sup>1</sup> of various species of mosquito<sup>2</sup> of the beetles, *Tenebrio molitor*,<sup>3</sup> *Tribolium confusum*,<sup>4, 5</sup> and *Plinus tectus*<sup>5</sup> and the moth, *Ephestia elutella*.<sup>5</sup> The beetles, *Silanus surinamensis*, *Sitodrepa panicea* and *Lasioderma serricorne* did not apparently require either aneurine or most other members of the vitamin B complex,<sup>5</sup> and this was shown to be due to the presence in these last three insect of intracellular symbiotic micro organisms capable of synthesising some of the vitamins, on sterilising the larvae no growth occurred in the absence of aneurine. This observation affords a striking parallel to the phenomenon of intestinal synthesis in animals. A number of early workers considered that the function of these intracellular symbionts might be the provision of accessory food substances,<sup>6</sup> and their predictions have been amply fulfilled.

Aneurine, together with other members of the vitamin B complex, was necessary for the growth of sterile larvae of the mosquito, *Aedes aegypti*, to the fourth instar.<sup>7</sup>

An attempt has been made to utilise insect larvae, for which aneurine is an essential nutrient, as a test organism in vitamin B<sub>1</sub> assays. Thus, Sarma *et al*<sup>8</sup> found that the pyruvic acid content of the larvae of the rice moth (*Corcyra cephalonica*) increased from about 20 to 164 mg per 100 g of dry weight when maintained on a vitamin B<sub>1</sub>-deficient diet for thirty five days, and that this decreased to half

## ANEURINE (THIAMINE)

within sixty-six hours of adding aneurine. The growth of larvae fed a vitamin B<sub>1</sub>-deficient diet, supplemented by graded doses of aneurine, was proportional to the amount of aneurine. This method of assay has not been adopted by other workers, however.

### References to Section 21

1. E. G. van t'Hoog, *Z. Vitaminforsch.*, 1935, 4, 300; 1936, 5, 118; E. L. Tatum, *Proc. Nat. Acad. Sci.*, 1939, 25, 490; 1941, 27, 193.
2. W. Trager and Y. SubbaRow, *Biol. Bull. Woods Hole*, 1938, 75, 75; Y. SubbaRow and W. Trager, *J. Gen. Physiol.*, 1940, 23, 561.
3. H. E. Martin and L. Hare, *Biol. Bull. Woods Hole*, 1942, 83, 428.
4. G. Fröbrich, *Z. vergl. Physiol.*, 1939, 27, 335; K. Offhaus, *ibid.*, 384.
5. G. Fraenkel and M. Blewett, *Nature*, 1943, 151, 703; 1943, 152, 506; *Biochem. J.*, 1943, 37, 686; *Proc. Roy. Soc. B.*, 1944, 132, 212.
6. V. B. Wigglesworth, *Parasitology*, 1929, 21, 288; P. Buchner, *Tiere und Pflanzen Symbiose*, Berlin, 1930; M. Aschner, *Z. Morph. Ökol. Tiere*, 1931, 20, 368; A. Koch, *Biol. Zbl.*, 1933, 53, 199; *Verh. dtsch. Zool. Ges.*, 1933, 35, 143.
7. L. Golberg, B. de Meillon and M. Lavoipierre, *J. Exp. Biol.*, 1945, 21, 84, 90.
8. P. S. Sarma and K. Bhagvat, *Current Sci.*, 1942, 11, 331; P. S. Sarma, G. B. L. Swami and M. Sreenivasaya, *ibid.*, 332; P. S. Sarma, *Indian J. Med. Res.*, 1943, 31, 173.

## 22. ANALOGUES OF ANEURINE

### Thiazole and Pyrimidine Compounds


In the course of the researches that led to the synthesis of aneurine, a number of compounds closely related to the vitamin were prepared, and their biological activities were determined. Subsequently, deliberate attempts were made to modify the aneurine molecule with a view to ascertaining the effect of such changes on the biological activity.

As already mentioned above, Todd *et al.*<sup>1</sup> prepared a substituted 3-pyrimidyl-thiazolium salt (see page 17) isomeric with aneurine, but differing from it in the absence of a methylene group joining the two rings, and in the orientation of the groups on the pyrimidine ring; it was inactive when tested on vitamin B<sub>1</sub>-deficient rats. It also failed to yield thiochrome on oxidation with potassium ferricyanide, but it gave a positive formaldehyde-azo test.

In a later paper, A. R. Todd and F. Bergel<sup>2</sup> described the preparation of several compounds differing from aneurine only in the nature of the substituents on the two rings. None of these analogues

# ANALOGUES

possessed vitamin B<sub>1</sub> activity Their constitution is represented by the following formula :



in which R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> were

	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Azo Test	Thiochrome Test
Compound 1	NH <sub>2</sub>	H	H	—	+
" 2	OH	H	H	—	—
" 3	OH	H	CH <sub>2</sub> · CH <sub>2</sub> OH	+	—
" 4	NH <sub>2</sub>	CH <sub>3</sub>	CH <sub>2</sub> · CH <sub>2</sub> OH	—	—
Aneurine	NH <sub>2</sub>	H	CH <sub>2</sub> · CH <sub>2</sub> OH	+	+

The first of these compounds differed from aneurine only in the ab-ence of the hydroxyethyl group which is therefore essential for biological activity, as might be expected, since the hydroxyl group is the point of attachment of the pyrophosphate radicle in cocarboxylase Compound 3 differed from aneurine only in the replacement of the amino group by a hydroxyl group, evidently the presence of the amino group is also essential The most surprising result of the series is the inactivity of compound 4, which merely contains an additional methyl group in the thiazole ring The loss of activity would be understandable if Williams and Zima's hypothesis (page 101) were true and cleavage of the thiazole ring were essential for aneurine to exercise its function, but this idea has not received support

H Andersag and K Westphal,<sup>3</sup> in the course of their synthesis of the vitamin, prepared an isomer of aneurine, 3-(4'-amino-6'-methyl-pyrimidyl-5'-methyl)-5-β hydroxyethyl-4-methyl-thiazolium chloride, which they stated to be active, although they did not record its activity relative to that of aneurine, F Schultz<sup>4</sup> found it to be only slightly active, however It gave a positive thiochrome reaction

B C J G Knight and H McIlwain<sup>5</sup> tested a number of aneurine analogues and pyrimidine and thiazole derivatives by means of a strain of *Staphylococcus aureus* that would not grow on a synthetic medium unless either aneurine or both the pyrimidine and thiazole moieties were present They found that 3-(4'-amino-2'-methyl-5'-pyrimidyl-methyl)-5-α-hydroxyethyl-4-methyl-thiazolium chloride, which differs from aneurine only in the position of the hydroxyl group



in the hydroxyethyl side-chain, and 3-(4'-amino 2'-chloro-6'-methyl-5'-pyrimidyl methyl)-5- $\beta$  hydroxyethyl 4 methyl-thiazolium chloride had only slight growth promoting activity, whilst the 2 methyl analogue of aneurine and the compound derived from aneurine by loss of the hydroxyethyl group were inactive

The bromide corresponding to the  $\alpha$ -hydroxyethyl compound prepared by Knight and McIlwain was prepared by Baumgarten *et al*,<sup>6</sup> who found it to have no antineuritic activity

Knight and McIlwain also tested the effect of various pyrimidine derivatives in place of 4 amino-5 aminomethyl 2 methyl-pyrimidine, the thiazole moiety being present in each instance. Substitution of aminomethyl group by the hydroxymethyl or thioformamidomethyl group resulted in active compounds, but all other changes in the molecule resulted in loss of activity. Similarly, the effect of changing the substituents attached to the thiazole ring was studied. Activity was retained when the  $\beta$  hydroxyethyl group was replaced by the  $\beta$  acetoxyethyl group and, to a less extent, by a  $\beta$ - or  $\gamma$  hydroxypropyl group. The introduction of an  $\alpha$ -hydroxyethyl group into the molecule and most other structural changes resulted in loss of activity. 4-Methyl 5-vinyl-thiazole, however, had a slight and delayed activity possibly due to hydration to the hydroxyethyl derivative

A micro organism that can utilise the two halves of the aneurine molecule is the flagellate, *Polytomella caeca* (see page 112). The effect on the response of this organism of changing the nature of the substituent at carbon atom 5 in the pyrimidine moiety was examined by M. Javillier and L. Emerique Blum.<sup>7</sup> They showed that when the substituent was a hydroxymethyl, formyl aminomethyl or cyano group, growth was stimulated, whereas the compounds containing a carboxyl, amido or methyl group on carbon atom 5 did not permit growth. It is easy to see how the compounds in the first series could readily be converted into aneurine, and how the compounds in the second group could be converted with great difficulty, if at all.

A micro organism that responds to the presence of either component of the aneurine molecule is *Rhizopus sunius*. Alcoholic fermentation by means of this organism was increased<sup>8</sup> by the addition of 4 amino 5-aminomethyl 2-methyl pyrimidine or the corresponding 5 thioformamidomethyl or 5 hydroxymethyl derivatives, but reduced by the addition of 4-amino 5 aminomethyl 2 ethyl pyrimidine, 4-amino-2, 5 dimethyl-pyrimidine, 4 hydroxy 2, 5 dimethyl pyrimidine, 4-amino-5-carbethoxy-2-methyl-pyrimidine, 4-amino 6 hydroxy-2-methyl pyrimidine or uracil. The structure of the thiazole moiety was less critical, and could be varied within wide limits without adversely affecting the fermentation, which was increased in the presence of the following compounds: 5  $\beta$  hydroxyethyl 4 methyl thiazole,

5- $\beta$ -hydroxyethyl-4-methyl-3-[4'-(5'-methyl-imidazolyl)]-thiazolium chloride, 3-benzyl-5- $\beta$ -hydroxyethyl-4-methyl-thiazolium chloride, 4-methyl-thiazole, 4:5-dimethyl-thiazole, 5- $\beta$ -acetoxyethyl-4-methyl-2-thiol-thiazole, 2-amino-4-methyl-thiazole and 4:5-dimethyl-2-thiol-thiazole. It is difficult to see how some of these compounds could act as precursors of aneurine, especially those compounds in which the  $\beta$ -hydroxyethyl group is lacking. It is more consistent with current views concerning the biosynthesis of aneurine to regard these thiazole compounds as having a general stimulating effect, rather than a specific action due to their conversion into aneurine.

5- $\beta$ -Hydroxyethyl-4-methyl-imidazole failed to support the growth of pea-roots or of *Phycomyces* \* so that the imidazole ring is apparently not a substitute for the thiazole ring.


The growth-promoting effects of a mixture of the thiazole and pyrimidine portions of aneurine, observed with such micro-organisms as *Slaphylococcus aureus*, *Polytomella caeca* and *Phycomyces Blakesleanus* (see page 108), were shown by E. and R. Abderhalden<sup>10</sup> to occur also with pigeons, vitamin B<sub>1</sub>-deficient birds showing a similar response to that produced by aneurine; the effect was more marked after oral administration than after intramuscular injection. No aneurine was synthesised from the two halves of the molecule by pigeon tissues *in vitro*.

The physiological activity of other pyrimidines and thiazoles was tested by S. Morii,<sup>11</sup> who found that 4-amino-5-hydroxymethyl-2-methyl-pyrimidine and the corresponding chloro- and bromomethyl compounds produced convulsions in vitamin B<sub>1</sub>-deficient pigeons, whereas 4-amino-5-aminomethyl-2-methyl-pyrimidine, 4-ethyl-2-amino-pyrimidine, 4-amino-6-ethyl-pyrimidine, uracil, thymine, and adenylic acid were inert. 5- $\beta$ -Hydroxyethyl-4-methyl-thiazole exerted a marked curative action on vitamin B<sub>1</sub>-deficient pigeons, and this was not enhanced by simultaneous administration of various pyrimidine derivatives, a result not necessarily in conflict with that recorded by E. and R. Abderhalden, who do not appear to have tested the compounds separately. No curative effect was observed on administration of N-(4'-amino-2'-methyl-5'-pyrimidyl-methyl)-5-hydroxy-3:4-bishydroxymethyl-6-methyl-pyridinium bromide hydrobromide or its triacetate, or with acetopropyl alcohol given together with 4-amino-2-methyl-5-thioformamidomethyl-pyrimidine or with methionol given together with 4-amino-5-aminomethyl-2-methyl-pyrimidine hydrochloride.

F. Schultz<sup>4</sup> prepared and tested on vitamin B<sub>1</sub>-deficient pigeons, thirty-nine compounds closely related to aneurine. Of these, sixteen showed some activity, one actually being more, though perhaps not significantly more, active than aneurine. Assuming aneurine to have

# ANEURINE (THIAMINE)


a biological activity of 2.5  $\mu\text{g}$  per unit, the activity of the compounds tested ranged from 2.1 to 11,800  $\mu\text{g}$  per unit. The compounds are listed in the table on page 121, in order of decreasing activity. Compounds 1 to 9 have the general formula



The presence of biological activity in compounds 1 to 9 indicates that the introduction of additional methylene groups at position 2 of the pyrimidine ring and position 4 of the thiazole ring generally reduced, but did not entirely destroy, vitamin B<sub>1</sub> activity. The removal of the methyl groups from either of these positions was accompanied by a marked reduction in activity.

Compound 10 is of considerable interest, in that the interposition of an additional group between the two rings would at first sight be expected to alter fundamentally the spatial arrangement of the molecule, yet some biological activity was apparently retained. The addition of a methyl group to the amino group or an increase in the number of carbon atoms in the hydroxyethyl group decreased the activity very considerably, whilst appreciable loss of activity also occurred when the hydroxyethyl group was replaced by a chloroethyl, an ethoxyethyl or, according to D. Price and F. D. Pickel,<sup>12</sup> an aminoethyl-group. The introduction of a methyl group into the 6 position of the pyrimidine ring reduced the activity almost to vanishing point, especially if the 2-methyl group was also removed, as in compound 16.

G. A. Stein *et al.*<sup>13</sup> found the bromide corresponding to compound 16 to be inactive. These workers also prepared the bromide corresponding to Schultz's compound 1 and confirmed that it possessed vitamin B<sub>1</sub> activity. In addition, Stein *et al.* prepared the two compounds



where R<sub>1</sub> = H and R<sub>2</sub> = CH<sub>3</sub> in the one instance, and R<sub>1</sub> = CH<sub>3</sub> and R<sub>2</sub> = H in the other and found them to be inactive.

F. Schultz,<sup>14</sup> reviewing the results previously reported by him, concluded that the activity manifested by certain compounds was not true vitamin B<sub>1</sub> activity, he recalled Funk's idea that beriberi could be cured either by administering the specific vitamin or by the


# ANALOGUES

Compound Aneurine Compound	R <sub>1</sub>	R <sub>2</sub>
1	C <sub>2</sub> H <sub>5</sub>	CH <sub>3</sub>
2	CH <sub>3</sub>	CH <sub>3</sub>
3	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>
4	C <sub>2</sub> H <sub>5</sub>	C <sub>2</sub> H <sub>5</sub>
5	" C <sub>2</sub> H <sub>5</sub>	C <sub>2</sub> H <sub>5</sub>
6	150 C <sub>2</sub> H <sub>5</sub>	C <sub>2</sub> H <sub>5</sub>
7	H	C <sub>2</sub> H <sub>5</sub>
8	CH <sub>3</sub>	" C <sub>2</sub> H <sub>5</sub>
9	C <sub>2</sub> H <sub>5</sub>	" C <sub>2</sub> H <sub>5</sub>
10	$\begin{array}{c} \text{N}=\text{C} \quad \text{NH}_2 \\   \quad   \\ \text{CH}_3 \text{---} \text{C} \quad \text{C} \text{---} \text{CH}_2 \text{---} \text{CH}_2 \text{---} \text{N} \\    \quad    \quad   \\ \text{N} \text{---} \text{CH} \quad \text{CH} \quad \text{Cl} \end{array}$	$\begin{array}{c} \text{CH}_3 \\   \\ \text{C}=\text{C} \quad \text{CH}_2 \quad \text{CH}_2\text{OH} \\   \quad   \\ \text{CH} \text{---} \text{S} \end{array}$ <p>.HCl</p>
11	$\begin{array}{c} \text{N}=\text{C} \quad \text{NH}_2 \\   \quad   \\ \text{CH}_3 \text{---} \text{C} \quad \text{C} \text{---} \text{CH}_2 \text{---} \text{N} \\    \quad    \quad   \\ \text{N} \text{---} \text{CH} \quad \text{CH} \quad \text{Cl} \end{array}$	$\begin{array}{c} \text{CH}_3 \\   \\ \text{C}=\text{C} \quad \text{CH}_2 \quad \text{CH}_2 \quad \text{CH}_2 \quad \text{CH}_2\text{OH} \\   \quad   \\ \text{CH} \text{---} \text{S} \end{array}$ <p>.HCl</p>
12	$\begin{array}{c} \text{N}=\text{C} \quad \text{NH} \quad \text{CH}_3 \\   \quad   \\ \text{CH}_3 \text{---} \text{C} \quad \text{C} \text{---} \text{CH}_2 \text{---} \text{N} \\    \quad    \quad   \\ \text{N} \text{---} \text{CH} \quad \text{CH} \quad \text{Cl} \end{array}$	$\begin{array}{c} \text{CH}_3 \\   \\ \text{C}=\text{C} \quad \text{CH}_2 \quad \text{CH}_2\text{OH} \\   \quad   \\ \text{CH} \text{---} \text{S} \end{array}$ <p>HCl</p>
13	$\begin{array}{c} \text{N}=\text{C} \quad \text{NH}_2 \\   \quad   \\ \text{CH}_3 \text{---} \text{C} \quad \text{C} \text{---} \text{CH}_2 \text{---} \text{N} \\    \quad    \quad   \\ \text{N} \text{---} \text{CH} \quad \text{CH} \quad \text{Cl} \end{array}$	$\begin{array}{c} \text{CH}_3 \\   \\ \text{C}=\text{C} \quad \text{CH}_2 \quad \text{CH}_2\text{Cl} \\   \quad   \\ \text{CH} \text{---} \text{S} \end{array}$ <p>.HCl</p>
14	$\begin{array}{c} \text{N}=\text{C} \quad \text{NH}_2 \\   \quad   \\ \text{CH}_3 \text{---} \text{C} \quad \text{C} \text{---} \text{CH}_2 \text{---} \text{N} \\    \quad    \quad   \\ \text{N} \text{---} \text{CH} \quad \text{CH} \quad \text{Cl} \end{array}$	$\begin{array}{c} \text{CH}_3 \\   \\ \text{C}=\text{C} \quad \text{CH}_2 \quad \text{CH}_2\text{OC}_2\text{H}_5 \\   \quad   \\ \text{CH} \text{---} \text{S} \end{array}$ <p>.HCl</p>
15	$\begin{array}{c} \text{N}=\text{C} \quad \text{NH}_2 \\   \quad   \\ \text{CH}_3 \text{---} \text{C} \quad \text{C} \text{---} \text{CH}_2 \text{---} \text{N} \\    \quad    \quad   \\ \text{N} \text{---} \text{CH} \quad \text{CH} \quad \text{Cl} \end{array}$	$\begin{array}{c} \text{CH}_3 \\   \\ \text{C}=\text{C} \quad \text{CH}_2 \quad \text{CH}_2\text{OH} \\   \quad   \\ \text{CH} \text{---} \text{S} \end{array}$ <p>.HCl</p>
16	$\begin{array}{c} \text{N}=\text{C} \quad \text{NH}_2 \\   \quad   \\ \text{CH} \text{---} \text{C} \text{---} \text{CH}_2 \text{---} \text{N} \\    \quad    \quad   \\ \text{N} \text{---} \text{C} \quad \text{CH}_3 \quad \text{Cl} \end{array}$	$\begin{array}{c} \text{CH}_3 \\   \\ \text{C}=\text{C} \quad \text{CH}_2 \quad \text{CH}_2\text{OH} \\   \quad   \\ \text{CH} \text{---} \text{S} \end{array}$ <p>.HCl</p>

# ANEURINE (THIAMINE)

adoption of measures that allowed sudden mobilisation of the reserve vitamins from organs and tissues. He therefore postulated that a substance with true vitamin activity should be able (a) to cure repeatedly beriberi spasm occurring several times in the same animal, (b) to keep the animal alive after cure, and (c) prevent the appearance of symptoms of vitamin B<sub>1</sub> deficiency. Tested in this way, the 2'-ethyl 4-methyl-, 2'-*n*-propyl-4-ethyl- and 4-ethyl analogues of aneurine (compounds 1, 4 and 6 above) had a true curative effect on pigeons, and moreover the substances appeared to act directly and not by conversion into aneurine.

The substances



which had previously been shown to have a pseudo-antineuritic action failed to achieve a second cure.

The superior activity of compound 1 over aneurine was confirmed by W. H. Schopfer,<sup>15</sup> using *Phycomyces Blakesleeanus*. Other compounds tested at the same time were less active, with the sole exception of cocarboxylase.

W. Huber<sup>16</sup> prepared 3-(2', 4'-diamino 5'-pyrimidyl-methyl) 5-β-hydroxyethyl-4-methyl-thiazolium chloride hydrochloride, and found it to be devoid of vitamin B<sub>1</sub> activity on rats at a level of 25 μg. This compound differs from aneurine in the presence of a second amino group in the pyrimidine ring in place of the methyl group.

Other compounds related to aneurine were prepared by E. R. Buchman and E. M. Richardson.<sup>17</sup> In these the β-hydroxyethyl group of aneurine hydrobromide was replaced by a hydrogen atom or an ethyl, vinyl, hydroxymethyl, α-hydroxyethyl or α-, β- or γ-hydroxy-*n*-propyl group. None of the compounds exhibited antineuritic activity when fed to rats at a level of 0.5 mg.


The 2-*n*-butylpyrimidine homologue of aneurine hydrobromide was prepared by G. A. Emerson and P. L. Southwick,<sup>18</sup> and found to inhibit growth and produce polyneuritis in rats fed a subnormal amount of aneurine. The effects were prevented by feeding excess

aneurine, one part of which counteracted the effect of about forty parts of the homologue. The homologue also decreased the survival period of rats maintained on a diet low in aneurine.

The isomer of aneurine in which the positions of the amino and methyl groups in the pyrimidine ring were reversed had no vitamin B<sub>1</sub> activity.<sup>19</sup>

### Hetero-vitamins B<sub>1</sub>

A particularly interesting substance would be obtained by replacing the thiazole ring with a pyridine ring. J. Finkelstein and R. C. Elderfield<sup>20</sup> synthesised two pyridine analogues, both of which were stated to be inactive for rats at a dose of 100 µg per rat whilst P. Baumgarten and A. Dornow<sup>21</sup> claimed to have prepared "hetero-vitamin B<sub>1</sub>", 1-(4'-amino-2-methyl-5'-pyrimidyl-methyl)-3-β-hydroxyethyl 2-methyl pyridinium bromide hydrobromide.



and its lower homologue in which the methyl group was absent from the pyridine ring, these compounds were said to possess 1/26th and 1/240th the activity of aneurine respectively. Subsequently however, they showed<sup>22</sup> that the compound was the α- and not the β hydroxyethyl pyridine analogue. A. H. Tracy and R. C. Elderfield<sup>23</sup> then announced the synthesis of a substance which they believed to be the true pyridine analogue of aneurine, noting that the compound was different in chemical properties from that of P. Baumgarten and A. Dornow<sup>21</sup> and from that prepared by F. C. Smelkes,<sup>24</sup> which had been stated to possess some activity. The activity of this new compound, called by them pyrithiamine, was tested by W. J. Robbins<sup>25</sup> on three different fungi. The growth of *Phycomyces Blakesleeanus* was not stimulated unless the thiazole half of aneurine was also present, indicating that this fungus could split the pyridine analogue and utilise the pyrimidine half for synthesising aneurine from the added thiazole compound. *Pythiomorpha gonapodioides* which grows in the absence of the thiazole half of the aneurine molecule if the pyrimidine portion is present, was able to grow in presence of the pyridine analogue only presumably degrading it and then utilising the pyrimidine portion. *Phytophthora cinnamomi*, which normally requires intact aneurine, would not grow when this was replaced by the pyridine analogue, even in presence of the pyrimidine or the thiazole portion.


## ANEURINE (THIAMINE)

Pyriethamine actually antagonises the growth of some micro-organisms (see page 126)

Unfortunately pyriethamine seems to have met a similar fate to Baumgarten and Dornow's pyridine analogue for A N Wilson and S A Harris<sup>25a</sup> claim that it does not possess the above structure assigned to it by Tracy and Elderfield. They in their turn claim to have prepared an authentic specimen of this elusive substance, and report that it has an absorption spectrum similar to that of aneurine. They have named the new substance neopyriethamine, and suggest that pyriethamine is a mixture of compounds having pyridine and pyrimidine moieties in the ratios 1 2, 1 3 1 4 etc. Neopyriethamine is a more potent antagonist of aneurine than is pyriethamine (see page 127)


W H Schopfer<sup>26</sup> tested the two compounds prepared by Baumgarten and Dornow, and found that, although they had only slight vitamin B<sub>1</sub> activity, they stimulated the growth of *Phycomyces Blakesleeanus* and *Ustilago violacea* in presence of the thiazole half of the aneurine molecule. These organisms therefore appear able to cleave the pyridinium derivatives and utilise the resulting pyrimidine portion for the synthesis of aneurine. Compounds with weak growth promoting activity were obtained by coupling the pyrimidine half of the aneurine molecule with 3-acetyl pyridine.<sup>26a</sup>

A pyrimidine analogue of aneurine 3 (4' amino 2' methyl 5' pyrimidyl methyl)-6-hydroxy 5 β hydroxyethyl 4 methyl pyrimidinum bromide hydrobromide



was prepared by Y A Tota and R C Elderfield<sup>27</sup> and tested by W J Robbins<sup>28</sup> on *Phycomyces Blakesleeanus* *Pythiomorpha gonapodioides* and *Phytophthora cinnamomi*. It had little or no effect on any of these moulds.

Another heterocyclic analogue of aneurine was tested by W H Schopfer<sup>26</sup> on *Phycomyces Blakesleeanus* and found to have no appreciable biological activity. This was the compound 3 [4' (5' methyl imidazolyl)] 5 β hydroxyethyl 4 methyl thiazolium chloride in which the pyrimidine ring was replaced by an imidazole ring.



3 Benzyl 5  $\beta$  hydroxyethyl 4 methyl thiazolium chloride was like wise inactive. As might be expected however both compounds stimulated the growth of *Phycomyces* when the pyrimidine half of the aneurine molecule was present in the culture fluid.

Erlenmeyer *et al*<sup>28a</sup> prepared two other analogues of aneurine in which the thiazole ring is replaced by an iminazole ring. They were obtained by coupling the pyrimidine half of the aneurine molecule with 5 hydroxymethyl and 5  $\beta$  hydroxyethyl 4 methyl iminazole.

### Simple Derivatives of Aneurine

Of the simple derivatives of aneurine all the halogen salts are active. It has been claimed<sup>29</sup> that aneurine iodide hydriodide m.p. 230 to 231°C is actually more potent than aneurine chloride hydrochloride but no suggestion has been put forward as to the reason for this.

The preparation of several water insoluble salts of aneurine for use in the enrichment of cereals was described by Huber *et al*<sup>30</sup>. Water soluble salts such as the chloride when used for this purpose are washed off in the rinsing preparatory to cooking with consequent loss of the vitamin. The 2 ethylhexyl sulphate the methylene bis (2 hydroxy 3 naphthoate) and cholestenone 6 sulphonate of aneurine were prepared and found to be sparingly soluble in water the last two being practically insoluble. All three were biologically active. Salts of other alkyl sulphuric acids could only be obtained as oils as also could the salts of isopropyl naphthalene sulphonic acid and dioctylsulphosuccinic acid. The aneurine salt of dibutylsulphosuccinic acid was found to be water soluble.

The only other simple derivatives of aneurine to be prepared are the esters. F. Schultz<sup>4</sup> found that the pyrophosphate (cocarboxylase) the monophosphate acetate benzoate and chaulmoograte had a more prolonged action than aneurine whilst the phenylurethane though active did not produce 100 % cures in vitamin B<sub>1</sub> deficient rats. The preparation of the orthophosphoric and pyrophosphoric esters of aneurine was described by J. Wejlard<sup>31</sup>. The latter was prepared not only by direct esterification of aneurine but also by condensation of 4 amino 5 bromomethyl-2 methyl pyrimidine hydrobromide with 5  $\beta$  hydroxyethyl 4 methyl thiazole pyrophosphate on the one hand and with 5  $\beta$ -chloroethyl 4 methyl thiazole in presence of silver pyrophosphate on the other. Wejlard also prepared aneurine sulphate but did not record its activity. 5  $\beta$  Hydroxyethyl 4 methyl thiazole pyrophosphate could not replace cocarboxylase in the enzymatic decarboxylation of pyruvic acid<sup>32</sup>. On the contrary it inhibited cocarboxylase activity presumably by competition with aneurine pyrophosphate for the specific enzyme carboxylase.



## Compounds related to Folic Acid

According to Busnel *et al*,<sup>33</sup> the growth of vitamin B<sub>1</sub> deficient pigeons is accelerated by several substances related to folic acid (see page 513), namely, isoxanthopterin, 2,6-dihydroxy-8,9-dimethylpteridine-2-amino-6-hydroxy-8,9-dimethylpteridine and desiminoisoxanthopterin carboxylic acid, these had approximately one tenth the activity of aneurine. Fluorescyanine, from carp scales, had a similar action to aneurine, although much weaker, in Peter's catatorulin test (page 28). All the above substances and, in addition, xanthopterin carboxylic acid and isoxanthopterin-carboxylic acid maintained normal growth and chronaxia in young rats deprived of aneurine. None of them, however, stimulated the growth of *Polytomella caeca* deprived of aneurine. So far, these results remain unconfirmed but, in view of the observations with *P. caeca*, it is unlikely that the effect is due to the presence of true vitamin B<sub>1</sub> activity in the folic acid analogues.

## Pyrithiamine

Pyrithiamine, the pyridine analogue of aneurine prepared by A. H. Tracy and R. C. Elderfield<sup>23</sup> was without growth promoting properties as has already been noted (see page 123). Nevertheless it is a most interesting substance as it inhibits the growth of several micro organisms for which aneurine is an essential growth factor. Thus O. Wyss<sup>34</sup> showed that it interfered competitively with the utilisation of aneurine by *Staphylococcus aureus* the addition of aneurine counteracting the inhibition due to pyrithiamine. This is an instance of competition between a growth factor and a growth inhibitor of analogous chemical structure of which the vitamin B complex provides many other examples (see pages 292, 345, 397, 546).

To neutralise the growth-stimulating effect of one molecule of aneurine on *S. aureus*, 666 to 750 molecules of pyrithiamine were required a value similar to that observed for sulphapyridine and *p*-aminobenzoic acid. For *E. coli*, the ratio between the amounts of growth inhibitor and growth factor that just counterbalanced one another was 20,000. Pyrithiamine is therefore a much less efficient antagonist towards aneurine for *E. coli* than for *S. aureus*. Similar variations with different organisms have been noted with other pairs of growth factors and inhibitors.

D. W. Woolley and A. G. C. White<sup>35</sup> correlated this difference in the response of different organisms with their requirements for aneurine. Organisms that required the intact aneurine molecule were inhibited by smaller amounts of pyrithiamine than organisms

that could utilise the pyrimidine and thiazole portions of the aneurine molecule. In other words, the more exacting the organism, the more sensitive it is to the effect of pyriethamine—a phenomenon also observed with other growth inhibitors.

Pyriethamine and certain derivatives of 6 aminopyrimidine inhibited the utilisation by *Lactobacillus fermenti* of aneurine pyrophosphate more readily than the utilisation of free aneurine.<sup>36</sup> Iodoacetate, malonate, dinitrophenol, fluoride and cyanide also inhibited growth and acid production by this organism in presence of aneurine or its mono or pyrophosphate. H. P. Sarett and V. H. Cheldelin<sup>36</sup> suggested that, when aneurine combines with the protein of the enzyme before being phosphorylated, a more stable form of cocarboxylase results than when combination takes place after phosphorylation.

Drug fastness has been observed with pyriethamine, as with most other antibacterial substances. This is a well known phenomenon in chemotherapy, and means the development of resistance to the inhibitory effect of an antibacterial substance. A strain of *Endomyces ternalis* resistant to pyriethamine was developed by D. W. Woolley<sup>37</sup> by conditioning it to gradually increasing concentrations of inhibitor. This strain was able to tolerate twenty five times the concentration that inhibited the parent strain. The pyriethamine fast strain required either aneurine or the pyrimidine half for growth, but in presence of small amounts of pyriethamine and in absence of aneurine, it converted a portion of the pyriethamine into the pyrimidine half.

Not only did pyriethamine inhibit the growth of several species of bacteria, but it also produced symptoms of vitamin B<sub>1</sub> deficiency in mice.<sup>38</sup> The effect was cumulative and delayed, and could be cured by the administration of aneurine at a level equal to 1/40th that of the pyriethamine.

### Neopyriethamine and Oxythiamine

Neopyriethamine hydrobromide (page 124) proved to be at least four times as active as pyriethamine as an antagonist of aneurine hydrochloride in the growth of rats.<sup>39</sup> The index of inhibition was about 10:1. It produced polyneuritic symptoms in mice, the animals developing complete paralysis of the hind legs.<sup>39</sup> It protected aneurine from destruction by carp thiaminase (page 25), being preferentially attacked by the enzyme.<sup>40</sup>

A somewhat less potent antagonist of aneurine is 3 (4' hydroxy-2 methyl pyrimidyl-5' methyl) 5  $\beta$  hydroxyethyl-4 methyl thiazolium chloride, first prepared by Todd and Bergel<sup>2</sup> and given the name oxythiamine by M. Soodak and L. R. Cerecedo,<sup>41</sup> who obtained it by treatment of aneurine with nitrous acid. Oxythiamine had little or

## ANEURINE (THIAMINE)

no vitamin B<sub>1</sub> activity, but was toxic to mice and rats, causing a decline in weight and a drop in food intake, unlike neopyrithiamine, it did not produce polyneuritic symptoms in rats<sup>39</sup> It was a potent antagonist of aneurine, however, and increased the levels of pyruvic and lactic acids in the blood of rats and the pyruvate lactate ratio<sup>42</sup> It increased the urinary excretion of aneurine, presumably because it displaced aneurine from the tissues,<sup>42</sup> and it inhibited the action of thiaminase on aneurine<sup>41</sup> It produced typical symptoms of vitamin B<sub>1</sub> deficiency in chicks<sup>43</sup> Because of its anti-vitamin B<sub>1</sub> activity, it was tested in poliomyelitis (see page 51), but was found to protect mice less effectively than did a vitamin B<sub>1</sub> free diet<sup>44</sup>

### Other Antagonists

Von Euler *et al*<sup>45</sup> claimed that salicylic acid and certain other acids inhibited the action of some enzyme systems, including the "aetiozymase" system, that is, the decarboxylation of pyruvic acid in presence of added cocarboxylase The effect was said to be enhanced by acetaldehyde, which is itself an inhibitor The extent of the inhibition by salicylic acid did not increase in proportion to the reduction in the cocarboxylase concentration The evidence, it was suggested, indicated that salicylic acid and other inhibitors acted by displacing coenzymes from attachment to the apoenzyme molecule or by attaching themselves to a group in the apoenzyme molecule not already occupied by the coenzyme This suggestion is actually another way of enunciating the Woods-Fildes hypothesis (see page 546), which satisfactorily explains the behaviour of pairs of inhibitors and growth factors, such as sulphanilamide and *p*-aminobenzoic acid, pantoyletaurine and pantothenic acid, pyridine- $\beta$  sulphonic acid and nicotinic acid, pyrithiamine and aneurine

The Woods-Fildes hypothesis demands a high degree of specificity between these pairs of substances, based on analogous chemical structure, and it is irrational to apply the hypothesis to a heterogeneous group of inhibitors such as that listed by von Euler *et al* If the effect noted really exists it can hardly be due to a competition between inhibitor and coenzyme in the sense in which Woods and Fildes used this conception, but rather to a non-specific type of poisoning

The only true analogue of aneurine other than pyrithiamine, neopyrithiamine and oxythiamine that appears to antagonise completely the growth promoting action of the vitamin is the *n* butyl homologue, which was shown<sup>18</sup> to produce aneurine deficiency in rats maintained on a suboptimal intake of aneurine, the symptoms were relieved by administration of aneurine

Attempts to find simple derivatives of thiazole that would inhibit

the growth of bacteria by competition with aneurine led to the discovery<sup>46</sup> that several thiol derivatives of thiazole were bacteriostatic but the inhibition was not reversed on addition of aneurine. In fact the bacteriostatic activity appeared to be a function of the thiol group rather than of the thiazole ring and quite unconnected with aneurine requirements.

### General Conclusions

The data summarised above on the vitamin B<sub>1</sub> activity of compounds related to aneurine has an obvious bearing on the question of enzyme specificity. The first generalisation that can be made—and this will be evident also from the discussion of the functions of other members of the vitamin B complex—is that specificity is not absolute: there is generally a group of compounds the activity of which increases to a maximum with one particular member. As it happens maximum vitamin B<sub>1</sub> activity is not exhibited by the compound that Nature chose to use for this purpose but by the next higher homologue. This is admittedly unusual. The second generalisation is that activity is confined to the compounds comprising a thiazole ring and a pyrimidine ring linked together at specific points by a chain of one or two carbon atoms. Compounds that are linked directly are inactive suggesting that a certain freedom of movement of the molecule is essential. The third generalisation is that the presence of a hydroxyl group in the side-chain attached to the thiazole ring is essential for activity obviously because without it no pyrophosphate could be formed. This must be a primary alcohol group but the side chain can apparently contain three carbon atoms although optimal activity is obtained with two. Fourthly one amino group in the pyrimidine ring and only one is essential and this is preferably a primary group. A quaternary nitrogen atom in the thiazole ring is also essential. Fifthly the nature of the alkyl groups attached to both rings is important: optimal activity was exhibited by compounds in which these together amounted to two or three carbon atoms and fell progressively as the number increased.

The antagonistic action of pyrithiamine, neopyrithiamine and oxythiamine are highly significant as although they have no vitamin B<sub>1</sub> activity they appear to be capable of displacing aneurine from attachment to the protein of the enzyme molecule. It has been customary to picture the attachment of a molecule at the surface of an enzyme as taking place at a particular point but the theory advanced by Linus Pauling to explain the formation of antibodies suggests that contact is more probably over a particular area rather than at a point.

# ANEURINE (THIAMINE)

The anti-aneurine properties of these three compounds probably depend on the fact that they bear a close structural similarity to aneurine, and are thereby able to attach themselves to that portion of the apoenzyme surface normally occupied by the aneurine molecule. The antagonist-apoenzyme complex so formed is, however, incapable of effecting the chemical changes characteristic of the aneurine apoenzyme complex, and pyruvic acid decarboxylation, for example, therefore ceases, and the organism—whether bacteria or animal—suffers in consequence from vitamin B<sub>1</sub> deficiency and cannot develop normally.

## References to Section 22

- 1 A R Todd, F. Bergel and Karimullah, *J. Chem Soc*, 1936 1559
- 2 A R Todd and F Bergel, *ibid*, 1937, 1504
- 3 H Andersag and K Westphal, *Ber*, 1937, 70, 2035
- 4 F. Schultz, *Z physiol Chem*, 1940, 265, 113
- 5 B C J G Knight and H McIlwain, *Biochem J*, 1938, 32, 1241
- 6 P. Baumgarten, A Dornow, K Gutschmidt and H Krehl, *Ber*, 1942, 75, 442
7. M Javillier and L Emerique Blum *Compt rend*, 1940 211, 374
- 8 W. H Schopfer, *Helv Physiol Pharm Acta*, 1943 1, 83
- 9 S W Fox, H Sargent and E R Buchman, *J Amer Chem Soc*, 1945, 67, 496
- 10 E and R Abderhalden, *Pflugers Archiv*, 1938, 240, 746
11. S Mori, *J Oriental Med*, 1941, 55, 9, *Biochem Z*, 1941, 309, 354
- 12 D Price and F D Pickel, *J Amer Chem Soc*, 1941, 63, 1067.
- 13 G A Stein, W L Sampson, J K Cline and J R Stevens, *ibid*, 2059.
- 14 F Schultz *Z physiol Chem*, 1941, 272, 29
- 15 W H Schopfer, *Arch Sci phys nat*, 1941, [V] 23, Suppl, 58
- 16 W Huber, *J Amer Chem Soc*, 1943, 65, 2222
- 17 E R Buchman and E M Richardson, *ibid* 1945, 67, 395
- 18 G A Emerson and P L Southwick, *J Biol Chem*, 1945, 160, 169
- 19 C C Price N J Leonard and R H Reitsema *J Amer Chem Soc*, 1946 68, 766
- 20 J Finkelstein and R C Elderfield *J Org Chem*, 1939 4, 365
- 21 P Baumgarten and A Dornow, *Ber*, 1940, 73, 44 156
- 22 P Baumgarten and A Dornow, *ibid*, 353
- 23 A H Tracy and R C Elderfield *Science*, 1940, 92, 180, *J Org Chem*, 1941, 6, 54
- 24 F C Smelkes *Science* 1939, 90, 113, *J Amer Chem Soc*, 1939, 61, 2562
- 25 W J Robbins *Proc Nat Acad Sci*, 1941 27, 419
- 25a A N Wilson and S A Harris, *J. Amer Chem Soc*, 1949 71, 2231
- 26 W H Schopfer, *Arch Sci phys nat*, 1941, [V], 23, Suppl, 64

# ANALOGUES

- 26a A Dornow and M Machens *Chem Ber* 1947 80, 502
- 27 Y A Tota and R C Elderfield *J Org Chem* 1942 7, 309
- 28 W J Robbins *Proc Nat Acad Sci* 1942 28, 352
- 28a H Erlenmeyer D Waldi and E Sorkin *Helv Chim Acta* 1948 31 32
- 29 J G Tolpin J R Foy and L R Cerecedo *J Amer Chem Soc* 1941 63, 2848
- 30 W Huber W Boehme and S C Laskowski *ibid* 1946 68, 187  
Merck & Co USP 2437504
- 31 J Weijlard *J Amer Chem Soc* 1942 64, 2279
- 32 E R Buchman E Heegaard and J Bonner *Proc Nat Acad Sci* 1940 26, 561
- 33 R G Busnel P Chaucard H Mazoué M Pesson R Vieillefosse and M Polanovski *Compt rend Soc Biol* 1944 138, 171  
R G Busnel P Chaucard H Mazoué A Pelow and M Polonovski *ibid* 366
- 34 C Wyss *J Bact* 1943 46, 483
- 35 D W Woolley and A G C White *J Exp Med* 1943 78, 489
- 36 H P Sarett and V H Cheldelin *J Biol Chem* 1944 156, 91
- 37 D W Woolley *Proc Soc Exp Biol Med* 1944 55, 179
- 38 D W Woolley and A G C White *J Biol Chem* 1943 189, 285
- 39 A J Eusebi and L R Cerecedo *Science* 1949 110 162
- 40 R R Sealock and H S White *J Biol Chem* 1949 181, 393
- 41 M Soodak and L R Cerecedo *J Amer Chem Soc* 1944 66, 1988 1949 71 3566 *Fed Proc* 1947 6 293
- 42 C E Frohman and H G Day *J Biol Chem* 1949 180 93
- 43 L J Daniel and L C Norris *Proc Soc Exp Biol Med* 1949 72 165
- 44 J H Jones C Foster and W Henle *ibid* 1948 69 454
- 45 H von Euler L Ahlstrom I Patterson and S Tingstam *Arkiv Kemi Min Geol* 1943 17A, No 8
- 46 E M Gibbs and F A Robinson *J Chem Soc* 1945 925

## RIBOFLAVINE

## 1. INTRODUCTION

IN THE COURSE of an investigation into the nature of pellagra, J Goldberger and R D Lillie<sup>1</sup> produced a deficiency disease in rats, characterised by ophthalmic and bilaterally symmetrical denuded areas. The factor that prevented these lesions was heat-stable, in contrast to vitamin B<sub>1</sub>, which is heat-labile. It was termed by Goldberger, the P P (pellagra preventive) factor, but was subsequently designated vitamin B<sub>2</sub> in Britain and vitamin G in the U S A<sup>2</sup>.

The symptoms reported by other workers as characteristic of vitamin B<sub>2</sub> deficiency varied considerably, however, and frequently differed markedly from those observed by Goldberger and Lillie. In particular, some workers reported only an absence of growth, whilst others noted the appearance of dermatitis in some of the experimental animals. It was shown by means of improved technique<sup>3</sup> that failure to grow and the onset of dermatitis were due to a deficiency of two different factors, and either symptom could be produced at will by omitting one factor or the other. The second factor was termed vitamin H in the U S A<sup>4</sup> and vitamin B<sub>6</sub> in Europe. Unfortunately, however, the term vitamin H has also been used to describe the factor now known as biotin (see page 404). Absence of vitamin B<sub>2</sub> was responsible for the failure of the experimental animals to grow, whilst absence of vitamin B<sub>6</sub> was responsible for the dermatitis—the so called rat "pellagra".

Thus, initially, the term vitamin B<sub>2</sub> was intended to describe the factor that cures pellagra, now known to be identical with nicotinic acid, but subsequently it came to be used to denote the rat growth factor, riboflavine.

The situation was further complicated by the production in dogs<sup>5</sup> of a deficiency disease known as canine blacktongue, so called from one of its characteristic manifestations, the diets used were similar to those required to produce rat "pellagra". Up to the end of 1934 it appeared probable that this condition, like rat "pellagra", was due to a deficiency of riboflavine, but in 1935-36 several workers<sup>6</sup> showed

## INTRODUCTION

that this was not so whilst Birch *et al*<sup>7</sup> differentiated the anti black tongue and the P P factors from riboflavine and vitamin B<sub>6</sub>. In 1937 Sebrell *et al*<sup>8</sup> confirmed the fact that riboflavine did not cure canine blacktongue whilst W J Dann<sup>9</sup> reported that it did not cure human pellagra and Fouts *et al*<sup>10</sup> successfully treated two pellagrins with an extract from which the riboflavine had been removed. Thus it was clearly demonstrated that riboflavine had no connection with pellagra except perhaps by way of complicating the condition.

In spite of the recognition that riboflavine was different from vitamin B<sub>6</sub> on the one hand and from the anti blacktongue and P P factors on the other the situation remained obscure. Three groups of workers<sup>11</sup> produced pellagra in chicks by feeding them on diets that had been heated. The responsible factor was called the filtrate factor to distinguish it from the eluate factor as vitamin B<sub>6</sub> was sometimes called the latter but not the former being adsorbed on fuller's earth. The filtrate factor was shown by C A Elvehjem and C J Koehn<sup>12</sup> to be different from riboflavine but on the other hand a filtrate factor concentrate was found by Fouts *et al*<sup>10</sup> to cure human pellagra and by C J Koehn and C A Elvehjem<sup>13</sup> to cure canine blacktongue. The human antipellagra factor was ultimately distinguished from the filtrate factor by W J Dann and Y Subbarow<sup>14</sup> who showed that whilst nicotinic acid cured human pellagra it did not cure chick pellagra.

### References to Section 1

- 1 J Goldberger and R D Lillie *U S Publ Health Rep* 1926 **41**, 1025
- 2 B Sure *J Amer Med Assoc* 1932 **99**, 26
- 3 A. G Hogan and L R Richardson *J Nutrition* 1934 **8**, 385
- 4 L E Booher *J Biol Chem* 1937 **118**, 223
- 5 J Goldberger and G A Wheeler *U S Publ Health Rep* 1928 **43**, 172
- 6 C P Rhoads and D K Miller *Science* 1935 **81**, 159 C J Koehn and C A Elvehjem *J Nutrition* 1936 **11**, 67
- 7 T W Birch P Gyorgy and L J Harris *Biochem J* 1935 **29**, 2830
- 8 W H Sebrell D J Hunt and R H Onstatt *U S Publ Health Rep* 1937 **52**, 235 W H Sebrell R H Onstatt and D J Hunt *ibid* 427
- 9 W J Dann *J Nutrition* 1936 **11**, 451
- 10 P J Fouts S Lepkovsky O M Helmer and T H Jukes *Proc Soc Exp Biol Med* 1936 **35**, 245
- 11 O L Kline J A Keenan C A Elvehjem and E B Hart *J Biol Chem* 1932 **99**, 295 S Lepkovsky and T H Jukes *ibid*



- 1935 111, 119, S Ansbacher, G C Supplee and R C Bender,  
*J Nutrition*, 1936 11, 529  
<sup>12</sup> C A Elvehjem and C J Koehn, *J Biol Chem*, 1935 108, 709  
<sup>13</sup> C J Koehn and C A Elvehjem, *J Nutrition*, 1936, 11, 67  
<sup>14</sup> W J Dann and Y SubbaRow, *ibid*, 1938 16, 183

## 2. ISOLATION OF RIBOFLAVINE

The first step towards an understanding of the nature of vitamin B<sub>2</sub> was taken by R Kuhn, P György and T Wagner-Jauregg,<sup>1</sup> who isolated from egg white a compound with a strong yellowish green fluorescence. They called this substance "ovoflavine", and showed that it stimulated the growth of rats, 100 µg a day producing an increase in weight of about 10 g per week. In the issue of the *Berichte* containing the paper by Kuhn *et al*, P Ellinger and W Koschara<sup>2</sup> reported the presence of similar fluorescent substances in milk, liver, kidney, urine, muscle, yeast and certain plant materials, and described the isolation of a crystalline fluorescent substance from whey. They proposed the name "lyochrome" for the group to which all these substances belonged, and both Kuhn and Koschara suggested that the pigments might be related to the "yellow enzyme" discovered in yeast by O Warburg and W Christian<sup>3</sup> in the preceding year. Kuhn showed, in fact, that one and the same substance, lumiflavine, was produced by irradiation of the yellow enzyme and of ovoflavine. Shortly after the publication of these papers, L E Booher<sup>4</sup> reported the preparation of a concentrate from whey powder that showed a strong yellow fluorescence and had growth promoting properties for the rat.

The isolation of fluorescent pigments from milk, liver, kidney, urine, malt, dandelion flowers, lucerne, egg yolk and the retinae of fishes was reported by Kuhn *et al*,<sup>5</sup> by Karrer *et al*,<sup>6</sup> by W Koschara,<sup>7</sup> and by H von Euler and E Adler,<sup>8</sup> and by Itter *et al*.<sup>9</sup>

At first these pigments were given specific names according to their origin, *e.g.* ovoflavine, lactoflavine, uroflavine and hepatoflavine, until it was realised that they were probably identical with one another. This was confirmed by a direct comparison of some of the compounds, but several were isolated in such small amounts that a rigid proof of identity was not possible. The substance was generally referred to as lactoflavine, until its constitution had been determined, when the name was altered to riboflavine. Shortly afterwards, the terminal "e" was dropped to avoid confusion with acriflavine and its analogues, which have an entirely different type of structure. Recently, however, there has been a tendency to revert to the original

spelling to conform with the recognised convention that the names of organic bases should end in *ine* and Riboflavine is now its official name in the British Pharmacopœia. Accordingly riboflavine is the spelling adopted in this book.

The method of isolation varied somewhat in different laboratories and with the raw materials employed but nearly all the workers used adsorption on fuller's earth (or in some instances lead sulphide) from a slightly acid aqueous or aqueous alcoholic extract. The resulting adsorbate was eluted with pyridine or pyridine-methanol-water mixture or dilute ammonia and the eluate after being concentrated was treated with a heavy metal such as silver or thallium to precipitate the flavine in the form of a salt. The free flavine was recovered from the precipitate by suitable treatment and recrystallised from water, dilute alcohol or dilute acetic acid. One of the most recent methods is that due to R. D. Greene and A. Black.<sup>10</sup>

The recovery of riboflavine from fermented liquors is discussed on page 152.

#### References to Section 2

- 1 R. Kuhn, P. György and T. Wagner-Jauregg *Ber.* 1933 66, 317, 576; *Naturwiss.* 1933 21, 560.
- 2 P. Ellinger and W. Koschara *Ber.* 1933 66, 315.
- 3 O. Warburg and W. Christian *Biochem. Z.* 1932 254, 438; 1933 266, 377.
- 4 L. E. Booher *J. Biol. Chem.* 1933 102, 39; 1934 107, 591.
- 5 R. Kuhn, H. Rudy and T. Wagner-Jauregg *Ber.* 1933 66, 1950; R. Kuhn and H. Kaltschmitt *ibid.* 1935 68, 128.
- 6 P. Karrer and K. Schöpp *Helv. Chim. Acta* 1934 17, 735, 771; 1936 19, E33.
- 7 W. Koschara *Ber.* 1934 67, 761.
- 8 H. von Euler and E. Adler *Z. physiol. Chem.* 1934 223, 105.
- 9 S. Itter, E. R. Orent and E. V. McCollum *J. Biol. Chem.* 1935 108, 579.
- 10 R. D. Greene and A. Black *J. Amer. Chem. Soc.* 1937 59, 1820.

### 3 CHEMICAL CONSTITUTION OF RIBOFLAVINE


Riboflavine has the empirical formula  $C_{17}H_{20}N_4O_6$ . It was found to be reversibly reduced by sodium dithionite solution by zinc in acid solution, by hydrogen in presence of a catalyst, by titanous chloride or by hydrogen sulphide in alkaline solution to a leuco-compound which was re-oxidised to riboflavine on shaking with air.<sup>1</sup> It was stable to most oxidising agents but chromic acid decomposed it with formation of ammonia, carbon dioxide and a nitrogen-free

compound, not identified. On acetylation it yielded a tetra-acetate, indicating the presence of four hydroxyl groups, <sup>2,3</sup> since oxidation with lead tetra acetate yielded formaldehyde,<sup>3</sup> it followed that a primary hydroxyl group was present in the  $\alpha$  position to a secondary hydroxyl group. Confirmation of this was subsequently obtained by the formation of a diacetone compound <sup>4</sup>. Riboflavine gave a positive murexide test,<sup>1</sup> indicating the presence of a purine group, whilst alkaline hydrolysis gave urea <sup>2</sup>.



### Lumiflavine

On irradiation in alkaline solution, riboflavine yielded lumiflavine,<sup>3,5</sup> with the empirical formula,  $C_{13}H_{12}N_4O_2$ . Thus, photolysis removed from riboflavine the elements  $C_4H_8O_4$  and, since lumiflavine was incapable of acetylation and failed to give formaldehyde on treatment with lead tetra acetate, it was concluded that a hydroxylated side-chain,  $CHOH-CHOH-CHOH-CH_2OH$ , had been removed.

Lumiflavine was sparingly soluble in water, but soluble in chloroform and, like the parent substance, it yielded urea on alkaline hydrolysis, together with an acidic substance,  $C_{12}H_{12}N_2O_3$ , which lost  $CO_2$  on heating to give a substance,  $C_{11}H_{12}N_2O$ .<sup>2,6</sup> Since two moles of water were taken up during the alkaline hydrolysis, R. Kuhn and H. Rudy <sup>6</sup> concluded that the latter must arise, not from a ureido or guanidino group, which would require only one mole of water, but from a ring. This must, therefore, contain two carbonyl groups, one forming urea and the other being hydrolysed to a carboxyl group. These changes can be represented as follows —



The decarboxylated compound,  $C_{11}H_{12}N_2O$ , which had the properties of a lactam, yielded 4-amino-1,2-dimethyl-5-methylamino-benzene (I) <sup>7</sup> when heated with sodium hydroxide, so that lumiflavine must be an alloxazine derivative (II).



## CHEMICAL CONSTITUTION

Since the methylamino group was not present in riboflavine the hydroxylated side-chain must be attached to the methylene group. This was supported by the observation of R. Kuhn and F. Bär<sup>8</sup> that the photolysis of riboflavine was closely simulated by the behaviour of 2-tetrahydroxybutyl quinoxaline, which on irradiation lost its hydroxylated side-chain. Just as lumiflavine had the same absorption spectrum as riboflavine so the product, quinoxaline, had the same absorption spectrum as its tetrahydroxybutyl derivative.

### Isalloxazines

Next, Kuhn and Weygrand<sup>9</sup> synthesised 9-methyl isalloxazine, m.p. 392°C by boiling N-methyl-o-phenylene diamine with alloxan in hydrochloric acid solution, it had properties closely resembling those of lumiflavine. Thus, with sodium dithionite, it yielded a leuco-derivative that was reconverted to a fluorescent substance on exposure to air. Its absorption spectrum was similar to that of riboflavine and it gave urea when boiled with baryta solution, the product was 1-methyl-2-keto-1,2-dihydroquinoxaline 3-carboxylic acid. In their next papers, Kuhn *et al.* described the preparation of 3,9-dimethyl-isalloxazine from N-methyl-o-phenylene diamine and methylalloxan,<sup>10</sup> and the synthesis of lumiflavine itself, m.p. 330°C, from 2-methyl-amino-4,5-dimethylaniline and alloxan,<sup>11</sup> thereby proving it to be 6,7,9-trimethyl-isalloxazine (II).

The complete synthesis was described in a subsequent paper by R. Kuhn and K. Reinemund<sup>12</sup> and is similar to that used for riboflavine (see page 140).


R. Kuhn and H. Rudy<sup>13</sup> isolated another degradation product of riboflavine resulting from the treatment of lumiflavine with alkali, and identified it as 6,7-dimethyl alloxazine which they synthesised from 3,4-dimethyl-o-phenylene diamine and alloxan. Both the synthetic substance and the product from riboflavine yielded 1,3,6,7-tetramethyl alloxazine on treatment with diazomethane.

A photolytic product was also obtained by Karrer *et al.*<sup>14</sup> by exposure of a flavine solution to sunlight with access of air. Lumichrome, as they called the substance had a characteristic absorption spectrum, gave a yellowish green fluorescence in alkaline solution and a sky blue fluorescence in aqueous or alcoholic solution, and was identified as 6,7-dimethyl alloxazine. Karrer *et al.* also obtained lumiflavine and showed that it was the 9-methyl derivative of lumichrome. They postulated that riboflavine was an N-tetrahydroxyamyl isalloxazine, since the side-chain split off in the formation of lumichrome gave a strong positive pentose reaction.

R Kuhn and F Weygand<sup>15</sup> condensed L-arabinamine and D-xylamine with halogeno-*o* nitrobenzene and halogeno *o* nitroxyene. The compounds obtained on reducing the products with stannous chloride in presence of alloxan had properties similar to those of riboflavine. In a later paper<sup>16</sup> they described synthetic 6,7-dimethyl-9-tetraacetyl-L-arabityl-isoalloxazine, m.p. 298° C., as resembling the tetraacetyl derivative of riboflavine in absorption spectrum, colour intensity, the effect of pH on the fluorescence and in optical rotation. The activity of this substance as a substitute for Warburg's yellow enzyme could not be tested, as it could not be adsorbed on the colloidal carrier.

Karrer *et al*<sup>17</sup> obtained the same substance by a slightly different route, in which arabinose was reductively condensed with N-monoacyl or N-monocarbethoxy *o*-phenylene diamine giving, after hydrolysis, N-(*o*-aminophenyl) arabinamine, other sugars gave analogous compounds. These were all converted to the corresponding isoalloxazines by condensation with alloxan. Karrer *et al* also noted the close resemblance of the arabityl compound to riboflavine, but found slight differences in m.p. and optical rotation. P. Karrer, K. Schöpp and F. Benz<sup>18</sup> then synthesised the D-xylityl and D-ribityl compounds and found that the latter was identical with riboflavine.

Riboflavine therefore has the structure



This paper is therefore the first to describe the synthesis of riboflavine, although a patent<sup>19</sup> based on this method was ante-dated by a patent covering the general reaction, filed earlier by the I.G. (see page 142). R. Kuhn<sup>20</sup> announced the successful synthesis five weeks after Karrer and his colleagues.

The identity of the synthetic and natural substances was confirmed by von Euler *et al*,<sup>21</sup> who reported the results of growth tests with synthetic riboflavine and other homologues prepared from different sugars. The D-ribityl compound was fully active, the L-arabityl compound was slightly active whilst the other derivatives tested were inactive. These and other compounds subsequently prepared are discussed in more detail on page 206.

A better method of condensing alloxan with pentitylamino

xyldines was introduced by R Kuhn and F Weygand<sup>22</sup> Whereas they experienced no difficulty in obtaining quantitative yield of lumiflavine the yields of riboflavine araboflavine etc were only 5 to 10 % of the theoretical Thus they attributed to the presence not of the sugar residue but of the methyl groups O Kuhlring and O Kaselitz<sup>23</sup> in attempting to prepare alloxazines had obtained pale yellow substances containing one molecule of water more than the alloxazines when the condensation was effected in neutral solution When the condensation was carried out in strongly acid solution however good yields of alloxazines were obtained When this method was applied to the synthesis of riboflavine with perchloric acid as the condensing agent it met with little or no success but the use of boric acid increased the yield to 95 % of the theoretical

### References to Section 3

- 1 P Ellinger and W Koschara *Ber* 1933 66, 1411
- 2 R Kuhn and T Wagner Jauregg *ibid* 1577
- 3 R Kuhn H Rudy and T Wagner Jauregg *ibid* 1950
- 4 R Kuhn H Rudy and F Weygand *ibid* 1935 68, 625
- 5 O Warburg and W Christian *Biochem Z* 1933 266, 377
- 6 R Kuhn and H Rudy *Ber* 1934 67, 892
- 7 R Kuhn and H Rudy *ibid* 1298
- 8 R Kuhn and F Bär *ibid* 898
- 9 R Kuhn and F Weygand *ibid* 1409
- 10 R Kuhn and F Weygand *ibid* 1459
- 11 R Kuhn K Reinemund and F Weygand *ibid* 1460
- 12 R Kuhn and K Reinemund *ibid* 1932
- 13 R Kuhn and H Rudy *ibid* 1936 1826
- 14 P Karrer H Salomon K Schopp E Schlitter and H Fritzsche *Helv Chim Acta* 1934 17, 1010
- 15 R Kuhn and F Weygand *Ber* 1934 67, 1939
- 16 R Kuhn and F Weygand *ibid* 1935 68, 166
- 17 P Karrer K Schopp F Benz and K Pfäehler *Helv Chim Acta* 1935 18, 69 *Ber* 1935 68, 216
- 18 P Karrer K Schöpp and F Benz *Helv Chim Acta* 1935 18 426
- 19 Hoffmann la Roche B P 457984
- 20 R Kuhn *Naturwiss* 1935 23 260
- 21 H von Euler P Karrer M Malmberg K Schopp F Benz and P Frei *Helv Chim Acta* 1935 18 522 *Stensk Kem Tids* 1935 47, 99
- 22 R Kuhn and F Weygand *Ber* 1935 68 1282
- 23 O Kuhlring and O Kaselitz *ibid* 1906 39, 1324

## 4. SYNTHESIS OF RIBOFLAVINE

In the synthetic method used by R. Kuhn *et al.*,<sup>1, 2</sup> calcium D-glucuronate was converted into D-arabinose by oxidation with ferric acetate and hydrogen peroxide (*cf.* R. C. Hockett and C. S. Hudson<sup>3</sup>), and the D-arabinose was converted into D-ribose by way of acetobromo-D-arabinose, diacetyl-D-arabinal, and D-arabinal, the overall yield being about 10 %. The oxime of D-ribose was reduced to D-ribamine and this was condensed with 1:2-dimethyl-4:5-dinitrobenzene by heating in 80 % alcohol for six hours at 130° C., giving 1:2-dimethyl-4-nitro-5-(D-1'-ribitylamino)-benzene. This was reduced to the corresponding amino derivative by catalytic hydrogenation in presence of platinum oxide, and the product was condensed with alloxan tetrahydrate in acetic acid solution containing boric acid. A 70 % yield of riboflavin, m.p. 291 to 292° C., was obtained.

Kuhn *et al.* also prepared 4-amino-1:2-dimethyl-5-(D-1'-ribitylamino)-benzene in two other ways. In the first method, 1:2-dimethyl-4:5-dinitrobenzene was converted by treatment with ammonia into 5-amino-1:2-dimethyl-4-nitrobenzene, which with phosgene yielded 4:5-dimethyl-2-nitro-phenylisocyanate. On treatment with alcohol this gave the corresponding carbethoxyamino compound, which on catalytic reduction gave 6-amino-1-carbethoxyamino-3:4-dimethylbenzene. On reductive condensation with ribose followed by hydrolysis, 4-amino-1:2-dimethyl-5-(D-1'-ribitylamino)-benzene was obtained.

In the second method, which was used for the preparation of the corresponding arabityl compound, 5-amino-1:2-dimethyl-4-nitrobenzene was heated with D-arabinose and the product was hydrogenated. These three methods of synthesis are summarised in the scheme shown on the opposite page.

The method used by the Swiss workers<sup>4</sup> differed somewhat from that of Kuhn *et al.* They nitrated *o*-xylene to give 3:4-dimethyl-1-nitrobenzene, which they reduced catalytically to 3:4-dimethylaniline, the overall yield being less than 20 %. The dimethylaniline was then converted into 3:4-dimethyl-1-carbethoxyaminobenzene by treatment with chloroformic ester, and this was nitrated to give 1-carbethoxyamino-3:4-dimethyl-6-nitrobenzene, which was then reduced catalytically to the corresponding amino compound. This was treated with ribose, obtained by the same route as in Kuhn's method, in the presence of hydrogen under pressure and a nickel catalyst, yielding 2-carbethoxyamino-4:5-dimethyl-phenyl-D-ribamine. This was hydrolysed and decarboxylated, and the resulting 2-amino-4:5-dimethyl-phenyl-D-ribamine was condensed with alloxan in presence of boric acid.






## RIBOFLAVINE

A somewhat better method (p. 143) was that of T. Reichstein and M. Steiger;<sup>10</sup> this gave about 36 g. of ribose from 1 kg. of calcium gluconate.

The mixture of ribonic acid and unchanged arabonic acid was freed from the latter by conversion to the calcium salt, and the ribonic acid was then isolated as the cadmium salt and converted to ribose by reduction with sodium amalgam.

Ribose can also be made in one stage from calcium altronate by oxidation with hydrogen peroxide in presence of ferric acetate<sup>11</sup> but, unfortunately, altronic acid is not readily available, although it can be made from cellobiose acetate:

Cellobiose octaacetate  $\longrightarrow$  Acetochloro-cellobiose  
 (+acetochloro-cellobiose)  $\longrightarrow$  cellobiose  $\xrightarrow{\text{Br}_2}$  altronic acid  
 or from sedoheptulose, a seven-carbon sugar occurring in *Sedum spectabile*.<sup>12</sup>








### Methods of Synthesis not involving Ribose

A method that avoided the use of D-ribose was discovered by F. Weygand,<sup>13</sup> who showed that the Amadori rearrangement was not limited to glucose, as had been previously supposed. He prepared, *inter alia*, 3:4-dimethylaniline-D-arabinoside by condensing D-arabinose with o-4-xylydine, and converted it into the D-isoarabinosamine by heating at 75° C. This yielded 3:4-dimethyl phenyl-D-ribamine on hydrogenation in alkaline solution. The product obtained by coupling with a diazo compound was reduced to the corresponding amine by the method of Karrer and Meerwein.<sup>5</sup> (See opposite page) Incidentally Weygand suggested that the vitamin B<sub>2</sub> activity of araboflavine (see page 206) might be due to contamination with riboflavine formed by an Amadori rearrangement.

A variant of Weygand's method was patented by the Miles Labs. Inc.<sup>14</sup> o-4-Xylydine was condensed with D-arabinose under conditions

# SYNTHESIS




that brought about an Amadori rearrangement, with formation of 3,4-dimethylphenyl-D-isoarabinosamine. This was coupled in the usual way with a diazonium salt, and the product was hydrogenated to reduce the carbonyl to a carbinol group and the azo to an amino group. The resulting compound was coupled with alloxan, dialuric acid, isodialuric acid or alloxantin.

Pfizer & Co.<sup>15</sup> used a different method for avoiding ribose, namely, acetylation of D-ribonamide, conversion of the product into tetraacetylribonic acid by treatment with nitrous acid and then reaction with phosphorus pentachloride to form the acid chloride. This was reduced catalytically in presence of palladium supported on barium sulphate, giving tetraacetyl D-ribose. This compound, which is claimed to exist in the aldehyde form, was hydrogenated in presence of o-4-xylidine, using Raney nickel or platinum as catalyst, giving tetraacetyl D-ribityl o-4-xylidine. This was coupled with a phenyl diazonium salt. In a similar method, due to Merck,<sup>16</sup> tetrabutyl-D-ribonamide was converted into tetrabutylribonic acid by the


# RIBOFLAVINE

action of oxides of nitrogen, and the acid was converted *via* the acid halide into tetrabutyl ribose, as in Pfizer's method

A somewhat different method of preparing N (D ribityl) 3,4-dimethylaniline, again without the use of D ribose, was described by Tishler *et al*<sup>17</sup>. D-Arabonic acid was converted into D-ribonic acid from which D-ribonolactone was prepared. This was reacted with 3,4-dimethylaniline and the product acetylated to give 3,4-dimethyl (tetraacetyl D-ribonyl) aniline. This with phosphorus pentachloride gave the chlorimine, which was reduced catalytically to the amine and then deacetylated.



Another method not involving ribose was described by M. Tishler and J. W. Wellman<sup>18</sup>. 3,4-Dimethylaniline was reductively condensed with tetraacetyl D-ribonitrile, which was prepared from ribonic acid *via* the amide. The resulting N-tetraacetyl D-ribityl 3,4-dimethylaniline was then coupled with *p*-nitrophenyl diazonium chloride and the product reduced to 5-tetraacetyl ribitylamino 4-amino-1,2-dimethylbenzene. This was hydrolysed and the product coupled not with alloxan as in the methods previously described but with 5,5-dichlorobarbituric acid, for contrary to the report of R. Kuhn and A. H. Cook<sup>19</sup> that alloxazines could not be prepared by the interaction of *o*-phenylene diamine and 5-bromo barbituric acid. Tishler *et al*<sup>20</sup> found that under certain conditions 5-chloro and 5,5-dichloro barbituric acids reacted with alkylated *o*-phenylene diamines to give alloxazines *e.g.* 4,5-dimethyl *o*-phenylene diamine and 5,5-dichloro barbituric acid gave 6,7-dimethylalloxazine.




# SYNTHESIS

The condensation was best carried out in pyridine. Similarly 5-amino-N-ribityl-o-4-xylydine and 5,5-dichloroributuric acid gave an excellent yield of riboflavin.

Subsequently, Tishler *et al*<sup>21</sup> found that o-aminoazo compounds reacted with barbituric acid to give riboflavin.

A similar method had been used previously by Bergel *et al*<sup>22</sup>. N-D-Ribityl-o-4-xylydine was converted into riboflavin by coupling with diazotised aniline and shaking the azo compound so obtained with excess alloxantin or diuric acid in an atmosphere of nitrogen and finally oxidising any leuco-riboflavin by shaking in air.



## References to Section 4

- 1 R. Kuhn and F. Weygand *Ber* 1935 68, 1001
- 2 R. Kuhn, K. Reinemund, F. Weygand and R. Ströbele *ibid* 1935 68, 1765
- 3 R. C. Hockett and C. S. Hudson *J. Amer. Chem. Soc.* 1934 56, 1632
- 4 P. Karrer, B. Becker, F. Benz, P. Frei, H. Salomon and K. Schöpp *Helv. Chim. Acta* 1935 18, 1435
- 5 P. Karrer and H. Meerwein *ibid* 1935 18, 1130; 1936 19, 264
- 6 I. G. B. P. 441692
- 7 Hoffmann-La Roche B. P. 457984
- 7a Hoffmann-La Roche B. P. 628410
- 8 I. G. B. P. 461245
- 9 R. Kuhn and R. Ströbele *Ber* 1937 70, 747, 773
- 10 T. Reichstein and M. Steiger *Helv. Chim. Acta* 1936 19, 189
- 11 C. S. Hudson U. S. P. 2162721
- 12 F. B. La Forge and C. S. Hudson *J. Biol. Chem.* 1917 30, 132.  
C. S. Hudson *J. Amer. Chem. Soc.* 1939 61, 343
- 13 F. Weygand *Ber* 1940 73, 1259
- 14 Miles Laboratories Inc. B. P. 594949
- 15 Pfizer & Co. Inc. B. P. 545360; 551491; 585212
- 16 Merck & Co. U. S. P. 2424341
- 17 M. Tishler, N. L. Wendler, K. Ladenburg and J. W. Wellman *J. Amer. Chem. Soc.* 1944 66, 1328; Merck & Co. U. S. P. 2420210
- 18 M. Tishler and J. W. Wellman U. S. P. 2261608
- 19 R. Kuhn and A. H. Cook *Ber* 1937 70, 761

- 20 M Tishler, J W Wellman and K Ladenburg, *J Amer Chem Soc* 1945, 67, 2165
- 21 M Tishler, K Pfister, R D Babson K Ladenburg and A J Fleming, *ibid* 1947, 69, 1487.
- 22 F Bergel A Cohen and J W Haworth *J Chem Soc*, 1945 165, B P 550169, 550836

## 5. MICROBIOLOGICAL PRODUCTION OF RIBOFLAVINE

It is unusual for a synthetic method of producing a commercially important chemical to be displaced by a method based on its isolation from natural sources, generally, the tendency is in the reverse direction. Yet the production of riboflavine can now be effected more cheaply by fermentation than by chemical synthesis.

Patents were filed as early as 1937 for the production of "vitamin B<sub>2</sub>" concentrates by fermenting whey or other milk by products with lactose fermenting yeasts, especially *Saccharomyces fragilis*, or with *Clostridium butylicum* several species of *Lactobacilli* or with moulds,<sup>1</sup> or by fermenting molasses or other carbohydrate mash with various strains of butanol producing *Clostridia*,<sup>2</sup> especially *Cl acetobutylicum*. The vitamin was recovered from the fermented liquors by adsorption and elution. This process often gave low yields, which were subsequently shown<sup>3</sup> to be due to the presence of certain metals, particularly iron. The use of a mash prepared from cereals containing only traces of these metals was said to give much higher yields—up to 2 mg of riboflavine per gram of dry matter. Fermentation of brown rice was also said to give good yields, especially in admixture with maize.<sup>4</sup>

### Fermentation with *Clostridia*

The first report in the scientific literature that a fluorescent pigment resembling riboflavine was produced by *Cl acetobutylicum* was made by I Yamasaki and W Yosimoto<sup>5</sup>. They used a sterilised starchy medium prepared from cereals and stated that the addition of calcium carbonate was necessary for the formation of optimal amounts. The riboflavine was recovered by adsorption on fuller's earth, elution of the adsorbate with aqueous pyridine methanol and precipitation with acetone. The process was protected by a patent filed in 1938<sup>6</sup>. The pigment was subsequently identified as riboflavine<sup>7</sup> and a detailed investigation was made<sup>8</sup> of the effect on the yield of varying the composition of the medium. It was found that iron had a markedly toxic effect 36 to 70 p.p.m. suppressing riboflavine production entirely. The deleterious effect of iron was confirmed by other workers<sup>9</sup>. The

addition of sufficient  $\alpha\alpha'$ -dipyridyl to inactivate all but a small amount of iron, increased the yield of riboflavin,<sup>10</sup> so that, for instance, in the fermentation of corn mash a yield of 2 to 13 mg of riboflavin per litre was obtained in presence of 1.5 mg of iron per litre. The addition of sodium sulphite was claimed<sup>11</sup> to result in consistently high yields, although the maximum amount produced (2 mg per g of dry solids) was not appreciably affected. The production of riboflavin by fermentation of whey or skimmed milk with *Cl. acetobutylicum* was also protected by patents.<sup>12</sup> Again, the concentration of iron in the mash was found to be very critical, and it was stated that, to obtain the best results, this should lie between 1 and 3 p.p.m. Yields of 0.24 to 2.2 mg per gram of dried material were claimed. The sensitivity of the fermentation to iron was confirmed by A. Leviton,<sup>13</sup> who found that less than 0.2 mg atom of ferrous (though not of ferric) iron per litre prevented the formation of riboflavin and destroyed any that was added to the fermentation liquor. Crystalline catalase counteracted the effect of the iron provided the concentration of iron did not exceed 0.29 mg atom per litre but in the presence of 0.33 mg atom per litre catalase had little effect. Low concentrations of sodium dithionite minimised the effect of iron whilst potassium iodide enhanced it. Riboflavin was destroyed by hydrogen peroxide in the presence, though not in the absence, of iron, and the addition of catalase or potassium iodide stabilised the riboflavin although it speeded up the destruction of the hydrogen peroxide.

A. Leviton suggested that the synthesis and decomposition of riboflavin during fermentation were intracellular processes involving the formation of hydrogen peroxide. When iron was present the hydrogen peroxide destroyed the riboflavin inside the cells, so that catalase had no effect. When less iron was present, hydrogen peroxide and riboflavin accumulated in the cell and then diffused into the culture fluid, where catalase destroyed the hydrogen peroxide and thus protected the riboflavin from destruction.

The production of riboflavin by butyl alcohol producing bacteria has also been patented.<sup>14</sup>

### Fermentation with *Candida*

A large number of different strains of yeast also produced riboflavin, although mostly in moderate amounts only.<sup>15</sup> Certain strains, however, were found to produce 10 to 60 mg per litre of fermented liquor.<sup>16</sup> In particular, most species and varieties of *Candida* produced substantial amounts of riboflavin, though only when glucose was used as the carbon source.<sup>17</sup> The highest yields were obtained from *C. guilliermondii* and *C. tropicalis* var. *Rhagii*.<sup>18</sup>

- 20 M Tishler, J W Wellman and K. Ladenburg, *J Amer. Chem Soc*, 1945, 67, 2165
- 21 M Tishler, K Pfister, R. D Babson, K Ladenburg and A J Fleming, *ibid*, 1947, 69, 1487.
- 22 F Bergel, A Cohen and J W Haworth, *J Chem Soc*, 1945, 165, B P 550169, 550836

## 5. MICROBIOLOGICAL PRODUCTION OF RIBOFLAVINE

It is unusual for a synthetic method of producing a commercially important chemical to be displaced by a method based on its isolation from natural sources, generally, the tendency is in the reverse direction. Yet the production of riboflavin can now be effected more cheaply by fermentation than by chemical synthesis.

Patents were filed as early as 1937 for the production of "vitamin B<sub>2</sub>" concentrates by fermenting whey or other milk by-products with lactose fermenting yeasts, especially *Saccharomyces fragilis*, or with *Clostridium butylicum*, several species of *Lactobacilli* or with moulds,<sup>1</sup> or by fermenting molasses or other carbohydrate mash with various strains of butanol-producing *Clostridia*,<sup>2</sup> especially *Cl acetobutylicum*. The vitamin was recovered from the fermented liquors by adsorption and elution. This process often gave low yields, which were subsequently shown<sup>3</sup> to be due to the presence of certain metals, particularly iron. The use of a mash prepared from cereals containing only traces of these metals was said to give much higher yields—up to 2 mg of riboflavin per gram of dry matter. Fermentation of brown rice was also said to give good yields, especially in admixture with maize.<sup>4</sup>

### Fermentation with *Clostridia*

The first report in the scientific literature that a fluorescent pigment resembling riboflavin was produced by *Cl acetobutylicum* was made by I Yamasaki and W Yositorne.<sup>5</sup> They used a sterilised starchy medium prepared from cereals, and stated that the addition of calcium carbonate was necessary for the formation of optimal amounts. The riboflavin was recovered by adsorption on fuller's earth, elution of the adsorbate with aqueous pyridine-methanol and precipitation with acetone. The process was protected by a patent filed in 1938.<sup>6</sup> The pigment was subsequently identified as riboflavin,<sup>7</sup> and a detailed investigation was made<sup>8</sup> of the effect on the yield of varying the composition of the medium. It was found that iron had a markedly toxic effect, 36 to 70 p.p.m. suppressing riboflavin production entirely. The deleterious effect of iron was confirmed by other workers.<sup>9</sup> The

addition of sufficient  $\alpha\alpha$  dipyridyl to inactivate all but a small amount of iron increased the yield of riboflavin<sup>10</sup> so that for instance in the fermentation of corn mash a yield of 2 to 13 mg of riboflavin per litre was obtained in presence of 1.5 mg of iron per litre. The addition of sodium sulphite was claimed<sup>11</sup> to result in consistently high yields although the maximum amount produced (2 mg per g of dry solids) was not appreciably affected. The production of riboflavin by fermentation of whey or skimmed milk with *Cl. acetobutylicum* was also protected by patents<sup>12</sup>. Again the concentration of iron in the mash was found to be very critical and it was stated that to obtain the best results this should lie between 1 and 3 p.p.m. Yields of 0.24 to 2.2 mg per gram of dried material were claimed. The sensitivity of the fermentation to iron was confirmed by A. Leviton<sup>13</sup> who found that less than 0.2 mg atom of ferrous (though not of ferric) iron per litre prevented the formation of riboflavin and destroyed any that was added to the fermentation liquor. Crystalline catalase counteracted the effect of the iron provided the concentration of iron did not exceed 0.29 mg atom per litre but in the presence of 0.33 mg atom per litre catalase had little effect. Low concentrations of sodium dithionite minimised the effect of iron whilst potassium iodide enhanced it. Riboflavin was destroyed by hydrogen peroxide in the presence though not in the absence of iron and the addition of catalase or potassium iodide stabilised the riboflavin although it speeded up the destruction of the hydrogen peroxide.

A. Leviton suggested that the synthesis and decomposition of riboflavin during fermentation were intracellular processes involving the formation of hydrogen peroxide. When iron was present the hydrogen peroxide destroyed the riboflavin inside the cells so that catalase had no effect. When less iron was present hydrogen peroxide and riboflavin accumulated in the cell and then diffused into the culture fluid where catalase destroyed the hydrogen peroxide and thus protected the riboflavin from destruction.

The production of riboflavin by butyl alcohol producing bacteria has also been patented<sup>14</sup>.

### Fermentation with *Candida*

A large number of different strains of yeast also produced riboflavin although mostly in moderate amounts only<sup>15</sup>. Certain strains however were found to produce 10 to 60 mg per litre of fermented liquor<sup>16</sup>. In particular most species and varieties of *Candida* produced substantial amounts of riboflavin though only when glucose was used as the carbon source<sup>17</sup>. The highest yields were obtained from *C. guilliermondia* and *C. tropicalis* var. *Rhagu*<sup>18</sup>.



The use of *C guillermundia* has been covered by a patent,<sup>19</sup> yields of 50 to 60 mg per litre being claimed. Good yields have also been obtained with *C flarer*.<sup>20</sup>

*C guillermundia* produced riboflavine on a medium in which either ammonium sulphate or urea was the sole source of nitrogen and *C flarer* with only urea as the nitrogen source, the iron content must not exceed about 50  $\mu$ g per litre. Under comparable conditions, the two species yielded 175 and 567 mg per litre respectively in shake flasks and 118 and 325 mg per litre in stirred, aerated tanks. *C flarer* yielded a preparation containing 97 mg of riboflavine per gram of solids.<sup>20a</sup>

An investigation into the effect of varying the constituents of the medium for *C guillermundia* showed<sup>21</sup> that the processes involved in growth were different from those involved in the production of riboflavine. Good growth was obtained with arabinose, galactose, inulin, maltose, mannitol, sorbose or xylose as the carbohydrate, but yields of riboflavine were low. With glucose, mannose, fructose or sucrose on the other hand, both growth and riboflavine production were good. Asparagine and glycine were good sources of nitrogen for riboflavine production.

### Fermentation with Moulds

High yields have also been recorded in fermentations with the mould, *Eremothecium Ashbyi*.<sup>22</sup> Thus A Raffy and M Fontaine, using a meat broth-peptone glucose agar, obtained a yield of 86 mg per litre of medium on the nineteenth day after inoculation, though on a liquid peptone glucose medium, in which growth was much slower, a yield of only 27 mg per litre was obtained after fifty-two days. The flavine was isolated by adsorption on frankonite and elution of the adsorbate. Considerably lower yields of riboflavine were obtained by fermentation under anaerobic conditions.<sup>23</sup>

W H Schopfer<sup>24</sup> studied the influence of various nutrients on riboflavine production, fermentation was conducted in the dark at 28° C in small flasks. Good growth was obtained on liquid media containing a variety of vegetable or animal extracts. With yeast extract, a yield of 30 mg per litre was obtained in seven days. Higher yields—up to 128 mg per litre—were claimed by J Renaud and M Lachaux<sup>25</sup> after twenty four days fermentation on a peptone glucose medium. Leucine and arginine were said<sup>26</sup> to be capable of replacing peptone for riboflavine production. The formation of riboflavine was inhibited by sulphaguanidine and other sulphonamides,<sup>27</sup> and the inhibition was reversed by peptone, but this effect was not related to the *p* aminobenzoic acid present.

Better yields were obtained by Moore *et al*<sup>28</sup> in shake cultures. With a yeast extract glucose peptone broth a concentration of 198 mg per litre of liquor or 4 mg per g of solid was obtained in seventy two hours and with distiller's thin stillage 124 mg per litre or 4.6 mg per g of solids. When supplemented with molasses or corn oil the yield was increased to 356 mg per litre. Cultures kept at low temperature produced less riboflavin, whilst lyophilised cultures lost the ability altogether. Maintenance of stock cultures on maltose broth at room temperature is advocated.

W. Ritter<sup>29</sup> separated *E. Ashbyi* into two strains, one white and one yellow, and found that the former synthesised only a fraction of the riboflavin produced by the latter. The higher yields obtained by the yellow variant were produced on wort agar, which gave up to 80 mg per litre. Biotin was essential for growth of the organism.

The most efficient method for the production of riboflavin by fermentation with *E. Ashbyi* appears to be submerged growth with continuous aeration and agitation. Patents covering this process were filed by Société des Usines chimiques Rhône-Poulenc<sup>29a</sup>, Commercial Solvents Corporation<sup>30</sup>, Pfizer & Co.<sup>31</sup>, Merck & Co.<sup>32</sup>, Lederle Labs. Inc.<sup>33</sup> and Roche Products Ltd.<sup>33a</sup> In every instance the recommended medium comprised a carbohydrate source such as glucose or molasses, together with a source of nitrogen such as peptone, animal tissue, yeast extract, corn steep liquor or skimmed milk. One patent<sup>30</sup> advocated as an additional supplement a metabolisable lipid such as corn, olive or peanut oil or cocoa butter, with alcohol fermentation residues and corn steep water. Yields of 436 mg per litre were obtained in four days, whilst a medium containing animal tissues<sup>33</sup> gave up to 400 mg per litre in a similar time, and a yeast extract-molasses medium 468 mg per litre.

Another micro-organism that appears to be of potential value in the microbiological production of riboflavin is *Ashbya gossypii*. Small yields were obtained by Guillermond *et al*<sup>34</sup> but considerably larger amounts were obtained by Wickerham *et al*<sup>35</sup> who used an orange-yellow variant, with an aerated cerelese yeast extract medium at 26° to 28° C. up to 380 mg per litre were produced after eight days. The highest recorded yields of riboflavin using *Ashbya gossypii* were obtained in shake cultures on a medium containing 4% glucose, 0.5% peptone and 0.5% corn steep liquor solids.<sup>36</sup> Titres of 500 to 600 mg per litre were obtained equivalent to more than 10 mg of riboflavin per g of solid.

Riboflavin was also obtained by fermentation with *Mycobacterium smegmatis*, yields varying according to the speed of growth and the nature of the medium.<sup>37</sup> The best yields were obtained in the absence of organic nitrogen. Fructose was the best source of carbon for growth.

and riboflavine production but xylose gave the highest yields of riboflavine although it resulted in poor growth. Potassium magnesium and sulphate ions were essential for riboflavine production. V. E. Pontovich<sup>38</sup> claimed to have isolated 2 mg of riboflavine per g from the mycelium of *Aspergillus flavus* whilst Tanner *et al*<sup>39</sup> found up to 1.38  $\mu$ g per ml in fermentation liquor from *Penicillium chrysogenum*. Of 240 moulds isolated from soil and compost all synthesised riboflavine especially large amounts being produced by species of *Fusarium*<sup>40</sup>

## Recovery

Various methods have been used to recover riboflavine from fermentation liquors. Thus it may be adsorbed on a suitable material such as fuller's earth or florisil and eluted from the adsorbate with for example polyhydric alcohols<sup>41</sup>. It may be extracted with butanol and then precipitated from the extract by addition of petroleum ether<sup>42</sup> or impurities may be precipitated from the fermentation liquors by means of acetone and the riboflavine recovered from the concentrated filtrate by the addition of more acetone<sup>43a</sup>. Spray or roller drying of the metabolism solution from *E. ashbyi* gave a product containing 0.2 to 6.0 mg of riboflavine per g of dry matter<sup>43</sup>. A novel method of isolation devised by Commercial Solvents Corporation<sup>44</sup> was to add a soluble reducing agent to the fermentation liquor such that an  $E_h$  of from -0.05 to -0.40 volt was produced and filter off the precipitate that formed; this contained most of the riboflavine. Alternatively the  $E_h$  was reduced to at least -0.096 volt by fermenting the metabolism solution anaerobically with such organisms as *Streptococcus faecalis*, *Escherichia coli* and *Clostridium acetobutylicum* and the precipitate that formed was centrifuged off<sup>45</sup>. This may contain up to 90 % of the riboflavine present in the fermentation liquor.

## References to Section 5

- 1 Seal test System Laboratories Ltd U S P 2128845
- 2 Commercial Solvents Corporation U S P 2202161 B P 527478
- 3 Commercial Solvents Corporation U S P 2326425 B P 553465
- 4 Commercial Solvents Corporation U S P 2368074 B P 553903 4
- 5 I. Yamasaki and W. Yosimoto *Biochem Z* 1938 297, 398
- 6 I. Yamasaki U S P 2297671
- 7 I. Yamasaki *Biochem Z* 1939 300, 160 *Proc Imp Acad Tokyo* 1940 16, 6
- 8 I. Yamasaki *Biochem Z* 1941 307 431
- 9 A. Saunders and L. S. McClung *J Bact* 1943 46 575
- 10 R. J. Hickey *Arch Biochem* 1945 8 439 R. J. Hickey and Commercial Solvents Corporation U S P 2425280


- 11 Commercial Alcohol Co Inc, U S P 2370177.
- 12 Western Condensing Co, U S P. 2369680, B P 602029 602031
- 13 A Leviton, *J Amer Chem Soc* 1946, 68, 835
- 14 Commercial Solvents Corporation, U S P 2425280
- 15 M Rogosa, *J Bact*, 1943 45, 459
- 16 P R Burkholder *Proc Nat Acad Sci*, 1943, 29, 166
- 17 W. H Schopfer and M Guilloud, *Compt. rend Soc Phys Hist nat Geneve*, 1944, 61, 232
- 18 W H Schopfer, *ibid*, 147, *Z. Vitaminforsch*, 1945, 16, 106.
- 19 P. R Burkholder and Research Corp, U S P. 2363227
- 20 F. W. Tanner, C. Vojnovich and J. M van Lanen, *Science*, 1945, 101, 180; F W. Tanner and J. M van Lanen, U S P 2424003
- 20a H Levine, J E Oyaas, L Wasserman, J. C. Hoogerheide and R M Stern, *Ind Eng Chem*, 1949, 41, 1665
21. P. R Burkholder, *Arch Biochem*, 1943, 3, 121.
- 22 A Guillermond, M Fontaine and A Raffy, *Compt rend.*, 1935 201, 1977, A Raffy and M Fontaine, *ibid*, 1937, 205, 1005, A Raffy and A Mirimanoff, *ibid*, 1938, 206, 1507, A Mirimanoff and A Raffy, *Helv Chim Acta* 1938, 21, 1004, *Bull Soc Chim biol*, 1938, 20, 1166
- 23 A Raffy, *Compt rend*, 1939 209, 900
- 24 W H Schopfer, *Z Vitaminforsch*, 1943-44, 14, 42 *Helv Chim Acta* 1944 27, 1017
- 25 J Renaud and M Lachaux *Compt rend*, 1944, 219, 498, 1945, 221, 187
- 26 W H Schopfer and M Guilloud *Experientia*, 1945 1, 1
- 27 W H Schopfer and M Guilloud *ibid* 333
- 28 H N Moore, G de Becze and E Schraffenberger, *J Bact*, 1947, 53, 502, H N Moore and G de Becze, *ibid*, 1947, 54, 40
- 29 W Rutter, *Schweiz Z Pathol Bakt* 1944, 7, 370
- 29a Société des Usines Rhône-Poulenc, B P 594015
- 30 Commercial Solvents Corporation, U S P 2374503, B P 623082
31. Pfizer & Co, B P 593953
- 32 Merck & Co, B P 593027
- 33 Lederle Labs Inc, U S P 2400710
- 33a Roche Products Ltd, B P 615847
- 34 A Guillermond M Fontaine and A Raffy, *Compt rend*, 1935, 201, 1977
- 35 L J Wickerham, M H Flickinger and R M Johnston, *Arch Biochem*, 1946, 9, 95 F W Tanner, L J Wickerham and J M van Lanen U S P 2445128
- 36 F W Tanner and J M van Lanen, *J Bact* 1947, 54, 38
- 37 R L Mayer and M Rodbart, *Arch Biochem*, 1946, 11, 49
- 38 V. E Pontovich *Biokhimiya* 1943 8, 297
- 39 F W Tanner, S E Pfeiffer and J M van Lanen, *Arch Biochem*, 1945, 8, 29
- 40 G L Peltier and R Borchers, *J Bact* 1947, 54, 519
- 41 S H Rubin and E de Ritter, *J Biol Chem*, 1945 158, 639. Commercial Solvents Corporation U S P. 2343254

- 42 Merck & Co, U S P 2355220  
 42a Merck & Co, B P 621401  
 43 Commercial Solvents Corporation U S P 2374503  
 44 Commercial Solvents Corporation, U S P 2367644, 2367646, B P 621468, 621552  
 45 R J Hickey, *Arch Biochem* 1946 11, 259, Commercial Solvents Corporation, U S P 2387023, B P 621469

## 6. PROPERTIES OF RIBOFLAVINE

Riboflavin is a bright yellow powder, m p  $292^{\circ}\text{C}$  and its solubility in water is 12 mg per 100 ml at  $27.5^{\circ}\text{C}$ , and 19 mg per 100 ml at  $40^{\circ}\text{C}$ . The aqueous solution has a strong yellowish green fluorescence, which is discharged by acids or alkalis, the fluorescence is maximal at pH 3 to 9. The solution is laevo rotatory,<sup>1</sup>  $[\alpha]_{\text{D}}^{20}$  being  $-114^{\circ}$  in a 0.1 N sodium hydroxide solution (concentration 0.125). In neutral or acid solution, however, the rotation is very much smaller. In presence of borax the rotation is strongly dextro rotatory  $[\alpha]_{\text{D}}^{20}$  being  $+340^{\circ}$  at pH 12. Riboflavin is soluble in aqueous alkali solutions.

In view of the low solubility in water, which complicates the problem of administering riboflavin, numerous methods have been suggested for preparing solutions containing a relatively high concentration of the vitamin. Thus the addition of urea or urethan,<sup>2</sup> sodium desoxycholate or N-methylacetamide<sup>3</sup> acetamide salts<sup>4</sup> boric acid<sup>5</sup> L-tyrosine amide<sup>5a</sup> tryptophan<sup>5b</sup> or propylene glycol with or without the addition of a monohydroxymonoalkoxybenzaldehyde<sup>6</sup> has been claimed to increase the solubility of riboflavin in water. Hoffmann La Roche<sup>6</sup> claimed the use of 2,4-dihydroxybenzoic acid or its monoalkyl ethers and of gentisic acid for this purpose, whilst the Winthrop Chemical Co.<sup>7</sup> claimed the use of borax which with alkali, was said to give the complex



Eli Lilly & Co.<sup>8</sup> used benzoic, aminobenzoic or hydrobenzoic acid and their salts, whilst M. R. Zentner<sup>9</sup> heated riboflavin with gallic acid in presence of a dilute mineral acid. Other methods of obtaining more concentrated solutions of riboflavin included the formation of the phthalic or succinic esters<sup>10</sup> and the citric, malic or tartaric esters<sup>10a</sup> and the formation of mono- and dimethylolriboflavin by reaction with formaldehyde<sup>10b</sup>. Riboflavin is soluble in nicotinamide solutions the solubility increasing at pH 5 from about 0.1% to about 2.5% when the nicotinamide concentration was increased from 5 to 50%.<sup>11</sup> Both the pyridine ring and the amide group of nicotinamide are involved.

## PROPERTIES

Riboflavine is sparingly soluble in ethyl alcohol (4.5 mg per 100 ml at 27.5° C), amyl alcohol, cyclohexanol, phenol or amyl acetate, but insoluble in acetone, ether, benzene or chloroform.

Riboflavine is amphoteric in nature, with an isoelectric point at pH 6.12. The dissociation constants are

$$K_a = 63 \times 10^{-12} \text{ and } K_b = 0.5 \times 10^{-8}.$$

On acetylation a tetraacetate, m.p. 242° C, is formed.

As already stated above (page 136), when an alkaline solution is irradiated, lumiflavine, m.p. 330° C, is produced, and this, being sparingly soluble in water, separates out from the irradiated solution.

Riboflavine is reduced to a colourless leuco compound on treatment with sodium dithionite solution, and the colour and fluorescence are restored on exposure to air.

Riboflavine has a characteristic absorption spectrum, the peaks of the absorption bands being situated at 221, 266, 359 and 445 mμ.

Crystalline riboflavine is stable in the dark at ordinary temperatures, but slowly decomposes on exposure to light. In solution it is unstable, especially when alkaline solutions are exposed to light. It is moderately stable to heat, and no appreciable destruction occurred, for example, when milk was incubated for twenty-two hours at 31 to 37° C,<sup>13</sup> or during the cooking of foods.<sup>14</sup> When, on the other hand, milk in bottles was exposed to sunlight more than half the riboflavine was destroyed within two hours.<sup>15, 16</sup> The rate of destruction by light increased as the temperature and pH were increased.<sup>14</sup>

So sensitive is riboflavine to the action of light that riboflavine assays (see page 159) should be carried out in dim light and preferably in a red light, a 150-watt lamp screened with a red cellophane filter has been recommended.<sup>17</sup> The light from the lamp normally employed in a Coleman spectrophotometer, however, does not cause appreciable destruction.

Riboflavine was said to be rendered more stable to light by the presence of sodium dithionite<sup>18</sup> or by heating with boric acid.<sup>19</sup> Solutions containing boric acid are recommended for injection, being said to be self-sterilising as well as photo stable.

Riboflavine was included in the Sixth Addendum (1945) to the British Pharmacopoeia 1932 which laid down tests for identity and purity. The monograph was slightly modified in the British Pharmacopoeia 1948. The prophylactic and therapeutic doses are given as 1 to 4 mg and 5 to 10 mg daily respectively.

### References to Section 6


- 1 R. Kuhn and H. Rudy *Ber.*, 1935, 68, 169. P. Karrer and H. Fritzsche, *Helv. Chim. Acta*, 1935, 18, 1026.

- 42 Merck & Co U S P 2355220  
 42a Merck & Co B P 621401  
 43 Commercial Solvents Corporation U S P 2374503  
 44 Commercial Solvents Corporation U S P 2367644 2367646  
 B P 621468 621552  
 45 R J Hickey *Arch Biochem* 1946 11, 259 Commercial Solvents  
 Corporation U S P 2387023 B P 621469

## 6 PROPERTIES OF RIBOFLAVINE

Riboflavin is a bright yellow powder m p  $292^{\circ}\text{C}$  and its solubility in water is 12 mg per 100 ml at  $27.5^{\circ}\text{C}$  and 19 mg per 100 ml at  $40^{\circ}\text{C}$ . The aqueous solution has a strong yellowish green fluorescence which is discharged by acids or alkalis the fluorescence is maximal at pH 3 to 9. The solution is laevo rotatory  $[\alpha]_{\text{D}}^{20}$  being  $-114^{\circ}$  in a 0.1 N sodium hydroxide solution (concentration 0.125). In neutral or acid solution however the rotation is very much smaller. In presence of borax the rotation is strongly dextro rotatory  $[\alpha]_{\text{D}}^{20}$  being  $+340^{\circ}$  at pH 12. Riboflavin is soluble in aqueous alkali solutions.

In view of the low solubility in water which complicates the problem of administering riboflavin numerous methods have been suggested for preparing solutions containing a relatively high concentration of the vitamin. Thus the addition of urea or urethan<sup>2</sup> sodium desoxycholate or N-methylacetamide<sup>3</sup> acetamidine salts<sup>4</sup> boric acid<sup>5</sup> tyrosine amide<sup>5a</sup> tryptophan<sup>5b</sup> or propylene glycol with or without the addition of a monohydroxymonoalkoxybenzaldehyde<sup>6a</sup> has been claimed to increase the solubility of riboflavin in water. Hoffmann La Roche<sup>6</sup> claimed the use of 2,4-dihydroxybenzoic acid or its monoalkyl ethers and of gentisic acid for this purpose whilst the Winthrop Chemical Co<sup>7</sup> claimed the use of borax which with alkali was said to give the complex



Eli Lilly & Co<sup>8</sup> used benzoic aminobenzoic or hydrobenzoic acid and their salts whilst M. R. Zentner<sup>9</sup> heated riboflavin with gallic acid in presence of a dilute mineral acid. Other methods of obtaining more concentrated solutions of riboflavin included the formation of the phthalic or succinic esters<sup>10</sup> and the citric malic or tartaric esters<sup>10a</sup> and the formation of mono and dimethylolriboflavin by reaction with formaldehyde<sup>10b</sup>. Riboflavin is soluble in nicotinamide solutions the solubility increasing at pH 5 from about 0.1% to about 2.5% when the nicotinamide concentration was increased from 5 to 50%<sup>11</sup>. Both the pyridine ring and the amide group of nicotinamide are involved.

## PROPERTIES

Riboflavine is sparingly soluble in ethyl alcohol (4.5 mg per 100 ml at 27.5° C), amyl alcohol, cyclohexanol, phenol or amyl acetate, but insoluble in acetone, ether, benzene or chloroform.

Riboflavine is amphoteric in nature, with an isoelectric point at pH 6.12. The dissociation constants are

$$K_a = 63 \times 10^{-12} \text{ and } K_b = 0.5 \times 10^{-8}$$

On acetylation a tetraacetate, m.p. 242° C, is formed.

As already stated above (page 136), when an alkaline solution is irradiated, lumiflavine, m.p. 330° C, is produced, and this, being sparingly soluble in water, separates out from the irradiated solution.

Riboflavine is reduced to a colourless leuco compound on treatment with sodium dithionite solution, and the colour and fluorescence are restored on exposure to air.

Riboflavine has a characteristic absorption spectrum, the peaks of the absorption bands being situated at 221, 266, 359 and 445 mμ.

Crystalline riboflavine is stable in the dark at ordinary temperatures, but slowly decomposes on exposure to light. In solution it is unstable, especially when alkaline solutions are exposed to light. It is moderately stable to heat and no appreciable destruction occurred, for example, when milk was incubated for twenty-two hours at 31 to 37° C,<sup>13</sup> or during the cooking of foods.<sup>14</sup> When, on the other hand, milk in bottles was exposed to sunlight more than half the riboflavine was destroyed within two hours.<sup>15, 16</sup> The rate of destruction by light increased as the temperature and pH were increased.<sup>14</sup>

So sensitive is riboflavine to the action of light that riboflavine assays (see page 159) should be carried out in dim light and preferably in a red light—a 150 watt lamp screened with a red cellophane filter has been recommended.<sup>17</sup> The light from the lamp normally employed in a Coleman spectrophotometer however does not cause appreciable destruction.

Riboflavine was said to be rendered more stable to light by the presence of sodium dithionite<sup>18</sup> or by heating with boric acid.<sup>19</sup> Solutions containing boric acid are recommended for injection, being said to be self-sterilising as well as photo stable.

Riboflavine was included in the Sixth Addendum (1945) to the British Pharmacopoeia 1932 which laid down tests for identity and purity. The monograph was slightly modified in the British Pharmacopoeia 1948. The prophylactic and therapeutic doses are given as 1 to 4 mg and 5 to 10 mg daily respectively.

### References to Section 6

1. R. Kuhn and H. Rudy *Ber.*, 1935, 68, 169. P. Karrer and H. Fritzsche *Helv. Chim. Acta* 1935, 18, 1026.




- 42 Merck & Co U S P 2355220  
 42a Merck & Co B P 621401  
 43 Commercial Solvents Corporation U S P 2374503  
 44 Commercial Solvents Corporation U S P 2367644 2367646  
 B P 621468 621552  
 45 R J Hickey *Arch Biochem* 1946 11, 259 Commercial Solvents  
 Corporation U S P 2387023 B P 621469

## 6 PROPERTIES OF RIBOFLAVINE

Riboflavin is a bright yellow powder m p  $292^{\circ}\text{C}$  and its solubility in water is 12 mg per 100 ml at  $27.5^{\circ}\text{C}$  and 19 mg per 100 ml at  $40^{\circ}\text{C}$ . The aqueous solution has a strong yellowish green fluorescence which is discharged by acids or alkalis the fluorescence is maximal at pH 3 to 9. The solution is laevo rotatory  $[\alpha]_{\text{D}}^{20}$  being  $-11.4^{\circ}$  in a 0.1 N sodium hydroxide solution (concentration 0.125). In neutral or acid solution however the rotation is very much smaller. In presence of borax the rotation is strongly dextro rotatory  $[\alpha]_{\text{D}}^{20}$  being  $+34.0^{\circ}$  at pH 12. Riboflavin is soluble in aqueous alkali solutions.

In view of the low solubility in water which complicates the problem of administering riboflavin numerous methods have been suggested for preparing solutions containing a relatively high concentration of the vitamin. Thus the addition of urea or urethane <sup>2</sup> sodium desoxycholate or N methylacetamide <sup>3</sup> acetamide salts <sup>4</sup> boric acid <sup>5</sup> / tyrosine amide <sup>5a</sup> tryptophan <sup>5b</sup> or propylene glycol with or without the addition of a monohydroxymonoalkoxybenzaldehyde <sup>5c</sup> has been claimed to increase the solubility of riboflavin in water. Hoffmann La Roche <sup>6</sup> claimed the use of 2, 4 dihydroxybenzoic acid or its monoalkyl ethers and of gentisic acid for this purpose whilst the Winthrop Chemical Co <sup>7</sup> claimed the use of borax which with alkali was said to give the complex



Eli Lilly & Co <sup>8</sup> used benzoic aminobenzoic or hydrobenzoic acid and their salts whilst M. R. Zentner <sup>9</sup> heated riboflavin with gallic acid in presence of a dilute mineral acid. Other methods of obtaining more concentrated solutions of riboflavin included the formation of the phthalic or succinic esters <sup>10</sup> and the citric malic or tartaric esters <sup>10a</sup> and the formation of mono and dimethylolriboflavin by reaction with formaldehyde <sup>10b</sup>. Riboflavin is soluble in nicotinamide solutions the solubility increasing at pH 5 from about 0.1 % to about 2.5 % when the nicotinamide concentration was increased from 5 to 50 % <sup>11</sup>. Both the pyridine ring and the amide group of nicotinamide are involved.

riboflavine had been removed by adsorption on norite at pH 5. Satisfactory assays of riboflavin in milk were obtained by this method. A fraction prepared from liver extract was used by Wagner *et al*,<sup>3</sup> whilst others have used rice polishings<sup>4</sup> and rice bran,<sup>5</sup> both of which were claimed to be more reliable sources of the vitamin B complex than whole wheat or yeast.

Chicks were used for riboflavin assays by T. H. Jukes,<sup>6</sup> but these appear to give less satisfactory results than rats.

### Microbiological Assays

The biological method of assay has now been completely superseded by the microbiological method, introduced by E. E. Snell and F. M. Strong.<sup>7</sup> They used a lactic acid producing organism, *Lactobacillus casei*  $\epsilon$ , now generally referred to in this country as *L. helveticus*, this will not grow in the absence, *inter alia*, of riboflavin. Using a suitable basal medium the amount of lactic acid produced is proportional to the concentration of added riboflavin. This method and its modifications have been extensively used in the assay of foodstuffs. The original medium employed by Snell and Strong consisted of alkali-treated peptone, cystine, yeast supplement, glucose and inorganic salts, but various modifications were made by later workers in order to improve the specificity of the medium and the growth response.

E. C. Barton-Wright,<sup>8</sup> for example, advocated the addition of xylose, asparagine, nicotinic acid and pantothenic acid to Snell and Strong's medium, whilst R. D. Greene and A. Black,<sup>9</sup> on the other hand, supplemented the original medium with ammonium sulphate, sodium acetate and photolysed yeast. With this modified medium, they obtained results in good agreement with those given by the rat growth method. M. Landy and D. M. Dicken<sup>10</sup> evolved a completely new medium which they used for the assay not only of riboflavin but also of pantothenic acid, nicotinic acid, folic acid, pyridoxine and biotin. It was a complex medium containing casein hydrolysate, sodium acetate, glucose, asparagine, tryptophan, cystine, inorganic salts, guanine, adenine, xanthine and uracil, aneurine, biotin, folic acid, calcium pantothenate, nicotinic acid and pyridoxine. For the assay of other vitamins, riboflavin was included and the particular vitamin being assayed was omitted.

Other workers showed that various substances might interfere with the microbiological estimation of riboflavin and suggested methods of overcoming the interference. Urea, for instance, inhibits the growth-promoting action of riboflavin,<sup>11</sup> so that to obtain satisfactory assays of urine a correction must be applied for the urea.

2. S. A. Schou and B. Fretheim, *Dansk. Tidsskr. Farm.*, 1940, 14, 97; Merck & Co., B.P. 4966/47.
3. R. Kuhn, *Klin. Woch.*, 1938, 17, 222.
4. A. E. Jurist, U.S.P. 2358331.
5. D. V. Frost, *J. Biol. Chem.*, 1942, 145, 693; U.S.P. 2388261.
- 5a. Wyeth Inc., U.S.P. 2445208.
- 5b. R. A. Harte and J. L. Chen, *J. Amer. Pharm. Assoc. Sci. Ed.*, 1949, 38, 568.
- 5c. American Cyanamid Co., U.S.P. 2449041; Wyeth Inc., U.S.P. 2449640.
6. Hoffmann-La Roche, B.P. 555346; U.S.P. 2349986, 2438880.
7. Winthrop Chemical Co., B.P. 560631; U.S.P. 2332548.
8. Eli Lilly & Co., U.S.P. 2395378.
9. M. R. Zentner, U.S.P. 2423074.
10. Merck & Co., U.S.P. 2358356; M. F. Furter, G. J. Haas and S. H. Rubin, *J. Biol. Chem.*, 1945, 160, 293.
- 10a. American Cyanamid Co., U.S.P. 2449003.
- 10b. K. Schoen and S. M. Gordon, *Arch. Biochem.*, 1949, 22, 149.
11. D. V. Frost, *J. Amer. Chem. Soc.*, 1947, 69, 1064; U.S.P. 2407412.
12. R. Kuhn and G. Moruzzi, *Ber.*, 1934, 67, 888.
13. B. Sure and Z. W. Ford, *Proc. Soc. Exp. Biol. Med.*, 1943, 54, 83.
14. R. R. Williams and V. H. Cheldelin, *Science*, 1942, 96, 22.
15. W. J. Peterson, F. M. Haig and A. O. Shaw, *J. Amer. Chem. Soc.*, 1944, 66, 662.
16. J. A. Ziegler, *ibid.*, 1039.
17. L. J. De Merre and W. S. Brown, *Arch. Biochem.*, 1944, 5, 181.
18. C. M. O'Malley and C. W. Sievert, *Ind. Eng. Chem.*, 1942, 34, 1117.
19. D. V. Frost, *J. Biol. Chem.*, 1942, 145, 693; Abbott Labs., U.S.P. 2388261.

## 7. ESTIMATION OF RIBOFLAVINE

### Biological Assays

Riboflavin is generally regarded as the component of the vitamin B<sub>2</sub> group responsible for increasing the growth rate of rats and chicks, but it is not unique in this respect, and other factors contribute materially to the growth of animals on a synthetic diet. Consequently the problem of developing a good biological method of assay resolves itself mainly into the problem of providing adequate amounts of the other members of the group in the diet, without at the same time introducing small amounts of riboflavin. Care must also be taken to prevent coprophagy, since riboflavin is synthesised by micro-organisms present in the contents of the gut (see page 183).

H. von Euler and M. Malmberg<sup>1</sup> and El Sadr *et al.*<sup>2</sup> used rats, the latter group of workers introducing the vitamin B<sub>2</sub> group into the diet in the form of an aqueous extract of whole liver from which the

Wright<sup>24</sup> recommended the general procedure of Snell and Strong with either of two modified media. For routine work he advocated a relatively simple medium, containing photolysed peptone, cystine, glucose, xylose, riboflavine-free yeast, nicotinic acid, calcium pantothenate and inorganic salts. The second medium, which was claimed to give a steeper standard curve and a slight extension of the assay range, was more complicated, and contained, in addition to the constituents listed above, tryptophan, adenine, guanine, uracil, xanthine, pyridoxine, and *p* aminobenzoic acid. In both instances, the growth response was measured by titration of the lactic acid produced.

The use of *Leuconostoc mesenteroides* was advocated by Kornberg *et al.*,<sup>25</sup> it was said to be sensitive to 0.0001  $\mu\text{g}$  per ml of riboflavine as against 0.02  $\mu\text{g}$  per ml for *L. helveticus*.

### Chemical Assays

Unlike other members of the vitamin B complex, riboflavine solutions are strongly fluorescent, and the intensity of the fluorescence is proportional to the concentration of riboflavine. Assays based on measurement of the fluorescence have been widely used perhaps more widely than the microbiological method which is of more recent date. The fluorimetric method appears to have been first used by M. van Eekelen and A. Emmerie<sup>26</sup> who eliminated interfering substances by oxidation with potassium permanganate (excess of which was removed with hydrogen peroxide) which is without effect on riboflavine. The intensity of the fluorescence of the purified solution was measured in a step-photometer. They found that the riboflavine could be adsorbed on lead sulphide and eluted with pyridine acetic acid without loss, and in later work this was introduced as an additional purification stage. The fluorometric method was also used by Supplee *et al.*,<sup>27</sup> S. M. Weisberg and I. Levin<sup>28</sup> and A. Z. Hodson and L. C. Norris.<sup>29</sup> The last named workers reduced all the pigments with sodium dithionite and stannous chloride and then reoxidised the riboflavine by shaking with air, this procedure did not reoxidise the interfering pigments. The fluorescence of the resulting solution was then measured in a fluorimeter (reading A). A second reading (B) was taken after the addition of a known amount of riboflavine, and a third reading (C) after reduction of the test solution with sodium dithionite. Finally, the reading (D) of a pure solution containing the same amount of riboflavine as that added to the test solution was recorded. The true riboflavine content of the unknown solution was calculated from the expression  $(A - C) \times \frac{D}{B - A}$ .

present Again, starch contains material that stimulates the growth of *L. helveticus*, leading to high results, to eliminate errors from this cause, preliminary treatment with takadiastase is recommended<sup>12</sup> E C Barton-Wright,<sup>13</sup> however, stated that digestion with acid or ptyalin was preferable to digestion with takadiastase Another stimulatory substance encountered in extracts of rice bran, wheat bran and whole wheat flour,<sup>14</sup> was not destroyed by takadiastase or papain, and no satisfactory method of eliminating it was discovered Yet other growth stimulating substances were reported by Bauernfeind *et al*<sup>15</sup> in certain foodstuffs, to eliminate these, the use of clarified aqueous extracts of the solvent-extracted material was recommended It has also been suggested that a photolysed extract of the product to be assayed might be added to the assay medium in order to compensate for the additional growth produced by the presence of such impurities Another stimulatory substance was obtained when certain types of foodstuff were autoclaved at 15 lb pressure with 0.1 N hydrochloric acid for 15 minutes, it was eliminated by adjusting to pH 4.5 and filtering off the precipitate that formed<sup>16</sup>

The amount of acid produced by *L. helveticus* was said to be altered by variations in the concentrations of metal ions<sup>17</sup> Small amounts of certain fatty acids also exerted an inhibitory effect on the organism<sup>18, 19</sup> whilst other fatty acids had a stimulatory effect<sup>21</sup> To prevent interference from this source, all materials should be extracted with ether chloroform or other suitable solvent after hydrolysis Solvent extraction was also employed in assaying buttermilk<sup>20</sup> In addition, the casein in the basal medium was replaced by 4 % gelatine plus 0.2 % of cystine

An important practical point in carrying out riboflavine assays is that great care must be taken to maintain the temperature of incubation constant<sup>21</sup> a variation of 4 to 5°C may cause marked differences in the growth response The temperature inside some types of bacteriological incubators varies considerably at different points, and these variations may be sufficiently great to give erroneous results with *L. helveticus* and indeed, with other micro-organisms

Although the customary method of measuring the growth response of *L. helveticus* is to titrate the lactic acid produced, a method has been proposed in which changes in the pH of the culture were measured and compared with those produced by the addition of known amounts of riboflavine<sup>22</sup> Another modification of the method utilises the Heatley technique for assaying antibiotics the test solution is put in holes cut in an agar plate seeded with *L. helveticus*, and the diameters of the zones of stimulation are measured after incubation of the plates<sup>23</sup>

In the face of this multiplicity of methods it is difficult to select, with any degree of confidence the most reliable E C Barton

eliminated interfering substances by precipitation with lead acetate and then recovered the riboflavin by adsorption on fuller's earth and elution with aqueous alcoholic alkali. The fluorescence was measured after treatment with potassium permanganate solution and again after destruction of the riboflavin by treatment with hot 0.1 N sodium hydroxide. The value thus obtained was subtracted from the first value the difference being proportional to the riboflavin concentration.

M Fujiwara and H Shimizu<sup>40a</sup> removed fluorescent impurities with a higher adsorption affinity than riboflavin on a column of pyridine treated zeolite and then adsorbed riboflavin and impurities with the same adsorption affinity on a column of a phenolsulphonic acid resin KH9 from which the riboflavin was eluted with a mixture of pyridine and acetic acid.

Some inorganic ions were said<sup>41</sup> to have a quenching effect on the fluorescence of riboflavin. The fluorescence was found to be maximal within the pH range 5.9 to 7.7. E. C. Slater and D. B. Morell<sup>42</sup> modified Najar's method by introducing an internal standard to correct for the quenching of the fluorescence by other constituents of biological extracts and also to check the specificity of the method by exposing test solutions for short controlled periods to sunlight. The rate of photochemical decomposition was dependent on the concentration of unidentified degradation products. Values obtained for urine by this method were in agreement with those obtained by biological assay. The addition of known amounts of riboflavin to test solutions was also used by Scott *et al.*<sup>43</sup> who also corrected for the presence of stable fluorescent substances by reducing riboflavin with dithionite a procedure which Slater and Morell claimed to give high results.

The treatment of biological materials preparatory to fluorimetric assay generally comprises some form of hydrolysis. Meat samples may be digested with clarase<sup>44</sup> or with papain or taka diastase<sup>45</sup> and cereals and other starchy foods with acid or taka diastase.

J. S. Andrews<sup>46</sup> published results obtained in collaborative assays of different flours including flours fortified with riboflavin. A wide spread was noted in the results reported from different laboratories with both the fluorimetric and microbiological methods of assay. Good recoveries were obtained in both methods but the absolute values obtained by the microbiological method were higher than those obtained by the fluorimetric method. With enriched flours direct readings of the fluorescence of the extracts gave results as satisfactory as those obtained when potassium permanganate or Florisil were employed for the removal of impurities.

Riboflavin nucleotides (page 191) can also be estimated fluorimetrically. At high salt concentrations the dinucleotide has 15 % of the fluorescence of a corresponding amount of free riboflavin but

W. S. Jones and W. Christiansen <sup>30</sup> used a similar method, in which, however, the reduction and re-oxidation steps were omitted; they employed a fluorophotometer for measuring the fluorescence.

G. E. Shaw <sup>31</sup> used another modification of the fluorimetric method. The alkaline riboflavine solution was irradiated and extracted with chloroform, and the fluorescence of the chloroform extract, which contained the lumiflavine, was then compared with that of a standard solution. A similar method had previously been used, though not very successfully, by Warburg and Christian. A. R. Kemmerer <sup>32</sup> found that the fluorimetric method of Hodson and Norris and the microbiological method of Snell and Strong gave more reliable results than a colorimetric method in which a methanolic solution containing acetic acid was treated with potassium permanganate and then with hydrogen peroxide.

A. E. Schumacher and G. F. Heuser <sup>33</sup> adopted a modification of the Hodson and Norris method, in which the fluorescence was measured after reduction with sodium dithionite solution and again after re-oxidation by air; the increase in the intensity of the fluorescence was proportional to the riboflavine concentration. The results were in good agreement with those obtained by biological assay, using chicks or rats. Other workers <sup>34, 35, 36</sup> also reported good agreement between the two types of assay, although the fluorimetric method gave unsatisfactory results with skeletal muscle, a blue fluorescent substance being obtained in the digest together with the riboflavine.

A somewhat different modification was used by Rubin *et al.* <sup>37</sup> In this method, the material was extracted in a Waring blender, digested with clarase at pH 4.5, treated with potassium permanganate solution at the same pH and then twice reduced with sodium dithionite at pH 4.5, instead of at pH 7.0 to 7.5, and re-oxidised. Good agreement with the microbiological method of assay was obtained.

The fluorimetric method was applied to urine by V. A. Najjar, <sup>38</sup> whose method has been adopted, with minor modifications, by other workers. The urine was acidified with acetic acid and saturated with sodium sulphate. The riboflavine was then extracted with pyridine-butanol, and interfering substances were destroyed by oxidation with potassium permanganate. After decomposing the excess of the latter by treatment with hydrogen peroxide, the fluorescence was measured, and the riboflavine content calculated from a standard curve. Urines low in riboflavine were first treated with lead sulphide to adsorb the riboflavine, which was subsequently eluted with a mixture of water, pyridine and acetic acid.

E. C. Barton-Wright and R. G. Booth <sup>39</sup> adopted Najjar's method for the assay of cereals, but found Super-filtral to be more satisfactory than lead sulphide for adsorption of the vitamin. M. Swaminathan <sup>40</sup>

## ESTIMATION

- 11 H Isbell J G Wooley and H F Fraser *U S Publ Health Rep* 1941 **56**, 282
- 12 M L Scott F E Randall and F H Hessell *J Biol Chem* 1941 **141**, 325
- 13 F C Barton Wright *Nature* 1942 **149**, 696
- 14 M I Wegner A R Kemmerer and G S Fraps *J Biol Chem* 1942 **144**, 731
- 15 J C Bauernfeind A L Sotier and C S Boruff *Ind Eng Chem Anal Ed* 1942 **14**, 666
- 16 M I Wegner A R Kemmerer and G S Fraps *J Biol Chem* 1942 **148**, 547
- 17 F W Chattaway F C Hippold and M Sandford *Biochem J* 1943 **37**, 298
- 18 F M Strong and L E Carpenter *Ind Eng Chem Anal Ed* 1942 **14**, 909
- 19 E Kodicek and A N Worden *Biochem J* 1945 **39**, 79
- 20 R A Sullivan A Beatty E Bloom and E Reeves *Arch Biochem* 1943 **2**, 333
- 21 S A Price and H C H Graves *Nature* 1944 **153**, 461
- 22 R H Silber and C W Mushett *J Biol Chem* 1942 **148**, 271
- 23 S A Price *Nature* 1948 **161**, 19
- 24 E C Barton Wright *Analyst* 1945 **70**, 285 *Practical Methods for the Microbiological Assay of the Vitamin B Complex and Essential Amino Acids* Ashe Laboratories Ltd London
- 25 H A Kornberg R S Langdon and V H Cheldelin *Anal Chem* 1948 **20**, 81
- 26 M van Eekelen and A Emmerie *Acta Brevia Neerland* 1935 **5**, 77 1936 **6**, 136
- 27 G C Supplee S Ansbacher G E Flanagan and Z M Hanford *J Dairy Sci* 1936 **19**, 215
- 28 S M Weisberg and I Levin *Ind Eng Chem Anal Ed* 1937 **9**, 523
- 29 A Z Hodson and L C Norris *J Biol Chem* 1939 **131**, 621
- 30 W S Jones and W Christiansen *J Amer Pharm Assoc* 1941 **30**, 270
- 31 G E Shaw *Pharm J* 1939 **143**, 222
- 32 A R Kemmerer *J Assoc Off Agric Chem* 1941 **24**, 413
- 33 A E Schumacher and G F Heuser *Ind Eng Chem Anal Ed* 1940 **12**, 203
- 34 K M Henry J Houston and S K Kon *Biochem J* 1940 **34**, 601
- 35 F O Van Duyne *J Biol Chem* 1941 **139**, 207
- 36 A D Emmett O D Bird R A Brown G Peacock and J M Vandenbelt *Ind Eng Chem Anal Ed* 1941 **13**, 219
- 37 S H Rubin E de Rutter R L Schuman and J C Bauernfeind *ibid* 1945 **17**, 136
- 38 V A Najjar *J Biol Chem* 1941 **141**, 355
- 39 F C Barton Wright and R G Booth *Biochem J* 1943 **37**, 25
- 40 M Swaminathan *Indian J Med Res* 1942 **30**, 37



after hydrolysis in 10 % trichloroacetic acid solution it is converted into the monophosphate which has the same fluorescence as riboflavine <sup>46a</sup>

### Physical Methods

J J Lingane and O L Davis <sup>47</sup> described a method of assaying riboflavine polarographically. Riboflavine is reduced very readily at the dropping mercury electrode, the optimal pH being 7.2. The potential at the dropping electrode is -0.47 volt and the diffusion current is proportional to the concentration of riboflavine over the range 2 to 50 p.p.m. Aneurine and nicotinic acid can also be estimated polarographically and, in fact, the three substances can be estimated simultaneously in the same solution, the resulting polarogram exhibiting separate and well-defined waves for each substance. Such a simultaneous assay is best carried out in unbuffered potassium chloride solution as the base solution, the potential of riboflavine is then -0.35 volt.

The oxidation-reduction potential of riboflavine was first measured by R Kuhn and G Moruzzi <sup>48</sup>. The shape of the titration curve depended on the pH and, according to K G Stern, <sup>49</sup> the slope of the curve at pH values between 6.0 and 12.4 corresponded to a two electron system, and between 4.0 and 1.0 to a one-electron system whilst at 0.4, two maxima appeared, indicating a two stage process. R Kuhn and R Ströbele <sup>50</sup> isolated three coloured intermediates—verdo-, chloro-, and rhodo flavine—in the conversion of riboflavine to leuco-riboflavine (see page 199).

### References to Section 7

- 1 H von Euler and M Malmberg *Z physiol Chem*, 1937, **250**, 158
- 2 M M El Sadr, T F Macrae and C E Work *Biochem J*, 1940 **34**, 601
- 3 J R Wagner, A E Axelrod, M A Lipton and C A Elvehjem, *J Biol Chem*, 1940, **136**, 357
- 4 M F Clarke, M Lechyccka and C A Cook *J Nutrition*, 1940, **20**, 133
- 5 H. R Street, *ibid*, 1941, **22**, 399
- 6 T H Jukes *ibid*, 1937, **14**, 223
- 7 E E Snell and F M Strong *Ind Eng Chem Anal Ed*, 1939 **11**, 346
- 8 E C Barton Wright *Nature*, 1942, **149**, 696, E C Barton Wright and R G Booth, *Biochem J*, 1943 **37**, 25
- 9 R D Greene and A Black, *J Amer Pharm Assoc*, 1943, **32**, 217
- 10 M Landy and D M Dicken, *J Lab Clin Med*, 1942, **27**, 1086

## ESTIMATION

- 11 H Isbell J G Wooley and H F Fraser *US Publ Health Rep* 1941 56, 282
- 12 M L Scott F E Randall and F H Hessel *J Biol Chem* 1941 141, 325
- 13 F C Barton Wright *Nature* 1942 149, 696
- 14 M I Wegner A R Kemmerer and G S Traps *J Biol Chem* 1942 144, 731
- 15 J C Bauernfeind A L Sotier and C S Boruff *Ind Eng Chem Anal Ed* 1942 14, 666
- 16 M I Wegner A R Kemmerer and G S Traps *J Biol Chem* 1942 146, 547
- 17 F W Chattaway F C Happold and M Sandford *Biochem J* 1943 37, 298
- 18 F M Strong and L E Carpenter *Ind Eng Chem Anal Ed* 1942 14, 909
- 19 E Kodicek and A N Worden *Biochem J* 1945 39, 79
- 20 R A Sullivan A Beatty E Bloom and E Reeves *Arch Biochem* 1943 2, 333
- 21 S A Price and H C H Graves *Nature* 1944 153, 461
- 22 R H Silber and C W Mushett *J Biol Chem* 1942 146, 271
- 23 S A Price *Nature* 1948 161, 19
- 24 E C Barton Wright *Analyst* 1945 70, 285 *Practical Methods for the Microbiological Assay of the Vitamin B Complex and Essential Amino Acids* Ashe Laboratories Ltd London
- 25 H A Kornberg R S Langdon and V H Cheldelin *Anal Chem* 1948 20, 81
- 26 M van Eekelen and A Emmerie *Acta Brevia Neerland* 1935 5, 77 1936 6, 136
- 27 G C Supplee S Ansbacher G E Flanagan and Z M Hanford *J Dairy Sci* 1936 19, 215
- 28 S M Weisberg and I Levin *Ind Eng Chem Anal Ed* 1937 9, 523
- 29 A Z Hodson and L C Norris *J Biol Chem* 1939 131, 621
- 30 W S Jones and W Christiansen *J Amer Pharm Assoc* 1941 30, 270
- 31 G E Shaw *Pharm J* 1939 143, 222
- 32 A R Kemmerer *J Assoc Off Agric Chem* 1941 24, 413
- 33 A E Schumacher and G F Heuser *Ind Eng Chem Anal Ed* 1940 12, 203
- 34 K M Henry J Houston and S K Kon *Biochem J* 1940 34 601
- 35 F O Van Duyne *J Biol Chem* 1941 139, 207
- 36 A D Emmett O D Bird R A Brown G Peacock and J M Vandenbelt *Ind Eng Chem Anal Ed* 1941 13, 219
- 37 S H Rubin E de Ritter R L Schuman and J C Bauernfeind *ibid* 1945 17, 136
- 38 V A Najjar *J Biol Chem* 1941 141, 355
- 39 E C Barton Wright and R G Booth *Biochem J* 1943 37, 75
- 40 M Swaminathan *Indian J Med Res* 1942 30, 37

- 40a M Fujiwara and H Shimizu *Anal Chem* 1949 **21**, 1009
- 41 P Ellinger and M Holden *Biochem J* 1944 **38**, 147
- 42 E C Slater and D B Morell *ibid* 1946 **40**, 644
- 43 M L Scott F W Hill L C Norris and G F Heuser *J Biol Chem* 1946 **165**, 65
- 44 W J Peterson D E Brady and A O Shaw *Ind Eng Chem Anal Ed* 1943 **15**, 634
- 45 B A McLaren S Cover and P B Pearson *Arch Biochem* 1944 **4**, 1
- 46 J S Andrews *Cereal Chem* 1943 **20**, 613 1944 **21**, 398
- 46a O A Bessey O H Lowry and R H Love *J Biol Chem* 1949 **180** 755
- 47 J J Lingane and O L Davis *J Biol Chem* 1941 **137**, 567
- 48 R Kuhn and G Moruzzi *Ber* 1934 **67**, 1220
- 49 K G Stern *Biochem J* 1934 **28**, 949
- 50 R Kuhn and R Ströbele *Ber* 1937 **70**, 753

## 8 OCCURRENCE OF RIBOFLAVINE IN FOODSTUFFS

The riboflavine contents of a large variety of foodstuffs were listed by M A Boas Fixsen and M H Roscoe<sup>1</sup> and most of the results recorded here are taken from their paper Wheat (whole) contained 0.02 to 0.17<sup>2</sup> and wheat germ 0.033 mg per 100 g barley (unsprouted) 0.01 barley (sprouted) 0.10 to 0.22 oats 0.02 maize 0.036 to 0.3 rice 0.04 to 0.05 and sorghum<sup>3</sup> 0.12 to 0.21 mg per 100 g White bread contained 0.03 to 0.076 mg per 100 g and bread from 98 % extraction flour 0.25 mg per 100 g<sup>4</sup>

The riboflavine content of flour increased three fold when the extraction was increased from the value of 73 % corresponding to white flour to 85 % corresponding to National wheat meal flour<sup>5</sup> Wheat germ contained more than three times and bran twice as much riboflavine as did wholemeal Riboflavine was present throughout the embryo the aleurone layer and the bran of the wheat berry<sup>6</sup>

Fruits contained the following amounts of riboflavine apple 0.005 to 0.03 banana 0.0075 to 0.048 date 0.03 fig 0.052 grape 0.005 grape fruit 0.024 orange (juice) 0.007 to 0.059 peach 0.007 pear 0.007 to 0.03 pineapple 0.013 to 0.13 and plum 0.025 mg per 100 g

Cocoanut contained 0.10 pecan 0.1 to 0.3 cashew 0.19 and peanut 0.17 to 0.75 mg per 100 g<sup>7</sup>

The following values were reported for a variety of vegetables French bean 0.03 to 0.566 soya bean 0.16 to 0.32 beetroot 0.085 cabbage 0.03 to 0.215 carrot 0.02 cauliflower 0.08 chicory 0.02 to 0.03 cucumber 0.004 lentil 0.068 lettuce 0.03 to 0.116



mg per 100 g, and the dorsal subcutaneous tissue 2.4 to 3.05 mg per 100 g. The eye on the other hand, which, from the association between ariboflavinosis and eye lesions in mammals, might have been expected to be a particularly good source of the vitamin contained only 0.1 to 0.7 mg per 100 g.

There appears to be a close connection between the occurrence in tissues of melanin and riboflavin the above high values being observed only with crustaceans that were heavily pigmented. Species containing no melanin generally contained no riboflavin, riboflavin was also found to be absent from the skin of albino animals. In the lower vertebrates, on the other hand, the melanocyte was very rich in riboflavin, reaching a value of 10 mg per 100 g in tissue from batrachians. Among higher vertebrates, however, including man, the riboflavin content of the melanocyte was very low, not exceeding 0.2 mg per 100 g of tissue.

The following values were recorded for different kinds of meat: beef, 0.04 to 0.35, pork,<sup>17</sup> 0.09 to 0.35, rabbit, 0.06 to 1.2, mutton 0.27, and chicken,<sup>18</sup> 0.05 to 0.35 mg per 100 g. Ox kidney contained 0.8 to 2.0, ox liver, 0.1 to 3.0, pig liver,<sup>17</sup> 4.4 and sheep's liver, 1.7 mg per 100 g.

In general, the liver and kidney of the pig, ox, calf and lamb were richer than other organs and tissues<sup>19</sup> in riboflavin. The liver, heart and gizzard of the chicken were likewise richer than the leg or heart muscle.<sup>20</sup>

Beef extracts contained the bulk of the riboflavin originally present in the fresh meat, five commercial samples containing 1.5 to 2.6 mg per 100 g so that a breakfast cup made with a teaspoonful of extract would supply up to 0.25 mg of riboflavin. Corned beef was correspondingly poorer in this factor, containing 0.07 to 0.18 mg per 100 g, that is about one fifth of the quantity present in roast beef.<sup>21</sup>

Dried yeast is, next to crustacean tissue, the richest known edible source of riboflavin values up to 12.4 mg per 100 g being recorded. Brewers' yeast was richer than bakers' yeast and *Torula* richer than brewers' yeast, which generally contained about 5 mg per 100 g.<sup>22</sup> The riboflavin in live yeast was not available, however, for animal or human nutrition and only partial absorption of riboflavin took place from two dried yeasts containing living cells.<sup>23</sup> Heating rendered the riboflavin available.

Many other fungi were relatively rich in riboflavin<sup>24</sup> containing up to 0.69 mg per 100 g. *Eremothecium Ashbyi* (see page 150) contained considerably more than any other micro organism tested, values up to 264 mg per 100 g of the moist material being recorded,<sup>25</sup> it is probably the richest of all known sources.

Tea contained about 0.9 mg of riboflavin per 100 g and the whole of this passed into the infusion as ordinarily prepared<sup>26</sup> Malt leaves contained a similar amount<sup>27</sup> Beers contained 0.5 to 1.45 µg of riboflavin per 100 ml per degree of original gravity, the actual value depending on the type of beer<sup>28</sup> A substantial proportion of the riboflavin present in the malt was extracted during the mashing process and thus was augmented during fermentation by the transfer of riboflavin from the yeast which synthesises it into the beer

Honey, pollen and royal jelly contained 0.026, 1.7 and 2.8 mg of riboflavin per 100 g respectively<sup>29</sup>

### References to Section 8

- 1 M. A. Boas Fixsen and M. H. Roscoe *Nutr. Abstr.* 1937 38 7, 843 1939-40 9, 820
- 2 R. A. McCance, E. M. Widdowson, T. Moran, W. J. S. Pringle and T. F. Macrae *Biochem. J.* 1945 30, 13
- 3 G. Knox, V. G. Heller and J. B. Sieglinger *Food Res.* 1944 9, 89
- 4 R. R. Sealock and A. H. Livermore *J. Nutrition* 1943 25, 265
- 5 A. M. Copping *Biochem. J.* 1943 37, 12
- 6 G. F. Somers, M. H. Coolidge and K. C. Hamner *Cereal Chem.* 1945 28, 333
- 7 R. Melville *Chem. and Ind.* 1947 304
- 8 E. Gleim, D. K. Tressler and F. Fenton *Food Res.* 1944 9, 471
- 9 E. Gleim, M. Albury, J. R. McCartney, K. Visnyei and F. Fenton *ibid.* 1946 11, 461 F. Fenton, E. Gleim, M. Albury, J. R. McCartney and K. Visnyei *ibid.* 468 F. Fenton, E. Gleim, A. Arnason, J. F. Thompson, M. Albury and M. Phillips *ibid.* 475
- 10 P. B. Pearson and A. L. Darnell *J. Nutrition* 1946 31, 51
- 11 P. Johnson, L. A. Maynard and J. K. Loosh *J. Dairy Sci.* 1941 24, 57
- 12 A. D. Holmes, C. P. Jones, A. W. Wertz and J. W. Kuzmeski *J. Nutrition* 1943 28, 337
- 13 L. J. Daniel and L. C. Norris *Food Res.* 1944 9, 312
- 14 R. A. Sullivan, E. Bloom and J. Jarmol *J. Nutrition* 1943 25 463
- 15 L. C. Norris and J. C. Bauernfeind *Food Res.* 1940 5, 521 W. J. Peterson, R. S. Dearslyne, R. E. Comstock and V. Weldon *Ind. Eng. Chem. Anal. Ed.* 1945 17, 370
- 16 R. G. Busnel *Compt. rend.* 1942 214, 189 1943 216, 85 162
- 17 R. C. Miller, J. W. Pence, R. A. Dutcher, P. T. Ziegler and M. A. McCarty *J. Nutrition* 1943 28, 261
- 18 E. E. Rice, E. J. Strandine, E. M. Squires and B. Lyddon *Arch. Biochem.* 1946 10, 251
- 19 O. Mickelsen, H. A. Waisman and C. A. Elvehjem *J. Nutrition* 1939 18 517
- 20 A. Z. Hodson *ibid.* 1940 20, 377



deficiency but this condition was not cured by pure riboflavin and moreover rats on a diet completely free from riboflavin and containing other members of the vitamin B complex did not develop cataract<sup>3</sup>. Only when rats were fed on a diet containing suboptimal amounts of riboflavin such as the Bourquin Sherman diet which supplies an average of 0.5  $\mu\text{g}$  of riboflavin per day did they exhibit a high incidence of cataract. Thus whereas corneal opacity and vascularisation<sup>4</sup> invariably resulted from a complete absence of the vitamin cataract formation only occurred with diets containing small amounts of riboflavin.

Changes in riboflavin intake were promptly reflected by changes in its concentration in the cornea<sup>5</sup>. Intense visible or ultra violet light had no effect on the riboflavin concentration and it was suggested that this rather unexpected insensitivity to light might be due to a combination of the flavine with an acceptor.

Other symptoms associated with a severe deficiency of riboflavin were a partial paralysis of the legs due to myelin degeneration of the muscle sheaths, atrophy of the testes, early involution of the thymus gland and structural alterations in the thyroid and adrenal glands<sup>6</sup>.

Prolonged deficiency of riboflavin also led<sup>4</sup> to neurological abnormalities such as loss of reflexes, myelin degeneration of peripheral nerves and the posterior column of the spinal cord.

Leucopenia with both a relative and an absolute decrease in the number of lymphocytes appeared to be an early sign of ariboflavinosis and in rats occurred prior to changes in the lens and cornea of the eye<sup>7</sup>. Granulocytopenia was also observed<sup>8</sup> in rats maintained on a purified diet deficient in riboflavin but it was cured by folic acid (see page 489) and not by riboflavin. An anaemia observed in some of the animals was partially relieved by riboflavin but was not affected by folic acid.

At low oxygen tensions the liver glycogen of riboflavin deficient rats was not increased to the same degree as in normal rats and the deficient animals had a lower blood sugar when fasted at sea level than had normal animals. The riboflavin content of the liver depended on the riboflavin intake<sup>9</sup>. L Cystine, DL tryptophan, L tyrosine, L histidine, glycine and D glutamic acid were more toxic to riboflavin-deficient rats than to adequately nourished animals<sup>10</sup>.

### Effect in other Mammals

The effects of riboflavin deficiency in mice were very similar to the effects in rats and were characterised by dermatitis, myelin degeneration and keratitis<sup>11</sup>. Pigs on a riboflavin deficient diet fuled



to grow at the normal rate,<sup>12, 13</sup> the hair became rough, dry and thin, whilst mottled erythematous eruptions developed on the skin, accompanied by scaling and ulceration. The lens of the eye became opaque, and cataracts were frequently formed. The animals developed hypoglycaemia and a normocytic anaemia, and acquired an abnormal gait. At autopsy, changes in the corneal epithelium were observed, together with microscopic haemorrhages in the adrenals, and lipid degeneration of the proximal tubules.

A similar picture was observed in riboflavine deficient dogs, which lost weight, developed dermatitis, conjunctivitis, vascularisation and opacity of the cornea, and muscular weakness in the hind quarters.<sup>14</sup> Some of the dogs exhibited fatty liver, a condition more generally associated with choline deficiency (see page 590), and tachycardia. They also developed a microcytic, hypochromic anaemia.

Riboflavine has also been shown to be essential for foxes,<sup>15</sup> in which the deficiency symptoms resemble those in the dog, and for horses<sup>16</sup> and monkeys.<sup>17</sup> Rhesus monkeys on a riboflavine deficient diet developed a dermatitis on the face, hands, legs and groin, together with a hypochromic, normocytic anaemia; in addition, they exhibited muscular inco-ordination. Some of the monkeys also developed fatty livers, and these were not due to inanition. Riboflavine was also shown to be essential for the cow, although adequate amounts are generally provided by bacterial synthesis in the rumen or intestine (see page 183). Symptoms of riboflavine deficiency have, however, been observed in the calf,<sup>18</sup> these included hyperaemia of the buccal mucosa, lesions of the cornea of the mouth along the edges of the lips, and around the navel, loss of appetite, poor growth, scours, excess salivation and lachrymation, and loss of hair. No vascularisation of the cornea or opacity of the lens was observed.

### Effect in Birds and Fish

Little has been reported concerning the effect of riboflavine deficiency in birds. Riboflavine is known to be necessary for the growth of chickens,<sup>19</sup> ducklings,<sup>20</sup> and turkey poults,<sup>21</sup> in its absence, chickens developed "curled-toe paralysis", whilst young turkeys grew slowly and developed dermatitis. The hatchability of hen eggs appeared to depend on the amount of riboflavine present in the diet, eggs laid by riboflavine-deficient hens showing a high embryo mortality.<sup>22</sup>

On a riboflavine deficient diet, young rainbow trout (*Salmo gairdneri irideus*) developed haemorrhagic eyes, livers, nose and operculum, together with an anaemia, which was partially cured by riboflavine, pyridoxine and choline and completely cured by whole liver.<sup>23</sup>

## EFFECT OF DEFICIENCY IN ANIMALS

### Riboflavin and Cancer

Cancer tissue contained amounts of riboflavin similar to those present in brain lung spleen and muscle<sup>24</sup> The absence of riboflavin from the diet of C<sub>3</sub>H mice reduced the growth rate of spontaneous mammary tumours as well as the growth rate of the animal whilst the addition of riboflavin to the diet increased the average number of tumours per mouse<sup>25</sup> Complete regression of lymphosarcoma implants followed the temporary induction of riboflavin deficiency in mice<sup>26</sup>

When certain carcinogenic dyes were added to the diet of rats the riboflavin content of the liver decreased the decrease being approximately proportional to the carcinogenicity<sup>28</sup> *m'* Methyl-*p* dimethylaminoazobenzene was the most effective of the compounds tested More riboflavin was stored in the liver when the basal diet contained 24 % of casein than with 12 % but the relative effects of the carcinogens was the same on either diet Although the food intake was reduced when the azo dyes were fed this was not responsible for the change in vitamin storage Imitation of the riboflavin intake reduced the ability of rat liver slices to destroy *N,N* dimethyl-*p* aminoazobenzene<sup>29a</sup>

### Effect on Infected Animals

The effect of riboflavin deficiency on the resistance of experimental animals to infection varied according to the nature of the invading organisms For example mice fed a diet deficient in riboflavin were said to be more susceptible than normal mice to *Pneumococcus* Type I<sup>27</sup> A similar result was obtained with aneurine-deficient animals and the effect was shown not to be due to the restricted food intake On the other hand treatment with riboflavin or aneurine at the time of infection did not appear to affect the mortality rate Riboflavin-deficient mice were also said to be more susceptible than normal mice to a spontaneous *Salmonella* infection<sup>28</sup> whereas they were apparently less susceptible than normal mice to the Lansing strain of the influenza virus<sup>29</sup> Similarly riboflavin deficient chicks exhibited less severe symptoms when infected with *Plasmodium lophurae* than did normal chicks and the severity of the disease appeared to increase on administration of riboflavin<sup>30</sup> Finally a deficiency of riboflavin (or aneurine) reduced the resistance of rats to infection by the worm *Nippostrongylus muris* and plasma from riboflavin (or aneurine) deficient animals was less effective than immune sera from normal animals in combating the infection<sup>31</sup>

The absence of any clear-cut connection between the susceptibility

## RIBOFLAVINE

of animals to infection and the vitamin B content of the diet may be disappointing but is hardly surprising. As will be seen subsequently (see page 203) riboflavine like aneurine is a growth factor for micro organisms as well as for animals and it is to be expected therefore that ingested riboflavine would stimulate the growth of the invading organisms to a similar or even greater extent than it benefits the host. It might well be imagined for example that where either the invading organism does not require the particular growth factor or this is not available to it administration of a vitamin or mixture of vitamins might help the host to resist infection whereas in other instances the beneficial effect on the host might be counter balanced by the stimulatory effect of the supplement on the micro organism. Thus it is suggested is the explanation of the variable effect of aneurine and riboflavine on animals infected with different parasites.

### References to Section 9

- 1 B Sure *J Nutrition* 1941 **22**, 295
- 2 H Chick T F Macrae and A N Worden *Biochem J* 1940 **34** 580
- 3 H M Baum J F Michaelree and E B Brown *Science* 1942 **95**, 24
- 4 H R Street G R Cowgill and H M Zimmerman *J Nutrition* 1941 **22**, 7
- 5 O A Bessey and O H Lowry *J Biol Chem* 1944 **155**, 635
- 6 J H Shaw and P H Phillips *J Nutrition* 1941 **22**, 345
- 7 C F Shukers and P L Day *ibid* 1943 **25**, 511
- 8 A Kornberg F S Daft and W H Sebrell *Arch Biochem* 1945 **8**, 431
- 9 M E Wickson and A F Morgan *J Biol Chem* 1946 **162**, 209
- 10 G J Martin *Proc Soc Exp Biol Med* 1946 **62**, 528
- 11 S W Lippincott and H P Morris *J Nat Cancer Inst* 1942 **2**, 601
- 12 A J Patek J Post and J Victor *Amer J Physiol* 1941 **133**, 47
- 13 M M Wintrobe W H Buschke R H Folts and S Humphreys *Johns Hopkins Hosp Bull* 1944 **25**, 102
- 14 R L Potter A E Axelrod and C A Elvehjem *J Nutrition* 1942 **24**, 449 H Spector A R Maass L Michaud C A Elvehjem and E B Hart *J Biol Chem* 1943 **150**, 75
- 15 A E Schaefer C K Whitehair and C A Elvehjem *J Nutrition* 1947 **34** 131
- 16 P B Pearson M K Sheybani and H Schmidt *Arch Biochem* 1944 **3** 467
- 17 H A Waisman *Proc Soc Exp Biol Med* 1944 **55**, 69 J M Cooperman H A Waisman K B McCall and C A Elvehjem *J Nutrition* 1945 **30**, 45
- 18 A C Wiese B C Johnson H H Mitchell and W B Nevens *ibid* 1947 **33**, 263

# EFFECT OF DEFICIENCY IN MAN

- 19 W. Bolton, *J. Agric. Sci.*, 1944, **34**, 198.
- 20 J. C. Fritz, W. Archer and D. Barker, *Poultry Sci.*, 1939, **18**, 449.
21. T. H. Jukes, E. L. R. Stokstad and M. Belt, *J. Nutrition*, 1947, **33**, 1.
- 22 C. H. Hunt, A. R. Winter and R. M. Bethke, *Poultry Sci.*, 1939, **18**, 330; A. L. Schumacher and G. F. Heuser, *ibid*, 369; A. L. Romanoff and J. C. Bauernfeind, *Anat. Rec.*, 1942, **82**, 11.
- 23 B. A. McLaren, E. F. Herman and C. A. Elvehjem, *Arch. Biochem.*, 1946, **10**, 453; B. A. McLaren, E. Keller, D. J. O'Donnell and C. A. Elvehjem, *ibid*, 1947, **15**, 169
- 24 M. A. Pollack, A. Taylor, J. Taylor and R. J. Williams, *Cancer Res.*, 1942, **2**, 739
25. H. P. Morris and W. van B. Robertson, *J. Nat. Cancer Inst.*, 1943, **3**, 479
- 25a. H. C. Stoerk and G. A. Emerson, *Proc. Soc. Exp. Biol. Med.*, 1949, **70**, 703.
- 26 A. C. Griffin and C. A. Baumann, *Arch. Biochem.*, 1946, **11**, 467
- 26a. C. J. Kensler, *J. Biol. Chem.*, 1949, **170**, 1079
27. J. G. Wooley and W. H. Sebrell, *U. S. Publ. Health Rep.*, 1942, **57**, 149
28. I. J. Kligler, K. Guggenheim and E. Buechler, *Proc. Soc. Exp. Biol. Med.*, 1944, **57**, 132
- 29 A. F. Rasmussen, H. A. Waisman and H. C. Lichstein, *ibid*, 92.
- 30 A. O. Seeler and W. H. Ott, *J. Infect. Dis.*, 1944, **75**, 175
31. J. Y. C. Watt, *J. Hygiene*, 1944, **39**, 145

## 10. EFFECT OF RIBOFLAVINE DEFICIENCY IN MAN

The results of riboflavin deficiency in man conform to the general pattern observed with experimental animals, and the most characteristic symptoms are eye lesions and skin lesions. There is, however, no unanimity amongst clinical workers as to which of the several individual lesions are due to the absence of riboflavin or of other members of the vitamin B complex. Indeed the clinical manifestations of riboflavin deficiency are less clearly defined than those associated with a deficiency of aneurine or of nicotinic acid, and appear to overlap to some extent with other deficiency symptoms, particularly with those of nicotinic acid deficiency.

Whilst it is possible that a pure riboflavin deficiency, uncomplicated by other vitamin deficiencies, may exist, it is more probable that it generally occurs as part of a multiple vitamin B deficiency, which can only be treated successfully with a mixture of factors, including riboflavin. Thus, for example, Vilter *et al.* obtained beneficial effects by treatment with riboflavin of pellagrins whose skin lesions had been cured by nicotinic acid but who still had vague symptoms of ill health.

### Skin Lesions

W H Sebrell and R E Butler<sup>2</sup> appear to have been the first to study artificial riboflavine deficiency in man, they found that ten out of eighteen women developed lesions in the angles of the mouth described as cheilosis, whilst the mucosa of the lips became red and shiny and seborrhoeic accumulations appeared on the face. The symptoms were cured by riboflavine but not by nicotinamide. Volunteers maintained for nine to seventeen months on a diet which supplied only 0.55 mg of riboflavine per 2200 cal developed angular stomatitis, seborrhoeic dermatitis, scrotal skin lesions and also diminished ability to perceive flicker<sup>2a</sup>. V P Sydenstricker *et al*<sup>3</sup> relieved cheilosis in five patients by treatment with riboflavine, nicotinic acid being ineffective.

V P Sydenstricker,<sup>4</sup> in fact, regarded cheilosis and glossitis as diagnostic of riboflavine deficiency, although these symptoms were often preceded or followed by seborrhoeic lesions of the ear, nose and forehead. The skin lesions, as well as the eye lesions, might yield *Staphylococcus aureus* or *Streptococcus haemolyticus* on culture, but the organisms disappeared after administration of riboflavine.<sup>5</sup> Cheilosis and seborrhoeic filiform excrescences on the face were observed in badly nourished Chinese and cleared up on treatment with riboflavine.<sup>6</sup> Cheilosis was also noted as a usual symptom of riboflavine deficiency in infants and children in districts of Alabama, U.S.A.<sup>7</sup> The children of mothers given riboflavine during pregnancy and lactation showed no symptoms of riboflavine deficiency.

T E Machella,<sup>8</sup> on the other hand, claimed that cheilosis was not an essential manifestation of riboflavine deficiency, for he observed a number of cases of apparent ariboflavinosis, with lesions of the lips, cornea and tongue, in which the cheilosis failed to respond to treatment with riboflavine. Some of the cases responded to pyridoxine and nicotinic acid and others to ascorbic acid. One of the few conditions that can be ascribed mainly to riboflavine deficiency is kwashiorkor,<sup>9</sup> which occurs in West Africa. The clinical response to riboflavine administration in this condition was, however, confined to the healing of epithelial lesions of the tongue, lips and external genitalia, the mortality being unaffected. The condition is regarded as due to riboflavine deficiency complicated by intercurrent disease and general inanition.

### Ocular Lesions

According to V P Sydenstricker,<sup>10</sup> lesions of the eye due to riboflavine deficiency in man may take the form of photophobia and dimness of vision at a distance or in poor light with, as one of the earliest

# EFFECT OF DEFICIENCY IN MAN

symptoms, a superficial vascularisation of the cornea progressing to severe interstitial keratitis. Rosacea keratitis was said to be improved by treatment with riboflavine. Similar ocular lesions were reported by H C Hou,<sup>11</sup> by Spies *et al* <sup>7, 12</sup> and by K W Cosgrove and P L Day.<sup>13</sup> Spies *et al*<sup>12</sup> treated patients who developed ocular disease on diets deficient in riboflavine with intravenous injections of riboflavine. Within forty-eight hours, there was subjective improvement in all cases, with a decrease in the ocular vasodilatation the photophobia, and the corneal ulceration. The number of haemolytic staphylococci, streptococci and xerosis bacilli in the exudate from the eyes decreased. Although many of the patients had irreparable eye damage, pain was relieved and vision was improved.

According to M K Gregory<sup>14</sup> riboflavine deficiency was characterised by superficial invasion of the cornea by fine capillaries arising from the apices of the marginal loops whilst I Mann<sup>15</sup> observed that an early sign of ariboflavinosis was the budding of new capillaries from the apices of limbal loops with extensions on to the true cornea. These were generally present around the whole circumference of the cornea in both eyes and should disappear after giving riboflavine.

There appears to be considerable doubt as to the value of corneal vascularisation as a diagnostic criterion of ariboflavinosis. H R Sandstead<sup>16</sup> and L Lehrfeld<sup>17</sup> for example remarked that not all types of corneal vascularisation could be cured by riboflavine whilst H Scarborough<sup>18</sup> showed that riboflavine had no effect on circum corneal injection which is therefore not diagnostic of ariboflavinosis. W M Fish<sup>19</sup> showed that the corneal vascularisation in acne rosacea was different from that in riboflavine deficiency and did not respond to riboflavine. Tisdall *et al*<sup>20</sup> however observed that the incidence of corneal vascularisation in Royal Canadian Air Force personnel was high and varied with the riboflavine content of the diet moreover a proportion of the cases responded with decreased vascularisation on administration of large doses of riboflavine. On the other hand no change in corneal vascularisation occurred with different levels of riboflavine in the diet. Similar results were obtained with Royal Air Force personnel<sup>21</sup> many of whom had corneal vascularisation in spite of receiving a satisfactory diet nor was the condition always improved by giving additional riboflavine. Similarly corneal vascularisation was observed in a high proportion of patients<sup>22</sup> but only in a small number of the cases did the condition appear to be due to riboflavine deficiency and not all of these were cured by riboflavine. It therefore appears that corneal vascularisation is often but by no means always, associated with riboflavine deficiency, and may sometimes be improved by riboflavine although it frequently requires an additional factor.

Vernal conjunctivitis is the name given to a form of conjunctivitis associated with the hot season in the tropics it was benefited by administration of riboflavine L Castellanos<sup>23</sup> suggested that the condition was due to riboflavine deficiency caused by the more rapid destruction of the vitamin by ultra violet light or by the greater demand for the vitamin in the hot season

# Other Conditions

Riboflavine deficiency often accompanies sprue and steatorrhoea on giving riboflavine the steatorrhoea disappeared and riboflavine was excreted in the urine<sup>24</sup> Riboflavine deficiency can also be caused by a lack of balance in the vitamin intake even when the riboflavine intake is relatively high<sup>25</sup> It may also be produced by an excessive metabolic demand as in pregnancy Of 900 pregnant women examined in Palestine for instance 190 had glossitis and heartburn during the last trimester the symptoms clearing up without treatment after delivery<sup>26</sup>

## References to Section 10

- 1 R W Vilter S P Vilter and T D Spies *J Amer Med Assoc* 1939 **112**, 420
- 2 W H Sebrell and R E Butler *US Publ Health Rep* 1938 **53**, 2282
- 2a M K Horwitt O W Hills C C Harvey E Liebert and D L Steinberg *J Nutrition* 1949 **39** 357
- 3 V P Sydenstricker L E Geeshin C M Templeton and J W Weaver *J Amer Med Assoc* 1939 **113**, 1697
- 4 V P Sydenstricker *Ann Int Med* 1941 **14** 1499 *Amer J Publ Health* 1941 **31**, 344
- 5 J W Riddle T D Spies and N P Hudson *Proc Soc Exp Biol Med* 1940 **45**, 361
- 6 H C Hou *Chinese Med J* 1941 **59**, 324
- 7 T D Spies W B Bean R W Vilter and N E Huff *Amer J Med Sci* 1941 **200** 697
- 8 T E Machella *ibid* 1942 **203**, 114 T E Machella and P R McDonald *ibid* 1943 **205** 214
- 9 W Hughes *Trans Roy Soc Trop Med* 1946 **39**, 437
- 10 V P Sydenstricker *Amer J Publ Health* 1941 **31**, 344 V P Sydenstricker W H Sebrell R M Cleckley and H D Kruse *J Amer Med Assoc* 1940 **114**, 2437 H D Kruse V P Sydenstricker W H Sebrell and H M Cleckley *US Publ Health Rep* 1940 **55**, 157
- 11 H C Hou *Chinese Med J* 1940 **58**, 616
- 12 T D Spies D J Perry R C Gogswell and W B Frommeyer *J Lab Clin Med* 1945 **30**, 751

- 13 K W Cosgrove and P L Day *Amer J Ophthal* 1942 25, 544
- 14 M K Gregory *Brit Med J* 1943 2, 134
- 15 I Mann *Amer J Ophthal* 1945 28, 243
- 16 H R Sandstead *US Publ Health Rep* 1942 57, 1821
- 17 L Lehrfeld *Arch Ophthal* 1944 31, 557
- 18 H Scarborough *Brit Med J* 1942 2, 601
- 19 W M Fish *Brit J Ophthal* 1943 27, 107, *Amer J Ophthal* 1944 27, 354
- 20 F F Tisdall J F McCreary and H Pearce *Canad Med Assoc J* 1943 49, 5 J F McCreary J V V Nicholls and F F Tisdall *ibid* 1944 51, 206
- 21 T K Lyle T F Macrae and P A Gardiner *Lancet* 1944 1, 393
- 22 W J Wellwood Ferguson *ibid* 431
- 23 L Castellanos *Arch Ophthal* 1944 31, 214
- 24 R Antognini *Schweiz med Woch* 1941 71, 510
- 25 I J Boerer C E Stanford and E Ryan *Amer J Med Sci* 1943 205, 544
- 26 K Braun Y M Bromberg and A Brzezinski *J Obstet Gynec* 1945 52, 43

## 11 METABOLISM OF RIBOFLAVINE

### Concentration of Riboflavin in Blood

The blood of man the rat and the calf were reported <sup>1</sup> to contain 5 µg of riboflavin per ml and that of the dog and pig 10 µg per ml. The microbiological assay method of Snell and Strong was used. No attempt appears to have been made to use blood concentrations for assessing the nutritional status of animals or human subjects with respect to riboflavin such as were made with aneurine. Indeed it has been said that there is no relation between blood concentration and dietary intake in the horse <sup>2</sup>.

### Urinary Excretion of Riboflavin

Riboflavin deficient dogs and rats excreted less riboflavin in the urine than did animals fed a normal diet <sup>3</sup>. The fall in excretion was observed before the other symptoms of riboflavin deficiency appeared. Riboflavin can be estimated in urine either by the microbiological method using *L. helveticus* <sup>4</sup> or fluorimetrically <sup>5</sup> (see page 157). When the former method is used a correction must be applied to compensate for the effect of urea the presence of which tends to suppress the growth of the organism <sup>6</sup>.

A relationship has been shown to exist between the urinary excretion



and the dietary intake of riboflavin in many species of animals, including man, but the relationship does not appear to be as simple as with some other members of the vitamin B complex. A group of rats on an adequate diet excreted  $24.6 \mu\text{g}$  per day in the urine,<sup>6</sup> whilst other rats on a poor diet excreted only about  $2 \mu\text{g}$  per day.<sup>7</sup> A horse excreted  $1.5 \text{ mg}$  per day,<sup>8</sup> but this value fell to less than  $30 \mu\text{g}$  per day on a restricted dietary intake of riboflavin. Following the oral administration of large amounts of riboflavin a very large apparent increase was observed in the amount excreted by goats and sheep when the fluorimetric method of assay was used whereas an increase of only about 20 % was observed when microbiological assays were employed.<sup>8</sup> With rats and humans on the other hand, good agreement was obtained between the microbiological and fluorimetric values.

Women on an adequate diet excreted  $357 \mu\text{g}$  of riboflavin per day in the urine and this value fell to  $77 \mu\text{g}$  per day on a diet containing only  $0.5 \text{ mg}$  of riboflavin per 2400 cal.<sup>9</sup> Other values recorded for the urinary excretion of humans on adequate diets were 320 to  $360 \mu\text{g}$  per day,<sup>7</sup> and 500 to  $800 \mu\text{g}$  per day.<sup>1</sup> In the last group of subjects the excretion fell rapidly to 50 to  $150 \mu\text{g}$  per day when the intake dropped to 1 to 2 mg per day, and rose again on increasing the intake to 2 to 5 mg per day. In another experiment,<sup>10</sup> the average daily urinary excretions on diets containing 0.28, 0.49, 0.66 and 7.1 mg per 1000 cal. were 119, 107, 150 and  $263 \mu\text{g}$  respectively, and increased to  $325 \mu\text{g}$  after two weeks on a diet supplying 9.63 mg per 1000 cal. Still higher values were recorded by Brewer *et al.*,<sup>11</sup> daily excretions of 70, 160, 130, 320, 1180 and  $1310 \mu\text{g}$  being obtained on daily intakes of 0.79, 1.04, 1.26, 1.62, 2.23 and 2.72 mg per day. Infants excreted 35 to  $50 \mu\text{g}$  per day on a diet deficient in riboflavin.<sup>11a</sup>

On self selected diets supplying 1.25 to 2.47 mg of riboflavin per day, young women excreted<sup>11b</sup> 36 to 50 % in the urine and 27 to 54 % in the faeces, following a 5 mg supplement between 24 and 44 % was eliminated in the urine. In no instance did the urinary and faecal excretion together exceed the intake. Oldham *et al.*<sup>12</sup> observed a correlation between riboflavin excretion and nitrogen balance, on a diet providing 1 mg of riboflavin daily for ten days 1.2 to 1.4 mg daily for a further ten days and 1 mg daily for a further ten day period with nitrogen intakes of 5.19 and 5 g daily in each ten day period respectively 40 to 60 % of the riboflavin was excreted in the first and third periods when the subjects were in negative nitrogen balance and 7 % when the subjects were in positive nitrogen balance. The urinary excretion of riboflavin increased in protein deficiency, and fell during recovery.<sup>13</sup>

### Assessment of Nutritional Status

The daily output of riboflavin is an unreliable method of assessing riboflavin deficiency,<sup>14</sup> since it only reflects the immediate dietary intake. A more satisfactory method of assessing nutritional status is to measure the response to a test dose of pure riboflavin, the method being similar in principle to that used in nutritional surveys relating

... ! . . . ple, employed intravenous  
that the amount of riboflavin excreted in the urine at half hourly intervals was related to the degree of riboflavin deficiency. M. Swaminathan<sup>7</sup> administered test doses of 1 to 10 mg orally to adequately nourished subjects and found that 80 to 85 % was excreted within twenty-four hours, whereas Keys *et al*,<sup>15</sup> who administered a 1-mg test dose to young men on a diet supplying slightly sub optimal amounts (0.31 mg per 1000 cal) of riboflavin obtained only a 12 % recovery in the urine. Similarly, R. D. Williams *et al*,<sup>16</sup> observed a progressive decrease in the urinary excretion of a 2-mg test dose administered to a subject maintained on a diet providing 0.35 mg of riboflavin per 1000 cal.

Axelrod *et al*,<sup>17</sup> however, claimed that even the test dose method was unsatisfactory for assessing nutritional status. They gave doses of 200 and 400  $\mu$ g of pure riboflavin per kg of bodyweight to several subjects, and failed to find any correlation between the percentage of the test dose retained and the amount excreted in the urine.

The volume of work carried out on the assessment of riboflavin deficiency by measuring the urinary excretion with or without administration of a test dose is considerably less than that undertaken in the case of ascorbic acid (see page 63) or of nicotinic acid (see page 252), and it is therefore impossible to reach any definite conclusion about the merits of the saturation test.

In spite of this, however, many attempts have been made to lay down criteria for diagnosing riboflavin deficiency. According to Feder *et al*,<sup>18</sup> an excretion of less than 0.3  $\mu$ g of riboflavin per ml of urine is indicative of riboflavin deficiency, whilst the concentration of riboflavin in a sample of fasting morning urine was claimed to be as valuable as a saturation test for estimating the degree of riboflavin deficiency. Oldham *et al*,<sup>19</sup> also reported a close relationship between the excretion rate and the response to a test dose, and suggested that the elimination of 1  $\mu$ g of riboflavin per hour by a fasting subject or the elimination of 20 % of a test dose within four hours of its administration was indicative of an adequate level of nutrition.

Hagedorn *et al*,<sup>20</sup> reported that an adult male, receiving 0.5 mg of riboflavin daily for five years, showed no signs of riboflavin

deficiency and excreted between 50 and 120  $\mu\text{g}$  of riboflavine daily. A similar result was obtained by Keys *et al.*,<sup>15</sup> who maintained a number of young men on a diet containing 0.31 mg of riboflavine per 1000 cal, that is, between 0.78 and 0.93 mg per day. They reported that 12 % of the intake, that is 94 to 112  $\mu\text{g}$ , was excreted daily, and that approximately the same proportion of a 1-mg test dose was recovered.

Subjects maintained on a synthetic diet and a natural diet which supplied 1.09 and 1.33 mg respectively of riboflavine daily excreted 152 to 165 and 174 to 229  $\mu\text{g}$  per day respectively. The one hour, fasting urinary excretion ranged from 3.7 to 10.9  $\mu\text{g}$ .<sup>21</sup> A number of women who received a daily intake of 0.79, 1.04, 1.26, 1.62, 2.23 and 2.72 mg of riboflavine excreted 70, 160, 130, 320, 1180 and 1310  $\mu\text{g}$  daily. Following a 3 mg test dose, 22, 30, 27, 31, 55 and 56 % respectively was excreted in the following twenty four hours.<sup>11</sup> The response to a test dose like the daily riboflavine excretion, varied inversely with the nitrogen balance.<sup>12</sup>

From the above evidence, therefore it would appear that an adequate intake of riboflavine results in the excretion in the urine of not less than about 200  $\mu\text{g}$  per day and in the elimination of not less than 20 % of a test dose within twenty four hours.

An observation which does not appear to have been adequately explained was made by B. Sure and Z. W. Ford,<sup>22</sup> who found that when rats maintained on a synthetic diet supplemented by five pure vitamins, were given subcutaneous injections of thyroxine (0.5 to 1 mg daily) the rate of excretion of riboflavine, though not of aneurine, was greatly increased. At the same time a large loss of bodyweight was produced and a large loss of riboflavine from many of the organs.

### Faecal Excretion

The faecal excretion of riboflavine varied considerably in different individuals but was less dependent than the urinary excretion on changes in the riboflavine content of the diet, being in fact remarkably constant in any one individual<sup>10</sup> (see page 185). Unlike the urinary excretion the faecal excretion bore no relationship to the nitrogen balance.<sup>12</sup>

### Riboflavine in other Body Fluids and Tissues

The hourly excretion of riboflavine in the sweat was 10  $\mu\text{g}$  and this value was not increased on administration of riboflavine.<sup>23</sup>

Injection of riboflavine into the blood stream caused an immediate increase in the concentration in the liver<sup>24</sup> and this was also increased

during digestion and assimilation even after a prolonged deficiency of riboflavin. This mobilisation was prevented by a deficiency of aneurine or pantothenic acid. The amount of riboflavin stored in the liver also increased when the amount of protein (casein) in the diet was increased—about one third of the increase could be accounted for by ingestion of increased amounts of methionine and none by ingestion of cystine.<sup>25</sup> In confirmation of this result A. V. Trufanov<sup>13</sup> found that although the free riboflavin in the livers of rats remained unchanged in protein deficiency the bound riboflavin fell at the same time the urinary excretion increased. Liver and muscle tissue from protein-deficient rats was incapable of synthesising flavine adenine dinucleotide.

The changes that took place in the riboflavin content of different tissues with increasing age were studied by Murray *et al*.<sup>26</sup> In thirty day old rats the muscle riboflavin was fairly constant at 4.13 to 4.28  $\mu\text{g}$  per g but at sixty days lower values were obtained and at 360 to 500 days still lower values. Values for liver were more variable and at thirty days were about six and at sixty days about nine times as high as in muscle. Blood values were still more variable ranging from 0.1 to 0.2  $\mu\text{g}$  per g.

Intravenously administered riboflavin was rapidly excreted into the small intestine of bilaterally nephrectomised rats.<sup>27</sup> excretion through the bile was relatively unimportant. Riboflavin was rapidly destroyed in the isolated large intestine but only slowly in the isolated loop of the duodenum. Intravenously injected riboflavin was not destroyed or eliminated by rats without an intestinal canal and both kidneys. Appreciable destruction occurred on incubation with liver, lung, heart, stomach and intestinal preparations.<sup>28</sup>

### Riboflavin in Pregnancy and Lactation

Pregnant women excreted less riboflavin in the urine than did non pregnant women<sup>29</sup> even when large doses (5 mg) were injected intravenously. After parturition the excretion remained at a low level but increased sometimes to the normal level on administration of a 5 mg dose. The riboflavin content of the placenta was not increased by the intravenous injection of 5 to 25 mg of riboflavin a few days or hours before parturition.

The human placenta contained 1.68 to 3.14  $\mu\text{g}$  of riboflavin per 100 g and of this 40 to 55 % was present in the free state.<sup>30</sup> The arterial and venous blood of the mother and the umbilical cord blood contained about 60  $\mu\text{g}$  per 100 ml the value being increased to 150  $\mu\text{g}$  per 100 ml two to three minutes after the intravenous injection into the mother of 30 to 50 mg of the vitamin. The value fell to

## RIBOFLAVINE

normal in twenty to sixty minutes. The injection increased the riboflavine content of the infant's urine but did not increase that of the placenta.

The concentration of riboflavine in human milk averaged  $17.3 \mu\text{g}$  per 100 ml <sup>29</sup> equivalent to  $68.8 \mu\text{g}$  per day and in the early stages of lactation was not affected by administration of riboflavine. During the later stages however the amount secreted in the milk could be substantially increased in this way. More recently an average value of  $60 \mu\text{g}$  per 100 ml has been reported <sup>30a</sup>.

According to Roderick *et al.* <sup>31</sup> the riboflavine content of human milk increased in the first ten days after parturition from 0.01 to 0.45 mg per day when the daily intake was 3.1 mg. The output in the milk at this stage accounted for 3 to 32 % of the intake and the urinary excretion for 12 to 82 %. The output in the mature milk amounted to 3 to 15 % of the intake and the corresponding urinary excretion to 26 to 61 %. The free riboflavine in the milk varied from 43 to 86 % of the total.

In France the average riboflavine content of breast milk was found to be  $32.4 \mu\text{g}$  per 100 ml in summer 1940 and  $27.5 \mu\text{g}$  per 100 ml in the winter. In 1942 the corresponding values were 23.3 and 20.1  $\mu\text{g}$  per 100 ml corresponding to a decrease in the riboflavine intake <sup>3</sup>.

### References to Section II

- 1 F M Strong R E Feeney B Moore and H T Parsons *J Biol Chem* 1941 **137**, 363
- 2 P B Pearson M K Sheyban and H Schmidt *Arch Biochem* 1944 **3**, 467
- 3 H F Fraser N H Topping and H Isbell *U S Publ Health Rep* 1940 **55**, 280
- 4 J W Ferrebee *J Clin Invest* 1940 **19**, 251
- 5 H Isbell J G Wooley and H F Fraser *U S Publ Health Rep* 1941 **56**, 282
- 6 L Laszt and L D Torre *Z Vitaminforsch* 1943 **13**, 77
- 7 M Swaminathan *Indian J Med Res* 1942 **30**, 37
- 8 P B Pearson and B S Schweigert *J Nutrition* 1947 **34** 443
- 9 W H Sebrell R E Butler J G Wooley and H Isbell *U S Publ Health Rep* 1941 **56**, 510
- 10 M V Davis H G Oldham and L J Roberts *J Nutrition* 1946 **32**, 143
- 11 W Brewer T Porter B Ingalls and M A Ohlson *ibid* 583
- 11a S E Snyderman K C Ketron H B Burch O H Lowry O A Bessey L P Guy and L E Holt *ibid* 1949 **39** 219
- 11b J N Harris and F I Scoular *ibid* 1949 **38** 435
- 12 H Oldham E Lounds and T Porter *ibid* 1947 **34**, 69
- 13 A V Trufanov *Biochimica* 1946 **11**, 33

# INTESTINAL SYNTHESIS

- 14 V A Najjar and L E Holt *Johns Hopkins Hosp Bull* 1941 69, 479
- 15 A Keys A F Henschel O Mickelsen J Brozek and J H Crawford *J Nutrition* 1944 27, 165
- 16 R D Williams H L Mason P L Cusick and R M Wilder *ibid* 1943 25, 361
- 17 A E Axelrod T D Spies C A Elvehjem and V Axelrod *J Clin Invest* 1941 20 229
- 18 V H Feder G T Lewis and H S Alden *J Nutrition* 1944 27, 347
- 19 H Oldham F Johnston S C Kleiger and H H Arismendi *ibid* 435
- 20 D R Hagedorn, E D Kyhos O A Germek and E L Sevringhaus *ibid* 1945 29, 179
- 21 M L Hathaway and D E Lobb *ibid* 1946 32, 9
- 22 B Sure and Z W Ford *Endocrin* 1943 32, 433
- 23 D M Tennant and R H Silber *J Biol Chem* 1943 148, 359
- 24 G C Supplee O G Jensen R C Bender and O J Kahlenberg *ibid* 1942 144, 79
- 25 W H Riesen B S Schweigert and C A Elvehjem *Arch Biochem* 1946 10, 387
- 26 A Z Murray L M Greenstein and H C Sherman *J Biol Chem* 1946 165, 91
- 27 H Selye *J Nutrition* 1943 25, 137
- 28 B Sure and Z W Ford *ibid* 1943 28, 659
- 29 V Dubrausky and S Blazso *Z Vitaminforsch* 1943 14, 2 13
- 30 W Neuweiler and Esterman *ibid* 1946 18, 74
- 30a J Sos *Z Vit Horm Ferment* 1947 1 369
- 31 C E Roderuck, M N Coryell H H Williams and I G Macy *Amer J Dis Child* 1945 70, 171
- 32 L Randon and A Raffly *Bull acad méd* 1943 127, 12
- Compt rend Soc Biol* 1942 138, 743

## 12 INTESTINAL SYNTHESIS OF RIBOFLAVINE

Normal rats were reported<sup>1</sup> to excrete 55.6  $\mu$ g of riboflavin daily in the faeces compared with 24.6  $\mu$ g in the urine. Adrenalectomised rats excreted somewhat more by both routes. However it is generally agreed that the values obtained for faecal riboflavin excretion cannot be used to assess nutritional status as they are determined solely by the extent of intestinal synthesis and not by the dietary intake. Thus the amount of riboflavin excreted in the faeces was approximately the same with an intake of 0.10 and 40  $\mu$ g per day.<sup>2,3</sup> The nature of the diet affected the amount of riboflavin synthesised in the gut and rats excreted larger amounts in the faeces on diets rich in dextrin or maize starch than on diets containing sucrose.

cellulose, lactose or lard<sup>4</sup> Riboflavine-deficient rats survived for a shorter time when fed on a high fat diet than on a high carbohydrate diet, and they developed a severe spastic paralysis of the hind quarters not observed in rats fed the high carbohydrate diet. Intestinal synthesis was also stimulated by feeding dried liver or a vitamin concentrate prepared from liver,<sup>5</sup> and animals given this supplement excreted more riboflavine both in the urine and in the faeces. Similarly, rats fed on fresh or dried milk excreted more riboflavine in the urine and faeces than did rats fed the same amount of riboflavine in the pure state. The larger faecal excretions were considerably reduced when succinyl sulphathiazole was added to the diet.<sup>6</sup> On the other hand, the riboflavine content of liver and muscle tissue was not affected when sulphonamide was added to the diet,<sup>7</sup> suggesting that the riboflavine reserves were not dependent to any appreciable extent on the vitamin produced by intestinal synthesis.

There is some evidence, however, that part of the riboflavine originating in this way may be utilised by animals, for caeectomised rats previously fed on sucrose showed an increased growth rate and increased riboflavine excretion when this was replaced by lactose, which favoured bacterial synthesis in the intestine.<sup>8</sup> The caecum in rats was presumably an important site of bacterial synthesis, since normal rats synthesised more riboflavine than caeectomised rats when lactose was the carbohydrate supplied, with sucrose, however, there was little difference between normal and caeectomised rats.

The phenomenon of refection has already been discussed (see page 75). Refected rats were found to be particularly useful for testing the effect of sulphonamides on the intestinal flora of rats. Addition of several sulphonamides to such animals reduced the amount of riboflavine excreted, this was restored to normal by administration of *p* aminobenzoic acid.<sup>9</sup>

The first report of intestinal synthesis in humans was made by Najjar *et al*<sup>10</sup> Twelve young men were maintained on a diet that provided 60 to 90  $\mu\text{g}$  of riboflavine per day. They remained perfectly healthy, without any signs of ariboflavinosis throughout the twelve-week period of the experiment. After a preliminary fall, the urinary excretion remained constant at 150 to 250  $\mu\text{g}$  per day, that is, at about twice the intake, whilst the faecal excretion amounted to 200 to 600  $\mu\text{g}$  per day, that is, up to six times the dietary intake. The ability of the large intestine to absorb riboflavine was demonstrated by giving a retention enema. An attempt to inhibit bacterial synthesis of riboflavine by administration of succinyl sulphathiazole for four weeks was, rather surprisingly, unsuccessful. Partial confirmation of these results was obtained by M. L. Hathaway and D. E. Lobb.<sup>11</sup>

who found that the faecal excretion of riboflavine was 3.7 to 3.8 times as great on a natural as on a synthetic diet, and actually exceeded the dietary intake in many instances.

Slightly different results were obtained by Denko *et al.*<sup>12</sup> to whose work reference has already been made (see page 77). They found that the combined faecal and urinary excretion of riboflavine by seven healthy young men on a normal diet was just about equal to the dietary intake of riboflavine, the amount excreted in the faeces (1.03 mg per day) was nearly twice that excreted in the urine (0.68 mg per day). Moreover, the faecal excretion remained the same on a vitamin-deficient diet and was unaffected by vitamin supplementation whereas the urinary excretion of riboflavine dropped markedly on a restricted diet, but returned to its original value on supplementation.<sup>13</sup> Similar results were obtained with infants.<sup>14</sup> Obviously these experimental subjects behaved in a different manner from those of Najjar *et al.*, who appear to have obtained somewhat unusual conditions. What the conditions are that will induce bacterial synthesis of riboflavine in man and so prevent the appearance of deficiency symptoms are not yet known but it is obviously of great scientific interest to determine them. The application of such knowledge to nutrition is also of considerable practical importance since it provides a possible alternative to treatment of riboflavine deficiency by administration of pure riboflavine or of concentrates.

Riboflavine, like aneurine is synthesised<sup>14</sup> by the intestinal organisms *Bacillus proteus vulgaris*, *B. lactis aerogenes*, *B. mesentericus*, *B. vulgatus*, *B. faecalis alcaligenes* and *Escherichia coli*.

### Synthesis of Riboflavine in Ruminants

A general outline of the work leading to the recognition that "vitamin B" was synthesised by the bacterial flora of the rumen of cattle and other ruminants has already been given (see page 79). Evidence for the synthesis of riboflavine was presented by L. W. McElroy and H. Goss<sup>15</sup> who found that the rumen of sheep receiving a ration containing less than 0.3 µg of riboflavine per g contained 33 µg per g, whilst the rumen of cows fed a similar ration contained 25 µg of riboflavine per g. The milk from these cows, after removal of the cream, contained 20 µg of riboflavine per g. Whereas the dietary intake was 1.8 mg per day, the amount excreted in the milk alone was 16 to 18 mg per day. Thus bacterial synthesis may largely be responsible for one of the main sources—milk—of riboflavine in the human dietary. These results were confirmed by Hunt *et al.*,<sup>16</sup> who showed that bacterial synthesis in the rumen of cattle was enhanced when the diet contained a large proportion of carbohydrate. On a ration of maize



lucerne and a protein supplement, the amount of riboflavin in the rumen exceeded that in the diet but when the maize was omitted the rumen contained less than the diet

*References to Section 12*

- 1 L. Laszt and L. D. Torre *Z. Vitaminforsch.* 1943 **13**, 77
- 2 B. Sure and Z. W. Ford *J. Nutrition* 1943 **28**, 659
- 3 H. G. Obermeyer, E. Wurtz and G. A. Emerson *Proc. Soc. Exp. Biol. Med.* 1945 **59**, 300
- 4 G. J. Mannering, D. Orsim and C. A. Elvehjem *J. Nutrition* 1944 **28**, 141
- 5 B. Sure *ibid.* 1945 **29**, 283
- 6 B. Sure *Arch. Biochem.* 1947 **12**, 389
- 7 B. S. Schweigert, L. J. Tepley, I. T. Greenhut and C. A. Elvehjem *Amer. J. Physiol.* 1945 **144**, 74
- 8 B. S. Schweigert, J. M. McIntire, L. M. Henderson and C. A. Elvehjem *Arch. Biochem.* 1945 **6**, 403
- 9 M. E. Coates, R. M. Henry, P. M. Kon, S. K. Kon, E. H. Mawson, J. E. Stanier and S. Y. Thompson *Nature* 1946 **157**, 262
- 10 V. A. Najjar, G. A. Johns, G. C. Medary, G. Fleischmann and L. E. Holt *J. Amer. Med. Assoc.* 1944 **126**, 357
- 11 M. L. Hathaway and D. E. Lobb *J. Nutrition* 1946 **32**, 9
- 12 C. W. Denko, W. E. Grundy, J. W. Porter, G. H. Berryman, T. E. Friedemann and J. B. Youmans *Arch. Biochem.* 1946 **10**, 33
- 13 C. W. Denko, W. E. Grundy, N. C. Wheeler, C. R. Henderson, G. H. Berryman, T. E. Friedemann and J. B. Youmans *ibid.* 1946 **11**, 109
- 13a S. E. Snyderman, K. C. Ketron, H. B. Burch, O. H. Lowry, O. A. Bessey, L. P. Guy and L. E. Holt *J. Nutrition* 1949 **39**, 219
- 14 R. C. Thompson *Univ. Texas Publ.* 1942 No 4237 p. 87. P. R. Burkholder and I. McVeigh *Proc. Nat. Acad. Sci.* 1942 **28**, 285
- 15 L. W. McElroy and H. Goss *J. Nutrition* 1940 **20**, 527
- 16 C. H. Hunt, C. H. Kirk, E. W. Burroughs, R. M. Bethke, A. F. Schalk and P. Gerlaugh *ibid.* 1941 **21**, 85. C. H. Hunt, L. W. Burroughs, R. M. Bethke, A. F. Schalk and P. Gerlaugh *ibid.* 1943 **25**, 207

### 13 ANIMAL AND HUMAN REQUIREMENTS OF RIBOFLAVINE

Attempts to assess human and animal requirements of riboflavin are complicated by the phenomenon of intestinal synthesis and in ruminants synthesis in the rumen. Human requirements can be calculated with a fair degree of certainty however as intestinal synthesis does not appear to be a usual source of riboflavin in man

## Human Requirements

There is general agreement that the minimum intake requisite to maintain normal health lies between 0.5 and 3 mg per day, although admittedly this is a somewhat wide range. Sebrell *et al.*,<sup>1</sup> as a result of excretion studies, suggested that a minimum intake of 3 mg per day was necessary, whilst Williams *et al.*<sup>2</sup> maintained a subject for 288 days on a diet that provided 0.35 mg of riboflavin per 1000 cal, that is, about 1 mg per day, and found that, although the percentage excretion of a 2 g test dose fell progressively, no clinical symptoms developed. They suggested that the minimum daily requirement was 0.5 mg per 1000 cal or about 1.25 mg per day. Brewer *et al.*<sup>3</sup> calculated the requirement of women to be 1.3 to 1.5 mg per day, on a diet supplying 2100 to 2300 cal per day whilst Horwitt *et al.*,<sup>3a</sup> from excretion studies over a prolonged period, suggested that the daily requirement of an adult was between 1.1 and 1.6 mg.

Macrae *et al.*,<sup>4</sup> using biological and microbiological methods of assay, which incidentally gave results in excellent agreement with one another, estimated the riboflavin contents of meals served in Royal Air Force messes, and found that on the average these yielded 2 mg of riboflavin per day. As there were no signs of riboflavin deficiency on these diets, they concluded that an intake of 2 mg per day was in excess of the minimum requirement. Oldham *et al.*<sup>5</sup> and Hagedorn *et al.*<sup>6</sup> stipulated a substantially lower figure for the minimum daily intake. The former observed a steady excretion with an intake of 0.5 mg per day whilst the latter failed to find any physical signs of riboflavin deficiency in an adult male maintained for five years on a diet also supplying 0.5 mg daily. Perhaps these lower values should be accepted with reserve until more is known about the possibility of intestinal synthesis supplying appreciable amounts of riboflavin.

The minimum riboflavin requirement of infants is 0.4 mg per day, thus maintained the urinary excretion above a 'safe' level of 50 µg per day and the serum concentration above a minimum of 0.5 µg per 100 ml and prevented symptoms of riboflavin deficiency.<sup>6a</sup> The most satisfactory criterion of nutritional status with respect to riboflavin is said to be the amount in the red blood cells which should not be less than 2.5 µg per 100 cells.

There has been a recent tendency to reduce the official figures for the riboflavin requirements of man and, whereas the US National Research Council's estimate in 1941 was 3.3 mg per day for a very active man, 2.2 mg for a sedentary man, 2.7 mg for a very active woman, and 1.8 mg for a sedentary woman, in 1945 these values were reduced to 2.6, 1.6, 2.0 and 1.5 mg per day respectively. Rations

in Great Britain during the war of 1939-45 were based on 70 % of the 1941 estimates,<sup>7</sup> whereas the actual consumption of riboflavin was 1.6 mg per day during 1939 to 1941, followed by a steady rise during the next two or three years to a maximum of 2.0 mg in 1944, then by a slight fall in 1945 and another rise in 1946 to 2.0 mg per day.<sup>8</sup>

### Requirements of Rats

A diet containing 3  $\mu$ g of riboflavin per g of air-dried food was adequate to support normal activity in adult rats and enabled them to live for a normal life-span.<sup>9</sup> It was inadequate to produce the normal growth rate in young rats, however, and for this purpose the riboflavin content had to be increased to 10  $\mu$ g per g. G. J. Mannering and C. A. Elvehjem<sup>10</sup> found that the food requirement of rats varied with the riboflavin intake. As the latter increased, less and less food was required in order to produce the same increment of growth, whilst rats receiving adequate amounts of riboflavin were able to grow at the same rate as rats on a diet partially deficient in riboflavin when the food intake of the former group was much lower than that of the latter. This suggests that food was utilised more efficiently when adequate amounts of riboflavin were available. However, the riboflavin deficient rats fed on a more liberal diet were much more active than the rats with a limited food intake and receiving adequate riboflavin. Riboflavin deficiency in rats led to an increased deposition of body fat.<sup>11</sup>

Rats on high protein and high fat diets required at least twice as much riboflavin as did rats on a normal diet in order to maintain an equal level of riboflavin in the organs and urine.<sup>12</sup> On a low fat diet, the animals required only about half the normal amount of riboflavin, which was calculated to be about 7.5  $\mu$ g per day. It was assumed that the different amounts required were due to differences in the amounts of riboflavin synthesised in the intestine in a form available to the organism.

### Requirements of Other Species of Mammals

The amount of riboflavin required by mice varied according to the strain.<sup>13</sup> The C57 strain gave maximal growth with 0.4 mg per 100 g of bodyweight and the A strain with 0.6 mg per 100 g. At a level of 0.2 mg per 100 g the C57 mice had a reduced red blood cell count and a lower muscle and liver riboflavin, whereas the A strain suffered no change.

Dogs required 15 to 100  $\mu$ g of riboflavin per kg of bodyweight per day to maintain normal health,<sup>14</sup> young growing pigs 40 to 66  $\mu$ g

# ANIMAL AND HUMAN REQUIREMENTS

per kg of bodyweight per day<sup>15</sup> and a horse 44  $\mu\text{g}$  per kg of bodyweight per day<sup>16</sup>. In mild cases, the symptoms of riboflavin deficiency in rhesus monkeys were relieved by the administration of 50  $\mu\text{g}$  of riboflavin per day for two to three weeks, but severe cases required 100 to 500  $\mu\text{g}$  daily.<sup>17</sup> The minimum daily intake necessary to maintain normal health was estimated to be 25 to 30  $\mu\text{g}$  per kg of bodyweight. Thus, the requirements of all species of mammals for which data are available, including man, are of the same order when calculated per kg of bodyweight.


## Requirements of Birds and Fish

To prevent the development of curled toe paralysis in chickens the diet should contain 3.6  $\mu\text{g}$  of riboflavin per g.<sup>18</sup> Ducklings required a similar amount for proper development.<sup>19</sup> For satisfactory egg production, the diet of hens should contain at least 2  $\mu\text{g}$  of riboflavin per g. With a diet containing 2.7  $\mu\text{g}$  per g, hens kept in pens laid eggs containing 24% of the ingested riboflavin whilst hens kept in batteries and fed a diet containing 3.3  $\mu\text{g}$  per g laid eggs containing 30% of the ingested riboflavin.<sup>20</sup> Young rainbow trout required 5 to 15  $\mu\text{g}$  of riboflavin per g of diet.<sup>21</sup>

## References to Section 13

- 1 W H Sebrell R E Butler J G Wooley and H Isbell *US Publ Health Rep* 1941 56, 510
- 2 R D Williams H L Mason P L Cusick and R M Wilder *J Nutrition* 1943 25, 361
- 3 W Brewer T Porter B Ingalls and M A Ohlson *ibid* 1946 32, 583
- 3a M K Horwitt O W Hills C C Harvey E Liebert and D L Steinberg *ibid* 1949 38, 357
- 4 T F Macrae E C Barton Wright and A M Copping *Biochem J* 1944 38, 132
- 5 H Oldham F Johnston S C Kleiger and H H Ansmend *J Nutrition* 1944 27, 435
- 6 D R Hagedorn E D Kyhos O A Germek and E L Sevringhaus *ibid* 1945 29, 179
- 6a S E Snyderman K C Ketron H B Burch O H Lowry O A Bessey L P Guy and L E Holt *ibid* 1949 39, 219
- 7 J C Drummond *Nutritional Requirements of Man in the Light of Wartime Experience* Royal Institute of Chemistry 1948
- 8 *Food Consumption Levels in the United Kingdom* HMSO 1947
- 9 L A Ellis A Zmachynsky and H C Sherman *J Nutrition* 1943 25, 153
- 10 G J Mannering and C A Elvehjem *ibid* 1944 28, 157
- 11 Le R Vons and H P Moore *ibid* 1943 25, 7

# RIBOFLAVINE




since flavines substituted in the 3 position did not form enzyme systems<sup>12</sup> and were devoid of vitamin activity

According to L Laszt and F Verzar,<sup>13</sup> the formation of riboflavin phosphoric ester was promoted by the hormones of the adrenal cortex and was inhibited by iodoacetic acid. They suggested that this accounted for the toxicity of iodoacetic acid, and claimed that the symptoms could be cured by administration of riboflavin phosphoric ester. H Rudy,<sup>14</sup> however, found that riboflavin was just as effective as riboflavin phosphoric ester in restoring the growth of rats poisoned with iodoacetic acid whilst J W Ferrebée<sup>15</sup> found that riboflavin phosphorylated as efficiently in adrenalectomised rats as in normal rats.

The second coenzyme, riboflavin adenine dinucleotide, is present in the enzymes known collectively as diaphorases. These are widely distributed in animal tissues and micro organisms and also occur in plants. The dinucleotide has been isolated from liver, kidney, heart muscle tissue, Jensen rat sarcoma and yeast.<sup>16</sup> To accomplish the apoenzyme was denatured by heat, the mixture was extracted with phenol and the dinucleotide was recovered from the phenol extract by addition of water and ether, and then precipitated from the aqueous solution as the silver salt. This was converted to barium salt which was recrystallised from water. The dinucleotide was split by hydrolysis with enzyme<sup>17</sup> or acid<sup>18</sup> into riboflavin phosphoric acid and adenosine-5' monophosphoric acid (adenylic acid) but how the two moieties are linked together has not been definitely established, nor is it known how they are linked to the apoenzyme.

A possible structure for the nucleotide is the following



When rats were maintained on a riboflavine-deficient diet, the heart and liver were found to contain less flavine adenine dinucleotide than the corresponding organs from normal rats<sup>19</sup> The dinucleotide was synthesised from riboflavine *in vitro* by human red blood cells when incubated at 30 to 34° C with a solution of riboflavine, or *in vivo* by red blood cells on ingestion of a suspension of riboflavine<sup>20</sup>

Riboflavine monophosphate and riboflavine adenine dinucleotide account for practically all the riboflavine present in rat kidney, and the dinucleotide accounts for 70 to 90 % of the total riboflavine in all tissues<sup>20a</sup>

### Flavine Mononucleotide : Cytochrome *c* Reductase

The first flavine enzyme to be recognised was the enzyme system that oxidised hexose-monophosphoric acid to phosphohexonic acid It was first isolated by O Warburg and W Christian<sup>21</sup> and is now known as "old" yellow enzyme They postulated that the oxidation was effected by the following chain-reaction

- (1) Hexose-monophosphate + triphosphopyridine nucleotide-protein  $\rightarrow$  dihydro-triphosphopyridine nucleotide protein + phosphohexonic acid,
- (2) Dihydro triphosphopyridine nucleotide-protein + flavoprotein  $\rightarrow$  triphosphopyridine nucleotide-protein + dihydro-flavoprotein,
- (3) Dihydro flavoprotein +  $O_2 \rightarrow$  flavoprotein +  $H_2O_2$

H Theorell<sup>22</sup> pointed out, however that the rate of oxidation of this dihydro flavoprotein at the oxygen tension of the organism was too small for dehydrogenation to occur by this route, and he suggested that cytochrome *c* was responsible for the reoxidation, though the rate of reaction of the "old" yellow enzyme with cytochrome *c* was also too small to account adequately for the facts Support was given to the suggestion, however, by the observation of E S G Barron<sup>23</sup> that the oxidation of hexose monophosphate by certain bacteria was completely inhibited by hydrogen cyanide, which is known to inhibit the action of cytochrome *c* Final proof of Theorell's hypothesis was afforded by Haas *et al*,<sup>24</sup> who isolated from yeast a new flavoprotein which reacted very rapidly with both oxidised cytochrome *c* and reduced triphosphopyridine nucleotide The prosthetic group of the new enzyme, which they called cytochrome *c* reductase, was shown to be alloxazine mononucleotide

The new enzyme, unlike the "old" yellow enzyme, reacted specifically with cytochrome *c*, but the prosthetic groups of cytochrome *c* reductase, the "old" yellow enzyme and amino acid oxidase proved

to be interchangeable<sup>25</sup> The enzyme was shown to be very unstable, thus accounting for its failure to escape detection It would appear that the "old" yellow enzyme was an artefact resulting from degradation of the true enzyme during the isolation procedure

Cytochrome *c* reductase had a molecular weight of 75,000 The affinity of the flavine for the protein was much greater than that of flavine adenine dinucleotide for the protein of amino acid oxidase, the respective dissociation constants being  $1 \times 10^{-9}$  and  $250 \times 10^{-9}$  mole per litre, the two yellow enzymes had intermediate values

A still purer preparation of the enzyme was obtained by Haas *et al*<sup>26</sup>

### Flavine Adenine Dinucleotide : Diaphorases

Although flavine mononucleotide appears to be present in only one enzyme, riboflavine adenine-dinucleotide occurs in several The first of these, diaphorase I, was shown to be present in heart muscle, and to dehydrogenate dihydro-coenzyme I, the second, diaphorase II was present in yeast and adrenal gland, and it dehydrogenated dihydro-coenzyme II<sup>27</sup> Reduced diaphorase I was dehydrogenated by cytochrome *b*<sup>28</sup> and possibly by cytochrome *a* Haas' "new" yellow enzyme<sup>25</sup> may be identical with diaphorase I

### The Schardinger Enzyme

Another enzyme now known to belong to the group of flavine enzymes is the Schardinger enzyme<sup>29</sup> which catalyses the oxidation of aldehydes to carboxylic acids It occurs in raw milk and is heat-labile, failure to detect its presence in milk is taken to indicate that the milk has been heated The aldehyde oxidase from milk also acts as a xanthine oxidase and as an oxidase of dihydro-coenzyme I Liver also contains an aldehyde oxidase,<sup>30</sup> which appears to be distinct from liver xanthine oxidase

### Xanthine Oxidase

Xanthine oxidase is the name given to the enzyme that dehydrogenates xanthine and hypoxanthine to uric acid<sup>31, 32</sup> The conversion of both hypoxanthine and xanthine to uric acid is effected by means of the same enzyme It can also bring about the dismutation of xanthine, giving hypoxanthine and uric acid<sup>33</sup> Xanthine oxidase occurs in milk and in liver, and appears to contain besides riboflavine, a red pigment of unknown constitution Green *et al*<sup>34</sup> isolated another brownish-red enzyme from top yeast, but, although it contained

flavine adenine dinucleotide it was inactive towards all the substrates tried it contained 0.86 % of flavine phosphate

A. E. Axelrod and C. A. Elvehjem<sup>35</sup> found that the xanthine oxidase content of rat liver was markedly reduced in rats fed a riboflavin deficient diet addition of the prosthetic group to the liver homogenate failed to increase the activity so that the reduction in activity would appear to be due to a deficiency of the protein part of the enzyme Addition of riboflavin to the diet however resulted in rapid restoration of the liver xanthine oxidase to normal

### D-Amino Acid Oxidase

The oxidation of amino acids to keto acids *via* imino acids is also brought about by an enzyme containing riboflavin adenine dinucleotide<sup>36-39</sup> and Axelrod *et al*<sup>40</sup> showed that a deficiency of riboflavin in the diet of rats reduced the D amino acid oxidase content of liver and kidney administration of riboflavin restored the enzyme activity to normal

This observation presumably explains why rats on a diet providing less than 2.5  $\mu$ g of riboflavin per day did not utilise protein as efficiently as rats fed 5  $\mu$ g or more per day<sup>40a</sup>

Krahl *et al*<sup>41</sup> claimed that the oxidation of  $\alpha$  alanine by D amino acid oxidase was inhibited by certain phenols containing nitro or halogen groups *e.g.* dinitrophenol at relatively high concentrations but Haas *et al*<sup>26</sup> showed that the pyridine-catalysed dehydrogenation of hexose-6 phosphate was even more strongly inhibited than the flavine enzyme

Hoagland *et al*<sup>42</sup> obtained a flavine containing compound from the elementary bodies of vaccinia 100 g of virus containing 1.1 to 1.5 mg of riboflavin The substance functioned as a coenzyme for D amino acid oxidase and was probably a flavine adenine dinucleotide

The specificity of D amino acid oxidase has been the subject of controversy but most workers agree that D glutamic acid and D lysine are not attacked by the isolated enzyme system Handler *et al*<sup>43</sup> found that the N methyl derivatives of DL methionine DL alanine and DL leucine were oxidised by D amino acid oxidase preparations J. R. Klein and H. Kamin<sup>44</sup> found that the enzyme was inhibited by benzoic acid

The D amino acid oxidase of *Neurospora*<sup>45</sup> deaminated some nineteen D amino acids with optimal activity at pH 8.0 to 8.5 Unlike the enzyme from animal tissues it is not inhibited by benzoic acid

A. Neuberger and F. Sanger<sup>46</sup> found that although D lysine was not deaminated by the enzyme  $\epsilon$  acetyl and  $\epsilon$  benzoyl lysine were oxidised at a moderate rate  $\epsilon$  methyl lysine however was not



attacked. They suggested that the free basic group in the  $\epsilon$  position might inhibit the enzyme by repelling another basic group in the oxidising enzyme.

The activity of D amino acid oxidase was inhibited by mepacrine.<sup>47</sup> The oxidation of glucose, lactate, pyruvate, malate and citrate by rat tissues was also inhibited by the drug, whilst E. Haas<sup>48</sup> found that it also inhibited cytochrome reductase, glucose 6 phosphate dehydrogenase and, to a slight extent, cytochrome oxidase. The addition of 1  $\mu$ g of riboflavine phosphate counteracted the inhibition of cytochrome reductase by 500  $\mu$ g of mepacrine.

### L-Amino Acid Oxidase.

An enzyme that oxidised L-amino acids was isolated from rat kidney and shown to be a flavoprotein.<sup>49</sup>

### Glycine Oxidase

Glycine oxidase is another flavoprotein, its existence was first recognised by Ratner *et al*.<sup>50</sup> It occurs in liver and kidney, and catalyses the oxidation of glycine to glyoxylic acid and ammonia, and of sarcosine to glyoxylic acid and methylamine. As isolated from lamb, cat and human kidneys, glycine oxidase showed no tendency to dissociate except in acid solution, but the enzyme from pig kidney was very unstable, and this was shown to be due to a factor in pig kidney possibly enzymic in nature. Exactly the same behaviour was observed with D amino acid oxidase from pig kidney and kidneys from other species. Unfortunately the early work on amino acid oxidase was done with preparations from pig kidney and the report that it was completely dissociated at neutral pH values must therefore, be accepted with reserve.

### Diamino Oxidase

D<sub>1</sub> and poly amines, such as histamine, cadaverine and spermine are converted into amino aldehydes by an enzyme similar to, but apparently not identical with amino acid oxidase.<sup>51</sup> The enzyme was purified by M. Laskowski.<sup>52</sup> Histaminase contains flavine adenine dinucleotide.<sup>53a</sup>

### Quinine Oxidase

Riboflavine was also present in an enzyme from rabbit liver that oxidised quinine and other quinoline derivatives to their carbostyryls. Isoquinolines, some pyridine derivatives and N<sup>1</sup> methyl nicotinamide were also oxidised.<sup>53</sup>

## Notatin

## FUNCTION

The oxidation of glucose to gluconic acid by micro-organisms is effected by another flavine enzyme<sup>54 55</sup> A preparation of this enzyme was isolated by Coulthard *et al*<sup>56</sup> from the metabolism solution of *Penicillium notatum* and was given the name notatin Other workers<sup>57 59</sup> isolated it from similar sources and called it penatin Notatin proved to be inhibitory in extremely high dilution to many bacteria in presence of glucose On investigation it was shown to effect the oxidation of glucose to gluconic acid with the production of hydrogen peroxide The hydrogen peroxide was responsible for the antibacterial activity The reduced form of the enzyme was oxidised by molecular oxygen That the antibacterial action was in fact due to the formation of hydrogen peroxide was confirmed by the demonstration that other flavoproteins were equally effective F Lipmann and C R Owen<sup>60</sup> and D E Green and R Pauli<sup>61</sup> showed that milk xanthine oxidase had similar properties but other flavoproteins were more difficult to test as it was impossible to free them from catalase that destroyed the hydrogen peroxide as it was formed

## Fumaric Hydrogenase

Fumaric acid is reduced to succinic acid by an enzyme system which contains riboflavine adenine dinucleotide<sup>62</sup> This enzyme was also shown to reduce maleic acid crotyl alcohol phenyl crotyl alcohol and geraniol but the rate of reduction of these compounds was only a fraction of the rate at which fumaric acid was reduced The identity of fumaric hydrogenase with eight other flavoproteins was excluded by subsequent work carried out by Fischer *et al*<sup>63</sup> but it may be identical with the xanthine oxidase like enzyme isolated by Green *et al*<sup>64</sup>

## Lactic and Pyruvic Acid Oxidases

Two other enzymes containing flavine adenine-dinucleotide are pyruvic acid oxidase<sup>64</sup> and an enzyme isolated from *Mycobacterium phlei* that was specific for the oxidation of lactic acid to pyruvic acid under anaerobic and to acetic acid under aerobic conditions<sup>65</sup>

## Luciferin

F H Johnson and H Eyring<sup>66</sup> showed that the substrate luciferin of the luminescent system of *Cypridina* consists of a pyridine nucleotide and a flavoprotein

The former acted as reductant, whilst the latter comprised the component capable of being excited by oxidation. Some of these excited molecules emitted radiations without being destroyed whilst others were destroyed by the energy absorbed. It is this latter phenomenon that is responsible for the degradation of riboflavine on exposure to light. The authors conclude "Thus, in luminous bacteria, light emission presumably occurs when flavoprotein, reduced by hydrogen from suitable substrates (*e.g.* glucose) *via* the dehydrogenase-coenzyme system, is oxidised directly by oxygen."

### **Oxidation of Flavoproteins**

The flavoprotein dinucleotides can be oxidised by molecular oxygen, but in the organism they are, like the mononucleotide, oxidised by cytochrome *c* and this explains why the oxidation of D amino acids and of pyruvic acid by bacteria possessing cytochromes is completely inhibited by hydrogen cyanide<sup>67, 68</sup>. When cytochrome is absent, as in some bacteria and protozoa, oxidation may be effected by molecular oxygen. The effect of cyanide on oxygen consumption and luminescence, respectively, indicates that most of the hydrogen proceeds stepwise, by electron transfer through the cytochrome haeme system, to oxygen. If chlorophyll were substituted for the related haeme molecule, the same system of catalysts operating in the reverse direction would lead to photosynthesis. In luminescence two hydrogen atoms were oxidised for each quantum emitted whilst in photosynthesis single hydrogen atoms were made available.

and, as already stated, it readily undergoes re-oxidation on shaking with air.

According to R. Kuhn and R. Strobele<sup>69</sup> the mechanism of the reduction is not just simple addition of hydrogen across the centre ring, but proceeds *via* three intermediate compounds, the bronze-green verdoflavine, the grass green chloroflavine and the carmine red rhodoflavine. These changes are represented by the formulæ on the opposite page (where R = ribityl).


### **Other Functions of Riboflavine : Riboflavine in the Eye**

The occurrence of flavines in the retinae of fishes has long been known and the possible importance of riboflavine for vision in dim light was confirmed by observations made by P. Karrer and H. Fritzsche<sup>70</sup> on the fluorescence curves of riboflavine and its


analogues. They found that maximum fluorescence occurred at a concentration similar to that in which the flavines occur in the eyes

# FUNCTION


Oxygen  
consumption




0




0.25



0.50



0.75



1.00

of fishes. This observation seems of particular significance in view of the clinical data (see page 174) associating the presence of opaque cornea and impaired vision in dim light with ariboflavino-1. It was

suggested that photolysis of riboflavin with precipitation of the sparingly soluble lumiflavin may be a factor in the mechanism

Riboflavin has also been shown to be present in the retinal pigment of the human eye, where it appears to play a rôle in light adaptation similar to that of rhodopsin in dark adaptation<sup>71</sup> Apparently, it has the property of transforming rays of short wave-length into yellowish green fluorescent light, for which the sensitivity of the eye is maximal It also protects the cones of the retina against excessive light Riboflavin is not re-synthesised in the absence of oxygen, and the ocular manifestations of ariboflavinosis are due to the inability of the body to make good the losses of riboflavin that occur on exposing the eye to light.

### Riboflavin and Liver Damage

Normally, when liver slices were incubated with a natural or synthetic oestrogen, the activity of the latter was destroyed The livers of rats reared on a vitamin B-deficient diet, however, were unable to effect this inactivation, but recovered the power of inactivating oestrone and oestradiol when aneurine or riboflavin was added to the diet,<sup>72</sup> pyridoxine, pantothenic acid, biotin and choline were ineffective in this respect Even aneurine and riboflavin, however, did not restore the ability of the liver to inactivate stilboestrol No explanation has been put forward to account for these observations, although, from the fact that administration of methionine also restored the oestrogen inactivating properties of the liver, it may be concluded that a deficiency of riboflavin and aneurine leads to a failure of liver function

An observation, perhaps connected with the foregoing was made by W Antopol and K Unna,<sup>73</sup> who showed that administration of large amounts, e.g. 10 mg three times per week, of riboflavin retarded the onset of pathological changes in the liver of rats promoted by the feeding of *p* dimethylaminoazobenzene, nicotinic acid had no effect

### References to Section 15

- 1 O Warburg and W Christian, *Biochem Z*, 1931, **242**, 206, 1932, **254**, 438, 1933 **257**, 492, 1933, **263**, 228, 1933 **266**, 377, *Naturwiss*, 1932, **20**, 688, 980
- 2 H Theorell *Biochem Z*, 1934, **275**, 37, 344, 1935 **278**, 263
- 3 F Weygand and H Stocher, *Z physiol Chem*, 1937, **247**, 167
- 4 F Weygand and L Birkofer, *ibid*, 1939 **261**, 172
- 5 H Theorell *Biochem Z*, 1935 **278**, 279
- 6 R A Kekwick and K O Pederson *Biochem J*, 1936, **30**, 2201

# FUNCTION

- 7 R Kuhn and H Rudy *Z physiol Chem* 1936 230, 47 Ber 1936 69, 1974 2034
- 8 I Banga A Szent Györgyi and L Vargha *Biochem Z* 1932 210, 228 248, 203 *Z physiol Chem* 1935 23, 286
- 9 H Rudy *Naturwiss* 1935 23, 286
- 10 R Kuhn and H Rudy *ibid* 1074
- 11 R Kuhn and H Rudy *ibid* 2557
- 12 R Kuhn and F Verzáz *Arch ges Physiol* 1935 238 693
- 13 L Laszt and F Verzáz *Arch ges Physiol* 1935 238 693
- 14 H Rudy *Z angew Chem* 1936 48, 323
- 15 J W Ferrebee *J Biol Chem* 1940 138, 719
- 16 P Harrer P Frei and H Meerwein *Helv Chim Acta* 1937 20, 79 P Harrer P Frei B H Ringier and H Bendas *ibid* 1938 21, 826 O Warburg W Christian and A. Gries *Biochem Z* 1938 295, 261 1938 207, 417 1938 298, 150
- 17 O Warburg and W Christian *ibid* 1938 298, 150
- 18 E P Abraham *Biochem J* 1939 33, 543
- 19 S Ochoa and R J Possiter *Nature* 1939 144, 787
- 20 J R Klein and H I Kohn *J Biol Chem* 1940 138, 177
- 20a O A Bessey O H Lowry and R H Love *ibid* 1949 180 755
- 21 O Warburg and W Christian *Biochem Z* 1932 254, 438 1933 266, 377
- 22 H Theorell *ibid* 1936 288 317 *Nature* 1936 138, 687
- 23 L S G Barron *Cold Spring Harbour Symposia Quant Biol* 1939 7, 154
- 24 E Haas B L Horecker and T R Hogness *J Biol Chem* 1940 138, 747
- 25 E Haas *Biochem Z* 1938 298, 378
- 26 E Haas C J Harrer and T R Hogness *J Biol Chem* 1942 143, 341
- 27 E Adler H von Euler G Günther and E D Plass, *Stand Arch Physiol* 1939 82, 61 E Adler H von Euler and G Günther *Nature* 1939 143, 641 E P Abraham and E Adler *Biochem J* 1940 34, 119
- 28 K Okunuki and E Yakusizi *Proc Imp Acad Tokyo* 1940 16, 144
- 29 F Schardinger *Z Untersuch Nahr Genussm* 1902 5, 1113
- 30 V Subrahmanyam D E Green and A H Gordon *Nature* 1939 144, 1016 A H Gordon D E Green and V Subrahmanyam *Biochem J* 1940 34, 764
- 31 E G Ball *Science* 1938 88 131 *Angew Chem* 1938 51, 738
- 32 J Biol Chem 1939 128, 51
- 33 H S Corran and D E Green *Biochem J* 1938 32, 2231 D E Green and H S Corran *Angew Chem* 1938 51, 738 H S Corran J G Dewan A H Gordon and D E Green *Biochem J* 1939 34 1694
- 34 D E Green *ibid* 1934 28, 1550
- 34 D F Green W C Knox and P K Stumpf *J Biol Chem* 1941 138 775

- 35 A E Axelrod and C A Elvehjem, *J Biol Chem*, 1941, 140, 725
- 36 O Warburg and W. Christian, *Biochem Z*, 1938, 295, 261, 1938 298, 150
- 37 E Negelein and H Bromel, *ibid*, 1939, 300, 225
- 38 F B Straub, *Nature*, 1938, 141, 603
- 39 H A Krebs *Z physiol Chem*, 1933 217, 191, 1933, 218, 157, *Biochem J*, 1935, 29, 1620
- 40 A E Axelrod, H A Sober and C A Elvehjem, *Nature*, 1939 144, 670
- 40a H L Mayfield and M T Hedrick, *J. Nutrition* 1949 37, 475
- 41 M E Krah1, A K Keltch and G H A Clowes, *J Biol Chem*, 1940, 136, 563
- 42 C L Hoagland, S M Ward, J E Smadel and T M Rivers *J Exp Med*, 1941, 74, 133
- 43 P Handler, F Bernheim and J R Klein, *J Biol Chem* 1941, 138, 203
- 44 J R Klein and H Kamin, *ibid*, 507
- 45 N H Horowitz, *ibid*, 1944 154, 141
- 46 A Neuberger and F Sanger, *Biochem J*, 1944, 38, 119
- 47 C L Wright and S C Sabine, *J Biol Chem*, 1944 155, 315
- 48 E. Haas, *ibid*, 321
- 49 M Blanchard, D E Green, V Nocito and S Ratner, *ibid*, 1945 161, 583
- 50 S Ratner, V Nocito and D E Green, *ibid*, 1944, 152, 49
51. E A Zeller, R Stern and N Wenk *Helv Chim Acta* 1940 23, 1
- 52 M Laskowski, *J Biol Chem*, 1942, 145, 457
- 52a R Kapeller-Adler, *Biochem J*, 1949 44, 70
- 53 W E Knox, *J Biol Chem*, 1946 163, 699
- 54 W Franke and M Deffner, *Annalen* 1937, 532, 1, 1939 541, 117
- 55 D Mueller, *Biochem Z*, 1928, 109, 136, 1929, 205, 111, 1929 213, 211 1931, 232, 423
- 56 C E Coulthard, R Michaelis, W F Short, G Sykes G E H Skrimshire, A F B Standfast, J H Birkinshaw and H Raistrick, *Nature*, 1942, 150, 634, *Biochem J*, 1945 39, 24
- 57 J R Van Bruggen F J Reithel C K Cam, P A Katzman E A Doisy R D Muir, E C Roberts, W L Gaby D M Homan and L R Jones, *J Biol Chem*, 1943 148 365
- 58 W Kocholaty *Arch Biochem* 1943, 2, 73
- 59 O Schales, *ibid* 487
- 60 F Lipmann and C R Owen, *Science*, 1943, 98, 246.
- 61 D E Green and R Pauli, *Proc Soc Exp Biol Med* 1943, 54, 148
- 62 F G Fischer, A Roedig and K Rauch *Naturwiss*, 1939 27, 197. F G Fischer and H Eysenbach, *Annalen* 1937, 529, 87, 1937. 530, 99
- 63 F G Fischer, A Roedig and K Rauch *ibid*, 1942 552, 203
- 64 F Lipmann, *Nature*, 1939, 143, 436

- 65 N L Edson, *Biochem J*, 1947 **41**, 145
- 66 F. H Johnson and H. Eyring, *J. Amer. Chem Soc*, 1944, **66**, 848
67. E. S. G. Barron and T. E. Friedemann, *J. Biol Chem*, 1941, **137**, 593.
- 68 F. Bernheim, M. L. C Bernheim and M. D. Webster, *ibid*, 1935, **110**, 165.
- 69 R Kuhn and R. Ströbele, *Ber*, 1937, **70**, 753.
- 70 P. Karrer and H. Fritzsche, *Helv. Chim Acta*, 1935, **18**, 911.
- 71 M. Heiman, *Arch. Ophthal*, 1942, **28**, 493
72. A. Segaloff and A. Segaloff, *Endocrin*, 1944, **34**, 346; K. Unna, H. O. Singher, C. J. Kensler, H. C. Taylor and C. P. Rhoads, *Proc. Soc. Exp. Biol Med*, 1944, **55**, 254; H. O. Singher, C. J. Kensler, H. C. Taylor, C. P. Rhoads and K. Unna, *J. Biol. Chem*, 1944, **154**, 79.
- 73 W. Antopol and K. Unna, *Cancer Res.*, 1942, **2**, 694.

## 16. RIBOFLAVINE IN THE NUTRITION OF MICRO-ORGANISMS

### Yeasts and Other Fungi

No yeast has been reported for which riboflavine is an essential growth factor<sup>1, 2, 3</sup> and, of seventeen moulds also examined, none required riboflavine. Riboflavine is not, in fact, a constituent of "bios" (see page 105)

Yeasts and moulds appear to be capable of synthesising riboflavine, some in astonishingly large amounts (see page 148)

### Bacteria

Bacteria vary greatly in their requirements for riboflavine. Some, such as *Bacillus proteus vulgaris*, *B. lactis aerogenes*, *B. mesentericus*, *B. vulgatus*, *B. faecalis alcaligenes* and *Escherichia coli*, are capable of synthesising it,<sup>4</sup> and the significance of this synthesis in the animal economy has already been discussed (see page 185). The tuberculosis bacterium does not require riboflavine<sup>4a</sup>. Some bacteria, on the other hand, are incapable of growth in the absence of riboflavine, but these are very few in number. *Lactobacillus helveticus* (*L. casei* c) is the best known of these and is the organism most commonly employed for the microbiological assay of riboflavine (see page 157), the closely related organism, *L. arabinosus*, does not require riboflavine. Other bacteria for which riboflavine is essential are *Streptococcus mastitidis*, *S. faecium*, *Bacterium bifidum*, and *Streptobacterium plantarum*,<sup>5</sup> *Bacillus Delbrückii*, *Streptobacterium casei*, *Leuconostoc Gayoni* and



## RIBOFLAVINE

*B. lactis acidii* <sup>6</sup> *Clostridium tetani* <sup>7</sup> *Erysipelothrix rhusiopathiae* and *Listerella monocytogenes* <sup>8</sup> *Leuconostoc mesenteroides* P 60 <sup>9</sup> and *Streptococcus faecalis* R (*S. lactis* R) <sup>10</sup> *L. helveticus* utilises riboflavine phosphate and flavine adenine dinucleotide for growth and acid production equally as well as riboflavine

Riboflavine is utilised by micro organisms whether they are able to synthesise it or whether they require an exogenous source of the vitamin H. McIlwain <sup>11</sup> estimated that in the five bacteria *Aerobacter aerogenes* *Serratia marcescens* *Pseudomonas fluorescens* *Proteus vulgaris* and *Clostridium butylicum* between 7200 and 11 000 molecules of riboflavine are present in each cell and that the rate of synthesis ranges from 2.4 to 11 molecules per cell per second. The turnover numbers for fumaric hydrogenase D amino acid oxidase and diaphorase for each of which flavine adenine dinucleotide is the coenzyme were 22.40 to 50 and 33 molecules per molecule of enzyme per second that is between 22 and 50 molecules of substrate react with each molecule of the enzyme per second. The rates of synthesis and inactivation of riboflavine indicate that these reactions are reactions of  $m\mu$  mol order in contrast to the ordinary reactions of the bacterial cell which are of  $\mu$ ml order. This matter is further discussed on page 284.

Riboflavine is associated with a possible explanation of the phenomenon of drug resistance that is the ability of certain micro organisms on repeated exposure to sub-lethal concentrations of a drug to acquire resistance to it. It has been suggested <sup>12</sup> that the flavoproteins of resistant cells may have become more easily dissociated due presumably to some alteration in the protein component. It was observed for instance that *Pneumococci* which had become resistant to acriflavine or mepacrine readily lost dehydrogenase activity on dilution or warming and that the activity was restored on addition of riboflavine. Susceptible cells did not exhibit this behaviour. Similarly an extract from resistant cells showed reduced activity when compared with a similar extract from susceptible cells. Riboflavine increased the activity of the former although the riboflavine contents of both types of cells were approximately the same.

### References to Section 16

- 1 P. R. Burkholder *Amer. J. Bot.* 1943 **30**, 206
- 2 P. R. Burkholder and I. McVeigh *Bull. Torrey Bot. Club* 1943 **70**, 372
- 3 P. R. Burkholder, I. McVeigh and D. Moyer *J. Bact.* 1944 **48**, 385
- 4 R. C. Thompson *Univ. Texas Publ.* 1942 No 4237 p. 87. P. R. Burkholder and I. McVeigh *Proc. Nat. Acad. Sci.* 1942 **28**, 285
- 4a H. C. Hou *Proc. Soc. Exp. Biol. Med.* 1949 **70**, 582
- 5 S. Orla Jensen, N. C. Otte and A. Snog Kjaer *Danske Videnskabs Selskabs Skrifter* 1936 **8**, No 5

## REQUIREMENTS OF INSECTS

- 6 L E Snell and F M Strong *Ind Eng Chem Anal Ed* 1939 11 346
- 7 R E Feeney J H Mueller and P A Miller *J Bact* 1943 48, 563
- 8 S H Hutner *ibid* 1942 43 629
- 9 M S Dunn N N Camien S Shankman W Frankl and L B Rockland *J Biol Chem* 1944 158 703
- 10 J L Stokes M Guinness I M Dwyer and M C Caswell *ibid* 1945 160, 35
- 11 H McIlwain *Nature* 1946 158 898
- 12 M G Seaver and J S Gots *J Bact* 1948 58 723

## 17 EFFECT OF RIBOFLAVINE ON HIGHER PLANTS

Riboflavin appears to have no stimulatory effect on the growth of higher plants and indeed it is said to be synthesised during the germination of oats wheat barley and maize<sup>1</sup> and in the root tips of various plant species<sup>2</sup>. The riboflavin content of cereals peas and beans increased considerably during germination—from 0.6–2.0 to 2.0–12.4  $\mu\text{g}$  per g of dry matter.

### References to Section 17

- <sup>1</sup> P R Burkholder *Science* 1943 97 562
- <sup>2</sup> J Bonner *Bot Gaz* 1942 103 581

## 18 RIBOFLAVINE REQUIREMENTS OF INSECTS

Riboflavin is essential for the normal development of the beetles *Plinus lectus* *Tribolium confusum* and *Silvanus surinamensis* and of the moth *Ephestia elutella* but not of the beetles *Sitodrepa panicea* and *Lasioderma serricorne*<sup>1</sup>. The difference in the requirements of the two groups of beetles was shown to be due as with aneurine (see page 115) to the presence in the last two insects of intracellular symbiotic micro-organisms capable of synthesising riboflavin which then became available to supply the metabolic needs of the host. Neither *Lasioderma* nor *Sitodrepa* grew in the absence of riboflavin when reared from sterilised eggs.

Riboflavin was also necessary for the development of the larvae of the mosquito *Aedes aegypti*<sup>2</sup> of *Tenebrio molitor*<sup>3</sup> of the fruit fly *Drosophila melanogaster*<sup>4</sup> and of the larvae of the rice moth *Corcyra cephalonica*<sup>5</sup>.

In two species of insects namely the American cockroach<sup>6</sup> *Periplaneta americana* and *Tineola bisselliella*<sup>7</sup> riboflavin accumulated in the Malpighian tubes even when the diet contained little or no

## RIBOFLAVINE

riboflavine In the cockroach the contents of the tubes were forty times as rich in riboflavin as is ox liver

### References to Section 18

- 1 G Fraenkel and M Blewett *Nature* 1941 147, 716 1943 151, 703 1943 152, 506, *Biochem J* 1943 37, 686 *Proc Roy Soc B* 1944 132, 212
- 2 L Golberg B de Meillon and M Lavoipierre *J Exp Biol* 1945 21, 84 90
- 3 H E Martin and L Hare *Biol Bull Woods Hole* 1942 83, 428
- 4 E L Tatum *Proc Nat Acad Sci* 1941 27, 193
- 5 P S Sarma *Indian J Med Res* 1943 31, 165
- 6 R L Metcalf and R L Patton *J Cell Comp Physiol* 1942 19, 373
- 7 R G Busnel and A Drilhon *Compt rend* 1943 216, 213

## 19 ANALOGUES OF RIBOFLAVINE

### Growth Stimulators

The first analogue of riboflavin to be prepared was 6,7-dimethyl-9-(L-ribo-1'-arabityl)-isoalloxazine which R. Kuhn and F. Weygand<sup>1</sup> synthesised before it was known that riboflavin was derived from ribose. It was found to possess vitamin B<sub>2</sub> activity though to a smaller degree than the D-ribo-1'-arabityl compound prepared subsequently. Other compounds with biological activity were synthesised later mainly by Karrer and his collaborators. In general these bore a close resemblance to riboflavin and it was evident that the molecule could not be greatly modified without loss of activity. Karrer *et al.*<sup>2</sup> found that even the L-ribo-1'-arabityl compound, the optical isomer of riboflavin, was inactive in rats in a dose of 20 µg per day. The following compounds were prepared and found to be active in rats:

- 6,7-dimethyl-9-(L-ribo-1'-arabityl)-isoalloxazine (araboflavin)<sup>1, 3</sup>
- 7-methyl-9-(D-ribo-1'-arabityl)-isoalloxazine<sup>2, 4</sup>
- 6-methyl-9-(D-ribo-1'-arabityl)-isoalloxazine<sup>4, 5</sup>
- 6-ethyl-7-methyl-9-(D-ribo-1'-arabityl)-isoalloxazine<sup>6</sup>

Their activity was approximately half that of riboflavin. F. Weygand<sup>8</sup> suggested however that the apparent activity of araboflavin might be due to the presence as a contaminant of riboflavin formed by an Amadori rearrangement (see page 144).

These analogues, with the possible exception of the arabityl derivatives, were also shown to stimulate the growth of *Streptococcus casei* and *B. lactis acidus*.<sup>7</sup>



# ANALOGUES

The following compounds were found to have no appreciable activity in rats.

6-7-dimethyl-9-(D-1'-xylityl)-isoalloxazine	3
" -9-(L-1'-rhamnityl)-	3
" -9-(D-1'-arabityl)-	3
7-methyl-9-(D-1'-dulcetyl)-	3
" -9-(L-1'-arabityl)-	3
" -9-(D-1'-sorbityl)-	3
" -9-(D-1'-mannityl)-	3
6-7-dimethyl-9-(L-1'-ribityl)-	3
" -9-(D-1'-lyxityl)-	3
" -9-(D-1'-desoxyribityl)-	3
7-ethyl-9-(D-1'-ribityl)-	3
6-ethyl-7-methyl-9-(L-1'-arabityl)-	3
5-6-benzo-9-(D-1'-ribityl)-	3
" -9-(L-1'-arabityl)-	3
6-7-dimethyl-9-(D-ribosido)-	3
" -9-(L-arabinosido)-	10
6-8-dimethyl-9-(D-1'-ribityl)-	10
" -9-(L-1'-arabityl)-	11
5-7-dimethyl-9-(D-1'-ribityl)-	11
" -9-(L-1'-arabityl)-	11

Several of these compounds were also tested on *S. casei* and *L. lactis acid*, and were likewise found to be inactive. 7  
6-7-Dimethyl-9-(D-1'-lyxityl) isoalloxazine (lyxoflavine) has been isolated from the human myocardium 5 mg being obtained from 10 kg 12a

The preparation of compounds related to lumiflavine was described by H. Lettré and M. E. Fernholz 12. These were a series of 9-alkyl-5:6-benzoflavines, made by condensing alloxan with 9-substituted naphthalene-*o*-diamines. The substituents ranged from the methyl to the cetyl group, and all the compounds were sparingly soluble in water. When injected subcutaneously, a water-soluble flavine of unknown constitution appeared in the urine within one hour of the injection. None of the compounds was active.  
Isoflavone (5-6-dimethyl-9-D-1'-ribityl isoalloxazine) (I) and 2-amino-4-5-dimethyl-1-ribitylamino-benzene (II)



had little growth-stimulating effect on *Lactobacillus helveticus*, but were able to enhance the effect of traces of riboflavine or flavine


## RIBOFLAVINE

adenine dinucleotide on this organism<sup>13</sup> In the presence of alloxan however, the ribitylamino compound (II) was a potent stimulator of *L. helveticus* Both riboflavine phosphate and flavine adenine diphosphate were as effective as riboflavine for growth and acid production in *L. helveticus*

Fluoresceyanine, in 50  $\mu$ g doses, accelerated the growth of rats maintained on a riboflavine deficient diet, and abolished the nervous symptoms from which the animals suffered<sup>14</sup>

### Growth Inhibitors

Not all the analogues of riboflavine that fail to stimulate the growth of organisms for which riboflavine is essential are merely inert to the organisms, for some inhibit their growth Thus, 6,7-dichloro-9-D-ribo-riboityl-isoalloxazine, which failed to stimulate the growth of two strains of *B. lactis acidus* that were unable to grow without riboflavine, and yeast, *Staph. aureus* and *Streptobacterium plantarum*, for which riboflavine was not essential, inhibited the growth of all these organisms with the exception of the yeast<sup>15</sup> Inhibition was competitive, being overcome by the addition of riboflavine The oxidation-reduction potential of the antagonist was  $-0.095$  v compared with  $-0.185$  v for riboflavine, possibly the dichloro compound is unable to replace riboflavine because its dihydro derivative is not sufficiently negative to hydrogenate oxygen Isoniboflavine<sup>16</sup> (5,6-dimethyl-9-D-ribo-riboityl-isoalloxazine) counteracted the growth promoting action of riboflavine in rats, whilst the phenazine analogue of riboflavine<sup>17</sup> (2,4-diamino-7,8-dimethyl-10-riboityl-5,10-dihydrophenazine)



produced riboflavine deficiency in bacteria, and the dinitrophenazine derivative from which it was prepared produced mild riboflavine deficiency in mice The effects of the compounds were overcome by adequate amounts of riboflavine Galactoflavine<sup>18</sup> (6,7-dimethyl-9-D-ribo-riboityl-isoalloxazine) inhibited the growth of rats receiving low levels of riboflavine Inhibition was competitive and was almost completely counteracted by a daily intake of 200  $\mu$ g of riboflavine A similar, though less marked effect was observed with D-araboflavine<sup>19</sup> in rats, but L-araboflavine had no such antagonistic effect


# ANALOGUES

The antagonism of the D isomer was not due to mechanical displacement of riboflavin from an enzyme system

Lumiflavin, the photolysis product of riboflavin, inhibited or stimulated the utilisation of riboflavin or flavine adenine dinucleotide by *L. helveticus*, according to the relative amounts present<sup>13</sup> Inhibition by lumiflavin was much greater with flavine adenine dinucleotide than with riboflavin, suggesting that riboflavin may be attached to the apo-enzyme before conversion to riboflavin phosphate or flavine adenine dinucleotide

Riboflavin was oxidised stoichiometrically to lumiflavin by *Pseudomonas riboflavina*, and this organism also attacked the ribityl group of analogues of riboflavin The oxidation was inhibited by phenyl 4 5-dimethyl isoalloxazine<sup>20</sup> but the inhibition was not competitive, since it was not reversed by high concentrations of riboflavin Moreover, this compound had no antiriboflavin activity in rats

Many substances that exhibited antimalarial activity were found to inhibit the growth-promoting effect of riboflavin on *L. helveticus*<sup>21</sup> These included mepacrine 2 *p*-chloroanilino-, 2 (6'-bromonaphthyl-2'-amino)-, and 2 *p*-chlorophenylguanidino 4 diethylaminoethylamino-1-methylpyrimidine This type of approach led to the elaboration of a number of new antimalarials but rather paradoxically the best of these, proguanil, did not antagonise riboflavin Isoalloxazines containing a basic side-chain e.g. 6 7-dimethyl 9- $\gamma$ -amino  $\beta$  hydroxy propyl isoalloxazine



had no antimalarial or bacteriostatic activity, and did not antagonise the growth promoting effect of riboflavin on *L. helveticus* or *E. coli*<sup>22</sup>

## References to Section 19

- 1 R. Kuhn and F. Weygand, *Ber.*, 1934, **67**, 2084
- 2 P. Karrer, H. Salomon, K. Schöpp, F. Benz and B. Becker, *Helv. Chim. Acta* 1935 **18**, 908
- 3 H. von Euler, P. Karrer, M. Malmberg, K. Schöpp, F. Benz, B. Becker and P. Frei *ibid.* 522
- 4 P. Karrer, H. von Euler, M. Malmberg and K. Schöpp, *Svensk Kem. Tids.* 1935 **47**, 153
- 5 P. Karrer and F. M. Strong, *Helv. Chim. Acta* 1935, **18**, 1343
- 6 P. Karrer and T. H. Quibell, *ibid.*, 1936, **19**, 1034

# RIBOFLAVINE

- 7 E F Moller *Angew Chem* 1940 53, 204
- 8 F Weygand *Ber* 1940 73, 1259
- 9 P Karrer H Salomon K Schopp and F Benz *Helv Chim Acta* 1935 18, 1143
- 10 R Kuhn and R Strobele *Ber* 1937 70, 747
- 11 R Kuhn P Desnuelle and F Weygand *ibid* 1293
- 12 H Lettré and M E Fernholz *ibid* 1940 73, 436
- 12a E S Pallares and H M Garza *Arch Biochem* 1949 22 63
- 13 H P Sarett *Fed Proc* 1945 4, 101 *J Biol Chem* 1946 162, 87
- 14 R G Busnel P Chaucard H Mazoué M Pesson and M Polonovski *Compt rend* 1943 217, 185
- 15 R Kuhn F Weygand and E F Moller *Ber* 1943 76, 1044
- 16 G A Emerson and M Tishler *Proc Soc Exp Biol Med* 1944 55, 184
- 17 D W Woolley *J Biol Chem* 1944 154, 31
- 18 G A Emerson E Wurtz and O H Johnson *ibid* 1945 160, 165
- 19 H von Euler and P Karrer *Helv Chim Acta* 1946 29 353
- 20 J W Foster *J Bact* 1944 47, 27 1944 48, 97
- 21 J Madinaveitia *Biochem J* 1946 40, 373
- 22 R R Adams C A Weisel and H S Mosher *J Amer Chem Soc* 1946 68, 883

## NICOTINIC ACID (NIAVIN)

## I INTRODUCTION

THE term pellagra was originally used rather loosely to describe a condition characterised by a bilaterally symmetrical eruption. As far back as 1918 J Goldberger G A Wheeler and V P Sydenstricker<sup>1</sup> claimed that pellagra as thus defined included at least two aetiologicaly distinct syndromes and suggested that two dietary factors might be involved. Seven years later J Goldberger and W F Tanner<sup>2</sup> announced that pellagra could be cured by yeast and called the responsible factor the PP (pellagra preventative) factor.

Pellagra is largely a disease of warm climates and has always been associated with the use of maize as the staple cereal though oats and rye may also produce pellagra if used as the sole cereal. Pellagra assumes a variety of forms mainly because other members of the vitamin B complex besides the pellagra preventative factor are in variably deficient in or missing from the pellagra producing diet.

The use of experimental animals in the investigation of pellagra did not meet with immediate success indeed the use of the three species rats chicks and dogs only led to bewildering and often contradictory results which at the time were extremely difficult to interpret. Thus a dermatitis similar to pellagra was produced artificially in rats by J Goldberger and R D Lillie<sup>3</sup> using a ration to which adequate amounts of an antineuritic concentrate had been added the rats were cured by administration of autoclaved yeast and it was hoped that a satisfactory animal test for the new factor had been discovered thus facilitating research on its isolation and identification. The hopes were not realised however for it was found difficult to use the onset of dermatitis as the basis of a quantitative method of assaying the PP factor content of foodstuffs. It therefore became customary to assay these by the growth produced in rats. W R Ackroyd however found that maize the pellagra producing cereal *par excellence* (see page 240) produced good growth in rats and it became evident that the rat growth method was not assaying the PP factor at all but another factor later shown to be riboflavin. Much of the old literature in which this method is used is therefore,



misleading As will be seen later (page 296), the so-called "pellagra like" dermatitis of rats is produced by yet another factor called B<sub>6</sub> P Gyorgy,<sup>4</sup> vitamin B<sub>6</sub>.

An attempt to find an animal the response of which to the PP factor was more specific than that of the rat was made by C A Elvehjem and C J Koehn,<sup>5</sup> who found that chicks, when fed on pellagra-producing diet, also developed a form of dermatitis, for a time, protection against chick "pellagra" and the production of normal growth were taken to be a measure of PP factor activity. Liver and a commercial extract of liver were found to be highly active whereas riboflavin was inactive. By fractionation of the liver extract a much richer concentrate of the chick dermatitis factor was obtained which also cured blacktongue in dogs,<sup>6</sup> and it seemed as though the production of dermatitis in chickens was in fact a valid test of PP-factor deficiency. Subsequently, however, it was found that the factor responsible for chick dermatitis (the so called filtrate factor) was not the PP-factor at all but the substance now known as pantothenic acid (see page 348).

In the ultimate, therefore, experiments with rats and chicks were unsuccessful, and progress in the elucidation of the nature of the pellagra-preventative factor came to depend on clinical tests supplemented by experiments with dogs. In a series of papers published between 1926 and 1934, Goldberger and his colleagues<sup>7</sup> reported the examination of a large number of foodstuffs by the addition of known quantities of the food to a pellagra producing diet and noting the incidence of pellagra in a group of patients.

Goldberger and his colleagues also carried out parallel tests with dogs<sup>8</sup> and thus work eventually demonstrated that the foodstuffs that cured pellagra in human beings also cured blacktongue in dogs whence it was concluded that the same dietary factor was responsible for both conditions.

Yeast was introduced in the treatment of pellagra by J Goldberger and W F Tanner<sup>9</sup> but large amounts had to be administered to make this form of treatment successful. Liver extracts gave better results and in 1937 Elvehjem *et al*<sup>10</sup> by fractionating a liver extract having marked anti blacktongue activity and subjecting the active fraction to high vacuum distillation isolated nicotinamide and showed that it and nicotinic acid were highly effective in curing canine blacktongue. H R Street and G R Cowgill<sup>11</sup> also obtained good results with nicotinic acid in blacktongue and Chick *et al*<sup>12</sup> in a corresponding condition in pigs (see page 238).

The beneficial effects of nicotinic acid on pellagrins was reported by Spies *et al*<sup>13</sup> by L J Harris<sup>14</sup> and by Smith *et al*<sup>15</sup>.

Actually nicotinic acid had been isolated in 1912 from yeast by

C Funk<sup>16</sup> and from rice bran by Suzuki *et al*<sup>17</sup> during attempts to isolate the anti beriberi factor. They observed that it had no beneficial effect in beriberi, and did not apparently suspect that they had actually isolated a vitamin capable of curing a different deficiency disease.

Nicotinic acid is known in the U.S.A. as niacin, this name having been coined to make the distinction between the vitamin and the alkaloid, nicotine, quite clear to the lay public.

### References to Section 1

- 1 J. Goldberger, G. A. Wheeler and V. P. Sydenstricker, *J. Amer. Med. Assoc.*, 1918, **71**, 944.
- 2 J. Goldberger and W. F. Tanner, *U.S. Pub. Health Rep.*, 1925, **40**, 58.
- 3 J. Goldberger and R. D. Lillie, *ibid.*, 1926, **41**, 201.
- 4 P. György, *Nature*, 1934, **133**, 498.
- 5 C. A. Elvehjem and C. J. Koehn, *J. Biol. Chem.*, 1935, **108**, 709.
- 6 C. A. Elvehjem and C. J. Koehn, *J. Nutrition* 1936 **11**, 67.
- 7 J. Goldberger, G. A. Wheeler, R. D. Lillie and L. M. Rogers, *U.S. Pub. Health Rep.* 1926 **41**, 297, J. Goldberger and G. A. Wheeler, *ibid.*, 1927, **42**, 1299-2383, 1929 **44**, 2769. G. A. Wheeler, *ibid.* 1931, **46**, 2663. 1933, **48**, 67, G. A. Wheeler and D. J. Hunt, *ibid.* 1933 **48**, 754, 1934 **49**, 732. 1926, **41**, 201.
- 8 J. Goldberger and G. A. Wheeler *ibid.*, 1928 **43**, 172, J. Goldberger, G. A. Wheeler, R. D. Lillie and L. M. Rogers, *ibid.*, 1928, **43**, 657-1385, J. Goldberger, G. A. Wheeler, L. M. Rogers and W. H. Sebrell, *ibid.* 1930 **45**, 273-1297, W. H. Sebrell, G. A. Wheeler and D. J. Hunt *ibid.*, 1935 **50**, 1333, G. A. Wheeler and W. H. Sebrell, *U.S. Nat. Inst. Health Bull.* 1933, 162.
- 9 J. Goldberger and W. F. Tanner, *U.S. Pub. Health Rep.*, 1925 **40**, 54.
- 10 C. A. Elvehjem, R. J. Madden, F. M. Strong and D. W. Woolley, *J. Amer. Chem. Soc.*, 1937, **59**, 1767.
- 11 H. R. Street and G. R. Cowgill, *Proc. Soc. Exp. Biol. Med.* 1937, **37**, 547.
- 12 H. Chick, T. F. Macrae, A. J. P. Martin and C. J. Martin, *Biochem. J.*, 1938, **32**, 10.
- 13 T. D. Spies, C. Cooper and M. A. Blankenhorn, *J. Amer. Med. Assoc.*, 1938, **110**, 622, T. D. Spies, *Lancet*, 1938, **1**, 252.
- 14 L. J. Harris, *Chem. and Ind.*, 1937, **56**, 1134.
- 15 D. T. Smith, J. M. Ruffin and S. G. Smith, *J. Amer. Med. Assoc.*, 1937 **109**, 2054.
- 16 C. Funk, *J. State Med.*, 1912, **20**, 341, *J. Physiol.*, 1913 **46**, 173, *Brit. Med. J.*, 1913 **1**, 814.
- 17 U. Suzuki and S. Matsunaga, *J. Agr. Tokyo Imp. Univ.*, 1912, **5**, 59, U. Suzuki, T. Shimamura and S. Okada *Biochem. Z.*, 1912, **43**, 89-99.

## 2. ISOLATION OF NICOTINIC ACID

As already noted, the identity of the PP-factor with nicotinamide and nicotinic acid was first established by Elvehjem *et al*,<sup>1</sup> who isolated nicotinamide from a liver extract (Eli Lilly) by molecular distillation.

Nicotinic acid can readily be isolated from natural sources by extraction of the acidified hydrolysed material with organic solvents. The nicotinic acid can be separated from the extract as such, or in the form of its esters or copper salt. The free acid is obtained from the copper salt by decomposition with hydrogen sulphide.

Nicotinamide can be isolated from natural sources by aqueous extraction, followed by partial hydrolysis with acid to liberate it from the combined form in which it exists, and then extraction with butanol or chloroform. The extract is fractionated by molecular distillation, nicotinamide distilling at 150 to 160° C at  $5 \times 10^{-4}$  mm.

### *Reference to Section 2*

- 1 C. A. Elvehjem, R. J. Madden, F. M. Strong and D. W. Woolley, *J. Amer. Chem. Soc.*, 1937, **59**, 1767; *J. Biol. Chem.* 1938, **123**, 137.

## 3. PREPARATION OF NICOTINIC ACID

### Synthesis of Nicotinic Acid

Nicotinic acid was first prepared in 1867 by C. Huber<sup>1</sup> by the oxidation of the alkaloid, nicotine, and this method is still in use for the commercial preparation of nicotinic acid. Nicotine is obtained from waste tobacco, and is widely employed as an insecticide. H. Weidel,<sup>2</sup> A. Pictet and G. Süssdorff,<sup>3</sup> E. Winterstein and A. B. Weinhagen,<sup>4</sup> and S. M. McElvain and R. Adams<sup>5</sup> used nitric acid for the oxidation, whilst R. Laiblin<sup>6</sup> used potassium permanganate solution which gave a particularly good yield, and Huber *et al*<sup>7</sup> used chromic acid. Most of the nicotinic acid crystallises out from the acidified oxidation product and the remainder (about 1%) can be recovered from the filtrate as the sparingly soluble zinc salt.<sup>7a</sup>

H. Weidel<sup>8</sup> also prepared nicotinic acid by the oxidation of picoline (a mixture of the  $\beta$  and  $\gamma$  isomers, b.p. 132 to 140° C, was used) with boiling potassium permanganate solution. He obtained a mixture of nicotinic and picolinic acids, which were separated by conversion to the copper salts, the copper salt of picolinic acid was less soluble and immediately separated out, whilst the copper salt of nicotinic acid was recovered subsequently from the filtrate. The two copper salts were decomposed with sulphuric acid, yielding free picolinic and

## PREPARATION

nicotinic acids respectively. Technical picoline was also used as the starting material by K. Hess and F. Leibbrandt<sup>9</sup> but the mixed acids obtained on oxidation were separated by extraction with absolute alcohol in which nicotinic acid was sparingly soluble. 3-Ethylpyridine<sup>10</sup>, 3-phenylpyridine<sup>11</sup> and 3,3'-dipyridyl<sup>12</sup> have also been used as starting materials for the preparation of nicotinic acid.

The preparation of nicotinic acid by the oxidation of picoline is like the oxidation of nicotine, a method now used commercially. It is more economical to purify the  $\beta$  picoline prior to oxidation than to separate nicotinic acid from the oxidation products of the other isomers. Purification can be effected by refluxing the technical picoline with phthalic anhydride, acetic anhydride, acetyl chloride, chlorosulphonic acid or sulphur dioxide with which the  $\gamma$  picoline and 2,6-lutidine react<sup>13</sup> by preferentially oxidising these substances in the vapour phase with air in presence of a vanadium and iron catalyst<sup>14</sup> or by removing the lutidine with urea and the  $\gamma$  picoline by heating with benzaldehyde or furfural<sup>15</sup>. The most attractive technical method of producing nicotinic acid from  $\beta$  picoline is one due to the Reilly Tar & Chemical Corp.<sup>16</sup> in which the picoline is oxidised in the vapour phase with air using vanadium and iron oxides as catalyst.  $\beta$  Picoline can also be oxidised by means of sulphuric acid in presence of a selenium compound<sup>17</sup>.

Yet a third method of preparation was used by Huber *et al.*<sup>7</sup> In this quinoline was oxidised by means of boiling alkaline potassium permanganate solution to quinolinic acid which slowly lost carbon dioxide on heating at 120° C. and more readily at 150° C. giving a moderate yield of nicotinic acid. Quinoline, alkyl quinolines and isoquinoline can be similarly oxidised by other oxidising agents such as nitric acid with or without the addition of a catalyst<sup>18</sup>. Sulphuric acid in presence of a selenium compound such as selenium oxychloride can also be used for the oxidation of quinoline<sup>17</sup>.

The oxidation of unsubstituted quinoline does not give good yields, however, because both the pyridine ring and the benzene ring are oxidised. Derivatives of quinoline substituted in the benzene ring are more suitable and the oxidation of 8-quinoline-sulphonic acid, 8-quinolinol and alizarine indigo blue for example gave better yields of nicotinic acid than did the oxidation of quinoline itself. Quinolinol however is not recommended as the oxidation is strongly exothermic and an explosion may result. 5,7-Dinitro-8-quinolinol prepared by nitration of 8-quinolinol is to be preferred; this gave a good yield of nicotinic acid on oxidation with nitric acid<sup>19</sup>.

The oxidation of nicotine,  $\beta$  picoline and quinoline to nicotinic acid by means of sulphuric acid in presence of various catalysts was studied by Woodward *et al.*<sup>20</sup> With nicotine the best yields were obtained

## NICOTINIC ACID (NIAICIN)

with selenium,  $\beta$  picoline gave lower yields than either nicotine or quinoline

Other methods are available for the preparation of nicotinic acid. Thus O. Fischer<sup>21</sup> obtained it from pyridine *via* pyridine sulphonic acid and cyano pyridine but the overall yield was not good and a better route was suggested by S. M. McElvain and M. A. Goese<sup>22</sup> in which pyridine was treated with bromine and hydrobromic acid to yield a dark red perbromide, this when heated at 300° C, yielded  $\beta$  bromopyridine which when heated with cuprous cyanide at about 170° C was converted into 3 cyanopyridine. This can be hydrolysed as in Fischer's method with acid or by means of alcoholic sodium hydroxide solution to nicotinic acid.

### Synthesis of Nicotinamide

Nicotinamide was first prepared in 1894 by reacting ethyl nicotinate with concentrated ammonia,<sup>23</sup> details of a more recent modification of this method were given by F. B. LaForge<sup>24</sup>. It can also be made by treating the acid chloride with ammonia, by passing ammonia gas into nicotinic acid at 230° C<sup>25</sup> or spraying molten ammonium nicotinate into ammonia gas at 140–200° C<sup>26</sup>, by the action of ammonium polysulphide on 3 acetylpyridine<sup>27</sup>, or by reacting nicotinic acid with urea,<sup>28</sup> preferably in presence of a molybdenum catalyst<sup>29</sup>. A useful technical process is based on the partial hydrolysis of 3-cyanopyridine with mineral acid<sup>30</sup> or with dilute sodium hydroxide solution, sodium carbonate solution or triethylamine in presence of hydrogen peroxide<sup>31</sup>. 3-Cyanopyridine can also be converted into nicotinamide by boiling an aqueous solution with the quaternary ammonium hydroxide resin IRA-400; an 86 to 90 % yield is claimed<sup>31a</sup>. Nicotinamide was produced in low yield when asparagine was heated with glutamic acid and perhaps with other acids<sup>32</sup>.

### References to Section 3

- 1 C. Huber *Annalen* 1867 **141**, 271 *Ber.* 1870 **3**, 849
- 2 H. Weidel *Annalen* 1873 **185**, 331, 346
- 3 A. Pictet and G. Sussdorff *Arch. sci. phys. nat.* (4) 1898 **5**, 113
- 4 E. Winterstein and A. B. Weinhagen *Helv. Chim. Acta* 1917, **100**, 181
- 5 S. M. McElvain and R. Adams *J. Amer. Chem. Soc.* 1923 **45**, 2738
- 6 R. Laublin *Annalen* 1879 **186**, 135
- 7 C. Huber, S. Hoogewerff and W. A. van Dorp *Rec. Trav. Chim. Pays Bas* 1882 **1**, 121
- 7a *J. C. H. S. D.* 2447234
- 8 *I.* 2004
- 9 *K. L. S.* *id.* 1917, **50**, 385

## PROPERTIES

- 10 H Weidel and K Hazura *Monatsh*, 1882, 3, 783
- 11 Z H Skraup and A Cobenzl *ibid*, 1883 4, 458
- 12 Z H Skraup and G Vortmann *ibid* 594
- 13 Reilly Tar & Chemical Corp B P 561722, 561723
- 14 Reilly Tar & Chemical Corp B P. 563273
- 15 Pittsburgh Coke & Iron Co, B P. 570427
- 16 Reilly Tar & Chemical Corp, B P 563274
- 17 Allied Chemical & Dye Corp U S P. 2436660
- 18 Reilly Tar & Chemical Corp, B P. 568889
- 19 A Zimmerli U S P. 2394650
- 20 C F Woodward C O Badgett and J G Kaufman *Ind Eng Chem*, 1944 36, 544
- 21 O Fischer, *Ber*, 1882, 15, 63
- 22 S M McElvain and M A Goese *J Amer Chem Soc*, 1941, 63, 2283
- 23 C Engler, *Ber*, 1894 27, 1787, F Pollak, *Monatsh* 1895, 18, 53
- 24 T. B LaForge, *J Amer Chem Soc*, 1928 50, 2477
- 25 S Keimatsu K Yokata and I Satoda, *J Pharm Soc, Japan*, 1933 53, 994
- 26 P W. Garbo, U S P 2427400
- 27 Ciba Ltd, B P 558774
- 28 Ciba Ltd, B P 561019
- 29 P W Garbo, U S P 2419831
- 30 Geigy Colour Co Ltd, I E Balaban and F Manchester, B P 575119
- 31 Pyridium Corp B P 563184
- 31a A. Galat, *J Amer Chem Soc*, 1948, 70, 3945
- 32 J R Bovarnick, *J Biol Chem*, 1943 149, 301, 1943, 151, 467, 1944 153, 1

## 4 PROPERTIES OF NICOTINIC ACID

### Nicotinic Acid

Nicotinic acid forms white needles m p 235.5 to 236.5° C. It is sparingly soluble in cold water, but soluble in hot water and alcohol, it is sparingly soluble in ether. It sublimes without decomposition on heating. It behaves as a base forming a crystalline hydrochloride, m p 274° C, and other salts and also as an acid, forming salts with metals, and esters with alcohol. The methyl ester is a solid, m p 38° C, and the ethyl ester a liquid, b p 223 to 224° C. Nicotinic acid forms an acid chloride, amide, hydrazide, etc.

Nicotinic acid sold in Great Britain for pharmaceutical purposes must conform to certain standards laid down in the Fourth Addendum to the British Pharmacopoeia 1932, and modified in the 1948 edition. Nicotinic acid tablets were included in the Seventh Addendum. The dosage is now given as 15 to 30 mg daily for prophylaxis and 50 to 250 mg daily for therapeutic use and the substance is normally dispensed in 50 mg tablets.

**Nicotinamide**

Nicotinamide is a white substance crystallising from benzene in needles, m p  $131^{\circ}\text{C}$ . It is very soluble in water (1 in 1) and in 95 % alcohol (1 in 1.5), soluble in glycerol (1 in 10), but only slightly soluble in ether. On distillation with phosphorus pentoxide it yields 3-cyanopyridine and on hydrolysis with acid or alkali it yields nicotinic acid. On heating in a dry tube, pyridine is evolved.

Nicotinamide sold in Great Britain for pharmaceutical purposes must conform to certain standards laid down in the Sixth Addendum of the British Pharmacopoeia 1932 and modified in the 1948 edition. Nicotinamide tablets were included in the Seventh Addendum. The therapeutic dose is the same as for the acid, and the substance is normally dispensed in 50 mg tablets.

Several N alkyl derivatives of nicotinamide are known, of which N diethyl-nicotinamide is the well-known heart stimulant, Nikethamide (Coramine).

**5. ESTIMATION OF NICOTINIC ACID**

It will already be evident from what has been said in the introduction that there is no satisfactory biological method of assaying the pellagra-preventative factor. Rats and chickens fail to respond specifically, whilst the prevention of blacktongue in dogs, although specific, does not constitute a convenient method of assay.

In spite of this, dogs were used for assaying foodstuffs by Waisman *et al*,<sup>1</sup> whilst Schaefer *et al*<sup>2</sup> described a diet consisting of casein and sucrose supplemented by aneurine, riboflavin, pantothenic acid and choline, which was said to produce an uncomplicated nicotinic acid deficiency in dogs, suitable for assay purposes.

Fortunately, nicotinic acid and nicotinamide can readily be estimated chemically or microbiologically, and the absence of a satisfactory biological method of assay is not a serious disadvantage.

**Chemical Methods based on the Vongerichten Reaction**

One of the first chemical tests proposed was a modification of Vongerichten's reaction for pyridine compounds.<sup>3</sup> P. Karrer and H. Keller<sup>4</sup> used the reaction to estimate the amount of nicotinic acid and nicotinamide in animal tissues. These were digested with water, the aqueous extract was neutralised with potassium hydroxide solution to liberate the nicotinic acid, the resulting solution was evaporated to dryness and the residue extracted with benzene. The extract was

## ESTIMATION

freed from benzene, the residue was fused with 2·4-dinitro 1-chlorobenzene and the melt dissolved in ether and the solution extracted with water. The intensity of the colour formed on adding one or two drops of potassium hydroxide solution was found to be proportional to the nicotinic acid content. Substantially the same method was used by Vilter *et al*<sup>5</sup> for the estimation of nicotinic acid and nicotinamide in urine. Urine contains other pyridine compounds in addition to these two substances, however, and, although trigonelline does not give a colour with dinitrochlorobenzene, nicotinuric acid, the conjugated compound of nicotinic acid with glycine interferes with the estimation, giving high results.

### Chemical Methods based on the König Reaction

The Vongerichten reaction proved to be rather inconvenient for analytical purposes, and the majority of workers have made use of the König reaction,<sup>6</sup> in which the pyridine compound is warmed with cyanogen bromide solution, and an organic base is then added. A yellow colour is formed, the intensity of which is proportional to the amount of pyridine compound present. The method was first applied to the estimation of nicotinic acid in foodstuffs by M. Swaminathan,<sup>7</sup> who used aniline as the base, this was also used by H. Kringstad and T. Naess.<sup>8</sup> E. Bandier and J. Hald<sup>9</sup> used metol (*p*-methylanilino-phenol sulphate) as the organic base in place of aniline, and found that nicotinamide gave a stronger colour than nicotinic acid, so that it was necessary to hydrolyse the amide to the acid before applying the reaction. E. Bandier<sup>10</sup> also used the method for the estimation of nicotinic acid in urine but, like Vilter *et al*,<sup>5</sup> encountered difficulties due to the presence of other pyridine compounds (page 252). These were overcome by hydrolysis with alkali in order to convert all the derivatives of nicotinic acid into the free acid, the values thus obtained being a measure of the total (free and combined) nicotinic acid in the urine.

Von Euler *et al*<sup>11</sup> used  $\beta$ -naphthylamine as the base whilst L. J. Harris and W. D. Raymond<sup>12</sup> worked out a method of estimating nicotinic acid in urine, using *p*-aminoacetophenone. This method was modified by E. Kodicek,<sup>13</sup> who stressed the importance of adhering rigidly to the detailed conditions laid down, if satisfactory results were to be obtained. Like Bandier, Kodicek used alkaline hydrolysis of biological materials to convert nicotinamide and other derivatives into nicotinic acid, impurities were then removed by precipitation with alcohol. W. S. Jones<sup>14</sup> used substantially the same method in conjunction with a fluorophotometer.

Hydrolysis with alkali, however, did not completely eliminate the



## NICOTINIC ACID (NIACIN)

errors of the method, and D Melnick and H Field<sup>15</sup> found that hydrolysates sometimes contained substances that reacted with aniline or *p* aminoacetophenone to give colours indistinguishable from the nicotinic acid colour, but that in presence of cyanogen bromide these interfering side-reactions did not occur. They therefore recommended that the base should not be included in the blank. Further slight modifications were introduced by H A Waisman and C A Elvehjem<sup>16</sup> and by W J Dann and P Handler<sup>17</sup>. The latter workers stated that metol was preferable to other bases, as the colour produced was more stable, but this preference for metol is not shared by other workers. According to M Swaminathan,<sup>18</sup> for example aniline and  $\beta$  naphthylamine give stronger colours than either metol or *p* aminoacetophenone. He found that heating the test solution with cyanogen bromide in alcohol gave colours two or three times as intense as those obtained in aqueous solution. Alcoholic extracts of urine, however gave interfering red colours.

Another base used in conjunction with cyanogen bromide is *p*-aminophenol, which was said to be less affected by light and *pH* than *p* aminoacetophenone<sup>19</sup>. *m*-Phenylene diamine,<sup>20</sup> orthoform<sup>21</sup> procaine<sup>22</sup> and *p* aminopropiophenone<sup>22a</sup> have also been used. Aniline would appear to be the base most generally used with *p* aminoacetophenone as a second favourite. The choice of base is perhaps of less importance than other considerations such as the procedures used for preparing the nicotinic acid extract and for eliminating the errors due to the existence of several forms of nicotinic acid, some biologically active and others inactive.

### Metabolites of Nicotinic Acid and Nicotinamide

One of these substances is the alkaloid, trigonelline, which occurs in the seeds of *Trigonella foenugraecum*, *Pisum sativum*, *Cannabis sativa* and *Strophanthus* spp. It is the betaine of nicotinic acid



and may be present in human urine in relatively large amounts, especially after the consumption of materials rich in trigonelline, such as coffee. In addition, however, it is formed from nicotinic acid in the human and animal organism and eliminated in the urine. It has no anti pellagra activity, so that methods of estimating nicotinic acid in vegetable materials should be capable of distinguishing it from

biologically active nicotinic acid derivatives. On the other hand in studying the metabolism of nicotinic acid (see page 252) it is essential to estimate the urinary trigonelline derived from dietary nicotinic acid whilst at the same time making due allowance for the trigonelline originally present as such in the diet—a problem to which no simple solution exists!

Fortunately comparatively few foods contain sufficiently large amounts of trigonelline to interfere seriously with the estimation of the other metabolites. Such foods should be avoided by subjects about to take part in metabolic experiments.

Another nicotinic acid derivative present in urine is nicotinuric acid (page 252). This does not exist in foodstuffs but is formed from nicotinic acid *in vivo* by conjugation with glycine. Its estimation in urine is essential in studying the metabolism of nicotinic acid.

Another pyridine compound formed *in vivo* from nicotinamide is  $N^1$  methylnicotinamide, the amide corresponding to trigonelline (page 254). It forms a strongly fluorescent compound ( $F_2$ ) on treatment with alkali so that its separate estimation where necessary presents no great difficulty. Conversion to  $N^1$  methylnicotinamide can actually be used for the estimation of nicotinamide. This is brought about by leaving a dilute methanolic solution of nicotinamide overnight with excess methyl iodide and evaporating. On treatment with alkali and isobutanol a fluorescence develops the intensity of which is proportional to the nicotinamide concentration.<sup>23</sup> Alternatively nicotinamide is treated with cyanogen bromide and alkali and the fluorescent product extracted with isobutanol. The second procedure gives a more intense fluorescence than the first (see also page 226).

The latter method was modified by Huff *et al.*<sup>51</sup> who used acetone in a single phase at an alkaline pH instead of extracting into isobutanol. E. Kodicek used methyl ethyl ketone instead of acetone but subsequently found that the use of a solvent was unnecessary.<sup>24</sup>

$N^1$  Methylnicotinamide is not the end product of nicotinamide metabolism, an oxidation product of the former,  $N^1$  methyl 6-pyridone 3-carboxylamide, being excreted at the same time (see page 255).<sup>25a</sup>

### Preparation of Extracts

A variety of methods have been employed for the preparation of extracts suitable for the estimation of nicotinic acid by means of the König reaction. Many workers followed the principle employed by E. Bandier<sup>10</sup> and by Vilter *et al.*<sup>5</sup> and used hydrolysis to convert nicotinamide and other nicotinic acid derivatives into free nicotinic acid whilst V. H. Cheldelin and R. R. Williams<sup>23</sup> found that many

## NICOTINIC ACID (NIACIN)

through the body. The simplest procedure is one in which all these substances are converted into free nicotinic acid, but errors will then be introduced if substantial amounts of the trigonelline present have been derived from the diet.

Early attempts to estimate nicotinic acid in urine by this method are those of E. Bandier<sup>10</sup> and L. J. Harris and W. D. Raymond,<sup>12</sup> already referred to. J. C. Roggen<sup>36</sup> heated the sample of urine with nitric acid to hydrolyse nicotinamide and nicotinuric acid to nicotinic acid and then added saturated potassium permanganate solution, which does not attack nicotinic acid, in order to oxidise interfering substances. The resulting solution was adsorbed on frankonite and the adsorbate was eluted with barium hydroxide solution. The colour was developed in the usual way with cyanogen bromide and aniline.

More satisfactory methods of estimating nicotinic acid in urine, capable of giving information of greater value in metabolic studies than a mere knowledge of the total free and combined nicotinic acid, are those in which nicotinic acid and each of its metabolites are separately estimated. Melnick and his colleagues<sup>15, 37, 38</sup> worked out a method of estimating total nicotinic acid, nicotinuric acid and trigonelline based on the fact that nicotinamide is hydrolysed when the urine is heated with 4N acid for half an hour, whereas nicotinuric acid is more stable and requires heating for five hours with 4N acid whilst trigonelline can only be hydrolysed to nicotinic acid by treatment with alkali. They used this method to study the fate of nicotinic acid in the organism (see page 253). F. W. Lamb<sup>39</sup> noted that the maximum extinction coefficient of the colour, and the time required for its development, varied for nicotinic acid, nicotinamide, pyridine and  $\beta$  picoline, and was characteristic for each substance. D. Melnick and B. L. Oser<sup>40</sup> devised a method of differentiating between nicotinamide and nicotinic acid, based on the observation that, when cyanogen bromide and aniline were added in quick succession, the two substances gave colours of different intensity. By evaluating the colour before and after acid hydrolysis, it was possible to obtain an approximate idea of the relative amounts of the two substances present in the mixture.

Perlzweig *et al*<sup>41</sup> devised a method of estimating total nicotinic acid and trigonelline separately in urine. Total nicotinic acid (excluding trigonelline) was estimated by boiling the urine with hydrochloric acid to hydrolyse all the nicotinic acid derivatives, with the exception of trigonelline, to nicotinic acid. This was then adsorbed on Lloyd's reagent, eluted with alkali and the colour developed as in Bandier and Hald's method. Trigonelline was estimated by treating with urea and alkali, which convert it into a substance giving a colour

identical with the nicotinic acid colour in a yield equivalent to 70 % of the theoretical conversion. The solution was treated with Lloyd's reagent as before and the colour evaluated. The value obtained in the second estimation was equivalent to the amount of nicotinic acid derivatives measured in the first estimation plus 70 % of the trigonelline.

Högborg *et al*<sup>42</sup> observed that the colour produced by nicotinamide was more intense and more stable in butanol solution than that produced by nicotinic acid so that if the coloured derivatives were extracted into butanol and the extract left for ten minutes the residual colour was due solely to nicotinamide. To estimate bound nicotinic acid and nicotinamide the material was heated with 0.1 N hydrochloric acid in a sealed tube at 100° C and the estimation repeated.

### Other Chemical and Physical Methods of Assay

Atkin *et al*<sup>43</sup> made use of the Hoffman reaction with bromine and potassium hydroxide to destroy nicotinamide in order to improve the accuracy of the microbiological method of assay (page 227). The same reaction was used by J. M. Goodyear and H. W. Murphy<sup>44</sup> as a method of estimation, the 3-aminopyridine into which nicotinamide was converted by this treatment being diazotised and coupled with N-1-naphthylethylenediamine. The intensity of the red dye thus produced was proportional to the amount of nicotinamide originally present.

J. J. Lingane and O. L. Davis<sup>45</sup> developed a polarographic method of estimating nicotinic acid which gives a characteristic wave, the position of which varies with the base solution used. The best results were obtained with a tetramethylammonium borate buffer solution of pH 9. Nicotinic acid then had a half-wave potential of -1.6 volts but an unbuffered potassium chloride solution gave quite satisfactory results. The method has the advantage that aneurine, riboflavin, and nicotinic acid can be estimated simultaneously in the same solution.

Nicotinamide is also reduced at the dropping mercury electrode<sup>46</sup> in alkaline solutions giving a well-defined wave at -1.6 to -1.7 volts, the height of which is proportional to the concentration of amide. The mechanism of the reaction is not known. N<sup>1</sup>-Methyl nicotinamide was reduced in two steps: the first at -1.025 volts is possibly due to the formation of a dimer and the second at -1.6 to -1.8 volts to the formation of a dihydro-derivative. Trigonelline gave a single step at -1.35 volts due to the formation of a dimer.

### Estimation of N<sup>1</sup>-Methylnicotinamide

As already stated ingested nicotinamide is partially converted into N<sup>1</sup> methylnicotinamide which can be estimated by conversion into a fluorescent substance by treatment with alkali

J W Huff and W A Perlzweig<sup>47</sup> used adsorption on Permutit at pH 4 to separate the substance from impurities and eluted it from the adsorbate by means of potassium chloride solution. It was then extracted into butanol aqueous alkali was added and the fluorescence evaluated. In estimating N<sup>1</sup>-methylnicotinamide in urine the preliminary adsorption on zeolite was unnecessary. Coulson *et al*<sup>48</sup> adsorbed on Decalso eluted with potassium chloride solution and then extracted the eluate with *sec* butanol after making alkaline. V A Najar<sup>49</sup> treated the solution with active charcoal adsorbed the N<sup>1</sup> methylnicotinamide on Permutit and eluted with potassium chloride solution as in the foregoing method the eluate was then made alkaline extracted with butanol and the fluorescence of the solution was evaluated in a fluorimeter. M Hochberg *et al*<sup>50</sup> also adsorbed on a zeolite.

Huff *et al*<sup>51</sup> improved the method by treating an aqueous alkaline solution with acetone instead of extracting into isobutanol. This produced a greenish blue fluorescence the intensity of which was proportional to the concentration of N<sup>1</sup> methylnicotinamide. E Kodicek<sup>24</sup> used methyl ethyl ketone in place of acetone but subsequently found that satisfactory results were obtained in the absence of a solvent.

### Estimation of N<sup>1</sup>-Methyl-6-pyridone-3-carboxylamide

The amount of N<sup>1</sup> methyl 6 pyridone 3 carboxylamide in urine was estimated by clarifying the urine with lead acetate saturating the filtrate with potassium carbonate and extracting with ether evaporating the extract to dryness dissolving the residue in acetone and measuring the fluorescence produced on addition of a small amount of concentrated potassium hydroxide solution. Alternatively the pyridone was estimated spectrophotometrically in an aqueous solution of the residue left after evaporation of the ethereal extract<sup>51a</sup>. A third method was to adsorb the pyridone on Lloyd's reagent elute with chloroform nitrate and measure the coloured product in alkaline solution<sup>51b</sup>.

### Microbiological Methods of Assay

An entirely different principle depending on the response of micro organisms to nicotinic acid has been used by a number of workers who claim that such methods are more expeditious and accurate than

chemical methods E E Snell and L D Wright<sup>52</sup> measured the amount of lactic acid produced by *Lactobacillus arabinosus* 175 on a synthetic medium containing all known growth factors except nicotinic acid and to which the test solution had been added and compared it with the amount produced on the basal medium containing known amounts of added nicotinic acid. The nicotinic acid contents of blood milk urine plant and animal extracts were estimated in this way with a fair degree of accuracy, as little as 0.05  $\mu\text{g}$  of nicotinic acid could be measured.

The method of Snell and Wright failed to give a linear standard curve with concentrations in excess of 0.2  $\mu\text{g}$  per 10 ml, but this objection was overcome by Krehl *et al*<sup>53</sup> who in addition to other modifications increased the concentration of glucose and buffer (sodium acetate) in the basal medium whilst H Isbell<sup>54</sup> advocated the addition of *p*-aminobenzoic acid to the medium. The medium was still further modified by E C Barton Wright,<sup>55</sup> whose method has been adopted as a standard procedure by most workers in this country. The medium consists of acid hydrolysed casein the preparation of which must be carefully carried out if satisfactory results are to be obtained. DL tryptophan and L-cystine glucose sodium acetate and xylose calcium pantothenate pyridoxine riboflavin *p*-amino benzoic acid and biotin adenine guanine uracil and xanthine and the usual inorganic salts. Barton Wright recommends that extracts be prepared in the same way as for riboflavin assays (page 158) although the growth of *L. arabinosus* is not stimulated by starch or free fatty acids. Hydrolysis is effected by autoclaving with N hydrochloric acid at 15 lb pressure for fifteen to twenty minutes. A similar method was made official in the U.S.A.<sup>56</sup>

Sarett *et al*<sup>57</sup> proposed to use for the assay of nicotinic acid with *L. arabinosus* a basal medium consisting of yeast extract peptone and liver extract treated with Lloyd's reagent to remove nicotinic acid.

A method for the microbiological estimation of nicotinamide in presence of nicotinic acid by means of *L. arabinosus* was devised by Atkin *et al*<sup>43</sup> who carried out two assays one before and one after the conversion of nicotinamide by treatment with bromine and potassium hydroxide into 3-aminopyridine which has no growth stimulating activity. The difference in the amount of lactic acid produced in the two tests was proportional to the amount of nicotinamide present.

Assay methods based on the response of *L. arabinosus* have been most commonly employed but other organisms have been used. P Fildes<sup>58</sup> found that *Proteus vulgaris* required nicotinic acid and A Lwoff and A Querido<sup>59</sup> used it for the estimation of nicotinic

## NICOTINIC ACID (NIAFIN)

acid and nicotinamide H Grossowicz and E Sherstinsky<sup>60</sup> used "*Proteus* HX 19" Dorfman *et al*<sup>61</sup> used *Shigella dysenteriae*, and Fraser *et al*<sup>62</sup> and Isbell *et al*<sup>63</sup> used *Shigella paradysenteriae*. Although these methods have the advantage of requiring less complex media than the Snell and Wright method, they involve a turbidimetric estimation of the amount of growth produced, this is less convenient and less accurate than a titration of lactic acid. Moreover, one of the organisms, *Proteus vulgaris*, responds to coenzymes I and II as well as to nicotinamide.

In fact, the only possible rival to *L. arabinosus* is *Lactobacillus casei* (*helveticus*) used by M. Landy and D. M. Dicken<sup>64</sup> for the assay of six B vitamins with one and the same medium. This contains casein hydrolysate and glucose, vitamins and pyrimidines, and is similar in composition to that used by Snell. Although the constituents are different, however, and the method gives in method.

*Leuconostoc mesenteroides* was used by B. C. Johnson<sup>65</sup> in conjunction with *L. arabinosus* to estimate nicotinic acid, nicotinamide and nicotinic acid in a mixture of the three, *L. mesenteroides* is unaffected by nicotinamide or nicotinic acid, and the increase in the response following hydrolysis with acid is proportional to the nicotinamide and nicotinic acid present. Nicotinic acid is estimated by measuring the difference in the response of *L. arabinosus* (the growth of which is stimulated by both nicotinic acid and nicotinamide) before and after hydrolysis and the amount of nicotinamide present is calculated by subtracting the value so obtained from the previous result.

A yeast, *Torula cremoris*, was used by W. L. Williams,<sup>66</sup> the growth of the organism being measured turbidimetrically. Differential assays of nicotinic acid, trigonelline and N<sup>1</sup>-methylnicotinamide were carried out with this organism by measuring the response before and after acid and alkaline hydrolysis.

A modification of the Heatley method of assaying antibiotics<sup>67</sup> has been tried out for the assay of growth factors, including nicotinic acid<sup>68</sup>. An agar plate was seeded with *L. arabinosus* and holes were cut in the agar or, alternatively, little porcelain cups were placed on the surface of the agar. Into the holes or the cups, a little of the test solutions and standards were poured, the plates were incubated and the diameters of the zone of "exhibition" (analogous to the zones of inhibition produced by antibiotics) were plotted against the logarithms of the concentrations. Although this gave a straight line the method suffered from the same disadvantages as the conventional microbiological assay together with the added disadvantage that the edges of the zones tended to be diffuse.

## ESTIMATION

Kynurenine and 3 hydroxyanthranilic acid two intermediates in the conversion of tryptophan into nicotinic acid (page 250) did not stimulate the growth of *L. arabinosus* *L. mesenteroides* *S. faecalis* *Pr. vulgaris* or *Torula cremoris* and therefore do not interfere with the estimation of nicotinic acid by any of these organisms <sup>68a</sup>

### Estimation of Coenzymes I and II

Several methods are available for the estimation of coenzymes I and II, di and triphospho pyridine nucleotides (see page 274). O Warburg and W Christian <sup>69</sup> estimated codehydrogenase II by measuring the amount of carbon dioxide evolved by the action on sodium bicarbonate of glycerophosphoric acid produced enzymatically with hexose monophosphate (Robison ester) as substrate, in addition to the coenzyme the specific apoenzyme and the yellow ferment must also be present. Jandorf *et al* <sup>70</sup> adopted the same method in principle but used the more readily accessible hexose diphosphate as substrate. D E Green and J Brasteaux <sup>71</sup> used oxidation of lactic acid by animal tissues as a method of estimation.

*Haemophilus parainfluenzae* which cannot synthesise codehydrogenase I or II from its constituents and cannot grow without one or the other can be used to estimate factor V the coenzyme like substance in blood or yeast <sup>72 73</sup>. This is presumably a mixture of the two coenzymes. Vilter *et al* <sup>74</sup> used *Bacillus influenzae* to estimate the factor V content of blood whilst K Myrback <sup>75</sup> and A E Axelrod and C A Elvehjem <sup>76</sup> used a yeast growth method which estimates coenzyme I but not coenzyme II. It is not certain whether these two methods of estimating factor V give comparable results.

A rapid method for the estimation of pyridine nucleotides in blood was developed by Levitas *et al* <sup>77</sup>. In this method the nucleotide was converted into N<sup>1</sup> methyl nicotinamide by treatment with alkali and this was then condensed with acetone to give the fluorescent compound referred to above (page 226). When attempts were made to apply this method to tissues low values were obtained <sup>78</sup>. The losses were due to the action of nucleotidases (page 279) and were avoided by the addition of nicotinamide which is a specific inhibitor of nucleotidase. This modification gave results in excellent agreement with those obtained by the microbiological method using *Haemophilus parainfluenzae*. When the values thus obtained for pyridine nucleotides were compared with the total nicotinic acid content of tissues as determined microbiologically with the aid of *L. arabinosus* it was found that all the nicotinic acid in rat tissues was in the form of pyridine nucleotide.



# NICOTINIC ACID (NIAICIN)

## References to Section 5

- 1 H A Waisman O Mickelsen J M McKibbin and C A Elvehjem  
*J Nutrition* 1940 **10**, 483 J M McKibbin H A Waisman  
O Mickelsen and C A Elvehjem, *Wisconsin Agric Exp Sta*  
*Bull* No 446
- 2 A E Schaefer J M McKibbin and C A Elvehjem *J Biol*  
*Chem* 1942 **144**, 679
- 3 E Vongenchten *Ber* 1899 **32**, 2571
- 4 P Karrer and H Keller *Helv Chim Acta* 1938 **21**, 463 1170  
1939 **22**, 1292
- 5 S P Vilter T D Spies and A P Mathews *J Biol Chem* 1938  
**125**, 85 *J Amer Chem Soc* 1938 **60**, 731
- 6 W König *J prakt Chem* 1904 **69**, 105 1904 **70**, 19
- 7 M Swaminathan *Nature* 1938 **141**, 830
- 8 H Kringstad and T Naess *Z physiol Chem* 1939 **260**, 108
- 9 E Bandier and J Hald *Biochem J* 1939 **33**, 264
- 10 E Bandier *ibid* 1787
- 11 H von Euler F Schlenk H Heiwinke and B Hogberg *Z physiol*  
*Chem* 1938 **256**, 208
- 12 L J Harris and W D Raymond *Biochem J* 1939 **33**, 2037
- 13 E Kodicek *ibid* 1940 **34**, 712 724
- 14 W S Jones *J Amer Pharm Assoc* 1941 **30**, 277
- 15 D Melnick and H Field *J Biol Chem* 1940 **135**, 53
- 16 H A Waisman and C A Elvehjem *Ind Eng Chem Anal Ed*  
1941 **13**, 221 \*
- 17 W J Dann and P Handler *J Biol Chem* 1941 **140**, 201
- 18 M Swaminathan *Indian J Med Res* 1941 **29**, 325
- 19 E Stotz *J Lab Clin Med* 1941 **26**, 1042
- 20 A E Teeri and S R Shimer *J Biol Chem* 1944 **153** 307
- 21 R G Martinek E R Kirch and G L Webster *ibid* 1943 **149**  
**245**
- 22 E C Barton Wright and R G Booth *Lancet* 1944 **1**, 565 P O  
Dennis and H G Rees *Analyst* 1949 **74** 481
- 22a C Klatzkin F W Norris and F Wokes *ibid* 447
- 23 J V Scudi *Science* 1946 **103**, 567
- 24 E Kodicek *Analyst* 1947 **72** 385 D K Chaudhuri and E  
Kodicek *Biochem J* 1949 **44** 343
- 24a W E Knox and W I Grossman *J Biol Chem* 1946 **166** 391  
1947 **168**, 363
- 25 V H Cheldelin and R R Williams *Ind Eng Chem Anal Ed*  
1942 **14**, 671
- 26 E B Hale G K Davis and H R Baldwin *J Biol Chem* 1942  
**146**, 553
- 27 K V Giri and B Naganna *Indian J Med Res* 1941 **29**, 125
- 28 K Taufel and F Dahle *Z Unters Lebensm* 1943 **85**, 414
- 29 Y L Wang and E Kodicek *Biochem J* 1943 **37**, 530
- 30 E M James F W Norris and F Wokes *Analyst* 1947 **72**, 327
- 31 D Melnick *Cereal Chem* 1947 **19**, 553

# ESTIMATION

- 32 Analytical Methods Committee *Analyst* 1946 71, 397
- 33 J R Klein W A Perlzweig and D Handler *J Biol Chem* 1942 145 27
- 34 M J C Allenson *ibid* 1943 147, 785
- 35 B D Kochhar *Indian J Med Res* 1940 28, 385
- 36 J C Roggen *Rec trav chim* 1943 62, 137
- 37 D Melnick and H Field *J Biol Chem* 1940 134 1
- 38 D Melnick W D Robinson and H Field *ibid* 1940 136, 131  
145
- 39 F W Lamb *Ind Eng Chem Anal Ed* 1943 15 352
- 40 D Melnick and B L Oser *ibid* 355
- 41 W A Perlzweig E D Levy and H P Sarett *J Biol Chem* 1940 136, 779
- 42 B Högborg F Schlenk and H von Euler *Arkiv Kemi Min Geol* 1942 15A, No 18
- 43 L Atkin A S Schultz W L Williams and C N Frey *J Amer Chem Soc* 1943 65, 992
- 44 J M Goodyear and H W Murphy *J Amer Pharm Assoc* 1944 33, 129
- 45 J J Lungane and O L Davis *J Biol Chem* 1941 137, 567
- 46 P C Tompkins and C L A Schmidt *Univ California Publ Physiol* 1943 8, 221
- 47 J W Huff and W A Perlzweig *J Biol Chem* 1943 150, 395  
483
- 48 R A Coulson P Ellinger and M Holden *Biochem J* 1944 38, 150
- 49 V A Najjar *Johns Hopkins Hosp Bull* 1944 74, 92
- 50 M Hochberg D Melnick and B L Oser *J Biol Chem* 1945 158 265
- 51 J W Huff W A Perlzweig and M Tilden *Fed Proc* 1945 4 92
- 51a F Rosen W A Perlzweig and I G Leder *J Biol Chem* 1949 179 157
- 51b W I M. Holman and D J de Lange *Biochem J* 1949 45 559
- 52 E E Snell and L D Wright *J Biol Chem* 1941 139, 675
- 53 W A Krehl F M Strong and C A Elvehjem *Ind Eng Chem Anal Ed* 1943 15, 471
- 54 H Isbell *J Biol Chem* 1942 144, 567
- 55 E C Barton Wright *Biochem J* 1944 38, 314
- 56 *J Assoc Off Agric Chem* 1947 30 44 82 398 Cf E Kodicek and C R. Pepper *J Gen Microbiol* 1948 2 292
- 57 H P Sarett R L Pederson and V H Cheldelin *Arch Biochem* 1945 7, 77
- 58 P Fildes *Brit J Exp Path* 1938 29, 239
- 59 A Lwoff and A Querido *Compt rend Soc Biol* 1938 129, 1039  
1938 130, 1569
- 60 H Grossowicz and E Sherstinsky *J Biol Chem* 1947 167, 101
- 61 A Dorfman S A Koser M Horwitt S Berkman and F Saunders *Proc Soc Exp Biol Med* 1940 43, 434

## NICOTINIC ACID (NIAICIN)

- 62 H F Fraser, N H Topping and W H Sebrell, *U S Publ Health Rep*, 1938, 53, 1836
- 63 H Isbell, J G Wooley, R E Butler and W H Sebrell, *J Biol Chem*, 1941, 139, 499
- 64 M Landy and D M Dicken, *J Lab Clin Med*, 1942 27, 1086
- 65 B C. Johnson, *J Biol Chem*, 1945, 159, 227
- 66 W. L. Williams, *ibid*, 1946, 166, 397
- 67 N. G Heatley, *Biochem J*, 1944 38, 61
- 68 S A Price *Nature*, 1948, 161, 20
- 68a B E Volcani and E E Snell, *Proc Soc Exp Biol Med*, 1948, 67, 511.
- 69 O Warburg and W Christian, *Biochem Z*, 1936, 287, 291
- 70 B J Jandorf, F W Klemperer and A B Hastings *J Biol Chem*, 1941, 138, 311
- 71 D E Green and J Brosteaux, *Biochem J*, 1936, 30, 1489
- 72 A Lwoff and M Lwoff, *Proc Roy Soc B*, 1937, 122, 352, 360, *Compt rend*, 1936, 203, 520
- 73 H I Kohn, *Biochem J*, 1938 32, 2075
- 74 R W Vilter, S P Vilter and T D Spies, *J Amer Med Assoc*, 1939, 112, 420
- 75 K Myrbäck, *Z physiol Chem*, 1928, 177, 158
- 76 A E Axelrod and C A Elvehjem, *J Biol Chem*, 1939, 131, 77
- 77 N Levitas J Robinson F Rosen, J W Huff and W A Perlzweig, *ibid*, 1947, 167, 169
- 78 J Robinson, N Levitas F Rosen and W A Perlzweig *ibid*, 1947, 170, 653

## 6. OCCURRENCE OF NICOTINIC ACID IN FOODSTUFFS

Nicotinic acid is widely distributed in foodstuffs and the values obtained by various workers have been tabulated by A L Bacharach<sup>1</sup> and R W McVicar and G H Berryman<sup>2</sup> The following summary is based on these tables but is supplemented by more recent information The earlier references given in these two reviews have been omitted In many instances, the higher and lower values recorded have been obtained by different methods of assay, some of which might not now be regarded as satisfactory

Wheat bread (brown) contains 12, wheat flour (wholemeal), 31 to 57,<sup>3</sup> and wheat flour (white), 09 to 11 mg per 100 g

Barley contains 25 to 30, maize (white), 07 to 15, maize (yellow), 12 to 30,<sup>4</sup> millet, 06 to 31,<sup>5</sup> oats, 10 to 11, rice (unpolished), 60, rice (milled), 16 to 32, rice (parboiled), 28 to 40, rice polishings, 88 to 28,<sup>5</sup> rye (whole), 13, wheat (whole) 40 to 53, wheat germ, 27 to 91, wheat bran, 50, sorghum, 20 to 79 mg per 100 g

It is worth noting that nicotinic acid is found in the germ and pericarp in rice (as well as in wheat), and that parboiling prevents its removal in the milling process, although it may subsequently be lost in washing and cooking.<sup>6</sup> Another point of very great nutritional significance is that maize contains only slightly less nicotinic acid than milled rice, and the association between pellagra and a maize diet cannot therefore be attributed solely to the low nicotinic acid content of maize. This point will be referred to later (see page 240).

Fruits are relatively deficient in nicotinic acid, as they are in most other members of the vitamin B complex. Apples, pears and tomatoes contain less than 0.5 mg per 100 g, whilst bananas, fresh figs, grapes, plums and peaches contain between 0.5 and 1.0 mg per 100 g. Cranberries contain 1.29 and dates 2.18 mg per 100 g.

Nuts are somewhat richer, raw peanuts containing 5.9 to 13, almonds 1.82 and chestnuts 1.17 mg per 100 mg. Coconut however, contains only 0.4 mg per 100 g.

The nicotinic acid content of vegetables varies. Potatoes contain 1.0 to 2.0, cabbage 0.3, carrots 0.5 to 1.5, spinach 0.7 to 1.7, broccoli, 1.0 to 1.5, lettuce, 0.5, cauliflower 0.6, cucumber, 0.3, onion, 0.1 and beets, 0.3 to 0.6 mg per 100 g. Legumes contain more nicotinic acid than do other vegetables. Peas (fresh) contain 1.0 to 2.0, peas (dry) 1.0, broad beans, 2.1, soya beans 1.2 to 4.8, lentils, 3.1, gram (Bengal) 4.7 and gram (red), 5.3 mg per 100 g.

Cow's milk contains 0.1 to 0.5 and human milk less than 0.1 mg per 100 ml. The nicotinic acid content of cow's colostrum is about the same as that of the milk.<sup>7</sup> The nicotinic acid content of cow's milk is less in the winter and early spring than in summer and early autumn. It also decreases regularly during the period of lactation.<sup>8</sup> Dried milk contains 5 to 15 mg per 100 g and fresh cheese 0.03 to 1.6 mg per 100 g.<sup>9</sup> When cheese is ripened, the nicotinic acid content is doubled or trebled. Ewe's colostrum and milk contain 0.2 and 0.4 mg per 100 ml.<sup>8</sup>

Hen's eggs contain less than 0.5 mg per 100 g in the white and about 1 mg per 100 g in the yolk.

Fish, on the whole, is a good source of nicotinic acid. The muscle of cod contains 1.7 to 3.0, of herring, 2.9 to 4.0, and of salmon 8.4 mg per 100 g. Roe rather surprisingly, contains less than the muscle from the same fish: cod roe containing 1.4 to 1.5, herring roe 2.1 and turbot roe, 2.3 mg per 100 g. Cod liver contains 1.6 mg per 100 g. Halibut contains 3.0 to 6.0,<sup>10</sup> mackerel, 5.5 to 7.2, mullet, 2.9, haddock, 0.9, crab, 2.6 to 2.8, oyster 1.3, and scallop, 1.4 mg per 100 g. Prawn and crab contain 2 to 4 mg per 100 g of fresh tissue.<sup>11</sup>

## NICOTINIC ACID (NIAICIN)

Salt water fish on the whole constitutes a richer source of nicotinic acid than fresh water fish <sup>12</sup> the highest value observed in eight varieties of salt-water fish purchased in Calcutta market being 3.1, and in thirteen varieties of fresh-water fish, 1.77 mg per 100 g Trout, however, contains 3.5 and perch 1.7 mg of nicotinic acid per 100 g <sup>10</sup>

Fish from Lake Michigan contained <sup>13</sup> lake herring, 2.3 to 5.5, common suckers, 1.1 to 1.3, carp, 1.5, burbot, 1.6, carp roe, 1.3, and herring roe 0.6 mg of nicotinic acid per 100 g Wide individual and seasonal variations were observed No significant loss occurred on freezing and subsequent storage for two to three months or on baking, smoked fish retained 66 to 72 % of the nicotinic acid originally present

Meat is another rich source of nicotinic acid, richer even than fish, and the following values are recorded for muscle tissue <sup>10</sup> ox, 3.8 to 10.2, calf, 4.9 to 18.0, horse, 4.7, pig, 3.3 to 13.0, rabbit, 6.5 to 13.0, chicken leg, 6.1 to 8.0, breast, 11.0 to 18.1, grouse, 6.5, and lamb, 5.4 to 10.2 mg per 100 g The amount of nicotinic acid in chicken muscle appeared to vary inversely with the aneurine content, dark muscle containing three times as much aneurine as pale muscle, but only one half to one third of the nicotinic acid <sup>14</sup>

In general, kidneys are richer than the corresponding muscle tissue <sup>10</sup> ox containing 6.5 to 19.4, pig, 4.1 to 15.5, calf, 8.3 to 10.0, rabbit, 3.8 to 16.2, sheep, 7.5 to 9.6 mg per 100 g, whilst liver is richer still, that of ox containing 7.6 to 27.5, calf, 11.5 to 22.5, horse 16.0, sheep 12.5 to 20.0, lamb 39.2 to 46.0, pig 9.7 to 27.5, rabbit 7.85 to 22.0, and chicken, 11.4 to 17.8 mg per 100 g Ox tongue contains 6.1 to 12.8 mg per 100 g

Other "offal" is a poorer source of nicotinic acid than kidney and liver the following values being recorded adrenal, ox, 5.0 to 6.0, adrenal sheep 13.5, brain, ox, 3.0 to 7.5, brain, rabbit 1.2, heart ox, 4.9 to 5.9, heart, pig 5.3 to 8.0, heart rabbit 3.4, heart sheep 6.0, lung ox 4.3 to 8.3, lung, rabbit, 0.9, ovary, pig, 3.8, pancreas ox, 2.7 to 5.0, pancreas, sheep 4.0, spleen, ox, 4.4 to 8.3, spleen pig 4.0 and testis, pig 4.4 mg per 100 g

In animal tissues nicotinic acid exists mainly in the form of nicotinamide or <sup>15</sup> more probably pyridine nucleotide <sup>16</sup> whereas plant tissues contain a smaller, often a very much smaller, proportion of nicotinamide

The richest readily available source of nicotinic acid as of other members of the vitamin B complex, is yeast Bakers' yeast contains 7.4 to 12.0 mg per 100 g, compressed yeast 25.7 mg per 100 g of dry matter and dry yeast 25 to 50 mg per 100 g Dried brewers yeast contains 34 to 93 and moist brewers yeast 9.1 to 10.2 mg per 100 g *Torula utilis* contains 20 to 38 mg per 100 g <sup>17, 18</sup> The yeast extract, Marmite contains 65.5 mg per 100 g <sup>19</sup>

## OCCURRENCE IN FOODSTUFFS

Beers and pale ales contain 0.45 to 0.82, strong ales 1.35 to 2.7, and stouts 0.62 to 1.1 mg per 100 ml <sup>20</sup> so that each pint provides approximately 5 mg. The daily requirement of nicotinic acid can therefore be provided by about two pints of beer.

Seven samples of tea, examined by the method of Wang *et al* were found <sup>21</sup> to contain 5.6 to 9.4 mg of nicotinic acid per 100 g, and most of this dissolved in boiling water when the tea was infused. Assuming that twenty-four cups can be prepared from  $\frac{1}{2}$  lb of tea, the daily requirement would be supplied by about twenty-four cups.

Raw coffee beans contain 1.6 to 4.4 mg of nicotinic acid per 100 g and roast coffee 9.5 to 26 mg per 100 g, dark roast coffee containing more than light roast <sup>22</sup>. The increase is explained by decomposition of trigonelline during roasting. Almost the whole of the nicotinic acid is extracted in making a cup of coffee and an average cup of white coffee contains 1 to 2 mg, that is one tenth to one fifth of the amount required per day. An attempt to assay coffee biologically by means of chicks was unsuccessful owing to the presence of toxic substances whilst the feeding of a charcoal eluate of coffee extract to black-tongue dogs produced symptoms of biotin deficiency <sup>23</sup>. On addition of biotin, the dogs responded normally to nicotinic acid.

Honey, pollen and royal jelly contain 0.11, 1.0 and 1.1 mg of nicotinic acid per 100 g respectively <sup>24</sup>.

### Effect of Processing Food on Nicotinic Acid Content

Less work has been carried out on the effect of cooking and storage on the nicotinic acid contents of food than with other members of the vitamin B complex, possibly because it is considerably more stable to heat than aneurine and more stable to light than riboflavin. Nevertheless, in calculating the dietary intake of nicotinic acid the losses caused by extraction of the vitamin into the water used in cooking fruit and vegetables must be taken into consideration. This may be up to 30 % of the amount present in the food <sup>25</sup>. Cooking water was found to contain 2 to 40 % and the liquid in canned vegetables 30 to 40 % of the total nicotinic acid. As already mentioned above roast coffee may contain several times the amount of nicotinic acid present in the raw bean, owing to decomposition of trigonelline. Raw milled rice lost 60 % of its nicotinic acid on washing and cooking whereas parboiled milled rice, that is, rice steamed in the husk, lost only 12 % <sup>26</sup>.

Roast beef retained nearly all the nicotinic acid present in the raw meat <sup>27</sup>. Beef extract is a rich source of nicotinic acid <sup>28</sup> as well as of riboflavin (see page 166), and seven samples of commercial meat extracts and meat juices contained 34.5 to 102.5 mg of nicotinic acid

## NICOTINIC ACID (NIACIN)

per 100 g A breakfast cup made with a teaspoonful of such an extract may supply up to 10 mg of nicotinic acid that is a days requirement The nicotinic acid content of corned beef was correspondingly low values ranging from 0.85 to 3.3 mg per 100 g being obtained compared with values of 4.5 to 8.5 mg per 100 g for fresh beef On an average four fifths of the original content was lost in the pickling process by extraction but hardly any by destruction even when nitrite was used

### References to Section 6

- 1 A L Bacharach *Nutr Abs* 1940 41 10, 459
- 2 R W McVicar and G H Berryman *J Nutrition* 1942 24 235
- 3 S Josem *Anal Assoc Quim Argentina* 1944 32, 185
- 4 K Mather and E C Barton Wright *Nature* 1946 157, 109
- 5 M Swaminathan *Indian J Med Res* 1941 29, 325
- 6 W R Aykroyd and M Swaminathan *ibid* 1940 27, 666
- 7 P B Pearson and A L Darnell *J Nutrition* 1946 31, 51
- 8 J M Lawrence B L Herrington and L A Maynard *ibid* 1946 32, 73
- 9 R A Sullivan E Bloom and J Jarmol *ibid* 1943 25, 463
- 10 W J Dann and P Handler *ibid* 1942 24, 153
- 11 M L Khorana M L Sarma and K V Giri *Indian J Med Res* 1942 30, 315
- 12 B de M Braganea *Ann Biochem Exp Med* 1944 4, 41
- 13 J F Klocke T Porter P I Tack E Laffler N S Henry and R Nitchals *Food Res* 1946 11, 179
- 14 E E Rice E J Strandine E M Squires and B Lyddon *Arch Biochem* 1946 10, 251
- 15 W A Krehl J de la Huerga C A Elvehjem and E B Hart *J Biol Chem* 1940 133, 53
- 16 J Robinson N Levitas F Rosen and W A Perlzweig *ibid* 1947 170, 653
- 17 H Fink and F Just *Biochem Z* 1940 303, 404
- 18 M Swaminathan *Indian J Med Res* 1942 30, 403
- 19 R G Booth and E C Barton Wright *Lancet* 1944 1, 565
- 20 F W Norris *J Inst Brew* 1945 51, 177
- 21 E B Hughes and F L Parkinson *Analyst* 1945 70 86
- 22 E B Hughes and R F Smith *J Soc Chem Ind* 1946 284
- 23 L J Teply W A Krehl and C A Elvehjem *Arch Biochem* 1945 6, 139
- 24 G Kitzes H A Schuette and C A Elvehjem *J Nutrition* 1943 26 241
- 25 W C Russell M W Taylor and J F Benk *ibid* 1943 25 275  
E Gleim M Albury J R McCartney K Visnyei and F Fenton  
*Food Res* 1946 11 461 F Fenton F Gleim M Albury  
J R McCartney and K Visnyei *ibid* 468
- 26 M Swaminathan *Indian J Med Res* 1941 29, 83

**7 EFFECT OF NICOTINIC ACID DEFICIENCY IN ANIMALS**

It has already been stated (page 211) that in the original experiments on the cause of pellagra rats and chickens did not respond with characteristic deficiency symptoms when maintained on a nicotinic acid deficient diet—the symptoms observed were in fact due to a deficiency of other vitamins. The diets used in these early experiments presumably contained tryptophan and as is now known rats do not require nicotinic acid if tryptophan is available being able to convert it into nicotinic acid (page 241). Moreover in some animals nicotinic acid may be provided by intestinal bacteria<sup>1</sup> although rats were not rendered nicotinic acid deficient by administration of sulphaguanidine<sup>2</sup> in these experiments however tryptophan was probably present in the diet.

**Rats**

Nicotinic acid deficiency can be induced in rats by feeding a diet substantially free from both nicotinic acid and tryptophan<sup>3</sup>. Growth is suppressed and the nicotinic acid content of the tissues is diminished. Under normal circumstances nicotinamide does not promote growth in the rat but actually inhibits it<sup>4</sup>. This adverse effect is attributed to the conversion of nicotinamide into N<sup>1</sup> methyl nicotinamide by methylation. This results in a smaller number of methyl groups than usual being available for essential metabolic processes. The administration of methionine or of choline plus homocystine prevented the inhibition of growth by nicotinamide but choline betaine homocystine or cystine alone had no effect. Nicotinic acid behaved differently from nicotinamide—it had no adverse effect on growth but caused fatty livers. These were prevented by methionine choline or betaine but were aggravated by cystine or homocystine. The apparent trigonelline excretion was greater after feeding nicotinamide than after feeding nicotinic acid and was increased by administration of methionine or choline.

Horses<sup>5</sup> and cows<sup>6</sup> like rats were able to synthesise all the nicotinic acid they required.

**Dogs**

The dog is the animal that most clearly demonstrates the effects of nicotinic acid deficiency. The most striking symptom is the appearance of the tongue which becomes very dark in colour hence the name applied to this condition—canine blacktongue. It was the onset of this symptom that Goldberger and his colleagues used as a test in their pioneer work on pellagra (see page 212). Dogs suffering



## NICOTINIC ACID (NIACIN)

clinicians for years, that milk and milk products, which are notoriously poor in nicotinic acid, are, nevertheless, amongst the most valuable of pellagra-preventive foodstuffs. Casein, the protein of milk, is a very good source of tryptophan and it is this that prevents nicotinic acid deficiency.

The observation that tryptophan increased the growth rate of rats fed on a diet containing corn grits was confirmed by H. Spector and H. H. Mitchell<sup>10</sup>. Subsequent work indicated<sup>11</sup> that administration of tryptophan led to the synthesis of nicotinic acid, which in turn led to an improved utilisation of nicotinic acid. Moreover, Krehl *et al.*<sup>12</sup> found that the growth of rats was not inhibited by indole-3-acetic acid or by cyanopyridine, indole or anthranilic acid, although pyridine-3-sulphonic acid (see page 291) suppressed growth. From this it would seem that the absence of both nicotinic acid and tryptophan from maize is a satisfactory explanation of its pellagragenic effect, and that it is unnecessary to postulate the existence of a toxic factor in maize, nor is the evidence for the existence of such a factor particularly strong. Symptoms of nicotinic acid deficiency were produced in pigs fed a diet containing a large proportion of maize,<sup>13</sup> and the symptoms were cured by the addition of tryptophan to the diet, or by replacing the maize by oats.

It has been demonstrated<sup>14-16</sup> that the pig, horse, cotton rat, chick, chick embryo and turkey, as well as the rat, are able to convert dietary tryptophan into nicotinic acid, which is excreted either as the free acid or as N<sup>1</sup>-methylnicotinamide (page 261). The mechanism of the transformation in animals is discussed below (page 249).

### Symptoms of Pellagra

The symptoms exhibited in pellagra and in "pseudo pellagrous conditions" (page 244) depend on whether or not the nicotinic acid deficiency is accompanied by a deficiency of other members of the vitamin B complex, and on the speed with which the body reserves are depleted. A chronic partial deficiency produces functional and anatomical changes quite different from those produced by an acute or total depletion of the vitamin reserves.<sup>17</sup> A partial deficiency, for instance, may produce mild biochemical disturbances, which in course of time may lead to irreversible anatomical changes, whereas a gross deficiency may cause severe functional disturbances, sometimes fatal, often without any gross anatomical lesions developing.

In classical pellagra, alcoholic pellagra and other pseudo pellagrous states, psychic disturbances generally precede other manifestations by weeks or months. The usual symptoms are lassitude, slight mental retardation, loss of memory for recent events, apprehension and a

tendency to confabulation, depression and mild delusional states may also develop. Similar symptoms were observed by Williams *et al*<sup>18</sup> in artificially induced aneurine deficiency, but the psychic manifestations in pellagra cannot be cured by administration of aneurine. After several relapses the mild psychoses are replaced by marked disorientation, hysterical and confusional episodes and sometimes by maniacal states. Advanced cases fail to respond to nicotinic acid presumably because the cerebral neurones are actually destroyed, whereas earlier cases respond dramatically to nicotinic acid or nicotinamide.

These psychic disturbances are followed, after a variable interval of time, by characteristic dermatitis, stomatitis (desquamation of the tongue) and glossitis with ulceration of the angles of the mouth—a condition now known as cheilosis and probably due to riboflavine deficiency (see page 174). P. Manson Bahr and O. N. Ransford<sup>19</sup> believe that the skin lesions of pellagra do not develop in temperate climates, but that the condition then manifests itself as stomatitis and chronic diarrhoea; they describe a case of this type that was rapidly cured by nicotinic acid. I. Katzenellenbogen<sup>20</sup> in Palestine, also described the successful treatment with nicotinic acid of cases of stomatoglossitis, in which there were no signs of pellagra except soreness of the tongue of the angles of the mouth, and of the throat. J. V. Landor,<sup>21</sup> on the other hand, described cases in the hospital at Singapore similar to pellagra in certain respects but different in others. Eczema of the scrotum and stomatitis were the most constant symptoms noted and the disease was not curable by nicotinic acid although the symptoms cleared up on the administration of yeast or marmite; this condition was therefore caused by a deficiency of other factors. Aykroyd *et al*<sup>22</sup> described twenty-four cases of stomatitis occurring among a rice-eating population in India. These were treated with nicotinic acid and only nine showed rapid improvement, whilst seven showed some improvement and eight none. The authors concluded that the stomatitis in question was not true pellagra but arose from a multiple vitamin deficiency.

Pellagra assumed epidemic proportions in the war of 1939-45 among American prisoners of war in the Philippines after six months on a diet made up largely of carbohydrates and deficient in animal proteins, fresh fruit, vegetables and calories.<sup>23</sup> The condition was remedied by a crude yeast culture, and with less satisfactory results, by pure vitamin preparations. As might be expected the symptoms were due to a multiple vitamin deficiency rather than to a deficiency of any one vitamin.

Nicotinic acid and nicotinamide generally have a beneficial effect in pellagra and "pseudo-pellagrous conditions", and are specific in

## NICOTINIC ACID (NIAICIN)

the treatment of what may be termed "classical" pellagra, 50 to 500 mg of nicotinic acid a day cured the dermatitis in the acute form of the disease and 150 to 500 mg a day in the chronic form. Doses up to 500 mg controlled the diarrhoea, but not the neuritis or mental symptoms.<sup>24</sup> Nicotinamide in 50-mg doses effected prompt improvement in patients with atrophy of the tongue, fissures of the tongue or atrophy of the papillae.<sup>25</sup>

### Excretion of Pigment

Pellagrins excrete a red pigment in the urine. According to C J Watson<sup>26</sup> this was not porphyrin, but urorosein,<sup>27</sup> derived from its chromogen, indolylacetic acid,<sup>28</sup> by the action of other substances, e.g. nitrites, present in the urine of pellagrins,<sup>29</sup> indirubin or a closely related substance was also present.<sup>30</sup> These pigments were not observed in normal urine, although indolylacetic acid is ordinarily present, being excreted by subjects who exhibit no clinical symptoms of nicotinic acid deficiency.<sup>29</sup> There appears to be no correlation between the presence of the chromogen and nicotinic acid deficiency or its disappearance on administration of nicotinic acid, but the conversion to urorosein appears to take place spontaneously only in association with the disease. Urorosein was not present in urine from dogs with blacktongue, nor was there any increase in the coproporphyrin excretion in canine blacktongue.<sup>31</sup>

The excessive coproporphyrinuria, frequently reported in alcoholic pellagrins (see page 245), is believed by C Rimington and Z A Leitner<sup>32</sup> to be due to liver damage by the alcohol or by the dietary deficiency. Out of fifteen proved cases of pellagra only two showed excessive porphyrinuria, and these were explicable on other grounds. It was concluded that porphyrinuria is not an essential feature of pellagra.

### "Pseudo-pellagrous Conditions"

Although "classical" pellagra is due to a deficiency of nicotinic acid related conditions are known in which a deficiency of other members of the vitamin B complex co exists with a nicotinic acid deficiency and, in this event, the clinical picture is atypical. Again, other examples of nicotinic acid deficiency occur in which the causes are different from those leading to true pellagra. For convenience these various forms of nicotinic acid deficiency have been referred to as "pseudo pellagrous conditions".

All such cases are benefited by nicotinic acid or nicotinamide and in some a complete cure may result. In others, however, additional members of the vitamin B complex have to be given together with

the nicotinic acid in order to obtain a complete cure. Cures invariably result following administration of yeast or liver.

Such cases are not examples of true pellagra but of a multiple vitamin B deficiency due to the absence of several members of the vitamin B complex, and several of the cases described in the literature as pellagra are more properly regarded as of this type. According to V. P. Sydenstricker,<sup>33</sup> the paraesthesiae, neuritic pains, diminished tendon reflexes, oedema and tachycardia, often seen in so called pellagra, are relieved by aneurine, whilst the anorexia, flatulence and constipation sometimes disappear at the same time. On the other hand the psychic manifestations only disappear on administration of nicotinic acid, which also controls the nausea and diarrhoea. At the same time, the typical red tongue, due to distended capillaries, becomes blanched and the stomatitis and other lesions heal rapidly. Certain of the patients who respond in this way, however, retain some of the lesions, or acquire others, probably as the result of riboflavine deficiency, for example, seborrhoeic dermatitis of the face ('shark skin') and fissures of the lip. In some patients, the tongue acquires a purplish red colour and becomes pebbly in appearance. W. H. Sebrell and R. E. Butler<sup>34</sup> reported similar symptoms in subjects fed a riboflavine deficient diet (see page 174) thus confirming the association of riboflavine and nicotinic acid deficiencies in 'pseudo pellagrous conditions'.

Symptoms of multiple vitamin deficiency were observed in pellagra in infants by T. Gillman and J. Gillman.<sup>35</sup> In addition to dermatitis and stomatitis, presumably due to nicotinic acid deficiency, greying of hair with alopecia, steatorrhoea and large fatty livers were noted, these symptoms are generally regarded as indicating a deficiency of pantothenic acid, *p*-aminobenzoic acid or inositol.

A different type of 'pseudo pellagrous condition', which benefits by administration of nicotinic acid, is 'alcoholic pellagra'.<sup>33</sup> This is the result of an excessive consumption of spirits, and is due to the fact that the metabolism of alcohol and glucose involves the same coenzyme system, so that the two sources of energy are in competition with one another for the available nicotinic acid which is essential for their oxidation. At the same time, the loss of nicotinic acid is not made good, a high proportion of the calorie intake being derived from the spirit, which, being a distillate, does not contain any of the vitamin B complex, although fermented liquors contain considerable amounts (see page 235). F. Mainzer and M. Krause<sup>36</sup> described a case in which a chronic whisky addict, suffering from delirium tremens associated with severe gastro intestinal manifestations and acute stomatitis, responded dramatically twelve hours after oral administration of nicotinic acid.

## NICOTINIC ACID (NIAVIN)

Another example of a pseudo pellagrous state is the toxic psychosis or exhaustion delirium sometimes seen after surgical operation or delivery<sup>17</sup> Such cases have no previous history of deficiency disease but may have been maintained in hospital on a restricted diet for the treatment of gastro intestinal disease, or their metabolic demands may have been increased by fever In these cases, the onset of delirium hallucinations or mania is frequently abrupt, but physical signs are absent In rare instances there may be acute stomatitis and glossitis with an abundance of Vincent's organisms Response to nicotinic acid or nicotinamide is rapid

Another condition, due at least in part to nicotinic acid deficiency, is Wernicke's syndrome,<sup>37</sup> characterised by clouding of the consciousness, cogwheel rigidities and uncontrollable grasping and sucking reflexes, many such patients have involvement of the mid brain and some peripheral neuropathy About half of the patients examined had clinical evidence of pellagra, and all were alcoholic The mortality rate was very high, but fell considerably when nicotinic acid treatment was introduced This condition is believed to represent the extreme picture of nicotinic acid deficiency

Another form of vitamin B deficiency results when diabetics are maintained on a high carbohydrate diet with insulin injections In this instance, energy is derived from carbohydrate in excess of the vitamin reserves, which are gradually depleted and not replaced Such cases respond well to nicotinic acid and riboflavine Another type of case where similar treatment is successful is the elderly or senile stuporous condition generally given glucose to combat dehydration,<sup>38</sup> nicotinic acid treatment reduced the mortality rate dramatically in such cases It has been suggested that this result may be due in part to the vasodilator effect of nicotinic acid increasing the supply of blood to the brain (see page 274), nicotinamide and nikethamide, however, which have no vasodilator effect, produce cures in cases of stupor and encephalopathy as rapidly as does nicotinic acid

Other factors that may precipitate symptoms of nicotinic acid deficiency are hard manual work and infection, both of which lead to a heightened metabolism and therefore to an increased consumption of coenzymes I and II, snake venom, which is known to inactivate coenzyme I and cyanogenetic glycosides, which may also inactivate coenzyme I by the liberation of hydrogen cyanide

### Other Conditions affected by Nicotinic Acid

Other conditions besides pellagra and "pseudo pellagra" may benefit by nicotinic acid treatment Thus, J D King<sup>39</sup> found that nicotinic acid cured Vincent's angina, an ulcerative infection of the

# EFFECT OF DEFICIENCY IN MAN

mouth and throat known as trench mouth among the troops during the war of 1914-18. Large numbers of fusiform bacilli and spirochetes invade the tonsils in this condition and similar organisms have been reported in patients suffering from pellagrous stomatitis and glossitis in the mouths of dogs with blacktongue and in pellagrous pigs and monkeys. King concluded that a pre pellagrous condition due to nicotinic acid deficiency was one of the predisposing factors in Vincent's angina.

V. P. Sydenstricker and R. M. Cleckley<sup>40</sup> used nicotinic acid for the treatment of psychiatric disorders unconnected with pellagra. Twenty nine patients with no signs of pellagra were treated and the psychic manifestations which included manic excitement, delusions, hallucinations, disorientation and delirium tremens disappeared promptly often dramatically. In other cases treated the underlying cause may have been a vitamin deficiency.

F. J. Neuwahl<sup>41</sup> following a similar line of reasoning tried nicotinic acid in angina pectoris where the mental symptoms are similar to those in pellagrous psychosis. Administration of the drug by mouth produced a decrease in the number and severity of attacks in some cases but in others the effect was transient. Better results were obtained by drip infusion of a nicotinic acid solution. The mechanism of this effect is still obscure but may be connected with the vasodilator action of nicotinic acid (see page 274).

The paroxysms in sixteen out of nineteen asthmatical subjects were relieved when nicotinic acid was injected intravenously and the frequency and severity of the attacks were reduced in sixteen out of thirty patients by oral doses taken between attacks.<sup>42</sup> This effect is also probably associated with the vasodilator action of nicotinic acid. Again over a hundred patients with idiopathic Meniere syndrome showed improvement on treatment with nicotinic acid<sup>43</sup> though nicotinamide had no effect. In such cases nicotinic acid owes its value to its vasodilator properties.

Nicotinic acid has been stated<sup>44</sup> to benefit intestinal irregularities in patients a claim that is consistent with the existence of excessive gut movement in dogs maintained on a blacktongue-producing diet. Nicotinic acid has been used with success in so-called radiation sickness the vomiting produced by X-ray therapy.<sup>45</sup> Several cases of lupus erythematosus were reported<sup>46</sup> to have responded rapidly to oral or parenteral administration of nicotinic acid.

## References to Section 8

- 1 J. Goldberger, G. A. Wheeler and V. P. Sydenstricker *J. Amer. Med. Assoc.* 1918 71 1944

# NICOTINIC ACID (NIAICIN)

- 2 W R Aykroyd and M Swaminathan *Indian J Med Res* 1940 27, 666
- 3 M Swaminathan *ibid* 1940 28, 91
- 4 P Handler *Proc Soc Exp Biol Med* 1943 52, 263
- 5 P Ellinger R A Coulson and R Benesch *Nature* 1944 154, 270
- 6 D W Woolley *J Biol Chem* 1946 163, 773
- 7 E Kodicek K J Carpenter and L J Harris *Lancet* 1946 2, 491
- 8 E Kodicek K J Carpenter and L J Harris *ibid* 1946 2, 716  
1947 2, 616
- 9 W A Krehl P S Sarma L J Teply and C A Elvehjem *Science* 1945 101, 489 *J Nutrition* 1946 31, 85 W A Krehl P S Sarma and C A Elvehjem *J Biol Chem* 1946 162, 403
- 10 H Spector and H H Mitchell *ibid* 1946 165, 37
- 11 W A Krehl J de la Huerga and C A Elvehjem *ibid* 1946 164 551
- 12 W A Krehl L M Henderson J de la Huerga and C A Elvehjem *ibid* 1946 168, 531, F Rosen and W A Perlzweig *Arch Biochem* 1947 15, 111
- 13 R W Luecke W N McMullen F Thorp and C Tull *J Nutrition* 1947 33, 251
- 14 F Rosen J W Huff and W A Perlzweig *J Biol Chem* 1946 163, 343 R W Luecke W N McMullen F Thorp and C Tull *J Animal Sci* 1946 5, 408 B S Schweigert P B Pearson and M C Wilkening *Arch Biochem* 1947 12, 139
- 15 S A Singal A P Briggs V P Sydenstricker and J M Littlejohn *J Biol Chem* 1946 166, 573 G M Briggs A C Groschke and R J Lillie *J Nutrition* 1946 32, 659 C Furman E E Snell and W W Cravens *Poultry Sci* 1947 26, 307
- 16 B S Schweigert H L German and M J Garber *J Biol Chem* 1948 174, 383
- 17 V P Sydenstricker *Proc Roy Soc Med* 1943 36, 169
- 18 R D Williams H L Mason R M Wilder and B F Smith *Arch intern Med* 1940 66, 785
- 19 P Manson Bahr and O N Ransford *Lancet* 1938 2, 426
- 20 I Katzenellenbogen *ibid* 1939 1, 1260
- 21 J V Landor *ibid* 1939 1, 1368
- 22 W R Aykroyd B G Krishnan and R Passmore *ibid* 1939 2 825
- 23 C F Lewis and M M Musselman *J Nutrition* 1946 32, 549
- 24 V H Musick *Amer J Digest Dis Nutr* 1939 5, 807
- 25 E L Sevringhaus and E D Kyhos *Arch intern Med* 1945 76, 31
- 26 C J Watson *Proc Soc Exp Biol Med* 1939 41, 591
- 27 M Nencki and M Sieber *J prakt Chem* 1882 26, 333
- 28 C A Hertler *J Biol Chem* 1908 4 253
- 29 C J Watson and J A Layne *Ann intern Med* 1943 19, 183
- 30 S Schwartz J F Marvin J A Layne and C J Watson *ibid*, 206

## BIOSYNTHESIS

- 31 C J Watson and J A Layne *ibid* 200
- 32 C Rimington and Z A Leitner *Lancet* 1945 2, 491
- 33 V P Sydenstricker *Ann intern Med* 1941 14, 1499
- 34 W H Sebrell and R E Butler *US Publ Health Rep* 1938 53, 2282
- 35 T Gillman and J Gillman *Arch intern Med* 1945 76, 63
- 36 F Mainzer and M Krause *Brit Med J* 1939 2, 331
- 37 N Jolliffe K M Bowman L A Rosenblum and H D Fein *J Amer Med Assoc* 1940 114, 307
- 38 R M Cleckley V P Sydenstricker and L E Geeslin *ibid* 1939 112, 2107
- 39 J D King *Lancet* 1940 2 32 *Brit Dental J* 1943 74, 113
- 40 V P Sydenstricker and R M Cleckley *Amer J Psychiat* 1941 98, 83
- 41 F J Neuwohl *Lancet* 1942 2, 419
- 42 G Melton *Brit Med J* 1943 1, 600
- 43 M Atkinson *Arch Otolaryngol* 1944 40, 101
- 44 L A Crandall F F Chesley D Hansen and J Dunbar *Proc Soc Exp Biol Med* 1939 41, 472
- 45 J W Graham *J Amer Med Assoc* 1939 113, 664
- 46 W W Kuhnau *Alin Woch* 1939 18, 1117

## 9 BIOSYNTHESIS OF NICOTINIC ACID

Two contrasting views have been advanced to account for the interchangeability of nicotinic acid and tryptophan. It is maintained on the one hand that tryptophan is directly converted into nicotinic acid in the tissues of animals and on the other that tryptophan acts as a catalyst for the synthesis of nicotinamide by intestinal bacteria.


The evidence supporting the first hypothesis is as follows. Symptoms of nicotinic acid deficiency in the pig<sup>1</sup> the dog<sup>2</sup> and in humans<sup>3</sup> were relieved by the administration of L tryptophan and the reserves of nicotinic acid and the urinary excretion of nicotinic acid metabolites were thereby increased. Administration of sulphasuxidine did not impair the action of tryptophan in relieving symptoms of pellagra in humans although such a result could be anticipated if the intestinal flora were involved. Moreover the *intravenous* administration of L-tryptophan to infants gave a prompt and large increase in the urinary output of N<sup>1</sup> methyl nicotinamide<sup>4</sup>. The synthesis of nicotinic acid by rats was apparently not affected by elimination of the bacterial flora<sup>5</sup> or by enterectomy<sup>6</sup> and nicotinic acid was synthesised from tryptophan by rat liver slices<sup>7</sup>. Indirect evidence in support of the view that tryptophan is converted directly into nicotinic acid is that the presence of pyridoxine is essential for



# NICOTINIC ACID (NIACIN)

nicotinic acid synthesis, none being formed when vitamin B<sub>6</sub>-deficient rats were given tryptophan<sup>8</sup> It is known that pyridoxine like compounds are involved in amino acid metabolism (page 330)

Further evidence has been obtained by C Heidelberg and his colleagues<sup>9</sup> from a study of the metabolism of tryptophan containing isotopic carbon, C<sup>14</sup>, at various positions in the molecule When DL tryptophan β C<sup>14</sup> (I) was fed to rabbits, dogs and rats, kynurenine (II) and kynurenic acid (III) containing C<sup>14</sup> were isolated together with nicotinic acid from which C<sup>14</sup> was absent On the other hand, when DL-tryptophan-3 C<sup>14</sup> (IV) was fed to the animals, kynurenine, 3 hydroxyanthranilic acid (V) and nicotinic acid, all containing C<sup>14</sup>, were isolated from the urine, in the last two compounds, the C<sup>14</sup> was in the carboxyl groups These changes can be represented as follows



When DL tryptophan containing C<sup>13</sup> in the carboxyl group was administered to rats<sup>10</sup> the N<sup>1</sup> methylnicotinamide excreted in the urine did not contain C<sup>13</sup>

That 3 hydroxyanthranilic acid is indeed an intermediate in the conversion of tryptophan into nicotinic acid is confirmed by the fact

that it can replace tryptophan in promoting the growth of rats<sup>11</sup> and that it is converted into nicotinic acid and quinolinic acid by rat liver slices<sup>12</sup>. Quinolinic acid was excreted by rats following intraperitoneal injection of 3-hydroxyanthranilic acid or L-tryptophan<sup>13</sup>. An analogous series of transformations to the foregoing has been shown to take place with certain microorganisms (see page 281). That L-kynurenine but not kynurenic acid is an intermediate in the synthesis of nicotinic acid is confirmed by the observation that the former but not the latter increased the N<sup>1</sup>-methylnicotinamide excretion in rats<sup>14</sup>.

The supporters of the contrary view that tryptophan merely stimulates the synthesis of nicotinic acid by intestinal bacteria are P. Ellinger and M. M. Abdel Kader<sup>15</sup>. They observed that although a mixed culture from rats' caecum was apparently able to produce nicotinamide from tryptophan, *Escherichia coli* was not able to effect this transformation in the absence of lactate, whereas ornithine and to a smaller extent glutamine and arginine were readily converted into nicotinamide. The synthesis was completely inhibited by 2, 4, 5 and 7-methyltryptophan. Since more N<sup>1</sup>-methylnicotinamide was excreted when tryptophan was given to rats orally than when given parenterally, and since less was excreted when the animals were given sulphasuxidine, it was concluded that the nicotinamide was synthesised by the intestinal flora and that the precursor was ornithine, not tryptophan. It is suggested that the latter is a catalyst stimulating the formation of ornithine.

These two views are not irreconcilable and in any event none of the evidence advanced in support of the intestinal synthesis hypothesis is opposed to the view that tryptophan can be converted into nicotinic acid directly in the tissues of animals.

The recognition of L-tryptophan as a precursor of nicotinic acid makes it necessary to assume that pellagra can only occur where there is deficiency of both nicotinic acid and tryptophan in the diet. By feeding two normal adults on a diet of known nicotinic acid content and estimating the urinary output of N<sup>1</sup>-methyl-6-pyridone-3-carboxylamide (page 255) and other nicotinic acid metabolites, W. I. M. Holman and D. J. de Lange<sup>16</sup> found that the ingestion of 12 g of L-tryptophan over the test period increased the nicotinic acid output by 145 and 181 mg in the two individuals. This implies that the tryptophan in the diet normally equal to about 11 g per day may be of great importance in the prevention of pellagra.

#### References to Section 9

1. R. W. Luecke, W. N. McMullen, F. Thorp and C. Tull, *J. Nutrit.* 1948, 36, 417.
1. Rosen and W. A. Perlzweig, *J. Biol. Chem.* 1949, 177, 163.

## NICOTINIC ACID (NIAICIN)

2. S. A. Singal, V. P. Sydenstrcker and J. M. Littlejohn, *J. Biol. Chem.*, 1948, **176**, 1051, 1063.
3. V. A. Najjar, L. E. Holt, G. A. Johns, G. C. Medairy and G. Fleischmann, *Proc. Soc. Exp. Biol. Med.*, 1946, **61**, 371; H. P. Sarett and G. A. Goldsmith, *J. Biol. Chem.*, 1949, **177**, 461; R. W. Vilter, J. F. Mueller and W. B. Bean, *J. Lab. Clin. Med.*, 1949, **34**, 409.
4. S. E. Snyderman, K. C. Ketron, R. Carretero and L. E. Holt, *Proc. Soc. Exp. Biol. Med.*, 1949, **70**, 569.
5. J. M. Hundley, *ibid.*, 592.
6. L. M. Henderson and L. V. Hanks, *ibid.*, 26.
7. W. W. Hurt, B. T. Scheer and H. J. Deuel, *Arch. Biochem.*, 1949, **21**, 37.
8. B. S. Schweigert and P. B. Pearson, *J. Biol. Chem.*, 1947, **168**, 555; G. H. Bell, B. T. Scheer and H. J. Deuel, *J. Nutrition*, 1948, **35**, 239.
9. C. Heidelberger, M. E. Gullberg, A. F. Morgan and S. Lepkovsky, *J. Biol. Chem.*, 1948, **175**, 471; C. Heidelberger, E. P. Abraham and S. Lepkovsky, *ibid.*, 1949, **176**, 1461; C. Heidelberger, *ibid.*, 1949, **179**, 139; C. Heidelberger, M. E. Gullberg, A. F. Morgan and S. Lepkovsky, *ibid.*, 143; C. Heidelberger, E. P. Abraham and S. Lepkovsky, *ibid.*, 151.
10. J. M. Hundley and H. W. Bond, *Arch. Biochem.*, 1949, **21**, 313.
11. H. K. Mitchell, J. F. Nyc and R. D. Owen, *J. Biol. Chem.*, 1948, **175**, 433; P. W. Albert, B. T. Scheer and H. J. Deuel, *ibid.*, 479.
12. B. S. Schweigert, *ibid.*, 1949, **178**, 707; B. S. Schweigert and M. M. Marquette, *ibid.*, 1949, **181**, 199.
13. L. M. Henderson, *ibid.*, 1949, **178**, 1005.
14. R. E. Kallio and C. P. Berg, *ibid.*, 1949, **181**, 333.
15. P. Ellinger and M. M. Abdel Kader, *Nature*, 1947, **160**, 675; 1949, **163**, 799; *Biochem. J.*, 1949, **44**, 285, 506; 1949, **45**, 276.
16. W. I. M. Holman and D. J. de Lange, *Nature*, 1950, **165**, 112.

## 10. METABOLISM OF NICOTINIC ACID

### Fate of Ingested Nicotinic Acid and Nicotinamide

The earliest attempts to study the fate of nicotinic acid in the body were confined to the estimation of the urinary excretion of free nicotinic acid and its amide. Normal subjects were said to excrete up to 30 mg. per day,<sup>1, 2</sup> whereas in pellagrins the amount excreted was extremely low.<sup>3</sup>

It was soon recognised, however, that ingested nicotinic acid was excreted in other forms, and the first derivatives of nicotinic acid to be recognised as metabolites were nicotinuric acid and trigonelline.

Melnick and his colleagues<sup>2,4</sup> worked out a method of estimating nicotinic acid, nicotinamide, nicotinuric acid and trigonelline separately in urine (see page 224) and used the method to study the fate of ingested nicotinic acid. They found that the total free and combined nicotinic acid in the urine increased when additional nicotinic acid was given. Most of the increase (over 50 %) was apparently due to trigonelline, a substantial proportion (36 %) to nicotinuric acid and only 13 % to nicotinic acid and nicotinamide. The ingestion of nicotinamide was followed by a slower excretion of nicotinic acid compounds. 80 to 90 % of which apparently consisted of trigonelline. The excretion of trigonelline was also increased by heavy smoking or by drinking coffee so that both these sources of interference must be eliminated in metabolic studies on nicotinic acid.

These and other results obtained prior to 1943 do not however take into account the excretion of part of the ingested nicotinic acid as  $N^1$  methylnicotinamide and  $N^1$  methyl 6 pyridone 3 carboxylamide which were discovered subsequently. The values reported for the urinary trigonelline probably included the  $N^1$  methylnicotinamide and the pyridone.

Rats were said to convert a substantial proportion of ingested nicotinic acid into trigonelline and nicotinuric acid, only a small amount being excreted unchanged.<sup>5</sup> Nicotinamide was apparently excreted mainly as trigonelline (but see below).


Somewhat similar results were obtained with dogs<sup>6</sup> which apparently excreted trigonelline and nicotinuric acid as the principal end products of nicotinic acid metabolism. On a blacktongue producing diet the amount of (apparent) trigonelline excreted fell to 0.1 mg per day and several 25 mg doses of nicotinic acid were required to increase the output to normal levels. On a diet containing 1.1 mg of nicotinic acid per kg, 50 % was excreted in the urine, 90 % of it in the form of (apparent) trigonelline. After saturation with nicotinic acid, 100 mg doses of nicotinamide were completely excreted as (apparent) trigonelline (75 to 94 %) and nicotinuric acid (6 to 25 %). Neither trigonelline nor nicotinuric acid was utilized by the dog.

Rabbits excreted 1.54 mg of nicotinic acid per day or 0.77 mg per kg of bodyweight per day in the urine when maintained on a normal diet but less than half that amount on a pellagra producing diet. The urinary excretion increased on administration of nicotinic acid.<sup>7</sup> According to M. Swaminathan,<sup>8</sup> rabbits on a diet low in nicotinic acid (0.7 mg per kg) excreted 0.15 mg of nicotinic acid and 0.086 mg of (apparent) trigonelline in the urine daily and almost similar amounts in the faeces. When given extra nicotinic acid, 15 to 20 % of it was excreted in the urine.

## NICOTINIC ACID (NIACIN)

It was prepared from N<sup>1</sup>-methylnicotinamide by the quinine-oxidising enzyme of rabbit liver,<sup>20</sup> and synthesised by treatment of N<sup>1</sup>-methyl-3-carboxy-6-pyridone (prepared by oxidising trigonelline with alkaline ferricyanide or by ring closure of coumalic acid with methylamine) with thionyl chloride and ammonia.<sup>21</sup> Methylation and oxidation of nicotinamide gave the isomer, N<sup>1</sup>-methyl-2-pyridone-3-carboxylamide.<sup>21a</sup>

Another metabolite was isolated from dried chick droppings by W. J. Dann and J. W. Huff<sup>22</sup> and identified as dinicotinyl ornithine:



Thus the metabolism of nicotinic acid and nicotinamide is extremely complex, and the early results reported in the literature may be misleading, as they do not take into account all the substances into which nicotinic acid may be converted.

### Excretion of Nicotinic Acid and its Metabolites in Urine

A true picture of the fate of nicotinic acid in the body was only obtained when the excretion of N<sup>1</sup>-methylnicotinamide was taken into account. The method used for estimating trigonelline, involving hydrolysis to nicotinic acid with strong alkali, also converts N<sup>1</sup>-methylnicotinamide into nicotinic acid, so that any F<sub>2</sub> present would, in the earlier studies, have been included in the values reported for trigonelline.<sup>23</sup> When 200 mg. of N<sup>1</sup>-methylnicotinamide were given orally to a normal adult, 55 mg of F<sub>2</sub> and 85 mg. of trigonelline were excreted within forty-eight hours, so that the organism is evidently capable of effecting the transformation of the amide into the betaine.

Hochberg *et al*<sup>24</sup> found that the urinary output of N<sup>1</sup>-methylnicotinamide on a diet yielding 23 mg. of nicotinic acid per day was 3 to 8 mg. daily, and that when this was supplemented with 50 to 200 mg. of nicotinamide, the excretion increased by an amount equivalent to about 20 % of the test dose over a twenty-four hour period; one-third of this was eliminated in the first four hours. On the other hand, O. Mickelsen and L. L. Erickson<sup>25</sup> found that the amounts of N<sup>1</sup>-methylnicotinamide excreted by normal subjects differed but little with diets providing from 0.12 to 22.4 mg. of nicotinic acid daily, so that merely measuring the excretion of N<sup>1</sup>-methylnicotinamide resulting from an unsupplemented diet could give no useful information as to the state of nicotinic acid nutrition. Johnson *et al.*<sup>26</sup> however, found that 94 % of the nicotinic acid derivatives excreted in

human urine consisted of N<sup>1</sup> methyl nicotinamide and that only 1 to 15 % was excreted in the form of the free acid and 35 to 45 % as nicotinamide. Thus opinions vary greatly as to the amounts of N<sup>1</sup> methyl nicotinamide excreted at different levels of nicotinic acid intake. A possible reason for these discordant results was suggested by W. A. Perlzweig and J. W. Huff<sup>27</sup> who found that when nicotinamide was administered orally to man 10 to 20 % was excreted in the form of N<sup>1</sup> methyl nicotinamide and that a similar amount was excreted when N<sup>1</sup> methyl nicotinamide itself was administered orally. When trigonelline was injected no appreciable conversion into N<sup>1</sup> methyl nicotinamide occurred whilst when N<sup>1</sup> methyl nicotinamide was injected intravenously 67 % was recovered unchanged in the urine. Perlzweig and Huff therefore suggested that the amount of N<sup>1</sup> methyl nicotinamide excreted is the resultant of at least two processes, one the conversion of nicotinic acid into N<sup>1</sup> methyl nicotinamide and the other the conversion of N<sup>1</sup> methyl nicotinamide into other substances. This was confirmed by subsequent work. Thus when rats were fed large amounts of nicotinic acid containing C<sup>13</sup> in the carboxyl group almost all of the isotopic carbon was recovered in the N<sup>1</sup> methyl nicotinamide excreted in the urine<sup>27a</sup> although in the mouse about 15 % of a dose of nicotinic acid or amide was lost by decarboxylation. For on feeding nicotinic acid containing C<sup>14</sup> in the carboxyl group or the corresponding amide 15 % of the C<sup>14</sup> appeared as exhaled carbon dioxide<sup>2b</sup>. In man the urinary excretion of N<sup>1</sup> methyl-6 pyridone-3-carboxylamide accounted for about 50 % of a dose of nicotinamide and when N<sup>1</sup> methyl nicotinamide was administered 20 % was excreted in the urine unchanged and 19 % as the pyridone<sup>2c</sup>. Relatively less pyridone and more N<sup>1</sup> methyl nicotinamide was excreted by infants than by adults<sup>2d</sup>.


The most complete data on the urinary excretion of nicotinic acid and its metabolites are those of P. Ellinger and M. M. Abdel Kader<sup>28</sup>. They found contrary to the claims made by many earlier workers that no trigonelline or nicotinuric acid was excreted by man or by the rat, cat, guinea pig or rabbit on a normal diet. The following values were obtained for the excretion of other metabolites (mg per day)

	Nicotinamide	Nicotinic acid	N <sup>1</sup> methyl nicotinamide
Man	0.640	0.2516	3.16
Rat	0.004016	0	0.030
Cat	0	0	0.0704
Guinea pig	0	0	0
Rabbit	0	0.515	0

## NICOTINIC ACID (NIACIN)

It was prepared from N<sup>1</sup>-methylnicotinamide by the quinine-oxidising enzyme of rabbit liver,<sup>20</sup> and synthesised by treatment of N<sup>1</sup>-methyl-3-carboxy 6-pyridone (prepared by oxidising trigonelline with alkaline ferricyanide or by ring closure of coumalic acid with methylamine) with thionyl chloride and ammonia.<sup>21</sup> Methylation and oxidation of nicotinamide gave the isomer, N<sup>1</sup> methyl-2-pyridone-3-carboxylamide.<sup>21a</sup>

Another metabolite was isolated from dried chick droppings by W J Dann and J W Huff<sup>22</sup> and identified as dinicotinyl ornithine



Thus the metabolism of nicotinic acid and nicotinamide is extremely complex, and the early results reported in the literature may be misleading, as they do not take into account all the substances into which nicotinic acid may be converted

### Excretion of Nicotinic Acid and its Metabolites in Urine

A true picture of the fate of nicotinic acid in the body was only obtained when the excretion of N<sup>1</sup> methylnicotinamide was taken into account. The method used for estimating trigonelline, involving hydrolysis to nicotinic acid with strong alkali, also converts N<sup>1</sup>-methylnicotinamide into nicotinic acid, so that any F<sub>2</sub> present would, in the earlier studies, have been included in the values reported for trigonelline.<sup>23</sup> When 200 mg of N<sup>1</sup>-methylnicotinamide were given orally to a normal adult, 55 mg of F<sub>2</sub> and 85 mg of trigonelline were excreted within forty eight hours, so that the organism is evidently capable of effecting the transformation of the amide into the betaine.

Hochberg *et al*<sup>24</sup> found that the urinary output of N<sup>1</sup> methyl-nicotinamide on a diet yielding 23 mg of nicotinic acid per day was 3 to 8 mg daily and that when this was supplemented with 50 to 200 mg of nicotinamide, the excretion increased by an amount equivalent to about 20 % of the test dose over a twenty-four hour period, one-third of this was eliminated in the first four hours. On the other hand, O Mickelsen and L L Erickson<sup>25</sup> found that the amounts of N<sup>1</sup>-methylnicotinamide excreted by normal subjects differed but little with diets providing from 0.12 to 22.4 mg of nicotinic acid daily, so that merely measuring the excretion of N<sup>1</sup>-methylnicotinamide resulting from an unsupplemented diet could give no useful information as to the state of nicotinic acid nutrition. Johnson *et al*<sup>26</sup> however, found that 94 % of the nicotinic acid derivatives excreted in

human urine consisted of  $N^1$  methyl nicotinamide and that only 1 to 15 % was excreted in the form of the free acid and 35 to 45 % as nicotinamide. Thus opinions vary greatly as to the amounts of  $N^1$ -methyl nicotinamide excreted at different levels of nicotinic acid intake. A possible reason for these discordant results was suggested by W. A. Perlzweig and J. W. Huff<sup>27</sup> who found that when nicotinamide was administered orally to man 10 to 20 % was excreted in the form of  $N^1$  methyl nicotinamide and that a similar amount was excreted when  $N^1$  methyl nicotinamide itself was administered orally. When trigonelline was injected no appreciable conversion into  $N^1$  methyl nicotinamide occurred whilst when  $N^1$  methyl nicotinamide was injected intravenously 67 % was recovered unchanged in the urine. Perlzweig and Huff therefore suggested that the amount of  $N^1$  methyl nicotinamide excreted is the resultant of at least two processes, one the conversion of nicotinic acid into  $N^1$  methyl nicotinamide and the other the conversion of  $N^1$  methyl nicotinamide into other substances. This was confirmed by subsequent work. Thus when rats were fed large amounts of nicotinic acid containing  $C^{13}$  in the carboxyl group almost all of the isotopic carbon was recovered in the  $N^1$  methyl nicotinamide excreted in the urine<sup>27a</sup> although in the mouse about 15 % of a dose of nicotinic acid or amide was lost by decarboxylation. For on feeding nicotinic acid containing  $C^{14}$  in the carboxyl group or the corresponding amide 15 % of the  $C^{14}$  appeared as exhaled carbon dioxide<sup>2b</sup>. In man the urinary excretion of  $N^1$  methyl-6-pyridone 3-carboxylamide accounted for about 50 % of a dose of nicotinamide and when  $N^1$  methyl nicotinamide was administered 20 % was excreted in the urine unchanged and 19 % as the pyridone<sup>2c</sup>. Relatively less pyridone and more  $N^1$  methyl nicotinamide was excreted by infants than by adults<sup>2d</sup>.

The most complete data on the urinary excretion of nicotinic acid and its metabolites are those of P. Ellinger and M. M. Abdel Kader<sup>28</sup>. They found contrary to the claims made by many earlier workers that no trigonelline or nicotinuric acid was excreted by man or by the rat, cat, guinea pig or rabbit on a normal diet. The following values were obtained for the excretion of other metabolites (mg per day)

	Nicotinamide	Nicotinic acid	$N^1$ -methyl nicotinamide
Man	0.640	0.25126	3.16
Rat	0.004016	0	0.030
Cat	0	0	0.0704
Guinea pig	0	0	0
Rabbit	0	0.515	0



# NICOTINIC ACID (NIAFIN)

Somewhat different results were obtained following the injection of nicotinic acid, nicotinamide and nikethamide (diethylnicotinamide) The values ( $\mu\text{g}$ ) found were :

	Compound ( $\mu\text{g}$ )	Excretion			
		Nicotin- amide	Nicotinic acid	Methyl- nicotin- amide	Trigonelline
Man	Nicotin- amide 100	1 8	0	25 0	0
	Nicotinic acid 100	2 5	0 9	21 2	0
	Niketh- amide 100	6 3	0	15 6	0
Rat	Nicotin amide 20	15-24	0	9-30	0
	Nicotinic acid 20	24 0	27 0	2 16	0
	Niketh- amide 20	36 8	0	10-33	0
Cat	Nicotin- amide 40	34 8	0	28 5	0
	Nicotinic acid 40	12 8	9 8	24 2	0
	Niketh- amide 40	18 9	0	16 1	0
Guinea-pig	Nicotin- amide 200	0	24 2	0	0
	Nicotinic acid 200	0	82 2	0	0
	Niketh- amide 50	19 2	40 8	0	0
Rabbit	Nicotin- amide 200	7-12	13-15	0	6 9
	Nicotinic acid 200	0	50 63	0	29 33
	Niketh- amide 200	4 8	9 9	0	6 9

Thus all the species examined, except the guinea pig were able to methylate either nicotinamide or nicotinic acid but methionine appeared to have no constant effect on the metabolism Nicotinic acid was aminated in man and in dogs, cats and rats but not in rabbits and guinea-pigs, whilst rabbits and guinea-pigs, but not the

other four species deaminated nicotinamide. When rabbits were given a meat bread diet in place of a diet of cabbage or oats, the methylating mechanism was suppressed completely and the deaminating mechanism partially.

Following oral or subcutaneous administration of 2 g of nicotinamide daily for three days goats, sheep and calves excreted slightly more  $N^1$  methylnicotinamide than usual, goats and sheep also excreted slightly more  $N^1$ -methyl 6-pyridone 3-carboxylamide but no measurable amount was excreted by calves.<sup>28a</sup>

### Assessment of Nutritional Status

It has been pointed out above (page 257) that the excretion of  $N^1$  methylnicotinamide by subjects given an unsupplemented diet cannot be used to measure nutritional status. More promising results were obtained when the increased excretion of  $N^1$  methylnicotinamide and other metabolites of nicotinic acid was estimated following the administration of a test dose of nicotinic acid or nicotinamide. G. A. Goldsmith<sup>29</sup> found that normal subjects given a 300 mg dose of nicotinamide by mouth excreted twice as much trigonelline (this would also have included any  $N^1$  methylnicotinamide) as hospital patients given the same treatment, whilst patients with pellagra or vitamin B complex deficiency excreted still less. He suggested that measurement of the nicotinic acid derivatives excreted within six hours of administering a 300 mg test dose of nicotinamide orally was a useful indication of nutritional status.

Perlzweig *et al.*<sup>30</sup> found that excretion of both trigonelline and nicotinic acid was increased after intravenous injection of a 500-mg dose of nicotinamide. "Normal" subjects however showed a lower excretion than did hospital patients, presumably because in this instance the latter were the more saturated with respect to nicotinic acid. The urinary excretion of nicotinic acid after a test dose was much less in pellagrins than in controls,<sup>31</sup> and the response to a test dose was said to be a better criterion of nicotinic acid deficiency than a low blood level.

According to P. Ellinger and R. A. Coulson,<sup>32</sup> from 2 to 8 mg of  $N^1$  methylnicotinamide are eliminated daily in the urine and this is increased by the ingestion of additional nicotinamide or nicotinic acid though significant amounts are stored in the body. They found that the elimination curve was constant for different individuals but that the height of the curve depended on the dietary intake and on the efficiency of the methylation mechanism of the body. They suggested that  $N^1$  methylnicotinamide was not the final metabolite, but that this was converted into other products not yet identified.

## NICOTINIC ACID (NIACIN)

(One of these is presumably N<sup>1</sup> methyl 6 pyridone 3 carboxylamide page 255) This view is also supported by the findings of W A Perlzweig and J W Huff<sup>27</sup> referred to above

Similar saturation tests were used by several other workers<sup>33 36</sup> in these the amount of N<sup>1</sup>-methylnicotinamide excreted in the urine in response to nicotinamide orally administered was measured Substantially lower excretions were observed in pellagrins than in healthy subjects<sup>33 35 36 37</sup> e.g. deficient subjects excreted up to 5 % only of the test dose compared with 8 to 25 % excreted by controls The excretion of acid hydrolysable nicotinic acid derivatives in normal subjects is remarkably constant and no significant difference was observed in the output of non pregnant women and women in early pregnancy<sup>39a</sup> In the last trimester of pregnancy however the amount excreted increased significantly and so did the proportion of a 50 mg test dose that was eliminated suggesting that the maternal organism requires additional coenzymes I and II in the last three months of pregnancy and that during this period there is a greater turnover of coenzymes

Not only may the extent to which N<sup>1</sup> methylnicotinamide is eliminated be influenced by the efficiency of the methylating mechanism but it will also depend on the efficiency of absorption from the intestine<sup>37 38</sup> This second factor affects the response in pellagrins but not in healthy persons A third factor that may influence nicotinamide saturation tests is the presence of bacteria in the intestine that either synthesise<sup>37, 39 40 42</sup> or destroy<sup>41 42</sup> nicotinamide

A critical study of the effect of methionine on the nicotinamide saturation test was undertaken by P Ellinger and S W Hardwick<sup>43</sup> who demonstrated that the test previously proposed by them<sup>38</sup> might be affected by exhaustion of the methyl donors of the body and therefore not provide a true picture of nicotinamide status It was found for instance that methionine gave a greater response after ingestion of 500 mg of nicotinamide than after ingestion of 100 mg Accordingly the test was modified the amount of N<sup>1</sup> methylnicotinamide excreted in the urine being estimated each day for eighteen days immediately after the third sixth ninth and twelfth collections 100 mg of nicotinamide were administered subcutaneously on the first and last orally on the second and rectally on the third occasion The percentage recovery of ingested nicotinamide was calculated for a twenty four hour and a seventy two hour period Three pellagrins gave a response of 3.28 mg and 5.35 mg after twenty four and seventy

N<sup>1</sup> Methylnicotinamide was excreted by the infants following the administration of nicotinamide nicotinic acid

or diethylnicotinamide, but in this instance methionine appeared to have no effect on the methylation<sup>41</sup>

### Conversion of Tryptophan into Nicotinic Acid and Its Metabolites

Another important factor that has to be borne in mind in attempting to assess the nicotinic acid status of any individual is the possibility that the administration of other substances besides nicotinic acid may result in an increased excretion of N<sup>1</sup> methyl nicotinamide. Tryptophan is of particular importance in this respect for, as already stated (page 241), the rat, pig, horse, cotton-rat, chick and turkey are able to convert dietary tryptophan into nicotinic acid<sup>42-45</sup>. Clearly therefore, different N<sup>1</sup> methyl nicotinamide excretions would be expected to occur on diets that differ markedly in the amount of tryptophan present.

Such variations were in fact found by Rosen *et al.*,<sup>42</sup> who showed that the amount of nicotinic acid excreted by rats dropped immediately when the casein in the diet was replaced by gelatine, which contains much less tryptophan. The addition of tryptophan led to a large increase in the excretion of nicotinic acid and N<sup>1</sup>-methyl nicotinamide, the amount of nicotinic acid was so large, in fact, that it exceeded the capacity of the animals to methylate it. Similarly P. Ellinger<sup>43</sup> observed a fall in the urinary N<sup>1</sup> methyl nicotinamide when rats were fed on a maize diet instead of a diet containing wheat and oats. As already mentioned wheat and oats contain much more tryptophan than does maize. When nicotinamide was given to the animals, followed by the injection of a mixture of chloroform and carbon tetrachloride, which causes liver damage, the excretion of N<sup>1</sup> methyl nicotinamide first increased and then fell markedly.

Similar observations were made by H. P. Sarett and G. A. Goldsmith<sup>40</sup> and Perlzweig *et al.*<sup>44</sup> with human subjects, the urinary excretion of N<sup>1</sup> methyl nicotinamide increasing on administration of L- or DL-tryptophan.

Horses behave rather differently from other animals in that on a normal diet they excrete only small amounts of N<sup>1</sup> methyl nicotinamide although, rather paradoxically, on a diet containing only 0.1 mg. of nicotinic acid per kg., they excreted N<sup>1</sup> methyl nicotinamide and no nicotinamide, nicotinic acid or glycuronide<sup>45</sup>. However, the oral ingestion of 2 g. of nicotinic acid daily led to the excretion of 18 to 54% of unchanged acid together with a little nicotinic acid, and the oral administration or subcutaneous injection of nicotinamide resulted in the excretion of 5% of unchanged amide, the remainder being unaccounted for. No increase in the excretion of trigonelline or N<sup>1</sup> methyl nicotinamide resulted from administration of either nicotinic acid or the amide.

Similarly when 6 g of DL-tryptophan were fed to horses, the amount of free nicotinic acid excreted increased two- to four fold whereas the N<sup>1</sup> methylnicotinamide remained unchanged <sup>47</sup> This was in marked contrast to the behaviour of cotton rats, which excreted large amounts of N<sup>1</sup> methylnicotinamide after ingestion of nicotinic acid or tryptophan

The amount of nicotinic acid formed from dietary tryptophan was increased when pyridoxine was added to the diet of rats or mice a result to be anticipated from the fact that administration of tryptophan accentuated pyridoxine deficiency in the rat and mouse (see page 331) Thus, when 100 mg of DL-tryptophan were added to the basal ration, rats fed pyridoxine excreted 810 to 2190  $\mu$ g of N<sup>1</sup> methylnicotinamide per day, whilst deficient animals excreted 180 to 485  $\mu$ g per day <sup>53</sup> With the basal diet only, the excretions were 95 to 185 and 45 to 140  $\mu$ g per day respectively The corresponding values for excreted nicotinic acid were 95 to 430, 16 to 35, 23 to 50, and 10 to 24  $\mu$ g per day

Conversely, when pyridoxine was omitted from the diet of rats the amount of excreted nicotinic acid and metabolites fell A similar result was obtained when aneurine or riboflavin but not pantothenic acid or pteroylglutamic acid were omitted When sulphasuxidine was added to a pteroylglutamic acid deficient diet however, nicotinic acid excretion was depressed although administration of sulphasuxidine when the diet contained pteroylglutamic acid did not affect the excretion <sup>53a</sup>

### Nicotinic Acid in Blood and Cerebrospinal Fluid

Some of the difficulties inherent in the estimation of nicotinic acid in urine apply to its estimation in blood

### Factor V

The earliest values for the nicotinic acid content of blood relate to its coenzyme, or as it was first called, factor V', content (see page 229) According to H von Euler and F Schlenk, <sup>54</sup> normal blood contained 4 to 8 mg of factor V per 100 ml, and 150  $\mu$ g of nicotinamide per 100 ml

The effect of nicotinic acid deficiency on the amount of coenzyme present in various tissues of the dog was studied by Kohn *et al* <sup>55</sup> and by M Pittman and H F Fraser, <sup>56</sup> who used *Haemophilus para influenzae* as the test organism They observed a decrease in the factor V content of the liver and muscle in blacktongue whilst Axelrod *et al*, <sup>57</sup> using a yeast fermentation method found a similar decrease

in the coenzyme I content of the liver and muscle of nicotinic acid deficient dogs and pigs. H. I. Kohn<sup>58</sup> and Vilter *et al*<sup>59</sup> observed that the factor V content of the blood of pellagrins increased after administration of nicotinic acid whilst H. I. Kohn and J. R. Klein<sup>60</sup> and Vilter *et al*<sup>61</sup> showed that incubation of defibrinated blood with nicotinic acid increased its factor V content. Ingestion of large amounts of nicotinic acid increased the coenzyme I content of the erythrocytes<sup>62</sup>.

Using *Bacillus influenzae* Vilter *et al*<sup>59, 63</sup> found that the factor V content of the blood decreased in pellagra but H. I. Kohn and F. Bernheim<sup>64</sup> using *H. parainfluenzae* failed to find any significant difference in the amount of factor V present in erythrocytes from pellagrins compared with controls. This was confirmed by Axelrod *et al*<sup>65</sup> using the yeast fermentation method<sup>66</sup> they found that the coenzyme I content of erythrocytes averaged 85  $\mu\text{g}$  per ml in controls 77 and 69  $\mu\text{g}$  per ml in sub-clinical and mild pellagra respectively and from 70 to 90  $\mu\text{g}$  per ml in severe cases. The amount in muscle on the other hand decreased from 382 in controls to 317, 258 and 214  $\mu\text{g}$  per g in sub-clinical, mild and severe pellagra respectively.

### Nicotinic Acid in Blood

B. D. Kochhar<sup>67</sup> using acid hydrolysis followed by colour development as in Swaminathan's method found that the nicotinic acid content of blood varied from 230 to 650  $\mu\text{g}$  per 100 ml with an average value of 367  $\mu\text{g}$  per 100 ml. These values presumably included the free nicotinic acid, nicotinamide, nicotinic acid and coenzymes I and II but not trigonelline or N<sup>1</sup>-methyl nicotinamide. Most of the nicotinic acid was present in the corpuscles, the value for serum being 62 to 170 with an average of 92  $\mu\text{g}$  per 100 ml. Cerebrospinal fluid was found to contain 56 to 120 with an average of 92  $\mu\text{g}$  per 100 ml of acid hydrolysable nicotinic acid derivatives.

Most of the nicotinic acid in dogs' blood was present in the red cells<sup>68</sup> the actual values found being 77 % in the erythrocytes, 12 % in the leucocytes and 11 % in the plasma. Oral administration of nicotinic acid increased the plasma nicotinic acid to a greater extent than the erythrocyte nicotinic acid. Oral administration of 200-mg doses of nicotinic acid daily to humans slightly increased the blood level up to a maximum value which was maintained as long as the additional nicotinic acid was given<sup>69</sup>. Oral administration of a single dose temporarily increased the blood level, a peak being reached after thirty minutes.

Nicotinic acid was taken up quantitatively by red blood cells *in vitro* and fixed in the cells in a non-diffusible form, presumably as

Similarly when 6 g of DL-tryptophan were fed to horses, the amount of free nicotinic acid excreted increased two- to four fold whereas the N<sup>1</sup> methylnicotinamide remained unchanged<sup>47</sup> This was in marked contrast to the behaviour of cotton rats, which excreted large amounts of N<sup>1</sup> methylnicotinamide after ingestion of nicotinic acid or tryptophan

The amount of nicotinic acid formed from dietary tryptophan was increased when pyridoxine was added to the diet of rats or mice a result to be anticipated from the fact that administration of tryptophan accentuated pyridoxine deficiency in the rat and mouse (see page 331) Thus, when 100 mg of DL tryptophan were added to the basal ration, rats fed pyridoxine excreted 810 to 2190  $\mu$ g of N<sup>1</sup>-methylnicotinamide per day, whilst deficient animals excreted 180 to 485  $\mu$ g per day<sup>53</sup> With the basal diet only, the excretions were 95 to 185 and 45 to 140  $\mu$ g per day respectively The corresponding values for excreted nicotinic acid were 95 to 430, 16 to 35, 23 to 50, and 10 to 24  $\mu$ g per day

Conversely, when pyridoxine was omitted from the diet of rats the amount of excreted nicotinic acid and metabolites fell A similar result was obtained when aneurine or riboflavin but not pantothenic acid or pteroylglutamic acid were omitted When sulphasuxidine was added to a pteroylglutamic acid deficient diet, however, nicotinic acid excretion was depressed although administration of sulphasuxidine when the diet contained pteroylglutamic acid did not affect the excretion<sup>53a</sup>

### Nicotinic Acid in Blood and Cerebrospinal Fluid

Some of the difficulties inherent in the estimation of nicotinic acid in urine apply to its estimation in blood

#### Factor V

The earliest values for the nicotinic acid content of blood relate to its coenzyme, or as it was first called, "factor V", content (see page 229) According to H von Euler and F Schlenk,<sup>54</sup> normal blood contained 4 to 8 mg of factor V per 100 ml, and 150  $\mu$ g of nicotinamide per 100 ml

The effect of nicotinic acid deficiency on the amount of coenzyme present in various tissues of the dog was studied by Kohn *et al*<sup>55</sup> and by M Pittman and H F Fraser,<sup>56</sup> who used *Haemophilus para influenzae* as the test organism They observed a decrease in the factor V content of the liver and muscle in blacktongue, whilst Axelrod *et al*,<sup>57</sup> using a yeast fermentation method found a similar decrease

in the coenzyme I content of the liver and muscle of nicotinic acid-deficient dogs and pigs. H I Kohn<sup>58</sup> and Vilter *et al*<sup>59</sup> observed that the factor V content of the blood of pellagrins increased after administration of nicotinic acid, whilst H I Kohn and J R Klein<sup>60</sup> and Vilter *et al*<sup>61</sup> showed that incubation of defibrinated blood with nicotinic acid increased its factor V content. Ingestion of large amounts of nicotinic acid increased the coenzyme I content of the erythrocytes.<sup>62</sup>

Using *Bacillus influenzae*, Vilter *et al*<sup>59, 63</sup> found that the factor V content of the blood decreased in pellagra, but H I Kohn and F Bernheim,<sup>64</sup> using *H parainfluenzae*, failed to find any significant difference in the amount of factor V present in erythrocytes from pellagrins, compared with controls. This was confirmed by Axelrod *et al*,<sup>65</sup> using the yeast fermentation method,<sup>66</sup> they found that the coenzyme I content of erythrocytes averaged 85  $\mu\text{g}$  per ml in controls 77 and 69  $\mu\text{g}$  per ml in sub-clinical and mild pellagra respectively and from 70 to 90  $\mu\text{g}$  per ml in severe cases. The amount in muscle, on the other hand decreased from 382 in controls to 317, 258 and 214  $\mu\text{g}$  per g in sub-clinical, mild and severe pellagra respectively.

### Nicotinic Acid in Blood

B D Kochhar,<sup>67</sup> using acid hydrolysis followed by colour development as in Swaminathan's method found that the nicotinic acid content of blood varied from 230 to 650  $\mu\text{g}$  per 100 ml with an average value of 367  $\mu\text{g}$  per 100 ml. These values presumably included the free nicotinic acid, nicotinamide, nicotinuric acid and coenzymes I and II, but not trigonelline or N<sup>1</sup> methyl nicotinamide. Most of the nicotinic acid was present in the corpuscles, the value for serum being 62 to 170 with an average of 92  $\mu\text{g}$  per 100 ml. Cerebrospinal fluid was found to contain 56 to 120 with an average of 92  $\mu\text{g}$  per 100 ml of acid hydrolysable nicotinic acid derivatives.

Most of the nicotinic acid in dogs' blood was present in the red cells<sup>68</sup> the actual values found being 77 % in the erythrocytes, 12 % in the leucocytes and 11 % in the plasma. Oral administration of nicotinic acid increased the plasma nicotinic acid to a greater extent than the erythrocyte nicotinic acid. Oral administration of 200-mg doses of nicotinic acid daily to humans slightly increased the blood level up to a maximum value which was maintained as long as the additional nicotinic acid was given.<sup>69</sup> Oral administration of a single dose temporarily increased the blood level, a peak being reached after thirty minutes.

Nicotinic acid was taken up quantitatively by red blood cells *in vitro* and fixed in the cells in a non diffusible form presumably as



## NICOTINIC ACID (NIACIN)

Similarly when 6 g of DL-tryptophan were fed to horses, the amount of free nicotinic acid excreted increased two- to four fold, whereas the N<sup>1</sup> methylnicotinamide remained unchanged.<sup>47</sup> This was in marked contrast to the behaviour of cotton rats, which excreted large amounts of N<sup>1</sup> methylnicotinamide after ingestion of nicotinic acid or tryptophan.

The amount of nicotinic acid formed from dietary tryptophan was increased when pyridoxine was added to the diet of rats or mice, a result to be anticipated from the fact that administration of tryptophan accentuated pyridoxine deficiency in the rat and mouse (see page 331). Thus, when 100 mg of DL-tryptophan were added to the basal ration, rats fed pyridoxine excreted 8 to 2190  $\mu$ g of N<sup>1</sup>-methylnicotinamide per day, whilst deficient animals excreted 180 to 485  $\mu$ g per day.<sup>53</sup> With the basal diet only, the excretions were 95 to 185 and 45 to 140  $\mu$ g per day respectively. The corresponding values for excreted nicotinic acid were 95 to 430, 16 to 35, 23 to 50, and 10 to 24  $\mu$ g per day.

Conversely, when pyridoxine was omitted from the diet of rats the amount of excreted nicotinic acid and metabolites fell. A similar result was obtained when aneurine or riboflavine, but not pantothenic acid or pteroylglutamic acid, were omitted. When sulphasuxidine was added to a pteroylglutamic acid deficient diet, however, nicotinic acid excretion was depressed, although administration of sulphasuxidine when the diet contained pteroylglutamic acid did not affect the excretion.<sup>53a</sup>

## Nicotinic Acid in Blood and Cerebrospinal Fluid

Some of the difficulties inherent in the estimation of nicotinic acid in urine apply to its estimation in blood.

### Factor V

The earliest values for the nicotinic acid content of blood relate to its coenzyme, or as it was first called, "factor V", content (see page 229). According to H von Euler and F Schlenk<sup>54</sup> normal blood contained 4 to 8 mg of factor V per 100 ml, and 150  $\mu$ g of nicotinamide per 100 ml.

The effect of nicotinic acid deficiency on the amount of coenzyme present in various tissues of the dog was studied by Kohn *et al*<sup>55</sup> and by M Pittman and H F Fraser<sup>56</sup> who used *Haemophilus para influenzae* as the test organism. They observed a decrease in the factor V content of the liver and muscle in blacktongue whilst Axelrod *et al*,<sup>57</sup> using a yeast fermentation method found a similar decrease

in the coenzyme I content of the liver and muscle of nicotinic acid deficient dogs and pigs. H. I. Kohn<sup>58</sup> and Vilter *et al.*<sup>59</sup> observed that the factor V content of the blood of pellagrins increased after administration of nicotinic acid whilst H. I. Kohn and J. R. Klein<sup>60</sup> and Vilter *et al.*<sup>61</sup> showed that incubation of defibrinated blood with nicotinic acid increased its factor V content. Ingestion of large amounts of nicotinic acid increased the coenzyme I content of the erythrocytes.<sup>62</sup>

Using *Bacillus influenzae*, Vilter *et al.*<sup>59, 63</sup> found that the factor V content of the blood decreased in pellagra, but H. I. Kohn and F. Bernheim,<sup>64</sup> using *H. parainfluenzae* failed to find any significant difference in the amount of factor V present in erythrocytes from pellagrins, compared with controls. This was confirmed by Axelrod *et al.*,<sup>65</sup> using the yeast fermentation method.<sup>66</sup> They found that the coenzyme I content of erythrocytes averaged 85  $\mu\text{g}$  per ml in controls, 77 and 69  $\mu\text{g}$  per ml in sub-clinical and mild pellagra respectively and from 70 to 90  $\mu\text{g}$  per ml in severe cases. The amount in muscle on the other hand decreased from 382 in controls to 317, 258 and 214  $\mu\text{g}$  per g in sub-clinical, mild and severe pellagra respectively.

### Nicotinic Acid in Blood

B. D. Kochhar,<sup>67</sup> using acid hydrolysis followed by colour development as in Swaminathan's method found that the nicotinic acid content of blood varied from 230 to 650  $\mu\text{g}$  per 100 ml with an average value of 367  $\mu\text{g}$  per 100 ml. These values presumably included the free nicotinic acid, nicotinamide, nicotinuric acid and coenzymes I and II, but not trigonelline or N<sup>1</sup> methyl nicotinamide. Most of the nicotinic acid was present in the corpuscles, the value for serum being 62 to 170 with an average of 92  $\mu\text{g}$  per 100 ml. Cerebrospinal fluid was found to contain 56 to 120 with an average of 92  $\mu\text{g}$  per 100 ml of acid hydrolysable nicotinic acid derivatives.

Most of the nicotinic acid in dogs' blood was present in the red cells,<sup>68</sup> the actual values found being 77 % in the erythrocytes, 12 % in the leucocytes and 11 % in the plasma. Oral administration of nicotinic acid increased the plasma nicotinic acid to a greater extent than the erythrocyte nicotinic acid. Oral administration of 200 mg doses of nicotinic acid daily to humans slightly increased the blood level up to a maximum value which was maintained as long as the additional nicotinic acid was given.<sup>69</sup> Oral administration of a single dose temporarily increased the blood level, a peak being reached after thirty minutes.

Nicotinic acid was taken up quantitatively by red blood cells *in vitro* and fixed in the cells in a non diffusible form presumably as

## NICOTINIC ACID (NIACIN)

coenzyme Nicotinamide was also taken up, but nearly all in a form that could be removed from the cells by repeated washings <sup>69a</sup>

The nicotinic acid content of blood or plasma in pellagra was very little different from that of controls,<sup>70</sup> nor did the coenzyme I content of erythrocytes vary significantly in different stages of pellagra <sup>65</sup> normal cells containing 85  $\mu\text{g}$  per ml and cells from pellagrins 70 to 90  $\mu\text{g}$  per ml This remarkable constancy in the amounts of nicotinic acid and its derivatives in blood, and the transitory nature of the increase resulting from the administration of nicotinic acid or the amide make the estimation of blood levels of no value in assessing nutritional status, and it is generally agreed that the only satisfactory method is one based on the excretion of nicotinic acid derivatives in response to a test dose of the acid or amide (page 259)

### Nicotinic Acid Content of Other Body Fluids and Tissues

Human milk is a poor source of nicotinic acid and contains less than cow's milk (see page 233) According to A Lwoff and his collaborators human milk contained only 0.07  $\mu\text{g}$  of the amide per 100 ml (estimated microbiologically by means of *Proteus*) in the first three to eight days after delivery, but after the third week this rose to 0.16 mg per 100 ml <sup>71</sup> At this stage, the requirements of the baby, assumed to be 0.78 mg per day, were satisfied by the ingestion of 500 ml of milk per day, but subsequently the demands increased to a level that could not be met solely by the amount present in the milk. The amount of nicotinamide present in early milk could be increased many fold by giving a 600 mg dose of the amide forty-eight hours before delivery, <sup>72</sup> for instance, when 600 mg doses were given daily for one month prior to delivery, the nicotinamide content of the milk was increased to 0.07 mg per 100 ml <sup>73</sup> This would appear to be an observation of considerable importance, as the human foetus has been said to have no store of nicotinamide, <sup>74</sup> this assertion must be accepted with reserve, however, for it has been shown that blood from the umbilical cord contains as much nicotinic acid as the maternal blood <sup>75</sup>

Coryell *et al* <sup>76</sup> found that the amount of nicotinic acid secreted in the milk during twenty four hours increased from 0.04 mg on the first day *post partum* to 2.94 mg on the tenth day, the intake being 16.5 mg per day The amount secreted in the mature milk varied from 0.52 to 2.02 mg per day Earlier results, in which the nicotinic acid content was expressed in mg per 100 ml, were 0.245 for the amount secreted on the tenth day and 0.176 to 0.196 mg per 100 ml for the mature milk Of the ingested nicotinic acid 7 % appeared in the milk and 3 % in the urine

Only traces of nicotinamide and no nicotinic acid were excreted in the sweat <sup>77</sup>

The amounts of nicotinic acid and its derivatives in certain tissues showed considerable variation according to the degree of nicotinic acid deficiency. Thus in the rat dog and pig the amount of total nicotinic acid and coenzyme I in the liver and muscles decreased progressively when the animals were maintained on a pellagra producing diet but the amounts in the brain and kidney cortex as well as in the blood showed little change <sup>57 78</sup> Similarly the coenzyme I content of striated muscle was higher in normal human tissue (382  $\mu\text{g}$  per g) than in tissue from pellagrins (214  $\mu\text{g}$  per g <sup>65</sup>) and the administration of nicotinic acid led to a marked increase in the coenzyme I content

In normal dogs 50 % of the nicotinic acid in the liver and 25 % of that in the muscle was present in the free state all the nicotinic acid in the kidney cortex on the other hand was combined <sup>78</sup>

The decrease in the tissue nicotinic acid of dogs with blacktongue was almost entirely due to a fall in the bound nicotinic acid. Rabbits also suffered a decrease in the amount of nicotinic acid present in the voluntary muscles when fed for three months on a nicotinic acid deficient diet <sup>79</sup>

Rats behaved differently from other species of animals. They showed no increase in the coenzyme I content of the muscle tissues when fed large amounts of nicotinic acid <sup>57</sup> and the coenzyme I contents of the liver kidney and thigh muscle fell by only 10 % when rats were maintained on a diet that produced blacktongue in dogs <sup>80</sup> This is due to the fact that rats synthesize nicotinic acid and are therefore independent of an external source of supply provided adequate tryptophan is present in the diet (page 241). All the nicotinic acid in the muscle and kidneys of rats was present as coenzyme but only 58 % of that in the liver was in the combined form <sup>81</sup>

Eggs contained 80  $\mu\text{g}$  of nicotinic acid a value that remained unchanged for eleven days but increased to 470  $\mu\text{g}$  after sixteen days and to 820  $\mu\text{g}$  on hatching <sup>82</sup> Most of the nicotinic acid was present as diphosphopyridine nucleotide <sup>83</sup>

#### References to Section 10

- 1 H von Euler and F Schlenk *Klin Woch* 1939 18, 1109  
D Melnick W D Robinson and H Field *J Biol Chem* 1940 138, 131 145
- 3 W W Kuhnau *Klin Woch* 1939 18, 1333
- 4 D Melnick and H Field *J Biol Chem* 1940 134, 1 1940 135, 53
- 5 J W Huff and W A Perlzweig *J Biol Chem* 1941 142, 401

pressure equivalent to 49 275 feet The increase in respiratory rate at low pressures was much less in treated than in untreated rats

Nicotinic acid, but not the amide, has a pronounced, though transient, vasodilator action This is the reason for the flushing and tingling of the skin and rise in the cutaneous temperature when nicotinic acid is taken orally The effect may be somewhat alarming for patients who have not been warned to expect it, but it soon passes off Nicotinamide does not have this effect <sup>7</sup> The vasodilator action of nicotinic acid is of value in conditions where it is desirable to increase the peripheral blood flow, such as gangrene of the mouth and indolent ulcers It also accounts for the ability of nicotinic acid to relieve severe idiopathic headache and migraine <sup>8</sup> Nicotinic acid, but not nicotinamide, increased the intracranial blood flow in human subjects, the effect running parallel with the flushing of the skin <sup>9</sup>

Nicotinamide was without effect on the blood sugar levels in normal subjects and in diabetic patients <sup>10</sup> Nicotinic acid and nicotinamide stimulated bile secretion and the former also increased the serum bilirubin and the excretion of urobilin <sup>11</sup>

#### References to Section 13

- 1 K K Chen C L. Rose and E B Robbins, *Proc Soc Exp Biol Med*, 1938, **38**, 241
- 2 K Unna *J Pharmacol*, 1939 **65**, 95
- 3 F G Brazda and R A Coulson *Proc Soc Exp Biol Med*, 1946 **62**, 19
- 4 P Ellinger G Fraenkel and M M Abdel Kader *Biochem J* 1947, **41**, 559
- 5 N W Shock and W H Sebrell *Amer J Physiol* 1946 **146**, 52
- 6 R M Calder *Proc Soc Exp Biol Med*, 1947, **65**, 76 1948, **68**, 642
- 7 H Field and W D Robinson *Amer J Med Sci* 1940 **199**, 275
- 8 J W Goldzieder and G L Popkin *J Amer Med Assoc*, 1946 **131**, 103
- 9 C. D Aring H W Ryder, E Roseman M Rosenbaum and E B Ferris *Arch Neurol, Psychiat* 1941, **46**, 649
- 10 J N Cumings *Brit Med J* 1947, **2**, 613
- 11 M Stefanini, *J Lab Clin Med*, 1949 **34**, 1039


## 14. FUNCTION OF NICOTINIC ACID

### Coenzymes I and II


By an unusual inversion of the customary course of events, the biological significance of nicotinic acid was understood before its importance in human nutrition was appreciated, for in 1935 O Warburg

## FUNCTION

and W Christian<sup>1</sup> showed that the coenzyme, codehydrogenase II, which is widely distributed in animal tissue, contained nicotinamide, and Albus *et al*<sup>2</sup> showed that it was a constituent of another coenzyme codehydrogenase I or cozymase which occurs in yeast and acts as a catalyst in alcoholic fermentation. Both coenzymes are compounds of adenine, nicotinamide, ribose and phosphoric acid, and were given the formulae



Coenzyme I



Coenzyme II

Coenzymes I and II are usually referred to as diphosphopyridine nucleotide and triphosphopyridine nucleotide respectively. They are essential links in a series of transformations the effect of which is to transfer hydrogen from a substrate which is thereby oxidised to molecular oxygen with the formation of water.

A method for the isolation of coenzyme I from bakers yeast was described by S Williamson and D E Green,<sup>3</sup> who obtained 500 mg of material with a purity of 65 % from 3.2 kg. A method of purifying the enzyme was described by F Schlenk.<sup>4</sup>

An improved method for the isolation of diphosphopyridine nucleotide was published by G A Le Page<sup>5</sup> who obtained from 1 lb of bakers yeast 50 to 70 mg of a preparation with a purity of about 63 %.

The constitution of coenzyme I or codehydrogenase I was established as follows. On hydrolysis it yielded adenine, nicotinamide and 2 moles of D ribose-phosphoric acid. The phosphoric acid was attached to the ribose in the 5 position because periodic acid failed to

liberate formaldehyde.<sup>6</sup> Alkaline hydrolysis yielded adenosine-di-phosphoric acid,<sup>7</sup> indicating the presence of a pyrophosphoric acid group. It was assumed that one of the phosphoric acid groups in cozymase (but not in dihydro cozymase) was neutralised by the nitrogen atom of the pyridine ring. That ribose is attached directly to the nicotinamide was established by the isolation of nicotinamide riboside from yeast codehydrogenase I, following hydrolysis with an enzyme preparation made from almond press cake.<sup>8</sup>

Codehydrogenase II on hydrolysis gave 1 mole of adenine, 1 mole of nicotinamide, 2 moles of D-ribose and 3 moles of phosphoric acid.<sup>9</sup> It differed from codehydrogenase I therefore in the presence of an additional phosphoric acid group. Codehydrogenase II was dibasic.

Neither coenzyme has been synthesised, but it has been claimed that codehydrogenase I can be converted into cozymase by treatment with phosphorus oxychloride in ether or by enzymic phosphorylation,<sup>10</sup> an observation which is hardly consistent with the above structure for triphosphopyridine nucleotide.

The synthesis of cozymase by red blood cells was enhanced both *in vitro* and *in vivo* by the presence of nicotinic acid or nicotinamide, the former being at least three times as effective as the latter,<sup>11</sup> the cells were freely permeable to both compounds. The enzymic destruction of cozymase, which follows haemolysis, was inhibited by nicotinamide, but not by the free acid. Cozymase synthesis by erythrocytes was not merely a reversal of the process of decomposition.

An aqueous extract of pigeon liver was found to contain a thermolabile enzyme system capable of synthesising triphosphopyridine nucleotide from ribose, nicotinamide and adenosine triphosphate.<sup>12</sup>

### Function of Coenzyme I

It appears probable that the two coenzymes combine with a variety of protein carriers, the apoenzymes, each of which is specific for a particular reaction, they are thus enabled to effect the dehydrogenation of a large number of substrates. Coenzyme I effects the conversion of  $\beta$ -hydroxybutyric acid into acetoacetic acid,<sup>13</sup> formic acid into carbon dioxide and water,<sup>14</sup> lactic acid into pyruvic acid,<sup>15</sup> malic acid into oxaloacetic acid,<sup>15</sup> alcohol into acetaldehyde,<sup>16</sup> glucose into gluconic acid,<sup>17</sup> glutamic acid into  $\alpha$ -ketoglutaric acid,<sup>18</sup>  $\alpha$ -glycerophosphoric acid into phosphoglyceric acid,<sup>19</sup> and phosphoglyceric aldehyde into diphosphoglyceric acid.<sup>20</sup> It also effects the dismutation of aldehyde into alcohol and acid<sup>21</sup> and the conversion of retinene into vitamin A.<sup>21a</sup> It is also said to be involved in the metabolism of testosterone by the liver.<sup>21b</sup>

Codehydrogenase I (coenzyme I or cozymase) occurs in all animal and plant cells in which carbohydrates are metabolised. Fresh yeast


contains about 0.5 g per kg and the heart muscle of man and the rabbit 0.4 g per kg. It also occurs in micro organisms (see page 282).

### Function of Coenzyme II

Coenzyme II also brings about the conversion of glucose into gluconic acid<sup>22</sup> and of glutamic acid into  $\alpha$  ketoglutaric acid,<sup>23</sup> but it also effects certain changes not brought about by coenzyme I. Thus glucose-6-phosphoric acid is converted into 6-phosphogluconic acid,<sup>24</sup> 6-phosphogluconic acid into phosphoketohexonic acid, and citric acid into D-ketoglutaric acid<sup>25</sup>. Coenzyme II also catalysed the decarboxylation of oxaloacetic acid by oxaloacetic carboxylase from pigeon liver, but not the exchange reaction between  $C^{14}O_2$  and the  $\beta$ -carbonyl carbon atom of oxaloacetic acid<sup>26</sup>.

Codehydrogenase II (or coenzyme II) appears to occur in all cells in association with codehydrogenase I, but the ratio of the two co-enzymes varies greatly in different tissues, *e.g.* yeast contains very little codehydrogenase II, whereas animal tissues may contain 40 to 80  $\mu$ g per g<sup>27</sup>.

In effecting these transformations, the codehydrogenases are reduced to the dihydro-forms, which are themselves dehydrogenated by flavine enzymes. As already explained in the chapter on ribo-flavine (page 191) the nucleotides are reduced in the process to dihydro-compounds, which are re-oxidised by the cytochrome cytochrome oxidase system. This is re-oxidised in turn by molecular oxygen with the ultimate formation of water as the end product. The transfer of hydrogen from the substrate at one end of the scale to oxygen at the other can be represented schematically as follows:




Many of the dehydrogenations effected by codehydrogenase I are reversible. For example, acetoacetic acid can be converted by dihydro-codehydrogenase I into  $\beta$  hydroxybutyric acid, pyruvic acid into



## NICOTINIC ACID (NIACIN)

lactic acid oxaloacetic acid into malic acid acetaldehyde into alcohol  
 α ketoglutaric acid (and ammonia) into glutamic acid and diphospho-  
 glyceric acid into phosphoglyceraldehyde It is possible that the  
 oxidation of dihydro codehydrogenase I may be brought about in  
 tissues by such coenzyme linked reactions <sup>28</sup> e.g. β hydroxybutyric  
 acid may be oxidised to acetoacetic acid and the dihydro coenzyme  
 thus formed may reduce an aldehyde to an alcohol

The inter convertibility of codehydrogenase I and II and dihydro  
 codehydrogenase I and II is due to the nicotinamide portion of  
 the molecule Karrer *et al* <sup>29</sup> studied a number of nicotinamide  
 derivatives as models for this reaction and found that only those  
 derivatives with a pentavalent nitrogen atom in the ring e.g. nicotin-  
 amide methiodide gave dihydro-compounds with an absorption  
 spectrum comparable with that of the dihydro coenzymes these  
 have two maxima at 260 and 340 mμ whereas the coenzymes them-  
 selves have only one peak at 260 mμ On reduction the nitrogen  
 atom became trivalent By a comparison of the dihydro coenzymes  
 with model dihydropyridine derivatives it was concluded that the  
 former were 1,2 dihydro derivatives so that the reduction of the  
 coenzymes can be represented as



W A Waters <sup>30</sup> suggested that the prosthetic group of the de-  
 hydrogenases provides an initial free radical



in a reaction chain

## Nucleotidase

It is generally assumed that nicotinic acid and nicotinamide are equally effective in the treatment of pellagra and related conditions and it seems likely that the normal body can convert the acid into the amide and so into the coenzyme. P. J. G. Mann and J. H. Quastel<sup>31</sup> however observed one difference between them. Brain extracts contain an enzyme nucleotidase which by hydrolysing cozymase inhibited the oxygen uptake of lactic acid in presence of lactic dehydrogenase and cozymase. Nicotinamide but not nicotinic acid inhibited the action of nucleotidase on cozymase. The exact significance of this phenomenon in therapeutics is not clear but if nicotinamide can prevent the destruction of cozymase it might explain why certain other substances such as quinolinic acid, coramine and pyrazine monocarboxylic acid (see page 288) are effective in pellagra. Other wise it is difficult to find a satisfactory explanation since many of these compounds cannot possibly be converted into nicotinamide although they may well be converted into substances that inhibit nucleotidase.

Nucleotidase occurs in a large number of animal tissues lung tissue being especially rich<sup>32</sup>. In the intact cell the enzyme is kept out of contact with pyridine nucleotides. It is suggested that the release of nucleotidase on damage of the lung may play an important rôle in the action of some lung irritants.

An enzyme that liberated nicotinamide from both cozymase and coenzyme II was shown to be present in preparations from the mammalian central nervous system<sup>33</sup>. Competition took place between the two coenzymes so that presumably a common enzyme is concerned this may be nucleotidase.

## References to Section 14

- 1 O. Warburg and W. Christian *Biochem. Z.* 1935 275, 464
- 2 H. Albus, F. Schlenk and H. von Euler *Z. physiol. Chem.* 1935 237, 1 *Biochem. Z.* 1936 286 140
- 3 S. Willamson and D. E. Green *J. Biol. Chem.* 1940 135 345
- 4 F. Schlenk *ibid.* 1942 148 619 F. Schlenk and T. Schlenk *Arch. Biochem.* 1947 14 131
- 5 G. A. Le Page *J. Biol. Chem.* 1947 168 623
- 6 H. von Euler, P. Karrer and B. Becker *Helv. Chim. Acta* 1936 19 1060
- 7 H. von Euler, F. Schlenk and R. Vestin *Naturwiss.* 1937 25 318
- 8 F. Schlenk *Arch. Biochem.* 1943 3 93
- 9 F. Schlenk *Naturwiss.* 1937 25 668
- 10 R. Vestin *ibid.* 667 H. von Euler and E. Bauer *Ber.* 1938 71, 411 H. von Euler and E. Adler *Z. physiol. Chem.* 1938 252 41

# NICOTINIC ACID (NIACIN)

- 11 P Handler and H I Kohn, *J Biol Chem*, 1943, **150**, 447
- 12 K I Altman and E A Evans *ibid* 1947, **169**, 462
- 13 D E Green J G Dewan and L F Leloir, *Biochem J*, 1937, **31**, 934, D E Green and J G Dewan, *ibid*, 1937, **31**, 1069, 1074
- 14 E Adler and M Sreenivasaya, *Z physiol Chem*, 1937, **240**, 24
- 15 D E Green, D M Needham and J G Dewan, *Biochem J*, 1937, **31**, 2327, D E Green and J Brosteaux, *ibid*, 1936, **30**, 1489, D E Green, *ibid*, 1936, **30**, 2095
- 16 E Negelein and H J Wulff, *Biochem Z*, 1937, **289**, 436, 1937, **293**, 351, O Warburg and W Christian, *Helv Chem Acta*, 1936 **19**, E79, H von Euler, E Adler and H Hellstrom *Z physiol Chem*, 1936, **241**, 239, C Lutwak-Mann, *Biochem J* 1938 **32**, 1364
- 17 D C Harrison, *ibid*, 1931, **25**, 1016, E Adler and H von Euler, *Z physiol Chem*, 1935 **232**, 6
- 18 H von Euler, E Adler, G Gunther and N B Das, *ibid*, 1938, **259**, 61
- 19 H von Euler, E Adler and G Gunther, *ibid*, 1937, **249**, 1
- 20 O Warburg and W Christian, *Biochem Z*, 1939 **301**, 221, 1939, **303**, 40
- 21 M Dixon and C Lutwak-Mann *Biochem J*, 1937, **31**, 1347, E Racker, *J Biol Chem*, 1949, **177**, 883
- 21a G. Wald, *Science*, 1949, **109**, 482.
- 21b M L Sweat and L T Samuels, *J. Biol Chem*, 1948, **175**, 1
- 22 N B Das *Z physiol Chem*, 1936 **238**, 269
- 23 H von Euler, E Adler, G Gunther and N B Das *ibid*, 1938, **259**, 61, H von Euler, E Adler and T S Eriksen *ibid* 1937 **248**, 227, E Adler, G Gunther and J E Everett, *ibid*, 1938 **255**, 27
- 24 O Warburg and W Christian *Biochem Z*, 1931, **242**, 206, 1932, **254**, 438, E Negelein and W Gerischer, *ibid*, 1936 **284**, 289
- 25 F Dickens *Biochem J*, 1938 **32**, 1626, F Lipmann, *Nature* 1936 **138**, 588 O Warburg and W Christian, *Biochem Z*, 1936, **287**, 440, 1936 **292**, 287
- 26 B Vennesland E A Evans and K I Altman *J Biol Chem*, 1947 **171**, 675
- 27 E Adler H von Euler, G Gunther and M Plass *Biochem J* 1939 **33**, 1028
- 28 J G Dewan and D E Green, *ibid*, 1937, **31**, 1074
- 29 P Karrer and O Warburg *Biochem Z*, 1936 **225**, 297, P Karrer, G Schwarzenbach, F Benz and U V Solmssen, *Helv Chim Acta* 1936 **19**, 811 P Karrer and F Benz *ibid*, 1936 **19**, 1028, P Karrer B H Ringier, J Buchi, H Fritzsche and U V Solmssen *ibid* 1937, **20**, 55, P Karrer G Schwarzenbach and G E Utzinger, *ibid* 1937, **20**, 72
- 30 W A Waters *J Chem Soc*, 1946 414
- 31 P J G Mann and J H Quastel, *Nature*, 1941, **147**, 326
- 32 E S G Barron Z B Miller and G R Bartlett, *J Biol Chem*, 1947 **171**, 791
- 33 H McIlwain and R Rodnight, *Biochem J*, 1949 **45**, 337

## 15. NICOTINIC ACID IN THE NUTRITION OF MICRO-ORGANISMS

Nicotinic acid, like aneurine and riboflavine, is necessary for the growth of certain micro organisms, and was identified as a component of "bios" by Schultz *et al*<sup>1</sup>

### Yeasts

Yeasts do not require nicotinic acid to the same extent as they require biotin, aneurine or pantothenic acid and, of seventy one kinds of yeasts tested by P R Burkholder,<sup>2</sup> only nine required nicotinic acid. These were *Candida pseudotropicalis*, *Mycoderma valida*, *M. vini*, *Saccharomyces fragilis*, *S. macedoniensis*, *Saccharomycodes ludwigii*, *Schizosaccharomyces pombe*, *Torulopsis sphaerica*, *Zygosaccharomyces marxianus* and *Z. lactis*. A S Schultz and L Atkin<sup>3</sup> found that in addition *Kloeckera brevis*, *Saccharomyces carlsbergensis* and *Torula cremoris* also required nicotinic acid. According to M Rogosa,<sup>4</sup> yeasts that ferment lactose require nicotinic acid, but yeasts that do not ferment lactose do not require nicotinic acid, but the above list contains representatives of both types.

Yeasts were found to take up nicotinic acid added to the medium on which they were grown.<sup>5</sup>

### Other Fungi

P R Burkholder<sup>2</sup> examined a number of moulds, but none of them required nicotinic acid.

By exposing *Neurospora crassa* to X rays and ultra-violet light, D Bonner and G W Beadle<sup>6</sup> obtained five different mutants. One of these, when grown on nicotinic acid or nicotinamide, produced two substances which exhibited nicotinic acid activity for one of the other mutants. The substances formed were believed to be a hydroxy pyridine-carboxylic acid and its methylation product.

One mutant of *N. crassa* was obtained which required tryptophan for growth and could not utilise indole and another which grew with either anthranilic acid, indole or tryptophan.<sup>6a</sup> When the latter mutant was grown on a medium containing anthranilic acid with C<sup>14</sup> in the side-chain, the nicotinic acid and tryptophan isolated from the mould tissue contained no C<sup>14</sup>, most of which was lost in the carbon dioxide formed during growth (see also page 250).

### Bacteria

Reference has already been made (page 226) to the use of *Lactobacillus arabinosus*, *L. helveticus* and *Leuconostoc mesenteroides* in

the microbiological assay of nicotinic acid, but many other bacteria also fail to grow in its absence. These include *Proteus vulgaris*,<sup>7</sup> *Pr morganii*,<sup>8</sup> *Shigella dysenteriae*<sup>9</sup> and *S paradysenteriae*<sup>10, 11, 12</sup>. Cultures of the dysentery bacteria could be trained to grow without nicotinic acid by repeated transfer into media containing progressively smaller amounts,<sup>13</sup> the variants so produced, however, grew better in the presence of optimal amounts of nicotinamide. Culture filtrates of the variants stimulated the growth of the parent strain, indicating that nicotinamide, or a substance biologically equivalent to it, must have been synthesised by the variant. Nicotinic acid was also essential for the growth of *Acetobacter suboxydans*,<sup>9, 14</sup> *Staphylococcus aureus*,<sup>15</sup> *Streptobacterium plantarum*<sup>16</sup> and *Clostridium tetani*.<sup>17</sup> A mutant of *Escherichia coli* that required nicotinamide was produced by Roepke *et al*.<sup>18</sup> Nicotinic acid enhanced the growth of *Leptospira icterohaemorrhagiae*<sup>19</sup> and of *Brucella abortus*, but not of *Br melitensis* the growth of which was actually inhibited.<sup>20</sup>

The cell content of *L. arabinosus* which assimilates nicotinic acid during growth rises to 0.750  $\mu\text{mol}$  per mg of dry weight. It exists in the cell as cozymase.<sup>20a</sup>

High concentrations of nicotinic acid or nicotinamide, *e.g.* of the order of 10 mg per ml, were found<sup>21</sup> to inhibit the growth of a number of representative bacteria in a simple medium, but in casein hydrolysate the inhibition was much less marked and was completely nullified by the addition of yeast extract. The phenomenon is believed to be an example of nutritional imbalance.

Nicotinamide suppressed the spread of tuberculosis in mice, the effect of 0.50 to 0.75 % in the diet being equivalent to that of 1 mg of streptomycin four times daily.<sup>21a</sup> It is unlikely that the effect is due to a direct antibacterial action of the nicotinamide.

Nicotinic acid is not an essential growth factor for *Bacillus paratyphosum* A, but is essential for the fermentation of carbohydrates by this organism, it must first be converted into cozymase.<sup>22</sup> Some organisms, *e.g.* *Haemophilus parainfluenzae* cannot utilise nicotinic acid or nicotinamide in the absence of D ribose and adenylic acid although they grow in presence of the mixture just as well as they do in presence of codehydrogenase I.<sup>23</sup> *H. parainfluenzae* was able to utilise nicotinamide nucleoside, dihydrocozymase and deamino cozymase, showing that the reaction it cannot perform is the combination of nicotinamide with ribose. The utilisation of nicotinic acid by many micro organisms is impeded by the presence of pyridine  $\beta$  sulphonic acid or its amide, which appears to interfere with its conversion into cozymase (see page 291). Several species of *Pasteurella* were stimulated by nicotinamide, but not by nicotinic acid<sup>24</sup> suggesting that these organisms are unable to convert the acid into the amide.

Bacteria that grow well without added nicotinic acid presumably synthesise sufficient for their needs. The formation of nicotinic acid on a synthetic medium was in fact demonstrated by P R Burkholder and I McVeigh<sup>25</sup> for *E coli*, *B aerogenes*, *B mesentericus* and *B vulgatus*.

According to M R Bovarnick,<sup>26</sup> the product obtained by heating glutamic acid, methionine or certain other amino acids with asparagine or iso-asparagine at 100° C at pH 7, could replace nicotinamide as a growth factor for *S dysenteriae*, *S aureus* and *L arabinosus*. The culture fluid was found to contain nicotinamide. According to P Ellinger and M M Abdel Kader,<sup>27</sup> however, ornithine was a more effective precursor of nicotinic acid. Using two strains of *E coli*, isolated from rat faeces and known to synthesise nicotinamide when grown in an ammonium lactate medium, they showed that the amount of nicotinamide synthesised was increased 4½ fold by ornithine and to the extent of only 50 to 70 % by glutamine and arginine. Ornithine was therefore utilised by *E coli* for the biosynthesis of nicotinamide, a conclusion of particular significance in view of the isolation of dinicotinyl ornithine from chick faeces (page 256). It was suggested that arginine and glutamine, with  $\delta$  amino groups, were probably converted into ornithine and thus exhibit a similar, though less marked effect.

No evidence was obtained to suggest that tryptophan could be converted into ornithine, and *E coli* could not convert tryptophan into nicotinamide. It may be however, that other intestinal organisms can effect the first part of this transformation for a mixed culture from rats' caecum was able to convert tryptophan into nicotinamide. On the other hand, ingestion of ornithine did not increase the output of N<sup>1</sup> methyl nicotinamide, perhaps the amino acid was utilised too rapidly for protein formation.

The synthesis of nicotinic acid by sulphonamide resistant and sulphonamide sensitive strains of *E coli* was not diminished by sulphathiazole.<sup>28</sup>

Nicotinic acid was destroyed during cell proliferation by *Pseudomonas fluorescens*<sup>29</sup> and by a mixed culture isolated from faeces.<sup>30</sup> Destruction was due to enzymic oxidation, which was inhibited by inhibitors of metal enzymes, e.g. sodium azide, or by surface active agents.<sup>31</sup> Thus, unless an adequate supply of nicotinic acid is maintained or an organism is able to synthesise it as rapidly as it is used up, the organism will fail to grow.

H McIlwain<sup>32</sup> has calculated the rate of production of nicotinic acid and the "turnover number" of enzymes containing it. He estimated that, making allowance for the vitamin that passed into the culture fluid, the five bacteria *Aerobacter aerogenes*, *Serratia marcescens*, *Pseudomonas fluorescens*, *Proteus vulgaris* and *Clostridium*

## NICOTINIC ACID (NIAICIN)

- 17 R E Feeney, J H Mueller and P A Miller, *J Bact*, 1943 48, 563
- 18 R R Roepke R L Libby and M H Small *ibid* 1944 48, 401
- 19 T G Ward and E B Starbuck, *Proc Soc Exp Biol Med*, 1941, 48, 19
- 20 G P Kerby, *J. Bact* 1939 37, 495
- 20a H McIlwain D A Stanley and D E Hughes *Biochem J*, 1949 44, 153
- 21 S A Koser and G J Kasai, *J. Bact*, 1947, 53, 743. 1947, 54, 20
- 21a D McKenzie, L Malone, S Kushner, J J Oleson and Y Subbarow, *J Lab Clin Med*, 1949, 33, 1249
- 22 I J Kligler and N Grossowicz, *J. Bact*, 1941, 42, 173
- 23 F Schlenk and W Gingrich, *J Biol Chem*, 1942, 143, 295
- 24 S A Koser, S Berkman and A Dorfman *Proc Soc Exp Biol Med* 1941, 41, 504
- 25 P R Burkholder and I McVeigh, *Proc Nat Acad Sci*, 1942, 28, 285
- 26 M R Bovarnick, *J Biol Chem*, 1943 148, 151, 1943 149, 301
- 27 P Ellinger and M M Abdel Kader, *Nature* 1947 160, 675
- 28 A K Miller, P Bruno and R M Berglund *J Bact*, 1947 54, 9
- 29 S A Koser and G R Baird, *J Infect Dis* 1944 75, 250
- 30 R Benesch *Lancet*, 1945 1, 718
- 31 C A Nichol and M Michaelis *Proc Soc Exp Biol Med* 1947, 68, 70
- 32 H McIlwain *Nature* 1946 158, 898
- 33 D E Hughes, *Biochem J*, 1949 45, xxxvi
- 34 G W Kidder, V C Dewey M B Andrews and R R Kidder, *J. Nutrition*, 1949 37, 521

## 16. EFFECT OF NICOTINIC ACID ON HIGHER PLANTS

Comparatively little study has been made of the nicotinic acid requirements of the higher plants. According to J Bonner,<sup>1</sup> nicotinic acid is indispensable for pea seedlings, whilst orchid seeds are said<sup>2</sup> to require the presence of nicotinic acid or pyridoxine before germination can take place, with pyridoxine, however, subsequent growth was poor, whereas nicotinic acid promoted normal development. Nicotinic acid may be one of the substances produced by the mycorrhizal fungus.

On the other hand, both nicotinic acid and nicotinamide markedly inhibited root growth in cress seedlings.<sup>3</sup> Nicotinic acid also enhanced the inhibitory effect of indole 3 acetic acid on the growth rate of asparagus stem tips in the dark, although by itself it had no effect.<sup>4</sup> No such effect was observed with cress seedlings.<sup>4a</sup>

Considerable increases in the nicotinic acid content occurred during the germination of oats, wheat, barley and maize.<sup>5</sup> The

amount of nicotinic acid in leaf tissue was generally higher in trisomic than in disomic maize <sup>6</sup> This increase is probably due to synthesis from tryptophan, which increased the nicotinic acid content of corn embryos when added to sterile cultures on which they were grown <sup>7</sup> and that of cabbage, broccoli and tomato leaves when supplied through the petioles <sup>8</sup> Tryptophan was apparently not converted into nicotinic acid by haricot beans <sup>9</sup>

*References to Section 16*

- 1 J Bonner *Plant Physiol*, 1938 **13**, 865
- 2 G R Noggle and F L Wynd *Bot Gaz*, 1942 **104**, 455, R B Bahme, *Science*, 1949 **109**, 522
- 3 L J Andus and J H Quastel *Nature*, 1947, **160**, 222
- 4 A W Galston *J Biol Chem*, 1947, **169**, 465
- 4a L. J. Andus, *Nature*, 1948, **162**, 811.
- 5 P R Burkholder, *Science*, 1943, **97**, 562
- 6 N H Giles, P R. Burkholder, I McVeigh and K S Wilson, *Genetics*, 1946, **31**, 216
- 7 A Nason, *Science*, 1949, **109**, 170
- 8 F G Gustafson, *ibid*, 1949 **110**, 279
- 9 T Terroine, *Compt rend Soc biol*, 1948 **227**, 367

## 17. NICOTINIC ACID REQUIREMENTS OF INSECTS

Nicotinic acid was found to be essential for the development of the fruit fly, *Drosophila melanogaster*,<sup>1</sup> of the moths, *Galleria mellonella* <sup>2</sup> and *Ephestia elutella*,<sup>4</sup> and of the beetles, *Pinus tectus* <sup>3</sup> *Tribolium confusum* <sup>3</sup> and *Silvanus surinamensis* <sup>3</sup> but not of the two beetles, *Sitodrepa panicea* and *Lasioderma serricorne* <sup>3</sup> When the larvae of these last two insects were sterilised however, normal development did not take place until several members of the vitamin B complex, including nicotinic acid, were added to the diet <sup>4</sup> This indicated that the reason why certain insects do not require endogenous sources of these vitamins is that they are provided by the intracellular symbionts The larvae of the mosquito, *Aedes aegypti*, required nicotinic acid as well as other vitamins to permit growth to the fourth instar <sup>5</sup>

*References to Section 17*

- 1 E L Tatum *Proc Nat Acad Sci*, 1941, **27**, 193
- 2 D L. Rubinstein and L. A. Shekun, *Nature* 1939, **143**, 1064
- 3 G Fraenkel and M Blewett, *ibid*, 1943 **151**, 703
- 4 G Fraenkel and M Blewett, *ibid*, 1943 **152**, 506 *Biochem J.* 1943 **37**, 686, *Proc Roy Soc B*, 1944 **132**, 212
- 5 L. Golberg B de Meillon and M Lavoispiere, *J Exp Biol.* 1945 **21**, 90



## 18 ANALOGUES OF NICOTINIC ACID

## Activity in Canine Blacktongue

The first report of the effects in pellagra and blacktongue of compounds other than nicotinic acid was that of Woolley *et al*<sup>1</sup> who found that only  $\beta$  picoline and the ethyl ester amide and (to a smaller extent) N methylamide of nicotinic acid cured blacktongue in dogs. picolinic acid (pyridine 2 carboxylic acid) quinolinic acid (pyridine 2,3 dicarboxylic acid) isonicotinic acid (pyridine 4 carboxylic acid) nipecotic acid (hexahydronicotinic acid) nicotinic acid diethylamide 6 methylnicotinic acid trigonelline pyridine and N<sup>1</sup> methylnicotinamide were inactive. SubbaRow *et al*<sup>2</sup> reported that  $\beta$  aminopyridine was as effective as nicotinic acid in curing blacktongue in dogs whilst Najjar *et al*<sup>3</sup> in contradiction to the findings of Woolley *et al*<sup>1</sup> reported that nicotinic acid diethylamide and N<sup>1</sup> methylnicotinamide were active and that the latter prevented fatty liver formation in rats so that its methyl group was apparently biologically active also<sup>4</sup>. According to Smith *et al*<sup>5</sup> the diethylamide had 1/15th the activity of nicotinic acid whilst L. J. Teply and C. A. Elvehjem<sup>6</sup> also found it to be active.

A difference of opinion also exists in respect of the activity of nicotinuric acid which according to Najjar *et al*<sup>3</sup> was effective and according to J. W. Huff and W. A. Perlzweig<sup>7</sup> and W. J. Dann and P. Handler<sup>8</sup> ineffective. Again Teply *et al*<sup>9</sup> found that N<sup>1</sup> methyl nicotinamide was inactive thus confirming Woolley's observation and contradicting the results obtained by Najjar *et al*<sup>3</sup>.

On the other hand there appears to be general agreement that quinolinic acid<sup>1,3,10,11</sup> and trigonelline<sup>1,3</sup> are inactive and that pyrazine monocarboxylic acid (I) and pyrazine dicarboxylic acid (II) which obviously bear a close structural relationship to nicotinic acid



(I)



(II)

and therefore might be expected to show some activity are of no value in the treatment of blacktongue<sup>10,11</sup>. Thiazole 5 carboxylic acid<sup>10</sup> pyrimidine 4 carboxylic acid<sup>11</sup> 3 aminopyridine<sup>11</sup> and 2 aminonicotinic acid<sup>11</sup> were also inactive.

Badgett *et al*<sup>12</sup> prepared a series of fourteen esters of nicotinic acid and fourteen substituted amides of such a type that when added to cereals no appreciable loss of the vitamin would occur on rinsing the cereal with water. The ethyl and lauryl esters and the

anilide were tested on dogs and found to possess considerable activity. Several esters of nicotinic acid also exhibited biological activity when tested on chicks,<sup>13</sup> the activity varied with the nature of the esterifying group. Ethyl, propyl and butyl nicotinate were as effective as the free acid in curing blacktongue in dogs and a similar condition in chicks,<sup>14</sup> their behaviour closely simulated that of a substance isolated from wheat bran.<sup>15</sup>

Esters of glycerol and two simple sugars were also found to cure blacktongue in dogs.<sup>15a</sup> When incorporated in rice they were not removed on subsequent cooking.

### Activity in Pellagra

Fewer discrepancies have been reported in the activities of nicotinic acid derivatives in pellagra than in blacktongue, although in some instances there is a marked difference in the behaviour of a particular substance in the two conditions, sufficiently striking, in fact, to suggest that whilst the conditions are analogous they are possibly due to a breakdown of carbohydrate metabolism at two different points. Thus, whereas quinolinic acid was found by four different groups of workers to be inactive in blacktongue, R. W. Vilter and T. D. Spies<sup>16</sup> found that it produced a dramatic response in pellagrins, and confirmed the subjective improvement by demonstrating that the coenzyme I and II content of the blood also increased to normal within twenty-four hours. T. D. Spies and his colleagues<sup>17</sup> found that, in addition to nicotinic acid and the amide, nicotinethyl and diethylamide and ethyl nicotinate were active in pellagra whilst  $\alpha$ -picoline, trigonelline and 2-aminopyridine were inactive. Results were inconclusive with  $\beta$ -picoline, 2,6-dimethylpyridine-3,5-dicarboxylic acid and pyridine-3,5-dicarboxylic acid. Similarly, pyrazine mono- and di-carboxylic acids, which according to two groups of workers were inactive in blacktongue, were found to cause prompt disappearance of glossitis in pellagrins,<sup>16,18</sup> whilst pyrazine monocarboxylic acid increased the coenzyme I content of erythrocytes and muscle to the same extent as did nicotinic acid.<sup>19</sup> According to T. D. Spies and his colleagues<sup>16,18</sup> it also increased the amount of 'factor V' (page 229), but this last observation was at variance with the results of W. J. Dann *et al.*,<sup>21</sup> who found, using *Haemophilus parainfluenzae* to estimate the activity, that neither pyrazine monocarboxylic acid nor quinolinic acid could effect an *in vivo* or *in vitro* synthesis of factor V in human blood.

According to Axelrod *et al.*,<sup>19</sup> however, "the antipellagic value of a compound is not necessarily associated with its ability to affect the coenzyme I content of tissues" since they found "definite clinical improvement" in pellagrins treated with pyrazine-monocarboxylic

acid and nicotinic acid diethylamide and this was not accompanied by changes in the coenzyme I content of the blood or tissue

The behaviour of nicotinic acid diethylamide was apparently much the same in pellagra and blacktongue, and the compound had 1/14th and 1/7th the activity of nicotinic acid respectively in the two conditions, <sup>6, 18, 20</sup>, it had no effect on the coenzyme I content of erythrocytes <sup>19</sup>

Huber *et al* <sup>21</sup> attempted to prepare derivatives of aneurine and nicotinic acid that could be added to cereals without being lost on subsequent washing with water. Nicotinic acid and its amide, in contrast to aneurine, failed to form satisfactory salts with methylene bis-(2-hydroxy-3-naphthoic acid) or 2 ethylhexyl sulphuric acid, the basicity of the ring nitrogen being apparently reduced by the presence of the carboxyl group. A series of *n*-alkyl esters of nicotinic acid was prepared, the properties of which agreed with those reported earlier by Badgett *et al*. These esters had too pronounced an odour for use in the enrichment of cereals, but they formed salts with methylene-bis-(2 hydroxy-3 naphthoic acid), and both the ethyl and butyl ester salts were sparingly soluble in water. After treatment with dilute alkali, both stimulated the growth of *L. arabinosus*.

N-(*p*-Carboxyphenyl)-nicotinamide, N-(phenylcarbamyl)-nicotinamide and N-(6-methoxy 8-quinolyl)-nicotinamide were sparingly soluble in water. The first two showed activity after standing in dilute alkali, but the last was inactive after standing in dilute sulphuric acid.

### Effect on Micro-organisms

The requirements of micro-organisms for nicotinic acid are even more specific than are those of animals, and B C J G Knight and H McIlwain <sup>22</sup> found that quinolinic acid, picolinic acid and isonicotinic acid, trigonelline, nicotinic acid diethylamide, nicotine, pyridine- $\beta$  sulphonic acid, 3-cyano pyridine,  $\beta$  picoline, 2, 4 dimethyl pyridine-3, 5-dicarboxylic acid and 2, 4, 6-trimethylpyridine 3, 5 dicarboxylic acid could not replace nicotinic acid as a growth factor for *Staphylococcus aureus*.

The requirements of *Proteus vulgaris* were just as specific, with two exceptions, for, whereas both organisms grew in presence of nicotinic acid, and its sodium and ammonium salts, ethyl nicotinate, nicotinamide and nicotinuric acid, *Pr. vulgaris* also grew in presence of nicotinic acid mono- and diethylamides, whilst *S. aureus* did not <sup>23, 24</sup>.  
<sup>24</sup> *S. aureus* <sup>24</sup> Accord-  
 acid and its analogues  
 stimulated the growth of *Pr. vulgaris* in the following molar concentra-

tions nicotinic acid,  $2 \times 10^{-8}$  to  $1 \times 10^{-6}$ , methyl nicotinate,  $3.7 \times 10^{-9}$  to  $2 \times 10^{-6}$ , nicotinamide,  $2 \times 10^{-8}$  to  $1 \times 10^{-6}$ , nicotinamide methiodide,  $0.8 \times 10^{-4}$  to  $0.6 \times 10^{-8}$ , nicotinic acid diethylamide,  $0.3 \times 10^{-4}$  to  $0.4 \times 10^{-2}$ , pyridine  $\beta$  sulphonic acid,  $1 \times 10^{-3}$  to more than  $0.3 \times 10^{-1}$ , pyridine  $\beta$  sulphonamide,  $2.7 \times 10^{-4}$  to  $1 \times 10^{-3}$ , pyridine- $\beta$  sulphonic acid diethylamide, dilution uncertain, 6-methylnicotinamide, less than  $0.6 \times 10^{-2}$  to  $0.5 \times 10^{-2}$ , methyl picolinate less than  $1.2 \times 10^{-3}$  to  $4.4 \times 10^{-3}$ , nicotine,  $1.6 \times 10^{-5}$  to  $0.5 \times 10^{-3}$ , thiazole 5 carboxylic acid,  $1.6 \times 10^{-4}$  to  $2 \times 10^{-2}$ , 2,6-dimethylnicotinamide, greater than  $3.6 \times 10^{-2}$ , 2-acetylnicotinic acid, greater than  $1.6 \times 10^{-2}$ , pyrazine-monocarboxylic acid, greater than  $1.1 \times 10^{-3}$ , pyrazine-dicarboxylic acid greater than  $1.6 \times 10^{-2}$ . Many of these results are at variance with those obtained by other workers, most of whom have found, for instance that pyridine  $\beta$  sulphonic acid and its amide cannot replace nicotinic acid for micro-organisms.

Thiazole-5-carboxylic acid amide did not replace nicotinic acid in the nutrition of *Pr. vulgaris*<sup>26</sup> or *S. aureus*,<sup>27</sup> but partially neutralised the growth stimulating effect of nicotinamide on the latter. Thiazole-5-sulphonic acid in large amounts could replace nicotinic acid or the amide for *S. aureus*.

1,2,5,6-Tetrahydronicotinic acid (gervacine) had a similar action to nicotinic acid both on *S. aureus* and *Pr. vulgaris*, dehydrogenation occurring very readily. Hexahydronicotinic acid was also utilised by both organisms, but its effect was not immediate, dehydrogenation apparently taking place with more difficulty than with the tetrahydro compound.<sup>28</sup> 1-Methyl-tetrahydronicotinic acid (arecaine) had no growth-stimulating action. Tetrahydronicotinic acid did not increase the oxygen uptake when added to pig's kidney or liver pulp.

Most esters of nicotinic acid proved to be only slightly active when tested on *L. arabinosus*.<sup>12</sup> Nipecotic acid had only 0.01% of the activity of nicotinic acid towards this organism.<sup>9</sup> A substance isolated from wheat bran was as active as nicotinic acid in blacktongue and in nicotinic acid deficiency in chicks,<sup>14</sup> but stimulated the growth of *L. arabinosus* only after hydrolysis with dilute alkali,<sup>15</sup> its properties suggested that it might be an ester.

### Substances Antagonistic to Nicotinic Acid

Although according to E. F. Möller, pyridine- $\beta$  sulphonic acid and its amide may have a slight stimulating action on the growth of *Pr. vulgaris* and *S. aureus* at relatively high dilutions and in the absence of nicotinic acid or amide, other workers have found that they inhibit the growth of these organisms. In presence of nicotinic acid or amide.<sup>29</sup>

the inhibitory action was reversed owing to competition between the two substances similar to that between *p* aminobenzoic acid and sulphanilamide (page 546) or between pantothenic acid and pantoyl taurine (page 381)

The growth of *Pr vulgaris* was partially inhibited by pyridine  $\beta$  sulphonic acid<sup>26</sup> at a concentration of  $4 \times 10^{-5}$  mole per l and completely at  $4 \times 10^{-3}$  mole per l. The inhibition was counteracted by nicotinic acid and by thiazole 5 carboxylic acid amide a close analogue of nicotinamide. The thiazole derivative had no inhibitory action on *Pr vulgaris*.

Pyridine  $\beta$  sulphonic acid did not inhibit the growth of *Streptobacterium plantarum*<sup>30</sup> but nicotinic acid methiodide and pyridine 3 sulphonamide methiodide were more effective than the sulphonic acid owing to the presence of the iodide ion. Thionicotinamide had some inhibitory effect. Some suppression of growth also occurred with picolinic acid and its amide and with quinoline 2 and 3 carboxylic acids. Thiazole 5 carboxylic acid amide had a slight inhibitory action on *S aureus*<sup>27</sup> but thiazole 5 sulphonic acid and 2 (thiazole 5' carboxylamido) pyridine were inert. Thiazole 4 sulphonic acid likewise possessed no inhibitory activity<sup>31</sup>.

Pyridine  $\beta$  sulphonic acid inhibited the dehydrogenation of lactic acid and of glucose when the concentration of the coenzyme was kept constant and that of the sulphonic acid was increased<sup>32</sup> so that the latter would appear to compete with the coenzyme for the apoenzyme. The inhibitory action decreased as the concentration of the coenzyme or of nicotinic acid or nicotinamide was increased. The affinity of cozymase for apodehydrogenase was two to three times that of pyridine  $\beta$  sulphonic acid whilst nicotinic acid, benzoic acid and benzene sulphonic acid had about half as much activity. The apodehydrogenase was about half as active as the cozymase.

The inhibition of the apodehydrogenase by the sulphonic acid was not due solely to the carboxylic or sulphonic acid groups but was rather a function of the whole molecule.

According to P. Karrer and W. Manz<sup>33</sup> the antagonistic action of pyridine 3 sulphonamide towards nicotinamide was probably not due to displacement of the latter by the former from codehydrogenase I or II. If however displacement actually does occur then the altered codehydrogenase is probably capable of reversible reduction since pyridine 3 sulphonamide methiodide and ethiodide were reduced by sodium dithionite to 1-methyl and 1-ethyl-1,2-dihydropyridine 3 sulphonamide respectively.

Pyridine  $\beta$  sulphonic acid exerted an antagonistic effect on the growth stimulation produced by tetrahydronicotinic acid to the same extent as with nicotinic acid<sup>28</sup>. Tetrahydronicotinic acid but not

hexahydronicotinic acid, inhibited the fermentative activity of apozymase and cozymase<sup>28</sup>

Pyridine  $\beta$  sulphonic acid did not produce symptoms of nicotinic acid deficiency when fed to mice<sup>34</sup>

Sulphapyridine, in common with many other sulphonamides, has a bacteriostatic action on *S. aureus*, but part of this is believed to be due to an antagonistic effect on nicotinic acid, although the addition of nicotinic acid did not counteract the effect<sup>35</sup> as it did with pyridine- $\beta$  sulphonic acid. Sulphapyridine inhibited the response of nicotinic acid deficient dogs to nicotinamide<sup>36</sup>. Sulphapyridine, like pyridine- $\beta$  sulphonic acid, had an affinity for apodehydrogenase and was able to displace cozymase and inhibit dehydrogenation<sup>32</sup>

Another substance antagonistic to nicotinic acid is 3-acetyl pyridine, which produced symptoms of nicotinic acid deficiency when fed at a level of 2 mg or more per day to mice maintained on a purified diet, the effect was abolished by administration of nicotinic acid<sup>37</sup> or tryptophan<sup>38</sup>. 3-Acetyl-pyridine had only a slight inhibitory effect on the growth of bacteria, and this was not reversed by nicotinic acid<sup>39</sup>

Sym-dimicotinylhydrazine did not antagonise nicotinic acid<sup>40</sup>

2 and 6 Fluoronicotinic acid<sup>41</sup> and 5 fluoronicotinic acid and its amide<sup>42</sup> have been prepared. The first two compounds did not inhibit the growth of *E. coli*, *S. aureus* or *S. viridans*, *in vitro* at a dilution of 1 in 2000. 6-Aminonicotinic acid on the other hand inhibited the growth of *S. aureus* at a dilution of 1 in 10<sup>6</sup>, and the inhibition was reversed by nicotinic acid or amide<sup>43</sup>

### Comparison of Activities of Nicotinic Acid Analogues on Different Species of Organisms

A comprehensive survey of the biological activity of various compounds related to nicotinic acid was made by Ellinger *et al*<sup>44</sup>. All the compounds tested had an action on the central nervous system. In some, the exciting action predominated, as in nicotinic acid and nicotinamide (see page 273), but many compounds were predominantly narcotic, death resulting from paralysis of the respiratory centre. All the compounds tested with the exception of trigonelline were considerably more toxic than nicotinic acid or even the amide. All the compounds which, it is generally agreed possess anti blacktongue activity namely nicotinic acid and its esters, nicotinamide and nicotinic acid were converted into N<sup>1</sup> methylnicotinamide by incubation with liver or kidney slices. Many alkylated derivatives of nicotinamide and also  $\beta$  picoline were similarly converted to N<sup>1</sup> methylnicotinamide.

Rats can utilise, besides nicotinic acid and nicotinamide, the alkyl

and monoaryl derivatives and many other compounds (see above) Insects were more exacting and *Tribolium confusum* could utilise only the acid its esters and the amide although slight activity was shown by nicotinylamide nicotin (4 methoxyphenyl) amide and nicotin phenylamide and very slight activity by nicotin mono and di ethyl amides nicotinbenzylamide quinolinic acid and  $\beta$  picoline Bacteria were still more exacting *L. arabinosus* utilised only the acid and amide quinolinic acid  $\beta$  picoline and nicotinonitrile *Proteus vulgaris* showed a response with nicotinethylamide quinolinic acid and  $\beta$  picoline whilst *Shigella sonnei* utilised only the acid and amide and to a very much smaller extent quinolinic acid and  $\beta$  picoline Thus summarising it can be said that the rat can utilise all the compounds available to insects and insects can utilise all the compounds that stimulate the growth of bacteria but the converse is not true in either instance

References to Section 18

- 1 D W Woolley F M Strong R J Madden and C A Elvehjem  
*J Biol Chem* 1938 124, 715
- 2 Y SubbaRow W J Dann and E Meilman *J Amer Chem Soc*  
1938 60, 1510 Y SubbaRow and W J Dann *ibid* 2565
- 3 V A Najjar M M Hammond M A English M B Wooden and  
C C Deal *Johns Hopkins Hosp Bull* 1944 74, 406
- 4 V A Najjar and C C Deal *J Biol Chem* 1946 162 741
- 5 D T Smith G Margolis and L H Margolis *J Pharmacol* 1940  
68, 458
- 6 L J Tepley and C A Elvehjem *Proc Soc Exp Biol Med* 1944  
55, 72
- 7 J W Huff and W A Perlzweig *J Biol Chem* 1942 142, 401
- 8 W J Dann and P Handler *Proc Soc Exp Biol Med* 1941 48  
355
- 9 L J Tepley W A Krehl and C A Elvehjem *ibid* 1945 58, 169
- 10 H A Waisman O Mickelsen J M McKibbin and C A Elvehjem  
*J Nutrition* 1940 19, 483
- 11 W J Dann H I Kohn and P Handler *ibid* 1940 19, viii  
1940 20, 477
- 12 C O Badgett R C Provost C L Ogg and C F Woodward *J*  
*Amer Chem Soc* 1945 67, 1138 C O Badgett and C F  
Woodward *ibid* 1947 69, 2907
- 13 G M Briggs T D Luckey L J Tepley C A Elvehjem and F B  
Hart *J Biol Chem* 1943 148, 517
- 14 W A Krehl C A Elvehjem and F M Strong *ibid* 1944 156 13
- 15 W A Krehl and F M Strong *ibid* 1
- 15a F M Strong L Lutwak and M A Farooque *Arch Biochem*  
1948 18 297
- 16 R W Vilter and T D Spies *Lancet* 1939 2, 423

# ANALOGUES

- 17 T D Spies W B Bean and R E Stone *J Amer Med Assoc* 1938 111, 584 T D Spies H M Grant and N E Huff *Southern Med J* 1938 31, 901 S P Vilter W B Bean and T D Spies *ibid* 1163
- 18 C E Bills F G McDonald and T D Spies *ibid* 1939 32, 793
- 19 A E Axelrod T D Spies and C A Elvehjem *J Biol Chem* 1941 138, 667
- 20 D T Smith J M Ruffin and S G Smith *J Nutrition* 1940 19, xiv
- 21 W Huber W Boehme and S C Laskowski *J Amer Chem Soc* 1946 68, 187
- 22 B C J G Knight and H McIlwain *Biochem J* 1938 32, 1241
- 23 M J Pelczar and J R Porter *J Bact* 1940 39, 429
- 24 M Landy *Proc Soc Exp Biol Med* 1938 38, 504
- 25 E F Moller and L Birkofer *Ber* 1942 75, 1108
- 26 H Erlenmeyer and W Wurgler *Helv Chim Acta* 1942 25 249
- 27 H Erlenmeyer H Bloch and H Kiefer *ibid* 1068
- 28 H von Euler B Högberg P Karrer H Salomon and H Ruckstuhl *ibid* 1944 27, 382
- 29 H McIlwain *Brit J Exp Path* 1940 21, 136
- 30 E F Möller and L Birkofer *Ber* 1942 75, 1118
- 31 H Erlenmeyer and H Kiefer *Helv Chim Acta* 1945 28, 985
- 32 H von Euler *Ber* 1942 75, 1876 E Adler H von Euler and B Skarzynski *Arkiv Kemi Min Geol* 1943 16A, No 9
- 33 P Karrer and W Manz *Helv Chim Acta* 1946 29, 1152
- 34 D W Woolley and A G C White *Proc Soc Exp Biol Med* 1943 52, 106
- 35 R West and A F Coburn *Trans Assoc Amer Physicians* 1940 55 173
- 36 A E Schaefer J M McKibbin and C A Elvehjem *J Biol Chem* 1942 144, 679
- 37 D W Woolley *ibid* 1945 157, 455
- 38 D W Woolley *ibid* 1946 162, 179
- 39 E Aubagen *Z physiol Chem* 1942 274 48
- 40 J A Gautier *Compt rend* 1946 222, 394
- 41 J T Minor G F Hawkins C A Vander Werf and A Roe *J Amer Chem Soc* 1949 71, 1125
- 42 G F Hawkins and A Roe *J Org Chem* 1949 14 378
- 43 J Schmidt Thome *Z Naturforsch* 1943 3b 136
- 44 P Ellinger G Fraenkel and M M Abdel Kader *Biochem J* 1947 41, 559



PYRIDOXINE (ADERMIN. VITAMIN B<sub>6</sub>)

## I. HISTORICAL

In the previous chapter, mention was made of the observation of J Goldberger and R D Lillie<sup>1</sup> that a pellagra-like dermatitis was produced in rats fed a vitamin B<sub>2</sub> deficient diet (page 211). For a time it was believed that this dermatitis was analogous to human pellagra and that the condition could be used as a test for the "PP-factor". In 1935, however, Birch *et al*<sup>2</sup> showed that this dermatitis which they preferred to call rat acrodynia was cured, not by the PP factor, but by another component of the vitamin B<sub>2</sub> group previously designated vitamin B<sub>6</sub> by P Gyorgy,<sup>3</sup> who defined it as "that part of the vitamin B complex which is responsible for the cure of a specific dermatitis developed by young rats on the vitamin free diet supplemented with vitamin B<sub>1</sub> and lactoflavin". On the other hand, a highly active pellagra-preventive concentrate was found to possess little or no vitamin B<sub>6</sub> activity. Thus, for the first time, a clear distinction was recognised between riboflavine, the PP-factor and vitamin B<sub>6</sub>.

At about the same time, C A Elvehjem and C J Koehn<sup>4</sup> were making observations on a form of dermatitis produced in chicks on a vitamin B<sub>2</sub> deficient diet, and they prepared a concentrate of the responsible substance from a commercial liver extract (Eli Lillys). This concentrate, although highly effective in chick dermatitis, was inactive in rat dermatitis, and the fractions that had been discarded in the course of its preparation were therefore tested on rats. One of them, presumably containing Gyorgy's vitamin B<sub>6</sub>, was found to be very active. The chick dermatitis factor was also investigated by S Lepkovsky and T H Jukes,<sup>5</sup> who found that, unlike the factor that cured rat dermatitis, it was not adsorbed on fuller's earth from aqueous solutions. The rat factor they called factor 1 and the chick factor, factor 2. They found that both factors were essential for puppies, and that a microcytic hypochromic anaemia developed in the absence of factor 1.

The first step toward the isolation of the new factor was taken by T W Birch and P Gyorgy,<sup>6</sup> who found that vitamin B<sub>6</sub> was present as an insoluble complex in fresh fish muscle and in wheat

germ, and that the vitamin was adsorbed from acid solution on fuller's earth and was precipitated by phosphotungstic acid. A M Copping<sup>7</sup> was able to make further distinctions between the symptoms of vitamin B<sub>6</sub> and riboflavin deficiencies in rats, the absence of vitamin B<sub>6</sub> produced dermatitis, with redness, swelling and oedema of the paws, ears, etc., whilst absence of riboflavin produced skin lesions, associated with loss of hair but unaccompanied by swelling or inflammation. She showed that the acrodynia was cured by an alcoholic extract of whole maize or wheat. C E Edgar and T I Macrae<sup>8</sup> showed that rats did not grow optimally on a vitamin B<sub>6</sub> free diet to which riboflavin had been added, but did so when an alcoholic extract of wheat germ or yeast was also added. Further work showed that neither the factor adsorbed on fuller's earth ("eluate factor") nor the factor remaining in solution after fuller's earth treatment ("filtrate factor") was effective alone, but that both were needed in order to obtain a maximal response. They stated that the "eluate factor" appeared to resemble György's vitamin B<sub>6</sub>, whilst the "filtrate factor" was similar to Lepkovsky and Jukes's factor 2.

One of the reasons for confusion concerning vitamin B<sub>6</sub> at this stage of its history was that different workers used different sources of the vitamin and different test animals, yet tended to assume that the corresponding fractions were equivalent. Thus, when Edgar *et al*<sup>9</sup> came to apply their fuller's earth treatment to liver extract, they obtained fractions that behaved differently from the corresponding fractions from yeast extract and they had to resort to other methods to secure parallel results.

A clearer picture of the syndromes associated with each factor was presented by Chick *et al*,<sup>10</sup> who found that rats deprived of riboflavin for a long time showed no increase in weight and developed an eczematous condition of the skin affecting especially the nostrils and eyes, that rats deprived of filtrate factor grew slowly and developed poor coats with matted fur that tended to become grey on the head and shoulders, and that rats deprived of vitamin B<sub>6</sub> developed dermatitis and, later, epileptiform fits. These fits could be prevented and cured by administration of 10 to 15 mg of the vitamin per day.<sup>11</sup> They were similar in appearance to fits observed in young pigs.

#### References to Section 1

- 1 J Goldberger and R D Lillie, *U S Publ Health Rep* 1926 41, 201
- 2 T W Birch, P György and L J Harris *Biochem J* 1935 29, 2830
- 3 P György, *Nature*, 1934 133, 498
- 4 C A Elvehjem and C J Koehn *J Biol Chem* 1935 108, 709
- 5 S Lepkovsky and T H Jukes *ibid.*, 1936 114, 109 1937 119, 1x, *J. Nutrition*, 1938, 16, 197

PYRIDOXINE (ADERMIN · VITAMIN B<sub>6</sub>)

## I. HISTORICAL

IN the previous chapter, mention was made of the observation of J Goldberger and R D Lillie<sup>1</sup> that a pellagra like dermatitis was produced in rats fed a vitamin B<sub>2</sub>-deficient diet (page 211). For a time it was believed that this dermatitis was analogous to human pellagra and that the condition could be used as a test for the "PP factor". In 1935, however, Birch *et al*<sup>2</sup> showed that this dermatitis which they preferred to call rat acrodynia, was cured, not by the PP factor, but by another component of the vitamin B<sub>2</sub> group, previously designated vitamin B<sub>6</sub> by P Gyorgy,<sup>3</sup> who defined it as "that part of the vitamin B complex which is responsible for the cure of a specific dermatitis developed by young rats on the vitamin-free diet supplemented with vitamin B<sub>1</sub> and lactoflavin". On the other hand, a highly active pellagra preventive concentrate was found to possess little or no vitamin B<sub>6</sub> activity. Thus, for the first time a clear distinction was recognised between riboflavin, the PP-factor and vitamin B<sub>6</sub>.


At about the same time, C A Elvehjem and C J Koehn<sup>4</sup> were making observations on a form of dermatitis produced in chicks on a vitamin B<sub>2</sub> deficient diet, and they prepared a concentrate of the responsible substance from a commercial liver extract (Eli Lilly's). This concentrate, although highly effective in chick dermatitis, was inactive in rat dermatitis, and the fractions that had been discarded in the course of its preparation were therefore tested on rats. One of them presumably containing Gyorgy's vitamin B<sub>6</sub>, was found to be very active. The chick dermatitis factor was also investigated by S Lepkovsky and T H Jukes,<sup>5</sup> who found that, unlike the factor that cured rat dermatitis, it was not adsorbed on fuller's earth from aqueous solutions. The rat factor they called factor 1 and the chick factor, factor 2. They found that both factors were essential for puppies, and that a microcytic hypochromic anaemia developed in the absence of factor 1.

The first step toward the isolation of the new factor was taken by T W Birch and P Gyorgy<sup>6</sup> who found that vitamin B<sub>6</sub> was present as an insoluble complex in fresh fish muscle and in wheat


R Kuhn and G Wendt<sup>1</sup> showed that, on treatment with diazomethane, vitamin B<sub>6</sub> (which they called adermin) yielded a methyl ether which was converted into a diacetyl ether on acetylation. They therefore concluded that all three oxygen atoms in adermin were present in the form of hydroxyl groups, one phenolic and the other two alcoholic and that, since diacetyl adermin methyl ether contained no active hydrogen atom, the nitrogen atom was tertiary.

The position of the phenolic hydroxyl group was established<sup>2</sup> by the fact that vitamin B<sub>6</sub>, like  $\beta$  hydroxypyridine, gave a positive reaction with the Folin Denis phenol reagent,<sup>3</sup> whereas  $\alpha$  and  $\gamma$ -hydroxypyridine did not. Confirmation was obtained by the close resemblance between the absorption spectra of vitamin B<sub>6</sub> and  $\beta$  hydroxypyridine. That the two alcoholic hydroxyl groups were not on adjacent carbon atoms was shown<sup>2</sup> by recovery of unchanged adermin methyl ether after treatment with lead tetraacetate.

Oxidation of the methyl ether with neutral potassium permanganate solution resulted in the formation of a lactone, C<sub>8</sub>H<sub>7</sub>O<sub>3</sub>N, by removal of four hydrogen atoms, suggesting that the aliphatic hydroxyl groups were in the 1, 4 or 1, 5 positions. Oxidation with alkaline potassium permanganate solution yielded the anhydride of a dicarboxylic acid, C<sub>8</sub>H<sub>5</sub>O<sub>4</sub>N, with loss of a molecule of carbon dioxide. Oxidation by barium permanganate<sup>4</sup> gave the dicarboxylic acid. By more cautious treatment with potassium permanganate, loss of carbon dioxide was avoided and a tricarboxylic acid, C<sub>8</sub>H<sub>5</sub>O<sub>7</sub>N, was obtained. From an examination of its absorption spectrum, it was concluded that the anhydride was either



and the tricarboxylic acid therefore



As the tricarboxylic acid gave a blood red colour with ferrous sulphate, characteristic of pyridine  $\alpha$ -carboxylic acid, whereas the dicarboxylic acid gave no such colour, formula II for the anhydride, and formula

## PYRIDOXINE

- 6 T W Birch and P Gyorgy *Biochem J* 1936 **30**, 304
- 7 A M Copping *ibid* 845
- 8 C E Edgar and T F Macrae *ibid* 1937 **31**, 879 893
- 9 C E Edgar M M El Sadr and T F Macrae *ibid* 1938 **32** 2225
- 10 H Chick T F Macrae and A N Worden *ibid* 1940 **34**, 580
- 11 H Chick M M El Sadr and A N Worden *ibid* 595

## 2 ISOLATION OF PYRIDOXINE

The isolation of vitamin B<sub>6</sub> in crystalline form was announced in 1938 from four different laboratories P György<sup>1</sup> and S Lepkovsky<sup>2</sup> obtained it from rice bran and yeast respectively by eluting the fuller's earth adsorbate with baryta and precipitating the active substance from the eluate with phosphotungstic acid after removal of inert material by precipitation with alcohol mercuric chloride and similar methods The precipitate was decomposed with baryta and the filtrate crystallised on being concentrated

J C Keresztesy and J R Stevens<sup>3</sup> isolated the vitamin from an adsorbate of rice extract whilst R Kuhn and G Wendt<sup>4</sup> used yeast in which they stated the vitamin was present as a non dialysable protein complex with the properties of an enzyme Pyridoxine was also isolated from rice bran in 1940 by T Matukawa<sup>5</sup> who used fractional adsorption acetylation and extraction with ether followed by hydrolysis

According to J V Scudi<sup>6</sup> rice bran contained a water soluble conjugate of low molecular weight in addition to free pyridoxine This was not precipitated by the usual protein precipitants and could be adsorbed on acid clay and eluted in a similar manner to pyridoxine

### References to Section 2

- 1 P Gyorgy *J Amer Chem Soc* 1938 **60**, 983
- 2 S Lepkovsky *Science* 1938 **87**, 169 *J Biol Chem* 1938 **124** 125
- 3 J C Keresztesy and J R Stevens *Proc Soc Exp Biol Med* 1938 **38**, 64 *J Amer Chem Soc* 1938 **60**, 1267
- 4 R Kuhn and G Wendt *Ber* 1938 **71**, 780 1118
- 5 T Matukawa *J Pharm Soc Japan* 1940 **60**, 216
- 6 J V Scudi *J Biol Chem* 1942 **145**, 637


## 3 CHEMICAL CONSTITUTION OF PYRIDOXINE

### Pyridoxine

Pyridoxine hydrochloride has the empirical formula C<sub>8</sub>H<sub>12</sub>O<sub>3</sub>NCI and its structural formula was worked out independently by R Kuhn and his fellow workers in Germany and by a group of workers in the USA

## SYNTHESIS

hydroxy 4 hydroxymethyl 2 methylpyridine by the following route



and showed that it differed from pyridoxamine in its chemical behaviour and in the absence of growth promoting activity. They also showed that the oxime of pyridoxal yielded pyridoxamine on catalytic hydrogenation thus establishing the fact that the formyl group was in the 4 and not the 5 position. The isomeric aldehyde 5 formyl 3 hydroxy 4 hydroxymethyl 2 methylpyridine was synthesised and shown to be different from pyridoxal and to have no significant growth promoting properties.

### References to Section 3

- 1 R Kuhn and G Wendt *Ber* 1938 **71**, 1534
- 2 R Kuhn and G Wendt *ibid* 1939 **72**, 305
- 3 O Folin and W Denis *J Biol Chem* 1912 **12**, 239 1915 **22**, 305
- 4 R Kuhn G Wendt and K Westphal *Ber* 1939 **72**, 310
- 5 R Kuhn H Andersag K Westphal and G Wendt *ibid* 309
- 6 E T Stiller J C Heresztesy and J R Stevens *J Amer Chem Soc* 1939 **61**, 1237
- 7 S A Harris E T Stiller and K Folkers *ibid* 1242
- 8 E E Snell B M Guirard and R J Williams *J Biol Chem* 1942 **143**, 519
- 9 E E Snell *ibid* 1944 **154**, 313 *J Amer Chem Soc* 1944 **66**, 2082 Research Corp and E E Snell B P 603289 603290
- 10 E E Snell *ibid* 1945 **67**, 194
- 11 S A Harris D Heyl K Folkers and E E Snell *J Biol Chem* 1944 **154**, 315 S A Harris D Heyl and K Folkers *J Amer Chem Soc* 1944 **66**, 2088


## 4 SYNTHESIS OF PYRIDOXINE

Pyridoxine was synthesised independently by the two groups of workers mentioned above and in addition by a group of Japanese workers.

S A Harris and K Folkers<sup>1</sup> used the method represented by the following series of transformations

## PYRIDOXINE

V for the tricarboxylic acid, could be excluded. Adermin must therefore be




Kuhn *et al*<sup>5</sup> synthesised the anhydride represented by formula I and found it to be identical with that from adermin, thus confirming that the latter must have structure VI or VII. They<sup>4</sup> also synthesised 3-methoxy-2-methyl pyridine 4,5-dicarboxylic acid and showed that it was identical with the dicarboxylic acid obtained by treating adermin methyl ether with barium permanganate.

Stiller *et al*<sup>6</sup> also obtained the lactone,  $C_9H_9O_2N$ , by treating the methyl ether of adermin with barium permanganate, together with a dibasic acid,  $C_9H_9O_5N$ , which they presumed to be 3-methoxy-2-methyl pyridine 4,5-dicarboxylic acid since it yielded a phthalein on fusion with resorcinol and a hydroxypicoline on being heated with calcium hydroxide. Its constitution was confirmed by synthesis, accomplished by S. A. Harris, E. T. Stiller and K. Folkers.<sup>7</sup>

### Pyridoxal and Pyridoxamine

As a result of a study of the effect of pyridoxine on micro organisms (see page 212), Snell *et al*<sup>8</sup> discovered the existence in various natural materials of two substances closely related to pyridoxine. These were identified as 4-formyl-3-hydroxy-5-hydroxymethyl-2-methyl pyridine to which the name pyridoxal was given, and 4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methyl pyridine, which is known as pyridoxamine.




ferricyanide and the latter by treatment with ammonia. Pyridoxal was converted into pyridoxamine by heating with casein hydrolysate or glutamic acid whilst the reverse change was effected by heating pyridoxamine with  $\alpha$ -ketoglutaric acid.<sup>10</sup> Other amino acids effected the transformation of pyridoxal into pyridoxamine, but not so readily as did glutamic acid.

The structure of these two substances was established by Harris *et al*<sup>11</sup> who synthesised the isomer of pyridoxamine, 5-aminomethyl-3-


# SYNTHESIS

The following method of preparing the starting material for this synthesis had been described in 1900 by S. Gabriel and J. Colman:<sup>5</sup>




Another method of synthesis leading to the formation of adermin monomethyl ether was described by S. Morii and K. Makino.<sup>6</sup> In this method, the initial step was the same as in the method of Harris and Folkers, and the subsequent stages differed only in detail.

The synthesis of pyridoxine was protected by the American workers in a series of patents, assigned to Merck & Co. These covered the following series of transformations:






# PYRIDOXINE



Subsequently, improved modifications of this method were devised. The synthetic material made by these workers was tested by Reedman *et al*<sup>2</sup> and shown to have the same degree of vitamin B<sub>6</sub>-activity as the natural vitamin, being fully active in rats in a dose of 100  $\mu$ g.

The synthetic methods adopted by Kuhn *et al*<sup>3</sup> and by A. Ichiba and K. Michi<sup>4</sup> were different from those used by the American workers and involved the use of 4-methoxy-3-methylisoquinoline as starting material. Ichiba and Michi used oxidation with alkaline potassium permanganate solution to effect the first step, whilst Kuhn *et al* nitrated the isoquinoline, reduced the nitro compound to the corresponding amino compound and then oxidised the latter with permanganate. The remaining stages used by these two groups of workers were identical, namely




References to Section 4

- 1 S A Harris and K Folkers *J Amer Chem Soc* 1939 **61**, 1245  
3307
- 2 E J Reedman W L Sampson and K Unna *Proc Soc Exp  
Biol Med* 1940 **43**, 112
- 3 R Kuhn K Westphal G Wendt and G Westphal *Naturwiss*  
1939 **27**, 469
- 4 A Ichiba and K Michi *Sci Papers Inst Phys Chem Res (Tokyo)*  
1939 **38** 173
- 5 S Gabriel and J Colman *Ber* 1900 **33**, 988
- 6 S Mori and K Makino *Enzymologia* 1939 **7**, 385
- 7 Merck & Co USP 2399347
- 8 Merck & Co BP 534916-7 USP 2422616
- 9 Merck & Co BP 543615 USP 2422617 2422622
- 10 Merck & Co BP 557804 USP 2422619
- 11 Merck & Co BP 557805 USP 2422618 2422620
- 12 Merck & Co BP 536249
- 13 Merck & Co USP 2422621
- 14 Merck & Co BP 603442
- 15 Hoffmann La Roche BP 550889
- 16 Hoffmann La Roche BP 550939
- 17 Hoffmann La Roche BP 552419
- 18 Hoffmann La Roche BP 556044
- 19 Hoffmann La Roche BP 556136 USP 2410938 41
- 20 Hoffmann La Roche BP 570365
- 21 Hoffmann La Roche BP 552808
- 22 Hoffmann La Roche BP 553097
- 22a Roche Products Ltd BP 625997 629450
- 23 Lederle Inc BP 567611 American Cyanamid Co BP 626368


## 5 PROPERTIES OF PYRIDOXINE

The first compound with vitamin B<sub>6</sub> activity to be isolated in the pure state was 3 hydroxy 4 5 bis hydroxymethyl-2 methyl pyridine




for which the name adermin was proposed by R Kuhn and pyridoxine by P György and R E Eckardt<sup>1</sup>. The latter name is to be preferred for György and Eckardt showed that crystalline vitamin B<sub>6</sub> hydrochloride unlike the crude concentrates with which the early results had been obtained generally failed to cure rat acrodynia and in the

Hoffmann-La Roche<sup>21</sup> also patented the condensation of malononitrile, malonic esters, malonic acid diamide or cyanacetamide with 2-amino-5-ethoxy-pent-2 3-en-4-one to give 4 ethoxymethyl-6 hydroxy-2-methyl pyridines containing a carbethoxy, amido or cyano group in position 5




A further patent<sup>22</sup> covers the condensation of acylacetones with malononitrile in presence of piperidine, dimethylamine, diethylamine or dipropylamine



Roche Products Ltd<sup>22a</sup> patented the conversion of 4 5 dicarbalkoxy 3 hydroxy 2 methyl pyridines (pyracin esters) into pyridoxine (a) by reacting with a phenylarylmethyldialkylammonium hydroxide to yield 3 arylmethoxy 4 5-dicyano 2 methyl-pyridine treating with ammonia to give the corresponding diamide dehydrating and then hydrogenating to 4 5 bis aminomethyl 3 hydroxy 2 methyl pyridine, or (b) by reducing with lithium aluminium hydride

Another method of synthesising pyridoxine was patented by Lederle Inc<sup>23</sup>



were destroyed by oxidising agents such as nitric acid at 100° C or potassium permanganate or hydrogen peroxide at room temperature <sup>1, 2</sup>

#### References to Section 6

- 1 M Hochberg, D Melnick and B L Oser, *J Biol Chem*, 1944, **155**, 129
- 2 E Cunningham and E E Snell, *ibid*, 1945, **158**, 491
- 3 D Melnick, M Hochberg H W Himes and B L Oser, *ibid*, 1945 **160**, 1
- 4 M Hochberg D Melnick, L Siegel and B L Oser, *ibid*, 1943, **148**, 253
- 5 H C Epley, *Amer J Pharm*, 1945 **117**, 265

### 7. ESTIMATION OF VITAMIN B<sub>6</sub>

#### Biological Assay


The biological estimation of pyridoxine by means of rats depends largely on finding a diet complete in all the vitamins except vitamin B<sub>6</sub>, and probably much of the earlier work was unsatisfactory because the diets used were not completely free from traces of the vitamin. Edgar *et al*<sup>1</sup> described a method of assaying 'eluate factor' (pyridoxine) and 'filtrate factor' (pantothenic acid) based on the growth response of rats to graded doses of each of the factors, but they did not claim that their method was completely satisfactory, whilst R C Bender and G C Supplee<sup>2</sup> stated that the growth rate of rats was not sufficiently specific for use in the estimation of vitamin B<sub>6</sub>, and used the onset of acrodynia as the basis of an assay method, they devised a basal diet that produced acrodynia in 100 % of their animals in six to eight weeks. They reported that in order to obtain optimal growth with vitamin B<sub>6</sub> another factor, factor II (presumably pantothenic acid), had to be added to the diet, thus confirming the work of Edgar *et al*.

T W Conger and C A Elvehjem<sup>3</sup> used a synthetic diet consisting of sucrose and casein supplemented by aneurine, riboflavine, nicotinic acid, choline and pantothenic acid with a fuller's earth filtrate from a butanol extract of liver to supply other members of the vitamin B complex. They claimed to obtain satisfactory results when the growth of rats was used as the criterion of response. Satisfactory results were also reported by M T Clarke and M Lechycka,<sup>4</sup> using a similar method, the dose response curve obtained by plotting the logarithm of the dose against the gain in weight was linear with amounts of pyridoxine ranging from 1 to 18 µg. Even the best biological method, however, takes at least a month to carry out<sup>5</sup>

## PYRIDOXINE

absence of other factors, led to secondary symptoms such as scaly skin, inflammation alopecia and occasionally, watery eyes

Pyridoxine hydrochloride is readily soluble in water (1 g in 45 ml), acetone and alcohol (1 g in 90 ml) and slightly soluble in ether and chloroform. It melts at 204 to 206° C, with decomposition. It gives a characteristic absorption spectrum with a single maximum at 292 mμ at pH 3 and two maxima at 255 and 325 mμ at pH 7.45. Harris *et al*<sup>2</sup> attributed this change in the absorption spectrum to a tautomeric change of the type



When the hydroxyl group was methylated the single absorption band at 280 mμ remained unchanged on altering the pH. Pyridoxine is optically inactive.

Other compounds with vitamin B<sub>6</sub> activity are described on pages 312-344.

### References to Section 5


- 1 P Gyorgy and R E Eckardt *Nature* 1939 144, 512
- 2 S A Harris T J Webb and K Folkers *J Amer Chem Soc* 1940 62, 3198

## 6 STABILITY OF VITAMIN B<sub>6</sub>

Pyridoxine hydrochloride is a remarkably stable substance in comparison with most other members of the vitamin B complex. Thus it was not destroyed on heating with 5N acid or alkali at 100° C by autoclaving in acid or alkaline solution or by heating at 45° C for 500 hours in a mixed oil preparation<sup>1, 2</sup>. Pyridoxal and pyridoxamine (see page 312) are also stable to hot acid or alkali although pyridoxal suffered some decomposition on being heated in alkaline solution<sup>2</sup>. All three substances can be autoclaved in 2N sulphuric acid without appreciable destruction occurring<sup>3</sup>.

Pyridoxine was rapidly destroyed on irradiation in neutral or alkaline solution although stable in acid solution<sup>1, 2, 4</sup>. Pyridoxal and pyridoxamine behaved similarly except that the latter was destroyed by direct sunlight in acid solution<sup>2</sup>. Red light was much less destructive than blue or unfiltered light and solutions kept better in amber bottles than in colourless bottles<sup>5</sup>. All three substances

This produces a blue pigment, presumably the indophenol



Pyridoxine did not give the reaction in presence of a borate buffer,<sup>15</sup> whereas 4-ethoxymethyl-3-hydroxy-5-hydroxymethyl-2-methyl-pyridine and 4,5-epoxydimethyl-3-hydroxy-2-methyl-pyridine gave colours with the reagent both in the presence and in the absence of borate, so that they could readily be distinguished from pyridoxine.<sup>16</sup> Unfortunately, however, it is not possible to correct for the presence of these substances in pyridoxine merely by subtracting the value found in presence of borate from that found in its absence, as the different compounds react with borate at different rates. It is preferable to remove interfering substances before colour development.

2,6-Dichloroquinone-chloroimide was also used by Bird *et al.*,<sup>17</sup> who carried out the coupling reaction in a veronal buffer solution, pH 7.8 to 8.0, and by Hochberg *et al.*,<sup>18</sup> who coupled in aqueous isopropanol solution. The method was said to give results in close agreement with the biological method when applied to foodstuffs<sup>19</sup> and to rice bran,<sup>20</sup> but not to liver or yeast.<sup>20</sup>

Pyridoxine exhibits a characteristic half wave potential at the dropping mercury electrode,<sup>21</sup> but the polarographic method does not seem to have been used for the estimation of pyridoxine.

### Microbiological Assay Methods

In recent years, there has been a marked increase in the use of microbiological methods of assay for the estimation of vitamin B<sub>6</sub> in foodstuffs. These led incidentally to the discovery of compounds with vitamin B<sub>6</sub>-activity other than pyridoxine.

The first microbiological method to be used was a yeast growth method due to Atkin *et al.*<sup>22</sup> The organism was a strain of *Saccharomyces cerevisiae* (No. 4228), which requires pyridoxine for growth. Extracts were prepared for assay by acid digestion, and the growth of the organism was measured turbidimetrically. A similar method was used by R. J. Williams *et al.*<sup>23</sup> and by Siegel *et al.*<sup>24</sup> The latter group of workers autoclaved the test material in acid suspension to liberate bound pyridoxine.

An attempt was made by Emery *et al.*<sup>25</sup> to develop a pyridoxine assay method using another yeast, *Kloeckera brevis*, which requires pyridoxine for growth, but the results were frequently at variance

## PYRIDOXINE

A modified vitamin B<sub>6</sub> deficient diet for rats was devised by Sarma *et al* <sup>6</sup>. This was based on sucrose and blood fibrin and when supplemented with up to 75 µg of pyridoxine hydrochloride per 100 g of diet, gave a linear growth curve. Pyridoxal and pyridoxamine had the same activity as pyridoxine when given separately by mouth or when injected intraperitoneally, but both exhibited reduced activity when given with the diet. Because of this, the results obtained when the method was applied to natural materials were somewhat lower than the results obtained by the yeast growth method (page 311).

### Colorimetric Methods of Estimation

R Kuhn and I Lów <sup>7</sup> were the first to describe a colour reaction for pyridoxine. They observed that diazotised sulphanilic acid coupled with the vitamin to give an orange coloured dyestuff and that a colour was obtained by treating pyridoxine with phosphotungstomolybic acid reagent and lithium hydroxide.

M Swaminathan <sup>8</sup> made use of the colour reaction with diazotised sulphanilic acid to estimate pyridoxine in foodstuffs. The material was first digested with pepsin or papain, and the protein degradation products were removed with phosphotungstic acid, and the purine and other bases by means of silver nitrate and baryta. The pyridoxine was then adsorbed from the filtrate, acidified to pH 1 to 2, on to Clarit, from which it was eluted with hot baryta solution. After neutralising the eluate, the colour was developed and compared with that of a standard. The method was used to estimate pyridoxine in urine.

This colour reaction was also used by Bina *et al*, <sup>9</sup> though they used a somewhat different method of preparing the pyridoxine extract. The food was first hydrolysed by autoclaving with dilute sulphuric acid and was then digested with a mixture of takadiastase and papain after which proteins and other interfering substances were precipitated with sodium tungstate. The filtrate was then treated with Superfiltrol and the adsorbed pyridoxine eluted with alkaline alcohol. These workers subsequently <sup>10</sup> modified the method by using the ion exchange resin, Amberlite IR-4, to purify the solution and diazotised *p*-aminoacetophenone in place of diazotised sulphanilic acid to develop the colour.

Another colour reaction was discovered by J C Keresztesy and J R Stevens, <sup>11</sup> who observed that ferric chloride gave a reddish brown colour with vitamin B<sub>6</sub>. R D Greene <sup>12</sup> made use of this reaction to estimate the vitamin in rich concentrates.

J V Scudi and his colleagues <sup>13</sup> made use of Gibbs reagent, <sup>14</sup> 2,6-dichloroquinone chloroimide, to estimate the vitamin in urine.

### Microbiological Assay of Pyridoxine in presence of Pyridoxamine and Pyridoxal

It will be clear from the foregoing that the estimation of vitamin B<sub>6</sub> activity by measuring the growth response of micro organisms may give misleading results, as different organisms respond in different degrees to the three substances. The lactic acid bacteria, for example, are useless for this purpose, as they show a greater response to pyridoxamine and pyridoxal than to pyridoxine. The method of M Landy and D M Dicken,<sup>32</sup> which utilises *L. helveticus*, is invalid for this reason. By means of a special medium *L. helveticus* can be used for the assay of pyridoxal.<sup>33a</sup>

Perhaps the most satisfactory method of estimating pyridoxine in presence of its two derivatives is that of Stokes *et al*,<sup>36</sup> in which use is made of an X-ray induced mutant of *Neurospora sitophila*<sup>37</sup> that requires pyridoxine but does not respond to pyridoxamine or pyridoxal. The medium is relatively simple consisting of sucrose, ammonium tartrate, ammonium citrate inorganic salts and a minute amount of biotin, it was modified slightly by E C Barton Wright.<sup>38</sup> The response is measured by weighing the dried mycelium. The results obtained were in good agreement with those obtained by biological assays. An important point to be borne in mind when carrying out assays with *N. sitophila* is that aneurine must be destroyed with sodium sulphite as the organism does not respond quantitatively to pyridoxine in the presence of aneurine, residual sulphite must be destroyed by addition of hydrogen peroxide.

L E Carpenter and F M Strong<sup>39</sup> confirmed the claim of Stokes *et al* that *Neurospora* assays gave results in good agreement with those obtained by the rat growth method but they failed to obtain consistent results and expressed a preference for the yeast growth method.

Pyridoxine pyridoxal and pyridoxamine can be separated by partition chromatography on a strip of filter paper and the position of the spots detected by laying the filter paper for a few minutes on the surface of an agar plate seeded with *S. carlsbergensis* and then incubating the plate.<sup>40</sup> Growth of the organism is stimulated around the areas in which the three substances are concentrated. pyridoxamine is held near the top of the paper and pyridoxine near the bottom with pyridoxal just above it.

### References to Section 7

- 1 C E Edgar, M M El Sadr and T F Macrae, *Biochem J* 1938, 32, 2200
- 2 R C Bender and G C Supplee *J Nutrition* 1940 20, 109
- 3 T W Conger and C A Elvehjem, *J Biol Chem* 1941 138, 555



with those obtained with *Neurospora sitophila* (see below) The successful use of *S. carlsbergensis* for microbiological assays has been reported by R. H. Hopkins and R. J. Pennington<sup>26</sup>

### "Pseudo-pyridoxine", Pyridoxal and Pyridoxamine

*Streptococcus faecalis* R, previously known as *S. lactis* R, requires pyridoxine for growth, but when attempts were made to utilise it for the assay of pyridoxine it was found<sup>27</sup> that the growth response was much greater, several times greater in fact, than could be accounted for by the pyridoxine content, as estimated chemically or biologically. It appeared that pyridoxine was converted prior to its utilisation by the organism into a more active metabolite, provisionally termed "pseudo pyridoxine", this also appeared to be present in some natural products. Although it was so much more active than pyridoxine on *S. faecalis* R "pseudo pyridoxine", formed either by treating synthetic pyridoxine with hydrogen peroxide or by autoclaving in presence of cystine, did not stimulate the growth of rats or yeast to a greater extent than did pyridoxine<sup>28</sup>

The nature of "pseudo pyridoxine" was elucidated by E. E. Snell,<sup>29</sup> who showed that substances with a greater growth promoting action on both *S. faecalis* R and *Lactobacillus helveticus* could be formed from pyridoxine by amination or by partial oxidation. Treatment with ammonia yielded a closely related amine, which he called pyridoxamine, whilst oxidation yielded an aldehyde, pyridoxal. Both compounds were more active towards *S. faecalis* and *L. helveticus* than was pyridoxine.

The constitution of pyridoxamine and pyridoxal was established by Harris *et al*<sup>30</sup> (see page 300)

Whereas pyridoxamine and pyridoxal had much the same growth promoting activity as pyridoxine for rats, some moulds and some yeasts, for many of the lactic acid bacteria their activity was several thousand fold greater<sup>31</sup>. The two compounds had little or no effect on *Saccharomyces cerevisiae* however but stimulated the growth of *S. carlsbergensis* to the same extent as did pyridoxine<sup>32</sup>. Pyridoxal and pyridoxamine had 2/5th and 4/5th respectively of the growth

<sup>33</sup>

re labile than pyridoxine (page 308), and readily react with other constituents of the medium, they are also destroyed by light. By using three different organisms—*L. helveticus*, *S. faecalis* and *S. carlsbergensis*—E. E. Snell<sup>34</sup> was able to show that pyridoxal and pyridoxamine, like pyridoxine, constituted essential growth factors in many natural

products

- 32 D Melnick M Hochberg H W Himes and B L Oser *ibid*  
1945 160, 1
- 33 T D Luckey G M Briggs C A Elvehjem and E B Hart  
*Proc Soc Exp Biol Med* 1945 58, 340
- 34 E E Snell *J Biol Chem* 1945 157, 491 J C Rabinowitz and  
E E Snell *ibid* 1947 169 631
- 35 M Landy and D M Dicken *J Lab Clin Med* 1942 27, 1086
- 35a J C Rabinowitz N I Mondy and E E Snell *J Biol Chem*  
1948 175, 147
- 36 J L Stokes A Larsen C R Woodward and J W Foster *J Biol  
Chem* 1943 150, 17
- 37 G W Beadle and E L Tatum *Proc Nat Acad Sci* 1941 27,  
499 1942 28, 234
- 38 E C Barton Wright *Biochem J* 1945 39, x *Analyst* 1945 70,  
283
- 39 L E Carpenter and F M Strong *Arch Biochem* 1944 3, 375
- 40 W A Winsten and E Eigen *Proc Soc Exp Biol Med* 1948 67,  
513

## 8 OCCURRENCE OF VITAMIN B<sub>6</sub> IN FOODSTUFFS

Vitamin B<sub>6</sub> occurs in most foodstuffs in the form of complexes<sup>1</sup> In addition to pyridoxine pyridoxal and pyridoxamine are present in variable proportions<sup>2</sup> This makes the estimation of the vitamin B<sub>6</sub> activity of a foodstuff a matter of some difficulty and this fact coupled with the virtual absence of frank vitamin B<sub>6</sub> deficiency in man probably accounts for the relative lack of information about the occurrence of vitamin B<sub>6</sub> in foodstuffs compared with the amount of data available for ascorbic or nicotinic acid for example

The method of estimation open to least criticism is the rat growth method since this estimates the biological activity of a substance directly without requiring any assumptions to be made concerning the relative vitamin B<sub>6</sub> activities of the three compounds This method was used by Schneider *et al*<sup>3</sup> by Henderson *et al*<sup>4</sup> by T W Conger and C A Elvehjem<sup>5</sup> and by Teply *et al*<sup>6</sup> The first group of workers expressed their results in arbitrary units making it difficult to relate them to the results obtained by subsequent workers They showed however that cereals and meat contained more vitamin B<sub>6</sub> than did fruit and vegetables the surprisingly high values reported by them for fats and vegetable oils were probably due to the absence of fat from the basal diet used in their assays

Atkin *et al*<sup>7</sup> and R J Williams *et al*<sup>8</sup> used a yeast growth method and J Bonner and R Dorland<sup>9</sup> and E C Barton Wright<sup>10</sup> the method based on the response of *Neurospora sitophila* M Swaminathan<sup>11</sup> made use of the colour reaction with diazotised

# PYRIDOXINE

- 4 M F Clarke and M Lechycka *J Nutrition* 1943 25, 571
- 5 A M C ----- D ----- J -----
- 6  
*J Biol Chem* 1946
- 7 R Kuhn and I Löw *Ber* 1939 72, 1453
- 8 M Swaminathan *Nature* 1940 185, 780, *Indian J Med Res*  
1940 28, 427 1941 29, 261
- 9 A F Bina J M Thomas and E B Brown *J Biol Chem* 1943  
148, 111
- 10 E B Brown A F Bina and J M Thomas *ibid* 1945 158,  
455
- 11 J C Keresztesy and J R Stevens, *J Amer Chem Soc* 1938 60  
1267
- 12 R D Greene *J Biol Chem* 1939 130, 513
- 13 J V Scudi K Unna and W Antopol *ibid* 1940 135, 371 J V  
Scudi H F Koonen and J C Keresztesy *Proc Soc Exp Biol  
Med* 1940 43, 118
- 14 H D Gibbs *J Biol Chem* 1927 72, 649
- 15 J V Scudi *ibid* 1941 139, 707
- 16 J V Scudi W A Bastedo and T J Webb *ibid* 1940 136,  
399
- 17 O D Bird J M Vandenbelt and A D Emmett *ibid* 1942  
142, 317
- 18 M Hochberg D Melnick and B L Oser *ibid* 1944 155, 109
- 19 A E Bottomley *Biochem J*, 1944 38, xxxi
- 20 M Hochberg D Melnick and B L Oser *J Biol Chem* 1944  
155, 119
- 21 J J Lingane and O L Davis *ibid* 1941 137, 567
- 22 L Atkin A S Schultz and C N Frey *J Amer Chem Soc* 1939  
61, 1931 L Atkin A S Schultz C N Frey and W L Williams  
*Ind Eng Chem Anal Ed* 1943 15, 141
- 23 R J Williams R E Eakin and J R McMahan *Univ Texas  
Publ* 1941 No 4137
- 24 L Siegel D Melnick and B L Oser *J Biol Chem* 1943 149,  
361
- 25 W B Emery N McLeod and F A Robinson *Biochem J* 1946  
40, 426
- 26 R H Hopkins and R J Pennington *ibid* 1947 41, 110
- 27 E E Snell B M Guirard and R J Williams *J Biol Chem*  
1942 143, 519
- 28 L E Carpenter C A Elvehjem and F M Strong *Proc Soc  
Exp Biol Med* 1943 54, 123
- 29 E E Snell *J Biol Chem* 1944 154, 313 *J Amer Chem Soc*  
1944 66, 2082
- 30 S A Harris D Heyl K Folkers and E E Snell *J Biol Chem*  
1944 154, 315 S A Harris D Heyl and K Folkers *J Amer  
Chem Soc* 1944 66, 2088
- 31 E E Snell and A N Rannefeld *J Biol Chem* 1945 157, 475

of the protein content of the diet, but with a constant protein intake the amount of pyridoxine in the tissues increased to a maximum with increasing amounts of dietary pyridoxine up to 200  $\mu\text{g}$  per day. Storage was directly proportional to protein intake, and maximum values were obtained with a pyridoxine intake of 25  $\mu\text{g}$  per day. On the other hand, Schweigert *et al*<sup>18</sup> found that the protein content of the diet did not affect the storage or depletion of pyridoxine.

Further evidence that a disturbance of normal protein metabolism occurs in vitamin B<sub>6</sub> deficiency is provided by the findings of Hawkins *et al*<sup>19</sup> that, on a high protein diet, the fasting blood levels of urea and non protein nitrogen increased when rats were deprived of vitamin B<sub>6</sub> and by the observation of G. J. Martin<sup>20</sup> that L tyrosine was less toxic to pyridoxine-deficient rats than to normal rats.

*Mice* The association between pyridoxine and protein metabolism noted in rats was confirmed in experiments on mice. The reserves of pyridoxine in the tissues of mice fed on a vitamin B<sub>6</sub> deficient diet decreased much more rapidly when the diet contained 50 % of casein than when it contained only 10 %, <sup>18</sup> whilst the mice on the high protein diet lost more weight and had a higher mortality than those on the low protein diet. The effects were not due to variations in caloric intake, in the urinary excretion of pyridoxine or in the tryptophan content of the diet. The pyridoxine content of the tissues increased as the pyridoxine content of the diet increased. At low levels of pyridoxine intake less pyridoxine was stored on the high protein than on the low protein diet but at high levels the high protein diet gave the higher pyridoxine storage. In young vitamin B<sub>6</sub> deficient mice cartilage growth and bone formation were inhibited the effect being accentuated on a high protein diet <sup>21</sup>

*Hamsters* When Syrian hamsters were fed on a vitamin B<sub>6</sub> deficient diet growth stopped in two or three weeks and food and water intake diminished. Muscular weakness developed changes in the fur occurred and increased amounts of xanthurenic acid were excreted in the urine. Deficient animals died after twelve or thirteen weeks and autopsy revealed a loss of fat tissue and atrophy of lymphoid tissues notably the thymus. Animals recovered after about nine weeks when given daily injections of 50  $\mu\text{g}$  of pyridoxine <sup>21a</sup>

*Dogs* In addition to anaemia deficient dogs also developed cardiac embarrassment, dyspepsia, tachycardia, dilation and hypertrophy of the right ventricle and right auricle, accumulation of serous fluid in the thorax and chronic passive congestion of the liver, degenerative changes were also found in the myelin sheaths of the peripheral nerves and spinal cord <sup>2</sup>

Dogs exhibited an increased urinary output of urea ammonia uric acid and creatinine when maintained on a vitamin B<sub>6</sub> deficient diet <sup>19</sup>

## PYRIDOXINE

was confirmed by W Antopol and K Unna,<sup>1</sup> who claimed that hyperkeratosis and acanthosis of the ears, paws and snout and an oedema of the corium were characteristic of vitamin B<sub>6</sub> deficiency, and were cured by pyridoxine. Fouts *et al*<sup>2</sup> were able to show that crystalline pyridoxine hydrochloride, like the crude concentrates previously used, cured a microcytic hypochromic anaemia in dogs, and this was confirmed by H J Borson and R S Mettier<sup>3</sup> and by Street *et al*<sup>4</sup>. The onset of anaemia is now regarded as a characteristic feature of vitamin B<sub>6</sub> deficiency, more characteristic indeed than dermatitis. Remission of the anaemia in dogs brought about by pyridoxine was only partial, however.<sup>5</sup> Nervous symptoms constitute another characteristic feature of vitamin B<sub>6</sub> deficiency, in chicks, these take the form of various convulsive movements<sup>6, 7</sup> and, in rats and pigs epileptiform fits.<sup>8</sup> Anaemia and nervous symptoms do not always occur together, however, turkeys for instance exhibiting hyperexcitability and convulsions, but not anaemia,<sup>9</sup> and young ducklings, severe anaemia, but not convulsions or paralysis<sup>10</sup> (see also page 320).

*Rats* In rats, anaemia is not a regular symptom of vitamin B<sub>6</sub> deficiency although latent erythropoiesis may be demonstrated by the impaired regeneration of the red blood cells after haemorrhage.<sup>11</sup> The total body iron and copper were significantly increased in pyridoxine-deficient rats.<sup>11a</sup>

Convulsions are more characteristic of vitamin B<sub>6</sub> deficiency in this species and, when young rats were suckled by mothers maintained since parturition on a vitamin B<sub>6</sub> deficient diet, spontaneous convulsive seizures developed towards the end of lactation.<sup>12</sup> These were alleviated by 10  $\mu$ g of pyridoxine per day, but even 50  $\mu$ g per day did not protect the animals against artificially induced seizures. No spontaneous seizures were observed when the mothers received between 25 and 150  $\mu$ g per day, but a high incidence of artificially induced seizures occurred, at higher levels of pyridoxine these were delayed and were less severe.

In pyridoxine deficiency, the basal metabolic rate of rats was depressed,<sup>13</sup> and the administration of pyridoxine to vitamin B<sub>6</sub> deficient rats caused a marked acceleration in the growth rate.<sup>14</sup> Vitamin B<sub>6</sub> deficiency increased the amount of protein and water in the body, more so in male than in female rats.<sup>15</sup>

A further illustration of the close connection between pyridoxine and protein metabolism, which is more fully discussed on page 330, is provided by the observation that acrodynia was more severe in pyridoxine deficient rats fed a casein-rich diet than in rats fed a low casein diet.<sup>16</sup> According to E C Sheppard and E W McHenry<sup>17</sup> the amount of pyridoxine in the liver, kidney and leg muscles of rats fed a vitamin B<sub>6</sub> deficient diet for twenty one days was independent

of the protein content of the diet, but with a constant protein intake the amount of pyridoxine in the tissues increased to a maximum with increasing amounts of dietary pyridoxine up to 200  $\mu\text{g}$  per day. Storage was directly proportional to protein intake, and maximum values were obtained with a pyridoxine intake of 25  $\mu\text{g}$  per day. On the other hand Schweigert *et al*<sup>18</sup> found that the protein content of the diet did not affect the storage or depletion of pyridoxine.

Further evidence that a disturbance of normal protein metabolism occurs in vitamin B<sub>6</sub> deficiency is provided by the findings of Hawkins *et al*<sup>19</sup> that, on a high protein diet the fasting blood levels of urea and non protein nitrogen increased when rats were deprived of vitamin B<sub>6</sub> and by the observation of G. J. Martin<sup>20</sup> that L tyrosine was less toxic to pyridoxine-deficient rats than to normal rats.

**Mice** The association between pyridoxine and protein metabolism noted in rats was confirmed in experiments on mice. The reserves of pyridoxine in the tissues of mice fed on a vitamin B<sub>6</sub> deficient diet decreased much more rapidly when the diet contained 50 % of casein than when it contained only 10 %<sup>18</sup> whilst the mice on the high protein diet lost more weight and had a higher mortality than those on the low protein diet. The effects were not due to variations in calorie intake, in the urinary excretion of pyridoxine or in the tryptophan content of the diet. The pyridoxine content of the tissues increased as the pyridoxine content of the diet increased. At low levels of pyridoxine intake, less pyridoxine was stored on the high protein than on the low protein diet but at high levels the high protein diet gave the higher pyridoxine storage. In young vitamin B<sub>6</sub> deficient mice cartilage growth and bone formation were inhibited the effect being accentuated on a high protein diet.<sup>21</sup>

**Hamsters** When Syrian hamsters were fed on a vitamin B<sub>6</sub> deficient diet growth stopped in two or three weeks and food and water intake diminished. Muscular weakness developed changes in the fur occurred and increased amounts of xanthurenic acid were excreted in the urine. Deficient animals died after twelve or thirteen weeks and autopsy revealed a loss of fat tissue and atrophy of lymphoid tissues notably the thymus. Animals recovered after about nine weeks when given daily injections of 50  $\mu\text{g}$  of pyridoxine.<sup>21a</sup>

**Dogs** In addition to anaemia, deficient dogs also developed cardiac embarrassment, dyspepsia, tachycardia, dilation and hypertrophy of the right ventricle and right auricle, accumulation of serous fluid in the thorax and chronic passive congestion of the liver, degenerative changes were also found in the myelin sheaths of the peripheral nerves and spinal cord.<sup>6</sup>

Dogs exhibited an increased urinary output of urea ammonia uric acid and creatinine when maintained on a vitamin B<sub>6</sub>-deficient diet.<sup>19</sup>

## PYRIDOXINE

- 16 L R Cerecedo and J R Foy, *Arch Biochem* 1944 5, 207
- 17 E C Sheppard and E W McHenry *J Biol Chem* 1946 165, 649
- 18 B S Schweigert H E Sauberlich C A Elvehjem and C A Baumann *ibid* 187
- 19 W W Hawkins M L MacFarland and E W McHenry *ibid* 1946 166 223
- 20 G J Martin *ibid* 389
- 21 R Silberberg and B M Levy *Proc Soc Exp Biol Med* 1948 67, 259
- 21a G Schwartzman and L Strauss *J Nutrition* 1949 38 131
- 22 M M Wintrobe M H Miller R H Follis H J Stein C Mushatt and S Humphreys *J Nutrition* 1942 24, 345
- 23 M M Wintrobe R H Follis M H Miller H J Stein R Alcayaga S Humphreys and G E Cartwright *Johns Hopkins Hosp Bull* 1943 72, 1
- 24 G E Cartwright and M M Wintrobe *J Biol Chem* 1948 172, 557
- 25 R H Follis and M M Wintrobe *J Exp Med* 1945 81 539
- 26 G E Cartwright M M Wintrobe and S Humphreys *J Biol Chem* 1944 153, 171
- 27 K B McCall H A Waisman C A Elvehjem and E S Jones *J Nutrition* 1946 31, 685
- 28 T D Luckey G M Briggs C A Elvehjem and E B Hart *Proc Soc Exp Biol Med* 1945 58, 340
- 29 M L Scott L C Norris G F Heuser and W F Bruce *J Biol Chem* 1945 158 291
- 30 B A McLaren E Keller D J O'Donnell and C A Elvehjem *Arch Biochem* 1947 15, 169
- 31 A E Axelrod B B Carter R H McCoy and R Geisinger *Proc Soc Exp Biol Med* 1947 66, 137
- 31a L R C Agnew and R Cook *Brit J Nutrition* 1949 2 321
- 32 H C Stoerk and H N Eisen *Proc Soc Exp Biol Med* 1946 62, 88
- 33 H C Lichstein H A Waisman, K B McCall C A Elvehjem and P F Clark *ibid* 1945 60, 279
- 34 B E Kline R R Rusch C A Baumann and P S Lavik *Cancer Res* 1943 3, 825

## 10 EFFECT OF VITAMIN B<sub>6</sub> DEFICIENCY IN MAN

There is no clear cut deficiency disease analogous to beriberi or pellagra attributable to the absence of vitamin B<sub>6</sub> from the diet and an uncomplicated vitamin B<sub>6</sub> deficiency has probably not been observed in humans except when deliberately induced. Even then human volunteers maintained for a period of two months on a vitamin B<sub>6</sub> deficient diet failed to show symptoms that could be attributed

specifically to lack of this factor, although mental symptoms and white blood cell changes were observed<sup>1</sup>. Not unnaturally, therefore, attention has mainly been directed to the effect of pyridoxine on different forms of anaemia and nervous symptoms, that is, on conditions associated with vitamin B<sub>6</sub> deficiency in animals.

### Anaemia

Spies *et al*<sup>1a</sup> claimed that the administration of 50 mg of pyridoxine relieved within four hours certain symptoms remaining after treatment of undernourished patients with nicotinic acid, aneurine and riboflavin. These symptoms included extreme nervousness, insomnia, irritability, abdominal pain, weakness and difficulty in walking. Subsequently, Vilter *et al*<sup>2</sup> reported that pellagrins with macrocytic anaemia, and patients with pernicious anaemia, experienced a sense of well-being following the daily injection for ten days of 50 to 100 mg of pyridoxine. Only a slight reticulocytosis occurred, however, though the white cell count increased in a striking manner (see page 324). Pyridoxine was shown to be different from the anti-pernicious anaemia factor, and since it failed to give an increased reticulocyte response after incubation with human gastric juice, from Castle's extrinsic factor (page 498).

Kark *et al*<sup>3</sup> showed that pyridoxine was without effect in idiopathic hypochromic anaemia and in nutritional macrocytic anaemia, it failed to improve cases of alcoholic pellagra and endemic pellagra. There is no evidence, therefore, that pyridoxine will cure the more usual types of human anaemia.

### Nervous Disorders

Nor is there convincing evidence of its value in the treatment of nervous disorders, although numerous workers have claimed that it has a beneficial effect in muscular dystrophy and related conditions, especially in association with tocopherol. Thus, W. Antopol and C. E. Schotland<sup>4</sup> reported considerable improvement in six cases of pseudo hypertrophic muscular dystrophy whereas H. M. Keith<sup>5</sup> reported no increase in muscle strength after the intramuscular injection of 100 to 200 mg weekly for two to eight months. Rosenbaum *et al*<sup>6</sup> however, claimed to have obtained an increase in muscle strength by the intravenous injection of pyridoxine in neurasthenic hyperthyroidism and ulcerative colitis but not in myasthenia gravis, whilst A. B. Baker<sup>7</sup> obtained some slight improvement in a small proportion of cases of idiopathic and arteriosclerotic parkinsonism, and Vilter *et al*<sup>8</sup> an increase in strength in cases of peripheral neuritis.



## PYRIDOXINE

due to arsenic the simultaneous administration of pyridoxine and tocopherol was said to give the best results. Some improvement was also reported by C. L. Miller<sup>9</sup> in cases of postencephalitic and idiopathic paralysis agitans after treatment with pyridoxine but in neither condition was there a return to normal. It had no beneficial effect in epilepsy<sup>10</sup>

### Miscellaneous

One of the few conditions in which pyridoxine has been successfully employed is in the treatment of nausea. Complete or considerable relief was obtained in nausea and vomiting of pregnancy<sup>11</sup> using a dose of 10 to 20 mg three or four times daily and in radiation sickness or nausea following exposure to X rays<sup>12</sup> this was checked by single or repeated intravenous injection of 25 mg of pyridoxine at twenty four to seventy two hourly intervals.

Pyridoxine has been claimed to be of value in certain forms of dermatitis for example in cheilosis<sup>13</sup> and in post adolescent acne vulgaris<sup>14</sup>

Pyridoxine was claimed to be effective in agranulocytic angina<sup>15</sup> and was said to increase the white cell count and granulocytes in patients with toxic granulocytopenia. It was suggested that pyridoxine might be the factor involved in the maturation of the polymorphonuclear leucocytes and the stimulation of granulocytopenia. Intravenous injections of pyridoxine (200 mg per day) caused a rapid increase in the leucocytes of patients who developed granulocytopenia as the result of treatment with thiouracil<sup>16</sup>

### References to Section 10

- 1 W. W. Hawkins and J. Barsky *Science* 1948 **108** 284
- 1a T. D. Spies, W. B. Bean and W. F. Ashe *J. Amer. Med. Assoc.* 1939 **112**, 2414
- 2 R. W. Vilter, H. S. Schiro and T. D. Spies *Nature* 1940 **145** 388
- 3 R. Kark, E. L. Lozner and A. P. Meiklejohn *Proc. Soc. Exp. Biol. Med.* 1940 **43**, 97
- 4 W. Antopol and C. E. Schotland *J. Amer. Med. Assoc.* 1940 **114** 1058
- 5 H. M. Keith *J. Pediat.* 1942 **20**, 200
- 6 E. E. Rosenbaum, S. Portis and S. Soskin *J. Lab. Clin. Med.* 1942 **27**, 763
- 7 A. B. Baker *J. Amer. Med. Assoc.* 1941 **116**, 2484
- 8 R. W. Vilter, C. D. Aring and T. D. Spies *ibid.* 1940 **115** 209
- 9 C. L. Miller *Minnesota Med.* 1942 **25** 22
- 10 J. T. Fox and G. M. Tullidge *Lancet* 1946 **2**, 343
- 11 H. B. Weinstein, Z. Wohl, G. J. Mitchell and G. F. Sustental *Amer. J. Obstet. Gynec.* 1944 **47**, 389

- 12 J R Maxfield A J McIlwain and J F Robertson *Radiology* 1943 **41**, 383
- 13 S G Smith and D W Martin *Proc Soc Exp Biol Med* 1940 **43** 660
- 14 N Jolliffe L A Rosenbaum and J Sawhill *J Invest Derm* 1942 **5**, 143
- 15 M M Cantor and J W Scott *Canad Med Assoc J* 1945 **52**, 368 *Fed Proc* 1945 **4** 85
- 16 E H Fishberg and J Forzimer *Proc Soc Exp Biol Med* 1945 **60** 181

## II METABOLISM OF PYRIDOXINE

The metabolism of pyridoxine was first studied by Scudl and his co workers. Using the reaction with 2,6-dichloroquinone chloroimide they showed<sup>1</sup> that at levels of 10 mg per kg or over normal or vitamin B<sub>6</sub>-deficient rats excreted 50 to 70 % of a test dose but at lower levels normal rats excreted a higher proportion of the test dose than did vitamin B<sub>6</sub> deficient animals. Dogs excreted only 20 % of a 25 to 500 mg dose of pyridoxine within one to six hours of oral administration and humans only 8.7 % of a 50 mg test dose given intravenously one hour previously or 7.6 % of a 100 mg dose given orally four hours previously.<sup>2</sup>

In humans the excretion of pyridoxine apparently varied with the age of the subject.<sup>3</sup> Most patients under fifty years of age excreting 8.4 % of a 50 mg test dose and most patients over fifty excreting 7.2 % and a few as little as 2.3 %. These were mostly chronic renal cases. Patients from five to fifteen years of age excreted an average of 21.3 %. The excretion of 8.0 % and 8.4 % of a test dose by adults was regarded by Spies *et al*<sup>4</sup> and by J Flexner and M R Chassin<sup>5</sup> respectively as indicating a normal level of nutrition.

M Swaminathan<sup>6</sup> stated that the daily excretion of pyridoxine in man was 400 to 560  $\mu$ g and that about 5 % of a 50 mg test dose was excreted by normal (Indian) adults. He also reported that<sup>6</sup> rats receiving 0.9  $\mu$ g of pyridoxine per day excreted 1.0  $\mu$ g per day in excess of the intake whereas rats receiving 10  $\mu$ g per day excreted 3.7  $\mu$ g. The vitamin B<sub>6</sub> content of the liver and muscle was lower on the unsupplemented than on the supplemented diet and the excess vitamin may have been derived from these tissues.

Unfortunately the inferences drawn from these early results on the excretion of pyridoxine by animals and humans were vitiated by the subsequent discovery that pyridoxine was converted *in vivo* into other substances which were excreted in the urine along with unchanged pyridoxine. These metabolites represented a large proportion

of the ingested pyridoxine and must therefore be taken into account in studies on the metabolism of pyridoxine

Scudi *et al* <sup>7</sup> for example found that man and the dog excreted a conjugated form of pyridoxine possibly a glucuronate or ethereal sulphate formed by attachment of the conjugating group to the 3 hydroxyl group this substance was not present in the urine of the rat A second conjugated compound apparently derived from 4 pyridoxic acid was isolated from the urine of humans and dogs 4 Pyridoxic acid (2 methyl 3 hydroxy 5 hydroxymethylpyridine 4-carboxylic acid page 344) was identified as a constituent of human urine by J W Huff and W A Perlzweig <sup>8</sup>

These new facts were taken into consideration by Johnson *et al* <sup>9</sup> in studying the effect of tropical conditions on the excretion of pyridoxine Young men were maintained for eight hours a day at a temperature of 37.8° C and a relative humidity of 70 % Of the vitamin B<sub>6</sub> excreted 85 % was in the form of 4 pyridoxic acid 4.0 to 4.5 % was pyridoxine and 7 to 8 % was pseudo pyridoxine The amount excreted in the sweat was one fifth of that in the urine and the proportion of the different forms was approximately the same When the diet was supplemented by 8 mg of pyridoxine per day 50 % of the supplement was recovered unchanged and 50 % as the metabolite The amount excreted in the urine was eight times that excreted in the sweat

The metabolism of the three forms of vitamin B<sub>6</sub> in humans was studied by J C Rabinowitz and E E Snell <sup>10</sup> Pyridoxal pyridoxamine and pyridoxine were estimated in the urine microbiologically (page 313) and pyridoxic acid fluorimetrically <sup>8</sup> The predominant metabolite when any of the three substances was fed was pyridoxic acid Next in amount were the unchanged substances when either pyridoxine or pyridoxal were fed but pyridoxamine yielded pyridoxal and pyridoxamine in approximately equal amounts The highest recovery with a 70 to 80 mg test dose was 70 % with pyridoxal pyridoxine gave a 45 % and pyridoxamine a 31 % recovery Normal urine contains no pyridoxine and variable amounts of the other compounds at least 90 % being pyridoxic acid

Vitamin B<sub>6</sub> deficient rats excreted a substance that gave a green pigment with iron and the excretion of this substance ceased within a few hours after administering pyridoxine <sup>10</sup> Vitamin B<sub>6</sub> deficient dogs excreted a similar chromogen <sup>11</sup> The nature of these excretion products is discussed further on pages 330-336

No attempt appears to have been made to estimate vitamin B<sub>6</sub> levels in human blood but assays with *S. carlsbergensis* have been carried out on the blood of monkeys <sup>12</sup> After two weeks on a vitamin B<sub>6</sub> deficient diet the blood level fell to 2 to 3 µg per 100 ml Controls

that received 1 mg of pyridoxine hydrochloride per day gave values of 5 to 20.8 (average 11.2)  $\mu\text{g}$  per 100 ml

*References to Section 11*

- 1 J V Scudl H F Koonen and J C Keresztesy *Proc Soc Exp Biol Med* 1940 43, 118
- 2 J V Scudl K Unna and W Antopol *J Biol Chem* 1940 135, 371
- 3 J Flexner and M R Chassin *J Clin Invest* 1941 20, 313
- 4 T D Spies R K Ladisch and W B Bean *J Amer Med Assoc* 1940 115, 839
- 5 M Swaminathan *Indian J Med Res* 1941 29, 561
- 6 M Swaminathan *ibid* 557
- 7 J V Scudl R P Buhs and D B Herd *J Biol Chem* 1942 142, 323
- 8 J W Huff and W A Perlzweig *ibid* 1944 155 345
- 9 B C Johnson T S Hamilton and H H Mitchell *ibid* 1945 158, 619
- 9a J C Rabinowitz and E E Snell *Proc Soc Exp Biol Med* 1949 70 235
- 10 S Lepkovsky and E Nielsen *J Biol Chem* 1942 144, 135
- 11 P J Fouts and S Lepkovsky *Proc Soc Exp Biol Med* 1942 50, 221
- 12 L. D Greenberg and J F Rinehart *ibid* 1949 70 20

## 12 INTESTINAL SYNTHESIS OF VITAMIN B<sub>6</sub>

The first hint that pyridoxine might be synthesised in animals by intestinal bacteria was given by Chick *et al*<sup>1</sup> who found that the addition of cereal starches to the diet reduced the incidence of dermatitis and epileptiform fits in rats maintained on a vitamin B<sub>6</sub> deficient diet they suggested that the starch favoured the growth of bacteria capable of synthesising pyridoxine or other substances with vitamin B<sub>6</sub> activity

Further evidence in support of this view was obtained by Sarma *et al*<sup>2</sup> who found that rats when maintained on a sucrose blood fibrin diet failed to grow but that when dextrin was substituted for sucrose growth was resumed and the excretion of 4 pyridoxic acid (page 326) increased. Sulphathalidine prevented growth whilst pyridoxine increased it whence it was concluded that dextrin favoured the intestinal synthesis of pyridoxine which was then utilised by the rat Rats on a vitamin B<sub>6</sub>-deficient diet grew slowly and if given sulphasuxidine died<sup>2a</sup> The deficiency was cured by pyridoxine

The existence of intestinal synthesis in man was demonstrated by

## PYRIDOXINE

Denko *et al* <sup>3</sup> who reported that the faecal excretion was as high on a restricted intake of pyridoxine as on a normal diet. Furthermore the faecal excretion was unaffected when the diet was supplemented by additional pyridoxine. The urinary excretion on the other hand fell moderately on the restricted diet and returned to normal on supplementation. On all diets the amount of pyridoxine excreted in the urine was greater than the amount excreted in the faeces and the total excretion was less than the dietary intake. Thus there is clear evidence that pyridoxine is synthesised in the intestine but not that it is utilised in man. In this respect pyridoxine falls into the group of B vitamins that includes aneurine, riboflavin and nicotinic acid rather than into the group that includes biotin and folic acid where there is a strong presumption that both synthesis and utilisation occur.

Pyridoxine is undoubtedly synthesised by ruminants, and L W McElroy and H Goss <sup>4</sup> found that dried sheep rumen and reticulum contained 10  $\mu\text{g}$  of pyridoxine per g and the rumen contents of a fistulated cow 8  $\mu\text{g}$  per g. In each instance the ration contained only 1 to 1.5  $\mu\text{g}$  of pyridoxine per g. The cow supplied milk with the normal pyridoxine content in spite of the fistula.

### References to Section 12

- 1 H Chick, T F Macrae and A N Worden *Biochem J* 1940 **34**, 580
- 2 P S Sarma, E E Snell and C A Elvehjem *J Biol Chem* 1946 **165**, 55
- 2a K J Carpenter, L J Harris and E Kodicek *Brit J Nutrition* 1948 **2**, vii
- 3 C W Denko, W A Grundy, J W Porter, G H Berryman, T E Friedemann and J B Youmans *Arch Biochem* 1946 **10**, 33  
C W Denko, W E Grundy, N C Wheeler, C R Henderson, G H Berryman, T E Friedemann and J B Youmans *ibid* 1946 **11**, 109
- 4 L W McElroy and H Goss *J Nutrition* 1940 **20**, 527

## 13 ANIMAL AND HUMAN REQUIREMENTS OF PYRIDOXINE

Considerable uncertainty exists concerning the requirements of animals and man for pyridoxine, not so much because of the possibility that pyridoxine may be synthesised by intestinal bacteria but rather because vitamin B<sub>6</sub> has a three fold function (page 330) one of which may conceivably be more readily put out of action than the others by a sub optimal intake of pyridoxine. In that event the level of pyridoxine necessary to enable one type of function to be carried on would be higher than the level necessary for another function to be maintained. Then too in attempting to assess

human requirements there is the added difficulty that pyridoxine deficiency does not result in the development of characteristic symptoms that can be used as a criterion of response

The quantity of pyridoxine required to produce normal growth in the rat was found to be 10  $\mu\text{g}$  per day up to 100  $\mu\text{g}$  were required to cure symptoms of vitamin B<sub>6</sub> deficiency<sup>1</sup> When maintained at a temperature of 91° F rats required twice the amount of pyridoxine found to be necessary at 68° F whilst chicks maintained at 91° F required four times the amount necessary at 70° F<sup>2</sup> Lactating rats required at least 50  $\mu\text{g}$  of pyridoxine per day to ensure that their offspring did not suffer from spontaneous seizures and at least 150  $\mu\text{g}$  per day to afford protection against artificially induced seizures

Symptoms of vitamin B<sub>6</sub> deficiency in young turkeys<sup>3</sup> and ducklings<sup>4</sup> were prevented by 3.0 and 2.5 mg of pyridoxine per kg of diet respectively

#### References to Section 13

- 1 E J Reedman W L Sampson and K Unna *Proc Soc Exp Biol Med* 1940 43, 112
- 2 C A Mills *Arch Biochem* 1942 1, 73
- 3 F H Bird F H Kratzer V S Asmundson and S Lepkovsky *Proc Soc Exp Biol Med* 1943 52, 44
- 4 D M Hegsted and M N Rao *J Nutrition* 1945 30, 367

### 14 PHARMACOLOGY OF PYRIDOXINE

According to K Unna and W Antopol<sup>1</sup> the toxicities (LD<sub>50</sub>) of pyridoxine and its hydrochloride are 3.1 and 3.7 g per kg of body weight respectively when given subcutaneously to rats and 4 and 6 g per kg when given orally According to Weigand *et al*<sup>2</sup> the LD<sub>50</sub> of pyridoxine by the intravenous route was 18.3 mg per kg for rats and 42.9 mg per kg for mice 200 mg were non toxic in man

Dogs given 20 mg per kg orally for seventy five days and monkeys given 10 mg per kg orally for thirty nine days and subcutaneously for 101 days suffered no ill-effects<sup>1</sup>

A solution containing one part of pyridoxine hydrochloride in 8000 caused only a brief inhibition of the movements of the isolated rabbit's gut but caused a lasting contraction of the guinea pig uterus<sup>2</sup> In a concentration of 0.0005 millimoles per litre pyridoxine hydrochloride significantly increased the work output of perfused frog's muscle<sup>3</sup> and the improvement was maintained when the concentration was increased ten fold Above this level however no further improvement occurred

*References to Section 14*

- 1 K Unna and W Antopol, *Proc Soc Exp Biol. Med*, 1940, 43, 116
- 2 C G Weigand, C R Echler and K K Chen, *ibid*, 147
- 3 N W Shock and W. H Sebrell, *Amer J. Physiol*, 1946, 146, 399

**15. FUNCTION OF PYRIDOXINE AND RELATED COMPOUNDS**

Pyridoxine, pyridoxal and pyridoxamine are now known to be concerned with the decarboxylation of amino acids, and with the transamination mechanism. All three compounds are apparently equally effective for both systems in rats, moulds and some yeasts, and are probably inter-convertible in these organisms. For many lactic acid bacteria, on the other hand, pyridoxal and pyridoxamine ("pseudo-pyridoxine") are up to 1000 times as effective as pyridoxine,<sup>1</sup> such organisms presumably are very inefficient in converting pyridoxine into the biologically active derivative. A third system for which a compound related to pyridoxine is essential is one that controls red blood cell formation. Each of these three functions will be considered in turn.

**Protein Metabolism**

Reference has already been made (page 318) to the fact that vitamin B<sub>6</sub> deficiency results in an increase in the body protein, that the protein content of the diet affects the severity of the symptoms of pyridoxine deficiency and that nitrogen metabolism is upset in pyridoxine deficient rats, mice and dogs. Subsequently, a connection was established between vitamin B<sub>6</sub> and tryptophan. Lepkovsky *et al*<sup>2</sup> noted that tryptophan metabolism differed in the dog and the rat and that the difference was paralleled by a difference in the symptoms of vitamin B<sub>6</sub> deficiency in the two species, the dog developed a severe anaemia and excreted little xanthurenic acid, whereas the rat developed only a mild anaemia and excreted large amounts of xanthurenic acid.

Vitamin B<sub>6</sub> deficient mice also excreted xanthurenic acid, and the amount varied with the quantity of casein or tryptophan in the diet.<sup>3</sup> Moreover, the more casein was added to the diet, the sooner did the animals die. The amount of chromogen excreted was reduced by administration of pyridoxine but the amount needed to restore the level of excretion to normal was three times as much with 60 % as with 20 % of casein.


Furthermore, administration of L-tryptophan reduced the survival time of vitamin B<sub>6</sub> deficient mice but to a smaller extent than did casein containing the same amount of tryptophan suggesting that other amino acids contributed to the phenomenon Tyrosine and histidine, however, were without effect, so was phenylalanine, although it gave rise to a urinary chromogen the excretion of which was unaffected by pyridoxine Cystine and methionine reduced the survival time of vitamin B<sub>6</sub> deficient rats <sup>3a</sup>

The amount of xanthurenic acid excreted by pigs was also increased when the animals were fed on a vitamin B<sub>6</sub> deficient diet <sup>4</sup> and high xanthurenic acid excretion was generally associated with faulty tryptophan metabolism Again pigs maintained on a diet in which nitrogen was supplied in the form of an acid hydrolysate of casein or as zein, neither of which contains tryptophan, failed to grow and developed a normocytic or microcytic normochromic anaemia, similar to that observed in vitamin B<sub>6</sub> deficient pigs <sup>5</sup>

### Decarboxylation of Amino Acids

A further advance was made when I C Gunsalus and W D Bellamy <sup>6</sup> observed that tyrosine decarboxylase (prepared from *Streptococcus faecalis* R) was stimulated by yeast extract, by pyridoxal (but not pyridoxamine) and by solutions of pyridoxine treated with cystine or hydrogen peroxide The activity of each preparation was proportional to its "pseudo pyridoxine" content as determined microbiologically

Pyridoxal however only became an effective coenzyme in presence of adenosine triphosphate <sup>7</sup> and the actual coenzyme was therefore presumed to be a phosphorylated pyridoxal possibly



A phosphate was synthesised by treating pyridoxal with thionyl chloride and reacting the product with silver dihydrogen phosphate or by treating pyridoxal in the cold with phosphoric acid

Cell free tyrosine decarboxylase was prepared from *S faecalis* R and resolved into its apoenzyme and coenzyme The latter was identified as a derivative of pyridoxal <sup>8</sup> W W Umbreit and I C Gunsalus <sup>9</sup> then showed that arginine and glutamic acid decarboxylases, prepared from *Escherichia coli*, could be activated by the same coenzyme that activated lysine and tyrosine decarboxylases, and that



## PYRIDOXINE


the synthetic codecarboxylase prepared from pyridoxal functioned as a coenzyme for all four amino acid decarboxylases

Pyridoxine pyridoxal and pyridoxamine were all converted into codecarboxylase by micro organisms that utilised them as a source of vitamin B<sub>6</sub> it was shown that with *S faecalis* R the conversion of pyridoxamine into codecarboxylase required the presence of a keto acid (see page 300) Organisms that grew in the absence of vitamin B<sub>6</sub> were able to synthesise codecarboxylase whilst the codecarboxylase content of rat tissue was dependent on the pyridoxine intake<sup>10</sup>

The properties of synthetic codecarboxylase were described by Gunsalus *et al*<sup>11</sup>

J Baddiley and E F Gale<sup>12</sup> prepared several cell free amino acid decarboxylases and resolved those responsible for the decarboxylation of L lysine L tyrosine L arginine and L ornithine into specific apoenzymes and a common coenzyme a concentrate of which was also prepared from yeast The decarboxylases for L histidine and L glutamic acid did not appear to contain the coenzyme Pyridoxal phosphate was found to act as a coenzyme for the decarboxylases of L lysine L tyrosine L arginine and L ornithine Lichstein *et al*<sup>13</sup> confirmed the observation that pyridoxal phosphate functioned as a coenzyme for L ornithine decarboxylase and showed that it was also the coenzyme of L dihydroxyphenylalanine decarboxylase

P Karrer and M Viscontin<sup>14</sup> suggested that the preparations of pyridoxal phosphate used by other workers were impure and that their biological activity was due to some other constituent They therefore synthesised pyridoxal 3 phosphate acetal



and pyridoxal 3 phosphate and claimed that both served as coenzymes for L tyrosine decarboxylase prepared from *S faecalis* and for L lysine L arginine and D glutamic acid decarboxylases prepared from three strains of *Escherichia coli* According to I C Gunsalus and W W Umbreit<sup>15</sup> however synthetic pyridoxal 3 phosphate acetal does not catalyse the decarboxylation of tyrosine and pyridoxal 3 phosphate has only 1/2000th to 1/3000th of the activity of the natural coenzyme the apparent codecarboxylase activity of Karrer and Viscontin's compounds being due to faulty testing technique Synthetic pyridoxal 5 phosphate on the other hand catalysed both the decarboxylation of tyrosine and at a higher concentration the glutamic aspartic transamination (page 333) Using acetone dried vitamin B<sub>6</sub> free cells



## PYRIDOXINE

- 25 M J K. Leonard and R H R. *J Biol Chem* 1944 157, 1
- 26 M G Kritzmann, *Nature* 1946 158, 103
- 27 A E Braunstein and M (
- 28 A E Braunstein and M (
- 29 E F Gale and H M R Epps *Biochem J* 1944 38, 235
- 30 E F Gale and H M R Tomlinson *Nature* 1946 158, 103
- 31 W W Umbreit W A Wood and I C Gunsalus *J Biol Chem* 1946 165, 731
- 32 C C Porter, I Clark and R H Silber *ibid* 1947 167, 573
- 33 B S Schweigert *ibid* 1947, 168, 283
- 34 W A Wood I C Gunsalus and W W Umbreit *ibid* 1947 170, 313
- 35 B S Schweigert and P B Pearson *ibid* 1947 168, 555, P B Junqueira and B S Schweigert *ibid* 1948 174, 605
- 36 F Rosen J W Huff and W A Perlzweig *J Nutrition* 1947 33, 561
- 37 C T Ling D M Hegsted and F J Stare *J Biol Chem* 1948 174, 803
- 38 M L Scott L C Norris G F Heuser and W F Bruce *J Biol Chem* 1945 158, 291

## 16 PYRIDOXINE IN THE NUTRITION OF MICRO-ORGANISMS

The requirements of micro organisms for pyridoxine are as varied as are their requirements for other members of the vitamin B complex. Pyridoxine has been identified as 'Bios VII' one of the constituents of bios the hypothetical substance alleged to be necessary for the growth of certain yeasts (page 404)

### Yeasts

Pyridoxine was shown to stimulate the growth of the yeast<sup>1 2</sup> *Saccharomyces cerevisiae* and according to P R Burkholder<sup>3</sup> of the following additional species *Mycoderma valida* *Saccharomyces carlsbergensis* var *mandshuricus*, *S chodati*, *S oviformis* *Saccharomycodes ludwigii* *Torulopsis dattila* *T uvae* *Brettanomyces bruxellensis* and *Pichia kluyveri*. It is also necessary for the growth of *Saccharomyces hansentiaspora valbyensis*<sup>4</sup> and *Kloeckera brevis*<sup>1</sup>

### Moulds

Pyridoxine also stimulated the growth of several different kinds of moulds. One of these was *Ceratostomella (Ophiostoma) ulmi* which is responsible for Dutch elm disease<sup>5-8</sup>. This fungus required both aneurine and pyridoxine but whereas the latter was essential for growth aneurine appeared to be only a supplementary growth factor<sup>7</sup>



D alanine<sup>17a</sup> It was in fact found that both *L. helveticus* and *S. faecalis* accumulated D alanine when grown on media containing either D alanine or pyridoxine and it seems more likely therefore that pyridoxine is necessary for the synthesis of D alanine as might be expected from other evidence (page 333) Not all species of lactic acid bacteria require pyridoxine some being able to synthesise it<sup>18</sup> Pyridoxine was essential for the growth of *Bacterium acetylcholini*<sup>19</sup> and *Streptobacterium plantarum*<sup>20</sup> however and also for *Clostridium tetani*<sup>21</sup>

The amounts of pyridoxine in the cells of the five bacteria *Aerobacter aerogenes* *Serratia marcescens* *Pseudomonas fluorescens* *Proteus vulgaris* and *Clostridium butylicum* were estimated by H McIlwain<sup>22</sup> to be equivalent to between 2100 and 6600 molecules per cell and the rates of synthesis at between 1 and 5 molecules per cell per second

### Protozoa

*Tetrahymena geleii* required 0.45 µg per ml of pyridoxine when the medium was sterilised by filtration or 0.25 µg per ml when sterilised by autoclaving the activity of the pyridoxine being increased when heated with amino acids<sup>23</sup> Pyridoxal and pyridoxamine were 100 to 500 times more effective

### References to Section 16

- 1 A S Schultz L Atkin and C N Frey *J Amer Chem Soc* 1939 **61**, 1931 A S Schultz and L Atkin *Arch Biochem* 1947 **14**, 369
- 2 R E Eakin and R J Williams *J Amer Chem Soc* 1939 **61**, 1932
- 3 P R Burkholder *Amer J Bot* 1943 **30**, 206 P R Burkholder and D Moyer *Bull Torrey Bot Club* 1943 **70** 372 *J Bach.* 1944 **48**, 385
- 4 C Marchant *Canad J Res* 1942 **20B** 21
- 5 W J Robbins and R Ma *Bull Torrey Bot Club* 1942 **69** 342 *Proc Nat Acad Sci* 1943 **29**, 172
- 6 P R Burkholder and I McVeigh *Science* 1942 **95**, 127
- 7 W H Schopfer *Arch Julius Klaus Stiftung* 1945 **20**, 27
- 8 N Fries *Naturwiss* 1942 **30**, 685 *Symbolae Botan Upsaliensis* 1943 **7**, No 2
- 9 W H Schopfer *Experientia* 1945 **1** 183
- 10 J L Stokes J W Foster and C R Woodward *Arch Biochem* 1943 **2**, 235
- 11 R C Wooster and V H Cheldelin *ibid* 1945 **8**, 311

## REQUIREMENTS OF INSECTS

- 12 F W Tanner S E Pfeiffer and J M van Lanen *ibid* 29
- 13 M Landy and D M Dicken *J Lab Clin Med* 1942 27, 1086
- 14 E E Snell *Proc Soc Exp Biol Med* 1944 55, 36
- 15 E E Snell *J Biol Chem* 1945 158, 497
- 16 E E Snell and B M Guirard *Proc Nat Acad Sci* 1943 29, 66
- 17 W Shive and G W Shive *J Amer Chem Soc* 1946 68, 117
- 17a J T Holden C Furman and E E Snell *J Biol Chem* 1949 178, 789 J T Holden and E E Snell *ibid* 799
- 18 N Bohonos B L Hutchings and W H Peterson *J Bact* 1942 44, 479
- 19 E F Möller *Z physiol Chem* 1939 260, 246
- 20 E F Möller *Angew Chem* 1940 53, 204
- 21 R E Feeney J H Mueller and P A Miller *J Bact* 1943 46, 563
- 22 H McIlwain *Nature* 1946 158, 898
- 23 G W Kidder and V C Dewey *Arch Biochem* 1949 21, 58

### 17 EFFECT OF PYRIDOXINE ON HIGHER PLANTS

Little attention appears to have been paid to the rôle of pyridoxine in the economy of plants and the only reported observation of this type is that pyridoxine and a few of its derivatives stimulated the growth of excised tomato roots <sup>1</sup>

It has been shown that the amounts of pyridoxine like that of several other members of the vitamin B complex increased during the germination of oats wheat barley and maize <sup>2</sup> The distribution of pyridoxine in tomato plants was similar to that of aneurine ribo flavine and pantothenic acid a concentration gradient was found to exist from the apex of the plant to the base with the highest concentrations in the young leaves and tops of the stems <sup>3</sup>

Pyridoxine is present in soil and natural manures <sup>4</sup>

#### *References to Section 17*

- 1 W J Robbins *Amer J Bot* 1942 29, 241
- 2 P R Burkholder *Science* 1943 97, 562
- 3 J Bonner and R Dorland *Arch Biochem* 1943 2, 451
- 4 M A Roulet *Experientia* 1948 4, 149

### 18 PYRIDOXINE REQUIREMENTS OF INSECTS

Pyridoxine is an essential vitamin for several insects including *Drosophila melanogaster* <sup>1</sup> the mosquito *Aedes aegypti* <sup>2-4</sup> the beetles *Tenebrio molitor* <sup>5</sup> *Tribolium confusum* <sup>6</sup> and *Plinus tectus* <sup>6</sup> and the moth *Ephestia elutella* <sup>6</sup> The beetles *Sitodrepa panicea* *Lasioderma serricorne* and *Sitonus surinamensis* on the other hand grew well on

## PYRIDOXINE

a diet not containing pyridoxine <sup>6</sup> The difference in the behaviour of the two groups of beetles was shown to be due to the presence in this second group of intracellular symbiotic micro organisms capable of supplying *inter alia* pyridoxine <sup>6-8</sup> for sterilised larvae failed to grow on a purified diet whereas the unsterilised larvae developed normally

Pyridoxine was essential for the growth of the larvae of the rice moth *Corcyra cephalonica* <sup>9</sup> On a vitamin B<sub>6</sub> deficient diet containing tryptophan these larvae excreted a yellow compound similar to but apparently not identical with xanthurenic acid <sup>9</sup> an observation recalling the excretion of xanthurenic acid by vitamin B<sub>6</sub> deficient dogs

### References to Section 18

- 1 E L Tatum *Proc Nat Acad Sci* 1939 25, 490 1941 27, 193
- 2 W Trager and Y SubbaRow *Biol Bull Woods Hole* 1938 76, 75
- 3 Y SubbaRow and W Trager *J Gen Physiol* 1940 23, 561
- 4 L Golberg B de Meillon and M Lavoipierre *J Exp Biol* 1945 21, 90
- 5 H E Martin and L Hare *Biol Bull Woods Hole* 1942 83, 428
- 6 G Fraenkel and M Blewett *Nature* 1943 151, 703 *Biochem J* 1943 37, 686
- 7 G Fraenkel and M Blewett *Nature* 1943 152, 506
- 8 M Blewett and G Fraenkel *Proc Roy Soc B* 1944 132, 212
- 9 P S Sarma *Indian J Med Res* 1943 31, 165 *Proc Soc Exp Biol Med* 1945 58, 140

## 19 ANALOGUES OF PYRIDOXINE

### Pyridoxine Derivatives

The anti dermatitic effect on rats of a series of pyridoxine derivatives was investigated by K Unna <sup>1</sup> whose results are summarised in the following table

Compound	Dose (mg)						
	0.05	0.1	0.25	0.5	1.0	2.0	2.5
Pyridoxine	+	+					
4 5 diacetate	+	+					
triacetate	+	+					
3 Methyl pyridoxine				0	(+)		+
4		(+)	(+)	+			
4 Ethyl		(+)	(+)	+			
4 5 Epoxy		0	0	0			(+)


where + indicates a cure in 75 % of the animals after fourteen days and (+) indicates a partial cure

Thus, acetylated pyridoxine was fully active on rats, as it also was on the mould, *Ceratostomella ulma*,<sup>2</sup> the bacteria, *S. faecalis*,<sup>2</sup> *L. helveticus*<sup>2</sup> and *Streptobacterium plantarum*,<sup>3</sup> on the yeast, *Saccharomyces oviformis*<sup>4</sup> and on excised tomato roots.<sup>5</sup> The 3-methyl, 4-methyl and 4-ethyl ethers had only about 10 % of the activity of pyridoxine for rats,<sup>1</sup> and little or no activity on tomato roots, bacteria<sup>2, 3</sup> or yeast.<sup>4</sup> The 4-methyl ether had anti-vitamin properties (page 345).

Replacement of the 4-hydroxy group of pyridoxine by a hydrogen atom to give 3-hydroxy-5-hydroxymethyl-2 : 4-dimethyl-pyridine, completely destroyed the activity for rats,<sup>1, 6</sup> for *Streptobacterium plantarum*<sup>3</sup> and for yeast.<sup>4</sup> The product, known as desoxypyridoxine, had anti-vitamin properties (page 345). Replacement of both alcoholic hydroxy groups to give 3-hydroxy-2 : 4 : 5-trimethyl-pyridine also destroyed the activity for rats<sup>1, 6</sup> and *S. plantarum*.<sup>3</sup>

3-Amino-5-aminomethyl-4-hydroxymethyl-pyridine was inactive for rats,<sup>1</sup> while 3-amino-5-aminomethyl-4-hydroxymethyl-pyridine and 3-amino-5-aminomethyl-4-hydroxymethyl-pyridine were inactive.

N-methylpyridoxine betaine :



were inactive for rats,<sup>7</sup> bacteria and yeasts.<sup>2</sup>

The complex formed between pyridoxine and boric acid was said to be as active for rats as the vitamin itself.<sup>8</sup>

### Isomers and Homologues

"Isopyridoxine", 2 : 5-bis-hydroxymethyl-3-hydroxy-4-methyl-pyridine was inactive for rats and only slightly active for *S. plantarum*.<sup>3</sup>

By a series of reactions analogous to that used in the synthesis of pyridoxine, S. A. Harris and A. N. Wilson<sup>9</sup> prepared the pyridoxine homologue, 2-ethyl-3-hydroxy-4 : 5-bis-hydroxymethylpyridine hydrochloride and found that it had only 1/200th of the activity of pyridoxine in vitamin B<sub>6</sub>-deficient rats. The compound was as active as pyridoxine on tomato roots, however.<sup>5</sup>

### Pyridoxal and Pyridoxamine

As already stated (page 312), pyridoxal and pyridoxamine have a greater growth-promoting activity than pyridoxine on the bacteria,



## PYRIDOXINE

a diet not containing pyridoxine <sup>6</sup> The difference in the behaviour of the two groups of beetles was shown to be due to the presence in this second group of intracellular symbiotic micro organisms capable of supplying *inter alia* pyridoxine <sup>6 8</sup> for sterilised larvae failed to grow on a purified diet whereas the unsterilised larvae developed normally

Pyridoxine was essential for the growth of the larvae of the rice moth *Corcyra cephalonica* <sup>9</sup> On a vitamin B<sub>6</sub> deficient diet containing tryptophan these larvae excreted a yellow compound similar to but apparently not identical with xanthurenic acid <sup>9</sup> an observation recalling the excretion of xanthurenic acid by vitamin B<sub>6</sub> deficient dogs

### References to Section 18

- 1 E L Tatum *Proc Nat Acad Sci* 1939 25, 490 1941 27, 193
- 2 W Trager and Y SubbaRow *Biol Bull Woods Hole* 1938 75, 75
- 3 Y SubbaRow and W Trager *J Gen Physiol* 1940 23, 561
- 4 L Golberg B de Meillon and M Lavoisier *J Exp Biol* 1945 21, 90
- 5 H E Martin and L Hare *Biol Bull Woods Hole* 1942 83, 428
- 6 G Fraenkel and M Blewett *Nature* 1943 151, 703 *Biochem J* 1943 37, 686
- 7 G Fraenkel and M Blewett *Nature* 1943 152, 506
- 8 M Blewett and G Fraenkel *Proc Roy Soc B* 1944 132, 212
- 9 P S Sarma *Indian J Med Res* 1943 31, 165 *Proc Soc Exp Biol Med* 1945 58, 140

## 19 ANALOGUES OF PYRIDOXINE

### Pyridoxine Derivatives

The anti-dermatitic effect on rats of a series of pyridoxine derivatives was investigated by K Unna <sup>1</sup> whose results are summarised in the following table


Compound	Dose (mg)						
	0.05	0.1	0.25	0.5	1.0	2.0	2.5
Pyridoxine	+	+					
4 5 diacetate	+	+					
triacetate	+	+					
3 Methyl pyridoxine				0	(+)		+
4		(+)	(+)	+			
4 Ethyl		(+)	(+)	+			
4 5 Epoxy		0	0	0			(+)

where + indicates a cure in 75 % of the animals after fourteen days and (+) indicates a partial cure

Thus acetylated pyridoxine was fully active on rats as it also was on the mould *Ceratostomella ulma*<sup>2</sup> the bacteria *S faecalis*<sup>2</sup> *L helveticus*<sup>2</sup> and *Streptobacterium plantarum*<sup>3</sup> on the yeast *Saccharomyces oviformis*<sup>4</sup> and on excised tomato roots<sup>5</sup> The 3 methyl 4 methyl and 4 ethyl ethers had only about 10 % of the activity of pyridoxine for rats<sup>1</sup> and little or no activity on tomato roots bacteria<sup>2 3</sup> or yeast<sup>4</sup> The 4 methyl ether had anti vitamin properties (page 345)

Replacement of the 4 hydroxy group of pyridoxine by a hydrogen atom to give 3 hydroxy 5 hydroxymethyl 2 4 dimethyl pyridine completely destroyed the activity for rats<sup>1 6</sup> for *Streptobacterium plantarum*<sup>3</sup> and for yeast<sup>4</sup> The product known as desoxypyridoxine had anti vitamin properties (page 345) Replacement of both alcoholic hydroxy groups to give 3 hydroxy 2 4 5 trimethyl pyridine also destroyed the activity for rats<sup>1 6</sup> and *S plantarum*<sup>3</sup>

3 Amino 5 aminomethyl 4 hydroxymethyl pyridine was inactive for rats<sup>1</sup> whilst 3 amino 5 aminomethyl 4 methoxymethyl 2 methyl pyridine and 3 hydroxy 2 methyl 4 5 methylenedioxyethylpyridine were inactive for micro-organisms<sup>2</sup> The methiodide of pyridoxine and N methylpyridoxine betaine



were inactive for rats<sup>7</sup> bacteria and yeasts<sup>2</sup>

The complex formed between pyridoxine and boric acid was said to be as active for rats as the vitamin itself<sup>8</sup>

### Isomers and Homologues

Isopyridoxine 2 5 bis hydroxymethyl 3 hydroxy 4 methyl pyridine was inactive for rats and only slightly active for *S plantarum*<sup>3</sup>

By a series of reactions analogous to that used in the synthesis of pyridoxine S A Harris and A N Wilson<sup>9</sup> prepared the pyridoxine homologue  $\alpha$ -ethyl 3 hydroxy 4 5 bis hydroxymethylpyridine hydrochloride and found that it had only 1/200th of the activity of pyridoxine in vitamin B<sub>6</sub> deficient rats The compound was as active as pyridoxine on tomato roots however<sup>6</sup>

### Pyridoxal and Pyridoxamine

As already stated (page 312) pyridoxal and pyridoxamine have a greater growth promoting activity than pyridoxine on the bacteria

*S. faecalis* R and *L. helveticus*,<sup>10</sup> whilst for other micro-organisms, such as *Saccharomyces carlsbergensis*,<sup>11</sup> the three compounds were about equally effective. A few micro-organisms, including *Saccharomyces cerevisiae*<sup>2</sup> and *pyridoxineless Neurospora sitophila*,<sup>12</sup> did not respond at all to pyridoxamine or pyridoxal.


Rats responded equally well to pyridoxine, pyridoxal and pyridoxamine, whilst for chicks,<sup>13</sup> pyridoxal and pyridoxamine had three-fifths and four-fourths respectively of the activity of pyridoxine.

The biological activity of pyridoxal phosphate for rats was equivalent to its pyridoxal content.<sup>14</sup>


Heyl *et al*<sup>15</sup> found that the following derivatives of pyridoxamine had 50 to 100 % of the activity of pyridoxine on rats: pyridoxyl- $\beta$ -phenyl ethylamine, pyridoxyl-tyramine, pyridoxyl-tryptamine, pyridoxyl-benzylamine, pyridoxyl-histamine and pyridoxyl-isobutylamine. They had little or no microbiological activity.<sup>15a</sup>

### Pyridoxic Acids and Lactones

Two pyridoxic acids exist, formed by the oxidation of one or other of the hydroxymethyl groups to a carboxyl group. These give rise to lactones, known as pyracins (page 336) :




4-Pyridoxic acid did not stimulate the growth of micro-organisms,<sup>16</sup> but the corresponding lactone,  $\beta$ -pyracin, had one-quarter the activity of pyridoxine for *S. lactis*, 1/50th for *L. helveticus* and 1/4000th for yeast.  $\alpha$ -Pyracin was also without appreciable growth-promoting properties on yeast.<sup>17</sup> According to Luckey *et al.*,<sup>18</sup>  $\alpha$ -pyracin had no vitamin B<sub>6</sub> activity in chicks, but Scott *et al.*<sup>18</sup> found that it promoted growth in chicks and significantly increased the haemoglobin content of the blood, as well as stimulated the growth of *L. helveticus*.  $\beta$ -Pyracin was more effective than  $\alpha$ -pyracin in promoting growth, but only slightly more effective in preventing anaemia.<sup>19</sup> In the absence of  $\alpha$ - or  $\beta$ -pyracin, but in presence of folic acid (page 485), a normocytic, hypochromic anaemia developed. Another closely related substance that prevented anaemia in chicks was 3-carboxy-4-hydroxymethyl-6-methyl-2-pyridone :<sup>20</sup>



### Growth Inhibitors

The first substance related to pyridoxine which was found to have inhibitory properties was 3 hydroxy 5 hydroxymethyl 2 4 dimethyl pyridine generally referred to as desoxypyridoxine (page 343)



W H Ott <sup>21</sup> showed that two moles of this substance antagonised the effect of one mole of pyridoxine in chicks producing symptoms of vitamin B<sub>6</sub> deficiency. Normal rats receiving desoxypyridoxine along with tryptophan excreted more xanthurenic acid and kynurenine (page 336) than animals receiving tryptophan alone whilst vitamin B<sub>6</sub>-deficient rats excreted even larger amounts of xanthurenic acid and kynurenine in presence of the anti vitamin <sup>22</sup>. The administration of pyridoxine reduced the excretion of these two substances to normal levels. It was suggested that desoxypyridoxine interfered with some phase of tryptophan metabolism. Other symptoms consistent with pyridoxine deficiency were observed in chicks, dogs and monkeys to which desoxypyridoxine was administered <sup>23</sup>. Desoxypyridoxine administered to female rats ten to twenty days prior to mating interfered with reproduction, the effect being counteracted by pyridoxine given on the day of mating <sup>23a</sup>. Desoxypyridoxine (1 mg) injected into eggs just prior to incubation resulted in 100 % mortality, this was prevented by simultaneous injection of any of the three forms of vitamin B<sub>6</sub> <sup>2,3</sup>.

Desoxypyridoxine did not inhibit the action of tyrosine decarboxylase but phosphorylated desoxypyridoxine displaced pyridoxal phosphate in the tyrosine decarboxylase system <sup>24</sup>. Administration of desoxypyridoxine produced marked regression of lymphosarcoma implants in mice but not when pyridoxine was added to the diet <sup>25</sup>. Tumour implants failed to develop in animals deprived of pyridoxine prior to the implantation. Desoxypyridoxine inhibited the multiplication of T<sub>2</sub><sup>+</sup> *E. coli* bacteriophage and the inhibition was reversed by pyridoxine <sup>25a</sup>.

Another substance with anti pyridoxine activity is 3 hydroxy 5 hydroxymethyl 4 methoxymethyl 2 methyl pyridine often though

erroneously referred to as methoxy pyridoxine. Four moles of this substance antagonised the growth promoting effect of one mole of pyridoxine in chicks<sup>26</sup>. Unlike desoxypyridoxine however it actually reduced the amount of xanthurenic acid and kynurenine excreted by rats when given together with tryptophan<sup>22</sup> whilst the excretion of 4 pyridoxic acid was increased. Thus although methoxypyridoxine has anti vitamin activity for the chick it has vitamin B<sub>6</sub> activity for the rat<sup>1</sup> being apparently demethylated in this animal to pyridoxine. Methoxypyridoxine produced symptoms of vitamin B<sub>6</sub> deficiency in chicks and dogs although in dogs the symptoms were less severe than with desoxypyridoxine due presumably to partial cleavage to pyridoxine<sup>23</sup>.

3 Hydroxy 4 hydroxymethyl 2 methyl pyridine 3 amino 5 amino methyl 4 ethoxymethyl 2 ethyl pyridine and 3 hydroxy 2 4 5 trimethyl pyridine ( didesoxypyridoxine ) were weak antagonists of pyridoxine<sup>26a</sup>.

Irradiation of pyridoxine pyridoxal and pyridoxamine gave products that inhibited the growth of Gram negative aerobic bacteria and to a lesser extent two strains of Gram positive cocci<sup>27</sup>. The anti bacterial activity was antagonised by certain amino acids but nothing is known about the chemical constitution of the inhibitory substance.

Pyridoxine was claimed to inhibit the activity of quinine and mepacrine against *Plasmodium lophurae* infections in ducklings when given in amounts several times greater than those required for the nutrition of the ducklings<sup>28</sup>. This led McCasland *et al*<sup>29</sup> to attempt the preparation of analogues of pyridoxine that might antagonise the pyridoxine required by the parasites. Various pyrimidines were synthesised but 4 hydroxy 2 hydroxymethyl 5 methyl 2 6 bis pyrimidine had no pyridoxine or anti pyridoxine activity for *S cerevisiae*.

#### References to Section 19

- 1 K Unna *Proc Soc Exp Biol Med* 1940 43, 122
- 2 E E Snell *J Amer Chem Soc* 1944 66, 2082
- 3 E F Moller *Z physiol Chem* 1939 260, 246 E F Moller  
O Frina F Jung and T Moll *Naturwiss* 1939 27, 228 E F  
Moller *Angew Chem* 1940 53, 204
- 4 P R Burkholder *Amer J Bot* 1943 30, 206
- 5 W J Robbins *ibid* 1942 29, 241
- 6 S A Harris *J Amer Chem Soc* 1940 62, 3203
- 7 S A Harris T J Webb and K Folkers *ibid* 3198
- 8 J V Scudl W A Bastedo and T J Webb *Proc Soc Exp Biol  
Med* 1940 43, 122 *J Biol Chem* 1940 136 399
- 9 S A Harris and A N Wilson *J Amer Chem Soc* 1941 63 2526

- 10 E E Snell *J Biol Chem* 1944 154 313
- 11 D Melnick M Hochberg H W Himes and B L Oser *ibid* 1945 160 1
- 12 G W Beadle and E L Tatum *Proc Nat Acad Sci* 1941 27, 499 1942 28 234
- 13 T D Luckey G M Briggs C A Elvehjem and E B Hart *Proc Soc Exp Biol Med* 1945 58 340
- 14 P S Sarma E E Snell and C A Elvehjem *J Biol Chem* 1946 165, 55
- 15 D Heyl E Luz S A Harris and K Folkers *J Amer Chem Soc* 1948 70, 1670 3429 3669
- 15a E E Snell and J C Rabinowitz *ibid* 3432
- 16 J W Huff and W A Perlzweig *J Biol Chem* 1944 155 345
- 17 P R Burkholder *Amer J Bot* 1943 30, 206
- 18 M L Scott L C Norris G F Heuser W F Bruce H W Coover W D Bellamy and I C Gunsalus *J Biol Chem* 1944 154, 713
- 19 M L Scott L C Norris G F Heuser and W F Bruce *ibid* 1945 158, 291 *J Amer Chem Soc* 1945 67, 157
- 20 W F Bruce and H W Coover *ibid* 1944 66, 2092
- 21 W H Ott *Proc Soc Exp Biol Med* 1946 61, 125
- 22 C C Porter I Clark and R H Silber *J Biol Chem* 1947 167, 573
- 23 C W Mushett R B Stebbins and M N Barton *Trans N Y Acad Sci* 1947 9, 291
- 23a M M Nelson and H M Evans *Proc Soc Exp Biol Med* 1948 68 274
- 23b W W Cravens and E E Snell *ibid* 1949 71 73
- 24 J M Beiler and G J Martin *J Biol Chem* 1947 169 345  
W W Umbreit and J G Waddell *Proc Soc Exp Biol Med* 1949 70 293
- 25 H C Stoerk, *J Biol Chem* 1947 171, 438
- 25a J G Wooley and M K. Murphy *ibid* 1949 178 869
- 26 W H Ott *Proc Soc Exp Biol Med* 1947 66, 215
- 26a G J Martin S Avakian and J Moss *J Biol Chem* 1948 174 495  
R P Mariella and J L Leech *J Amer Chem Soc* 1949 71 331
- 27 G Schwartzman and A Fisher *J Biol Chem* 1947 167, 345
- 28 A O Seeler *Proc Soc Exp Biol Med* 1944 57, 113
- 29 G E McCasland D S Tarbell R B Carlin and N Shakespeare *J Amer Chem Soc* 1946 68, 2390  
G E McCasland and D S Tarbell *ibid* 2393

## CHAPTER VI

# PANTOTHENIC ACID

---

### I. HISTORICAL

THE story of pantothenic acid is closely bound up with that of pyridoxine. Both factors occur together in yeast and liver, and were separated from one another by treatment with fuller's earth, pyridoxine (the "eluate factor") was retained on the adsorbent, whilst pantothenic acid (the "filtrate factor") remained in the filtrate. The first concentrate of pantothenic acid substantially free from other factors was prepared from liver by C. A. Elvehjem and C. J. Koehn<sup>1</sup> and by S. Lepkovsky and T. H. Jukes.<sup>2</sup> As the factor was found to be effective in preventing and curing dermatitis in chicks, but not in rats, it became known as the "chick antidermatitis factor", and chicks were used for assaying it.

Edgar *et al.*<sup>3</sup> prepared a yeast concentrate with properties similar to those of Lepkovsky and Jukes' "factor 2", and showed that it stimulated the growth of rats, a method of assaying the factor was devised, based on this property.

Progress in the purification of the new vitamin was slow, partly because it did not readily give rise to derivatives of a type that might facilitate its isolation and characterisation, and partly because it was present in admixture with other substances difficult to separate from it.

The concentrates prepared by S. Lepkovsky and T. H. Jukes<sup>2</sup> and by C. E. Edgar and T. F. Macrae<sup>3</sup> resembled one another in most respects,<sup>4</sup> thus, the active fraction could be extracted from acid aqueous solutions by ether, butyl alcohol or amyl alcohol, it could be precipitated from alcoholic solution by barium hydroxide and it could be adsorbed on norit. Woolley *et al.*<sup>5</sup> prepared the barium salt, and purified it by extraction with absolute alcohol, most of the activity passing into the soluble fraction. They also made an inactive acetyl derivative, from which the activity was regenerated by hydrolysis. This acetyl compound could be purified by high-vacuum distillation. From this evidence it was concluded that the factor was an acid containing one or more hydroxyl groups. G. H. Hitchings and Y. SubbaRow<sup>6</sup> also prepared a concentrate of the substance and showed that it was a growth factor for rats.

A year later Woolley *et al*<sup>7</sup> reported that the chick antidermatitis factor was destroyed by alkali and that  $\beta$  alanine could be isolated from the product. They reactivated the acidic portion of the alkali inactivated concentrate by acetylation conversion of the product into an acid chloride by treatment with thionyl chloride and reaction with  $\beta$  alanine ethyl ester in pyridine solution followed by hydrolysis with cold sodium hydroxide solution. The substance thus obtained was effective in curing chick dermatitis.

The authors noted a resemblance between the chick factor and pantothenic acid a substance that R. J. Williams<sup>8</sup> had shown many years before to be one of the components of bios the hypothetical factor essential for the growth of yeast. The name is derived from the Greek meaning from everywhere on account of its widespread occurrence. Its chemical constitution was not known but R. J. Williams<sup>8</sup> had described a method of preparing a concentrate of pantothenic acid from sheep's liver and had listed some of its properties. Shortly after the publication of the paper by Woolley *et al* T. H. Jukes<sup>10</sup> tested the calcium salt of Williams' pantothenic acid on chicks and found that it was markedly active in curing chick dermatitis when administered in a dose of 10 mg.

Weinstock *et al*<sup>11</sup> then reported the isolation of  $\beta$  alanine from alkali inactivated pantothenic acid and showed that  $\beta$  alanine could replace pantothenic acid for some micro organisms though not for others. This strengthened the presumption that the chick antidermatitis factor was identical with pantothenic acid and further support was given by the fact that a varnish like calcium salt prepared from liver extract<sup>12</sup> by a procedure similar to that used by Williams in preparing calcium pantothenate gave good growth when fed to rats maintained on a synthetic diet and behaved like pantothenic acid in stimulating the growth of *Streptococcus haemolyticus* and the diphtheria bacillus.

The identity of the liver filtrate factor with pantothenic acid was confirmed by Lythgoe *et al*<sup>13</sup> who isolated  $\beta$  alanine from the hydrolysate and re-combined it with the lactone half of the molecule. Lythgoe *et al* also presented evidence that the filtrate factor was not a single entity but comprised at least three factors: (a) factor  $\alpha$  identical with pantothenic acid; (b) factor  $\beta$  which unlike factor  $\alpha$  was not extractable from acid solutions by amyl alcohol; and (c) factor  $\gamma$ .

Similar results were obtained by Black *et al*<sup>14</sup> and J. J. Oleson and S. Black<sup>15</sup> who reported that rats required both pantothenic acid and a factor termed by D. V. Frost and C. A. Elvehjem<sup>16</sup> the alcohol ether precipitate factor or factor W and that the two together were not so active as a crude liver extract which therefore contained at least



isopropyl ether and with acetone from pyridine solution About 3 g of crude (40 %) calcium salt was obtained from 250 kg of liver

In an improved process the charcoal eluate was heated with barium hydroxide to pH 8 and the precipitate containing the barium pantothenate was dissolved in absolute alcohol and filtered The filtrate was concentrated and acetone was added giving a precipitate containing barium pantothenate The free acids were liberated by the addition of sulphuric acid giving a concentrate containing 20 to 25 % of pantothenic acid

Y SubbaRow and G H Hitchings<sup>2</sup> also used liver as starting material This was freed from fat by extraction with solvent the aqueous extract was then treated with mercuric acetate to remove impurities the filtrate treated with charcoal and the adsorbate eluted with pyridine methanol water Impurities were removed from the eluate by precipitation with phosphotungstic acid and uridine (uracil-D riboside) was removed by crystallising the concentrated filtrate from methanol Pantothenic acid was then precipitated from the methanol solution by means of barium hydroxide and impurities were removed from the precipitate by repeated treatment with phosphotungstic acid Finally the pantothenic acid was adsorbed on acid activated alumina and recovered by elution

The isolation of pantothenic acid from molasses and rice bran was described by Mohammad *et al*<sup>3</sup>

#### References to Section 2

- 1 R J Williams J H Truesdail H H Weinstock E Rohrmann C M Lyman and C H McBurney *J Amer Chem Soc* 1938 **60**, 2719 H K Mitchell H H Weinstock E E Snell S R Stanbery and R J Williams *ibid* 1940 **62**, 1776
- 2 Y SubbaRow and G H Hitchings *ibid* 1939 **61**, 1615
- 3 A Mohammad O H Emerson G A Emerson and H M Evans *J Biol Chem* 1940 **133**, 17


### 3 CHEMICAL CONSTITUTION AND SYNTHESIS OF PANTOTHENIC ACID

The presence of a carboxyl group in pantothenic acid was proved by esterification<sup>1</sup> whilst the presence of two hydroxyl groups was indicated by a determination of active hydrogen<sup>2</sup> The observation that pantothenic acid condensed with acetaldehyde acetone or benzaldehyde indicated the presence of an  $\alpha\beta$   $\alpha\gamma$  or  $\alpha\delta$  glycol

The details of the degradation experiments that finally established the constitution of pantothenic acid were given in two papers by

Mitchell *et al*<sup>3</sup> and by Stiller *et al*<sup>4</sup> In the first of these papers the non  $\beta$  alanine fraction of the pantothenic acid molecule was shown to contain an  $\alpha$  hydroxyl group since it yielded formic acid on hydrolysis with sulphuric acid and carbon monoxide on dehydration with sulphuric acid at  $140^{\circ}\text{C}$  Since the acid lactonised spontaneously it probably contained a  $\gamma$  hydroxyl group as well and the absence of a  $\beta$  hydroxyl group was presumed from the formation of an unsaturated derivative of the type  $\text{R}-\text{CH}=\text{CH}-\text{COOH}$  on dehydration and the fact that oxidation with lead tetra acetate periodic acid or hypiodite did not destroy the activity as it would have done had the substance been an  $\alpha\beta$  glycol Accordingly the following  $\alpha$  hydroxy- $\gamma$ -lactones were synthesised and coupled with  $\beta$  alanine  $\alpha$  hydroxy- $\gamma$ -valerolactone  $\alpha$  hydroxy  $\beta$  methyl- $\gamma$ -butyrolactone and  $\alpha$  hydroxy  $\alpha$  methyl  $\gamma$ -butyrolactone The products showed definite but slight physiological activity when tested on *Streptococcus lactis* (which is unaffected by excess  $\beta$  alanine)


In the second of the papers the lactone obtained on acid hydrolysis was purified by molecular sublimation and obtained pure m.p.  $92$  to  $93^{\circ}\text{C}$   $[\alpha]_{\text{D}}^{20} = 49.8$  It had the empirical formula  $\text{C}_8\text{H}_{10}\text{O}_3$  It was therefore a derivative not of valeric acid as had been assumed previously but of caproic acid It contained one active hydrogen atom and yielded an acetate dinitrobenzoate and *p* nitrobenzoate A Kuhn Roth determination gave a result equivalent to  $26\%$  of C methyl group indicating the presence of a *gem* dimethyl group This was confirmed by the formation of acetone on treatment with barium permanganate The conclusion that the lactone was  $\alpha$  hydroxy  $\beta\beta$ -dimethyl- $\gamma$ -butyrolactone was established by the following series of degradations



Natural pantolactone is laevorotatory whereas pantoic acid is dextrorotatory

The partial synthesis of pantothenic acid from this lactone and  $\beta$  alanine ethyl ester or better since this avoided hydrolysis of the pantothenic ester by heating the lactone with the sodium salt of  $\beta$  alanine was described by R. J. Williams *et al*<sup>5</sup> and by S. H. Babcock

and T H Jukes<sup>6</sup> The complete synthesis described by Stiller *et al*<sup>7</sup> was as follows



Synthetic pantothenic acid proved to have only half the growth promoting action of the natural acid on *Lactobacillus helveticus* but Stiller *et al*<sup>7</sup> resolved the sodium salt of pantoic acid into its optically active isomers by treatment with quinine hydrochloride and then reacted each separately with  $\beta$  alanine ester obtaining in this way D and L pantothenic acid The former was active on micro organisms rats and chicks whilst the latter was inactive

A different synthesis was later described by D W Woolley<sup>8</sup> The sodium salt of pantoic acid was converted *via* the acetyl derivative into the acid chloride which was coupled with  $\beta$  alanine in aqueous solution in the presence of alkali

The synthesis of racemic pantothenic acid was also described by T Reichstein and A Grussner<sup>9</sup> who used a similar method to that of Williams *et al* They resolved pantolactone with quinine and in a later paper<sup>10</sup> described the resolution of pantothenic acid with quinine or cinchonidine methydrroxide and noted the biological activity of the optically active pantothenic acids confirming the results obtained by Williams and his co-workers M Gatzl Fichter *et al*<sup>11</sup> prepared the crystalline sodium salt of pantothenic acid by hydrolysis of the ester with baryta and decomposition of the barium salt

R T Major and J Finkelstein<sup>12</sup> resolved pantolactone by means of the methydrroxides of quinine quinidine and cinchonine whilst E T Stiller and P F Wiley<sup>13</sup> used quinine methydrroxide for resolving racemic pantothenic acid itself They stated that the alkaloids were not sufficiently strong bases to give stable salts of pantothenic acid whereas the methydrroxides being more strongly basic gave salts sufficiently stable to enable the pure D and L salts to be separated these yielded D and L pantothenic acid respectively on decomposition Pantolactone has also been resolved with the aid of brucine and of diacetyl D tartaric anhydride<sup>14</sup>

R Kuhn and T Wieland<sup>15</sup> described the preparation of a concentrate from fish liver of a factor which stimulated the growth of *Streptobacterium plantarum* This concentrate yielded on hydrolysis  $\beta$  alanine

L-leucine,  $\alpha$ -hydroxy- $\beta\beta$  dimethyl  $\gamma$ -butyrolactone and a homologous lactone,  $C_{17}H_{32}O_3$ , which gave an inactive substance when coupled with  $\beta$  alanine. Although pantothenic acid was not actually isolated, there is little doubt that it was the active constituent of the concentrate.

Kuhn and Wieland<sup>16</sup> synthesised pantothenic acid by condensing pantolactone with  $\beta$  alanine benzyl ester and catalytically hydrogenating the product to remove the benzyl group. The racemic pantothenic acid so obtained was resolved by means of quinine or cinchonidine. The latter was preferred, as the cinchonidine salt of D pantothenic acid was less soluble than that of the L-isomer, enabling it to be isolated in good yield, whereas quinine D pantothenate was more soluble than the salt of the L-isomer and therefore more difficult to isolate.

Other variants of the general method for the preparation of pantothenic acid were described by H. C. Parke and E. J. Lawson<sup>17</sup>. Fusion at  $150^\circ\text{C}$  of the sodium salt of DL- and D pantoic acid with  $\beta$  alanine gave a 90 and 60 % yield respectively of sodium DL-pantothenate and sodium D pantothenate. A novel method of preparing sodium DL pantothenate was fusion at  $100^\circ\text{C}$  of DL pantamide with the sodium salt of  $\beta$  alanine. This gave a 70 % yield. Finally, sodium D pantothenate was prepared in 90 % yield by heating pantolactone with the sodium salt of  $\beta$  alanine in isopropanol.

Patents covering these different methods of preparation were filed by various commercial firms. Merck & Co., for example, protected the preparation of pantothenic acid by reacting  $\beta$  alanine, its salts or esters with an  $\alpha$  keto or  $\alpha$  hydroxy acid capable of lactonising,<sup>18</sup> by fusing  $\beta$  alanine or a salt with pantolactone<sup>19</sup> or by reacting pantolactone with  $\beta$  alanine and an ester of  $\beta$ -alanine in presence of an alkali metal or alkaline earth metal hydroxide or alcoholate at  $0^\circ\text{C}$  in an alcoholic or aqueous medium.<sup>20</sup> DL Pantothenic acid was resolved by means of quinine, quinine methydrate, cinchonidine, brucine, strychnine or ephedrine.<sup>21</sup> Alternatively pantoic acid was resolved by fractional crystallisation of an alkaloidal salt,<sup>22</sup> and D- or L-pantothenic acid was prepared from the appropriate lactone by reaction with  $\beta$  alanine.<sup>23</sup> The condensation of D pantolactone with  $\beta$ -alanine was also patented by F. Hoffmann-La Roche & Co.<sup>24</sup>

A number of novel methods were patented by F. Hoffmann-La Roche & Co., and Roche Products Ltd. Thus esters of pantothenic acid were prepared by catalytic hydrogenation of  $\beta$  nitropropionic esters in presence of pantolactone.<sup>25</sup> The reaction of pantolactone with  $\beta$  alanine in alcoholic or aqueous alcoholic solution was also protected.<sup>26</sup> A third method of preparation was to react pantolactone with the acetal of  $\beta$  aminopropionaldehyde and convert the resulting pantothenic aldehyde acetal to calcium pantothenate by

oxidation with oxalic acid and hydrogen peroxide and neutralisation with calcium carbonate<sup>27</sup> Yet another method of preparation comprised the oxidation of N-D pantoyl 3'-hydroxypropylamine<sup>28</sup> or N-D-pantoyl 3' 4'-dihydroxybutylamine<sup>29</sup> or their derivatives first with barium or potassium permanganate to give the aldehyde and then with silver oxide to give pantothenic acid, the N-D pantoyl hydroxyalkylamines were prepared by condensing pantolactone with alkanolamines<sup>30</sup> Resolution of DL-pantothenic acid was effected through the quinine salt,<sup>31</sup> and pure calcium D pantothenate was prepared either by acidifying the sodium salt, neutralising with calcium carbonate and crystallising from alcohol<sup>32</sup> or by adding calcium chloride to a solution of the sodium salt in alcohol<sup>33</sup>

National Oil Products Co protected the preparation of pantothenic acid by acylation of a salt of pantoic acid, conversion to the acid chloride by treatment with thionyl chloride, reaction with a  $\beta$  alanine alkyl ester, followed by hydrolysis of the resulting pantothenic ester<sup>34</sup> Calcium pantothenate was prepared by reacting the calcium salt of  $\beta$  alanine with pantolactone in anhydrous methanol or ethanol<sup>35</sup> Lederle Labs, Inc prepared the calcium salt by the action of metallic calcium on a mixture of  $\beta$  alanine and pantolactone,<sup>36</sup> by reacting pantolactone in anhydrous alcohol with the calcium salt of  $\beta$  alanine, prepared *in situ* from  $\beta$  alanine and calcium hydride, calcium amide, calcium carbide, calcium hydroxide or cyanamide, but not metallic calcium,<sup>37</sup> or by the interaction of the calcium salt of  $\beta$  alanine and pantoic acid amide in methanol<sup>38</sup> Parke, Davis & Co protected the preparation of sodium D pantothenate, first, by heating  $\beta$  alanine and sodium D pantoate at 170 to 180° C for fifteen minutes<sup>39</sup> and secondly, by heating the sodium salt of  $\beta$  alanine with D pantolactone in anhydrous ethanol or isopropanol<sup>40</sup>

### Preparation of Pantolactone

Since most of the methods of preparing pantothenic acid involve the condensation of pantolactone with  $\beta$  alanine, considerable attention has been devoted to the preparation of these two substances

The method used by Stiller *et al* (page 354) is the one in general use, but minor modifications have been described in the patent literature F Hoffmann La Roche & Co,<sup>41</sup> for example, prepared pantolactone by the action of sodium cyanide on formylisobutyraldol bisulphite compound and hydrolysis of the resulting cyanhydrin, whilst Roche Products Ltd<sup>42</sup> prepared the optically active D pantolactone from the racemic compound by treatment with chlorosulphonic acid and pyridine to give pantolactone hydrogen sulphonic acid, fractional crystallisation of the strychnine salt of this acid and

hydrolysis of the strychnine D lactone sulphate to the optically active lactone Merck & Co <sup>42a</sup> used brucine for resolving pantolactone

Parke Davis & Co <sup>43</sup> patented the preparation of pantolactone by the interaction of formaldehyde isobutyraldehyde sodium cyanide and sodium bisulphite giving  $\beta$  hydroxy  $\alpha\alpha$  dimethylpropionaldehyde cyanhydrin which yielded pantolactone on acid hydrolysis

### Preparation of $\beta$ -Alanine and its Esters

A large number of methods have been described for the preparation of  $\beta$  alanine and its esters F Weygand <sup>44</sup> prepared  $\beta$  alanine ethyl ester by hydrogenation of ethyl cyanacetate in presence of platinum oxide whilst Lederle Labs Inc prepared  $\beta$  alanine itself by hydrogenating cyanacetic acid in presence of platinum oxide or palladium <sup>45</sup> or by hydrogenating cyanacetamide and hydrolysing the resulting  $\beta$  alanine amide <sup>46</sup> National Oil Products Co <sup>47</sup> hydrogenated methyl or ethyl cyanacetate in presence of sulphuric acid whilst F Hoffmann La Roche & Co <sup>48</sup> hydrogenated potassium cyanacetate in ammoniacal solution using a nickel catalyst Lederle Labs Inc prepared  $\beta$  alanine by the addition of ammonia to acrylonitrile at  $150^{\circ}\text{C}$  <sup>49</sup> or to a salt of acrylic acid <sup>50</sup> It has also been prepared by the action of ammonia on bis  $\beta$ -cyanoethylamine <sup>51</sup> on thiodihydroacrylonitrile <sup>52</sup> on ethylene cyanhydrin <sup>53</sup> and on  $\beta$  alkoxypionitriles <sup>54</sup>

A Galat <sup>55</sup> prepared  $\beta$  alanine by the addition of phthalimide to acrylonitrile followed by acid hydrolysis of the  $\beta$  phthalimidopropionitrile  $\beta$  Alanine hydrochloride was converted into  $\beta$  alanine by the use of lithium hydroxide A variant of this method is to fuse phthalic acid or anhydride with an ester of  $\beta\beta$  imino dipropionic acid capable of forming a volatile acrylic ester and hydrolysing the phthalimido propionic ester so formed <sup>56</sup> Finally esters of  $\beta$  alanine can be prepared by reduction of nitropropionic esters <sup>57</sup>

### References to Section 3

- 1 R. J Williams H H Weinstock E Rohrmann J H Truesdail H K Mitchell and C E Meyer *J Amer Chem Soc* 1939 **61**, 454
- 2 R J Williams and R Moser *ibid* 1934 **56**, 169
- 3 H K Mitchell H H Weinstock E E Snell S R Stanbery and R J Williams *ibid* 1940 **62**, 1776
- 4 E T Stiller J C Keresztesy and J Finkelstein *ibid* 1779
- 5 R J Williams H K Mitchell H H Weinstock and E E Snell *ibid* 1784
- 6 S H Babcock and T H Jukes *ibid* 1678
- 7 E T Stiller S A Harris J Finkelstein J C Keresztesy and K. Folkers *ibid* 1785

- 8 D. W. Woolley, *J. Amer Chem Soc*, 1940, 62, 2251
- 9 T. Reichstein and A. Grussner, *Helv Chim Acta*, 1940, 23, 650
- 10 A. Grussner, H. Gätzl-Fichter and T. Reichstein *ibid*, 1276
- 11 M. Gätzl-Fichter, M. Reich and T. Reichstein, *ibid*, 1941, 24, 185
- 12 R. T. Major and J. Finkelstein, *J. Amer Chem Soc*, 1941, 63, 1368
- 13 E. T. Stiller and P. F. Wiley, *ibid*, 1237
- 14 R. Bental and M. Tishler, *ibid*, 1946, 68, 1463
- 15 R. Kuhn and T. Wieland, *Ber*, 1940, 73, 962, 971
- 16 R. Kuhn and T. Wieland, *ibid*, 1941, 74, 218
- 17 H. C. Parke and E. J. Lawson, *J. Amer Chem Soc*, 1941, 63, 2869
- 18 Merck and Co, B P 535988, U S P. 2396477
- 19 Merck and Co, B P 551883
- 20 Merck and Co, B P 553317
- 21 Merck and Co, B P 552365 554558
- 22 Merck and Co, B P. 552705
- 23 Merck and Co, B P 554407, 551990
- 24 F. Hoffmann La Roche & Co, B P 552036
- 25 F. Hoffmann La Roche & Co, B P 551990
- 26 F. Hoffmann-La Roche & Co, B P 552581
- 27 Roche Products Ltd, B P 552713
- 28 F. Hoffmann La Roche & Co, B P 569083
- 29 F. Hoffmann La Roche & Co, B P 580509
- 30 F. Hoffmann La Roche & Co, B P 568355
- 31 F. Hoffmann-La Roche & Co, B P 550593
- 32 Roche Products Ltd, B P 559893
- 33 F. Hoffmann-La Roche B P 562267
- 34 National Oil Products Co, B P 552326
- 35 National Oil Products Co, B P 557761.
- 36 Lederle Labs, Inc, B P 561877
- 37 Lederle Labs, Inc, B P 571915
- 38 Lederle Labs, Inc, B P 566858
- 39 Parke Davis & Co, B P 564996
- 40 Parke Davis & Co, B P 565976
- 41 F. Hoffmann-La Roche & Co, B P 547923
- 42 Roche Products Ltd, B P 570341
- 42a Merck & Co, B P. 626498
- 43 Parke Davis & Co, U S P 2399362
- 44 F. Weygand *Ber*, 1941, 74, 256
- 45 Lederle Labs, Inc, B P 557849, U S P 2401547
- 46 Lederle Labs, Inc, B P 657850
- 47 National Oil Products Co, B P 558494
- 48 F. Hoffmann-La Roche & Co, B P 561574
- 49 Lederle Labs, Inc, B P 558682
- 50 Lederle Labs, Inc, B P 561013
51. American Cyanamid Co, U S P 2334163
- 52 American Cyanamid Co, U S P. 2335653.
- 53 American Cyanamid Co, Can P 417165

- 54 American Cyanamid Co USP 2335605 Lederle Labs Inc  
 USP 2336067  
 55 A Galat *J Amer Chem Soc* 1945 67, 1414  
 56 Nopco Chemical Co BP 627816  
 57 F Hoffmann La Roche & Co BP 551990

#### 4 PROPERTIES OF PANTOTHENIC ACID

D Pantothenic acid has not been obtained in the free state and is usually supplied in the form of its sodium or calcium salt. The sodium salt is a white very hygroscopic solid crystallising in colourless needles m p 122 to 124° C with a specific rotation of  $[\alpha]_D^{15} = +29^\circ$  or  $[\alpha]_D^{25} = +27^\circ$  in water the concentration of the solution being 1 g. According to H C Parke and E J Lawson<sup>1</sup> it is much less hygroscopic after crystallisation from absolute ethyl or isopropyl alcohol. The calcium salt is a white powder less hygroscopic than the sodium salt. It was obtained crystalline by Levy *et al*<sup>2</sup> and by J H Ford<sup>3</sup> who recorded a m p of 170 to 172° C.

Quinine D pantothenate has m p 136° C and optical rotation  $[\alpha]_D^{19} = -95^\circ$  whilst quinine L pantothenate has m p 183.5° C and optical rotation  $[\alpha]_D^{18} = -121^\circ$  both rotations being measured in water.<sup>4</sup> Cinchonidine D pantothenate has m p 178 to 179° C and optical rotation  $[\alpha]_D^{18} = -62.8^\circ$  in water.<sup>5</sup>

Ethyl D pantothenate is a colourless oil with an optical rotation of  $[\alpha]_D^{19} = +36.8^\circ$  in absolute alcohol.

#### References to Section 4

- 1 H C Parke and E J Lawson *J Amer Chem Soc* 1941 63, 2869
- 2 H Levy J Weijlard and E T Stiller *ibid* 2846
- 3 J H Ford *ibid* 1946 68, 1666
- 4 A Grussner H Gätzl Fichter and T Reichstein *Helv Chim Acta* 1940 23, 1276
- 5 R Kuhn and T Wieland *Ber* 1941 74 218

#### 5 STABILITY OF PANTOTHENIC ACID

Pantothenic acid is one of the more heat stable members of the vitamin B complex but the pH of its solutions must be kept approximately neutral as it is readily hydrolysed under acidic or alkaline conditions. The substance has maximum stability over the pH range 5.5 to 7.0.<sup>1</sup>

#### Reference to Section 5

- 1 D V Frost *Ind Eng Chem Anal Ed* 1943 15, 306



## 6. ESTIMATION OF PANTOTHENIC ACID

Attention has already been directed (page 348) to early attempts to estimate the 'filtrate factor' by its effect on the growth of rats and chicks, but it is doubtful if such methods are sufficiently specific to do more than give very approximate results, although T H Jukes<sup>1</sup> used chicks to measure the pantothenic acid contents of a variety of foodstuffs, and J D S Bacon and G N Jenkins<sup>2</sup> described an apparently satisfactory method of assay using rats.

Up to the present no chemical method of estimation has been proposed, although J J Lingane and O L Davis<sup>3</sup> found that pantothenic acid was reduced at the dropping mercury electrode. Its polarogram was not sufficiently well defined however, for the polarographic method to be used for its estimation.

### Microbiological Methods of Assay

The only satisfactory methods of assay so far published have been microbiological methods, and these have been extensively used. Among the first micro organisms to be tested for this purpose were *Streptococcus lactis*, *Bacillus brassicae* and *Propionibacterium pentosaceum*<sup>4</sup> but these failed to give satisfactory results. The first successful method was devised by Pennington *et al*<sup>5</sup> who used *Lactobacillus helveticus* the organism introduced by Snell and Strong for the estimation of riboflavine (page 157). The turbidity of cultures grown on a suitable medium or the amount of lactic acid produced was proportional to the amount of pantothenic acid added. Strong *et al*<sup>6</sup> described a similar method using the same organism whilst H R Skeggs and L D Wright<sup>7</sup> developed an analogous method with *L. arabinosus* as test organism. M J Pelczar and J R Porter<sup>8</sup> used *Proteus morganii* the growth of which on a suitable medium was proportional to the amount of pantothenic acid present. The amount of growth was measured by determining the bacterial nitrogen or by measuring the change in pH or the increase in turbidity. The method was claimed to be highly specific but the organism also responded to pantoic acid. *L. helveticus* was the organism used by M Landy and D M Dicken<sup>9</sup> in the method developed by them for the assay of six members of the vitamin B complex using the same basal medium. Modifications to the medium of Pennington *et al* were suggested by J L Stokes and B B Martin<sup>10</sup> who found that merely increasing the amounts of glucose and sodium acetate increased the production of acid and by A E Light and M F Clarke<sup>11</sup>. Good agreement was reported by Hoag *et al*<sup>12</sup> for results obtained with *L. helveticus* and *L. arabinosus* but the response was greater and more rapid with the latter. Growth was measured either turbidimetrically after fourteen

hours or by titration after twenty four to thirty hours. Other bacteria that have been used for the assay of pantothenic acid are *Streptobacterium plantarum*<sup>13 14</sup> and *Lactobacillus bulgaricus*<sup>15</sup>

Yeast was used by Atkin *et al*<sup>16</sup> with a medium containing ammonium sulphate as the source of nitrogen together with sufficient asparagine to prevent interference by  $\beta$  alanine which also stimulates the growth of yeast. *Saccharomyces cerevisiae* var *ellipsoideus* was found to be suitable for the assay of pantothenic acid by Emery *et al*<sup>17</sup> who also obtained promising results with another yeast *Kloeckera brevis*

A possible complication in the microbiological assay of pantothenic acid is that the two products formed by the hydrolysis of pantothenic acid namely  $\beta$  alanine and pantoic acid may stimulate the growth of the micro organism used. For this reason only organisms that respond specifically to pantothenic acid should be used or else some method must be introduced of suppressing the effect of the degradation products. An example of this is the use of asparagine to suppress the response of yeast to  $\beta$  alanine

### Microbiological Response to $\beta$ -Alanine and Pantoic Acid

$\beta$  Alanine can be estimated by measuring first the growth response of yeast which is stimulated by pantothenic acid and  $\beta$  alanine and then that of *Streptobacterium plantarum* which responds to pantothenic acid only and subtracting the second result from the first<sup>14</sup>. *Corynebacterium diphtheriae* like yeast also responds to both  $\beta$  alanine and pantothenic acid<sup>18</sup>. *Acetobacter suboxydans* on the other hand responds to pantoic acid but not to  $\beta$  alanine<sup>19</sup> and can therefore be used for the assay of pantolactone. As already noted *Proteus morganii* responds to both pantothenic acid and pantolactone

### Preparation of Solutions for Assay

It is particularly important to prevent hydrolysis of pantothenic acid during its liberation from foodstuffs in which it generally occurs in the bound state. In their original method Pennington *et al*<sup>5</sup> autoclaved the material with or without previous autolysis under benzene whilst other authors have used enzymes such as clara e or mylase P to liberate pantothenic acid<sup>6 16 20 21 22</sup>. A mixture of chicken liver enzyme and intestinal phosphatase is said to be even more effective<sup>23</sup>. With some sources of pantothenic acid such as malt products treatment with cold dilute alkali solution prior to digestion with papain and takadiastase increased the extraction 2 to 4 fold<sup>24</sup>

A further difficulty encountered in the assay of foodstuffs with

## 6. ESTIMATION OF PANTOTHENIC ACID

Attention has already been directed (page 348) to early attempts to estimate the "filtrate factor" by its effect on the growth of rats and chicks, but it is doubtful if such methods are sufficiently specific to do more than give very approximate results, although T H Jukes<sup>1</sup> used chicks to measure the pantothenic acid contents of a variety of foodstuffs, and J D S Bacon and G N Jenkins<sup>2</sup> described an apparently satisfactory method of assay, using rats

Up to the present no chemical method of estimation has been proposed, although J J Lingane and O L Davis<sup>3</sup> found that pantothenic acid was reduced at the dropping mercury electrode. Its polarogram was not sufficiently well defined, however, for the polarographic method to be used for its estimation

### Microbiological Methods of Assay

The only satisfactory methods of assay so far published have been microbiological methods, and these have been extensively used. Among the first micro organisms to be tested for this purpose were *Streptococcus lactis*, *Bacillus brassicae* and *Propionibacterium pentosaceum*,<sup>4</sup> but these failed to give satisfactory results. The first successful method was devised by Pennington *et al*,<sup>5</sup> who used *Lactobacillus helveticus*, the organism introduced by Snell and Strong for the estimation of riboflavine (page 157). The turbidity of cultures grown on a suitable medium or the amount of lactic acid produced was proportional to the amount of pantothenic acid added. Strong *et al*<sup>6</sup> described a similar method, using the same organism, whilst H R Skeggs and L D Wright<sup>7</sup> developed an analogous method with *L. arabinosus* as test organism. M J Pelczar and J R Porter<sup>8</sup> used *Proteus morgani*, the growth of which on a suitable medium was proportional to the amount of pantothenic acid present. The amount of growth was measured by determining the bacterial nitrogen or by measuring the change in pH or the increase in turbidity. The method was claimed to be highly specific, but the organism also responded to pantoic acid. *L. helveticus* was the organism used by M Landy and D M Dicken<sup>9</sup> in the method developed by them for the assay of six members of the vitamin B complex using the same basal medium. Modifications to the medium of Pennington *et al* were suggested by J L Stokes and B B Martin<sup>10</sup> who found that merely increasing the amounts of glucose and sodium acetate increased the production of acid and by A E Light and M F Clarke<sup>11</sup>. Good agreement was reported by Hoag *et al*<sup>12</sup> for results obtained with *L. helveticus* and *L. arabinosus*, but the response was greater and more rapid with the latter, growth was measured either turbidimetrically after fourteen

hours or by titration after twenty four to thirty hours. Other bacteria that have been used for the assay of pantothenic acid are *Streptobacterium plantarum*<sup>13, 14</sup> and *Lactobacillus bulgaricus*<sup>15</sup>

Yeast was used by Atkin *et al*,<sup>16</sup> with a medium containing ammonium sulphate as the source of nitrogen, together with sufficient asparagine to prevent interference by  $\beta$  alanine, which also stimulates the growth of yeast. *Saccharomyces cerevisiae* var *ellipsoideus* was found to be suitable for the assay of pantothenic acid by Emery *et al*,<sup>17</sup> who also obtained promising results with another yeast, *Kloeckera brevis*

A possible complication in the microbiological assay of pantothenic acid is that the two products formed by the hydrolysis of pantothenic acid, namely  $\beta$  alanine and pantoic acid, may stimulate the growth of the micro-organism used. For this reason, only organisms that respond specifically to pantothenic acid should be used, or else some method must be introduced of suppressing the effect of the degradation products. An example of this is the use of asparagine to suppress the response of yeast to  $\beta$  alanine

### Microbiological Response to $\beta$ -Alanine and Pantoic Acid

$\beta$  Alanine can be estimated by measuring first the growth response of yeast, which is stimulated by pantothenic acid and  $\beta$  alanine, and then that of *Streptobacterium plantarum* which responds to pantothenic acid only and subtracting the second result from the first.<sup>14</sup> *Corynebacterium diphtheriae* like yeast also responds to both  $\beta$  alanine and pantothenic acid.<sup>18</sup> *Acetobacter suboxydans* on the other hand, responds to pantoic acid but not to  $\beta$  alanine,<sup>19</sup> and can therefore be used for the assay of pantolactone. As already noted *Proteus morganii* responds to both pantothenic acid and pantolactone

### Preparation of Solutions for Assay

It is particularly important to prevent hydrolysis of pantothenic acid during its liberation from foodstuffs in which it generally occurs in the bound state. In their original method Pennington *et al*<sup>5</sup> autoclaved the material with or without previous autolysis under benzene, whilst other authors have used enzymes, such as cl<sub>2</sub>rase or mylase P to liberate pantothenic acid.<sup>6, 16, 20, 21, 22</sup> A mixture of chicken liver enzyme and intestinal phosphatase is said to be even more effective.<sup>23</sup> With some sources of pantothenic acid such as malt products treatment with cold dilute alkali solution prior to digestion with papain and takadiastase increased the extraction 2 to 4 fold.<sup>24</sup>

A further difficulty encountered in the assay of foodstuffs with

*L. helveticus* was interference by other growth stimulants, subsequently shown to be fatty acids, this phenomenon was first encountered in the assay of riboflavine (page 158) and interference from this source was overcome by extraction of the medium and test solution with solvent, as in the assay of riboflavine<sup>25</sup>

### References to Section 6

- 1 T H Jukes, *J. Nutrition* 1941, 21, 193
- 2 J D S Bacon and G N Jenkins, *Biochem J.*, 1943 37, 492
- 3 J J Lingane and O L Davis, *J. Biol Chem.*, 1941, 137, 567
- 4 H K Mitchell, H H Weinstock, E E Snell, S R Stanbery and R J Williams, *J Amer Chem Soc* 1940, 62, 1776, 1779, 1785 1791
- 5 D Pennington, E E Snell and R J Williams, *J Biol Chem.*, 1940, 135, 213, D Pennington, E E Snell, H K Mitchell J. R McMahan and R J Williams, *Univ Texas Pub*, 1941 No 4137, 14
- 6 F M Strong R E Feeney and A Earle, *Ind Eng Chem Anal Ed.*, 1941, 13, 566
- 7 H R Skeggs and L D Wright, *J Biol Chem.*, 1944, 156, 21
- 8 M J Pelczar and J R Porter, *Proc Soc Exp Biol Med*, 1940, 43, 151, *J Biol Chem.*, 1941, 139, 111
- 9 M Landy and D M Dicken, *J Lab Clin Med*, 1942, 27, 1086
- 10 J L Stokes and B B Martin, *J Biol Chem.*, 1943, 147, 483
- 11 A E Light and M F Clarke, *ibid.*, 739
- 12 E H Hoag, H P Sarett and V H Cheldelin, *Ind Eng Chem., Anal Ed.*, 1945, 17, 60
- 13 R Kuhn and T Wieland *Ber.*, 1940, 73, 962
- 14 N Nielsen, V Hartelius and G Johansen, *Naturwiss.*, 1943 31, 550
- 15 K Bhagvat, *Current Sci.*, 1944 13, 75
- 16 L Atkin W L Williams, A S Schultz and C. N Frey, *Ind Eng Chem., Anal Ed.*, 1944, 16, 67
- 17 W B Emery, N McLeod and F A Robinson, *Biochem J.*, 1946, 40, 426
- 18 J H Mueller and A W Klotz, *J Amer Chem Soc.*, 1938, 60, 3086
- 19 H P Sarett and V H Cheldelin, *J Biol Chem.*, 1945, 159, 311
- 20 H A Waisman L M Henderson, J M McIntire and C A Elvehjem, *J Nutrition* 1942, 23, 239
- 21 A H Buskirk and R A Delor, *J. Biol Chem.*, 1942, 145, 707
- 22 E Willerton and W H Cromwell *Ind Eng Chem., Anal Ed.*, 1942, 14, 603
- 23 J B Neilands and F M Strong, *Arch Biochem.*, 1948 19, 287
- 24 J S Harrison *Nature*, 1949 163, 798, *Analyst*, 1949, 74, 597
- 25 F M Strong and L E Carpenter, *ibid.*, 909

## 7. OCCURRENCE OF PANTOTHENIC ACID IN FOODSTUFFS

W H Peterson and C A Elvehjem<sup>1</sup> showed that the "chick anti dermatitis factor" was present in yeast, whilst Waisman *et al*<sup>2</sup> estimated the minimal protective levels for chicks of certain animal tissues, and reported that liver and kidney were the richest sources of pantothenic acid, which was also present in heart, spleen, brain, pancreas, tongue and lung, muscle was but a poor source. Most of the early values recorded for the pantothenic acid content of foodstuffs are due to T H Jukes,<sup>3</sup> who also used the chick assay method. He found yeast to be the richest source, with 140 to 350  $\mu\text{g}$  per g of dry weight. Other rich sources were liver, containing 25 to 60, egg 8 to 48, egg yolk, 50 to 100, and broccoli, 46  $\mu\text{g}$  per g.

The following were moderately good sources: whole milk 13 to 42, skim milk, 21 to 43, buttermilk, 35 to 56, whey, 24 to 57, lean beef, 10, canned salmon, 7, wheat, 11, wheat bran, 24, wheat germ 7, barley, 10, yellow corn 8, polished rice 4, potatoes, 65, split peas, 20 to 22, carrots, 2, tomatoes, 1, spinach, 12, kale, 23 to 36, onion, 12, orange, 07, banana 07, and walnuts, 8  $\mu\text{g}$  per g.

The following foodstuffs were poor sources containing less than 1  $\mu\text{g}$  per g: canned beans, canned peas, turnips, beets, egg white, prunes, raisins, canned peaches, apples and almonds.

According to Teply *et al*<sup>4</sup> the pantothenic acid content of wheat averaged about 13  $\mu\text{g}$  per g, ranging from 9 to 17  $\mu\text{g}$  per g according to the variety. Patent flour contained 57, first clear flour, 96, second clear flour, 128, and wheat germ 153  $\mu\text{g}$  per g. Wholemeal flour was richer in pantothenic acid than 85% extraction flour and this, in turn, was richer than white (73% extraction) flour, wheat germ contained twice as much as wholemeal.<sup>5</sup>

Cow's colostrum contained less pantothenic acid than cow's milk, namely 22 compared with 37  $\mu\text{g}$  per ml, and ewe's colostrum less than ewe's milk, namely, 26 against 37  $\mu\text{g}$  per ml.<sup>6</sup> The pantothenic acid content of cow's milk rose to 4  $\mu\text{g}$  per ml during the first nine days of lactation and then fell to the normal level of 35  $\mu\text{g}$  per ml.<sup>7</sup>

Waisman *et al*<sup>8</sup> assayed different animal tissues by the microbiological method after digestion with an enzyme preparation, pantothenic acid was liberated fairly completely by pancreatin and to a more limited extent by other enzymes with a lower proteolytic activity. They found that beef, pork, lamb and chicken tissues were good sources of pantothenic acid. In general, liver and kidney were the richest sources containing 44 to 88 and 32 to 49  $\mu\text{g}$  per g respectively. Striated muscle contained 7 to 21, heart 12 to 25, brain about 36 and spleen 13  $\mu\text{g}$  of pantothenic acid per g. Cooking and

commercial processing destroyed 20 to 40 % of the pantothenic acid present in the raw meat

Fresh cheese contained 13 to 96  $\mu\text{g}$  of pantothenic acid per g<sup>9</sup> and the amount increased 2 to 3 fold on ripening Sorghum contained 103 to 159  $\mu\text{g}$  per g<sup>10</sup>

According to P B Pearson and C J Burgin<sup>11</sup> the richest known source of pantothenic acid is royal jelly, the special food given to those bee larvae that are destined to become queens Many attempts have been made to determine the factor or factors in royal jelly responsible for this astonishing transformation, for queen and worker bees are produced from identical larvae, the difference in development being due solely to the nature of the food which each receives It has frequently been suggested that the activity of royal jelly may be due to the presence of vitamins, especially the fertility vitamin E, or of hormones, especially the gonadotrophic hormone, but the amounts of these factors present are not sufficiently high to account for this remarkable effect of royal jelly Pearson and Burgin, using the microbiological method of assay, found that royal jelly contained an average of 183  $\mu\text{g}$  per g of fresh weight or 511  $\mu\text{g}$  per g of dry weight, as compared with 200 and 180  $\mu\text{g}$  per g of dry weight respectively for yeast and liver, the next richest sources Kitzes *et al*<sup>12</sup> confirmed the high pantothenic acid content of royal jelly, obtaining a value of 320  $\mu\text{g}$  per g, but they also showed that it contained an exceptionally large amount of biotin (page 424) A satisfactory explanation of the curious effect of royal jelly does not yet appear to have been found, as pantothenic acid alone will not bring about the transformation of bee larvae into queens (see page 390) Pollen contained about 30  $\mu\text{g}$  of pantothenic acid per g<sup>12, 13</sup> and honey only 0.55  $\mu\text{g}$  per g<sup>12</sup>

Tea contains about 30  $\mu\text{g}$  of pantothenic acid per g<sup>14</sup>

#### References to Section 7

- 1 W H Peterson and C A Elvehjem, *J Nutrition*, 1939 **18**, 181
- 2 H A Waisman O Mickelsen and C A Elvehjem, *ibid*, 247
- 3 T H Jukes *ibid*, 1942, **21**, 193
- 4 L J Teply F M Strong and C A Elvehjem, *ibid*, 1942 **24**, 167
- 5 A M Copping, *Biochem J* 1943 **37**, 12
- 6 P B Pearson and A L Darnell, *J Nutrition*, 1946 **31**, 51
- 7 J M Lawrence, B L Herrington and L A Maynard *ibid*, 1946 **32**, 73
- 8 H A Waisman L M Henderson, J M McIntire and C A Elvehjem *ibid* 1942, **23**, 239
- 9 R A Sullivan E Bloom and J Jarmol *ibid*, 1943 **25**, 463
- 10 G Knox, V G Heller and J B Sieglinger, *Food Res*, 1944 **9**, 89
- 11 P B Pearson and C J Burgin *Proc Soc Exp Biol Med*, 1941 **48**, 415

- 12 G Kitzes H A Schuette and C A Elvehjem *J Nutrition*, 1943 26, 241
- 13 P B Pearson *Proc Soc Exp Biol Med* 1942 51, 291
- 14 L A M Bradford and E B Hughes, *Analyst* 1945 70, 2

## 8 EFFECT OF PANTOTHENIC ACID DEFICIENCY IN ANIMALS

### Effect on Skin and Hair of Rats

Although the first symptom to be associated with pantothenic acid deficiency was the development of dermatitis in chicks,<sup>1 2</sup> a connection between pantothenic acid deficiency and pigment formation in the hair of black or piebald rats was recognised even before the structure of the "filtrate factor" was known. Thus Oleson *et al*<sup>3</sup> Mohammad *et al*<sup>4</sup> and Chuck *et al*<sup>5</sup> observed that a "filtrate factor" concentrate prevented the greying of hair (achromotrichia) induced in rats by feeding a purified diet, whilst G Lunde and H Kringstad<sup>6</sup> showed that grey hair in foxes could similarly be prevented by administration of a concentrate containing an alkali labile factor which they called vitamin B<sub>x</sub>.

This ability to prevent grey hair in rats was also possessed by a preparation containing 40 to 50 % of pantothenic acid<sup>7, 8</sup> and by pure pantothenic acid<sup>9, 10</sup>. The growth rate of the animals was also increased by the addition of the vitamin to the diet. György *et al*<sup>7, 8</sup> stated that pantothenic acid was not the only member of the vitamin B complex that could cure achromotrichia and suggested that biotin might have a similar effect. As will be seen subsequently *p* amino-benzoic acid (page 551) folic acid (page 487) and inositol (page 572) are also capable under certain conditions of preventing grey hair in rats.

According to G A Emerson and H M Evans<sup>11</sup> and to P L Pavcek and H M Baum<sup>12</sup> pantothenic acid did not restore the fur of rats to its original state but resulted in stippling. Inositol did not improve the condition further<sup>11</sup> but administration of cystine<sup>12</sup> resulted in complete recovery. According to R R Williams<sup>13</sup> pantothenic acid did not cure achromotrichia, but this extreme view does not appear to have received support from other workers. Rustiness could be produced in the fur of albino rats by the omission of pantothenic acid and choline from the diet, and the condition was prevented by giving pantothenic acid with choline—an observation of considerable significance in the light of more recent work on the function of pantothenic acid (see page 391).

D W Woolley<sup>14</sup> observed that pantothenic acid cured hairlessness (alopecia) in mice induced by feeding certain purified diets, thus, like achromotrichia is a condition associated with other members of



the vitamin B complex. Alopecia has also been observed in piebald rats fed a purified diet deficient in pantothenic acid, and was accompanied by mild generalised scaling of the paws and tail and pattern greying<sup>15</sup>. The dermatitis and pattern-greying, but not the scaliness of the paws and tail, were cured by pantothenic acid. According to L. R. Richardson and A. G. Hogan<sup>16</sup> the dermatitis was cured by pyridoxine and pantothenic acid together but not by either separately.

### **Haemorrhages and Degeneration of the Adrenal Glands in Rats**

Another symptom observed in pantothenic acid deficient rats, and possibly specifically associated with this deficiency, is "blood-caked whiskers"<sup>9, 17</sup>. This was accompanied by haemorrhages under the skin and in the adrenal cortex. A condition analogous to blood-caked whiskers, due to the secretion of porphyrin from the lachrymal glands was induced in rats by restricting the water intake to 25 to 50 % of normal.<sup>18</sup> Since the adrenal cortex is known to regulate water metabolism, it seems likely that blood-caked whiskers may be a secondary symptom due to degeneration of the adrenals, which was observed in pantothenic acid deficient rats by Daft *et al*,<sup>19</sup> in addition to epistaxis, ocular exudates, "spectacled eyes" and loss of hair. According to L. L. Ashburn<sup>20</sup> the adrenals in such cases showed congestion, haemorrhage, atrophy, necrosis, fibrosis and cortical fat depletion. The spleen and pancreas were normal, however, though testicular function was impaired and the upper epiphyseal cartilage showed hypoplasia. These symptoms disappeared or decreased in severity on administration of pantothenic acid, whereas untreated controls grew worse.

The occurrence of adrenal haemorrhage and necrosis in pantothenic acid deficient rats was confirmed by W. D. Salmon and R. W. Engel<sup>21</sup> by Supplee *et al*<sup>22</sup> and by Ugami *et al*.<sup>23</sup> However, the addition of adrenal cortex extract, desoxycorticosterone acetate, thyroid or anterior pituitary extract failed to cure the symptoms of pantothenic

- 1 deficiency.<sup>24</sup> Pantothenic acid deficient rats, unlike animals
- 3 reared on an adequate diet, did not exhibit lymphopenia two
- 4 weeks after either swimming or the administration of adrenocortico-
- 5 steroid hormone indicating that changes in the adrenal cortex are
- 6 brought about by pantothenic acid deficiency.<sup>24a</sup>
- 7

32

### **Adaptions in Rats**

Spincott and H. P. Morris<sup>25</sup> reported that the adrenals of pantothenic acid deficient rats were normal, but noted myelin degeneration of the sciatic nerve and spinal cord. This supported the findings of H. Phillips and R. W. Engel<sup>26</sup> that pantothenic

acid was necessary for the maintenance of the normal intact structure of the spinal cord in chicks (page 368)

H W Deane and J M McKibbin<sup>27</sup> suggested that a deficiency of pantothenic acid acted as an "alarming stimulus on the pituitary", causing hypertrophy and over production of corticosterone like steroids from the zona fasciculata

Pantothenic acid deficiency has been said to stimulate the production of body fat<sup>28</sup> It may also result in inflammatory changes in the respiratory tract of rats, leading to bronchitis and bronchopneumonia and lobular hepatitis and fatty infiltration of the liver,<sup>29</sup> at the same time, the erythrocytes and haemoglobin increased and leucocytosis occurred Carter *et al*<sup>30</sup> however, found that pantothenic acid deficient rats developed a severe hypochromic anaemia, with a fall in haemoglobin erythrocytes and polymorphonuclear leucocytes accompanied by splenomegaly, myeloid transformation, hyperplasia of the bone marrow and failure of the erythropoietic and leucopoietic cells to mature Administration of pantothenic acid restored the blood picture to normal Like Lippincott and Morris, they observed no pathological changes in the adrenal cortex It has been stated that pantothenic acid reduces the toxic effects of thyroglobulin in rats<sup>31</sup> A deficiency of pantothenic acid may aggravate the symptoms of biotin deficiency induced in rats by feeding succinylsulphathiazole<sup>32</sup> Administration of biotin protected against the biotin deficiency and at the same time reduced the severity of the symptoms of pantothenic acid deficiency

According to Taylor *et al*<sup>33</sup> the number of young rats in a litter was increased by 25 % when 100  $\mu$ g of calcium pantothenate daily was added to the diet although the day old offspring had relatively smaller brains and hearts than had controls In confirmation of this observation M M Nelson and H M Evans<sup>34</sup> reported that pantothenic acid deficiency adversely affected reproduction in the rat for, when animals were made deficient sixteen to twenty three days before mating or even as late as the day of mating either no implantation occurred or the foetuses were resorbed or defective Pantothenic acid deficiency did not affect reproduction when instituted on the thirteenth day of gestation The effect on reproduction was not due to inanition or other dietary deficiencies

Pantothenic acid deficient rats also suffered changes in the cornea<sup>31a</sup> and developed ulcers of the tongue<sup>31b</sup> and duodenal ulcers<sup>31c</sup>

## Dogs

Some of the results of pantothenic acid deficiency in dogs resemble those in rats, but there are important differences Thus Fouts *et al*<sup>35</sup> observed that pantothenic acid deficient dogs lost weight and appetite

and developed anaemia, whilst Shaeffer *et al*<sup>36</sup> noted the onset of fatty livers and haemorrhagic kidney degeneration. According to J V Scudl and M Hamlin<sup>37</sup> and R H Silber,<sup>38</sup> the production of fatty livers was the most constant, if not the only, pathological change associated with a deficiency of pantothenic acid. However, other symptoms have been recorded by other workers. For example Shaeffer *et al*<sup>36</sup> observed increased respiratory and heart rate, convulsions, gastrointestinal symptoms, mottled thymus glands and gastritis or enteritis in addition to the symptoms noted above. Mottled thymus glands was a symptom also observed in "filtrate factor" deficiency in foxes.<sup>39</sup>

Bly *et al*<sup>40</sup> also recorded gastrointestinal disturbances in dogs including a 50 % decrease in gastrointestinal motility and a 40 to 65 % decrease in the rates of digestion and absorption of protein and carbohydrate, administration of calcium pantothenate cured the condition immediately. According to A O Seeler and R H Silber,<sup>41</sup> the onset of pantothenic acid deficiency in adult dogs was very slow and signs might not be observed for four and a half years.

### Pigs

Pantothenic acid is also essential for the growth of young pigs and a deficiency results in symptoms similar to those observed in rats, including a subnormal appetite, emaciation, loss of co ordination ("goose stepping"), loss of hair, excessive nasal secretion, diarrhoea and gastritis with involvement of the large intestine, degenerative changes in the peripheral nerves, posterior root ganglia and the posterior roots and posterior funiculi of the spinal cord.<sup>42 43</sup> At autopsy, diffuse hyperemia was noted,<sup>44</sup> with an increase in the size of the lymphoid follicles and formation of small ulcers leading to inflammatory changes involving the large intestine. The mucosa lining cells were atrophied, with abscess formation and ulceration. The animals also suffered from a normocytic anaemia, accompanied by a fall in the serum chloride and an increase in the carbon dioxide-combining capacity of the blood.

### Monkeys

In the monkey, pantothenic acid deficiency was characterised by lack of growth, ataxia, greying and thinning of the fur, anaemia, diarrhoea and cachexia.<sup>45</sup> Pantothenic acid brought about incomplete remission of these symptoms.

### Chicks

As already noted, chicks suffering from a deficiency of pantothenic acid developed dermatitis<sup>46, 47</sup> and lesions of the spinal cord.<sup>27</sup> These

included myelin and axon degeneration, but there was no degradation of the peripheral nerves<sup>48</sup> Black Minorca chicks showed partial depigmentation of the feathers<sup>49</sup> Some evidence exists<sup>47</sup> for believing that pantothenic acid is essential for reproduction in the hen

The pantothenic acid content of eggs depended on the diet of the hens,<sup>50</sup> but remained remarkably constant during the embryonic development of the chick<sup>51</sup> Hens fed on diets containing 3.9, 8.6 and 15.7  $\mu\text{g}$  of pantothenic acid per dry produced eggs containing 4.9, 7.9 and 14.0  $\mu\text{g}$  per g respectively, these hatched into chicks containing 5.2, 8.3 and 13.6  $\mu\text{g}$  per g

## Fish

It has been stated<sup>52</sup> that pantothenic acid is an essential factor, together with riboflavin and pyridoxine, for young rainbow trout, but McLaren *et al*<sup>53</sup> showed that the anaemia which was attributed to a deficiency of these three factors was cured by a mixture of riboflavin, pyridoxine and choline Nevertheless they showed<sup>54</sup> that pantothenic acid was necessary for trout to the extent of 1 to 2  $\mu\text{g}$  per 100 g of diet In its absence, the fish developed clubbed gills

## Effect on Infection

Pantothenic acid deficient rats were found to be less susceptible than normal rats to type I pneumococcus infection<sup>55</sup> and pantothenic acid-deficient mice were more resistant than normal mice to Theiler's encephalomyelitis virus though not to the Lansing strain of poliomyelitis<sup>56</sup> Some impairment of antibody response was observed in pantothenic acid-, as well as in pyridoxine deficient rats Pantothenic acid deficiency increased the severity of *Trypanosoma lewisi* infection in rats<sup>58</sup> and the supplementing of a diet with pantothenic acid caused a *T. evansi* infection to develop more slowly<sup>59</sup>

## References to Section 8

- 1 C A Elvehjem and C J Koehn, *Nature*, 1934, 134, 1007, *J Biol Chem*, 1935, 108, 709
- 2 S Lepkovsky and T H Jukes *ibid*, 1936, 114, 109
- 3 J J Oleson, C A Elvehjem and E B Hart, *Proc Soc Exp Biol Med*, 1939, 42, 283
- 4 A Mohammad O H Emerson, G A Emerson and H M Evans, *J Biol Chem*, 1940, 133, 17
- 5 H Chick, T F Macrae and A N Worden *Biochem J*, 1940, 34, 580
- 6 G Lunde and H Kringstad *Naturwiss*, 1939, 27, 755
- 7 P György and C E Poling *Science*, 1940, 92, 202, *Proc Soc. Exp Biol Med*, 1940, 48, 773

# PANTOTHENIC ACID

- 8 P Gyorgy, C E Poling and Y SubbaRow *J Biol Chem* 1940 132, 789
- 9 K Unna G V Richards and W L Sampson *J Nutrition* 1941 22, 553
- 10 L M Henderson J M McIntire H A Waisman and C A Elvehjem *ibid*, 1942 23, 47
- 11 G A Emerson and H M Evans *Proc Soc Exp Biol Med* 1941 48, 655
- 12 P L Pavcek and H M Baum *ibid* 1941 47, 271
- 13 R R Williams *Science* 1940 92, 561
- 14 D W Woolley *Proc Soc Exp Biol Med* 1941 48 565
- 15 M Sullivan and J Nicholls *Arch Dermat Syphil* 1942 45 917
- 16 L R Richardson and A G Hogan *Proc Soc Exp Biol Med* 1940 44, 583
- 17 K Unna *J Nutrition* 1940 20, 565
- 18 F H J Figue and W B Atkinson *Proc Soc Exp Biol Med* 1941 48, 112
- 19 F S Daft W H Sebrell S H Babcock and T H Jukes *US Publ Health Rep* 1940 55, 1333
- 20 L L Ashburn *ibid* 1337
- 21 W D Salmon and R W Engel *Proc Soc Exp Biol Med* 1940 45, 621
- 22 G C Supplee R C Bender and O J Kahlenberg *Endocrinology* 1942 30, 355
- 23 S Ugami Y Yamao K Michi S Funahashi S Emoto and A Ichiba *Sci Papers Inst Phys Chem Res, Tokyo* 1941 38 312
- 24 C W Mushett and K Unna *J Nutrition* 1941 22, 565
- 24a M E Dumm P Ovando P Roth and E P Ralli *Proc Soc Exp Biol Med* 1949 71 368
- 25 S W Lippincott and H P Morris *J Nat Cancer Inst* 1941 2 39
- 26 P H Phillips and R W Engel *J Nutrition* 1939 18, 227
- 27 H W Deane and J M McKibbin *Endocrinology* 1946 38 385
- 28 Le R Voris and H P Moore *ibid* 1943 25, 7
- 29 R Jurgens and H Pfaltz *Z Vitaminforsch* 1944 14, 243
- 30 C W Carter R G Macfarlane J R O'Brien and A H T Robb Smith *Biochem J* 1945 39, 339
- 31 J Abelin *Experientia* 1945 1, 231
- 32 G A Emerson and E Wurtz *Proc Soc Exp Biol Med* 1944 57, 47
- 33 A Taylor D Pennington and J Thacker *J Nutrition* 1943 25 389
- 34 M M Nelson and H M Evans *ibid* 1946 31, 497
- 34a L L Bowles W K Hall V P Sydenstricker and C W Hock *ibid* 1949 37, 9

- 34b D E Ziskin M Karshan G Stein and D A Dragoff *ibid* 1949 71 374
- 34c B N Berg T F Zucker and L M Zucker *Proc Soc Exp Biol Med* 1949 71 374
- 35 P J Fouts O M Helmer and S Lepkovsky *J Nutrition* 1940 19, 393
- 36 A E Shaeffer J M McKibbin and C A Elvehjem *J Biol Chem* 1942 143, 321
- 37 J V Scudl and M Hamlin *J Nutrition* 1944 27, 425
- 38 R H Silber *ibid* 1942 24, 273
- 39 A F Morgan and H M Simms *ibid* 1940 20, 627
- 40 C G Bly F W Heggeness and E S Nasset *ibid* 1943 28, 161
- 41 A O Seeler and R H Silber *ibid* 1945 30, 111
- 42 E H Hughes *J Agric Res* 1942 64, 185
- 43 M M Wintrobe M H Miller R H Follis H J Stein C Mushatt and S Humphreys *J Nutrition* 1942 24, 345
- 44 M M Wintrobe R H Follis R Alcayaga M Paulson and S Humphreys *Johns Hopkins Hosp Bull* 1943 73, 313
- 45 K B McCall H A Waisman C A Elvehjem and E S Jones *J Nutrition* 1946 31, 685
- 46 M H Dimick and A Lepp *ibid* 1940 20, 413
- 47 M B Gillis G F Heuser and L C Norris *ibid* 1942 23, 153
- 48 J H Shaw and P H Phillips *ibid* 1945 29, 107
- 49 T C Groody and M E Groody *Science* 1942 95, 655
- 50 E E Snell E Aline J R Couch and P B Pearson *J Nutrition* 1941 21 201
- 51 P B Pearson V H Melass and R M Sherwood *Arch Biochem* 1945 7, 353
- 52 A L Durr and C M McKay *N Y Conservation Dept Cortland Hatchery Rep* 1942 No 11
- 53 B A McLaren E F Herman and C A Elvehjem *Arch Biochem* 1946 10 433
- 54 B A McLaren E Keller D J O'Donnell and C A Elvehjem *ibid* 1947 15 169
- 55 H D West M J Bent R E Rivera and R E Tisdale *ibid* 1944 3, 321
- 56 H C Lichstein H A Waisman C A Elvehjem and P F Clark *Proc Soc Exp Biol Med* 1944 56, 3
- 57 A E Axelrod B B Carter R H McCoy and R Geisinger *ibid* 1947 66, 137 P P Ludovici A E Axelrod and B B Carter *ibid* 1949 72 81
- 58 E R Becker J Taylor and C Fuhrmeister *Iowa State Coll J Sci* 1947 21 237
- 59 H N Ray and S Harbans *Nature* 1948 162 849

## PANTOTHENIC ACID

### 9 EFFECT OF PANTOTHENIC ACID DEFICIENCY IN MAN

There is no evidence that uncomplicated pantothenic acid deficiency has ever been observed in man, nor is there any record of pantothenic acid deficiency having been produced artificially in man as, for instance, by maintaining volunteers on a synthetic diet containing sub optimal amounts of this factor. It is therefore impossible to describe any symptoms that can be attributed solely to a deficiency of pantothenic acid although some of the symptoms noted in various forms of vitamin B complex deficiency may well have been due to the presence of inadequate amounts of pantothenic acid in the diets responsible.

The reason for the apparent lack of interest in the effect of pantothenic acid deficiency in man is possibly due to the fact that the symptoms noted in animals do not indicate that any particularly important metabolic changes occur such as are associated with a deficiency of aneurine or nicotinic acid or even of riboflavine. Indeed the only symptom of deficient animals that has aroused interest among clinical investigators is achromotrichia. The fact that administration of pantothenic acid prevents grey hair in experimental animals maintained on a deficient diet suggested that the same result might be produced by its administration to elderly humans although there is no evidence to suggest that the greying of human hair is associated with a deficiency of this or any other vitamin. Not only were hopes aroused but claims were actually made that pantothenic acid was a cure for this particular manifestation of senility, and certain pharmaceutical houses in the U.S.A. were not slow to exploit the idea. In fact the only clinical report that might be regarded as substantiating such a claim is a very guarded statement by Brandalcone *et al*.<sup>1</sup> that "some restoration of colour" occurred in two out of forty nine elderly grey haired patients when treated with 100 mg of calcium pantothenate together with 100 mg of *p*-aminobenzoic acid and 50 g of yeast daily for eight months. Even this modest response was not observed in subsequent experiments by the same authors<sup>2</sup> and by I. Kerlan and R. P. Herwick<sup>3</sup> and it is reasonably safe to conclude that pantothenic acid does not cause grey hair to return to its original colour in human beings.

#### References to Section 9

- 1 H. Brandalcone, E. Main and J. M. Steele *Proc Soc Exp Biol Med* 1943 53, 47
- 2 H. Brandalcone, E. Main and J. M. Steele *Amer J Med Sci* 1944 208, 315
- 3 I. Kerlan and R. P. Herwick *J Amer Med Assoc* 1943 123, 391

## 10. METABOLISM OF PANTOTHENIC ACID

## Blood Concentration

The concentration of pantothenic acid in normal human blood was stated by Stanbery *et al*<sup>1</sup> to vary from 18 to 34  $\mu\text{g}$  per 100 ml, with an average of 20  $\mu\text{g}$  per 100 ml, and by M J Pelczar and J R Porter<sup>2</sup> to be between 3 and 9  $\mu\text{g}$  per 100 ml. H McIlwain and I Hawking<sup>3</sup> reported a value of 20 to 40  $\mu\text{g}$  per 100 ml for whole human blood or plasma and values of 40 to 80  $\mu\text{g}$  per 100 ml for rat blood and 200 to 400  $\mu\text{g}$  per 100 ml for mouse blood. The pantothenic acid concentration of chicken blood and plasma was found to be 43.6 and 51.6  $\mu\text{g}$  per 100 ml on an adequate diet and slightly lower on a less adequate diet,<sup>4</sup> about 86 % of the pantothenic acid was present in the plasma.

Following the intravenous injection of sodium or calcium pantothenate normal human subjects immediately began to excrete pantothenic acid in the urine and the blood concentration rose by 50 % in three hours.<sup>5</sup> In patients suffering from pellagra, beriberi or riboflavin deficiency, however, the concentration in the blood decreased. When pantothenic acid was injected into normal subjects the riboflavin as well as the pantothenic acid level of the blood increased and, conversely, administration of riboflavin increased the pantothenic acid, as well as the riboflavin concentration of the blood. R H Silber and K Unna<sup>6</sup> confirmed the rapid increase in the blood concentration that followed the intravenous injection into dogs of 4 mg per kg of bodyweight and noted that the value fell to normal within two hours. They were unable to find any change, however, in the blood riboflavin concentration following pantothenate injection or in the pantothenic acid concentration following injection of riboflavin. The amount of pantothenic acid in the blood of rabbits decreased 20 to 30 % after administration of 5 to 10 g of glucose.<sup>7</sup> Most of the pantothenic acid in the blood was present in the combined form, the complex being thrown down by protein precipitants.<sup>8</sup>

## Pantothenic Acid in Tissues and Body Fluids

The pantothenic acid contents of different human tissues varied considerably, the following values being recorded by Nielsen *et al*<sup>9</sup>: muscle, 4; liver, 40; kidney, 30; spleen, 20; nerve, 3; pancreas, 7; adrenals, 5; and pylorus, 10  $\mu\text{g}$  per g of dry matter. Free  $\beta$  alanine was only found in the liver (150  $\mu\text{g}$  per g) and pancreas (7.5  $\mu\text{g}$  per g).

According to R H Silber,<sup>10</sup> the tissues, as well as the blood of depleted dogs contained less pantothenic acid than the tissues of controls dosed with the vitamin but, compared with normal dogs,



## PANTOTHENIC ACID

low levels were found only in the liver, muscle and brain. Repeated oral administration increased the tissue level above normal and delayed subsequent depletion.

Chicken muscle contained between 1 and 4  $\mu\text{g}$  of pantothenic acid per g, and the pattern of distribution followed that of aneurine and riboflavine (pages 72, 181).<sup>11</sup> The amount of pantothenic acid in chicken liver bore little relation to the intake, but this influenced the amount present in the leg muscle and breast tissue.<sup>4</sup> With very high levels of intake these three tissues contained 45, 17 and 11  $\mu\text{g}$  per g respectively. When pantothenic acid was given to deficient chicks, deposition of the vitamin in the leg and breast tissues occurred rapidly.

A large drop in the pantothenic acid content of the liver of rats occurred when hepatoma were induced by the feeding of *p* dimethylaminazobenzene.<sup>12</sup> Human and rat cancers contained approximately the same amounts of pantothenic acid as did non cancerous spleen, lung and skeletal muscle, which are poorer in this factor than the liver, heart, kidney and brain.

Human milk contained 48  $\mu\text{g}$  of pantothenic acid per 100 ml on the first day of parturition, and the amount increased rapidly to 24.5  $\mu\text{g}$  per 100 ml by the fourth day and then more slowly to 30.4  $\mu\text{g}$  per 100 ml by the tenth day. The average value of mature milk was about 250  $\mu\text{g}$  per 100 ml.<sup>13</sup> Cow's and ewe's milk contained similar amounts and showed similar changes.

Spector *et al*<sup>14</sup> recorded a value of 3.8  $\mu\text{g}$  per 100 ml for the amount of pantothenic acid excreted in the sweat under normal conditions. This amount was unaffected by the administration of 18 mg of pantothenic acid per day. Under hot moist conditions 31 % of an 18 mg dose was recovered in the urine, and the total urinary and dermal excretion increased by 11.6 % to 3.8 to 5.7 mg per day.

### Urinary Excretion of Pantothenic Acid

Human urine contained between 70 and 600  $\mu\text{g}$  per 100 ml of pantothenic acid,<sup>2, 3</sup> and the amount excreted per day was found to be from 2.5 to 5 mg.<sup>14, 15</sup> D. M. Tennant and R. H. Silber<sup>16</sup> reported that the normal urinary excretion of 24  $\mu\text{g}$  per hour increased to 50  $\mu\text{g}$  per hour after dosage with the vitamin. Humans excreted approximately 10 % of an orally administered dose of calcium pantothenate within four hours.<sup>17</sup> The renal output of pantothenic acid after oral administration of 100 mg of the vitamin was not significantly less in patients with pernicious anaemia than in normal subjects.<sup>18</sup>

Rat urine contained 100 to 200  $\mu\text{g}$  of pantothenic acid per 100 ml,<sup>2, 3</sup> and there was a rapid increase in the rate of excretion following the injection of pantothenic acid. Pantothenic acid deficient mice

rapidly excreted pantothenic acid in which the nitrogen atom was replaced by the  $N^{15}$  isotope when this was administered parentally<sup>19</sup> The fact that  $N^{15}$  was absent from a number of tissues showed that pantothenic acid was not metabolised by mice in a manner analogous to the amino acids Urinary pantothenic acid excretion in rats was higher on a diet containing 64 % of casein than on one containing 24 %<sup>20</sup>

Dogs with a bladder fistula excreted 7.2  $\mu$ g of pantothenic acid in two hours, and there was no increased excretion two hours after oral administration of 1 mg of pantothenic acid per kg of bodyweight After an oral dose of 4 mg per kg, however, 0.9 to 5.0 % was excreted in two hours<sup>6</sup> Following the intravenous injection of 1 and 4 mg per kg, 22 to 31 % and 41 to 57 % respectively of the dose was excreted, the excretion being maximal after forty and twenty minutes, respectively More pantothenic acid was excreted following an oral dose than after subcutaneous injection With unlimited access to food, dogs excreted up to 50 % of the dietary pantothenic acid in the faeces but no increase in the faecal excretion occurred after intravenous administration of calcium pantothenate<sup>17</sup>

It is not known what degradation products of pantothenic acid are formed *in vivo*, but it is known<sup>21</sup> that pantolactone is not one of the substances formed in man The excretion of pantolactone was the same whether it was given orally or intravenously suggesting that intestinal bacteria did not attack the lactone ring The excretion of pantoic acid on the other hand was slightly less after oral than after intravenous administration suggesting that it was partially decomposed by the intestinal flora

The amount of pantothenic acid excreted in the faeces was slightly greater after oral administration of pantolactone, possibly owing to modified metabolism of the intestinal bacteria

#### References to Section 10

- 1 S R Stanbery E E Snell and T D Spies *J Biol Chem*, 1940, 135, 353
- 2 M J Pelczar and J R Porter *Proc Soc Exp Biol Med* 1941, 47, 3
- 3 H McIlwain and F Hawking *Lancet* 1943 1, 449
- 4 P B Pearson, V H Melass and R M Sherwood *J Nutrition* 1946 32, 187
- 5 T D Spies S R Stanbery R J Williams T H Jukes and S H Babcock *J Amer Med Assoc*, 1940 115, 523
- 6 R H Silber and K Unna *J Biol Chem*, 1942 142, 623
- 7 L D Wright, *ibid* 445
- 8 L D Wright *ibid*, 1943 147, 261

## PANTOTHENIC ACID

- 9 N Nielsen V Hartelius and V Schmidt *Naturwiss* 1943 31, 550
- 10 R H Silber *J Nutrition* 1944 27, 425
- 11 E E Rice E J Strandine E M Squires and B Lyddon *Arch Biochem* 1946 10, 251
- 12 A Taylor M A Pollack M J Hofer and R J Williams *Cancer Res* 1942 2 752
- 13 M N Coryell M E Harris S Miller H H Williams and I G Macy *Amer J Dis Child* 1945 70, 150
- 14 H Spector T S Hamilton and H H Mitchell *J Biol Chem* 1945 161, 145
- 15 L D Wright and E Q Wright *Proc Soc Exp Biol Med* 1942 49, 80
- 16 D M Tennant and R H Silber *J Biol Chem* 1943 148, 359
- 17 R H Silber *Arch Biochem* 1945 7, 329
- 18 C E Meyer I F Burton and C E Sturgis *Proc Soc Exp Biol Med* 1942 49, 363
- 19 B Lustig A R Goldfarb and B Gerstl *Arch Biochem* 1944 5 59
- 20 M M Nelson F van Nonhuys and H M Evans *J Nutrition* 1947 34, 189
- 21 H P Sarett *J Biol Chem* 1945 159, 321

## II INTestinal SYNTHESIS OF PANTOTHENIC ACID

Evidence for the synthesis of pantothenic acid by micro organisms in the rumen of ruminants was presented by L W McElroy and H Goss<sup>1</sup> who observed that the dried contents of the rumen and the reticulum of sheep and cows maintained on a diet low in the vitamin B complex contained respectively twenty five and twenty to thirty fold the amount of pantothenic acid present in the diet whilst milk from these cows contained twice the amount of pantothenic acid ingested in the diet another illustration of the possible importance of this phenomenon in human nutrition

Only indirect evidence is available to indicate that pantothenic acid is synthesised in the intestines of animals Thus pantothenic acid deficiency was induced in experimental animals by the feeding of sulphonamides<sup>2 3</sup> which presumably inhibited the development of the intestinal flora L D Wright and A D Welch<sup>3</sup> found that administration of succinylsulphathiazole not only caused severe symptoms of pantothenic acid deficiency but considerably reduced the pantothenic acid content of the liver the storage of riboflavine and nicotinic acid on the other hand was unaffected whilst that of biotin and folic acid was increased Neither the symptoms of pantothenic acid deficiency nor the low level in the liver was affected by

increasing the daily intake of the vitamins but yielded to treatment with biotin and a folic acid concentrate illustrating the close association between different members of the vitamin B complex. The authors concluded that the utilisation of pantothenic acid depended on the availability of biotin and folic acid.

Pantothenic acid deficiency in the rat was accentuated by feeding purified beef blood fibrin in place of casein,<sup>4</sup> possibly because this source of protein was less favourable than casein for the growth of the intestinal flora.

Direct evidence that pantothenic acid is synthesised by the intestinal flora in man was obtained by Denko *et al*,<sup>5</sup> who found that both on a normal and on a restricted diet the combined faecal and urinary excretion exceeded the dietary intake although not to the same extent as with *p*-aminobenzoic acid, folic acid and biotin (see page 435). Moreover, although on the restricted diet the urinary excretion was increased by administration of pantothenic acid the faecal excretion was virtually independent of the dietary intake. It is not certain whether or not the pantothenic acid formed by the intestinal bacteria can be utilised in man.

#### References to Section 11

- 1 L. W. McElroy and H. Goss *J. Nutrition* 1941 **21**, 405
- 2 H. D. West, N. C. Jefferson and R. E. Rivera *ibid* 1943 **25**, 471
- 3 L. D. Wright and A. D. Welch *Science* 1943 **97**, 426 *J. Nutrition* 1944 **27**, 55
- 4 M. M. Nelson and H. M. Evans *Proc. Soc. Exp. Biol. Med.* 1947 **66**, 299
- 5 C. W. Denko, W. A. Grundy, J. W. Porter, G. H. Berryman, T. E. Friedemann and J. B. Youmans *Arch. Biochem.* 1946 **10**, 33.  
C. W. Denko, W. E. Grundy, N. C. Wheeler, C. R. Henderson, C. H. Berryman, T. E. Friedemann and J. B. Youmans *ibid* 1946 **11**, 109

## 12 HUMAN AND ANIMAL REQUIREMENTS OF PANTOTHENIC ACID

There is surprising unanimity in the figures quoted by different authors for the pantothenic acid requirement of the rat, most workers agreeing that the minimal dose necessary to prevent achromotrichia and produce adequate growth lies between 50 and 100  $\mu\text{g}$  per day.<sup>1-3</sup> Estimates of the dose required to cure achromotrichia range from 20 to 40,<sup>6</sup> 50<sup>1</sup> and 100  $\mu\text{g}$  per day,<sup>6</sup> whilst the following amounts have been suggested as being necessary to promote growth: 40,<sup>6</sup> 50,<sup>3,7</sup>

80<sup>5</sup> and 50 to 100  $\mu\text{g}$  per day<sup>8</sup> According to K Unna and G V Richards<sup>9</sup> the daily maintenance requirement for the rat falls from 100  $\mu\text{g}$  at three weeks of age to 25  $\mu\text{g}$  at ten weeks but it is not related to weight or food consumption K Schwartz<sup>10</sup> stated that after an induction period, each  $\mu\text{g}$  of additional pantothenic acid produced a 62.5 mg increase in the weight of young rats up to 20 g but that to increase the weight further the presence of another factor known as 'factor 125' (see page 608), was necessary The nature of this additional factor seems never to have been elucidated The amount of pantothenic acid required to maintain the health of rats was not increased by a rise in temperature being the same at 91° F as at 68° F, namely, 6 mg per kg of bodyweight<sup>11</sup>

The requirements for mice appear only to have been given in terms of the dietary intake, they are stated to be 2 mg per 100 g of diet<sup>12</sup>

Puppies are said<sup>13</sup> to require 100  $\mu\text{g}$  of calcium pantothenate per kg of bodyweight per day—considerably less, weight for weight, than the amount accepted as being necessary for the rat Shetland ponies required proportionately less, namely 38  $\mu\text{g}$  per kg per day<sup>13a</sup>

Black Minorca chicks on a pantothenic acid deficient diet exhibited a partial depigmentation of the feathers (page 369), which was prevented by as little as 5  $\mu\text{g}$  per day of pantothenic acid<sup>14</sup> More was required to maintain optimal reproduction and egg production however, namely, 1200 to 1700 and 700  $\mu\text{g}$  per 100 g of food respectively<sup>15</sup> From 750 to 1000  $\mu\text{g}$  per 100 g of diet were required to ensure that the eggs hatched and that the chickens survived and showed no signs of pantothenic acid deficiency The minimum blood level consistent with satisfactory reproductive performance was 0.45 mg per ml and the minimum amount in the egg 9.5  $\mu\text{g}$  About 200  $\mu\text{g}$  per 100 g of food was considered sufficient for maintenance although 900  $\mu\text{g}$  per 100 g of diet were necessary for maximum growth<sup>18</sup> Ducklings required 1100  $\mu\text{g}$  per 100 g of diet for satisfactory growth<sup>17</sup>

#### References to Section 12

- 1 P Gyorgy and C E Poling *Science* 1940 92, 202
- 2 K Unna and W L Sampson *Proc Soc Exp Biol Med* 1940 45, 309
- 3 K Unna *J Nutrition* 1940, 20, 565
- 4 K Unna G V Richards and W L Sampson *ibid* 1941 22, 553
- 5 L M Henderson J M McIntire H A Waisman and C A Elvehjem *ibid* 1942 23, 47
- 6 G A Emerson and H M Evans *Proc Soc Exp Biol Med* 1941, 46, 655
- 7 K Schwartz, *Z physiol Chem* 1942 275, 245
- 8 J D S Bacon and G N Jenkins *Biochem J* 1943 37, 492

- 9 K. Unna and G. V. Richards *J Nutrition*, 1942, 23, 545
- 10 K. Schwartz, *Z physiol Chem*, 1942, 275, 232
11. C. A. Mills, *Arch Biochem*, 1942, 1, 73
- 12 D. W. Woolley, *Proc Soc Exp Biol Med*, 1941, 48, 565
- 13 A. E. Shaefer, J. M. McKibbin and C. A. Elvehjem, *J Biol Chem* 1942, 143, 321.
- 13a P. B. Pearson and H. Schmidt, *J. Animal Sci*, 1948, 7, 78.
- 14 T. C. Groody and M. E. Groody, *Science*, 1942 95, 655
- 15 M. B. Gillis, G. F. Heuser and L. C. Norris, *J. Nutrition*, 1943 26, 285, 1948, 35, 351
- 16 D. M. Hegsted and T. R. Riggs, *ibid*, 1949, 37, 361
17. D. M. Hegsted and R. L. Perry, *ibid*, 1948, 35, 411

### 13. PHARMACOLOGY OF PANTOTHENIC ACID

The pharmacological properties of calcium pantothenate were studied by K. Unna and J. Greslin,<sup>1</sup> who found that the toxic dose (LD 50) for mice was 10.27 and 0.92 g per kg by the oral, subcutaneous and intraperitoneal routes respectively, death occurred through respiratory failure. For rats the value of LD 50 was 3.4 g per kg by the subcutaneous route. Rats suffered no ill effects when given 10 g per kg by mouth, and five dogs and one monkey were not affected by a dose of 1 g per kg by mouth. Rats developed normally when given 200 mg of calcium pantothenate daily for 190 days, and dogs given 50 mg per kg of bodyweight daily for six months and monkeys given 1 g per day for six months showed no ill effects.

The subcutaneous injection of a 1 to 10 % solution of calcium pantothenate into rabbits or the instillation of a 10 % solution into the conjunctival sac caused no irritation. The blood pressure and respiration of a cat were not influenced by the intravenous injection of 10 to 50 mg per kg, and the heart rate was unchanged. The volume of urine excreted was not affected. No effect on the intestine or uterus of a rabbit could be detected in concentrations up to 1 part in 10 000 parts.

Spies *et al*<sup>2</sup> reported that the intravenous injection of a solution containing 100 mg of calcium or sodium pantothenate produced no change in the blood pressure, pulse, temperature or respiration of normal human subjects.

#### References to Section 13

- 1 K. Unna and J. G. Greslin, *Proc Soc Exp Biol Med* 1940, 45, 311, *J. Pharmacol*, 1941, 73, 85
- 2 T. D. Spies, S. R. Stanberry, R. J. Williams, T. H. Jukes and S. H. Babcock, *J. Amer Med Assoc*, 1940, 115, 523

## 14. PANTOTHENIC ACID IN THE NUTRITION OF MICRO-ORGANISMS

**Bacteria**

As already stated (see page 360), pantothenic acid is essential for the growth of *Streptococcus lactis*, *Bacillus brassicae*, *Propionibacterium pentosaceum*, *Lactobacillus helveticus*, *L. arabinosus* and *Proteus morganii*, the last three organisms have been used for the microbiological assay of pantothenic acid. It is also essential for the growth of *Streptococcus haemolyticus* and *Diplococcus pneumoniae*,<sup>1</sup> of *Clostridium tetani*,<sup>2</sup> of *Clostridium welchii*,<sup>3</sup> of "exacting" strains of *Corynebacterium diphtheriae*<sup>4</sup> (other strains do not require pantothenic acid if  $\beta$  alanine is available), of some species of *Pasteurella*<sup>5</sup> and *Brucella*,<sup>6</sup> of *Streptobacterium plantarum*,<sup>7</sup> of five species of *Propionibacterium*,<sup>8</sup> of three strains of *Shigella paradysenteriae*,<sup>9</sup> and of a number of species of lactic acid bacteria.<sup>10</sup> *Clostridium botulinum* required biotin, aneurine and choline, but pantothenic acid could apparently substitute for aneurine and choline.<sup>11</sup>

The amounts of pantothenic acid in the cells of five bacteria that did not require an extra cellular source of pantothenic acid, namely, *Aerobacter aerogenes*, *Serratia marcescens*, *Pseudomonas fluorescens*, *Proteus vulgaris* and *Clostridium butylicum* were estimated by H. McIlwain<sup>12</sup> at 24,000 and 96,000 molecules per cell and the rate of synthesis at 5 to 40 molecules per cell per second.

*Escherichia coli* synthesised pantothenic acid at the rate of 50 molecules per cell per second in the absence of  $\beta$  alanine and at ten times this rate when  $\beta$  alanine was present.<sup>13</sup> *Pseudomonas aeruginosa* synthesised it at the rate of 9 and 30 molecules per cell per second in the absence and presence respectively of pantoic acid.<sup>3</sup>

Pantothenic acid was inactivated (see below) by *Streptococcus haemolyticus* (non proliferating) at a rate equivalent to 23 to 41 molecules per cell per second,<sup>14</sup> and the rate was not appreciably altered when the conditions were varied. Pantothenic acid was not synthesised by this organism and both growth and pantothenic acid metabolism were inhibited to the same extent by pantoyltaurine and similar antagonists (see below). Pantothenic acid was metabolised by *Proteus morganii* at a velocity ranging from 25 to 120 molecules per cell per second.


These reactions are therefore of approximately the same order, falling into the class termed by McIlwain  $\mu\text{mol}$  order reactions. The significance of this has already been discussed (page 284).

According to G. M. Hills,<sup>15</sup> the oxygen uptake of a pantothenic acid deficient culture of *Proteus morganii* was increased seven fold by the addition of pantothenic acid. The most important substrate

influenced by pantothenic acid was pyruvic acid but some effect was observed with lactic acid and certain  $C_4$  and  $C_5$  dicarboxylic acids. Pantothenic acid did not however affect the fermentation of glucose confirming the absence of a correlation between glycolysis and the presence of pantothenic acid noted below. Dorfman *et al*<sup>16</sup> also found that pantothenic acid stimulated the oxygen uptake of *P. Morganii* in presence of lactic or pyruvic acid.

### Pantoyltaurine

Several of the bacteria that require preformed pantothenic acid have been used to test growth inhibitors that act by antagonising the growth promoting effect of pantothenic acid. The best known of these antagonists is pantoyltaurine which is derived from pantothenic acid by replacement of the carboxyl group by a sulphonic acid group



This compound was prepared independently by E. E. Snell<sup>17</sup> in the U.S.A. by R. Kuhn, T. Wieland and E. T. Moller<sup>18</sup> in Germany and by J. W. Barnett and T. A. Robinon<sup>19</sup> and H. McIlwain<sup>20</sup> in this country.

It inhibits the growth of all organisms that require preformed pantothenic acid e.g. *L. arabinosus*<sup>17</sup>, *L. pentosus*<sup>17</sup>, *S. lactis*<sup>17</sup>, *Propionibacterium pentosaceum*<sup>17</sup>, *Leuconostoc mesenteroides*<sup>17</sup>, *Streptobacterium plantarum*<sup>18</sup>, *Streptococcus haemolyticus*<sup>20</sup>, *Diplococcus pneumoniae*<sup>20</sup> and exacting strains of *C. diphtheriae*<sup>20</sup> but not of organisms that synthesise their own pantothenic acid either completely such as *E. coli* or from added  $\beta$  alanine such as the non exacting strains of *C. diphtheriae*. Where inhibition occurred it could be completely overcome by addition of more pantothenic acid so that inhibition is of the competitive type of which other instances are provided by *p*-aminobenzoic acid and sulphanilamide (page 546) and nicotinic acid and pyridine- $\beta$  sulphonic acid (page 291). The amide of pantoyltaurine, pantoyltauramide<sup>19, 20</sup> also inhibited the growth of many of the above organisms but was less effective than pantoyltaurine. It appeared to act by the same mechanism as pantoyltaurine. Other inhibitors related to pantothenic acid are discussed on page 397.

The effects of pantoyltaurine and pantoyltauramide are markedly different with different organisms although the amount of pantothenic acid needed for optimal growth of each organism is approximately the same for a number of bacteria. H. McIlwain<sup>20</sup> calculated the antibacterial indices of the two inhibitors that is the ratio of



# PANTOTHENIC ACID

the molar concentration of inhibitor to that of promoter necessary to produce inhibition of growth. He obtained the following results

	DL-Pantoyltaurine	DL-Pantoyltauramide
<i>Streptococcus haemolyticus</i>	500	—
<i>Streptococcus lactis</i>	8000	2000
<i>Propionibacterium pentosaceum</i>	8000	—
<i>Diplococcus pneumoniae</i>	1000	10,000-50,000
<i>Corynebacterium diphtheriae</i>	—	—
Exact	—	—
Less exact	500	2000-10,000
<i>Lactobacillus arabinosus</i>	5000	—
<i>Lactobacillus pentosus</i>	1000-2000	—
<i>Leuconostoc mesenteroides</i>	133 000	—
	133,000	—

Pantoyltaurine was believed to act by displacing pantothenic acid from an essential enzyme system and so preventing it from functioning (see page 390), and it was hoped that a new therapeutic agent, equal in importance to the sulphonamides, might have resulted. In fact, this hope was not realised, and neither pantoyltaurine nor its many derivatives (page 397) appear to be capable of inhibiting the growth *in vivo* of organisms that it readily inhibits *in vitro*. The reason for this is that in most instances pantothenic acid present in the blood of the host, and there is then insufficient "free" pantoyltaurine left over to inhibit the growth of the invading organism.

Only by selecting a test animal which had a relatively low concentration of pantothenic acid in the blood was a therapeutic effect observed, and it was found that, whereas mice infected with a haemolytic streptococcus died however much pantoyltaurine was administered, rats could be protected by giving frequent massive doses of the inhibitor.<sup>21</sup> Under these conditions the ratio of pantoyltaurine to pantothenic acid was kept above the value required for *in vitro* activity. When the blood pantothenic acid concentration was artificially increased however, pantoyltaurine ceased to be effective.

Since human blood contains a somewhat lower concentration of pantothenic acid than rat blood, it is possible that pantoyltaurine might be effective in humans, but the response would not be likely to be dramatic and the dose would have to be very large. Pantoyltaurine had no trypanocidal or antimalarial activity in experimental animals. In spite of the fact that pantoyltaurine is of no practical therapeutic importance, it has been responsible for throwing much new light on chemotherapy and on the phenomenon of drug resistance and probably more is known about the mode of action of pantoyltaurine than of any other chemotherapeutic substance, thanks mainly to the work of H. McIlwain.

### Pantoyltaurine Resistance

Sulphonamide resistant streptococci are sensitive to pantoyltaurine<sup>21</sup> whilst pantoyltaurine-resistant strains, produced by repeated subculturing of the organisms in presence of the inhibitor, were as susceptible to sulphanilamide as were normal strains,<sup>22</sup> showing that cross resistance does not necessarily develop to different chemotherapeutic agents. The variable resistance to pantoyltaurine of different natural and experimentally produced strains of *C. diphtheriae* was correlated with their ability to grow with  $\beta$  alanine in place of pantothenic acid. Resistant strains synthesised pantothenic acid during growth, and the ability to perform this synthesis is believed to explain their resistance.

The resistance developed by *Str. haemolyticus* however, appeared to be due to a different mechanism, as many of the naturally resistant and all the experimentally produced resistant strains, needed pantothenic acid during growth. The pantoyltaurine fast streptococci and some pantoyltaurine insensitive strains were made susceptible to pantoyltaurine by the addition of salicylic acid suggesting that pantoyltaurine resistant streptococci possessed metabolic processes alternative to those affected by pantoyltaurine and inhibited by salicylic acid.

A connection between the specific antibacterial action of salicylic acid on *Staphylococcus aureus* and pantothenic acid had been established earlier by G. Ivanovics<sup>23</sup> who showed that this antibacterial action could be neutralised by small amounts of pantothenic acid or pantolactone, but not by  $\beta$  alanine. The degree of inhibition was proportional to the pantothenic acid concentration. With *Proteus morganii*, inhibition of growth by salicylic acid was similarly neutralised by pantothenic acid but in this instance the degree of inhibition was independent of the amount of pantothenic acid. *Pr. morganii*, unlike *Staph. aureus*, cannot synthesise pantothenic acid or pantoic acid. Several amino acids were able to antagonise the effect of salicylic acid, the most effective being methionine. Thus the specific antibacterial effect of salicylic acid appears to be associated with the inhibition of an enzymic process for synthesising pantoic acid. This is supported by the observation<sup>24</sup> that pantoic acid was nine times as effective as pantolactone in antagonising the inhibitory action of salicylic acid on *E. coli* which suggests moreover, that pantoic acid rather than pantolactone, is the precursor of pantothenic acid.

It seems evident, therefore, that pantoyltaurine and salicylic acid each block a different route to pantothenic acid synthesis or utilisation.

There also appears to be a connection between the antibacterial action of sulphapyridine and pantothenic acid for it has been observed

that <sup>25</sup> in rats on a diet low in caseinogen, administration of sulphapyridine produced retardation of growth and other symptoms of pantothenic acid deficiency, which were relieved by giving pantothenic acid. This result might, of course, have been due to an inhibitory effect of sulphapyridine on the bacterial flora which under normal circumstances may supply part of the normal pantothenic acid requirements of the animal, but West *et al* <sup>26</sup> suggested that sulphapyridine antagonised pantothenic acid directly, making it unavailable, not only for the host, thereby leading to the onset of symptoms of pantothenic acid deficiency, but also for the invading bacteria. Sulphapyridine may constitute a third method of blocking one of the routes by which pantothenic acid is synthesised or utilised.

### Mechanism of the Inhibitory Action of Pantoyltaurine

Haemolytic streptococci grown in presence of adequate amounts of pantothenic acid exhibited a short lag phase, then a well marked logarithmic phase, during which growth rate was optimal and finally, a stationary phase which was reached in three to four hours. Reduction of the pantothenic acid concentration to sub optimal levels had little effect on the duration of the lag phase or on the rate of growth but reduced the stationary population. The addition of pantoyltaurine had quite a different effect. In presence of excess pantothenic acid pantoyltaurine had no effect on the stationary population, but increased the lag period and reduced the rate of growth in the first half of the logarithmic phase, though not to any considerable extent the growth rate in the second half. Thus pantothenic acid appeared to lead to the formation of substances necessary for normal growth and the action of pantoyltaurine was to reduce the formation of these substances so that the rate of growth was limited <sup>27</sup>. Furthermore, pantothenic acid was found to disappear from streptococcal cultures the disappearance being independent of the growth or viability of the organism, but associated with glycolysis, for when glycolysis was prevented, pantothenic acid metabolism ceased. Addition of pantoyltaurine however inhibited pantothenic acid metabolism without a corresponding inhibition of glycolysis. These facts are understandable if it is assumed that both glycolysis and the presence of excess pantothenic acid are necessary for the formation of a substance essential for streptococcal growth, and that pantoyltaurine interfered with the metabolism of pantothenic acid, but not with the energy yielding process of glycolysis <sup>14</sup>. The nature of the substance formed by pantothenic acid is discussed in a later section (page 390).

Six other compounds (see page 398) which inhibited growth and which, like pantoyltaurine, were antagonised by pantothenic acid,

were also found to inhibit pantothenic acid metabolism whilst other related compounds did not some of these did not inhibit growth whilst others although they inhibited growth were unaffected by pantothenic acid Pantoyltaurine and the six other compounds that inhibited pantothenic acid metabolism showed wide variations in the concentrations necessary to produce inhibition but in every instance their ability to inhibit metabolism paralleled their ability to inhibit growth Similarly the concentrations of pantoyltaurine required to inhibit growth and pantothenic acid metabolism in five different micro-organisms ran parallel These observations lend further support to the view that inhibition of pantothenic acid metabolism is responsible for the effect of pantoyltaurine (and related compounds) on growth<sup>28</sup> Although low concentrations of pantoyltaurine delayed the growth of haemolytic streptococci even relatively high concentrations had no immediate effect when added to growing cultures there was a lag of an hour or more The action of pantothenic acid in antagonising inhibition by pantoyltaurine was also a delayed one Pantothenic acid metabolism however was inhibited immediately by pantoyltaurine both in streptococci and in *C. diphtheriae* and the process started again immediately the pantoyltaurine was withdrawn The metabolism of pantothenic acid normally took place in considerable excess of the needs of the organisms and during the latent period they probably utilised materials previously made in excess This was confirmed by the observation that when pantoyltaurine was added in a concentration sufficient to inhibit pantothenic acid metabolism but not to inhibit growth growth ceased almost immediately on addition of further pantoyltaurine<sup>29</sup>

By studying the effect of various reagents on the pantothenic acid content of two strains of  $\beta$  haemolytic streptococci H McIlwain<sup>30</sup> showed that the bacterial cells normally contained 15 to 50  $\mu\text{mol}$  of firmly bound pantothenic acid per g of dry matter This could only be removed by autolysis or enzymic digestion whereas loosely combined pantothenic acid was readily removed by washing with saline at 37° C Pantoyltaurine did not remove the firmly bound protein and similarly sulphanilamide did not release firmly bound *p* aminobenzoic acid from the cells McIlwain therefore suggested that pantoyltaurine and sulphanilamide act as bacteriostatic agents by preventing the binding by susceptible bacteria of pantothenic acid and *p* aminobenzoic acid respectively in a form in which they can function inside the cell

### Moulds

Pantothenic acid stimulated the growth of *Penicillium digitatum*<sup>31</sup> but *P. chrysogenum* synthesised pantothenic acid the culture fluid

containing ten times as much as the basal medium <sup>32</sup> *Aspergillus niger*, *Penicillium wolkmanni*, two unnamed species of *Penicillium*, *Rhizopus sinensis* and *Rh. nigrans* also synthesised pantothenic acid <sup>33</sup>

One strain of *Neurospora* produced considerable amounts of pantothenic acid in presence of pantolactone and  $\beta$  alanine, and very little in their absence, whilst another strain, differing from it by a single gene, produced no pantothenic acid in either instance <sup>33a</sup>

## Yeasts

Pantothenic acid was essential for the growth of a number of yeasts, including *Candida pseudotropicalis*, *Mycoderma valida*, *Saccharomyces cerevisiae*, *S. cerevisiae* var *ellipsoideus*, *S. chodatii*, *S. fragilis*, *S. logoi*, *S. macedoniensis*, *S. oviformis*, *S. tubiformis*, *Saccharomycodes ludwigii*, *Schizosaccharomyces pombe*, *Zygosaccharomyces barkeri*, *Z. mandshuricus*, *Z. nadsoni*, *Z. pastori*, *Z. priorianus*, *Z. felsineus*, *Z. marxianus*, *Z. variabilis*, *Z. japonicus*, *Torulopsis sphaerica*, *Saccharomyces chevalieri*, *S. behrensianus*, *S. anomalus belgicus*, *S. bacillaris*, *S. exiguus*, *Torula thermantitaneum*, *T. colliculosa*, *T. cremoris* and *Kloeckera brevis* <sup>34, 35</sup>

The growth of a strain of *S. cerevisiae* was stimulated by an amount of pantoic acid equal to 600 times that required to combine with the  $\beta$  alanine present when suboptimal amounts of the latter were employed <sup>36</sup> No stimulation occurred when the acid was added after an interim period. Pantoic acid appeared to have a stimulative action of its own, which could be demonstrated in presence of pantothenic acid or of optimal amounts of  $\beta$  alanine. Pantolactone had no such effect. The effect of pantoyltaurine on the Gebruder-Mayer strain of *S. cerevisiae*, which gives good growth only in the presence of pantothenic acid or  $\beta$  alanine, was tested by E. E. Snell <sup>17</sup> He found, as with *L. arabinosus* and other exacting bacteria, that pantoyltaurine inhibited growth induced by pantothenic acid, and that the inhibition was reversed by additional pantothenic acid. Growth induced by  $\beta$  alanine was not inhibited by pantoyltaurine, nor was it affected by taurine.

In presence of an excess of pantothenic acid, yeast cells utilise it but do not synthesise additional amounts. At lower concentrations the amount of growth is proportional to the pantothenic acid concentration, whilst at still lower concentrations mutants capable of synthesising the vitamin are produced <sup>36a</sup>

## Other Micro-organisms

Addition of calcium pantothenate to a diet low in aneurine, riboflavin and pantothenic acid increased the number of oocysts eliminated by rats infected with *Eimeria nieschulzi*. The further addition

of pyridoxine caused a still further increase in the number of oocysts excreted<sup>37</sup>

### Biosynthesis of Pantothenic Acid

Both halves of the pantothenic acid molecule function as growth factors,  $\beta$  alanine for some strains of *Corynebacterium diphtheriae*<sup>4</sup> and pantoic acid for *Acetobacter suboxydans*<sup>38</sup> and *Clostridium septicum*<sup>39</sup>. These organisms synthesise pantothenic acid by coupling  $\beta$  alanine with pantoic acid for the culture solution stimulated the growth of *L. helveticus* which does not respond to either half of the molecule<sup>39</sup>. According to T. Wieland and E. F. Möller,<sup>40</sup> yeast frozen in liquid air and subjected to dialysis with aeration had a diminished capacity for synthesising pantothenic acid from  $\beta$  alanine and pantolactone. The ammonium ion and probably the carbonate and acetate ions activated the synthesis and the ammonium ion also catalysed the synthesis of pantothenic acid from  $\beta$  alanine and pantamide.

From what has been said above it is evident that many antagonists of pantothenic acid owe their effect to interference with the synthesis of pantothenic acid from pantoic acid and  $\beta$  alanine although pantoyl-tyrosine acts by interfering with the utilisation of pantothenic acid to form substances essential for the growth of the bacterial cell. The nature of the substance produced by the metabolism of pantothenic acid is discussed below (page 390).

Salicylic acid owes its antibacterial action to its ability to interfere with the synthesis of pantoic acid<sup>22, 23, 39</sup> whilst other antagonists, for example  $\alpha$  and  $\gamma$  hydroxy  $\beta\beta$  dimethylbutyric acid and  $\beta\gamma$ -dihydroxy  $\beta$  methylbutyric acid apparently prevent the coupling of  $\beta$  alanine with pantoic acid<sup>38</sup>. Another growth inhibitor cysteic acid acts by interfering with the formation of  $\beta$  alanine by the decarboxylation of aspartic acid<sup>41</sup>. In *E. coli*, pantothenic acid and  $\beta$  alanine completely prevented the toxic effects of cysteic acid, and the rate of synthesis of pantothenic acid was determined by the ratio of cysteic acid to aspartic acid. Glutamic acid was three times as effective as aspartic acid in preventing the toxic effects of cysteic acid owing to its conversion by transamination into  $\alpha$  ketoglutaric acid which had a 'sparing action' on pantothenic acid that is it permitted the cells to grow at a lower rate of pantothenic acid synthesis, citric acid and *cis* aconitic acid had a similar effect but oxaloacetic and pyruvic acid the precursors of *cis* aconitic acid were inactive<sup>42</sup>. Glutamic acid also enhanced the growth of *S. cerevisiae* and *S. carlsbergensis* in presence of suboptimal amounts of pantothenic acid, the 'sparing action' in this instance is attributed to the combination of glutamic acid with pantothenic acid or  $\beta$  alanine to give a substance which had greater growth promoting activity<sup>43</sup>.

Pantothenic acid also prevented the toxic action of 2-chloro 4 aminobenzoic acid on *E coli*, being even more effective than *p* amino benzoic acid. At high levels of the inhibitor antagonism was more complete when methionine as well as pantothenic acid was present<sup>44</sup>. It is not known what stage of pantothenic acid synthesis is affected by 2 chloro 4 aminobenzoic acid.

## References to Section 14

- 1 L Rane and Y SubbaRow *J Biol Chem* 1940 **134**, 455
- 2 J H Mueller and P A Miller *ibid* 1941 **140**, 933
- 3 J T Tamura A A Tytell M J Boyd and M A Logan *J Bact* 1941 **42**, 148
- 4 J H Mueller and A W Klotz *J Amer Chem Soc* 1938 **60**, 3086  
W C Evans W R C Handley and F C Happold  
*Brit J Exp Path* 1939 **20**, 396
- 5 S Berkman F Saunders and S A Koser *Proc Soc Exp Biol Med* 1940 **44**, 68
- 6 S A Koser B B Breslove and A Dorfman *J Infect Dis* 1941 **69**, 114
- 7 E F Moller *Angew Chem* 1940 **53**, 204
- 8 R C Thompson *J Bact* 1943 **48**, 99
- 9 A J Weil and J Black *Proc Soc Exp Biol Med* 1944 **55**, 24
- 10 V H Cheldelin E H Hoag and H P Sarett *J Bact* 1945 **49**, 41
- 11 C Lamanna and C Lewis *ibid* 1946 **51**, 398
- 12 H McIlwain *Nature* 1946 **158**, 898
- 13 H McIlwain *Biochem J*, 1946 **40**, 269
- 14 H McIlwain and D E Hughes *ibid* 1944 **38**, 187
- 15 G M Hills *ibid* 1943 **37**, 418
- 16 A Dorfman S Berkman and S A Koser *J Biol Chem* 1942 **144**, 393
- 17 E E Snell *ibid* 1941 **139**, 975 1941 **141**, 121
- 18 R Kuhn T Wieland and E F Moller *Ber* 1941 **74**, 1605
- 19 J W Barnett and F A Robinson *Biochem J* 1942 **38**, 364
- 20 H McIlwain *ibid* 417
- 21 H McIlwain and F Hawking *Lancet* 1943 **1**, 449
- 22 H McIlwain *Brit J Exp Path* 1943 **24**, 203
- 23 G Ivanovics *Z physiol Chem* 1942 **276**, 33
- 24 P G Stansly and M E Schlosser *J Biol Chem* 1945 **161**, 513
- 25 H D West N C Jefferson and R E Rivera *J Nutrition* 1943 **25**, 471
- 26 H D West M J Bent R E Rivera and R E Tisdale *Arch Biochem* 1944 **3**, 321
- 27 H McIlwain *Biochem J* 1944 **38**, 97
- 28 H McIlwain and D E Hughes *ibid* 1945 **39**, 133
- 29 H McIlwain *ibid* 279
- 30 H McIlwain *ibid* 329
- 31 R C Wooster and V H Cheldelin *Arch Biochem* 1945 **8**, 311

## REQUIREMENTS OF INSECTS

- 32 F W Tanner S E Pfeiffer and J M van Lanen *ibid* 29
- 33 N Nielsen and V Hartelius *Compt rend Trav Lab Carlsberg Sér Physiol* 1945 24, 117
- 33a R W Wagner and B M Guirard *Proc Nat Acad Sci* 1948 34 398
- 34 P R Burkholder *Amer J Bot* 1943 30, 206 P R Burkholder and D Moyer *Bull Torrey Bot Club* 1943 70, 372 *J Bact* 1944 48, 385
- 35 A S Schultz and L Atkin *Arch Biochem* 1947 14, 369
- 36 V Hartelius and G Johansen *Compt rend Trav Lab Carlsberg Sér Physiol* 1946 24, 133
- 36a C C Lindegren and C Rant *Ann Missouri Bot Gard* 1947 34 85
- 37 E R Becker and L Smith *Iowa State Coll J Sci* 1942 16 443
- 38 V H Cheldelin and C A Schink *J Amer Chem Soc* 1947 69, 2625
- 39 F J Ryan R Ballentine E Stolovy M E Corson and L K Schneider *ibid* 1945 67, 1857 F J Ryan L K Schneider and R Ballentine *J Bact* 1947 53, 417
- 40 T Wieland and E F Möller *Z physiol Chem* 1942 272 232
- 41 J M Ravel and W Shive *J Biol Chem* 1946 166, 407
- 42 W Shive W W Ackermann J M Ravel and J E Sutherland *J Amer Chem Soc* 1947 69, 2567
- 43 T E King and V H Cheldelin *Arch Biochem* 1948 16, 231
- 44 T E King R L Stearman and V H Cheldelin *J Amer Soc* 1948 70 3969

## 15 EFFECT OF PANTOTHENIC ACID ON HIGHER PLANTS

According to E F Pratt and R J Williams<sup>1</sup> pantothenic acid concentrates influenced the metabolism of plant tissues P R Burkholder<sup>2</sup> reported that the amount of pantothenic acid as well as of other vitamins increased during the germination of oats wheat barley and maize

### References to Section 15

- 1 E F Pratt and R J Williams *J Gen Physiol* 1939 22, 637
- 2 P R Burkholder *Science* 1943 97, 562

## 16 PANTOTHENIC ACID REQUIREMENTS OF INSECTS

Pantothenic acid is an essential vitamin for the fruit fly *Drosophila melanogaster*<sup>1</sup> for the larvae of the mealworm *Tenebrio molitor*<sup>2</sup> for mosquito larvae<sup>3</sup> for the beetles *Tribolium confusum*<sup>4</sup> and *Ptinus tectus*<sup>4</sup> and the moth *Ephestia elutella*<sup>4</sup> *Silanus surinamensis*



*Sitodrepa panicea* and *Lasioderma serricorne*, however, grew normally in the absence of the vitamin B complex<sup>4</sup> but if the larvae were grown under sterile conditions the addition of vitamin B complex including pantothenic acid to the diet was essential for the development of the insects. It was concluded from this that intracellular symbiotic micro organisms supplied the vitamin B complex requirements of these insects under ordinary conditions.

In common with other members of the vitamin B complex pantothenic acid must be present in the diet of the mosquito *Aedes aegypti* to permit larval growth to the fourth instar<sup>5</sup>.

Reference has already been made (page 364) to the relatively large amounts of pantothenic acid (and biotin) in royal jelly, the food on which bee larvae destined to become queens are reared and which is apparently the only factor that determines whether larvae are to become workers or queens. This amazing property of royal jelly is not due solely to its high content of pantothenic acid or biotin because the addition of pantothenic acid to the normal food of the larvae did not bring about the metamorphosis effected by royal jelly.

#### References to Section 16

- 1 E L Tatum *Proc Nat Acad Sci* 1941 **27**, 193
- 2 H E Martin and L Hare *Biol Bull Woods Hole* 1942 **83**, 428
- 3 Y SubbaRow and W Trager *J Gen Physiol* 1940 **23**, 561
- 4 G Fraenkel and M Blewett *Nature* 1943 **151**, 703 1943 **152**, 506, *Biochem J* 1943 **37**, 686, M Blewett and G Fraenkel *Proc Roy Soc B* 1944 **132**, 212
- 5 L Golberg B de Meillon and M Lavoipierre *J Exp Biol* 1945 **21**, 90

### 17. FUNCTION OF PANTOTHENIC ACID

Some light was thrown on the function of pantothenic acid in bacteria by the researches on pantoyltaurine and other antagonists already referred to (page 381). The conclusion drawn by H McIlwain from this work was that pantoyltaurine interfered with the metabolism of pantothenic acid and thus impeded the formation of a substance or substances essential for normal growth. Glycolysis was also essential for the formation of this substance but pantothenic acid did not play any part in this energy yielding process. That pantothenic acid did not affect the fermentation of glucose was observed by G M Hills<sup>1</sup> and by P C Teague and R J Williams<sup>2</sup>. The latter workers also showed that it had no effect on the rate of phosphorylation of glucose on the rate of decarboxylation of pyruvic acid by yeast juice or on the oxygen consumption of homogenised chick tissues during

the utilisation of glucose, and they concluded that pantothenic acid was not a dissociable coenzyme for the glycolytic systems investigated.

Dorfman *et al.*<sup>3</sup> found that calcium pantothenate increased the oxygen uptake of *Proteus morganii* when lactic or pyruvic acid was used as substrate, and concluded that pantothenic acid played a part in the oxidation of pyruvic to acetic acid. G. M. Hills<sup>1</sup> made a similar observation. These results were supported by the work of Pilgrim *et al.*,<sup>4</sup> who found that the oxidation of pyruvic acid by liver tissue was retarded by a deficiency of pantothenic acid and biotin.

M. G. Sevag and M. N. Green<sup>5</sup> suggested a different rôle for pantothenic acid, for they obtained evidence that it was in some way connected with the metabolism of tryptophan. *Staphylococcus aureus* required tryptophan for growth, but this could be replaced by pantothenic acid if glucose were also present. Moreover, the growth of *S. aureus* was inhibited by sulphonamides in presence of glucose and most amino acids, whether pantothenic acid was absent or not. The inhibition was abolished, however, when tryptophan was added. They interpreted this result to mean that sulphonamides inhibited the reactions leading to the synthesis of tryptophan and that pantothenic acid played a part in these reactions. So far, this suggestion has not received support from the work of other investigators.

A more satisfactory explanation of the function of pantothenic acid is that of Lipmann *et al.*,<sup>6</sup> who postulated that pantothenic acid was the prosthetic group of a coenzyme necessary for acetylation. F. Lipmann<sup>7</sup> had previously isolated from liver a coenzyme that catalysed the acetylation of aromatic amines and had shown<sup>8</sup> that it also acetylated choline and was apparently identical with the activator of choline acetylation reported by W. Feldberg and T. Mann,<sup>9</sup> D. Nachumansohn and M. Berman,<sup>10</sup> and M. A. Lipton.<sup>11</sup> A purified preparation of this coenzyme, known as "Coenzyme A", was found to contain about 10 % of pantothenic acid, and the activity of different preparations was found to run parallel with their pantothenic acid contents. This theory is consistent with the observation of G. M. Hills<sup>1</sup> and Dorfman *et al.*<sup>3</sup> that pantothenic acid takes part in the oxidation of pyruvic acid to acetic acid, for G. D. Novelli and F. Lipmann<sup>12</sup> showed that the increased oxidation of pyruvic acid that occurred when pantothenic acid was added to pantothenic acid-deficient organisms was due to the synthesis of coenzyme A. In *L. arabinosus*, 90 % of the pantothenic acid could be accounted for as coenzyme A, which was present in negligible amounts in pantothenic acid-deficient organisms. The addition of pantothenic acid to the culture medium increased the rate of synthesis of coenzyme A and, consequently, the rate of pyruvic acid oxidation. Pantothenic acid increased acetylcholine formation by *Lactobacillus plantarum*.<sup>13</sup>

## PANTOTHENIC ACID

By using two cultures of yeast, one rich and one poor in coenzyme A, G D Novell and F Lipmann<sup>13</sup> demonstrated that the coenzyme was concerned with the primary attack on acetate since this disappeared from solution twice as rapidly with the high coenzyme yeast as with the low, and when ethanol was used as substrate acetate accumulated in the solution with the low coenzyme yeast but not with the yeast rich in coenzyme A

A method of assaying coenzyme A, based on the observation that when pigeon liver extract undergoes autolysis it loses its ability to acetylate sulphanilamide, was used to determine the distribution of the coenzyme in nature, reactivation of the extract was proportional to the coenzyme A concentration<sup>14</sup> It was found to be a general constituent of living organisms liver, *Clostridium butylicum* and *Proteus morgani* were especially rich sources Coenzyme A was as active as free pantothenic acid when given intraperitoneally to chicks but by the oral route it had only 60 % of the activity<sup>15</sup> Whereas normal rats acetylated 70 % of the *p* aminobenzoic acid excreted following the injection of a 1- or 2.5 mg dose pantothenic acid deficient rats excreted only 50 and 37 % respectively, the simultaneous injection of 1 mg of calcium pantothenate increased the acetylation to normal<sup>16</sup>

Administration of pantothenic acid failed to increase the acetylation of *p* aminobenzoic acid in diabetic rats although normal values were obtained after injection of insulin adenosine triphosphate acetyl phosphate diacetyl or dicarboxylic acids of the tricarboxylic acid cycle<sup>17</sup> It is suggested that insulin may promote the reaction between pyruvic acid and the tricarboxylic acid cycle a suggestion not inconsistent with the view that pantothenic acid is associated with the conversion of pyruvic acid into acetic acid

Preparations of coenzyme A made from pigeon liver extracts acetylated acetic acid (giving acetoacetic acid) and sulphanilamide<sup>18</sup> whilst pantothenic acid deficient rats excreted much less sulphanilamide in the acetylated form than did controls<sup>19</sup>

The coenzyme A content of rats maintained on a pantothenic acid deficient diet remained normal for two to three weeks and then fell to a level 35 to 50 % that of normal Ducklings showed a more rapid depletion and the injection of pantothenic acid restored the value to normal<sup>20</sup> Liver slices from pantothenic acid deficient rats or ducks showed a decreased ability to utilise pyruvic acid All the pantothenic acid can be liberated from coenzyme A and made available for microbiological assay by incubation with a mixture of intestinal phosphatase and fresh pigeon liver extract assays confirmed the earlier observation that most if not all the pantothenic acid in living cells is bound in the form of coenzyme A<sup>21</sup> Coenzyme A stimulated

the growth of *A. suboxydans* the response being greater than that produced by an equivalent amount of pantothenic acid<sup>22</sup> By incubating  $\beta$  alanine or pantothenic acid with glutamic acid in presence of resting cells a product was obtained with up to 1000 times the activity of  $\beta$  alanine or pantothenic acid on yeast but this result could not always be obtained the product being sometimes quite inactive A conjugate of pantothenic acid isolated from pork heart was twice as active as pantothenic acid on *A. suboxydans* but appeared to differ from coenzyme A<sup>23</sup>

### References to Section 17

- 1 G M Hills *Biochem J* 1943 **37**, 418
- 2 P C Teague and R J Williams *J Gen Physiol* 1942 **25**, 777
- 3 A Dorfman S Berkman and S A Koser *J Biol Chem* 1942 **144** 393
- 4 F J Pilgrim A E Axelrod and C A Elvehjem *ibid* 1942 **145**, 237
- 5 M G Sevag and M N Green *ibid* 1944 **154**, 719 *J Bact* 1944 **48**, 631 *Amer J Med Sci* 1944 **207**, 686
- 6 F Lipmann N O Kaplan G D Novelli L C Tuttle and B M Gurard, *J Biol Chem* 1947 **167**, 869
- 7 F Lipmann *Fed Proc* 1945 **4**, 97 *J Biol Chem* 1945 **160**, 173
- 8 F Lipmann and N O Kaplan *ibid* 1946 **162**, 743
- 9 W Feldberg and T Mann *J Physiol* 1946 **104** 411
- 10 D Nachmansohn and M Berman *J Biol Chem* 1946 **165**, 551
- 11 M A Lipton *Fed Proc* 1946 **5**, 145
- 12 G D Novelli and F Lipmann *J Bact* 1947 **54**, 19 *Arch Biochem* 1947 **14** 23
- 12a E Rowett *J Gen Microbiol* 1948 **2** 25
- 13 G D Novelli and F Lipmann *J Biol Chem* 1947 **171**, 833
- 14 N O Kaplan and F Lipmann *ibid* 1948 **174**, 37
- 15 D M Hegsted and F Lipmann *ibid* 89
- 16 T R Ruggs and D M Hegsted *ibid* 1948 **172**, 539, 1949 **178**, 669
- 17 F C Charalampous and D M Hegsted *ibid* 1949 **180**, 623
- 18 M Soodak and F Lipmann *ibid* 1948 **175** 999
- 19 M E Shils H M Seligman and L J Goldwater *J Nutrition* 1949 **37** 227
- 20 R E Olson and N O Kaplan *J Biol Chem* 1948 **175** 515
- 21 G D Novelli N O Kaplan and F Lipmann *ibid* 1949 **177**, 97
- 22 G D Novelli R M Flynn and F Lipmann *ibid* 493
- 23 T E King L M Locher and V H Cheldelin *Arch Biochem* 1948 **17**, 483 T E King I G Fels and V H Cheldelin *J Amer Chem Soc* 1949 **71**, 131

## PANTOTHENIC ACID

By using two cultures of yeast, one rich and one poor in coenzyme A G D Novelli and F Lipmann<sup>13</sup> demonstrated that the coenzyme was concerned with the primary attack on acetate since this disappeared from solution twice as rapidly with the high coenzyme yeast as with the low and when ethanol was used as substrate acetate accumulated in the solution with the low coenzyme yeast but not with the yeast rich in coenzyme A

A method of assaying coenzyme A based on the observation that when pigeon liver extract undergoes autolysis it loses its ability to acetylate sulphanilamide was used to determine the distribution of the coenzyme in nature, reactivation of the extract was proportional to the coenzyme A concentration<sup>14</sup> It was found to be a general constituent of living organisms liver *Clostridium butylicum* and *Proteus morganii* were especially rich sources Coenzyme A was as active as free pantothenic acid when given intraperitoneally to chicks but by the oral route it had only 60 % of the activity<sup>15</sup> Whereas normal rats acetylated 70 % of the *p* aminobenzoic acid excreted following the injection of a 1 or 2.5 mg dose pantothenic acid deficient rats excreted only 50 and 37 % respectively, the simultaneous injection of 1 mg of calcium pantothenate increased the acetylation to normal<sup>16</sup>

Administration of pantothenic acid failed to increase the acetylation of *p* aminobenzoic acid in diabetic rats although normal values were obtained after injection of insulin adenosine triphosphate acetyl phosphate diacetyl or dicarboxylic acids of the tricarboxylic acid cycle<sup>17</sup> It is suggested that insulin may promote the reaction between pyruvic acid and the tricarboxylic acid cycle a suggestion not inconsistent with the view that pantothenic acid is associated with the conversion of pyruvic acid into acetic acid

Preparations of coenzyme A made from pigeon liver extracts acetylated acetic acid (giving acetoacetic acid) and sulphanilamide<sup>18</sup> whilst pantothenic acid deficient rats excreted much less sulphanilamide in the acetylated form than did controls<sup>19</sup>

The coenzyme A content of rats maintained on a pantothenic acid deficient diet remained normal for two to three weeks and then fell to a level 35 to 50 % that of normal Ducklings showed a more rapid depletion and the injection of pantothenic acid restored the value to normal<sup>20</sup> Liver slices from pantothenic acid deficient rats or ducks showed a decreased ability to utilise pyruvic acid All the pantothenic acid can be liberated from coenzyme A and made available for microbiological assay by incubation with a mixture of intestinal phosphatase and fresh pigeon liver extract assays confirmed the earlier observation that most if not all the pantothenic acid in living cells is bound in the form of coenzyme A<sup>21</sup> Coenzyme A stimulated

the growth of *A. suboxydans* the response being greater than that produced by an equivalent amount of pantothenic acid<sup>22</sup>. By incubating  $\beta$  alanine or pantothenic acid with glutamic acid in presence of resting cells a product was obtained with up to 1000 times the activity of  $\beta$  alanine or pantothenic acid on yeast but this result could not always be obtained the product being sometimes quite inactive. A conjugate of pantothenic acid isolated from pork heart was twice as active as pantothenic acid on *A. suboxydans* but appeared to differ from coenzyme A<sup>23</sup>.

# References to Section 17

- 1 G M Hills *Biochem J* 1943 **37**, 418
- 2 P C Teague and R J Williams *J Gen Physiol* 1942 **25**, 777
- 3 A Dorfman S Berkman and S A Koser *J Biol Chem* 1942 **144**, 393
- 4 F J Pilgrim A E Axelrod and C A Elvehjem *ibid* 1942 **145**, 237
- 5 M G Sevag and M N Green *ibid* 1944 **154**, 719 *J Bact* 1944 **48**, 631 *Amer J Med Sci* 1944 **207**, 686
- 6 F Lipmann N O Kaplan G D Novelli L C Tuttle and B M Guirard *J Biol Chem* 1947 **167**, 869
- 7 F Lipmann *Fed Proc* 1945 **4**, 97 *J Biol Chem* 1945 **160**, 173
- 8 F Lipmann and N O Kaplan *ibid* 1946 **162**, 743
- 9 W Feldberg and T Mann *J Physiol* 1946 **104**, 411
- 10 D Nachmansohn and M Berman *J Biol Chem* 1946 **165**, 551
- 11 M A Lipton *Fed Proc* 1946 **5**, 145
- 12 G D Novelli and F Lipmann *J Bact* 1947 **54**, 19 *Arch Biochem* 1947 **14**, 23
- 12a E Rowett *J Gen Microbiol* 1948 **2**, 25
- 13 G D Novelli and F Lipmann *J Biol Chem* 1947 **171**, 833
- 14 N O Kaplan and F Lipmann *ibid* 1948 **174**, 37
- 15 D M Hegsted and F Lipmann *ibid* 89
- 16 T R Riggs and D M Hegsted *ibid* 1948 **172**, 539, 1949 **178**, 669
- 17 F C Charalampous and D M Hegsted *ibid* 1949 **180**, 623
- 18 M Soodak and F Lipmann *ibid* 1948 **175**, 999
- 19 M E Shils H M Seligman and L J Goldwater *J Nutrition* 1949 **37**, 227
- 20 R E Olson and N O Kaplan *J Biol Chem* 1948 **175**, 515
- 21 G D Novelli N O Kaplan and F Lipmann *ibid* 1949 **177**, 97
- 22 G D Novelli R M Flynn and F Lipmann *ibid* 493
- 23 T E King L M Locher and V H Cheldelin *Arch Biochem* 1948 **17**, 483 T E King I G Fels and V H Cheldelin *J Amer Chem Soc* 1949 **71**, 131

## 18 PANTOTHENIC ACID ANALOGUES

**Pantothenic Acid and its Derivatives**

It has already been stated (page 354) that L pantothenic acid is inactive on bacteria<sup>1</sup> rats and chicks<sup>2</sup>. Simple derivatives of D pantothenic acid generally exhibited activity when tested on rats but not on micro organisms. For example the acetate<sup>3</sup> benzoate<sup>3</sup> and di-phosphate<sup>4</sup> were active on rats but inactive on bacteria and ethyl monoacetyl pantothenate<sup>5, 6</sup> and ethyl pantothenate<sup>5, 6</sup> were as effective as an equivalent amount of calcium pantothenate in promoting the growth of pantothenic acid deficient rats and chicks but stimulated the growth of *L. helveticus* only slightly. Pantothenic acid *p* nitrobenzoate was also inactive when tested microbiologically<sup>6</sup>. Apparently the rat and presumably other mammals are able to convert such derivatives which are not available to the organism *per se* into the free vitamin.

A. L. Neal and F. M. Strong<sup>7</sup> found that pantothenic acid in liver yeast cheese and eggs was accompanied by as much as half its equivalent of an alkali stable substance utilised by *L. helveticus* with the same degree of efficiency as pantothenic acid and by chicks four times as efficiently. This substance has not been adequately characterised but it is believed to be a substitution product of pantothenic acid.

 **$\beta$ -Alanine and Related Compounds**

As has already been pointed out (page 361)  $\beta$  alanine can serve as a growth factor for certain species of yeast<sup>8, 9</sup> certain strains of *C. diphtheriae*<sup>10, 11</sup> and to a certain extent apparently for rats<sup>12, 13</sup>. Micro organisms that can thus utilise  $\beta$  alanine have been shown to convert it into pantothenic acid<sup>9, 11</sup> (page 387).

$\alpha$  Methyl  $\beta$  alanine had only 0.0006 of the activity of  $\beta$  alanine towards the Gebruder Mayer strain of bakers yeast and partially antagonised the growth promoting effect of  $\beta$  alanine<sup>14</sup>. Isoleucine and  $\beta$  aminobutyric acid also antagonised the action of  $\beta$  alanine on yeast<sup>15</sup>.

**Analogues Derived from  $\beta$ -Alanine**

Most of the analogues synthesised in the course of elucidating the structure of pantothenic acid showed less than 1 % of the activity of pantothenic acid or none at all when tested on micro organisms. These compounds included  $\alpha\delta$  dihydroxyvaleryl  $\beta$  alanine<sup>16, 17, 18</sup>  $\alpha\gamma$  dihydroxyvaleryl  $\beta$  alanine<sup>17, 18</sup>  $\alpha\gamma$ -dihydroxybutyryl  $\beta$  alanine<sup>18</sup>  $\alpha\gamma$ -di-hydroxy  $\beta$  n  
 $\beta$  alanine  
caproyl  $\beta$  alanine<sup>19</sup>

Mitchell *et al*<sup>19</sup> found only one substance the so called hydroxy

pantothenic acid ( $\alpha$  hydroxy  $\beta\beta$  bishydroxymethyl butyryl  $\beta$  alanine) with appreciable pantothenic acid activity thus had 20 % of the activity of pantothenic acid when tested on *Lactobacillus helveticus* E Zschuesche and H K Mitchell<sup>20</sup> also observed some activity in  $\alpha$  hydroxy  $\beta\beta$  bishydroxymethyl butyryl  $\beta$  alanine when tested on rats

T Reichstein and A Grüssner<sup>17</sup> reported that  $\alpha\gamma$  dihydroxyvaleryl- $\beta$  alanine and  $\alpha\delta$  dihydroxyvaleryl  $\beta$  alanine had the same activity as  $\beta$  alanine on rats but were inactive on lactic acid bacteria Mention has already been made (page 354) of the inactivity of the compound prepared by R Kuhn and T Wieland by coupling  $\beta$  alanine with the lactone  $C_{12}H_{12}O_5$

Several derivatives of  $\beta$  alanine were prepared by J W Barnett and F A Robinson<sup>21</sup> and were shown by H McIlwain<sup>22</sup> to have practically no stimulating action on the growth of *Streptococcus haemolyticus* *Staphylococcus aureus* or *Proteus morganii* The following had only  $5 \times 10^{-6}$  of the activity of pantothenic acid  $\gamma$ -hydroxy  $n$  butyryl  $\beta$  alanine  $\beta\delta$  dihydroxy- $\gamma\gamma$ -dimethylvaleryl  $\beta$  alanine ( homo pantothenic acid )  $\gamma$  hydroxy  $\beta\beta$  dimethylbutyryl  $\beta$  alanine ( de soxypantothenic acid )  $\delta$  hydroxy- $\gamma\gamma$  dimethyl  $\Delta^2$   $\beta$  pentenoyl  $\beta$  alanine ( dehydrohomopantothenic acid ) and pantoyltauramide whilst pantoyltaurine homopantoyltaurine and  $\gamma$  hydroxy  $n$  butyryl  $\beta$  alanine had no growth promoting action  $\beta$  Ethyl  $\alpha\gamma$  dihydroxy  $\beta$  methyl butyryl  $\beta$  alanine had less effect than pantothenic acid on *S. plantarum*<sup>23</sup> These results emphasise the high degree of structural specificity of pantothenic acid

Several of these compounds were found to inhibit the growth of bacteria for which pantothenic acid is an essential growth factor (see page 397)

The  $\beta$  alanides of  $\alpha$  and  $\gamma$  hydroxy  $\beta\beta$  dimethylbutyric acid and  $\beta\gamma$ -dihydroxy  $\beta$  methylbutyric acid had a slight growth stimulating activity on *Acetobacter suboxydans* *L. arabinosus* and Gebruder Mayer yeast possibly owing to hydrolysis with liberation of  $\beta$  alanine<sup>23</sup>

The ethyl ester of DL  $\alpha$  amino  $\gamma$ -hydroxy  $\beta\beta$  dimethyl butyryl  $\beta$  alanine had no pantothenic acid activity when tested on rats or *L. arabinosus*<sup>23a</sup> It has been suggested that the corresponding amino acid  $\alpha$  amino- $\gamma$  hydroxy  $\beta\beta$  dimethyl butyric acid (pantonine) is the precursor of pantoic acid in the synthesis of pantothenic acid<sup>24</sup> The keto acid corresponding to pantothenic acid namely  $\gamma$ -hydroxy- $\alpha$  keto- $\beta\beta$ -dimethyl butyryl  $\beta$  alanine likewise had no biological activity<sup>25</sup>

#### Analogues Derived from Amino Acids other than $\beta$ -Alanine

Replacement of the  $\beta$  alanine portion of pantothenic acid by other amino acids invariably leads to loss of activity Thus Weinstock *et*



## PANTOTHENIC ACID

al<sup>24</sup> found that the pantoyl derivatives of  $\alpha$  alanine,  $\beta$  aminobutyric acid, aspartic acid and lysine were inactive when tested microbiologically, although  $\beta$ -pantoylamino-butyric acid was claimed by Hoffmann-La Roche<sup>25</sup> to have pantothenic acid activity. The pantoyl derivatives of L-leucine<sup>26</sup> and of lysine, leucine, valine and taurine<sup>27</sup> were reported to have no growth promoting activity.

$\alpha$ -Methyl-pantothenic acid (N-pantoyl  $\alpha$ -methyl- $\beta$  alanine) had only 0.001 to 0.001 of the potency of pantothenic acid for stimulating growth and acid production in *L. helveticus*, *L. arabinosus* and *S. faecalis* R, and 0.002 to 0.0003 of the activity of pantothenic acid in stimulating the growth of the Gebruder-Mayer and Fleischmann strains of bakers' yeast.<sup>14</sup> It had a slight antagonistic effect towards pantothenic acid.  $\beta$ -Methyl pantothenic acid ( $\beta$  pantoylamino-butyric acid) however inhibited the growth of *Streptobacterium plantarum* (page 399) where the ratio of methyl-pantothenic acid to pantothenic acid exceeded 200:1, the growth of yeast was not affected, although respiration was greatly reduced.

Several other pantoyl-amino acids have been shown to possess inhibitory activity (see pages 398-400).

## Analogues Derived from Amino Alcohols and Amines

So far consideration has been given only to analogues of pantothenic acid that contain a free carboxyl group, that is, to pantoyl-amino acids and substances derived from them by changes in the pantoyl portion of the molecule. A large number of substances have been prepared and tested for pantothenic acid activity, however, they do not possess a free carboxyl group. The most important of these are pantothényl alcohol or panthenol.

$\text{CH}_2\text{OH}-\text{C}(\text{CH}_3)_2-\text{CHOH}-\text{CO}-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{OH}$

was prepared by H. Pfaltz<sup>28</sup> who reported that it was as effective as pantothenic acid in preventing achromotrichia in black rats. Its methyl homologue, 3-pantoylamino-butanol 2, was only slightly active however, whilst 2-pantoylaminoethanol and  $\gamma$ -pantoylbutyric acid were quite inactive. Pantothényl alcohol did not stimulate the growth of bacteria but was quite a strong inhibitor of bacterial growth (page 400). None of the other compounds derived from alcohols or amines stimulated bacterial growth and many had inhibitory properties.

In warm blooded animals panthenol was converted into pantothenic acid<sup>29</sup> more of which was excreted by humans following a dose of panthenol than after administration of the same weight of pantothenic acid.<sup>30</sup> Panthenol had 90% of the activity of pantothenic acid, gram for gram in chicks.<sup>31</sup>

Pantothenic aldehyde was only slightly active as a growth stimulant for *L. helveticus*, but had one-fifth the activity of pantothenic acid for rats.<sup>8</sup>

### Growth Inhibitors

The preparation of pantoyltaurine<sup>21, 22, 30, 31</sup> and its inhibitory action on the growth of micro-organisms have already been described (page 381). Pantoyltaurine is perhaps the best known of the growth inhibitors allied to pantothenic acid from which it differs in the replacement of the carboxyl by a sulphonic acid group. It is believed to compete with pantothenic acid for an active enzyme system of which pantothenic acid is the prosthetic group, presumably coenzyme A, and the two are able to displace one another from combination with the enzyme. The ratio of the concentration of pantoyltaurine to that of pantothenic acid necessary to inhibit bacterial growth, a ratio which H. McIlwain<sup>22</sup> has termed the 'antibacterial index', varies from 500 for *Streptococcus haemolyticus* and exacting strains of *Corynebacterium diphtheriae* to 1000 for *Diplococcus pneumoniae* and *Lactobacillus arabinosus*, 5000 for non-exacting strains of *C. diphtheriae*, 8000 for *Streptococcus faecalis* and *Propionibacterium pentosaceum* and 133 000 for *Lactobacillus pentosus* and *Leuconostoc mesenteroides*. Pantoyltauramide was considerably less effective against these organisms<sup>22</sup> its antibacterial index ranging from 2000 for *S. haemolyticus* and 2000 to 10 000 for the exacting strains of *C. diphtheriae* to 10 000 to 50 000 for *Diplococcus pneumoniae*; it failed to inhibit the other organisms tested. The antibacterial index of homopantoyltaurine<sup>21</sup> ( $\beta\delta$  dihydroxy- $\gamma\gamma$ -dimethylvaleryltaurine) was 20 000 when tested on *S. haemolyticus*.<sup>22</sup>

The above data were obtained with the aid of racemic pantoyltaurine and pantoyltauramide. E. E. Snell<sup>32</sup> tested the isomers prepared from (+)- and (-) pantolactone and found that the sulphonic acid from the (-) lactone was ten times as active as that from the (+) lactone, in spite of the fact that partial racemisation had undoubtedly occurred during the condensation. Thus growth inhibition showed the same configurational specificity as did growth promotion by pantothenic acid.

There appears to be a divergence of opinion concerning the ability of pantoyltaurine to cause symptoms of pantothenic acid deficiency in animals. According to Snell *et al.*<sup>33</sup> long-continued daily oral administration at a dose level of 200 mg per kg of bodyweight produced such symptoms in three to four weeks, but other workers failed to produce symptoms of pantothenic acid deficiency in mice,<sup>34</sup> hamsters<sup>34</sup> and rats.<sup>35</sup>

Desoxypantoyltaurine ( $\alpha$  hydroxy  $\beta\beta$ -dimethylbutyryltaurine) unlike pantoyltaurine, did not inhibit bacterial growth, nor did it

stimulate the growth of *Acetobacter suboxydans* as did pantoyltaurine which was hydrolysed liberating pantoic acid which the organism utilised<sup>23</sup>

Although pantoyltaurine was a powerful inhibitor of bacterial growth *in vitro* the results of *in vivo* tests were disappointing rats however were protected from the effects of haemolytic streptococci by giving frequent large doses (see page 382) As already explained the failure of pantoyltaurine to exert a more pronounced chemotherapeutic effect was due ultimately to the antagonistic action of the pantothenic acid present in the blood of the animals but the condition was undoubtedly aggravated by the rapid elimination of the substance in the urine this necessitated the giving of frequent injections in order to maintain the blood concentration at a sufficiently high level Attempts to prepare derivatives of pantoyltaurine that might be excreted less readily have therefore been made J W Barnett<sup>36</sup> prepared N pantoyl  $\beta$  aminoethylthiol bis (pantoyl  $\beta$  aminoethyl) monosulphide disulphide sulfoxide and sulphone which were tested on *L. arabinosus* and *Strep. haemolyticus*<sup>37</sup> None of the compounds was more active than pantoyltaurine but the disulphide and the thiol were almost equally active and their effects were reversed by pantothenic acid The antibacterial index of the disulphide and of the sulphone was 40 000 against *Strep. haemolyticus* They had no *in vivo* activity against *Strep. haemolyticus* in rats Three aryl substituted analogues of pantoyltaurine namely  $\beta$  ( $\alpha\gamma$  dihydroxy  $\beta\beta$  dimethylbutyramido)  $\alpha$  phenylethane sulphonic acid  $\beta$  ( $\alpha\gamma$  dihydroxy  $\beta\beta$  diphenylbutyramido) ethane sulphonic acid and  $\beta$  ( $\alpha$  tosyl- $\gamma$  hydroxy  $\beta\beta$  dimethylbutyramido) ethane sulphonic acid were prepared by Barnett *et al.*<sup>38</sup> but had neither *in vitro* nor *in vivo* activity

A further series of compounds some of which were tested by H McIlwain and D E Hughes<sup>37</sup> was prepared by Madinaveitia *et al.*<sup>39</sup> These were pantamide panthydrazide N ( $\beta$  diethylaminoethyl) pantamide N (5 diethylamino 2 pentyl) pantamide N pantoyl phenylalanine N pantoyl hexahydroanthranilic acid N pantoyl nipecotic acid  $\beta$  (N pantoylaminoethyl)-*p* tolylsulphone  $\beta$  (N pantoylaminoethyl) *p* aminophenyl sulphone  $\beta$  (N pantoylaminoethyl) *p* methoxyphenyl sulphone and N pantoyl-*p* anisidine In this series the pantoyl group was combined with other radicals associated with chemotherapeutic activity However the only compounds that showed striking anti bacterial activity when tested against *L. helveticus* were panthydrazide and to a smaller extent pantamide The former had no therapeutic action however on rats infected with *Strep. pyogenes* but the amide derived from 4 amino-phenyl  $\beta$  aminoethyl sulphone showed slight therapeutic activity under these conditions According to McIlwain and Hughes pant

## ANALOGUES

hydrazide and pantamide had antibacterial indices of 4000 and 20 000 respectively against *Strep haemolyticus*

As pantothenic acid is the only growth factor known to be essential for *Plasmodium* <sup>39a</sup> Mead *et al* <sup>39b</sup> tested the activity of *d* pantoyltaurine and several of its derivatives in malaria, *d* pantoyltauramide was found to be active in vivo. This observation has resulted in a large number of N substituted pantoyltauramides being made but although pantoyltauramido-4-chlorobenzene was four to sixteen times as effective as quinine in *P gallinaceum* infections in chicks none of the compounds appears to have any clinical value <sup>39c</sup>. The antimalarial effect of pantoyltauramide was neutralised by one quarter of its weight of pantothenic acid, <sup>39d</sup> and this may explain the disappointing result obtained with antimalarials of this type.

Many sulphur free analogues of pantothenic acid have been found to inhibit the growth of bacteria. Thus  $\gamma$  hydroxy *n* butyryl  $\beta$  alanine and  $\gamma$  hydroxy *n* valeryl  $\beta$  alanine were inhibitory to *S haemolyticus* and *C diphtheriae* but the effect was not reversed by pantothenic acid <sup>21, 22</sup>. They also inhibited the growth of *E coli*, *Proteus vulgaris* and *Staph aureus* which are not inhibited by pantoyltaurine and which are capable of synthesising pantothenic acid. With *E coli* the inhibitory effect was not prevented by the addition of pantothenic acid but inhibition by the hydroxybutyryl derivative was partially reversed in the case of *Pr vulgaris*. Thus inhibition by these particular compounds would appear to be of the non-competitive type but associated in some way as yet undisclosed with pantothenic acid.

As already mentioned (see page 396)  $\alpha$  and  $\beta$  methylpantothenic acid <sup>14, 15</sup> inhibited bacterial growth as did several other pantoyl amino acids. For *Streptobacterium plantarum*  $\beta$  methylpantothenic acid (pantoyl  $\beta$  aminobutyric acid) had an antibacterial index of 200 <sup>15</sup> whilst the values for other organisms were <sup>40</sup> for *Lactobacillus helveticus* 250 for *L arabinosus* 1500 for *Leuconostoc mesenteroides* 2000 and for *Lactobacillus fermenti* 5000. This last named organism is particularly resistant to pantoyltaurine and pantothenyl alcohol. Pantoyl isoserine and pantoyl  $\beta$  amino isobutyric acid were less effective the corresponding antibacterial indices being 1000 and 2500, 1000 and 2500, 1000 and 5000 and > 50 000 respectively. In some instances complete inhibition was not obtained the reason being apparently that at these high concentrations they acted as growth stimulants. A homologue of pantothenic acid *N* (2,3-dihydroxy  $\beta\beta$ -dimethylvaleryl)  $\beta$  alanine inhibited the growth of lactic acid bacteria and the inhibition was reversed by pantothenic acid <sup>41</sup>. Rather surprisingly the taurine analogue was less active than the  $\beta$  alanine derivative <sup>41a</sup>.

# PANTOTHENIC ACID

Pantothenyl alcohol N pantoylethanolamine N pantoylallylamine N pantoyl *n* propylamine N pantoylethylamine and N pantoylglycine also inhibited the growth of micro organisms for which pantothenic acid is essential and the inhibition was competitive<sup>42</sup> The antibacterial indices of pantothenyl alcohol and N pantoyl 4 amino 2 butanol the most potent of these inhibitors were<sup>41</sup> for *L. mesenteroides* 700 and 600 for *L. helveticus* 100 000 and 20 000 for *L. arabinosus* 50 000 and 10 000 and for *L. fermenti* 200 000 All compounds were tested in the racemic form but it was shown that pantothenyl alcohol derived from the (–) lactone was more active than the isomer from the (+) lactone<sup>42</sup> Growth inhibition by pantothenyl alcohol did not run parallel with pantoyltaurine inhibition and it is assumed that the modes of action of the two compounds are different

Subsequently W Shive and E E Snell<sup>43</sup> prepared and tested other pantoyl derivatives and obtained the following antibacterial indices using *Leuconostoc mesenteroides* as test organism

DL Pantothenyl alcohol	350
DL-N Pantoylethylamine	10 000
<i>n</i> propylamine	5000
<i>n</i> butylamine	750
<i>n</i> amylamine	1500
<i>n</i> heptylamine	2000
isopropylamine	25 000
isobutylamine	2500
isoamylamine	5000
sec butylamine	75 000
β methoxyethylamine	4000
β phenylethylamine	15 000
DL Pantothenonitrile	10 000
DL-Pantothenylamine	40 000

Rather different values were obtained with *L. arabinosus* and *L. helveticus* in many instances Pantoyltaurine and N pantoyl *n* butylamine also interfered with the utilisation of pantothenic acid by *Pseudomonas* spp<sup>44</sup>

D W Woolley and M L Collyer<sup>45</sup> prepared phenylpantothenone (N pantoylaminoethyl phenyl ketone) and showed that it inhibited bacterial growth and that the inhibition was reversed by pantothenic acid This compound therefore behaved like pantoyltaurine inhibition being competitive Methylpantothenone (N pantoylaminoethyl methyl ketone) exhibited growth inhibitory properties but the inhibition was not reversed by pantothenic acid

The antagonistic effect of pantothenic acid towards phenyl pantothenone was only exhibited with micro organisms for which the

## ANALOGUES

vitamin was essential. With other organisms phenylpantothenone was antagonised by amino acids with *S. cerevisiae* for instance histidine was the most active followed by glutamic acid<sup>46</sup>.

A number of pantothenic acid analogues were prepared by Rapport *et al*<sup>47</sup> and of these N-carbobenzyloxy  $\beta$ -alaninamide (+) pantoyl diethyl aspartate and sodium (+)  $\beta$ -pantoylamino  $\beta$ -4-aminophenyl propionate were tested for antimalarial activity.

Phenylpantothenone exhibited antimalarial activity, and this led Singher *et al*<sup>48</sup> to test the effect of (-)  $\alpha$ , $\gamma$ -dihydroxy  $\beta\beta$ -dimethyl N (2-phenylmercaptoethyl) butyramide on *Plasmodium*. This compound was also tested on *Trichomonas vaginalis* which requires pantothenic acid for growth. It was also tested against *T. fo* and was effective namely,

phenylethyl butyramide (+) pantoyltauryl aniside and N-2-benzylethyl  $\alpha$ , $\gamma$ -dihydroxy  $\beta\beta$ -dimethylbutyramide. None of these compounds was active in vivo in monkeys or humans.

### References to Section 18

- 1 E. T. Stiller, S. A. Harris, J. Finkelstein, J. C. Keresztesy and K. Folkers *J. Amer. Chem. Soc.* 1940 **62**, 1785.
- 2 A. Grüssner, M. Gatz, F. Richter and T. Reichstein *Helv. Chim. Acta* 1940 **23**, 1276.
- 3 D. W. Woolley, H. A. Waitsman, O. Mickelsen and C. A. Elvehjem *J. Biol. Chem.* 1938 **125**, 715.
- 4 D. W. Woolley *ibid.* 1940 **134**, 461.
- 5 K. Unna and C. W. Mushett *Amer. J. Physiol.* 1942 **135**, 267.
- 6 S. A. Harris, G. A. Boyack and K. Folkers *J. Amer. Chem. Soc.* 1941 **63**, 2662.
- 7 A. L. Neal and F. M. Strong *ibid.* 1943 **65**, 1659.
- 8 U. Schindler and D. Reichstein *Pharm. Acta Helv.* 1945 **79**.
- 9 H. H. Weinstock, H. K. Mitchell, E. F. Pratt and R. J. Williams *J. Amer. Chem. Soc.* 1939 **61**, 1421.
- 10 J. H. Mueller *Proc. Soc. Exp. Biol. Med.* 1937 **36**, 706. J. H. Mueller and A. W. Klotz *J. Amer. Chem. Soc.* 1938 **60**, 3086.
- 11 W. C. Evans, W. R. C. Handley and F. C. Happold *Brit. J. Exp. Path.* 1939 **20**, 396.
- 12 M. Hoffer and T. Reichstein *Nature* 1939 **144**, 72.
- 13 M. M. El-Sadr, H. G. Hind, T. F. Macrae, C. E. Work, B. Lythgoe and A. R. Todd *ibid.* 73.
- 14 M. A. Pollack *J. Amer. Chem. Soc.* 1943 **65**, 1335.
- 15 N. Nielsen and G. Johansen *Naturwiss.* 1943 **31**, -35.
- 16 A. Subbarow and L. Rane *J. Amer. Chem. Soc.* 1939 **61**, 1616.
- 17 T. Reichstein and A. Grüssner *Helv. Chim. Acta* 1940 **23**, 650.
- 18 H. K. Mitchell, H. H. Weinstock, E. F. Snell, S. R. Stanbery and R. J. Williams *J. Amer. Chem. Soc.* 1940 **62**, 1776.

# PANTOTHENIC ACID

- 19 H K Mitchell, E E Snell and R J Williams, *J Amer Chem Soc*, 1940 **62**, 1791
- 20 E Zschiesche and H K Mitchell *Proc Soc Exp Biol Med* 1940, **45**, 565
- 21 J W Barnett and F. A Robinson, *Biochem J*, 1942, **38**, 357, 364
- 22 H McIlwain *ibid* 417
- 22a T. Wieland and E F. Möller, *Chem Ber*, 1948, **81**, 316
- 23 V H Cheldelin and C A Schink *J Amer Chem Soc*, 1947 **69**, 2625
- 23a F W Holly, R A Barnes, F R Koniousky and K Folkers *ibid*, 1948, **70**, 3088
- 23b W W Ackermann and H Kirby, *J Biol Chem*, 1948, **175**, 483, W. W Ackermann and W Shive, *ibid*, 867
- 23c T Wieland, *Chem Ber*, 1948, **81**, 323, S H Lipton and F M Strong, *J. Amer Chem Soc*, 1949, **71**, 2364
- 24 H H Weinstock, E L May, A Arnold and D Price *J Biol Chem*, 1940, **135**, 343
- 25 F Hoffmann-La Roche and Co., B P. 570533
- 26 R Kuhn and T Wieland *Ber*, 1940, **73**, 962
- 27 N Nielsen, V Hartehus and G Johansen, *Naturwiss* 1944 **32**, 294, *Compt. rend Trav Lab Carlsberg, Sér Physiol*, 1944 **24**, 39
- 28 H Pfaltz, *Z Vitaminforsch*, 1943, **13**, 236
- 29 E Burlet, *ibid*, 1944 **14**, 318
- 29a S H Rubin, J M Cooperman M E Moore and J Scheiner, *J Nutrition*, 1948, **35**, 499
- 29b D M Hegsted, *Proc Soc Exp Biol Med*, 1948, **69**, 571
- 30 E E Snell, *J Biol Chem*, 1941, **139**, 975
- 31 R Kuhn, T Wieland and E F Moller *Ber* 1941 **74**, 1605
- 32 E E Snell, *J Biol Chem*, 1941 **141**, 121
- 33 E E Snell L Chan, S Spiridanoff E L Way and C D Leake *Science*, 1943 **97**, 168, *Fed Proc*, 1943 **2**, 92
- 34 D W Woolley and A G C White, *Proc Soc Exp Biol Med* 1943 **52**, 106
- 35 K Unna *ibid* 1943 **54**, 55
- 36 J W Barnett, *J Chem Soc*, 1944, 5
- 37 H McIlwain and D E Hughes *Biochem J*, 1945 **39**, 133
- 38 J W Barnett D J Dupré B J Holloway and F A Robinson *J Chem Soc*, 1944, 94
- 39 J Madinaveitia A R Martin F L Rose and G Swain *Biochem J* 1945 **39**, 85 B P 578251
- 39a W. Trager, *J Exp Med*, 1943 **77**, 411
- 39b J F Mead, M M Rapport, A E Senear J T Maynard and J B Koepfli, *J Biol Chem*, 1946, **163**, 465
- 39c S Brackott, E Waletzky and M Baker, *J Parasit*, 1946 **32**, 453, R Winterbottom, J W Clapp W H Miller, J P English and R O Robln, *J Amer Chem Soc*, 1947, **69**, 1393, American Cyanamid Co, U S P 2459111
- 39d W. Cantrell, *J Parasit* 1949, **35**, 220
- 40 W Shive and E E Snell *Science*, 1945 **102**, 401

# ANALOGUES

- 41 W Drell and M S Dunn *J Amer Chem Soc* 1946 68, 1868
- 41a W Drell and M S Dunn, *ibid* 1948, 70, 2057.
- 42 E E Snell and W Shive *J Biol Chem* 1945 158, 551
- 43 W Shive and E E Snell *ibid* 1945 160, 287, Research Corp ,  
U S P 2446615
- 44 W I Metzger *J Bact* 1947 54, 135
- 45 D W Woolley and M L Collyer *J Biol Chem* 1945 159, 265
- 46 D W Woolley *ibid* 1946 163, 481
- 47 M M Rapport J F Mead J T Maynard A E Senear and  
J D Koepfli *J Amer Chem Soc* 1947 69, 2561
- 48 H O Singher N Millman and M R Bosworth *Proc Soc Exp  
Biol Med* 1948 67, 388
- 49 G Johnson and A B Kupferberg *ibid* 390



## I. INTRODUCTION

THE discovery that certain strains of yeast would not grow on a medium consisting solely of sugar and inorganic salts led E Wildiers<sup>1</sup> in 1901 to postulate the existence in yeast extracts and wort of a substance necessary for the growth of certain yeasts. This hypothetical substance he called 'bios'. Yeasts were found to differ greatly in their requirements for bios, certain wild yeasts grew and developed without it, whereas others showed no signs of growth in its absence.

The complex nature of bios was first recognised in 1922 by E I Fulmer and V E Nelson,<sup>2</sup> who showed that it consisted of at least two substances. Shortly afterwards W Lash Miller<sup>3</sup> succeeded in fractionating it into three substances all essential for growth.

The first of these, which was termed Bios I was shown by E V Eastcott<sup>4</sup> to be meso inositol. The second fraction, Bios IIA was identified by W Lash Miller<sup>5</sup> as  $\beta$ -alanine supplemented by L leucine and by C Rainbow and L R Bishop<sup>6</sup> as pantothenic acid. The discrepancy is explained by the fact that some yeasts require only  $\beta$  alanine whilst others require the whole pantothenic acid molecule.

The third factor Bios IIB, was shown to be identical with biotin isolated by F Kogl and B Tonnies<sup>7</sup> in the form of a crystalline methyl ester from egg yolk. Other factors of the bios group were subsequently identified by Miller and his co workers, and by Rainbow and Bishop. These include aneurine which appears to be identical with the factor previously called Bios V,<sup>8</sup> pyridoxine<sup>9</sup> and nicotinic acid<sup>10</sup>.

In addition to being a growth factor for micro organisms biotin was also recognised to be a vitamin, that is, a factor essential for the growth of animals. In 1927 M A Boas Fixsen<sup>11</sup> observed that the feeding of raw egg white to rats produced an eczema like dermatitis accompanied by loss of hair. She found that the condition was cured by a protective factor X present in liver. What was apparently the same factor was recognised by P Gyorgy<sup>12</sup> who called it vitamin H, and subsequently showed<sup>13</sup> that it possessed properties similar to those of biotin prepared by Kogl and Tonnies from egg yolk.

## INTRODUCTION

Hegsted *et al*<sup>14</sup> observed that chicks fed a purified diet containing adequate pantothenic acid developed a dermatitis which was cured by vitamin H. Biotin was also shown to be identical with coenzyme R<sup>13 15</sup> a growth and respiratory factor essential for the nitrogen fixing *Rhizobia* present in the root nodules of legumes<sup>16</sup>

Actually the substance isolated by Kogl and Tönnis<sup>7</sup> from egg yolk though very similar in chemical and biological properties to the substance isolated by du Vigneaud and György<sup>13</sup> from liver is probably not identical with it. Kogl and L. J. ten Ham<sup>17</sup> found that apparently significant differences existed between the melting points and optical rotations of the two forms and they designated the factor from egg yolk  $\alpha$  biotin and that from liver  $\beta$  biotin. The methyl esters of the two substances also differed in melting point and optical rotation whilst a mixture of  $\alpha$  and  $\beta$  biotin methyl esters had a melting point 20 to 30° lower than that of either of the pure esters. The activity of  $\beta$  biotin in the yeast test was almost twice that of  $\alpha$  biotin although more recent tests against five different micro organisms suggests that  $\alpha$  biotin has 90 to 96 % of the activity of  $\beta$  biotin<sup>18</sup>

### References to Section 1

- 1 E Wildiers *La Cellule* 1901 18, 313
- 2 E I Fulmer and V E Nelson *Proc Iowa Acad Sci* 1922 29, 371
- 3 W Lash Miller *Science* 1924 58, 197
- 4 E V Eastcott *J Phys Chem* 1928 32, 1094
- 5 W Lash Miller *Trans Roy Soc Canada* III 1936 30, 99
- 6 C Rainbow and L R Bishop *J Inst Brewing* 1939 45, 593
- 7 F Kogl and B Tönnis *Z physiol Chem* 1936 242, 43
- 8 W Lash Miller *Trans Roy Soc Canada* III 1937 31, 169
- 9 A S Schultz L Atkin and C N Frey *J Amer Chem Soc* 1939 61, 1931
- 10 A S Schultz L Atkin and C N Frey *ibid* 1938 60, 1514
- 11 M A Boas Fixsen *Biochem J* 1927 21, 712
- 12 P György *Z östl Fortbild* 1931 28, 377 417 *J Biol Chem* 1937 119, xliii 1939 131, 733
- 13 P György D B Melville D Burk and V du Vigneaud *Science* 1940 91, 243 V du Vigneaud D B Melville P György and C S Rose *ibid* 1940 92, 62
- 14 D M Hegsted J J Oleson R C Mills C A Elvehjem and E B Hart *J Nutrition* 1940 20, 599
- 15 R Nilsson G Bjälfoe and D Burstrom *Naturwiss* 1939 27, 389 P M West and P W Wilson *Science* 1939 89, 607
- 16 F E Allison S R Hoover and D Burk *ibid* 1933 78, 217
- 17 F Kogl and E J ten Ham *Naturwiss* 1943 31, 208 *Z physiol Chem* 1943 279, 140
- 18 K K Krueger and W H Peterson *J Biol Chem* 1948 173 497

## BIOTIN

### 2. ISOLATION OF BIOTIN

#### $\alpha$ -Biotin

The procedure used by F Kögl and B Tönnis<sup>1</sup> to isolate  $\alpha$  biotin methyl ester from egg-yolk was as follows. The yolks of 1000 fresh eggs were treated with acetone and the filtrate was concentrated and treated with four volumes of alcohol. The active precipitate was dissolved in water and impurities were removed by precipitation with lead acetate. The filtrate was freed from lead, and phosphotungstic acid was added to precipitate the active principle. The precipitate was decomposed with baryta and the solution was shaken with charcoal. After washing the adsorbate with 50 % alcohol, an active fraction was obtained by elution with 60 % acetone containing 2.5 % of ammonia. A second precipitation with phosphotungstic acid and decomposition with baryta gave an active fraction soluble in alcohol. This was freed from impurities by precipitation with mercuric chloride and then esterified with methanolic hydrogen chloride. Further impurities were removed by precipitation with picrolonic acid and then with rufanic acid. Finally, a very potent preparation was obtained by decomposition of the reneckate, the yield being 4 mg, or 8 % of the material originally present. From a second preparation, starting with a large quantity of dried egg yolk, the methyl ester was obtained in crystalline form by high vacuum distillation and crystallisation from a mixture of chloroform and light petroleum. The substance had a m.p. of 146 to 147° C and was active on *Saccharomyces* in a dilution of 1 in 10,000,000,000.

An improved method of isolating biotin from egg yolk was subsequently described by F Kögl and L Pons,<sup>2</sup> who used molecular distillation to purify the crude product, by means of this modification, the yield was increased to 10 or 20 %. The biotin methyl ester was crystallised from mesityl oxide which gave a purer product, m.p. 161 to 165° C.

#### $\beta$ -Biotin

György *et al*<sup>3</sup> used the following method for the preparation of a "vitamin H" concentrate from liver. A residue obtained in the preparation of Campolon<sup>4</sup> was digested with papain or autoclaved with acid, and the active factor was concentrated by a variety of operations, including adsorption on charcoal, elution with a mixture of pyridine, methanol and water, precipitation with phosphotungstic acid, and precipitation with gold chloride. Yeast autolysates were also concentrated by similar methods, but the procedure was more difficult than with liver.

V du Vigneaud *et al*<sup>4</sup> used as the starting material a liver concen-

trate prepared by high pressure hydrolysis of an alcohol-insoluble fraction of beef liver. Inert material was precipitated with alcohol and acetone, and an active fraction was precipitated by means of phosphotungstic acid, and the precipitate was decomposed with barium hydroxide. Pure biotin ester was prepared from this concentrate by esterification with methanolic hydrogen chloride, followed by two chromatographic adsorptions on Brockmann alumina. The yield from 5 litres of liver concentrate was 70 mg. F. Kögl and E. J. ten Ham<sup>2</sup> prepared  $\beta$  biotin from a liver concentrate by chromatographic adsorption on norit, elution with ammoniacal acetone, esterification, chromatographic adsorption of the ester from chloroform on alumina and elution with a mixture (9:1) of acetone and methanol, followed by re-adsorption on alumina from acetone, elution with a mixture of acetone and methanol and finally, hydrolysis to the free acid.

Biotin was also prepared from milk. A concentrate was esterified with acid methanol, and the ester was chromatographed first on Decalco and then on activated alumina.<sup>3</sup> The crude crystalline ester obtained on elution was purified by washing with ethyl acetate, sublimation *in vacuo* and re-crystallisation from a mixture of ether and methanol. The free biotin obtained on hydrolysis was identical with the biotin from liver. A yield of 25 to 40% was obtained.

#### References to Section 2

- 1 F. Kögl and B. Tonnies, *Z. physiol. Chem.* 1936 **242**, 43
- 2 F. Kögl and L. Pons, *ibid.* 1941 **289**, 61
- 3 P. Gyorgy, R. Kuhn and E. Lederer, *J. Biol. Chem.* 1939 **131**, 745
- 4 V. du Vigneaud, K. Hofmann, D. B. Melville and P. Gyorgy, *ibid.*, 1941 **140**, 643
- 5 F. Kögl and E. J. ten Ham, *Z. physiol. Chem.*, 1943 **279**, 140
- 6 D. B. Melville, K. Hofmann, E. Hague and V. du Vigneaud, *J. Biol. Chem.*, 1942 **142**, 615


### 3. CHEMICAL CONSTITUTION OF BIOTIN

#### Chemical Constitution of $\beta$ -Biotin


$\beta$  Biotin methyl ester, m.p. 166 to 167° C., has the empirical formula  $C_{11}H_{18}O_3N_2S$ ,<sup>1</sup> and free  $\beta$  biotin, m.p. 230 to 232° C., has the formula,  $C_{10}H_{16}O_3N_2S$ .<sup>2</sup>

Biotin is a carboxylic acid and, on treatment with alkali,<sup>3</sup> it gave a sulphur-containing diamino-carboxylic acid  $C_9H_{14}O_3N_2S$  (II), containing one CO group less than biotin. This was interpreted as indicating the presence of a NN' substituted cyclic urea group. On oxidation with hydrogen peroxide, it yielded a sulphone (III) suggesting that the sulphur was present as a thio-ether linkage. F. Kögl





# BIOTIN







and T J de Man <sup>4</sup> suggested that the sulphur formed part of a ring. The diamino carboxylic acid on oxidation with nitric acid or potassium permanganate yielded, amongst other compounds, adipic acid <sup>5</sup>. Biotin methyl ester was converted *via* the hydrazide into an azide which, with boiling absolute alcohol, yielded an ethyl urethane  $C_{12}H_{21}O_3N_3S$  <sup>5, 6</sup>. By the action of hydrochloric acid this gave a monoamine,  $C_8H_{17}ON_3S$  (IV), and both this and the urethane were converted by the action of barium hydroxide into the same triamine  $C_8H_{19}N_3S$  (V). The monoamine had the same structure as biotin except that the carboxyl group was replaced by an amino group whilst the triamine corresponded to the diamino-carboxylic acid referred to above. Unlike the diamino acid, however, the triamine did not give adipic acid on oxidation with nitric acid or potassium permanganate, whence it was concluded that the carboxyl group of adipic acid was the carboxyl group originally present in biotin, the adipic acid resulting from a side chain and not from a cyclic structure.

By the action of concentrated hydrochloric acid at 200° C, biotin sulphone was converted <sup>7</sup> into the sulphone of the diamino carboxylic acid (IV) which, on treatment with phosgene, was reconverted into the original biotin sulphone.

Of the several formulae proposed by du Vigneaud and his colleagues, <sup>6</sup> formula I ( $R = H$ ) was shown to be correct <sup>8</sup>.

In the first place, hydrogenolysis of biotin with Raney nickel yielded desthiobiotin (VII) which on acid hydrolysis yielded a desthio diamino carboxylic acid,  $C_8H_{20}O_2N_2$  (VIII). This, on oxidation with alkaline periodate, gave pimelic acid, treatment with phenanthrene quinone gave a quinoxaline. Secondly, exhaustive methylation of the diaminocarboxylic acid followed by acid hydrolysis, yielded small amounts of thiophan-2 valeric acid (IX) <sup>9</sup>.


These reactions are summarised in the schematic representation on pages 408 and 409.

### Chemical Constitution of $\alpha$ -Biotin


The constitution of  $\alpha$  biotin, prepared from egg-yolk, was investigated by F Kögl and his colleagues. It was hydrolysed <sup>4, 10</sup> by concentrated hydrochloric acid at 200° C, giving a diamino carboxylic acid  $C_9H_{15}O_2N_2S$ , suggesting the presence of a cyclic urea group. On oxidation with alkaline permanganate, biotin sulphone was obtained and it was suggested that the sulphur atom was part of a ring.

Biotin methyl ester added on 1 mole of methyl iodide to give methyl biotin sulphonium iodide, whilst on oxidation of the ester, biotin sulphone methyl ester was obtained. This on vigorous hydrolysis yielded a  $C_9$ -diamino sulphocarboxylic acid, thus proving that the urea group and the sulphur atom were present in different rings.


had they been present in one ring two fragments would have resulted




To obtain information regarding the position of the carboxyl group the diamino-carboxylic acid was oxidised with lead tetraacetate,<sup>11</sup> 2 moles were consumed, one by the sulphur atom, and one either by an  $\alpha$  amino acid as in (a) or by a 1,2 diamine, as in (b)



The decision between these two alternatives was made by further oxidation of the aldehydic product with permanganate, 1.8 moles were taken up, thus favouring the first of the alternatives. This choice was supported by the observation that cold esterification of the resulting acid gave a basic ester; this could only have been derived from reaction (a) and not from (b). Finally the intermediate aldehyde was isolated as a 2,4-dinitrophenylhydrazone with the expected nitrogen content. It appeared to follow from this that the urea grouping formed part of a 6- and not a 5-membered ring, and  $\alpha$  biotin was therefore assumed to be a derivative of 2-ketohexahydro-pyrimidine 4-carboxylic acid




When the amino acid obtained by permanganate oxidation of the aldehyde was esterified in hot solution, ammonia was eliminated and an unsaturated ester was produced




in agreement with the known behaviour of  $\beta$  amino acids. On oxidation of the free acid with permanganate, 4 atoms of oxygen were utilised and the product was a sulphocarboxylic acid, isolated as the *m* toluidine salt. To identify this sulphocarboxylic acid it was fused with alkali<sup>12</sup> model experiments indicating that  $\beta$  sulphocarboxylic acids yield unsaturated carboxylic acids by this procedure. An unsaturated acid was in fact obtained and on hydrogenation *d,l*  $\alpha,\beta$ -dimethylbutyric acid,  $(\text{CH}_3)_2\text{CH}-\text{CH}(\text{CH}_3)-\text{COOH}$ , was isolated. Various  $\beta$  and  $\gamma$  sulphonic acids derivable from this acid were synthesised and the methyl ester anhydride of  $\beta$ -carboxy- $\gamma$  methylbutane sulphonic acid was shown to be identical with the corresponding derivative of the sulphocarboxylic acid from biotin.

This evidence therefore leads to the structure




for the  $\alpha$  biotin of egg yolk. The difference between this formula and that assigned to  $\beta$  biotin would account for the fact that the diamino acid sulphone from  $\alpha$  biotin is so much more easily hydrolysed than the corresponding compound from  $\beta$  biotin but on the other hand it is a little difficult to believe that two molecules differing so markedly from one another would possess the same highly specific growth promoting properties.

Convincing as the above evidence apparently was the formula proposed for  $\alpha$  biotin was withdrawn by Kōgl and his colleagues when they learnt of the results obtained by the American workers on  $\beta$  biotin and on reconsideration of the evidence they advanced the alternative formula





# CHEMICAL CONSTITUTION

Oxidative degradation of a substance with this formula could yield  $\beta$ -carboxy- $\gamma$ -methyl butane sulphonic acid by the following series of reactions



Treatment of model thio ethers with lead tetra acetate however did not confirm the course of the above oxidation since it gave a sulphone and not a sulphoxide

The method of degradation used by du Vigneaud and his colleagues with  $\beta$  biotin however should be capable of distinguishing between the two possible formulae (a) the pyrimidine formula which should give the triamine (I) with two amino groups on one carbon atom and therefore yield an aldehyde by loss of ammonia and (b) the imidazo line formula which should give a stable triamine (II)



F. Kogl and W. A. J. Borg<sup>12</sup> therefore converted  $\alpha$  biotin methyl ester into the hydrazide and then *via* the azide into the urethane. This was hydrolysed with hydrochloric acid instead of baryta the agent used by du Vigneaud in order to prevent splitting off of ammonia. The product of this reaction proved to be a stable triamine  $\text{C}_8\text{H}_{19}\text{N}_3\text{S}$  identified as its picrolonate.

This result was incompatible with the formula first proposed by Kogl but consistent with his second formula which is now generally accepted.  $\alpha$  and  $\beta$  Biotin are therefore closely related substances which would be expected to exhibit comparable biological properties. It would have been very surprising indeed to find such unique properties in two such unrelated molecules as those represented by du Vigneaud's formula for  $\beta$  biotin and Kogl's original structure for  $\alpha$  biotin.

## BIOTIN


References to Section 3  
K. Hofmann

- BIOTIN
- References to Section 3*
- 1 V du Vigneaud K Hofmann and D B Melville *J Biol Chem* 1941 **140**, 643
  - 2 V du Vigneaud K Hofmann D B Melville and J R Rachele *ibid* 763
  - 3 K Hofmann D B Melville and V du Vigneaud *ibid* 207
  - 4 F Kogl and T J de Man *Z physiol Chem* 1941 **260** 81
  - 5 K Hofmann D B Melville and V du Vigneaud *J Amer Chem Soc* 1941 **63**, 3237
  - 6 V du Vigneaud K Hofmann and D B Melville *J Amer Chem Soc* 1942 **64**, 188
  - 7 D B Melville K Hofmann and V du Vigneaud *J Biol Chem* 1942 **145**, 101
  - 8 V du Vigneaud D B Melville K Folkers D E Wolf R Mazingo J C Keresztesy and S A Harris *ibid* 1942 **146** 475
  - 9 D B Melville A W Moyer K Hofmann and V du Vigneaud *ibid* 487
  - 10 F Kogl and L Pons *Z physiol Chem* 1941 **260**, 61
  - 11 F Kogl H Erxleben and J H Verbeck *ibid* 1942 **276**, 63
  - 12 F Kogl J H Verbeck H Erxleben and W A J Borg *ibid* 1943 **279**, 121
  - 13 F Kogl and W A J Borg *ibid* 1944 **281**, 65


**$\beta$ -Biotin**

#### 4 SYNTHESIS OF BIOTIN


The formula assigned to  $\beta$  biotin was confirmed by synthesis accomplished in 1943 by Harris *et al* <sup>1 2 3</sup> according to the following method using L cystine and chloroacetic acid as starting materials



# SYNTHESIS



The methyl  $\gamma$ -formylbutyrate used to introduce the valeric acid side-chain was prepared from glutaric acid via the anhydride, the monomethyl ester and  $\gamma$ -carbomethoxy butyryl chloride. A method of preparing compound II via the di-ethyl ester of N-benzoyl-(carboxymethyl-mercapto)-alanine from N-benzoyl-serine was used as an alternative step





Fractional crystallisation of VI yielded two racemates of methyl 3-acetamido 4-benzamidotetrahydrothiophene-2-valerate. These on hydrolysis yielded the corresponding 3,4-diamino tetrahydrothiophene 2-valeric acids (VII) as sulphates. Treatment with phosgene yielded two racemates of 2'-ketoimid-azolidino-(4' 5' 3 4) thiophan-2-valeric acid (VIII) which are distinguished as *dl*-biotin, m.p. 232°C and *dl*-allobiotin, m.p. 194 to 196°C. The former was resolved through its esters with *l*-mandelic acid to give a compound identical with natural biotin. Subsequently, the "unnatural" isomer, *l*-biotin, was obtained by esterification of racemic biotin with mandelic acid. A better method of preparing *l*-biotin was to crystallise the quinidine methoxide salt, thus gave the *d* isomer in poor yield and in an impure state. The best method of preparing *d* biotin was by means of the *L*-arginine salt. Subsequently the preparation of a third isomer of  $\beta$  biotin from the reduction product of compound VI was described, this is termed *dl*-epiallobiotin and it decomposes without melting, commencing at 195°C. This compound on hydrogenolysis with Raney nickel gave

# BIOTIN

the same desthuo compound as did *dl* allobiotin, namely, *dl* desthuoallobiotin. It was inactive for yeast, whereas *dl* desthuobiotin was half as active as *d* biotin (page 449).

One or two of the known racemic pairs must therefore have the *trans* configuration at the nitrogen atom, as in I, and the other or others the *cis*-configuration, as in II,



although it had previously been thought that compounds having two five-membered saturated heterocyclic rings fused through adjacent carbon atoms would exist only in the *cis* form.

Further investigation<sup>6</sup> showed that the *cis* configuration at the nitrogen atom was present in biotin and the *trans*-configuration in allobiotin and *epiallobiotin*, for, as already noted, biotin on hydrogenolysis with Raney nickel yielded desthuobiotin, whereas the other two isomers yielded desthuoallobiotin. Moreover, allobiotin and *epiallobiotin* were obtained when the methyl ester of 3 acetamido 4 benzamidotetrahydrothiophene 2-valeric acid was subjected to hydrogenolysis, hydrolysis and treatment with phosgene.


Formula I therefore represents *dl*-allobiotin and *dl*-*epiallobiotin*, whilst formula II represents *dl*-biotin.

Harris *et al*<sup>7</sup> described the synthesis of *dl* biotin, *dl*-allobiotin and *dl*-*epiallobiotin* by the method previously used for the synthesis of biotin (page 414). The two dehydro esters obtained by reductive acetylation of the oximes were separately reduced with hydrogen in presence of palladium. The product from one was the *dl*-diamido ester, m p 152 to 153° C, which is the precursor of *dl* biotin whilst the other gave the *dl* allodiamido ester, m p 172 to 173° C, together with the *dl*-*epiallodiamido* ester, m p 185 to 187° C, the precursors respectively of allobiotin and *epiallobiotin*.

*dl*-Allobiotin and *dl* *epiallobiotin* are configuratively identical with one other about the asymmetric carbon atoms to which the nitrogen atoms are attached. *dl* Biotin had 50 % of the activity of natural biotin, whilst *dl* allobiotin and *dl*-*epiallobiotin* were essentially inactive towards *L. arabinosus* (see page 446).

# SYNTHESIS


Three of the four possible racemic  $\beta$  biotins were synthesised by Gruener *et al*<sup>8</sup> from 2- $\delta$  methoxy butyl 3 keto 4-carbomethoxythiophan



This was converted into the cyanhydrin the cyano group of which was converted into the carbomethoxy group and the hydroxy group removed by chlorination and hydrogenation. The two carbomethoxy groups were converted into amino groups via the dihydrazide diazide and diurethane and the diamine was reacted with phosgene. The  $\delta$  methoxy group was then converted into a carboxy group via the bromide and cyanide. This method was patented by F Hoffmann La Roche & Co<sup>9</sup>.

From the dihydrazide m p 204 to 205°C *dl*  $\psi$   $\beta$  biotin m p 221 to 222°C (methyl ester m p 149°C) was obtained whilst the non crystalline dihydrazide fraction gave *dl* iso  $\beta$  biotin m p 182 to 183°C (methyl ester m p 166 to 167°C) and *dl*  $\beta$  biotin m p 234 to 235°C (methyl ester m p 130 to 132°C). *dl* iso  $\beta$  biotin and *dl*  $\psi$   $\beta$  biotin were inactive towards *Saccharomyces cerevisiae* and *Lactobacillus helveticus*. It was shown subsequently<sup>10</sup> that *dl*  $\beta$  biotin was identical with the synthetic biotin of Harris *et al* but that neither iso  $\beta$  biotin nor  $\psi$   $\beta$  biotin was a pure stereoisomer.


Another method of synthesis was described by Baker *et al*<sup>11</sup> in which a general method of synthesising the *cis* and *trans* forms of 2 alkyl thiophan 3 4-dicarboxylic acids was devised and used for the synthesis of 2 ( $\delta$ -carboxybutyl) thiophan 3 4 *trans*-dicarboxylic acid. In one method the following series of reactions was employed






# BIOTIN

A better method of synthesising this tricarboxylic acid, which gave a 23 % over-all yield from pimelic acid in seven steps, was as follows



and thence *via* the cyanhydrin as before

The conversion of the tri-carboxylic acid into 2-( $\delta$  carboxybutyl)-3 4-diaminothiophan involved the selective dégradation of the two nuclear carboxyl groups without affecting the side-chain carboxyl group. This was accomplished by degrading the carboxyl groups one at a time. The *trans* diamino-carboxylic acid thus obtained yielded *dl*-epiallobiotin on treatment with phosgene. Biotin resulted by the similar treatment of the *cis*-diamino-carboxylic acid prepared by a rather different series of reactions from a common intermediate, a *cis* uracil with the structure



This synthesis confirmed that biotin had a *cis* configuration at the bridgehead of the two rings, whilst *epiallobiotin* and *allobiotin* had the *trans*-configuration


A fourth stereoisomer of biotin, known as *epibiotin* was obtained from the *cis*-diamino carboxylic acid that yielded biotin itself. *dl* *epi*-Biotin, m p 190 to 191° C, was biologically inactive when assayed with

# SYNTHESIS

*S. cerevisiae* On treatment with Raney nickel, it was converted into the biologically active *dl* desthiobiotin

Some of these methods have been patented by Lederle Labs Inc <sup>11a</sup>

An entirely different type of synthesis from those already described was patented by Roche Products Ltd <sup>12</sup> The most striking feature of this method is that the imidazolidine ring is built up before the thiophane ring



The  $\delta$  methoxy group was converted into the carboxy group via the bromide and cyanide, and, finally, the protective benzoyl group was removed by means of sodium and ammonia

# BIOTIN

## $\alpha$ -Biotin

$\alpha$  Biotin has not been synthesised up to the present time. The preparation of a possible intermediate 2 ethoxalyl 4 ethyl 3 keto thiophan was described by Ghosh *et al*<sup>13</sup>

### References to Section 4

- 1 S A Harris D E Wolf R Mozingo and K Folkers *Sci* 1943 97, 447
- 2 S A Harris D E Wolf R Mozingo R C Anderson G E Arth N R Easton D Heyl A N Wilson and K Folkers *J Amer Chem Soc* 1944 66, 1756
- 3 S A Harris N R Easton D Heyl A N Wilson and K Folkers *ibid* 1944 66, 1757
- 4 D E Wolf R Mozingo S A Harris R C Anderson and K Folkers *ibid* 1945 67, 2100
- 5 S A Harris R Mozingo D E Wolf A N Wilson G E Arth and K Folkers *ibid* 1944 66, 1800
- 6 S A Harris R Mozingo D E Wolf A N Wilson and K Folkers *ibid* 1945 67, 2102
- 7 S A Harris D E Wolf R Mozingo G E Arth R C Anderson N R Easton and K Folkers *ibid* 1945 67, 2096
- 8 A Grüssner J P Bourquin and O Schnider *Helv Chim Acta* 1945 28, 517
- 9 F Hoffmann La Roche and Co BP 589210 USP 2417326
- 10 A Grüssner J P Bourquin and O Schnider *Helv Chim Acta* 1946 29, 770
- 11 B R Baker M V Querry S R Safir and S Bernstein *J Org Chem* 1947 12, 138
- 12 G B Brown B R Baker S Bernstein and S R Safir *ibid* 1947 12, 155
- 13 G B Brown M D Armstrong A W Moyer W P Anslow B R Baker M V Querry S Bernstein S R Safir *ibid* 1947 12, 160
- 14 B R Baker M V Querry S Bernstein *ibid* 1947 12, 174
- 15 B R Baker M V Querry W L McEwen and S Bernstein *ibid* 1947 12, 186
- 16 S R Safir L Dorfman and Y SubbaRow *ibid* 1947 12, 322
- 17 Baker W L McEwen and W N Kinley *ibid* 1947 12, 322
- 18 Lederle Labs Inc BP 615798 617435
- 19 Roche Products Ltd BP 628902
- 20 R Ghosh J F W McOmie and J P Wilson *J Chem Soc* 1945 705

## 5 PROPERTIES OF BIOTIN

Both forms of biotin are white crystalline solids with acidic properties.  $\alpha$  and  $\beta$  Biotin have mps 220° C and 232 233° C respectively and  $[\alpha]_D^{20} = +51^\circ$  and  $+92^\circ$  respectively in 0.1 N sodium

## ESTIMATION

hydroxide They form crystalline methyl esters with m p s 161 to 162° C and 163 to 164° C respectively and  $[\alpha]_D^{21} = +47^\circ$  and  $+39^\circ$  respectively in chloroform<sup>1</sup> According to du Vigneaud *et al*<sup>2</sup> the methyl ester of biotin isolated from liver has m p 166 to 167° C and  $[\alpha]_D^{21} = +57^\circ$

$\alpha$  and  $\beta$  Biotin methyl esters are sparingly soluble in ether and in light petroleum somewhat more soluble in benzene or cyclohexane and soluble to the extent of about 1 % in methanol In general halogenated hydrocarbons alcohols and ketones are good solvents for the esters mesityl oxide phorone methyl heptenone and allylbenzene being particularly useful for purposes of crystallisation<sup>3</sup>

$\beta$  Biotin is surface active<sup>4</sup>

### References to Section 5

- 1 F Kögl and E J ten Ham *Naturwiss* 1943 **31**, 208
- 2 V du Vigneaud K Hofmann D B Melville and P Gyorgy *J Biol Chem* 1941 **140**, 643
- 3 F Kögl and L Pons *Z physiol Chem* 1941 **280**, 61
- 4 V R Williams and H B Williams *J Biol Chem* 1949 **177**, 745

## 6 STABILITY OF BIOTIN

Biotin is inactivated by acid and alkali and by many  $\alpha$  amino acid reagents though not by ninhydrin<sup>1</sup> It is not destroyed by acylating or alkylating agents or by carbonyl reagents It is inactivated by hydrogen peroxide and by rancid oils and fats with a high peroxide content the rate of destruction is less in presence of  $\alpha$  tocopherol<sup>2</sup> Since the product was active on yeast but not on *L. helveticus* (see page 452) it is most probably biotin sulphone Biotin is also inactivated by choline<sup>3</sup>

### References to Section 6

- 1 G B Brown and V du Vigneaud *J Biol Chem* 1941 **141**, 85
- 2 P L Pavcek and G M Shull *ibid* 1942 **146**, 351
- 3 J S Harrison and E J Miller *Analyst* 1949 **74** 463

## 7 ESTIMATION OF BIOTIN

### Microbiological Methods

The method first used for the estimation of biotin was a yeast growth method<sup>1, 2</sup> which is not applicable to the examination of turbid or highly coloured solutions as the growth response is measured turbidimetrically Nevertheless the method gives good results where

## BIOTIN

it can be applied<sup>3, 4</sup> Turbidimetric methods have also been described using *B. radicicola*<sup>4</sup> and *Rhizobium trifolii*<sup>5</sup> as test organisms

Biotin can be estimated more satisfactorily, however, by means of *Lactobacillus helveticus*<sup>6</sup> or *L. arabinosus*,<sup>7</sup> as the response with these organisms is measured by titrating the lactic acid produced Improvements in the *L. helveticus* method were subsequently described<sup>8</sup> including a method which was capable of assaying six members of the vitamin B complex with the same basal medium<sup>9</sup> The *L. arabinosus* method, although it gives lower titres than the *L. helveticus* method is preferred by some workers<sup>10</sup> As in other assays with *Lactobacilli* it is essential to remove fatty material from the medium and test solution, as lipoids have a stimulatory effect on the organisms<sup>11</sup>

Other organisms that have been tested for use in the assay of biotin are "choleless" *Neurospora crassa*<sup>12</sup> and *Candida guilliermondii*<sup>13</sup> Oleic acid and "Tween 80" alone or in combination with aspartic acid gave some response with the first of these organisms in the absence of biotin<sup>13a</sup>

Some of these organisms respond not only to biotin but also to certain related compounds (see pages 446-454)

The agar plate method devised by N. G. Heatley<sup>14</sup> for the assay of antibiotics has been used by T. I. Williams<sup>15</sup> for the estimation of biotin by means of *S. cerevisiae* A slight modification of the method in which paper discs were used in place of cups gave good results with both *S. cerevisiae* and *L. arabinosus*<sup>15a</sup>

In the earliest assays, extraction with hot water was used to prepare the test solutions,<sup>16</sup> but it was subsequently found that larger amounts of biotin were obtained after autolysis<sup>2</sup> or hydrolysis or a combination of both According to Thompson *et al.*<sup>17</sup> drastic hydrolysis with 6N sulphuric acid gives the best results, although it undoubtedly causes some destruction of biotin

### Other Methods

No chemical or physical method of estimating biotin exists at the present time

### References to Section 7

- 1 F. Kögl and B. Tönnis *Z. physiol. Chem.* 1936 242, 43
- 2 E. E. Snell, R. E. Eakin and R. J. Williams *J. Amer. Chem. Soc.* 1940 62, 175
- 3 R. Hertz *Proc. Soc. Exp. Biol. Med.* 1943 52, 15
- 4 N. Nielsen and V. Hartehus, *Biochem. Z.* 1941 42 311, 317
- 5 P. M. West and P. W. Wilson *Enzymologia* 1940 8, 152
- 6 G. M. Shull, B. L. Hutchings and W. H. Peterson *J. Biol. Chem.* 1942 142, 913

- 7 L D Wright and H R Skeggs *Proc Soc Exp Biol Med* 1944 56 95
- 8 G M Shull and W H Peterson *J Biol Chem* 1943 151, 201  
 F T Tomlinson and W H Peterson *Arch Biochem* 1944 5, 221
- 9 M Landy and D M Dicken *J Lab Clin Med* 1942 27, 1086
- 10 E C Burton Wright *Analyst* 1945 70 283
- 11 V R Williams and E A Pieger *Ind Eng Chem Anal Ed* 1945 17, 127 V R Williams *J Biol Chem* 1945 159 237
- 12 A Z Hodson *ibid* 1945 157, 383
- 13 W B Emery N McLeod and F A Robinson *Biochem J* 1946 40 426
- 13a A Z Hodson *J Biol Chem* 1949 179, 49
- 14 N G Heatley *ibid* 1944 38, 61
- 15 T I Williams *Nature* 1948 161, 19
- 15a D S Genghof C W H Partridge and F H Carpenter *Arch Biochem* 1948 17, 413
- 16 F Kogl and W van Hasselt *Z physiol Chem* 1936 243, 189
- 17 R C. Thompson R E Eakin and R J Williams *Science* 1941 94, 589

## 8 OCCURRENCE OF BIOTIN IN FOODSTUFFS

The materials richest in biotin are probably egg yolk liver and yeast all of which have been used as sources for its isolation. It is also present in kidney and cow's milk but not in rice polishings beef muscle or human milk.<sup>1</sup> Cow's milk contained 11 to 37  $\mu\text{g}$  of biotin per litre the value rising to a maximum after the first few days and then falling.<sup>2</sup> It occurs in a large variety of seeds.<sup>3</sup> Oat seedlings contained somewhat larger amounts in the root and coleoptile tips than in other parts. Biotin was also found in the aqueous extracts of many tissues of dogs cows calves and hens.<sup>4</sup> The tissues of dogs contained on the average 0.004  $\mu\text{g}$  per g the tissues of cows 0.007  $\mu\text{g}$  per g and of the hen 0.02  $\mu\text{g}$  per g. The liver and kidney of all species of animals examined were particularly rich in biotin.<sup>5</sup> A high proportion of the biotin originally present remained in meat after cooking.<sup>5</sup>

Fresh cheese contained from 0.011 to 0.076  $\mu\text{g}$  per g of biotin and the amount increased 2 or 3 fold on ripening.<sup>6</sup>

In yeast and animal products biotin appeared to exist mainly in a combined water insoluble form whereas in vegetable material and plants it existed predominantly as a water soluble form. In cereals and nuts however a considerable proportion was present in combination with protein. To obtain satisfactory analyses of yeast and meat

therefore, hydrolysis with dilute acid or with trypsin should be used to ensure liberation of combined biotin.<sup>7, 8</sup>

Royal jelly was an exceptionally rich source of biotin, as it was of pantothenic acid, containing 4.1  $\mu\text{g.}$  per g.; pollen and honey contained 0.25 and 0.00066  $\mu\text{g.}$  per g. respectively.<sup>9</sup>

Biotin was present in soil and natural manures, and the amount in pasture land was increased by farmyard manure. The soil concentration varied with the depth, but in lake deposits biotin was detected to a depth of 9 metres.<sup>10</sup>

#### References to Section 8

1. P. György, *J. Biol. Chem.*, 1939, **131**, 733.
2. J. M. Lawrence, B. L. Herrington and L. A. Maynard, *J. Nutrition*, 1946, **32**, 73.
3. F. Kögl and A. J. Haagen-Smit, *Z. physiol. Chem.*, 1936, **243**, 209.
4. F. Kögl and W. von Hasselt, *ibid.*, 189.
5. B. S. Schweigert, E. Nielsen, J. M. McIntire and C. A. Elvehjem, *J. Nutrition*, 1943, **28**, 65.
6. R. A. Sullivan, E. Nielsen and J. Jarmol, *ibid.*, 1943, **25**, 463.
7. R. C. Thompson, R. E. Eakin and R. J. Williams, *Science*, 1941, **94**, 589.
8. J. O. Lampen, G. P. Bahler and W. H. Peterson, *J. Nutrition*, 1943, **23**, 11; J. P. Bowden and W. H. Peterson, *J. Biol. Chem.*, 1949, **178**, 533.
9. G. Kitzes, H. A. Schuette and C. A. Elvehjem, *J. Nutrition*, 1943, **26**, 241.
10. M. A. Roulet, *Experientia*, 1948, **4**, 149.

### 9. EFFECT OF BIOTIN DEFICIENCY IN ANIMALS

#### Rats and Mice

As already mentioned above, biotin deficiency produced by feeding raw egg white to rats is characterised by an eczema-like dermatitis, paralysis or spasticity of the hind legs and the so-called "spectacle-eye" condition caused by loss of hair around the eyes. Although nutritional achromotrichia was relieved by pantothenic acid,<sup>1</sup> the dermatitis and other symptoms did not respond to pantothenic acid, or to riboflavine, pyridoxine or inositol, but were cured by administration of 2  $\mu\text{g.}$  of biotin per day,<sup>2</sup> the growth rate was also increased thereby. When biotin-deficient rats were treated with biotin (0.5 to 1.0  $\mu\text{g.}$  per day), the animals recovered, but their coats became grey in a different pattern from that assumed by pantothenic acid-deficient rats.<sup>3</sup> Cooked white of egg did not produce biotin deficiency, the responsible factor being heat-labile (see page 427).

Biotin deficiency in rats resulted in lesions of the thymus, testes, epididymis, skin and muscles, but there was no degeneration of the spinal cord or sciatic nerves<sup>4</sup>. Rats required biotin for gestation and for the birth of viable young and probably for lactation also<sup>5</sup>. Indeed the stress of lactation appeared to induce a mild biotin deficiency even without adding avidin or a sulphonamide to the diet<sup>6a</sup>. The severity and time of onset of symptoms of biotin deficiency were not modified when succinylsulphathiazole was given at the same time as raw egg white,<sup>6</sup> but administration of succinylsulphathiazole alone produced a combined biotin and folic acid deficiency in rats<sup>7</sup>.

Biotin deficiency in mice was characterised by alopecia,<sup>8</sup> which was more severe when sulphasuxidine was added to the diet (see page 434). The fur of black mice became rusty or grey<sup>8a</sup>. Biotin was essential for reproduction and lactation in mice<sup>8b</sup>.

### Chicks

In chicks, dermatitis and perosis were the chief manifestations of biotin deficiency induced by feeding egg white<sup>9, 10</sup> and it has been suggested<sup>10</sup> that the development and cure of these symptoms might be used for the biological assay of biotin. Injection of 0.65  $\mu\text{g}$  per day of crystalline biotin methyl ester prevented the perosis, but was insufficient to prevent the dermatitis<sup>11</sup>. The typical dermatitis was prevented and growth was promoted in chicks by feeding 7 to 10  $\mu\text{g}$  of biotin per 100 g. of diet<sup>12</sup>.

Biotin is also said to be necessary for normal embryonic development in the hen's egg,<sup>13</sup> thus when hens were maintained on a biotin-deficient diet the percentage of eggs hatching was reduced by about 80 %, although egg production was not affected.

Biotin deficiency was produced in chicks on a diet of sucrose and acid washed, alcohol-extracted casein without the administration of egg white. Although dermatitis was regularly produced, the onset of perosis was erratic. The addition of raw egg white produced perosis quickly<sup>14</sup>. It was prevented by feeding 1  $\mu\text{g}$  of biotin per day, but dermatitis was only cured completely by injection of 2 to 5  $\mu\text{g}$  per day. A mild biotin deficiency in chicks did not cause neurological lesions, such as were observed in pantothenic acid deficiency<sup>15</sup>.

### Turkeys

Turkeys, like chicks developed dermatitis and perosis when reared on a biotin deficient diet<sup>16</sup>. The former symptom was cured by biotin, but the latter required in addition, choline and a factor prepared from yeast extract by adsorption on charcoal or fuller's earth and elution by aqueous ammonia.



## Monkeys

The symptoms of chronic biotin deficiency observed in *monkeys* were a thinning of the fur and a gradual reduction in the colour of the hair<sup>17</sup> These symptoms were cured or prevented by 20  $\mu\text{g}$  of biotin per day Acute biotin deficiency was produced by feeding egg white or by adding 3 % of succinylsulphathiazole to the diet, both conditions were relieved by administration of 20  $\mu\text{g}$  of biotin per day

## Dogs

Puppies fed a synthetic diet deficient in the vitamin B complex but supplemented with aneurine, riboflavine, nicotinic acid, pyridoxine, pantothenic acid, inositol, *p* aminobenzoic acid and choline, developed a progressive paralysis after 7½ to 48 weeks A cure was effected in a few hours by administration of 100  $\mu\text{g}$  of synthetic biotin per kg of bodyweight<sup>18</sup>

## Pigs

Biotin deficiency was produced in pigs by feeding 30% of desiccated egg white in the diet It was characterised by alopecia spasticity of the hind legs, cracks in the feet and dermatosis accompanied by dryness, roughness and a brownish exudate

These symptoms could be prevented by intramuscular injection of 100  $\mu\text{g}$  of biotin daily into each pig<sup>19</sup> The same symptoms were produced by administration of phthalylsulphathiazole, although sulphaguanidine had no effect Biotin prevented the symptoms and inositol largely alleviated them<sup>20</sup> Pigs fed a diet containing all the other members of the vitamin B complex showed no increased growth when biotin was added to the diet

## Cows

The dairy calf required an exogenous supply of biotin, otherwise paralysis of the hind quarters developed This was curable by biotin<sup>21</sup>

## Fish

Biotin was found to be necessary for young rainbow trout an anaemia developing in its absence<sup>22</sup> From 0.005 to 0.025 mg per 100 g of diet was necessary to prevent deficiency symptoms from developing

## Avidin

The first attempt to isolate the factor in egg white responsible for producing biotin deficiency in rats and chicks was made by R E Eakin E E Snell and R J Williams,<sup>23</sup> who showed that biotin was inactivated by egg white *in vitro* and that it was immaterial how crude the biotin preparation was. Purification of the egg white factor for which the name avidin was suggested,<sup>24</sup> was effected by precipitation with acetone and five sixths saturation of the aqueous solution with ammonium sulphate. The biotin was not released from the complex by dialysis but could be recovered after the complex had been steam sterilised. This was consistent with the observation that cooked egg white did not inactivate biotin. Avidin was eventually obtained in crystalline form,<sup>24</sup> when it was shown to have the properties of a protein with a large carbohydrate moiety. A similar substance was isolated by D W Woolley and L G Longworth,<sup>25</sup> it had an isoelectric point at pH 10 and was homogeneous in electrophoresis and sedimentation experiments.

The discovery of the inactivation of biotin by avidin is of obvious importance in nutrition. P György and C S Rose<sup>26</sup> showed that whole egg contained an excess of avidin the biotin in the yolk being unable to neutralise all the avidin in the white. Thus in order to utilise the biotin in eggs\* these must be cooked in order to destroy the avidin. A case of biotin deficiency resulting from a diet consisting exclusively of raw eggs has been described.<sup>27</sup>

P György and C S Rose<sup>28</sup> also showed that biotin was present in egg yolk in a non-dialysable form of high molecular weight which stimulated the growth of yeast and of rats made biotin deficient by means of egg white. Biotin was not released from the biotin avidin complex by incubation with pepsin trypsin pancreatin papain or with liver, muscle or blood but was liberated by oxidation with 0.45 % hydrogen peroxide at pH 3. Avidin was destroyed by light especially in presence of riboflavin and biotin could be liberated from the complex by irradiation.<sup>29</sup>

A form of biotin that will not combine with avidin has been stated to exist in normal rat urine human urine and urine from rats fed egg white but not in any other biological materials (see page 433).<sup>30</sup>

K Meyer<sup>31</sup> and W L Laurence<sup>32</sup> suggested that since biotin increased the lytic action of lysozyme and avidin the biotin avidin complex might be identical with lysozyme, the factor that brings about lysis of bacteria. Alderton *et al.*,<sup>33</sup> however, failed to confirm the stimulatory effect of biotin on the lytic action of purified crystalline lysozyme, which was in fact shown to contain only traces of biotin. Moreover, lysis by avidin preparations was not increased by biotin, and avidin did not inhibit the lytic action of lysozyme.

## Monkeys

## BIOTIN

The symptoms of chronic biotin deficiency observed in monkeys were a thinning of the fur and a gradual reduction in the colour of the hair<sup>17</sup>. These symptoms were cured or prevented by 20  $\mu\text{g}$  of biotin per day. Acute biotin deficiency was produced by feeding egg white or by adding 3 % of succinylsulphathiazole to the diet, both conditions were relieved by administration of 20  $\mu\text{g}$  of biotin per day.

## Dogs

Puppies fed a synthetic diet deficient in the vitamin B complex but supplemented with aneurine, riboflavin, nicotinic acid, pyridoxine, pantothenic acid, inositol, *p*-aminobenzoic acid and choline, developed a progressive paralysis after 7½ to 48 weeks. A cure was effected in a few hours by administration of 100  $\mu\text{g}$  of synthetic biotin per kg of bodyweight<sup>18</sup>.

## Pigs

Biotin deficiency was produced in pigs by feeding 30% of desiccated egg white in the diet. It was characterised by alopecia, spasticity of the hind legs, cracks in the feet and dermatosis accompanied by dryness, roughness and a brownish exudate.

These symptoms could be prevented by intramuscular injection of 100  $\mu\text{g}$  of biotin daily into each pig<sup>19</sup>. The same symptoms were produced by administration of phthalylsulphathiazole, although sulphaguanidine had no effect. Biotin prevented the symptoms and inositol largely alleviated them<sup>20</sup>. Pigs fed a diet containing all the other members of the vitamin B complex showed no increased growth when biotin was added to the diet.

## Cows

The dairy calf required an exogenous supply of biotin, otherwise paralysis of the hind quarters developed. This was curable by biotin<sup>21</sup>.

## Fish

Biotin was found to be necessary for young rainbow trout, an anaemia developing in its absence<sup>22</sup>. From 0.005 to 0.025 mg per 100 g of diet was necessary to prevent deficiency symptoms from developing.



## BIOTIN

Avidin has been shown to occur not only in the eggs of birds and amphibia, but also in the genital tract, and avidin production can be induced experimentally in the oviduct of sexually immature chicks by the administration of oestrogen followed by progesterone. Administration of oestrogen alone increased the biotin content of the blood five fold, and when this was followed by progesterone the amount of avidin in the oviduct increased but the blood biotin was not affected<sup>33a</sup>. It is clear, therefore, that avidin as well as biotin is associated with reproduction.

### Biotin and Fatty Livers

G Gavin and E W McHenry<sup>34</sup> claimed that feeding rats with biotin on diets low in cholesterol produced fatty livers containing 0.67 to 1.25 % of cholesterol whilst R Okey<sup>35</sup> showed that the addition of biotin to the diet of guinea pigs doubled the amount of cholesterol in the liver. According to Best *et al.*,<sup>36</sup> however, biotin produced no selective deposition of cholesterol in the liver. They found on the contrary, that there was a constant relationship between the accumulation of cholesteryl esters in liver and the deposition of glycerides in the liver, and that biotin did not affect this relationship. They therefore suggest that the term 'biotin fatty liver' should be abandoned (see page 573).

### Biotin and Pantothenic Acid

There appears to be a connection between biotin deficiency and pantothenic acid<sup>37</sup> since the symptoms of biotin deficiency induced in weanling rats by administration of succinylsulphathiazole were aggravated when a pantothenic acid deficiency was also present. The feeding of biotin protected the animals against these changes and in addition reduced the severity of the symptoms of pantothenic acid deficiency. Furthermore, L D Wright and A D Welch<sup>38</sup> observed signs of severe pantothenic acid deficiency, including achromotrichia when rats receiving a highly purified diet containing all the B factors known to be required by the rat, including pantothenic acid were treated with succinylsulphathiazole. The symptoms were accompanied by a marked reduction in the pantothenic acid content of the liver and were relieved by administration of biotin and a folic acid concentrate. Thus the utilisation of pantothenic acid appears to depend on the availability of folic acid and biotin which are not normally required by rats being apparently synthesised in the gut by bacteria.

### Biotin and Infected Animals

A deficiency of biotin increased the severity of *Plasmodium lophurae* infection in chicks<sup>39</sup> but had no effect on the susceptibility of Swiss mice to experimental poliomyelitis<sup>40</sup> Biotin deficiency in rats led to a delayed or lowered production of the antibody that inhibited the reproduction of *Trypanosoma lewisi*<sup>41</sup> so that the parasites multiplied unchecked

### Biotin and Cancer

Nakahara *et al*<sup>42</sup> reported that rats were protected against cancer induced by butter yellow (NN dimethyl amino-azo benzene) by administering liver and yeast supplements This observation was followed up by du Vigneaud *et al*<sup>43</sup> to determine whether the effect was due to biotin They gave concentrates of biotin prepared from liver and yeast to susceptible rats together with butter yellow and obtained indications of a protective effect Marked protection was also obtained with casein supplemented by riboflavine When pure biotin was given however either with or without the protective casein riboflavine supplement the incidence of liver tumours among the mice was markedly increased It would appear that not only has biotin no protective effect in cancer but that it actually destroys the effect of the protective factor present in yeast and liver and is therefore a pro-carcinogenic substance It was suggested that avidin the egg white injury factor might have a beneficial effect on cancer

This was tested by Kensler *et al*<sup>44</sup> who fed a diet rich in egg white and avidin to mice with spontaneous mammary carcinoma but could observe no favourable effect on the disease Nor was the effect of high levels of egg white any more marked on mice with Flexner Jobling carcinoma or mouse sarcoma 180 Avidin equivalent to 16 to 40 times the amount necessary to combine with the dietary biotin was fed over a period of thirty weeks to a patient with mammary carcinoma and to another with lymphatic leukemia without any apparent improvement being observed in the patient's condition<sup>45</sup> oddly enough no clinical signs of biotin deficiency appeared nor was the urinary excretion of biotin reduced The inability of avidin to affect the course of cancer was confirmed by I I Kaplan<sup>46</sup> who gave the whites of 36 to 47 eggs daily to cancer patients maintained on a diet low in biotin without effecting a cure although there was some improvement in certain of the cases

Animal experiments were also carried out by Kline *et al*<sup>47</sup> They fed rats 0.06% of butter yellow in highly purified diets containing a sub-protective level of riboflavine together with heated or unheated

egg white or casein. The animals fed casein showed an incidence of liver tumours amounting to 77 to 88 % whilst groups of rats on egg white showed an incidence of tumours ranging from 0 to 18 %. The injection of biotin did not increase the incidence of tumours however and since symptoms of biotin deficiency developed on the unheated egg white diet but not on the heated diet it was evident that the protection afforded by egg white against hepatoma formation was independent of any relation between biotin and avidin.

The biotin content of cancerous tissue ranged from 20 to 100  $\mu\text{g}$  per g the lowest value being 5  $\mu\text{g}$  per g for human ovarian adenocarcinoma and the highest 200  $\mu\text{g}$  per g for rat hepatoma<sup>48</sup>. These values are within the range recorded for non cancerous brain lung spleen and muscle tissue and much below the values accepted for liver and kidney.

#### References to Section 9

- 1 P Gyorgy and C E Poling *Proc Soc Exp Biol Med* 1940 45, 773
- 2 E Nielsen and C A Elvehjem *ibid* 1941 48 349 *J Biol Chem* 1942 144, 405
- 3 G A Emerson and J C Keresztesy *Proc Soc Exp Biol Med* 1942 51, 358
- 4 J H Shaw and P H Phillips *ibid* 406
- 5 C Kennedy and L S Palmer *Arch Biochem* 1945 7, 9
- 5a M M Nelson and H M Evans *ibid* 1948 18, 477
- 6 G A Emerson and E Wurtz *Proc Soc Exp Biol Med* 1945 59 297
- 7 H R Skeggs and L D Wright *J Nutrition* 1946 32 375
- 8 E Nielsen and A Black *ibid* 1944 28, 203
- 8a J W Wilson E H Leduc and D H Winston *ibid* 1949 38 73
- 8b L Mirone and L R Cerecedo *Arch Biochem* 1947 15 324
- 9 L W McElroy and T H Jukes *Proc Soc Exp Biol Med* 1940 45, 296
- 10 S Ansbacher and M Landy *ibid* 1941 48 3
- 11 T H Jukes and F H Bird *ibid* 1942 49, 231
- 12 D M Hegsted R C Mills G M Briggs C A Elvehjem and E B Hart *J Nutrition* 1942 23, 175
- 13 W W Cravens E E Sebesta J G Halpin and E B Hart *Proc Soc Exp Biol Med* 1942 50, 101 W W Cravens W H McGibbon and E E Sebesta *Anat Rec* 1944 90 55 J R Couch W W Cravens C A Elvehjem and J G Halpin *Arch Biochem* 1949 21 77
- 14 L R Richardson A G Hogan and O N Miller *Univ Missouri Agr Exp Stat Res Bull* 1942 343
- 15 J H Shaw and P H Phillips *J Nutrition* 1945 29 107
- 16 H Patrick R V Boucher R A Dutcher and H C Knandel *Proc Soc Exp Biol Med* 1941 48, 456 *J Nutrition* 1943 26 197

# EFFECT OF DEFICIENCY IN ANIMALS

- 17 H A Waisman, K B McCall and C A Elvehjem, *ibid*, 1945 29, 1.
- 18 S G. Smith, *Amer J. Physiol*, 1945 144, 175
- 19 T J. Cunha, D C Lindley and M E Finsinger, *J. Animal Sci.*, 1946, 5, 219
- 20 D C. Lindley and T. J Cunha, *J Nutrition*, 1946, 32, 47.
- 21 A. C. Wiese, B C. Johnson and W B Nevens, *Proc. Soc Exp Biol Med*, 1946, 62, 521.
- 22 B A McLaren, E Keller, D J O'Donnell and C. A. Elvehjem, *Arch Biochem*, 1947, 15, 169
- 23 R E Eakin, E. E Snell and R J Williams, *J. Biol. Chem*, 1940, 138, 801.
- 24 D. Pennington, E E Snell and R E Eakin, *J. Amer Chem Soc*, 1942, 64, 469
- 25 D W. Woolley and L G Longworth, *J Biol Chem*, 1942 142, 285
- 26 P. György and C S Rose *Proc Soc Exp Biol Med*, 1942, 49, 294
- 27 V P. Sydenstricker, *et al*, *Semana med españ*, 1943 6, 356
- 28 P. György and C S Rose, *Proc Soc Exp Biol Med*, 1943 53, 55
- 29 P. György, C S Rose and R Tomarelli *J Biol Chem* 1942, 144, 169
- 30 E J.-H. Chu and R J Williams, *J Amer Chem Soc*, 1944 66, 1678.
- 31 K. Meyer, *Science*, 1944, 89, 391
- 32 W. L. Laurence, *ibid*, 392
- 33 G Alderton, J C Lewis and H L Fevold *ibid*, 1945 101, 151, G. Alderton and W H Ward, *J Biol Chem*, 1945, 157, 43
- 33a R Hertz and W H Sebrell *Science*, 1942 96, 257. R M Fraps, R. Hertz and W H Sebrell *Proc Soc Exp Biol Med*, 1943, 52, 140, 142. R Hertz F G Dhyse and W W Tullner, *Endocrinology*, 1949, 45, 451
- 34 G Gavin and E W McHenry, *J Biol Chem*, 1941, 141, 619
- 35 R Okey, *ibid*, 1946, 165, 383
- 36 C H Best, C C Lucas, J M Patterson and J H Ridout, *Biochem J*, 1946, 40, 368.
- 37 G A Emerson and E Wurtz, *Proc Soc Exp Biol Med*, 1944, 57, 47
- 38 L D Wright and A. D Welch, *Science*, 1943, 97, 426
- 39 A. O Seeler, W. H Ott and M E Gundel, *Proc Soc Exp Biol Med*, 1944 55, 107
- 40 H C Lachstein, H A Waisman, K B McCall C A Elvehjem and P. F. Clark, *ibid* 1945, 60, 279
- 41 F. E. Caldwell and P. György, *J Infect Dis*, 1947, 81, 197
- 42 W Nakahara, K Mori and T Huziwara, *Cann*, 1938 32, 465, 1939 33, 13, 57, 406
- 43 V. du Vigneaud, J. M Spangler, D Burk, C J Kensler, K Sugiura and C. P. Rhoads, *Science*, 1942, 95, 174
- 44 C. J Kensler, C. Wadsworth, K Sugiura C P Rhoads, K Dittmer and V. du Vigneaud, *Cancer Res*, 1943, 3 823



- 45 C P Rhoads and J C Abels *J Amer Med Assoc* 1943 121, 1261
- 46 I I Kaplan *Amer J Med Sci*, 1944 207, 733
- 47 H E Kline, J A Miller and H P Rusch, *Cancer Res*, 1945 5, 641
- 48 M A Pollack, A Taylor, A Woods R C Thompson and R J Williams, *ibid*, 1942, 2, 748

## 10. EFFECT OF BIOTIN DEFICIENCY IN MAN

The symptoms of biotin deficiency in human beings were first reported by V P Sydenstricker *et al*<sup>1</sup> Four volunteers were fed on a diet containing minimal amounts of biotin and 30 % of the total calorie intake in the form of egg white During the third and fourth weeks, all developed "a fine scaly desquamation without pruritis", which disappeared spontaneously in seven to ten days Nothing further happened until the seventh week, when one man developed a maculosquamous dermatitis of the neck, hands, arms and legs During the seventh and eighth weeks all showed a pronounced greyish pallor of the skin and mucous membranes, which was out of all proportion to the blood picture No capillary engorgement occurred as in pellagra or ariboflavinosis, the tongues remaining pale During the ninth and tenth weeks the skin became increasingly dry with marked reticulation and a return of the fine branny desquamation After the fifth week, symptoms resembling vitamin B<sub>1</sub> deficiency were observed, mild depression followed by extreme lassitude, somnolence, muscle pains and hyperaesthesia After the tenth week anorexia with occasional nausea was evident Two patients showed definite electrocardiographic changes The blood picture was characterised by a diminution in the haemoglobin, erythrocytes and volume of the packed red cells, together with a slight increase in the bile pigments and a large rise in the serum cholesterol After seven to eight weeks the urinary excretion of biotin was 3.5 to 7.3  $\mu\text{g}$  per day as compared with 29 to 52  $\mu\text{g}$  per day on a normal diet When biotin was given at a level of 75 to 300  $\mu\text{g}$  per day by injection there was prompt relief of the symptoms in three to five days and the urinary excretion at once rose to 55  $\mu\text{g}$  per day

Three cases have been described<sup>2</sup> of infants with a mild skin lesion on the face which resembled that observed in artificially produced biotin deficiency Raw egg white made the lesions worse, whilst biotin methyl ester brought about immediate improvement with complete disappearance of the lesions in three weeks A case of biotin deficiency resulting from a diet consisting solely of raw eggs has already been referred to (page 427)

*References to Section 10*

- 1 V P Sydenstricker S A Singal A P Briggs N M de Vaughn and H Isbell *Science* 1942 95, 176 *J Amer Med Assoc* 1942 118 1199
- 2 A Brown *Glasgow Med J* 1948 20 309

**11 METABOLISM OF BIOTIN**

Sydenstricker *et al*<sup>1</sup> found the amount of biotin excreted in the urine by human subjects on a normal diet to be 29 to 52  $\mu\text{g}$  per day which fell to 3.5 to 7.3  $\mu\text{g}$  per day after seven to eight weeks on a biotin-deficient diet. After administration of 75 to 300  $\mu\text{g}$  of biotin per day the urinary excretion increased after three to five days to 55  $\mu\text{g}$  per day. T W Oppel<sup>2</sup> reported an excretion of 14 to 111  $\mu\text{g}$  per day by normal subjects on an unrestricted diet and Gardner *et al*<sup>3</sup> an excretion of 11 to 183  $\mu\text{g}$  per day. The amount increased as much as five fold immediately following the administration of a large dose of crude biotin by mouth. The faecal excretion varied from 17 to 208  $\mu\text{g}$  per day and also increased when biotin was given by mouth.

The precise nature of the excretion product of biotin has not been determined but it is known that some at least of the biotin in normal rat and human urine does not combine with avidin<sup>2, 4</sup>. D Burk and R J Winzler<sup>5</sup> gave specific names to the different fractions e.g. the heat labile avidin uncombinable fraction active for yeast but not *Rhizobium* was termed miotin the heat stable avidin combinable component was termed tiotin and the avidin combinable fraction inactive for yeast but active for *Rhizobium* was termed rhiotin. Miotin and tiotin were transformed into an avidin combinable form by yeast but they were not identical with the diamino carboxylic acid (page 407) as they were not converted into biotin by the action of phosgene.

The amount of biotin in human milk was small for the first four or five days after parturition and then rose gradually to 0.38  $\mu\text{g}$  per 100 ml by the tenth day. The amount in the mature milk was 0.80 to 0.82  $\mu\text{g}$  per 100 ml<sup>6</sup>.

*References to Section 11*

- 1 V P Sydenstricker S A Singal A P Briggs N M de Vaughn and H Isbell *Science* 1942 95 176 *J Amer Med Assoc* 1942 118 1199
- 2 T W Oppel *Amer J Med Sci* 1942 204 886
- 3 J Gardner H T Parsons and W H Peterson *Arch Biochem* 1945 8 339 *Amer J Med Sci* 1946 211 198

## BIOTIN

4. E. J.-H. Chu and R. J. Williams, *J. Amer. Chem. Soc.*, 1944, 66, 1678.
5. D. Burk and R. J. Winzler, *Science*, 1943, 97, 57.
6. M. N. Coryell, M. E. Harris, S. Miller, H. H. Williams and I. G. Macy, *Amer. J. Dis. Child.*, 1945, 70, 150.

## 12. INTESTINAL SYNTHESIS OF BIOTIN

The synthesis of biotin by the intestinal flora of experimental animals was first demonstrated by the administration of sulphonamides, which inhibited the growth of the bacteria that produced biotin. Daft *et al.*,<sup>1</sup> for example, showed that rats given sulphaguanidine and sulphasuxidine developed dermatitis, necrosis of the heart muscle, haemorrhage into various organs and the subcutaneous tissues, and liver damage. The symptoms were prevented by administration of crystalline biotin. Similar observations were made by G. J. Martin,<sup>2</sup> by E. Nielsen and C. A. Elvehjem,<sup>3</sup> by Neumann *et al.*,<sup>4</sup> by G. A. Emerson and E. Wurtz,<sup>5</sup> and by A. D. Welch and L. D. Wright.<sup>6</sup> The symptoms of biotin deficiency in rats maintained on a diet containing 1 % of succinyl sulphathiazole were not prevented by the addition of *p*-aminobenzoic acid to the diet.<sup>4</sup> Only a small amount of biotin was synthesised by rats on a riboflavine-deficient diet,<sup>7</sup> and by mice on a synthetic diet.<sup>8</sup> The amount of biotin and folic acid stored in the liver was less in rats maintained on a purified diet adequate in the vitamin B complex than in rats fed the stock diet,<sup>9</sup> and was further decreased when succinylsulphathiazole was added to the diet. The inference to be drawn from this observation, namely that biotin and folic acid are synthesised by the intestinal flora and then somehow utilised by the animals is supported by the results obtained by Barki *et al.*,<sup>10</sup> who found that rats maintained on a purified diet under conditions that prevented coprophagy grew better when biotin and folic acid were added to the diet, whereas these supplements made little difference to the growth of rats kept in ordinary screen-bottom cages. The biotin and folic acid contents of the liver were also reduced, and the results suggest, therefore, that rats may obtain part of their biotin and folic acid requirements by ingesting their faeces. Direct absorption from the gut must take place to some extent, however, as the amounts of biotin and folic acid in the liver were still further depressed when succinylsulphathiazole was added to the diet. As already mentioned (page 428), pantothenic acid-deficiency due to the addition of succinyl sulphathiazole to the diet was corrected by administration of biotin and folic acid concentrates,<sup>10</sup> the utilisation of pantothenic acid obviously being dependent

on the availability of biotin and folic acid either from the diet or from the intestinal flora

Waisman *et al*<sup>11</sup> drew attention to the close similarity between the symptoms of biotin deficiency caused by feeding egg white and those produced by the administration of succinylsulphathiazole and G A Emerson and E Wurtz<sup>12</sup> showed that the addition of succinylsulphathiazole to a diet containing dried egg white did not modify the severity or time of onset of biotin deficiency whether or not the diet contained liver in order to secure growth the diet had to contain biotin plus liver or folic acid It would seem from this evidence that dried egg white makes unavailable not only dietary biotin but also biotin derived from bacterial synthesis in the intestine This was confirmed by McGregor *et al*<sup>13</sup> who showed that biotin from a non dietary source was eliminated in the faeces of rats fed raw egg white the amount of biotin in the urine and faeces far exceeding that in the diet The excess biotin was presumably derived from the intestinal bacteria and not from biotin reserves in the body

Proof that intestinal synthesis occurs in man was obtained from metabolic experiments Thus T W Oppel<sup>14</sup> showed that whereas the urinary output of biotin was roughly proportional to the intake the daily faecal excretion greatly exceeded the intake The total excretion on a diet supplying 30 to 40  $\mu\text{g}$  per day was in fact three to six times this amount Incidentally faeces unlike urine contained no non avidin combining fraction (page 433) These observations were confirmed by Gardner *et al*<sup>15</sup> who found that in women the total biotin output was nine three and 15 times the intake with diets containing small moderate and large amounts of biotin respectively

These results were also confirmed by Denko *et al*<sup>16</sup> (see page 377) who in addition found that on a restricted diet a moderate decrease in the urinary excretion of biotin occurred the amount being roughly equal to the dietary intake The faecal excretion on the other hand greatly exceeded the intake on the restricted diet

Several organisms are probably responsible for the intestinal synthesis of biotin Certainly *B proteus vulgaris* can synthesise all known members of the vitamin B complex<sup>17 18</sup> whilst *E coli* *B lactis aerogenes* *B faecalis* *alcaligenes* *B mesentericus* and *B vulgatus* produce *inter alia* biotin<sup>18</sup>

The effect of feeding various carbohydrates on the faecal flora and so on the intestinal synthesis of biotin in the hen was studied by Johansson *et al*<sup>19</sup> With sucrose as carbohydrate the faeces were nearly devoid of coliform organisms which were replaced by yeasts The coliform count was highest in hens receiving dextrin or a mixture of sucrose and lactose Intestinal synthesis of biotin occurred in hens fed the basal ration with added dextrin but not with sucrose or

## BIOTIN

lactose. Ground whole oats and oat groats also supported intestinal synthesis, the effect being more marked with the former. The synthesis and absorption of biotin were directly related to the level of oats in the diet.<sup>20</sup>

### References to Section 12

1. F. S. Daft, L. L. Ashburn and W. H. Sebrell, *Science*, 1942, 88, 32.
2. G. J. Martin, *Proc. Soc. Exp. Biol. Med.*, 1942, 51, 353.
3. E. Nielsen and C. A. Elvehjem, *J. Biol. Chem.*, 1942, 145, 713.
4. F. W. Neumann, M. M. Krider and H. G. Day, *Proc. Soc. Exp. Biol. Med.*, 1943, 52, 257.
5. G. A. Emerson and E. Wurtz, *ibid.*, 1944, 57, 47.
6. A. D. Welch and L. D. Wright, *J. Nutrition*, 1943, 25, 555.
7. E. Nielsen, G. M. Shull and W. H. Peterson, *ibid.*, 1942, 24, 523.
8. E. Nielsen and A. Black, *ibid.*, 1944, 28, 203.
9. L. D. Wright and A. D. Welch, *ibid.*, 1944, 27, 55.
- 9a. V. H. Barki, P. H. Derse, R. A. Collins, E. B. Hart and C. A. Elvehjem, *ibid.*, 1949, 37, 443.
10. L. D. Wright and A. D. Welch, *Science*, 1943, 87, 426.
11. H. A. Waisman, K. B. McCall and C. A. Elvehjem, *J. Nutrition*, 1945, 29, 1.
12. G. A. Emerson and E. Wurtz, *Proc. Soc. Exp. Biol. Med.*, 1945, 58, 297.
13. M. A. McGregor, H. T. Parsons and W. H. Peterson, *J. Nutrition*, 1947, 33, 517.
14. T. W. Opper, *Amer. J. Med. Sci.*, 1942, 204, 886.
15. J. Gardner, H. T. Parsons and W. H. Peterson, *Arch. Biochem.*, 1945, 8, 339; *Amer. J. Med. Sci.*, 1946, 211, 198.
16. C. W. Denko, W. E. Grundy, J. W. Porter, G. H. Berryman, T. E. Friedemann and J. B. Youmans, *Arch. Biochem.*, 1946, 10, 33; C. W. Denko, W. E. Grundy, N. C. Wheeler, C. R. Henderson, G. H. Berryman, T. E. Friedemann and J. B. Youmans, *ibid.* 1946, 11, 109.
17. R. C. Thompson, *Univ. Texas Publ.*, No. 4237, p. 87.
18. P. R. Burkholder and I. McVeigh, *Proc. Nat. Acad. Sci.*, 1942, 28, 285.
19. K. R. Johansson, S. K. Shapiro and W. B. Sarles, *J. Bact.*, 1947, 54, 35; 1948, 56, 619; J. R. Couch, W. W. Cravens, C. A. Elvehjem and J. G. Halpin, *J. Nutrition*, 1948, 35, 57.
20. J. R. Couch, M. L. Sunde, W. W. Cravens, C. A. Elvehjem and J. G. Halpin, *ibid.*, 1949, 37, 251.

## 13. ANIMAL AND HUMAN REQUIREMENTS OF BIOTIN

It is obvious, from what has been said already about the metabolism of biotin and the existence of bacterial synthesis in the gut of many animal species, that it is not easy to assess the biotin require-

ments of animals with any degree of confidence. It is not known how much of the biotin produced by the intestinal flora is normally available to the host and whether changes in the diet, which can certainly affect the amount of biotin synthesised by them (page 435), can affect the extent to which biotin can be utilised.

Bearing in mind the possibility that present day estimates may have to be revised in the light of future observations, the following values have been recorded for the daily requirements of different animal species: for the rat,  $2^1$  and  $0.5$  to  $1.0^2 \mu\text{g}$ , for chicks,  $1^3$  and  $0.65^4 \mu\text{g}$  (supplied by a diet containing  $7$  to  $10 \mu\text{g}$  of biotin per  $100 \text{ g}^5$ ), for turkeys  $40$  'rat units'  $^6$  for monkeys,  $20 \mu\text{g}$ ,  $^7$  and for pigs  $100 \mu\text{g}$ .  $^8$  Chick embryos failed to develop if the yolk contained less than  $50 \text{ m}\mu\text{g}$  of biotin per g but  $150 \text{ m}\mu\text{g}$  per g supported growth  $^9$ .

No precise estimate of the human requirements of biotin appears to be available, but subjects made biotin deficient quickly became normal when  $75$  to  $300 \mu\text{g}$  of biotin were injected per day  $^{10}$ .

#### References to Section 13

- 1 E. Nielsen and C. A. Elvehjem *Proc Soc Exp Biol Med* 1941, **48**, 349
- 2 G. A. Emerson and J. C. Keresztesy *ibid* 1942 **51**, 358
- 3 L. R. Richardson, A. G. Hogan and O. N. Miller, *Univ Missouri Agric Exp Stat Res Bull* 1942 343. J. H. Shaw and P. H. Phillips *J Nutrition* 1945 **29**, 107
- 4 T. H. Jukes and F. H. Bird *Proc Soc Exp Biol Med*, 1942 **49**, 231
- 5 D. M. Hegsted, R. C. Mills, G. M. Briggs, C. A. Elvehjem and E. B. Hart *J Nutrition* 1942 **23**, 175
- 6 H. Patrick, R. V. Boucher, R. A. Dutcher and H. C. Knandel, *Proc Soc Exp Biol Med* 1941 **48**, 456
- 7 H. A. Waisman, K. B. McCall and C. A. Elvehjem *J Nutrition* 1945 **29**, 1
- 8 T. J. Cunha, D. C. Lindley and M. E. Ensminger *J Animal Sci* 1946 **5**, 219
- 9 J. R. Couch, W. W. Cravens, C. A. Elvehjem and J. G. Halpin *J Nutrition* 1948 **35**, 57
- 10 V. P. Sydenstricker, S. A. Singal, A. P. Briggs, N. M. de Vaughn and H. Isbell *Science* 1942 **95**, 176 *J Amer Med Assoc*, 1942 **118**, 1199

#### 14 PHARMACOLOGY OF BIOTIN

The intravenous injection of  $250 \mu\text{g}$  of biotin per kg of bodyweight into anaesthetised cats had no effect on the blood pressure, heart rate or respiration  $^1$ . No effect was produced on strips of guinea pig uterus,

rabbit uterus or on rabbit intestine when these were suspended in solutions containing up to 1 part in 40,000 of biotin or when a frog's heart was perfused *in situ* with a solution containing 200  $\mu\text{g}$  of biotin

Feeding excess biotin caused fatty livers, which contained large amounts of cholesterol. The effect was inhibited by egg white lipocain or inositol when these were given at the same time as the biotin<sup>2</sup> (see page 572)

#### References to Section 14

- 1 J L Schmidt and M Landy, *Proc Soc Exp Biol Med* 1942 49, 82
- 2 G Gavin and E W McHenry *J Biol Chem*, 1941, 141, 619

### 15. BIOTIN IN THE NUTRITION OF MICRO-ORGANISMS

#### Yeasts

Biotin is an important growth factor for a number of micro organisms and can be detected by the yeast growth method (page 421) in as low a concentration as 1 part in 10,000,000,000<sup>1</sup>. It is essential for the growth of many strains of *Saccharomyces cerevisiae*<sup>2</sup> and for the vast majority of a large number of other yeasts tested<sup>3</sup>. Many yeasts can utilise instead of biotin, desthiobiotin (page 447) which is transformed into biotin within the cells<sup>4</sup>. Bacteria, however cannot utilise desthiobiotin in this way. Biotin was the only member of the vitamin B complex that definitely increased the production of alcohol by yeast<sup>5</sup>.

The biotin content of different yeasts varies considerably the lowest value found in a series tested being 0.23  $\mu\text{g}$  per g and the highest 7.6  $\mu\text{g}$  per g<sup>6a</sup>. Some yeasts e.g. *S. cerevisiae*, took up large amounts of biotin from the culture medium whereas others, e.g. *Endomyces magnusii*, took up hardly any, although both require biotin for growth, obviously the uptake is not correlated with the requirement in different species. *Torulopsis utilis* and *Hansenula anomala* which synthesise biotin, also did not take up biotin from the medium.

#### Other Fungi

Biotin was necessary for the growth of a number of moulds including *Lophodermum pinastri* and *Ashbya (Nematospora) gossypii*,<sup>6</sup> *Trichophyton album*,<sup>7</sup> *Eremothecium ashbyi*,<sup>8</sup> *Neurospora sitophila* and its 'pyridoxineless' X ray mutant,<sup>9</sup> *Hypholoma fasciculare*<sup>7</sup> and *Marasmius androsaceus*<sup>10</sup>. Biotin also stimulated the growth of

*Penicillium digitatum*, the effect being more pronounced above pH 6.5 than at pH 3.0<sup>11</sup> Other moulds which required biotin were *Ascoidea rubescens*, *Ophiostoma fagi*, *O. piliferum* and *Mutula paludosa*<sup>12</sup>

Some fungi, however, can synthesise biotin. For example, *Phycomyces blakesleeanus* on a synthetic medium containing asparagine and glucose produced a good deal of biotin, the greater part of which accumulated in the medium<sup>13</sup> The yield of biotin increased with temperature, with the amount of asparagine and in presence of traces of certain metals. *Penicillium chrysogenum* also synthesised biotin, although only in small amounts<sup>12</sup> Desthiobiotin was a normal intermediate in the biosynthesis of biotin by this mould<sup>14</sup>

An organism that cannot synthesise biotin will grow in a synthetic medium if this is also inoculated with an organism that synthesises biotin, and it is even possible for each of the organisms to supply the other with an essential growth factor that it cannot itself produce. This is believed to account for the phenomenon of symbiosis.

## Bacteria

Biotin was essential for the growth of *Lactobacillus helveticus*<sup>15</sup> and *L. arabinosus*<sup>16</sup> and indeed for all species of *Lactobacilli* tested by Rogosa *et al.*<sup>17</sup> Unlike yeasts, however, these organisms cannot utilise desthiobiotin in place of biotin<sup>18</sup> *L. helveticus* can utilise the methyl ester of biotin, though growth and fermentation were slower than with free biotin<sup>19</sup> Three strains of *Leuconostoc*, *L. mesenteroides*, *L. dextranicum* and *L. dextranicum elae* required biotin for growth when the medium contained invert sugar, glucose or fructose but grew without biotin on a sucrose medium<sup>19a</sup> Biotin was also essential for *B. radicola*,<sup>20, 21</sup> *Rhizobium trifolii*<sup>20, 21</sup> *Staphylococcus aureus*<sup>22</sup> *Streptobacterium plantarum*<sup>23</sup> and four species of *Propionibacteria*<sup>24</sup> It was also necessary for maximum growth of *Clostridium tetani*<sup>25</sup> *Cl. botulinum*,<sup>26</sup> *Cl. kluyveri*<sup>27</sup> three strains of *Cl. acetobutylicum*<sup>28</sup> and about twenty other species of *Clostridia*<sup>29</sup> *B. polymyxa* required only biotin of the vitamin B complex whilst *B. macerans* and *B. acetoaceticus* required both biotin and aneurine<sup>30</sup> Biotin was apparently the only growth factor required by *Neisseria sicca*<sup>31</sup>

The biotin requirements of bacteria can be observed by the effects of avidin on their growth<sup>32</sup>

A biotin-deficient mutant of *E. coli* was isolated by C. H. Gray and E. L. Tatum<sup>33</sup>

The amount of biotin present in the five bacteria *Aerobacter aerogenes*, *Serratia marcescens*, *Pseudomonas fluorescens*, *Proteus vulgaris* and *Clostridium butylicum* ranged from 420 to 1800 molecules per cell and the rate of synthesis from 0.08 to 3.2 molecules per cell per second<sup>34</sup>



# BIOTIN

## References to Section 15

- 1 F Kogl and B Tonnies *Z physiol Chem* 1936 242, 43
- 2 R J Williams R E Eakin and E E Snell *J Amer Chem Soc* 1940 62, 1204 L H Leonian and V G Lilly *Amer J Bot* 1942 29, 459
- 3 P R Burkholder *ibid* 1943 30, 206 P R Burkholder and D Moyer *Bull Torrey Bot Club* 1943 70, 372 P R Burkholder I McVeigh and D Moyer *J Bact* 1944 48, 385 A S Schultz and L Atkin *Arch Biochem*, 1947 14, 369
- 4 J L Stokes and M Gunness *J Biol Chem* 1945 157, 121
- 5 V de Souza and M Sreenivasaya *J Sci Ind Res India* 1945 4, 384
- 5a W S Chang and W H Peterson *J Bact* 1949 58 33
- 6 F Kogl and N Fries *Z physiol Chem* 1937 249, 93
- 7 W H Schopfer and S Blumer *Z Vitaminforsch* 1942 59, 106
- 7 Ber Schueitz *Bot Ges* 1943 53, 409
- 8 W H Schopfer *Helv Chim Acta* 1944 27, 1017
- 9 J L Stokes J W Foster and C R Woodward *Arch Biochem* 1943 2, 235
- 10 G Lindeberg *Symbol bot Upsalienses* 1944 VIII 2, 1
- 11 R C Wooster and V H Cheldelin *Arch Biochem* 1945 311
- 12 F W Tanner S E Pfeiffer and J M van Lanen *ibid* 29
- 13 W H Schopfer *Z Vitaminforsch* 1943 14, 42
- 14 E L Tatum *J Biol Chem* 1945 160, 455
- 15 G M Shull B L Hutchings and W H Peterson *ibid* 1942 142, 913
- 16 L D Wright and H R Skeggs *Proc Soc Exp Biol Med* 1944 58, 95
- 17 M Rogosa R P Tittsler and D S Geib *J Bact* 1947 54, 13
- 18 K Dittmer D B Melville and V du Vigneaud *Science* 1944 89, 203
- 19 J L Stokes and M Gunness *Proc Soc Exp Biol Med* 1943 54, 28
- 19a W W Carlson and V Whiteside Carlson *ibid* 1949 71, 416
- 20 P M West and P W Wilson *Enzymologia* 1939 8, 152
- 21 R Nilsson G Bjälfoe and D Burstrom *Naturwiss* 1939 27, 389
- 22 F Kogl and W J van Wagtenonk *Rec trav chim* 1938 57, 747
- 23 R Kuhn and K Schwartz *Ber* 1941 74, 1617
- 24 R C Thompson *J Bact* 1943 48, 99
- 25 R E Feeney J H Mueller and P A Miller *ibid* 563
- 26 C Lamanna and C Lewis *ibid* 1946 51, 398
- 27 B T Bornstein and H A Barker *ibid* 1948 55, 222
- 28 R Reyes Teodoro and M N Michelson *Arch Biochem* 1944 4, 291 1945 6, 471
- 29 J O Lampen and W H Peterson *ibid* 1943 2, 443

## REQUIREMENTS OF INSECTS

- 30 H Katznelson *J Bact* 1944 48, 495
- 31 Z J Ordal and R K Busch *ibid* 1946 51, 791
- 32 M Landy D M Dicken M M Becking and W R Mitchell  
*Proc Soc Exp Biol Med* 1942 49 441
- 33 C H Gray and E L Tatum *Proc Nat Acad Sci* 1944 30  
404
- 34 H McIlwain *Nature* 1946 158 898

## 16 EFFECT OF BIOTIN ON PLANTS

Biotin and aneurine were claimed by F Kögl and A J Haagen Smit<sup>1</sup> to be phyto hormones since each increased the growth of pea embryos grown in a synthetic medium the effect of the two compounds together was greater than that of either alone The amount of biotin like that of other members of the vitamin B complex increased during the germination of oats wheat barley and maize<sup>2</sup>

### *References to Section 16*

- 1 F Kögl and A J Haagen Smit *Z physiol Chem* 1936 243, 209
- 2 P R Burkholder *Science* 1943 97, 562

## 17 BIOTIN REQUIREMENTS OF INSECTS

Biotin is essential for the optimal growth of *Tribolium confusum*<sup>1 2</sup> and of *Sitotroga panicea* *Lasioderma serricorne* and *Plinus lectus* but not of *Silvanus surinamensis*<sup>3</sup> The diaminocarboxylic acid derived from biotin (page 407) could partially replace biotin for *Tribolium* The sterilised larvae of *Lasioderma* showed less satisfactory growth than normal larvae without biotin so that biotin may be a more important factor in the absence of symbionts<sup>4</sup> (see page 115) Biotin was necessary for the growth of mosquito larvae (*Aedes aegypti*) to the fourth instar<sup>5</sup> It could be replaced by small amounts of oleic acid or lecithin

Pollen and royal jelly are rich in biotin as well as in pantothenic acid (page 364) and it has been suggested that these two members of the vitamin B complex may be concerned with the development of bee larvae into queen bees<sup>6</sup>

The addition of raw egg white to the diet of the larvae of the rice-moth (*Corcyra cephalonica*) inhibited growth and caused death in twenty-eight days Avidin produced the same effect When larvae fed on egg white for fourteen days were given a diet rich in biotin growth was resumed and the increase in weight was approximately proportional to the amount of biotin added<sup>7</sup>

## References to Section 15

- 1 F Kogl and B Tonnies *Z physiol Chem* 1936 242, 43
- 2 R J Williams R E Eakin and E E Snell *J Amer Chem Soc* 1940 62, 1204 L H Leonian and V G Lilly *Amer J Bot* 1942 29, 459
- 3 P R Burkholder *ibid* 1943 30, 206 P R Burkholder and D Moyer *Bull Torrey Bot Club* 1943 70, 372 P R Burkholder I McVeigh and D Moyer *J Bact* 1944 48, 385 A S Schultz and L Atkin *Arch Biochem* 1947 14, 369
- 4 J L Stokes and M Gunness *J Biol Chem* 1945 157, 121
- 5 V de Souza and M Sreenivasaya *J Sci Ind Res India* 1945 4, 384
- 5a W S Chang and W H Peterson *J Bact* 1949 58, 33
- 6 F Kogl and N Fries *Z physiol Chem* 1937 249, 93
- 7 W H Schopfer and S Blumer *Z Vitaminforsch* 1942 59, 106 *Ber Schweiz Bot Ges* 1943 53, 409
- 8 W H Schopfer *Helv Chim Acta* 1944 27, 1017
- 9 J L Stokes J W Foster and C R Woodward *Arch Biochem* 1943 2, 235
- 10 G Lindeberg *Symbol bot Upsalienses* 1944 VIII 2, 1
- 11 R C Wooster and V H Cheldelin *Arch Biochem* 1945 8, 311
- 12 F W Tanner S E Pfeiffer and J M van Lanen *ibid* 29
- 13 W H Schopfer *Z Vitaminforsch* 1943 14, 42
- 14 E L Tatum *J Biol Chem* 1945 160, 455
- 15 G M Shull B L Hutchings and W H Peterson *ibid* 1942 142 913
- 16 L D Wright and H R Skeggs *Proc Soc Exp Biol Med* 1944 58, 95
- 17 M Rogosa R P Tittsler and D S Geib *J Bact* 1947 54, 13
- 18 K Dittmer D B Melville and V du Vigneaud *Science* 1944 99, 203
- 19 J L Stokes and M Gunness *Proc Soc Exp Biol Med* 1943 54, 28
- 19a W W Carlson and V Whiteside Carlson *ibid* 1949 71, 416
- 20 P M West and P W Wilson *Enzymologia* 1939 8, 152
- 21 R Nilsson G Bjalfoe and D Burstrom *Naturwiss* 1939 27, 389
- 22 F Kogl and W J van Wagtendonk *Rec trav chim* 1938 57, 747
- 23 R Kuhn and K Schwartz *Ber* 1941 74, 1617
- 24 R C Thompson *J Bact* 1943 46, 99
- 25 R E Feeney J H Mueller and P A Miller *ibid* 563
- 26 C Lamanna and C Lewis *ibid* 1946 51, 398
- 27 B T Bornstein and H A Barker *ibid* 1948 55, 222
- 28 R Reyes Teodoro and M N Michelson *Arch Biochem* 1944 4 291 1945 6, 471
- 29 J O Lampen and W H Peterson *ibid* 1943 2, 443

## REQUIREMENTS OF INSECTS

- 30 H Katznelson *J Bact* 1944 48, 495
- 31 Z J Ordal and R K Busch *ibid* 1946 51, 791
- 32 M Landy D M Dicken M M Bicking and W R Mitchell  
*Proc Soc Exp Biol Med* 1942 49, 441
- 33 C H Gray and E L Tatum *Proc Nat Acad Sci* 1944 30,  
404
- 34 H McIlwain *Nature* 1946 158, 898

## 16 EFFECT OF BIOTIN ON PLANTS

Biotin and aneurine were claimed by F Kögl and A J Haagen Smit<sup>1</sup> to be phyto hormones since each increased the growth of pea embryos grown in a synthetic medium the effect of the two compounds together was greater than that of either alone The amount of biotin like that of other members of the vitamin B complex increased during the germination of oats wheat barley and maize<sup>2</sup>

### References to Section 16

- 1 F Kögl and A J Haagen Smit *Z physiol Chem* 1936 243, 209
- 2 P R Burkholder *Science* 1943 97, 562

## 17 BIOTIN REQUIREMENTS OF INSECTS

Biotin is essential for the optimal growth of *Tribolium confusum*<sup>1 2</sup> and of *Sitotroga panicea* *Lasioderma serricorne* and *Plinus tectus* but not of *Sitona surinamensis*<sup>3</sup> The diaminocarboxylic acid derived from biotin (page 407) could partially replace biotin for *Tribolium* The sterilised larvae of *Lasioderma* showed less satisfactory growth than normal larvae without biotin so that biotin may be a more important factor in the absence of symbionts<sup>4</sup> (see page 115) Biotin was necessary for the growth of mosquito larvae (*Aedes aegypti*) to the fourth instar<sup>5</sup> It could be replaced by small amounts of oleic acid or lecithin

Pollen and royal jelly are rich in biotin as well as in pantothenic acid (page 364) and it has been suggested that these two members of the vitamin B complex may be concerned with the development of bee larvae into queen bees<sup>6</sup>

The addition of raw egg white to the diet of the larvae of the rice moth (*Corcyra cephalonica*) inhibited growth and caused death in twenty-eight days Avidin produced the same effect When larvae fed on egg white for fourteen days were given a diet rich in biotin growth was resumed and the increase in weight was approximately proportional to the amount of biotin added<sup>7</sup>

## BIOTIN

### References to Section 17


- 1 G Fraenkel and M Blewett, *Nature*, 1942 149, 301, 1942 150, 177, 1943 151, 703
- 2 H Rosenthal and T Reichstein, *ibid*, 1942, 150, 546
- 3 G Fraenkel and M Blewett, *Biochem J*, 1943 37, 686
- 4 M Blewett and G Fraenkel *Proc Roy Soc B*, 1944 132, 212
- 5 L Golberg B de Meillon and M Lavoipierre *J Exp Biol*, 1945 21, 90, W. Trager, *J Biol Chem*, 1949, 176, 1211
- 6 G Kitzes H A Schuette and C A Elvehjem *J Nutrition* 1943 28, 241
- 7 P S Sarma, *Indian J Med Res*, 1944 32, 149

## 18 FUNCTION OF BIOTIN

Miller *et al*<sup>1</sup> sought to determine the function of biotin by estimating the amounts present in a number of enzyme preparations, but they failed to detect a single enzyme that contained more than one molecule of biotin per molecule, and accordingly concluded that biotin was only present as an impurity. D Burk and R J Winzler<sup>2</sup> suggested that biotin was the prosthetic group of a coenzyme that catalysed the transfer of carbon dioxide, whilst Koser *et al*<sup>3</sup> suggested that it was concerned with the synthesis of aspartic acid, since the latter stimulated the growth of *Torula cremoris* in the absence of biotin. This was confirmed five years later, when Stokes <sup>4</sup> *et al* showed that *S faecalis* R L *helveticus* and *L arabinosus* failed to grow unless about 1  $\mu\text{g}$  of biotin and 1 mg of aspartic acid per 10 ml were added to the medium but that if the biotin concentration were increased to 10  $\mu\text{g}$  per 10 ml the addition of aspartic acid was unnecessary. Aspartic acid was therefore synthesised by organisms grown in presence of excess biotin. Oxybiotin and the diaminocarboxylic acid (page 407) could replace biotin for this purpose, but larger quantities were required. *L arabinosus* was able to synthesise aspartic acid from glutamic acid plus oxaloacetic acid, fumaric acid plus malic acid or succinic acid, and from alanine plus oxaloacetic acid but biotin did not play any part in these reactions. Apparently therefore, the enzyme system containing biotin was not concerned with the final stage in the synthesis of aspartic acid but with one of the intermediate stages.

### Carboxylation and Decarboxylation

Using *E coli* H C Lichstein and W W Umbreit<sup>5</sup> showed that aspartic acid was degraded according to the following scheme



## BIOTIN

decarboxylation of oxaloacetic acid, however, by the observations of Ochoa *et al.*,<sup>8</sup> who isolated from pigeon and turkey livers an enzyme that catalysed the reversible conversion of L-malic acid to pyruvic acid plus carbon dioxide and the decarboxylation of oxaloacetic acid to pyruvic acid. In biotin-deficient turkeys the amount of this enzyme, though not of other enzymes catalysing related reactions was markedly reduced but, unfortunately, the purified enzyme did not contain biotin.

H A Lardy and his co-workers,<sup>9</sup> however, have produced evidence suggesting that biotin may be associated with carbon dioxide fixation in several different enzyme reactions, not only in micro organisms but also in animals. Thus, in presence of biotin, *L. arabinosus* fixed  $C^{14}$  from bicarbonate into cellular aspartic acid, but no fixation occurred when the medium contained less than 0.05  $\mu\text{g}$  of biotin per ml, or when aspartic acid or an anti-biotin was added. Again,  $C^{14}$  fixation occurred to a greater extent in normal rats than in biotin deficient animals, and the livers of biotin deficient animals synthesised citrulline at half the rate of normal or vitamin B<sub>6</sub> deficient animals, the rate was increased to normal by the intraperitoneal injection of biotin containing  $C^{14}$  was prepared by reacting the diamino carboxylic acid (page 407) with radioactive phosgene. When added to cultures of *L. arabinosus* under conditions requiring its participation in carbon dioxide fixation, there was no replacement of  $C^{14}$  by  $C^{12}$ , so that the ureido carbonyl group is apparently not transferred during carbon dioxide fixation.<sup>10</sup>

## Deamination

Carbon dioxide fixation does not appear to be the only function of biotin and according to H C Lichstein and W W Umbreit,<sup>11</sup> it can also restore the ability of *E. coli* to deaminate aspartic acid, serine and threonine when this is lost by the cells having been left at pH 4 for thirty minutes at 27 to 37° C. Thus biotin appeared to be connected with reaction (a) in the above scheme, as well as with reaction (d). Similar results were obtained with other bacterial species and aspartic acid deaminase activity was restored by adenylic acid as well as by biotin. In no instance was the alanine, phenylalanine, methionine or glutamic acid deaminase activity affected by biotin.<sup>12</sup>

Axelrod *et al.*,<sup>13</sup> however, failed to confirm these results, but H C Lichstein<sup>14</sup> showed that this was due to their use of an unsuitable medium. Adenylic acid was shown to be necessary for the activation of biotin for the stimulation of cell free aspartic acid deaminase,<sup>15</sup> and a deaminase activator that was neither biotin nor adenylic acid was isolated from yeast by paper partition chromatography.<sup>16</sup> It supported the growth of *S. cerevisiae* (Java strain) in a biotin deficient

# FUNCTION

medium and on hydrolysis biotin was liberated supporting the growth of *S. cerevisiae* 139 which does not respond to the coenzyme

## Oxidation of Pyruvic and Lactic Acids

A suggestion by Summerson *et al*<sup>17</sup> that biotin may be concerned with the oxidation of pyruvic acid and lactic acid indicates yet another possible function of biotin. The evidence for the suggestion was that carbon dioxide production was markedly increased when biotin was added to liver slices from biotin deficient rats respiring in a solution containing lactate or pyruvate as substrate. These results are supported by similar observations made by Olson *et al*<sup>18</sup> on the respiration of ventricle slices from biotin deficient ducks. In presence of succinate the oxygen uptake was much less than normal and the accumulation of lactic acid decreased. In addition the production of  $\text{CO}_2$  from carbon dioxide from labelled succinate by ventricle slices was much less with tissue from biotin-deficient ducks than with tissue from controls.

## References to Section 18

- 1 D R Miller J O Lampen and W H Peterson *J Amer Chem Soc* 1943 65, 2369
- 2 D Burk and R J Winzler *Science* 1943 97, 57
- 3 S A Koser M H Wright and A Dorfman *Proc Soc Exp Biol Med* 1942 51, 204
- 4 J L Stokes A Larsen and M Gunness *J Bact* 1947 54, 19
- 5 H C Lichstein and W W Umbreit *ibid* 1947 170, 613
- 6 H A Lardy R L Potter and C A Elvehjem *ibid* 1947 170, 329
- 7 W Shive and L L Rogers *ibid* 1947 169, 451
- 7a A E Axelrod S E Purvis and K Hofmann *ibid* 1948 170, 695
- 8 S Ochoa A Mehler M L Blanchard T H Jukes C E Hoffmann and M A Regan *ibid* 1947 170, 413
- 9 H A Lardy R L Potter and R H Burris *J Biol Chem* 1949 179, 721
- 10 P R MacLeod and H A Lardy *ibid* 1949 179, 721
- 11 S MacLeod S Grisolia P P Cohen and H A Lardy *ibid* 1949 180, 1003
- 12 D B Melville J G Pierce and C W H Partridge *ibid* 1947 170, 299
- 13 H C Lichstein and W W Umbreit *ibid* 1947 170, 423
- 14 H C Lichstein and J F Christman *ibid* 1948 175, 649
- 15 A E Axelrod K Hofmann S E Purvis and M Mayhall *ibid* 1949 177, 487
- 16 H C Lichstein *ibid* 1949 177, 487
- 17 H C Lichstein and J F Christman *J Bact* 1949 58, 565
- 18 W H Summerson J M Lee and C W H Partridge *Science* 1944 100, 250
- 19 R E Olson, O N Miller, J J Topper and F J Stare *J Biol Chem* 1948 175, 503



## 19. ANALOGUES OF BIOTIN

## Pimelic Acid

The nutritional requirements of *Corynebacterium diphtheriae* were studied by J H Mueller *et al.*<sup>1</sup> who showed that the growth of this organism was stimulated by various fractions prepared from animal tissues, in addition to a number of amino acids. One of the constituents of these fractions was identified as pimelic acid<sup>2</sup> and synthetic pimelic acid proved to be equally active. Mueller's observations were confirmed by Evans *et al.*<sup>3</sup> using *gravis*, *intermedius* and *mitis* strains of *C. diphtheriae*. Du Vigneaud *et al.*<sup>4</sup> showed that biotin could replace pimelic acid for the Allen strain of *C. diphtheriae*, although pimelic acid produced slightly more growth than biotin at the maximum level of  $1.5 \mu\text{g}$ , biotin was more effective than pimelic acid however, at low concentrations. Pimelic acid is probably utilised by some strains of this organism for the synthesis of biotin, much as some strains utilise  $\beta$  alanine in place of pantothenic acid. Thirteen different organisms tested by W J Robbins and R Ma<sup>5</sup> failed to grow on an otherwise complete medium in which biotin was replaced by pimelic acid alone or accompanied by L-cystine, glutathione or methionine.

## Isomers of Biotin

Synthetic *d* biotin and natural biotin had identical growth promoting activities for three bacteria, one yeast and a fungus. *l* Biotin and *dl* allobiotin supported the growth of bacteria only in large amounts and this slight activity was probably due to contamination with traces of *d* biotin.<sup>6</sup>

On rats maintained on a diet containing egg white *dl* biotin was half as active as natural biotin,<sup>7</sup> whilst *l* biotin was without effect at seven and a half times and *dl* allobiotin at ten times, the level of biotin.



Synthetic *d* biotin was as effective as natural biotin<sup>8</sup> in promoting growth and preventing dermatitis in chicks fed a purified diet containing 15 % of raw egg white. *l*-Biotin and *dl*-biotin were inactive.

## Homologues of Biotin

Rather surprisingly perhaps increasing or decreasing the length of the valeric acid side-chain of biotin not only almost completely destroys the growth promoting activity of the molecule but converts it into a growth inhibitory substance. Although nor biotin ( $n=3$ ) and homo biotin ( $n=5$ ) can replace biotin for *Saccharomyces globosus* and one strain of *S. cerevisiae* they and other homologues are potent antagonists of biotin for other strains of the latter and for *S. fragilis*, *Zygosaccharomyces barkeri* and *L. helveticus*<sup>9a</sup> (page 453).

# Analogues of Biotin

2- $\gamma$  Hydroxypropyl 2' ketoimidazolidino (4' 5' 3 4) thiophene <sup>9</sup> (I) and *dl* tetrahydrobiotin <sup>10</sup> (II)



were inactive when tested on *S cerevisiae* and on *L arabinosus* or *L helveticus* neither had anti biotin activity Analogues of biotin in which the valeric acid side-chain was replaced by  $\gamma$  phenoxy  $\gamma$  benzyloxy and  $\gamma$  hydroxy *n* propyl groups were also without biotin activity for *L arabinosus* or *S cerevisiae* and without anti biotin activity <sup>11</sup>

## Biotin Sulphone

Oxidation of biotin gave a sulphone (page 407) which stimulated the growth of yeast Even with large amounts however growth did not increase beyond a relatively low maximum which was only about one third of that obtained with biotin <sup>12</sup> The sulphone had only about 0.1 % the activity of biotin when the two were compared at a level that produced one quarter of the maximal growth Biotin sulphone like desthiobiotin has anti biotin activity (see page 452)

## Degradation Products of Biotin

The diamino-carboxylic acid 3 4 diamino tetrahydrothiophene 2 valeric acid derived from biotin by treatment with alkali (page 407) was found to stimulate the growth of yeast in a biotin free medium <sup>13</sup> It possessed about one tenth the activity of biotin and its action was not inhibited by avidin It had 4 to 7 % of the activity of biotin for *Lactobacilli* <sup>6</sup> Diaminopelargonic acid which on treatment with phosgene yields desthiobiotin had one tenth the activity of desthiobiotin towards yeast <sup>14</sup> The diamino-tetrahydrothiophene 2 valeric acids corresponding to *dl* allo and *dl* *epi* allo-biotin were inactive at levels 100 to 250 times that at which biotin was active <sup>7</sup>





## Desthiobiotin

When biotin was treated with Raney nickel an atom of sulphur is lost giving desthiobiotin (page 410) This was found to stimulate the growth of yeast but not of *L helveticus* <sup>6, 15</sup> This diver e effect on the two micro-organisms was shown to be due to the ability of










# BIOTIN

yeast to convert desthiobiotin into biotin since the former disappeared from the incubated culture and was replaced by a substance with growth promoting properties for *L. helveticus* <sup>6 18</sup>

Desthiobiotin was synthesised in several ways J L Wood and V du Vigneaud <sup>17</sup> used the following method




Melville <sup>18</sup> prepared it by the action of phosgene in alkaline solution on its degradation product, ζη diaminopelargonic acid whilst R Duschinsky and L A Dolan <sup>19</sup> synthesised it by the following route



# ANALOGUES

Another route was used by Bourquin *et al*<sup>20</sup>:



*dl*-Nordesthiobiotin was prepared by an analogous series of reactions. Substantially the same method was used by G. Swain,<sup>20a</sup> except that the amino group was introduced by chlorination with sulphuryl chloride, followed by amination with potassium phthalimide

Although *dl*-desthiobiotin was active towards *Saccharomyces cerevisiae*, *dl*-nordesthiobiotin was not, nor was *dl*- $\psi$ -desthiobiotin, prepared by the action of Raney nickel on *dl*- $\psi$ - $\beta$  biotin

According to Rubin *et al*<sup>21</sup> synthetic *dl* desthiobiotin had half the activity of *d* biotin towards *S. cerevisiae*, but only 0.01 to 0.1 % of the activity of biotin on rats made biotin-deficient by the addition of egg white or succinylsulphathiazole to the diet

That desthiobiotin is converted by certain organisms into biotin was confirmed by L. H. Leonian and V. G. Lilly,<sup>22</sup> who showed that 12 yeasts and 4 filamentous fungi grown on desthiobiotin converted it into a substance active for *L. arabinosus*, *L. heliolicus*, *Rhizobium trifolii* 205 and *Sordaria fimicola*, all of which are unable to utilise desthiobiotin. *S. cerevisiae* 'old process', however, when grown in presence of biotin and desthiobiotin, yielded substances with biotin activity for the two *Lactobacilli*, but not for *R. trifolii*


Desthiobiotin had the same activity as biotin for *Neurospora crassa*, *E. coli* and *Penicillium notatum*, 21464 but was inactive for *P. chrysogenum* 62078<sup>23</sup> This last organism apparently synthesises desthiobiotin and the addition of pimelic acid increased the amount produced. This gives further support to the view that desthiobiotin is an intermediate in the biosynthesis of biotin. Desthiobiotin could replace biotin as a growth factor for several *Clostridia*<sup>24</sup>

The thiourea analogue of desthiobiotin, 5-methyl-2-thio-imidazolidone-4-*n*-hexoic acid, had a very slight growth-promoting activity towards yeast, and this was completely inhibited by avidin<sup>25</sup> Towards *L. heliolicus* it showed a low anti biotin activity in comparison with that of desthiobiotin (page 452)

## BIOTIN

$\alpha$ -Isopropyl-5-methyl-2-imidazolidone-4-propionic acid, the structural isomer of desthiobiotin corresponding to Kogl's revised formula for  $\alpha$ -biotin (page 412), had neither growth-promoting activity towards *S. cerevisiae* or *L. helveticus* nor anti biotin activity towards *L. helveticus* <sup>26</sup>

The higher homologue of desthiobiotin, homodesthiobiotin was synthesised by the following route <sup>27</sup>



It was devoid of biotin activity when tested on *S. cerevisiae* but had anti-biotin activity (page 452). A method similar to the above was also used for the preparation of desthiobiotin.

Two other homologues of desthiobiotin, 2-imidazolidone 4-*n* hexoic acid and 5-ethyl-2-imidazolidone-4-*n*-hexoic acid, were also without biotin activity towards *S. cerevisiae* and *L. helveticus* <sup>28</sup>. They antagonised the growth promoting effect of biotin, however (page 452).

### Oxybiotin


Oxybiotin <sup>29</sup> or O heterobiotin, one of the four possible racemic forms of 2'-keto imidazolidino (4' 5' 3 4)-tetrahydrofuran-2-*n* valeric acid was synthesised by the route <sup>30</sup> shown on opposite page.

According to Duschinsky *et al* <sup>31</sup> oxybiotin had 25 % of the growth promoting activity of *d*-biotin towards *L. helveticus* or *Saccharomyces cerevisiae* and, according to Pilgrim *et al* <sup>32, 33</sup> 50 % of the activity of *d*-biotin towards *L. arabinosus*, 40 % towards *L. helveticus*, 15 % towards *Rhizobium trifolii* and 25 and 8 % towards *S. cerevisiae* when compared at half maximal and maximal growth respectively.

Rubin *et al* <sup>34</sup> found it to have 28 % of the activity of biotin for *S. cerevisiae* (5 strains) and *L. helveticus*, and 50 % for *L. arabinosus*. They also found that it was inactivated by avidin in the same stoichiometric proportions as was biotin, whilst its growth-promoting action on *L. helveticus* was inhibited by desthiobiotin. Oxybiotin could replace biotin as a growth factor for several *Clostridia*, <sup>24</sup> and for *Lactobacillus pentosus* <sup>24a</sup>.

Oxybiotin can be estimated by comparing the growth produced in

# ANALOGUES



cultures of *L. arabinosus* and *S. faecalis*,<sup>35</sup> and subtracting the true biotin content, as indicated by the response of *S. faecalis*, from the apparent biotin content, as indicated by *L. arabinosus*. It can also be estimated by first destroying biotin with Raney nickel which does not affect oxybiotin and then assaying the solution microbiologically.<sup>34</sup>

Oxybiotin cured egg white injury in the rat, being 5 to 10 % as effective as *d* biotin in this respect<sup>34, 37, 38</sup>. It also cured symptoms of biotin deficiency in chicks having 17 to 33 % of the activity of *d*-biotin<sup>39, 40</sup>. Its activity fell off with increasing dosage, and oxybiotin was found in liver and muscle when large doses were given.<sup>40</sup>

The diamino-carboxylic acid, 3,4-diaminotetrahydrofuran-2-valeric acid from oxybiotin was inactive for *S. cerevisiae* and for *L. arabinosus*.<sup>33</sup> Replacement of the carboxyl group of oxybiotin by a primary alcohol group gave a compound with 1/300 the activity of biotin. Oxybiotin, its methyl ester and the corresponding alcohol combined with avidin in the same molecular proportion as did biotin.<sup>33</sup>

Rubin *et al*.<sup>34</sup> assumed that oxybiotin was converted to biotin or a vitamer of similar activity, but it is now certain that oxybiotin does not owe its activity to conversion into biotin. K. Hofmann and T. Winnick<sup>41</sup> developed a method of estimating oxybiotin by first destroying any biotin present by oxidation with o-or N-potassium

## BIOTIN

permanganate, which does not attack oxybiotin, and then testing the solution with yeast for growth-stimulating activity. They were thus able to show that *S. cerevisiae* and *R. trifolii* grown in presence of oxybiotin utilised the compound as such and not after conversion into biotin. Thus the sulphur atom is not essential for biological activity. This conclusion was confirmed by Axelrod *et al.*<sup>42</sup> for *S. cerevisiae*, by K. K. Krueger and W. H. Peterson<sup>24a</sup> for *L. pentosus* and by McCoy *et al.*<sup>42a</sup> for chicks.

Oxybiotin was prepared from the second *cis*-isomer of 3,4-diaminotetrahydrofuran-2-valeric acid, but neither of the *trans*-isomers reacted with phosgene, in striking contrast to the corresponding thiophen compounds, all four of which reacted to give cyclic ureides<sup>4,5</sup>. A series of homologues of oxybiotin, in which the side-chain contained two to six methylene groups, were prepared by Hofmann *et al.*<sup>43</sup>. None of the compounds had appreciable biotin activity, and none had any anti biotin activity at a molar inhibition ratio of 500,000. The nor- ( $n = 3$ ), homo ( $n = 5$ ) and bis-homo ( $n = 6$ ) analogues had anti oxybiotin activity, however, at ratios of 143,000, 30,000, and 7400 respectively; the bis-nor- ( $n = 2$ ) analogue had no activity. With *L. arabinosus*, only the homo compound had any activity, a ratio of 225,000.

## Growth Inhibitors



A number of analogues related to biotin had an inhibitory effect on the growth of certain micro organisms owing to their ability to compete with biotin for some metabolic process essential for the activity of the cell. Some of these substances functioned as growth promoters under some conditions.

Biotin sulphone, for instance, although a growth factor for yeast (page 447) inhibited the growth of *L. helveticus*, *L. arabinosus* and *Staphylococcus aureus*,<sup>44</sup> 280 moles of the sulphone antagonising 1 mole of biotin.<sup>12</sup> The addition of biotin counteracted the inhibitory effect of the sulphone.

Another substance that behaved both as a growth inhibitor and as a growth promoter was desthiobiotin (page 410). This had a molar inhibition ratio of 200,000 for *S. cerevisiae* and of 1,000,000 for *L. helveticus*<sup>17, 45</sup>. Homodesthiobiotin (page 450) and 5 methyl 2 imidazolidone had no anti biotin activity,<sup>27</sup> but two other homologues of desthiobiotin, 2 imidazolidone-4 *n* hexoic acid and 5 ethyl 2 imidazolidone 4 *n* hexoic acid (page 450) antagonised the activity of biotin.<sup>28</sup>  $\alpha$  I-opropyl 5 methyl 2 imidazolidone-4 propionic acid had no anti biotin activity,<sup>26</sup> whilst the thiourea analogue of desthiobiotin (page 449) exhibited only a slight growth inhibitory activity.<sup>25</sup>

A series of four imidazolidone aliphatic acids were synthesised by Dittmer *et al.*<sup>46</sup> these differed from desthiobiotin and its homologues in the absence of the methyl group. These compounds inhibited *S. cerevisiae* and *L. helveticus* and the effect was counteracted by biotin.<sup>47, 48</sup> Imidazolidone *n* hexoic acid was the most potent with a molar inhibition ratio of 126 000 for *L. helveticus* and 760 000 for yeast; it also inhibited types II and III pneumococci and *E. coli*. It was much more effective with desthiobiotin as the growth stimulant so that it probably functions by competing with desthiobiotin for an enzyme system that synthesises biotin. The antibacterial index for the competitive inhibition of desthiobiotin by imidazolidone caproic acid was increased from 100 to 300 by exogenous  $\alpha$  ketoglutaric acid. The significance of this observation has already been discussed (page 443).

Two other potent anti biotins were  $\gamma$  (3, 4 ureylene cyclohexyl) butyric acid and  $\gamma$  (2, 3 ureylene cyclohexyl) butyric acid which have a formal resemblance to biotin.



Rather surprisingly the former inhibited *L. helveticus* but not *S. cerevisiae* whereas the latter inhibited *S. cerevisiae* but not *L. helveticus*.<sup>49</sup>

$\gamma$  (3, 4 Ureylene cyclohexyl) butyric acid and also biotin sulphone were more potent antagonists of *dl* oxybiotin with *L. arabinosus* than of *d* biotin; for at certain levels the action of oxybiotin was completely counteracted whereas that of *d* biotin was scarcely affected.<sup>50</sup>

The following homologues of biotin and their derivatives were found to be antagonistic to biotin both for *S. cerevisiae* 139 and for *L. helveticus*: *dl* norbiotin, *dl* homobiotin, *dl* bis homobiotin and *dl* tris homobiotin, *dl* homobiotin sulphone, *dl* bis homobiotin sulphone and *dl* tris homobiotin sulphone.<sup>51</sup> Of these homobiotin was the most potent, being probably the most potent anti biotin known for both micro-organisms.


Some but not all of these compounds also inhibited *L. arabinosus*. With oxybiotin as growth factor the homologues of biotin were more effective than the sulphones in inhibiting *L. helveticus* and *S. cerevisiae* but the sulphones were more effective with *L. arabinosus*.<sup>5</sup> Homologues of oxybiotin containing 2, 3, 5 and 6 methylene groups in the side-chain were prepared and tested as antagonists of biotin and



## BIOTIN

oxybiotin with *S. cerevisiae*, *L. arabinosus* and *Streptococcus haemolyticus*, most of the compounds were extremely potent with oxybiotin as growth factor but almost inactive with biotin<sup>53</sup>. Homo oxybiotin ( $n = 5$ ) had no protective effect on mice infected with *S. haemolyticus*.

The sulphonic acid analogues of oxybiotin and homo oxybiotin



were synthesised by Hofmann *et al.*<sup>53, 54</sup>. The *dl* oxybiotin sulphonic acid and the corresponding thiol and benzylthioether had pronounced antibiotin and anti oxybiotin activity for a number of micro organisms. The *dl* homo oxybiotin sulphonic acid however had slight growth promoting activity although the corresponding thiol and benzyl thioether were inhibitory to *S. cerevisiae*.

4 Methyl 5 ( $\epsilon$  sulphoamyl) 2 imidazolidone the sulphonic acid analogue of desthiobiotin also inhibited the growth of *S. cerevisiae* especially when oxybiotin or desthiobiotin was the growth factor the compound had no effect on *L. helveticus*<sup>55</sup>.

### References to Section 19

- 1 J H Mueller K S Klise E F Porter and A Graybiel *J Bact* 1933 **25**, 509 J H Mueller *ibid* 1935 **29**, 515 1935 **30** 513  
J H Mueller and I Kapnick *ibid* 525 J H Mueller *ibid* 1936 **32**, 207 J H Mueller and Y SubbaRow *ibid* 1937 **34** 153
- 2 J H Mueller *Science* 1937 **85**, 502 *J Biol Chem* 1937 **119** 124 *J Bact* 1937 **84** 163
- 3 W C Evans F C Happold and W R C Handley *Brit J Exp Path* 1939 **20**, 41
- 4 V du Vigneaud K Dittmer E Hague and B Long *Science* 1942 **96**, 186
- 5 W J Robbins and R Ma *ibid* 406
- 6 J L Stokes and M Gunness *J Biol Chem* 1945 **157**, 121
- 7 G A Emerson *ibid* 127
- 8 W H Ott *ibid* 131
- 8a M R Belcher and H C Lichstein *J Bact* 1949 **58** 565
- 9 L C Cheney and J R Piening *J Amer Chem Soc* 1945 **67** 729 731 2213
- 10 S R Safir S Bernstein B R Baker W L McEwen and Y SubbaRow *J Org Chem* 1947 **12**, 475

- 11 L C Cheney and J R Piening *J Amer Chem Soc* 1945 67, 2252
- 12 K Dittmer and V du Vigneaud *Science* 1944 100, 129 *Arch Biochem* 1944 4, 229
- 13 V du Vigneaud K Dittmer K Hofmann and D B Melville *Proc Soc Exp Biol Med* 1942 50, 374
- 14 D B Melville *J Amer Chem Soc* 1944 66 1422
- 15 D B Melville K Dittmer G B Brown and V du Vigneaud *Science* 1943 98, 497
- 16 K Dittmer D B Melville V du Vigneaud *Proc Soc Exp Biol Med* 1944 99, 203 *Science* 1944 99, 203
- 17 J L Wood and V du Vigneaud *J Amer Chem Soc*, 1945 67, 210
- 18 D B Melville *ibid* 1944 66, 1422
- 19 R Duschinsky and L A Dolan *ibid* 1945 67, 2079
- 20 J P Bourquin O Schneider and A Grussner *Helv Chim Acta* 1945 28, 528
- 20a G Swain *J Chem Soc* 1948 1552
- 21 S H Rubin L Dreker and E H Moyer *Proc Soc Exp Biol Med* 1945 58, 352
- 22 L H Leonian and V G Lilly *J Bact* 1945 49, 291
- 23 E L Tatum *J Biol Chem* 1945 160 455
- 24 D Perlman *Arch Biochem* 1948 16 79
- 24a K. K. Krueger and W H Peterson *J Bact* 1948 55 693
- 25 G B Brown and V du Vigneaud *J Biol Chem* 1946 163, 761
- 26 G B Brown and M F Ferger *J Amer Chem Soc* 1946 68, 1507
- 27 H McKennis and V du Vigneaud *ibid* 832
- 28 R Duschinsky and L A Dolan *ibid* 2350
- 29 K Hofmann and A E Axelrod *Arch Biochem* 1946 11 375
- 30 K Hofmann *J Amer Chem Soc* 1945 67 1459 B P 615901 615908 615909 617260
- 31 R Duschinsky L A Dolan D Flower and S H Rubin *Arch Biochem* 1945 6, 480
- 32 F J Pilgrim A E Axelrod T Winnick and K Hofmann *Science* 1945 102, 35
- 33 T Winnick K Hofmann F J Pilgrim and A E Axelrod *J Biol Chem* 1945 161, 405
- 34 S H Rubin D Flower F Rosen and L Dreker *Arch Biochem* 1945 8, 79
- 35 T D Luckey P R Moore and C A Elvehjem *Proc Soc Exp Biol Med* 1946 61, 97
- 36 K Hofmann T Winnick and A E Axelrod *J Biol Chem* 1947 169, 191
- 37 A E Axelrod F J Pilgrim and K Hofmann *ibid* 1946 163 191
- 38 K Hofmann R H McCoy J R Felton A E Axelrod and F J Pilgrim *Arch Biochem* 1945 7, 393
- 39 R H McCoy J R Felton and K Hofmann *ibid* 1946 9 141
- 40 P R Moore T D Luckey C A Elvehjem and E B Hart *Proc Soc Exp Biol Med* 1946 61, 185
- 41 K Hofmann and T Winnick *J Biol Chem* 1945 160, 449

- 42 A E Axelrod B C Flinn and K Hofmann *J Biol Chem* 1947 **169**, 195
- 42a R H McCoy J M McKibbin A E Axelrod and K Hofmann *ibid* 1949 **176** 1319 1327
- 42b K Hofmann *J Amer Chem Soc* 1949 **71**, 164
- 43 K Hofmann C Chen A Bridgwater and A E Axelrod *J Amer Chem Soc* 1947 **69**, 191
- 44 K Hofmann D B Melville and V du Vigneaud *J Biol Chem* 1941 **141**, 207
- 45 V G Lilly and L H Leonian *Science* 1944 **99**, 203
- 46 K Dittmer M F Ferger and V du Vigneaud *J Biol Chem* 1946 **163**, 19
- 47 L L Rogers and W Shive, *ibid*, 1947 **169**, 57
- 48 K Dittmer and V du Vigneaud *ibid* 63
- 49 J P English R C Clapp Q P Cole I F Halverstadt J O Lampen and R O Roblin *J Amer Chem Soc* 1945 **67**, 295
- 50 A E Axelrod J De Woody and K Hofmann *J Biol Chem* 1946 **163**, 771
- 51 M W Goldberg L H Sternbach S Kaiser S D Heineman J Scheiner and S H Rubin *Arch Biochem* 1947 **14**, 480
- 52 S H Rubin and J Scheiner *ibid* 1949 **23**, 400
- 53 A F Axelrod and K Hofmann *J Biol Chem* 1949 **180** 525
- 54 K Hofmann A Bridgwater and A E Axelrod *J Amer Chem Soc* 1947 **69**, 1550 1949 **71**, 1253
- 55 R Duschinsky and S H Rubin *ibid* 1948 **70** 2546

## CHAPTER VIII

# THE FOLIC ACID COMPLEX

---

### I INTRODUCTION

#### Folic Acid

One of the most complicated chapters in the story of the vitamin B complex is that relating to folic acid. When certain fastidious micro-organisms such as *Lactobacillus helveticus* (frequently referred to especially in U.S.A. as *L. casei* c) and *Streptococcus faecalis* R (previously called *S. lactis* R) are transferred to a synthetic medium containing in addition to amino acids all the members of the vitamin B complex so far discussed little or no growth occurs. The addition of certain concentrates prepared from natural sources produces optimal growth however and folic acid is the name given to one such factor obtained in 1941 from spinach leaves (hence its name) by H. K. Mitchell, E. E. Snell and R. J. Williams.<sup>1</sup>

The two essential steps in the preparation of this substance were adsorption on charcoal and elution of the active principle from the adsorbate by means of aqueous ammonia (steps also used in the preparation of several other growth factors since shown to be closely related chemically and biologically to folic acid). It is convenient therefore to discuss all these substances together and refer to them collectively as the folic acid complex.

#### Norit Eluate Factor or *L. casei* Factor

One of these substances is the factor first called the norit eluate factor and subsequently known as the *L. casei* factor. This was first described by E. E. Snell and W. H. Peterson<sup>2</sup> who stated that certain lactic acid bacteria when grown in a medium containing amino acids and all the known growth factors required in addition two new growth factors isolated from liver, one adsorbed and the other not adsorbed on norit. They were accordingly distinguished as the norit eluate factor and norit filtrate factor respectively. The former was concentrated by a series of additional steps giving a product that resembled the naturally occurring purines in several respects.

The best source of the new factor was solubilized liver which was also used by E. L. R. Stokstad<sup>3</sup> in making a somewhat purer

# BIOTIN

- 42 A E Axelrod B C Flinn and K Hofmann *J Biol Chem* 1947 169, 195
- 42a R H McCoy J M McKibbin A E Axelrod and K Hofmann *ibid* 1949 178 1319 1327
- 42b K Hofmann *J Amer Chem Soc* 1949 71, 164
- 43 K Hofmann C Chen A Bridgwater and A E Axelrod *J Amer Chem Soc* 1947 69, 191
- 44 K Hofmann D B Melville and V du Vigneaud *J Biol Chem* 1941 141, 207
- 45 V G Lilly and L H Leonian *Science* 1944 99, 203
- 46 K Dittmer M F Ferger and V du Vigneaud *J Biol Chem* 1946 163, 19
- 47 L L Rogers and W Shive, *ibid*, 1947 169, 57
- 48 K Dittmer and V du Vigneaud *ibid* 63
- 49 J P English R C Clapp Q P Cole I F Halverstadt J O Lampen and R O Roblin *J Amer Chem Soc* 1945 67, 295
- 50 A E Axelrod J De Woody and K Hofmann *J Biol Chem* 1946 163, 771
- 51 M W Goldberg L H Sternbach S Kaiser S D Heineman J Scheiner and S H Rubin *Arch Biochem* 1947 14, 480
- 52 S H Rubin and J Scheiner *ibid* 1949 23, 400
- 53 A F Axelrod and K Hofmann *J Biol Chem* 1949 180 525
- 54 K Hofmann A Bridgwater and A E Axelrod, *J Amer Chem Soc* 1947 69, 1550 1949 71, 1253
- 55 R Duschinsky and S H Rubin *ibid* 1948 70 2546

## CHAPTER VIII

# THE FOLIC ACID COMPLEX

---

### 1. INTRODUCTION

#### Folic Acid

One of the most complicated chapters in the story of the vitamin B complex is that relating to folic acid. When certain fastidious microorganisms such as *Lactobacillus helveticus* (frequently referred to especially in U.S.A. as *L. casei*  $\epsilon$ ) and *Streptococcus faecalis* R (previously called *S. lactis* R) are transferred to a synthetic medium containing in addition to amino acids all the members of the vitamin B complex so far discussed little or no growth occurs. The addition of certain concentrates prepared from natural sources produces optimal growth; however, and folic acid is the name given to one such factor obtained in 1941 from spinach leaves (hence its name) by H. K. Mitchell, E. E. Snell and R. J. Williams.<sup>1</sup>

The two essential steps in the preparation of this substance were adsorption on charcoal and elution of the active principle from the adsorbate by means of aqueous ammonia (steps also used in the preparation of several other growth factors since shown to be closely related chemically and biologically to folic acid). It is convenient therefore to discuss all these substances together and refer to them collectively as the folic acid complex.

#### Norit Eluate Factor or *L. casei* Factor

One of the substances is the factor first called the norit eluate factor and subsequently known as the *L. casei* factor. This was first described by E. E. Snell and W. H. Peterson<sup>2</sup> who stated that certain lactic acid bacteria when grown in a medium containing amino acids and all the known growth factors required in addition two new growth factors isolated from liver, one adsorbed and the other not adsorbable on norit. They were accordingly distinguished as the norit eluate factor and norit filtrate factor respectively. The former was concentrated by a series of additional steps giving a product that resembled the naturally occurring purines in several respects.

The best source of the new factor was solidified liver which was also used by E. L. R. Stokstad<sup>3</sup> in making a somewhat purer

## THE FOLIC ACID COMPLEX

preparation (see page 467) This had the properties of a purine pyrimidine dinucleotide or a mixture of the two mononucleotides, and could be replaced as a growth factor by a mixture of guanine and thymine, although larger amounts of these were required in order to produce the same response (page 513) Compared with the folic acid of Mitchell, Snell and Williams, Snell and Peterson's factor and Stokstad's factor were relatively crude, and this in part accounts for the conclusion reached at the time by Mitchell *et al* that folic acid was not identical with either of these factors

The nonit eluate factor from liver was still further purified by Hutchings *et al*<sup>6</sup> who showed that it was essential for the nutrition of the chick although there was an element of doubt as to the identity of the bacterial and chick factors, as the one preparation was not tested for both types of activity The method of isolation and the behaviour towards inactivating agents were, however, identical with those reported by earlier workers, and it was subsequently observed<sup>6</sup> that purified preparations of this chick factor not only promoted growth but also resulted in increased haemoglobin formation and normal feathering of chicks

The picture then became a trifle confused following the publication of a paper by E L R Stokstad<sup>8</sup> describing the preparation of a nonit eluate factor from yeast Although the product stimulated the growth of *L. helveticus* to the same extent as did the liver factor, it had only half the activity of the liver factor towards *S. faecalis* R Stokstad therefore concluded that the two factors were different and suggested that the liver factor might be identical with the vitamin B<sub>12</sub> of Pfiffner *et al*<sup>7</sup> (see page 469) The intimate relationship between the *L. casei* factor (in its various forms) and vitamin B<sub>12</sub> received further support from a report<sup>9</sup> that a pure preparation of the nonit eluate factor made by fermentation (see page 468) had been found to stimulate the growth of *L. helveticus* and *S. faecalis* R and also to increase the growth rate of chicks This fermentation product has sometimes been referred to as "the third *L. casei* factor"

### SLR Factor

A fourth factor, described by Keresztesy *et al*<sup>10</sup>, differed from the three *L. casei* factors in being inert towards *L. helveticus* (*L. casei*), although effective in stimulating the growth of *S. lactis* R (*S. faecalis* R) Accordingly it was named the *S. lactis* R factor, abbreviated to SLR factor Subsequently, Stokes *et al*<sup>10</sup> found that folic acid could replace the SLR factor for all bacteria that could utilise the latter and that folic acid was produced when *S. faecalis* R was grown on a folic acid free medium containing the SLR factor The SLR factor failed to produce folic acid when incubated with rat liver suspensions,

## INTRODUCTION

however whereas incubation of the *L. casesi* factor with fresh chick liver caused a marked increase in the folic acid content as measured by *S. faecalis* R.<sup>11</sup> The increase was twice as great when pyracin (page 336) was present in the incubation mixture. This action of pyracin is believed to be due either to conjugation with the *L. casesi* factor or to its incorporation into an enzyme system that brings about the conversion of the *L. casesi* factor to folic acid.

### Vitamin B<sub>6</sub>

A fifth factor closely related to both folic acid and the three *L. casesi* factors was described in 1939-40 by A. G. Hogan and E. M. Parrott.<sup>12</sup> This was prepared from liver by a process involving adsorption on fuller's earth followed by elution. It was found to correct a hyperchromic macrocytic anaemia in chicks and in consequence was named vitamin B<sub>6</sub>, the suffix indicating its association with the nutrition of the chick. Further purification of vitamin B<sub>6</sub> was effected by A. G. Hogan and his colleagues,<sup>13</sup> who pointed out that the factor had properties very similar to those of the liver *L. casesi* factor. Isolation of the pure factor<sup>14</sup> and a comparison of its properties with those of the *L. casesi* factor confirmed this close relationship. Moreover crystalline vitamin B<sub>6</sub><sup>15</sup> maintained normal growth and feathering in chicks in addition to preventing the development of a macrocytic hyperchromic anaemia, leucopenia and thrombocytopenia whilst the purified folic acid of H. K. Mitchell and R. J. Williams<sup>16</sup> also stimulated the growth of chicks.

Further work on vitamin B<sub>6</sub> however revealed a state of affairs comparable with that obtaining in the case of the *L. casesi* factor: vitamin B<sub>6</sub> concentrates differing in their biological activities according to whether they were produced from liver or from yeast. Binkley *et al.*<sup>17</sup> for example found that vitamin B<sub>6</sub> concentrates prepared from yeast almost completely failed to stimulate the growth of *L. helveticus* but they became highly active following enzymatic digestion. From such digests a crystalline compound was isolated that stimulated the growth of both *L. helveticus* and *S. faecalis* R and also cured the anaemia and increased the growth rate of chicks. They accordingly reserved the name vitamin B<sub>6</sub> for the liver factor and gave the name vitamin B<sub>6</sub> conjugate to the factor present in yeast.

Later this same group of workers reported<sup>18</sup> the isolation of vitamin B<sub>6</sub> conjugate in crystalline form and confirmed its ineffectiveness as a growth factor for *L. helveticus* and *S. faecalis* R and its inability to cure a nutritional macrocytic anaemia in chicks. After digestion with an enzyme preparation made from hog kidney the crystalline factor like the crude factor previously described was found



preparation (see page 467) This had the properties of a purine pyrimidine dinucleotide or a mixture of the two mononucleotides, and could be replaced as a growth factor by a mixture of guanine and thymine, although larger amounts of these were required in order to produce the same response (page 513) Compared with the folic acid of Mitchell, Snell and Williams, Snell and Peterson's factor and Stokstad's factor were relatively crude, and this in part accounts for the conclusion reached at the time by Mitchell *et al* that folic acid was not identical with either of these factors

The norit eluate factor from liver was still further purified by Hutchings *et al* <sup>4</sup> who showed that it was essential for the nutrition of the chick, although there was an element of doubt as to the identity of the bacterial and chick factors, as the one preparation was not tested for both types of activity The method of isolation and the behaviour towards inactivating agents were, however, identical with those reported by earlier workers, and it was subsequently observed <sup>5</sup> that purified preparations of this chick factor not only promoted growth but also resulted in increased haemoglobin formation and normal feathering of chicks

The picture then became a trifle confused, following the publication of a paper by E L R Stokstad, <sup>6</sup> describing the preparation of a norit eluate factor from yeast Although the product stimulated the growth of *L. helveticus* to the same extent as did the liver factor, it had only half the activity of the liver factor towards *S. faecalis* R Stokstad, therefore, concluded that the two factors were different and suggested that the liver factor might be identical with the vitamin B<sub>9</sub> of Pfaffner *et al* <sup>7</sup> (see page 469) The intimate relationship between the *L. casei* factor (in its various forms) and vitamin B<sub>9</sub> received further support from a report <sup>8</sup> that a pure preparation of the norit eluate factor made by fermentation (see page 468) had been found to stimulate the growth of *L. helveticus* and *S. faecalis* R and also to increase the growth rate of chicks This fermentation product has sometimes been referred to as "the third *L. casei* factor"

### SLR Factor

A fourth factor, described by Keresztesy *et al* <sup>9</sup>, differed from the three *L. casei* factors in being inert towards *L. helveticus* (*L. casei*), although effective in stimulating the growth of *S. lactis* R (*S. faecalis* R) Accordingly it was named the *S. lactis* R factor, abbreviated to SLR factor Subsequently, Stokes *et al* <sup>10</sup> found that folic acid could replace the SLR factor for all bacteria that could utilise the latter and that folic acid was produced when *S. faecalis* R was grown on a folic acid-free medium containing the SLR factor The SLR factor failed to produce folic acid when incubated with rat liver suspensions,

however, whereas incubation of the *L. casei* factor with fresh chick liver caused a marked increase in the folic acid content as measured by *S. faecalis* R<sup>11</sup>. The increase was twice as great when pyracin (page 336) was present in the incubation mixture. This action of pyracin is believed to be due either to conjugation with the *L. casei* factor or to its incorporation into an enzyme system that brings about the conversion of the *L. casei* factor to folic acid.

### Vitamin B<sub>6</sub>

A fifth factor, closely related to both folic acid and the three *L. casei* factors, was described in 1939-40 by A. G. Hogan and E. M. Parrott<sup>12</sup>. This was prepared from liver by a process involving adsorption on fuller's earth followed by elution. It was found to correct a hyperchromic macrocytic anaemia in chicks, and, in consequence, was named "vitamin B<sub>6</sub>" the suffix indicating its association with the nutrition of the chick. Further purification of vitamin B<sub>6</sub> was effected by A. G. Hogan and his colleagues<sup>13</sup> who pointed out that the factor had properties very similar to those of the liver *L. casei* factor. Isolation of the pure factor<sup>14</sup> and a comparison of its properties with those of the *L. casei* factor confirmed this close relationship. Moreover, crystalline vitamin B<sub>6</sub><sup>15</sup> maintained normal growth and feathering in chicks in addition to preventing the development of a macrocytic hyperchromic anaemia, leucopenia and thrombocytopenia, whilst the purified folic acid of H. K. Mitchell and R. J. Williams<sup>16</sup> also stimulated the growth of chicks.

Further work on vitamin B<sub>6</sub> however, revealed a state of affairs comparable with that obtaining in the case of the *L. casei* factor, vitamin B<sub>6</sub> concentrates differing in their biological activities according to whether they were produced from liver or from yeast. Binkley *et al.*,<sup>17</sup> for example, found that vitamin B<sub>6</sub> concentrates prepared from yeast almost completely failed to stimulate the growth of *L. helveticus*, but they became highly active following enzymatic digestion, from such digests a crystalline compound was isolated that stimulated the growth of both *L. helveticus* and *S. faecalis* R and also cured the anaemia and increased the growth rate of chicks. They accordingly reserved the name vitamin B<sub>6</sub> for the liver factor, and gave the name vitamin B<sub>6</sub> conjugate to the factor present in yeast.

Later, this same group of workers reported<sup>18</sup> the isolation of vitamin B<sub>6</sub> conjugate in crystalline form and confirmed its ineffectiveness as a growth factor for *L. helveticus* and *S. faecalis* R and its ability to cure a nutritional macrocytic anaemia in chicks. After digestion with an enzyme preparation made from hog kidney, the crystalline factor, like the crude factor previously described, yielded

microbiologically active vitamin B<sub>6</sub>. K K Krueger and W H Peterson,<sup>19</sup> on the other hand, reported that vitamin B<sub>6</sub> concentrates prepared from yeast were just as active towards *L. helveticus* and *S. faecalis* R as were similar preparations from liver

O D Bird and M Robbins<sup>20</sup> also found that both micro organisms responded to vitamin B<sub>6</sub> conjugate although *L. helveticus* responded in an abnormal manner, not only to crude preparations of vitamin B<sub>6</sub> and the conjugate, but also to the crystalline conjugate. The divergence from the standard curve was in fact particularly noticeable with the latter. After incubation with vitamin B<sub>6</sub> conjugase (see page 479), all the preparations gave a response corresponding closely to that of the standard. With *S. faecalis* R the response fell almost on the standard curve even without incubation with vitamin B<sub>6</sub> conjugase.

It was not unreasonable, therefore, on the basis of this evidence to suppose that folic acid, the three *L. casei* factors, the SLR factor and vitamin B<sub>6</sub> and its conjugate were very closely related. Unfortunately, however, several other growth factors under investigation at about the same time also appeared to be closely related to the seven factors so far discussed and it became difficult to determine the relationships of all these factors to one another.

### Other Chick Factors

Other factors that appeared to be related in some way to the folic acid complex were the factor U of E L R Stokstad and P D V Manning,<sup>21</sup> factors R and S of A E Schumacher, G F Heuser and L C Norris,<sup>22</sup> and vitamins B<sub>10</sub> and B<sub>11</sub> of Briggs *et al*<sup>23</sup> (see also page 614).

The guinea pig factor, factor GPF 1, of D W Woolley and H Sprince<sup>24</sup> also appeared to be closely related to the group.

### Vitamin M and Xanthopterine

In 1932, L Wills and H S Bilimoria<sup>25</sup> showed that monkeys developed anaemia, leucopenia and granulocytopenia when maintained on a diet similar to that associated with human tropical macrocytic anaemia in India. The anaemic monkeys were cured by administration of a yeast extract. Similar results were obtained by Langston *et al*<sup>26</sup> who also showed that the leucopenia and granulocytopenia were relieved by concentrates prepared from either liver or yeast, they termed the responsible factor, vitamin M.

A year previously, R Tchesche and R J Wolf<sup>27</sup> had reported that an anaemia induced in rats by the feeding of goats' milk could be cured by administration of xanthopterine, the yellow pigment

isolated by C. Schöpf and E. Becker<sup>28</sup> from the wings of the brimstone butterfly (*Gonepteryx rhamni*) and, in 1941, R. W. Simmons and E. R. Norris<sup>29</sup> showed that both synthetic xanthopterine and xanthopterine isolated from liver could cure an anaemia observed in Chinook salmon. J. R. Totter and P. L. Day,<sup>30</sup> therefore, tested xanthopterine in anaemic monkeys and found that, whilst it relieved the blood changes in nutritional cytopenia, it failed to cure the other manifestations of vitamin M deficiency. They also claimed that xanthopterine cured the leucopenia and increased the growth rate of sulphasuxidine treated rats, but this claim was not substantiated by the work of B. Ransone and C. A. Elvehjem<sup>31</sup> or of Day *et al.*<sup>32</sup>

Although xanthopterine had a definite beneficial effect on vitamin M deficient monkeys, the effect of folic acid was even more striking<sup>33</sup> the growth rate being increased and the leucopenia and granulocytopenia relieved. The loss of hair (alopecia) was not, however, remedied by folic acid, whereas biotin cured this condition but did not affect the blood picture. Pantothenic acid, choline, *p*-aminobenzoic acid, pyridoxine and inositol were without appreciable effect in vitamin M deficiency, but a highly purified sample of the *L. casei* factor relieved the granulocytopenia in this condition<sup>34</sup>. Folic acid also cured fish anaemia,<sup>35</sup> although it had only one fifth the activity of xanthopterine. On the other hand, xanthopterine failed to cure anaemic vitamin B<sub>6</sub> deficient chicks<sup>36</sup>.

These data suggested that vitamin M was closely related to folic acid, vitamin B<sub>6</sub> and the *L. casei* factors and possibly identical with one of them, whereas xanthopterine was a simpler type of substance altogether and an inadequate substitute for these factors in the treatment of vitamin M deficient monkeys.

An objection to the hypothesis that folic acid might be identical with vitamin M was that the folic acid contents of various substances, as determined by the original microbiological method of assay using *L. helveticus* and *S. faecalis* R, completely failed to account for the vitamin M activities of the same substances when tested on monkeys. Totter *et al.*,<sup>37</sup> following up an observation of L. D. Wright and A. D. Welch<sup>38</sup> that fresh rat liver could synthesise folic acid from xanthopterine, incubated a preparation of brewers' yeast with fresh rat liver, fresh chicken liver and liver from a vitamin M deficient monkey. On assaying the digests with *S. faecalis* R, they obtained a 15 fold or even larger increase in the folic acid content.

When synthetic xanthopterine was incubated with the liver preparations in the same way, considerable amounts of folic acid were found to have been produced, except in the case of chicken liver. These results appeared to indicate that yeast contained a precursor, which liver tissue could convert into folic acid, and that the amount

of potential rather than actual folic acid in a substance was a measure of its vitamin M activity. They also seemed to suggest that xanthopterin might be a precursor of vitamin M, although Wright *et al*<sup>39</sup> offered another suggestion, namely, that free folic acid in rat liver was converted by liver enzymes into a substance having little or no microbiological activity and that the reaction was inhibited by xanthopterin. Although, on the basis of their experimental data, they could not exclude the possibility that folic acid might be synthesised from xanthopterin, they favoured the hypothesis of a metabolite-antimetabolite relationship.

That vitamin M is simply free plus combined folic acid appears to be a valid conclusion from the most recent paper on vitamin M deficiency, in which Day *et al*<sup>40</sup> reported that intramuscular injection of a highly purified *L. casei* factor, which was relatively inert towards *S. faecalis* R, cured both the anaemia and leucopenia of vitamin M-deficient monkeys in a total dose of 3 mg given over several days, prompt remission of the blood dyscrasia and a dramatic improvement in the clinical condition of the animals occurred. Xanthopterin was only slightly active when given orally, and was inactive by injection, again suggesting that it might serve as a precursor of vitamin M. The *L. casei* factor became as active as a standard vitamin B<sub>12</sub> preparation in stimulating *S. faecalis* R after treatment with vitamin B<sub>12</sub> conjugase (page 479).

### Anti-sulphonamide Factor

Totter and Day's unconfirmed observation on the effect of xanthopterin on sulphasuxidine-treated rats, although misleading at the time, served a useful purpose in directing attention to the close analogy between the effects of vitamin M deficiency in monkeys and sulphonamide administration in rats. Thus, although the response of sulphasuxidine treated rats to xanthopterin was suspect, the response to folic acid was definite, and both G. J. Martin<sup>41</sup> and C. A. Elvehjem and his colleagues<sup>42</sup> found that folic acid plus biotin cured the symptoms caused by administration of sulphasuxidine to rats.

Pantothenic acid, inositol and *p*-aminobenzoic acid have at various times been claimed to cure the achromotrichia (greying of hair) and alopecia (loss of hair) resulting from the administration of sulphonamides, but the response to the combined effect of folic acid and biotin was more striking than any obtained with the other vitamins.

The results obtained by Martin and by Elvehjem and his colleagues were confirmed by F. S. Daft and W. H. Sebrell,<sup>43</sup> who found that crystalline folic acid cured the leucopenia and granulocytopenia caused

## INTRODUCTION


by feeding sulphonamides to rats, whilst A D Welch and L D Wright<sup>44</sup> showed that the increase in prothrombin time caused by administration of sulphasuxidine was overcome by feeding a mixture of folic acid and biotin and, to a smaller extent, by giving each factor separately. This result strongly supports the view that the effect of folic acid and biotin is to stimulate bacterial growth in the intestine (page 487), the bacteria synthesise vitamin K as well as vitamin B factors. It is the reduction in vitamin K synthesis, of course, that results in the increased prothrombin time.

Mallory *et al*,<sup>45</sup> in view of the similarity in behaviour of an enzymatic digest of yeast and of a liver extract on the growth and white blood cell counts of sulphasuxidine treated rats, also favoured the hypothesis that the factor antagonistic to the effects of sulphonamides in rats was identical with vitamin M.

Further work confirmed the ability of various forms of folic acid to reverse the effects of sulphonamide treatment, and also indicated that this effect was probably due to stimulation of the growth of intestinal bacteria (page 487).

From this somewhat lengthy discussion of the biological properties of folic acid, the *L. casei* factors, the SLR factor, vitamin B<sub>6</sub>, vitamin M, the anti-sulphonamide factor and xanthopterin, the general conclusion must be that all these factors are in some way related to one another and, although some may be identical, the differences are sufficiently marked in other instances to lead one to believe that they are not all identical. In the ultimate, the only real test of identity is an examination of the chemical properties of the pure substances themselves. These have recently been made available and the constitution of several of the factors has been determined and some of them have been synthesised.

The first announcement that the constitution of the *L. casei* factor had been determined and its synthesis accomplished was made by Angier *et al*.<sup>46</sup> Unfortunately, the note merely reported the synthesis of a compound identical with the *L. casei* factor of liver, and stated that it stimulated the growth of *L. helveticus* and *S. faecalis* R, and promoted growth and haemoglobin formation in the chick. Not until nearly twelve months later did Angier *et al*.<sup>47</sup> disclose the chemical constitution of the *L. casei* factor and the method of synthesis. The formula assigned to the liver *L. casei* factor was



## THE FOLIC ACID COMPLEX

The systematic name of this substance is N-[4-{{(2-amino-4-hydroxy-6-pteridyl)-methyl}-amino}-benzoyl]-glutamic acid. Fermentation *L. casei* factor, which was found to contain three glutamic acid residues, was converted into the racemic form of the liver *L. casei* factor by anaerobic alkaline hydrolysis. The name of the liver factor was abbreviated to pteroyl-glutamic acid, pteronic acid being the short name for 4-{{(2-amino-4-hydroxy-6-pteridyl)-methyl}-amino}-benzoic acid. The latter was synthesised by a method similar to that used for the synthesis of the *L. casei* factor (see page 474), and was found to be active for *S. faecalis* R, but inactive for *L. helveticus* and the chick. Its biological activity thus resembled that of the SLR factor, although the two are not identical (page 473). The fermentation *L. casei* factor, containing three glutamic acid residues, was given the name pteroyldiglutamylglutamic acid or, more briefly if less accurately, pteroyltriglutamic acid, whilst yeast vitamin B<sub>6</sub> conjugate, which contained seven glutamic acid residues,<sup>48</sup> was called pteroylhexa-glutamylglutamic acid or pteroylheptaglutamic acid.

The heptaglutamate was essentially inactive on micro-organisms whereas the triglutamate was active. Since vitamin B<sub>6</sub> conjugase converted the conjugate into vitamin B<sub>6</sub>, it must be classified as a peptidase and, since it did not liberate vitamin B<sub>6</sub> from the methyl ester of the conjugate, it must be a carboxypeptidase. Finally, since it liberated glutamic acid from *p*-aminobenzoyl- $\gamma$ -glutamyl- $\gamma$ -glutamylglutamic acid, from synthetic pteroyltriglutamate and from the natural fermentation factor, but not more than 1 molecular equivalent in each instance, it must be classified as a  $\gamma$ -glutamic acid carboxypeptidase, requiring at least two terminal glutamic acid molecules in a peptide chain.<sup>49</sup>

The constitution of folic acid itself has not been conclusively settled, as it has not been isolated in the pure state. According to D. A. Hall,<sup>50</sup> however, a folic acid concentrate prepared from spinach

prepared from poppy-straw, but not a similar concentrate from wheat. This is taken to indicate that "folic acid" from vegetable sources is different from "folic acid" of animal origin.

### References to Section I

1. H. K. Mitchell, E. E. Snell and R. J. Williams, *J. Amer. Chem. Soc.*, 1941, 63, 2284.
2. E. E. Snell and W. H. Peterson, *J. Biol. Chem.*, 1939, 128, xciv; *J. Bact.*, 1940, 36, 273.
3. E. L. R. Stokstad, *J. Biol. Chem.*, 1941, 139, 475.

- 4 B L Hutchings N Bohonos D M Hegsted C A Elvehjem and W H Peterson *ibid* 1941 140, 681 B L Hutchings N Bohonos and W H Peterson *ibid* 1941 141, 521
- 5 R C Mills G M Briggs C A Elvehjem and E B Hart *Proc Soc Exp Biol Med* 1942 49, 186
- 6 E L R Stokstad *J Biol Chem* 1943 149, 573
- 7 J J Pflüger S B Binkley F S Bloom R A Brown O D Bird A D Emmett A G Hogan and B L O Dell *Science* 1943 97, 404
- 8 B L Hutchings E L R Stokstad N Bohonos and N H Slobodkin *ibid* 1944 99, 371
- 9 J C Keresztesy F L Ruckes and J L Stokes *ibid* 1943 97, 465
- 10 J L Stokes J C Keresztesy and J W Foster *ibid* 1944 100, 522
- 11 L J Daniel M L Scott L C Norris and G F Heuser *J Biol Chem* 1945 160, 265
- 12 A G Hogan and E M Parrott *ibid* 1938 128, xlv 1940 132, 507
- 13 L R Richardson A G Hogan and R J Karrasch *J Nutrition* 1942 24, 65 B L O Dell and A G Hogan *J Biol Chem* 1943 149, 323
- 14 J J Pflüger S B Binkley E S Bloom R A Brown O D Bird A D Emmett A G Hogan and B L O Dell *Science* 1943 97, 404
- 15 C J Campbell R A Brown and A D Emmett *J Biol Chem* 1944 152, 483
- 16 H K Mitchell and R J Williams *J Amer Chem Soc* 1944 66, 271
- 17 S B Binkley O D Bird E S Bloom R A Brown D G Calkins C J Campbell A D Emmett and J J Pflüger *Science* 1944 100, 36
- 18 J J Pflüger D G Calkins B L O Dell E S Bloom R A Brown C J Campbell and O D Bird *ibid* 1945 102, 228
- 19 H K Krueger and W H Peterson *J Biol Chem* 1945 158, 145
- 20 O D Bird and M Robbins *ibid* 1946 163, 661
- 21 E L R Stokstad and P D V Manning *ibid* 1938 125, 687
- 22 A E Schumacher G F Heuser and L C Norris *ibid* 1940 135, 313
- 23 G M Briggs T D Luckey C A Elvehjem and E B Hart *ibid* 1943 148, 163
- 24 D W Woolley and H Sprince *ibid* 1944 153, 687
- 25 L Wills and H S Bismoria *Indian J Med Res* 1937 20, 391
- 26 W C Langston W J Darby C F Shukers and P L Day *J Exp Med* 1938 68, 923
- 27 R Tschesche and R J Wolf *Z physiol Chem* 1937 248, 34
- 28 C Schöpf and E Becker *Annalen* 1936 524, 49 124
- 29 R W Simmons and F R Norris *J Biol Chem* 1941 140, 679, 1945 158 449



## THE FOLIC ACID COMPLEX

- 30 J R Totter and P L Day *J Biol Chem* 1943 147, 257
- 31 B Ransone and C A Elvehjem *ibid* 1943 151, 109
- 32 H G Day K G Wakim W H Zimmerman and L S McClung  
*J Nutrition* 1946 31, 355
- 33 H A Waisman and C A Elvehjem *ibid* 1943 28 361 S  
Saslaw H E Wilson C A Doan and J L Schwab *Science*  
1943 87, 514 J R Totter C F Shukers J Kolson V Mims  
and P L Day *Fed Proc* 1943 2, 72 *J Biol Chem* 1944  
152 147
- 34 P L Day V Mims J R Totter E L R Stokstad B L  
Hutchings and N H Sloane *ibid* 1945 157, 423
- 35 H K Mitchell and R J Williams *J Amer Chem Soc* 1944 66  
271
- 36 B L O Dell and A G Hogan *J Biol Chem* 1943 149, 323
- 37 J R Totter V Mims and P L Day *Science* 1944 100, 223
- 38 L D Wright and A D Welch *ibid* 1943 98, 179
- 39 L D Wright H R Skeggs and A D Welch *Fed Proc* 1944 3  
88
- 40 P L Day V Mims and R J Totter *J Biol Chem* 1945  
161, 45
- 41 G J Martin *Proc Soc Exp Biol Med* 1942 51, 353
- 42 E Nielsen and C A Elvehjem *J Biol Chem* 1942 145, 713  
B Ransone and C A Elvehjem *ibid* 1943 151, 109
- 43 F S Daft and W H Sebrell *US Publ Health Rep* 1943 58, 1542
- 44 A D Welch and L D Wright *J Nutrition* 1943 25, 555
- 45 M E Mallory V Mims R J Totter and P L Day *J Biol Chem*  
1944 158, 317
- 46 R B Angier J H Boothe B L Hutchings J H Mowat J  
Semb E L R Stokstad Y SubbaRow C W Waller D B  
Cosulich M J Fahrenbach M E Hultquist E Kuh E H  
Northey D R Seeger J P Sickels and J M Smith *Science*  
1945 102, 227
- 47 R B Angier J H Boothe B L Hutchings J H Mowat J  
Semb E L R Stokstad Y SubbaRow C W Waller D B  
Cosulich M J Fahrenbach M F Hultquist E Kuh E H  
Northey D R Seeger J P Sickels and J M Smith *ibid* 1946  
103, 667
- 48 J J Pffner D G Calkins E S Bloom and B L O Dell *J Amer*  
*Chem Soc* 1946 68, 1392
- 49 A Kazenko and M Laskowski *J Biol Chem* 1948 173, 217
- 50 D A Hall *Biochem J* 1947 41, 287

## 2 ISOLATION OF FOLIC ACID

A feature common to the isolation of all the factors comprising the folic acid complex is that all are adsorbed on charcoal and eluted more or less completely by aqueous or alcoholic ammonia

## Folic Acid

Folic acid was prepared from spinach leaves by H K Mitchell, E E Snell and R J Williams,<sup>1</sup> and purified to such an extent that the product was 137,000 times as active as a standard material (Wilson liver fraction B). The spinach was extracted with water, acidified to about pH 3 and the extract stirred with charcoal and filtered. The adsorbate was eluted with hot 2.8 % ammonia and the eluate re-adsorbed on charcoal. The second adsorbate was eluted with hot aqueous aniline, and the adsorption and elution repeated once more. The activity in the final eluate was precipitated first with lead acetate and then with ammoniacal silver nitrate solution, the precipitates being regenerated with ammonium sulphate and ammonium chloride respectively. The solution from the silver regeneration was adsorbed on fuller's earth and the adsorbate eluted with 5 % ammonia. Further purification was effected by fractional elution from ammonia and by precipitation of the acid from a concentrated solution of the ammonium salt.

Quantitative studies of the adsorption of folic acid on charcoal were described by Frieden *et al*.<sup>2</sup> They observed that folic acid was more easily eluted from adsorbates made from crude preparations than from adsorbates from relatively pure solutions. This difference is attributed to the presence in the cruder solutions of interfering substances that reduce the adsorption affinity of the charcoal for folic acid.

## The *L casei* Factors

The method used by E E Snell and W H Peterson<sup>3</sup> for the isolation of the nonit eluate factor from 'solubilised liver' was as follows. The extract was diluted 20 fold with water, the pH adjusted to 3.0 with sulphuric acid and the liquor filtered and stirred with nonit. The adsorbate after being washed with water, was stirred with 50 % ethanol, filtered and then eluted three times with a mixture of pyridine-ethanol water (1:2:1). In a modification of the method elution was carried out with 2 % aqueous ammonia. Further purification was achieved by evaporating the eluate to dryness, dissolving the residue in water and precipitating with picric acid. The picrate fraction which was insoluble in water and ether but soluble in alcohol, contained the bulk of the activity. Considerable losses attended this procedure.

A somewhat similar method was used by E L R Stokstad<sup>4</sup>. 'Solubilised liver' was adsorbed on nonit and the adsorbate was eluted with 0.5 N ammonia in 70 % methanol. Final purification was effected by fractionally precipitating the manganese salt of the

factor with methanol. No further purification was effected by precipitation with heavy metals or by fractional precipitation from a concentrated aqueous solution.

The method used in isolating the pure crystalline liver *L. casei* factor was described in detail by Stokstad *et al*<sup>5</sup>. A liver extract prepared by precipitating an aqueous extract of liver with alcohol was used as the starting material. It was adjusted to pH 8.5 and heated to coagulate impurities and the filtrate was acidified to pH 3 and stirred with norit. The adsorbate was eluted with 0.5 N ammonia in 60 % ethanol at 70° C and the eluate was acidified to pH 1.3 and adsorbed on a column of Superfiltrol which was eluted with 0.5 N ammonia in 60 % ethanol. The eluate was concentrated and neutralised to pH 7.0 and the *L. casei* factor was precipitated as the barium salt by adding alcohol and barium chloride. The barium salt was dissolved in 0.2 N methanolic hydrogen chloride and the solution left at 25° C for an hour to convert the factor into its methyl ester. The mixture was evaporated to dryness, the residue was dissolved in water, acidified to pH 6 to 7 and extracted with *n*-butanol. The solution was chromatographed on a column of Superfiltrol which was washed with 92.5 % acetone and then eluted with 75 % acetone.

<sup>1</sup>The fermentation *L. casei* factor was produced by aerobic fermentation with an unidentified bacterium belonging to the genus *Corynebacterium*. The fermentation liquor which contained 3 to 5 µg per ml<sup>6</sup> was acidified to pH 3.0 and stirred with norit. The adsorbate was washed with water and 50 % ethanol and eluted with aqueous alcoholic ammonia at 70° C. The eluate was neutralised and the barium salt of the *L. casei* factor was precipitated by adding alcohol and barium chloride solution. The barium salt was dissolved in methanolic hydrogen chloride and allowed to stand in order to convert the factor into its methyl ester. The mixture was neutralised and evaporated to dryness and the residue dissolved in water. The solution was extracted with *n*-butanol and the extract evaporated to dryness. The residue was dissolved in hot methanol and precipitated by cooling, the process being repeated with modifications several times until pure. The purified ester was then hydrolysed with baryta solution and the hydrolysate treated with Florisil to remove impurities and then with barium chloride and alcohol to precipitate the barium salt of the factor. This was dissolved in water, hydrochloric acid was added and the solution was cooled to 0° C. The precipitate was redissolved in acidulated water containing a little calcium or sodium chloride and the solution was cooled giving a crystalline precipitate of the pure *L. casei* factor.

Vitamin B<sub>6</sub> and Vitamin B<sub>12</sub> Conjugate

Vitamin B<sub>6</sub> was isolated from beef liver by the following procedure.<sup>7</sup> An extract was made with acidulated water and, after concentration, alcohol was added to 50 % by volume and filtered. The precipitate was washed with 50 % alcohol and the combined filtrate and washings were concentrated to a syrup. This was re-dissolved in water, acidified to pH 1 and stirred with fuller's earth. The adsorbate was eluted with 0.2 N-ammonium hydroxide and the eluate concentrated, acidified to pH 1 and stirred with Superfiltrol. The adsorbate was eluted with 1 % ammonia in 50 % alcohol and the eluate concentrated. Various purification procedures were tried out at this point, e.g., norit adsorption at pH 3 and elution with 10% ammonia, adsorption at pH 4.3 on Amberlite IR4 and elution with 10% ammonia, and precipitation with barium hydroxide, zinc sulphate or phosphotungstic acid. The last method was the only one that gave a sufficient degree of purification together with a sufficiently high recovery to be of value.

The method used by Pfiffner *et al.*<sup>8</sup> for the isolation of vitamin B<sub>6</sub> (pteroylglutamic acid) from hog liver was as follows. The autolysed tissue was extracted with hot water, the extract was concentrated under reduced pressure and filtered through a column of Amberlite IR4. The adsorbate was eluted with aqueous ammonia, and the eluate concentrated and stirred with Superfiltrol. This adsorbate was eluted with aqueous alcoholic ammonia and the eluate concentrated and stirred with norit. This third adsorbate was also eluted with aqueous alcoholic ammonia and the adsorption on norit and elution then repeated. The final concentrate was extracted first at pH 5.6 with butanol and the extract discarded and then at pH 3. This second extract, which contained the activity, was evaporated and the resulting solid was extracted four times with boiling 90 % methanol. The combined extracts were treated with baryta and the insoluble barium salts were filtered off. The water soluble barium salts were then precipitated by the addition of zinc acetate and the precipitate decomposed with ammonium oxalate. The zinc oxalate was filtered off and the filtrate was acidified to pH 2.8 when the crude vitamin separated out. It was leached out with baryta and re-precipitated by acidifying the solution to pH 2.8. It was then crystallised from hot water.

One process was simplified by esterifying the crude zinc salt with methanolic hydrogen chloride and precipitating the methyl ester by adjusting the concentrated solution to pH 3.

Horse liver was found to be a much richer source of vitamin B<sub>6</sub> than was hog liver and, using this as the starting material, the process could be still further simplified by omitting the butanol extraction and the precipitation of the barium salts from methanol.

## THE FOLIC ACID COMPLEX

One process used for the isolation of vitamin B<sub>9</sub> conjugate from yeast was as follows <sup>8</sup> A plasmolysed extract of brewers' yeast was dissolved in warm water and the liquor acidified to pH 3 and filtered. The filtrate was stirred with norit, and the adsorbate was eluted with hot aqueous alcoholic ammonia. The eluate was concentrated and re-adsorbed on norit and the adsorbate eluted as before. The concentrated eluate was extracted at pH 5.5 to 6 with butanol, the extract discarded, and the aqueous solution re-extracted at pH 3. The activity remaining in the aqueous solution was due almost entirely to vitamin B<sub>9</sub> conjugate, the solution having scarcely any activity towards *L. helveticus* or *S. faecalis*. It was converted by digestion with hog kidney into vitamin B<sub>9</sub>, which was isolated by the procedure described above.

Another method used to prepare vitamin B<sub>9</sub> conjugate <sup>8a</sup> was to percolate dried brewers' yeast with 60 % alcohol, which extracted inert material, and then to percolate with slightly acid 45 to 50 % alcohol, which extracted the conjugate. A further quantity of inert material was removed from the extract by addition of alcohol to a concentration of 70 % and adjusting the pH to 3, the conjugate was then precipitated by adjusting the pH of the filtrate to 5.5 to 6.0.

### SLR Factor

The best source of the SLR factor was the liquor from *Rhizopus nigricans* fumaric acid fermentations <sup>9</sup>. The factor was isolated by adsorption on charcoal, elution, chromatographic purification and crystallisation. It was shown to be a pterine for which the name rhizopterin was proposed.

### Xanthopterin

Xanthopterin was isolated from a liver extract <sup>10</sup> by precipitation with silver hydroxide and silver nitrate, regeneration with hydrochloric acid, adsorption on fuller's earth, elution with 20 % pyridine, evaporation to dryness, precipitation of the barium salt, and regeneration with hydrochloric acid and sodium carbonate.

### References to Section 2

- 1 H. K. Mitchell, E. E. Snell and R. J. Williams *J. Amer. Chem. Soc.*, 1941, **63**, 2284, 1944 **66**, 267.
- 2 E. H. Frieden, H. K. Mitchell and R. J. Williams *ibid.* 269.
- 3 E. E. Snell and W. H. Peterson *J. Bact.* 1940, **56**, 273.
- 4 E. L. R. Stokstad *J. Biol. Chem.*, 1941, **130**, 475.

- 5 E L R Stokstad B L Hutchings and Y SubbaRow *Ann N Y Acad Sci* 1946 48 261 *J Amer Chem Soc* 1948 70, 3
- 6 B L Hutchings E L R Stokstad N Bohonos N H Sloane and Y SubbaRow *Ann N Y Acad Sci* 1946 48, 265 *J Amer Chem Soc* 1948 70, 1
- 7 B L O Dell and A G Hogan *J Biol Chem* 1943 149 323
- 8 J J Pflieger S B Binkley E S Bloom and B L O Dell *J Amer Chem Soc* 1947 69, 1476
- 8a R D Greene *J Biol Chem* 1949 179 1075
- 9 E L Riches L Chalet and J C Keresztesy *J Amer Chem Soc* 1947 69 2749
- 10 R W Simmons and E R Norris *J Biol Chem* 1941 140, 679

### 3 CHEMICAL CONSTITUTION OF FOLIC ACID

#### *L. casei* Factors

The first formula to be assigned to a member of the folic acid group was that given by Angier *et al*<sup>1</sup> to the liver *L. casei* factor (see page 463). This formula was based on the following evidence<sup>1 2 3 4</sup>. The fermentation *L. casei* factor on anaerobic alkaline hydrolysis was converted into the *dl* form of the liver *L. casei* factor the activity towards *L. helveticus* (*L. casei*) decreasing and the activity towards *S. faecalis* R increasing markedly. At the same time two moles of  $\alpha$  amino acid were liberated. When the fermentation factor was hydrolysed under aerobic alkaline conditions rapid inactivation occurred and two fractions were formed in equimolar amounts the first was highly fluorescent whilst the second gave a positive test for an aromatic amine.

The fluorescent compound was a dibasic acid  $C_7H_5N_5O_3$  which on heating lost carbon dioxide to give a monobasic acid. Oxidation of the fluorescent compound with chlorine water followed by hydrolysis with 0.1 N hydrochloric acid resulted in the formation of guanidine. This fact together with the ultra violet absorption spectrum fluorescence and other properties suggested the presence of a 2 amino-pteridine derivative containing a hydroxyl and a carboxyl group.

The compound was shown to be 2 amino-4 hydroxypteridine-6-carboxylic acid by comparison with a synthetic specimen prepared by the chlorination with phosphorus pentachloride of 2 amino-4, 7 dihydroxypteridine-6-carboxylic acid<sup>5</sup> followed by reduction with hydrogen iodide. The position of the unchanged hydroxyl group was established by decarboxylation and identification of the product as 2 amino 4 hydroxy pteridine by comparison with a specimen

## THE FOLIC ACID COMPLEX

synthesised from 2 4 5 triamino-6-hydroxy-pyrimidine and glyoxal

The aromatic amine fraction on acid hydrolysis yielded *p* amino-benzoic acid and an  $\alpha$  amino acid, subsequently identified as glutamic acid. Microbiological assay indicated that three moles of the latter were liberated from each mole of amine.

When the fermentation *L. casei* factor was treated with sulphurous acid a pteridine fraction and an aromatic amine were formed. The former contained a carbonyl group and on standing in dilute alkal solution in the absence of air, underwent a type of Cannizzaro reaction yielding 2 amino 4 hydroxypteridine 6 carboxylic acid and 2 amino 4 hydroxy 6 methyl pteridine. The latter was identified by comparison with a sample prepared by decarboxylation of 2 amino 4 hydroxy-6-pteridine-acetic acid, which in turn was prepared from 2 4 5 triamino 6 hydroxy pyrimidine and methyl  $\gamma$ -dimethoxy acetoacetate.

Final proof that the methyl group of 2 amino-4 hydroxy 6-methyl pteridine was in the 6 position was obtained by degradation of the compound to 2 amino 5 methylpyrazine by the method of J. Weijlard *et al*.<sup>6</sup>


The liberation of the aromatic amine and the pteridine moiety indicated that the latter was attached to the amino group of *p* amino benzoic acid. The necessity for oxygen in the alkaline cleavage of the *L. casei* factor with other considerations, suggested the presence of a methylene group and this view was supported by the fact that cleavage of *N* benzyl *p* aminobenzoic acid with alkali was accelerated by the presence of oxygen.

Proof of the above structure for the liver *L. casei* factor was obtained by synthesis (see page 474).

The evidence so far discussed throws no light on the manner in which the three glutamic acid residues are linked together in the fermentation *L. casei* factor. There are five theoretically possible isomers of the triglutamate and two possible isomers of pteroyldiglutamate. Mowat *et al*.<sup>7</sup> synthesised pteroyl  $\alpha$  glutamylglutamic acid and pteroyl  $\gamma$ -glutamylglutamic acid and showed that they had only a slight activity towards *L. helveticus* and *S. faecalis* R so that the latter was not identical with the fermentation factor. Pteroyl  $\gamma$ -glutamylglutamic acid on *S. faecalis* R and *L. helveticus* whilst pteroyl  $\gamma$  glutamyl  $\gamma$ -glutamylglutamic acid and the acid chloride of  $\alpha$  ethyl of pteroyl  $\gamma$  glutamylglutamic acid had a low activity for *S. faecalis* R and a high activity for *L. helveticus* thus resembling the fermentation factor with which it is probably identical.<sup>8</sup>

**SLR Factor (Rhizopterine)**

On treatment with alkali rhizopterine yielded aporhizopterine  $C_{14}H_{10}N_6O_3Na_2$  <sup>9</sup> subsequently shown to be identical with pterotic acid <sup>10</sup> since it liberated *p*-aminobenzoic acid on pyrolysis or hydrolysis gave guanidine on oxidation and a dihydroxypteridine on treatment with nitrous acid. The other substance produced on hydrolysis was identified as formic acid. Rhizopterine is therefore formyl pterotic acid with the structure



This structure was confirmed by treating synthetic pterotic acid with formic acid when a substance identical with rhizopterine was obtained.

*References to Section 3*


- 1 R B Angier J H Boothe B L Hutchings J H Mowat J Semb F L R Stokstad Y SubbaRow C W Waller D B Cosulich M J Fahrenbach M E Hultquist E Kuh E H Northey D R Seeger J P Sickels and J M Smith *Science* 1946 **103**, 667
- 2 F L R Stokstad B L Hutchings J H Mowat J H Boothe C W Waller R B Angier J Semb and Y SubbaRow *Ann NY Acad Sci* 1946 **48**, 269 *J Amer Chem Soc* 1948 **70**, 5
- 3 J H Mowat J H Boothe B L Hutchings E L R Stokstad C W Waller R B Angier J Semb D B Cosulich and Y SubbaRow *Ann NY Acad Sci* 1946 **48**, 279 *J Amer Chem Soc* 1948 **70**, 14
- 4 B L Hutchings E L R Stokstad J H Mowat J H Boothe C W Waller R B Angier J Semb and Y SubbaRow *ibid* 10
- 5 R Purmann *Annalen* 1941 **548**, 284
- 6 J Wejlard M Tishler and A E Erickson *J Amer Chem Soc* 1945 **67**, 802
- 7 J H Mowat B L Hutchings R B Angier E L R Stokstad J H Boothe C W Waller J Semb and Y SubbaRow *ibid* 1948 **70**, 1096
- 8 J H Boothe J H Mowat B L Hutchings R B Angier C W Waller E L R Stokstad J Semb A L Gazzola and Y SubbaRow *ibid* 1099
- 9 F L Rickes N R Trenner J B Conn and J C Keresztesy *ibid* 1947 **69** 2751
- 10 D E Wolf R C Anderson E A Kaczka S A Harris G E Arth P L Southwick R Mazingo and K Folkers *ibid* 2753



## 4 SYNTHESIS OF FOLIC ACID

Liver *L casei* Factor

Angier *et al*<sup>1</sup> synthesised the liver *L casei* factor (pteroylglutamic acid) by four different methods. In the first<sup>1,2</sup> equimolecular amounts of 2,4,5 triamino 6 hydroxypyrimidine, *p* aminobenzoyl L glutamic acid and 2,3 dibromopropionaldehyde were reacted together in presence of an acetate buffer




giving a product containing 15 % of the active compound. The dihydro compound was first formed and oxidised during the reaction to the aromatic compound. The crude preparation was dissolved in dilute alkali, impurities were precipitated by the addition of barium chloride followed by ethanol to a concentration of 20 % and the solution was then freed from barium, adjusted to pH 7.0, filtered and extracted three times with 10 volume portions of butanol. The aqueous phase was concentrated, acidified to pH 3.0 and cooled to 0-5°C. The precipitate that formed was redissolved in dilute alkali, the solution treated with charcoal, acidified to pH 3.0 and the active compound crystallised from hot water. The product was identical in its chemical and physical properties with the *L casei* factor isolated from liver.

The second method of synthesis was slightly different<sup>1,3,2,3</sup>. Dibromopropionaldehyde was reacted with pyridine and the product was condensed with 2,4,5 triamino 6 hydroxypyrimidine and potassium iodide to give N[(2-amino-4-hydroxy-6-pteridyl)methyl]pyridinium iodide. This was then condensed with *p* aminobenzoyl L-glutamic acid by heating with sodium methoxide in ethylene glycol at 140°C. The product again contained 15 % of the active compound and was purified as described above.

Pteric acid was synthesised by both the above methods using *p* aminobenzoic acid in place of *p* aminobenzoyl L glutamic acid<sup>1,2,3</sup>.

A third method of synthesis<sup>4</sup> was to treat reductone (2,3-dihydroxyacrylaldehyde) with *p* aminobenzoylglutamic acid, esterify the resulting *p* (2,3-dihydroxy-2-ene-propylideneamino) benzoylglutamic acid and condense the ester with 2,4,5 triamino 6 hydroxypyrimidine —



In a fourth method<sup>5</sup> 2 amino 4 hydroxy 6 methylpteridine prepared by reduction of 2 amino 4 hydroxy 6 pteridylmethyl pyridinium iodide was either brominated or chlorinated and the product condensed with the diethyl ester of *p* aminobenzoylglutamic acid

All these and several similar methods were patented by the American Cyanamid Co.<sup>6</sup> Thus in place of 2 3 dibromopropionaldehyde there may be used 3 halogeno 2 isonitrosopropionaldehydes 2 2 3 trihalogeno-propionaldehydes 2 halogeno 3 alkoxypropionaldehydes 1 1 dihalogeno 2 3 epoxypropanes 1 1 3-trihalogenoacetones or 2 2 3 trihalogenoalkylaldehydes. In addition a patent was filed by the same company to cover the preparation of pteroylglutamic acid from the corresponding diaminopteridine by heating in an aqueous solvent under alkaline conditions. 1 1 Dichloroacetone and 1 1 dichloro 3 bromoacetone were used by F. E. King and P. C. Spensley.<sup>7</sup>

P. Karrer and R. Schwyzer<sup>8</sup> developed a new method of synthesizing pteroylglutamic acid in which 2 4 5 triamino-6-hydroxy pyrimidine was condensed with glyceraldehyde or dihydroxyacetone giving a mixture of 2 amino 4 hydroxy 6 hydroxymethylpteridine and 2 amino 4 hydroxy 7 hydroxymethylpteridine. The former gave pteroylglutamic acid with *p* aminobenzoylglutamic acid. Reaction of the pyrimidine with glyceraldehyde di-*p* toluenesulphonate and *p* aminobenzoylglutamic acid in presence of sodium iodide also yielded pteroylglutamic acid.

Roche Products Ltd.<sup>9</sup> patented processes for the preparation of pteroylglutamic acid by reacting 2 amino 4 hydroxy 6-hydroxy methylpteridine with thionyl chloride and then treating the product with *p* aminobenzoylglutamic acid or by hydrogenating a mixture of the pteridine and *p* nitrobenzoylglutamic acid. Hoffmann La Roche & Co.<sup>10</sup> condensed 2 4 5 triamino-6 hydroxy pyrimidine with a ketohexose and oxidised the resulting 2 amino 4 hydroxy 6-tetrahydroxybutylpteridine with lead tetra acetate or some similar reagent capable of effecting glycol cleavage. The 2 amino-4 hydroxy 6-pteridylaldehyde so formed was hydrogenated in an inert solvent or formic acid in presence of *p* aminobenzoylglutamic acid and a catalyst giving pteroylglutamic acid. Any formyl pteroylglutamic acid produced at the same time was converted into pteroylglutamic acid by treatment with ammonia. H. S. Forrest and J. Walker<sup>11</sup> found that in the presence of hydrazine glucose and fructose reacted with 2 4 5 triamino 6 hydroxypyrimidine to give 2 amino-4 hydroxy-6-D arabotetrahydroxybutylpteridine whereas in the absence of hydrazine 2 amino 4 hydroxy 7 D arabotetrahydroxybutylpteridine was formed.

# Fermentation *L. casei* Factor

Pteroyl  $\gamma$ -glutamyl  $\gamma$ -glutamyl glutamic acid was synthesised<sup>12</sup> by reacting diethyl glutamate with the acid chloride of  $\alpha$  ethyl carbobenzoxyglutamate to give the carbobenzoxy dipeptide hydrolyzing to remove the protective benzyl group giving triethyl  $\gamma$ -glutamylglutamate and then repeating the series of reactions with another molecule of  $\alpha$  ethyl carbobenzoxy glutamate acid chloride and finally hydrolysing the tetraethyl ester of  $\gamma$  glutamyl  $\gamma$  glutamylglutamic acid and converting to the pteroyl derivative


A simplified method was subsequently described<sup>13</sup> The *p* nitro benzoyl derivative of  $\gamma$ -ethyl glutamate was converted *via* the  $\gamma$  hydrazide into the  $\gamma$  azide which was reacted either with triethyl  $\gamma$  glutamylglutamate giving triethyl *p* nitrobenzoyl  $\gamma$  glutamyl  $\gamma$  glutamylglutamic acid direct or with  $\gamma$ -ethyl glutamate giving  $\gamma$  ethyl *p* nitrobenzoyl  $\gamma$  glutamylglutamate which was converted into the tripeptide by a repetition of the same procedure The *p* nitrobenzoyl derivative was then reduced and the amino compound converted into pteroyltriglutamate

# SLR Factor (Rhizopterine)


Rhizopterine was synthesised by treating synthetic pteric acid with formic acid<sup>14</sup>

# Xanthopterine

Xanthopterine was synthesised by R. Purmann<sup>15</sup> by reacting 2, 4, 5 triamino 6 hydroxy pyrimidine with dichloroacetic acid and then cyclising the resulting 2, 4 diamino 5 dichloroacetyl amino 6 hydroxy pyrimidine by treatment with silver oxide



The starting material was prepared by the condensation of guanidine with phenylazocycanoacetic ester and reduction of the azo group in the product



Xanthopterine can also be prepared in good yield by reduction of leucopterine<sup>16</sup> dihydroxanthopterine is formed on further reduction

References to Section 4

- 1 R B Angier J H Boothe B L Hutchings J H Mowat J Semb E L R Stokstad Y SubbaRow C W Waller D B Cosulich M J Fahrenbach M E Hultquist E Kuh E H Northey D R Seeger J P Sickels and J M Smith *Science* 1946 **103**, 667 *Ann NY Acad Sci* 1946 **48**, 283
- 2 Waller *et al* *J Amer Chem Soc* 1948 **70**, 19
- 3 Hultquist *et al* *ibid* 23
- 4 Angier *et al* *ibid* 25
- 5 Boothe *et al* *ibid* 27
- 6 American Cyanamid Co USP 2442836 7 2442867 2443165 2444002 2444005 Brit App 12491/48 14216/48 24564/48 25001 2/48 3413/49
- 7 F E King and P C Spensley *Nature* 1949 **164**, 574
- 8 P Karrer and R Schwyzer *Helv Chim Acta* 1948 **31** 777
- 9 Roche Products Ltd BP 624394 630751
- 10 Hoffmann La Roche & Co BP 626171 628305 Roche Products Ltd BP 631516
- 11 H S Forrest and J Walker *J Chem Soc* 1949 2077
- 12 J H Boothe J H Mowat B L Hutchings R B Angier C W Waller E L R Stokstad J Semb A L Gazzola and Y SubbaRow *J Amer Chem Soc* 1948 **70** 1099
- 13 J H Boothe J Semb C W Waller R B Angier J H Mowat B L Hutchings E L R Stokstad and Y SubbaRow *ibid* 1949 **71**, 2304
- 14 D E Wolf R C Anderson E A Kaczka S A Harris G E Arth P L Southwick R Mazingo and K Folkers *ibid* 1947 **69** 2753
- 15 R Purmann *Annalen* 1940 **546**, 98
- 16 J R Totter *J Biol Chem* 1944 **154**, 105

## 5 PROPERTIES OF FOLIC ACID

### Folic Acid

H K Mitchell and R J Williams<sup>1</sup> assigned the formula  $C_{15}H_{15}O_6N_5$  to the folic acid isolated from spinach leaves and stated that it was free from sugars or polyhydroxy compounds but contained a xanthopterin-like moiety since its absorption spectrum resembled that of xanthopterin\*. The relationship of folic acid to other members of the group has not definitely been established but there is some evidence to suggest that it is not identical with the liver *L. cases* factor<sup>2</sup>

### Liver *L. cases* Factor (Vitamin B<sub>12</sub>)

Crystalline vitamin B<sub>12</sub> was isolated from liver by Pfaffner *et al*<sup>3</sup> and E L R Stokstad<sup>4</sup> who obtained it from hot water in the form of yellow platelets which melted above 360° C. The empirical formula

was  $C_{21}H_{24}N_7O_8$ . The solubility of the substance in water at pH 3 was approximately 10  $\mu$ g per ml at 2° C and 0.5 mg per ml at 100° C.<sup>6</sup> The factor was insoluble in the common organic solvents, but soluble in glacial acetic acid, phenol and methanol.<sup>7</sup> The extinction coefficients in 0.1 N sodium hydroxide were

$$E_{1\text{ cm}}^{1\%} \text{ 255 m}\mu, 565, 282 \text{ m}\mu, 350, 365 \text{ m}\mu, 195$$

### Fermentation *L. casei* Factor

The fermentation *L. casei* factor differed from the liver factor in its biological activity, whereas it was 60 to 80 % as active as the liver compound towards *L. helveticus*, it was only 4 to 6 % as active for *S. faecalis* R.<sup>8</sup> No reliable combustion figures could be obtained for the substance which clearly had a composition different from that of liver factor, however.<sup>8</sup> The absorption spectrum was similar to that of the liver factor, but the extinction coefficients were lower, indicating that the fermentation factor had a higher molecular weight.<sup>8</sup>

### Vitamin B<sub>6</sub> Conjugate

Vitamin B<sub>6</sub> conjugate, prepared from yeast by Pfaffner *et al.*<sup>9</sup> had a lower nitrogen content than had vitamin B<sub>6</sub> and although the absorption spectra of the two substances were similar, the relative values of the extinction coefficients indicated that the molecule of the conjugate was nearly three times as big as that of vitamin B<sub>6</sub>. It had practically no growth-promoting action for either *L. helveticus* or *S. lactis* R.

### SLR Factor (Rhizopterin)

Rhizopterin had the empirical formula,  $C_{15}H_{12}N_6O_4$  and was highly active towards *S. lactis* R, but substantially inactive towards *L. helveticus*. Unlike the *L. casei* factors, it did not stimulate growth

was insoluble in the common organic solvents and water but soluble in mineral acids and alkalis. It was therefore difficult to purify by crystallisation but yielded a crystalline complex with luteo ethylene diaminocobaltic chloride and ammonia,<sup>11</sup> treatment of the complex with dilute acetic acid yielded pure rhizopterin.

### Xanthopterin

Xanthopterin is a yellow solid with a melting point higher than 400° C, and it can be crystallised only with great difficulty. It is very sparingly soluble in organic solvents and cold water, but readily soluble in hot water and in hot ethylene glycol and glycerol.

## STABILITY

### References to Section 5

- 1 H K Mitchell and R J Williams *J Amer Chem Soc* 1944 **66**, 271
- 2 H K Mitchell *ibid* 274
- 3 F A Hall *Biochem J* 1947 **41**, 287
- 4 J J Pflüger S B Binkley E S Bloom R A Brown O D Bird A D Emmett A G Hogan and B L O'Dell *Science* 1943 **97**, 404
- 5 E L R Stokstad *J Biol Chem* 1943 **149**, 573
- 6 E L R Stokstad B L Hutchings and Y Subbarow *J Amer Chem Soc* 1948 **70**, 3
- 7 B L O'Dell *Univ Microfilms Ann Arbor* 1944 **5**, No 2 19
- 8 B L Hutchings E L R Stokstad N Bohonos and N H Slobodkin *Science* 1944 **99**, 371 B L Hutchings E L R Stokstad N Bohonos N H Sloane and Y Subbarow *J Amer Chem Soc* 1948 **70**, 1
- 9 J J Pflüger D G Calkins B L O'Dell E S Bloom R A Brown C J Campbell and O D Bird *Science* 1945 **102**, 228
- 10 E L Rickes L Chaiet and J C Keresztesy *J Amer Chem Soc* 1947 **69**, 2749
- 11 D E Wolf R C Anderson E A Kaczka S A Harris G E Arth P L Southwick R Mazingo and K Folkers *ibid* 2753

## 6 STABILITY OF FOLIC ACID

Pteroylglutamic acid is labile to acid 70 to 100 % of the activity being destroyed on autoclaving at pH 1<sup>1 2</sup>. It becomes progressively more stable as the pH increases and is relatively stable to heat within the pH range 4 to 12. At pH 6.8 for instance solutions can be sterilised by heating for thirty minutes without loss of potency.

Folic acid is partially inactivated by lead and mercury salts<sup>1</sup> and by treatment with sulphite<sup>2</sup>. Aeration at pH 10 also causes partial inactivation<sup>2</sup>.

In pure solutions it is rapidly inactivated by light<sup>2 3</sup> with formation of *p*-aminobenzoylglutamic acid<sup>3</sup> and 2-amino-4-hydroxy-6-formylpteridine<sup>3a</sup> the latter is converted first into the corresponding acid and then into 2-amino-4-hydroxypteridine.

### Vitamin B<sub>6</sub> Conjugase

Vitamin B<sub>6</sub> conjugate (pteroylheptaglutamic acid) is converted into pteroylglutamic acid by the action of an enzyme known as vitamin B<sub>6</sub> conjugase (page 460). This is present in pig kidney<sup>4</sup> the liver and small intestine of the pig<sup>5</sup> in ox liver<sup>5</sup> chick pancreas<sup>5</sup> chick liver<sup>7</sup> and almonds<sup>4</sup>. The enzyme also converts pteroyltriglutamic acid into pteroylglutamic acid Day *et al*<sup>8</sup> obtaining a 23 fold

increase in the activity of a concentrate of the fermentation *L. casei* factor towards *S. faecalis* R on incubation with vitamin B<sub>6</sub> conjugase

Vitamin B<sub>6</sub> conjugase is also produced often in considerable amounts by many micro organisms<sup>6</sup> but it does not appear to be present in moulds or yeasts and only in small amounts in potatoes<sup>4</sup> The enzyme was shown to be different from kidney nucleosidase the acid phosphatase of almond or potato the alkaline phosphatase of the small intestine and the  $\beta$  glucosidase of almond

The activity of the enzyme was inhibited by nucleic acid and sulphydryl combining reagents<sup>9</sup>

The purification of vitamin B<sub>6</sub> conjugase was described by Laskowski *et al*<sup>10</sup> The process involved treatment with calcium phosphate gel precipitation with alcohol and repeated concentration of the solution and salting out with sodium sulphate A method of estimating the enzyme in animal tissues was worked out and this was used to ascertain its distribution The enzyme was found to be widely distributed in the rat's body the pancreas brain intestinal mucosa and bone showed much higher values than the liver Chicken pancreas intestinal mucosa and liver were very good sources A similar distribution of the enzyme was observed by Bird *et al*<sup>11</sup> They noted that the optimal pH for activity was generally 4.5 but that enzyme preparations from chick and turkey pancreas were most effective at pH 7.0 to 7.5 Yeast extract contained a potent inhibitor of the enzyme The vitamin B<sub>6</sub> contents of several preparations of vitamin B<sub>6</sub> conjugate were estimated microbiologically after digestion with vitamin B<sub>6</sub> conjugase

#### References to Section 6

- 1 B L O Dell and A G Hogan *J Biol Chem* 1943 **149**, 323
- 2 E P Daniel and O L Kline *ibid* 1947 **170**, 739
- 3 E L R Stokstad D Fordham and A de Grunigen *ibid* 1947 **167**, 877
- 3a O H Lowry O A Bessey and E J Crawford *ibid* 1949 **180**, 389
- 4 O D Bird S B Binkley E S Bloom A D Emmett and J J Pfiffner *ibid* 1945 **157**, 413
- 5 V Mims and M Laskowski *ibid* 1945 **160**, 493
- 6 P R Burkholder I McVeigh and K Wilson *Arch Biochem* 1945 **7**, 287
- 7 L J Daniel M L Scott L C Norris and G F Heuser *J Biol Chem* 1945 **160**, 265
- 8 P L Day V Mims and J R Totter *ibid* 1945 **161**, 45
- 9 V Mims M E Swendseid and O D Bird *ibid* 1947 **170**, 367
- 10 M Laskowski V Mims and P L Day *ibid* 1945 **157**, 731
- 11 O D Bird M Robbins J M Vandenberg and J J Pfiffner *ibid* 1946 **163**, 649

## 7 ESTIMATION OF FOLIC ACID

## Microbiological Methods

Although chicks were used extensively in studying the relation ship between different members of the folic acid group of factors the methods used to assay preparations of these factors and foodstuffs containing them have invariably involved the use of micro organisms particularly *L. helveticus* and *S. faecalis* R. These as already noted respond to different degrees with the different factors. Pteric acid and the SLR factor for instance stimulate *S. faecalis* R but not *L. helveticus* pteroylglutamate stimulates both pteroyltriglutamate (fermentation *L. casei* factor) stimulates *L. helveticus* but not *S. faecalis* R and pteroylheptaglutamate (vitamin B<sub>6</sub> conjugate) stimulates neither organism.

In their original method Mitchell *et al*<sup>1</sup> used *S. faecalis* R which was also used by Elvehjem and his colleagues<sup>2</sup> who modified the medium in order to obtain greater acid production and thus increase the titre.

*L. helveticus* was used by M. Landy and D. M. Dicken<sup>3</sup>. The medium was the same as that used for the assay of five other members of the vitamin B complex but had the disadvantage of requiring a large number of constituents.

As might be expected the chief difficulty in assaying folic acid arises from the differences in the response elicited by the different forms of the factor. The object of assaying foodstuffs for example is to determine the total folic acid content that is the amount of material that could be utilised by the healthy animal for growth and haemopoiesis and to this extent a biological method using the chick or the monkey would be superior to any microbiological assay method. Such a method does not appear to exist however and workers have therefore been forced to use microbiological methods in combination with some process of hydrolysis to convert the microbiologically inactive forms into forms that would produce a response. Cheldelin *et al*<sup>4</sup> advocated digestion with takadiastase which they claimed to give maximum folic acid values whilst Laskowski *et al*<sup>5</sup> recommended digestion with an extract of chick pancreas for yeast extracts and autoclaving at pH 4 for twelve hours for liver preparations.

Bird *et al*<sup>6</sup> described a method of hydrolysing vitamin B<sub>6</sub> conjugate by means of vitamin B<sub>6</sub> conjugase prepared from hog kidney or almonds. The total folic acid was then estimated microbiologically with *L. helveticus*.

Although the conjugase from hog kidney is said to give satisfactory results with plant materials<sup>7</sup> a combination of hog kidney and chick pancreas enzymes gave higher results than either alone<sup>8</sup>. Lower



results were obtained by the microbiological assay of milk following digestion with chick pancreas than by assay with chicks <sup>9</sup>

### Chemical Methods

A chemical method of estimating folic acid was described by Hutchings *et al* <sup>10</sup> It was based on the observation that pteroyl glutamic acid and related compounds were cleaved by reduction with zinc and acid giving a pteridine and an aromatic amine. The latter was estimated colorimetrically by reaction with N naphthylethylenediamine. Interference due to the presence of adenine, adenosine and nucleic acid was eliminated by reducing with titanous chloride instead of with zinc and acid <sup>11</sup>

Pteroylglutamic acid can also be estimated fluorimetrically <sup>12</sup> On oxidation with potassium permanganate it is converted into 2 amino 4 hydroxypteridine 6 carboxylic acid which fluoresces strongly at 470 m $\mu$  when irradiated with light of wave length 365 m $\mu$ . The intensity of the fluorescence is proportional to the concentration. When interfering pigments are present the oxidation product is isolated chromatographically.

Pteroylglutamic acid can also be estimated polarographically except when iron is present <sup>13</sup> With 1 % tetramethylammonium hydroxide solution pH 9.0 to 9.5 as the base solution, it has a half wave potential *versus* the S.C.E. of 0.98 volt. With cadmium as an internal standard the error of the estimation is only  $\pm 2$  %.

### References to Section 7

- 1 H K Mitchell, E E Snell and R J Williams *J Amer Chem Soc* 1941 **63**, 2284. H K Mitchell and E E Snell *Univ Texas Publ* 1941 No 4137 36.
- 2 T D Luckey, G M Briggs and C A Elvehjem *J Biol Chem* 1944 **152** 157. L J Tepley and C A Elvehjem *ibid* 1945 **157**, 303.
- 3 M Landy and D M Dicken *J Lab Clin Med* 1942 **27**, 1086.
- 4 V H Cheldeln, M A Eppright, E E Snell and B M Gurard *Univ Texas Publ* 1942 No 4237 32.
- 5 M Laskowski, V Mims and P L Day *J Biol Chem* 1945 **157**, 731.
- 6 O D Bird, B Bressler, R A Brown, C J Campbell and A D Emmett *ibid* 1945 **159**, 631.
- 7 O E Olson, E E C Fager, R H Burras and C A Elvehjem *Arch Biochem* 1948 **18** 261.
- 8 A Sreenivasan, A E Harper and C A Elvehjem *J Biol Chem* 1949 **177** 117.
- 9 A Z Hodson *J Nutrition* 1949 **38** 25.

- 10 B L Hutchings E L R Stokstad J H Boothe J H Mowat  
C W Waller R B Angier J Semb and Y SubbaRow *J Biol Chem* 1947 168 705
- 11 A J Glazko and L M Wolf *Arch Biochem* 1949 21 241
- 12 V Allfrey L J Teply C Geffen and C G King *J Biol Chem*  
1949 178 465
- 13 W J Mader and H A Frediani *Anal Chem* 1948 12 1199

## 8 OCCURRENCE OF FOLIC ACID COMPLEX

Folic acid has been reported to be present<sup>1</sup> in liver kidney yeast mushrooms grass and other green leaves

Milk has a very low folic acid content although A D Welch and L D Wright<sup>2</sup> failed to produce folic acid deficiency in rats when a milk diet was used in conjunction with a poorly absorbed sulphonamide such as succinylsulphathiazole. Moreover the hepatic tissues of such rats were found to contain more microbiologically active material than the livers of rats fed a purified diet supplemented with a comparable amount of folic acid. Welch and Wright suggested that milk contained a substance itself microbiologically inactive which served as a growth factor for rats. The presence of a conjugated form of folic acid was in fact confirmed by A Z Hodson<sup>3a</sup> who assayed milk microbiologically after digestion with chick pancreas conjugase. Unfortunately inconsistent results were obtained with different test organisms *L. helveticus* giving a value of 11 to 74  $\mu\text{g}$  per g and *S. faecalis* a value of 0.9 to 2.4  $\mu\text{g}$  per g still higher results were obtained by a chick assay method. In spite of these inconsistencies the results explain the observation of Cooperman *et al.*<sup>3</sup> that milk is a good source of the monkey anaemia factor. Most of this was present in the skim milk and hardly any in the cream. raw whey was also a good source of the factor. Milk as well as liver and certain grains were good sources of the SLR factor but leafy materials were in general poor sources of both.<sup>4</sup> Good correlation was observed between the effect of crude preparations on anaemic monkeys and their effect on *S. faecalis* R but correlation was less satisfactory with purified materials.

Folic acid is also present<sup>5</sup> in many micro-organisms the highest yields (0.25 to 1.67 mg per ml) being obtained from *B. subtilis* *B. vulgaris* *Serratia marcescens* and a Gram negative bacillus from chick intestine.

The amount of monkey anti anaemia factor<sup>6</sup> in fresh liver was greater than in whole liver powder but lyophilised liver retained the total amount present in the fresh liver. Beef and pork livers were equally potent.

Xanthopterine has been shown to be present in liver <sup>7</sup> and in the eye of the dog fish, *Squalus acanthias* and of *Alligator mississippiensis* <sup>8</sup>

#### References to Section 8

- 1 H K Mitchell, E E Snell and R J. Williams, *J Amer Chem Soc*, 1941, **63**, 2284
- 2 A D Welch and L D Wright, *Science*, 1944 **100**, 153
- 2a A Z Hodson, *J Nutrition*, 1949 **38**, 25
- 3 J M Cooperman W R Ruegamer and C A Elvehjem *Proc Soc Exp Biol Med*, 1946, **62**, 101
- 4 W R Ruegamer, J M Cooperman, E M Sporn E E Snell and C A Elvehjem, *J Biol Chem*, 1947, **167**, 861
- 5 P R Burkholder, I McVeigh and K Wilson *Arch Biochem* 1945, **7**, 287
- 6 L D Wright, H R Skeggs A D Welch, K L Sprague and P A Mattis, *J Nutrition*, 1945 **29**, 289
- 7 R W Simmons and E R Norris *J Biol Chem*, 1941, **140**, 679, 1945 **158**, 449
- 8 A Pirie and D M Simpson, *Biochem J*, 1946, **40**, 14

### 9. EFFECT OF FOLIC ACID DEFICIENCY IN ANIMALS

The effects of different members of the folic acid complex on different species of animals have already been described at some length in the introductory section, with the primary object of showing how the different factors are related to one another. In addition to their growth-promoting effects on micro organisms, the compounds are characterised by their ability to cure anaemia, leucopenia and granulocytopenia in chicks and monkeys fed purified diets, and in rats treated with sulphaguanidine or sulphasuxidine.

#### Chicks

As already stated (page 459), crude specimens of vitamin B<sub>9</sub><sup>1</sup> and of the liver *L. casei* factor <sup>2</sup> prevented anaemia and promoted growth in chicks. The purified factors had similar effects. Crystalline vitamin B<sub>9</sub> maintained normal growth and feathering in chicks and prevented the development of a macrocytic hyperchromic anaemia leucopenia and thrombocytopenia,<sup>3</sup> whilst crystalline vitamin B<sub>9</sub> conjugate cured a nutritional macrocytic anaemia in chicks <sup>4</sup>. A purified preparation of the fermentation *L. casei* factor <sup>5</sup> and purified folic acid <sup>6</sup> stimulated growth in chicks.

An apparently significant difference between the response of chicks to vitamin B<sub>9</sub> and to the *L. casei* factor was, however, reported by

Petering *et al* <sup>7</sup> Chicks were maintained on a purified diet, which resulted in poor growth, poor feathering, anaemia and high mortality. The symptoms were prevented by yeast or liver extract containing 22 to 44  $\mu\text{g}$  of vitamin  $\text{B}_6$  but 4- or 5 pyridoxic acid (page 344) alone did not improve the condition of the birds, and the *L. casei* factor alone had only a slight effect. The *L. casei* factor and 4 pyridoxic acid together, however, increased the growth rate and haemoglobin formation, although to a smaller degree than did vitamin  $\text{B}_6$ .

Again, when only crude preparations were available, there was a difference of opinion as to whether vitamin  $\text{B}_6$  was the only anti-anaemic factor necessary for chicks. On the one hand, L. C. Norris and G. F. Heuser and their co-workers <sup>8</sup> maintained that it was only effective in presence of  $\alpha$ - or  $\beta$  pyracin (see page 344) and that a deficiency of vitamin  $\text{B}_6$  or of the *L. casei* factor caused a macrocytic, normochromic anaemia, whilst lack of  $\beta$  pyracin caused a normocytic, hypochromic anaemia. They asserted that less  $\beta$  pyracin and *L. casei* factor were required for growth than for the prevention of anaemia. Hutchings *et al* <sup>9</sup> on the other hand found that the addition of  $\beta$  pyracin to the *L. casei* factor was not necessary for growth or haemoglobin formation in the chick. Subsequently, when the pure substance became available, they showed <sup>10</sup> that the effect of synthetic pteroylglutamic acid on the feathering of chicks was not enhanced by, *inter alia*, *p* aminobenzoic acid,  $\beta$  pyracin or *p* aminophenyllactic acid, nor was it modified by the addition of intestinal antiseptics. Some of the inconsistent results obtained were doubtless due to the presence in the diet of variable amounts of vitamin  $\text{B}_{12}$ , which was not then known to be a factor essential for haemopoiesis (page 530).

Folic acid was twice as effective in the chick by injection as by oral administration <sup>11</sup>

Consistent results were obtained with the synthetic factors, and chicks deprived of folic acid for the first four weeks of life responded dramatically to pteroylglutamic acid <sup>12, 13</sup>. Moreover mole for mole pteroylglutamic acid and pteroyltriglutamic acid were utilised equally well by the chick for growth and prevention of anaemia, and the addition of 4 pyridoxic acid lactone had no significant effect on the utilisation of pteroyltriglutamic acid <sup>14</sup>.

The response of chicks to folic acid, however, depended to a considerable extent on the diet <sup>15</sup>. The smallest response was obtained with high fat diets or with diets in which glucose, sucrose or starch was the sole carbohydrate, whilst the best response was obtained with diets rich in protein and with a low fat content or with maize meal or dextrin as carbohydrates. Whole liver added to a diet containing sucrose gave a greater response than could be accounted for by the folic acid present. This, of course, suggested the existence of other

## THE FOLIC ACID COMPLEX

growth factors necessary for chicks, since then vitamin B<sub>12</sub> has been recognised to be such a factor (page 530)

In addition to its other effects, synthetic pteroylglutamic acid cured a perosis in chicks resulting from the feeding of a diet adequate in choline (page 590), biotin and manganese<sup>18</sup>. The condition was rendered more severe by sulphasuxidine, and it was therefore suggested that the effect was due to the folic acid stimulating the growth of intestinal bacteria, which in turn synthesised the antiperotic factor

Pteroyl glutamic acid was also a chromotrichial factor for the chick<sup>12</sup>

A biological property of folic acid apparently unconnected with the phenomena so far discussed is one concerned with the action of stilboestrol on the oviducts of chicks. Normally, the weight of these organs is increased on administration of the oestrogen but this did not occur in folic acid deficient chicks, although pantothenic acid deficient birds behaved normally. Administration of the *L* cases factor resulted in the response becoming normal. The response to stilboestrol was also reduced when chicks maintained on an adequate diet were given the folic acid antagonist, 7 methyl folic acid (page 519) and the inhibition was reversed by folic acid<sup>17</sup>

No nerve lesions were observed in folic acid deficient chicks<sup>18</sup>. Folic acid-deficient chicks gave a response to some other factors besides the recognised members of the folic acid complex. Thus, an increase in growth, feathering and haemoglobin formation was observed with preparations of vitamins B<sub>10</sub> and B<sub>11</sub><sup>19</sup>, the precise nature of which is not yet known (page 614)

Similarly the growth and haemoglobin response of chicks to factor R could not be accounted for by the amount of preformed folic acid in the preparation. The folic acid content was however, increased by incubation with chick liver, rat liver or hog kidney<sup>20</sup>, the last named being the most effective and liberating folic acid in amounts sufficient to account for the response obtained with chicks. It was therefore concluded that factor R was a mixture of folic acid conjugates. The response to factor R was not affected by succinyl sulphathiazole

### Turkeys

On a vitamin B<sub>6</sub> deficient diet, turkey poults developed a spastic cervical paralysis<sup>21</sup> which terminated in death within twenty four to thirty six hours. In addition growth was delayed and a moderate degree of anaemia developed, the erythrocytes being larger in diameter, with less dense and larger nuclei<sup>22</sup>. Pteroylglutamic acid or the triglutamate were equally effective in curing the symptoms<sup>22a</sup>

## Rats

As already noted (page 462) folic acid, in conjunction with biotin, cured the achromotrichia caused by administration of sulphonamides to rats<sup>23, 24</sup> whilst folic acid alone cured the leucopenia and granulocytopenia observed in such rats<sup>25</sup> and corrected the vitamin K deficiency produced by sulphasuxidine<sup>26</sup>. These early observations were confirmed by subsequent investigations in which various forms of folic acid were used. Thus Higgins,<sup>27</sup> using the sulphones, promin and promizole, to produce an experimental hypochromic anaemia in young rats maintained on a purified high-carbohydrate diet, showed that vitamin B<sub>12</sub> given at the rate of 80 µg per day had a pronounced curative effect. Similarly, the *L. casei* factor cured a leucopenia and granulocytopenia produced in rats by administration of succinyl sulphathiazole, whilst the marrow responded with "spectacular myeloid proliferation"<sup>28</sup>.

Again, rats that had ceased to grow and in which characteristic deficiency symptoms had developed following administration of sulphaguanidine responded to liver extract or to a folic acid concentrate plus biotin<sup>29</sup> with a reduced mortality rate of 14 % and disappearance of liver and spleen lesions. At the same time the bone marrow became hyperplastic.

That the action of sulphonamides on haemopoiesis is probably mediated through the agency of intestinal bacteria appears to be a legitimate deduction from the work of B. L. O. Dell and A. G. Hogan,<sup>30</sup> who showed that reducing the level of pyridoxine or feeding sulphaguanidine increased the incidence of anaemia in chicks. They suggested that in both instances growth of the intestinal bacteria that normally synthesised vitamin B<sub>12</sub> was suppressed. The absence of other factors essential for the growth of the intestinal bacteria might equally well result in suppression of the intestinal flora leading to a deficiency of vitamin B<sub>12</sub> and so to an increase in the incidence of anaemia.

Further evidence on the nature of intestinal synthesis was advanced by A. K. Miller<sup>31</sup> who confirmed the results obtained by previous workers that folic acid and biotin together corrected the deficiency symptoms caused by feeding 0.5 to 2.0 % of succinyl or phthalylsulphathiazole with the diet. He also noted a marked decrease in the coliform count of the faeces, but no significant change in the total aerobes, total anaerobes or anaerobic spores. Neither sulphonamide-resistant nor sulphonamide-sensitive strains of *E. coli* were able to synthesise as much folic acid when grown in presence of a sulphonamide as when grown in its absence. He therefore concluded that *E. coli* or, at all events, coliform organisms were responsible for the synthesis of folic acid in the gut (see page 505).

Still further confirmation of the part played by the intestinal

bacteria of rats in preventing anaemia was provided by Sebrell and his colleagues,<sup>32</sup> who showed that rats fed a purified diet containing succinylsulphathiazole and subjected to repeated bleeding developed a severe anaemia, which was prevented or cured by the *L. casei* factor. The effect of the latter was enhanced by  $\beta$  pyracin.<sup>33</sup>

The *L. casei* factor also corrected a granulocytopenia in rats fed a highly purified diet deficient in riboflavine, although riboflavine itself was ineffective.<sup>34</sup> Some of the rats, on the other hand, developed an anaemia that responded erratically to riboflavine, but not to the *L. casei* factor. The granulocytopenia was also cured by crystalline folic acid.

Schweigert *et al*<sup>35</sup> found that rats fed on a basal dextrin diet with 1 % of succinylsulphathiazole failed to grow and that the vitamin B<sub>6</sub> content of the livers decreased though there was no effect on the riboflavine reserves. Addition of solubilised liver increased the vitamin B<sub>6</sub> content of the livers 5 to 9 fold.

Rats with sulphonamide induced leucopenia and granulocytopenia were also cured by a yeast concentrate which possessed less than 0.4 % of the microbiological activity to be expected from its biological activity.<sup>36</sup> This was enhanced, however, by treatment with acid alkali or enzyme. The properties of the yeast factor thus resembled those of vitamin B<sub>6</sub> conjugate. Liver extracts also appeared to contain microbiologically inactive substances that were effective on rats, but they were not activated by treatment with acids, alkalis or enzymes. These substances may represent new forms of *L. casei* factor.

According to Wright *et al*<sup>37</sup> the ease with which symptoms of folic acid deficiency develop in rats depends on the nature of the diet. Thus much larger quantities of succinylsulphathiazole (10 to 20 %) had to be added to a diet of powdered milk than to highly purified diets of comparable folic acid content in order to produce folic acid deficiency. They also observed that the folic acid deficiency syndrome could co-exist with a high faecal elimination of folic acid (page 505). Rats fed exclusively on powdered milk excreted large amounts of folic acid in the faeces and this was reduced by administration of the sulphonamide.

Day *et al*<sup>38</sup> also reported that folic acid restored the growth rate of rats maintained on a milk diet to which sulphasuxidine had been added, and noted that the sulphonamide brought about a reduction in the number of coliform bacteria in the caecum and in the total bacterial count. These results suggest that the symptoms produced by administration of sulphonamides are connected with the reduction in the numbers of bacteria in the intestine and that administration of folic acid in some way reverses this effect.

Pteroylglutamic acid did not affect the anaemia that resulted when rats on a purified diet were given thiourea, but it did correct the granulocytopenia that occasionally accompanied the anaemia and which was regularly produced when, in addition to thiourea, thyroid powder or thyroxine was given<sup>39</sup> Pantothenic acid deficient rats sometimes develop granulocytopenia or anaemia or both and in this instance also, pteroylglutamic acid relieved the granulocytopenia (when alone), but not the anaemia<sup>40</sup> The anaemia, when alone, was relieved by pantothenic acid When both granulocytopenia and anaemia occurred together, both pantothenic acid and folic acid were required Feeding protein free or low-casein diets to rats also resulted in granulocytopenia and anaemia<sup>41</sup> To rectify the granulocytopenia in this instance both casein and pteroylglutamic acid were necessary

Synthetic pteroylglutamic acid at a level of 110  $\mu\text{g}$  per day increased the bodyweight and the leucocyte count of lactating rats, but no further increase was obtained by giving larger amounts<sup>42</sup> Larger amounts (275  $\mu\text{g}$  per day) were necessary in order to effect a significant improvement in the weaning weights of the young but doubling this amount did not bring about any further improvement Pteroylglutamic acid has a beneficial effect on both lactation and reproduction, and rats fed on a diet containing succinylsulphathiazole and deficient only in pteroylglutamic acid for 1 to 3 months before breeding showed impaired reproduction<sup>43</sup> whilst the addition of 0.5 % of an antagonist resulted in 100 % resorptions even without prior deficiency<sup>44</sup>

Crystalline pteroylheptaglutamate increased the total leucocytes and granulocytes in sulphasuxidine-treated rats as effectively as did pteroylglutamic acid when given orally and only slightly less effectively when injected, the presence of an inhibitor of vitamin B<sub>12</sub> conjugase did not affect the utilisation of the conjugate<sup>45</sup>

## Mice

Folic acid is also essential for mice and according to E. Nielsen and A. Black<sup>46</sup> the deficiency symptoms were rendered more acute when 0.6 % of sulphasuxidine was added to the diet Franklin *et al.*,<sup>47</sup> however, failed to produce symptoms of pteroylglutamic acid deficiency in mice by giving sulphasuxidine One of the symptoms apparently characteristic of folic acid deficiency in mice is poor lactation performance, this was considerably improved by the administration of folic acid concentrates and of the pure factor<sup>48</sup>

Pteroylglutamic acid-deficient mice also show a reduction in the counts of all the cellular elements of the circulating blood and



maturation arrest of the bone marrow, suggesting that pteroylglutamic acid may not be necessary for the formation of the immature blood elements but is necessary for maturation after the primitive elements have been formed <sup>48a</sup>

### Guinea-pigs

D. W. Woolley and H. Sprince <sup>49</sup> identified folic acid as one of the growth factors required by the guinea pig, this had previously been designated GPF-1

### Dogs

W. A. Krehl and C. A. Elvehjem <sup>50</sup> found that young dogs maintained on a nicotinic acid deficient diet until severe symptoms of black tongue developed responded poorly to supplements of nicotinic acid and soon died despite the administration of what would normally have been adequate amounts of nicotinic acid. When the basal diet was supplemented with a folic acid concentrate (from "solubilised liver") the response to nicotinic acid was consistently good.

### Foxes

On a diet free from the vitamin B complex, but containing aneurine, riboflavin, pyridoxine, nicotinic acid, pantothenic acid and choline, foxes developed anaemia and anorexia, lost weight and eventually died <sup>51</sup>. Administration of folic acid resulted in immediate recovery with rapid regeneration of haemoglobin and red blood cells. Yeast folic acid conjugate was not utilised by foxes, but the substance was effective after hydrolysis with kidney enzyme. Folic acid was not the only factor required, however.

### Mink

Absence of folic acid from the diet caused deficiency symptoms in the mink characterised by irritability, weakness, bloody faecal discharge, anorexia, loss of weight, fall in the white cell count and eventually death <sup>52</sup>. Folic acid cured most of these symptoms promptly but another factor appeared to be necessary for maintenance of weight and for haemoglobin regeneration.

### Pigs

Folic acid alone or in combination with *p*-aminobenzoic acid, inositol or biotin appeared to have no beneficial effect on the growth or appearance of pigs although haemoglobin formation was stimulated to a small extent <sup>53</sup>. On the contrary symptoms of biotin deficiency

were produced these were more acute when sulphasuxidine was also added to the diet <sup>53a</sup> With sulphasuxidine alone a normocytic anaemia was produced which was cured by the administration of pteroylglutamic acid A more severe anaemia was produced by the addition of a crude folic acid antagonist to the diet <sup>53a</sup> <sup>54,5</sup> the effects of which were overcome more effectively by a mixture of pteroylglutamic acid and biotin than by the former alone

### Monkeys

Vitamin M was the name assigned by Langston *et al* <sup>54</sup> to a factor in liver and yeast that relieved leucopenia and granulocytopenia in monkeys (see page 460) These symptoms were partially relieved by xanthopterin and completely by a pure specimen of the fermentation *L. casei* factor <sup>55</sup> and by synthetic pteroylglutamic acid <sup>56</sup>

Vitamin M deficiency is characterised by loss of weight leucopenia granulocytopenia anaemia bloody discharge gingivitis necrosis of the gums loss of appetite and susceptibility to dysentery Autopsy revealed ulcerated colon liver damage and adrenal changes <sup>56</sup>

Injection of 2 to 6 mg of synthetic pteroylglutamic acid was followed by a dramatic increase in the leucocyte and reticulocyte counts A prompt but transient increase in red blood cells occurred within twenty four hours followed by a return to the previous low levels and several days later by a more permanent increase

Folic acid however may not be the only factor responsible for vitamin M deficiency for Cooperman *et al* <sup>57</sup> in the course of an investigation into the effect of riboflavin deficiency maintained rhesus monkeys on a diet containing all the other members of the vitamin B complex including a norit eluate preparation from liver and observed a fall in the red and white blood cell count which was not restored to normal by the administration of large doses of riboflavin Addition of whole liver to the diet restored the normal blood picture When monkeys were maintained on a similar diet containing adequate riboflavin but no folic acid growth was slow and white blood cell counts become low The addition to the diet of vitamin B<sub>6</sub> vitamin B<sub>12</sub> conjugate or *L. casei* factor only partially remedied the deficiency symptoms Concentrates of vitamin B<sub>10</sub> and B<sub>11</sub> had no effect It appeared that a deficiency of folic acid precipitated a deficiency of the monkey anaemia factor this was characterised by lack of growth a low level of haemoglobin and a reversal of the lymphocyte neutrophile ratio The animals were cured by treatment with whole liver indicating the presence therein of an anti anaemia factor additional to folic acid This was also present in raw milk and stimulated the growth of *S. faecalis* R <sup>58</sup> In this respect it resembled the SLR factor but differed from it in being heat labile

R Hertz<sup>59</sup> observed that sexually immature monkeys maintained on a synthetic diet deficient in folic acid failed to show the normal response to oestradiol benzoate, thus showing a similar response to that exhibited by folic acid-deficient chicks (page 486)

### Fish

According to McLaren *et al*,<sup>60</sup> young rainbow trout developed anaemia in the absence of folic acid. This was cured by the addition to the diet of 0.1 to 0.5 mg of folic acid per 100 g. It is worth recording that *p* aminobenzoic acid stimulated growth in the presence of folic acid, the only instance in animals where the two factors have distinctive effects.

### Folic Acid and Resistance to Infection

Monkeys exhibited an increased resistance to experimental poliomyelitis when suffering from a chronic but not an acute folic acid deficiency.<sup>61</sup> Folic acid had no effect on experimental toxoplasmosis in mice, but the protection afforded by sulphathiazole was neutralised by folic acid.<sup>62</sup> Similarly, the chemotherapeutic action of sulphadiazine on psittacosis virus was antagonised by *p* aminobenzoic acid and pteroylglutamic acid, competitively in the former instance and non-competitively in the latter.<sup>63</sup> This suggests that the primary action of sulphadiazine in psittacosis is against the incorporation of *p* amino benzoic acid into pteroylglutamic acid by the virus. Large doses of sulphadiazine failed to inhibit the virus when pteroylglutamic acid was supplied, so that it evidently synthesises the vitamin in the absence of sulphonamide and utilises it for growth.

### Folic Acid and Cancer

Leuchtenberger *et al*<sup>64</sup> claimed that a folic acid concentrate and the crystalline fermentation *L. casei* factor inhibited the growth of transplanted sarcomas in mice. Later<sup>65</sup> they found that whereas the liver *L. casei* factor did not produce regression of spontaneous breast cancer in mice the fermentation *L. casei* factor was effective in eleven out of twenty eight mice. Synthetic pteroyltriglutamic acid 'Teropterin' did not, however, produce regeneration of 6C<sub>3</sub>HED tumours in C<sub>3</sub>H mice, although it partially inhibited the effect of mustard gas on lymphosarcoma 6C<sub>3</sub>HED.<sup>66</sup>

Synthetic folic acid has been tested, with not very encouraging results on various forms of malignant disease in humans (see page 501)

## References to Section 9

- 1 A G Hogan and E M Parrott *J Biol Chem* 1939 128, xlv  
1940 132, 507
- 2 B L Hutchings N Bohonos D M Hegsted C A Elvehjem and  
W H Peterson *ibid* 1941 140, 681 B L Hutchings N  
Bohonos and W H Peterson *ibid* 1941 141, 521
- 3 C J Campbell R A Brown and A D Emmett *ibid* 1944 152,  
483
- 4 J J Pflüger D G Calkins B L O'Dell E S Bloom R A  
Brown C J Campbell and O D Bird *Science* 1945 102, 228
- 5 B L Hutchings F L R Stokstad N Bohonos and N H Slobo-  
din *ibid* 1944 99, 371
- 6 H K Mitchell and R J Williams *J Amer Chem Soc* 1944 66,  
271
- 7 H G Petering J P Marvel C E Glauser and J Waddell *J  
Biol Chem* 1946 162, 477
- 8 F W Hill L C Norris and G F Heuser *J Nutrition* 1944 28,  
175 M L Scott L C Norris G F Heuser and W F Bruce  
*J Biol Chem* 1945 158, 291
- 9 B L Hutchings J J Oleson and E L R Stokstad *ibid* 1946  
163, 447
- 10 J J Oleson B L Hutchings and N H Sloane *ibid* 1946 165,  
371
- 11 D V Frost and F P Dann *Science* 1946 104, 492
- 12 D V Frost F P Dann and F C McIntire *Proc Soc Exp Biol  
Med* 1946 61, 65
- 13 E I Robertson G F Fiala M L Scott L C Norris and G F  
Heuser *ibid* 1947 64, 441
- 14 T H Jukes and E L R Stokstad *J Biol Chem* 1947 168,  
563
- 15 T D Luckey P R Moore C A Elvehjem and E B Hart *Proc  
Soc Exp Biol Med* 1946 62, 307
- 16 L J Daniel F A Farmer and L C Norris *J Biol Chem* 1941  
163, 349
- 17 R Hertz and W H Sebrell *Science* 1944 100, 293 R Hertz  
*Endocrinology* 1945 37, 1 *Science* 1948 107, 300
- 18 J H Shaw and P H Phillips *J Nutrition* 1945 29, 107
- 19 T D Luckey P R Moore C A Elvehjem and E B Hart *Science*  
1946 103, 682
- 20 L W Charkey L J Daniel F A Farmer L C Norris and G F  
Heuser *Proc Soc Exp Biol Med* 1947 64, 102
- 21 L R Richardson A G Hogan and H L Kempster *J Nutrition*  
1945 30, 151
- 22 T H Jukes E L R Stokstad and M Belt *ibid* 1947 33, 1
- 22a B S Schweigert *Arch Biochem* 1949 20, 41
- 23 G J Martin *Proc Soc Exp Biol Med* 1947 51, 353
- 24 E Nielsen and C A Elvehjem *J Biol Chem* 1942 145, 713  
B Ransone and C A Elvehjem *ibid* 1943 151, 109

Folic acid gives perfectly satisfactory results in the treatment of nutritional anaemias, including pernicious anaemia of pregnancy, nutritional macrocytic anaemia, and the sprue syndromes, because in these conditions there is no danger of spinal cord disease.<sup>26</sup> The variable results obtained in sprue may be due to the fact that the disease assumes different forms in different places; thus contrasting results were obtained with Asiatic and non-tropical sprue.

### **Etiology of Pernicious Anaemia**

Although the use of liver and liver extracts in the treatment of pernicious anaemia has long been known, the treatment is quite empirical and until recently nothing was known about the way in which liver extracts worked or, indeed, what was the nature of the physiological or biochemical lesion responsible for pernicious anaemia. The theory most generally favoured was that of W. B. Castle,<sup>27</sup> who suggested that "the haemopoietic factor effective in Addisonian pernicious anaemia is normally formed by the interaction of a gastric (intrinsic) and a food (extrinsic) factor. . . . In Addisonian pernicious anaemia, the intrinsic factor is usually absent. . . . In other types of macrocytic anaemia also the specific factor in liver extract is lacking as a result of absence of food (extrinsic) or of gastric (intrinsic) factor; of defective absorption of their reaction products from the gastrointestinal tract; or of some combination of these pathogenic factors."<sup>28</sup>

Castle's theory was re-examined by several workers after the effect of folic acid in haemopoiesis had been discovered. According to Welch *et al.*,<sup>29</sup> pteroylheptaglutamic acid was ineffective in the treatment of pernicious anaemia when given orally and did not become effective when administered simultaneously with or after normal human gastric juice so that it appears unlikely that the conjugated form of folic acid can be Castle's extrinsic factor. The heptaglutamate was likewise ineffective when given intramuscularly, and the amount of folic acid excreted in the urine was not increased, as it was when pteroylglutamic acid, liver extract, or conjugate incubated with conjugase was injected.<sup>30</sup> On the other hand, normal subjects exhibited an increased urinary excretion of folic acid following injection of the conjugate, whence it was concluded that normal subjects but not pernicious anaemia patients can utilise the conjugate. Since purified liver extracts added to bone-marrow extracts appeared to bring about the formation of pteroylglutamic acid from the heptaglutamate, it was suggested that liver extract may contain either a component of a conjugase system or a substance capable of counteracting inhibitors of conjugase activity. Similar observations were made and similar conclusions were reached by L. S. P. Davidson and R. H. Girdwood,<sup>31</sup>

who made the further suggestion that the anti anaemia factor in liver might be the product formed by the interaction of Castle's extrinsic factor with the intrinsic factor of the alimentary tract. This may be absorbed from the intestine and stored in the livers of normal individuals, but not in the livers of patients with pernicious anaemia.

Although the heptaglutamate is not converted into free folic acid by the action of normal gastric juice, it is altered thereby and the digested material did not yield free folic acid when incubated with liver homogenate<sup>31a</sup>. Gastric juice from pernicious anaemia patients, on the other hand, had no effect on the heptaglutamate, whilst juice from sprue patients behaved like normal gastric juice. Since pteroyl-triglutamate produced reticulocytosis in cases of pernicious anaemia,<sup>31b</sup> the effect of normal gastric juice on the heptaglutamate cannot be simply to convert it into the triglutamate. It has also been shown<sup>31c</sup> that the normal gastric juice combines with vitamin B<sub>12</sub> to give a microbiologically inactive complex (page 543), whereas the gastric juice from pernicious anaemia patients is inactive, the latter appears to be deficient in two respects therefore. It has been suggested that apoerythrin, the factor in normal gastric juice that combines with vitamin B<sub>12</sub>, is Castle's intrinsic factor and vitamin B<sub>12</sub> the extrinsic factor and, in that event, it is possible that this reaction is essential for the absorption and storage of vitamin B<sub>12</sub> in the absence of which folic acid is not liberated from the diet.

That pteroylglutamic acid is necessary for the normal production of red blood cells and the real operative agent that transforms a pathological megaloblastic bone marrow into the physiological normoblastic state is suggested by the observations of Meyer *et al*<sup>31d</sup> on the effect of folic acid antagonists. They found that when a sufficient amount of an antagonist was administered together with liver extract, the anticipated rise in red blood cells and haemoglobin did not occur, reticulocytosis was repressed and megaloblasts remained in the bone marrow. The effect of vitamin B<sub>12</sub> was also inhibited.

Although the liberation of folic acid is therefore one of the functions of vitamin B<sub>12</sub>, it does not appear to be the only one since vitamin B<sub>12</sub> and folic acid are not biologically equivalent. Thus neither pteroylglutamic acid nor its conjugate had a direct action on primitive erythrocytes *in vitro*, whereas potent liver extracts caused them to mature<sup>32</sup>. Normal human and rat serum also contained the maturation factor, whereas serum from a pernicious anaemia patient did not. Pteroylglutamic acid also failed to increase the maturation of bone-marrow cells suspended in this deficient serum.

It has also been suggested as an alternative theory that the anti pernicious anaemia factor is concerned with the synthesis of folic acid in the body, but an objection to this is that purified liver extracts

were ineffective in the vitamin M-deficient monkey,<sup>33</sup> rat<sup>34</sup> and chick<sup>35</sup> Furthermore, folic acid does not appear to be a precursor of the anti pernicious anaemia factor, since the latter does not contain either a pterine nucleus or an aromatic amine such as *p* aminobenzoic acid (page 533)

Patients with macrocytic anaemia (nutritional), sprue, pernicio is anaemia of pregnancy and idiopathic refractory megaloblastic anaemia are, however, refractory to the injection of potent purified liver extracts, despite the presence of a megaloblastic bone marrow Such patients respond to orally administered whole liver, proteolysed liver, liver extract or folic acid According to L S P Davidson and R H Girdwood<sup>31</sup> these types of anaemia are due not to defective production of the factor responsible for liberating free folic acid from the conjugated form but to the absence of conjugated folic acid either as the result of a dietary deficiency or of failure to absorb folic acid from the food Hence injections of liver extract fail to cure these conditions, whereas free folic acid is effective The efficacy of proteolysed or oral liver extracts may be due to the presence of folic acid conjugates

Thus the most satisfactory theory that can be put forward at the present time to account for the different forms of anaemia is that

“ h not for  
pteroyl  
absorbed,

a nutritional anaemia will result If, on the other hand, they are present but the gastric juice is defective in apoerythrem the absorption of vitamin B<sub>12</sub> from the food is impaired and the conversion of folic acid conjugates into free folic acid and certain other transformations not at present characterised do not take place and pernicious anaemia supervenes Folic acid or its conjugates given by mouth cure nutritional anaemias but not pernicious anaemia whilst free folic acid but not its conjugates cure the haematological but not the neurological symptoms of pernicious anaemia Vitamin B<sub>12</sub> has no effect on nutritional anaemia because in this condition the liver already has adequate supplies whereas it is effective in pernicious anaemia by injection because it is the effecting, amongst other reactions the acid It is ineffective by mouth because before it can be absorbed and stored in the liver

The theory that liver extracts contain a factor that liberates free folic acid from conjugates stored in the body thus initiating the haemopoietic response, is not accepted by all workers however For instance Suarez *et al*<sup>36</sup> claimed that sprue responded to treatment with as well as folic acid and that some

pernicious anaemia patients also responded. T. D. Spies and his colleagues<sup>37</sup> also stated that pernicious anaemia as well as sprue and nutritional macrocytic anaemia responded satisfactorily to conjugates. On the other hand it has been pointed out that conjugates are difficult to prepare and may well be contaminated with free folic acid. It has also been shown as already noted that the gastric juice in sprue resembles that in normal subjects and in that event it is not surprising that conjugates should be effective in sprue.

### Effect of Folic Acid on Other Blood Disorders

Folic acid was used successfully on two cases of agranulocytosis the granulocytes returning to the blood stream within forty eight hours<sup>38</sup>. When however folic acid was given together with pyridoxine to a group of patients suffering from granulocytopenia following treatment with sulphonamides only half gave a response and this was not maintained in many of the cases<sup>39</sup>. In another series of cases of agranulocytosis<sup>39a</sup> the apparent response to folic acid was actually proved to be due to spontaneous remission.

The liver *L. casei* factor was also used successfully in the treatment of leucopenia following radiation therapy<sup>40</sup> although no response was obtained in patients with refractory macrocytic anaemias. Folic acid was also given to patients receiving deep X ray treatment for various conditions many had less nausea vomiting and depressive symptoms than a control group<sup>41</sup>. It has been stated<sup>41a</sup> however that folic acid has no effect on X ray induced anaemia.

### Folic Acid and Cancer

Although folic acid appeared to inhibit the growth of certain types of tumour in experimental animals pteroyldiglutamic acid and pteroyltriglutamic acid had no effect on the cancer in cases of advanced neoplastic disease although the patients experienced some subjective improvement<sup>42</sup>. This may be due to an analgesic effect however as the triglutamate is said to increase the pain threshold in man<sup>43</sup>.

#### References to Section 10

- 1 J. L. Berry, T. D. Spies and C. A. Doan *Southern Med J* 1945 **38** 590
- 2 T. D. Spies, C. F. Vilter, M. B. Koch and M. H. Caldwell *ib id* **707**
- 3 C. F. Vilter, T. D. Spies and M. B. Koch *ib id* **781**
- 4 T. D. Spies *Lancet* 1946 **1** 225 *J. Amer. Med. Assoc.* 1946 **130** 474
- 5 C. V. Moore, O. S. Berbaum, A. D. Welch and L. D. Wright *J. Lab. Clin. Med.* 1945 **30** 1056



# THE FOLIC ACID COMPLEX

- 6 W J Darby and E Jones *Proc Soc Exp Biol Med* 1945 80, 259 W J Darby E Jones and H C. Johnson *Science* 1946 103, 108 J *Amer Med Assoc* 1946 130, 780
- 7 T D Spies I Milanes A Menendez and M B Koch *J Lab Clin Med* 1946 31, 227 T D Spies R M Suarez and F Hernandez Morales *Science* 1946 104 75
- 8 W W Zuelzer and F N Ogden *Proc Soc Exp Biol Med* 1946, 81, 176 *Amer J Dis Child* 1946 71, 211 W W Zuelzer *J Amer Med Assoc* 1946 131, 7
- 9 P Manson Bahr and O Clarke *Lancet* 1946 2, 903
- 10 J F Wilkinson M C G Israels and F Fletcher *ibid* 156
- 11 E L R Stokstad and T H Jukes *Proc Soc Exp Biol Med* 1946 82, 112
- 12 W Jacobson and D M Simpson *Biochem J* 1946 40, 3 9
- 13 L Golberg B de Meillon and J F Murray *Nature* 1947 180 22
- 14 H Levy *Brit Med J* 1947 1, 412
- 15 T D Spies *J Amer Med Assoc* 1946 130, 474
- 16 R. J Harrison and J C White *Lancet* 1946 2, 787
- 17 T D Spies and R E Stone *ibid* 1947 1, 174
- 18 L S P Davidson and R H Girdwood *ibid* 1946 2 373 *Brit Med J* 1947 1, 587 I S P Davidson R H Girdwood and E M Innes *Lancet* 1947 1, 511
- 19 G A Goldsmith *Proc Soc Exp Biol Med* 1947 64 115
- 20 R J G Morrison and C R St Johnston *Lancet* 1947 1, 636
- 21 L B Carruthers *ibid* 1946 1, 849
- 22 C F Vilter R W Vilter and T D Spies *J Lab Clin Med* 1947 32, 262
- 23 J F Ross H Belding and B L Fargel *Blood* 1948 3, 68
- 24 J F Wilkinson *Brit Med J* 1948 1 771 M C G Israels and J F Wilkinson *ibid* 1949 2 1073
- 24a H Poliakoff A Sternbach W H Walker R L Kascht and L M Meyer *Proc Soc Exp Biol Med* 1949 72 392
- 25 L S P Davidson and R H Girdwood *Lancet* 1948 1, 360
- 26 C R Das Gupta and J B Chatterjee *Indian Med Gaz* 1946 81 402 T D Spies G G Lopez R E Stone F Milanes R L Toca and T Aramburu *Lancet* 1948 1 239
- 27 W B Castle *Amer J Med Sci* 1929 178, 748 W B Castle W C Townsend and C W Heath *ibid* 1930 180, 305
- 28 J Watson and W B Castle *ibid* 1946 211, 513
- 29 A D Welch R W Heinle E M Nelson and H V Nelson *J Biol Chem* 1946 164 787 *Ann NY Acad Sci* 1946 48 347 R W Heinle and A D Welch *ibid* 343
- 30 F H Bethell M C Meyers G A Andrews M E Swendsen O D Bird and R A Brown *J Lab Clin Med* 1947 32, 3
- 31 L S P Davidson and R H Girdwood *Brit Med J* 1947 1, 567
- 31a H G Buyze and C Engel *Biochim Biophys Acta* 1948 2 217 *Nature* 1949 163 135
- 31b J F Wilkinson and M C G Israels *Lancet* 1949 2 689

- 31c J L Ternberg and R E Eakin *J Amer Chem Soc* 1949 **71**, 3858
- 31d L M Meyer N D Ritz A Cuccese J Rutzky A Sawitsky and G Bock *Amer J Med Sci* 1949 **218** 197
- 32 E E Hays *Proc Soc Exp Biol Med* 1946 **62**, 558
- 33 P L Day V Mms J R Totter E L R Stokstad B L Hutchings and N H Sloane *J Biol Chem* 1945 **157**, 423
- 34 F S Daft and W H Sebrell *US Publ Health Rep* 1943 **58**, 1542
- 35 T H Jukes and F L R Stokstad *J Biol Chem* 1947 **168**, 563
- 36 R M Suarez A D Welch R W Heinle R M Suarez jnr and E M Nelson *J Lab Clin Med* 1946 **31**, 1294
- 37 T D Spies *Southern Med J* 1946 **39** 634 T D Spies and R E Stone *ibid* 1947 **40** 46 T D Spies G G Lopez F Milanes and T Aramburu *J Amer Med Assoc* 1947 **134** 18
- 38 D A K Black and S W Stanbury *Lancet* 1947 **1**, 827
- 39 H M Denny M L Menten and E Graff *Amer J Med Sci* 1946 **211**, 671
- 39a J H Waelsch *Lancet* 1948 **2** 888
- 40 C J Watson W H Sebrell J L McKelvey and F S Daft *Amer J Med Sci* 1945 **210** 463
- 41 C A Doan *ibid* 1946 **212** 257
- 41a S P Stearnes *Proc Soc Exp Biol Med* 1948 **69** 518
- 42 S Farber E C Cutler J W Hawkins J H Harrison E C Peirce and G G Lenz *Science* 1947 **106** 619 L M Meyer *Trans NY Acad Sci* 1948 **10** 99 M J Kleiner *ibid* 71
- S P Lehr L T Wright S Weintraub and I Arons *ibid* 75
- 43 D Slaughter *Science* 1949 **109** 286

## 11 METABOLISM OF FOLIC ACID

According to Steinkamp *et al*<sup>1</sup> normal subjects excreted in the urine 2 to 4  $\mu$ g per day of pteroylglutamic acid as estimated microbiologically with *S faecalis* R. Following oral administration of a test dose 15 to 75 % with an average of 28.5 % was recovered in the urine.

The amount excreted increased with the amount administered being as much as 50 % with a 5 mg oral dose nearly all was excreted within six hours<sup>10 16</sup>. The di and tri glutamate but not the heptaglutamate were converted into pteroylglutamic acid<sup>16</sup>. Monkeys reacted differently and the addition to a folic acid deficient diet of various forms of pteroylglutamic acid failed to increase the urinary or faecal excretion appreciably the former only amounted to about 1 % and the latter to much less than 1 % of a 1 mg dose<sup>16</sup>.

## THE FOLIC ACID COMPLEX

In a patient with pernicious anaemia, receiving 0.85 mg. of synthetic folic acid daily, approximately 15 % was excreted in the urine. Following the intramuscular injection of 30 mg. of conjugate, no increase occurred in the amount of folic acid excreted, but the injection of a further 11 mg. resulted in the excretion of 4.1 mg. in the following 48 hours.<sup>2</sup> On the other hand, a normal individual, whose output of folic acid was consistently 3  $\mu$ g. per day, excreted 10 to 22 % respectively of a dose of 800  $\mu$ g. of synthetic folic acid given intramuscularly on each of two successive days and 8.4 and 8.2 % respectively of an equivalent dose (2800  $\mu$ g.) of the conjugate similarly injected. This observation supports the theory that pernicious anaemia is characterised by inability to utilise folic acid conjugate (see page 500).

The effect of pteric acid on the urinary excretion of folic acid was studied by Franklin *et al.*<sup>3</sup> Following the oral administration of 2 to 10 mg., only a small amount of pteric acid was excreted in the urine, whereas after intravenous injection 15 to 46 % was recovered in the urine. Only about 1 % was recovered in the form of pteroylglutamic acid, however, so that pteric acid was poorly absorbed from the gastro-intestinal tract and only a very small proportion of injected material was converted into pteroylglutamic acid.

Denko *et al.*<sup>4</sup> observed that more folic acid was excreted in the faeces than in the urine and that both together exceeded the dietary intake, confirming that a synthesis of folic acid takes place to a considerable extent in man, just as it does in animals. Other evidence indicates that this synthesis is effected by the intestinal flora (see page 505).

Humans excrete folic acid in the sweat,<sup>5</sup> and the amount may be 5- or 6-fold the amount eliminated per hour in the urine under conditions of profuse sweating.

Following the intravenous injection of pteroylglutamic acid or the triglutamate, an increase in the blood concentration took place which reached a maximum two hours later.<sup>6</sup> When the triglutamate was injected intramuscularly, two-thirds of the amount remaining in the blood-stream two hours later was present in the form of the monoglutamate.<sup>7</sup> The blood of many animals, including man, contains folic acid conjugase capable of releasing pteroylglutamic acid from the heptaglutamate.<sup>8</sup>

### References to Section 11

1. R. Steinkamp, C. F. Shukers, J. R. Totter and P. L. Day, *Proc. Soc. Exp. Biol. Med.*, 1946, **62**, 556.
- 1a. T. H. Jukes, A. L. Franklin, E. L. R. Stokstad and J. W. Boehne, *J. Lab. Clin. Med.*, 1947, **32**, 1350.
- 1b. P. L. Day and J. R. Totter, *J. Nutrition*, 1948, **36**, 803.

- 10 T D Spies G G Lopez R E Stone F Milanes R O Brandenburg and T Aramburu *Int Z Vit Forsch* 1947 19 1
- 2 A D Welch R W Heinle E M Nelson and H V Nelson *Ann N Y Acad Sci* 1946 48, 347
- 3 A L Franklin E L R Stokstad and T H Jukes *Proc Soc Exp Biol Med* 1947 66, 576
- 4 C W Denko W E Grundy J W Porter G H Berryman T E Friedemann and J B Youmans *Arch Biochem* 1946 10, 33
- 5 B C Johnson T S Hamilton and H H Mitchell *J Biol Chem* 1945 159, 425
- 6 B S Schweigert *J Lab Clin Med* 1948 33 1271
- 7 G Toennies and D L Gallant *ibid* 1949 34 501
- 8 R E Simpson and B S Schweigert *Arch Biochem* 1949 20 32  
R Wolff L Drouet and R Karlin *Science* 1949 109 612

## 12 INTESTINAL SYNTHESIS OF FOLIC ACID

Reference has already been made (page 461) to the production of folic acid deficiency in rats by administration of sulphasuxidine and other sulphonamides <sup>1-3</sup> and to the fact that large amounts of folic acid are excreted in human faeces <sup>4</sup> (see page 504). The faecal excretion is largely independent of the dietary intake of folic acid and so apparently is the urinary excretion which decreased only slightly on a restricted diet. This may be taken to indicate that some at least of the folic acid synthesised by the intestinal flora may be utilised in man. The rat may also be able to utilise the folic acid so produced <sup>5</sup> although even in the rat symptoms of folic acid deficiency can co-exist with a high faecal elimination of folic acid <sup>6</sup>. Rabbits can apparently utilise folic acid synthesised by the intestinal flora as the administration of sulphasuxidine markedly reduced the urinary excretion of folic acid <sup>6a</sup>. If humans can in fact utilise folic acid from this source then patients with pernicious anaemia are not only unable to utilise conjugated folic acid derived from the diet but also folic acid produced by intestinal synthesis. Similarly patients with nutritional macrocytic anaemia must be suffering not only from a dietary deficiency but also from an inability to absorb the vitamin from the gut.

In point of fact the only direct evidence on the extent to which folic acid synthesised by the intestinal flora can be utilised in man is an observation by Grundy *et al* <sup>7</sup> that absorption does not take place. These workers found that when phthalylsulphathiazole was given for several days to volunteers maintained on carefully controlled diets the faecal excretion of *L. casei* factor fell to about 10 % of its original value and increased again when administration of the drug ceased. The amount of folic acid excreted in the urine did not fall with the

## THE FOLIC ACID COMPLEX

decrease in the faecal excretion, as it certainly should have done if folic acid were being absorbed from the gut

Chicks also appear unable to utilise folic acid produced by synthesis in the intestine, since the addition of succinylsulphathiazole to the diet did not affect growth, feathering or haemoglobin formation<sup>6</sup>

### References to Section 12

- 1 G J Martin *Proc Soc Exp Biol Med* 1942 51, 353
- 2 E Nielsen and C A Elvehjem *J Biol Chem* 1942 145, 713  
B Ransone and C A Elvehjem *ibid* 1943 151, 109
- 3 F S Daft and W H Sebrell *US Publ Health Rep* 1943 58, 1542
- 4 C W Denko W E Grundy J W Porter G H Berryman T E Friedemann and J B Youmans *Arch Biochem* 1946 10, 33  
C W Denko W E Grundy N C Wheeler C R Henderson G H Berryman T E Friedemann and J B Youmans *ibid* 1946 11, 109
- 5 B L O Dell and A G Hogan *J Biol Chem* 1943 149, 323
- 6 L D Wright H R Skeggs A D Welch K L Sprague and P A Mattis *J Nutrition* 1945 29, 289
- 6a R E Simpson B S Schweigert and P B Pearson *Proc Soc Exp Biol Med* 1949 70, 611
- 7 W E Grundy M Freed H C Johnson C R Henderson and G H Berryman *Arch Biochem* 1947 15, 187
- 8 E I Robertson L J Daniel F A Farmer L C Norris and G F Heuser *Proc Soc Exp Biol Med* 1946 62, 97

## 13 HUMAN AND ANIMAL REQUIREMENTS OF FOLIC ACID

### Chicks

Chickens required 10  $\mu\text{g}$  per day of synthetic *L. casei* factor to promote normal feathering and pigmentation caused by folic acid deficiency<sup>1</sup>. Five  $\mu\text{g}$  gave fair feathering but marked depigmentation and 2.5  $\mu\text{g}$  were ineffective.

According to Robertson *et al*<sup>2</sup> chicks required 25  $\mu\text{g}$  per 100 g of ration in order to survive up to six weeks of age 45  $\mu\text{g}$  per 100 g for growth and haemoglobin formation at four weeks 45  $\mu\text{g}$  per 100 g for growth at six weeks 35  $\mu\text{g}$  per 100 g for haemoglobin formation at six weeks and not less than 55  $\mu\text{g}$  per 100 g for feathering at six weeks. The addition of 1 to 2 % of sulphasuxidine did not affect growth feathering or haemoglobin formation. A diet containing 42  $\mu\text{g}$  per 100 g was adequate for egg production and hatchability<sup>3</sup> and storage of pteroylglutamic acid did not take place below this level<sup>2b</sup>.

## HUMAN AND ANIMAL REQUIREMENTS

### Monkeys

In order to prevent vitamin M deficiency in monkeys 100  $\mu\text{g}$  per day of liver vitamin B<sub>12</sub> or of synthetic *L. casei* factor or 200 to 300  $\mu\text{g}$  per day of yeast vitamin B<sub>12</sub> conjugate were required.<sup>3</sup>

### Humans

No direct information is yet available as to the amount of folic acid that must be ingested in the diet in order to maintain a normal individual in full health but an estimate of the probable folic acid requirements of humans can be made from a consideration of the amounts that have to be given to maintain a normal blood picture in patients with pernicious or other types of anaemia. Such estimates have been made by L. S. P. Davidson and R. H. Girdwood<sup>4</sup> who stated that the daily requirement of folic acid was 0.5 to 1 mg although the recommended dose for the initial treatment of pernicious anaemia is higher—5 to 10 mg daily by mouth.

For the initial maintenance therapy of nutritional megaloblastic anaemia, pernicious anaemia of pregnancy, idiopathic refractory megaloblastic anaemia or the sprue syndrome 5 to 10 mg of folic acid per day are advocated. In the first two diseases treatment can be stopped when the blood count is normal but in idiopathic refractory megaloblastic anaemias treatment for life is necessary at a suggested dose level of 5 mg daily. The maintenance treatment in sprue will vary according to the response and folic acid may have to be supplemented by oral liver extract or proteolysed liver. From these data therefore the probable human requirement of folic acid is up to 5 mg per day.

### Rats

To cure all the symptoms of folic acid deficiency in rats 5  $\mu\text{g}$  of pteroylglutamic acid were said to be required per day<sup>5</sup> whereas to cure the granulocytopenia only 5.7  $\mu\text{g}$  were required per week.<sup>6</sup> Larger amounts were needed during pregnancy and particularly during lactation.<sup>7</sup>

### References to Section 13

- 1 D. V. Frost, F. P. Dann and F. C. McIntire *Proc. Soc. Exp. Biol. Med.* 1946 **61**, 65.
- 2 E. J. Robertson, L. J. Daniel, F. A. Farmer, L. C. Norris and G. F. Heuser *ibid.* 1946 **62**, 97.
- 2a B. S. Schweigert, H. L. German, P. B. Pearson and R. M. Sherwood *J. Nutrition* 1948 **35**, 89. W. W. Cravens and J. G. Halpin *ibid.* 1949 **37**, 127.

## THE FOLIC ACID COMPLEX

- 2b. J. R. Totter, W. E. Martindale, M. McKee, C. K. Keith and P. L. Day, *Proc. Soc. Exp. Biol. Med.*, 1949, 70, 435.
3. J. M. Cooperman, C. A. Elvehjem, K. B. McCall and W. R. Ruegamer, *ibid.*, 1946, 62, 92.
4. L. S. P. Davidson and R. H. Girdwood, *Brit. Med. J.*, 1947, 1, 587.
5. C. F. Asenjo, *J. Nutrition*, 1948, 36, 601.
6. S. J. Darke and C. White, *Brit. J. Nutrition*, 1948, 2, ix.
7. M. B. Williamson, *Proc. Soc. Exp. Biol. Med.*, 1949, 70, 336.

## 14. PHARMACOLOGY OF FOLIC ACID

### Pteroylglutamic Acid

The pharmacological properties of pteroylglutamic acid were described by Harned *et al.*<sup>1</sup> The acute intravenous toxicity was very low, the following values being obtained for LD<sub>50</sub>: mice, 600; rat, 500; rabbit, 410; guinea-pig, 120 mg. per kg. of bodyweight. In the rat, most of the deaths occurred within thirty minutes of the injection, and followed a violent convulsion, which was mainly toxic. In rabbits and guinea-pigs many of the deaths were delayed and in these instances were due to renal damage, pteroylglutamic acid being precipitated in the tubules. Male mice tolerated dosages that were lethal to females.<sup>2</sup>

When rabbits were given 50 mg. per kg. per day intraperitoneally for ten weeks, there was a possible retardation of growth, but no difference between the treated and control group was observed as regards blood picture, number of deaths or general appearance. At autopsy, however, the treated group showed signs of renal injury. Similarly in rats given 75 mg. per kg. per day intraperitoneally, growth was slightly depressed but no other effect was observed except renal damage.

Pteroylglutamic acid did not affect the respiration of the dog or cat in doses up to 100 mg. per kg. intravenously, or the rabbit in doses up to 50 mg. per kg. A temporary rise in blood pressure occurred in the dogs following injection and a slight rise or fall in the cats. The substance had no appreciable effect on the rabbit ileum, it did not affect the blood sugar of fasted rats, produced no irritation when injected intracutaneously into guinea-pigs, and had no diuretic activity.

### Xanthopterine

The pharmacological properties of xanthopterine were described by H. Hörlein.<sup>3</sup> He found it to be virtually non-toxic when administered orally, whilst the lethal dose of the sodium salt given intravenously was 50 mg. per kg. for mice, 30 mg. per kg. for rabbits and

7.5 mg per kg for cats. The toxicity of leucopterine was of the same order.

#### References to Section 14

- 1 B K Harned R W Cunningham H D Smith and M C Clark  
*Ann N Y Acad Sci* 1946 **48**, 289
- 2 A Taylor and N Carmichael *Proc Soc Exp Biol Med* 1949 **71**  
544
- 3 H Horlein *Arch Exp Path Pharmacol* 1941 **108**, 258

## 15 FOLIC ACID IN THE NUTRITION OF MICRO-ORGANISMS

### Essential Growth Factors

It has already been stated (page 457) that folic acid and the *L. casei* factor were originally recognised by virtue of their ability to stimulate the growth of *L. helveticus* (*L. casei*  $\epsilon$ ) and *S. faecalis* R. and that (page 459) vitamin B<sub>9</sub> now known to be identical with the liver *L. casei* factor pteroylglutamic acid although originally recognised as an anti anaemia factor for the chick, also stimulated the growth of these two bacteria. The fermentation *L. casei* factor pteroyltriglutamic acid however is a growth factor for *L. helveticus* but not for *S. faecalis* R. whilst vitamin B<sub>9</sub> conjugate pteroylheptaglutamic acid is not a growth factor for either but has to be converted into the monoglutamate by the action of vitamin B<sub>9</sub> conjugase before becoming effective (page 479). Pteronic acid and the SLR factor (rhizopterine) on the other hand are growth factors for *S. faecalis* R. but not for *L. helveticus*. Finally it is relevant to note that *p* aminobenzoic acid is a growth factor in its own right although its rôle in the nutrition of micro-organisms is to some extent bound up with that of folic acid (see page 563).

Folic acid is also a growth factor for *Clostridium tetani*<sup>1</sup> and for the ciliate *Tetrahymena geleii*<sup>2</sup>. The latter is unique among micro-organisms in that its growth is stimulated by folic acid conjugate<sup>2a</sup> which is twice as active as an equivalent weight of pteroylglutamic acid.

### Synthesis of Folic Acid

Most organisms however appear to be capable of synthesising folic acid although some will only do so if provided with a particular part of the molecule. For example *Aerobacter aerogenes* was found<sup>3</sup> to synthesise folic acid and the amount produced was materially increased when xanthopterine was added to the culture medium. It



## THE FOLIC ACID COMPLEX

is not clear whether in this instance xanthopterin is a precursor of folic acid or an essential growth factor for the organism or whether its similarity to a hypothetical intermediate enables it to inhibit the synthesis or utilisation of the intermediate. It has already been noted (page 461) that the folic acid content of incubated rat liver can be increased by addition of xanthopterin<sup>4</sup> and here again it is not clear whether xanthopterin is a precursor of folic acid or whether folic acid is converted by enzymes in the liver into a substance that is microbiologically inactive xanthopterin inhibiting this transformation, the latter explanation is that favoured by Wright *et al*

Folic acid is also synthesised by *E. coli*. A. K. Miller<sup>5</sup> observed that less was synthesised *in vitro* by both sulphonamide sensitive and sulphonamide resistant strains when grown in presence of sulphanilamide than by the same strains when grown in a sulphonamide free medium. By contrast, the amount of biotin synthesised by the organisms was unaffected by the presence of the antibacterial drug. These results suggest that the sulphonamides may interfere with the synthesis of folic acid by some micro organisms, the well known antagonism between the sulphonamides and *p*-aminobenzoic acid (page 546) extending to folic acid. The inhibitory action of sulphadiazine on *Plasmodium gallinaceum* for example is completely antagonised by pteroylglutamic acid<sup>6a</sup> which also partially antagonised the antimalarial activity of chloroquine.

The fermentation *L. casei* factor, pteroyltriglutamic acid was isolated from a filtrate obtained by aerobic fermentation of an unidentified species of *Corynebacterium*<sup>6</sup> (page 468). Folic acid is probably synthesised in the intestinal tract by coliform organisms (page 487).<sup>7</sup>

*L. arabinosus* was shown<sup>8</sup> to synthesise pteroylglutamic acid when excess *p*-aminobenzoic acid was present. The amount so produced was dependent on the nature of the amino acids present. Pteroylglutamic acid and pteric acid however, were only a partial substitute for *p*-aminobenzoic acid for stimulating the growth of *L. arabinosus* and it is probable therefore that *p*-aminobenzoic acid has other functions in the bacterial cell besides that of serving as a precursor of pteroylglutamic acid.

*Streptobacterium plantarum* also synthesised pteroylglutamic acid<sup>9</sup>. Only glucose and *p*-aminobenzoic acid were essential but glutamic acid had a stimulatory action. The synthesis of pteroylglutamic acid was inhibited by sulphonamides and the inhibition was antagonised competitively by *p*-aminobenzoic acid.

*Flavobacterium buccalis* converted pteroylglutamic acid into pteric acid<sup>10</sup> whilst *S. lactis*, *R. S. faecalis* and *S. zymogenes* converted rhizopterin into folic acid or a substance with similar activity.<sup>11</sup>

## Folic Acid Content of Micro-organisms

By microbiological assay with *L. helveticus* Burkholder *et al*<sup>12</sup> estimated the vitamin B<sub>9</sub> contents of autolysed and enzyme digested cultures of 82 strains of bacteria 369 yeasts and 94 moulds. They found chicken pancreas to be the best agent for releasing the vitamin from its conjugate. No increase in the vitamin B<sub>9</sub> content of bacteria and yeasts was obtained when xanthopterin was added to the culture media. Many of the organisms produced considerable amounts of vitamin B<sub>9</sub> conjugase.

The amounts of folic acid present in the five bacteria *Aerobacter aerogenes*, *Serratia marcescens*, *Pseudomonas fluorescens*, *Proteus vulgaris* and *Clostridium butylicum* ranged from 180 to 1200 molecules per cell and the rate of synthesis from 0.25 to 1.2 molecules per cell per second<sup>13</sup>.

## Folic Acid in Viruses

The psittacosis virus can apparently synthesise pteroylglutamic acid since *p*-aminobenzoic acid and pteric acid competitively antagonised the inhibition of growth of the virus by sulphadiazine and pteroylglutamic acid antagonised the inhibition non-competitively.<sup>14</sup>

## References to Section 15

- 1 J. H. Mueller and P. A. Miller *Proc. Soc. Exp. Biol. Med.* 1942 **49**, 211, 648. *J. Bact.* 1942 **43**, 763.
- 2 G. W. Kidder and R. C. Fuller *Science* 1946 **104**, 160.
- 2a G. W. Kidder and V. C. Dewey *Proc. Nat. Acad. Sci.* 1947 **33**, 95.
- 3 L. D. Wright and H. R. Skeggs *Proc. Soc. Exp. Biol. Med.* 1944 **55**, 92.
- 4 L. D. Wright, H. R. Skeggs and A. D. Welch *Fed. Proc.* 1944 **3**, 88.
- 5 A. K. Miller *Proc. Soc. Exp. Biol. Med.* 1944 **57**, 151.
- 5a J. Greenberg *Proc. Soc. Exp. Biol. Med.* 1949 **71**, 306.
- 6 B. L. Hutchings, E. L. R. Stokstad, N. Bohonos, N. H. Sloane and Y. Subbarow *Ann. N. Y. Acad. Sci.* 1946 **48**, 265.
- 7 A. K. Miller *J. Nutrition* 1945 **29**, 143.
- 8 H. P. Sarett *J. Biol. Chem.* 1947 **171**, 265.
- 9 R. H. Nimmo-Smith, J. Lascelles and D. D. Woods *Brit. J. Exp. Path.* 1948 **29**, 264.
- 10 L. Lemon, J. P. Sickels, B. L. Hutchings, M. E. Hultquist and J. M. Smith *Arch. Biochem.* 1948 **19**, 311.
- 11 Merck & Co. Inc. B.P. 613992.
- 12 P. R. Burkholder, I. McVeigh and K. Wilson, *Arch. Biochem.* 1945 **7**, 287.
- 13 H. McIlwain *Nature* 1946 **158**, 898.
- 14 H. P. Morgan *J. Exp. Med.* 1948 **88**, 285.

## THE FOLIC ACID COMPLEX

Replacement of the 4-hydroxy group by the 4-thiol group did not appreciably reduce the activity, possibly on account of the lability of this group, but replacement of the 2-hydroxy group or of both hydroxy groups gave compounds of low activity. Replacement of either hydroxy group by an amino group weakened the activity, giving compounds with only one-tenth the potency. The amino compounds appeared to be effective *per se* and not by conversion into thymine.

Another derivative of uracil that stimulated the growth of *L. helveticus* was orotic acid, uracil-4-carboxylic acid.<sup>6</sup>

In addition to replacing folic acid in the nutrition of micro-organisms, thymine has also been shown<sup>7</sup> to bring about remissions in Addisonian pernicious anaemia and in macrocytic anaemia, provided very high doses (4.5 g. or more daily) were given. When attempts were made to relieve the symptoms of folic acid deficiency in animals by means of thymine, however, it was found to be completely ineffective,<sup>8</sup> nor did it increase growth or affect haemoglobin formation in the chick.<sup>9</sup>

Histidine could replace folic acid for growth and acid production of *S. faecalis* R, possibly by conversion into a pyrimidine compound.<sup>10</sup>

### Pteridines and Analogues

A number of compounds have been prepared in which the pteridine ring is replaced by another heterocyclic ring. Most of these proved to be growth inhibitors (page 516), but N-{4-(4-quinazoline)-benzoyl}-glutamic acid<sup>11</sup> had 1/1000 to 1/10,000 the growth promoting activity of folic acid for *S. faecalis* R.

Formyl-folic acid, prepared by heating pteroylglutamic acid with formic acid and acetic anhydride (*cf.* the preparation of rhizopterin, page 476) was found to be as effective as folic acid in stimulating the growth of *S. faecalis* R and *L. helveticus*.<sup>12</sup> N<sup>10</sup>-Nitrosopteroyl glutamic acid was as effective as the parent compound on *S. faecalis* and on chicks.<sup>12a</sup>

Daniel *et al.*<sup>9</sup> examined the effect of some sixty compounds, mainly substituted pteridines, on growth and haemoglobin formation in chicks. Several compounds, *e.g.* 2-amino-4:6-dihydroxy-7-carboxypteridine, 2:4-dihydroxy-6(or 7)-hydroxy-7(or 6)-carboxymethylpteridine, 2-amino-4-hydroxy-6(or 7)-hydroxy-7(or 6)-methylpteridine and 2:4-dihydroxy-6(or 7)-hydroxy-7(or 6)-methylpteridine increased the weight of the chicks, but had no effect on haemoglobin formation. Other compounds, *e.g.* 2-amino-4-hydroxy-7-carboxypteridine, 2:4-diamino-7-carboxypteridine, 2:4-dihydroxy-7-carboxypteridine and 2-mercapto-4-hydroxy-7-carboxypteridine had little or no effect on growth but stimulated haemoglobin formation. Some compounds had an inhibitory effect on either growth or haemoglobin formation or

both whilst one compound increased weight but reduced haemoglobin formation (page 518)

### Folic Acid, *p*-Aminobenzoic Acid and Sulphonamides

The discovery that *p* aminobenzoic acid was present in the folic acid molecule directed attention to the relationship between the growth promoting activities of the two substances and of compounds intermediate between them. *p* Aminobenzoic acid stimulated the growth of organisms for which pteroylglutamic acid was not an essential growth factor (see page 556) and *vice versa*. The matter was of especial interest in view of the fact that sulphonamides owe their antibacterial properties to competition with *p* aminobenzoic acid for an enzyme system essential for the life of the bacterial cell (page 546).

The first attempt to determine the relative functions of *p* amino benzoic acid and pteroylglutamic acid in the nutrition of micro organisms was made by J. O. Lampen and M. J. Jones<sup>12</sup> who found that *L. helveticus* and *S. faecalis* R were not inhibited by sulphadiazine in a basal medium free from *p* aminobenzoic acid when either pteroyl glutamic acid or thymine was added. The antagonism between sulphadiazine and *p* aminobenzoyl L glutamic acid was competitive whereas that between sulphadiazine and folic acid or thymine was not. These observations led the authors to suggest that sulphonamides owed their antibacterial action to their ability to interfere with the synthesis of pteroylglutamic acid from *p* aminobenzoic acid.

Similar results were obtained with sulphanilamide, sulphathiazole and sulphapyridine. Inhibition of sulphonamide activity also occurred with *L. arabinosus* but not with *E. coli*, *S. aureus* or *D. pneumoniae*. Pteroylglutamic acid would therefore be expected to interfere with sulphonamide therapy in relatively few infections.

A mutant of *E. coli* that required *p* aminobenzoic acid for growth was not stimulated by folic acid or by thymine alone<sup>14</sup> but a mixture of thymine, purines and amino acids was able to replace *p* amino-benzoic acid for this strain.

The Ralston strain of *S. faecalis* was found to synthesise pteroyl glutamic acid although at a sub-optimal rate<sup>15</sup>. In this instance inhibition by sulphonamides was antagonised non-competitively by pteroylglutamic acid, pteroyltriglutamic acid and thymine. The amount required for sulphonamide antagonism was approximately the same as that required by *S. faecalis* R for growth. Similarly strains of *Enterococcus* that could not synthesise pteroylglutamic acid but required the addition of the preformed factor were insensitive to sulphonamides whereas strains that were able to synthesise the factor were sensitive except when pteroylglutamic acid was added to the medium. *S. faecalis* R and *L. helveticus* grown in presence of ptero c

## THE FOLIC ACID COMPLEX

acid were resistant to sulphonamides, but pteric acid had a slight anti sulphonamide activity for *S faecalis* (Ralston) and *S zymogenes* 26C1. These observations were interpreted as confirming the theory that pteroylglutamic acid is synthesised from *p* aminobenzoic acid.

Still further support for this theory was obtained by a comparison of the ability of various compounds related to *p* aminobenzoic acid to replace it as a growth-promoter for *L arabinosus*.<sup>16</sup> *p* Aminobenzoylglutamic acid, pteric acid, pteroylglutamic acid and pteroyltriglutamic acid were all less active than *p* aminobenzoic acid mole for mole. High concentrations of thymine could replace *p* aminobenzoic acid but with thymine the presence of a purine was necessary.

The inhibition of *L arabinosus* by sulphanilamide was antagonised non competitively by pteroylglutamic acid, pteroyltriglutamic acid and by thymine. *p* Aminobenzoylglutamic acid was about as active as *p* aminobenzoic acid in antagonising low concentrations of sulphonamide, but much less active against higher concentrations. *p* Aminobenzoylglutamic acid and pteroylglutamic acid were less active than *p* aminobenzoic acid on *Streptobacterium plantarum*, and inhibition of this organism by sulphonamides was antagonised non competitively by pteroylglutamic acid and by thymine. As with *L arabinosus* the activity of *p* aminobenzoylglutamic acid approached that of *p* aminobenzoic acid against low sulphonamide concentrations, but was much less against high concentrations.

It is suggested that pteroylglutamic acid, the purines and thymine are products of enzyme systems in which *p* aminobenzoic acid functions. *p* Aminobenzoylglutamic acid appears to be utilised by the two organisms only after conversion into *p* aminobenzoic acid.

In view of these observations, the reported existence of a conjugated form of *p* aminobenzoic acid is of considerable significance. K C Blanchard<sup>17</sup> advanced evidence suggesting that, in yeast, *p* aminobenzoic acid was combined with protein, and Ratner *et al*<sup>18</sup> succeeded in isolating a polypeptide containing 8 % of *p* aminobenzoic acid. This was subsequently shown to be linked through the carboxyl group with a chain of ten or eleven L glutamic acid residues. This conjugate accounted for 20 to 30 % of the total *p* aminobenzoic acid content of the yeast. Its constitution bears an obvious resemblance to that of vitamin B<sub>9</sub> conjugate.


### Growth Inhibitors

Replacement of the methyl group of thymine (page 513) by an amino or hydroxy group resulted in the formation of compounds with inhibitory activity e.g. 5 hydroxyuracil, 5 aminouracil, 5-carbamidouracil and nearly all 2, 4 diaminopyrimidines and their condensed ring derivatives.<sup>5</sup> Growth was restored by the addition of

## ANALOGUES

more thymine or folic acid. This suggested that these substances displaced thymine from an active enzyme centre thus supporting the hypothesis first advanced by J. I. Stokes<sup>1</sup> that thymine is the product of an enzyme system of which folic acid is the prosthetic group. Results with other compounds however were not consistent with this hypothesis. 5-Bromouracil for example completely inhibited the growth of *L. helieticus* in presence of thymine but not of folic acid whilst 5-nitouracil prevented the growth of *L. helieticus* in presence of folic acid but not of thymine. It would appear therefore that thymine and folic acid act independently of one another and are not components of one and the same system.

A series of diaminopteridines with anti-folic acid properties was synthesised by Mallette *et al*<sup>19</sup>. These with the general formula



were as follows —

- (1) 2, 4-diamino-6, 7-dimethylpyrimido(4, 5-b)pyrazine
- (2) 2
- (3) 2
- (4) 2
- (5) 2


The growth of *S. faecalis*, *L. helieticus* and *L. arabinosus* (without *p*-aminobenzoic acid) was inhibited by several of these compounds. Folic acid overcame this inhibition, the antagonism being competitive.<sup>20</sup> The inhibition indexes of compounds (1) and (4) were 5000 and 10 respectively with *S. faecalis* and 50 000 and 200 000 with *L. helieticus*.<sup>20a</sup> Against *E. coli* and *Staph. aureus* compounds (1) and (4) were the most effective. Sulphathiazole exhibited a synergistic action with both.<sup>21</sup> The carboxypteridines however had little effect on *E. coli* and only showed a synergistic effect with sulphathiazole when tested on *Staph. aureus*. Compound (5) had only a slight antibacterial action on either organism but showed a considerable synergistic effect with sulphathiazole. The pteridines and sulphathiazole showed synergism with *L. arabinosus* also. Folic acid completely overcame the inhibition of growth brought about by low levels of pteridine and sulphonamide but with high levels the antagonism was only partial; this antagonism was competitive. If on the other hand the inhibition of pteridine or sulphonamide were studied separately, the effect of added folic acid was non-competitive. High levels of folic acid antagonised the growth

## THE FOLIC ACID COMPLEX

inhibition of *E. coli* and *S. aureus* caused by sulphonamides, although J. O. Lampen and M. J. Jones<sup>15</sup> had found that low levels of folic acid did not. With *L. arabinosus* the antagonism of sulphonamide inhibition by folic acid was non competitive. This kind of synergism between the pteridines and sulphonamides is not unexpected as they are competing with two different parts of the folic acid molecule. The sulphonamides interfere with the functioning of an enzyme that synthesises folic acid, whilst the inhibitory pteridines presumably compete with the formation of an enzyme of which folic acid is the prosthetic group. Substitution of the amino groups in 2,4-diamino-6,7-diphenylpteridine by acetyl or methyl groups or the introduction of amino, acetylamino or hydroxyl groups into the phenyl nuclei considerably increased the inhibitory action on *S. faecalis*<sup>21a</sup>.

Several of the pteridine derivatives tested by Daniel *et al.*<sup>9</sup> (page 514) inhibited growth and haemoglobin formation in chicks, notably 2-amino-4-hydroxy-6,7-dimethylpteridine and 2-amino-4-hydroxy-6,7-diphenylpteridine. Several other compounds had no effect on growth but reduced the haemoglobin, and one compound, 2-amino-4-hydroxy-6(or 7)-hydroxy-7(or 6) methylpteridine, increased the weight but depressed haemoglobin formation. The inhibitory compounds interfered with folic acid metabolism, for reduced levels of the vitamin were found in the liver and blood after administration of the substance.

The most important growth inhibitors related to pteroylglutamic acid, however, are either homologues or compounds derived from pteroylglutamic acid by the replacement of one or more substituent by some other group. To facilitate the description of these compounds, the atoms comprising the pteroyl radicle have been numbered as follows:



It has also become customary to describe the compound obtained by replacing for example the 4 hydroxy group by a 4 amino group as 4-aminopteroylglutamic acid, an inaccuracy that can only be excused on the grounds that the correct name would be too cumbersome for general use.

### 7-Methylfolic Acid

One close structural analogue of folic acid with growth inhibitory properties is 7-methylfolic acid or, to give it its full chemical name,

N (4 [(2 amino 4 hydroxy-7 methyl 6-pteridyl) methyl] amino) benzoyl) L glutamic acid<sup>22</sup> This was prepared by the same reaction as that used to synthesise folic acid except that 2,3-dibromobutyraldehyde was used in place of 2,3-dibromopropionaldehyde. It inhibited competitively the growth promoting action of folic acid the ratio of inhibitor to metabolite being 150 by a mechanism different from that involved in sulphonamide inhibition. Thus the inhibitory action of sulphathiazole towards *S. aureus* was neutralised by *p*-aminobenzoic acid and by pteronic acid but not by glutamic acid, *p*-aminobenzoyl glutamic acid or pteroylglutamic acid whereas the action of 7-methyl folic acid was neutralised by pteroylglutamic acid, pteronic acid and *p*-aminobenzoic acid but not by *p*-aminobenzoylglutamic acid<sup>23</sup>. This suggests that the synthesis of pteronic acid is the first step in the formation of pteroylglutamic acid and that methylfolic acid prevents the synthesis of pteroylglutamic acid by interfering with the formation of pteronic acid and its union with glutamic acid. But methylfolic acid also displaced preformed pteroylglutamic acid and like the sulphonamides it interfered with the incorporation of *p*-aminobenzoic acid into pteroylglutamic acid. The effect of methylfolic acid was counteracted by sulphathiazole this being an example of mutual interference by two antagonists.

The inhibitory action of 7-methylfolic acid was 1500 antagonised by formylfolic acid (page 514) which was actually about thirty times as effective as folic acid having an antibacterial index of 3000 with *S. faecalis* R<sup>12</sup>. Synthetic rhizopterin (page 476) was two to three times as effective as folic acid in preventing inhibition. The toxicity of 7-methylfolic acid was increased by heating with formic acid. These results suggest that rhizopterin may be converted directly into formylfolic acid.

7-Methylfolic acid also antagonised the growth promoting action of pteroylglutamic acid on *L. helveticus* and on rats and again the antagonism was competitive<sup>24</sup>. The effect in rats was to produce symptoms more acute than those produced by feeding a purified diet plus succinylsulphathiazole. 7-Methylfolic acid also produced symptoms of folic acid deficiency in mice although such symptoms cannot normally be induced merely by feeding a purified diet plus succinylsulphathiazole. It also aggravated a folic acid deficiency in chicks maintained on a purified diet and reduced the response normally elicited in immature chicks by stilboestrol<sup>25</sup> (page 486).

The antagonist likewise interfered with the metabolism of pteroyl glutamic acid in the pig interrupting growth and significantly inhibiting the formation of erythrocytes and granulocytes<sup>26</sup>. This interference was overcome even though administration of the antagonist was continued by feeding normal human gastric juice.



together with a crude source of the extrinsic factor (page 498) from which pteroylglutamic acid had been eliminated

The antibacterial index of 7-methylfolic acid was approximately 30 for *L. helveticus* in the absence of purines and pyrimidines.<sup>27</sup> The addition to the medium of adenine, guanine, hypoxanthine or xanthine increased the antibacterial index to about 100. Thymine alone had no effect but, in the presence of purines, the antibacterial index was increased to over 1000. This evidence appears to give further support to the theory of J. L. Stokes<sup>1</sup> that folic acid is concerned in the biosynthesis of thymine.

The inhibitory action of methylfolic acid for *L. helveticus* was antagonised by liver extracts to an extent 15 times greater than could be accounted for by their folic acid contents. A concentrate was prepared from hog liver that was somewhat more active than folic acid in antagonising the effect of methylfolic acid on *L. helveticus* and 10 to 100 times as effective with *S. faecalis* R. The new factor has been named folinic acid and proved to be as effective a growth factor for these two organisms as is folic acid. It also stimulated the growth of *Leuconostoc citrovorum*, an organism on which folic acid has no effect. On mild acid hydrolysis folinic acid was apparently converted into folic acid.<sup>27a</sup>

### 9-Methylfolic Acid, N<sup>10</sup>-Methylfolic Acid and 9:N<sup>10</sup>-Dimethylfolic Acid

9-Methylfolic acid also antagonises folic acid, but is much less potent than 7-methylfolic acid having an antagonist activity of only 0.1 with *S. faecalis* R.<sup>27b</sup> N<sup>10</sup>-Methylpteroylglutamic acid was much more potent, with an antagonist activity of 100 against *S. faecalis* R, but N<sup>10</sup>-phenacylpteroylglutamic acid was much less active. 9-N<sup>10</sup>-Dimethylpteroylglutamic acid had an antagonist activity of 3.4.<sup>27a</sup>

### Pteroylaspartic Acid

A homologue of a rather different type, which likewise had anti-folic acid properties was pteroylaspartic acid.<sup>28</sup> This has one methylene group less in the amino acid radicle than has folic acid and it was shown to be antagonistic to folic acid both with *L. helveticus* and with the chick. With *S. faecalis* R the inhibitor prevented the utilisation of pteric acid, pteroylglutamic acid, pteroyl- $\gamma$ -glutamylglutamic acid and pteroyl- $\gamma$ -glutamyl- $\gamma$ -glutamylglutamic acid. In all instances, the inhibition was competitive in nature.

## Amino-folic Acids

A compound derived from pteroylglutamic acid by the replacement of the hydroxyl group by an amino group also had growth inhibitory activity.<sup>29</sup> This was N [4 {(2,4-diamino-6-pteridyl)methyl} amino] benzoyl glutamic acid generally referred to as 4-aminopteroylglutamic acid or Aminopterin. It was prepared from 2,4,5,6-tetraamino pyrimidine by a reaction analogous to that used for the preparation of pteroylglutamic acid. The compound had inhibition ratios for half maximum inhibition of the growth of *S. faecalis* R of 1.9, 0.7 and 0.4 at pteroylglutamic acid concentrations of 0.003, 0.005 and 0.01  $\mu$ g per 10 ml respectively. The compound was highly toxic to mice and at levels less than 0.3 mg per kg of diet the toxicity was partially neutralised by pteroylglutamic acid but this had no effect with amounts of 1 to 3 mg per kg of diet.<sup>30</sup>

4-Aminopteroylglutamic acid was also an antagonist for pteroylglutamic acid in rats and chickens and here also the inhibition was not strictly competitive in nature.<sup>31</sup> It produced folic acid deficiency in rats with loss of weight, hypoplasia of the bone marrow and intestinal lesions with diarrhoea,<sup>32</sup> and abnormalities in chick embryos that were not prevented by large doses of folic acid.<sup>33</sup> In dogs 4-aminopteroylglutamic acid produced a sprue-like syndrome with diarrhoea, peripheral leucopenia, depletion of the bone marrow and changes in the blood picture.<sup>34</sup> Haematological changes were also produced when the compounds were administered to guinea pigs.<sup>35</sup> Pteroylaspartic acid and 7-methylfolic acid did not produce these changes although they potentiated the effect of 4-aminopteroylglutamic acid.

4-Aminopteroylglutamic acid depressed the response of the oviducts of frogs to oestradiol whereas folic acid potentiated the effect. The effect of Aminopterin was not reversed by folic acid in 100-fold concentration. It is suggested that folic acid antagonists may exert their inhibitory effects by interfering with folic acid utilisation, depressing nucleic acid synthesis and retarding the rate of cell division.<sup>36</sup> Aminopterin also interfered with the depressive influence of oestradiol on the rat prostate.<sup>37</sup>

4-Aminopteroylglutamic acid inhibited the growth of *E. coli* but the inhibition was not reversed by pteroylglutamic acid although it was reversed by thymidine or a liver extract. *Lactobacillus leichmannii* was also inhibited by 4-aminopteroylglutamic acid and in this instance the inhibition was reversed by pteroylglutamic acid at low concentrations of inhibitor and by thymidine at higher concentrations.<sup>38</sup>

Aminopterin had no effect on the growth of psittacosis virus.<sup>39</sup>

## THE FOLIC ACID COMPLEX

that thymine can replace folic acid in the nutrition of certain microorganisms but also by the observation that thymine reversed the antagonistic effect of some uracil derivatives on folic acid<sup>9</sup> and in the presence of purine increased many fold the antibacterial index of 'methylfolic acid' for *L. helveticus*<sup>10</sup>

A partial deficiency of pteroylglutamic acid lowered the desoxyribonucleic acid content of *L. helveticus* without affecting the ribonucleic acid whereas a deficiency of riboflavine or biotin or an excess of thymine increased both<sup>10a</sup>

It has also been suggested<sup>11</sup> that pteroylglutamic acid is involved in the synthesis of the porphyrin portions of metalporphyrin enzymes since pteroylglutamic acid partially reversed the inhibitory action of cyanide, caffeine and hydrogen peroxide on *S. faecalis*

Pteroylglutamic acid strongly inhibited the activity of xanthine oxidase and of a xanthopterin oxidase prepared from either milk or liver<sup>12</sup>. Pteric acid also inhibited the latter enzyme but pteroyldi- and tri glutamic acid had no effect. Milk contained an enzyme that transformed pteroylglutamic acid into a substance that had no inhibitory action on xanthopterin oxidase<sup>13</sup>

6 Pteridylaldehyde, obtained by the hydrolysis of pteroylglutamic acid in sulphurous acid was found to be 200 to 400 times as active as folic acid in inhibiting xanthine oxidase and also more active than folic acid in inhibiting xanthopterin oxidase<sup>14</sup>. It also inhibited quinone oxidase

Thus folic acid and related compounds are capable of affecting a number of different enzyme systems and it remains to be seen which of these are of physiological significance

### References to Section 19

- 1 J E Davis *Science* 1946 **104**, 37 *Amer J Physiol* 1946 **147**, 404
- 1a R D Hawkins *Arch Biochem* 1948 **17**, 97
- 1b J S Dinning C K Keith and P L Day *ibid* 1949 **24** 463
- 2 B L O Dell J M Vandebelt E S Bloom and J J Pflieger  
*J Amer Chem Soc* 1947 **69**, 250
- 3 G Rodney M E Swendseid and A L Swanson *J Biol Chem*  
1947 **168**, 395 1949 **179** 19
- 4 M E Swendseid I F Burton and F H Bethell *Proc Soc Exp  
Biol Med* 1943 **52**, 202
- 5 C W Woodruff and W J Darby *J Biol Chem* 1948 **172**, 851  
C W Woodruff M E Charrington A K Stockell and W J  
Darby *ibid*, 1949 **178**, 861
- 5a C D Govan and H H Gordon *Science* 1949 **109**, 332
- 6 G J Martin and J M Beiler *Arch Biochem* 1947 **15**, 201
- 7 G J Martin L Tolman and R Brendel *ibid* 323

# FUNCTION

- 8 J L Stokes *J Bact* 1944 47, 433, 1944 48, 201
- 9 G H Hitchings E A Falco and H B Sherwood *Science* 1945 102, 251
- 10 L L Rogers and W Shive *J Biol Chem* 1948 172, 751
- 10a W H Prussoff L J Teply and C G King *ibid* 1949 176 1309
- 11 J R. Totter E Sims and P L Day *Proc Soc Exp Biol Med* 1947 66, 7
- 12 H M Kalckar and H Klenow *J Biol Chem* 1948 172, 349  
B H J Hofstee *ibid* 1949 176, 633 J N Williams and C A Elvehjem *Proc Soc Exp Biol Med*, 1949 71, 303
- 13 H M Kalckar and H Klenow *J Biol Chem* 1948 172, 351
- 14 H M Kalckar N O Kjeldgaard and H Klenow *ibid* 1948 174, 771

## CHAPTER IX

# VITAMIN B<sub>12</sub> (ERYTHROTIN)

---

### 1. INTRODUCTION

IN 1926, G R Minot and W P Murphy<sup>1</sup> demonstrated that patients with pernicious anaemia could be maintained in normal health by ingestion of liver. Subsequently it was discovered that the injection of liver extracts gave more reliable results with less inconvenience to the patients. Since that time, the use of liver extracts has become routine practice in the treatment not only of Addisonian pernicious anaemia, but also of pernicious anaemia due to tapeworm, pernicious anaemia of pregnancy, nutritional megaloblastic anaemia, megaloblastic anaemia of infancy and childhood and megaloblastic anaemia accompanying steatorrhoea. Three types of liver extracts are in use—"refined" extracts with a relatively low concentration of total solids derived from a large amount of liver, "crude" extracts with a much higher total solids content and "proteolysed" extracts in which the liver tissue is partially broken down before extraction in order to liberate more of the active principle. Some anaemias respond more readily to proteolysed and crude liver extracts than to refined extracts and there are many clinicians who maintain that refined extracts fail to keep the blood picture normal for more than a limited period.

Folic acid, as has already been pointed out (page 484), is an anti-anaemic factor that is only successful in megaloblastic forms of anaemia, it has no effect in subacute combined degeneration of the cord, and may actually increase the severity of the nervous symptoms in pernicious anaemia. Clearly folic acid is different from the substance in liver extract that cures pernicious anaemia, and potent refined liver extracts do, in fact, contain negligible amounts of folic acid.

Attempts to fractionate liver extracts with the object of isolating the anti-pernicious anaemia factor have always been difficult because no chemical test for the factor exists, and no animal or micro organism was known that would respond specifically to the factor. The isolation of more or less pure preparations of the anti-pernicious anaemia factor was announced in the same week by E L Smith<sup>2</sup> and Rickes *et al*<sup>3</sup>. The former obtained by chromatography two red pigments from an

ox liver concentrate prepared by a method previously described by W B Emery and L F J Parker<sup>4</sup> Better yields were obtained from proteolysed liver extracts than from non proteolysed extracts One pigment appeared to be produced from the other by proteolysis In the early stages of the fractionation clinical tests with pernicious anaemia patients in relapse were used to follow the course of purification but in the later stages the colour of the fractions was used for this purpose The most active preparation gave a response with a dose containing only 0.3 mg of total solids and in addition to being anti anaemic was effective in sub acute combined degeneration of the cord The product was not pure and was not homogeneous when examined in the Tiselius apparatus It contained neither folic acid nor xanthopterin and had a molecular weight of about 3000

Rickes *et al*<sup>5</sup> claimed to have isolated the anti pernicious anaemia factor in the pure state and gave it the name vitamin B<sub>12</sub> They gave no information about its properties or method of isolation beyond the fact that the substance formed red needles which did not melt below 300° C and contained cobalt Vitamin B<sub>12</sub> was shown to be identical with one of two unidentified growth factors required by *Lactobacillus lactis* Dorner both of these were present in refined liver extracts<sup>6</sup> Crystalline vitamin B<sub>12</sub> gave a positive response in three cases of Addisonian pernicious anaemia following single intramuscular injections of 3.6 and 150 µg respectively<sup>6</sup>

Subsequently E L Smith<sup>7</sup> crystallised the anti pernicious anaemia factor from liver and found it to contain 4 % of cobalt and assuming this to represent one atom per molecule three atoms of phosphorus per molecule The phosphorus content of Smith's factor apparently differentiates it from the vitamin B<sub>12</sub> of other workers for both Ellis *et al*<sup>8</sup> and Brink *et al*<sup>9</sup> stated that the Co : P ratio was 1 : 1 and not 1 : 3 This discrepancy may perhaps be explained by the existence of several forms of vitamin B<sub>12</sub>, all clinically active A second form known as vitamin B<sub>12a</sub> was obtained by catalytic hydrogenation of vitamin B<sub>12</sub><sup>10</sup> it was somewhat less active than the latter and had a similar but not identical absorption spectrum A third form vitamin B<sub>12b</sub> was isolated together with vitamin B<sub>12</sub> from liver and a culture of *Streptomyces aureofaciens*<sup>11</sup> it likewise differed from vitamin B<sub>12</sub> in its absorption spectrum Vitamin B<sub>12c</sub> has been isolated from *S. griseus* which is now an important commercial source of this factor<sup>12</sup>

It has also been claimed<sup>13</sup> that vitamin B<sub>12</sub> exists in certain substances in the form of conjugates inactive in pernicious anaemia until they have been digested with hog's stomach mucosa or with pancreatic enzyme extracts These conjugates it is suggested may be Castle's extrinsic factor (see page 498)

## References to Section I

1. G. R. Minot and W. P. Murphy, *J. Amer. Med. Assoc.*, 1926, **87**, 470.
2. E. L. Smith, *Nature*, 1948, **161**, 638.
3. E. L. Rickes, N. G. Brink, F. R. Koniuszy, T. R. Wood and K. Folkers, *Science*, 1948, **107**, 396; 1948, **108**, 135.
4. W. B. Emery and L. F. J. Parker, *Biochem. J. Proc.*, 1946, **40**, iv.
5. M. S. Shorb, *Science*, 1948, **107**, 397.
6. R. West, *ibid.*, 398.
7. E. L. Smith, *Nature*, 1948, **162**, 144.
8. B. Ellis, V. Petrow and G. F. Snook, *J. Pharm. Pharmacol.*, 1949, **1**, 60, 287.
9. N. G. Brink, D. E. Wolf, E. Kaczka, E. L. Rickes, F. R. Koniuszy, T. R. Wood and K. Folkers, *J. Amer. Chem. Soc.*, 1949, **71**, 1854.
10. E. Kaczka, D. E. Wolf and K. Folkers, *ibid.*, 1514.
11. J. V. Pierce, A. C. Page, E. L. R. Stokstad and T. H. Jukes, *ibid.*, 2952.
12. E. L. Rickes, N. G. Brink, F. R. Koniuszy, T. R. Wood and K. Folkers, *Science*, 1948, **108**, 634.
13. K. Hausmann, *Lancet*, 1949, **2**, 962.

## 2. ISOLATION, PURIFICATION AND PROPERTIES OF VITAMIN B<sub>12</sub>

### Isolation and Purification

Vitamin B<sub>12</sub> was prepared from either liver extract or a culture of *S. griseus* by chromatographic adsorption on activated alumina or charcoal.<sup>1</sup> The former was eluted with methanol or aqueous methanol and the latter with an aqueous solution of acetone, butanol or benzyl alcohol. In either instance, the eluate was evaporated, and the residue dissolved in alcohol. After filtration the solution was evaporated and the residue dissolved in methanol. Vitamin B<sub>12</sub> was precipitated from this solution by the addition of acetone or ether, the precipitate was dissolved in water and the solution treated with acetone. The resulting precipitate was dissolved in methanol and several volumes of acetone were added to precipitate the vitamin, which was then dissolved in water and acetone added until a turbidity formed. On standing, red crystals of vitamin B<sub>12</sub> separated out.

Concentrates of vitamin B<sub>12</sub> were also purified prior to crystallisation by counter-current distribution between water and a mixture (3:1) of toluene and *o*-cresol.

Partition chromatography has also been used to purify vitamin B<sub>12</sub>. Strips of filter paper developed with wet *n*-butanol were used preparatory to microbiological assay<sup>2</sup> (page 534), whilst columns of

## ISOLATION PURIFICATION AND PROPERTIES

starch developed with a mixture (1 : 2 : 1) of 0.1 N hydrochloric acid  $\pi$  propanol and  $\pi$  butanol were claimed<sup>3</sup> to effect a high degree of purification

### Properties

Vitamin B<sub>12</sub> forms red needle like birefringent crystals with no definite melting point but they darken at about 210° to 220° C. It is soluble in water methanol ethanol and phenol but substantially insoluble in acetone ether and chloroform. In aqueous solution it gives a characteristic absorption spectrum with maxima at 278 361 and 550 m $\mu$ . the values of  $\epsilon_{1\text{cm}}^{1\%}$  at these wave lengths were 119 187 and 59 respectively<sup>1</sup>. An aqueous solution of vitamin B<sub>12</sub> gave an absorption spectrum with maxima at 273 351 and 525 m $\mu$ .<sup>4</sup>

Analysis of vitamin B<sub>12</sub> indicated a formula approximating to C<sub>61-64</sub> H<sub>86-92</sub> N<sub>14</sub> O<sub>13</sub> PCo and a molecular weight of about 1490. Vitamin B<sub>12</sub> is l rotatory and hydrolysis did not liberate  $\alpha$  amino acids

### Chemical Constitution

The chemical constitution of vitamin B<sub>12</sub> is not yet known but degradation experiments have revealed the structure of certain parts of the molecule. Alkaline fusion yielded substances which reacted in the same way as pyrroles with *p* dimethylaminobenzaldehyde<sup>5</sup> and acid hydrolysis gave 5,6 dimethylbenzimidazole the structure of which was confirmed by synthesis<sup>6</sup>. Thus the molecules of vitamin B<sub>12</sub> and riboflavin contain the same nucleus. Acid hydrolysis also liberated ammonia and a ninhydrin reacting substance which appeared to be 2 aminopropanol.<sup>7</sup>

### References to Section 2

- 1 Merck & Co. S. African Pat. 7724
- 2 W. F. J. Cuthbertson and E. L. Smith *Biochem. J. Proc.* 1949 44 v. 1949 45 xii. G. E. Shaw *ibid.* 1949 44 lii. W. A. Winsten and E. Eigen *J. Biol. Chem.* 1949 181 109.
- 3 H. Borsook, C. L. Deasy, A. J. Haagen Smit, G. Keighlev and P. H. Lowy *Science* 1949 110 528.
- 4 J. V. Pierce, A. C. Page, E. L. R. Stokstad and T. H. Jukes *J. Amer. Chem. Soc.* 1949 71 2952.
- 5 N. G. Brink, D. E. Wolf, E. A. Kaczka, E. L. Rickes, F. R. Komuszy, T. R. Wood and K. Folkers *ibid.* 1854.
- 6 N. G. Brink and K. Folkers *ibid.* 2951. F. R. Holliday and V. Petrow *J. Pharm. Pharmacol.* 1949 1, 734. G. R. Beaver, F. R. Holliday, F. A. Johnson, B. Ellis, P. Mamalis, V. Petrow and B. Sturgeon *ibid.* 957.
- 7 B. Ellis, V. Petrow and G. F. Snook *ibid.* 735 950.



## VITAMIN B<sub>12</sub> (ERYTHROTIN)

### References to Section I

1. G. R. Minot and W. P. Murphy, *J. Amer. Med. Assoc.*, 1926, 87, 470.
2. E. L. Smith, *Nature*, 1948, 161, 638.
3. E. L. Rickes, N. G. Brink, F. R. Konuszy, T. R. Wood and K. Folkers, *Science*, 1948, 107, 396, 1948, 108, 135.
4. W. B. Emery and L. F. J. Parker, *Biochem. J. Proc.*, 1946, 40, iv.
5. M. S. Shorb, *Science*, 1948, 107, 397.
6. R. West, *ibid.*, 398.
7. E. L. Smith, *Nature*, 1948, 162, 144.
8. B. Ellis, V. Petrow and G. F. Snook, *J. Pharm. Pharmacol.*, 1949, 1, 60, 287.
9. N. G. Brink, D. E. Wolf, E. Kaczka, E. L. Rickes, F. R. Konuszy, T. R. Wood and K. Folkers, *J. Amer. Chem. Soc.*, 1949, 71, 1854.
10. E. Kaczka, D. E. Wolf and K. Folkers, *ibid.*, 1514.
11. J. V. Pierce, A. C. Page, E. L. R. Stokstad and T. H. Jukes, *ibid.*, 2952.
12. E. L. Rickes, N. G. Brink, F. R. Konuszy, T. R. Wood and K. Folkers, *Science*, 1948, 108, 634.
13. K. Hausmann, *Lancet*, 1949, 2, 962.

## 2. ISOLATION, PURIFICATION AND PROPERTIES OF VITAMIN B<sub>12</sub>

### Isolation and Purification

Vitamin B<sub>12</sub> was prepared from either liver extract or a culture of *S. griseus* by chromatographic adsorption on activated alumina or charcoal<sup>1</sup>. The former was eluted with methanol or aqueous methanol and the latter with an aqueous solution of acetone, butanol or benzyl alcohol. In either instance, the eluate was evaporated, and the residue dissolved in alcohol. After filtration the solution was evaporated and the residue dissolved in methanol. Vitamin B<sub>12</sub> was precipitated from this solution by the addition of acetone or ether, the precipitate was dissolved in water and the solution treated with acetone. The resulting precipitate was dissolved in methanol and several volumes of acetone were added to precipitate the vitamin, which was then dissolved in water and acetone added until a turbidity formed. On standing, red crystals of vitamin B<sub>12</sub> separated out.

Concentrates of vitamin B<sub>12</sub> were also purified prior to crystallisation by counter-current distribution between water and a mixture (3:1) of toluene and o-cresol.

Partition chromatography has also been used to purify vitamin B<sub>12</sub>. Strips of filter paper developed with wet n-butanol were used preparatory to microbiological assay<sup>2</sup> (page 534), whilst columns of

## ISOLATION PURIFICATION AND PROPERTIES

starch developed with a mixture (1 : 2 : 1) of 0.1 N hydrochloric acid, *n*-propanol and *n*-butanol were claimed<sup>2</sup> to effect a high degree of purification.

### Properties

Vitamin B<sub>12</sub> forms red needle like birefringent crystals with no definite melting point but they darken at about 210° to 220° C. It is soluble in water, methanol, ethanol and phenol but substantially insoluble in acetone, ether and chloroform. In aqueous solution it gives a characteristic absorption spectrum with maxima at 278, 361 and 550 mμ. The values of  $E_{1\%}^{1\text{cm}}$  at these wave-lengths were 119, 187 and 59 respectively.<sup>1</sup> An aqueous solution of vitamin B<sub>12</sub> gave an absorption spectrum with maxima at 273, 351 and 525 mμ.<sup>4</sup>

Analysis of vitamin B<sub>12</sub> indicated a formula approximating to C<sub>61-64</sub> H<sub>86-92</sub> N<sub>14</sub> O<sub>13</sub> PCo and a molecular weight of about 1490. Vitamin B<sub>12</sub> is *l* rotatory and hydrolysis did not liberate α-amino acids.

### Chemical Constitution

The chemical constitution of vitamin B<sub>12</sub> is not yet known, but degradation experiments have revealed the structure of certain parts of the molecule. Alkaline fusion yielded substances which reacted in the same way as pyrroles with *p*-dimethylaminobenzaldehyde<sup>5</sup> and acid hydrolysis gave 5,6-dimethylbenzimidazole, the structure of which was confirmed by synthesis.<sup>6</sup> Thus the molecules of vitamin B<sub>12</sub> and riboflavin contain the same nucleus. Acid hydrolysis also liberated ammonia and a ninhydrin reacting substance which appeared to be 2-aminopropanol.<sup>7</sup>

### References to Section 2

1. Merck & Co. S. African Pat. 7724
2. W. F. J. Cuthbertson and F. L. Smith *Biochem. J. Proc.* 1949 44 v. 1949 45 xii. G. E. Shaw *ibid.* 1949 44 lv. W. A. Winsten and F. Eigen *J. Biol. Chem.* 1949 181 109.
3. H. Borsook, C. L. Deasy, A. J. Haagen Smit, G. Heghley and P. H. Lowy *Science* 1949 110 528.
4. J. V. Pierce, A. C. Page, E. L. R. Stokstad and T. H. Jukes *J. Amer. Chem. Soc.* 1949 71 1952.
5. N. G. Brink, D. F. Wolf, E. A. Maczka, F. L. Rakes, F. R. Koniusz, T. R. Wood and K. Folkers *ibid.* 1954.
6. N. G. Brink and K. Folkers *ibid.* 1951. E. R. Holliday, V. Petrow *J. Pharm. Pharmacol.* 1949 1 34. G. R. Best and B. Sturgeon *ibid.* 1957.
7. B. Ellis, V. Petrow and G. F. Snook *ibid.* 1950.

3. ESTIMATION OF VITAMIN B<sub>12</sub>

## Microbiological Methods

It has already been stated that vitamin B<sub>12</sub> is identical with one of the factors necessary for the growth of *Lactobacillus lactis* Dorner and this organism was the first to be used for the assay of vitamin B<sub>12</sub>,<sup>1</sup> the growth response being measured either turbidimetrically or by titration of the lactic acid produced. *L. lactis* responds to 0.01  $\mu$ g per ml of vitamin B<sub>12</sub>. This organism is not entirely satisfactory, however. In the first place, it responds to thymidine in the absence of vitamin B<sub>12</sub>,<sup>2</sup> and in the second place it readily produces mutants that grow without vitamin B<sub>12</sub>, and the composition of the medium and the conditions of growth have to be carefully standardised if consistent results are to be obtained.<sup>3</sup> The first of these objections is avoided by carrying out a preliminary separation of the vitamin B<sub>12</sub> from other growth factors by paper partition chromatography (page 532). The filter paper strip can either be laid on an agar plate seeded with *L. lactis* and the zones of stimulation measured after incubation<sup>4</sup> or it can be cut into small pieces and each one separately assayed in test tubes in the ordinary way.<sup>5</sup>

A variety of media have been employed for the growth of *L. lactis* as several laboratories failed to obtain satisfactory results with Shorb's medium,<sup>6, 7</sup> the addition of tomato juice and Tween 80 is said to be necessary.<sup>3, 8</sup> Inconsistent results can also be obtained if the amount of air in the tubes varies from one experiment to another. Thus under anaerobic conditions, produced by the addition of reducing substances or by the removal of oxygen, *L. lactis* will grow in the absence of vitamin B<sub>12</sub>, whereas on aeration or addition of oxidising substances growth is inhibited and the inhibition can be overcome by vitamin B<sub>12</sub>, carbon dioxide is essential for growth in any event.<sup>8</sup> Thus, assuming sufficient carbon dioxide to be present, the response will increase with the amount of oxygen in the atmosphere of the tubes or with the amount of oxidising substances, e.g. peroxides in the tube itself. This presumably explains why in the absence of vitamin B<sub>12</sub> the amount of growth varies with the diameter of the tubes,<sup>9</sup> and why the cup plate method of assay gives more consistent results than assays using test-tubes.<sup>6, 10</sup> With the former the standard deviation (66 % confidence limits) is said to be  $\pm 10$  % and with the titrimetric method  $\pm 21$  %. Using the cup technique, *L. lactis* gave no response to thymidine, desoxyribonucleic acid or ascorbic acid.<sup>10</sup>

On the whole, more satisfactory results have been obtained with another *Lactobacillus*, *L. leichmannii*,<sup>11</sup> which is more stable and less exacting in its requirements than *L. lactis*.<sup>12</sup> This organism has also been used in conjunction with paper chromatography, the paper strips

either being laid on agar plates seeded with the organism<sup>13</sup> or cut into pieces and each separately assayed<sup>14</sup> The cup-plate assay method also gives good results with *L. leichmannii*<sup>10</sup>

A study of the nutritional requirements of two strains of *L. leichmannii* was made by Hoffmann *et al*<sup>15</sup> They used a basal medium containing glucose sodium acetate sodium citrate trypsin digested casein acid hydrolysed casein salts cystine asparagine tryptophan Tween 80 pyrimidines and members of the vitamin B complex It was found that a growth factor was formed on autoclaving and that some vitamin B<sub>12</sub> was destroyed The first difficulty was overcome either by replacing the glucose by sucrose or by the addition of thio glycolic acid or asparagus extract Thioglycolic acid also protected the vitamin B<sub>12</sub> from destruction during autoclaving The growth stimulating effect of thymidine and other desoxyribosides was measured and corrected for by assaying the samples before and after heating with 0.2N sodium hydroxide at 100° C for 30 minutes which destroys vitamin B<sub>12</sub> but does not affect desoxyribosides

An organism of a different type used for the assay of vitamin B<sub>12</sub> was *Euglena gracilis* var *bacillaris* which exhibited a quantitative response to the vitamin but was not stimulated by thymidine<sup>16</sup> Whereas *L. leichmannii* required a concentration of at least 0.1 mμg per ml to produce a measurable growth response *Euglena* required one-tenth of this amount

### Animal Assays

Vitamin B<sub>12</sub> appears to be a component of the animal protein factor (page 539) which can be assayed by measuring the growth response of chicks or rats fed diets containing soya bean meal as the sole source of protein Attempts have been made to use these methods for the assay of vitamin B<sub>12</sub> concentrates but they do not seem to be specific for vitamin B<sub>12</sub> as the results were sometimes inconsistent with those obtained by microbiological assay or clinical tests on pernicious anaemia patients More consistent results were obtained when a thyrotoxic condition was first induced in the experimental animals by feeding iodinated casein but it has been claimed that this test also is not specific for vitamin B<sub>12</sub> (page 541) Thus liver extracts active in pernicious anaemia failed to stimulate the growth of chicks and crude liver extracts discarded from anti pernicious anaemia fractions were highly active<sup>17</sup> whereas vitamin B<sub>12</sub> replaced the animal protein factor activity of injectible liver preparations when tested on thyrotoxic chicks<sup>18</sup> With normal chicks maximum growth was not obtained until other supplements were added<sup>19</sup>

Mice have also been used for the assay of animal protein factor

3. ESTIMATION OF VITAMIN B<sub>12</sub>

## Microbiological Methods

It has already been stated that vitamin B<sub>12</sub> is identical with one of the factors necessary for the growth of *Lactobacillus lactis* Dorner and this organism was the first to be used for the assay of vitamin B<sub>12</sub>,<sup>1</sup> the growth response being measured either turbidimetrically or by titration of the lactic acid produced. *L. lactis* responds to 0.01  $\mu$ g per ml of vitamin B<sub>12</sub>. This organism is not entirely satisfactory however. In the first place it responds to thymidine in the absence of vitamin B<sub>12</sub>,<sup>2</sup> and in the second place it readily produces mutants that grow without vitamin B<sub>12</sub> and the composition of the medium and the conditions of growth have to be carefully standardised if consistent results are to be obtained.<sup>3</sup> The first of these objections is avoided by carrying out a preliminary separation of the vitamin B<sub>12</sub> from other growth factors by paper partition chromatography (page 532). The filter paper strip can either be laid on an agar plate seeded with *L. lactis* and the zones of stimulation measured after incubation<sup>4</sup> or it can be cut into small pieces and each one separately assayed in test tubes in the ordinary way.<sup>5</sup>

A variety of media have been employed for the growth of *L. lactis* as several laboratories failed to obtain satisfactory results with Shorb's medium.<sup>6,7</sup> the addition of tomato juice and Tween 80 is said to be necessary.<sup>3,6</sup> Inconsistent results can also be obtained if the amount of air in the tubes varies from one experiment to another. Thus under anaerobic conditions produced by the addition of reducing substances or by the removal of oxygen *L. lactis* will grow in the absence of vitamin B<sub>12</sub> whereas on aeration or addition of oxidising substances growth is inhibited and the inhibition can be overcome by vitamin B<sub>12</sub>. carbon dioxide is essential for growth in any event.<sup>8</sup> Thus assuming sufficient carbon dioxide to be present the response will increase with the amount of oxygen in the atmosphere of the tubes or with the amount of oxidising substances e.g. peroxides in the tube itself. This presumably explains why in the absence of vitamin B<sub>12</sub> the amount of growth varies with the diameter of the tubes<sup>9</sup> and why the cup plate method of assay gives more consistent results than assays using test tubes.<sup>6,10</sup> with the former the standard deviation (66 % confidence limits) is said to be  $\pm 10$  % and with the titrimetric method  $\pm 21$  %. Using the cup technique *L. lactis* gave no response to thymidine, desoxyribonucleic acid or ascorbic acid.<sup>10</sup>

On the whole more satisfactory results have been obtained with another *Lactobacillus* *L. leichmannii*<sup>11</sup> which is more stable and less exacting in its requirements than *L. lactis*.<sup>12</sup> This organism has also been used in conjunction with paper chromatography the paper strips

either being laid on agar plates seeded with the organism<sup>13</sup> or cut into pieces and each separately assayed<sup>14</sup>. The cup-plate assay method also gives good results with *L. leichmannii*<sup>10</sup>.

A study of the nutritional requirements of two strains of *L. leichmannii* was made by Hoffmann *et al*<sup>15</sup>. They used a basal medium containing glucose, sodium acetate, sodium citrate, trypsin digested casein, acid hydrolysed casein, salts, cystine, asparagine, tryptophan, Tween 80, pyrimidines and members of the vitamin B complex. It was found that a growth factor was formed on autoclaving and that some vitamin B<sub>12</sub> was destroyed. The first difficulty was overcome either by replacing the glucose by sucrose or by the addition of thioglycolic acid or asparagus extract. Thioglycolic acid also protected the vitamin B<sub>12</sub> from destruction during autoclaving. The growth-stimulating effect of thymidine and other desoxyribosides was measured and corrected for by assaying the samples before and after heating with 0.2N sodium hydroxide at 100° C for 30 minutes, which destroys vitamin B<sub>12</sub> but does not affect desoxyribosides.

An organism of a different type used for the assay of vitamin B<sub>12</sub> was *Euglena gracilis* var *bacillaris* which exhibited a quantitative response to the vitamin but was not stimulated by thymidine<sup>16</sup>. Whereas *L. leichmannii* required a concentration of at least 0.1 µg per ml to produce a measurable growth response, *Euglena* required one-tenth of this amount.

### Animal Assays

Vitamin B<sub>12</sub> appears to be a component of the animal protein factor (page 539), which can be assayed by measuring the growth response of chicks or rats fed diets containing soya bean meal as the sole source of protein. Attempts have been made to use these methods for the assay of vitamin B<sub>12</sub> concentrates but they do not seem to be specific for vitamin B<sub>12</sub>, as the results were sometimes inconsistent with those obtained by microbiological assay or clinical tests on pernicious anaemia patients. More consistent results were obtained when a thyrotoxic condition was first induced in the experimental animals by feeding iodinated casein, but it has been claimed that this test also is not specific for vitamin B<sub>12</sub> (page 541). Thus liver extracts active in pernicious anaemia failed to stimulate the growth of chicks and crude liver extracts discarded from anti pernicious anaemia fractions were highly active,<sup>17</sup> whereas vitamin B<sub>12</sub> replaced the animal protein factor activity of injectible liver preparations when tested on thyrotoxic chicks<sup>18</sup>. With normal chicks maximum growth was not obtained until other supplements were added.<sup>19</sup>

Mice have also been used for the assay of animal protein factor,

## VITAMIN B<sub>12</sub> (ERYTHROTIN)

### 3. ESTIMATION OF VITAMIN B<sub>12</sub>

#### Microbiological Methods

It has already been stated that vitamin B<sub>12</sub> is identical with one of the factors necessary for the growth of *Lactobacillus lactis* Dorner, and this organism was the first to be used for the assay of vitamin B<sub>12</sub>.<sup>1</sup> the growth response being measured either turbidimetrically or by titration of the lactic acid produced. *L. lactis* responds to 0.01 mμg per ml of vitamin B<sub>12</sub>. This organism is not entirely satisfactory, however. In the first place, it responds to thymidine in the absence of vitamin B<sub>12</sub>.<sup>2</sup> and in the second place it readily produces mutants that grow without vitamin B<sub>12</sub> and the composition of the medium and the conditions of growth have to be carefully standardised if consistent results are to be obtained.<sup>3</sup> The first of these objections is avoided by carrying out a preliminary separation of the vitamin B<sub>12</sub> from other growth factors by paper partition chromatography (page 532). The filter paper strip can either be laid on an agar plate seeded with *L. lactis* and the zones of stimulation measured after incubation<sup>4</sup> or it can be cut into small pieces and each one separately assayed in test tubes in the ordinary way.<sup>5</sup>

A variety of media have been employed for the growth of *L. lactis* as several laboratories failed to obtain satisfactory results with Shorb's medium,<sup>6, 7</sup> the addition of tomato juice and Tween 80 is said to be necessary.<sup>3, 6</sup> Inconsistent results can also be obtained if the amount of air in the tubes varies from one experiment to another. Thus under anaerobic conditions, substances or by the removal of absence of vitamin B<sub>12</sub> whereas substances growth is inhibited and the inhibition can be overcome by vitamin B<sub>12</sub>. carbon dioxide is essential for growth in any event.<sup>8</sup> Thus assuming sufficient carbon dioxide to be present, the response will increase with the amount of oxygen in the atmosphere of the tubes or with the amount of oxidising substances e.g. peroxides, in the tube itself. This presumably explains why in the absence of vitamin B<sub>12</sub> the amount of growth varies with the diameter of the tubes,<sup>9</sup> and why the cup plate method of assay gives more consistent results than assays using test tubes.<sup>6, 10</sup> with the former the standard deviation (66 % confidence limits) is said to be  $\pm 10$  % and with the titrimetric method  $\pm 21$  %. Using the cup technique, *L. lactis* gave no response to thymidine, desoxyribonucleic acid or ascorbic acid.<sup>10</sup>

On the whole, more satisfactory results have been obtained with another *Lactobacillus*, *L. leichmannii*<sup>11</sup> which is more stable and less exacting in its requirements than *L. lactis*.<sup>12</sup> This organism has also been used in conjunction with paper chromatography, the paper strips

either being laid on agar plates seeded with the organism<sup>13</sup> or cut into pieces and each separately assayed<sup>14</sup> The cup-plate assay method also gives good results with *L. leichmannii*<sup>10</sup>

A study of the nutritional requirements of two strains of *L. leichmannii* was made by Hoffmann *et al*<sup>15</sup> They used a basal medium containing glucose, sodium acetate, sodium citrate, trypsin-digested casein, acid-hydrolysed casein, salts, cystine, asparagine, tryptophan, Tween 80, pyrimidines and members of the vitamin B complex It was found that a growth factor was formed on autoclaving and that some vitamin B<sub>12</sub> was destroyed The first difficulty was overcome either by replacing the glucose by sucrose or by the addition of thioglycolic acid or asparagus extract Thioglycolic acid also protected the vitamin B<sub>12</sub> from destruction during autoclaving The growth-stimulating effect of thymidine and other desoxyribosides was measured and corrected for by assaying the samples before and after heating with 0.2N sodium hydroxide at 100° C for 30 minutes, which destroys vitamin B<sub>12</sub> but does not affect desoxyribosides

An organism of a different type used for the assay of vitamin B<sub>12</sub> was *Euglena gracilis* var *bacillaris* which exhibited a quantitative response to the vitamin but was not stimulated by thymidine<sup>16</sup> Whereas *L. leichmannii* required a concentration of at least 0.1 µg per ml to produce a measurable growth response *Euglena* required one tenth of this amount

### Animal Assays

Vitamin B<sub>12</sub> appears to be a component of the animal protein factor (page 539), which can be assayed by measuring the growth response of chicks or rats fed diets containing soya bean meal as the sole source of protein Attempts have been made to use these methods for the assay of vitamin B<sub>12</sub> concentrates but they do not seem to be specific for vitamin B<sub>12</sub>, as the results were sometimes inconsistent with those obtained by microbiological assay or clinical tests on pernicious anaemia patients More consistent results were obtained when a thyrotoxic condition was first induced in the experimental animals by feeding iodinated casein, but it has been claimed that this test also is not specific for vitamin B<sub>12</sub> (page 541) Thus liver extracts active in pernicious anaemia failed to stimulate the growth of chicks and crude liver extracts discarded from anti pernicious anaemia fractions were highly active,<sup>17</sup> whereas vitamin B<sub>12</sub> replaced the animal protein factor activity of injectible liver preparations when tested on thyrotoxic chicks<sup>18</sup> With normal chicks maximum growth was not obtained until other supplements were added<sup>19</sup>

Mice have also been used for the assay of animal protein factor,



# VITAMIN B<sub>12</sub> (ERYTHROTIN)

one method being based on measuring the growth rate of mice born of mothers maintained on a purified diet, and the other on counteracting the growth retardation of mice fed thyroid active material<sup>20</sup> The growth of vitamin B<sub>12</sub> depleted rats was used by Frost *et al*<sup>21</sup> for the assay of vitamin B<sub>12</sub> with apparently good correlation with the micro biological assay method but crystalline vitamin B<sub>12</sub> according to B H Ershoff<sup>22</sup> was ineffective in counteracting the growth retardation of hyperthyroid rats

## References to Section 3

- 1 M S. Shorb, *Science*, 1948, **107**, 397
- 2 L D Wright, H R Skeggs and J W. Huff, *J Biol Chem*, 1948, **175**, 457
- 3 M S Shorb and G M Briggs, *ibid*, 1949, **176**, 1463
- 4 W F J Cuthbertson and E L Smith, *Biochem J. Proc*, 1949 **44**, v, 1949, **45**, xii
- 5 G E Shaw, *ibid* 1949, **44**, liv, *J Pharm Pharmacol*, 1949 **1**, 695
- 6 W F J Cuthbertson *Biochem J Proc*, 1949 **44**, v.
- 7 G E Shaw, *Nature*, 1949 **164**, 186
- 8 L K Koditschek, D Hendlin and H B Woodruff, *J Biol Chem* 1949, **179**, 1093, M C Caswell, L K Koditschek and D Hendlin, *ibid*, 1949, **180**, 125
- 9 R D Greene, A J Brook and R B McCormack *ibid*, 1949, **178**, 999
- 10 J C Foster, J A Lally and H B Woodruff, *Science*, 1949 **110**, 507
- 11 H R Skeggs, J W Huff L D Wright and D K Bosshardt, *J Biol Chem*, 1949 **176**, 1459, C E Hoffmann E L R Stokstad, A L Franklin and T H Jukes, *ibid*, 1465
- 12 B F Capps, N L Hobbs and S H Fox *J Biol Chem*, 1949 **178**, 517
- 13 W A Winsten and E Eigen, *ibid*, 1949, **177**, 989
- 14 H Yacowitz L C Norris and G F Heuser, *Proc Soc Exp Biol Med* 1949, **71**, 372
- 15 C E Hoffmann, E L R Stokstad, B L Hutchings, A C Dornbush and T H Jukes, *J Biol Chem*, 1949 **181**, 635
- 16 S H Hutner, L Provasoli, E L R Stokstad, C E Hoffmann M Belt, A L Franklin and T H Jukes *Proc Soc Exp Biol Med*, 1949 **70**, 118
- 17 C A Nichol, A R Robblee, W W Cravens and C A Elvehjem, *J Biol Chem* 1949 **177**, 631.
- 18 C A Nichol L S Dietrich, W. W Cravens and C A Elvehjem, *Proc Soc Exp Biol Med*, 1949, **70**, 40
- 19 E L R Stokstad T H Jukes, J V Pierce, A C Page and A L Franklin, *J Biol Chem*, 1949, **180**, 647
- 20 D, K Bosshardt, W J Paul K O Doherty, J W Huff and R H Barnes, *J Nutrition*, 1949, **37**, 21
- 21 D V Frost H H Fricke and H C Spruth, *Proc Soc Exp Biol Med*, 1949, **72**, 102
22. B H Ershoff, *ibid*, 1949, **71**, 209

4. OCCURRENCE OF VITAMIN B<sub>12</sub>

Comparatively few assays have yet been reported of the vitamin B<sub>12</sub> content of natural materials and, in view of the divergent views as to the specificity of both microbiological methods and animal assays, such results as have been published should perhaps be accepted with reserve until confirmed.

Using a rat growth method, Lewis *et al*<sup>1</sup> found desiccated sheep rumen contents, beef liver and kidney, chicken liver, condensed fish solubles and dried streptomycin slop to be the richest sources of vitamin B<sub>12</sub>, these contained between 35 and 50 µg. per 100 g. Herring stickwater and desiccated pig adrenals contained about 15 µg. per 100 g., beef and mutton about 5, veal about 4, horsemeat 7.5, pork, 1 to 3, casein, milk powder and cheese, 2 to 3, and egg yolk 2.8 µg. per 100 g. Plant materials showed no measurable activity.

Extracts prepared by digestion with pancreatin in the case of animal products and with pancreatin plus takadiastase in the case of plant materials gave the following values when assayed with *L. leichmannii*:<sup>2</sup> liver extract, 39, fish meal and condensed fish solubles 9 to 10, crude casein, 10 meat scraps 4, alfalfa leaf meal 4, soya bean meal and yellow corn, 1, dried brewers' yeast 0.8, and wheat, 0.7 µg. per 100 g.

Pig liver gave active extracts only in summer and autumn, whereas calf liver showed no such seasonal variation.<sup>3</sup> There appeared to be no correlation between the microbiological response and the clinical potency of liver extracts,<sup>2</sup> though this, of course, may well be due to the extreme inaccuracy of the method used to assess clinical potency, ten different liver extracts on sale in the U.S.A. gave values ranging from 0.087 to 2.17 µg. per U.S.P. unit of anti-pernicious anaemia activity, although 1 µg. of the pure vitamin had approximately 1 U.S.P. unit of activity. The vitamin B<sub>12</sub> potency of a number of liver extracts tested in this country ranged from 0.2 to 22 µg. per ml.<sup>4</sup>

The liver, heart, small intestine and femoral muscles of vitamin B<sub>12</sub>-depleted rats contained no vitamin B<sub>12</sub> whereas the kidney retained a substantial quantity.<sup>5</sup> Extracts active in pernicious anaemia were obtained from human livers, from the livers of twenty-six species of mammals and three species of fish, whereas inactive extracts were obtained from the livers of sea lion, reptiles and amphibians.<sup>6</sup> A satisfactory extract was prepared from whale liver.<sup>7</sup>

*References to Section 4*

- 1 U. J. Lewis, U. D. Register, H. T. Thompson and C. A. Elvehjem  
*Proc. Soc. Exp. Biol. Med.*, 1949, **72**, 479, 1949 **70**, 167
- 2 H. T. Peeler, H. Yacowitz and L. C. Norris, *ibid.*, 515



days prior to and for fourteen days during injection of vitamin B<sub>12</sub>,<sup>12</sup> supporting the hypothesis that vitamin B<sub>12</sub> makes folic acid available to the organism, when the Aminopterin was discontinued, a second reticulocyte response was obtained. Four patients with untreated pernicious anaemia excreted in the faeces a factor that stimulated *L. lactis* in an amount equivalent to 0.3 to 1.8 µg per g. of vitamin B<sub>12</sub>, an amount in excess of that required to cure pernicious anaemia. This was presumably produced by bacterial synthesis in the intestine.

That vitamin B<sub>12</sub> has other functions than that of stimulating haemopoiesis is perhaps the conclusion to be drawn from the observations of Wetzel *et al.*,<sup>13</sup> who tested the effect of the vitamin on a group of eleven children in "varying states of recovery from simple growth failure". Five were said to respond dramatically with increased physical vigour, alertness, better general behaviour and increase of appetite. In a case of severe allergic bronchitis, the symptoms vanished during the first week of treatment. These striking results may be connected with the effect of vitamin B<sub>12</sub> on the utilisation of protein (see below).

### Effect on the Growth of Animals

Cary *et al.*<sup>14</sup> described a factor, factor X, the absence of which resulted in a decline in the growth rate of rats, a decline that became more marked the higher the protein content of the diet. This factor appeared to be similar to the so-called animal protein factor (APF), which increased the hatchability of hens' eggs<sup>15</sup> and the growth rate of chicks maintained on an all vegetable protein ration,<sup>16</sup> and to a factor in cow manure that stimulated the growth of chicks<sup>16, 17</sup>.

Crystalline vitamin B<sub>12</sub> was found to exhibit animal protein factor activity on chicks fed soya bean meal as the sole source of protein; it was as effective as the cow manure factor in stimulating the growth of chicks.<sup>18</sup> It also increased the growth rate of rats on a factor X deficient diet, showing that vitamin B<sub>12</sub> plays a fundamental role in the utilisation of protein.<sup>19</sup> In fact, evidence appears to be accumulating that vitamin B<sub>12</sub> is concerned with transmethylation. In the first place, on a diet complete in the known vitamins the growth of chicks was improved by supplementation with choline or betaine; the addition of a liver paste containing little choline was even more effective and supplementation with choline or betaine then had little effect.<sup>20</sup> Secondly, crystalline vitamin B<sub>12</sub> increased the growth rate of chicks on a diet low in choline, whilst renal injury in rats due to a low intake of choline and methionine was minimised by the addition of vitamin B<sub>12</sub> to the diet, and the gain in weight was also increased though not when adequate amounts of choline were fed.<sup>21</sup> Thirdly, vitamin B<sub>12</sub>

## VITAMIN B<sub>12</sub> (ERYTHROTIN)

- 3 J. Dedichen, *Lancet*, 1949, 1, 369
- 4 W F J Cuthbertson J F Lloyd, W B Emery and K A Lees  
*J Pharm Pharmacol*, 1949, 1, 705
- 5 U J Lewis, U D Register and C A Elvehjem, *Proc Soc Exp Biol Med* 1949, 71, 509
- 6 J F. Wilkinson, *Lancet*, 1949 1, 249 336
- 7 J. Innes and H N. Robson, *ibid*, 1949, 2, 606

## 5. EFFECT OF VITAMIN B<sub>12</sub> ON ANIMALS AND MAN

### Effect on Man

Crystalline vitamin B<sub>12</sub> prepared from liver extracts gave a positive response when injected intramuscularly into patients with Addisonian pernicious anaemia in doses as small as 3 µg,<sup>1</sup> although to produce a maximum reticulocyte response 6 to 10 µg were required<sup>2</sup> the actual amount varying with the individual. An average maintenance dose was 10 µg every two weeks<sup>3</sup>. Vitamin B<sub>12</sub> was also effective in nutritional macrocytic anaemia and tropical sprue, and relieved sub-acute combined degeneration of the cord in pernicious anaemia<sup>4</sup>. The lingual manifestations of pernicious anaemia also responded<sup>5</sup> although neither this condition nor the neurological symptoms responded to pteroylglutamic acid.

Vitamin B<sub>12</sub> prepared from *S. griseus* cultures<sup>6</sup> and vitamin B<sub>12</sub> prepared from *S. aureofaciens* cultures<sup>7</sup> were apparently as effective in pernicious anaemia as vitamin B<sub>12</sub> prepared from liver extracts. A crude concentrate prepared from beef muscle was also effective when injected intramuscularly in pernicious anaemia patients in doses equivalent to 1 µg of vitamin B<sub>12</sub> daily<sup>8</sup>. Concentrates of a cobalt containing substance were prepared from cultures of *S. griseus* and from cow dung both were inactive in pernicious anaemia but became active after digestion with hog stomach mucosa or pancreatic enzyme<sup>9</sup>.

Vitamin B<sub>12</sub> was more effective by injection than by mouth and most patients responded slowly to oral vitamin B<sub>12</sub> in amounts thirty to sixty times those required by the parenteral route<sup>10</sup>. Vitamin B<sub>12</sub> gave no response orally unless given with normal human gastric juice and an alcoholic extract of beef muscle also gave a good response only when given with normal gastric human juice<sup>11</sup>.

Vitamin B<sub>12</sub> is ineffective in nutritional anaemias due to a deficiency of folic acid (page 500) and cases have been reported where folic acid has to be administered before a response to vitamin B<sub>12</sub> can be obtained. The response to vitamin B<sub>12</sub> was delayed and sub-optimal when 1 mg per day of the folic acid antagonist Aminopterin was given for two

days prior to and for fourteen days during injection of vitamin B<sub>12</sub><sup>12</sup> supporting the hypothesis that vitamin B<sub>12</sub> makes folic acid available to the organism when the Aminopterin was discontinued a second reticulocyte response was obtained. Four patients with untreated pernicious anaemia excreted in the faeces a factor that stimulated *L. lactis* in an amount equivalent to 0.3 to 1.8 µg per g of vitamin B<sub>12</sub> an amount in excess of that required to cure pernicious anaemia. This was presumably produced by bacterial synthesis in the intestine.

That vitamin B<sub>12</sub> has other functions than that of stimulating haemopoiesis is perhaps the conclusion to be drawn from the observations of Wetzel *et al.*,<sup>13</sup> who tested the effect of the vitamin on a group of eleven children in varying states of recovery from simple growth failure. Five were said to respond dramatically with increased physical vigour, alertness, better general behaviour and increase of appetite. In a case of severe allergic bronchitis the symptoms vanished during the first week of treatment. These striking results may be connected with the effect of vitamin B<sub>12</sub> on the utilisation of protein (see below).

### Effect on the Growth of Animals

Cary *et al.*<sup>14</sup> described a factor, factor X, the absence of which resulted in a decline in the growth rate of rats, a decline that became more marked the higher the protein content of the diet. This factor appeared to be similar to the so-called animal protein factor (APF) which increased the hatchability of hens' eggs<sup>15</sup> and the growth rate of chicks maintained on an all vegetable protein ration<sup>16</sup> and to a factor in cow manure that stimulated the growth of chicks<sup>16, 17</sup>.

Crystalline vitamin B<sub>12</sub> was found to exhibit animal protein factor activity on chicks fed soya bean meal as the sole source of protein: it was as effective as the cow manure factor in stimulating the growth of chicks<sup>18</sup>. It also increased the growth rate of rats on a factor X deficient diet, showing that vitamin B<sub>12</sub> plays a fundamental role in the utilisation of protein<sup>19</sup>. In fact, evidence appears to be accumulating that vitamin B<sub>12</sub> is concerned with transmethylation. In the first place, on a diet complete in the known vitamins, the growth of chicks was improved by supplementation with choline or betaine; the addition of a liver paste containing little choline was even more effective and supplementation with choline or betaine then had little effect<sup>20</sup>. Secondly, crystalline vitamin B<sub>12</sub> increased the growth rate of chicks on a diet low in choline, whilst renal injury in rats due to a low intake of choline and methionine was minimised by the addition of vitamin B<sub>12</sub> to the diet and the gain in weight was also increased, though not when adequate amounts of choline were fed<sup>21</sup>. Thirdly, vitamin B<sub>12</sub>

## VITAMIN B<sub>12</sub> (ERYTHROTIN)

- 3 J. Dedichen, *Lancet*, 1949, 1, 369
- 4 W F J Cuthbertson, J F Lloyd, W B Emery and K A Lees  
*J Pharm Pharmacol*, 1949, 1, 705
- 5 U. J Lewis, U D Register and C A Elvehjem, *Proc Soc Exp Biol Med*, 1949, 71, 509
6. J. F. Wilkinson, *Lancet*, 1949, 1, 249 336
7. J. Innes and H N. Robson, *ibid*, 1949, 2, 606.

### 5. EFFECT OF VITAMIN B<sub>12</sub> ON ANIMALS AND MAN

#### Effect on Man

Crystalline vitamin B<sub>12</sub> prepared from liver extracts gave a positive response when injected intramuscularly into patients with Addisonian pernicious anaemia in doses as small as 3  $\mu$ g,<sup>1</sup> although to produce a maximum reticulocyte response 6 to 10  $\mu$ g were required,<sup>2</sup> the actual amount varying with the individual. An average maintenance dose was 10  $\mu$ g every two weeks.<sup>3</sup> Vitamin B<sub>12</sub> was also effective in nutritional macrocytic anaemia and tropical sprue, and relieved sub-acute combined degeneration of the cord in pernicious anaemia.<sup>4</sup> The lingual manifestations of pernicious anaemia also responded,<sup>5</sup> although neither this condition nor the neurological symptoms responded to pteroylglutamic acid.

Vitamin B<sub>12</sub> prepared from *S. griseus* cultures<sup>6</sup> and vitamin B<sub>12</sub> prepared from *S. aureofaciens* cultures<sup>7</sup> were apparently as effective in pernicious anaemia as vitamin B<sub>12</sub> prepared from liver extracts. A crude concentrate prepared from beef muscle was also effective when injected intramuscularly in pernicious anaemia patients in doses equivalent to 1  $\mu$ g of vitamin B<sub>12</sub> daily.<sup>8</sup> Concentrates of a cobalt containing substance were prepared from cultures of *S. griseus* and from cow dung both were inactive in pernicious anaemia but became active after digestion with hog stomach mucosa or pancreatic enzyme.<sup>9</sup>

Vitamin B<sub>12</sub> was more effective by injection than by mouth and most patients responded slowly to oral vitamin B<sub>12</sub> in amounts thirty to sixty times those required by the parenteral route.<sup>10</sup> Vitamin B<sub>12</sub> gave no response orally unless given with normal human gastric juice, and an alcoholic extract of beef muscle also gave a good response only when given with normal gastric human juice.<sup>11</sup>

Vitamin B<sub>12</sub> is ineffective in nutritional anaemias due to a deficiency of folic acid (page 500) and cases have been reported where folic acid has to be administered before a response to vitamin B<sub>12</sub> can be obtained. The response to vitamin B<sub>12</sub> was delayed and sub optimal when 1 mg per day of the folic acid antagonist Aminopterin was given for two

## Other Biological Properties

Rats fed rations containing thyroid active materials required a factor present in liver, fish solubles and tomatoes<sup>34</sup> The factor was present in anti pernicious anaemia active fractions but whereas J J Bethell and H A Lardy<sup>31</sup> and G A Emerson<sup>35</sup> found vitamin B<sub>12</sub> to be active B H Ershoff<sup>36</sup> found it to be ineffective Inconsistent results were obtained when attempts were made to use hyperthyroid rats for the assay of vitamin B<sub>12</sub> (page 535)

Vitamin B<sub>12</sub> did not produce a response in cobalt deficient lambs either after injection of 125 µg or after being fed orally for 6 weeks<sup>37</sup>

Crystalline vitamin B<sub>12</sub> prevented gizzard erosion in chicks<sup>38</sup>

Vitamin B<sub>12</sub> like pteroylglutamic acid increased the incidence and size of Rous tumour implants in chicks and the effect of the two substances given together was greater than that of either alone<sup>39</sup>

## References to Section 5

- 1 R West Science 1948 107 398
- 2 B E Hall and D C Campbell *J Lab Clin Med* 1948 33 1646  
C C Ungley *Lancet* 1948 1 771 *Brit Med J* 1948 2 154
- 3 C C Ungley *ibid* 1949 2 1370
- 4 J C Patel *ibid* 1948 2 934 T D Spies R E Stone and  
T Aramburu *Southern Med J* 1948 41 487 522 T D Spies  
G G Lopez F Milanes R L Toca and B Culver *ibid* 523  
L Berk D Denny Brown M Finland and W B Castle *New  
England J Med* 1948 239 328 T D Spies R E Stone  
G G Lopez F Milanes T Aramburu and R L Toca *Postgrad  
Med* 1948 4 89 T D Spies R M Suarez G G Lopez  
F Milanes R E Stone R L Toca T Aramburu and S Kartus  
*J Amer Med Assoc* 1949 139 521 T D Spies and  
R M Suarez *Blood* 1948 3 1213
- 5 R E Stone and T D Spies *J Lab Clin Med* 1948 33 1019  
J F Schieve and R W Rundles *ibid* 1949 34 439
- 6 D M Dunlop and W M Wilson *Lancet* 1949 1 754 C M  
Miller and E H Moorhouse *Brit Med J* 1949 2 1511
- 7 H Lichtman J Watson V Ginsberg J V Pierce E L R  
Stokstad and T H Jukes *Proc Soc Exp Biol Med* 1949 72  
643
- 8 E H Morgan E E Hall and D C Campbell *Proc Staff Meetings  
Mayo Clinic* 1949 24 594
- 9 K Hausmann *Lancet* 1949 2 962
- 10 T D Spies R E Stone G G Lopez F Milanes R L Toca and  
T Aramburu *ibid* 1454
- 11 F H Gardner J W Harris R F Schilling and W B Castle  
*J Lab Clin Med* 1949 34 1502
- 12 F H Bethell M C Meyers and R B Neligh *ibid* 1948 33 1477



## VITAMIN B<sub>12</sub> (ERYTHROTIN)

had a marked lipotropic effect when injected into rats fed a high fat diet<sup>22</sup> and, finally, the administration of vitamin B<sub>12</sub> to rats preceding acute carbon tetrachloride intoxication prevented liver injury<sup>23</sup>

Stimulation of the growth of rats and chicks maintained on purified diets has been used for the assay of vitamin B<sub>12</sub> with conflicting results (page 535) With the diets used, the response was presumably not always due solely to the vitamin B<sub>12</sub> present

### Relation between Vitamin B<sub>12</sub> and Folic Acid

As already pointed out (page 499), pteroylglutamic acid and vitamin B<sub>12</sub> are not biologically equivalent Thus, the administration of vitamin B<sub>12</sub> to folic acid deficient chicks increased the growth rate without any effect on feathering, whereas pteroylglutamic acid improved feathering but had no effect on growth<sup>24</sup> The so-called vitamins B<sub>10</sub> and B<sub>11</sub> deficiencies (page 614) are probably deficiencies of vitamin B<sub>12</sub> and folic acid respectively Again, pteroylglutamic acid failed to increase the sub-optimal growth rate of rats fed a purified diet plus sulphasuxidine, but cured the leucocytopenia, whereas a liver extract produced good growth<sup>25</sup> The effect of vitamin B<sub>12</sub> on the growth of chicks was enhanced by ascorbic acid, and the amount of folic acid stored in the liver was higher when vitamin B<sub>12</sub> and ascorbic acid were given together than with vitamin B<sub>12</sub> alone<sup>26</sup> Both pteroylglutamic acid and vitamin B<sub>12</sub> were essential for pigs,<sup>27</sup> but vitamin B<sub>12</sub> alone was not so effective as a concentrate of the animal protein factor, suggesting that the latter may contain another substance besides vitamin B<sub>12</sub><sup>28</sup> Whereas the addition of pteroylglutamic acid to a diet deficient in both folic acid and vitamin B<sub>12</sub> reduced the amount of D amino acid oxidase present in the livers of chickens, the addition of vitamin B<sub>12</sub> increased it,<sup>29</sup> other enzymes were not affected

### Relation of Vitamin B<sub>12</sub> to Thymine

Thymine has a haemopoietic action in tropical sprue similar to that produced by pteroylglutamic acid (page 514), though the clinical response was less dramatic.<sup>30</sup> It also brings about a response in nutritional macrocytic anaemia and pernicious anaemia, but several thousand parts of thymine were required to produce the same response as one part of pteroylglutamic acid, and several thousand parts of pteroylglutamic acid to produce the same response as one part of vitamin B<sub>12</sub><sup>31</sup> Thymine also produced reticulocytosis in splenectomised rabbits<sup>32</sup> Thymidine, however, failed to produce a reticulocyte response in a patient with pernicious anaemia,<sup>33</sup> so that care should be taken to eliminate thymidine in assaying vitamin B<sub>12</sub> preparations microbiologically (page 534)

6. VITAMIN B<sub>12</sub> AND MICRO-ORGANISMSVitamin B<sub>12</sub> as Growth Factor

As already mentioned (page 534), vitamin B<sub>12</sub> is an essential growth factor for *Lactobacillus lactis* Dorner and *L. leichmannii*, and both these organisms have been used for its assay. In the absence of vitamin B<sub>12</sub>, thymidine and several purines stimulated the growth of both organisms, although only in much higher concentrations<sup>1</sup>. It has been suggested that vitamin B<sub>12</sub> may function as a coenzyme in the conversion of thymine into thymidine, and that the biochemical lesion in pernicious anaemia may be an inability to synthesise certain nucleosides especially thymidine from purines or pyrimidines. The curative effects of pteroylglutamic acid may well be due to increased thymine synthesis (page 527) which by a mass action effect yields additional amounts of thymidine. The hypothesis that in *Lactobacilli* vitamin B<sub>12</sub> is involved in nucleic acid synthesis is supported by the observation that it causes an increase in the phosphorus uptake of *L. leichmannii* and an increase in the desoxyribonucleic acid fraction<sup>2</sup>. Although ascorbic acid is not a growth factor for *L. leichmannii*, it augments the growth promoting action of casein hydrolysate on this organism, an effect shared with other reducing agents such as thio glycolic acid and glutathione. It is believed that these substances protect the small amounts of vitamin B<sub>12</sub> in trypsin and casein from destruction by oxidation during the autoclaving of the medium<sup>3</sup>. Vitamin B<sub>12</sub> combines with a non dialysable heat labile substance in normal gastric juice to form a complex erythrein which is non dialysable and not dissociated by dialysis. In this form vitamin B<sub>12</sub> is not available to *L. lactis*, *L. leichmannii* or *E. coli*, but is released by heat<sup>4</sup>. The heat labile factor apoerythrein also appears to be present in hog gastric mucosa and may be Castle's intrinsic factor (page 498). It can be assayed by measuring the growth inhibition of *E. coli* produced by the addition of known amounts of the juice to cultures containing vitamin B<sub>12</sub>. Each ml. of normal gastric juice was found to be capable of combining with 15 to 60 µg of vitamin B<sub>12</sub> whereas each ml. of gastric juice from pernicious anaemia patients combined with only 1 to 5 µg of vitamin B<sub>12</sub>.

Vitamin B<sub>12</sub> is not essential for the growth of *S. faecalis* R or *Leuconostoc citrovorum*<sup>5</sup>.

Vitamin B<sub>12</sub> is essential for the growth of the alga, *Euglena gracilis* var. *bacillaris*, another organism that has been used for the assay of vitamin B<sub>12</sub>. It does not respond to thymidine<sup>6</sup>.

Vitamin B<sub>12</sub> appears to be the only substance used in the synthesis of thymidine.

# VITAMIN B<sub>12</sub> (ERYTHROTIN)

13. N. C. Wetzel, W. C. Fargo, I. H. Smith and J. Helikson, *Science*, 1949, **110**, 651.
14. C. A. Cary, A. M. Hartman, L. P. Dryden and G. D. Likely, *Fed. Proc.*, 1946, **5**, 128; A. M. Hartman, *ibid.*, 137.
15. R. B. Nestler, T. C. Byerly, N. R. Ellis and H. W. Titus, *Poultry Sci.*, 1936, **15**, 67.
16. J. C. Hammond, *ibid.*, 1944, **23**, 471.
17. M. Rubin and H. R. Bird, *J. Biol. Chem.*, 1946, **163**, 387; H. R. Bird, M. Rubin and A. C. Groschke, *ibid.*, 1948, **174**, 611.
18. W. H. Ott, E. L. Rickes and T. R. Wood, *ibid.*, 1947; R. J. Lillie, C. A. Denton and H. R. Bird, *ibid.*, 1949, **176**, 1477; R. J. Lillie, H. W. Olsen and H. R. Bird, *Proc. Soc. Exp. Biol. Med.*, 1949, **72**, 598.
19. A. M. Hartman, L. P. Dryden and C. A. Cary, *Arch. Biochem.*, 1949, **23**, 165.
20. M. B. Gillis and L. C. Norris, *J. Biol. Chem.*, 1949, **179**, 487.
21. A. E. Schaefer, W. D. Salmon and D. R. Strength, *Proc. Soc. Exp. Biol. Med.*, 1949, **71**, 193.
22. V. A. Drill and H. M. McCormick, *ibid.*, 1949, **72**, 388.
23. H. Popper, D. Koch-Weser and P. B. Szanto, *ibid.*, 1949, **71**, 688.
24. C. A. Nichol, L. S. Dietrich, C. A. Elvehjem and E. B. Hart, *J. Nutrition*, 1949, **39**, 287.
25. J. H. Jones, C. S. Rogers and C. H. Stone, *ibid.*, 579.
26. L. S. Dietrich, C. A. Nichol, W. J. Mouson and C. A. Elvehjem, *J. Biol. Chem.*, 1949, **181**, 915.
27. R. W. Heinle, A. D. Welch and J. A. Pritchard, *J. Lab. Clin. Med.*, 1948, **33**, 1647.
28. T. J. Cunha, J. E. Burnside, D. M. Buschman, R. S. Glasscock, A. M. Pearson and A. L. Shealy, *Arch. Biochem.*, 1949, **23**, 324.
29. J. N. Williams, C. A. Nichol and C. A. Elvehjem, *J. Biol. Chem.*, 1949, **180**, 689.
30. T. D. Spies, W. B. Frommeyer, G. G. Lopez, R. L. Toca and G. Gwinner, *Lancet*, 1946, **1**, 883.
31. T. D. Spies, R. E. Stone, G. G. Lopez, F. Milanese, R. L. Toca and T. Aramburu, *ibid.*, 1948, **2**, 519.
32. E. M. Bavin and T. R. Middleton, *Nature*, 1946, **158**, 627.
33. C. C. Ungley, *Lancet*, 1949, **1**, 164.
34. J. J. Bethell and H. A. Lardy, *J. Nutrition*, 1949, **37**, 495.
35. G. A. Emerson, *Proc. Soc. Exp. Biol. Med.*, 1949, **70**, 392.
36. B. H. Ershoff, *ibid.*, 1949, **71**, 209.
37. D. E. Becker, S. E. Smith and J. K. Loosli, *Science*, 1949, **110**, 71.
38. C. W. Mushett and W. H. Ott, *Poultry Science*, 1949, **28**, 850.
39. J. J. Oleson and P. A. Little, *Proc. Soc. Exp. Biol. Med.*, 1949, **71**, 226.

6. VITAMIN B<sub>12</sub> AND MICRO-ORGANISMSVitamin B<sub>12</sub> as Growth Factor

As already mentioned (page 534), vitamin B<sub>12</sub> is an essential growth factor for *Lactobacillus lactis* Dorner and *L. leichmannii*, and both these organisms have been used for its assay. In the absence of vitamin B<sub>12</sub>, thymidine and several purines stimulated the growth of both organisms, although only in much higher concentrations<sup>1</sup>. It has been suggested that vitamin B<sub>12</sub> may function as a coenzyme in the conversion of thymine into thymidine, and that the biochemical lesion in pernicious anaemia may be an inability to synthesise certain nucleosides, especially thymidine, from purines or pyrimidines. The curative effects of pteroylglutamic acid may well be due to increased thymine synthesis (page 527), which by a mass action effect yields additional amounts of thymidine. The hypothesis that in *Lactobacilli* vitamin B<sub>12</sub> is involved in nucleic acid synthesis is supported by the observation that it causes an increase in the phosphorus uptake of *L. leichmannii* and an increase in the desoxyribonucleic acid fraction<sup>2</sup>. Although ascorbic acid is not a growth factor for *L. leichmannii*, it augments the growth promoting action of casein hydrolysate on this organism, an effect shared with other reducing agents such as thio-glycolic acid and glutathione. It is believed that these substances protect the small amounts of vitamin B<sub>12</sub> in trypsin and casein from destruction by oxidation during the autoclaving of the medium<sup>3</sup>. Vitamin B<sub>12</sub> combines with a non dialysable, heat labile substance in normal gastric juice to form a complex erythrein which is non dialysable and not dissociated by dialysis. In this form vitamin B<sub>12</sub> is not available to *L. lactis*, *L. leichmannii* or *E. coli*, but is released by heat<sup>4</sup>. The heat labile factor apoerythrein also appears to be present in hog gastric mucosa and may be Castle's intrinsic factor (page 498). It can be assayed by measuring the growth inhibition of *E. coli* produced by the addition of known amounts of the juice to cultures containing vitamin B<sub>12</sub>. Each ml of normal gastric juice was found to be capable of combining with 15 to 60 mμg of vitamin B<sub>12</sub>, whereas each ml of gastric juice from pernicious anaemia patients combined with only 1 to 5 mμg of vitamin B<sub>12</sub>.

Vitamin B<sub>12</sub> is not essential for the growth of *S. faecalis* R or *Leuconostoc citroforum*<sup>5</sup>.

Vitamin B<sub>12</sub> is essential for the growth of the alga, *Euglena gracilis* var *bacillaris*, another organism that has been used for the assay of vitamin B<sub>12</sub>, it does not respond to thymidine<sup>6</sup>.

Vitamin B<sub>12</sub> appears to be one of the rate-limiting factors in the synthesis of bacteriophage T4r, but it was not apparently utilised as

## VITAMIN B<sub>12</sub> (ERYTHROTIN)

a component of the virus, since there was not sufficient of the vitamin present to provide one molecule per virus particle.<sup>7</sup>

### Synthesis of Vitamin B<sub>12</sub> by Micro-organisms

Vitamin B<sub>12</sub> is synthesised by the mould, *Streptomyces griseus*, and vitamin B<sub>12b</sub> by *S. aureofaciens* (page 531). It is also synthesised, apparently in the form of a complex inactive in human pernicious anaemia but active in chicks, by a non-motile, rod-shaped organism isolated from hen droppings.<sup>8</sup> It is probably synthesised by bacteria in the rumen of sheep<sup>9</sup> and, as might be expected, the synthesis is promoted by the ingestion of cobalt.<sup>10</sup>

The presence of a cobalt-containing substance similar to vitamin B<sub>12</sub> in cow-dung<sup>11</sup> is presumably due to bacterial synthesis in the rumen or intestine of cattle, and it has also been suggested that vitamin B<sub>12</sub> may be synthesised by the intestinal flora in humans, and even in patients suffering from pernicious anaemia (page 539).

### References to Section 6

1. L. D. Wright, H. R. Skeggs and J. W. Huff, *J. Biol. Chem.*, 1948, **175**, 457; W. Shive, J. M. Ravel and W. M. Harding, *ibid.*, 1948, **175**, 991.
2. I. Z. Roberts, R. B. Roberts and P. H. Abelson, *J. Bact.*, 1949, **58**, 709.
3. A. D. Welch and M. F. Wilson, *Arch. Biochem.*, 1949, **22**, 486.
4. J. L. Ternberg and R. E. Eakin, *J. Amer. Chem. Soc.*, 1949, **71**, 3858.
5. M. H. Wright, *Science*, 1949, **110**, 257; H. E. Sauberlich, *Arch. Biochem.*, 1949, **24**, 224.
6. S. H. Hutner, L. Provasoli, E. L. R. Stokstad, C. E. Hoffmann, M. Belt, A. L. Franklin and T. H. Jukes, *Proc. Soc. Exp. Biol. Med.*, 1949, **70**, 118.
7. R. B. Roberts and M. Sands, *J. Bact.*, 1949, **58**, 710.
8. E. L. R. Stokstad, A. C. Page, J. V. Pierce, A. L. Franklin, T. H. Jukes, R. W. Heinle, M. Epstein and A. D. Welch, *J. Lab. Clin. Med.*, 1948, **33**, 860.
9. P. H. Abelson and H. H. Darby, *Science*, 1949, **110**, 566.
10. H. R. Marston and H. J. Lee, *Nature*, 1949, **164**, 529.
11. K. Hausmann, *Lancet*, 1949, **2**, 962.


## CHAPTER X

# *p*-AMINO BENZOIC ACID

---

### 1. INTRODUCTION

In 1932, F. Mietzsch and J. Klarer<sup>1</sup> synthesised the substance 4-sulphonamido-2',4'-diaminoazobenzene dihydrochloride to which the name *Prontosil rubrum* was subsequently given



This compound was shown by G. Domagk<sup>2</sup> and others to kill hæmolytic streptococci in mice, although it had no activity *in vitro*. Trefouel *et al.*<sup>3</sup> prepared other azo compounds of a similar type and noted that the sulphonamide group appeared to be essential for antibacterial activity. They suggested that all these compounds were reduced in the body to *p*-aminobenzene sulphonamide or as it is now universally called *sulphanilamide*



and that this was the curative agent. Tests on this substance first prepared by P. Gelmo<sup>4</sup> in 1908, showed that it was in fact as active as *Prontosil* against streptococci, but in striking contrast to *Prontosil* it was highly active *in vitro* as well as *in vivo*.<sup>5</sup> The presence of *sulphanilamide* in the blood of patients under treatment with *Prontosil* was demonstrated by A. T. Fuller,<sup>6</sup> thus confirming the hypothesis of Trefouel *et al.*

The discovery of the highly potent antibacterial activity of *sulphanilamide* was of the greatest importance in medicine. In the first place, it gave a new impetus to chemotherapy, for hitherto the search for antibacterial substances that could safely be used on patients and at the same time eliminate the infection had been singularly unsuccessful, indeed the use of antiseptics such as acriflavine in the treatment of wounds during the 1914-18 war had discredited chemotherapy because they damaged the tissues surrounding the wound. Secondly, it led to the preparation of thousands of derivatives of *sulphanilamide*, several of which were shown to be either more potent than the parent

## *p* AMINO BENZOIC ACID

substance or effective against organisms not inhibited by sulphanil amide

It was only natural that many attempts should have been made to find an explanation of the striking antibacterial properties of sulphanilamide and its derivatives and several plausible theories were put forward. The one that received most support and the one now generally accepted was based on the observation that the inhibitory effect of sulphanilamide could be prevented by various substances such as peptone <sup>7</sup> fractions from *Streptococcus* <sup>8</sup> and *Brucella abortus* <sup>9</sup> and certain enzymes <sup>10</sup> and tissue extracts <sup>11</sup>. D. D. Woods <sup>12</sup> fractionated the anti sulphanilamide fraction of yeast and found that the purified substance possessed many of the properties of *p* aminobenzoic acid. On testing synthetic *p* aminobenzoic acid he found that this in fact did neutralise the antibacterial action of sulphanilamide and he therefore suggested that sulphanilamide inhibited the growth of bacteria by competing with *p* aminobenzoic acid for certain enzymes essential for their growth. F. R. Selbie <sup>13</sup> confirmed Woods' observations by showing that mice succumbed to a streptococcal infection when *p* aminobenzoic acid was administered simultaneously with sulphanilamide. On the basis of this evidence P. Fildes <sup>14</sup> expressed Wood's theory in more general terms and suggested that *p* aminobenzoic acid was an essential metabolite although not necessarily a growth factor for all organisms that are inhibited by sulphanilamide.

Subsequently S. D. Rubbo and J. M. Gillespie <sup>15</sup> succeeded in isolating pure *p* aminobenzoic acid from yeast. They found that it could be titrated against sulphanilamide by using the growth of microorganisms as the end point: 1 mole antagonising 23 000 moles of sulphanilamide. Other workers <sup>16</sup> showed that *p* aminobenzoic acid similarly antagonised the antibacterial effects of derivatives of sulphanilamide e.g. sulphathiazole, sulphapyridine and sulphadiazine.

Strauss *et al.* <sup>17</sup> made a careful study of the inhibition of the sulphonamides by *p* aminobenzoic acid and found that (a) the sulphonamides varied in the extent to which *p* aminobenzoic acid affected them: the bacteriostatic action of 10 mg % of sulphathiazole, sulphapyridine and sulphanilamide being inhibited by 0.04, 0.02 and 0.004 mg % of *p* aminobenzoic acid respectively. (b) the addition of *p* aminobenzoic acid to bacteria at different stages of growth could revive a culture in the presence of sulphapyridine at any stage in the growth curve as long as there are any viable organisms. (c) after ingestion of *p* aminobenzoic acid by humans the urine interfered with the action of sulphathiazole on *Escherichia coli* although to a smaller extent than did added *p* aminobenzoic acid of the same concentration as measured colorimetrically, indicating that some change such as conjugation or oxidation had taken place in the

excreted *p* aminobenzoic acid (d) one hour after ingestion of *p* amino benzoic acid and sulphathiazole the blood was not bacteriostatic to *Pneumococcus* just as if *p* aminobenzoic acid had been added *in vitro* and (e) although effective in preventing bacteriostasis *p* aminobenzoic acid did not prevent sulphonamide fever and rash whether given subsequently or simultaneously

Further support to the theory of Woods and Fildes was given by S D Rubbo and J M Gillespie<sup>18</sup> who found that *Clostridium acetobutylicum* required *p* aminobenzoic acid for growth and that the amount of sulphanilamide required to inhibit growth was dependent on the amount of *p* aminobenzoic acid present. One part by weight of *p* aminobenzoic acid antagonised 26 000 parts of sulphanilamide.

The discovery of the antagonistic effect of sulphanilamide and *p* aminobenzoic acid led to the discovery of other pairs of chemically related substances, one a growth stimulant and the other a growth inhibitor. S D Rubbo and J M Gillespie<sup>18</sup> for example reported that *p* aminophenylacetic acid was a growth factor for *Clostridium acetobutylicum* and that *p* aminophenylmethane sulphonic acid acted as a growth inhibitor for this organism. Other examples have already been discussed (pages 126 292 345 397).

#### References to Section I

- 1 F Mietzsch and J Klarer D R P 607537
- 2 G Domagk *Deut med Woch* 1935 61, 250 928
- 3 J Tréfouel Mme J Tréfouel F Nitti and D Bovet *Compt rend Soc Biol* 1935 120, 756
- 4 P Gelmo *J prakt Chem* 1906 (2) 77, 369
- 5 L Colebrook, G A H Buttle and R A Q O'Meara *Lancet* 1936 2, 1323
- 6 A T Fuller *ibid* 1937 1, 194
- 7 J S Lockwood *J Immunology* 1938 35, 155 J S Lockwood and H M Lynch *J Amer Med Assoc* 1940 114, 935
- 8 T C Stamp *Lancet* 1939 2, 10
- 9 H N Green *Brit J Exp Path* 1940 21, 38
- 10 R West and A F Coburn *J Exp Med* 1940 72, 91
- 11 C M MacLeod *ibid* 217
- 12 D D Woods *Brit J Exp Path* 1940 21, 74
- 13 F R Selbie *ibid* 90
- 14 P Fildes *Lancet* 1940 1, 956
- 15 S D Rubbo and J M Gillespie *Nature* 1940 146, 838
- 16 E Strauss J H Dingle and M Finland *Proc Soc Exp Biol Med* 1941 46, 131 133 W W Spink and J Jernsta *ibid* 1941 47, 395
- 17 E Strauss F C Lowell and M Finland *J Clin Invest* 1941 20, 189
- 18 S D Rubbo and J M Gillespie *Lancet* 1942 1, 36



## 2 ISOLATION OF *p*-AMINO BENZOIC ACID

As already mentioned (page 546) the isolation of *p* aminobenzoic acid from yeast and its unequivocal identification was first accomplished by S D Rubbo and J M Gillespie<sup>1</sup> but an improved method of isolation was described by K C Blanchard<sup>2</sup> in the following year

An aqueous alcoholic extract of yeast was extracted with ether and the ethereal extract evaporated. The residue was made slightly alkaline with ammonia, treated with basic lead acetate and the filtrate acidified and extracted with ether. The extract was re treated with basic lead acetate and re extracted with ether when crystals of *p* aminobenzoic acid (m p 186.4° C), separated from the final extract. On acetylation of the mother liquors crystals of *p* acetylaminobenzoic acid (m p 259.5° C) were obtained. Altogether the equivalent of 1.6 mg of *p* aminobenzoic acid was isolated from 1 kg of yeast about one half that estimated to be present. The extraction was repeated on a sample of plasmolysed yeast heated at 80° C to destroy enzymes and on another sample of the same yeast which had been allowed to autolyse. From these two samples *p* acetylaminobenzoic acid equivalent to 2.7 and 4.7 mg of *p* aminobenzoic acid per kg was isolated corresponding to 57 and 60 % of the amounts estimated to be present in these two preparations. Thus *p* aminobenzoic acid appeared to exist in yeast in combined form from which it was released on autolysis.

This was confirmed by Ratner *et al*<sup>3</sup> who by a process involving precipitation with a silver salt, fractionation of the lead and barium salts and precipitation from alcohol ether or alcohol acetone solutions isolated from 50 kg of dried yeast 400 mg of a polypeptide containing 8 % of *p* aminobenzoic acid. This had no anti sulphonamide activity but free *p* aminobenzoic acid was liberated on hydrolysis with acid or alkali. The peptide contained a chain of ten or eleven glutamic acid residues to which the *p* aminobenzoic acid was attached through its carboxyl group<sup>4</sup>. Thus the conjugate was analogous in structure to vitamin B<sub>6</sub> conjugate (page 464). It accounted for 20 to 30 % of the total *p* aminobenzoic acid content of yeast.

### References to Section 2

- 1 S D Rubbo and J M Gillespie *Nature* 1940 146 838
- 2 K C Blanchard *J Biol Chem* 1941 140, 919
- 3 S Ratner M Blanchard A F Coburn and D E Green *ibid* 1944 155, 689
- 4 S Ratner M Blanchard and D E Green *ibid* 1946 164 691

3. ESTIMATION OF *p*-AMINOBENZOIC ACID

## Chemical Methods

H Tauber and S Laufer<sup>1</sup> observed that when *p* dimethylamino-benzaldehyde was reacted with *p* aminobenzoic acid in glacial acetic acid, a yellow colour was produced, the intensity of which was proportional to the concentration of *p* aminobenzoic acid. They suggested that the reaction might be used for the estimation of *p*-aminobenzoic acid. L R Kirch and O Bergeim<sup>2</sup> proposed the use of a colour reaction with diazotised aneurine for the estimation of *p*-aminobenzoic acid in urine, whilst H W Eckert<sup>3</sup> used the colour formed with dimethyl- $\alpha$  naphthylamine for its estimation in blood. Conjugated *p* aminobenzoic acid was estimated after hydrolysis with acid. Another method of assay, which appears to be more in the nature of an identification and purity test, comprises the dissolution of the *p*-aminobenzoic acid in dilute hydrochloric acid and titration with bromine, as in the estimation of phenol<sup>4</sup>.

## Microbiological Methods

Chemical methods of assay do not appear to have found favour in the estimation of *p* aminobenzoic acid and microbiological methods have been extensively used, just as they have in the case of other members of the vitamin B complex. The first method was due to M Landy and D M Dicken,<sup>5</sup> who proposed the use of *Acetobacter suboxydans* as the test organism. The basal medium consisted of casein hydrolysate, glycerol, pantothenic acid, nicotinic acid, tryptophan, cystine and salts, and the growth of the organism was measured turbidimetrically. The method was used for the estimation of *p*-aminobenzoic acid in animal tissues, blood, body fluids, cereals and yeast, and appeared to be highly specific. J C Lewis<sup>6</sup> suggested the use of *Lactobacillus arabinosus* 17-5 with a basal medium similar to that of Landy and Dicken, but supplemented with additional members of the vitamin B complex. The growth response in this instance, however, was measured by titrating the lactic acid produced. Digestion with dilute alkali was used to liberate bound *p* aminobenzoic acid, strong alkali or acids resulting in partial inactivation. The method was used to estimate *p* aminobenzoic acid in foodstuffs and was said to be very specific.

According to Mitchell *et al.*,<sup>7</sup> the method of Landy and Dicken gave a response equivalent to only a fraction of the total *p* amino benzoic acid present after acid or alkaline hydrolysis, even after enzymic hydrolysis or autolysis, low results were obtained. They advocated hydrolysis with 6N-sulphuric acid at 115° C for one hour.

## *p* AMINOBENZOIC ACID

Subsequently they<sup>8</sup> described a method of assaying *p* aminobenzoic acid in a variety of foodstuffs and animal tissues by means of a mutant of *Neurospora crassa*. The use of yet another organism *Clostridium acetobutylicum* was proposed by J O Lampen and W H Peterson<sup>9</sup> who recommended alkaline hydrolysis for the liberation of *p* amino benzoic acid. *Cl acetobutylicum* had the advantage of requiring an incubation time of only twenty to twenty four hours and was capable of estimating dilutions of *p* aminobenzoic acid as low as 0.00004 µg per ml<sup>10</sup>

### References to Section 5

- 1 H Tauber and S Laufer *J Amer Chem Soc* 1941 **63**, 1488
- 2 E R Kirch and O Bergeim *J Biol Chem* 1943 **148**, 445
- 3 H W Eckert *ibid* 197
- 4 M E Martin and M W Green *Bull Nat Formulary Comm* 1947 **15**, 106
- 5 M Landy and D M Dicken *J Biol Chem* 1942 **146**, 109
- 6 J C Lewis *ibid* 441
- 7 H K Mitchell E R Isbell and R C Thompson *ibid* 1943 **147**, 485
- 8 R C Thompson E R Isbell and H K Mitchell *ibid* 1943 **148**, 281
- 9 J O Lampen and W H Peterson *ibid* 1944 **153**, 193
- 10 R D Housewright and S A Koser *J Infect Dis* 1944 **75**, 113

## 4 OCCURRENCE OF *p*-AMINOBENZOIC ACID IN FOODSTUFFS

The occurrence of *p* aminobenzoic acid in foodstuffs is obviously correlated to some extent with the occurrence of folic acid (page 483) but whereas an estimate of the total (free and combined) *p* amino benzoic acid would include any *p* aminobenzoic acid present as folic acid, *p* aminobenzoic acid occurs in foodstuffs in the free state and in compounds other than folic acid. It has already been stated for example (page 548) that in yeast 20 to 30 % of the *p* aminobenzoic acid is present in combination with a polypeptide of glutamic acid.

A limited amount of information is available concerning the *p* aminobenzoic acid contents of foodstuffs. These invariably contain appreciably more *p* aminobenzoic acid than the amount equivalent to the folic acid present.

The following values were obtained for cereals: wheat germ 1.0<sup>1</sup>, wheat middlings 0.52<sup>1</sup>, oats 0.5<sup>2</sup>, rolled oats 0.33<sup>1</sup>, maize meal 0.3<sup>1</sup> and alfalfa meal 2.0 µg per g<sup>1</sup>.

Fresh spinach contained 0.6<sup>3</sup>, dried carrots 0.18<sup>4</sup> and dried cabbage 9.7 µg per g<sup>4</sup>.

Fresh calf liver contained 0.2,<sup>1</sup> and ox liver 2.5  $\mu\text{g}$  per g<sup>2</sup>

Dried whole egg contained 0.2 to 0.36 dried egg yolk 0.8 and dried egg albumen 0.055  $\mu\text{g}$  per g<sup>4</sup> Skim milk contained 0.004<sup>4</sup> and whole milk 0.15  $\mu\text{g}$  per ml<sup>1</sup>

As might be expected yeast was the richest source of *p* aminobenzoic acid containing from 4<sup>2</sup> to 100<sup>1</sup>  $\mu\text{g}$  per g Mushrooms contained 1.3  $\mu\text{g}$  per g<sup>2</sup>

#### References to Section 4

- 1 M Landy and D M Dicken *J Biol Chem* 1942 146, 109
- 2 H K Mitchell E R Isbell and R C Thompson *ibid* 1943 147, 485
- 3 R C Thompson E R Isbell and H K Mitchell *ibid* 1943 148, 281
- 4 J C Lewis *ibid* 1942 146, 441

### 5 EFFECT OF *p*-AMINOBENZOIC ACID DEFICIENCY IN ANIMALS

The recognition of *p* aminobenzoic acid as a growth factor for micro-organisms (page 546) was soon followed by evidence of its biological importance for higher animals and man S Ansbacher<sup>1</sup> was the first to suggest that it might be a member of the vitamin B complex following the discovery that it cured grey hair in rats and also in mice<sup>2</sup> when these were fed a synthetic diet G A Emerson<sup>3</sup> however failed to confirm these observations but they were substantiated by the subsequent work of G J Martin and S Ansbacher<sup>4</sup> who showed that *p* aminobenzoic acid also counteracted the action of hydroquinone which causes greying of hair in cats<sup>5</sup> and mice and of sulphanilamide<sup>6</sup> and succinyl sulphathiazole<sup>7</sup> which have a similar effect in rats Moreover the colour change normally produced by the action of tyrosinase on dihydroxyphenylalanine was modified by *p* aminobenzoic acid *in vitro* suggesting that it interfered with melanin formation<sup>8</sup> The interference was not specific however since sulphanilamide and alanine though not pantothenic acid (which has also been claimed to possess chromatrichial properties) behaved similarly

According to B Sure<sup>9</sup> *p* aminobenzoic acid was essential for reproduction and lactation in the rat

Since the deficiency symptoms resulting from feeding a purified diet to rats were aggravated by succinylsulphathiazole and at least partially removed by *p* aminobenzoic acid Briggs *et al*<sup>10</sup> suggested that the factor required to prevent these symptoms might be

## *p*-AMINO BENZOIC ACID

synthesised by bacteria in the gut. Apparently the symptoms were more or less completely cured by the addition of folic acid to the diet.<sup>11</sup> *p*-Aminobenzoic acid failed to cure the greying resulting from a deficiency of pantothenic acid.<sup>12</sup>

Grey hair has been claimed to be symptomatic not only of *p*-aminobenzoic acid deficiency, but also of pantothenic acid deficiency (see page 365), biotin deficiency (see page 424), folic acid deficiency (see page 487) and inositol deficiency (see page 572). It is possible that *p*-aminobenzoic acid is a chromotrichial factor because it is converted into folic acid, which is especially effective in stimulating the growth of the intestinal bacteria (see page 505), but such an explanation cannot apply to other members of the vitamin B complex, which are obviously not inter-convertible. The true explanation of the existence of several chromotrichial factors must be that many members of the vitamin B complex are capable of stimulating the growth of the intestinal flora, when this has been depressed either by feeding a purified diet or as the result of treatment with a sulphonamide, and that once the intestinal bacteria have regained their full vigour, they synthesise the factor necessary for the formation of melanin.

Indirect confirmation of this hypothesis was provided by Coates *et al.*,<sup>13</sup> who found that refected rats (page 75) were entirely dependent on the symbiotic microflora for their supply of essential growth factors and were therefore particularly suitable for detecting interference with the activity of these organisms by growth inhibitors. They showed that sulphapyrazine, sulphathiazole, sulphaguanidine, sulphasuxidine and sulphathalidine reduced the excretion of aneurine and that the addition of *p* aminobenzoic acid restored the excretion to normal.

The effect of *p* aminobenzoic acid on the intestinal flora also accounts for its ability to cure a hypoprothrombinaemia produced in young rats by feeding sulphasuxidine.<sup>14</sup> The *p* aminobenzoic acid stimulated the growth of the bacteria in the intestinal tract and these then synthesised the vitamin K necessary to restore the blood clotting mechanism to normal.

*p* Aminobenzoic acid was not apparently necessary for growth in the pig,<sup>15</sup> but it appeared to be essential for young trout.<sup>16</sup> In its absence these developed pale livers, 10 to 20 mg per 100 g of diet being necessary to prevent this condition.

### References to Section 5

- 1 S Ansbacher *Science* 1941, 93, 164
- 2 G J Martin and S Ansbacher, *Proc Soc Exp Biol Med* 1941 48, 118
- 3 G A Emerson *ibid* 1941, 47, 448
- 4 G J Martin and S Ansbacher *J Biol Chem* 1941, 138, 441

- 5 H Oetzel, Jr & E. A. F. F. *Proc Soc Exp Biol Med* 1943 310
- 6 G. J. V. *Proc Soc Exp Biol Med* 1943 31 56
- 7 L. D. W. & A. D. W. *Proc Soc Exp Biol Med* 1943 97 46
- 8 G. J. V. & W. A. W. *Proc Soc Exp Biol Med* 1943 47, 75
- 9 B. S. *Proc Soc Exp Biol Med* 1943 28 5
- 10 G. M. B. & T. D. L. *Proc Soc Exp Biol Med* 1943 52, 7
- 11 G. J. V. *Proc Soc Exp Biol Med* 1943 51, 353
- 12 L. M. H. & J. M. V. *Proc Soc Exp Biol Med* 1943 23, 47
- 13 M. E. C. & R. M. H. *Proc Soc Exp Biol Med* 1946 15, 6
- 14 H. G. D. & G. W. *Proc Soc Exp Biol Med* 1943 26 598
- 15 T. J. C. & L. H. B. *Proc Soc Exp Biol Med* 1947 34 173
- 16 B. A. M. & E. K. *Proc Soc Exp Biol Med* 1947 15, 169

## 6 EFFECT OF *p*-AMINO BENZOIC ACID DEFICIENCY IN MAN

The possibility that by analogy with its effects in experimental animals *p*-aminobenzoic acid might have a favourable effect in nutritional achromotrichia in man was first suggested by B. I. Sieve.<sup>1</sup> Attempts to restore the colour of grey hair in elderly men and women by means of *p*-aminobenzoic acid were unsuccessful however. In one experiment<sup>2</sup> only two out of nineteen subjects showed any improvement when given *p*-aminobenzoic acid together with calcium pantothenate and yeast. In another experiment<sup>3</sup> only three out of eighty-eight cases of achromotrichia given 100 mg. of *p*-aminobenzoic acid three times daily for ten to twelve weeks showed any tendency to repigmentation and in one of these the pigmentation disappeared again soon after treatment was stopped. Any claims therefore that preparations containing *p*-aminobenzoic acid are of value in restoring the grey hair of elderly patients to its former colour are completely unjustified and there is no scientific evidence in support of them.

It has been claimed<sup>4</sup> that ointments containing *p*-aminobenzoic acid protect the skin against sunburn and that *p*-aminobenzoic acid and local anaesthetics such as procaine derived from it protect the injected area from the erythema action of ultra violet light when injected intracutaneously. Irradiated solutions of *p*-aminobenzoic acid were said to cause inflammation when injected intradermally in man.

Several workers observed that *p*-aminobenzoic acid had a leucopenic

## *p*-AMINOBENZOIC ACID

effect when given to patients infected with rickettsiae<sup>5</sup> (see page 557) It was therefore tried out in the treatment of patients with chronic lymphatic leukemia and chronic myeloid leukemia It caused a profound fall in the leucocyte count when administered in doses of 50 g a day The haemoglobin content of the blood was reduced slightly<sup>6</sup> The division of myeloid cells appeared to be stimulated at low concentrations and depressed at high concentrations

### *References to Section 6*

1. B F Sieve, *Science*, 1941, **94**, 257
2. H Brandalcone E Main and J M Steele, *Proc Soc Exp Biol Med*, 1943 **53**, 47
3. J. J Eller and L A Diaz, *N Y Sta J Med*, 1943 **43**, 1331
4. S Rothman and J Rabin *J Invest Dermat*, 1942, **5**, 445
5. A. Yeomans, J C Snyder, E S Murray, C J D Zarafonetus and R S Ecke, *J Amer Med Assoc*, 1944 **126**, 349, P K Smith, *ibid*, 1946, **131**, 1114, N A Tierney, *ibid*, 280
6. H. B May and J Vallence-Owen, *Lancet*, 1948, **2**, 607

## 7. METABOLISM OF *p*-AMINOBENZOIC ACID

*p* Aminobenzoic acid is excreted in human urine, probably in conjugated form, and in human faeces (see pages 77, 78)<sup>1</sup> By using *p*-aminobenzoic acid containing N<sup>15</sup>, Lustig *et al*<sup>2</sup> demonstrated that the substance was neither stored nor utilised by mice

The average concentration of *p* aminobenzoic acid in human sweat was 0.24 µg per 100 ml<sup>3</sup>

There is convincing evidence that *p* aminobenzoic acid is synthesised by the intestinal flora of humans, for Denko *et al*<sup>1</sup> found that the faecal excretion greatly exceeded the dietary intake It is not known whether the *p*-aminobenzoic acid so formed is absorbed

Administration of *p*-aminobenzoic acid to guinea pigs resulted in a decrease of the bacterial population of the intestine and in the total disappearance of the Gram negative lactose-fermenting bacilli<sup>4</sup>

### *References to Section 7*

1. E Strauss, F C Lowell and M Finland *J Clin Invest*, 1941, **20**, 189, C W Denko W E Grundy, J W Porter, G H Berryman T E Friedemann and J B Youmans *Arch Biochem*, 1946 **10**, 33, C W Denko W E Grundy, N C Wheeler, C R Henderson G H Berryman, F E Friedemann and J B Youmans, *ibid*, 1946, **11**, 109
2. B Lustig, A R Goldfarb and B Gerstl *Arch Biochem*, 1944 **5**, 59
3. B C Johnson H H Mitchell and T S Hamilton *J Biol Chem* 1945, **161**, 357
4. D M Whitney and L Amgstein, *J Bact*, 1946, **52**, 400

8. PHARMACOLOGY OF *p*-AMINOBENZOIC ACID

The toxicity of *p* aminobenzoic acid was studied by C C Scott and E B Robbins,<sup>1</sup> who found that it was more toxic to mice and dogs than to rats when given orally, but more toxic to rats than to mice when the sodium salt was given intravenously. The values of LD<sub>50</sub> were 2.85, 1.3 and 7.6 g. per kg for mice, dogs and rats respectively by the oral route, and 4.6 and 2.8 g per kg for mice and rats respectively by the intravenous route. Oral doses in excess of 1 g per kg generally caused death in dogs, following acute gastro enteritis and haemorrhage into the small intestine. Acute necrosis of the liver was produced by 2 g per kg or more. Rats tolerated 1.4 g per kg per day by mouth for a month without ill effects.

It has been stated<sup>2</sup> however, that adult rats fed a diet containing 3 % of *p* aminobenzoic acid developed enlarged thyroid glands after about a month, but this was not confirmed by C D Sullivan and J W Archdeacon,<sup>3</sup> who gave 7.5 mg of *p*-aminobenzoic acid daily for forty-eight days by the intraperitoneal route and could observe no change in the weight of the thyroid glands. Body growth was inhibited, however, and the adrenals were slightly enlarged.

*References to Section 8*

- 1 C C Scott and E B Robbins, *Proc Soc Exp Biol Med* 1942, **40**, 184
- 2 A S Gordon, E D Goldsmith and H A Charipper *Endocrinology*, 1945 **37**, 223
- 3 C D Sullivan and J W Archdeacon *ibid*, 1947, **41**, 325

9. *p*-AMINOBENZOIC ACID IN THE NUTRITION OF MICRO-ORGANISMS**Bacteria requiring *p*-Aminobenzoic Acid**

The Woods-Gildes theory (page 546) postulated that *p*-aminobenzoic acid was an essential metabolite of all micro organisms susceptible to the action of the sulphonamides. Although some of these organisms can synthesise it for themselves others require it pre-formed in the medium before they can grow, in such instances, *p* aminobenzoic acid is also an essential growth factor. The first micro-organisms shown to require *p* aminobenzoic acid were *Clostridium acetobutylicum*<sup>1</sup> and *Streptobacterium plantarum*<sup>2</sup>

*Clostridium acetobutylicum* has been used for the microbiological assay of *p* aminobenzoic acid (page 550) and so have *Acetobacter*



## *p*-AMINO BENZOIC ACID

*suboxydans* and *Lactobacillus arabinosus*, which also fail to grow in the absence of *p* aminobenzoic acid <sup>3, 4</sup> Other *Clostridia* for which *p* aminobenzoic acid is essential are *Cl butylicum*,<sup>5</sup> *Cl felsineum*,<sup>5</sup> and *Cl kluyveri* <sup>6</sup> It was also essential for *Lactobacillus helveticus* and *L pentosus*,<sup>7</sup> and an X-ray mutant of *Escherichia coli* <sup>8</sup>

### Bacterial Synthesis of *p*-Aminobenzoic Acid

*p*-Aminobenzoic acid is synthesised by many bacteria <sup>9</sup> Sulphathiazole-resistant strains of *Staph aureus* produced more than susceptible strains,<sup>9, 10</sup> and the additional *p* aminobenzoic acid was sufficient to account for the fastness of these strains to sulphathiazole <sup>11</sup> H McIlwain <sup>12</sup> showed that some of the *p* aminobenzoic acid present in the cells of haemolytic streptococci could readily be removed by washing with saline and that only the tightly bound portion was responsible for sulphonamide fastness Sulphonamide resistant strains of *D pneumoniae* and *Shigella paradysenteriae* showed no increase in the ability to synthesise *p* aminobenzoic acid

The amounts of *p* aminobenzoic acid in *Aerobacter aerogenes*, *Serratia marcescens* *Pseudomonas aeruginosa*, *Streptococcus haemolyticus* and *Escherichia coli* were calculated by H McIlwain <sup>13</sup> to be 7700, 3100, 4700 3800 and 17,000 molecules per cell respectively The corresponding rates of synthesis were 4.0, 1.2, 5.5, 1.1 and 3.9 molecules per cell per second

Three X ray mutants of *E coli*, however, required *p* aminobenzoic acid for growth but this could be replaced by a combination of amino acids a purine and thymine the presence of methionine in the amino acid mixture was essential <sup>13a</sup> In a medium containing these supplements the mutants were resistant to the action of sulphonamides The evidence suggests that *p* aminobenzoic acid plays a part in the synthesis of purines and thymine, methionine and possibly other amino acids, thus resembling vitamin B<sub>12</sub> and folic acid (pages 515 539, 543) Pteroylglutamic acid did not replace *p*-aminobenzoic acid however, as a growth factor for the mutants

A soil bacillus belonging to the *Pseudomonaceae* was isolated which developed an enzyme specific for the oxidation of *p*-aminobenzoic acid to carbon dioxide water and ammonia <sup>14</sup> The growth of this organism was inhibited by sulphapyridine, and *p* aminobenzoic acid counteracted the inhibition The organism could be used to identify *p* aminobenzoic acid in amounts as small as 10 µg It was used by Spink *et al* <sup>15</sup> to demonstrate that a sulphonamide resistant strain of *Staph aureus* produced more *p* aminobenzoic acid than a non resistant strain, confirming the result obtained by Landy *et al* <sup>11</sup>

### Antibacterial Action of *p*-Aminobenzoic Acid

The growth of certain gram negative organisms e.g. *E. coli* was inhibited by 1:1 in 150 solution of sodium *p* aminobenzoate and the growth of *M. tuberculosis* by 1:1 in 1000 solution. Gram positive organisms were not affected by 1:1 in 100 solution<sup>15a</sup>. The severity of experimental tuberculosis in guinea pigs was mitigated by the oral administration of about 100 mg daily of *p* aminobenzoic acid and the survival time of the animals was increased but neither the development of the infection nor the eventual fatal outcome was prevented<sup>1 b</sup>. On the other hand *p* aminobenzoic acid accelerated the onset of experimental typhoid in mice and shortened the survival time<sup>15c</sup>.

### Moulds and Yeasts

*p*-Aminobenzoic acid was essential for the growth of an X ray mutant of *Neurospora crassa*<sup>16</sup> and of *Rhodotorula aurantiaca*<sup>17</sup>. It accelerated the growth of *Penicillium roquefortii* and *Byssoschlamys fulva* but inhibited the growth of *Aspergillus niger*<sup>18</sup>. It neutralised the inhibitory action of sulphanilamide on *Penicillium digitatum*, *Fusarium coeruleum* and *Botrytis allii*<sup>19</sup>.

One mutant of *N. crassa* actually required sulphonamides for growth and was inhibited by *p* aminobenzoic acid. The inhibition was completely antagonised by sulphonamides<sup>19a</sup>. A double mutant carrying the gene for sulphonamide requirement and a gene for failure to synthesise *p* aminobenzoic acid required both substances for growth.

### Other Micro-organisms

The growth of *Strigomonas oncopelti* was inhibited by sulphanilamide and the inhibition was counteracted by *p* aminobenzoic acid in concentrations 264 000 times that of the sulphanilamide<sup>20</sup>. *p* Amino benzoic acid had no effect on experimental toxoplasmosis in mice but it nullified the protection afforded by sulphathiazole<sup>21</sup>. Clinical improvement in cases of amoebiasis followed the administration of *p* aminobenzoic acid<sup>21a</sup>.

### Viruses and Rickettsiae

*p* Aminobenzoic acid was remarkably effective in murine typhus

Rocky Mountain spotted fever as against typhus but it had no effect

## *p* AMINOBENZOIC ACID

on the organisms of lymphogranuloma venereum or psittacosis<sup>23</sup> *p* Aminobenzoic acid had an anti rickettsial activity in the guinea pig in a dose of 0.3 g per 100 g of diet<sup>24</sup> and has been tried out with considerable success in rickettsial infections in man<sup>25</sup>. Thus in twenty cases of louse borne typhus an initial dose of 4 to 8 g of *p* amino benzoic acid was given followed by 2 g every two hours this maintained a blood concentration of between 10 and 20 mg per 100 ml. The symptoms were less severe in the treated patients than in the untreated controls and the duration of the fever was considerably shorter. Similar beneficial results were obtained in twenty nine patients with endemic (murine) typhus and in eighteen patients with tsutsugamushi disease. A large number of cases of Rocky Mountain spotted fever have been successfully treated with *p* aminobenzoic acid which is now regarded as the drug of choice. The dose for children is 0.9 g per kg of bodyweight<sup>26</sup>.

The chemotherapeutic activity of sulphadiazine on psittacosis virus was antagonised competitively by *p* aminobenzoic acid and non competitively by pteroylglutamic acid suggesting that the sulphonamide exerted its effect by interfering with the incorporation of *p* aminobenzoic acid into pteroylglutamic acid by the virus<sup>27</sup>. *p* Aminobenzoic acid also reversed the action of sulphadiazine on the viruses of mouse pneumonitis and lymphogranuloma venereum<sup>28</sup>.

### References to Section 9

- 1 S D Rubbo and J M Gillespie *Nature* 1940 **146**, 838 *Lancet* 1942 **1**, 36
- 2 R Kuhn and K Schwartz *Ber* 1941 **74B**, 1617
- 3 M Landy and D M Dicken *J Biol Chem* 1942 **146**, 109
- 4 J C Lewis *ibid* 441
- 5 J O Lampen and W H Peterson *Arch Biochem* 1943 **2** 443
- 6 B T Bornstein and H A Barker *J Bact* 1948 **55**, 222
- 7 E E Snell and H K Mitchell *Arch Biochem* 1942 **1**, 93
- 8 J O Lampen R R Roepke and M J Jones *J Biol Chem* 1946 **164**, 789
- 9 M Landy N W Larkum and E J Oswald *Proc Soc Exp Biol Med* 1943 **52**, 338
- 10 R D Housewright and S A Koser *J Infect Dis* 1944 **75** 113
- 11 M Landy N W Larkum E J Oswald and E Streightoff *Science* 1943 **97**, 295
- 12 H McIlwain *Biochem J* 1945 **39**, 329
- 13 H McIlwain *Nature* 1946 **158**, 898
- 13a J O Lampen M J Jones and R R Roepke *J Biol Chem* 1949 **180** 423

# FFFECT ON HICHER PLANTS

- 14 G S Mirick *J Exp Med* 1943 78, 255
- 15 W W Spink L D Wright J J Vivino and H R Skeggs *ibid* 1944 78, 331
- 15a R Lecoq and J Solomides C R Acad Sci 1947 225 1392
- 15b B M Bloomberg S Afr J Med Sci 1947 12 1
- 15c B M Bloomberg *ibid* 5
- 16 R. C. Thompson E R Isbell and H K Mitchell *J Biol Chem* 1943 148, 281
- 17 W J Robbins and R M Science 1944 100 85
- 18 G W K Cavill and J M Vincent *Nature* 1945 155 301 J Soc Chem Ind 1948 67, 25
- 19 P W Brian *Nature* 1944 153 83
- 19a S Emerson *J Bact* 1947 54 195
- 20 M Lwoff and A Lwoff *Ann Inst Pasteur* 1945 71, 206
- 21 W K Summers *Proc Soc Exp Biol Med* 1947 60 509
- 21a K G Dwork *Bull N Y Acad Med* 1948 24 391
- 22 D Greiff H Pinkerton and V Moragues *J Exp Med* 1944 80 561
- 23 H L Hamilton H Plotz and J E Smadel *Proc Soc Exp Biol Med* 1945 58, 255 H L Hamilton *ibid* 1945 59, 220
- 24 L Anigstein and D M Whitney *J Bact* 1946 52 402
- 25 A Yeomans J C Snyder E S Murray C J D Zarafonet s and R S Ecke *J Amer Med Assoc* 1944 126 349 P K Smith *ibid* 1946 131, 1114 N A Tierney *ibid* 280
- 26 W J Hendricks and M Peters *Jediat* 1947 30 72 C J Tichenor S Ross and P A McLendon *ibid* 1947 31 1
- 163 S Ross P A McLendon and H J Davis *Pediatrics* 1946 2
- 163 L E Fraser H Rosenblum and J A Daneiger *Arter J Dis Child* 1948 75 493 C G Hooten W S Hoo en and J E Mitchell *Virginia Med Monthly* 1949 78 121
- 27 H R Morgan *Proc Soc Exp Biol Med* 1948 67 29
- 28 C T Huang and M D Eaton *J Bact* 1949 58 73

## 10 EFFECT OF p-AMINO BENZOIC ACID ON HIGHER PLANTS

p Aminobenzoic acid has not been shown to have any specific effect on the growth of plants but it neutralised the inhibitory effect of sulphani lamide on the growth of oat roots 1

p Aminobenzoic acid in company with aneurine biotin and pyridine was found to be present in soil and natural manures 2

References to Section 10

- 1 P W Brian *Nature* 1944 153, 83
- 2 M A Roulet *Experientia* 1948 4 149

## 11. *p*-AMINO BENZOIC ACID REQUIREMENTS OF INSECTS

*p* Aminobenzoic acid may have some effect on the growth of the larvae of *Tribolium confusum* and *Plinus tectus*, but it is not essential in the same way as are other members of the vitamin B complex<sup>1</sup>

### Reference to Section 11

1. G Fraenkel and M Blewett, *Nature*, 1942, 150, 177; 1943 151, 703

## 12. ANALOGUES OF *p*-AMINO BENZOIC ACID

Very few compounds related to *p*-aminobenzoic acid have growth-promoting properties. Thus, the methyl and ethyl esters were reported to have only 0.1 % of the activity of the acid against *Cl acetobutylicum*<sup>1, 2</sup> and *Streptobacterium plantarum*, whilst procaine had 10 to 20 % of the activity against the former organism,<sup>1, 2</sup> but only 1 % of the activity against the latter<sup>3</sup>. Tutocaine also had about 1 % of the activity of *p* aminobenzoic acid against *S. plantarum*, whilst pantocaine was even less effective<sup>1, 3</sup>. *N*-Acyl-*p* aminobenzoic acids were only slightly active, but *p* nitrobenzoic acid and the *N* glycosides were as active as the acid itself towards *Cl acetobutylicum*<sup>1</sup>. *p*-Aminophenylacetic acid had only 0.1 % of the activity of *p*-aminobenzoic acid against this organism, whilst *o* aminobenzoic acid, isonicotinic acid, *p*-hydroxybenzoic acid and folic acid were inactive<sup>1</sup>. *p*-Amino-, *p*-nitro- and *p* chloroacetylbenzoylglycine had between 10 and 100 % of the activity of *p* aminobenzoic acid<sup>2</sup>.

*p*-Nitrobenzoic acid does not invariably stimulate the growth of micro organisms, however, for, according to Rosenthal *et al.*,<sup>4</sup> it inhibited the growth of certain bacteria. *p* Aminobenzamide<sup>5</sup> and some other sulphur-free analogues of *p* aminobenzoic acid have similar properties. Thus, according to E. Auhagen,<sup>6</sup> the growth-promoting effect of *p* aminobenzoic acid on *S. plantarum* was counteracted by *p* aminobenzophenone, *p* aminoacetophenone and *pp'*-diaminobenzophenone. The last-named was the most active of the three, being one fifth to one-third as effective as sulphanilamide, it exhibited a slight antibacterial action in mice infected with streptococci, gonococci and meningococci.

The bacteriostasis induced by *p* nitrobenzoic acid and *p* aminobenzamide was examined further by Johnson *et al.*,<sup>7</sup> who found that the compounds were not effective against all bacteria inhibited by the sulphonamides. Thus they inhibited the growth of *E. coli* but not of *S. haemolyticus*, furthermore, with *E. coli* inhibition lasted only for a

## ANALOGUES

short time, the organisms beginning to grow again after forty eight hours. It would appear, therefore that some organisms are able to convert these two substances readily into *p* aminobenzoic acid whereas others can do so only with difficulty.

Johnson *et al* prepared thirty five other compounds related to *p* aminobenzoic acid and tested their effect on the growth of *E. coli*, *S. haemolyticus* and *D. pneumoniae*. The results of their work can be summarised as follows. Substitution of *p* aminobenzoic acid in the 2 or 3 position with for example a methyl or methoxymethyl or a halogen atom yielded bacteriostatic compounds and the introduction of a second group destroyed the activity. Replacement of the amino group by any group other than the nitro group gave a inactive substance whilst replacement of the carboxyl group had a variable result. Thus, *p* aminoacetophenone and 3-methyl-4-aminobenzamide had bacteriostatic properties whilst other compounds of this type showed growth promoting activity and yet others were completely inactive. 4-amino-4-carboxydiphenylamine inhibited the growth of *Strep. haemolyticus*, *Staph. aureus* and *E. coli* to the same extent as sulphanilamide.\*

2-Chloro-4-aminobenzoic acid exhibited similar properties to *p* aminobenzoic acid but was a growth inhibitor for *S. haemolyticus* and *D. pneumoniae* but a growth inhibitor for *E. coli* at high concentration and a bacteriostatic agent at lower concentrations.

The only naphthalene compound tested, 4-amino-1-naphthol, was bactericidal at high but inactive at low concentration. Two thiophene compounds, 5-nitrothiophene-2-carboxylic acid and 5-nitrothiophene-2-carboxylic acid were highly inhibitory toward *S. haemolyticus*, but the former was ten times as active as the latter against *E. coli*. The only thiazole compound tested, 4-aminothiazole-5-carboxylic acid, was inactive and both 5-nitro-2-furoic acid and 5-acetyl-amino-furoic acid were inactive. 6-Aminopyridine-3-carboxylic acid however, was as active as sulphanilamide against *S. haemolyticus* and eight times as active against *E. coli*, being about as active as sulphapyridine against both organisms.

*p* Aminobenzoic acid reversed the activity of all the compounds that had bacteriostatic properties.

2-Aminopyrimidine-5-carboxylic acid had no antibacterial action on *Strep. pyogenes in vitro* but had a slight antagonistic effect towards sulphanilamide, although inferior in this respect to *p* aminobenzoic acid.\* Of a series of derivatives of *p* aminobenzoic acid substituted in the nucleus the most potent antibacterials were 3-hydroxy- and 3-chloro-4-aminobenzoic acid and 3,4-diaminobenzoic acid\*. The first of these had one third to one ninth the activity of sulphanilamide and had a definite but feeble therapeutic effect in mice infected

## *p* AMINOBENZOIC ACID

with haemolytic streptococci or pneumococci. Five other compounds 3 methyl and 2-chloro 4 aminobenzoic acid 4 amino iso phthalic acid 4 (4 aminobenzamido) benzoic acid and ethyl 4 amino benzoate completely antagonised the growth inhibitory action of sulphanilamide<sup>10</sup>

### References to Section 12

- 1 J O Lampen and W H Peterson *Arch Biochem* 1943 2, 443
- 2 R D Housewright and S A Koser *J Infect Dis* 1944 75, 113
- 3 E F Moller and K Schwartz *Ber* 1941 74B, 1612 O Dann and E F Möller *Chem Ber* 1947 80, 21
- 4 S Rosenthal H Bauer and E Elvove *U S Publ Health Rep* 1939 54, 1317
- 5 J Hirsch *Science* 1942 96, 140
- 6 E Auhagen *Z physiol Chem* 1942 274, 48
- 7 O H Johnson D E Green and R Pauli *J Biol Chem* 1944 153, 37
- 7a A T Fuller C R Harington R Pitt Rivers and J M L Stephen *J Chem Soc* 1948 241
- 8 A R Martin F L Rose and G Swain *Nature* 1944 154, 639
- 9 D Wyss M Rubin and F Strandskov *Proc Soc Exp Biol Med* 1943 52, 155
- 10 A R Martin and F L Rose *Biochem J* 1945 39, 91

## 13 FUNCTION OF *p*-AMINOBENZOIC ACID

The relationship between *p* aminobenzoic acid and sulphanilamide and the significance of the Woods Fildes theory have already been discussed (page 546). If this theory is correct *p* aminobenzoic acid and sulphanilamide compete with one another for an enzyme system essential for the activity of the bacterial cell. This enzyme is probably concerned with the synthesis of folic acid (page 515) since pteroylglutamic acid non competitively reverses the antibacterial action of sulphanilamide.

*p* Aminobenzoic acid however is not the only antagonist for the sulphonamides for in presence of sub-optimal amounts of *p* aminobenzoic acid adenine guanine xanthine and hypoxanthine nullified the bacteriostatic effect of sulphanilamide against *L. arabinosus* and *L. pentosus*<sup>1</sup>. Any of these purines antagonised the effect of sulphanilamide on *L. pentosus* or *L. helveticus* in the absence of *p* aminobenzoic acid. With *L. pentosus* the effect of the purines appeared to depend on the presence of a growth factor that was not *p* aminobenzoic acid. In the absence of *p* aminobenzoic acid the growth of *Cl. acetobutylicum* was stimulated by adenine guanine xanthine and uracil<sup>2</sup>.

Methionine also antagonised the inhibitory action of sulphanilamide on *E. coli*, having about one-third the activity of the purines in this respect.<sup>3</sup> It is possible therefore that *p*-aminobenzoic acid functions in the synthesis of methionine as well as of the purine bases, although folic acid is apparently concerned only with the latter. 4-Amino-2-chlorobenzoic acid was a specific inhibitor of methionine synthesis by *E. coli*. Methionine was also able to stimulate the growth of an X-ray mutant of *E. coli*, giving a response additional to that produced by *p*-aminobenzoic acid.<sup>4</sup> Thymine and other purines were inactive on this strain, and pteroylglutamic acid had less than 0.001 % of the activity of *p*-aminobenzoic acid, suggesting that the latter has a function independent of its association with folic acid.

On the other hand, the biological importance of *p*-aminobenzoic acid is undoubtedly associated in part with its conversion to folic acid. Thus *p*-aminobenzoylglutamic acid, pteric acid, pteroylglutamic acid and pteroyltriglutamic acid could replace *p*-aminobenzoic acid as a growth factor for *L. arabinosus*, although they were all less active on a molar basis.<sup>5</sup> The inhibition of *L. arabinosus* by sulphanilamide was antagonised non-competitively by these substances, with the exception of pteric acid, as well as by thymine

#### References to Section 13

1. E. E. Snell and H. K. Mitchell, *Arch Biochem.*, 1942, **1**, 93.
2. R. D. Housewright and S. A. Koser, *J. Infect. Dis.*, 1944, **75**, 113.
3. W. Shive and E. C. Roberts, *J. Biol. Chem.*, 1946, **162**, 463.
4. J. O. Lampen, R. R. Roepke and M. J. Jones, *ibid.*, 1946, **164**, 789.
5. J. O. Lampen and M. J. Jones, *ibid.*, 1947, **170**, 133.



## INOSITOL

## 1. INTRODUCTION

THE discovery by E Wildiers<sup>1</sup> of "bios", the hypothetical substance necessary for the growth of certain yeasts, and its resolution into a number of individual factors, has already been discussed (page 404). The first of these substances to be identified was bios I, which was shown by E V Eastcott<sup>2</sup> to be identical with *meso* inositol, one of the eight stereo isomers of hexahydroxycyclohexane. This substance had been known since 1850 when it was discovered in muscle by D Scherer<sup>3</sup>. It was shown to be a cyclic hexahydroxy alcohol by L Maquenne<sup>4</sup> in 1887 and synthesised by H Wieland and R S Wishart<sup>5</sup> in 1914.

Although inositol thus became the first member of the bios complex, it was not recognised as a growth factor for animals until 1940, when D W Woolley<sup>6</sup> showed that mice reared on a diet deficient in inositol lost weight and became hairless. It was subsequently demonstrated that mice and other species of animals showed other characteristic symptoms besides alopecia when made inositol deficient (see page 572).

Inositol was therefore added to the list of substances essential for the growth of micro organisms and higher animals and was regarded by many workers as a member of the vitamin B complex.

There have been some misgivings, however, about the inclusion of inositol in the vitamin B complex, as the amount of inositol required by animals and micro organisms is very considerably greater than their requirements for other members of the vitamin B complex.

Similarly, the amounts of inositol present in many foodstuffs far exceed their contents of other members of the complex. These considerations suggest that inositol must play a different rôle in the economy of living organisms from that of aneurine or nicotinic acid for example, and that it is a structural component of living tissue rather than a catalyst of metabolic reactions. Indeed inositol has some of the characteristics of the amino acids, many of which are also essential for the growth of animals and micro organisms. Inositol and choline (page 582) may, in fact, be regarded as a link between the vitamins and amino acids.

*References to Section 1*

- 1 E Wildiers *La Cellule* 1901 18, 313
- 2 L V Eastcott *J Phys Chem* 1928 32, 1094
- 3 D Scherer *Annalen* 1850 73, 322
- 4 L Maquenne *Ann Chim* 1887 12, 80
- 5 H Wieland and R S Wishart *Ber* 1914 47, 2082
- 6 D W Woolley *Science* 1940 92, 384 *J Biol Chem* 1940 136, 113

**2 ISOLATION OF INOSITOL**

D W Woolley<sup>1</sup> isolated inositol from the 70 % alcohol insoluble fraction of an aqueous liver extract hydrolysed with concentrated hydrochloric acid. Impurities were removed by means of normal lead acetate solution and the inositol was then precipitated with basic lead acetate solution. After decomposing the precipitate with sulphuric acid the inositol was precipitated by baryta in alcoholic solution and the precipitate decomposed with carbon dioxide. The inositol was dissolved in the minimum amount of water and alcohol was added to the solution until crystallisation occurred.

*Reference to Section 2*

- 1 D W Woolley *J Biol Chem* 1941 139, 29

**3 CHEMICAL CONSTITUTION AND SYNTHESIS OF INOSITOL**

Inositol was shown to be a cyclic hexahydroxy alcohol as long ago as 1887<sup>1</sup> but its configuration was not established with certainty until 1942. One of the reasons for the slow progress in the elucidation of its structure was that reactions found to be of value in determining the structure of the sugars proved to be non specific when applied to the cyclic alcohols.

The structure of *meso* inositol was established by degradation of partly phosphorylated inositols by oxidation with potassium permanganate and the identification of the oxidation products. There are eight possible configurations of hexahydroxycyclohexane. By the action of phosphatase on phytin an optically active tetraphosphoric ester<sup>2</sup> and an optically inactive monophosphoric ester of *meso* inositol were obtained<sup>3</sup>. The formation of the former proved that *meso* inositol could not have all its hydroxyl groups on one side of the

ring, whilst the formation of the inactive monophosphoric ester excluded the formula with four adjacent hydroxyl groups on one side of the ring and the other two groups on the other side

Oxidation of a mixture of the mono- and di-phosphoric esters of *meso*-inositol yielded *meso*-tartaric acid and racemic tartaric acid. This result excluded the formula with alternate hydroxyl groups above and below the ring, since this contains only *trans* hydroxyl groups and therefore cannot give rise to *meso* tartaric acid on oxidation. Oxidation of *meso*-inositol itself by alkaline permanganate solution gave a mixture of trihydroxyglutaric acid, *d*- (III) and *l*-talomucic acids and *d*- (IV) and *l*-saccharic acids. This evidence indicated that *meso*-inositol could have either formula I or formula II








T Posternak<sup>4</sup> decided between these formulae by studying the oxidation product obtained by the action of *Acetobacter suboxydans* on *meso*-inositol. This substance, inosose (V), gave on oxidation a mixture of *d*- (VI) and *l*-idosaccharic acid and, on reduction, regenerated *meso*-inositol and produced at the same time another naturally occurring cyclitol, scyllitol (VII). *Meso* Inositol must therefore have the structure represented by (I)

The structure assigned to *meso*-inositol by T Posternak was confirmed by G Dangschat and H O L Fischer<sup>5</sup>. The tetra acetate of *meso*inositol, obtained from the tetra acetyl-monoacetone derivative by removal of acetone, was oxidised with lead tetra-acetate giving a dialdehyde, which on further oxidation gave a mixture of the tetra-acetyl derivatives of the diethyl esters of *d*- (VI) and *l*-ido-accharic acids

*meso*-Inositol has been synthesised by hydrogenation of hexa hydroxybenzene<sup>6</sup>. With Raney nickel as catalyst a mixture of *meso*-inositol, scyllitol and other cyclitols was formed. Scyllitol crystallised out from a 50 % aqueous methanol solution and *meso*-inositol from a 90 % aqueous methanol solution. Several attempts have been made to synthesise *meso* inositol by other routes, but without success<sup>7, 8</sup>

#### References to Section 3

- 1 L Maquenne *Ann Chim*, 1887, 12, 80
- 2 T Posternak, *Helv Chim Acta*, 1935 18, 1283
- 3 R J Anderson, *J Biol Chem*, 1914 18, 441
- 4 T Posternak *Helv Chim Acta*, 1942 25, 746
- 5 G Dangschat and H O L Fischer, *Naturwiss* 1942 30, 146
- 6 H Wieland and R S Wishart, *Ber*, 1914, 47, 2082, R C Anderson and E S Wallis, *J Amer Chem Soc*, 1948, 70, 2931
- 7 F Micheel, *Annalen*, 1932, 486, 77.
- 8 Y. Hamamura, *Proc Imp Acad Tokyo*, 1934



#### 4. PROPERTIES OF INOSITOL

*meso* Inositol has m p 225 to 226° C and forms a dihydrate, m p 218° C<sup>1</sup> It is very soluble in water, 1 part dissolving in 5.7 parts at 24° C, slightly soluble in alcohol but insoluble in ether and other organic solvents It has a sweet taste

It is best characterised as the hexa-acetate m.p 213° C *meso* Inositol is often referred to as *l* inositol

*Reference to Section 4*

1 D W Woolley, *J Biol Chem*, 1941, 139, 29

#### 5. ESTIMATION OF INOSITOL

##### Biological Methods

D W Woolley<sup>1</sup> devised a biological method for the assay of inositol, based on the development of alopecia in mice In the original diet yeast extract was used, but better results were subsequently obtained by replacing this with a mixture of synthetic vitamins

##### Chemical Methods

The earliest chemical method for the estimation of inositol was the extremely laborious one of isolating the substance and either weighing it,<sup>2</sup> or determining the carbon content of the isolated material by a micro combustion method<sup>3</sup>

A simpler method was used by P Fleury and J Marque<sup>4</sup> for the estimation of polyhydric alcohols, in which the test solution is heated with potassium mercuric iodide and sodium hydroxide in presence of a suspension of barium sulphate As the alcohol is oxidised, metallic mercury is formed as a finely divided powder This is dissolved by the addition of iodine, the excess of which is titrated with sodium thiosulphate solution The method was improved by L Young<sup>5</sup> to give a greater degree of accuracy with smaller amounts of inositol (1 to 5 mg) and further modified by R A Gregory<sup>6</sup> mainly by simplifying the extraction procedure The tissues were heated with 10 % potassium hydroxide solution and the alkali and incidentally, unwanted impurities were removed by the addition of a zinc salt, the filtrate was then clarified by means of acid mercuric sulphate solution After removal of mercury by hydrogen sulphide, the inositol was precipitated with alcoholic baryta and barium removed from the precipitate The purified inositol was then oxidised by potassium mercuric iodide

A better chemical method of assay was developed by B S Platt

and G E Glock<sup>7</sup> The dried tissue was extracted with water and the fractions insoluble in 70 % acetone and soluble in ether were both removed from the extract Glucose was then removed by fermentation with yeast and both acidic and basic substances were removed by adsorption on ion exchange materials The free inositol in the solution was then quantitatively oxidised with periodic acid and the excess estimated iodometrically Water soluble combined inositol was estimated after acid hydrolysis of the aqueous extract

### Microbiological Methods

With inositol as with so many other members of the vitamin B complex biological and chemical methods of estimation have given place to microbiological methods which are generally less tedious and more accurate than biological methods and more specific than chemical methods

The first microbiological assay method was that of D W Woolley<sup>8</sup> who used the Hansen No 1 strain of Toronto yeast *Saccharomyces cerevisiae* This was grown on a basal medium consisting of glucose casein hydrolysate salts other members of the vitamin B complex and an aqueous extract of malt sprouts to supply bios II The response of the organism to graded doses of the test solution and of a standard inositol solution was measured turbidimetrically The error was estimated to be not more than 5 or 6 % A similar procedure was used by R J Wilhams *et al*<sup>9</sup> but in this instance the Gebruder Meyer strain of yeast was employed V Jurist and J R Foy<sup>10</sup> also used yeast but in their basal medium the only constituents of uncertain composition were casein hydrolysate and a folic acid concentrate Atkin *et al*<sup>11</sup> used *S carlsbergensis*

G W Beadle<sup>12</sup> used a mutant of *Neurospora crassa* which was claimed to have the advantage over yeast that the basal medium was simpler and the mould did not grow at all in the absence of inositol Amounts of inositol ranging from 5 to 30  $\mu\text{g}$  per 20 ml could be estimated with an error of  $\pm 0.3 \mu\text{g}$

Burkholder *et al*<sup>13</sup> used the yeast *Kloeckera brevis* for the assay of inositol whilst Emery *et al*<sup>14</sup> compared the response obtained with this organism and that given by another yeast *Schizosaccharomyces pombe*

### References to Section 5

- 1 D W Woolley *J Biol Chem* 1940 130, 113 1941 130, 79.  
*J Nutrition* 1941 21, Suppl 17
- 2 L B Winter *Biochem J* 1934 28, 6 1940 34 249
- 3 J Needham *ibid* 1923 17, 422 431
- 4 P Fleury and J Marquet *Compt rend* 1939 188, 1686 *J Pharm Chim* 1929 [8] 10, 241

## INOSITOL

5. L. Young, *Biochem. J.*, 1934, 28, 1428, 1435.
6. R. A. Gregory, *ibid.*, 1935, 29, 2798.
7. B. S. Platt and G. E. Glock, *ibid.*, 1943, 37, 709.
8. D. W. Woolley, *J. Biol. Chem.*, 1941, 140, 453; *J. Exp. Med.*, 1942, 75, 277.
9. R. J. Williams, A. K. Stout, H. K. Mitchell and J. R. McMahan, *Univ. Texas Publ.*, 1941, No. 4137, 27.
10. V. Jurist and J. R. Foy, *J. Bact.*, 1944, 47, 434.
11. L. Atkin, A. S. Schultz, W. L. Williams and C. N. Frey, *Ind. Eng. Chem., Anal. Ed.*, 1943, 15, 141.
12. G. W. Beadle, *J. Biol. Chem.*, 1944, 156, 683.
13. P. R. Burkholder, I. McVeigh and D. Moyer, *J. Bact.*, 1944, 48, 385.
14. W. B. Emery, N. McLeod and F. A. Robinson, *Biochem. J.*, 1946, 40, 426.

## 6. OCCURRENCE OF INOSITOL

Inositol occurs in most animal and plant tissues, fruits and cereal grains being especially good sources. Yeasts and certain other micro-organisms contain relatively large amounts,<sup>1</sup> and this is reflected in the relatively enormous amounts of inositol present in yeast extracts in comparison with their contents of other members of the vitamin B complex.<sup>2</sup> Thus, whereas the amounts of aneurine and pantothenic acid present in three different yeast extracts were of the order of 100  $\mu\text{g.}$  per g., the amount of inositol present varied between 1000 and 3000  $\mu\text{g.}$  per g. Relatively large amounts (2000 to 3000  $\mu\text{g.}$  per g.) were also present in crude liver extracts.

Inositol was shown<sup>3</sup> to be present in liver in a water-soluble, alcohol-insoluble, non-dialysable form, presumably in combination with a protein. It was also shown to be present in the form of a complex in heart muscle,<sup>4, 5</sup> and was isolated from thyroid<sup>6</sup> and from kidneys, spleen and testes.<sup>7</sup> All the inositol present in brain cephalin was in the form of a phosphatide, diphosphoinositide.<sup>7a</sup>

In plants, inositol occurs in the form of its phosphoric esters. Inositol monophosphoric ester and triphosphoric ester have been shown to exist in wheat bran,<sup>8</sup> but the commonest inositol compound in cereals is the hexaphosphoric ester, phytic acid. The mixed calcium magnesium hydrogen salt of this acid, known as phytin, occurs in a large variety of plant materials, particularly cereals. Phytic acid forms a very stable calcium salt, in which neither the calcium nor the phosphorus can be utilised. Thus the phytic acid in oats renders non-available the whole of the calcium present in the cereal and, what is worse, immobilises much of the calcium present in other constituents of the diet, such as milk.<sup>9</sup> The phytic acid present

accounts for the rachitogenic action of oatmeal observed many years ago the immobilisation of a part of the dietary calcium by the phytic acid reducing the calcium/phosphorus ratio to such an extent that rickets may supervene. Phytic acid is also capable of immobilising other metals for example iron but in general the results are less serious than with calcium.

Inositol was isolated from the phosphatides of the tubercle bacillus by R. J. Anderson<sup>10</sup> whilst the phosphatides of soyabean were shown to contain inositol monophosphoric ester<sup>11</sup>. Subsequently D. W. Woolley<sup>12</sup> showed that soyabean phosphatide contained a complex of inositol monophosphoric ester with galactose, ethanolamine, tartaric acid, oleic acid and saturated fatty acid.

The chemical methods of estimating inositol have been used to only a very small extent for estimating inositol in foodstuffs but L. Young<sup>13</sup> using the iodomercurate method (page 568) obtained the following values for the inositol content of various animal tissues: ox brain 149-111, sheep brain 172-176, sheep heart muscle 154 to 170, dog heart muscle 156-174, rabbit skeletal muscle 16-27 and ox skeletal muscle less than 5 mg per 100 g.

D. W. Woolley<sup>14</sup> using a yeast growth method obtained remarkably high values for ox liver and ox heart namely 340 and 1600 mg per 100 g. The heart muscle of other species of animals contained considerably less inositol however<sup>15</sup>.

The following values were obtained by D. W. Woolley<sup>14</sup> for various other natural substances: maize 50, oats 100, alfalfa leaf meal 210, brewers yeast 500 and whole milk 50 mg per 100 g. Wheat flour contained 110 mg of inositol per 100 g and bread made from 98% extraction flour 64 mg per 100 g<sup>16</sup>.

#### References to Section 6

- 1 F. Kögl and W. van Hasselt *Z. physiol. Chem.* 1936 242, 43
- 2 W. B. Emery, N. McLeod and F. A. Robinson *Biochem. J.* 1946 40, 426
- 3 D. W. Woolley *J. Biol. Chem.* 1941 139, 29
- 4 F. Rosenberger *Z. physiol. Chem.* 1910 64, 341
- 5 L. B. Winter *Biochem. J.* 1934 28, 6
- 6 A. E. Meyer *Proc. Soc. Exp. Biol. Med.* 1946 62, 111
- 7 P. B. Hawk, B. L. Oser and W. H. Summerson *Practical Physiological Chemistry* 1947
- 7a J. Folch *J. Biol. Chem.*, 1949 177, 497-505
- 8 R. J. Anderson *J. Biol. Chem.* 1914 18, 425-441; 1915 20, 463
- 9 D. C. Harrison and E. Mellanby *Biochem. J.* 1939 33, 1660
- 10 R. J. Anderson *J. Amer. Chem. Soc.* 1930 52, 1607
- 11 E. Klenk and R. Sakal *Z. physiol. Chem.* 1939 258, 33
- 12 D. W. Woolley *J. Biol. Chem.* 1943 147, 581



- 13 L Young *Biochem J*, 1934 28, 1435
- 14 D W Woolley *J Biol Chem* 1941, 140, 453
- 15 A N Woods J Taylor M J Hofer G A Johnson R L Kane  
and J R McMahan *Univ Texas Publ*, 1942, No 4237
- 16 R R Sealock and A H Lavermore, *J Nutrition*, 1943 25, 265

## 7. EFFECT OF INOSITOL DEFICIENCY IN ANIMALS

### Mice and Rats

As already stated (page 564), the first symptoms of inositol deficiency to be recorded were alopecia and loss of weight<sup>1</sup>. These were observed in mice fed a ration of sucrose, purified casein, salts, cod liver oil, corn oil, yeast extract, aneurine, riboflavine, nicotinic acid pyridoxine pantothenic acid  $\beta$  alanine and choline. The hair was restored by administration of a non dialysable fraction from liver, the responsible factor being subsequently isolated and identified as inositol (page 565). This was effective at a level of 10 mg per g of diet, whilst phytin (the calcium magnesium salt of phytic acid) was effective at a level of 100 mg per 100 g. D W Woolley<sup>2</sup> showed that the absence of pantothenic acid, as well as inositol, from the diet of mice produced alopecia and that the inositol deficient mice, but not the pantothenic acid deficient mice, recovered spontaneously. A deficiency of pantothenic acid had also a more marked effect on the weight of the animals than had a deficiency of inositol. The anti alopecia activity of inositol in mice was confirmed by Martin *et al*,<sup>3</sup> who also observed that it caused reddening of the skin. P L Pavcek and H M Baum<sup>4</sup> showed that the denudation around the eyes of rats, a symptom used by W Halliday and H M Evans<sup>5</sup> for the assay of vitamin B<sub>6</sub>, cleared up on administration of inositol whilst Cunha *et al*,<sup>6</sup> showed that loss of hair took place in rats maintained on a diet consisting of maize, soya bean lucerne, minerals halibut liver oil, folic acid and pyridoxine and that growth of the hair was restored by the addition of 0.3 % of inositol to the diet.

In contrast to *p* aminobenzoic acid inositol had an unfavourable effect on lactation in the rat, the effect was counteracted by *p* aminobenzoic acid<sup>7</sup>.

### Lipotropic Effect

The production of fatty livers in rats by feeding a beef liver fraction was found to be prevented by the simultaneous administration of various tissues or cereal extracts<sup>8</sup> or of inositol,<sup>9</sup> whilst fatty livers produced by feeding biotin were also prevented by inositol<sup>8</sup>. Choline also had lipotropic properties (page 582) but, whereas it was effective

## EFFECT OF DEFICIENCY IN ANIMALS

in the treatment of fatty livers produced by aneurine and partially effective in the treatment of cholesterol fatty livers it was said to have little effect on fatty livers produced by beef liver<sup>9</sup> or biotin<sup>10</sup>. Inositol on the other hand was said to have no effect on aneurine fatty livers<sup>10</sup>. That the two compounds probably operate by different mechanisms was confirmed by J. C. Forbes' observation<sup>11</sup> that the effect of inositol and choline together was greater than either alone. Choline reduced the liver cholesterol esters more effectively than did inositol whilst the lipotropic effect of inositol was abolished by corn oil<sup>12</sup>.

According to Best *et al*<sup>13</sup> however there is no evidence that biotin produces a selective deposition of cholesterol esters in the liver or that inositol has a specific effect on bound cholesterol or that the fatty livers observed after administration of biotin are particularly resistant to choline. On the contrary the accumulation of cholesterol esters in liver bore a constant relationship to the deposition of glyceride in the liver and the administration of biotin did not affect this relationship. Best *et al* confirmed the synergistic effect of choline and inositol on the liver lipins and the greater efficacy of choline in reducing the liver glycerides and cholesterol esters but could find no evidence in support of any effect of choline, inositol or biotin on the absolute amount of phospholipin or free cholesterol in the liver or kidney lipides. They recommended that the term 'biotin fatty livers' should be abandoned and suggested that Gavin and McHenry's results were due to their having overlooked the presence of choline in beef liver.

### Other Species of Animals

An increase in the growth rate was produced by the administration of inositol to cotton rats<sup>14</sup>, guinea pigs<sup>15</sup> and hamsters<sup>16</sup>. In hamsters inositol counteracted a reproductive disorder produced by feeding an inositol deficient diet<sup>17</sup>.

Chicks also exhibited an increased growth rate when given inositol<sup>18</sup> which prevented an encephalomalacia and exudative diathesis due to vitamin E deficiency<sup>19</sup>.

Unlike rats and mice inositol-deficient dogs did not develop alopecia but exhibited decreased peristalsis of the stomach and small intestine with delayed gastric emptying, hypertonicity, hypomotility and formation of gas<sup>2, 20</sup>.

In pigs inositol alleviated the symptoms produced by administration of sulphathalidine<sup>21</sup>. These symptoms resembled those of biotin deficiency and were prevented by giving biotin (page 426). Inositol had no beneficial effect however when given to pigs maintained on a diet containing the other members of the vitamin B complex<sup>21, 22</sup>.

- 13 L Young *Biochem J* 1934, 28, 1435
- 14 D W Woolley, *J Biol Chem*, 1941, 140, 453.
- 15 A N Woods J Taylor, M J Hofer, G A Johnson, R L Kane  
and J R McMahan *Univ Texas Publ*, 1942, No 4237
- 16 R R Sealock and A H Livermore *J Nutrition* 1943, 25, 265

## 7. EFFECT OF INOSITOL DEFICIENCY IN ANIMALS

### Mice and Rats

As already stated (page 564), the first symptoms of inositol deficiency to be recorded were alopecia and loss of weight<sup>1</sup> These were observed in mice fed a ration of sucrose, purified casein salts, cod liver oil, corn oil, yeast extract, aneurine, riboflavine, nicotinic acid, pyridoxine, pantothenic acid,  $\beta$  alanine and choline The hair was restored by administration of a non dialysable fraction from liver, the responsible factor being subsequently isolated and identified as inositol (page 565) This was effective at a level of 10 mg per g of diet, whilst phytin (the calcium magnesium salt of phytic acid) was effective at a level of 100 mg per 100 g D W Woolley<sup>2</sup> showed that the absence of pantothenic acid, as well as inositol, from the diet of mice produced alopecia and that the inositol deficient mice, but not the pantothenic acid deficient mice, recovered spontaneously A deficiency of pantothenic acid had also a more marked effect on the weight of the animals than had a deficiency of inositol The anti alopecia activity of inositol in mice was confirmed by Martin *et al*,<sup>3</sup> who also observed that it caused reddening of the skin P L Pavcek and H M Baum<sup>4</sup> showed that the denudation around the eyes of rats, a symptom used by W Halliday and H M Evans<sup>5</sup> for the assay of vitamin B<sub>6</sub> cleared up on administration of inositol whilst Cunha *et al*,<sup>6</sup> showed that loss of hair took place in rats maintained on a diet consisting of maize, soya bean lucerne, minerals, halibut liver oil, folic acid and pyridoxine and that growth of the hair was restored by the addition of 0.3 % of inositol to the diet

In contrast to *p* aminobenzoic acid, inositol had an unfavourable effect on lactation in the rat, the effect was counteracted by *p* amino-benzoic acid<sup>7</sup>

### Lipotropic Effect

The production of fatty livers in rats by feeding a beef liver fraction was found to be prevented by the simultaneous administration of various tissues or cereal extracts<sup>8</sup> or of inositol,<sup>9</sup> whilst fatty livers produced by feeding biotin were also prevented by inositol<sup>8</sup> Choline also had lipotropic properties (page 582) but, whereas it was effective

in the treatment of fatty livers produced by aneurine and partially effective in the treatment of cholesterol fatty livers, it was said to have little effect on fatty livers produced by beef liver<sup>9</sup> or biotin<sup>10</sup>. Inositol, on the other hand, was said to have no effect on aneurine fatty livers<sup>10</sup>. That the two compounds probably operate by different mechanisms was confirmed by J. C. Forbes' observation<sup>11</sup> that the effect of inositol and choline together was greater than either alone. Choline reduced the liver cholesteryl esters more effectively than did inositol, whilst the lipotropic effect of inositol was abolished by corn oil<sup>12</sup>.

According to Best *et al.*,<sup>13</sup> however, there is no evidence that biotin produces a selective deposition of cholesteryl esters in the liver or that inositol has a specific effect on bound cholesterol or that the fatty livers observed after administration of biotin are particularly resistant to choline. On the contrary, the accumulation of cholesteryl esters in liver bore a constant relationship to the deposition of glyceride in the liver, and the administration of biotin did not affect this relationship. Best *et al.* confirmed the synergistic effect of choline and inositol on the liver lipins and the greater efficacy of choline in reducing the liver glycerides and cholesteryl esters, but could find no evidence in support of any effect of choline, inositol or biotin on the absolute amount of phospholipin or free cholesterol in the liver or kidney lipides. They recommended that the term "biotin fatty livers" should be abandoned and suggested that Gavin and McHenry's results were due to their having overlooked the presence of choline in beef liver.

### Other Species of Animals

An increase in the growth rate was produced by the administration of inositol to cotton rats<sup>14</sup>, guinea pigs<sup>15</sup> and hamsters<sup>16</sup>. In hamsters, inositol counteracted a reproductive disorder produced by feeding an inositol deficient diet<sup>17</sup>.

Chicks also exhibited an increased growth rate when given inositol<sup>18</sup> which prevented an encephalomalacia and exudative diathesis due to vitamin E deficiency<sup>19</sup>.

Unlike rats and mice, inositol-deficient dogs did not develop alopecia but exhibited decreased peristalsis of the stomach and small intestine with delayed gastric emptying, hypertonicity, hypomotility and formation of gas<sup>2, 20</sup>.

In pigs inositol alleviated the symptoms produced by administration of sulphathalidine<sup>21</sup>. These symptoms resembled those of biotin deficiency and were prevented by giving biotin (page 426). Inositol had no beneficial effect however when given to pigs maintained on a diet containing the other members of the vitamin B complex<sup>21, 22</sup>.

Slow growth and a normocytic anaemia were produced in turkey poult by a deficiency of inositol <sup>23</sup>

Inositol deficiency in young rainbow trout resulted in degeneration of the fins and in distended stomachs <sup>24</sup> The symptoms were prevented by 25 to 50 mg per 100 g of diet

### Effect on Infected Animals

Inositol had no effect on the susceptibility of Swiss mice to experimental poliomyelitis <sup>25</sup>

### Inositol and Cancer

The inositol content of transplanted epidermal carcinoma in mice was more than twice that of normal epidermis, but methylcholanthrene treated epidermis contained only the normal amount <sup>26</sup>

Inositol inhibited the growth of transplanted tumours in mice when given intravenously <sup>27</sup> Its effect on transplanted sarcoma in mice was counteracted by *p* aminobenzoic acid and other compounds <sup>28</sup>

#### References to Section 7

- 1 D W Woolley *Science* 1940 **92**, 384 *J Biol Chem* 1940 **136**, 113 1941 **139**, 29 *J Nutrition* 1941 **21**, Suppl 17
- 2 D W Woolley *Proc Soc Exp Biol Med* 1941 **46**, 565 *J Exp Med* 1942 **75**, 277
- 3 G J Martin M R Thompson and J de Carvajal Forero *Amer J Digest Dis* 1941 **8**, 290
- 4 P I Pavcek and H M Baum *Science* 1941 **93**, 502
- 5 W Halliday and H M Evans *J Nutrition* 1937 **14**, 45
- 6 T J Cunha S Kirkwood P H Phillips and G Bohstedt *Proc Soc Exp Biol Med* 1943 **54**, 236
- 7 B Sure *J Nutrition* 1943 **26**, 275
- 8 G Gavin and E W McHenry *J Biol Chem* 1941 **139**, 485
- 9 M L MacFarland and E W McHenry *ibid* 1945 **159** 605 1948 **176**, 429
- 10 G Gavin J M Patterson and E W McHenry *ibid* 1943 **148**, 275
- 11 J C Forbes *Proc Soc Exp Biol Med* 1943 **54**, 89
- 12 J M R Beveridge and C C Lucas *J Biol Chem* 1945 **157**, 311
- 13 C H Best C C Lucas J M Patterson and J H Ridout *Science* 1946 **103**, 12 *Biochem J* 1946 **40**, 368 494
- 14 J M McIntire B S Schweigert and C A Elvehjem *J Nutrition* 1944 **27**, 1
- 15 A G Hogan and J W Hamilton *ibid* 1942 **23**, 533
- 16 J M Cooperman H A Waisman and C A Elvehjem *Proc Soc Exp Biol Med* 1943 **52**, 250
- 17 J W Hamilton and A G Hogan *J Nutrition* 1944 **27**, 213

## HUMAN AND ANIMAL REQUIREMENTS

- 18 D M Hegsted G M Briggs R C Mills C A Elvehjem and E B. Hart *Proc Soc Exp Biol Med* 1941 47, 376
- 19 H Dam *J Nutrition* 1944 27, 193
- 20 G J Martin M R Thompson and J de Carvajal Forero *Amer J Digest Dis* 1942 8, 268
- 21 D C Lindley and T J Cunha *J Nutrition* 1946 32, 47
- 22 T J Cunha L H Bustad W E Ham D R Cordy E C McCulloch L F Woods G H Conner and M A McGregor *ibid* 1947 34, 173
- 23 T H Jukes E L R Stokstad and M Belt *ibid* 1947 33, 1
- 24 B A McLaren E Keller D J O'Donnell and C A Elvehjem *Arch Biochem* 1947 15, 169
- 25 H C Lichstein H A Whisman K B McCall C A Elvehjem and P F Clark *Proc Soc Exp Biol Med* 1945 60, 279
- 26 E L Tatum M G Ritchey E V Cowdry and L F Wicks *J Biol Chem* 1946 163, 675 M G Ritchey L F Wicks and E L Tatum *ibid* 1947 171, 51
- 27 D Laszlo and C Leuchtenberger *Science* 1943 97, 515
- 28 J C Keresztesy D Laszlo and C Leuchtenberger *Cancer Res* 1946 6, 128

## 8 EFFECT OF INOSITOL DEFICIENCY IN MAN

Administration of inositol to patients with gastro intestinal cancer reduced the characteristic fatty infiltration of the liver<sup>1</sup> and it has been suggested<sup>2</sup> that the lipotropic action of inositol may be of value in the treatment of psoriasis. It has been stated<sup>3</sup> that a compound of  $\alpha$  tocopherol and inositol is of value in the treatment of muscular dystrophy but the claim has not been substantiated by other workers.

Symptoms of uncomplicated inositol deficiency in man do not appear ever to have been encountered nor have they apparently been artificially induced in volunteers.

### *References to Section 8*

- 1 J C Abels C W Kupel G T Pack and C P Rhoads *Proc Soc Exp Biol Med* 1943 54 157
- 2 P Gross and B M Kesten *Arch Derm Syph* 1941 47, 376
- 3 A T Milhorat and W E Bartels *Science* 1945 101, 93

## 9 HUMAN AND ANIMAL REQUIREMENTS OF INOSITOL

The importance of inositol in human and animal nutrition has not been established with the same degree of certainty as with other members of the vitamin B complex. It many ways inositol exhibits

## INOSITOL

anomalous behaviour, although not perhaps to the same extent as choline (page 582). As already pointed out (page 564), it exists in foodstuffs in far larger amounts than do other members of the vitamin B complex, and cases of inositol deficiency in man have never been recorded.

R J Williams<sup>1</sup> has estimated that humans require about 1 g of inositol per day per 2500 cal of diet compared with only about 1 mg per day of aneurine or riboflavine.

### *Reference to Section 9*

- 1 R J Williams, *J Amer Med Assoc*, 1942, 119, 1

## 10. METABOLISM OF INOSITOL

The inositol concentration of normal human blood plasma ranged from 0.37 to 0.76 mg per 100 ml. The daily ingestion of 1.5 g of inositol generally produced a moderate rise<sup>1</sup>.

Under normal conditions, human subjects excreted 0.626 mg of inositol per hour in the urine and 0.027 mg per hour in the sweat<sup>2</sup>. The average inositol content of human sweat was 21 µg per 100 ml and the value did not increase significantly after administration of 50 mg of inositol per day. In a hot, moist atmosphere, the average amount of inositol excreted in the sweat during eight hourly periods was 0.118 mg per hour. The corresponding amount excreted in the urine during twenty-four hours was 0.494 mg per hour.

When a solution containing 250 mg of inositol was given orally to rats, about twenty-four hours were required for complete absorption. No increase in the liver glycogen occurred, although less than 1 % of the dose was excreted in the urine. Fasting did not affect the inositol content of the blood, liver, testis and heart of rats, and the oral administration of inositol to fasted animals did not increase the amount present in any of the tissues except the heart<sup>3</sup>. At least 7 % of inositol ingested by rats was converted into glucose<sup>4</sup>.

Rat tissues contained amounts of inositol ranging from 21 mg per 100 g in the muscle to 123 mg per 100 g in the kidney, of these amounts, 13 and 88 mg per 100 g were present in the free state<sup>5</sup>. These amounts remained virtually unchanged after administration of inositol confirming earlier observations<sup>6</sup> that the rat can synthesise inositol.

### *References to Section 10*

- 1 S Sonne and H Sobotka *Arch Biochem*, 1947, 14, 93  
2 B C Johnson, H H Mitchell and T S Hamilton *J Biol Chem*, 1945, 161, 357

## NUTRITION OF MICRO ORGANISMS

- 3 V D Wiebelhaus J J Bethell and H A Lardy *Arch Biochem* 1947 13 379
- 4 M R Stetten and D Stetten *ibid* 1946 164, 85
- 5 B S Platt and G E Glock *Biochem J* 1943 37, 709
- 6 J Needham *ibid* 1924 18, 891

## 11 INTESTINAL SYNTHESIS OF INOSITOL

What evidence there is supports the view that inositol is synthesised by the intestinal flora for D W Woolley<sup>1</sup> showed that mice on a diet containing pantothenic acid synthesised inositol and that bacteria isolated from the intestines of animals that had recovered spontaneously from alopecia (page 572) synthesised more inositol than micro organisms from animals that did not recover spontaneously. Furthermore E Nielsen and A Black<sup>2</sup> showed that inositol deficiency could be produced in rats by administration of a sulphonamide

### References to Section 11

- 1 D W Woolley *J Exp Med* 1942 75 277
- 2 E Nielsen and A Black *Proc Soc Exp Biol Med* 1944 55, 14

## 12 INOSITOL IN THE NUTRITION OF MICRO-ORGANISMS

As already pointed out (page 564) *meso* inositol is a constituent of the bios complex and is essential for the growth of *Saccharomyces cerevisiae*<sup>1</sup>. It stimulates the growth of *Nematospora gossypii*<sup>2</sup>, *Rhizopus strombosus*<sup>3</sup>, *Eremothecium ashbyi*<sup>4</sup> and *Trichophyton faviforme*<sup>5</sup> but for most of these organisms it would appear to be a complementary rather than an essential growth factor. It also stimulated the growth of the following yeasts<sup>6</sup> *Candida albicans*, *Kloeckera brevis*, *Mycoderma valida*, *M. vini*, *Pichia belgica*, *Saccharomyces bayanus*, *S. uvarum*, *Saccharomyces ludwigii*, *Schizosaccharomyces pombe*, *Torulopsis stellata*, *Zygosaccharomyces japonicus* and *Z. priorianus*. It was also essential for *Saccharomyces carlsbergensis*, *S. chevalieri*, *S. logos*, *Torula colliculosa* and *Schizosaccharomyces versatilis*<sup>6</sup>.

### References to Section 12

- 1 E V Eastcott *J Phys Chem* 1928 32, 1094
- 2 F Högl and N Fries *Z physiol Chem* 1937 249 9
- 3 W H Schopfer *Compt rend Soc Physique Hist nat Geneve* 1942 59, 107 *Helv Chim Acta* 1944 27, 468
- 4 W H Schopfer *ibid* 1017



## INOSITOL

- 5 P R Burkholder and D Moyer *Bull Torrey Bot Club* 1943 70, 372 P R Burkholder *Amer J Bot* 1943 30, 206 P R Burkholder I McVeigh and D Moyer *J Bact* 1944 48, 385  
6 A S Schultz and L Atkin *Arch Biochem* 1947 14, 369

### 13 INOSITOL IN HIGHER PLANTS

The inositol content of oats wheat barley and maize increased considerably during germination <sup>1</sup>

Soil and natural manures were found to contain inositol as well as aneurine, biotin, pyridoxine and *p* aminobenzoic acid <sup>2</sup>

#### References to Section 13

- 1 P R Burkholder *Science* 1943 97, 562  
2 M A Roulet *Experientia* 1948 4, 149

### 14 INOSITOL REQUIREMENTS OF INSECTS

According to G Fraenkel and M Blewett <sup>1</sup> inositol is of only slight value in the nutrition of *Tribolium confusum* and *Plinus tectus* and of no importance in the nutrition of other beetles investigated. Nevertheless inositol may be of significance in the economy of insects for R E Slade <sup>2</sup> suggested that the potent insecticide lindane (Gammexane) the active component of which is the  $\gamma$ -isomer of 1 2 3 4 5 6 hexachlorocyclohexane may be due to interference with a process involving *meso*-inositol to which of course it bears a formal resemblance. S Kirkwood and P H Phillips <sup>3</sup> did in fact show that the inhibition of yeast by lindane but not of other inhibitory hexachlorocyclohexanes that were without insecticidal properties was reversed by *meso*-inositol and Burton *et al* <sup>4</sup> showed that the growth of *Nematospora gossypii* was retarded by lindane in presence of small but not large amounts of *meso* inositol. The results suggested that other compounds related to *meso* inositol might have an insecticidal action but neither the hexamethyl ether nor the mono acetyl pentamethyl ether of *meso* inositol had more than a slight toxic action on flies <sup>5</sup>

In addition to its toxic action on insects and micro organisms lindane produces mitosis in higher plants. Its mitotic action on *Allium Cepa* was inhibited by *meso*-inositol but not by *d* inositol or D sorbitol <sup>6</sup>. On the other hand so was the mitotic action of colchicine so that the phenomenon can hardly be regarded as an example of a metabolite-anti metabolite relationship. Again W H Schopfer and his colleagues <sup>7</sup> were unable to confirm the existence of an antagonistic action of *meso* inositol towards lindane either with *E*

## ANALOGUES

*ashbyi* or *S. cerevisiae* or with pea roots and it must therefore be concluded that the antagonistic action of inositol towards lindane if it exists at all is not comparable with the anti vitamin activity of such substances as sulphanilamide and pantoyltaurine

### References to Section 14

- 1 G Fraenkel and M Blewett *Nature* 1943 151, 703
- 2 R E Slade *Chem and Ind* 1945 314
- 3 S Kirkwood and P H Phillips *J Biol Chem* 1946 163, 251
- 4 H W Burton S E Jacobs and A Goldstein *Nature* 1946 158, 22
- 5 J C McGowan *J Soc Chem Ind* 1947 66, 446
- 6 E Chargaff R N Stewart and B Magasanik *Science* 1948 108, 556
- 7 W H Schopfer T Posternak and M L Bossi *Schweiz Z Path Bakt* 1947 10, (4) 443 W H Schopfer and M L Bein *Experientia* 1948 4, 147

## 15 ANALOGUES OF INOSITOL









The biological activity of *meso* inositol (I) is not shared by its stereo isomers or by closely related compounds with one or two exceptions. Thus *d* (II) and *l* inositol pinitol and quebrachitol the corresponding monomethyl ethers and quercitol (III) were inactive in counteracting alopecia in mice and as growth factors for yeast but mytilitol (IV) a cyclitol which occurs in mussels exhibited some activity towards both organisms<sup>1</sup>. Scyllitol (V) as well as its homologue mytilitol had some growth promoting action on *Rhizopus sinuatus* and isomytilitol (VI) the methyl homologue of *meso*-inositol, was slightly more active. oxy mytilitol and oxy isomytilitol were inactive<sup>2</sup>. These results indicate that three *cis* hydroxy groups are essential for biological activity.

The growth stimulating action of *meso* inositol on *Rhizopus sinuatus* and *Eremothecium ashbyi* was not shared by  $\alpha$   $\beta$  or  $\gamma$ -cyclohexane-1 2 3 triol<sup>3</sup>. Three diastereoisomeric inosamines monoamino analogues of inositol were prepared<sup>4</sup> but their biological activity has not been recorded.

Phytin the calcium magnesium hydrogen salt of inositol phosphoric ester (page 570) cured alopecia in mice at a level of 100 mg per 100 g of diet being about one-tenth as active as inositol itself but it was inactive as a growth factor for yeast<sup>5</sup>. Inositol hexa acetate was active on mice but inactive on yeast whilst quinic acid (VII) and inosose (VIII) were inactive on yeast and had an uncertain effect in

# INOSITOL

mice. Inositol mono- and tetra-phosphoric esters had 5 and 2 % of the potency of inositol for yeast <sup>5</sup>



When the six hydroxyl groups of inositol were replaced by chlorine atoms to give hexachlorocyclohexane, the well-known insecticide, lindane (page 578), the growth-promoting activity of the molecule was lost completely and replaced by growth-inhibitory activity, the chloro-compound inhibited the growth of both yeast <sup>6</sup> and fungi <sup>7</sup>

## References to Section 15

- 1 D W Woolley, *J Biol Chem*, 1941, 140, 461
- 2 W H Schopfer *Helv Chim Acta*, 1944, 27, 468
- 3 T Posternak and F Ravenna, *Helv Chim. Acta*, 1947, 30, 441.

- 4 H E Carter R H Clarke B Lytle and G E McCasland *J Biol Chem* 1948 175 683
- 5 D W Woolley *Science* 1940 82 384 *J Biol Chem* 1940 138, 113 1941 139 29 *J Nutrition* 1941 21 Suppl 17
- 6 S Kirkwood and P H Phillips *J Biol Chem* 1946 163 251
- 7 H W Burton S E Jacobs and A Goldstein *Nature* 1946 158, 22

## 16 FUNCTION OF INOSITOL

Nothing is yet known with certainty concerning the function of inositol. According to R J Williams *et al* <sup>1</sup> the amount of inositol in pancreatic amylase (4 mg per g) is sufficient to suggest that it may be an integral part of the enzyme even if the molecular weight is no more than 44 000. The suggestion was strengthened by the observation that lindane inhibited the action of pancreatic  $\alpha$  amylase and the inhibition was competitively prevented by inositol <sup>2</sup>.

A J Rosenberg <sup>3</sup> observed that the growth of *Clostridium saccharo butyricum* was inhibited by malonate and that the inhibition was counteracted by boron and *meso*-inositol. *d* and *l* inositol and quercitol were inactive. He therefore suggested that malonate inhibited the synthesis by the organism of the *meso* inositol necessary for growth.

It is quite possible that inositol may not be a prosthetic group of an enzyme as most other members of the vitamin B complex have proved to be but merely a structural component of living tissue. In this event inositol (and also choline) are anomalous members of the vitamin B complex possibly serving as a link between the vitamins which act as metabolic catalysts and the amino acids which are essential in the building up of animal and plant tissues.

### References to Section 16

- 1 R J Williams F Schlenk and M A Eppright *J Amer Chem Soc* 1944 66 896
- 2 R L Lane and R J Williams *Arch Biochem* 1948 19 329
- 3 A J Rosenberg *Compt rend* 1946 222 1310

## 1 INTRODUCTION

CHOLINE has been known since 1862 when it was discovered by A Strecker<sup>1</sup> in bile. Its inclusion in the vitamin B complex requires even more justification than the inclusion of inositol for it differs markedly from the other members of the complex.

In 1924 N T Fisher<sup>2</sup> and Allan *et al*<sup>3</sup> independently discovered that depancreatized dogs maintained on insulin developed large fatty livers the formation of which was prevented by feeding fresh beef pancreas. a few years later J M Hershey<sup>4</sup> found that egg yolk lecithin also prevented fatty liver formation. In 1934 C H Best<sup>5</sup> and M E Huntsman<sup>6</sup> showed that the accumulation of fatty acid in the livers of rats maintained on a diet containing 40 % of beef fat was prevented by the inclusion of choline or betaine in the diet and in the following year, C H Best and J H Ridout<sup>7</sup> showed that choline or betaine likewise prevented the deposition of fat in the liver resulting from the feeding of cholesterol. Best *et al*<sup>7</sup> concluded that since fatty liver formation caused by feeding fat was due to an increase in the neutral fat fraction and that caused by cholesterol was due to the formation of cholesteryl esters choline and betaine were concerned with the metabolism of both fat and cholesterol. Choline was also found to prevent the formation of fatty livers due to the feeding of sucrose<sup>8</sup>. Thus choline accelerated the removal of fat from rats liver under a variety of dietetic conditions whilst the amount of choline in the diet was an important factor in determining the level of fat in the liver.

Thus superficially at all events choline appeared to possess the essential characteristics of a vitamin in being necessary for the well being of an experimental animal and having to be supplied pre formed in the diet. In its absence characteristic deficiency symptoms appeared and these were cured by administration of choline.

The suggestion that choline should be regarded as a member of the vitamin B complex was made independently by B Sure<sup>9</sup> and P Gyorgy and H Goldblatt<sup>10</sup> in 1940. The former showed that it

was essential for the growth and lactation of rats and the latter confirmed the observations of previous workers that rats fed a diet low in choline even though supplemented by aneurine and riboflavine developed fatty infiltration of the liver. The addition of pyridoxine resulted in the formation of necrotic renal lesions similar to those encountered in cystine intoxication. The severity of the lesions was reduced by substituting egg white for sucrose in the diet. This increased the methionine-cystine ratio which had already been shown<sup>11, 12</sup> to affect fatty liver formation, an excess of cystine favouring and an excess of methionine preventing fatty livers. Administration of choline prevented the renal changes and also sometimes exerted a lipotropic effect.

Shortly afterwards choline was shown<sup>13</sup> to be essential for growth and prevention of perosis in growing chicks although choline-deficient chicks had not developed fatty livers at four weeks of age and bone phosphatase values were normal in chicks suffering from perosis due to choline deficiency.

The formation of renal lesions in young rats on a choline deficient diet was confirmed by W. H. Griffith and D. J. Mulford<sup>14</sup> who showed that the non-protein nitrogen of the blood was also increased. The possibility of survival and renal repair depended on the severity of the lesions. Most members of the vitamin B complex were without effect on the severity of the symptoms but nicotinic acid had a slight beneficial effect.

In spite of the strong resemblance between the behaviour of choline and that of other vitamins in animals there has been considerable hesitation about accepting choline as a vitamin. One difficulty is that it occurs in the body in such large amounts compared with other members of the vitamin B complex (with the possible exception of inositol, page 564) as to suggest that it is a structural component of the body rather than a metabolic catalyst. Moreover relatively enormous amounts are normally ingested by animals and humans, the daily requirement being estimated at 35 to 100 mg per kg of bodyweight for different species of animals (page 594) compared with a daily requirement of only 15 to 30  $\mu$ g per kg of bodyweight per day of aneurine or riboflavine.

The demand for choline exceeds even that of inositol (page 576) and is actually of the same order as the requirement for certain amino acids. Inositol and choline may usefully be considered as links connecting the vitamin B complex proper with the amino acids, inositol being more closely related to the vitamin B complex and choline to the amino acids.

Another possible argument against the inclusion of choline in the vitamin B complex is that it has never been shown to be associated

## CHOLINE

## I. INTRODUCTION

CHOLINE has been known since 1862 when it was discovered by A Strecker<sup>1</sup> in bile. Its inclusion in the vitamin B complex requires even more justification than the inclusion of inositol, for it differs markedly from the other members of the complex.

In 1924 N F Fisher<sup>2</sup> and Allan *et al*<sup>3</sup> independently discovered that depancreatized dogs maintained on insulin developed large fatty livers the formation of which was prevented by feeding fresh beef pancreas. A few years later, J M Hershey<sup>4</sup> found that egg yolk lecithin also prevented fatty liver formation. In 1932 C H Best and M E Huntsman<sup>5</sup> showed that the accumulation of fatty acids in the livers of rats maintained on a diet containing 40 % of beef fat was prevented by the inclusion of choline or betaine in the diet and in the following year, C H Best and J H Ridout<sup>6</sup> showed that choline or betaine likewise prevented the deposition of fat in the liver resulting from the feeding of cholesterol. Best *et al*<sup>7</sup> concluded that since fatty liver formation caused by feeding fat was due to an increase in the neutral fat fraction and that caused by cholesterol was due to the formation of cholesteryl esters, choline and betaine were concerned with the metabolism of both fat and cholesterol. Choline was also found to prevent the formation of fatty livers due to the feeding of sucrose<sup>8</sup>. Thus choline accelerated the removal of fat from rat's liver under a variety of dietetic conditions, whilst the amount of choline in the diet was an important factor in determining the level of fat in the liver.

Thus superficially at all events choline appeared to possess the essential characteristics of a vitamin in being necessary for the well being of the animal.

The suggestion that choline should be regarded as a member of the vitamin B complex was made independently by B Sure<sup>9</sup> and P Gyorgy and H Goldblatt<sup>10</sup> in 1940. The former showed that it

was essential for the growth and lactation of rats and the latter confirmed the observations of previous workers that rats fed a diet low in choline even though supplemented by aneurine and riboflavin developed fatty infiltration of the liver. The addition of pyridoxine resulted in the formation of necrotic renal lesions similar to those encountered in cystine intoxication. The severity of the lesions was reduced by substituting egg white for sucrose in the diet. This increased the methionine-cystine ratio which had already been shown<sup>11, 12</sup> to affect fatty liver formation, an excess of cystine favouring and an excess of methionine preventing fatty livers. Administration of choline prevented the renal changes and also sometimes exerted a lipotropic effect.

Shortly afterwards choline was shown<sup>13</sup> to be essential for growth and prevention of perosis in growing chicks although choline-deficient chicks had not developed fatty livers at four weeks of age and bone phosphatase values were normal in chicks suffering from perosis due to choline deficiency.

The formation of renal lesions in young rats on a choline deficient diet was confirmed by W. H. Griffith and D. J. Mulford<sup>14</sup> who showed that the non-protein nitrogen of the blood was also increased. The possibility of survival and renal repair depended on the severity of the lesions. Most members of the vitamin B complex were without effect on the severity of the symptoms but nicotinic acid had a slight beneficial effect.

In spite of the strong resemblance between the behaviour of choline and that of other vitamins in animals there has been considerable hesitation about accepting choline as a vitamin. One difficulty is that it occurs in the body in such large amounts compared with other members of the vitamin B complex (with the possible exception of inositol, page 564) as to suggest that it is a structural component of the body rather than a metabolic catalyst. Moreover relatively enormous amounts are normally ingested by animals and humans, the daily requirement being estimated at 35 to 100 mg per kg of bodyweight for different species of animals (page 594) compared with a daily requirement of only 15 to 30  $\mu$ g per kg of bodyweight per day of aneurine or riboflavin.

The demand for choline exceeds even that of inositol (page 576) and is actually of the same order as the requirement for certain amino acids. Inositol and choline may usefully be considered as links connecting the vitamin B complex proper with the amino acids, inositol being more closely related to the vitamin B complex and choline to the amino acids.

Another possible argument against the inclusion of choline in the vitamin B complex is that it has never been shown to be associated



in man with a specific deficiency disease this being frequently regarded as one of the essential criteria of a vitamin. This argument is not a very strong one however for as has already been pointed out several other substances that are undoubtedly vitamins are not associated with characteristic deficiency diseases in man. Actually, the existence of a deficiency disease in Nature is largely fortuitous due first to the existence of a foodstuff which either does not contain a substance essential for human nutrition or from which such a substance has been removed in some way and secondly the use of that foodstuff as a staple or at least as a major article of diet. Clearly the accidental combination of these two factors would be less likely to occur with substances such as choline or inositol or for that matter amino acids which are present in virtually all foodstuffs and which are required in relatively large amounts. In such instances there is such a wide margin between the amount normally present in foodstuffs and the minimum amount necessary to support life that the worst that can happen is a mild and often temporary deficiency state leading to vague symptoms of ill health. Acute symptoms would only be observed in human volunteers maintained on diets from which the factor had been deliberately and more or less completely removed.

Another serious objection to the inclusion of choline in the vitamin B complex is its inability to stimulate the growth of micro organisms with one or two exceptions (page 596). It can hardly be regarded as a member of the bios complex and in this respect differs sharply from inositol which it resembles in other ways.

#### References to Section 1

- 1 A Strecker *Annalen* 1862 **123**, 353
- 2 N F Fisher *Amer J Physiol* 1924 **67**, 634
- 3 F N Allan D J Bowie J J R Macleod and W L Robinson  
*Brit J Exp Path* 1924 **5**, 75
- 4 J M Hershey *Amer J Physiol* 1930 **93**, 657
- 5 C H Best and M E Huntsman *J Physiol* 1932 **75**, 405
- 6 C H Best and J H Ridout *ibid* 1933 **78**, 415
- 7 C H Best H J Channon and J H Ridout *ibid* 1934 **81**,  
409
- 8 C H Best and M E Huntsman *ibid* 1935 **83**, 255
- 9 B Sure *J Nutrition* 1940 **19**, 71
- 10 P Gyorgy and H Goldblatt *J Exp Med* 1940 **72**, 1
- 11 V du Vigneaud *J Biol Chem* 1939 **131**, 57
- 12 W H Griffith and N J Wade *ibid* 567
- 13 D M Hegsted R C Mills C A Elvehjem and E B Hart *ibid*  
1941 **138**, 459
- 14 W H Griffith and D J Mulford *J Nutrition* 1941 **21**, 633

## 2 ISOLATION, CHEMICAL CONSTITUTION AND SYNTHESIS OF CHOLINE


### Isolation

Choline was discovered in 1862 by A. Strecker<sup>1</sup> who isolated it from the bile of cattle and pigs. It has also been isolated from a large variety of fungi and flowering plants especially from the seeds of the latter. In animals it is a constituent of phospholipids e.g. brain and egg yolk lecithin and sphingomyelin and of acetylcholine the mediator of nerve impulse transmission.

Choline was isolated from egg yolk by the following method<sup>2</sup>. The yolks were extracted with ether and the insoluble residue was extracted with hot alcohol. The combined extracts were evaporated to dryness and the residue was heated with methanolic barium hydroxide solution. After removal of the excess baryta with carbon dioxide the filtrate was evaporated and the residue taken up in water and filtered. The filtrate was again evaporated and the residue taken up in alcohol, filtered and the filtrate treated with mercuric chloride solution. The precipitate that formed was filtered off and dissolved in hot water and hydrogen sulphide was passed into the solution. The mercury sulphide precipitate was filtered off and the filtrate evaporated. Dilute hydrochloric acid was added to the residue and the solution was again evaporated. The residue was taken up in alcohol, the solution diluted with water and the choline precipitated with alcoholic cadmium chloride solution.

### Constitution and Synthesis

Choline was shown to be  $\beta$  hydroxyethyl trimethyl ammonium hydroxide



by A. Baeyer<sup>3</sup> and A. Wurtz<sup>4</sup>. It was first synthesised by the action of trimethylamine on  $\beta$ -chloroethyl alcohol or ethylene oxide<sup>4</sup> but it has also been prepared by heating  $\beta$  bromoethyl trimethyl ammonium bromide in aqueous solution at 160° C.<sup>5</sup> or in alcoholic potassium hydroxide solution at 120° C.<sup>6</sup> It is more conveniently made however by hydrolysis of lecithin with acid<sup>7</sup> or alkali<sup>8</sup>.

### References to Section 2

- 1 A. Strecker *Annalen* 1862 **123** 353
- 2 F. W. Schmidt *Z. physiol. Chem.* 1907 **53**, 428
- 3 A. Baeyer *Annalen* 1866 **140**, 306 1867 **142** 322
- 4 A. Wurtz *ibid.* 1868 *Suppl.* 6 116 197

- 5 M Kruger and P Bergell *Ber* 1903 **38**, 2901
- 6 R Lucius *Arch Pharm* 1907, **245**, 246
- 7 G Moruzzi, *Z physiol Chem*, 1908 **55**, 352
- 8 H MacLean *ibid*, 360

### 3. PROPERTIES OF CHOLINE

Choline is a strong base, which can be crystallised only with great difficulty. It is hygroscopic and very soluble in water and absolute alcohol, but insoluble in ether. It is generally made available as the chloride, which forms colourless needles of no definite m.p.

Choline chloride forms double salts with gold chloride, mercuric chloride, and platonic chloride, and these can be used for the characterisation of choline, although their melting-points vary with the rate of heating. Thus, W Gulewitsch<sup>1</sup> recorded m.p.s. of 241 to 243° C, 249 to 251° C and 213 to 216° C respectively, whilst M Krüger and P Bergell<sup>2</sup> obtained values of 233 to 234° C and 245 to 246° C for the m.p.s. of the platonic chloride and gold chloride double salts.

#### *References to Section 3*

- 1 W Gulewitsch *Z physiol Chem*, 1898 **24**, 513
- 2 M Kruger and P Bergell, *Ber* 1903 **38**, 2901

### 4. ESTIMATION OF CHOLINE

#### Chemical Estimation

All the chemical methods now in use for the estimation of choline depend on the precipitation of the sparingly soluble reineckate. This was first used by F. J. R. Beattie,<sup>1</sup> who dissolved the reineckate in acetone and measured the colour of the solution, this was proportional to the amount of choline originally present. A. D. Marenzi and C. E. Cardini<sup>2</sup> also estimated choline by precipitation of the reineckate but estimated the amount of chromium in the precipitate by means of Cazeneuve's reagent<sup>3</sup> (diphenylcarbazide), evaluating the colour so formed in a photometer. Beattie's method was used, with slight modifications, for the estimation of choline in foodstuffs by Jacob *et al*,<sup>4</sup> R. W. Engel<sup>5</sup> and D. Glick,<sup>6</sup> all of whom precipitated the reineckate from acid solution. Entenman *et al*<sup>7</sup> used almost exactly the same method but precipitated the reineckate from alkaline solution. The two methods gave similar results when applied to alcohol ether extracts of plasma, but Glick's method gave lower results than that of Entenman *et al* when applied to alcohol ether extracts of liver.<sup>8</sup> The use of the cadmium chloride complex has also been suggested for the estimation of choline.<sup>8a</sup>

## Microbiological Assays

For the microbiological assay of choline, the so-called *cholineless* strain of *Neurospora crassa* has been used. This was obtained by N H Horowitz and G W Beadle<sup>9</sup> by irradiation of *N. crassa* with ultra violet light. It was used by R W Luecke and P B Pearson<sup>10</sup> for the estimation of choline in blood, urine and animal tissues. An improved medium was described by A Z Hodson<sup>11</sup>.

## References to Section 4

- 1 F J R Beattie, *Biochem J*, 1936 30, 1554
- 2 A D Marenzi and C E Cardini *Rev Soc argent Biol*, 1942, 18, 265
- 3 P Cazeneuve *Compt rend*, 1900 131, 346
- 4 H P Jacob, C A Baumann and W J Meek *J Biol Chem*, 1941, 138, 571
- 5 R W Engel *ibid* 1942, 144, 701
- 6 D Glick *ibid*, 1944 156, 643
- 7 C Entenman, A Taurog and I L Chaikoff *ibid* 1944 155, 13
- 8 C Entenman and I L Chaikoff *ibid* 1945 160, 377
- 8a W Seaman, J J. Hugonet and W Leibmann, *Anal Chem*, 1949 21, 411
- 9 N H Horowitz and G W Beadle *J Biol Chem* 1943 150, 325
- 10 R W Luecke and P B Pearson *ibid* 1944 153, 259, 1944 155, 507
- 11 A Z Hodson *ibid* 1945 157, 383

## 5 OCCURRENCE OF CHOLINE IN FOODSTUFFS

Very complete information is available concerning the choline content of foodstuffs. Cereals and cereal products contain up to 1 mg per g and meat and fish up to 5 or 6 mg per g, so that as has already been remarked (page 584) choline is present in these foodstuffs in much larger amounts than other members of the vitamin B complex. The only foodstuffs completely devoid of choline are fruits, whilst vegetables with the exception of legumes, generally contain much less than do cereals and animal products.

## Cereals

The following values were obtained by R W Engel<sup>1</sup> for the choline content of cereals: wheat, 0.92, wheat bran 1.43, wheat germ 4.1, oats 0.94, rolled oats 1.51, barley, 1.39, polished rice, 0.88, rice polishings, 1.26, yellow corn, 0.37, corn meal, 0.42, white flour 0.52 and molasses (blackstrap), 0.86 mg per g of fresh weight. D Glick<sup>2</sup> obtained the following values: hard spring wheat, 0.71 to

107, hard winter wheat, 0.58 to 0.96, soft winter wheat, 0.74 to 1.01, oats, 1.01 to 1.29 and barley, 0.96 to 1.20 mg per g, whilst Willstaedt *et al*<sup>3</sup> obtained results of the same order, namely white bread, 0.625, black bread, 0.565, wheat grits, 0.75, oatmeal, 1.03, and rice, 1.07 mg per g

The choline contents of flours of different degrees of extraction and of offals ran parallel to the lipin phosphorus and lecithin contents. Commercial bleaching had no effect on the choline content of cereals<sup>2</sup>

## Vegetables

R.W. Engel<sup>1</sup> found the following amounts of choline in vegetables: snapbeans, 3.40, soya beans, 3.00, peas, 2.63, cowpeas, 2.57, asparagus, 1.28, cabbage, 2.51 and spinach, 2.38 mg per g of sun-dried material. Potatoes contained 1.06, carrots, 0.95, turnips 0.94 and sweet potatoes, 0.35 mg per g of fresh material. Some what different values were obtained by Willstaedt *et al*<sup>3</sup> who found in Brussels sprouts, 1.03, leek, 0.095, carrots, 0.04, spinach 0.38, lettuce, 0.03, potato, nil, beetroot, nil, parsley, 0.16, celery, 0.17, parsnip, 0.41, horse radish 0.48, onion, nil, tomato, nil, peas 0.55, peas (dried), 1.88, and beans (dried), 1.81 mg per g. D. Gluck<sup>2</sup> found soya beans to contain 2.37 mg per g. Leguminous vegetables therefore contained appreciably more choline than did most other vegetables.

## Fruits

According to Willstaedt *et al*<sup>3</sup> apples, plums, melons and raisins contained no choline.

## Meat

Meat is one of the richest sources of choline, and the following values were obtained by R.W. Engel<sup>1</sup>: pig liver, 5.52, pig kidneys, 4.56, 3.17, pig heart, 2.31, ham, 0.88, pork chops, 0.77, lamb kidney, 3.60, lamb shoulder, 1.19, lamb chops, 1.07, beef liver, 6.30, beef kidney, 3.33, beef roundsteak 0.95, beef rib roast 0.82, chicken liver, 3.42, and chicken kidney, 2.23 mg per g of fresh tissue.

According to McIntire *et al*<sup>4</sup> the muscle tissue of veal, lamb, pork and beef contained 0.7 to 1.4 mg of choline per g and the kidney, liver and heart appreciably larger amounts—up to 5 mg per g. No appreciable loss of choline occurred on cooking or curing meat. Somewhat similar values were obtained by Willstaedt *et al*,<sup>3</sup> namely: calf liver, 6.50, ox liver, 4.85, and pig kidneys, 3.31 mg per g.

**Fish**

Fresh salmon contained 1.81 cod 2.00 and herring 1.27 mg of choline per g<sup>3</sup> whilst trout muscle contained 0.87 and fish meal 3.29 mg per g<sup>1</sup>

**Miscellaneous**

Fresh milk contained 0.147 mg per ml and dried skim milk powder and dried whole milk powder 1.59 and 1.07 mg per g respectively<sup>1</sup>. According to R. W. Engel<sup>1</sup> butter contained no choline but Willstaedt *et al.*<sup>2</sup> found 0.40 mg per g. Cheese contained 0.48<sup>1</sup> and 0.56<sup>3</sup> mg per g. Egg white contained negligible amounts of choline but the yolk contained 17.13 mg per g<sup>1</sup>.

Several different species of edible fungi contained amounts of choline ranging from 0.2 to 0.7 mg per g<sup>3</sup>.

*References to Section 5*

- 1 R. W. Engel *J. Nutrition* 1943 25, 441
- 2 D. Gluck *Cereal Chem.* 1945 22, 95
- 3 H. Willstaedt, M. Borggard and H. Lieck *Z. Vitaminforsch.* 1946 18, 25
- 4 J. M. McIntire, B. S. Schweigert and C. A. Elvehjem *J. Nutrition* 1944 28, 219

**6 EFFECT OF CHOLINE DEFICIENCY IN ANIMALS**

Brief reference has already been made (page 582) to the association of choline deficiency with fatty liver formation in rats and with perosis in chicks and to the fact that methionine and betaine have biological properties similar to those of choline. The reason for the close resemblance between choline, betaine and methionine is discussed subsequently (page 598).

**Rats**

The symptoms of choline deficiency in the rat were fully described by J. M. Patterson and E. W. McHenry<sup>1</sup>. The animals showed loss of weight, paralysis of the hind limbs, loss of hair and a hunched posture. The kidneys were enlarged and haemorrhagic whilst the livers were slightly larger than those of animals fed adequate amounts of choline and showed fatty infiltration. The kidneys contained less phospholipins than normal. The renal haemorrhages were prevented by choline, an observation confirmed by R. W. Engel<sup>2</sup> who at the same time noted that the liver fat did not return to normal until

inositol was added to the diet. Diets deficient in pyridoxine or essential fatty acids produced fatty livers even when supplied with adequate amounts of choline. The addition of choline to the diet reduced the incidence of lesions in the fore-stomach of rats receiving cystine and white flour.<sup>3</sup> The cirrhosis produced in rats by feeding a choline deficient diet was prevented by hypothyroidism induced either by thyroidectomy or by feeding thiouracil, *p* aminobenzoic acid or sulphonamides.<sup>4</sup>

Other symptoms produced by choline deficiency in rats were anaemia,<sup>5</sup> hypertension,<sup>6</sup> enlargement of the adrenal cortex and atrophy of the thymus.<sup>7</sup>

### Chicks

According to T. H. Jukes,<sup>8</sup> the perosis that developed in chicks maintained on a purified diet was cured by choline when manganese was present, but L. R. Richardson and A. G. Hogan<sup>9</sup> found that the perosis was not cured by choline and manganese alone, requiring in addition an aqueous extract of liver or the eluate from a fuller's earth adsorbate of liver. Methionine did not cure the perosis.<sup>8</sup>

According to D. S. McKittick,<sup>10</sup> the choline required by chicks may be divided into two parts. One part, the essential choline, is used in tissue formation, and the other part, the replaceable choline, in transmethylation (page 600).

### Turkeys

Turkeys, like chicks, developed perosis on a choline deficient diet. The symptoms were cured by choline, but not by betaine.<sup>11, 12</sup>

### Dogs

A choline-deficient diet, devised by McKibbin *et al*,<sup>13</sup> proved fatal to pups in three weeks. The animals showed fatty infiltration of the liver, an increase in the plasma phosphatase, impaired bromosulphonaphthalein elimination and a fall in the plasma cholesterol and cholesterol esters. In very severe cases, the prothrombin time was also increased, the blood haemoglobin was decreased and the haematocrit and plasma proteins were reduced. The total cholesterol content of the liver was unchanged, but the total lipins increased 3- to 4 fold. The ratio, liver weight/body weight, was not correlated with the choline content of the diet, but the morphological changes in the liver were correlated with the impairment of liver function.<sup>14</sup> The kidneys were not morphologically abnormal, and the only tissue affected besides the liver was the thymus, which showed atrophic changes. The addition of choline to the diet of choline-deficient pups

resulted in a rapid increase in food consumption and weight, an improvement in liver function and the withdrawal of lipin from the liver,<sup>15</sup> liver function was restored to normal within five to ten days.

Choline chloride cured fat embolism produced in dogs by bone marrow curettage<sup>16</sup> The action of the pancreatic extract known as lipocac,<sup>17</sup> which prevented fatty infiltration of the liver in depancreatized dogs, was shown to be due to its choline content<sup>18</sup>

### Other Animals

Fatty infiltration of the liver is not a symptom of choline deficiency in guinea pigs, which appear to lack hepatic choline oxidase activity<sup>19</sup> Hamsters develop fatty livers on a choline deficient diet, but not to the same degree as rats<sup>20</sup> Pigs also develop fatty livers, gain weight more slowly than normal animals, display inco-ordination and a lack of rigidity at the joints and suffer from renal glomerular occlusion and some tubular epithelial necrosis<sup>21</sup>

### Fish

Choline was essential for young rainbow trout, the fish developing haemorrhagic kidneys and intestines in its absence, these symptoms were prevented by 5 to 10 mg of choline per 100 g of diet<sup>22</sup>

### Lipotropic Action of Choline and Inositol

The lipotropic action of choline and inositol together was greater than that of either alone<sup>23</sup> Moreover, choline brought about a greater reduction in the cholesteryl ester content of the liver than did inositol<sup>24</sup> According to Gavin *et al*<sup>25</sup> choline was effective in the treatment of fatty livers due to aneurine and partially effective for cholesterol fatty livers but it had little effect on biotin fatty livers, whereas inositol was effective in the treatment of biotin fatty livers, but not of aneurine fatty livers According to Best *et al*,<sup>26</sup> however, there is no evidence for assuming that biotin fatty livers are unique or that inositol is more effective than choline in their treatment, they suggested that Gavin *et al* overlooked the fact that the beef liver fraction used by them to produce fatty livers contained choline, so that the response to treatment was due to the combined effect of choline and inositol and not to inositol alone as they apparently assumed Best *et al* furthermore showed that inositol had no preferential effect in reducing the amount of cholesteryl esters or glycerides in the liver, on the contrary, it was less effective than choline in this respect, and it did not prevent, as did choline or methionine, the occurrence of haemorrhagic kidneys They confirmed the synergistic effect of choline and inositol on liver lipins Neither had any



effect on the absolute amount of phospholipin or free cholesterol in the liver nor on kidney lipids

### Choline and Cancer

The choline content of transplanted epidermal carcinoma in mice was two and a half times that of the normal epidermis but methyl cholanthrene treated epidermis contained only the normal amounts<sup>27</sup>

#### References to Section 6

- 1 J M Patterson and E W McHenry *J Biol Chem* 1942 **145**, 207
- 2 R W Engel *J Nutrition* 1942 **24**, 175
- 3 G A Sharpless and M Sabol *ibid* 1943 **25**, 113
- 4 P Handler *J Biol Chem* 1948 **173**, 295
- 5 R W Engel *J Nutrition* 1948 **36** 739
- 6 W S Hartcroft and C H Best *Brit Med J* 1949 **1** 423
- 7 R E Olson and H W Deane *J Nutrition* 1949 **39** 31
- 8 T H Jukes *J Nutrition* 1941 **21**, Suppl 13 1941 **22**, 315
- 9 L R Richardson and A G Hogan *Proc Soc Exp Biol Med* 1941 **48**, 459
- 10 D S McKittrick *Arch Biochem* 1948 **18** 437
- 11 T H Jukes *J Nutrition* 1940 **20**, 445
- 12 M Rhuan R J Evans and J L St John *ibid* 1943 **25**, 1
- 13 J M McKibbin S Thayer and F J Stare *J Lab Clin Med* 1944 **29**, 1109
- 14 F R Dutra and J M McKibbin *ibid* 1945 **30**, 301
- 15 J M McKibbin R M Ferry S Thayer E G Patterson and F J Stare *ibid* 422
- 16 E M Monson and C Dennis *Proc Soc Exp Biol Med* 1949 **70** 330
- 17 J van Prohaska L R Dragstedt and H P Harms *Amer J Physiol* 1936 **117** 166 175
- 18 A N Wick *Arch Biochem* 1949 **20** 113
- 19 P Handler *Proc Soc Exp Biol Med* 1949 **70** 70
- 20 P Handler and F Bernheim *ibid* 1949 **72**, 569
- 21 B C Johnson and M F James *J Nutrition* 1948 **36** 339  
A L Neumann J L Krider M F James and B C Johnson  
*ibid* 1949 **38** 195
- 22 B A McLaren E F Herman and C A Elvehjem *Arch Biochem* 1946 **10**, 433 B A McLaren E Keller D J O Donnell and C A Elvehjem *ibid* 1947 **15**, 169
- 23 J C Forbes *Proc Soc Exp Biol Med* 1943 **54**, 89
- 24 J M R Beveridge and C C Lucas *J Biol Chem* 1945 **157**, 311
- 25 G Gavin J M Patterson and E W McHenry *ibid* 1943 **148** 275
- 26 C H Best C C Lucas J M Patterson and J H Ridout *Science* 1946 **103**, 12 *Biochem J* 1946 **40**, 368 J H Ridout C C Lucas J M Patterson and C H Best *ibid* 494

- 27 E L Tatum M G Ritchey E V Cowdry and L F Wicks *J Biol Chem* 1946 **163**, 675 M G Ritchey L F Wicks and E L Tatum *ibid* 1947 **171**, 51

## 7 EFFECT OF CHOLINE DEFICIENCY IN MAN

There appears to be no case on record of choline deficiency in man but since choline exhibited such a marked lipotropic action in animals it is not surprising that it should have been tried out in the treatment of acute and chronic diseases of the liver in man. Several therapeutic trials of choline in hepatic cirrhosis have been made but as none of the experiments was adequately controlled they do not provide a conclusive answer to the question of how far choline deficiency is responsible for this condition. G O Broun and R O Muether<sup>1</sup> treated four cases with 1 g of choline chloride daily for up to two years whilst A H Russakoff and H Blumberg<sup>2</sup> gave up to 6 g per day to six cases with ill effects in only one case. J S Richardson<sup>3</sup> gave 1.5 g of choline chloride per day for eight days to sixteen patients with infective hepatitis but the treatment was ineffective.

Moosnick *et al*<sup>4</sup> reported that a refractory case of pernicious anaemia was cured by the intravenous injection of 1 g of choline chloride daily and suggested that fatty infiltration of the liver had prevented the formation of the liver principle and that when the infiltration was removed by the choline the ability of the liver to produce the anti-pernicious anaemia principle was restored.

### References to Section 7

- 1 G O Broun and R O Muether *J Amer Med Assoc* 1942 **118**, 1403
- 2 A H Russakoff and H Blumberg *Ann Int Med* 1944 **21**, 848
- 3 J S Richardson *Brit Med J* 1945 **2**, 156
- 4 F B Moosnick E M Schleicher and W E Peterson *J Clin Invest* 1945 **24**, 278

## 8 METABOLISM OF CHOLINE

Very little choline is excreted in the urine or faeces. Thus after administration of 40 g of the chloride per day for six days to sheep only 0.7 to 2.5 % of the ingested choline was recovered from the urine. There was no accumulation of choline in the liver, kidney or plasma<sup>1</sup>. Similarly dogs fed 5 g of choline chloride per day for six days excreted only 0.5 % in the urine and there was no increase in the plasma concentration.

The total choline excreted by humans in the faeces, urine and

sweat was only 0.7 to 1.5 % of the intake (624 to 899 mg) and most of this was recovered from the urine.<sup>2</sup> A change in the temperature and relative humidity did not affect the total amount excreted, but more appeared in the sweat.

The concentration of choline in the plasma was reduced in depancreatized dogs maintained on insulin, and the fall was associated with the development of fatty livers.<sup>3</sup> The fall in the plasma choline could be prevented by a fraction prepared from pancreas, and this also prevented fatty formation in depancreatized dogs, it did not contain choline. The average choline content of human serum was lowest in July—five times as much was present in February and March.<sup>4</sup>

#### References to Section 8

- 1 R W Luecke and P B Pearson *J. Biol. Chem.*, 1945 **158**, 561
- 2 B C Johnson T S Hamilton and H H Mitchell *ibid.*, 1945 **159**, 5
- 3 I L Chaikoff C Entenman and M L Montgomery, *ibid.* 1945 **160**, 387
- 4 J A Schlegel, *Proc Soc Exp Biol Med*, 1949 **70**, 695

### 9. HUMAN AND ANIMAL REQUIREMENTS OF CHOLINE

Estimates of the amount of choline chloride required by rats vary considerably. Thus, 10 to 20 mg,<sup>1</sup> 4 to 6 mg,<sup>2</sup> 10 mg,<sup>3</sup> 3 mg<sup>4</sup> and 12 to 15 mg<sup>5</sup> per day are the amounts stated by different groups of workers to be necessary to prevent fatty liver formation. Another group of workers claimed that as much as 20 mg per day were required to prevent rustiness in albino rats,<sup>6</sup> whilst Wistar (albino) rats were said to require only 4 to 6 mg daily compared with 10 mg daily found to be necessary to prevent fatty liver formation in hooded rats of the Wisconsin strain.<sup>7</sup> An average value for the choline requirement of rats could therefore be about 100 mg per day per kg of bodyweight. The amount of choline required increased with the temperature at which animals were kept, from 0.75 g per kg of diet at 68° F to 5 g per kg at 90° F.<sup>8</sup>

According to one group of workers<sup>9</sup> dogs required 50 to 100 mg of choline chloride per 100 g of ration, or 25 to 100 mg per kg of bodyweight per day, whilst C Entenman and I L Chaikoff<sup>10</sup> found the daily requirement to be about 35 mg per kg of bodyweight.

According to O D Abbott and C U de Masters,<sup>11</sup> chicks required about 75 mg per kg of bodyweight.

Willstaedt *et al*<sup>12</sup> estimated the human requirement of choline by assaying the amounts present in a normal diet and found that the daily intake varied from 502 to 1047 mg per day with an average value of 646 mg. According to this calculation therefore humans

require proportionately less choline than animals about 9 mg per kg of bodyweight

As will be seen later (page 600) choline can be replaced to some extent by methionine but the two substances are only partly biologically equivalent. Choline was a more effective supplement than methionine for the rat 3.8 parts of the latter being equivalent to 1 part of the former<sup>5</sup>. The total methionine requirement of rats on a choline free diet was 1.2 g per 100 g of diet half of this was required for growth and half for lipotropic purposes. Methionine did not increase the growth rate further when the diet contained 100 to 200 mg of choline per 100 g<sup>13</sup>. Chicks required 1% of methionine in the diet for optimal growth<sup>14</sup> and young pigs 0.8% of methionine and 0.1% of choline<sup>15</sup>.

#### References to Section 9

- 1 H J Channon J V Loach and G R Tristram *Biochem J* 1938 32, 1322
- 2 W H Griffith *J Nutrition* 1941 22, 239
- 3 R W Engel *ibid* 1942 24 174
- 4 H Pfaltz *Z Vitaminforsch* 1942 22, 193
- 5 G C Supplee L S Gall and J F Caul *J Dairy Sci* 1945 28, 435
- 6 H S Owens M Trautman and E Woods *Science* 1941 93, 406
- 7 D H Copeland *Proc Soc Exp Biol Med* 1944 57, 33
- 8 C A Mills *Arch Biochem* 1942 1, 73 *Proc Soc Exp Biol Med* 1943 54, 265
- 9 A E Schaefer J M McKibbin and C A Elvehjem *ibid* 1941 47, 365 J M McKibbin S Thayer and F J Stare *J Lab Clin Med* 1944 29, 1109 F R Dutra and J M McKibbin *ibid* 1945 30, 301
- 10 C Entenman and I L Chaikoff *J Biol Chem* 1946 138, 477
- 11 O D Abbott and C U de Masters *J Nutrition* 1940 19, 47
- 12 H Willstaedt M Borggard and H Lueck *Z Vitaminforsch* 1946 18, 25
- 13 C R Treadwell *J Biol Chem* 1945 160, 601
- 14 A A Klose and H J Almquist *ibid* 1941 138, 467
- 15 A L Neumann J L Krider M F James and B C Johnson *J Nutrition* 1949 38 195

#### 10 PHARMACOLOGY OF CHOLINE

Choline chloride had a value of LD<sub>50</sub> equal to 3.4 g per kg of bodyweight when given orally to rats in a concentration of 500 to 670 mg per ml and a value of 6.1 g per kg when given in a concentration of 200 to 400 mg per ml<sup>1</sup>. The addition of 1% of choline

chloride to the diet produced no toxic effect in 60 g rats, but 10 % stopped growth and intermediate amounts retarded growth<sup>2</sup>. No pathological changes were observed at autopsy. The addition of 1, 2 and 4 % of choline to the diet reduced the growth rate of chicks by 12, 13.8 and 23.8 % respectively, but no other toxic effects were observed<sup>3</sup>. The administration of 400 mg of choline chloride per kg of bodyweight to dogs with experimentally induced fatty livers for more than three weeks did not produce any adverse effects<sup>4</sup> but, according to J. E. Davis,<sup>5</sup> prolonged administration of choline to dogs caused a fall in the red blood cells. He attributed this to the vasodilator effect of choline and the consequent increased supply of blood and oxygen to the bone marrow, since atropine, which blocks the vasodilator action of choline but not its lipotropic effect, restored the erythrocytes to normal. G. E. Cartwright and M. M. Wintrobe<sup>6</sup> failed to observe any effect of choline on the red blood cells in man.

Choline has a vasodilator effect, but this is very much less marked than that of acetyl choline<sup>7</sup>.

#### References to Section 10

- 1 M. W. Neuman and H. C. Hodge, *Proc Soc Exp Biol Med*, 1945 **58**, 87
- 2 H. C. Hodge *ibid* 212
- 3 V. H. Melass, P. B. Pearson and R. M. Sherwood *ibid*, 1946 **62**, 174
- 4 A. Kaplan and I. L. Chaikoff, *J Biol Chem*, 1937, **120**, 647
- 5 J. E. Davis *Amer J Physiol* 1944 **142**, 402, *Science*, 1947 **105**, 43
- 6 G. E. Cartwright and M. M. Wintrobe, *J Amer Med Assoc*, 1945 **127**, 911
- 7 F. W. Mott and W. D. Halliburton, *Proc Roy Soc*, 1899 **65**, 91, A. Lohmann, *Arch Physiol* 1906 **118**, 215, A. Desgrez and J. Chevalier, *Compt rend*, 1908, **146**, 89, J. Gautrelet, *ibid*, 1909 **148**, 995

## II. CHOLINE IN THE NUTRITION OF MICRO-ORGANISMS

Comparatively few organisms have been discovered that require choline for growth. A Type III pneumococcus was reported as being unable to grow in the absence of choline<sup>1</sup> and *Clostridium botulinum* was found to require choline<sup>2</sup>.

Of thirty-five compounds related to choline only one, aminoethanol, was able to support the growth of pneumococcus in the absence of choline,<sup>1</sup> this micro organism is able, apparently, to convert amino ethanol into choline.

## REQUIREMENTS OF INSECTS

A clearer understanding of the biosynthesis of choline was obtained with the aid of mutants of *Neurospora crassa*, one of which has already been mentioned as having been used for the microbiological assay of choline (page 587). These *choliness* mutants of *N. crassa*, although able to synthesise the methyl donor, methionine, were unable to synthesise the methyl acceptor, dimethylaminoethanol.<sup>3</sup>

Mutant 47904 produced a substance which was identified as monomethylaminoethanol, this replaced choline for another strain, 34486.<sup>4</sup> It was concluded that strain 47904 was unable to convert methylaminoethanol into choline, whereas in strain 34486 the synthesis of choline was blocked prior to the formation of methylaminoethanol, probably at the stage involving the formation of this substance from aminoethanol.

### References to Section 11

- 1 E. Badger *J. Biol. Chem.* 1944 **153**, 183. *J. Bact.* 1944 **47**, 509.
- 2 C. Lamanna and C. Lewis *ibid.* 1946 **51**, 398.
- 3 T. H. Jukes and A. C. Dornbush *Proc. Soc. Exp. Biol. Med.* 1945 **58**, 142.
- 4 N. H. Horowitz *J. Biol. Chem.* 1946 **162**, 413.

## 12. CHOLINE REQUIREMENTS OF INSECTS

Choline was essential for the growth of larvae of *Ptinus tectus* and *Lasioderma serricorne* but not of the larvae of *Tribolium confusum* and *Sitotroga panicea* under ordinary conditions.<sup>1</sup> When the larvae of the last named beetle were sterilised however choline had to be added to the diet in order for growth to continue, so that this insect and possibly also *Lasioderma* contains symbionts that synthesise choline.

The cockroach *Blattella germanica* also required choline for growth.<sup>2</sup> This could not be replaced by either aminoethanol or methylaminoethanol but the addition of methionine, dimethylaminoethanol and betaine in that order stimulated growth on a choline deficient diet. Insects fed betaine contained nearly as much choline as those fed an equivalent amount of choline.

### References to Section 12

- 1 G. Fraenkel and M. Blewett *Nature* 1943 **151**, 703. 1943 **152**, 506. *Biochem. J.* 1943 **37**, 686. *Proc. Roy. Soc.* 1944 **132**, 212.
- 2 J. L. Noland and C. A. Baumann *Proc. Soc. Exp. Biol. Med.*, 1949 **70**, 198.


## 13. FUNCTION OF CHOLINE

Reference has already been made to the prevention and cure of fatty livers in rats by administration of choline, betaine or methionine and to the fact that the compounds are not completely biologically equivalent

Before discussing the part that choline plays in the economy of the animal body, it is necessary to examine more closely the relationship between choline, betaine and methionine

## Methionine

Methionine is a sulphur-containing amino acid with the formula (I)




Like choline, it has the property of preventing fatty liver formation in rats fed a high fat, low choline diet<sup>1</sup> This property was not possessed by its demethyl derivative, homocysteine (II), the higher homologue of cysteine (III),<sup>2</sup> and this striking difference indicated that the lipotropic action of methionine was probably associated with the labile methyl group This was confirmed, and additional light thrown on the connection between methionine and choline, when W C Rose and E E Rice<sup>3</sup> showed that homocysteine was lipotropic when given at the same time as tiki tiki or a milk concentrate to supply the vitamin B complex It was inferred from this that these supplements contained an unknown factor necessary for the methylation of homocysteine Du Vigneaud *et al*<sup>4</sup> showed that the factor was choline (a) by acetylating the concentrates and demonstrating pharmacologically the presence of acetylcholine, (b) by actually isolating choline as the reineckate, and (c) by showing that homocysteine and choline chloride produced the same increase in weight as methionine and also—what is more significant perhaps—prevented the formation of fatty livers in precisely the same way as methionine They therefore concluded that one of the functions of the methyl group of methionine was to make possible the synthesis of choline in the body

In order to obtain direct evidence in support of this hypothesis methionine in which the hydrogen atoms of the methyl group had been replaced by deuterium atoms was fed to rats maintained on a diet

# FUNCTION

deficient in methionine and choline <sup>5</sup> Choline was isolated from the carcasses as the chloroplatinate and creatine as the creatinine zinc chloride complex Prolonged feeding of deuterio methionine yielded choline and creatine containing 85 % of the theoretical deuterium contents Oxidation of the choline with permanganate yielded trimethylamine containing all the deuterium originally present in the choline thus proving that the deuterium had been retained in the methyl groups

In a similar experiment deuterio choline was fed to animals on a methionine- and choline free diet containing homocystine Creatine isolated from the body tissues contained 24 to 29 % of the theoretical maximum proving that under certain conditions choline can function as a methyl donator Aminoethanol was shown <sup>6</sup> to be the methyl acceptor in the formation of choline since the administration of aminoethanol containing N<sup>15</sup> led to the formation of choline containing N<sup>15</sup> Similarly guanidinoacetic acid was shown <sup>7, 8</sup> to be the precursor of the amidine and glycine moieties of creatine by the use of compounds containing N<sup>15</sup> These experiments indicate that the following transformations can be effected in the rat



In this last reaction homocystine and choline constituted a more effective methylating system for guanidinoacetic acid than did homocystine and choline suggesting that homocystine may be the carrier of methyl groups *in vivo* <sup>9</sup>

When deuterio-creatinine was fed to rats and then ordinary methionine the rate at which deuterium disappeared from the urinary creatinine was not affected by the level of methionine in the diet showing that the rate of methyl transfer from methionine was not proportional to the methionine intake <sup>10</sup>

A deficiency of choline cannot entirely be made good by the administration of methionine nor can a deficiency of methionine be



## CHOLINE


made good by giving choline, for a certain minimum amount of methionine is needed by both the rat<sup>11</sup> and the chick<sup>12</sup> for purposes unconnected with methylation. Similarly, when a severe choline deficiency was induced in chicks<sup>13, 14</sup> or turkeys,<sup>15</sup> methionine could not replace choline in preventing the characteristic perosis. This suggests that the anti perotic action of choline is distinct from its growth promoting and lipotropic actions.

A combined severe choline and partial methionine deficiency was induced in chicks by H. J. Almquist and C. R. Grau.<sup>16</sup> The addition of methionine to the diet increased the gain in weight to about two thirds of the normal value. Better, but still limited, growth was obtained with a partial deficiency of methionine and ample amounts of choline. That choline and methionine were only partially biologically equivalent was confirmed by D. S. McKittrick,<sup>17</sup> who found that for optimal growth white Leghorn chicks required 0.5 % of methionine and 0.1 % of choline chloride, together with an additional 0.25 % of methionine or an additional 0.45 % of choline chloride, or an equivalent mixture of the two. Excess methionine depressed the growth and this could be counteracted by adding a methyl acceptor such as glycocyamine, or serine.

In rat liver, choline is partly responsible for the conversion of glycine into serine.<sup>17a</sup>

### Betaine and Sarcosine


Methionine is not the only substance that can serve as a substitute for choline for under certain conditions, betaine



is capable of exerting a growth effect in the chick equivalent to that of choline,<sup>18</sup> especially in presence of ethanolamine.<sup>19</sup> Like methionine, however, it did not cure perosis in chicks,<sup>14, 16, 20</sup> nor could it completely replace choline or methionine, but only that portion of the one that could be replaced by the other.<sup>17</sup>

Betaine containing deuterio methyl groups and N<sup>15</sup> was shown to be an effective methyl donor,<sup>21</sup> and the methyl groups appeared in the tissue choline as quickly as they did from dietary deuterio choline. There was a discrepancy, however, between the amount of N<sup>15</sup> and deuterium in the choline, indicating that betaine was not converted as a whole into choline. Dimethylglycine containing deuterium gave rise to choline and creatine only to a very limited extent. Sarcosine containing N<sup>15</sup> and deuterium was also an effective methylating agent, but creatine was formed much more slowly from sarcosine than from choline.<sup>22</sup>

Two other substances which are able to replace the "replaceable choline" <sup>17</sup> are dimethylthetin (IV) and dimethyl  $\beta$  propiothetin (V) <sup>20</sup>



The latter was isolated from algae, and may be present in pineapple

### Transmethylation Reactions

It is evident, therefore, that in the animal body, a number of substances exist that are capable of donating a methyl group to another substance, which serves as acceptor. These reactions are now referred to collectively as transmethylation reactions and are recognised to be of considerable importance in metabolism. The formation of choline and creatine from methionine, of methionine from choline and of choline from betaine are examples of transmethylation reactions, but other reactions are in competition with them for the available supplies of labile methyl groups. One of these is the methylation of nicotinamide to give N<sup>1</sup> methylnicotinamide (page 254), and the lipotropic effect of choline was reduced by the addition of nicotinic acid to the diet <sup>23, 24</sup> because some of the additional methyl groups supplied by the choline were utilised in methylating nicotinamide. Other substances conceivably formed by methylation *in vivo* are adrenaline ergothioneine anserine and dimethyl sulphone.

### Function of Choline

Choline is therefore essential for the functioning of the animal organism and its partial replacement by methionine or betaine is simply due to the fact that these substances are able to promote the formation of choline from aminoethanol or from mono- or dimethylaminoethanol (page 599). They are not completely biologically equivalent because they are responsible for the methylation of other substances and choline has other functions in addition to its methylating action.

The lipotropic action of choline is believed to be due to its incorporation into phospholipid molecules which facilitate the transport and metabolism of fatty acids <sup>25</sup>. It seems probable however, that choline acts by stimulating the formation and utilisation of fats in the liver rather than by increasing fat transport in the plasma, as it increased the turnover of liver lecithin, but not that of the plasma phosphatides <sup>26</sup>. Aminoethanol, methylaminoethanol and dimethylaminoethanol had a similar action, but diethanolamine reduced phosphorylation because it was incorporated into phospholipids that

were less easily metabolised and thus accumulated in the liver<sup>27</sup> Inositol may likewise owe its lipotropic effect to its incorporation into phospholipids The ethyl homologue of choline (page 603) is also lipotropic and can likewise be incorporated into phospholipid molecules It has been suggested<sup>28</sup> that the action of insulin in depancreatized dogs may be to liberate bound methionine from the dietary protein making it available for the synthesis of choline which then exerts a lipotropic effect

Choline is also responsible for certain *in vivo* methylations it stimulates growth and it prevents perosis in chicks and turkeys Little is known about the manner in which choline exerts these effects but they appear to be independent properties of the choline molecule since closely related analogues only possess one or at most two of these functions (page 603)

Finally choline is the precursor of acetylcholine and indeed it has itself a vasodilator action although much less marked than that of acetylcholine (page 596)

#### References to Section 13

- 1 H F Tucker and H C Eckstein *J Biol Chem* 1937 **121**, 479
- 2 S A Singal and H C Eckstein *Proc Soc Exp Biol Med* 1939 **41**, 512
- 3 W C Rose and E E Rice *J Biol Chem* 1939 **130**, 305
- 4 V du Vigneaud H M Dyer and M W Kies *ibid* 1939 **130**, 325 V du Vigneaud J P Chandler A W Moyer and D M Keppel *ibid* 1939 **131**, 57
- 5 V du Vigneaud M Cohn J P Chandler J R Schenck and S Simmonds *ibid* 1941 **140**, 625
- 6 D Stetten *ibid* 1941 **138**, 437
- 7 K Bloch and R Schoenheimer *ibid* 167
- 8 H Borsook and J W Dubnoff *ibid* 1940 **132**, 559
- 9 H Borsook and J W Dubnoff *ibid* 1945 **160**, 635
- 10 M Cohn S Simmonds J P Chandler and V du Vigneaud *ibid* 1946 **162**, 343
- 11 M Womack and W C Rose *ibid* 1941 **141**, 375
- 12 H J Almquist and C R Grau *J Nutrition* 1945 **29** 219
- 13 C R Grau and H J Almquist *ibid* 1943 **26**, 631
- 14 T H Jukes *J Biol Chem* 1940 **134** 789 *J Nutrition* 1941 **22**, 315
- 15 T H Jukes *ibid* 1941 **20**, 251
- 16 H J Almquist and C R Grau *ibid* 1944 **27**, 263 C R Grau and H J Almquist *ibid* 1943 **26**, 631
- 17 D S McKittrick *Arch Biochem* 1947 **15**, 133 1948 **18** 437
- 17a W Sakami *J Biol Chem* 1949 **179** 495
- 18 H J Almquist and C R Grau *J Biol Chem* 1943 **149**, 575


## ANALOGUES

- 19 J. McGinnis, L C Norris and G F Heuser, *Proc Soc Exp Biol Med*, 1942, **51**, 293
- 20 J McGinnis, L C Norris and G F. Heuser, *ibid*, 1944, **58**, 197
- 21 V du Vigneaud, S Simmonds J. F Chandler and M Cohn, *J. Biol Chem*, 1946, **185**, 639
- 22 V du Vigneaud, S Simmonds and M Cohn, *ibid*, 1946, **188**, 47
- 22a J W Dubnoff and H Borsook, *ibid*, 1948, **176**, 789
- 23 W H Griffith and D J Mulford *J. Nutrition* 1941, **21**, 633
- 24 J C Forbes *ibid* 1941, **22**, 359
- 25 C S McArthur, *Science*, 1946 **104**, 222
- 26 D B Zilversmit C Entenman and I L Chaikoff, *J. Biol Chem*, 1948, **176**, 193, C Artom and W E Cornatzer, *ibid*, 949
- 27 C Artom, W E Cornatzer and M Crowder, *ibid*, 1949, **180**, 495
- 28 I L Chaikoff, C Entenman and M L Montgomery, *J Biol Chem*, 1945 **160**, 489

### 14. ANALOGUES OF CHOLINE

The only compounds, other than choline or betaine, that supported the growth of young rats on a diet free from methionine but containing homocystine were simple derivatives of choline, such as lecithin and phosphorylcholine, and ethyl- $\beta$ -hydroxyethyltrimethylammonium chloride<sup>1</sup> Another homologue of choline, diethyl- $\beta$ -hydroxyethyl-methylammonium chloride prevented perosis in chicks, but did not promote growth, whilst the triethylanalogue triethyl  $\beta$  hydroxyethyl ammonium chloride, was neither anti-perotic nor growth promoting<sup>2</sup> Betaine was inactive in both respects, but the corresponding aldehyde had a weak growth-promoting and anti perotic activity<sup>2</sup> The triethyl compound however, prevented renal haemorrhage in rats<sup>3</sup> and was lipotropic, being incorporated, like choline, into the phospholipid molecule<sup>4</sup>

A particularly interesting analogue of choline is  $\beta$  hydroxyethyl-trimethyl arsonium chloride the so-called arsenocholine



This compound was not able to methylate homocystine either in the rat<sup>1</sup> or the chick,<sup>5</sup> but it had lipotropic activity<sup>6</sup> and promoted growth and prevented perosis in chicks<sup>7, 8</sup> Apparently, therefore, it could replace choline in every function except that of transmethylation The result emphasises the variety of functions possessed by choline

Sulfocholine,  $\beta$  hydroxyethyl dimethyl sulphonium chloride, behaved in a similar way to arsenocholine and, although unable to methylate homocystine, it prevented fatty liver formation and renal haemorrhages in rats fed a methyl free diet<sup>9a</sup> Since dimethyl

sulphide was isolated from the livers it would appear that the lipotropic action of sulphocholine is due to its incorporation into liver phospholipids in place of choline. Dimethylthetin and dimethyl propiothetin were also lipotropic.

Although only the above compounds have a lipotropic effect in the absence of methionine and the presence of homocystine both mono- and dimethylaminoethanol prevented perosis in chicks fed a basal diet deficient in choline and methionine whilst dimethylaminoethanol but not the mono derivative increased the growth rate though much less effectively than choline.<sup>9</sup> Both compounds stimulated growth to the same extent as choline when methionine was added. Using *cholineless* mutants of *Neurospora crassa* Jukes *et al*<sup>10</sup> and N. H. Horowitz<sup>11</sup> showed that aminoethanol was converted into choline in three steps and feeding experiments with mono- and dimethylaminoethanol containing deuterio methyl groups proved that these compounds were precursors of choline in animals.<sup>12</sup>

The low growth promoting activity of dimethylaminoethanol is believed to be due to the inability of the animal to utilise the methyl groups present in the molecule indicating that when choline takes part in transmethylation reactions it releases only one methyl group giving rise to dimethylaminoethanol which would thus assume a pivotal position as both the immediate precursor and the principal demethylation product of choline.

Although the triethyl analogue of choline had a slight lipotropic action in rats it was toxic to mice and the toxicity was neutralised by an equal amount of choline. It also blocked the contraction of isolated frog muscle by choline but not by acetylcholine and it was therefore suggested that the compound interfered with the formation of acetylcholine from choline.<sup>13</sup>

#### References to Section 14

- 1 A. W. Moyer and V. du Vigneaud *J. Biol. Chem.* 1942 **143** 373
- 2 T. H. Jukes *J. Nutrition* 1941 **21** Suppl. 13
- 3 J. M. Patterson and E. W. McHenry *J. Biol. Chem.* 1942 **145** 207
- 4 C. S. McArthur *Science* 1946 **104**, 222
- 5 H. J. Almquist and T. H. Jukes *Proc. Soc. Exp. Biol. Med.* 1942 **51**, 243
- 6 A. D. Welch *J. Biol. Chem.* 1941 **137**, 173. A. D. Welch and R. L. Landan *ibid.* 1942 **144**, 581
- 7 H. J. Almquist and C. R. Grau *J. Nutrition* 1944 **27**, 263
- 8 T. H. Jukes and A. D. Welch *J. Biol. Chem.* 1943 **146**, 19
- 8a G. A. Maw and V. du Vigneaud *ibid.* 1948 **178** 1029 1037
- 9 T. H. Jukes and J. J. Oleson *ibid.* 1945 **157**, 419. T. H. Jukes, J. J. Oleson and A. C. Dornbush *J. Nutrition* 1945 **30** 219

# ANALOGUES

- 10 T H Jukes A C Dornbush and J J Oleson *Fed Proc* 1945  
4, 157
- 11 N H Horowitz *J Biol Chem* 1946 162, 413
- 12 V du Vigneaud J P Chandler S Simmonds A W Moyer and  
M Cohn *ibid* 1946 164, 603
- 13 A S Keston and S B Wortis *Proc Soc Exp Biol Med* 1946  
61, 439

## CHAPTER XIII

# MISCELLANEOUS WATER-SOLUBLE GROWTH FACTORS

---

### I. INTRODUCTION

THERE is no reason to believe that membership of the vitamin B complex is restricted to the compounds described in the preceding chapters, although it is doubtful if substances of such outstanding nutritional and therapeutic importance as aneurine and nicotinic acid remain to be discovered. This is perhaps a sweeping and unwise generalisation to make, but it appears to be warranted by evidence from clinical tests and animal experiments that the most serious symptoms of vitamin B complex deficiency are more or less completely relieved by aneurine, nicotinic acid and riboflavine.

For example, Elsom *et al*<sup>1</sup> studied the clinical effects of a deficiency of the whole vitamin B complex and observed that many of the symptoms, including anorexia and mental symptoms, were improved by administration of aneurine alone, although other symptoms, such as delayed motility of the small intestine, a macrocytic anaemia and oedema of the upper and lower extremities, were not affected by either aneurine or riboflavine, but were relieved by administration of yeast. It is probable that many of these symptoms could have been relieved by other members of the vitamin B complex had these been available in 1940 when the work was carried out. From this point of view the results of Keys *et al*,<sup>2</sup> carried out in 1945, are perhaps of greater significance. They maintained eight normal young men on a diet providing 33,000 cals and 75 g of protein a day together with 0.18 mg of aneurine, 0.25 mg of riboflavine and 3.5 mg of nicotinic acid per 1000 cals. Another four men were given in addition 1 mg of aneurine, 1 mg of riboflavine and 10 mg of nicotinamide daily. The only difference between the two groups after 161 days was that the first had a slightly higher concentration of pyruvic acid in the blood than the second group. At the end of this time two men from the first group were given a diet containing negligible amounts of all three B vitamins, they showed increasing anorexia from the seventh to the

## INTRODUCTION

twenty first day and other signs of "subjective distress" but no objective signs of vitamin deficiency

These two papers seem to indicate that the earliest symptoms of a vitamin B complex deficiency are due to a deficiency of aneurine, which appears to be the most critical of the B vitamins in human nutrition. The second paper suggests, in addition, that human subjects can be maintained in apparently normal health by the addition of aneurine, riboflavine and nicotinic acid to a diet deficient in the vitamin B complex, and this conclusion is supported by the fact that excellent results have been obtained in the treatment of vitamin B complex deficiency with these three factors only. A. G. Clarke and I. Prescott,<sup>3</sup> for instance, successfully treated seventeen cases which exhibited symptoms such as depression, psychoneurosis, anxiety, polyneuritis, glossitis, angular stomatitis and cheilosis, with 3 to 9 mg of aneurine, 3 to 9 mg of riboflavine and 100 to 500 mg of nicotinic acid daily.

From the standpoint of human nutrition therefore, it is doubtful whether any other members of the vitamin B complex of fundamental importance remain to be discovered. There is also strong evidence for believing that aneurine is the most important member of the vitamin B complex in animal nutrition, for a deficiency of this factor is the first of the B vitamin deficiencies to manifest itself, and it gives rise to the most serious symptoms. Thus, E. C. Miller and C. A. Baumann<sup>4</sup> found that rats died within three weeks on a vitamin B<sub>1</sub> deficient diet containing all the other members of the vitamin B complex, but suffered no ill effects when deprived of nicotinic acid or choline only. On a riboflavine deficient diet, they ceased to grow but apparently remained otherwise normal for four months when they developed deficiency symptoms and died after seven to twelve months. On a pantothenic acid free diet, growth ceased within a month and about half the animals died within five months.

The impression gained from animal experiments and clinical experience is that a vitamin B complex deficiency can be largely, though not completely, remedied by administration of aneurine, riboflavine and nicotinic acid. Some of the other B vitamins may of course be supplied by intestinal synthesis. In any event, it appears unsound in theory and possibly dangerous in practice to treat a multiple deficiency with one B vitamin only, for A. I. Morgan<sup>5</sup> using dogs and Supplee *et al*<sup>6</sup> using rats obtained evidence that this sometimes precipitated a deficiency of another factor, although K. Unna and J. D. Clark<sup>7</sup> found that prolonged administration of large amounts of individual vitamins to rats on a diet deficient in one or more factors did not aggravate the deficiency state.



*References to Section 1*

- 1 K O S Elsom F H Lewy and G W Heublein *Amer J Med Sci* 1940 **200**, 757
- 2 A Keys A F Henschel H L Taylor O Mickelsen and J Brozek *Amer J Physiol* 1945 **144**, 5
- 3 A G Clarke and F Prescott *Brit Med J* 1943 **2**, 503
- 4 E C Miller and C A Baumann *J Nutrition* 1944 **27**, 319
- 5 A F Morgan *Science* 1941 **93**, 261
- 6 G C Supplee R C Bender and Z M Hanford *J Amer Pharm Assoc* 1942 **31**, 194
- 7 K Unna and J D Clark *Amer J Med Sci* 1942 **204**, 364

## 2 INADEQUACY OF KNOWN VITAMINS FOR ANIMALS

Although aneurine riboflavine and nicotinic acid are undoubtedly the most important of the B vitamins for both animals and humans there is abundant evidence from animal experiments that other water soluble nutritional factors exist in addition to the recognised members of the vitamin B complex vitamin C and vitamin P These are not of major importance in human or animal nutrition and their absence generally results in comparatively trivial disturbances in the well being of experimental animals although a prolonged deficiency may sometimes result in death

### Mice and Rats

E R Norris and J Hauschildt<sup>1</sup> claimed that another factor in addition to aneurine nicotinic acid riboflavine pyridoxine and filtrate factor was necessary to prevent skin lesions and loss of hair in mice fed a purified diet Similarly K Schwartz<sup>2</sup> claimed that a new factor was necessary to increase the weight of pantothenic acid deficient rats beyond the limit reached by administration of pantothenic acid alone the factor was termed factor 125 because with pantothenic acid alone the growth rate began to decrease when the rats weighed 125 g

### Dogs

Dogs manifested symptoms of deficiency when fed a purified diet supplemented by a mixture of synthetic B vitamins Schaefer *et al*<sup>3</sup> found that a factor in liver restored the growth and prevented anorexia in dogs maintained on a casein sucrose diet supplemented by aneurine riboflavine nicotinic acid pyridoxine pantothenic acid and choline whilst Smith *et al*<sup>4</sup> found that a factor in yeast supplemented pyridoxine in improving the blood picture and general health of dogs

## INADEQUACY OF KNOWN VITAMINS FOR ANIMALS

maintained on a diet containing seven synthetic B vitamins, but no pyridoxine P J Fouts<sup>5</sup> observed that dogs receiving a low protein diet supplemented with aneurine, riboflavine pyridoxine, nicotinic acid and pantothenic acid developed a deficiency syndrome characterised by loss of weight, moderate anaemia, dermal and peptic ulcers and fatty cirrhotic livers ultimately most of the animals died. A high protein diet prevented the condition, but the growth rate was sub optimal. A partial improvement resulted from the feeding of choline, liver extract or a filtrate factor preparation from rice bran, and complete improvement, except for a fibrosis of the liver, from administration of the liver extract together with large amounts of choline. A somewhat similar result was obtained by D V Frost and F P Dann,<sup>6</sup> who fed pups on a synthetic diet, supplemented by aneurine, riboflavine nicotinic acid, pantothenic acid, pyridoxine and choline and noted that they developed deficiency symptoms. These were relieved by administration of yeast liver paste or a liver extract fraction insoluble in 70 % alcohol.

Fox pups and mink kits also developed deficiency symptoms on a purified diet. These were relieved by feeding fresh liver.<sup>6a</sup>

### Pigs

Russell *et al*<sup>7</sup> maintained weanling pigs for up to 469 days on a purified diet supplemented with aneurine riboflavine nicotinic acid, pyridoxine pantothenic acid *p* aminobenzoic acid and choline. The animals grew as well during the first three months as did pigs on a commercial feed but later growth was slower although there was nothing in the behaviour or appearance of the deficient animals to differentiate them from their more adequately nourished litter mates. They failed to reproduce on mating however and the addition of dried liver to the ration did not restore the reproductive function.

### Chicks and Pigeons

That synthetic rations are not completely adequate for chicks has been demonstrated by several workers. Gillis *et al*<sup>8</sup> for example, reported that liver extracts contained a heat stable factor essential for reproduction in hens although it did not increase the hatchability of eggs whilst a growth factor for chicks was reported to be present in cow manure by M Rubin and H R Bird.<sup>9</sup> It was heat stable and non-dialysable soluble in water and 50 % and 90 % ethyl alcohol but insoluble in chloroform and ether. It was differentiated from folic acid factors U, R and S and from vitamins B<sub>12</sub> and B<sub>12</sub>, but appears to be related to vitamin B<sub>12</sub> (see page 544).

Pigeons also developed deficiency symptoms including a severe

anaemia, when maintained on a purified diet supplemented by aneurine, riboflavine, nicotinic acid, pyridoxine and pantothenic acid,<sup>10</sup> the anaemia was cured by extracts of yeast, liver or rice bran. Pigeons have also been said to require a weight restoration factor (page 611).

The inference underlying all this work is, of course, that new factors essential for the well-being of animals, and distinct from the known members of the vitamin B complex are present in the supplements used to relieve the deficiency symptoms. It will be noted that in most instances the material used as the supplement was an extract prepared from either liver or yeast, both of which, as already noted are excellent sources of most members of the vitamin B complex. In none of this work, however, was any serious attempt made to isolate and purify the responsible factor. Such attempts have been made with certain other factors, however, and the concentrates so obtained have been shown to produce the same effect in animals as the original crude extracts. Many of these concentrates, although still relatively impure, have been given specific names, some implying that the active principle is a vitamin or even a member of the vitamin B complex.

Claims for the isolation of a new vitamin have often rested on very flimsy evidence, because the preparations originally obtained have been highly impure and no subsequent attempts have been made to purify them, much less to isolate the responsible factor in the pure state. For this reason many of the older 'vitamins' are now to be regarded as of historical interest only (see page 613), although many factors described in the recent literature merit more serious attention and may ultimately achieve recognition as vitamins. These are factors now under active investigation, which appear to have a reasonable chance of being isolated in the pure state. Once this has been done their biological properties can be examined to confirm that the activity supposed to be characteristic of them really is a function of the pure substance and not of an impurity from which it has previously not been separated.

It is felt that a brief account of the factors to which specific names have been given is necessary to make this survey complete, whether the factors belong to the group that is now only of historical interest or whether they are strong favourites for ultimate recognition as members of the vitamin B complex.

#### *References to Section 2*

- 1 E. R. Norris and J. Hauschildt *Science*, 1940, **92**, 316
- 2 K. Schwartz *Z. physiol. Chem.*, 1942, **275**, 232
- 3 A. E. Schaefer, J. M. McKibbin and C. A. Elvehjem *J. Nutrition*, 1942, **23**, 491.

## VITAMINS B<sub>3</sub>, B<sub>4</sub> AND B<sub>5</sub>

- 4 S G Smith H Hawfield R Curry R Connar and J Collins  
*J Elisha Mitchell Sci Soc* 1943 59 117
- 5 P J Fouts *J Nutrition* 1943 25 217
- 6 D V Frost and F P Dann *ibid* 1944 27, 355
- 6a A E Schaefer C K Whitehair and C A Elvehjem *ibid* 1948  
35 147 A E Schaefer S B Tove C K Whitehair and C A  
Elvehjem *ibid* 157
- 7 W C Russell A E Teeri and K Unna *ibid* 1948 35, 321
- 8 M B Ellis G F Heuser and L C Norris *ibid* 1942 23, 153
- 9 M Rubin and H R Bird *J Biol Chem* 1946 163 387 393
- 10 H R Street *J Nutrition* 1944 28 395

## 3 VITAMINS B<sub>3</sub>, B<sub>4</sub> and B<sub>5</sub>

### Vitamins B<sub>3</sub> and B<sub>5</sub>

Vitamin B<sub>3</sub> is the name given to a factor present in yeast which according to R R Williams and R E Waterman<sup>1</sup> was necessary to restore to normal the weight of pigeons maintained on a vitamin B complex-deficient diet after the polyneuritic symptoms had been cured by administration of vitamin B<sub>1</sub> it was unstable to heat L Randon and R Lecoq<sup>2</sup> had earlier reported the existence of a similar factor destroyed by alkaline autoclaving

Evidence for the existence of a third alkali labile factor in addition to vitamins B<sub>1</sub> and B<sub>2</sub> was obtained by Carter *et al*<sup>3</sup> who found that a fraction from liver alleged to contain this factor vitamin B<sub>3</sub> cured heart block in pigeons fed on polished rice they also found that large amounts of vitamin B<sub>1</sub> did not fully restore the weight of pigeons thus apparently confirming the existence of vitamin B<sub>3</sub> Vitamin B<sub>3</sub> was shown to be necessary for the chick as well as for the pigeon by Eddy *et al*<sup>4</sup>

Further support for the existence of vitamin B<sub>3</sub> was provided by J R O'Brien<sup>5</sup> who like Carter *et al* showed that a vitamin B<sub>1</sub> concentrate administered at a level equivalent to forty times the anti neuritic dose failed to restore fully the weight of pigeons fed a diet of autoclaved polished rice An alcoholic extract of wheat or yeast was effective in restoring the weight to normal and an extract made after acid hydrolysis was still more effective but an aqueous extract was quite inactive J R O'Brien confirmed the instability of vitamin B<sub>3</sub> not only to heat but also on storage or exposure to air

The first note of doubt regarding the *bona fides* of vitamin B<sub>3</sub> was struck by C W Carter<sup>6</sup> who observed that the weight of pigeons was fully restored when caseinogen was added to the diet suggesting that the so-called vitamin B<sub>3</sub> deficiency was due to an inadequate intake of protein The cardiac arrhythmia previously attributed to

vitamin B<sub>5</sub> deficiency was not affected by the caseinogen and was only cured by the addition of an extract prepared from wheat germ. As the result of subsequent work carried out jointly, C W Carter and J R O'Brien<sup>7</sup> reached the conclusion that caseinogen only fully restored the weight of pigeons under certain special conditions and that vitamin B<sub>3</sub> was needed in addition. They described the preparation of a concentrate from liver and attempts to purify the factor. They found that most of the activity was adsorbed on fuller's earth. Their results appeared to substantiate the earlier claims for the existence of vitamin B<sub>5</sub>.

Unfortunately, neither vitamin B<sub>3</sub> nor vitamin B<sub>5</sub> has ever been isolated in the pure state, and it is therefore impossible to decide whether they ought to be recognised as distinctive factors or not. In the light of more recent work, which has indicated the large number of water soluble factors that are required by the chick (page 613), and presumably by pigeons also, it is reasonable to suppose that the concentrates of vitamins B<sub>3</sub> and B<sub>5</sub> which the Oxford workers used, owed their activity to the presence of these other factors. J G Lee and A G Hogan<sup>8</sup> for instance, concluded that vitamins B<sub>3</sub> and B<sub>5</sub> were multiple in nature, the former being a source of pantothenic acid and the latter of pyridoxine, but doubtless choline, biotin, folic acid and vitamin B<sub>12</sub> also contributed to the effects produced.

### Vitamin B<sub>4</sub>

Vitamin B<sub>4</sub> is the name given to a heat-labile factor claimed by V Reader<sup>9</sup> to be necessary for rats when maintained on a diet of autoclaved cereals. In the absence of vitamin B<sub>4</sub> the rats not only ceased to grow but developed a hunched back, protruding jowls and a wobbly gait. Administration of a vitamin B<sub>1</sub> concentrate brought about a gradual recovery which was believed to be due to the relief of anorexia and a corresponding increase in the vitamin B<sub>4</sub> intake.<sup>10</sup>

Kline *et al.*<sup>11</sup> produced a vitamin B<sub>4</sub> deficiency in rats by using purified caseinogen and dextrin, crystalline vitamin B<sub>1</sub> and a highly purified concentrate of "vitamin B<sub>2</sub>". The deficiency symptoms were relieved by feeding peanuts, which were assumed to be rich in vitamin B<sub>4</sub>. Subsequently they observed<sup>12</sup> that brain, kidney and liver tissue also relieved the symptoms.

Subsequent workers failed to confirm the existence of vitamin B<sub>4</sub> and according to R L Swank and O A Bessey,<sup>13</sup> for example, a deficiency of vitamin B<sub>1</sub> would account for the paralysis in deficient rats making it unnecessary to postulate the existence of vitamin B<sub>4</sub>, whilst Briggs *et al.*,<sup>14</sup> using a diet with which they had previously produced vitamin B<sub>4</sub> deficiency in rats, found that the typical paralysis

was prevented and growth was promoted by the addition to the diet of arginine glycine and cystine. There seems to be little justification therefore for retaining vitamin B<sub>4</sub> as a legitimate component of the vitamin B complex and we may therefore regard vitamins B<sub>7</sub>, B<sub>8</sub> and B<sub>9</sub> as of historical interest only.

### References to Section 3

- 1 R R Williams and R T Waterman *J Biol Chem* 1928 78, 311
- 2 L. Random and R Lecoq *Compt rend* 1926 182, 1408
- 3 C W Carter H W Kinnersley and R A Peters *Biochem J* 1930 24 1764
- 4 W H Eddy S Gurn and J C Keresztesy *J Biol Chem* 1930 87, 729
- 5 J R O'Brien *Biochem J* 1934 28 926
- 6 C W Carter *ibid* 933
- 7 C W Carter and J R O'Brien *ibid* 1935 29, 2746 1936 30, 43 1937 31, 2270
- 8 J G Lee and A G Hogan *Missouri Agric Exp Stat Bull* 1942 342
- 9 V Reader *Biochem J* 1929 23 689 1930 24, 77 1827 H W Kinnersley J R O'Brien R A Peters and V Reader *ibid* 1933 27, 225
- 10 C A Elvehjem and A Arnold *Nature* 1936 137, 109
- 11 O L Kline C A Elvehjem and E B Hart *Biochem J* 1936 30, 780
- 12 O L Kline H R Bird C A Elvehjem and E B Hart *J Nutrition* 1936 11, 515
- 13 R L Svanck and O A Bessey *ibid* 1941 22, 77
- 14 G M Briggs T D Luckey C A Elvehjem and E B Hart *J Biol Chem* 1943 150 11

### 4 VITAMINS B<sub>10</sub>, B<sub>11</sub>, B<sub>13</sub> AND B<sub>14</sub>

In a paper published in 1943 Briggs *et al*<sup>1</sup> stated that chicks required two new factors for proper feathering and growth in addition to those already recognised. These were named vitamins B<sub>10</sub> and B<sub>11</sub> respectively these numbers being selected because there are at the present time nine vitamins of the B complex concerned in chick nutrition seven of which have been well established as necessary namely thiamine riboflavin pantothenic acid choline nicotinic acid pyridoxine and biotin. The two other members inositol and folic acid appear to be necessary for the chick.

This explains the absence of any information in the literature about vitamins B<sub>7</sub>, B<sub>8</sub> and B<sub>9</sub> which may have puzzled a good many people these vitamins have never in fact existed! There is thus

a gap between vitamin B<sub>8</sub>, which has been fully discussed in Chapter V, and vitamin B<sub>10</sub>

### Vitamins B<sub>10</sub> and B<sub>11</sub>

Concentrates of vitamins B<sub>10</sub> and B<sub>11</sub><sup>1</sup> were prepared from liver. Both factors were soluble in water, and were adsorbed on norit and superfiltrol at pH 3 and eluted from the adsorbates by means of aqueous alcoholic ammonia. Both factors were synthesised by a certain strain of *Mycobacterium tuberculosis* in presence of *p*-aminobenzoic acid.<sup>2</sup>

The existence of vitamins B<sub>10</sub> and B<sub>11</sub> was apparently confirmed by the observation of McGinnis *et al*<sup>3</sup> that growth and feather pigmentation were impaired when chicks were reared on a diet of maize, peanut meal, casein, soya bean oil, cod liver oil and salts, supplemented by aneurine, riboflavine, pyridoxine, pantothenic acid and glycine.

The symptoms said to be characteristic of a deficiency of vitamins B<sub>10</sub> and B<sub>11</sub>, however, have been shown to be produced by a diet deficient in folic acid and vitamin B<sub>12</sub>. The addition of vitamin B<sub>12</sub> increased the growth rate, but did not improve feathering, whereas the addition of folic acid improved feathering but the growth rate still remained sub optimal.<sup>4</sup> Clearly, therefore, vitamins B<sub>10</sub> and B<sub>11</sub> cannot be regarded as established members of the vitamin B complex.

### Vitamin B<sub>13</sub>

An unidentified growth factor was isolated from distillers' dried solubles by A. F. Novak and S. M. Hauge.<sup>5</sup> This factor, termed provisionally vitamin B<sub>13</sub>, stimulated the growth of rats at a level of 2 µg and gave a maximal response at 10 µg per day. It was isolated by a process that included extraction with acid, precipitation of inert material with alcohol, chromatographic adsorption of impurities on fuller's earth, precipitation of the active fraction with phosphotungstic acid and separation by chloroform extraction.

cell proliferation and haemopoiesis was enhanced by certain enzyme preparations such as xanthine oxidase from milk rat liver homogenate and rat gastric mucosa extract the activity of vitamin B<sub>11</sub> was not affected. The enzyme-treated pterines had about the same activity as vitamin B<sub>11</sub>.

#### References to Section 4

- 1 G M Briggs T D Luckey C A Elvehjem and E B Hart *J Biol Chem* 1943 **148** 163
- 2 R C Mills G M Briggs T D Luckey and C A Elvehjem *Proc Soc Exp Biol Med* 1944 **58** 240
- 3 J McGinnis L C Norris and G F Heuser *J Biol Chem* 1942 **145** 341
- 4 C A Nichol L S Dietrich C A Elvehjem and E B Hart *J Nutrition* 1949 **39** 287
- 5 A F Novak and S M Hauge *J Biol Chem* 1948 **174** 235 647
- 6 E R Norris and J J Majnarch *Science* 1949 **109** 32 33

## 5 VITAMIN L AND FACTORS U, W, R AND S

### Vitamin L

Vitamin L is the name given by Nakahara *et al*<sup>1</sup> to a factor said to be essential for the lactation of rats. Its name represents a return to the original system of naming the vitamins in which successive letters of the alphabet are used. Its discovery occurred shortly after that of the fat soluble anti haemorrhagic vitamin K and was followed in turn by the discovery of vitamin M which as already observed is now regarded as a conjugate of folic acid.

Nakahara *et al*<sup>2</sup> subsequently claimed to have separated vitamin L into two fractions vitamin L<sub>1</sub> and vitamin L<sub>2</sub> neither of which could replace the other. Unfortunately although these factors were claimed to be distinct from the filtrate factor and factor W they appear not to have been isolated in the pure state and so their relationship to other members of the vitamin B complex cannot be determined. Folley *et al*<sup>3</sup> failed to confirm the existence of a lactation factor for rats.

### Factor U

Another factor of doubtful status is the factor U of E L R Stokstad and P D V Manning<sup>4</sup>. This was said to be required by chicks on a diet of polished rice and washed fish meal supplemented by riboflavin and the chick antidermatitis factor. In a later paper<sup>5</sup> a factor U concentrate was shown to contain vitamin B<sub>6</sub> which would have accounted for some of its activity.



**Factor W**

The factor W of D V Frost and C A Elvehjem <sup>6</sup> has already been discussed (page 349). It would appear to be an impure preparation of the filtrate factor. Another filtrate factor, possibly identical with factor W, is factor B<sub>W</sub>, claimed by H Kringstad and G Lunde <sup>7</sup> to be essential for the growth of rats. This factor was present in both liver and yeast and differed from pantothenic acid in being stable to alkali and not extracted at pH 1 by ether. Liver and yeast also contained a closely related factor, termed factor B<sub>X</sub>, which prevented grey hair in rats. The precise status of these factors has never been determined.

**Factors R and S**

Schumacher *et al* <sup>8</sup> designated as factors R and S two unidentified factors necessary for the growth of chicks. Extracts of these factors were prepared by Hill *et al* <sup>9</sup> from dried brewers' yeast by aqueous extraction at 80 to 85° C, by extraction with acid or by digestion with takadiastase. The extracts were concentrated under reduced pressure, the pH was adjusted to 1.6 and factor S precipitated by the addition of ten volumes of alcohol. After adjusting the pH of the filtrate to 7.0, factor R separated on standing, the filtrate contained folic acid. Thus neither factor was identical with pteroylglutamic acid but factor R is possibly a conjugated form of folic acid. Factor S is now known to be identical with strepogenin <sup>10</sup>.

**Strepogenin**

In 1944, H Sprince and D W Woolley <sup>11</sup> prepared concentrates from solubilised liver extract by six different methods and tested them as growth factors for haemolytic streptococcus, *Streptococcus lactis* and *L. helveticus*. Since the relative activities of the concentrates towards these organisms were substantially the same, it was concluded that one and the same factor was probably responsible for the growth stimulation in each instance. It was given the name of "strepogenin" since "its presence is necessary for streptococci of group A to generate". Tryptic digests of many pure proteins, *e.g.* insulin, trypsinogen, trypsin, chymotrypsin and chymotrypsinogen, ribonuclease, tobacco mosaic virus, haemoglobin and casein, were found to be good sources of strepogenin <sup>12</sup>. Not only was strepogenin a growth factor for micro organisms, but it also stimulated the growth of mice <sup>13</sup>. The growth rate of mice was reduced when the animals were fed on a diet containing hydrolysed casein together with cystine and tryptophan and restored either by replacing these substances by intact casein or by supplementing them with a tryptic digest of casein <sup>14</sup>. This indicated that strepogenin was associated with a protein molecule, and this was

confirmed by the increased growth rates of mice fed proteins rich in strepogenin proteins such as egg white that contained little strepogenin had little growth promoting activity<sup>15</sup>

D W Woolley<sup>16</sup> showed that strepogenin was a peptide of glutamic acid. He observed that it neutralised the effect of the tomato wilting agent lycomarasmin which is elaborated by *Fusarium lycopersici*. On hydrolysis this substance yields aspartic acid glycine and pyruvic acid and is probably a tripeptide of serine glycine and aspartic acid<sup>17</sup>. D W Woolley therefore synthesised serylglycyl aspartic acid and glycylyseryl aspartic acid and showed that they had a wilting action on tomato leaves equal to one sixth and one half to one quarter the activity of lycomarasmin. Arguing that strepogenin might have glutamic acid in place of the aspartic acid of lycomarasmin D W Woolley synthesised L serylglycyl L glutamic acid and found that it had one fortieth the activity of strepogenin towards *L. helveticus* and antagonised the wilting action of serylglycyl aspartic acid. Strepogenin activity was also observed in glycylyserylglutamic acid alanyl glycyglutamic acid glycyalanylglutamic acid and glycyglutamic acid. Serylglycyl aspartic acid was antagonistic to the growth promoting activity of strepogenin. The strepogenin activity of serylglycyl glutamic acid was confirmed by W A Krehl and J S Fruton<sup>18</sup>.

Further investigation showed however that lycomarasmin contained a new amino acid  $\alpha$  hydroxyalanine attached by a common nitrogen atom to the amino group of glycy lasparagine<sup>19</sup>. Additional peptides were synthesised and of these  $\alpha$  hydroxy  $\alpha$  acetyl amino propionylglycyl aspartic acid was as active as lycomarasmin<sup>20</sup>.

The position occupied by strepogenin in protein molecules was investigated<sup>21</sup>. In insulin it apparently occurs at the end of the peptide chain with glycine as the end group. It occupies a similar position in trypsinogen but probably not in casein.

A factor that may be identical with strepogenin was found to be necessary for normal growth and survival of the mealworm *Tenebrio molitor* in addition to eight known vitamins. It was named vitamin B<sub>T</sub> provisionally<sup>22</sup>.

#### References to Section 5

- 1 N Nakahara and F Inuka *Sci Papers Inst Phys Chem Research Tokyo* 1933 22 301 1934 24 33 W Nakahara F Inukai and S Kato *Proc Imp Acad Tokyo* 1934 10 268
- 2 W Nakahara F Inuka S Kato and S Ugami *Sci Papers Inst Phys Chem Research Tokyo* 1936 20 47 W Nakahara F Inukai and S Ugami *ibid* 1935 28 152 1937 31 42 1938 34 50 1939 36 312 1940 38 24 *Proc Imp Acad Tokyo* 1936 12 289 1938 14 9 *Science* 1938 87 37 1940 91 431

## MISCELLANEOUS WATER-SOLUBLE GROWTH FACTORS

- 3 S J Folley, E W Ikin S K Kon and H M S Watson, *Biochem J*, 1938 **32**, 1988
- 4 E L R Stokstad and P D V Manning *J Biol Chem* 1938, **125**, 687
- 5 E L R Stokstad, P D V Manning and R E Rogers *ibid* 1940 **132**, 463
- 6 D V Frost and C A Elvehjem, *ibid*, 1937, **119**, xxxiv
- 7 H Kringstad and G Lunde *Z physiol Chem* 1939 **261**, 110, G Lunde and H Kringstad *Naturwiss*, 1940, **28**, 157, *J Nutrition*, 1940, **19**, 321
- 8 A E Schumacher, G F Heuser and L C Norris, *J Biol Chem.*, 1940 **135**, 313
- 9 F W Hill, L C Norris and G F Heuser, *J Nutrition*, 1944 **28**, 175
- 10 M L Scott L C Norris and G F Heuser, *J Biol Chem*, 1947, **167**, 261
- 11 H Sprince and D W Woolley *J Exp Med* 1944 **80**, 213
- 12 H Sprince and D W Woolley *J Amer Chem Soc* 1945 **67**, 1734
- 13 D W Woolley and H Sprince *Fed Proc*, 1945, **4**, 164
- 14 D W Woolley, *J Biol Chem*, 1945 **159**, 753
- 15 D W Woolley, *ibid*, 1946 **162**, 383
- 16 D W Woolley *ibid*, 1946 **166**, 783, 1948 **172**, 71
- 17 P A Plattner and N Clauson Kaas *Helv Chim Acta* 1944 **28**, 188
- 18 W A Krehl and J S Fruton *J Biol Chem*, 1948 **173**, 479
- 19 D W Woolley, *ibid*, 1949 **176**, 1291
- 20 D W Woolley, *ibid*, 1299
- 21 D W Woolley, *ibid*, 1947, **171**, 443
- 22 G Fraenkel M Blewett and M Coles *Nature* 1948 **161**, 981 G Fraenkel, *Brit J Nutrition*, 1948, **2**, 1

## 6. MISCELLANEOUS GROWTH FACTORS FOR ANIMALS

### Grass Juice Factor

The 'grass juice factor' is a relatively labile vitamin, said by Kohler *et al*<sup>1</sup> to be necessary for normal growth in rats and guinea pigs. It was obtained from grass juice by shaking with a mixture of chloroform and amyl alcohol, removing proteins and then treating with charcoal. The activity was present in the filtrate.

A substance apparently identical with it was reported by M D Cannon and G A Emerson,<sup>2</sup> who found that guinea-pigs failed to thrive on a highly purified diet, supplemented by vitamins in amounts adequate for rats unless either lettuce or grass was given. The factor was water soluble and stable at 100° C for one hour. The same factor was isolated from the fraction of an aqueous liver extract that

was precipitated by 70 % alcohol and then solubilised by the action of enzymes<sup>3</sup> It was said to be different from folic acid

Guinea pigs required two other factors not essential for rats or chicks These were present in yeast and winter milk respectively<sup>4</sup> and also in linseed oil meal<sup>3 5</sup> What may or may not have been the same three factors were termed by D W Woolley and H Sprince<sup>6</sup> factors GPF<sub>1</sub> GPF<sub>2</sub> and GPF<sub>3</sub> The first of these was probably identical with folic acid and the second with a mixture of cellulose and casein K A Kuiken<sup>7</sup> also claimed that guinea pigs required unknown factors in rice polish brewers yeast dried grass or liver and that commercial casein contained a further factor absent from vitamin free casein

### Cartilage Factors

Hegsted *et al*<sup>8</sup> claimed that a factor present in cartilage kidney and rice was necessary for chicks which in the absence of this factor developed a dermatitis similar to that observed in pantothenic acid deficiency Robinson *et al*<sup>9</sup> reported that chondroitin sulphuric acid could serve as a growth factor for both the rat and the chick and that its effect was different from that of the anti dermatitis factor found in a filtrate from rice polishings that is presumably pantothenic acid

According to a later paper by Hegsted *et al*<sup>10</sup> the cartilage factor is a combination of chondroitin glycine and arginine each alone failed to stimulate the growth of chicks and even when combined the weight restoration was not equal to that obtained with cartilage Chondroitin alone however gave a marked response when the amount of casein in the diet was increased Subsequently it was shown<sup>11</sup> that cystine must also be present if growth equivalent to that produced by cartilage was to be obtained

A combination of these four factors prevented gizzard erosion which had been attributed to the absence of a specific factor by H J Almquist and his colleagues<sup>12</sup> and by C A Elvehjem and his colleagues<sup>13</sup> H R Bird and J J Oleson<sup>14</sup> believed that the anti gizzard erosion factor was present in a chondroitin fraction from cartilage whilst H J Almquist<sup>15</sup> believed that it was cholic acid It has now been shown that vitamin B<sub>12</sub> prevents gizzard erosion in chicks<sup>13a</sup>

### Zoopherin

A factor similar to the chick factor from cow manure (page 544) was termed nutritional factor X by Cary *et al*<sup>16</sup> Both factors may be identical with the factor termed by Zucker *et al*<sup>17</sup> zoopherin Zoopherin deficiency revealed itself in rats after the natural lactation period by a marked growth restraint high mortality high blood urea

## MISCELLANEOUS WATER-SOLUBLE GROWTH FACTORS

and a low white cell count. The chick factor from cow manure completely relieved symptoms of zoopherin deficiency in rats and fractions from crude but not vitamin free casein liver extract powder and 'fish solubles', had similar properties. Zoopherin was not present in dried yeast. It appears to be related to vitamin B<sub>12</sub>.

### References to Section 6

- 1 G O Kohler C A Elvehjem and E B Hart *J Nutrition* 1938 **15**, 445
- 2 M D Cannon and G A Emerson *ibid* 1939 **18**, 155
- 3 G J Mannering M D Cannon H V Barki C A Elvehjem and E B Hart *J Biol Chem* 1943 **151**, 101
- 4 H A Sober G J Mannering M D Cannon C A Elvehjem and E B Hart *J Nutrition* 1942 **24**, 503
- 5 D W Woolley *J Biol Chem* 1942 **143**, 679
- 6 D W Woolley and H Sprince *ibid* 1945 **157**, 447
- 7 K A Kuiken *Univ Pittsburgh Bull* 1944 **40**, 142
- 8 D M Hegsted J J Oleson C A Elvehjem and E B Hart *J Biol Chem* 1940 **133**, xli
- 9 H E Robinson R E Gray F F Chesley and L A Crandall *J Nutrition* 1939 **17**, 227
- 10 D M Hegsted S W Hier C A Elvehjem and F B Hart *J Biol Chem* 1941 **139**, 863
- 11 G M Briggs R C Mills C A Elvehjem and E B Hart *ibid* 1942 **144**, 47
- 12 H J Almquist and E L R Stokstad *Nature* 1936 **137**, 581  
*J Nutrition* 1937 **13**, 339 H J Almquist *ibid* 1937 **14**, 241  
*Poultry Sci* 1938 **17**, 155
- 13 H R Bird C A Elvehjem and E B Hart *J Biol Chem* 1936 **114**, x H R Bird O L Kline C A Elvehjem E B Hart and J G Halpin *J Nutrition* 1936 **12**, 571
- 14 H R Bird and J J Oleson *J Biol Chem* 1938 **123**, xi
- 15 H J Almquist *Science* 1938 **87**, 538 H J Almquist and E Mecchi *J Biol Chem* 1938 **126**, 407
- 15a C W Mushett and W H Ott *Poultry Sci* 1949 **28** 850
- 16 C A Cary A M Hartman L P Dryden and G D Likely *Fed Proc* 1946 **5**, 128
- 17 L M Zucker T F Zucker V Babcock and P Hollester *Arch Biochem* 1948 **16**, 115

## 7 MISCELLANEOUS GROWTH FACTORS FOR MICRO-ORGANISMS

The factors so far discussed were discovered as the result of feeding tests on laboratory animals. There are other factors however the existence of which has been revealed by their ability to stimulate the

growth of micro-organisms. One or two of the factors already discussed, for example, streptogenin (page 616) and vitamin B<sub>12</sub> (page 530), are growth factors for micro organisms as well as for animals, but there are in addition factors that have been recognised solely by virtue of their action on micro organisms, and have not yet been tested for growth-promoting activity in animals.

The exacting organism, *Lactobacillus helveticus*, has been used by a large number of workers to test for the presence of new factors. Thus, M. A. Pollack and M. Lindner<sup>1</sup> obtained a fraction which was active on this organism and which resembled folic acid in some respects, it was not very soluble in organic solvents, for instance, and was stable in weakly acidic or alkaline solution but not in presence of strong acid or alkali. It appeared to be amphoteric, however, and was not readily adsorbed from solution and was precipitated by flavianic acid and heavy metals. The activity of this factor was attributed by E. J.-H. Chu and R. J. Williams,<sup>2</sup> to the presence of *p*-aminobenzoic acid, material with vitamin B<sub>9</sub> activity and various amino acids and peptides.

Other growth factors for *L. helveticus* were isolated from whole liver by Chattaway *et al.*<sup>3</sup> One, Factor 1, was also required for the growth of *gravis* and *intermedius* strains of *Corynebacterium diphtheriae*, and was present in casein hydrolysate as well as in liver. It was not precipitated by saturation with ammonium sulphate, not extracted from aqueous solution by butyl or amyl alcohol, nor by phenol or *p*-cresol, it gave no precipitate with lead, silver or phosphotungstic acid, it was not adsorbed on fuller's earth at pH 3, but was adsorbed on norit at pH 3 and eluted by alcoholic ammonia. Another factor, Factor 2, accelerated the initial growth of *L. helveticus*, and was similar to Pollack and Lindner's factor, it was partially precipitated by ammonium sulphate and was soluble in butyl alcohol. A third factor, Factor 3, was principally responsible for acid production by *L. helveticus*, it was soluble in butyl alcohol, phenol and *p*-cresol, but not in amyl alcohol, and was precipitated by lead, silver and phosphotungstic acid. Factor 3 also appears to exist in a combined form, insoluble in organic solvents. A number of synthetic glutamic acid peptides had growth-promoting activity.

A number of growth factors for *L. helveticus* were isolated from liver by Barton-Wright *et al.*<sup>4</sup> in the course of attempts to prepare a concentrate of folic acid. Various fractions were obtained that stimulated the growth of *L. helveticus* and *S. lactis* R., these differed from folic acid in being soluble in chloroform. Two, designated Factors HL1 and HL3, were adsorbed on Decalso, but differed from one another in their growth promoting activity, whilst the third Factor HL4, was not adsorbed on Decalso. It was possible that

Factor HL1 was a mixture of Factors HL3 and HL4, but these were certainly different from one another, since they exerted a synergistic action. Another growth factor for *L. helveticus* and *S. lactis* R exists in malt-sprouts.<sup>4a</sup>

F R Smith<sup>5</sup> obtained evidence for the existence of a new factor in yeast extract. This was essential for the growth of certain strains of *S. lactis*, and could not be replaced by any known vitamin or combination of amino acids. The factor was not precipitated by lead, silver, mercury, copper or zinc salts, and was not adsorbed on fuller's earth or activated carbon. It was insoluble in organic solvents and was destroyed by heating to 210° C under reduced pressure.

V H Cheldelin and T R Riggs<sup>6</sup> isolated a factor essential for the growth of *L. gayoni* 8289 from yeast and liver extracts by adsorption on norit and elution with ammonia. It was amphoteric but apparently not a protein, although it appeared to be combined with a protein in natural materials.

Metcalf *et al.*<sup>7</sup> observed that certain vegetables, particularly tomato juice, contained a growth factor for *L. fermentum*. The new factor, which could be partially replaced by aneurine, was named the T factor.

Claims have also been made for the existence of growth factors for *Clostridium sporogenes* in partially digested proteins,<sup>8</sup> for *Lactobacillus bulgaricus* in yeast,<sup>9</sup> and for *Leuconostoc citrovorum* in liver, peptone and yeast extract.<sup>10</sup> This last factor was distinguished from vitamin B<sub>12</sub> by the fact that it was stable to alkali and did not stimulate the growth of *L. leichmannii*.

The growth requirements of the protozoan, *Tetrahymena geleii*, have been referred to several times before, but in addition to requiring certain recognised B vitamins for growth, this organism also appears to need other factors, termed factor IIA or "protogen" and factors IIB' and IIB". Some of these may be identical with factors required by *L. helveticus* and *S. faecalis*.<sup>11</sup>

Finally, reference should be made to the fact that many purines and pyrimidines stimulate the growth of micro organisms, and some of the new factors recently described may ultimately prove to be identical with some of these. Thus factor Z, which promotes the growth of *Phycomyces blakesleeanus*, is probably identical with hypoxanthine, which is a growth factor for this organism in presence of aneurine.<sup>12, 13</sup> Hypoxanthine also stimulated the growth of *Spirillum serpens*, whilst guanine and adenine, although inactive when added separately, together increased the growth of the organism.<sup>14</sup>

Uracil stimulated the growth of *S. aureus*,<sup>15</sup> *S. pyogenes*,<sup>16</sup> *S. salivarius*,<sup>17</sup> certain species of *Lactobacillus*,<sup>18</sup> *Clostridium tetani*,<sup>19</sup> and *Shigella flexneriae*.<sup>20</sup>

# FACTORS FOR MICRO ORGANISMS

## References to Section 7

- 1 M A Pollack and M Lindner *J Biol Chem* 1943 147, 183
- 2 E J H Chu and R J Williams *ibid* 1944 155, 9
- 3 F W Chattaway F C Happold M Sandford B Lythgoe and A R Todd *Nature* 1943 151, 559 F W Chattaway F C Happold and M Sandford *Biochem J* 1944 38 111 F W Chattaway D E Dolby and F C Happold *ibid* 1948 43 567 F W Chattaway D E Dolby D E Hall and F C Happold *ibid* 1949 45 592 D E Dolby F C Happold and M Sandford *Nature* 1944 153 619
- 4 E C Barton Wright W B Emery and F A Robinson *ibid* 771 *Biochem J* 1945 39, 334
- 4a L G Colio and V Babb *J Biol Chem* 1948 174 405
- 5 F R Smith *J Bact* 1943 46, 369
- 6 V H Cheldelin and T R Riggs *Arch Biochem* 1946 10, 19
- 7 D Metcalf G J Hucker and D C Carpenter *J Bact* 1946 51, 381
- 8 G M Shull and W H Peterson *Arch Biochem* 1948 18 97
- 9 W L Williams E Hoff Jørgensen and E F Snell *J Biol Chem* 1949 177 933
- 10 H E Sauberlich and C A Baumann *ibid* 1948 176 165 1949 181 871 H P Broquist E L R Stokstad C E Hoffmann M Belt and T H Jukes *Proc Soc Exp Biol Med* 1949 71, 549
- 11 E L R Stokstad C E Hoffmann M A Regan D Fordham and T H Jukes *Arch Biochem* 1949 20 75 G W Kidder and V C Dewey *ibid* 433 E E Snell and H P Broquist *ibid* 1949 23 326
- 12 W J Robbins and F Kavanagh *Proc Nat Acad Sci* 1942 28, 65
- 13 H Hurm *Z Vitaminforsch* 1945 16 69
- 14 D Pennington *Proc Nat Acad Sci* 1942 28, 272
- 15 G M Richardson *Biochem J* 1936 30, 2184
- 16 D W Woolley *J Exp Med* 1941 73, 487 A W Bernheimer W Gillman G A Hottle and A M Pappenheimer *J Bact* 1942 43, 494
- 17 K L Smiley C F Niven and J M Sharman *ibid* 1943 45, 445 C F Niven and K L Smiley *J Biol Chem* 1943 150 1
- 18 E E Snell and H K Mitchell *US Proc Nat Acad Sci* 1941 27, 1
- 19 R L Feeney J H Mueller and P A Miller *J Bact* 1943 46, 563
- 20 S H Hutner *Arch Biochem* 1944 4 119



## CHAPTER XIV

### CONCLUSION

---

IN the preceding pages, the story of the vitamin B complex has been told in considerable detail. From the point of view of human and animal nutrition, the survey has indicated the paramount importance of aneurine, riboflavine and nicotinic acid, notwithstanding the fact that these substances may sometimes be synthesised in the intestine by the bacterial flora. Pyridoxine and pantothenic acid would appear to be of less importance, whilst the other members of the complex are *probably never responsible for serious deficiency diseases in man or, for that matter, in animals, except under very artificial conditions*.


As has already been pointed out, however, the association with deficiency diseases, although of great importance for the physical welfare of mankind, is by no means the most important characteristic of the vitamin B complex when an attempt is made to assess its significance in biochemistry, for the appearance of a deficiency disease depends on an unusual combination of circumstances (page 584).

The real significance of the vitamin B complex was appreciated more fully when its importance in the nutrition of micro organisms came to be recognised, although the presence of the whole vitamin B complex in yeast and liver, both centres of intense metabolic activity, was suggestive, and work on the stimulation of tissue respiration by the B vitamins had already indicated their close association with enzyme reactions. The stimulatory action of these substances on the growth of micro organisms, however, revealed their fundamental importance for living organisms of all types.

It is now clear that the vitamin B complex is an assemblage of biologically related substances that are essential for the metabolic activity of all living cells, and that their close association in yeast and liver is no mere accident. The fundamental rôle of riboflavine and nicotinic acid in effecting the transfer of hydrogen from substrates to molecular oxygen has already been discussed in Chapters III and IV. In the absence of these two substances, the dehydrogenation of a large number of substances cannot take place. Just what this means can best be appreciated by a consideration of the processes whereby glucose is transformed into carbon dioxide and water.

## CONCLUSION

The first stage in this transformation takes place in the absence of oxygen by a process referred to as anaerobic glycolysis. This is represented as follows




The presence of cozymase and diaphorase I is essential for the dehydrogenation of glyceraldehyde diphosphate to diphosphoglyceric acid and of pyruvic acid to lactic acid.


This series of changes represents the biochemical reactions that occur during the contraction of muscle, but the recovery of muscle to its original state involves another series of changes, which provides the energy necessary for the reconversion of most of the lactic acid back to glucose and thence into glycogen, in which form carbohydrate is stored in the muscle tissue. This energy is derived from the complete oxidation of the remainder of the lactic acid to carbon dioxide and water. This apparently simple transformation, known as respiration, which occurs in bacteria, yeast and protozoa as well as in animal tissues, is in reality exceedingly complex, and again involves riboflavin and nicotinic acid-containing coenzymes at several stages. The lactic acid is first oxidised back to pyruvic acid, which is then further oxidised by one of two routes.

The first of these is known as the 'oxaloacetic acid cycle' and was discovered by A. Szent-Györgyi in 1936. This process comprises the fixation of carbon dioxide to pyruvic acid to give oxaloacetic acid, which then takes up hydrogen to yield a mixture of fumaric and malic acids. These subsequently give up the hydrogen again with regeneration of oxaloacetic acid.

## THE VITAMIN B COMPLEX




The second route whereby pyruvic acid is dehydrogenated was discovered by H A Krebs and was originally called the 'citric acid cycle', because the formation of citric acid was believed to be one of the stages involved. It was subsequently shown, however, that iso-citric acid is actually the intermediate product, and that citric acid is only a by-product. Consequently, the name, "citric acid cycle" has been abandoned in favour of the term, 'tricarboxylic acid cycle'. In its present form this can be represented as follows



## CONCLUSION

The conversion of isocitric acid into oxalosuccinic acid involves triphosphopyridine nucleotide and diaphorase II, whilst the dehydrogenation of malic acid to oxaloacetic acid requires the presence of cozymase and diaphorase I. Nor is this all, for the tricarboxylic acid cycle is now known to be intimately linked with fatty acid metabolism through oxaloacetic acid, which is the pivot around which both fat and carbohydrate metabolism revolve. It has been shown that fatty acids with an even number of carbon atoms undergo  $\beta$  oxidation to acetoacetic acid or a homologue, and that these are then converted into acetyl phosphate which condenses with oxaloacetic acid to give *cis* aconitic acid. This is transformed into isocitric acid which then passes through the tricarboxylic acid cycle. Propionic acid is oxidised to pyruvic acid, which is either converted into acetyl phosphate or metabolised through the tricarboxylic acid cycle. These changes are represented as follows:



In the absence of enzymes containing nicotinic acid or riboflavine the metabolism of both fatty acids and carbohydrates is blocked, and this explains why the presence of these two substances is vital for the continued existence of all living cells.

Riboflavine and nicotinic acid are not the only B vitamins essential for fatty acid and carbohydrate metabolism, however. Aneurine pyrophosphate is a coenzyme necessary for the conversion of pyruvic acid into lactic acid, acetic acid, acetoacetic acid and oxaloacetic acid, probably it activates the molecule preparatory to its oxidation.

or condensation with another molecule (page 102) This adequately explains the importance of aneurine in nutrition, for pyruvic acid occupies one of the key positions in both fat and carbohydrate metabolism The conversion of pyruvic acid into acetic acid, however, also involves pantothenic acid (page 391), without which biological acetylations cannot take place It is possible that the link between fatty acid metabolism and the tricarboxylic acid cycle may also be broken in its absence, although this has not yet been proved

Another member of the vitamin B complex concerned with fat and carbohydrate metabolism is biotin, which appears to be a constituent of the coenzyme of oxaloacetic acid decarboxylase (page 443) This is responsible for the conversion of oxaloacetic acid into pyruvic acid and, presumably, for the fixation of carbon dioxide by pyruvic acid It may also be concerned with the conversion of oxalo succinic acid into  $\alpha$ -ketoglutaric acid

Thus practically all the B vitamins, of which sufficient knowledge is available, appear to be involved in carbohydrate and fatty acid metabolism

In addition to their function as hydrogen carriers in association with various dehydrogenases, the flavine nucleotides are also necessary for the oxidation of D amino acids to the corresponding keto-acids and for the oxidation of diamino acids and glycine (page 195), whilst cozymase is essential for the conversion of glutamic acid into  $\alpha$  keto-glutaric acid (page 278) Thus the oxidation of amino acids also depends on the presence of riboflavine and nicotinic acid

Amino acids undergo other changes besides oxidation, and these involve another member of the vitamin B complex, pyridoxine, which is apparently not concerned with carbohydrate metabolism As already noted (page 331), pyridoxal phosphate is the coenzyme responsible for the decarboxylation of the amino acids, L lysine, L tyrosine, L histidine, L arginine, L ornithine and L-glutamic acid with the formation of the corresponding amines Pyridoxal phosphate also catalyses the transfer of an amino group from an amino acid to a keto acid with the formation of a second amino acid, and it appears to be responsible for the synthesis of tryptophan from indole and serine

A considerable amount of research work is at present being carried out on the mechanism of enzyme reactions, and the next few years will doubtless provide many further examples of reactions in which known members of the vitamin B complex are involved In addition, it is not unlikely that other substances having analogous properties will be discovered and that these will have all the characteristics that we have come to associate with the components of the vitamin B complex Thus, they should produce characteristic deficiency

## CONCLUSION

symptoms in suitable experimental animals when these are maintained on a diet from which the factor is missing but which is otherwise complete, and they should cure these deficiency symptoms when added to the diet, they should stimulate the growth of exacting strains of micro-organisms when grown on a medium deficient in the factor, but otherwise adequate for growth, and their growth-promoting action on micro organisms, and possibly on animals too, should be antagonised by substances that closely resemble them in chemical structure, most important of all, they should be present in enzyme systems responsible for specific biochemical reactions

It must not, of course, be assumed that all coenzymes have vitamins as their prosthetic groups. Cytochrome, for instance, contains iron-porphyrin, whilst peroxidase and catalase contain other iron compounds, and ascorbic acid oxidase contains copper. Again, glutathione is a coenzyme for glyoxalase and possibly for many other enzymes, for there is a long list of enzyme systems that appear to depend for their activity on the presence of sulphhydryl groups. The vitamin B complex, therefore comprises only one special class of substances essential for the activity of coenzymes, it is characterised by the fact that its members cannot, except in certain circumstances, be produced by the organisms that require them, but have to be supplied ready made in the diet.

In concluding this survey, I can only express the hope that my attempt to systematise the large mass of information now available will have given the reader a clear picture of the chemical and biological behaviour of each member of the vitamin B complex, and an appreciation of the important function the group as a whole performs in the economy of mammals and birds, insects, plants and micro-organisms. I hope, too, that I have conveyed something of the sense of confusion, almost chaos that seemed to herald the discovery of each new vitamin. It was rather as though one were watching the weaving of some large tapestry without knowing anything of the ultimate design. At first one saw only jumbled patches of colour, formless and meaningless but as the work progressed these patches resolved themselves one by one into familiar objects that one recognised and that became of greater and greater significance as the picture grew, until finally one could perceive the meaning and purpose of the whole picture. Even now the tapestry is incomplete, and we do not fully understand its purport. Perhaps we never shall though we may comprehend its meaning more fully as we watch the weaving of other tapestries related in some way to the one that has formed the subject of this book.

# AUTHOR INDEX

- ABBOTT Labs , 155, 156  
 Abbott, O D , 594, 595  
 Abdel Kader, M M , 251, 252, 257, 266,  
 273, 274, 283, 286, 293, 295  
 Abderhalden, E , 119, 130  
 — R , 119, 130  
 Abelin, J , 367, 370  
 Abels, J C , 69, 74, 429, 432, 575  
 Abelson, P H , 543, 544  
 Abraham, E P , 192, 194, 201, 250, 252  
 Acheson, R M , 523, 526  
 Ackermann, W W , 387, 389, 395, 402  
 Adams, R , 214, 216  
 — R R , 209, 210  
 Adler, E , 134, 135, 194, 201, 276, 277,  
 279, 280, 292, 293, 295  
 Agnew, L R C , 320, 322  
 Ahlstrom, L , 128, 131  
 Ahmad, B , 64, 73  
 Albanese, A A , 84, 85  
 Albert, P W , 251, 252  
 Albury, M , 44, 45, 46, 165, 167, 235,  
 236  
 Albus, H , 275, 279  
 Alcayaga, R , 320, 322, 368, 371  
 Alden, H S , 179, 183  
 Alderton, G , 427, 431  
 Alexander, B , 38, 42, 66, 70, 72, 73, 74,  
 76, 78, 80, 81, 84, 85  
 Alexopoulos, C J , 110, 113  
 Alne, E , 369, 371  
 Allan, F N , 582, 584  
 Allbone, E C , 66, 73  
 Allen, D I , 43, 45  
 Allison, M J C , 223, 231  
 Allfrey, V , 482, 483  
 Allgeier, A M , 489, 494  
 Allied Chemical and Dye Corp , 215, 217  
 Allison, F E , 405  
 Almquist, H J , 595, 600, 602, 603, 604,  
 619, 620  
 Alt, H , 523, 526  
 Altman, K I , 276, 277, 280  
 American Cyanamid Co , 8, 154, 156,  
 214, 216, 306, 307, 357, 358, 359, 399,  
 402, 475, 477  
 Ames, S R , 334, 337  
 Amiard, G , 95, 104  
 Andersag, H , 15, 19, 21, 22, 117, 130,  
 300, 301  
 Anderson, R C , 414, 415, 416, 420, 473,  
 476, 477, 478, 479, 566  
 Anderson, R J , 565, 566  
 Andrews G A , 498, 502  
 — J S , 161, 164  
 — M B , 285, 286  
 Andus, L J , 286, 287  
 Angelescu, C , 90, 103  
 Angier, R B , 463, 466, 471, 472, 473,  
 474, 475, 476, 477, 482, 483, 520, 522,  
 525  
 Angstein, L , 554, 558, 559  
 Ansbacher, S , 133, 134, 150, 163, 425,  
 430, 551, 552, 553  
 Anslow, W P , 417, 420  
 Antognini, R , 176, 177  
 Antopol, W , 48, 54, 88, 89, 200, 203,  
 318, 321, 323, 324, 325, 327, 329, 330  
 Aramburu, T , 498, 501, 502, 503, 505,  
 538, 540, 541, 542  
 Archdeacon, J W , 555  
 Archer, W , 170, 173, 189, 190  
 Aring, C D , 274, 323, 324  
 Arismendi, H H , 83, 85, 179, 183, 187,  
 189  
 Armour Research Foundation, 22, 23  
 Armstrong, M D , 417, 420  
 Arnason, A , 44, 46, 165, 167  
 Arnold, A , 396, 402, 612, 613  
 Arons, I , 501, 503  
 Arth, G E , 414, 415, 416, 420, 473, 476,  
 477, 478, 479  
 Artom, C , 601, 603  
 Ascham, J K , 315, 317  
 Aschner, M , 115, 116  
 Asenjo, C F , 507, 508  
 Ashburn, L L , 48, 54, 366, 370, 434,  
 436, 489, 494  
 Ashe, W F , 323, 324  
 Asher, S P , 60, 61  
 Asmundson, V S , 318, 320, 321, 329  
 Atkin, L , 33, 34, 36, 106, 112, 225, 227,  
 231, 281, 285, 311, 314, 315, 316, 317,  
 338, 340, 361, 362, 386, 389, 404, 405,  
 438, 440, 569, 570, 577, 578  
 Atkinson, M , 247, 249  
 — W B , 366, 370  
 Auhagen, E , 293, 295, 560, 562  
 Austin, C R , 52, 55  
 Avakian, S , 346, 347, 514, 524  
 Aykroyd, W R , 233, 236, 241, 243, 248  
 Ayre, J E , 61

# AUTHOR INDEX

- Axelrod, A E, 52, 55, 157, 162, 170,  
 172, 179, 183, 188, 190, 195, 202,  
 229, 232, 262, 263, 265, 267, 268,  
 280, 290, 295, 320, 322, 369, 371,  
 391, 393, 443, 444, 445, 450, 451,  
 452, 453, 454, 455, 456, 487, 494  
 — A R, 523, 526  
 — V, 179, 183  
 Azavedo, M D, 26, 27  
  
 BABB, V, 622, 623  
 Babcock, S H, 353, 357, 366, 370, 373,  
 375, 379  
 — V, 619, 620  
 Babbitt, B P, 53, 56  
 Babson, R D, 147, 148  
 Bacharach, A L, 36, 37, 232, 236  
 Bacon, J D S, 360, 362, 377, 378  
 Baddiley, J, 332, 337  
 Badger, E, 596, 597  
 — L F, 52, 55  
 Badgett, C O, 215, 217, 288, 291, 294  
 Bär, F, 137, 139  
 Baeyer, A, 585  
 Bahler, G P, 424  
 Bahme, R B, 286, 287  
 Bailey, M J, 43, 45  
 Baird, G R, 260, 267, 283, 286  
 Baker, A B, 323, 324  
 — A Z, 82, 85  
 — B R, 417, 420, 447, 454  
 — M, 399, 402  
 Balaban, I E, 216, 217  
 Baldwin, H R, 222, 230  
 — I L, 107, 112  
 Ball, E G, 194, 201  
 Ballentine, R, 387, 389  
 Bandier, E, 219, 221, 224, 230  
 Banga, I, 95, 104, 191, 201  
 Bantz, A C, 282, 285  
 Bardos, T J, 520, 525  
 Barger, G, 38, 42  
 Barker, D, 170, 173, 189, 190  
 — H A, 439, 440, 556, 558  
 Barki, V H, 434, 436, 619, 620  
 Barnes, B, 44, 45, 46  
 — R A, 395, 402  
 — R H, 536  
 Barnett, J W, 381, 388, 395, 397, 398,  
 402  
 Barron, E S G, 99, 100, 102, 105, 193,  
 198, 201, 203, 279, 280  
 Barsky, J, 323, 324  
 Bartels, W E, 575  
 Barton, M N, 345, 346, 347  
 Ba
- Bass, A D, 492, 495  
 Bastedo, W A, 311, 314, 343, 346  
 Bauer, E, 276, 279  
 — F K, 91, 103  
 — H, 560, 562  
 Bauernfeind, J C, 158, 160, 163, 165,  
 167, 170, 173  
 Bauld, W A G, 61  
 Baum, H M, 169, 172, 365, 370, 572,  
 574  
 Baumann, C A, 171, 173, 319, 321, 322,  
 330, 337, 586, 587, 597, 607, 608, 622,  
 623  
 Baumgarten, P, 118, 123, 124, 130  
 Bavin, E M, 540, 542  
 Beadle, B W, 23, 27  
 — G W, 281, 285, 313, 315, 344, 347,  
 569, 570, 587  
 Bean, W B, 174, 175, 176, 249, 252,  
 289, 295, 323, 324, 325, 327.  
 Beattie, F J R, 586, 587  
 Beatty, A, 158, 163  
 Beaven, G R, 533  
 Bechdel, S L, 75, 79, 80  
 Becker, B, 140, 147, 206, 207, 209, 276,  
 279  
 — D E, 541, 542  
 — E, 461, 465  
 — E R, 369, 371, 387, 389  
 Beiler, J M, 345, 347, 527, 528  
 Bein, M L, 578, 579  
 Belcher, M R, 446, 454  
 Belding, H, 497, 502  
 Bell, G H, 250, 252  
 Bellamy, W D, 331, 332, 337, 344, 347  
 Belt, M, 170, 173, 239, 240, 486, 493,  
 519, 521, 522, 524, 525, 535, 536, 543,  
 544, 574, 575, 622, 623  
 Bendas, H, 192, 201  
 Bender, R C, 133, 134, 180, 183, 309,  
 313, 366, 370, 607, 608  
 Benesch, R, 241, 248, 260, 267, 268,  
 269, 271, 283, 286  
 Benevolevskaja, Z V, 21, 22  
 Benham, R W, 96, 104, 110, 113  
 Benk, J F, 45, 46, 235, 236  
 Benson, R A, 65, 69, 73  
 Bent, M J, 369, 371, 384, 388  
 Bentel, R, 354, 358  
 Benz, F, 138, 139, 140, 147, 206, 207,  
 209, 254, 266, 278, 280  
 Berg, B N, 367, 371  
 — C P, 251, 252  
 — R L, 46, 52, 54, 56  
 Bergeim, O, 37, 42, 549, 550  
 — — — — — 130, 147,



- Berk, L., 538, 541.  
 Berkman, S., 228, 231, 282, 285, 286,  
 380, 381, 388, 391, 393  
 Berman, L., 523, 526  
 — M., 391, 393  
 Bernal, J. D., 22, 23  
 Bernheim, F., 195, 198, 202, 203, 254,  
 263, 266, 268, 591, 592  
 — M. L. C., 198, 203, 254, 266  
 Bernheimer, A. W., 622, 623  
 Bernstein, S., 417, 420, 447, 454  
 Berry, J. L., 495, 501  
 Berryman, G. H., 236, 269, 270,  
 435, 436, 504.  
 Bessey, O. A., 46  
 178, 182, 185, 186, 187, 189, 193, 201,  
 479, 480, 612, 613  
 Best, C. H., 428, 431, 573, 574, 582, 584,  
 590, 591, 592  
 Bethell, J. J., 541, 542, 576, 577  
 Bethell, F. H., 498, 502, 527, 528, 539,  
 541  
 Bethke, R. M., 79, 80, 81, 170, 173, 185,  
 186  
 Beveridge, J. M. R., 573, 574, 591, 592  
 Bhagvat, K., 26, 27, 115, 116, 361, 362  
 Bickling, M. M., 439, 441  
 Bierbaum, O. S., 496, 501  
 Bilhaud, M., 264, 268  
 Bilmoria, H. S., 460, 465  
 Bills, C. E., 289, 295  
 Bina, A. F., 310, 314  
 Binkley, S. B., 458, 459, 465, 469, 470,  
 471, 477, 479, 480  
 Birch, T. W., 30, 32, 90, 103, 133, 296,  
 297, 298,  
 Bird, F. H., 318, 320, 321, 329, 425, 430,  
 437  
 — H. R., 539, 542, 609, 611, 619, 620  
 — O. D., 160, 163, 311, 314, 458, 459,  
 460, 465, 477, 478, 479, 480, 481,  
 482, 484, 489, 493, 494, 498, 502,  
 517, 524  
 Birkhauser, H., 88, 89  
 Birkinshaw, J. H., 197, 202  
 Birkofer, L., 191, 200, 290, 292, 295  
 Bishop, L. R., 404, 405  
 Bissell, G. W., 70, 74  
 Bjälfoe, G., 405, 439, 440  
 Black, A., 135, 157, 162, 425, 430, 434,  
 436, 489, 494, 577  
 — D. A. K., 501, 503  
 — J., 282, 285, 380, 388  
 — S., 349, 351  
 Blalock, J. V., 39, 42  
 Blanchard, K. C., 516, 524, 548  
 — M., 196, 202, 548  
 — M. L., 444, 445  
 Blankenhorn, M. A., 212, 213  
 Blazso, S., 181, 182, 183  
 Blewett, M., 115, 116, 205, 206, 287, 341,  
 342, 389, 390, 441, 442, 512, 513, 560,  
 578, 579, 597, 617, 618  
 Bloch, H., 291, 292, 295  
 — K., 599, 602  
 Bloom, E., 158, 163, 165, 167, 233, 236,  
 364  
 — E. S., 458, 459, 464, 465, 466, 469,  
 470, 471, 477, 478, 479, 480, 484  
 493, 527, 528  
 Bloomberg, B. M., 557, 559  
 — H. M., 560  
 164, 167,  
 404, 405  
 Bock, G., 499, 503  
 Boehme, W., 125, 131, 290, 295  
 Boehne, J. W., 503, 504  
 Boerer, I. J., 176, 177  
 Boggiano, E. M., 522, 525  
 Bohonos, N., 340, 341, 458, 465, 468,  
 471, 478, 479, 484, 493, 510, 511  
 Bohstedt, G., 572, 574  
 Boley, L. E., 53, 56  
 Bolliger, A., 52, 55  
 Bolton, W., 170, 173, 189, 190  
 Bond, H. W., 250, 252, 257, 266  
 — T. J., 520, 525  
 Bone, J. F., 491, 495  
 Bonner, D., 281, 285  
 — J., 108, 112, 114, 115, 125, 131,  
 205, 286, 287, 315, 317, 341  
 Booher, L. E., 132, 133, 134, 135  
 Booth, A. N., 79, 81  
 — R. G., 23, 24, 27, 40, 42, 45, 83, 85,  
 157, 160, 162, 163, 166, 168, 220,  
 230, 234, 235, 236  
 Boothe, J. H., 463, 466, 471, 472, 473,  
 474, 475, 476, 477, 482, 483, 520, 522,  
 525  
 Borchers, R., 152, 153  
 Borg, W. A. J., 412, 413, 414  
 Borggard, M., 588, 589, 594, 595  
 Bornstein, B. T., 439, 440, 556, 558  
 Borson, H. J., 318, 321  
 Borsook, H., 66, 73, 533, 599, 601, 602,  
 603  
 Boruff, C. S., 158, 163  
 Bosse, M. D., 487, 494  
 Bosshardt, D. K., 534, 536  
 Bossi, M. L., 578, 579  
 Bosworth, M. R., 401, 403  
 Bottomley, A. E., 311, 314  
 Boucher, R. V., 425, 430, 437  
 Boulanger, P., 190  
 Bourquin, J. P., 417, 420, 449, 455  
 Bovarnick, M. R., 216, 217, 283, 286  
 Bovet, D., 545, 547

- Bowden J P 424  
 Bowie D J 582 584  
 Bowles L L 367 370  
 Bowman K M 246 249  
 Boxer G F 50 55  
 Boyack G A 394 401  
 Boyd E M 86 89  
 — M J 380 388  
 Brackott S 399 402  
 Bradford E A M 167 168 364 365  
 Brady D F 161 164  
 Braganca B de M 234 236  
 Brandalcone H 372 553 554  
 Brandenburg R O 503 505  
 Braude R 238 240  
 Braun K 176 177  
 Braunstein A E 334 335 338  
 Brazda F G 273 274  
 Brendel R 527 528  
 Brendler H 521 525  
 Breslove B B 380 388  
 Bressler B 481 482  
 Breer W 178 180 182 187 189  
 Brian P W 55 559  
 Bridgewater A 452 454 456  
 Briggs A P 269 271 432 433 437  
 — G M 239 240 270 272 273 289  
 294 312 315 320 322 344 347  
 425 430 437 458 460 465 481  
 482 513 524 534 536 551 553  
 573 575 612 613 614 615 619  
 620  
 Brink N G 530 531 532 533  
 Brömel H 195 202  
 Bromberg Y M 176 177  
 Brook A J 534 536  
 Broquist H P 107 112 622 623  
 Brosteaux J 229 232 276 280  
 Brown G O 593  
 Brown A 432 433  
 — E B 40 42 169 172 310 314  
 — E V 17 21  
 — G B 417 420 421 447 449 450  
 452 455  
 — R A 37 38 41 42 75 80 160  
 163 458 459 465 477 478 479  
 481 482 484 489 493 494 498  
 502 517 524  
 — R E 40 42  
 — W S 155 156  
 Brozek J 60 61 179 183 606 608  
 Bruce W F 320 322 337 338 344  
 347 485 493  
 Bruno P 283 286  
 Brzezinski A 176 177  
 Buchman E R 12 13 14 15 66 73  
 119 120 125 130 131  
 Buchner P 115 116  
 Büchi J 278 280  
 Buechler E 51 55 171 173  
 Buhs R P 326 327  
 Bnzell H H 33 36  
 Burch H B 178 182 185 186 187  
 189  
 Burchenal J H 523 526  
 — J R 523 526  
 Burgin C J 364  
 Burill M W 48 54  
 Burk D 404 405 429 431 433 434  
 447 445  
 Burkholder P R 79 81 106 109 112  
 113 114 115 149 150 153 185 186  
 203 204 205 281 283 285 286 287  
 338 340 341 343 344 346 347 386  
 389 435 436 438 440 441 479 480  
 483 484 511 512 569 570 577 578  
 Burlet E 396 402  
 Burn J H 28 32  
 Burnside J L 540 542  
 Burris R H 334 338 444 445 481  
 482  
 Burroughs E W 79 80 81 185 186  
 Burström D 405 439 440  
 Burt A S 47 54  
 Burton H W 578 579 580 581  
 — I F 374 376 527 528  
 Busch R K 439 441  
 Buschke W H 170 172 331 337  
 Buschman D M 540 542  
 Buskirk A H 361 362  
 Busnel R G 126 131 165 167 205  
 206 208 210  
 Bustad L K 490 491 495 552 553  
 573 574  
 Butler B 333 337  
 — R E 174 176 178 182 187 189  
 228 232 245 249 282 285  
 Buttle G A H 545 547  
 Buyze H G 499 502  
 Byerly T C 539 542  
 Cain C H 197 02 517 518 524  
 Calder R M 273 274  
 Caldwell F E 429 431  
 — M H 495 501  
 Calkins D G 459 464 465 466 478  
 479 484 493  
 Camen N N 204 05  
 Campbell C J 459 462 478 479 481  
 482 484 493  
 — D C 538 542  
 Cannon H C 81 84  
 — M D 618 619 620  
 Cantor M M 324 325  
 Cantrell W 399 402  
 Capps B F 534 536  
 Carbajal C A P 40 42  
 Cardini C E 586 587  
 Carlson R B 346 347  
 Carlson W E 25 27

- De Finis, M. L., 47, 54  
 Deffner, M., 197, 202  
 De Grunigen, A., 479, 480  
 De la Hueraga, J., 234, 236, 242, 248, 271, 272  
 De Lange, E. J., 226, 231, 251, 252, 257, 266  
 Delor, R. A., 361, 362, 514, 524  
 De Man, T. J., 410, 414  
 De Masters, C. U., 594, 595  
 De Meillon, B., 115, 116, 205, 206, 287, 341, 342, 390, 441, 442, 496, 502, 512, 513  
 De Merre, L. J., 155, 156  
 Denis, W., 299, 301  
 Denko, C. W., 77, 80, 185, 186, 269, 270, 271, 272, 327, 328, 377, 435, 436, 504, 505, 506, 554  
 Dennis, C., 591, 592  
 — P. O., 220, 230  
 Denny, H. M., 501, 503  
 Denny-Brown, D., 538, 541  
 Denton, C. A., 539, 542  
 Deodhar, T., 271, 272  
 De Renzo, E. C., 321, 327  
 De Ritter, E., 152, 153, 160, 163.  
 De Ropp, R. S., 523, 526  
 Derse, P. H., 434, 436  
 Desgrez, A., 596  
 Desnuelle, P., 207, 210  
 De Soldati, L., 52, 56  
 De Souza, V., 438, 440  
 Deuel, H. J., 44, 45, 91, 103, 249, 252  
 Deutsch, E., 69, 74  
 — H. F., 34, 36  
 De Vaughn, N. M., 432, 433, 437  
 Devi, P., 26, 27  
 Dewan, J. G., 194, 201, 276, 278, 280  
 De Wardener, H. E., 58, 61  
 Dewey, V. C., 285, 286, 340, 341, 509, 511, 622, 623  
 De Woody, J., 453, 456  
 Dhyse, F. G., 428, 431  
 Diamond, L. K., 523, 526  
 Dias, M. V., 87, 89  
 Diaz, L. A., 553, 554  
 Dicken, D. M., 157, 162, 228, 232, 313, 315, 339, 341, 360, 362, 422, 423, 439, 441, 481, 482, 549, 550, 551, 556, 558  
 Dickens, F., 277, 280  
 Dietrich, L. S., 535, 536, 540, 542, 614, 615  
 Digonnet, L., 264, 268  
 Dimick, M. K., 318, 321, 368, 371  
 Dingle, J. H., 546, 547  
 Dingwall, R. W., 86, 89  
 Dinning, J. S., 527, 528  
 Dittmer, K., 429, 431, 439, 440, 446, 447, 448, 452, 453, 454, 455, 456  
 Dixon, M., 276, 280  
 Doan, C. A., 461, 466, 495, 501, 503  
 Doisy, E. A., 47, 54, 197, 202  
 Dolan, L. A., 448, 450, 452, 455  
 Dolby, D. E., 621, 623  
 Dolger, H., 66, 73  
 Domagk, G., 545, 547  
 Donath, W. F., 11, 12, 28, 32  
 Dorfman, A., 228, 231, 282, 285, 286, 380, 381, 388, 391, 393, 442, 445  
 — F., 51, 55  
 — L., 417, 420  
 Dorland, R., 315, 317, 341  
 Dornbush, A. C., 535, 536, 597, 604, 605  
 Dornow, A., 118, 123, 124, 130, 131  
 Dragiff, D. A., 367, 371  
 Dragstedt, L. R., 591, 592  
 Drake, T. G. H., 189, 190  
 Dreker, L., 449, 450, 451, 455  
 Drell, W., 399, 400, 403  
 Drilhon, A., 205, 206  
 Drill, V. A., 48, 54, 540, 542  
 Drouet, L., 504, 505  
 Drummond, J. C., 1, 9, 10, 11, 12, 28, 32, 84, 85, 188, 189, 272, 273  
 Dryden, L. P., 539, 542, 619, 620  
 Dubnoff, J. W., 599, 601, 602, 603  
 Dubrausky, V., 181, 182, 183  
 Dumm, M. E., 366, 370  
 Dunbar, J., 247, 249  
 Dunlop, D. M., 538, 541  
 Dunsen, M. S., 201, 205, 206, 207, 208  
 Dutoit, C., 60, 61  
 Dutra, F. R., 590, 592, 594, 595  
 Du Vigneaud, V., 7, 404, 405, 406, 407, 410, 414, 421, 429, 431, 439, 440, 446, 447, 448, 450, 452, 453, 454, 455, 456, 583, 584, 598, 599, 600, 602, 603, 604, 605  
 Dwork, K. G., 557, 559  
 Dwyer, I. M., 204, 205  
 Dyer, H. M., 598, 602  
 Eakin, R. E., 33, 36, 311, 314, 315, 316, 317, 338, 340, 421, 422, 423, 424, 427, 431, 438, 440, 499, 503, 514, 519, 524, 543, 544  
 Earle, A., 360, 361, 362  
 Eastcott, E. V., 404, 405, 564, 565, 577  
 Easton, N. R., 414, 416, 420  
 Eaton, M. D., 558, 559  
 Echler, C. R., 329, 330  
 Eckardt, R. E., 307, 308, 317

- Ecke, R S, 554, 558, 559  
 Eckert, H W, 549, 550  
 Eckstein, H C, 508, 602  
 Eddy, W H, 611, 613  
 Eden, E, 76, 80  
 Edgar, C E, 297, 298, 309, 313, 348, 351  
 Edie, E S, 11, 12, 28, 32  
 Edlbacher, S, 97, 105  
 Edson, N L, 197, 203  
 Edwards, P C, 523, 525  
 Egana, E, 60, 61  
 Eggleston, L V, 96, 98, 104  
 Eigen, E, 313, 315, 532, 533, 535, 536  
 Eijkman, C, 2, 3, 6, 9  
 Eisen, H N, 320, 322  
 Eisenstadt, W S, 62, 63  
 Elderfield, R C, 123, 124, 126, 130, 131  
 Elh Lilly & Co, 154, 156  
 Elion, G B, 513, 516, 522, 524, 525  
 Ellenberg, M, 66, 73  
 Eller, J J, 553, 554  
 Ell  
 Ellis, B, 531, 532, 533  
 — L N, 188, 189  
 — N R, 52, 56, 539, 542  
 El Sadr, M M, 156, 162, 297, 298, 309, 313, 318, 321, 348, 351, 394, 401  
 Elsom, K O S, 49, 55, 59, 61, 79, 81, 82, 85, 606, 608  
 Elvehjem, C A, 25, 27, 44, 45, 51, 53, 55, 56, 79, 81, 93, 94, 96, 104, 132, 133, 134, 157, 162, 166, 167, 168, 170, 172, 173, 179, 181, 183, 184, 186, 188, 351, 361, 362, 363, 364, 365, 368, 369, 370, 371, 377, 378, 379, 391, 393, 394, 401, 405, 423, 424, 425, 426, 429, 430, 431, 434, 435, 436, 437, 441, 442, 443, 445, 451, 455, 458, 460, 461, 462, 465, 466, 481, 482, 483, 484, 485, 486, 487, 488, 490, 491, 492, 493, 494, 505, 506, 507, 508, 513, 524, 528, 529, 535, 536, 537, 538, 540, 542, 551, 552, 553, 573, 574, 575, 583, 584, 588, 589, 591, 592, 594, 595, 608, 609, 610, 611, 612, 613, 614, 615, 616, 618, 619, 620  
 Elvove, E, 560, 562  
 Emerique-Blum, L, 35, 37, 112, 113, 118, 130  
 Emerson, G A, 70, 74, 122, 130, 171, 173, 183, 186, 208, 210, 352, 365, 366, 369, 370, 377, 378, 424, 425, 428, 430, 431, 434, 435, 436, 437, 446, 447, 454, 541, 542, 551, 552, 618, 620  
 — O H, 352, 365, 369  
 — S, 557, 559  
 Emery, W B, 35, 37, 106, 112, 311, 314, 361, 362, 422, 423, 531, 532, 537, 538, 569, 570, 571, 621, 623  
 Emmanuelowa, A, 269, 271  
 Emmerie, A, 159, 163  
 Emmett, A D, 10, 37, 38, 41, 42, 160, 163, 311, 314, 458, 459, 465, 477, 479, 480, 481, 482, 484, 493  
 Emoto, S, 366, 370  
 Endicott, K M, 487, 494  
 Engel, C, 499, 502  
 — R W, 366, 368, 370, 586, 587, 588, 589, 590, 592, 594, 595  
 Engler, C, 216, 217  
 Entenman, C, 586, 587, 594, 595, 601, 603  
 Epley, H C, 308, 309  
 Eppright, M A, 40, 42, 481, 482, 581  
 Epps, H M R, 335, 338  
 Epstein, M, 519, 524, 544  
 Erickson, A E, 472, 473  
 — L L, 256, 266  
 Erksen, T S, 277, 280  
 Erikson, J, 108, 112  
 — W, 291, 292, 295  
 — 28, 131.  
 — 7, 280.  
 — E V, 189, 190  
 — H M, 49, 54, 345, 347, 352, 365, 366, 369, 370, 377, 378, 425, 430, 489, 494, 572, 574  
 — R J, 590, 592  
 — W C, 381, 387, 388, 394, 401, 446, 454  
 — W H, 11, 12, 28, 32.  
 Everett, J E, 277, 280.  
 Everitt, G M, 53, 56  
 Eyring, H, 197, 203  
 Eysenbach, H, 197, 202.  
 FALLING, A, 97, 105.  
 Fager, L E C, 481, 482

- Fahrenbach, M J, 463, 466, 471, 473,  
 474, 475, 477, 522, 525  
 Falco, E A, 513, 516, 524, 528, 529  
 Farber, S, 501, 503, 523, 526  
 Fargo, W C, 539, 542  
 Farley, D L, 69, 74  
 Farmer, F A, 486, 493, 506, 507  
 Farouque, M A, 289, 294  
 Farrer, K T H, 23, 24, 27  
 Fay, J, 491, 495  
 Featherston, W P, 238, 240  
 Feder, V H, 179, 183  
 Feeney, R E, 111, 113, 177, 178, 182,  
 204, 205, 282, 286, 340, 346, 360, 361,  
 362, 439, 440, 622, 623  
 Fehuly, L, 104  
 Fein, H D, 246, 249  
 Feldberg, W, 391, 393  
 Fels, I G, 393  
 Felton, J R, 451, 455  
 Fenton, F, 44, 45, 46, 165, 167, 235,  
 236  
 — P F, 188, 190  
 Ferger, M F, 450, 452, 453, 455  
 Fernholz, M E, 207, 210  
 Ferrebee, J W, 25, 27, 49, 54, 72, 74,  
 177, 182, 192, 201  
 Ferris, E B, 274  
 Ferry, R M, 591, 592  
 Fevold, H L, 427, 431  
 Fiala, G F, 485, 493  
 Fieger, E A, 422, 423  
 Field, H, 23, 27, 37, 41, 64, 73, 220, 224,  
 230, 231, 237, 239, 252, 253, 264, 265,  
 268, 273, 274  
 Figge, F H J, 366, 370  
 Fildes, P, 128, 227, 231, 282, 285, 546,  
 547  
 Finch, L, 66, 73  
 Fincke, M L, 44, 46  
 Fink, H, 44, 45, 106, 112, 234, 236, 523,  
 526  
 Finkelstein, J, 13, 14, 15, 16, 21, 123,  
 130, 353, 354, 357, 394, 401  
 Finlaad, M, 538, 542, 546, 547, 554  
 Fischer, F G, 197, 202  
 — H O L, 566  
 — O, 216, 217  
 Fish, W M, 175, 177  
 Fishberg, E H, 324, 325  
 Fisher, A, 334, 337, 346, 347  
 — N F, 582, 584  
 Fitzgerald, E E, 36, 37  
 Flanagan, G E, 159, 163  
 Fleischmann, G, 184, 186, 249, 252, 260,  
 267  
 Fleming, A J, 147, 148  
 Flesher, A M, 85, 87, 89  
 Fletcher, F, 496, 502  
 Fleury, P, 568, 569  
 Flexner, J, 325, 327  
 Flickinger, M H, 151, 153  
 Flinn, B C, 452, 456  
 Florijn, E, 70, 74  
 Flower, D, 450, 451, 455  
 Flynn, R M, 393  
 Foà, N L, 237, 239  
 — P P, 69, 74, 87, 89, 237, 239  
 Foeste, A, 79, 81  
 Folch, J, 570, 571  
 Folin, O, 299, 301  
 Folkers, K, 299, 300, 301, 304, 307, 308,  
 312, 314, 343, 344, 346, 347, 354, 357,  
 394, 395, 401, 402, 410, 414, 415, 416,  
 420, 473, 476, 477, 478, 479, 530, 531,  
 532, 533  
 Folley, S J, 615, 618  
 Follis, R H, 52, 55, 56, 170, 172, 238,  
 240, 320, 322, 331, 337, 368, 371  
 Fontaine, M, 150, 151, 153  
 Forbes, E B, 48, 54  
 — J C, 573, 574, 591, 592, 601, 603  
 Ford, J H, 359  
 — Z W, 48, 54, 66, 73, 155, 156, 180,  
 181, 183, 186  
 Fordham, D, 479, 480, 622, 623  
 Forrest, H S, 475, 477, 523, 526  
 Forster, O, 332, 337  
 Forzimer, J, 324, 325  
 Foster, C, 51, 55, 128, 131  
 — J C, 534, 535, 536  
 — J W, 209, 210, 313, 315, 339, 340,  
 438, 440, 458, 465  
 Foust, C E, 332, 337  
 Fouts, P J, 133, 318, 321, 326, 327, 367,  
 371, 609, 611  
 Fox, J T, 324  
 — S H, 534, 536  
 — S W, 119, 130  
 Foy, J R, 125, 131, 318, 321, 322, 331,  
 337, 569, 570  
 Fraenkel, G, 115, 116, 205, 206, 273,  
 274, 287, 293, 295, 341, 342, 389, 390,  
 441, 442, 512, 513, 560, 578, 579, 597,  
 627, 628  
 Fraenkel Conrat, H, 38, 42  
 Franke, W, 197, 202  
 Frankl, W, 204, 205  
 Franklin, A L, 489, 494, 503, 504, 505,  
 519, 521, 522, 524, 525, 534, 535, 536,  
 543, 544  
 Fraps, G S, 158, 163  
 — R M, 428, 431  
 Fraser, H F, 157, 163, 177, 182, 228,  
 232, 262, 267, 282, 285  
 — L E, 558, 559  
 Frazer, A C, 270, 272  
 Frazier, E I, 260, 267  
 Frediani, H A, 482, 483  
 Free, A H, 50, 55

# AUTHOR INDEX

- Freed, A. M., 26, 27  
 — M., 505, 506  
 Freeman, M. L. H., 492, 495.  
 Frei, P., 138, 139, 140, 147, 192, 201, 206, 207, 209  
 Fretheim, B., 154, 156  
 Freudenthal, P., 29, 32, 75, 80  
 Frey, C. N., 33, 34, 36, 76, 80, 225, 227, 231, 281, 285, 311, 314, 315, 316, 317, 338, 340, 361, 362, 404, 405, 569, 570  
 Fricke, H. H., 536.  
 Fridencia, L. S., 29, 32, 75, 80  
 Friedemann, T. E., 77, 80, 185, 186, 198, 203, 269, 270, 271, 272, 327, 328, 377, 435, 436, 504, 505, 506, 554  
 Frieden, E. H., 467, 470  
 Friedman, L., 50, 55  
 Fries, N., 109, 113, 338, 340, 438, 440, 577.  
 Frina, O., 343, 346.  
 Fritz, J. C., 170, 173, 189, 190.  
 Fritzsche, H., 137, 139, 154, 155, 198, 203, 278, 280.  
 Fröbrich, G., 115, 116  
 Frohman, C. E., 128, 131  
 Frohring, W. O., 51, 55  
 Frommeyer, W. B., 175, 176, 514, 524, 540, 542.  
 Frost, D. V., 24, 27, 154, 155, 156, 318, 319, 321, 349, 350, 351, 359, 485, 486, 493, 506, 507, 536, 609, 611, 616, 618  
 Fruton, J. S., 617, 618  
 Führmeister, C., 369, 371  
 Fujiwara, M., 161, 164  
 Fuller, A. T., 545, 547, 561, 562  
 — R. C., 509, 511.  
 Fulmer, E. I., 404, 405  
 Funahashi, S., 366, 370  
 Funk, C., 6, 9, 10, 11, 12, 50, 55, 90, 103, 213.  
 Furman, C., 242, 248, 340, 341  
 Furter, M. F., 154, 156  
 GABRIEL, S., 393, 397  
 Gaby, W. L., 197, 202.  
 Gätzl-Fichter, H., 354, 358, 359, 394, 491.  
 Galat, A., 216, 217, 357, 359  
 Gale, E. F., 332, 335, 337, 338  
 Gall, L. S., 594, 595  
 Gallant, D. L., 504, 505  
 Galaton, A. W., 286, 287  
 Gamm, I., 166, 168  
 Garber, M., 68, 73  
 — M. J., 242, 248  
 Garbo, P. W., 216, 217  
 Gardner, P. A., 175, 177  
 Gardner, F. H., 538, 541  
 — J., 433, 435, 436  
 Garza, H. M., 207, 210  
 Gautier, J. A., 293, 295  
 Gautrelet, J., 596  
 Gavard, R., 523, 526  
 Gavin, G., 49, 55, 428, 431, 438, 572, 573, 574, 591, 592  
 Gazzola, A. L., 472, 473, 476, 477, 522, 525.  
 Geeslin, L. E., 174, 176, 246, 249  
 Geffen, C., 482, 483  
 Geib, D. S., 439, 440  
 Geiger, A., 91, 103.  
 Geigy Colour Co., 216, 217  
 Geisinger, R., 320, 322, 369, 371  
 Gelmo, P., 545, 547  
 Genghof, D. S., 422, 423  
 Gennis, J., 59, 61  
 George, W. L., 519, 524  
 Gescher, W., 277, 280  
 Gerlaugh, P., 79, 80, 81, 185, 186  
 German, H. L., 242, 248, 506, 507.  
 Germek, O. A., 179, 183, 187, 189  
 Gerstl, B., 375, 376, 554  
 Ghosh, R., 420  
 Gibbs, E. M., 129, 131.  
 — H. D., 310, 314  
 Giffit, H. H., 66, 73  
 Gilbert, H., 79, 81.  
 Giles, N. H., 287  
 Gillespie, J. M., 546, 547, 548, 555, 558  
 Gillis, M. B., 368, 369, 371, 378, 379, 539, 542, 609, 611  
 Gillman, J., 245, 249  
 — T., 245, 249  
 — W., 622, 623  
 Ginsberg, V., 538, 541  
 Gingrich, W., 282, 286  
 Girdwood, R. H., 497, 498, 500, 502, 507, 508  
 Giri, K. V., 222, 230, 233, 236  
 Gisiger, L., 114, 115  
 Glasscock, R. S., 540, 542.  
 Glauser, C. E., 485, 493  
 Glaxo Laboratories Ltd., 8.  
 Glazko, A. J., 482, 483  
 Gleim, E., 44, 45, 46, 165, 167, 235, 236.  
 Glick, D., 48, 54, 88, 89, 586, 587, 588, 589  
 Glock, G. E., 569, 570, 576, 577  
 Goese, M. A., 216, 217.  
 Göth, A., 90, 103  
 Gogswell, R. C., 175, 176  
 Goldberg, L., 115, 116, 205, 206, 257, 341, 342, 390, 441, 442, 496, 502, 512, 513.  
 Goldberg, M. W., 453, 456.  
 Goldberger, J., 7, 10, 132, 133, 211, 212, 213, 240, 247, 296, 297.  
 Goldblatt, H., 582, 584  
 Goldfarb, A. R., 375, 376, 554  
 Goldinger, J. M., 100, 102, 103  
 Goldsmith, E. D., 521, 525, 555.

# THE VITAMIN B COMPLEX

- Goldsmith, G A, 249, 252, 259, 261, 266, 267, 497, 502  
 Goldstein, A, 578, 579, 580, 581  
 Goldwater, L J, 392, 393  
 Goldzierer, J W, 274  
 Goodhart, R, 35, 36, 58, 59, 61, 68, 73.  
 Goodland, R L, 25, 27  
 Goodyear, J M, 225, 231  
 Gordon, A H, 194, 201  
 — A S, 555  
 — E S, 263, 267  
 — H H, 527, 528  
 — M, 514, 519, 524  
 — S M, 154, 156  
 Gorham, A T, 69, 74  
 Goss, H, 79, 81, 185, 186, 327, 328, 376, 377  
 Gots, J S, 204, 205  
 Govan, C D, 527, 528  
 Graff, E, 501, 503  
 Graham, J W, 247, 249  
 Grant, H M, 289, 295  
 Grau, C R, 600, 602, 603, 604  
 Graves, H C H, 158, 163  
 Gray, C H, 439, 441  
 — R E, 619, 620  
 Graybiel, A, 446, 454  
 Green, D E, 194, 196, 197, 201, 202, 229, 232, 275, 278, 279, 280, 334, 335, 337, 516, 524, 548, 560, 562  
 — H H, 74, 79, 80  
 — H N, 540, 547  
 — M N, 391, 393  
 — M W, 549, 550  
 — R G, 25, 27  
 Greenberg, J, 510, 511  
 — L D, 326, 327  
 Greene, R D, 135, 157, 162, 310, 314, 470, 471, 534, 536  
 Greenhut, I T, 184, 186, 488, 494  
 Greenstein, L M, 181, 183  
 Greenwood, D A, 23, 27  
 Gregory, M K, 175, 177  
 — R A, 568, 570  
 Greiff, D, 557, 559  
 Greslin, J G, 190, 379  
 Grewe, R, 13, 15, 19, 22  
 Griese, A, 192, 201  
 Griffin, A C, 171, 173  
 Griffith, W H, 583, 584, 594, 595, 601, 603  
 Grijs, H, 3, 9  
 Grisolia, S, 444, 445  
 Grob, C A, 512, 513  
 Groody, M E, 369, 371, 378, 379  
 — T C, 369, 371, 378, 379  
 Groschke, A C, 242, 248, 539, 542  
 Gross, P, 487, 494, 575  
 — R, 72, 74  
 Grossman, W L, 221, 230, 255, 256, 266  
 Grossowicz, H, 95, 104, 111, 113, 228, 231, 282, 286  
 Grüssner, A, 354, 358, 359, 394, 395, 401, 417, 420, 449, 455  
 Grundy, W E, 77, 80, 185, 186, 269, 270, 271, 272, 327, 328, 377, 435, 436, 504, 505, 506, 554  
 Gubler, C J, 318, 321  
 Gudjonsson, S, 29, 32, 75, 80  
 Gue, I, 39, 42  
 — C, 104, 221, 226, 227, 280  
 — R C, 64, 73  
 Guhr, G, 35, 36  
 Guillermond, A, 150, 151, 153  
 Guilloud, M, 149, 150, 153  
 Guirard, B M, 300, 301, 312, 314, 339, 341, 386, 389, 391, 393, 481, 482  
 Gulewitsch, W, 586  
 Gullberg, M E, 250, 252  
 Gundel, M E, 429, 431  
 Gunness, M, 204, 205, 438, 439, 440, 442, 445, 446, 447, 448, 454  
 Gunsalus, I C, 331, 332, 334, 335, 336, 337, 338, 344, 347  
 Gurn, S, 13, 15, 611, 613  
 Gustafson, F G, 287  
 Gutschmidt, K, 118, 130  
 Guy, L P, 84, 85, 178, 182, 185, 186, 187, 189  
 Gwinner, G, 540, 542  
 György, P, 133, 134, 135, 212, 213, 296, 297, 298, 307, 308, 317, 365, 369, 370, 377, 378, 404, 405, 406, 407, 421, 423, 424, 427, 429, 430, 431, 582, 584  
 HAAG, E, 106, 110, 112, 113  
 — J R, 26, 27  
 Haagen-Smit, A J, 330, 337, 423, 424, 441, 533  
 Haas, E, 193, 194, 195, 196, 201, 202  
 — G J, 154, 156  
 Hagedorn, A B, 523, 526  
 — D R, 179, 183, 187, 189  
 Hague, E, 407, 410, 446, 454  
 Haig, F M, 154, 156  
 Hamovici, H, 87, 89  
 Hald, J, 219, 230  
 Hale, E B, 222, 230  
 — F, 333, 337  
 Haley, T J, 85, 86, 87, 89.  
 Hall, B E, 538, 541  
 — D A, 404, 466, 477, 479, 514, 523, 524, 525  
 — D E, 621, 623  
 — E E, 538, 541  
 — W K, 367, 370.

# AUTHOR INDEX

- Freed, A M, 26, 27  
 — M, 505, 506  
 Freeman, M L H, 492, 495  
 Frei, P, 138, 139, 140, 147, 192, 201, 206, 207, 209  
 Fretheim, B, 154, 156  
 Freudenthal, P, 29, 32, 75, 80  
 Frey, C N, 33, 34, 36, 76, 80, 225, 227, 231, 281, 285, 311, 314, 315, 316, 317, 338, 340, 361, 362, 404, 405, 569, 570  
 Frieden, L H, 401, 410  
 Friedman, L, 50, 55  
 Fries, N, 109, 113, 338, 340, 438, 440, 577  
 Frina, O, 343, 346  
 Fritz, J C, 170, 173, 189, 190  
 Fritzsche, H, 137, 139, 154, 155, 198, 203, 278, 280  
 Fröbrich, G, 115, 116  
 Frohman, C E, 128, 131  
 Frohning, W O, 51, 55  
 Frommeyer, W B, 175, 176, 514, 524, 540, 542  
 Frost, D V, 24, 27, 154, 155, 156, 318, 319, 321, 349, 350, 351, 359, 485, 486, 493, 506, 507, 536, 609, 611, 616, 618  
 Fruton, J S, 617, 618  
 Führmeister, C, 369, 371  
 Fujiwara, M, 161, 164  
 Fuller, A T, 545, 547, 561, 562  
 — R C, 509, 511  
 Fulmer, E I, 404, 405  
 Funahashi, S, 366, 370  
 Funk, C, 6, 9, 10, 11, 12, 50, 55, 90, 103, 213  
 Furman, C, 242, 248, 340, 341  
 Furter, M F, 154, 156  
 GABRIEL, S, 303, 307  
 Gaby, W L, 197, 202  
 Gätz-Fichter, H, 354, 358, 359, 394, 401  
 Galat, A, 216, 217, 357, 359  
 Gale, E F, 332, 335, 337, 338  
 Gall, L S, 594, 595  
 Gallant, D L, 504, 505  
 Galston, A W, 286, 287  
 Gammo, I, 166, 168  
 Garber, M, 68, 73  
 — M J, 242, 248  
 Garbo, P W, 216, 217  
 Gardiner, P A, 175, 177  
 Gardner, F H, 538, 541  
 — J, 433, 435, 436  
 Garza, H M, 207, 210  
 Gautier, J A, 293, 295  
 Gautrelet, J, 596  
 Gavard, R, 523, 526  
 Gavin, G, 49, 55, 428, 431, 438, 572, 573, 574, 591, 592  
 Garzola, A L, 472, 473, 476, 477, 522, 525  
 Geeslin, L E, 174, 176, 246, 249  
 Geffen, C, 482, 483  
 Geib, D S, 439, 440  
 — A, 51, 103  
 George, W L, 519, 524  
 Gerischer, W, 277, 280  
 Gerlaugh, P, 79, 80, 81, 185, 186  
 German, H L, 242, 248, 506, 507  
 Germek, O A, 179, 183, 187, 189  
 Gerstl, B, 375, 376, 554  
 Ghosh, R, 420  
 Gibbs, E M, 129, 131  
 — H D, 310, 314  
 Giff, H H, 66, 73  
 Gilberg, H, 79, 81  
 Giles, N H, 287  
 Gillespie, J M, 546, 547, 548, 555, 558  
 Gillis, M B, 368, 369, 371, 378, 379, 539, 542, 609, 611  
 Gillman, J, 245, 249  
 — T, 245, 249  
 — W, 622, 623  
 Ginsberg, V, 538, 541  
 Gingrich, W, 282, 286  
 Girdwood, R H, 497, 498, 500, 502, 507, 508  
 Giri, K V, 222, 230, 233, 236  
 Gisiger, L, 114, 115  
 Glasscock, R S, 540, 542  
 Glausier, C E, 485, 493  
 Glaxo Laboratories Ltd, 8  
 Glazko, A J, 482, 483  
 Gleim, E, 44, 45, 46, 165, 167, 235, 236  
 Glück, D, 48, 54, 88, 89, 586, 587, 588, 589  
 Glock, G E, 569, 570, 576, 577  
 Goese, M A, 216, 217  
 Göth, A, 90, 103  
 Gogswell, R C, 175, 176  
 Golberg, L, 115, 116, 205, 206, 287, 341, 342, 390, 441, 442, 496, 502, 512, 513  
 Goldberg, M W, 453, 456  
 Goldberger, J, 7, 10, 132, 133, 211, 212, 213, 240, 247, 296, 297  
 Goldblatt, H, 582, 584  
 Goldfarb, A R, 375, 376, 554  
 Goldinger, J M, 100, 102, 105  
 Goldsmith, E D, 521, 525, 555

h. 371



## THE VITAMIN B COMPLEX

- Heitman, H., 18, 22, 32  
Heiwinke, H., 219, 230  
Helikson, J., 539, 542  
Heller, V. G., 164, 167, 364  
Hellström, H., 276, 280  
Helmer, O. M., 133, 318, 321, 367, 371  
Hemingway, A., 96, 104  
Henderson, C. R., 77, 80, 185, 186, 270, 272, 327, 328, 377, 435, 436, 505, 506, 554  
— L. M., 79, 81, 184, 186, 242, 248, 249, 251, 252, 271, 272, 315, 316, 317, 361, 362, 363, 364, 365, 370, 377, 378, 552, 553  
Hendlin, D., 534, 536  
Hendricks, W. J., 558, 559  
Henle, W., 51, 55, 128, 131  
Hennessy, D. J., 11, 12, 38, 39, 42  
Henry, K. M., 160, 163  
— N. S., 234, 236  
— R. M., 184, 186, 552, 553  
Henschel, A. F., 60, 61, 179, 180, 183, 606, 608  
Herd, D. B., 326, 327  
Herman, E. F., 171, 173, 369, 371, 591, 592  
Hernandez Morales, F., 496, 502  
Herr, D. S., 11, 12  
Herrick, J. A., 110, 113  
Herrington, B. L., 233, 236, 363, 364, 423, 424  
Hershey, J. M., 582, 584  
Herter, C. A., 244, 248  
Hertz, R., 422, 428, 431, 486, 492, 493, 495, 519, 524  
Herwick, R. P., 372  
Hess, K., 215, 216  
Hessell, F. H., 158, 163  
Heube, W., 51, 55  
Heublein, G. W., 606, 608  
Heuser, G. F., 160, 161, 163, 164, 170, 173, 320, 322, 336, 338, 344, 347, 368, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999,

# AUTHOR INDEX

- Hoogewerff, S., 214, 215, 216  
Hooten, C. G., 558, 559  
— W. S., 558, 559  
Hoover, S. R., 405  
Hopkins, F. G., 6  
— R. H., 167, 168, 312, 314  
Horecker, B. L., 193, 201  
Horowitz, N. H., 195, 202, 586, 587, 597, 604, 605  
Horwitt, M., 228, 231, 282, 285  
— M. K., 60, 61, 91, 103, 174, 176, 187, 189  
Hottle, G. A., 622, 623  
Hou, H. C., 64, 73, 174, 175, 176, 203, 204  
Housewright, R. D., 550, 556, 558, 560, 562  
Houston, J., 160, 163  
Huang, C.-T., 558, 559  
Huber, C., 214, 215, 216  
— W., 122, 125, 130, 131, 290, 295  
Hucker, G. J., 622, 623  
Hudson, C. S., 140, 144, 147  
— N. P., 174, 176  
Huenschmann, H., 87, 89  
Huff, J. W., 221, 226, 229, 231, 232, 242, 248, 253, 254, 256, 257, 260, 261, 265, 266, 267, 271, 272, 288, 294, 326, 327, 336, 338, 344, 347, 534, 536, 543, 544  
— N. E., 174, 175, 176, 289, 295  
Hughes, D. E., 282, 284, 286, 380, 384, 385, 388, 398, 402  
— E. B., 36, 37, 167, 168, 235, 236, 364, 365  
— E. H., 189, 190, 238, 240, 272, 273, 368, 371  
— W., 174, 176  
Hugonet, J. J., 586, 587  
Hulse, M. C., 72, 74  
Hultquist, M. E., 463, 466, 471, 472, 473, 474, 475, 477, 510, 511, 520, 521, 522, 525  
Humphrey, M. J., 260, 267  
Humphreys, J., 520, 525  
— S., 52, 55, 56, 170, 172, 238, 240, 320, 322, 331, 337, 368, 371  
Hundley, J. M., 48, 54, 237, 239, 249, 250, 252, 257, 266  
Hunt, C. H., 79, 80, 81, 170, 173, 185, 186  
— D. J., 133, 212, 213  
Huntsman, M. E., 582, 584  
Hurni, H., 622, 623  
Hurt, W. W., 249, 252  
Hutchings, B. L., 340, 341, 422, 439, 440, 458, 461, 463, 465, 466, 468, 471, 473, 474, 475, 476, 477, 478, 479, 482, 483, 484, 485, 491, 493, 495, 500, 503, 510, 511, 520, 521, 522, 525, 535, 536  
Hutner, S. H., 204, 205, 535, 536, 543, 544, 622, 623  
Hutzler, E. W., 72, 74  
Huzita, S., 44, 46  
Huziwara, T., 429, 431  
ICHIBA, A., 302, 307, 366, 370  
ICI Ltd., 19, 22  
IG Farbenindustrie A. G., 13, 15, 20, 22, 138, 142, 143, 147  
Ikin, E. W., 615, 618  
Imai, T., 15  
Inagaki, T., 37, 42  
Ingalls, B., 178, 180, 182, 187, 189  
Innes, E. M., 497, 502, 521, 525  
— J., 521, 525, 537, 538  
Inukai, F., 615, 617  
Isamid, V., 47, 54  
Isbell, E. R., 549, 550, 551, 557, 559  
— H., 157, 163, 177, 178, 182, 187, 189, 227, 228, 231, 232, 282, 285, 432, 433, 437  
Israels, M. C. G., 496, 497, 499, 502  
Itter, S., 134, 135  
Ivanovics, G., 383, 387, 388  
JACKSON, B., 86, 89  
— S. H., 189, 190  
Jacob, A., 38, 42  
Jacobi, H. P., 586, 587  
Jacobs, S. E., 578, 579, 580, 581  
Jacobsohn, K. R., 26, 27  
Jacobson, W., 496, 502, 523, 526  
James, E. M., 222, 230  
— M. F., 591, 592, 595  
Jandorf, B. J., 229, 232  
Jansen, B. C. P., 10, 11, 12, 28, 32, 38, 40, 42  
Jarmol, J., 165, 167, 233, 236, 364, 423, 424  
Javillier, M., 112, 113, 118, 130  
Jefferson, N. C., 376, 377, 384, 388  
Jenkins, G. N., 360, 362, 378  
Jensen, O. G., 180, 183  
Jequier, R., 95, 104  
Jermsta, J., 546, 547  
Joffe, P. M., 57, 61  
Johansen, G., 29, 32, 75, 80, 361, 362, 386, 389, 394, 396, 399, 401, 402  
Johansson, K. R., 435, 436  
Johns, G. A., 184, 186, 249, 252, 260, 267  
Johnson, B. C., 53, 56, 170, 172, 228, 232, 237, 239, 256, 265, 266, 268, 326, 327, 426, 431, 504, 505, 554, 576, 591, 592, 594, 595  
— E., 83, 85  
— E. A., 533  
— F. H., 197, 203  
— G., 401, 403



# AUTHOR INDEX

- Kiefer, H. 291, 292, 295  
 Kies, M W. 598, 602  
 Kihlberg, B. 24, 27  
 King, C G. 482, 483, 528, 529  
 — F E. 475, 477, 523, 526  
 — J D. 246, 249  
 — T E. 387, 388, 389, 393  
 Kinley, W N. 417, 420  
 Kunnersley, H W. 11, 12, 28, 30, 32, 37, 41, 90, 103, 611, 612, 613  
 Kirby, H. 395, 402  
 Kirch, E R. 37, 42, 220, 230, 549, 550  
 Kirk, C. H. 79, 81, 185, 186  
 Kirkwood, S. 572, 574  
 Kitzes, G. 44, 45, 167, 168, 235, 236, 317, 364, 365, 424, 441, 442, 513  
 Kjeldgaard, N O. 528, 529  
 Klarer, J. 545, 547  
 Klatzkin, C. 220, 230  
 Kleiger, S C. 71, 74, 83, 84, 85, 179, 183, 187, 189  
 Klein, J R. 193, 195, 201, 202, 223, 231, 262, 267  
 Kleiner, M J. 501, 503  
 Kleinzeller, A. 96, 104  
 Klemperer, F W. 229, 232  
 Klenk, E. 571  
 Klenow, H. 528, 529  
 Kugler, I J. 95, 104, 111, 113, 171, 173, 282, 286  
 Kline, B E. 321, 322  
 — H E. 429, 432  
 — O L. 50, 55, 133, 479, 480, 612, 613, 619, 620  
 Klise, K S. 446, 454  
 Klocke, J F. 234, 236  
 Klose, A A. 595  
 Klotz, A W. 361, 362, 380, 387, 388, 394, 401  
 Knandel, H C. 425, 430, 437  
 Kniazuk, M. 48, 54  
 Knight, B C J G. 117, 118, 130, 282, 285, 290, 295  
 Knott, E M. 29, 32, 71, 74, 84, 85  
 Knox, G. 164, 167, 364  
 — P. 87, 89  
 — W E. 194, 196, 197, 201, 202, 221, 230, 255, 256, 266  
 Knutsen, M H. 75, 79, 80  
 Koch, A. 115, 116  
 — M B. 263, 268, 495, 496, 501, 502  
 Kochhar, B D. 223, 231, 259, 263, 266, 268  
 Kocholaty, W. 197, 202  
 Koch-Weser, D. 540, 542  
 Kodicek, E. 158, 163, 219, 221, 222, 223, 226, 230, 231, 241, 248, 272, 273, 327, 328  
 Koditschek, L K. 534, 536  
 Kögl, F. 7, 109, 113, 404, 405, 406, 407, 410, 411, 412, 413, 414, 421, 422, 423, 424, 438, 439, 440, 441, 570, 571, 577  
 Koehn, C J. 132, 133, 134, 212, 213, 239, 240, 296, 297, 348, 350, 365, 369  
 König, W. 219, 230  
 Koepfli, J B. 399, 401, 402, 403  
 Kohler, G O. 618, 620  
 Kohn, H I. 193, 201, 229, 232, 262, 263, 265, 267, 276, 280, 288, 294  
 Kolson, J. 461, 466  
 Kon, P M. 75, 80, 184, 186, 552, 553  
 — S K. 75, 80, 160, 163, 184, 186, 238, 240, 552, 553, 615, 618  
 Koniuszy, F R. 395, 402, 530, 531, 532, 533  
 Koones, H F. 310, 314, 325, 327  
 Kornberg, A. 169, 172, 318, 321, 488, 489, 494  
 — H A. 159, 163  
 Koschara, W. 134, 135, 136, 139  
 Koser, S A. 228, 231, 260, 267, 282, 283, 285, 286, 380, 381, 388, 391, 393, 442, 445, 549, 550, 556, 558, 560, 562, 563  
 Krah, M E. 195, 202  
 Krampitz, L O. 26, 27, 97, 99, 105  
 Kratzer, F H. 318, 320, 321, 329  
 Krause, M. 245, 249  
 — M A. 318, 321  
 Kraut, H. 65, 73  
 Kraybill, H R. 23, 27  
 Krebs, H A. 93, 96, 98, 104, 195, 202, 626  
 Krehl, H. 118, 130  
 — W A. 227, 231, 234, 235, 236, 237, 238, 239, 240, 241, 242, 248, 271, 272, 288, 289, 291, 294, 490, 494, 617, 618  
 Kreisler, O. 60, 61, 91, 103  
 Krier, J L. 591, 592, 595  
 — M M. 434, 436, 552, 553  
 Kringstad, H. 219, 230, 350, 351, 365, 369, 616, 618  
 Krishnan, B G. 243, 248  
 Kritzman, M G. 97, 105, 334, 335, 337, 338  
 Krueger, K K. 405, 450, 452, 455, 460, 465, 513, 524  
 Krüger, H. 71, 74  
 — M. 585, 586  
 Kruse, H D. 174, 176  
 Köhling, O. 139  
 Kub, E. 463, 466, 471, 473, 474, 475, 477, 520, 522, 525  
 Kuhn, R. 7, 38, 42, 87, 89, 134, 135, 136, 137, 138, 139, 140, 142, 143, 146, 147, 154, 155, 156, 162, 164, 190, 191, 198, 201, 203, 206, 207, 208, 209, 210, 298, 299, 300, 301, 302, 307, 310, 314,

- Kuhn, R (*contd*), 354, 355, 358, 359, 361, 362, 381, 388, 396, 397, 402, 406, 407, 439, 440, 555, 558  
 Kuhnau, J, 82, 85  
 Kuhnau, W. W., 247, 249, 252, 265  
 Kuiken, K. A., 619, 620  
 Kupel, C. W., 575  
 Kupferberg, A. B., 401, 403  
 Kushida, M. N., 523, 526  
 Kushner, S., 282, 286  
 Kuzmeski, J. W., 44, 45, 165, 167  
 Kyhos, E. D., 179, 183, 187, 189, 244, 248  
  
 LACHAUX, M., 150, 153  
 Ladenburg, K., 146, 147, 148  
 Ladisch, R. K., 325, 327  
 Laffler, E., 234, 236  
 LaForge, F. B., 144, 147, 216, 217  
 Laiblin, R., 214, 216  
 Lally, J. A., 534, 535, 536  
 Lamanna, C., 111, 113, 380, 388, 439, 440, 596, 597  
 Lamar, M. V., 41, 42.  
 Lamb, F. W., 224, 231  
 Lampen, J. O., 424, 439, 440, 442, 445, 453, 456, 515, 516, 518, 524, 550, 556, 558, 560, 562, 563  
 Landan, R. L., 603, 604  
 Landor, J. V., 243, 248  
 Landwehr, G., 66, 70, 73, 74, 76, 78, 80, 81, 84, 85  
 Landy, M., 157, 162, 228, 232, 290, 295, 313, 315, 339, 341, 360, 362, 422, 423, 425, 430, 437, 438, 439, 441, 481, 482, 549, 550, 551, 556, 558  
 Lane, R. L., 82, 85, 581  
 Langdon, R. S., 159, 163  
 Langham, W. H., 257, 264, 266, 268, 281, 285  
 Langston, W. C., 460, 465, 491, 495  
 Lankford, C. E., 111, 113  
 Lardy, H. A., 443, 444, 445, 541, 542, 576, 577  
 Larkum, N. W., 556, 558  
 Larsen, A., 313, 315, 442, 445  
 Lascelles, J., 510, 511  
 Laser, H., 34, 36  
 Laskowski, M., 196, 202, 464, 466, 479, 480, 481, 482  
 — S. C., 125, 131, 290, 295  
 Laszlo, D., 492, 495, 574, 575  
 Laszt, L., 178, 182, 183, 186, 192, 201  
 Laufer, S., 549, 550  
 Laurence, W. L., 427, 431  
 Lauritsen, M., 52, 56, 331, 337  
 Lavik, P. S., 321, 322  
 Lavoipierre, M., 115, 116, 205, 206, 287, 341, 342, 390, 441, 442, 512, 513  
 Lawrence, J. M., 233, 236, 363, 364, 423, 424  
 Laws, C. L., 62, 63  
 Lawson, E. J., 355, 358, 359  
 Layne, J. A., 244, 248, 249  
 Leake, C. D., 397, 402.  
 Lechicka, M., 157, 162, 309, 314  
 Lecoq, R., 557, 559, 611, 613  
 Leder, I. G., 226, 231.  
 Lederer, E., 406, 407.  
 Lederle Labs Inc., 8, 151, 153, 306, 307, 356, 357, 358, 419, 420  
 Leduc, E. H., 425, 430  
 Lee, H. J., 544.  
 — J. G., 612, 613  
 — J. M., 444, 445  
 — T., 56, 61.  
 Leech, J. L., 346, 347  
 Lees, K. A., 537, 538.  
 Lehr, S. P., 501, 503.  
 Lehrfeld, L., 175, 177  
 Leibbrandt, F., 215, 216  
 Leibmann, W., 586, 587  
 Leifer, E., 257, 264, 266, 268, 281, 285  
 Lein, J., 281, 285.  
 Leitner, Z. A., 62, 63, 244, 249  
 Lelour, L. F., 276, 280, 334, 335, 337  
 Lemon, L., 510, 511  
 Lennox, B., 58, 61.  
 Lenz, G. G., 501, 503  
 Leonard, M. J. K., 334, 338  
 — N. J., 123, 130  
 Leong, P. C., 64, 73  
 Leonian, L. H., 108, 112, 438, 440, 449, 452, 455, 456  
 Le Page, G., 275, 279  
 Lepkovsky, S., 49, 54, 133, 250, 252, 296, 297, 298, 318, 320, 321, 326, 327, 329, 330, 337, 348, 351, 365, 367, 369, 371  
 Lepp, A., 368, 371  
 Lettré, H., 207, 210  
 Leuchtenberger, C., 492, 495, 574, 575  
 — R., 492, 495  
 Levi, J. E., 38, 42  
 Levin, I., 159, 163  
 — W. C., 523, 526  
 Levine, H., 150, 153  
 Levitas, N., 229, 232, 234, 236, 261, 267  
 Leviton, A., 149, 153  
 Levy, B. M., 319, 322  
 — E. D., 224, 231  
 — H., 49, 54, 359, 496, 502  
 — M., 265, 268  
 Lewis, C., 111, 113, 380, 388, 439, 440, 596, 597  
 — C. F., 243, 248  
 — G. T., 67, 73, 179, 183  
 — J. C., 427, 431, 549, 550, 551, 556, 558

- Lewis, L., 65, 73, 79  
 — U. J., 537, 538  
 Lewisohn, R., 492, 495  
 Lewy, F. H., 606, 608  
 Libby, R. L., 282, 286  
 Lichtstein, H. C., 51, 52, 55, 171, 173,  
 321, 322, 332, 333, 334, 337, 369, 371,  
 429, 431, 442, 444, 445, 446, 454, 492,  
 495, 574, 575  
 Lichtman, H., 538, 541  
 Liebert, E., 60, 61, 174, 176, 187, 189  
 Liechti, A., 86, 89  
 Lieck, H., 588, 589, 594, 595  
 Light, A. E., 360, 362, 522, 525  
 — R. F., 76, 80  
 Likely, G. D., 539, 542, 610, 620  
 Lillie, R. D., 10, 132, 133, 211, 212, 213,  
 296, 297  
 — R. J., 242, 248, 539, 542  
 Lilly, V. G., 108, 112, 438, 440, 449, 452,  
 455, 456  
 Lindeberg, G., 438, 440  
 — — — — — C. C., 286, 287  
 Lounds, E., 178, 180, 182  
 Love, R. H., 162, 164, 193, 201  
 Löw, I., 310, 314  
 Lowell, F. C., 546, 547, 554  
 Lowry, J. V., 48, 54  
 — O. H., 162, 164, 169, 172, 178, 182,  
 185, 186, 187, 189, 193, 201,  
 479, 480  
 Lowy, P. H., 533  
 Lozner, E. L., 323, 324  
 Lu, G. D., 90, 92, 103  
 Lucas, C. C., 428, 431, 573, 574, 591,  
 592  
 Lucrus, R., 585, 586  
 Luckey, T. D., 239, 240, 270, 272, 289,  
 294, 312, 315, 320, 322, 344, 347, 451,  
 455, 460, 465, 481, 482, 485, 486, 493,  
 513, 524, 551, 553, 612, 613, 614, 615  
 Ludovici, P. P., 369, 371  
 Ludwig, A. S., 87, 89  
 Luecke, R. W., 48, 49, 54, 237, 239, 242,  
 248, 249, 251, 261, 267, 272, 273, 587,  
 593, 594  
 Lukens, F. D. W., 59, 61  
 Lunde, G., 350, 351, 365, 369, 616, 618  
 Luros, G. O., 10  
 Lustig, B., 375, 376, 554  
 — — — — — R., 282, 283  
 Lippincott, S. W., 109, 174, 300, 370  
 Lipschitz, M. A., 94, 104  
 Lipton, W. A., 109, 174, 300, 370  
 — S.  
 Little, A. A., 523, 520, 541, 542  
 — R., 44, 46  
 Littlejohn, J. M., 242, 248, 249, 252,  
 261, 265, 267, 268  
 Livermore, A. H., 25, 26, 27, 164, 167,  
 571, 572  
 Lloyd, J. F., 537, 538  
 Loach, J. V., 594, 595  
 Lobb, D. E., 180, 183, 184, 186  
 Locher, L. M., 393  
 Locke, E., 523, 526  
 Lockwood, J. S., 546, 547  
 Loewe, I., 87, 89  
 — S., 87, 89  
 Logan, M. A., 380, 388  
 Lohmann, A., 596  
 — K., 93, 104  
 Long, B., 446, 454  
 Longenecker, H. E., 49, 55, 318, 321  
 Longworth, L. G., 427, 431  
 Loosli, J. K., 165, 167, 541, 542  
 Lopez, G. G., 498, 502, 503, 505, 538,  
 540, 541, 542  
 Louis, L., 43, 45  
 — — — — — S., 227, 229,  
 231, 234, 244, 245, 557, 559  
 — M., 112, 113, 229, 232, 557, 559  
 — — — — — R., 266, 267, 234, 236, 374, 376  
 — — — — — 177  
 — — — — — S., 100, 102, 105, 333,  
 334, 335, 336  
 Lynch, H. M., 546, 547  
 Lythgoe, B., 348, 349, 351, 394, 401,  
 621, 623  
 Lytle, B., 579, 581  
 Ma, R., 110, 113, 338, 339, 340, 446, 454,  
 557, 559  
 Maass, A. R., 53, 56, 170, 172, 188, 190  
 Macdonald, W. J., 57, 61  
 MacFarland, M. L., 319, 322, 572, 573,  
 574  
 Macfarlane, R. G., 367, 370  
 Machella, T. E., 174, 176  
 Machens, M., 124, 131  
 Mackinnon, J. E., 110, 113  
 MacLean, H., 585, 586  
 MacLeod, C. M., 544, 547  
 Macleod, J. J. R., 582, 584  
 MacLeod, P. R., 444, 445  
 Macrae, T. F., 156, 162, 164, 167, 168,  
 172, 175, 177, 187, 189, 212, 213, 238,  
 240, 297, 298, 309, 313, 318, 321, 327,  
 328, 348, 349, 351, 365, 369, 394, 401

- Macy, I G, 182, 183, 264, 268, 374, 376,  
 433, 434  
 Madden, R J, 212, 213, 214, 262, 265,  
 267, 288, 294  
 Mader, W J, 482, 483  
 Madinaveitia, J, 209, 210, 398, 402  
 Madsen, H, 76, 80  
 — L L, 52, 56  
 Magasanik, B, 578, 579  
 Magyar, I, 64, 68, 73  
 Main, E, 372, 553, 554  
 Mainzer, F, 245, 249  
 Majnarich, J J, 522, 525, 614, 615  
 Major, R T, 350, 351, 354, 358  
 Makino, K, 15, 303, 307  
 Mallette, M F, 517, 524  
 Mallory, M E, 463, 466  
 Malmberg, M, 138, 139, 156, 162, 206,  
 207, 209  
 Malone, L, 282, 286  
 Mamalis, P, 533  
 Manchester, F, 216, 217  
 Mann, I, 175, 177  
 — P J G, 279, 280  
 — T, 391, 393  
 Mannering, G J, 184, 186, 188, 189,  
 619, 620  
 Manning, P D V, 460, 465, 615, 618  
 Mano C, 62, 63, 86, 87, 89  
 Manson-Bahr, P, 243, 248, 496, 502  
 Manz, W, 292, 295  
 Maquenne, L, 564, 565, 566  
 Marchant, C, 106, 112, 338, 340  
 Marenzi, A D, 586, 587  
 Margolis, G, 288, 294  
 — L H, 259, 266, 288, 294  
 Mariella R P, 346, 347  
 Marque, J, 568, 569  
 Marquette, M M, 68, 73, 166, 168, 251,  
 252  
 Marston, H R, 544  
 Martin, A J P, 212, 213, 238, 240  
 — A R, 398, 402, 561, 562  
 — B B, 360, 362  
 — C J, 212, 213, 238, 240  
 — D W, 324, 325  
 — G J, 169, 172, 319, 322, 345, 346,  
 347, 434, 436, 462, 466, 487, 493,  
 505, 506, 514, 519, 524, 527, 528,  
 551, 552, 553, 572, 573, 574, 575  
 — H E, 115, 116, 205, 206, 341, 342,  
 389, 390  
 — M E, 549, 550  
 Martindale, W E, 506, 508  
 Martinek, R G, 220, 230  
 Marvel, J P, 485, 493  
 Marvin, J F, 244, 248  
 Mason, H L, 39, 42, 58, 59, 61, 65, 73,  
 83, 85, 179, 183, 187, 189, 243, 248  
 Masunaga, E, 52, 55  
 Mather, K, 232, 236  
 Mathews, A P, 219, 221, 230  
 Matrone, G, 35, 37  
 Matsunaga, S, 213  
 Mattick, A T R, 75, 80  
 Mattis, P A, 483, 484, 488, 494, 505,  
 506  
 Mattocks, A M, 523, 525  
 Matukawa, T, 298  
 Maw, G A, 603, 604  
 Mawson, E H, 184, 186, 552, 553  
 Maxfield, J R, 324, 325  
 May, E L, 396, 402  
 — H B, 554  
 Mayer, R L, 151, 153  
 Mayfield, H L, 97, 105, 195, 202  
 Mayhall, M, 444, 445  
 Maynard, J T, 399, 401, 402, 403  
 — L A, 165, 167, 233, 236, 363, 364,  
 423, 424  
 Mazoué, H, 126, 131, 208, 210  
 McArthur, C S, 601, 603, 604  
 McBurney, C H, 351, 352  
 McCall, K B, 53, 56, 170, 172, 189, 190,  
 238, 240, 320, 321, 322, 368, 371, 426,  
 429, 431, 435, 436, 437, 491, 492, 495,  
 507, 508, 573, 575  
 McCance, R A, 164, 167  
 McCartney, J R, 44, 45, 46, 165, 167,  
 235, 236  
 McCarty, M A, 45, 166, 167  
 McCasland, G E, 346, 347, 579, 581  
 McClung, L S, 148, 152, 461, 466, 488,  
 494  
 McClure, F J, 48, 54  
 McCollum, E V, 37, 41, 90, 103, 134,  
 135  
 McCormack, R B, 534, 536  
 McCormick, H M, 540, 542  
 McCoy, R H, 320, 322, 369, 371, 451,  
 452, 455, 456  
 McCreary, J F, 175, 177  
 McCulloch, E C, 52, 55, 56, 490, 495,  
 552, 553, 573, 575  
 McDonald, F G, 289, 295  
 — P R, 174, 176  
 McElroy, L W, 79, 81, 185, 186, 327,  
 328, 376, 377, 425, 430  
 McElvain, S M, 214, 216, 217  
 McEwen, W L, 417, 420, 447, 454  
 McGibbon, W H, 425, 430  
 McGinnis, J, 600, 603, 614, 615  
 McGowan, J C, 578, 579  
 McGregor, M A, 435, 436, 490, 495, 552,  
 553, 573, 575  
 McHenry, E W, 49, 55, 318, 319, 322,  
 428, 431, 438, 572, 574, 590, 591, 592,  
 603, 604  
 McIlwain, A J, 324, 325

## AUTHOR INDEX

- [illegible]



## THE VITAMIN B COMPLEX

- Millman, N . 401, 403  
Mills, C A , 50, 55, 62, 63, 82, 85, 329,  
378, 379, 594, 595  
— R C , 272, 273, 405, 425, 430, 437,  
458, 465, 551, 553, 573, 575, 583,  
584, 614, 615  
— S D , 523, 526  
Mims, V , 461, 462, 463, 466, 479, 480,  
481, 482, 491, 495, 500, 503  
Minarich, C E , 114, 115  
Minnum, C E , 114, 115  
Minor, J T , 293, 295  
Minot, G R , 57, 61, 530, 532  
Mirnick, G S , 556, 559  
Mirimanoff, A , 150, 153  
Mirone, L , 425, 430, 489, 494  
Mitch " F " 55 — — — — — 56 57 58 59
- Morgan, A F , 71, 74, 169, 172, 250, 252,  
368, 371, 607, 608  
— B G E , 28, 31, 32, 48, 54  
— E H , 538, 541  
— H P , 511  
— H R , 492, 495, 521, 525, 558, 559  
Morgenstein, M , 62, 63  
Mori, K , 429, 431  
Morri, S , 119, 130, 303, 307  
Morrin, H P , 169, 171, 172, 173, 366,  
370  
— S , 36, 37  
Morrison, R J G , 497, 502  
Moruzzi, G , 155, 156, 162, 164, 585, 586  
Moseley, O , 333, 337  
Moser, R , 352, 357  
Moskowitz, H S , 300, 370
- 519, 524
- — — — — 471, 472, 473,  
474, 475, 476, 477, 482, 483, 520, 522,  
525  
Moyer, A W , 410, 414, 417, 420, 598,  
602, 603, 604, 605  
— D , 106, 109, 112, 113, 203, 204,  
281, 285, 338, 340, 386, 389, 438,  
440, 569, 570, 577, 578  
— E H , 449, 455  
— J C , 38, 42, 44, 46  
Mozingo, R , 410, 414, 415, 416, 420,  
473, 476, 477, 478, 479  
Mueller, D , 197, 202  
— J F , 249, 252  
— J H , 111, 113, 204, 205, 282, 286,  
340, 341, 361, 362, 380, 387, 388,  
394, 401, 439, 440, 446, 454, 509,  
511, 622, 623  
Muether, R O , 593  
Muir, R D , 197, 202  
Mulford, D J , 583, 584, 601, 603  
Mull, J W , 65, 73  
Murphy, E A , 49, 54  
— H W , 225, 231  
— M K , 345, 347  
— W P , 530, 532  
Murray, A Z , 181, 183  
— E S , 554, 558, 559  
— J F , 496, 502, 512, 513  
Mushatt, C , 320, 322, 368, 371  
Mushett, C W , 158, 163, 343, 346, 347,  
366, 370, 394, 401, 541, 542, 619, 620  
Musick, V H , 244, 248  
Musil, M N , 110, 113  
Musselman, M M , 243, 248  
Myrbäck, K , 24, 27, 229, 232.
- NACHMANSOHN, D , 391, 393  
Naess, T , 219, 230  
Naganna, B , 222, 230

# AUTHOR INDEX

- Najjar, V A, 39, 42, 52, 55, 64, 72, 73, 74, 76, 80, 160, 163, 179, 183, 184, 186, 226, 231, 249, 252, 254, 260, 266, 288, 294
- Nakahara, N, 615, 617
- W, 429, 431.
- Nason, A, 287
- Nasset, E S, 94, 104, 368, 371
- National Oil Products Co, 356, 358
- Neal, A L, 394, 401
- Needham, D M, 276, 280
- J, 568, 569, 576, 577
- Needles, W, 58, 61
- Neglein, E, 195, 202, 276, 277, 280
- Neilands, J B, 361, 362
- Neligh, R B, 539, 541
- Nelson, E M, 50, 55, 498, 500, 502, 503, 504, 505
- H V, 498, 502, 504, 505
- M M, 345, 347, 367, 370, 375, 376, 377, 425, 430, 489, 494
- V E, 404, 405
- Nemur, R L, 84, 85
- Nencki, M, 244, 248
- Ness, H T, 68, 73
- Nestler, R B, 539, 542
- Neuberger, A, 195, 202
- Neuman, M W, 595, 596
- Neumann, A L, 591, 592, 595
- F W, 434, 436
- Neuwahl, F J, 247, 249
- Neuweiler, W, 64, 69, 71, 72, 73, 74, 181, 183
- Nevens, W B, 53, 56, 170, 172, 239, 426, 431
- Nichol, C A, 283, 286, 535, 536, 542, 614, 615
- Nicholls, J, 366, 370
- J V V, 175, 177
- Nicholson, J T L, 49, 55, 79, 81, 82, 85
- Nielsen, E, 326, 327, 423, 424, 425, 430, 434, 436, 437, 462, 466, 487, 489, 493, 494, 505, 506, 577
- N, 361, 362, 373, 376, 386, 389, 394, 396, 399, 401, 402, 422
- Nier, A O, 96, 104
- Nigrelli, R F, 521, 525
- Nilsson, R, 404, 405
- Nimmo Smith, R H, 510, 511, 523, 526
- Nitchals, R, 234, 236
- Nitti, F, 545, 547
- Nitzberg, T, 68, 73
- Norris, E R, 461, 465, 470, 471, 484, 522, 525, 608, 610, 614, 615
- T W, 220, 222, 230, 235, 236
- L C, 128, 131, 159, 161, 163, 164, 165, 167, 320, 322, 337, 338, 344, 347, 368, 369, 371, 378, 379, 459, 460, 465, 479, 480, 485, 486, 488, 493, 494, 506, 507, 514, 517, 518, 524, 535, 536, 537, 539, 542, 600, 603, 609, 611, 614, 615, 616, 618
- Northey, L H, 463, 466, 471, 473, 474, 475, 477
- Novak, A F, 614, 615
- Novelli, G D, 391, 392, 393
- Nyc, J F, 251, 252, 281, 285
- O BANION, E E, 552, 553
- Obermeyer, H G, 34, 36, 70, 74, 183, 186
- O'Brien, J R, 367, 370, 611, 612, 613
- Ochoa, S, 95, 104, 193, 201, 444, 445
- O'Dell, B L, 458, 459, 461, 464, 465, 466, 469, 470, 471, 477, 478, 479, 480, 484, 487, 493, 494, 505, 506, 527, 528
- Odintzova, E N, 106, 107, 112
- O'Doherty, K, 536
- O'Donnell, D J, 170, 173, 189, 190, 239, 240, 320, 322, 369, 371, 426, 431, 492, 495, 552, 553, 574, 575, 591, 592
- Odoriz, J B, 47, 54
- Oettel, H, 551, 553
- Ogden, F N, 496, 502
- Ogg, C L, 289, 291, 294
- Olcott, C T, 76, 80
- Oldham, H, 83, 85, 178, 179, 180, 182, 183, 187, 189
- H G, 70, 74, 84, 85, 178, 180, 182
- Oleson, J J, 282, 286, 349, 351, 365, 369, 405, 485, 493, 520, 521, 522, 525, 541, 542, 604, 605, 619, 620
- Olsen, H W, 539, 542
- Olson, O E, 481, 482
- R E, 392, 393, 445, 590, 592
- O'Malley, C M, 155, 156
- O'Meara, R A Q, 545, 547
- Omori, S, 37, 42, 44, 46
- Orent, L R, 134, 135
- Organ, J G, 39, 42
- Orimo, R, 92, 104
- Orla Jensen, S, 203, 204
- Noggle, G R, 286, 287
- Noland, J L, 597
- Nopco Chemical Co, 357, 358

# THE VITAMIN B COMPLEX

- Orsini, D , 184, 186, 318, 321  
 Orter, R H , 53, 56  
 Osborne, T B , 75, 80, 81, 84  
 Oser, B L , 26, 27, 224, 226, 231, 256,  
 266, 308, 309, 311, 312, 314, 315, 317,  
 344, 347, 570, 571  
 Oswald, E J , 556, 558  
 Ott, M , 487, 494  
 — W H , 171, 173, 345, 346, 347,  
 429, 431, 446, 454, 539, 541, 542,  
 619, 620  
 Otte, N C , 203, 204  
 Ovando, P , 366, 370  
 Owen, C R , 197, 202  
 — P S , 25, 27, 72, 74  
 — R D , 251, 252  
 Owens, H S , 594, 595  
 Oyaas, J E , 150, 153  
  
 PACK, G T , 575  
 Paganelli, V , 523, 526  
 Page, A C , 531, 532, 533, 535, 536, 544  
 Pallares, E S , 207, 210  
 Palmer, L S , 44, 45, 48, 49, 54, 317,  
 425, 430  
 Papageorge, E , 41, 42, 67, 73  
 Pappenheimer, A M , 622, 623  
 Pargel, B L , 497, 502  
 Parke, H C , 355, 358, 359  
 Parke, Davis & Co , 356, 357, 358  
 Parker, D , 72, 74  
 — L F J , 531, 532  
 Parkinson, F L , 235, 236  
 Parrott, E M , 459, 465, 484, 493  
 Parsons, H T , 68, 73, 79, 81, 166, 168,  
 177, 178, 182, 433, 435, 436  
 Partridge, C W H , 422, 423, 444, 445  
 Parvé, E P S , 34, 36, 72, 74  
 Passmore, R , 28, 32, 243, 248  
 Patek, A J , 170, 172  
 Patel, J C , 538, 541  
 Patrick, H , 423, 430, 437  
 Patterson, E G , 591, 592  
 — I , 128, 131  
 — J M , 428, 431, 573, 574, 589, 591,  
 592  
 — P A , 521, 522, 525  
 Patton, R A , 318, 321  
 — R L , 205, 206  
 Paul, W J , 536  
 Pauli, R , 197, 202, 560, 562  
 Paulson, M , 368, 371  
 Pavcek, P L , 365, 370, 421, 572, 574  
 Payette, A , 109, 112  
 Peacock, G , 37, 38, 41, 42, 160, 163  
 Pearce, H , 175, 177  
 Pearson, A M , 540, 542  
 — P B , 44, 45, 161, 164, 165, 167,  
 170, 172, 177, 182, 189, 190, 233,  
 236, 237, 239, 242, 248, 250, 252,  
 Pearson, P B (contd) , 253, 259, 261, 262,  
 266, 267, 270, 271, 272, 336, 338,  
 363, 364, 365, 369, 371, 373, 374,  
 375, 378, 379, 505, 506, 507, 587,  
 593, 594, 596,  
 Pederson, K O , 191, 200  
 — R L , 227, 231  
 Peeler, H T , 537  
 Peirce, E C , 501, 503  
 Pelczar, M J , 282, 285, 290, 295, 360,  
 362, 373, 374, 375  
 Pelou, A , 126, 131  
 Peltier, G L , 152, 153  
 Pence, J W , 45, 52, 56, 166, 167  
 Pennington, D , 360, 361, 362, 367, 370,  
 427, 431, 622, 623  
 — R J , 312, 314  
 Pepper, C R , 231  
 Perkins, J , 44, 46  
 Perlman, D , 449, 450, 455  
 Perlzweig, W A , 39, 42, 221, 223, 224  
 226, 229, 231, 232, 234, 236, 242, 248,  
 249, 251, 253, 254, 256, 257, 259, 260,  
 261, 265, 266, 267, 271, 272, 288, 294,  
 326, 327, 336, 338, 344, 347  
 Perrault, C , 109, 112  
 Perry, D J , 175, 176  
 — R L , 189, 190, 378, 379  
 Pesson, M , 126, 131, 208, 210  
 Petering, H G , 485, 493, 514, 524  
 Peters, J B , 70, 74  
 — M , 558, 559  
 — R A , 11, 12, 28, 30, 32, 37, 38, 41,  
 42, 90, 92, 94, 95, 102, 103, 105,  
 611, 612, 613  
 Peterson, C , 43, 45  
 — W E , 593  
 — W H , 107, 112, 282, 285, 340,  
 341, 363, 364, 405, 422, 423, 424,  
 433, 434, 435, 436, 438, 439, 440,  
 442, 445, 450, 452, 455, 457, 458,  
 460, 464, 465, 467, 470, 484, 493,  
 513, 524, 550, 556, 558, 560, 562,  
 622, 623  
 — W J , 155, 156, 161, 164, 165, 167  
 Petrow, V , 531, 532, 533  
 Pfaehler, K , 138, 139  
 Pfaltz, H , 367, 370, 396, 402, 594, 595  
 Pfeiffer, S E , 152, 153, 339, 341, 386,  
 389, 439, 440  
 Pliffler, J J , 458, 459, 464, 465, 466,  
 469, 470, 471, 477, 478, 479, 480, 484,  
 493, 527, 528  
 Pfister, K , 147, 148  
 Pfizer & Co , 145, 147, 151, 153  
 Philips, F S , 521, 525  
 Phillips, M , 44, 46, 165, 167  
 — P H , 46, 47, 54, 169, 172, 366, 368,  
 369, 370, 371, 425, 430, 437, 486,  
 493, 572, 574, 578, 579, 580, 581

- Pick, E. P., 86, 87, 89  
 Pickel, F. D., 120, 130  
 Pictet, A., 214, 216  
 Piening, J. R., 447, 454, 455  
 Pierce, J. G., 444, 445  
 — J. V., 531, 532, 533, 535, 536, 538,  
     541, 544  
 — M., 523, 526  
 Pilgrim, I. J., 391, 393, 450, 451, 455  
 Pinkerton, H., 557, 559  
 Pirie, A., 484  
 Pittman, M., 262, 267  
 Platt, D. S., 37, 42, 64, 73, 90, 92, 103  
     569, 570, 576, 577  
 Plattner, P. A., 617, 618  
 Platz, B. R., 50, 55, 315, 317  
 Plotka, C., 95, 104  
 Plotz, H., 558, 559  
 Pocock, R., 189, 190  
 Polanowski, M., 126, 131, 208, 210  
 Poliakov, H., 497, 502  
 Poling, C. E., 365, 369, 370, 377, 378,  
     424, 430  
 Pollack, H., 66, 73  
 — M. A., 171, 173, 374, 376, 394, 396,  
     399, 401, 430, 432, 621, 623  
 Pollak, F., 216, 217  
 — J. J., 93, 104  
 Pons, L., 406, 407, 410, 414, 421  
 Pontovich, V. E., 152, 153  
 Poore, E., 49, 54  
 Popkin, G. L., 274  
 Popper, H., 540, 542  
 Porter, C. C., 336, 338, 345, 346, 347  
 — E. P., 440, 454  
 — J. R., 282, 285, 290, 295, 360, 362,  
     373, 374, 375  
 — J. W., 77, 80, 185, 186, 269, 271,  
     327, 328, 377, 435, 436, 504, 505,  
     506, 554  
 — T., 178, 180, 182, 187, 189, 234,  
     236, 260, 267  
 — W. E., 45  
 Portis, S., 323, 324  
 Possiter, R. J., 193, 201  
 Post, J., 170, 172  
 Posternak, T., 565, 566, 578, 579, 580  
 Potter, R. L., 170, 172, 188, 190, 443  
     444, 445  
 — V. R., 94, 104  
 Power, M. H., 59, 61  
 Prados, M., 46, 54  
 Pratt, E. F., 349, 351, 389, 394, 401  
 Prebluda, H. J., 37, 41  
 Prescott, F., 607, 608  
 Preston, F. W., 523, 526  
 Price, C. C., 123, 130  
 — D., 120, 130, 396, 402  
 — L. L., 68, 73, 166, 168  
 — S. A., 158, 163, 228, 232  
 Pringle, A., 522, 525  
 — W. J. S., 164, 167  
 Pritchard, J. A., 522, 525, 540, 542  
 Prout, L. M., 25, 27  
 Provasoli, L., 535, 536, 543, 544  
 Provost, R. C., 288, 291, 294  
 Prussoff, W. H., 528, 529  
 Pulkki, L. H., 45  
 Purrmann, R., 471, 473, 476, 477  
 Purvis, S. E., 443, 444, 445  
 Puutula, K., 45  
 Pyke, M., 45  
 Pyridium Corp., 216, 217  
 RABIN, J., 553, 554  
 Rabinowitz, J. C., 312, 313, 315, 326,  
     327, 334, 337, 344, 347  
 Rachele, J. R., 407, 414  
 Racker, E., 276, 280  
 Raffy, A., 150, 151, 153, 182, 183  
 Rainbow, C., 404, 405  
 Raistrick, H., 197, 202  
 Ralli, E. P., 366, 370  
 Randall, F. E., 158, 163  
 Random, L., 182, 183, 611, 613  
 Rane, L., 350, 351, 380, 388, 394, 401  
 Rannefeld, A. N., 312, 314, 330, 337  
 Ransford, O. N., 243, 248  
 Ransone, B., 461, 462, 466, 487, 493,  
     505, 506  
 Rant, C., 386, 389  
 Rao, M. N., 318, 320, 321, 329  
 Raoul, V., 255, 266  
 Rapport, M. M., 399, 401, 402, 403  
 Rasmussen, A. F., 51, 55, 171, 173  
 Ratner, S., 196, 202, 516, 524, 548  
 Rauch, K., 197, 202  
 Ravel, J. M., 387, 389, 514, 519, 524  
     543, 544  
 Ravenna, F., 579, 580  
 Ray, H. N., 369, 371  
 Raymond W. D., 37, 41, 219, 224, 230  
 Reader, V., 30, 32, 611, 613  
 Redelings, E., 44, 46  
 Reedman, E. J., 302, 307, 329  
 Rees, H. G., 220, 230  
 Reeves, E., 158, 163  
 Regan, M. A., 444, 445, 622, 623  
 Register, U. D., 537, 538  
 Reich, M., 354, 356

## THE VITAMIN B COMPLEX

- 654

- Ross, J. F., 497, 502  
 — S., 558, 559  
 Roth, L. J., 257, 264, 266, 268  
 — P., 366, 370  
 Rothman, S., 553, 554  
 Roulet, M. A., 114, 115, 341, 424, 559, 578  
 Rowett, E., 391, 393  
 Rowland, V., 72, 74  
 Rowlands, E. N., 35, 36, 68, 73  
 Roy, S. C., 103, 105  
 — S. K., 103, 105  
 Rubbo, S. D., 546, 547, 548, 555, 558  
 Rubin, M., 539, 542, 561, 562, 609, 611  
 — S. H., 152, 153, 154, 156, 160, 163, 316, 317, 396, 402, 449, 450, 451, 453, 454, 455, 456  
 Rubinstein, D. L., 287  
 Ruckstuhl, H., 291, 292, 293, 295  
 Rudy, H., 134, 135, 136, 137, 139, 154, 155, 191, 192, 201  
 Ruegamer, W. R., 238, 240, 483, 491, 495, 507, 508  
 Ruehle, A. E., 12, 13, 14, 15  
 Ruffin, J. M., 212, 213, 260, 267, 295  
 Rundles, R. W., 538, 541  
 Rusch, H. P., 429, 432  
 — R. R., 321, 322  
 Russakoff, A. H., 593  
 Russell, W. C., 235, 236, 609, 611  
 Rutledge, M. M., 264, 268  
 Rutzky, J., 499, 503  
 Ryan, E., 176, 177  
 — F. J., 387, 389  
 Ryder, H. W., 274  
 Rydin, H., 28, 32  
  
 SABINE, S. C., 196, 202  
 Sabol, M., 590, 592  
 Safir, S. R., 417, 420, 447, 454  
 Sakai, R., 571  
 Sakami, W., 600, 602  
 Sakurai, Y., 37, 42, 44, 46  
 Salcedo, J., 72, 74  
 Salmon, W. D., 366, 370, 539, 542  
 Salomon, H., 137, 139, 140, 147, 206, 207, 209, 291, 292, 293, 295  
 Samarina, O., 334, 335, 337  
 Sampath, A., 523, 526  
 Sampson, W. L., 54, 56, 85, 89, 120, 130, 302, 307, 329, 365, 370, 377, 378  
 Samuels, L. T., 276, 280  
 Sandford, M., 158, 163, 621, 623  
 Sands, M., 544  
 Sandstead, H. R., 175, 177  
 Sanger, F., 195, 202  
 Sarett, H. P., 35, 37, 110, 113, 127, 131, 208, 209, 210, 224, 227, 231, 249, 252, 253, 259, 261, 266, 267, 360, 361, 362, 375, 376, 380, 388, 510, 511  
 Sárty, E., 47, 54  
 Sargent, H., 119, 130  
 Sarles, W. B., 435, 436  
 Sarma, M. L., 233, 236  
 — P. S., 115, 116, 205, 206, 237, 239, 241, 248, 271, 272, 310, 314, 327, 328, 334, 337, 342, 344, 347, 441, 442  
 Sarson, H. S., 44, 45  
 Saslaw, S., 461, 466  
 Sato, A., 92, 104  
 Satoda, I., 216, 217  
 Sauberlich, H. L., 319, 322, 543, 544, 622, 623  
 Saunders, A., 148, 152  
 — F., 228, 231, 282, 285, 380, 388  
 Sawhill, J., 324, 325  
 Sawitsky, A., 499, 503, 523, 526  
  
 Schales, O., 197, 202  
 Schalk, A. F., 79, 80, 81, 185, 186  
 Schardinger, F., 194, 201  
 Scheer, B. T., 249, 250, 251, 252  
 Scheff, L., 62, 63  
 Scheiner, J., 316, 317, 396, 402, 453, 456  
 Schenck, J. R., 599, 602  
 Scherer, D., 564, 565  
 Schieve, J. F., 538, 541  
 Schilling, R. F., 538, 541  
 Schindler, U., 394, 397, 401  
 Schink, C. A., 387, 389, 395, 398, 402  
 Schiro, H. S., 323, 324  
 Schlegel, J. A., 594  
 Schleicher, E. M., 593  
 Schlenk, F., 94, 104, 219, 225, 230, 231, 252, 261, 265, 267, 275, 276, 279, 282, 286, 333, 334, 337, 581  
 — T., 275, 279  
 Schlitter, E., 137, 139  
 Schlosser, M. E., 383, 388  
 Schmidt, C. L. A., 225, 231  
 — F. W., 585  
 — H., 170, 172, 177, 182, 189, 190, 270, 272, 378, 379  
 — J. L., 437, 438  
 — V., 373, 376  
 Schmidt Thome, J., 293, 295  
 Schneider, H. A., 315, 317  
 — L. K., 387, 389  
 Schneider, O., 417, 420, 449, 455  
 Schoen, K., 154, 156  
 Schoenheimer, R., 599, 602  
 Schöpf, C., 461, 465

- Spies, T D (*contd.*), 265, 267, 268, 289,  
290, 294, 295, 323, 324, 325, 327, 373,  
375, 379, 495, 496, 497, 498, 501, 502,  
503, 505, 514, 524, 538, 540, 541, 542
- Spilman, F., 259, 266
- Spink, W W., 546, 547, 556, 559
- Spiridanoff, S., 397, 402
- Spitzer, E H., 25, 27
- Spohn, A., 28, 29, 32
- Sporn, E M., 483, 494
- Sprague, K L., 483, 484, 488, 494, 505,  
506
- Sprince, H., 460, 465, 490, 494, 616, 618,  
619, 620
- Spruth, H C., 536
- Squires, E M., 166, 167, 234, 236, 374,  
376
- Sreenivasan, A., 481, 482
- Sreenivasaya, M., 115, 116, 276, 280,  
438, 440
- Stamp, T C., 546, 547
- Stanbery, S R., 351, 352, 353, 357, 360,  
362, 373, 375, 379, 394, 401
- Stanbury, S W., 501, 503
- Standfast, A F B., 197, 202
- Stanford, C E., 176, 177
- Stanier, J E., 184, 186, 552, 553
- Stanley, D A., 282, 286  
— R. H., 349, 351
- Stansly, P G., 383, 388
- Starbuck, E B., 282, 286
- Stare, F J., 239, 240, 336, 338, 445, 590,  
591, 592, 594, 595
- Starling, D., 523, 525
- Stearman, R L., 388, 389
- Stearnes, S P., 501, 503
- Stebbins, R B., 345, 346, 347
- Steele, J M., 372, 553, 554
- Stefanini, M., 274
- Steiger, M., 144, 147
- Stein, G., 367, 371  
— G A., 18, 22, 120, 130  
— H J., 52, 55, 56, 238, 240, 254,  
266, 320, 322, 368, 371  
— W., 62, 63
- Steinberg, C L., 62, 63  
— D L., 174, 176, 187, 189
- Steinbock, H., 49, 50, 54, 55, 315, 317
- Steinkampf, R., 503, 504
- Stenhouse, H., 259, 266
- Stephen, J M L., 561, 562
- Stepp, W., 82, 85
- Stern, E L., 86, 89  
— K G., 94, 100, 104, 105, 162, 164  
— R., 196, 202  
— R M., 150, 153
- Sternbach, A., 497, 502  
— L H., 453, 456
- Stetten, D., 50, 55, 576, 577, 599, 602  
— M R., 576, 577
- Stevens, J. R., 18, 22, 120, 130, 298,  
300, 301, 310, 314
- Stewart, C A., 261, 267  
— L C., 488, 494  
— R. N., 578, 579  
— W B., 33, 36  
— W S., 35, 37
- Stickney, J. M., 523, 526
- Stiles, M H., 62, 63
- Still, E V., 71, 74
- Stiller, E T., 300, 301, 353, 354, 357,  
359, 394, 401
- St John, J L., 590, 592
- St Johnston, C R., 497, 502
- Stocher, H., 191, 200
- Stockell, A K., 527, 528
- Stoerk, H C., 171, 173, 320, 322, 345,  
347
- Stokes, J L., 204, 205, 313, 315, 339,  
340, 360, 362, 438, 439, 440, 442, 445,  
446, 447, 448, 454, 458, 465, 513, 517,  
520, 524, 527, 529
- Stokstad, E L. R., 170, 173, 239, 240,  
457, 458, 460, 461, 463, 464, 465, 466,  
467, 468, 470, 471, 472, 473, 474, 475,  
476, 477, 478, 479, 480, 482, 483, 484,  
485, 486, 489, 491, 493, 495, 496, 500,  
502, 503, 504, 505, 510, 511, 519, 520,  
521, 522, 524, 525, 531, 532, 533, 534,  
535, 536, 538, 541, 543, 544, 574, 575,  
615, 618, 619, 620, 622, 623
- Stolovy, E., 387, 389
- Stone, C H., 540, 542  
— R E., 289, 295, 497, 498, 501, 502,  
503, 505, 538, 540, 541, 542
- Stotz, E., 46, 52, 54, 56, 220, 230
- Stout, A K., 569, 570
- Strandine, E J., 166, 167, 234, 236, 374,  
376
- Strandskov, F., 561, 562
- Straub, F B., 195, 202  
— G J., 40, 42
- Strauss, E., 546, 547, 554  
— L., 319, 322  
— M B., 57, 61
- Strecker, A., 582, 584, 585
- Street, H R., 157, 162, 169, 172, 212,  
213, 318, 321, 610, 611
- Streightoff, E., 556, 558
- Strength, D R., 539, 542
- Stringer, W J., 167, 168
- Ströbele, R., 140, 143, 147, 162, 164,  
198, 203, 207, 210
- Strom, J E., 66, 70, 73, 74, 84, 85
- Strong, F M., 157, 158, 162, 163, 177,  
178, 182, 204, 205, 206, 209, 212, 213,  
214, 227, 231, 288, 289, 291, 294, 312,  
313, 314, 315, 316, 317, 360, 361, 362,  
363, 364, 394, 395, 401, 402
- Stumpf, P K., 194, 197, 201

## AUTHOR INDEX

- Stumpff, G., 65, 73  
Sturgeon, B., 533  
Sturgis, C. L., 374, 376  
Suarez, R. M., 496, 500, 502, 503, 538,  
541  
— R. M., Jr., 500, 501  
Subbarow, Y., 115,  
286, 288, 294, 341,  
351, 352, 365, 366, 370, 380, 388, 389,  
390, 394, 401, 417, 420, 446, 447, 454,  
455, 456, 457, 458, 459, 460, 461, 462,  
463, 464, 465, 466, 467, 468, 469, 470,  
471, 472, 473, 474, 475, 476, 477, 478,  
479, 480, 481, 482, 483, 484, 485, 486,  
487, 488, 489, 490, 491, 492, 493, 494,  
495, 496, 497, 498, 499, 500, 501, 502,  
503, 504, 505, 506, 507, 508, 509, 510,  
511, 512, 513, 514, 515, 516, 517, 518,  
519, 520, 521, 522, 523, 524, 525, 526,  
527, 528, 529, 530, 531, 532, 533, 534,  
535, 536, 537, 538, 539, 540, 541, 542,  
543, 544, 545, 546, 547, 548, 549, 550,  
551, 552, 553, 554, 555, 556, 557, 558,  
559, 560, 561, 562, 563, 564, 565, 566,  
567, 568, 569, 570, 571, 572, 573, 574,  
575, 576, 577, 578, 579, 580, 581, 582,  
583, 584, 585, 586, 587, 588, 589, 590,  
591, 592, 593, 594, 595, 596, 597, 598,  
599, 600, 601, 602, 603, 604, 605, 606,  
607, 608, 609, 610, 611, 612, 613, 614,  
615, 616, 617, 618, 619, 620, 621, 622,  
623, 624, 625, 626, 627, 628, 629, 630,  
631, 632, 633, 634, 635, 636, 637, 638,  
639, 640, 641, 642, 643, 644, 645, 646,  
647, 648, 649, 650, 651, 652, 653, 654,  
655, 656, 657, 658, 659, 660, 661, 662,  
663, 664, 665, 666, 667, 668, 669, 670,  
671, 672, 673, 674, 675, 676, 677, 678,  
679, 680, 681, 682, 683, 684, 685, 686,  
687, 688, 689, 690, 691, 692, 693, 694,  
695, 696, 697, 698, 699, 700, 701, 702,  
703, 704, 705, 706, 707, 708, 709, 710,  
711, 712, 713, 714, 715, 716, 717, 718,  
719, 720, 721, 722, 723, 724, 725, 726,  
727, 728, 729, 730, 731, 732, 733, 734,  
735, 736, 737, 738, 739, 740, 741, 742,  
743, 744, 745, 746, 747, 748, 749, 750,  
751, 752, 753, 754, 755, 756, 757, 758,  
759, 760, 761, 762, 763, 764, 765, 766,  
767, 768, 769, 770, 771, 772, 773, 774,  
775, 776, 777, 778, 779, 780, 781, 782,  
783, 784, 785, 786, 787, 788, 789, 790,  
791, 792, 793, 794, 795, 796, 797, 798,  
799, 800, 801, 802, 803, 804, 805, 806,  
807, 808, 809, 810, 811, 812, 813, 814,  
815, 816, 817, 818, 819, 820, 821, 822,  
823, 824, 825, 826, 827, 828, 829, 830,  
831, 832, 833, 834, 835, 836, 837, 838,  
839, 840, 841, 842, 843, 844, 845, 846,  
847, 848, 849, 850, 851, 852, 853, 854,  
855, 856, 857, 858, 859, 860, 861, 862,  
863, 864, 865, 866, 867, 868, 869, 870,  
871, 872, 873, 874, 875, 876, 877, 878,  
879, 880, 881, 882, 883, 884, 885, 886,  
887, 888, 889, 890, 891, 892, 893, 894,  
895, 896, 897, 898, 899, 900, 901, 902,  
903, 904, 905, 906, 907, 908, 909, 910,  
911, 912, 913, 914, 915, 916, 917, 918,  
919, 920, 921, 922, 923, 924, 925, 926,  
927, 928, 929, 930, 931, 932, 933, 934,  
935, 936, 937, 938, 939, 940, 941, 942,  
943, 944, 945, 946, 947, 948, 949, 950,  
951, 952, 953, 954, 955, 956, 957, 958,  
959, 960, 961, 962, 963, 964, 965, 966,  
967, 968, 969, 970, 971, 972, 973, 974,  
975, 976, 977, 978, 979, 980, 981, 982,  
983, 984, 985, 986, 987, 988, 989, 990,  
991, 992, 993, 994, 995, 996, 997, 998,  
999, 1000
- Takamatsu, A., 92, 104  
Tamura, J. T., 380, 388  
Tanner, F. W., 150, 151, 152, 153, 339,  
341, 386, 388, 439, 440  
— W. F., 211, 212, 213  
Tashell, D. S., 6, 11  
Taylor, A., 171, 173, 367, 370, 374, 376,  
430, 432, 508, 509  
— E. C., 517, 518, 524  
— E. L., 76, 80  
— H. C., 200, 203  
— H. L., 60, 61, 606, 608  
— J., 76, 80, 171, 173, 369, 371, 571,  
572  
— M. W., 235, 236  
— S. G., 523, 526  
Teague, P. C., 390, 393  
Teeri, A. E., 220, 230, 609, 611  
Templeton, C. M., 174, 176  
Ten Ham, E. J., 405, 407, 421  
Tennant, D. M., 71, 74, 180, 183, 374,  
376  
Teply, L. J., 184, 186, 235, 236, 237, 239,  
240, 241, 248, 270, 271, 272, 288, 289,  
290, 291, 294, 315, 316, 317, 363, 364,  
481, 482, 483, 488, 494, 528, 529  
Terberg, J. L., 499, 503, 543, 544  
Terrone, T., 287  
Therrell, A., 74, 79, 80  
Theorell, H., 191, 193, 200.  
Thiersch, J. B., 521, 525  
Thomas, A. W., 43, 45  
— B., 26, 27  
— J. M., 310, 314  
Thomasson, H. J., 72, 74  
Thompson, H. T., 537  
— J. F., 44, 46, 165, 167  
— M. R., 572, 573, 574, 575  
Thompson, R. C., 79, 81, 185, 186, 203,  
204, 380, 388, 422, 423, 424, 430,  
432, 435, 436, 439, 440, 549, 550,  
551, 557, 559  
— R. H. S., 28, 32  
— S. Y., 184, 186, 552, 553  
Thornton, J. J., 11, 12  
Thorp, F., 242, 248, 249, 251, 261, 267,  
272, 273  
— W. T. S.,



# THE VITAMIN B COMPLEX

- Tichenor, C J, 558, 559  
 Tierney, N A, 558, 559  
 Tilden, M, 221, 226, 231  
 Tingstam, S, 128, 131  
 Tisdale, R E, 369, 371, 384, 388  
 Tisdall, F F, 175, 177  
 Tishler, M, 146, 147, 148, 354, 358, 472, 473  
 Tittsler, R P, 439, 440  
 Titus, H W, 539, 542  
 Toca, R L, 498, 502, 538, 540, 541, 542  
 Todd, A R, 15, 17, 21, 38, 42, 116, 130, 348, 351, 394, 401, 621, 623  
 Toennies, G, 504, 505  
 Tönnis, B, 404, 405, 406, 407, 421, 422, 438, 440  
 Tolman, L, 518, 524, 527, 528  
 Tolpin, J G, 125, 131  
 Toman, J E P, 53, 56  
 Tomarelli, R, 427, 431  
 Tomey, L F, 75, 80  
 Tomlinson, F F, 422, 423  
 — H M R, 335, 338  
 Tompkins, P C, 225, 231  
 Toomey, J A, 51, 55  
 Topper, Y J, 445  
 Topping, N H, 177, 182, 228, 232, 282, 285  
 Torda, C, 89  
 Torre, L D, 178, 182, 183, 186  
 Torres-Bracamonte, F, 71, 74  
 Tota, Y A, 124, 131  
 Totter, J R, 461, 462, 463, 466, 476, 477, 479, 480, 491, 495, 500, 503, 504, 506, 508, 528, 529  
 Tove, S B, 609, 611  
 Toverud, K V, 65, 71, 73  
 Townsend, W C, 498, 502  
 Tracy, A H, 123, 124, 126, 130  
 Trager, W, 115, 116, 341, 342, 389, 390, 399, 402, 441, 442  
 Trautman, M, 594, 595  
 Treadwell, C R, 595  
 Trélouel, J, 545, 547  
 — Mme J, 545, 547  
 Trenner, N R, 473  
 Tressler, D K, 38, 42, 44, 45, 46, 165, 167  
 Tristram, G R, 594, 595  
 Truesdail, J H, 351, 352, 357  
 Trufanov, A V, 178, 182  
 Truhlar, J, 38, 42  
 Tschelintzev, G V, 21, 22  
 Tschesche, R, 13, 15, 460, 465  
 Tucher, H F, 598, 602  
 Tull, C, 242, 248, 249, 251, 261, 267, 272, 273  
 Tullidge, G M, 324  
 Tullner, W W, 428, 431  
 Tullo, J W, 167, 168  
 Tuttle, L C, 391, 393  
 Tytell, A A, 380, 388  
 UGAMI, S, 366, 370, 615, 617  
 Umbreit, W W, 331, 332, 334, 335, 336, 337, 338, 345, 347, 442, 444, 445  
 Ungley, C C, 538, 540, 541  
 Unna, K, 49, 54, 86, 89, 190, 200, 203, 273, 274, 302, 307, 318, 321, 325, 327, 329, 330, 342, 343, 346, 365, 366, 370, 373, 374, 375, 377, 378, 379, 394, 397, 401, 402, 607, 608, 609, 611  
 Unterköfer, L A, 282, 285  
 Utzinger, G E, 278, 280  
 VALLENCE-OWEN, J, 554  
 Vallin, I, 24, 27  
 Van Brugen, J R, 197, 202  
 Vandenbelt, J M, 160, 163, 311, 314, 480, 527, 528  
 Van den Broek, W A, 34, 36  
 Van den Linden, A C, 34, 36  
 Vander Werf, C A, 293, 295  
 — H, 513, 516, 524  
 Van Dorp, W A, 214, 215, 216  
 Van Duyn, F O, 160, 163  
 Van Eekelen, M, 159, 163  
 Van Etten, C, 52, 56  
 Van Hasselt, W, 422, 423, 424, 570, 571  
 Van Klaveren, F W, 38, 42  
 Van Lanen, J M, 107, 112, 150, 151, 152, 153, 281, 285, 339, 341, 386, 389, 439, 440  
 Van Nonhuys, F, 375, 376  
 Van Prohaska, J, 591, 592  
 Van t Hoog, E G, 115, 116  
 Van Veen, A G, 82, 85  
 Van Wagtenonk, W J, 439, 440  
 Vargha, L, 191, 201  
 Velluz, L, 95, 104  
 Vennesland, B, 277, 280  
 Verbeck, J H, 411, 412, 414  
 Verzár, F, 192, 201  
 Vestin, R, 94, 104, 276, 279  
 Vetter, H, 38, 42  
 Victor, J, 170, 172  
 Vieillefosse, R, 126, 131  
 Viljoen, P R, 74, 79, 80  
 Vilter, C F, 495, 497, 501, 502, 514, 514  
 — R W, 173, 175, 176, 229, 232, 249, 252, 263, 267, 289, 294, 323, 324, 497, 502  
 — S P, 173, 176, 219, 221, 229, 230, 232, 263, 267, 268, 289, 295  
 Vincent, J M, 557, 559  
 Vinson, L J, 62, 63, 489, 494  
 Viollier, G, 97, 105  
 Viscontini, M, 102, 105, 332, 337, 523, 526

# AUTHOR INDEX

- Visnyei, K. 44, 45, 46, 165, 167, 235, 236  
 Vivanco, F. 348, 351  
 Vivino, J. J. 556, 559  
 Vojnovich, C. 150, 153  
 Vogt Möller, J. 92, 104  
 Volcani, B. 220, 232  
 Vonder Heide, E. C. 523, 526  
 Von Euler, H. 94, 104, 128, 131, 134, 135, 138, 139, 156, 162, 194, 201, 206, 207, 208, 209, 210, 219, 225, 230, 231, 252, 262, 265, 267, 275, 276, 277, 279, 291, 292, 293, 295  
 Vongerichten, E. 218, 230  
 Von Muralt, A. 86, 87, 89  
 Vorhaus, M. G. 82, 85  
 Voris, Le R. 48, 50, 54, 55, 188, 189, 318, 321, 367, 370  
 Vortmann, G. 215, 217  
 Vowles, R. B. 94, 104  
  
 WACHSMUTH, H. 41, 42  
 Waddell, J. 485, 493  
 — J. G. 345, 347  
 Wade, N. J. 583, 584  
 Wadsworth, C. 429, 431  
 Waelsch, J. H. 501, 503  
 Wagner, J. R. 157, 162  
 — R. W. 386, 389  
 Wagner-Jauregg, T. 38, 42, 134, 135, 136, 139  
 Wahler, L. 48, 54  
 Waisman, H. A. 51, 52, 53, 55, 56, 166, 167, 170, 172, 189, 190, 218, 220, 230, 288, 294, 315, 316, 317, 318, 320, 321, 322, 348, 349, 351, 361, 362, 363, 364, 365, 368, 369, 370, 371, 377, 378, 394, 401, 426, 429, 431, 433, 436, 437, 461, 466, 491, 495, 532, 553, 573, 574, 575  
 Wakim, K. G. 461, 466, 488, 498, 552, 553  
 Wald, G. 86, 89, 276, 280  
 Waldis, D. 125, 131  
 Waldo, J. F. 94, 104  
 Waletzky, E. 399, 402  
 Walker, H. F. 26, 27  
 — J. 475, 477, 523, 526  
 — W. H. 497, 502  
 Waller, C. W. 463, 466, 471, 472, 473, 474, 475, 476, 477, 482, 483, 520, 522, 525  
 Wallis, E. S. 506  
 Wang, Y. L. 39, 40, 42, 64, 65, 73, 222, 223, 230  
 Wapner, S. 38, 42  
 Warburg, O. 134, 135, 136, 139, 191, 192, 193, 195, 200, 201, 202, 229, 232, 275, 276, 277, 278, 279, 280  
 Ward, S. M. 195, 202  
 — T. G. 282, 286  
 Ward, W. H. 427, 431  
 Wasserman, L. 150, 153  
 Waterman, R. E. 11, 12, 14, 82, 85, 611, 613  
 Waters, W. A. 278, 280  
 Watson, C. J. 244, 248, 249, 501, 503  
 — H. M. S. 615, 618  
 — J. 498, 502, 538, 547  
 Watt, J. Y. C. 52, 55, 171, 173  
 Way, E. L. 397, 402  
 Weaver, J. W. 174, 176  
 Webb, F. R. 62, 63  
 — T. J. 308, 311, 314, 343, 346  
 Webley, D. M. 97, 98, 99, 103  
 Webster, A. 11, 12, 28, 32  
 — G. L. 220, 230  
 — M. D. 198, 203  
 Weese, H. 85, 89  
 Wegner, M. I. 79, 81, 158, 163  
 Weidel, H. 214, 215, 216  
 Weigand, C. G. 329, 330  
 Weijlard, J. 125, 131, 359, 472, 473  
 Weil, A. J. 282, 285, 380, 388  
 Weil Malherbe, H. 94, 104  
 Weinhausen, A. B. 214, 216  
 Weinstein, H. B. 324  
 — H. R. 69, 74, 87, 89  
 Weinstock, H. H. 349, 351, 352, 353, 357, 360, 362, 394, 396, 401, 402  
 Weintraub, S. 501, 503  
 Weir, D. R. 490, 494, 523, 526  
 Weissberg, S. M. 159, 163  
 Weischer, A. 65, 73  
 Weisel, C. A. 209, 210  
 Weissman, N. 49, 54, 72, 74  
 Weitz, L. W. 64, 73  
 Welch, A. D. 376, 377, 428, 431, 434, 436, 461, 462, 463, 466, 483, 484, 487, 488, 490, 494, 496, 498, 500, 501, 502, 503, 504, 505, 506, 510, 511, 519, 523, 524, 526, 540, 542, 543, 544, 551, 553, 603, 604  
 Weldon, V. 165, 167  
 Wellman, J. W. 146, 147, 148  
 Wellwood-Ferguson, W. J. 175, 177  
 Wendler, N. L. 146, 147  
 Wendt, G. 298, 299, 300, 301, 302, 307  
 Wenk, N. 196, 202  
 Werkman, C. H. 94, 96, 97, 99, 104, 105  
 Wertheim, J. M. 87, 89  
 Wertz, A. W. 44, 45, 165, 167  
 West, H. D. 369, 371, 376, 377, 384, 388  
 — P. M. 35, 37, 111, 113, 404, 405, 422, 439, 440  
 — R. 293, 295, 531, 532, 538, 541, 546, 547  
 Westenbrink, H. G. K. 34, 36, 40, 42, 49, 54, 72, 74, 90, 93, 103, 104  
 Westerfeld, W. W. 46, 47, 52, 54, 56

- Western Condensing Co, 149, 153  
 Westphal, G, 302, 307.  
 — K, 15, 19, 21, 22, 117, 130, 299,  
 300, 301, 302, 307.  
 Weswig, P H, 26, 27.  
 Wetzel, N C, 539, 542  
 Weygand, F., 136, 137, 138, 139, 140,  
 144, 147, 191, 200, 201, 206, 208, 209,  
 210, 357, 358  
 Wheeler, G A, 10, 132, 133, 211, 212,  
 213, 240, 247  
 — K A, 44, 46  
 — N C, 77, 80, 185, 186, 270, 272,  
 327, 328, 377, 435, 436, 505, 506,  
 554  
 White, A G C, 126, 127, 131, 293, 295,  
 397, 402  
 — C, 507, 508  
 — E G, 238, 240  
 — H S, 127, 131.  
 — J C, 496, 502  
 Whitehair, C K, 170, 172, 490, 494,  
 609, 611  
 Whiteside Carlson, V, 439, 440  
 Whitney, D M, 554, 558, 559  
 Wick, A N, 591, 592  
 Wickerham, L J, 151, 153  
 Wicks, L F, 574, 575, 592, 593  
 Wickson, M E, 169, 172  
 Widdowson, E M, 164, 167  
 Widenbauer, F, 71, 74  
 Wiebelhaus, V D, 576, 577  
 Wiegand, C, 256, 266  
 Wieland, H, 564, 565, 566  
 — T, 87, 89, 354, 358, 359, 361, 362,  
 381, 387, 388, 389, 395, 396, 397,  
 402  
 Wiener, S, 167, 168  
 Wiese, A C, 170, 172, 237, 239, 426,  
 431  
 Wigglesworth, U B, 115, 116  
 Wildemann, L, 70, 74, 76, 80  
 Wilder, R M, 59, 61, 83, 85, 179, 183,  
 187, 189, 243  
 Wildiers, E, 4, 105, 112, 404, 405, 564,  
 565  
 Wiley, P F, 354, 358  
 Wilkening, M C, 242, 248, 261, 262,  
 267  
 Wilkinson, C F, 264, 268  
 — J F, 35, 36, 68, 73, 496, 497, 499,  
 502, 537, 538  
 Willerton, E, 361, 362  
 Williams, H B, 421  
 — H H, 72, 74, 182, 183, 264, 268,  
 374, 376, 433, 434  
 — J N, 528, 529, 540, 542  
 — R D, 39, 42, 59, 60, 61, 65, 73, 83,  
 85, 179, 183, 187, 189, 243, 248  
 — R H, 70, 74  
 Williams, R J, 7, 8, 33, 36, 40, 42, 171, 173,  
 300, 301, 311, 312, 314, 315, 316,  
 317, 338, 340, 349, 350, 351, 352,  
 353, 357, 360, 361, 362, 373, 374,  
 375, 376, 379, 389, 390, 393, 394,  
 401, 402, 421, 422, 423, 424, 427,  
 430, 431, 432, 433, 434, 438, 440,  
 457, 459, 461, 464, 465, 466, 467,  
 470, 477, 479, 481, 482, 483, 484,  
 493, 513, 524, 569, 570, 576, 581,  
 621, 623  
 — R R, 7, 11, 12, 13, 14, 15, 16, 21,  
 33, 36, 82, 83, 85, 101, 105, 155,  
 156, 221, 230, 365, 370, 611, 613  
 — T I, 422, 423  
 — V R, 421, 422, 423  
 — W L, 225, 227, 228, 231, 232, 311,  
 314, 315, 316, 317, 361, 362, 569,  
 570, 622, 623  
 Williamson, A, 79, 81  
 — M B, 507, 508  
 — S, 275, 279  
 Wills, L, 460, 465  
 Willstaedt, H, 37, 42, 166, 168, 588,  
 589, 594, 595  
 Wilson, A N, 124, 127, 130, 343, 346,  
 414, 415, 416, 420  
 — H E, 461, 466  
 — J P, 420  
 — J W, 425, 430  
 — K, 479, 480, 483, 484, 511  
 — K S, 287  
 — M P, 543, 544  
 — P W, 35, 37, 111, 113, 404, 405,  
 422, 439, 440  
 — W M, 538, 541  
 Windaus, A, 13, 15  
 Winegar, A H, 253, 266, 270, 272  
 Winnick, T, 450, 451, 455  
 Winsten, W A, 313, 315, 532, 533, 535,  
 536  
 Wintrobe, M M, 52, 55, 56, 170, 172,  
 238, 240, 318, 320, 321, 322, 331, 337,  
 368, 371, 491, 495, 596  
 Winzler, R J, 433, 434, 442, 445  
 Wisansky, W A, 551, 553  
 Wishart, R S, 564, 565, 566  
 Wisnicky, W, 25, 27  
 Wittle, E L, 517, 524  
 Wittman, P, 60, 61  
 Witzberger, C M, 65, 69, 73  
 Wöhmman, M, 13, 15  
 Wohl, Z, 324  
 Wokes, F, 39, 42, 220, 222, 230

# AUTHOR INDEX

- Wolf, D., 52, 55  
 — D E, 410, 414, 415, 416, 420, 473,  
 476, 477, 478, 479, 531, 532, 533  
 — L M, 482, 483  
 — R J, 460, 465  
 Wolff, H G, 89  
 — J A, 523, 526  
 — R, 504, 505  
 Woll, E, 523, 526  
 Wollenberger, A, 41, 42  
 Womack, M, 600, 602.  
 Wood, H G, 96, 104  
 — J L, 448, 452, 455  
 — S, 333, 337  
 — T R, 530, 531, 532, 533, 539, 542  
 — W A, 335, 336, 338  
 Wooden, M B, 288, 294  
 Woodruff C W, 527, 528  
 — H B, 534, 535, 536  
 Woods, A, 430, 432  
 — D D, 128, 510, 511, 546, 547.  
 — E, 594, 595  
 — L F, 490, 495, 552, 553  
 Woodward, C F, 215, 217, 288, 291,  
 294  
 — C R, 313, 315, 339, 340, 438, 440  
 Wooley, J G, 51, 55, 157, 163, 171, 173,  
 177, 178, 182, 187, 189, 228, 232, 238,  
 240, 265, 268, 272, 273, 282, 285, 345,  
 347  
 Woolley, D W, 26, 27, 126, 127, 131,  
 212, 213, 214, 241, 248, 288, 293, 294,  
 295, 348, 349, 350, 351, 354, 358, 365,  
 370, 378, 379, 394, 397, 400, 401, 402,  
 403, 427, 431, 460, 465, 490, 494, 522,  
 525, 564, 565, 568  
 574, 577, 579, 580  
 619, 620, 622, 623  
 Wooster, R C, 339  
 440  
 Worden, A N, 158, 163, 168, 172, 297,  
 298, 318, 321, 327, 328, 365, 369  
 Work, A R, 349, 351  
 — C E, 156, 162, 348, 349, 351  
 401  
 Wortis, S B, 604, 605  
 Wright, C L, 196, 202  
 — E Q, 374, 376  
 — L D, 227, 231, 360, 362, 373, 374,  
 375, 376, 377, 422, 423, 425, 429,  
 430, 431, 434, 436, 439, 440, 461,  
 462, 463, 466, 483, 484, 487, 488,  
 Wright, L D (*contd*), 494, 496, 501, 505,  
 506, 509, 510, 511, 534, 536, 543,  
 544, 551, 553, 556, 559  
 — M D, 82, 83, 85  
 — M H, 282, 285, 442, 445, 543, 544  
 — W B, 522, 525  
 Würgler, W, 291, 292, 293  
 Wulff, H. J, 276, 280  
 Wurtz, A., 585  
 — E, 183, 186, 208, 210, 367, 370,  
 425, 428, 430, 431, 434, 435, 436  
 Wyeth Inc, 154, 156  
 Wynd, F L, 286, 287  
 Wyss, A, 86, 89  
 — C, 126, 131  
 — D, 561, 562.  
 — F, 86, 89  
 YACOWITZ, H, 535, 536, 537  
 Yakusiki, L., 194, 201.  
 Yamao, Y, 366, 370  
 Yamasaki, I, 148, 152  
 Yang, E F, 37, 42, 64, 73  
 Yeomans, A, 554, 558, 559  
 Yokata, K, 216, 217  
 Yosotome, W, 148, 152  
 Yost, D M, 66, 73  
 Youmans, J B, 77, 80, 185, 186, 269,  
 270, 271, 272, 327, 328, 377, 435, 436,  
 504, 505, 506, 554  
 Young, E G, 83, 85  
 — L, 568, 570, 571, 572  
 — N F, 264, 268  
 Yudkin, J, 65, 73  
 . . . . . 559  
 . . . . .  
 . . . . .  
 — . . . . . 50  
 Zilversmit, D B, 601, 603  
 Zima, O, 101, 102, 105  
 Zimmerli, A, 215, 217  
 . . . . . 18, 321.  
 . . . . .  
 . . . . .  
 Zmachinsky, A, 188, 189  
 Zschiesche, E, 395, 402  
 Zucker, I. M, 367, 371, 619, 620  
 — T F, 367, 371, 619, 620  
 Zuelzer, W W, 496, 502

# SUBJECT INDEX

- ACETIC acid, 627, 628  
 — —, guanidino-, 599  
 Acetoacetic acid, 392, 627  
*Acetobacter suboxydans*, 282, 361, 387, 393, 395, 398, 549, 555, 566  
 Acetone, 1 : 1-dichloro-, 475  
 —, halogenated derivatives of, 475  
 Acetophenone, *p*-amino-, 560, 561  
 Acetylation, pantothenic acid as co-enzyme for, 391, 628.  
 Acetylcholine, 87, 391, 585, 596, 602, 604  
 Acetyl phosphate, 627  
*Achromotrichia*, 365, 372, 424, 428, 462, 486, 487, 551, 552, 553  
 Acid clay as adsorbent, 11.  
*Acne vulgaris*, 324  
*cis*-Aconitic acid, 387, 443, 626, 627.  
 Acridine, 204, 545  
 Acrodynia See Rat pellagra  
 Acrylic acid,  $\beta$  amidino- $\alpha$ -cyano-, 20.  
*Actinomyces*, spp., 110  
 Adenine, 520, 562, 622  
 Adenosine-5'-phosphoric acid, 192.  
 Adenylic acid, 119, 192, 444  
 Adermin See Pyridoxine  
 Adipic acid, 410  
 Adrenal cortex hormone, 192  
 Adrenal glands, 366, 537  
 Adrenaline, 527, 601  
 Adrenocorticotrophic hormone, 366  
*Aedes aegypti*, 115, 205, 287, 341, 390, 441, 512  
*Aerobacter aerogenes*, 111, 204, 283, 340, 380, 439, 509, 511, 556  
 Aetiozymase, 128  
 Agranulocytic angina, 324  
 Agranulocytosis, 501  
 $\alpha$ -Alanine, 195, 339  
 —, carboxymethylmercapto-, 414  
 —, —, *N*-benzoyl-, 414, 415  
 —, deaminase, 444  
 —, *N*-methyl-, 195  
 —, pantoyl-, 396  
 $\beta$  Alanine, 349, 353, 354, 355, 357, 361, 373, 381, 386, 387, 393, 394, 404  
 —,  $\alpha$ -amino  $\gamma$  hydroxy- $\beta\beta$ -dimethylbutyryl-, ethyl ester, 395  
 —, benzyl ester, 355  
 —,  $\alpha\gamma$ -dihydroxybutyryl-, 394  
 —,  $\alpha\epsilon$ -dihydroxy caproyl-, 350, 394  
 —,  $\alpha\gamma$ -dihydroxy- $\beta\beta$ -dimethylvaleryl-, 399  
 —,  $\beta\delta$ -dihydroxy- $\gamma\gamma$ -dimethylvaleryl-, 395  
 $\beta$ -Alanine,  $\alpha\gamma$ -dihydroxy- $\alpha$ -methylbutyryl-, 353, 394.  
 —,  $\alpha\gamma$ -dihydroxy- $\beta$ -methylbutyryl-, 353, 394  
 —,  $\beta\gamma$ -dihydroxy- $\beta$ -methylbutyryl-, 395  
 —,  $\alpha\gamma$ -dihydroxyvaleryl-, 353, 394, 395  
 —,  $\alpha\delta$ -dihydroxyvaleryl-, 350, 394, 395  
 —,  $\beta$ -ethyl- $\alpha\gamma$ -dihydroxy- $\beta$ -methylbutyryl-, 395  
 —, ethyl ester, 350, 353, 354, 357  
 —,  $\alpha$ -hydroxy- $\beta\beta$ -bishydroxymethylbutyryl-, 395  
 —,  $\gamma$ -hydroxybutyryl-, 395, 399  
 —,  $\alpha$ -hydroxy- $\beta\beta$ -dimethylbutyryl-, 395  
 —,  $\gamma$ -hydroxy- $\beta\beta$ -dimethylbutyryl-, 395  
 —,  $\delta$ -hydroxy- $\gamma\gamma$ -dimethyl- $\Delta^{\alpha\beta}$ -pentenoyl-, 395  
 —,  $\gamma$ -hydroxy- $\alpha$ -keto- $\beta\beta$ -dimethylbutyryl-, 395  
 —,  $\gamma$ -hydroxyvaleryl-, 399  
 —,  $\alpha$ -methyl-, 394  
 —,  $\alpha$ -methyl *N*-pantoyl-, 396  
 Aldehyde oxidase, 194  
 Ale, vitamin content of, 44, 235, 317  
 Alfalfa leaf meal, vitamin content of, 537, 550, 571  
 Alimentary tract, effect of aneurine deficiency on, 53  
 Alizarine indigo blue, 215  
 Allergic effect of aneurine, 62  
 Allobiotin, 415, 416, 418  
*epi*-Allobiotin, 415, 416, 418  
 Alloxan, 142, 145  
 Alloxantin, 143, 145, 147  
 Alloxazine, 6 7-dimethyl-, 137  
 —, 1 3 6 7 tetramethyl-, 137  
 Allylamine, pantoyl-, 400  
 Almonds, vitamin content of, 43, 233, 363  
 Alopecia, 168, 365, 425, 461, 462, 568, 572  
 Altronic acid, 144  
 Amberlite as adsorbent, 11  
 Amination *in vivo*, 258, 259  
 Amines, acetylation of, 391.  
 —, effect on aneurine, 24  
 Amino acid metabolism, 97

- Amino acid oxidase, 193, 195, 196, 204, 540
- Amino acids, deamination of, 444
- —, decarboxylation of, 331, 628
- —, oxidation of, 628
- p*-Aminobenzoic acid
- acetylation of, 392
- analogues of, 560-562
- anti-sulphonamide action of, 184, 385, 388, 492, 510, 515, 516
- chromotrichial effect of, 372.
- conjugates of, 516
- effect of deficiency in animals, 551-553
- effect of deficiency in man, 553
- effect on aneurine, 24
- effect on higher plants, 559
- esters of, 560-562
- estimation of, 549-550
- function of, 562-563
- in nutrition of micro-organisms, 509, 555-559
- intestinal synthesis of, 554
- isolation of, 548
- metabolism of, 554
- occurrence in foodstuffs, 550-551
- pharmacology of, 555
- recognition as vitamin, 545-547, 551
- relation to folic acid, 485, 515, 516, 562, 563
- requirements of insects, 560
- p*-Aminobenzoic acid, N acyl, 560
- — N-glycosides, 560
- — polyglutamate, 548
- Aminopherase, 334, 335
- Aminopterin, 521, 522, 523, 527, 538, 539
- Amoebiasis, 557
- Amylamine, pantoyl-, 400
- Amylase, 581
- Anaemia, aplastic, 496, 497
- , association with aneurine deficiency, 57, 58
- , — — pyndoxine deficiency, 318, 320, 323, 330, 331, 336
- , — — riboflavine deficiency, 169, 170
- , hypoplastic, 497
- , megaloblastic, 500, 507, 530
- , nutritional macrocytic, 495-501, 526, 530, 538
- of pregnancy, 496-500, 530
- , pernicious, 495-501, 507, 526, 530, 538
- , treatment with choline, 593
- , — — folic acid, 458, 459, 460, 461, 462, 484-491, 495-501, 526-528
- , — — vitamin B<sub>12</sub>, 530, 538
- Anaerobic glycolysis, 625
- Analogues of *p*-aminobenzoic acid, 560-562
- aneurine, 116-131.
- biotin, 446-456
- choline, 603 605
- folic acid, 513-526.
- inositol, 579-581.
- nicotinic acid, 288-295
- pantothenic acid, 394-403
- pyndoxine, 342-347.
- riboflavine, 206 210
- Anaphylaxis due to aneurine, 62.
- Aneurine
- absorption spectrum of, 22
- acetylcholine and, 87
- analogues of, 116-131.
- animal and human requirements of, 81-85
- antagonists of, 126-129
- biological estimation of, 28-32.
- cancer and, 61
- carbohydrate metabolism and, 50, 90
- chemical constitution of, 12-15
- chemical estimation of, 37-42
- crystalline forms of, 22
- discovery of, 9-10, 404
- effect of deficiency in animals, 46 56
- effect of deficiency in man, 56-61
- effect of excessive dosage with, 62-63
- effect on higher plants, 113-115.
- fat metabolism and, 49
- fatty liver formation and, 573, 591.
- function of, 90-105
- human and animal requirements of, 81-85
- in nutrition of micro-organisms, 105-113
- intestinal synthesis of, 74-81.
- isolation of, 10-12
- metabolism of, 63-74
- microbiological assay of, 32-37
- occurrence in foodstuffs, 43-46
- pharmacological action of, 85 89
- properties of, 22-23
- reactions of, 22
- requirements of insects, 115-116
- solubility of, 22
- stability of, 23-27
- synthesis of, 15-22
- toxicity of, 84
- vitamin C and, 103
- Aneurine acetate, 125
- benzoate, 125
- chaulmoograte, 125
- cholestenone-6-sulphonate, 125
- dibutylsulphosuccinate, 125
- dioctylsulphosuccinate, 125
- 2-ethylhexyl sulphate, 125
- iodide, 125

## THE VITAMIN B COMPLEX

- Aneurine isopropyl-naphthalene sulphonate, 125  
— methylene - bis - (2 - hydroxy - 3 - naphthoate), 125  
— monophosphate, 94, 125  
— phenylurethane, 125  
— pyrophosphate, 93, 125, 627  
— sulphate, 125  
— triphosphate, 95  
Angina pectoris, 247  
—, Vincent's, 246  
Aniline, 4 - amino - 1, 2 -  
    (tetraacetyl - D - ribityl-), 146  
—, 3, 4-dimethyl-, 140, 142, 146  
—, 3, 4-dimethyl-6-methylamino-, 136, 137  
—, 3, 4-dimethyl-6-nitro-, 143  
—, 3, 4-dimethyl-N-(tetraacetyl-D-ribityl)-, 145  
—, 3, 4-dimethyl-N-(tetraacetyl-D-ribonyl)-, 146  
Aniline - D - arabinoside, 3, 4-dimethyl-, 144  
Animal protein factor, 535, 539, 540  
*p*-Anisidine, N-pantoyl-, 398  
Anserine, 601  
Antagonists of aneurine, 126-129  
— biotin, 452-454  
— folic acid, 516-523  
— nicotinic acid, 291-293  
— pantothenic acid, 381-387, 397-401  
— pyridoxine, 345, 346  
— riboflavine, 208-209  
Anthranilic acid, 242, 281  
— —, conversion into tryptophan, 336  
— —, hexahydro N pantoyl, 396  
— —, 3-hydroxy-, 229, 250, 251  
Antibacterial index, 381, 397  
Antibody response, effect of aneurine deficiency on, 52  
— —, — pantothenic acid deficiency on, 369  
— —, — pyridoxine deficiency on, 320  
Antimalarials and riboflavine, 209  
Anti-metabolites See Antagonists  
Anti-pernicious anaemia activity, test for, 530, 531  
Antihistaminic activity, 160, 161  
— —, 233, 363, 588  
D-Arabinol, 140  
D-Arabinose, 140, 143  
Araboflavine, 144, 206, 208  
Arabonic acid, 143  
Arecaidine, 291  
Arginine, 251, 628  
— decarboxylase, 331, 332  
— —, glycylyseryl-, 617  
— —, pantoyl-, 396  
— —, —, diethyl ester, 401  
— —, serylglycyl-, 617  
*Aspergillus flavus*, 152  
— *niger*, 386, 557  
— *oryzae*, 107.  
Asthma, 247  
Avidin, 427, 429, 430, 433, 439, 441, 450, 451  
Azobenzene, 2'-4'-diamino-4-sulphon-amido, dihydrochloride, 545  
—, *p*-dimethylamino-, 200  
*Bacillus acetolactylicus*, 439  
— *brassicae*, 360, 380  
— *Delbrückii*, 203  
— —, 35  
— —  
— —  
— *macerans*, 439  
— *mesentericus*, 79, 185, 203, 283, 435  
— *paraater*, 111  
— *paratyphosum* A, 282  
— *polymyxa*, 439  
— *proteus vulgaris*, 79, 185, 203, 435  
— *radicicola*, 422, 439  
— *subtilis*, 483  
— *vulgatus*, 79, 185, 203, 283, 435, 483  
Bacteria, vitamin requirements of, 110, 203, 281, 294, 339, 380, 439, 509, 555  
Bacterial synthesis of aneurine, 79, 111, 115  
— — biotin, 439  
— — folic acid, 509, 510  
— — nicotinic acid, 269, 283-285.  
— — pantothenic acid, 380  
— — pyridoxine, 340  
— — riboflavine, 204  
Bacteriophage, 345, 543  
*Bacterium acetylcholinum*, 340  
— *bifidum*, 203  
Bananas, vitamin content of, 43, 164, 233, 363  
Barbituric acid, 5-chloro, 146





- Blackcurrants, vitamin content of, 43  
 Blacktongue in dogs, 132  
*Blattella germanica*, 597  
 ' Blood caked whiskers ', 366  
 Blood, aneurine in, 68, 69  
 —, choline in, 594  
 —,  
 —,  
 —,  
 —,  
 —,  
 264  
 —, pantothenic acid in, 373  
 —, pyridoxine in, 326  
 —, riboflavine in, 177, 181  
 —, thiaminase in, 26  
*Botrytis allii*, 557  
 Bracken, inactivation of aneurine by, 26  
 Bradycardia in rats, 30, 48  
 Brain tissue, respiration of, 92  
*Brassica alba*, 114  
 Brazil nuts, vitamin content of, 43  
 Bread, vitamin content of, 43, 164, 232, 316, 571, 588  
 British Pharmacopoeia, 23, 30, 38, 155, 217, 218  
*Brillanomyces bruxellensis*, 338  
 Broccoli, vitamin content of, 233, 363  
*Brucella abortus*, 282  
 — *melitensis*, 282  
 — spp., 380  
 Brussels sprouts, vitamin content of, 44, 588  
 Burbot, vitamin content of, 234  
 Butane - sulphonic acid,  $\beta$  - carboxy -  $\gamma$  methyl-, 412, 413  
 2-Butanol, 3-pantoylamino-, 396  
 —, 4-pantoylamino-, 400  
 Butter, vitamin content of, 165, 589  
 Butylamine, 3' 4'-dihydroxy-N-pantoyl-, 356  
 —, N pantoyl-, 400  
 Butyramide,  $\alpha\gamma$  - dihydroxy -  $\beta\beta$  - di - methyl - N 2 - (benzylethyl) -, 401  
 —, — N - (2 - phenylmercaptoethyl) -, 401  
 —, — N - (2 - phenylsulphenylethyl) -, 401  
 Butyric acid, metabolism of, 627  
 Butyric acid,  $\beta$  amino-, 394  
 —,  $\alpha$  - amino -  $\beta\beta$  - dimethyl  $\gamma$  - hydroxy See Pantonic acid  
 —,  $\alpha\gamma$  - dihydroxy -  $\beta\beta$  - dimethyl See Pantonic acid  
 —,  $\beta\gamma$  - dihydroxy  $\beta$  methyl-, 387  
 —,  $\alpha\beta$  - dimethyl-, 412  
 —,  $\gamma$  formyl-, methyl ester 415  
 —,  $\alpha$  hydroxy- $\beta\beta$  - dimethyl-, 387  
 Butyric acid,  $\gamma$  - hydroxy  $\beta\beta$  - dimethyl-, 387  
 —,  $\gamma$  - pantoyl-, 396  
 —,  $\beta$  pantoylamino-, 396  
 —,  $\gamma$  - (2 3 - ureylene - cyclohexyl) -, 453  
 —,  $\gamma$  - (3 4 - ureylene - cyclohexyl) -, 443, 453  
 $\gamma$ -Butyrolactone,  $\alpha$  aceto-, 16  
 —,  $\alpha$  - hydroxy -  $\beta\beta$  - dimethyl See Pantolactone  
 —,  $\alpha$  hydroxy  $\alpha$  methyl-, 353  
 —,  $\alpha$  - hydroxy  $\beta$  methyl-, 353  
*Byssochlamys fulva*, 557  
 CABBAGE, vitamin content of, 164, 233, 316, 550, 588  
 Cadaverine, 196  
 Calves, aneurine deficiency in, 53  
 —, riboflavine deficiency in, 170  
 Cancer, aneurine and, 61  
 —, biotin and, 429  
 —, choline and, 592  
 —, folic acid and, 492, 501, 522, 523  
 —, inositol and, 574  
 —, pantothenic acid and, 374  
 —, pyridoxine and, 321, 345  
 —, riboflavine and, 171  
 —, vitamin B<sub>12</sub> and, 541  
*Candida albicans*, 577  
 — *deformans*, 106  
 — *flavescens*, 150  
 — *guilliermondii*, 149, 150, 422  
 — *pseudotropicalis*, 281, 386  
 — *suaveolens*, 106  
 — *tropicalis* var *Rhagis*, 149, 150  
 Canine blacktongue, 132, 212, 237, 288  
 Carbohydrate metabolism, 50, 191, 625-629  
 Carboxylation, 442  
 Carp tissues, thiaminase in, 25  
 Carp, vitamin content of, 234  
 Carrots, vitamin content of, 43, 164, 233, 363, 550, 588  
 Cartilage factors, 619  
 Casein, 537, 616 617, 619 620  
 Cashew nuts, vitamin content of, 164  
 Catalase, 629  
 Cataract, 167 170  
 Cataturin test, 28, 92  
 Cats, *p*-aminobenzoic acid deficiency in, 551  
 —, aneurine deficiency in, 53  
 Cauliflower, vitamin content of, 43, 164, 233  
 Celery, vitamin content of, 588  
 Cellobiose octaacetate, 144  
 Celtribiose, 144  
*Ceratostomella fagi*, 339  
 — *multianudata*, 339

# SUBJECT INDEX

- Ceratostomella piliferum*, 339  
 — *pluriannulatum*, 339  
 — spp. 109, 110  
 — *ulms*, 109, 338, 343  
 Cereals, estimation of aneurine in, 40.  
 —, — nicotinic acid in, 222  
 Cerebral beriberi, 58
- 364, 423, 537, 589  
 Cheilosis, 174, 324
- 234, 363  
 Chicks, feather formation in, 613 614  
 — new growth factors required by, 609  
 — vitamin deficiency in, 47, 170, 239, 320, 368, 425, 484, 485, 486, 573, 590  
 — vitamin requirements of, 189, 329, 378, 437, 506, 594  
 Chicory, vitamin content of, 164  
*Chilomonas paramecium*, 112  
*Chlamydomonas orbicularis*, 112  
 Chloroflavine, 198, 199  
 Chloroguanide, 510  
*Chlorogonium tetragamum*, 112  
 Cholesterol fatty livers, 573 582 591  
 Choline  
   acetylation of, 391  
   analogues of, 603-605  
   animal and human requirements of, 594-595  
   cancer and, 592  
   chemical constitution of, 585  
   effect of deficiency in animals, 589-593  
   — — man, 593  
   estimation of, 586-587  
   fatty liver formation and, 582  
   function of, 598-603  
   human and animal requirements of, 594-595  
   in nutrition of micro-organisms, 596-597  
   isolation of, 585  
   metabolism of, 593-594  
   methylation of nicotinic acid by, 254, 255  
   occurrence in foodstuffs, 587-589  
   pharmacological action of, 595  
   phosphoryl, 603  
   properties of, 586  
   recognition as vitamin, 582 584
- Choline—(continued)  
   requirements of insects, 597  
   synthesis of, 585  
 Choline esterase and folic acid, 526  
 Choline oxidase and folic acid, 527  
 Chondroitin, 619  
 — sulphuric acid, 619
- 112  
 2  
 methyl-, dimethyl ester of, 304  
 Citric acid, 96, 387, 626
- 148, 149.  
 3, 562  
 — *botulinum*, 111, 380, 439, 596  
 — *butylicum*, 111, 148, 204, 283, 380, 392, 439, 511, 556  
 — *felsineum*, 556  
 — *kluyveri*, 439 556  
 — *saccharobutyricum*, 581  
 — *septicum*, 387  
 — *sporogenes*, 622  
 — spp., 449, 450  
 — *tetani*, 111, 204, 282, 340, 380, 439, 509, 622  
 — *welchii*, 380  
 Cocarboxylase, assay of, 38, 40  
 —, biological activity of, 94, 95 125  
 —, chemical constitution of, 93  
 —, excretion of, 65  
 —, preparation of, 94  
 —, stability of, 26  
 Cockroach, 205  
 Coconuts, vitamin content of, 43, 164, 233  
 Cod, vitamin content of, 165, 233, 589  
 Codehydrogenase I, 229, 275, 276, 278, 625, 627, 628  
 — II, 229, 275, 276, 278  
 Coenzyme I, 229, 263, 276  
 — II, 229 277  
 — A, 391  
 — R, 405  
 Coenzymes, members of vitamin B complex as, 629  
 — I and II, estimation of, 228, 229, 262, 274, 289  
 Coffee, vitamin content of, 235  
 Colostrum, vitamin content of, 71, 165, 233, 363  
 Cooking effect on vitamins in foodstuffs, 44, 165, 235, 363, 423  
 Coprophagy, 156  
 Coproporphyrinuria, 244  
 Coramine, 218  
*Corcyra cephalonica*, 115, 205, 342, 441

- Corn. See Maize  
*Coryne sarcoides*, 109  
*Corynebacterium diphtheriae*, 349, 361, 380, 381, 382, 383, 385, 387, 394, 397, 399, 446, 621  
 — spp., 468, 510  
 — 73  
 — 237.  
 426  
 Cozymase See Codehydrogenase I  
 Crab, vitamin content of, 165, 233  
 Cranberries, vitamin content of, 233  
 Creatine, 599, 600, 601  
 Creatinine, 599  
 Crotyl alcohol, 197  
 — —, phenyl-, 197  
 Cucumbers, vitamin content of, 164, 233  
 Currants, vitamin content of, 43  
 Cyanogenetic glycosides, 246  
 Cyclohexane, 1 2 3 4 5 6-hexachloro-, 578  
 — 1 2 3 triol, 579  
*Cypridina*, 197  
 Cysteic acid, 387  
 Cystine, 254, 255  
 Cytochrome, 629  
 — a, 194, 277  
 — b, 194, 277  
 — c, 193, 198, 277  
 — c reductase, 193, 194, 196  
 — oxidase, 196, 277  
 Cytoflav, 191  
 Cytosine, 5 methyl-, 513  
*Cytospora*, spp 109
- DATES, vitamin content of, 43, 164  
 Deamination, 444  
 Decalco, use in aneurine assays, 39  
 Decarboxylation, 442  
 Dehydration, effect on vitamins in foodstuffs, 44, 165  
 Desoxypyridoxine, 336, 343, 345  
 Desoxyribonucleic acid, 528  
 Desthiobiotin, 416  
 Desthiobiotin, 410, 416, 419, 438, 439, 443, 447, 448, 449, 452  
 $\psi$  Desthiobiotin, 449  
 Dialuric acid, 145, 147  
 Diamino acids, oxidation of, 628  
 Diamino oxidase, 196  
 Diaphorase, 192, 194, 204, 625, 627  
 Diethanolamine, 601  
 Dihydro-coenzyme I, 194 277  
 — II, 194, 277  
 Dihydro flavoprotein, 193 277  
 Dihydro triphosphopyridine nucleotide, 193
- Dihydroxyphenylalanine decarboxylase, 332  
 Dimethyl sulphone, 601  
 Dinicotinyl hydrazine, 293,  
 Diphenylamine, 4 amino-4'-carboxy-, 560  
 Diphosphoglyceric acid, 625  
 Diphosphopyridine nucleotide, 229, 275  
*Diplococcus pneumoniae*, 380, 381, 382, 397, 515, 556, 561  
 3 3'-Dipyridyl, 215  
 Dismutation of pyruvic acid, 95  
 Dogs, new growth factors required by, 608  
 —, vitamin deficiency in, 52, 170, 237, 319, 367, 426, 490, 573, 590  
 —, vitamin requirements of, 82, 188, 378, 594  
*Drosophila melanogaster*, 115, 205, 287, 341, 389  
 Drug-fastness, 127, 204, 383  
 Ducklings, vitamin deficiency in, 170, 239, 320  
 —, vitamin requirements of, 189, 329, 378
- Egg white factor, 425, 427  
 Eggs, vitamin content of, 44, 45, 165, 233, 265, 363, 423, 537, 551, 589  
*Eimeria nieschulzi*, 386  
 Eluate factor, 133, 297, 348  
 Encephalomyelitis virus, effect of aneurine deficiency on, 51  
*Endomyces magnusii*, 107, 110, 438  
 — *ternalis*, 107, 127  
*Enterococci*, 513, 515  
 Enzyme reactions, 628  
 Enzymes, riboflavine content of, 190  
 —, use in aneurine assays, 40  
*Ephesia elutella*, 115, 205, 287, 341, 389  
 — *kuehniella*, 512  
*Eremothecium Ashbyii*, 110, 150, 166, 438, 577, 578, 579  
 Ergothioneine, 601  
*Erysipelothrix rhusiopathiae*, 204  
 Erythrocytes, aneurine in, 69  
 Erythrotin See Vitamin B<sub>11</sub>  
*Escherichia coli*, 79, 126, 185, 203, 251, 282, 283, 293, 381, 387, 388, 399, 439, 442, 444, 449, 453, 487, 510, 515, 517, 518, 521, 543, 546, 556, 560, 561, 563  
 Essential metabolites, 546  
 Ethane - sulphonic acid,  $\beta$  - ( $\alpha$ -di-hydroxy- $\beta\beta$ -dimethylbutyramido)  $\alpha$  phenyl-, 398  
 — —,  $\beta$ -( $\alpha$ -dihydroxy- $\beta\beta$ -diphenylbutyramido)-, 398  
 — —,  $\beta$ -( $\beta\beta$ -dimethyl- $\gamma$ -hydroxy- $\alpha$ -tosylbutyramido), 398  
 Ethanol, amino-, 596, 597, 599, 601

- Ethanol,  $\beta$ -chloro-, 585  
 —, dimethylamino-, 597, 601, 604  
 —, methylamino-, 597, 601, 604  
 —, 2 pantoylamino-, 396, 400  
 Ethylamine,  $\beta$  methoxy-N-pantoyl,  
 400  
 —, N pantoyl-, 400  
 E  
 —  
 — dross-, 603  
 — — —, ethyl-dimethyl- $\beta$ -hydroxy-,  
 603  
 — — —, triethyl  $\beta$  hydroxy-, 602, 603,  
 604  
 — — —, hydroxide,  $\beta$  hydroxy trimethyl-,  
 585  
 Ethyl arsonium chloride,  $\beta$  hydroxy-  
 trimethyl, 603  
 Ethyl sulphonium chloride, dimethyl-  
 $\beta$  hydroxy-, 603  
 Ethylthiol,  $\beta$  pantoylamino-, 398  
*Euglena gracilis* var *bacillaris*, 535 543  
 Extrinsic factor, 498, 499, 531  
 Eye lesions and riboflavine, 168, 169,  
 170, 173, 174, 200  
 Eye, riboflavine in, 198, 199, 200  
 F, 254  
 F<sub>1</sub>, 39, 221, 254  
 Factor B<sub>w</sub>, 350, 616  
 — B<sub>x</sub>, 616  
 — HL<sub>1</sub>, 621, 622  
 — HL<sub>3</sub>, 621, 622  
 — HL<sub>4</sub>, 621, 622  
 — R, 460, 486, 616  
 — S, 460, 616  
 — T, 622  
 — U, 460, 615  
 — V, 229, 262, 263, 289  
 — W, 349, 350, 615, 616  
 — X, 539, 619  
 — Z, 622  
 —  $\alpha$ , 349  
 —  $\beta$ , 349  
 —  $\gamma$ , 349  
 — 1, 296, 348  
 — 2, 296, 348  
 — IIA, 622  
 — IIB', 622  
 — IIB'', 622  
 — 125, 608  
 Faecal excretion of *p*-aminobenzoic  
 acid, 77, 78, 554  
 — — — aneurine, 70, 75, 76, 77, 78, 79  
 — — — biotin, 77, 78, 433, 435  
 — — — choline, 593  
 — — — folic acid, 77, 78, 503, 504, 505  
 — — — nicotinic acid, 77, 78, 268, 269  
 Faecal excretion of pantothenic acid, 77,  
 78, 375, 377  
 — — — pyridoxine, 77, 78, 328  
 — — — riboflavine, 77, 78, 180, 183, 184,  
 185  
 Fat metabolism, 49, 627, 629  
 Fatty acids, metabolism of, 627  
 Fatty livers, 428, 438, 572, 582, 583, 589,  
 590, 598  
 Feather formation in chicks, 458, 459,  
 484, 485, 506, 540, 613, 614  
 Fermentation *L. casei* factor, 458, 464,  
 468, 471, 472, 476, 478, 481, 491, 510  
 Fermentation liquors, recovery of ribo-  
 flavine from, 152  
 Fern poisoning in cattle, 26  
 Figs, vitamin content of, 164, 233  
 Filtrate factor, 133, 297, 348, 360  
 Fish, vitamin content of, 44, 165, 233,  
 234, 316, 587, 589  
 —, vitamin deficiency in, 170, 239,  
 320, 369, 426, 492, 552, 574, 591  
 Fish anaemia, 461  
 — meal, vitamin content of, 537  
 — solubles, vitamin content of, 537  
 Flagellates, aneurine requirement of,  
 112  
 Flavine adenine dinucleotide See Ribo-  
 flavine adenine dinucleotide  
 — mononucleotide See Riboflavine  
 mononucleotide  
*Flavobacterium buccalis*, 510  
 Flavoprotein, 193, 198, 204, 277  
 Flies, inositol and, 578  
 Flounder, vitamin content of, 165  
 Flour, vitamin content of, 43, 164, 232,  
 316, 363, 571, 587, 588  
 Fluoresceyanine, 126, 208  
 Foetus, aneurine in, 71  
 Folic acid  
 analogues of, 513-526  
 animal and human requirements of,  
 506-507  
 antagonists of, 516-523  
 chemical constitution of, 463, 471-  
 473  
 discovery of, 457  
 effect of deficiency in animals, 484-  
 495  
 — — — man, 495-503  
 estimation of, 481-483  
 function of, 526-529  
 human and animal requirements of,  
 506-507  
 in higher plants, 512  
 in nutrition of insects, 512-513  
 — — — micro-organisms, 509-511  
 intestinal synthesis of, 505-506  
 isolation of, 466-471  
 metabolism of, 503 505



- [illegible]

# THE VITAMIN B COMPLEX

- IDOSACCHARIC acid, 566  
 Imidazole, 5 -  $\beta$  - hydroxyethyl - 4 -  
   methyl-, 119  
 2-Imidazolidone, 5-methyl-, 452  
   -, 4 - methyl - 5 - ( $\epsilon$  - sulphoamyl) -, 454  
 2 - Imidazolidone - 4 - " - hexoic acid, 450, 452, 453  
   -, 5-ethyl, 450, 452  
   -, 5-methyl See Desthiobiotin  
 2 - Imidazolidone - 4 - propionic acid,  $\alpha$ -isopropyl-5-methyl-, 450, 452  
 Indole, 242, 281, 335, 336  
 Indole-3 acetic acid, 241, 242, 244, 255, 286  
 Infantile beriberi, 91  
 Infected animals, effect of aneurine deficiency on, 51  
   -, -, biotin deficiency on, 429  
   -, -, folic acid deficiency on, 492  
   -, -, inositol deficiency on, 574  
   -, -, pantothenic acid deficiency on, 369  
   -, -, pyridoxine deficiency on, 320  
   -, -, riboflavine deficiency on, 171  
 Influenza virus, 52  
 Inosamine, 579  
 Inositol  
   analogues of, 579 581  
   animal and human requirements of, 575-576  
   chemical constitution of, 565-567  
   effect of deficiency in animals, 572-575  
   - - man, 575  
   estimation of, 568 570  
   function of, 581  
   in higher plants, 578  
   in nutrition of micro-organisms, 577 578  
   intestinal synthesis of, 577  
   isolation of, 565  
   metabolism of, 576 577  
   occurrence of, 570 572  
   properties of, 568  
   recognition as a vitamin, 404, 564  
   requirements of insects, 578 579  
   synthesis of 566  
 Inositol, monoorcetyl pentamethyl-, 578  
 Inositol, 579, 581  
 Inositol hexaphosphoric ester, 570  
   -, hexacetate, 568 579  
   -, monophosphoric ester, 570, 580  
   -, tetraphosphoric ester, 580  
   -, triphosphoric ester, 570  
 Inosose, 566, 579  
 Insects, *p* aminobenzoic acid requirements of, 560  
   Insects, aneurine requirements of, 115-116  
   -, biotin requirements of, 441-442  
   -, choline requirements of, 597  
   -, folic acid requirements of, 512-513  
   -, inositol requirements of, 578  
   -, nicotinic acid requirements of, 287, 294  
   -, pantothenic acid requirements of, 389  
   -, pyridoxine requirements of, 342.  
   -, riboflavine requirements of, 206  
 Insulin, 392, 602, 616, 617.  
 Intestinal synthesis, 6, 77, 78, 552  
   - of *p*-aminobenzoic acid, 77, 554  
   - aneurine, 74-81, 84  
   - biotin, 77, 78, 434-436  
   - folic acid, 77, 78, 463, 487, 488  
   - 505-506, 510  
   - inositol, 577  
   - nicotinic acid, 268-272  
   - pantothenic acid, 376-377.  
   - pyridoxine, 327-328  
   - riboflavine, 183-186  
 Intracellular symbiotic micro-organisms in insects, 115, 205, 287, 342, 390  
 Intrinsic factor, 498, 499, 543  
 Iron porphyrin, 629  
 Isoalloxazine, 5 6 - benzo - 9 - (L-1'-arabityl), 207.  
   -, -, 9-(D-1'-ribityl)-, 207  
   -, 6 7 - dichloro - 9 - (D-1'-ribityl), 208  
   -, 3 9-dimethyl-, 137  
   -, 6 7 - dimethyl - 9 - ( $\gamma$  - amino - hydroxypropyl)-, 209  
   -, -, 9-(L-arabinosido)-, 207.  
   -, 5 7 - dimethyl - 9 - (L-1'-arabityl), 207  
   -, 6 7 - dimethyl - 9 - (L-1'-arabityl), 138, 206, 207  
   -, 6 8 - dimethyl - 9 - (L-1'-arabityl)-, 207  
   -, 6 7 - dimethyl - 9 - (D-1'-desoxy-ribityl)-, 207  
   -, -, 9-(D-1'-dulcetyl)-, 208  
   -, 6 7-dimethyl-9 (D-1'-lyxitlyl), 207  
   -, 4 5-dimethyl 9 phenyl-, 209  
   -, 6 7 - dimethyl - 9 - (L-1'-rhamnityl)-, 207  
   -, 5 6 - dimethyl - 9 - (D-1'-ribityl)-, 207, 208  
   -, 5 7 - dimethyl - 9 - (D-1'-ribityl)-, 207  
   -, 6 7 - dimethyl - 9 - (D-1'-ribityl) See Riboflavine  
   -, -, 9 (L-1'-ribityl)-, 207

- [illegible]



## THE VITAMIN B COMPLEX

[illegible]

# SUBJECT INDEX

- 589  
 Millet, vitamin content  
 Mink, effect of vitamin deficiency on, 490  
 Miotin, 433  
 Mitosis, 578  
*Mitrula paludosa*, 439  
 — *pusilla*, 109  
 Molasses, vitamin content of, 587  
 Monkey anaemia, 460, 491.  
 Monkeys, effect of vitamin deficiency on, 53, 170, 238, 320, 368, 426, 491  
 —, vitamin requirements of, 189, 437, 507.  
 Mosquito, 115, 205, 287, 341, 389, 390, 441, 512  
 Moulds, synthesis of riboflavin by, 148  
 —, vitamin requirements of, 108, 203, 281, 338, 385, 557, 577  
*Mucor Ramannianus*, 108, 109  
 Mullet, vitamin content of, 233  
 Multiple vitamin B complex deficiency, 60, 244, 245, 606, 607  
*Munia maja*, 11  
 Muscle, changes during contraction of, 625  
 —, vitamin content of, 44, 166, 181, 234, 316, 363, 567, 571, 588  
 Muscular dystrophy, 323, 575  
 Mushrooms, vitamin content of, 43, 483, 551  
 Mussels, thiaminase in, 26  
 Mutton, vitamin content of, 44, 166, 234, 316, 363, 537, 588  
 Myasthenia gravis, 323  
*Mycobacterium smegmatis*, 151  
 — *tuberculosis*, 203, 557  
*Mycoderma lipolytica*, 106  
 — *valida*, 106, 281, 338, 386, 577  
 — *vari*, 106, 281, 577  
 Mycorrhizal fungus, 109  
 Mytilitol, 579  
 1-NAPHTHOIC acid, 4-amino-, 561  
 Nausea, relief of, by pyridoxine, 324  
*Neisseria sicca*, 439  
*Nematospira gossypii*, 577, 578  
 Neopyrithiamine, 124, 127, 128  
 Nervous symptoms, association of pyridoxine deficiency with, 318, 323  
 5 *Neurospora crassa*, 281, 422, 449, 550, 557, 569, 587, 597, 604  
 2 — *sitophila*, 312, 313, 315, 339, 344, 438  
 — spp 386  
 24  
 acid,  
 227, 228  
 —, isolation of, 212, 214  
 —, pharmacological action of, 273-274  
 —, preparation of, 216  
 —, properties of, 218  
 —, N (*p*-carboxyphenyl)-, 290  
 —, NN-diethyl See Nikethamide  
 —, 2, 6-dimethyl-, 291  
 —, 5-fluoro-, 293  
 —, N (6-methoxy-8-quinolyl)-, 290  
 —, N<sup>1</sup> methyl 196, 221, 223, 226, 228, 253, 254, 256, 257, 258, 259, 260, 261, 262, 268, 269, 288, 291, 292, 293, 601  
 —, 6 methyl-, 291  
 —, N-phenylcarbonyl-, 290  
 —, thio-, 292  
 Nicotinbenzylamide 294  
 Nicotine 213, 214, 216, 290, 291  
 Nicotinic acid  
 analogues of, 288-295  
 animal and human requirements of, 272, 273  
 biosynthesis of, 249, 252  
 effect of deficiency in animals, 237-240  
 — — man 240-249  
 effect on aneurine, 24  
 esters of, 217, 288, 289, 290, 291, 294  
 estimation of, 218-232  
 function of, 274-280  
 human and animal requirements of, 272-273  
 in higher plants, 286, 287  
 in nutrition of micro-organisms, 281-286  
 intestinal synthesis of, 268, 272  
 isolation of, 212, 214  
 metabolism of, 252, 268  
 occurrence in foodstuffs, 232-236  
 pharmacological action of, 273, 274  
 preparation of, 214-216  
 properties of, 217  
 recognition as vitamin, 4, 211-213, 404  
 requirements of insects, 287



- Pantothenic acid—(continued)  
 discovery of 4 348 351 401  
 effect of deficiency in animals 365  
 371  
 — — man 372  
 esters of 355  
 estimation of 360 362  
 function of 390 393  
 human and animal requirements of  
 377 379  
 in higher plants 389  
 in nutrition of micro-organisms 380  
 389  
 intestinal synthesis of 376-377  
 isolation of 351 352  
 metabolism of 375 376  
 occurrence in foodstuffs 363 365  
 pharmacological action of 379  
 properties of 350  
 requirements of insects 389  
 resolution of 355 356  
 stability of 359  
 synthesis of 352 359  
 toxicity of 379  
 Pantothenic acid  $\alpha$  methyl 396 399  
 — —  $\beta$  methyl 396 399  
 — — acetate 394  
 — — — ethylester 394  
 — — benzoate 394  
 — — diphosphate 394  
 — — ethyl ester 394  
 — —  $p$  nitrobenzoate 394  
 — aldehyde 397  
 — — acetate 355  
 Pantothenonitrile 400  
 398 399 400  
 Paralysis agitans 324  
 Parkinsonism 323  
 Pareley vitamin content of 588  
 Parsnip vitamin content of 588  
 Pasteurella spp 282 380  
 Peaches vitamin content of 43 164  
 233 363  
 Peanuts vitamin content of 43 164  
 233  
 Pears vitamin content of 43 164 233  
 Peas vitamin content of 43 164 205  
 233 363 588  
 P can nuts vitamin content of 43 164  
 Pelargonic acid  $\gamma$ -diamino 447 448  
 Pellagra 7 132 133 211 240 242 289  
 Penatin 197  
 Penicillium chrysogenum 152 339 385  
 439 449  
 — digitatum 339 385 439 557  
 — notatum 197 449  
 Penicillium roquefortii 557  
 — wolkmanni 386  
 Perch vitamin content of 234  
 Periplaneta americana 205  
 Perosis 425 486 583 590, 600 602  
 Peroxidase 629  
 Phalanger aneurine deficiency in 52  
 Phenazine 2 4-d amino 5 10 di  
 hydro 7 8 dimethyl 10 ribityl  
 208  
 — 2 4-dinitro 5 10 dihydro 7 8  
 dimethyl 10-ribityl 208  
 Phenylacetic acid  $p$  amino 547 560  
 Phenylalanine N pantoyl 398  
 Phenylalanine decarboxylase 441  
 Phenyl D isocarabinoxamine 3 4-  
 dimethyl 144 145  
 Phenylisocyanate 4 5 dimethyl 2  
 nitro- 140  
 Phenyllicetic acid  $p$  amino 485  
 Phenylmethane sulphonc acid  
 $p$  amino 547  
 Phenylpantothenone 400 401  
 Phenyl D ribamine 2 amino 4 5  
 dimethyl 140 142 146  
 — 2 carbethoxyamino 4 5-dimethyl  
 140  
 — 3 4-dimethyl 142 144  
 Phenyl sulphone  $\beta$  (N pantoylamino  
 ethyl)  $p$  amino 398  
 — — —  $p$  methoxy 398  
 Phialophora terrucosa 109  
 Phosphatides 585 601  
 $\alpha$  Phosphoglyceric acid 625  
 Phosphohexonic acids 193  
 Phosphopyruvic acid 675  
 Phosphorylation of aneurine 70  
 Photosynthesis 108  
 97  
 Phycomyces Blakesleeanus 35 108 110  
 119 123 124 125 439 627  
 — nitens 109  
 Phytic acid 570  
 Phytin 565 570 572 579  
 Phytophthora cinnamomi 108 113 124  
 — erythroseptica 108  
 — infestans 109  
 Pichia belgica 106 577  
 — Drombrouskii 106  
 — kluyveri 338  
 Picoline 214 215 216 288 289 290  
 293 294  
 Picolinic acid 214 88 290 29  
 — — amide 297  
 — — ester 291  
 Pigeons assay of aneurine by means of  
 10 11 28 119  
 — effect of vitamin deficiency in 46  
 609  
 — vitamin requirements of 8

# THE VITAMIN B COMPLEX

- Pigs, effect of vitamin deficiency in, 52, 169, 238, 320, 368, 426, 490, 491, 573, 591, 609
- , vitamin requirements of, 188, 417
- Pimelic acid, 410, 418, 446, 449
- Pineapple, vitamin content of, 43, 164
- Pine kernels, vitamin content of, 43
- Pinitol, 579
- Pityrosporum ovale*, 110
- Placenta, riboflavine in, 181
- Plant hormone, aneurine as, 113, 114
- , 441
- , biotin as, 441
- Plants, effect of vitamins on, 113-115
- , 205, 341, 389, 441, 512, 550, 570, 571, 578
- , vitamin content of, 43, 165, 205, 316, 341, 363, 512, 550, 570, 571, 578
- , on, 171, 239, 346, 429
- Plums, vitamin content of, 43, 164, 233, 588
- Pneumococci*, 204, 453, 547, 596
- Pneumococcus* infection, effect of vitamins on, 51, 171, 369
- Polarographic estimation of vitamins, 41, 162, 225, 311
- Poliomyelitis virus, effect of vitamins on infection with, 51, 321, 369, 429, 492, 5
- Pollen, 317
- Polymer
- man, 57
- rats, 29, 48
- Polyporus abietinus*, 109
- *adustus*, 109
- *Spraguei*, 109
- Polytoma caudatum*, 112
- *ocellatum*, 112
- Polytomella caeca*, 112, 118, 119, 126
- Ponies, pantothenic acid requirements of, 378
- Pork, vitamin content of, 44, 166, 234, 316, 363, 537, 588
- Porphyrin, secretion of, 366
- Porphyrin containing enzymes, 528
- Potatoes, vitamin content of, 35, 44, 164, 233, 363, 588
- PP factor, 132, 211
- Prawns, vitamin content of, 233
- Pregnancy, polyneuritis of, 57
- , riboflavine excretion in, 181
- Procaine, 560
- Processing of foodstuffs, effect on vitamin content, 44, 165, 235
- Proguanil, 209
- Prontosil rubrum, 545
- Propionibacterium pentosaceum*, 360, 380, 381, 382, 397
- Propionic acid, metabolism of, 627
- ,  $\beta$ -4-aminophenyl- $\beta$ -pantoyl-amino-, 401
- , 356
- , N-pantoyl-, 400
- Protective factor X, 401
- , manganin, 204, 300, 301, 300, 303, 391, 392, 395
- *vulgaris*, 111, 204, 227, 228, 229, 264, 282, 283, 284, 290, 291, 292, 294, 340, 380, 399, 439, 511
- "Protogen", 622
- Protozoa, vitamin requirements of, 285, 340
- Prunes, vitamin content of, 43, 363
- "Pseudo- $\beta$ -biotin", 417
- Pseudomonas aeruginosa*, 380, 556
- *fluorescens*, 111, 204, 283, 340, 380, 439, 511
- *riboflavina*, 209
- Pteridine, 2-amino-6-hydroxy-, 479
- , 2-amino-4-hydroxy-, 471, 479
- , —6-7-dimethyl-, 518
- , —6-7-diphenyl-, 518
- , —6 (or 7) hydroxy-7 (or 6)-methyl-, 514, 518
- , —6-hydroxymethyl-, 475
- , —7-hydroxymethyl-, 475
- , —6-methyl-, 472, 475
- , —7-methyl-, 522, 614
- , —6-tetrahydroxybutyl-, 475
- , 2-amino-6-hydroxy-8-9-dimethyl-, 126
- , 2-4-diamino-, 517
- , —6-7-dimethyl-, 517
- , —6-7-diphenyl-, 517
- , 2-6-dihydroxy-8-9-dimethyl-, 126
- , 2-4-dihydroxy-6 (or 7) hydroxy-7 (or 6) methyl-, 514
- Pteridine 6-acetic acid, 2-amino-4-hydroxy-, 472
- Pteridine 6-carboxylic acid, 2-amino-4-7-dihydroxy-, 471

# SUBJECT INDEX

- Pteridine-6-carboxylic acid, 2-amino-4-hydroxy-, 471, 472, 479, 482  
Pteridine-7-carboxylic acid, 2-amino-4,6-dihydroxy-, 514  
—, —-4-hydroxy-, 514  
—, 2,4-diamino-, 514, 517  
—, 2,4-dihydroxy-, 514  
Pteridine-7 (or 6)-carboxylic acid, 2,4-dihydroxy-6 (or 7)-hydroxy-, 514  
Pteridine-7-carboxylic acid, 4-hydroxy-2-mercapto-, 514  
Pteridine-6,7-dicarboxylic acid, 2,4-diamino-, 517  
Pteridyl-6-aldehyde, 528  
—, 2-amino-4-hydroxy-, 475  
Pteric acid, 464, 474, 481, 504, 509, 510, 516, 519, 520, 528  
—, 4-amino-N<sup>10</sup>-methyl-, 523  
Pteroylaspartic acid, 520, 521, 523, 527  
—, 4-amino-, 522, 523  
Pteroyldiglutamic acid, 501, 503, 520, 528  
Pteroyldiglutamylglutamic acid See Pteroyltriglutamic acid  
Pteroylglutamic acid See Folic acid  
—, 4-amino- See Aminopterin  
—, —-9-N<sup>10</sup>-dimethyl-, 522, 523  
—, —-9-methyl-, 523  
—, —-N<sup>10</sup>-methyl-, 522, 523  
—, N<sup>10</sup>-phenacyl-, 520  
Pteroylheptaglutamic acid, 464, 472, 481, 489, 498, 499, 503, 504, 509  
Pteroylhexaglutamylglutamic acid See Pteroylheptaglutamic acid  
Pteroyltriglutamic acid, 464, 472, 476, 481, 485, 501, 503, 504, 509, 510, 515, 516, 520, 523, 528  
*Pinus lectus*, 115, 205, 287, 341, 389, 441, 512, 560, 578, 597  
Purine, 2,6-diamino-, 523  
Purines as growth factors for microorganisms, 622  
Pyracine, 304, 336, 337, 344, 459, 485, 488, 512  
Pyrazine, 2-amino-5-methyl-, 472  
Pyrazine-dicarboxylic acid, 288, 289, 291  
—-monocarboxylic acid, 279, 288, 289, 291  
Pyridine, 288  
—, 3-acetyl-, 293  
—, 4-alkoxymethyl-3-hydroxy-5-hydroxymethyl-2-methyl-, 302, 304, 311  
—, 3-amino-, 225, 227, 288, 289  
—, 3-amino-5-aminomethyl-4-ethoxymethyl-2-ethyl-, 346  
—, —-4-hydroxymethyl-, 343  
—, —-4-methoxymethyl-2-methyl-, 343  
Pyrone, 2,4-dihydroxy-, 514  
—, 2,4-dihydroxy-, 514  
—, 3-cyano-, 216, 218, 242, 290  
—, 4:5-epoxydimethyl-3-hydroxy-2-methyl-, 304, 311  
—, 3-ethyl-, 215  
Pyridine-3-acetic acid, 255  
Pyridine-3-carboxylic acid, 6-amino-, 561  
Pyridine-4-carboxylic acid, 3-hydroxy-5-hydroxymethyl-2-methyl- See 4-Pyridoxic acid  
Pyridine-3,5-dicarboxylic acid, 289  
—, 2,4-dimethyl-, 290  
—, 2,6-dimethyl-, 289  
—, 2,4,6-trimethyl-, 290  
—, 4,5-dicarboxylic acid, 3-hydroxy-2-methyl-, 306  
—, 3-methoxy-2-methyl-, 300, 302, 304  
—, 3-sulphonamide, 291, 292  
—, 1-ethyl-1,2-dihydro-, 292  
—, methiodide, 292  
Pyridine-3-sulphonic acid, 216, 242, 290, 291, 292, 293  
—, diethylamide, 291  
Pyridinium bromide hydrobromide, 1-(4'-amino-2'-methylpyrimidyl)-5'-methyl)-5-hydroxy-3,4-bis(hydroxymethyl)-6-methyl-, 119

# THE VITAMIN B COMPLEX

Pyridinium bromide hydrobromide 1	Pyridoxine triacetate 342
— — — — —	— — — — —
— — — — — methyl 123	— $\beta$ phenylethylamine 344
2 Pyridone 3 carboxylamide N <sup>1</sup> methyl 256	— tryptamine 344
6 Pyridone 3 carboxylamide N <sup>1</sup> methyl 221 223 226 253 255 257 260	— tyramine 344
6 Pyridone 3 carboxylic acid N <sup>1</sup> methyl 256	Pyrimidine 4 amino-5 aminomethyl 2 ethyl 118
Pyridoxal biological properties of 343	— — — 2 methyl 17 18 19 20 118 119
344	— — 5 bromomethyl 2 methyl 15 17 20 21 119
— chemical constitution of 300	— — 5 carboxy 2 methyl 118
— estimation of 312 313	— — 5 chloromethyl 2 methyl 119
— preparation of 301	— — 5 cyano-2 methyl 17
— stability of 308	— — 2 5-dimethyl 12 118
Pyridoxal phosphate 331 344 628	— — 5 ethoxymethyl 2 methyl 21 33
— 3 phosphate 332	— 2 amino 4-ethyl 119
— — acetal 332	— 4 amino 6 ethyl 119
— 5 phosphate 332	— — — 5 thioformamido 17
Pyridoxamine biological properties of 343 344	— — 6-hydroxy 2 methyl 118
— chemical constitution of 300	— — 5 hydroxymethyl 2 methyl 118 119
— estimation of 312 313	— — 2 methyl 5 thioformamido methyl 17 18 19 118 119
— preparation of 301	— 2 (6 bromonaphthyl 2 amino) 4 diethylaminoethylamino 6 methyl 209
— stability of 308	— 4 chloro-5-cyano 2 methyl 17
Pyridoxic acid 326 344 346 485	— 2 <i>p</i> chloroanilino 4 diethyl aminoethylamino-6 methyl 209
Pyridoxine	— 2 <i>p</i> chlorophenylguanid no 4 diethylaminoethylamino 6 methyl 209
analogues of 342 347	— 5-cyano 4 hydroxy 2 methyl 17
animal and human requirements of 328 329	— 2 4-diam no 5-d chloroacetyl no 6 hydroxy 476
antagonists of 345 346	— — 5 methyl 513
chemical constitution of 298 301	— 5 ethoxymethyl-4 hydroxy 2 methyl 13 15 16
discovery of 296 298 404	— 4 hydroxy 2 5-dimethyl 118
effect of deficiency in animals 317 322	— — 2 6 bis (hydroxymethyl) 5 methyl 346
— — man 322 325	— 2 hydroxy 5 methyl 4 thio 513
estimation of 309 315	— 2 4 5 6 tetraamino 521 522
function of 262 330 338	— 2 4 5 triamino 6-hydroxy 472 474 475 476
human and animal requirements of 328 329	Pyrimidine 5 acetic acid 4-chloro 2 methyl 20
in higher plants 341	— — 4 hydroxy 2 methyl 16 20
in nutrition of micro-organisms 110 338 341	— 4-carboxylic acid 288
intestinal synthesis of 327 328	— 5 carboxylic acid 2 amino 561
isolation of 298	Pyrimidines as growth factors for micro organisms 622
metabolism of 325 327	— inhibition of thiaminase by 25
occurrence in foodstuffs 315 317	Pyrimidinium bromide hydrobromide 3 (4 amino 2 methyl 5 pyrimidylmethyl) 6 hydroxy 5 $\beta$ hydroxyethyl 4 methyl 124
pharmacological action of 329 330	
properties of 307 308	
requirements of insects 341 342	
stability of 308 309	
synthesis of 301 307	
Pyridoxine 4 5-epoxy 342	
— 4 ethyl 342	
— 3 methyl 342	
— 4 methyl 342 345	
Pyridoxine beta ne N methyl 343	
— boric acid complex 343	
— 4 5-diacetate 342 343	

- Pyruvic acid, 51, 90, 93, 95, 102, 106, 110, 197, 387, 391, 444, 445, 625, 626, 627, 628  
 — — oxidase, 197  
*Pythiomypha gonapodioides*, 108, 123, 124  
 QUEBRACHITOL, 579  
 Quercitol, 579, 581.  
 Quinic acid, 579  
 Quinine oxidase, 196, 528  
 Quinoline, 215, 216  
 — -2-carboxylic acid, 292  
 — -3-carboxylic acid, 292  
 — -8-sulphonic acid, 215  
 Quinoline derivatives, enzymic oxidation of, 196  
 Quinolinic acid, 215, 251, 279, 288, 289, 290, 294  
 8 Quinolinol, 215  
 —, 5 7-dinitro-, 215  
 Quinone-chloroimide, 2, 6-dichloro-, 310  
 Quinoxaline, 523  
 —, 2 tetrahydroxybutyl-, 137  
 RABBIT meat, vitamin content of, 166, 234  
 Rabbits, effect of vitamin deficiency in, 238  
 Rachitogenic activity of oatmeal, 571  
 Radiation sickness, 247, 324  
 Radishes, vitamin content of, 164  
 Raisins, vitamin content of, 43, 163, 588  
 Raspberries, vitamin content of, 43  
 Rat dermatitis factor See Pyridoxine  
 Rat leprosy, 52  
 Rat pellagra, 132, 211, 296, 307, 317  
 Rats, effect of vitamin deficiency in, 47, 168, 237, 318, 366, 424, 487-489, 551, 572, 589  
 —, use in vitamin assays, 28, 156, 309  
 —, vitamin requirements of, 82, 188, 329, 377, 437, 507, 594, 608  
 Red currants, vitamin content of, 43  
 Reductone, 474  
 Refection, 75, 184, 552  
 Renal haemorrhages, 589  
 Resins, ion-exchange, 11  
 Respiration, 92, 625  
 Retina, riboflavin in, 200  
 Rhotin, 433  
*Rhizobia*, 405  
*Rhizobium trifolii*, 422, 433, 439, 449, 450, 452  
*Rhodotorula aurantiaca*, 557  
 — *rubra*, 109  
 D-Ribamine, 140  
 Riboflavin  
 analogues of, 206, 210  
 aneurine and, 49  
 animal and human requirements of, 186-190  
 antagonists of, 208  
 cancer and, 171  
 chemical constitution of, 135-139  
 discovery of, 132, 134  
 effect of deficiency in animals, 168-173  
 — — man, 173-177  
 effect on infected animals, 171  
 estimation of, 156-164  
 faecal excretion of, 180  
 function of, 190-203  
 human and animal requirements of, 186-190  
 in higher plants, 205  
 in nutrition of micro-organisms, 203-205  
 in pregnancy and lactation, 181  
 intestinal synthesis of, 183-186  
 isolation of, 134-135  
 metabolism of, 177, 183  
 microbiological production of, 148-154  
 occurrence in foodstuffs, 164-168  
 pharmacological action of, 190  
 properties of, 154-156  
 recovery from fermentation liquors, 152  
 requirements of insects, 205-206  
 separation from aneurine, 11  
 solubility of, 154  
 stability of, 155  
 synthesis of, 140-148  
 urinary excretion of, 177  
 Riboflavin adenine dinucleotide, 192, 193, 194, 204, 208, 209  
 — mononucleotide, 191, 193  
 — nucleotides, estimation of, 161  
 — -5 phosphoric acid, 191, 192, 193, 204, 208, 209  
 D Ribonamide, 145  
 —, tetrabutyl-, 145  
 D-Ribonic acid, 143, 146  
 — —, tetraacetyl-, 145  
 — —, tetrabutyl-, 145  
 D Ribonolactone, 146  
 D Ribonitrile, tetraacetyl-, 146  
 Ribonuclease, 616



# THE VITAMIN B COMPLEX

- Ribonucleic acid, 528  
D Ribose, 140, 143  
—, tetraacetyl-, 145  
—, tetrabutyl-, 146  
Rice, vitamin content of, 43, 45,  
232, 233, 235, 316, 363, 587.  
Rice birds, 11, 28  
— polishings, 9, 10, 11, 587  
Rickettsiac, effect of *p*-aminobenzoic  
acid on, 557-558  
235, 317, 364, 390, 424, 441, 513.  
Rumen, vitamin synthesis in, 75, 79,  
185, 328, 537  
Rye, vitamin content of, 43, 232  
SACCHARIC acid, 566  
*Saccharomyces anomalous belgicus*, 386  
— *bacillaris*, 386  
— *bayanus*, 577  
— *behrensianus*, 386  
— *carlsbergensis*, 281, 312, 313, 316,  
326, 344, 387, 569, 577  
— — var *mandshuricus*, 338  
— *cerevisiae*, 33, 106, 311, 312, 338,  
454, 569, 577, 579  
— — var *ellipsoideus*, 106, 361, 386  
— *chevalieri*, 386, 577  
— *chodati*, 338, 386  
— *exiguus*, 386  
— *fragilis*, 106, 148, 281, 386, 446  
— *galactosus*, 106  
— *globosus*, 106, 446  
— *hanseniaspora valbeyensis*, 106, 338  
— *logos*, 577  
— *macedoniensis*, 35, 106, 281, 386  
— *muciparus*, 106  
— *oviformis*, 338, 343, 386  
— *tubiformis*, 386  
— *uvarum*, 577  
— *validus*, 106  
*Saccharomycodes ludwigii*, 106, 281, 338,  
386, 577  
Salicylic acid, 128, 383, 387  
Salmon, vitamin content of, 233, 363,  
589  
*Salmonella* infection, effect of aneurine  
deficiency in, 51.  
— — — riboflavine deficiency in, 171  
Sarcosine, 196, 600  
Savoys, vitamin content of, 43  
Scallops, vitamin content of, 233  
Schardinger enzyme, 194  
*Schizosaccharomyces pombe*, 281, 386,  
569, 577  
Serine, 600  
—, N-benzoyl-, 415  
Serine deaminase, 444  
*Serratia marcescens*, 111, 204, 283, 340,  
556,  
622  
— *sonnei*, 294  
Shrimps, thiaminase in, 26.  
*Silvanus surinamensis*, 115, 205, 287,  
341, 389, 441, 512  
*Sitodrepa panicea*, 115, 205, 287, 341,  
389, 441, 512, 597  
Skin lesions due to riboflavine deficiency,  
168, 169, 170, 173, 174  
SLR factor, 458, 470, 473, 476, 478, 481,  
483, 491, 509, 519  
Snake venom, 246  
Soil, vitamins in, 114, 341, 424, 559,  
578  
232,  
Soyabean, vitamin content of, 43, 164,  
233, 537, 588  
— phosphatides, 571  
Spermine, 196  
Sphingomyelin, 585  
Spinach, vitamin content of, 43, 165,  
233, 363, 457, 550, 588  
*Spirillum serpens*, 622  
*Sporotrichon schencki*, 109  
Sprue, 270, 496, 497, 498, 499, 501, 507,  
538  
*Staphylococcus aureus*, 35, 100, 111, 119,  
126, 208, 282, 283, 290, 291, 292, 293,  
383, 391, 395, 399, 439, 452, 515, 517,  
518, 519, 523, 556, 561, 622  
*Stegobium paniceum* See *Sitodrepa*  
*panicea*  
*Stercum frustulosum*, 109  
Stilboestrol, 200, 486  
Storage of foodstuffs, effect on vitamin  
content, 45, 165, 235  
Streptogenin, 616, 617  
*Streptobacterium casesi*, 203, 206  
— *plantarum*, 203, 208, 282, 292, 340,  
343, 354, 361, 380, 381, 395, 396,  
399, 439, 510, 516, 555, 560  
*Streptococcus faecalis* R, 204, 229, 312,  
339, 340, 343, 344, 353, 360, 380,  
381, 382, 396, 397, 442, 451, 457,  
458, 459, 460, 461, 462, 463, 464,



## THE VITAMIN B COMPLEX

[illegible]

- Torulopsis utae*, 338  
 Toxicity of *p*-aminobenzoic acid, 555  
 — aneurine, 62, 85  
 — biotin, 437  
 — choline, 595  
 — folic acid, 508.  
 — nicotinamide, 273  
 — nicotinic acid, 273  
 — pantothenic acid, 379  
 — pyridoxine, 329  
 — riboflavine, 190  
 Toxoplasmosis, 557.  
*Trametes cinnabarina*, 109  
 — *serialis*, 109  
 Transamination, 97, 333, 443  
 Transmethylation, 539, 601, 604  
 Trench mouth, 247.  
*Tribolium confusum*, 115, 205, 287, 294,  
 341, 389, 441, 512, 560, 578, 597  
 Tricarboxylic acid cycle, 626, 627  
*Tricholoma nudum*, 109  
*Trichomonas foetus*, 401  
 — *gallinae*, 401  
 — *vaginalis*, 401  
*Trichophyton album*, 109, 438  
 — *faciforme*, 109, 577  
 — *sulphureum*, 109  
 — *violaceum*, 109  
*Trichosurus vulpulus*, 52  
 Trigonelline, 219, 220, 221, 223, 224,  
 228, 235, 252, 253, 257, 258, 261, 269  
 288, 290  
 Triphosphopyridine nucleotide, 193, 229  
 275, 627  
 Trishomobiotin, 453  
 — sulphone, 453  
 Trout, effect of vitamin deficiency in,  
 170, 189, 239, 320, 369, 426, 492,  
 552, 574, 591  
 —, vitamin content of, 234, 589  
 Trypanosome infection, effect of vita-  
 min deficiency on, 369, 429  
 Trypsin, 616  
 Trypsinogen, 616, 617  
 Tryptophan, metabolism of, 330, 331,  
 391  
 —, precursor of nicotinic acid, 237, 241,  
 249, 261, 262, 265, 270, 271, 281,  
 285, 287, 293, 336  
 —, synthesis of, 335, 336, 391, 628  
 —, 2-methyl-, 251  
 —, 4-methyl-, 251  
 —, 5-methyl-, 251  
 —, 7-methyl-, 251  
 Tryptophanase, 336  
 Tubercle bacillus phosphatides, 571  
 Tuberculosis, 557  
 Turbot, vitamin content of, 233  
 Turkeys, effect of vitamin deficiency in,  
 170, 239, 320, 425, 486, 574, 590  
 Turkeys, vitamin requirements of, 329,  
 437  
 Turnips, vitamin content of, 44, 165,  
 363, 588  
 Tutocaine, 560  
 Typhus, 557, 558  
 Tyrosine, 527, 628  
 — decarboxylase, 331, 332, 345  
 ULCERATIVE colitis, 323, 497  
 Uracil, 118, 119, 562, 622  
 —, 5-amino-, 516  
 —, 5-bromo-, 517  
 —, 5-carbamido-, 516  
 —, 5-hydroxy-, 516  
 Uric acid, 194  
 Urinary excretion of *p* aminobenzoic  
 acid, 77, 78, 554  
 — — aneurine, 63, 77, 78  
 — — biotin, 77, 78, 433, 435  
 — — choline, 593  
 — — folic acid, 77, 78, 503, 504, 505  
 — — inositol, 576  
 — — nicotinamide, 252  
 — — nicotinic acid, 77, 78, 252  
 — — pantothenic acid, 77, 78, 374, 377  
 — — pyridoxine, 77, 78, 325, 328  
 — — riboflavine, 77, 78, 177, 185  
 Urine, estimation of aneurine in, 38, 64  
 —, — nicotinic acid in, 219, 222, 223,  
 227  
 —, — pyridoxine in, 310, 311, 326  
 —, — riboflavine in, 157, 160, 161, 177  
 Uroflavine, 134  
 Urorosein, 244, 255  
*Ustilago scabioseae*, 109  
 — *violacea*, 109  
 VALERIC acid,  $\alpha$ , $\delta$ -dihydroxy-, 350  
 $\gamma$ -Valerolactone,  $\alpha$ -hydroxy-, 353  
 Valine pantoyl-, 396  
 Vincent's angina, 246  
 Virus infection effect of *p* amino-  
 benzoic acid on 557  
 —, — vitamin deficiency on, 51, 171,  
 492, 521  
 Viruses, folic acid in, 511  
 Vision in dim light, effect of riboflavine  
 on, 193, 199, 200  
 Vitamin B, 9, 10  
 — complex deficiency, effect of mul-  
 tiple, 606, 607  
 — B<sub>1</sub>, 132  
 — B<sub>2</sub>, 611  
 — B<sub>6</sub>, 46, 612

# THE VITAMIN B COMPLEX

- Vitamin B<sub>3</sub>, 611  
 — B<sub>6</sub>. See Pyridoxine.  
 — B<sub>10</sub>, 460, 486, 491, 540, 613, 614  
 — B<sub>11</sub>, 460, 486, 491, 540, 613, 614  
 Vitamin B<sub>12</sub>  
   chemical constitution of, 533  
   discovery of, 530-532  
   effect in animals, 539-540  
   — man, 538-539  
   estimation of, 534-536  
   excretion of, 539-544  
   in nutrition of micro-organisms, 543-544  
   intestinal synthesis of, 539, 544  
   isolation of, 532  
   occurrence of, 537-538  
   properties of, 533  
   relation to folic acid, 499-500, 526, 540  
 Vitamin B<sub>12a</sub>, 531  
 — B<sub>12b</sub>, 531, 538  
 — B<sub>13</sub>, 614  
 — B<sub>14</sub>, 614  
 — B<sub>15</sub>, 458, 459, 469, 477  
 — conjugase, 460, 462, 464, 479, 480, 481, 483, 504, 509, 511  
 — conjugate, 459, 464, 469, 470, 478, 479, 481, 491  
 — B<sub>17</sub>, 617  
 — B<sub>18</sub>, 365  
 — C, 103  
 — E, 364  
 — G, 10, 132  
 — H, 132, 404, 406  
 — K, 487, 552  
 — L, 615  
 — M, 460, 491  
 Vitamins, characteristics of, 628 629  
 —, inadequacy for animals of known, 608 610  
 Vongerichten reaction, 218  
 WALNUTS, vitamin content of, 43, 363  
 Watercress, vitamin content of, 44  
 Wernicke's syndrome, 58, 246.  
 Wheat and wheat products, vitamin content of, 43, 45, 164, 232, 316, 363, 537, 550, 571, 587, 588  
 Woods-Fildes hypothesis, 128, 546, 562  
 XANTHINE, 294, 520, 562  
 — oxidase, 194, 195, 197, 528, 615  
 Xanthopterin, 460-462, 470, 476, 478, 484, 491, 508, 509, 510, 512, 513, 522, 614  
 —, dihydro-, 476, 522  
 Xanthopterin oxidase, 528  
 Xanthopterin-carboxylic acid, 126, 522  
 Xanthurenic acid, 319, 330, 331, 336, 342, 345, 346  
 YEAST, vitamin content of, 44, 166, 234, 316, 363, 423, 483, 537, 546, 548, 551, 570, 571.  
 Yeasts, synthesis of aneurine by, 106  
 —, — cocarboxylase by, 107  
 —, — riboflavine by, 148  
 —, vitamin requirements of, 105, 203, 281, 338, 386, 404, 405, 438, 546, 548, 557, 577  
 Yellow enzyme, 134, 191  
 ZEOLITES as adsorbents, 11  
 Zoopherin, 619  
*Zygosaccharomyces barkeri*, 386, 446  
 — *felisneus*, 386  
 — *japonicus*, 106, 386, 577  
 — *lactis*, 281.  
 — *mandshuricus*, 106, 386  
 — *marxianus*, 281, 386  
 — *nadsoni*, 386  
 — *pastori*, 386  
 — *priorianus*, 106, 386, 577  
 — *variabilis*, 386

